0001641172-25-002589.txt : 20250403 0001641172-25-002589.hdr.sgml : 20250403 20250403164544 ACCESSION NUMBER: 0001641172-25-002589 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 121 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250403 DATE AS OF CHANGE: 20250403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CareCloud, Inc. CENTRAL INDEX KEY: 0001582982 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] ORGANIZATION NAME: 06 Technology EIN: 223832302 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36529 FILM NUMBER: 25810305 BUSINESS ADDRESS: STREET 1: 7 CLYDE ROAD STREET 2: SOMERSET CITY: SOMERSET STATE: NJ ZIP: 08873 BUSINESS PHONE: 7328735133 MAIL ADDRESS: STREET 1: 7 CLYDE ROAD STREET 2: SOMERSET CITY: SOMERSET STATE: NJ ZIP: 08873 FORMER COMPANY: FORMER CONFORMED NAME: MTBC, Inc. DATE OF NAME CHANGE: 20190206 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL TRANSCRIPTION BILLING, CORP DATE OF NAME CHANGE: 20130731 10-K/A 1 form10-ka.htm
true FY 0001582982 http://fasb.org/us-gaap/2024#RestructuringCostsAndAssetImpairmentCharges http://fasb.org/us-gaap/2024#RestructuringCostsAndAssetImpairmentCharges 0001582982 2024-01-01 2024-12-31 0001582982 CCLD:CommonStockParValue0.001PerShareMember 2024-01-01 2024-12-31 0001582982 CCLD:Sec8.75SeriesCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember 2024-01-01 2024-12-31 0001582982 CCLD:Sec8.75SeriesBCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember 2024-01-01 2024-12-31 0001582982 2024-06-30 0001582982 2025-03-11 0001582982 2023-01-01 2023-12-31 0001582982 2024-10-01 2024-12-31 0001582982 2024-12-31 0001582982 2023-12-31 0001582982 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001582982 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2024-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001582982 us-gaap:CommonStockMember 2023-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001582982 us-gaap:RetainedEarningsMember 2023-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001582982 us-gaap:TreasuryStockCommonMember 2023-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001582982 us-gaap:CommonStockMember 2022-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001582982 us-gaap:RetainedEarningsMember 2022-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001582982 us-gaap:TreasuryStockCommonMember 2022-12-31 0001582982 2022-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001582982 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001582982 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001582982 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001582982 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-12-31 0001582982 us-gaap:CommonStockMember 2024-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001582982 us-gaap:RetainedEarningsMember 2024-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001582982 us-gaap:TreasuryStockCommonMember 2024-12-31 0001582982 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-12-31 0001582982 CCLD:MTBCPrivateLimitedMember 2004-12-31 0001582982 CCLD:MTBCPrivateLimitedMember CCLD:FounderAndExecutiveChairmanMember 2004-12-31 0001582982 CCLD:MTBCBaghPvtLtdMember 2022-04-01 0001582982 CCLD:MTBCBaghPvtLtdMember CCLD:FounderAndExecutiveChairmanMember 2022-04-01 0001582982 srt:MinimumMember 2024-12-31 0001582982 srt:MaximumMember 2024-12-31 0001582982 us-gaap:ComputerEquipmentMember srt:MinimumMember 2024-12-31 0001582982 CCLD:RevenueCycleManagementMember srt:MinimumMember 2024-12-31 0001582982 CCLD:RevenueCycleManagementMember srt:MaximumMember 2024-12-31 0001582982 CCLD:GroupPurchasingOrganizationAndMedicalPracticeManagementMember srt:MinimumMember 2024-12-31 0001582982 CCLD:GroupPurchasingOrganizationAndMedicalPracticeManagementMember srt:MaximumMember 2024-12-31 0001582982 2023-08-31 2023-08-31 0001582982 CCLD:HealthcareITMember 2023-10-31 2023-10-31 0001582982 CCLD:HealthcareITMember 2023-12-12 2023-12-12 0001582982 2023-01-01 0001582982 CCLD:MedicalPracticeManagementSegmentMember 2024-12-31 0001582982 CCLD:MedicalPracticeManagementSegmentMember 2023-12-31 0001582982 us-gaap:CustomerRelationshipsMember 2023-12-31 0001582982 CCLD:CapitalizedSoftwareMember 2023-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0001582982 us-gaap:CustomerRelationshipsMember 2024-01-01 2024-12-31 0001582982 CCLD:CapitalizedSoftwareMember 2024-01-01 2024-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2024-01-01 2024-12-31 0001582982 us-gaap:CustomerRelationshipsMember 2024-12-31 0001582982 CCLD:CapitalizedSoftwareMember 2024-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2024-12-31 0001582982 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2024-12-31 0001582982 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2024-12-31 0001582982 us-gaap:CustomerRelationshipsMember 2022-12-31 0001582982 CCLD:CapitalizedSoftwareMember 2022-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0001582982 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0001582982 CCLD:CapitalizedSoftwareMember 2023-01-01 2023-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2023-01-01 2023-12-31 0001582982 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2023-12-31 0001582982 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2023-12-31 0001582982 us-gaap:ComputerEquipmentMember 2024-12-31 0001582982 us-gaap:ComputerEquipmentMember 2023-12-31 0001582982 CCLD:OfficeFurnitureAndEquipmentMember 2024-12-31 0001582982 CCLD:OfficeFurnitureAndEquipmentMember 2023-12-31 0001582982 us-gaap:TransportationEquipmentMember 2024-12-31 0001582982 us-gaap:TransportationEquipmentMember 2023-12-31 0001582982 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001582982 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001582982 CCLD:AssetsNotPlacedInServiceMember 2024-12-31 0001582982 CCLD:AssetsNotPlacedInServiceMember 2023-12-31 0001582982 CCLD:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001582982 CCLD:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001582982 CCLD:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001582982 CCLD:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001582982 CCLD:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001582982 CCLD:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001582982 us-gaap:NonUsMember 2024-12-31 0001582982 us-gaap:NonUsMember 2023-12-31 0001582982 us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001582982 CCLD:SVBCreditFacilityMember 2017-10-01 2017-10-31 0001582982 CCLD:SVBCreditFacilityMember srt:MinimumMember 2018-09-30 0001582982 CCLD:SVBCreditFacilityMember srt:MaximumMember 2018-09-30 0001582982 CCLD:SVBCreditFacilityMember 2018-07-01 2018-09-30 0001582982 CCLD:SVBCreditFacilityMember 2021-09-30 0001582982 CCLD:SVBCreditFacilityMember 2021-07-01 2021-09-30 0001582982 CCLD:SVBCreditFacilityMember 2023-02-28 0001582982 CCLD:SVBCreditFacilityMember 2023-02-28 2023-02-28 0001582982 CCLD:SVBCreditFacilityMember 2023-08-30 0001582982 CCLD:SVBCreditFacilityMember 2023-08-31 0001582982 CCLD:SVBCreditFacilityMember 2023-08-30 2023-08-31 0001582982 CCLD:SVBCreditFacilityMember 2024-03-31 0001582982 CCLD:SVBCreditFacilityMember 2024-04-01 0001582982 CCLD:SVBCreditFacilityMember 2024-01-01 2024-12-31 0001582982 CCLD:SVBCreditFacilityMember 2024-12-31 0001582982 CCLD:SVBDebtAgreementMember 2017-10-01 2017-10-31 0001582982 CCLD:SVBDebtAgreementMember 2017-10-31 0001582982 CCLD:SVBCreditFacilityMember srt:MinimumMember 2017-10-31 0001582982 CCLD:SVBDebtAgreementMember CCLD:AdditionalWarrantMember 2017-10-31 0001582982 CCLD:SVBDebtAgreementMember 2024-01-01 2024-12-31 0001582982 CCLD:SVBCreditFacilityMember CCLD:NinthLoanModificationAgreementMember 2024-09-30 0001582982 CCLD:SVBCreditFacilityMember CCLD:NinthLoanModificationAgreementMember 2024-10-30 0001582982 CCLD:VehicleFinancingNotesMember srt:MinimumMember 2024-01-01 2024-12-31 0001582982 CCLD:VehicleFinancingNotesMember srt:MaximumMember 2024-01-01 2024-12-31 0001582982 CCLD:InsuranceFinancingMember 2024-12-31 0001582982 CCLD:VehicleFinancingNotesMember 2024-12-31 0001582982 CCLD:HealthcareITMember CCLD:TechnologyEnabledBusinessSolutionsMember 2024-01-01 2024-12-31 0001582982 CCLD:HealthcareITMember CCLD:TechnologyEnabledBusinessSolutionsMember 2023-01-01 2023-12-31 0001582982 CCLD:HealthcareITMember CCLD:ProfessionalServicesMember 2024-01-01 2024-12-31 0001582982 CCLD:HealthcareITMember CCLD:ProfessionalServicesMember 2023-01-01 2023-12-31 0001582982 CCLD:HealthcareITMember CCLD:PrintingAndMailingServicesMember 2024-01-01 2024-12-31 0001582982 CCLD:HealthcareITMember CCLD:PrintingAndMailingServicesMember 2023-01-01 2023-12-31 0001582982 CCLD:HealthcareITMember CCLD:GroupPurchasingServicesMember 2024-01-01 2024-12-31 0001582982 CCLD:HealthcareITMember CCLD:GroupPurchasingServicesMember 2023-01-01 2023-12-31 0001582982 CCLD:MedicalPracticeManagementMember 2024-01-01 2024-12-31 0001582982 CCLD:MedicalPracticeManagementMember 2023-01-01 2023-12-31 0001582982 CCLD:ChronicCareManagementMember 2024-01-01 2024-12-31 0001582982 CCLD:ChronicCareManagementMember 2023-01-01 2023-12-31 0001582982 CCLD:RemotePatientMonitoringMember 2024-01-01 2024-12-31 0001582982 CCLD:RemotePatientMonitoringMember 2023-01-01 2023-12-31 0001582982 CCLD:ProfessionalServicesMember us-gaap:UnbilledRevenuesMember 2024-01-01 2024-12-31 0001582982 CCLD:ProfessionalServicesMember us-gaap:UnbilledRevenuesMember 2023-01-01 2023-12-31 0001582982 CCLD:RevenueCycleManagementMember 2024-12-31 0001582982 CCLD:GroupPurchasingServicesMember 2024-12-31 0001582982 CCLD:ReferralFeesMember 2024-12-31 0001582982 us-gaap:OtherNoncurrentAssetsMember 2024-12-31 0001582982 us-gaap:OtherNoncurrentAssetsMember 2023-12-31 0001582982 us-gaap:TradeAccountsReceivableMember us-gaap:AccountingStandardsUpdate201613Member 2023-01-01 0001582982 us-gaap:SeriesAPreferredStockMember CCLD:CertificateOfAmendmentMember 2024-09-11 2024-09-11 0001582982 us-gaap:SeriesAPreferredStockMember 2024-09-11 2024-09-11 0001582982 us-gaap:SeriesAPreferredStockMember 2024-09-11 0001582982 CCLD:TreasuryStockOneMember 2024-01-01 2024-12-31 0001582982 CCLD:AtTheMarketFacilityMember 2024-12-31 0001582982 CCLD:AtTheMarketFacilityMember 2024-01-01 2024-12-31 0001582982 CCLD:AtTheMarketFacilityMember 2023-01-01 2023-12-31 0001582982 us-gaap:PreferredStockMember 2024-12-31 0001582982 CCLD:AtTheMarketFacilityMember us-gaap:SeriesBPreferredStockMember srt:MaximumMember 2024-01-01 2024-12-31 0001582982 us-gaap:SeriesBPreferredStockMember CCLD:AtTheMarketFacilityMember 2024-01-01 2024-12-31 0001582982 us-gaap:SeriesBPreferredStockMember CCLD:AtTheMarketFacilityMember 2023-01-01 2023-12-31 0001582982 us-gaap:SeriesAPreferredStockMember 2020-11-04 0001582982 us-gaap:SeriesBPreferredStockMember 2024-02-15 0001582982 us-gaap:SubsequentEventMember us-gaap:SeriesBPreferredStockMember 2025-02-15 0001582982 srt:ScenarioForecastMember us-gaap:SeriesBPreferredStockMember 2026-02-15 0001582982 srt:ScenarioForecastMember us-gaap:SeriesBPreferredStockMember 2027-02-15 0001582982 CCLD:SeriesAAndSeriesBPreferredStockMember 2024-01-01 2024-12-31 0001582982 CCLD:SeriesAAndSeriesBPreferredStockMember 2024-09-11 2024-09-11 0001582982 CCLD:SeriesAAndSeriesBPreferredStockMember 2023-01-01 2023-12-31 0001582982 2024-09-11 2024-09-11 0001582982 2024-09-12 2024-09-12 0001582982 us-gaap:WarrantMember 2023-12-31 0001582982 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001582982 us-gaap:WarrantMember 2024-12-31 0001582982 CCLD:RamapoAnesthesiologistsPCMember 2023-12-22 2023-12-22 0001582982 CCLD:RamapoAnesthesiologistsPCMember CCLD:AccruedExpensesMember 2023-12-22 0001582982 2021-03-01 2021-03-31 0001582982 2024-04-30 0001582982 2024-09-01 2024-09-30 0001582982 CCLD:PhysicianMember 2024-01-01 2024-12-31 0001582982 CCLD:PhysicianMember 2023-01-01 2023-12-31 0001582982 CCLD:PhysicianMember 2024-12-31 0001582982 CCLD:PhysicianMember 2023-12-31 0001582982 CCLD:ExecutiveChairmanMember 2024-01-01 2024-12-31 0001582982 CCLD:ExecutiveChairmanMember 2023-01-01 2023-12-31 0001582982 us-gaap:RelatedPartyMember 2024-12-31 0001582982 us-gaap:RelatedPartyMember 2023-12-31 0001582982 CCLD:FormerNonIndependentDirectorsMember us-gaap:SeriesBPreferredStockMember CCLD:ConsultingAgreementMember 2022-06-01 2022-06-30 0001582982 CCLD:FormerNonIndependentDirectorsMember us-gaap:SeriesBPreferredStockMember CCLD:ConsultingAgreementMember 2023-02-01 2023-02-28 0001582982 CCLD:FormerNonIndependentDirectorsMember us-gaap:SeriesBPreferredStockMember CCLD:ConsultingAgreementMember 2024-01-01 2024-01-31 0001582982 CCLD:FormerNonIndependentDirectorsMember CCLD:ConsultingAgreementMember 2024-02-01 2024-02-01 0001582982 CCLD:FormerNonIndependentDirectorsMember CCLD:ConsultingAgreementMember 2024-02-12 2024-02-12 0001582982 CCLD:FormerNonIndependentDirectorsMember CCLD:ConsultingAgreementMember 2024-09-01 2024-09-01 0001582982 CCLD:FormerNonIndependentDirectorsMember CCLD:ConsultingAgreementMember 2024-01-01 2024-12-31 0001582982 CCLD:TalkMDCliniciansMember 2024-01-01 2024-12-31 0001582982 us-gaap:SubsequentEventMember 2025-01-01 2025-12-31 0001582982 CCLD:SeveranceAndSeparationCostsMember 2023-12-31 0001582982 CCLD:EquityAwardsAccelerationCostsAssociatedWithSeveranceMember 2023-12-31 0001582982 CCLD:OtherExitRelatedCostsMember 2023-12-31 0001582982 CCLD:SeveranceAndSeparationCostsMember 2024-01-01 2024-12-31 0001582982 CCLD:EquityAwardsAccelerationCostsAssociatedWithSeveranceMember 2024-01-01 2024-12-31 0001582982 CCLD:OtherExitRelatedCostsMember 2024-01-01 2024-12-31 0001582982 CCLD:SeveranceAndSeparationCostsMember 2024-12-31 0001582982 CCLD:EquityAwardsAccelerationCostsAssociatedWithSeveranceMember 2024-12-31 0001582982 CCLD:OtherExitRelatedCostsMember 2024-12-31 0001582982 CCLD:SeveranceAndSeparationCostsMember 2022-12-31 0001582982 CCLD:EquityAwardsAccelerationCostsAssociatedWithSeveranceMember 2022-12-31 0001582982 CCLD:OtherExitRelatedCostsMember 2022-12-31 0001582982 CCLD:SeveranceAndSeparationCostsMember 2023-01-01 2023-12-31 0001582982 CCLD:EquityAwardsAccelerationCostsAssociatedWithSeveranceMember 2023-01-01 2023-12-31 0001582982 CCLD:OtherExitRelatedCostsMember 2023-01-01 2023-12-31 0001582982 CCLD:DefinedContributionRetirementPlanForUSEmployeesMember 2024-01-01 2024-12-31 0001582982 CCLD:DefinedContributionRetirementPlanForUSEmployeesMember 2023-01-01 2023-12-31 0001582982 CCLD:DefinedContributionRetirementPlanForPakistanEmployeesMember 2024-01-01 2024-12-31 0001582982 CCLD:DefinedContributionRetirementPlanForPakistanEmployeesMember 2023-01-01 2023-12-31 0001582982 CCLD:DefinedContributionRetirementPlanForSriLankaEmployeesMember 2024-01-01 2024-12-31 0001582982 CCLD:DefinedContributionRetirementPlanForSriLankaEmployeesMember 2023-01-01 2023-12-31 0001582982 CCLD:TwoThousandFourteenEquityIncentivePlanMember CCLD:EmployeesOfficersDirectorsAndConsultantsMember 2014-04-30 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:CommonStockMember 2017-04-14 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesAPreferredStockMember 2017-04-14 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesAPreferredStockMember 2018-12-31 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:CommonStockMember 2020-05-31 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesAPreferredStockMember 2020-05-31 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:CommonStockMember 2022-12-31 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember CCLD:FiveOutsidesMembersofTheBoardMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember CCLD:FiveOutsidesMembersofTheBoardMember 2023-01-01 2023-12-31 0001582982 CCLD:EmployeeMember 2022-01-01 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember 2023-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2023-02-01 2023-02-28 0001582982 us-gaap:SeriesBPreferredStockMember 2023-10-01 2023-10-31 0001582982 us-gaap:SeriesBPreferredStockMember 2024-03-01 2024-03-31 0001582982 us-gaap:SeriesBPreferredStockMember 2024-05-01 2024-05-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-12-31 0001582982 CCLD:DirectOperatingCostsMember 2024-01-01 2024-12-31 0001582982 CCLD:DirectOperatingCostsMember 2023-01-01 2023-12-31 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001582982 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-12-31 0001582982 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-12-31 0001582982 CCLD:NetLossOnLeaseTerminationsUnoccupiedLeaseChargesAndRestructuringCostsMember 2024-01-01 2024-12-31 0001582982 CCLD:NetLossOnLeaseTerminationsUnoccupiedLeaseChargesAndRestructuringCostsMember 2023-01-01 2023-12-31 0001582982 country:PK 2024-01-01 2024-12-31 0001582982 country:PK 2023-01-01 2023-12-31 0001582982 CCLD:FederalMember 2024-12-31 0001582982 CCLD:FederalMember CCLD:BetweenTwoThousandThirtyOneAndTwoThousandThirtyEightMember 2024-12-31 0001582982 CCLD:FederalMember CCLD:IndefiniteLifeMember 2024-12-31 0001582982 CCLD:FederalMember CCLD:CareCloudAndMeridianAcquisitionsMember 2024-12-31 0001582982 CCLD:StateMember 2024-12-31 0001582982 stpr:NJ 2024-12-31 0001582982 CCLD:HealthcareITMember us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 0001582982 CCLD:MedicalPracticeManagementMember us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 0001582982 us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 0001582982 CCLD:HealthcareITMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-12-31 0001582982 CCLD:MedicalPracticeManagementMember us-gaap:OperatingSegmentsMember 2023-01-01 2023-12-31 0001582982 us-gaap:OperatingSegmentsMember 2023-01-01 2023-12-31 0001582982 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-12-31 0001582982 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001582982 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001582982 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001582982 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0001582982 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001582982 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001582982 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001582982 us-gaap:SubsequentEventMember 2025-01-30 0001582982 us-gaap:SubsequentEventMember 2025-01-31 0001582982 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2025-03-01 2025-03-31 0001582982 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember CCLD:IndividualShareholdersMember 2025-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CCLD:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-K/A

(Amendment No. 1)

 

(Mark one)

 

☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2024

 

or

 

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission File Number: 001-36529

 

 

CareCloud, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   22-3832302

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

7 Clyde Road

Somerset, New Jersey

  

 

08873

(Address of principal executive offices)

 

 

 (Zip Code)

  

(732) 873-5133

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   CCLD   Nasdaq Global Market
8.75% Series A Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share  

CCLDP

  

Nasdaq Global Market

8.75% Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share  

CCLDO

  

Nasdaq Global Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

As of June 30, 2024, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $19.1 million, based on the last reported trading price of the common stock on that date, as reported on the Nasdaq Global Market.

 

At March 11, 2025, the registrant had 42,316,513 shares of common stock, par value $0.001 per share, outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025 are incorporated by reference into Part III, Items 10, 11, 12, 13, and 14 of this Annual Report on Form 10-K.

 

 

 

 
 

 

EXPLANATORY NOTE

 

This Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) amends the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Annual Report”) of CareCloud, Inc. filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2025 (the “Original Filing Date”). In this Amendment No. 1, unless the context indicates otherwise, the designations “CareCloud,” the “Company,” “we,” “us” or “our” refer to CareCloud, Inc. and its subsidiaries.

 

This Amendment No. 1 is being filed solely to correct a typographical error in the Report of Independent Registered Public Accounting Firm (the “Audit Opinion”) of Rosenberg Rich Baker Berman, P.A. (“RRBB”) contained in the 2024 Annual Report, by replacing “March 13, 2024” with “March 13, 2025” under the signature in the Audit Opinion. In addition, this Amendment No. 1 includes a new consent of RRBB as Exhibit 23.1 hereto, a new consent of Grant Thornton LLP as Exhibit 23.2 hereto and new certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 as Exhibits 31.1, 31.2, 31.3, 32.1, 32.2 and 32.3 hereto.

 

Pursuant to Rule 12b-15 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we have repeated the entire text of Item 8 of the 2024 Annual Report in this Amendment No. 1. However, there have been no changes to the Company’s financial statements and notes thereto or the text of such item (other than the change stated in the immediately preceding paragraph to replace “March 13, 2024” with “March 13, 2025” under the signature in the Audit Opinion).

 

Except as described above, no other amendments are being made to the 2024 Annual Report. This Amendment No. 1 does not reflect events occurring after Original Filing Date or modify or update any disclosure contained in the 2024 Annual Report in any way other than to reflect the amendments discussed above and reflected below. Accordingly, this Amendment No. 1 should be read in conjunction with the 2024 Annual Report and our other filings with the SEC.

 

 

 

 

Table of Contents

 

Forward-Looking Statements 3
Summary of Risk Factors 4
PART I 8
Item 1. Business 8
Item 1A. Risk Factors 17
Item 1B. Unresolved Staff Comments 38
Item 1C. Cybersecurity 38
Item 2. Properties 39
Item 3. Legal Proceedings 40
Item 4. Mine Safety Disclosures 40
PART II 40
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 40
Item 6. [Reserved] 41
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 41
Item 7A. Quantitative and Qualitative Disclosures about Market Risk 55
Item 8. Financial Statements and Supplementary Data 55
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 55
Item 9A. Controls and Procedures 56
Item 9B. Other Information 57
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 57
PART III 57
Item 10. Directors, Executive Officers and Corporate Governance 57
Item 11. Executive Compensation 57
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 57
Item 13. Certain Relationships and Related Transactions, and Director Independence 57
Item 14. Principal Accountant Fees and Services 57
PART IV 58
Item 15. Exhibits and Financial Statement Schedules 58
Signatures 64

 

2
 

 

Forward-Looking Statements

 

Certain statements that we make from time to time, including statements contained in this Annual Report on Form 10-K, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact contained in this Annual Report on Form 10-K are forward-looking statements. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “shall,” “should,” “could,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “seeks,” “estimates,” “forecasts,” “predicts,” “possible,” “potential,” “target,” or “continue” or the negative of these terms or other comparable terminology. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this Annual Report on Form 10-K include, without limitation, statements reflecting management’s expectations for future financial performance and operating expenditures (including our ability to continue as a going concern, to raise additional capital and to succeed in our future operations), expected growth, profitability and business outlook, increased sales and marketing expenses, and the expected results from the integration of our acquisitions.

 

Forward-looking statements are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties, and other factors that may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. These factors include, among other things, the unknown risks and uncertainties that we believe could cause actual results to differ from these forward-looking statements as set forth under the heading, “Risk Factors” and elsewhere in this Annual Report on Form 10-K. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to:

 

●our ability to manage our growth, including acquiring, partnering with, and effectively integrating acquired businesses into our infrastructure and avoiding legal exposure and liabilities associated with acquired companies and assets;
   
●our ability to retain our clients and revenue levels, including effectively migrating new clients and maintaining or growing the revenue levels of our new and existing clients;
   
●our ability to maintain operations in Pakistan, Azad Jammu and Kashmir, and Sri Lanka (together, the “Offshore Offices”) in a manner that continues to enable us to offer competitively priced products and services;
   
●our ability to keep pace with a rapidly changing healthcare industry;
   
●our ability to consistently achieve and maintain compliance with a myriad of federal, state, foreign, local, payor and industry requirements, regulations, rules, laws and contracts;
   
●our ability to maintain and protect the privacy of confidential and protected Company, client and patient information;
   
●our ability to develop new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards and third-party software platforms and technologies, and protect and enforce all of these and other intellectual property rights;
   
●our ability to attract and retain key officers and employees, and the continued involvement of Mahmud Haq as Executive Chairman and A. Hadi Chaudhry and Stephen Snyder as Co-Chief Executive Officers, all of which are critical to our ongoing operations and growing our business;

 

3
 

 

●our ability to realize the expected cost savings and benefits from our restructuring activities and structural cost reductions;
   
●our ability to comply with covenants contained in our credit agreement with our senior secured lender, Silicon Valley Bank, a division of First Citizens Bank, and other future debt facilities;
   
●our ability to continue to pay our monthly dividends which were suspended in December 2023 and resumed in February 2025 to the holders of our Series A and Series B preferred stock;
   
●our ability to incorporate AI into our products faster and more successfully than our competitors, protecting the privacy of medical records and cybersecurity threats;
   
●our ability to compete with other companies developing products and selling services competitive with ours, and who may have greater resources and name recognition than we have;
   
●our ability to effectively integrate, manage and keep our information systems secure and operational in the event of a cyber-attack;
   
●our ability to respond to the uncertainty resulting from pandemics, epidemics or other public health emergencies and the impact they may have on our operations, the demand for our services, our projected results of operations, financial performance or other financial metrics or any of the foregoing risks and economic activity in general;
   
●our ability to keep and increase market acceptance of our products and services;
   
●changes in domestic and foreign business, market, financial, political and legal conditions; and
   
●other factors disclosed in this Annual Report on Form 10-K or our other filings with the Securities and Exchange Commission (the “SEC”).

 

Although we believe that the expectations reflected in the forward-looking statements contained in this Annual Report on Form 10-K are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. You should read this Annual Report on Form 10-K with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we currently expect. Except as required by law, we are under no duty to update or revise any of such forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this Annual Report on Form 10-K.

 

Summary of Risk Factors

 

The following is a summary of the principal risks and uncertainties that could materially adversely affect our business, financial condition and results of operations. You should read this summary together with the more detailed description of each risk factor contained in “Risk Factors” in Part 1, Item 1A below.

 

Risks Related to our Business

 

  ●We operate in a highly competitive industry, and our competitors may be able to compete more efficiently or evolve more rapidly than we do, which could have a material adverse effect on our business, revenue, growth rates and market share.
    
  ●If we are unable to successfully introduce new products or services or fail to keep pace with advances in technology, we would not be able to maintain our customers or grow our business, which will have a material adverse effect on our business.
    
  ●The continued success of our business model is heavily dependent upon our offshore operations, and any disruption to those operations will adversely affect us.
    
  ●Our offshore operations expose us to additional business and financial risks which could adversely affect us and subject us to civil and criminal liability.
    
  ●We may be adversely affected by global climate change or market responses to such change.
    
  ●Changes in the healthcare industry could affect the demand for our services and may result in a decrease in our revenues and market share.

 

  ●If providers do not purchase our products and services or delay in choosing our products or services, we may not be able to grow our business.
    
  ●If the revenues of our customers decrease, or if our customers cancel or elect not to renew their contracts, our revenue will decrease.
    
  ●As a result of our variable sales and implementation cycles, we may be unable to recognize revenue from prospective customers on a timely basis and we may not be able to offset expenditures.
    
  ●We are required to collect sales and use taxes on certain products and services we sell in certain jurisdictions. We may be subject to liability for past sales and incur additional related costs and expenses, and our future sales may decrease.
    
  ●If we lose the services of Mahmud Haq as Executive Chairman, A. Hadi Chaudhry and Stephen Snyder as Co-Chief Executive Officers, or other members of our management team, or if we are unable to attract, hire, integrate and retain other necessary employees, our business would be harmed.
    
  ●We may be unable to adequately establish, protect or enforce our patents, trade secrets and other intellectual property rights and we may incur significant costs in enforcing our intellectual property rights.

 

4
 

 

  ●Claims by others that we infringe or may infringe on their intellectual property could force us to incur significant costs or revise the way we conduct our business.
    
  ●Current and future litigation against us could be costly and time-consuming to defend and could result in additional liabilities.
    
  ●Our proprietary software or service delivery platform may not operate properly, which could damage our reputation, give rise to claims against us, or divert application of our resources from other purposes, any of which could harm our business and operating results.
    
  ●If our security measures are breached or fail and unauthorized access is obtained to a customer’s data, our service may be perceived as insecure, the attractiveness of our services to current or potential customers may be reduced, and we may incur significant liabilities.
    
  ●Our products and services are required to meet the interoperability standards, which could require us to incur substantial additional development costs or result in a decrease in revenue.
    
  ●Disruptions in internet or telecommunication service or damage to our data centers could adversely affect our business by reducing our customers’ confidence in the reliability of our services and products.
    
  ●We may be subject to liability for the content we provide to our customers and their patients.
    
  ●We are subject to the effects of payer and provider conduct that we cannot control and that could damage our reputation with customers and result in liability claims that increase our expenses.
    
  ●Failure by our clients to obtain proper permissions and waivers may result in claims against us or may limit or prevent our use of data, which could harm our business.
    
  ●Any deficiencies in our financial reporting or internal controls could adversely affect our business and the trading price of our securities.
    
  ●We may not be able to negotiate a credit facility at reasonable terms as the current credit facility expires in October 2025.
    
  ●We maintain our cash at financial institutions often in balances that exceed federally insured limits.
    
  ●Our goodwill was subject to impairment in 2023 and may be subject to further impairment in the future, which could have a material adverse effect on our results of operations, financial condition, or future operating results.
    
  ●We are a party to several related-party agreements with our founder and Executive Chairman, Mahmud Haq, which have significant contractual obligations. These agreements are reviewed by our Audit Committee on an annual basis.
    
  ●We depend on key information systems and third-party service providers.
    
  ●Systems failures, cyberattacks or other events and resulting interruptions in the availability of or degradation in the performance of our websites, applications, products or services could harm our business.
    
  ●Data privacy, identity protection and information security compliance may require significant resources and present certain risks.
    
  ●We use artificial intelligence in our business, and challenges with properly managing its use could result in reputational and competitive harm, legal liability, and adversely affect our results of operations.
    
  ●Rapid technological change in the telehealth industry presents us with significant risks and challenges.
    
  ●Our business, financial condition, results of operations and growth may be adversely affected by pandemics, epidemics or other public health emergencies, such as COVID-19.

 

5
 

 

Risks Related to Macroeconomics Conditions

 

  ●Our operations and performance depend significantly on global and regional economic conditions and adverse economic conditions can materially adversely affect our business, results of operations and financial condition.
    
  ●Our managed medical practices and customers could face supply chain issues that would disrupt their ability to service patients and therefore, impact our revenue.
    
  ●Volatility in currency exchange rates may adversely affect our financial condition, results of operations and cash flows.

 

Risks Related to Our Acquisition Strategy

 

  ●At the current prices of our common and Preferred Stock, we may be unable to execute accretive acquisitions.
    
  ●We may be unable to retain customers following their acquisition, which may result in a decrease in our revenues and operating results.
    
  ●Acquisitions may subject us to liability with regard to the creditors, customers, and shareholders of the sellers.
    
  ●Future acquisitions may result in potentially dilutive issuances of equity securities, the incurrence of indebtedness and increased amortization expense.

 

Regulatory Risks

 

  ●The healthcare industry is heavily regulated. Our failure to comply with regulatory requirements could create liability for us, result in adverse publicity and negatively affect our business.
    
  ●If we do not maintain the certification of our EHR solutions pursuant to the HITECH Act and Cures Act, our business, financial condition and results of operations will be adversely affected.
    
  ●If a breach of our measures protecting personal data covered by HIPAA or the HITECH Act occurs, we may incur significant liabilities.
    
  ●If we or our customers fail to comply with federal and state laws governing submission of false or fraudulent claims to government healthcare programs and financial relationships among healthcare providers, we or our customers may be subject to civil and criminal penalties or loss of eligibility to participate in government healthcare programs.
    
  ●Potential healthcare reform and new regulatory requirements placed on our products and services could increase our costs, delay or prevent our introduction of new products or services, and impair the function or value of our existing products and services.
    
  ●Additional regulation of the disclosure of medical information outside the United States may adversely affect our operations and may increase our costs.
    
  ●Our services present the potential for embezzlement, identity theft, or other similar illegal behavior by our employees.

 

Risks Related to Ownership of Shares of Our Common Stock

 

  ●The conversion of the Series A Preferred Stock into common stock in March 2025 (the “Conversion”) increased the total number of outstanding shares, potentially diluting the value of existing common shareholders’ equity.
    
  ●Series A Preferred Stock shareholders gained full voting rights upon conversion of their preferred shares into common stock.
    
  ●The conversion of the Series A Preferred Stock could be perceived negatively by the market.
    
  ●The Company’s potential for future issuances of common stock following the conversion could be limited.
    
  ●Our revenues, operating results and cash flows may fluctuate in future periods and we may fail to meet investor expectations, which may cause the price of our common stock to decline.
    
  ●Healthcare reform may have a material adverse effect on the Company’s financial condition and results of operations.
    
  ●Future sales of shares of our common stock could depress the market price of our common stock.
    
  ●As of December 31, 2024, Mahmud Haq controlled 31% of our outstanding shares of common stock, which prevented investors from influencing significant corporate decisions.
    
  ●Provisions of Delaware law, of our amended and restated charter and amended and restated bylaws may make a takeover more difficult, which could cause our common stock price to decline.

 

6
 

 

  ●Any issuance of additional preferred stock in the future may dilute the rights of our existing stockholders.
    
  ●We do not intend to pay cash dividends on our common stock.
    
  ●Complying with the laws and regulations affecting public companies will increase our costs and the demands on management and could harm our operating results.
    
  ●We are a smaller reporting company and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.

 

Risks Related to Ownership of Shares of Our Preferred Stock

 

  ●As a result of the Conversion, there may not be an organized trading market for the Series A Preferred Stock.
    
  ●In December 2023 we suspended the payment of the dividends on the Preferred Stock. The Company resumed paying monthly dividends in February 2025, paying one month of the arrearage. We may not be able to continue to pay dividends on the Preferred Stock if we fall out of compliance with our loan covenants and are prohibited by our bank lender from paying dividends or if we have insufficient cash to make dividend payments.
    
  ●Our Series A and Series B Preferred Stock rank junior to all of our indebtedness and other liabilities.
    
  ●We may issue additional shares of Preferred Stock and additional series of preferred stock that rank on parity with the Preferred Stock as to dividend rights, rights upon liquidation or voting rights.
    
  ●Market interest rates may materially and adversely affect the value of the Preferred Stock.
    
  ●Holders of the Preferred Stock may be unable to use the dividends-received deduction and may not be eligible for the preferential tax rates applicable to “qualified dividend income”.
    
  ●Our Preferred Stock has not been rated.
    
  ●The market price of our Series B Preferred Stock is variable and is substantially affected by various factors.
    
  ●A holder of Preferred Stock has extremely limited voting rights.
    
  ●The Preferred Stock is not convertible at the option of the holder and investors will not realize a corresponding upside if the price of the common stock increases.
    
  ●Although payment of the suspended dividends resumed in February 2025, there are still dividends in arrears and we may be unable to raise additional capital without incurring excessive dilution.

 

7
 

 

PART I

 

Item 1. Business

 

Overview

 

CareCloud, Inc., (together with its consolidated subsidiaries, “CareCloud”, the “Company,” “we,” “us” and/or “our”) is a leading provider of technology-enabled services and generative AI solutions that redefine the healthcare revenue cycle management process. We provide technology-enabled revenue cycle management and a full suite of proprietary cloud-based solutions to healthcare providers, from small practices to enterprise medical groups, hospitals, and health systems throughout the United States. Healthcare organizations today operate in highly complex and regulated environments. Our suite of technology-enabled solutions helps our clients increase financial and operational performance, streamline clinical workflows, and improve the patient experience.

 

Our portfolio of proprietary software and business services includes: technology-enabled business solutions that maximize revenue cycle management and create efficiencies through platform agnostic AI-driven applications; cloud-based software that helps providers manage their practice and patient engagement while leveraging analytics to improve provider performance; digital health services to address value-based care and enable the delivery of remote patient care; healthcare IT professional services & staffing to address physician burnout, staffing shortages and leverage consulting expertise to transition into the next generation of healthcare; and, medical practice management services to assist medical providers with operating models and the tools needed to run their practice.

 

Our high-value business services, such as revenue cycle management, are often paired with our cloud-based software, premiere healthcare consulting and implementation services, and on-demand workforce staffing capabilities for high-performance medical groups and health systems nationwide.

 

Our technology-enabled business solutions can be categorized as follows:

 

●Technology-enabled revenue cycle management:

○Revenue Cycle Management (“RCM”) services including end-to-end medical billing, eligibility, analytics, and related services, all of which can be provided utilizing our technology platform and robotic process automation tools or leveraging a third-party system;
○Medical coding and credentialing services to improve provider collections, back-end cost containment, and drive total revenue realization for our healthcare clients; and
○Healthcare claims clearinghouse which enables our clients to electronically scrub and submit claims and process payments from insurance companies.

 

●Cloud-based software:

○Electronic Health Records, which are easy to use and sometimes integrated with our business services, and enable our healthcare provider clients to deliver better patient care, streamline their clinical workflows, decrease documentation errors, and potentially qualify for government incentives;
○Practice Management (“PM”) software and related capabilities, which support our clients’ day-to-day business operations and financial workflows, including automated insurance eligibility software, a robust billing and claims rules engine, and other automated tools designed to maximize reimbursement;
○Artificial intelligence (“AI”):
●CareCloud cirrusAI is designed to serve as a digital healthcare assistant, helping to enhance clinical decision-making, streamline workflows, reduce administrative burdens, optimize revenue management, and promote patient-centered care. The functions include:
●AI-Powered Clinical Decision Support: CareCloud cirrusAI Guide automates clinical data input, and assists clinicians in workflow tasks, providing real-time, evidence-based recommendations and personalized suggestions via Vertex AI’s generative AI tools for providers to consider. This innovation can lead to enhanced diagnosis accuracy and treatment planning.

 

8
 

 

●AI-Powered Virtual Support Assistant: CareCloud cirrusAI Chat facilitates natural language conversations with practice staff members, offering valuable assistance in navigating CareCloud Electronic Health Records (“EHR”) workflows. This tool streamlines post-training and onboarding for new staff, reducing response times and providing real-time assistance, ultimately saving time.
●AI-Driven Appeals: CareCloud cirrusAI Appeals generates customized appeal letters by analyzing patient claim details, the appeal’s reason, and the specific payer involved for healthcare workers to review, edit, and send. This functionality supports CareCloud’s RCM teams in optimizing providers’ RCM and securing proper reimbursement.
●CareCloud cirrusAI integrates with CareCloud’s EHR solution, talkEHR, making it easily accessible to providers of all sizes.
○Patient Experience Management (“PXM”) solutions designed to transform interactions between patients and their clinicians, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services, contactless digital check-in solutions, messaging, and online appointment scheduling tools;
○Business Intelligence (“BI”) and healthcare analytics platforms that allow our clients to derive actionable insights from their vast amount of data; and
○Customized applications, interfaces, and a variety of other technology solutions that support our healthcare clients.

 

●Digital health:

○Chronic care management is a program that supports care for patients with chronic conditions by certified care managers that operate under the supervision of the patient’s regular physician;
○Remote patient monitoring enables patient data collected outside the clinical setting through remote devices to be fed into their provider’s EHR to enable proactive patient care; and
○Telemedicine solutions which allow healthcare providers to conduct remote patient visits and extend the timely delivery of care to patients unable to travel to a provider’s office.

 

●Healthcare IT professional services & staffing:

○Professional services consisting of a broad range of consulting services including full software implementations and activation, revenue cycle optimization, data analytic services, and educational training services;
○Strategic advisory services to manage system evaluations and selection, provide interim management, and operational assessments; and
○Workforce augmentation and on-demand staffing to support our clients as they expand their businesses, seek highly trained personnel, or struggle to address staffing shortages.

 

Our medical practice management solutions include:

 

●Medical practice management:

○Medical practice management services are provided to medical practices. In this service model, we provide the medical practice with appropriate facilities, equipment, supplies, support services, nurses and administrative support staff. We also provide management, bill-paying and financial advisory services.

 

9
 

 

 

The modernization of the healthcare industry, along with the increased adoption of value-based care models, is transforming nearly every aspect of a healthcare organization from policy to providers; clinical care to member services, devices to data, and ultimately the quality of the patient’s experience as a healthcare consumer.

 

Our solutions enable clients to increase financial and operational performance, streamline clinical workflows, get better insight through data, and make better business and clinical decisions, resulting in improvement in patient care and collections while reducing administrative burdens and operating costs.

 

We create elegant, user-friendly applications that solve many of the challenges facing healthcare organizations. We partner with organizations to develop customized, best-in-class solutions to solve their specific challenges while ensuring they also meet future regulatory and organizational requirements and market demands.

 

Market Overview

 

In June 2024, Centers for Medicare & Medicaid Services (“CMS”)1 reported that over 2023-2032, the average National Health Expenditures (“NHE”) growth (5.6%) is projected to outpace that of average Gross Domestic Product (“GDP”) growth (4.3%) resulting in an increase in the health spending share of GDP from 17.3% in 2022 to 19.7% in 2032.

 

Additionally, analysts from the Imarc have estimated the U.S. Healthcare IT industry market to be approximately $104 billion in 2024 and is projected to reach $325.2 billion by 2033, growing at a 13.1% compound annual growth rate (“CAGR”).2 Its largest sub-segment, RCM, is reported to be nearly $155.6 billion in 2023 and is projected to grow at a 10.18% CAGR through 2030 according to Grand View Research.3 The U.S. EHR market was estimated to be valued at $11.4 billion in 2023 and expected to grow at a CAGR of 2.24% from 2024 to 2030.4 The Telehealth market is estimated to be approximately $42.54 billion in 2024 with a CAGR of 23.8% from 2025 to 2030.5

 

Our Market Opportunity

 

Considering the evolving needs of our clients and the market, we believe we continue to be uniquely positioned to provide tremendous value and support for our clients. We believe there are dynamics at play that are significantly increasing the market need for our products and services. These market dynamics present opportunities for us to innovate and focus on impacting the day-to-day challenges our clients face as they work to provide excellent patient care, all while managing and expanding their businesses.

 

Medical practices and health systems alike are transitioning to increasingly complex reimbursement delivery models. As an example, the industry has been gradually shifting from fee-for-service payments to value-based/clinical outcomes-based care payments. This transition comes in a multitude of forms including reimbursement models associated with quality incentive programs, capitation payments models, bundled payments, and at-risk payer contracts.

 

 

1 National Health Expenditure Projections 2023-2032

2 U.S. Healthcare IT Market Size, Share, Growth 2025-2033

3 U.S. Revenue Cycle Management Market Size Report, 2030

4 U.S. Electronic Health Records Market | Industry Report 2030

5 U.S. Telehealth Market Size & Share | Industry Report, 2030

 

10
 

 

There are continuing legislative and regulatory reform efforts, as well as growing compliance requirements mandated by the federal government and other governmental agencies. This ever-evolving regulatory landscape increases the pressure placed on healthcare organizations to stay abreast of these changes and to remain in compliance. The complexities associated with emerging reimbursement models and continued government regulations present opportunities for us as healthcare organizations seek out partners that offer a broad range of software and services to help meet their needs.

 

Our clients also have to account for the rising cost of health insurance, changes in health benefit plan design, and the impact that these factors have had on the increase in patient consumerism. Patients are seeking lower cost care in response to insurance carriers shifting more of the cost burden onto patients, causing healthcare organizations to reconsider the full patient experience. Healthcare providers now need to think more deeply about patient expectations. This is especially true as COVID-19 has reshaped the sector and accelerated its digital transformation.

 

Further compounding the burden of rising health insurance cost is the ongoing shift in patient demographics. As the national population ages into Medicare eligibility, the reimbursement received for procedures and services provided to these patients decreases. Medicaid is now the largest insurance product in the country and continues to grow. Reimbursements overall are not increasing at the same rate as costs, driving providers and practices to search for increased efficiencies and savings wherever possible.

 

Strategic-thinking healthcare organizations across the country are aggressively addressing these new realities and are finding opportunities for growth and expansion. We see medical groups across the country and within all specialties and market segments, growing through consolidation and investing in their businesses at an accelerated pace. This is also leading clients to focus on delivering emerging and disruptive care delivery settings. Much of this change is driving executives and leaders to assess their IT and data strategy and reevaluate their adoption of next generation healthcare solutions. The healthcare industry has seen tremendous change over the last few years, with COVID-19 ushering in a new era of digital health. Our study of the evolving needs of our clients leads us to believe that there will be an increasing need for our services and products and emerging needs for the products and services that we are already developing.

 

These trends will fuel growth over the next several years. In order for healthcare organizations to continue to succeed, these new realities require robust solutions and careful execution. Legacy tools that once powered these healthcare organizations are insufficient to support their growth and long-term strategies. Our solutions facilitate the transition needed by these organizations to adopt the next generation of healthcare solutions to drive their future growth. Our expansive product and services portfolio enables us to displace competitors and gain market share across a vast array of specialties, care settings and customer segments across the country.

 

Our Business Strategy

 

The Company is focused on reducing costs, maintaining profitability and generating positive free cash flow in order to continue paying the Preferred Stock dividends, including those that are in arrears. CareCloud is a market leading provider of technology-enabled and integrated end-to-end Software-as-a-Service (“SaaS”) solutions that help our clients with the business of medicine. Our mission is to redefine the next generation of technology-enabled revenue cycle solutions. To that end, we invest significant resources toward improving our current offerings and building new solutions that help transform our clients’ organizations with next generation technology. We expect to have increased software capabilities and offer additional complementary business services that will address the needs of the ever-changing, dynamic market conditions of the U.S. healthcare space.

 

To achieve our objective and mission, we employ the following strategies:

 

Providing comprehensive next generation RCM solutions to medical practices and hospitals. We believe that healthcare providers are in need of an integrated, end-to-end solution and a flexible service delivery model to manage the different facets of their businesses, from care delivery software, to claim submission, financial reporting, and data analytics.

 

Enhancing our solutions. We intend to continue to enhance our solutions with new functionality and features leveraging our own teams, partnerships, and acquisitions. We will continue to dedicate resources to research and development to bolster our existing applications and drive new opportunities for innovation on behalf of our clients.

 

11
 

 

Expanding into new categories/specialties/markets. We are focused on always reassessing the market landscape, seeking new opportunities to meet the needs of the clients in our addressable market with our products and services. This means developing new and exciting technologies, launching new services, entering new specialties that can leverage our solutions and enabling growth for our clients or expanding into adjacent markets that we may not serve today.

 

Relentlessly driving organic growth to expand our client base. We believe the market for our expansive value proposition is underserved, and we will continue to make investments to create awareness of our brand, optimize our sales and implementation lifecycles, and capture greater market share. We are investing in our sales and marketing activities, partners, and products to expand our client footprint.

 

Extending our relationships with existing clients. Our CareCloud Wellness offerings have been well-received allowing us to generate additional recurring revenue from existing clients. We intend to increase the number of SaaS subscription licenses and services purchased by our current clients as they use our solutions. We are also focused on converting SaaS clients into higher revenue per client offerings such as revenue cycle management and other business services. This expansion of services typically represents a 3-4x increase in overall revenue per client.

 

Leveraging significant cost advantages provided by our technology and global workforce. Our unique business model includes our cloud-based software and a cost-effective offshore workforce located in our Offshore Offices. We believe this operating model provides us with significant cost advantages compared to other revenue cycle management companies and it allows us to significantly reduce the operational costs of the companies we acquire.

 

Developing our partner ecosystem. We offer an integrated partner ecosystem providing healthcare organizations access to a variety of innovative solutions that complement our suite of products and services. Our partner ecosystem is a comprehensive collection of apps, services, specialty solutions, and clinical connections. This is an integral part of our vision to be the premier cloud-based platform for healthcare.

 

As the market continues to evolve, we may choose to build or partner for some or all of these solutions in order to broaden our product set. In the longer term, we also envision how this will allow for frictionless flow of information and care-coordination capabilities between medical providers and their patients.

 

Additionally, given the nature of our large data repository, which is ever-growing as each patient encounter is captured, opportunities exist to potentially monetize this data in an identified manner to help improve clinical outcomes and other financial metrics.

 

Our Offerings

 

Our solutions are designed to systematically drive clinical quality and patient outcomes, streamline staff and provider workflows and reimbursements, as well as support different settings of care and healthcare models. Our product and service strategy is simple: we build products and deliver solutions that meet our clients’ needs.

 

Through the combination of our continued development of next generation solutions and strategic acquisition strategy, we provide comprehensive products and services tailored for small medical practices, large physician groups and health systems, as well as industry partners. We continue to optimize our technology offerings by integrating them into our application ecosystem and with other industry solutions. The interconnectivity of our solutions will continue driving a consolidation of brands within our product architecture, aimed at improving the awareness and alignment of our products to targeted industry segments.

 

12
 

 

 

Our robust product and service portfolio allows us to be both methodical and nimble across the healthcare organizations and market segments we serve while providing a framework to create solution sets for the market today and more importantly, for what our clients will need tomorrow.

 

We believe that our fully integrated solutions uniquely address the challenges in the industry. In most cases the standard fee for our complete, integrated, end-to-end solution is based upon a percentage of each client’s healthcare-related revenues, with a monthly minimum fee, plus a nominal one-time setup fee, which is competitively priced.

 

Research and Development

 

Our research and development focuses are on enhancing and expanding our service offerings while ensuring all offerings meet regulatory compliance standards. We continually update our software and technology infrastructures, regularly execute releases of new software enhancements, and adapt our offerings to better serve our medical group and health system clients confronting rapid changes in the healthcare market space.

 

Our agile software development methodology is designed to ensure that each software release is properly designed, built, tested, and released. Our product, engineering, quality assurance, and development operations teams are located both onshore and offshore. We complement our internal efforts with services from third-party technology providers for infrastructure, healthcare ecosystem connectivity needs such as prescriptions, clinical laboratories, or specific application requirements.

 

We also employ product management, user experience, and product marketing personnel who work continually on improvements to our products and services design.

 

13
 

 

Clients

 

 

We estimate that as of December 31, 2024, we provided software and services to approximately 40,000 providers (which we define as physicians, nurses, nurse practitioners, therapists, physician assistants and other clinicians that render bills for their services) practicing in approximately 2,600 independent medical practices and hospitals, representing 80 specialties and subspecialties in 50 states allowing for low revenue concentration risk.

 

In addition, we served approximately 150 clients that are not medical practices, but are primarily service organizations who serve the healthcare community. The foregoing numbers include clients leveraging any of our products or services and are based in part upon estimates where the precise number of practices or providers is unknown.

 

We service clients ranging from small practices to large groups and health systems. Our clients span from the single doctor independent medical practices to large medical groups, including an enterprise specialty-specific healthcare organization with more than 3,000 providers located across multiple states. We also service large major academic medical institutions, small and large hospitals and health systems with service areas covering millions of patients.

 

Sales and Marketing

 

Over the past several years, organic growth has been a Company-wide focus. We have developed sales and marketing capabilities aimed at driving the growth of our client base, including small medical practices, large groups, and health systems. We expect to expand by selling our complete suite of software and services to new clients and up-selling additional solutions into our existing client base. We have a direct sales force including team members focused on specific functional or divisional areas, such as CareCloud Force (workforce augmentation) and medSR (healthcare IT consulting). This direct sales force is supplemented by offshore staff who support our sales and marketing efforts. In addition, our direct sales are augmented through our partner initiatives and marketing campaigns. We continue to leverage and optimize various digital channels to present our solutions, identify national events to demonstrate our integrated capabilities and expand our participation in thought leadership and social communications to connect with the healthcare community.

 

14
 

 

Our Growth Levers

 

We believe that we are in a good position to grow through organic growth and partnerships.

 

 

Organic Growth and Direct Sales

 

We have organized our sales force into different segments to promote the respective products and services for that segment and best address our clients’ needs and our markets. With this design, our sales team can address a client’s specific needs, whether a new client is seeking our products or services for the first time, or a current client is in need of additional solutions.

 

Our marketing team operates in support of our sales force and provides specialized demand generation capabilities for sales efforts, product marketing to align solutions and segments, customer communication and upselling initiatives, and drives a national tradeshow strategy to showcase our brand. Our sales approach is consultative in nature for most of our offerings, which generally includes an analysis based on a prospective client’s needs, crafting service proposals, and negotiating contracts that culminate in the commencement of services.

 

Our go-to-market strategy is designed to meet our customers’ needs. Our vast array of products and services allow us to craft solutions that can meet our customers’ unique needs within a specific product category, client segment, or both.

 

Growth through Partnerships

 

In addition to our direct sales force, we maintain business relationships with third parties that utilize, promote, or support our sales or services within specific industries or geographic regions. Some of these partners are customers through CareCloud Force and others are more traditional channel partners who help promote our solutions. We believe we can further accelerate organic growth through industry participants, whereby we utilize them as channel partners to offer integrated solutions to their clients. We have entered into such engagements with industry participants, and developed application interfaces with numerous EHR systems, together with device and lab integration to support these relationships.

 

Competition

 

The market for RCM, practice management, EHR solutions, and related services is highly competitive, and we expect competition to increase in the future. We face competition from other providers of both integrated and stand-alone RCM providers, practice management, and EHR solutions, including competitors who utilize a web-based platform and providers of locally installed software systems.

 

Many of our competitors have longer operating histories, greater brand recognition and greater financial marketing. We also compete with various regional RCM companies, some of which may continue to consolidate and expand into broader markets. We expect that competition will continue to increase as a result of incentives provided by various governmental initiatives, and consolidation in both the information technology and healthcare industries. Large groups and health systems that have grown through consolidation often realize economies of scale by establishing billing and management offices to perform many of the services we offer themselves. In addition, our competitive edge could be diminished or completely lost if our competition develops similar offshore operations in Pakistan or other countries, such as India and the Philippines, where labor costs are lower than those in the U.S. (although higher than in Pakistan). Pricing pressures could negatively impact our margins, growth rate and market share.

 

15
 

 

We believe we have a competitive advantage, as we are able to deliver our industry-leading solutions at competitive prices because we leverage a combination of our proprietary software, which automates our workflows and increases efficiency, together with a global team that includes more than 250 experienced health industry experts onshore. These experts are supported by our highly educated and specialized offshore workforce of approximately 3,300 team members at labor costs that we believe are approximately 15% the cost of comparable U.S. employees.

 

Our unique business model has allowed us to become a leading consolidator in our industry sector, gaining us a reputation for acquiring and positively transforming distressed competitors into an accretive acquisition.

 

Employees

 

Including the employees of our subsidiaries, as of December 2024, the Company employed approximately 3,650 people worldwide on a full-time basis. Approximately 75% of our employees are focused on service and client delivery functions, approximately 9% are assigned to research and development, and approximately 1% are engaged in sales and marketing. The balance of the employees is classified as general and administrative, which includes support staff to maintain our offshore offices, a function that many businesses in other geographies might choose to outsource. We also utilize the services of a small number of part-time employees. In addition, all officers of the Company work on a full-time basis. During 2025, we anticipate further reducing our employee count.

 

Voting Rights of Our Directors, Executive Officers, and Principal Stockholders

 

As of December 31, 2024, approximately 38% of both the shares of our common stock and voting power of our common stock are held by our directors and executive officers. Therefore, they have the ability to control the outcome of matters submitted to our stockholders for approval, including the election of our directors, as well as the overall management and direction of our Company.

 

Corporate Information

 

We were incorporated in Delaware on September 28, 2001, under the name Medical Transcription Billing, Corp., and legally changed our name to MTBC, Inc. in February 2019. On March 29, 2021, we legally changed the name of the Company to CareCloud, Inc. Our principal executive offices are located at 7 Clyde Road, Somerset, New Jersey 08873, and our telephone number is (732) 873-5133. Our website address is www.CareCloud.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report on Form 10-K, and you should not consider information on our website to be part of this document.

 

CareCloud.com, CareCloud, MTBC, A Unique Healthcare IT Company, and other trademarks and service marks of CareCloud appearing in this Annual Report on Form 10-K are the property of the Company. Trade names, trademarks and service marks of other companies appearing in this Annual Report on Form 10-K are the property of their respective holders.

 

We are a smaller reporting company. As a smaller reporting company, we may take advantage of specified reduced reporting requirements and are relieved of certain other significant requirements that are otherwise generally applicable to public companies. As a smaller reporting company, we have reduced disclosure obligations regarding executive compensation in our Annual Report, periodic reports and proxy statements and provide only two years of audited financial statements in our Annual Report and our periodic reports. For 2024, the Company was not required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended. The Company is a non-accelerated filer.

 

Where You Can Find More Information

 

Our website, which we use to communicate important business information, can be accessed at: www.CareCloud.com. We make our Annual Reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports available free of charge on or through our website as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (“SEC”). Materials we file with or furnish to the SEC may also be read and copied at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. Also, the SEC’s website (www.sec.gov) contains reports, proxy and information statements, and other information that we file electronically with the SEC.

 

16
 

 

Item 1A. Risk Factors

 

Risks Related to Our Business

 

We operate in a highly competitive industry, and our competitors may be able to compete more efficiently or evolve more rapidly than we do, which could have a material adverse effect on our business, revenue, growth rates and market share.

 

The market for revenue cycle management and healthcare IT solutions is highly competitive, and we expect competition to increase in the future. We face competition from other providers of both integrated and stand-alone practice management, EHR and RCM solutions, including competitors who utilize a web-based platform and providers of locally installed software systems. Our competitors include larger healthcare IT companies, such as athenahealth, Inc., eClinicalWorks, Greenway Medical Technologies, Inc., NextGen, R1 RCM and Veradigm, all of which may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards, regulations or customer needs and requirements. Many of our competitors have longer operating histories, greater brand recognition and greater financial marketing and other resources than us. We also compete with various regional RCM companies, some of which may continue to consolidate and expand into broader markets. We expect that competition will continue to increase as a result of incentives provided by the Health Information Technology for Economic and Clinical Health (“HITECH”) Act, and consolidation in both the information technology and healthcare industries. Competitors may introduce products or services that render our products or services obsolete or less marketable. Even if our products and services are more effective than the offerings of our competitors, current or potential customers might prefer competitive products or services to our products and services. In addition, our competitive edge could be diminished or completely lost if our competition develops similar offshore operations in Pakistan or other countries, such as India and the Philippines, where labor costs are lower than those in the U.S. (although higher than in Pakistan). Pricing pressures could negatively impact our margins, growth rate and market share.

 

In order to operate more efficiently, control costs and improve profitability, we incurred $606,000 and $645,000 of restructuring costs in 2024 and 2023, respectively, primarily consisting of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements. We expect to incur approximately an additional $100,000 of restructuring costs in 2025. There can be no assurance that these actions will achieve their intended benefits.

 

If we are unable to successfully introduce new products or services or fail to keep pace with advances in technology, we would not be able to maintain our customers or grow our business, which will have a material adverse effect on our business.

 

Our business depends on our ability to adapt to evolving technologies and industry standards and upgrade existing products and introduce new products and services accordingly. If we cannot adapt to changing technologies and industry standards, including changing requirements of third-party applications and software and meet the requirements of our customers, our products and services may become obsolete, and our business would suffer significantly. Because both the healthcare industry and the healthcare IT technology market are constantly evolving, our success will depend, in part, on our ability to continue to enhance our existing products and services, develop new technology that addresses the increasingly sophisticated and varied needs of our customers, respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis, educate our customers to adopt these new technologies, and successfully assist them in transitioning to our new products and services. The development of our proprietary technology entails significant technical and business risks. We may not be successful in developing, using, marketing, selling, or maintaining new technologies effectively or adapting our proprietary technology to evolving customer requirements, emerging industry standards or changing third party applications, and, as a result, our business and reputation could materially suffer. We may not be able to introduce new products or services on schedule, or at all, or such products or services may not achieve market acceptance or existing products or services may cease to function properly. A failure by us to timely adapt to ever changing technologies or our failure to regularly upgrade existing or introduce new products or to introduce these products on schedule could cause us to not only lose our current customers but also fail to attract new customers.

 

17
 

 

The continued success of our business model is heavily dependent upon our offshore operations, and any disruption to those operations will adversely affect us.

 

The majority of our operations, including the development and maintenance of our web-based platform, our customer support services and medical billing activities, are performed by our highly educated workforce of approximately 3,300 employees in our Offshore Offices. Approximately 98% of our offshore employees are in our Pakistan Offices and our remaining employees are located at our smaller offshore operation center in Sri Lanka. The performance of our operations in our Pakistan Offices, and our ability to maintain our Offshore Offices, is an essential element of our business model, as the labor costs where our Pakistan Offices are located are substantially lower than the cost of comparable labor in India, the United States and other countries, and allows us to competitively price our products and services. Our competitive advantage will be greatly diminished and may disappear altogether if our operations in our Pakistan Offices are negatively impacted.

 

Pakistan and Sri Lanka have in the past experienced and could in the future continue to experience periods of political and social unrest, war and acts of terrorism. Our operations in our offshore locations may be negatively impacted by these and a number of other factors, including currency fluctuations, cost of labor and supplies, power grid and infrastructure issues, vandalism, and changes in local law, as well as laws within the United States relating to these countries. Client mandates or preferences for onshore service providers may also adversely impact our business model. Our operations in our Offshore Offices may also be affected by trade restrictions, such as tariffs or other trade controls. If we are unable to continue to leverage the skills and experience of our highly educated workforce, particularly in our Pakistan Offices, we may be unable to provide our products and services at attractive prices, and our business would be materially and negatively impacted or discontinued.

 

We believe that the labor costs in our Offshore Offices are approximately 15% of the cost of comparably educated and skilled workers in the U.S. If there were potential disruptions in any of these locations, they could have a negative impact on our business.

 

Our offshore operations expose us to additional business and financial risks which could adversely affect us and subject us to civil and criminal liability.

 

The risks and challenges associated with our operations outside the United States include laws and business practices favoring local competitors; compliance with multiple, conflicting and changing governmental laws and regulations, including employment and tax laws and regulations; and fluctuations in foreign currency exchange rates. Foreign operations subject us to numerous stringent U.S. and foreign laws, including the Foreign Corrupt Practices Act of 1977, as amended (“FCPA”), and comparable foreign laws and regulations that prohibit improper payments or offers of payments to foreign governments and their officials and political parties by U.S. and other business entities for the purpose of obtaining or retaining business. Safeguards we implement to discourage these practices may prove to be less than effective and violations of the FCPA and other laws may result in severe criminal or civil sanctions, or other liabilities or proceedings against us, including class action lawsuits and enforcement actions from the SEC, Department of Justice and overseas regulators.

 

We may be adversely affected by global climate change or market responses to such change.

 

The long-term effects of climate change are difficult to predict and may be widespread. The impacts may include physical risks (such as severe rains and flooding as a result of climate change that has been experienced in Pakistan), social and human effects (such as population dislocations or harm to health and well-being), and other adverse effects. The effects could impair, for example, the availability and cost of certain products and energy (including utilities), which in turn may impact our ability to procure goods or services required for the operation of our business at the quantities and levels we require. We may bear losses incurred as a result of, for example, physical damage to, or destruction of, our facilities (such as our operation centers), and business interruption due to weather events that may be attributable to climate change. These events and impacts could materially adversely affect our business operations, financial position, or results of operation.

 

Changes in the healthcare industry could affect the demand for our services and may result in a decrease in our revenues and market share.

 

As the healthcare industry evolves, changes in our customer base may reduce the demand for our services, result in the termination of existing contracts, and make it more difficult to negotiate new contracts on terms that are acceptable to us. For example, the current trend toward consolidation of healthcare providers may cause our existing customer contracts to terminate as independent practices are merged into hospital systems or other healthcare organizations. Such larger healthcare organizations may have their own practice management, and EHR and RCM solutions, reducing demand for our services. If this trend continues, we cannot assure you that we will be able to continue to maintain or expand our customer base, negotiate contracts with acceptable terms, or maintain our current pricing structure, which would result in a decrease in our revenues and market share.

 

18
 

 

If providers do not purchase our products and services or delay in choosing our products or services, we may not be able to grow our business.

 

Our business model depends on our ability to sell our products and services. Acceptance of our products and services may require providers to adopt different behavior patterns and new methods of conducting business and exchanging information. Providers may not integrate our products and services into their workflow and may not accept our solutions and services as a replacement for traditional methods of practicing medicine. Providers may also choose to buy our competitors’ products and services instead of ours. Achieving market acceptance for our solutions and services will continue to require substantial sales and marketing efforts and the expenditure of significant financial and other resources to create awareness and demand by providers. If providers fail to broadly accept our products and services, our business, financial condition and results of operations will be adversely affected.

 

If the revenues of our customers decrease, or if our customers cancel or elect not to renew their contracts, our revenue will decrease.

 

Under most of our customer contracts, which include RCM, we base our charges on a percentage of the revenue that our customer collects through the use of our services. Many factors may lead to decreases in customer revenue, including:

 

  ● reduction of customer revenue as a result of changes to the Patient Protection and Affordable Care Act (“ACA”) or fluctuations in medical appointments due to future pandemics;
  ● a rollback of the expansion of Medicaid or other governmental programs;
  ● reduction of customer revenue resulting from increased competition or other changes in the marketplace for physician services;
  ● failure of our customers to adopt or maintain effective business practices;
  ● actions by third-party payers of medical claims to reduce reimbursement;
  ● government regulations and government or other payer actions or inactions reducing or delaying reimbursement;
  ● interruption of customer access to our system; and
  ● our failure to provide services in a timely or high-quality manner.

 

As a result of our variable sales and implementation cycles, we may be unable to recognize revenue from prospective customers on a timely basis and we may not be able to offset expenditures.

 

The sales cycle for our services can be variable, typically ranging from two to four months from initial contact with a potential customer to contract execution to six to twelve months to rollout services which require each customer to participate. During the sales cycle, we expend time and resources in an attempt to obtain a customer without recognizing revenue from that customer to offset such expenditures. Our implementation cycle is also variable, typically ranging from two to four months from contract execution to completion of implementation. Each customer’s situation is different, and unanticipated difficulties and delays may arise as a result of a failure by us or by the customer to meet our respective implementation responsibilities or by the customer for failure to disclose material information to meet implementation requirements. During the implementation cycle, we expend substantial time, effort, and financial resources implementing our services without recognizing revenue. Even following implementation, there can be no assurance that we will recognize revenue on a timely basis or at all from our efforts. In addition, cancellation of any implementation after it has begun may involve loss to us of time, effort, and expenses invested in the canceled implementation process, and lost opportunity for implementing paying customers in that same period of time.

 

19
 

 

We are required to collect sales and use taxes on certain products and services we sell in certain jurisdictions. We may be subject to liability for past sales and incur additional related costs and expenses, and our future sales may decrease.

 

We may lose sales or incur significant expenses should states be successful in imposing additional state sales and use taxes on our products and services. A successful assertion by one or more states that we should collect sales or other taxes on the sale of our products and services that we are currently not collecting could result in substantial tax liabilities for past sales, decrease our ability to compete with healthcare IT vendors not subject to sales and use taxes, and otherwise harm our business. Each state has different rules and regulations governing sales and use taxes, and these rules and regulations are subject to varying interpretations that may change over time. We review these rules and regulations periodically and, when we believe that our products or services are subject to sales and use taxes in a particular state, we voluntarily approach state tax authorities in order to determine how to comply with their rules and regulations. We cannot assure you that we will not be subject to sales and use taxes or related penalties for past sales in states where we believe no compliance is necessary.

 

If the federal government were to impose a tax on imports or services performed abroad, we might be subject to additional liabilities. At this time, there is no way to predict whether this will occur or estimate the impact on our business.

 

Vendors of products and services like ours are typically held responsible by taxing authorities for the collection and payment of any applicable sales and similar taxes. If one or more taxing authorities determine that taxes should have, but have not, been paid with respect to our products or services, we may be liable for past taxes in addition to taxes going forward. Liability for past taxes may also include very substantial interest and penalty charges. Nevertheless, customers may be reluctant to pay back taxes and may refuse responsibility for interest or penalties associated with those taxes. If we are required to collect and pay back taxes and the associated interest and penalties, and if our customers fail or refuse to reimburse us for all or a portion of these amounts, we will have incurred unplanned expenses that may be substantial. Moreover, imposition of such taxes on our products and services going forward will effectively increase the cost of those products and services to our customers and may adversely affect our ability to retain existing customers or to gain new customers in the states in which such taxes are imposed.

 

We may also become subject to tax audits or similar procedures in states where we already pay sales and use taxes. The incurrence of additional accounting and legal costs and related expenses in connection with, and the assessment of, taxes, interest, and penalties as a result of audits, litigation, or otherwise could be materially adverse to our current and future results of operations and financial condition.

 

If we lose the services of Mahmud Haq as Executive Chairman, A. Hadi Chaudhry and Stephen Snyder as Co-Chief Executive Officers, or other members of our management team, or if we are unable to attract, hire, integrate and retain other necessary employees, our business would be harmed.

 

Our future success depends in part on our ability to attract, hire, integrate and retain the members of our management team and other qualified personnel. In particular, we are dependent on the services of Mahmud Haq, our founder, principal stockholder and Executive Chairman, and A. Hadi Chaudhry and Stephen Snyder as Co-Chief Executive Officers. Mr. Haq is instrumental in managing our offshore operations in our Pakistan Offices and coordinating those operations with our U.S. activities. The loss of Mr. Haq, who would be particularly difficult to replace, could negatively impact our ability to effectively manage our cost-effective workforce in our Pakistan Offices, which enables us to provide our products and solutions at attractive prices. Our future success also depends on the continued contributions of our other executive officers and certain key employees, each of whom may be difficult to replace, and upon our ability to attract and retain additional management personnel. Competition for such personnel is intense, and we compete for qualified personnel with other employers. We may face difficulty identifying and hiring qualified personnel at compensation levels consistent with our existing compensation and salary structure. If we fail to retain our employees, we could incur significant expenses in hiring, integrating and training their replacements, and the quality of our services and our ability to serve our customers could diminish, resulting in a material adverse effect on our business.

 

We may be unable to adequately establish, protect or enforce our patents, trade secrets and other intellectual property rights and we may incur significant costs in enforcing our intellectual property rights.

 

Our patents, trademarks, trade secrets, copyrights, and other intellectual property rights are important assets to us. Various events outside of our control pose a threat to our intellectual property rights, as well as to our products, services, and technologies. For instance, any of our current or future intellectual property rights may be challenged by others or invalidated through administrative process or litigation. Any of our pending or future patent applications, whether or not being currently challenged, may not be issued with the scope of the claims we seek, if at all.

 

Our success depends in part upon our ability to establish, protect and enforce our patents, trade secrets and other intellectual property and proprietary rights. If we fail to establish, protect or enforce these rights, we may lose customers and important advantages in the market in which we compete. We rely on a combination of patent, trademark, copyright and trade secret law and contractual obligations to protect our key intellectual property rights, all of which provide only limited protection. Our intellectual property rights may not be sufficient to help us maintain our position in the market and our competitive advantages.

 

20
 

 

Trade secrets may not be protectable if not properly kept confidential. We strive to enter into non-disclosure agreements with our employees, customers, contractors and business partners to limit access to and disclosure of our proprietary information. However, the steps we have taken may not be sufficient to prevent unauthorized use of our customer information, technology, and adequate remedies may not be available in the event of unauthorized use or disclosure of our trade secrets and proprietary information. Our ability to protect the trade secrets of our acquired companies from disclosure by the former employees of these acquired entities may be limited by law in the jurisdiction in which the acquired company and/or former employee resides, and/or where the disclosure occurred, and this leaves us vulnerable to the solicitation of the customers we acquire by former employees of the acquired business that join our competitors.

 

Accordingly, despite our efforts, we may be unable to prevent third parties from using our intellectual property for their competitive advantage. Any such use could have a material adverse effect on our business, results of operations and financial condition. Monitoring unauthorized uses of and enforcing our intellectual property rights can be difficult and costly. Legal intellectual property actions are inherently uncertain and may not be successful, and may require a substantial amount of resources and divert our management’s attention.

 

We have taken efforts to protect our proprietary rights, including a combination of license agreements, confidentiality policies and procedures, confidentiality provisions in employment agreements, confidentiality agreements with third parties, and technical security measures, as well as our reliance on copyright, patent, trademark, trade secret and unfair competition laws. These efforts may not be sufficient or effective. For example, the secrecy of our trade secrets or other confidential information could be compromised by our employees or by third parties, which could cause us to lose the competitive advantage resulting from those trade secrets or confidential information. Unauthorized third parties may try to copy or reverse engineer portions of our products or otherwise infringe upon, misappropriate or use our intellectual property. We may not be able to discover or determine the extent of any unauthorized use of our proprietary rights. We may also conclude that, in some instances, the benefits of protecting our intellectual property rights may be outweighed by the expense.

 

In addition, our platforms incorporate “open source” software components that are licensed to us under various public domain licenses. Open source license terms are often ambiguous, and there is little or no legal precedent governing the interpretation of many of the terms of certain of these licenses. Therefore, the potential impact of such terms on our business is somewhat unknown. Further, some enterprises may be reluctant or unwilling to use cloud-based services, because they have concerns regarding the risks associated with the security and reliability, among other things, of the technology delivery model associated with these services. If enterprises do not perceive the benefits of our services, then the market for these services may not expand as much or develop as quickly as we expect, either of which would adversely affect our business, financial condition, or operating results.

 

Legal standards relating to the validity, enforceability and scope of protection of intellectual property rights are uncertain and still evolving. The laws of some foreign countries may not be as protective of intellectual property rights as those in the United States, and effective intellectual property protection may not be available in every country in which our products and services are distributed.

 

Any impairment of our intellectual property rights, or our failure to protect our intellectual property rights adequately, could give our competitors access to our technology and could materially and adversely impact our business and operating results. Any increase in the unauthorized use of our intellectual property could also divert the efforts of our technical and management personnel and result in significant additional expense to us, which could materially and adversely impact our operating results. Finally, we may be required to spend significant resources to monitor and protect our intellectual property rights, including with respect to legal proceedings, which could result in substantial costs and diversion of resources and could materially and adversely impact our business, financial condition and operating results.

 

21
 

 

Claims by others that we infringe or may infringe on their intellectual property could force us to incur significant costs or revise the way we conduct our business.

 

Our competitors protect their proprietary rights by means of patents, trade secrets, copyrights, trademarks and other intellectual property. We have not conducted an independent review of patents and other intellectual property issued to third parties, who may have patents or patent applications relating to our proprietary technology. We may receive letters from third parties alleging, or inquiring about, possible infringement, misappropriation or violation of their intellectual property rights. Any party asserting that we infringe, misappropriate or violate proprietary rights may force us to defend ourselves, and potentially our customers, against the alleged claim. These claims and any resulting lawsuit, if successful, could subject us to significant liability for damages and/or invalidation of our proprietary rights or interruption or cessation of our operations. Any such claims or lawsuit could:

 

  ● be time-consuming and expensive to defend, whether meritorious or not;
  ● require us to stop providing products or services that use the technology that allegedly infringes the other party’s intellectual property;
  ● divert the attention of our technical and managerial resources;
  ● require us to enter into royalty or licensing agreements with third-parties, which may not be available on terms that we deem acceptable;
  ● prevent us from operating all or a portion of our business or force us to redesign our products, services or technology platforms, which could be difficult and expensive and may make the performance or value of our product or service offerings less attractive;
  ● subject us to significant liability for damages or result in significant settlement payments; and/or
  ● require us to indemnify our customers.

 

Furthermore, during the course of litigation, confidential information may be disclosed in the form of documents or testimony in connection with discovery requests, depositions or trial testimony. Disclosure of our confidential information and our involvement in intellectual property litigation could materially adversely affect our business. Some of our competitors may be able to sustain the costs of intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, any litigation could significantly harm our relationships with current and prospective customers. Any of the foregoing could disrupt our business and have a material adverse effect on our business, operating results and financial condition.

 

In addition, contentions by a third party such as a vendor or partner that we may pose a threat to their intellectual property can disrupt our ability to work with such party and/or our customers who rely upon that third party’s product or services. Withdrawal of participation by key vendors or partners would cause a disruption of services to our clients and a loss of customers, which could negatively affect our business and financial performance.

 

Current and future litigation against us could be costly and time-consuming to defend and could result in additional liabilities.

 

We may from time to time be subject to legal proceedings and claims that arise in the ordinary course of business, such as claims brought by current and former clients in connection with commercial disputes and employment claims made by our current or former employees. Claims may also be asserted by or on behalf of a variety of other parties, including government agencies, patients of our physician clients, stockholders, the sellers of the businesses that we acquire, or the creditors of the businesses we acquire. Any litigation involving us may result in substantial costs and may divert management’s attention and resources, which may seriously harm our business, overall financial condition, and operating results. Insurance may not cover existing or future claims, be sufficient to fully compensate us for one or more of such claims, or continue to be available on terms acceptable to us. A claim brought against us that is uninsured or underinsured could result in unanticipated costs, thereby reducing our operating results and leading analysts or potential investors to reduce their expectations of our performance resulting in a reduction in the trading price of our stock.

 

Our proprietary software or service delivery platform may not operate properly, which could damage our reputation, give rise to claims against us, or divert application of our resources from other purposes, any of which could harm our business and operating results.

 

We may encounter human or technical obstacles that prevent our proprietary or acquired applications from operating properly. If our applications do not function reliably or fail to achieve customer expectations in terms of performance, customers could assert liability claims against us or attempt to cancel their contracts with us. This could damage our reputation and impair our ability to attract or maintain customers.

 

22
 

 

There are particular risks when we inherit technologies through the companies we acquire. These technologies, often developed by distressed companies, were not created under our direct supervision and control and therefore may not have been developed in accordance with our standards. Such acquired technologies could, and at times do, contain operational deficiencies, defects, glitches or bugs that may not be discovered immediately or otherwise could have been avoided had we built the technology ourselves. Whether technology we develop or technology we acquire, we will need to replace certain components and remediate software defects or bugs from time to time. There can be no assurance that such defects or bugs, or the process of remediating them, will not have a material impact on our business. Our inability to promptly and cost-effectively correct a product defect could result in the Company having to withdraw an important product from market, damage to our reputation, and result in material costs and expenses, any of which could have a material impact on our revenue, margins, and operating results.

 

Moreover, information services as complex as those we offer have in the past contained, and may in the future develop or contain, undetected defects or errors. We cannot assure you that material performance problems or defects in our products or services will not arise in the future. Errors may result from receipt, entry, or interpretation of patient information or from interface of our services with legacy systems and data that we did not develop and the function of which is outside of our control. Despite testing, defects or errors may arise in our existing or new software or service processes. Because changes in payer requirements and practices are frequent and sometimes difficult to determine except through trial and error, we are continuously discovering defects and errors in our software and service processes compared against these requirements and practices. These defects and errors and any failure by us to identify and address them could result in loss of revenue or market share, liability to customers or others, failure to achieve market acceptance or expansion, diversion of development resources, injury to our reputation, and increased service and maintenance costs. Defects or errors in our software might discourage existing or potential customers from purchasing our products and services. Correction of defects or errors could prove to be impossible or impracticable. The costs incurred in correcting any defects or errors or in responding to resulting claims or liability may be substantial and could adversely affect our operating results.

 

In addition, customers relying on our services to collect, manage, and report clinical, business, and administrative data may have a greater sensitivity to service errors and security vulnerabilities than customers of software products in general. We market and sell services that, among other things, provide information to assist healthcare providers in tracking and treating patients. Any operational delay in or failure of our technology or service processes may result in the disruption of patient care and could cause harm to patients and thereby create unforeseen liabilities for our business.

 

Our customers or their patients may assert claims against us alleging that they suffered damages due to a defect, error, or other failure of our software or service processes. A product liability claim or errors or omissions claim could subject us to significant legal defense costs and adverse publicity, regardless of the merits or eventual outcome of such a claim.

 

Our physicians rely on our platforms (including the platforms we acquired) to be certified by the Office of the National Coordinator for Health Information Technology (“ONC”). If this certification were to be challenged, we might face liability related to any incentive that the physicians received in reliance upon such certification.

 

If our security measures are breached or fail and unauthorized access is obtained to a customer’s data, our service may be perceived as insecure, the attractiveness of our services to current or potential customers may be reduced, and we may incur significant liabilities.

 

Our services involve the web-based storage and transmission of customers’ proprietary information and patient information, including health, financial, payment and other personal or confidential information. We rely on proprietary and commercially available systems, software, tools and monitoring, as well as other processes, to provide security for processing, transmission and storage of such information. Because of the sensitivity of this information and due to requirements under applicable laws and regulations, the effectiveness of our security efforts is very important. We maintain servers, which store customers’ data, in the U.S. and offshore. Servers that store patient health records are stored in the U.S. We also process, transmit and store some data of our customers on servers and networks that are owned and controlled by third-party contractors in India and elsewhere. Increasingly, threat actors are targeting the healthcare industry with ransomware and other malicious software. If our security measures are breached or fail as a result of third-party action, acts of terror, social unrest, employee error, malfeasance or for any other reasons, someone may be able to obtain unauthorized access to customer or patient data. Improper activities by third parties, advances in computer and software capabilities and encryption technology, new tools and discoveries and other events or developments may facilitate or result in a compromise or breach of our security systems. Our security measures may not be effective in preventing unauthorized access to the customer and patient data stored on our servers. If a breach of our security occurs, we could face damages for contract breach, penalties for violation of applicable laws or regulations, possible lawsuits by individuals affected by the breach and significant remediation costs and efforts to prevent future occurrences. In addition, whether there is an actual or a perceived breach of our security, the market perception of the effectiveness of our security measures could be harmed and we could lose current or potential customers.

 

23
 

 

Our products and services are required to meet the interoperability standards, which could require us to incur substantial additional development costs or result in a decrease in revenue.

 

Our customers and the industry leaders enacting regulatory requirements are concerned with and often require that our products and services be interoperable with other third-party healthcare information technology suppliers. Although our products comply with the latest ONC standards and provide seamless and secure access, use and sharing of electronic health records, market forces or regulatory authorities could create software interoperability standards that would apply to our solutions, and if our products and services are not consistent with those standards, we could be forced to incur substantial development costs. There currently exists a comprehensive set of criteria for the functionality, interoperability and security of various software modules in the healthcare information technology industry. However, those standards are subject to continuous modification and refinement. Maintaining compliance with industry interoperability standards and related requirements could result in larger than expected software development expenses and administrative expenses in order to conform to these requirements. These standards and specifications, once finalized, will be subject to interpretation by the entities designated to certify such technology. We will incur increased development costs in delivering solutions if we need to change or enhance our products and services to be in compliance with these varying and evolving standards. If our products and services are not consistent with these evolving standards, our market position and sales could be impaired and we may have to invest significantly in changes to our solutions.

 

Disruptions in internet or telecommunication service or damage to our data centers could adversely affect our business by reducing our customers’ confidence in the reliability of our services and products.

 

Our information technologies and systems are vulnerable to damage or interruption from various causes, including acts of God and other natural disasters, war and acts of terrorism and power losses, computer systems failures, internet and telecommunications or data network failures, operator error, losses of and corruption of data and similar events. Our customers’ data, including patient health records, reside on our own servers located in the U.S., and our Offshore Offices. Although we conduct business continuity planning to protect against fires, floods, other natural disasters and general business interruptions to mitigate the adverse effects of a disruption, relocation or change in operating environment at our data centers, the situations we plan for and the amount of insurance coverage we maintain may not be adequate in any particular case. In addition, the occurrence of any of these events could result in interruptions, delays or cessations in service to our customers. Any of these events could impair or prohibit our ability to provide our services, reduce the attractiveness of our services to current or potential customers and adversely impact our financial condition and results of operations.

 

In addition, despite the implementation of security measures, our infrastructure, data centers, or systems that we interface with or utilize, including the internet and related systems, may be vulnerable to physical break-ins, hackers, improper employee or contractor access, computer viruses, programming errors, denial-of-service attacks or other attacks by third-parties seeking to disrupt operations or misappropriate information or similar physical or electronic breaches of security. Any of these can cause system failure, including network, software or hardware failure, which can result in service disruptions. As a result, we may be required to expend significant capital and other resources to protect against security breaches and hackers or to alleviate problems caused by such breaches.

 

We may be subject to liability for the content we provide to our customers and their patients.

 

We provide content for use by healthcare providers in treating patients. This content includes, among other things, patient education materials, coding and drug databases developed by third parties, and prepopulated templates providers can use to document visits and record patient health information. If content in the third-party databases we use is incorrect or incomplete, adverse consequences, including death, may give rise to product liability and other claims against us. A court or government agency may take the position that our delivery of health information directly, including through licensed practitioners, or delivery of information by a third-party site that a consumer accesses through our solutions, exposes us to personal injury liability, or other liability for wrongful delivery or handling of healthcare services or erroneous health information. Our liability insurance coverage may not be adequate or continue to be available on acceptable terms, if at all. A claim brought against us that is uninsured or under-insured could harm our business. Even unsuccessful claims could result in substantial costs and diversion of management resources.

 

We are subject to the effect of payer and provider conduct that we cannot control and that could damage our reputation with customers and result in liability claims that increase our expenses.

 

We offer electronic claims submission services for which we rely on content from customers, payers, and others. While we have implemented features and safeguards designed to maximize the accuracy and completeness of claims content, these features and safeguards may not be sufficient to prevent inaccurate claims data from being submitted to payers. Should inaccurate claims data be submitted to payers, we may experience poor operational results and be subject to liability claims, which could damage our reputation with customers and result in liability claims that increase our expenses.

 

24
 

 

Failure by our clients to obtain proper permissions and waivers may result in claims against us or may limit or prevent our use of data, which could harm our business.

 

Our clients are obligated by applicable law to provide necessary notices and to obtain necessary permission waivers for use and disclosure of the information that we receive. If they do not obtain necessary permissions and waivers, then our use and disclosure of information that we receive from them or on their behalf may be limited or prohibited by state or federal privacy laws or other laws. This could impair our functions, processes, and databases that reflect, contain, or are based upon such data and may prevent use of such data. In addition, this could interfere with or prevent creation or use of rules, and analyses or limit other data-driven activities that benefit us. Moreover, we may be subject to claims or liability for use or disclosure of information by reason of lack of valid notice, permission, or waiver. These claims or liabilities could subject us to unexpected costs and adversely affect our operating results.

 

Any deficiencies in our financial reporting or internal controls could adversely affect our business and the trading price of our securities.

 

As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting.

 

In the future, if we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. In addition, our internal control over financial reporting would not prevent or detect all errors and fraud. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.

 

If there are material weaknesses or failures in our ability to meet any of the requirements related to the maintenance and reporting of our internal controls, investors may lose confidence in the accuracy and completeness of our financial reports, which in turn could cause the price of our common stock and preferred stock to decline. Moreover, effective internal controls are necessary to produce reliable financial reports and to prevent fraud. If we have deficiencies in our internal controls, it may negatively impact our business, results of operations and reputation. In addition, we could become subject to investigations by Nasdaq, the SEC or other regulatory authorities, which could require additional management attention and which could adversely affect our business.

 

We may not be able to negotiate a credit facility at reasonable terms as the current credit facility expires in October 2025.

 

Our $10 million credit facility with Silicon Valley Bank, a division of First Citizens Bank, (“SVB”) expires in October 2025. The Company believes it will be able to enter into a new credit facility that will provide sufficient liquidity at favorable terms either with SVB or another lending institution. However, negotiations have not yet started, and we may not be able to obtain a credit facility that provides sufficient liquidity at favorable terms.

 

We maintain our cash at financial institutions, often in balances that exceed federally insured limits.

 

The financial markets recently have encountered volatility associated with concerns about the balance sheets of banks, especially small and regional banks who may have significant losses associated with investments that make it difficult to fund demands to withdraw deposits and other liquidity needs. Although the federal government has announced measures to assist these banks and protect depositors, some banks have already been impacted and others may be materially and adversely impacted. Our business is dependent on bank relationships, and we are proactively monitoring the financial health of such bank relationships. Continued strain on the banking system may adversely impact our business, financial condition and results of operations.

 

25
 

 

Our goodwill was subject to impairment in 2023 and may be subject to further impairment in the future, which could have a material adverse effect on our results of operations, financial condition, or future operating results.

 

We perform an annual goodwill impairment test on October 31st of each year, or more frequently if indicators for potential impairment exist. As a result of the 2023 annual goodwill impairment test, we recorded impairment charges of approximately $2 million at that time. Indicators that were considered included significant changes in performance relative to expected operating results, significant negative industry or economic trends, or a significant decline in our stock price and/or market capitalization or enterprise value for a sustained period of time. While we believe the assumptions used in determining whether there was an impairment and the amount of any resulting impairment were reasonable and commensurate with the views of a market participant, changes in key assumptions in the future, including increasing the discount rate, lowering forecast for revenue and operating margin, selection of guideline public companies or lowering the long-term growth rate, could result in additional charges; similarly, one or more changes in these assumptions in future periods due to changes in circumstances could result in additional future impairments. There was a triggering event at August 31, 2023, but it was determined that there was no impairment. During December 2023, the Company had an additional triggering event as a result of the suspension of the payment of the dividends on the Preferred Stock. As a result of a December 2023 triggering event, the Company recorded additional impairment charges of approximately $40 million. We cannot predict if or when additional future goodwill impairments may occur. Any additional goodwill impairments could have material adverse effects on our operating results, net assets, or our cost of, or access to, capital, which could harm our business. For the year ended December 31, 2024, no additional goodwill impairment was recorded. See Note 3, Goodwill and Intangible Assets - Net, to our consolidated financial statements in this Annual Report on Form 10-K for more details.

 

We are a party to several related-party agreements with our founder and Executive Chairman, Mahmud Haq, which have significant contractual obligations. These agreements are reviewed by our Audit Committee on an annual basis.

 

Since inception, we have entered into several related-party transactions with our founder and Executive Chairman, Mahmud Haq, which subject us to significant contractual obligations. We believe these transactions reflect terms comparable to those that would be available from third parties. Our independent audit committee has reviewed these arrangements and continues to do so on an annual basis. Although we have procedures in place to identify related party transactions, it is possible that such transactions could occur without being contemporaneously identified, reviewed and approved by the Audit Committee.

 

We depend on key information systems and third-party service providers.

 

We depend on key information systems to accurately and efficiently transact our business, provide information to management and prepare financial reports. These systems and services are vulnerable to interruptions or other failures resulting from, among other things, natural disasters, terrorist attacks, software, equipment or telecommunications failures, processing errors, computer viruses, other security issues or supplier defaults. Security, backup and disaster recovery measures may not be adequate or implemented properly to avoid such disruptions or failures. Any disruption or failure of these systems or services could cause substantial errors, processing inefficiencies, security breaches, inability to use the systems or process transactions, loss of customers or other business disruptions, all of which could negatively affect our business and financial performance.

 

Systems failures, cyberattacks or other events and resulting interruptions in the availability of or degradation in the performance of our websites, applications, products or services could harm our business.

 

As cybersecurity attacks continue to evolve and increase, our information systems could also be penetrated or compromised by internal and external parties’ intent on extracting confidential information, disrupting business processes or corrupting information. Our systems may experience service interruptions or degradation due to hardware and software defects or malfunctions, computer denial-of-service and other cyberattacks, human error, earthquakes, hurricanes, floods, fires, natural disasters, power losses, disruptions in telecommunications services, fraud, military or political conflicts, such as the conflicts in Ukraine and the Middle East, terrorist attacks, computer viruses, or other events. Our systems are also subject to break-ins, sabotage and intentional acts of vandalism. Some of our systems are not fully redundant and our disaster recovery planning is not sufficient for all eventualities. We have experienced and will likely continue to experience system failures, denial of service attacks and other events or conditions from time to time that interrupt the availability or reduce the speed or functionality of our websites and mobile applications. These events likely will result in loss of revenue. A prolonged interruption in the availability or reduction in the speed or other functionality of our websites and mobile applications could materially harm our business. Frequent or persistent interruptions in our services could cause current or potential users to believe that our systems are unreliable, leading them to switch to our competitors or to avoid our sites, and could permanently harm our reputation and brands. Moreover, to the extent that any system failure or similar event results in damages to our customers or their businesses, these customers could seek significant compensation from us for their losses and those claims, even if unsuccessful, would likely be time-consuming and costly for us to address. These risks could arise from external parties or from acts or omissions of internal or service provider personnel. Such unauthorized access could disrupt our business and could result in the loss of assets, litigation, remediation costs, damage to our reputation and failure to retain or attract customers following such an event, which could adversely affect our business.

 

26
 

 

Data privacy, identity protection and information security compliance may require significant resources and presents certain risks.

 

We collect, store, have access to and otherwise process certain confidential or sensitive data, including proprietary business information, patient data, personal data or other information that is subject to privacy and security laws, business information and/or customer imposed controls. Despite our efforts to protect such data, our business and our products may be vulnerable to security incidents, theft, improper use of our products, systems, software solutions or networks, unauthorized access, use, disclosure, modification or destruction of information, defective products and operational disruptions. The actual or perceived risk of theft, loss, fraudulent use or misuse of customer, employee or other data as a result of a cybersecurity incident, as well as non-compliance with applicable industry standards or our contractual or other legal obligations or privacy and information security policies regarding such data, could result in costs, fines, litigation or regulatory actions. We could face similar consequences in the future if we, our suppliers, customers or other third parties experience the actual or perceived risk of theft, loss, fraudulent use or misuse of data, including as a result of employee error or malfeasance, or as a result of the imaging, software, security and other products we incorporate into our products. Such an event could lead customers to select the products and services of our competitors. A cybersecurity incident could harm our reputation, cause unfavorable publicity or otherwise adversely affect certain potential customers’ perception of the security and reliability of our services as well as our credibility and reputation, which could result in lost sales.

 

We operate in an environment in which there are different and potentially conflicting data privacy laws in effect in the various U.S states and foreign jurisdictions in which we operate and we must understand and comply with each law and standard in each of these jurisdictions while ensuring the data is secure. Government enforcement actions can be costly and interrupt the regular operations of our business, and violations of data privacy laws can result in fines, reputational damage and civil lawsuits, any of which may adversely affect our business, reputation and financial statements.

 

Some of our contracts do not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. While we maintain general liability insurance coverage and coverage for errors or omissions, such coverage might not be adequate or otherwise protect us from liabilities or damages with respect to claims alleging compromises of customer data, that such coverage will continue to be available to us on acceptable terms or at all, or that such coverage will pay future claims. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business.

 

We use artificial intelligence in our business, and challenges with properly managing its use could result in reputational and competitive harm, legal liability, and adversely affect our results of operations.

 

We currently incorporate artificial intelligence (“AI”) solutions into our intelligent cloud products, and these applications will become important in our operations over time. Our competitors or other third parties may incorporate AI into their products and offerings quicker or more successfully than us, which could impair our ability to compete effectively and adversely affect our results of operations. Additionally, if the content, analyses, or recommendations that AI applications assist in producing are, or are alleged to be inaccurate, deficient, or biased, our business, financial condition, and results of operations may be adversely affected. The use of AI applications has resulted in, and may in the future result in, cybersecurity incidents that implicate the sensitive data of customers analyzed within such applications. Any such cybersecurity incidents related to our use of AI applications for analysis of sensitive data could adversely affect our reputation and results of operations. AI also presents emerging ethical issues and if our use of AI becomes controversial, we may experience brand or reputational harm, competitive harm, or legal liability. The rapid evolution of AI, including potential government regulation of AI and its various uses will require significant resources to develop, test and maintain our intelligence cloud platform, offerings, services, and features to help us implement AI ethically in order to minimize any unintended, harmful impact.

 

Rapid technological change in the telehealth industry presents us with significant risks and challenges.

 

The telehealth market is characterized by rapid technological change, changing consumer requirements, short product lifecycles and evolving industry standards. Our success will depend on our ability to enhance our solution with next-generation technologies and to develop or to acquire and market new services to access new consumer populations. There is no guarantee that we will possess the resources, either financial or personnel, for the research, design and development of new applications or services, or that we will be able to utilize these resources successfully and avoid technological or market obsolescence. Further, there can be no assurance that technological advances by one or more of our competitors or future competitors will not result in our present or future applications and services becoming uncompetitive or obsolete.

 

27
 

 

Our business, financial condition, results of operations and growth may be adversely affected by pandemics, epidemics or other public health emergencies, such as COVID-19.

 

We are subject to risks related to a public health crisis such as a global pandemic similar to the coronavirus (COVID-19). Numerous governmental jurisdictions, including the State of New Jersey where we maintain our principal executive offices, and those in which many of our U.S. and international offices are based may impose “shelter-in-place” orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of public health emergencies. Such orders or restrictions, and the perception that such orders or restrictions could occur, could result in business closures, work stoppages, slowdowns and delays, work-from-home policies, travel restrictions and cancellation of events, among other effects, thereby negatively impacting our customers, employees, and offices, among others.

 

A recession or prolonged economic contraction as a result of health emergencies could harm the business and results of operations of our enterprise customers, resulting in potential business closures, layoffs of employees and a significant increase in unemployment in the United States and elsewhere. The occurrence of any such events may lead to reduced income for customers and reduced size of workforces, which could reduce our revenue and harm our business, financial condition and results of operations.

 

The prolonged impact of these public health emergencies is highly uncertain and unpredictable, depending upon the severity and duration of the emergency and the effectiveness of actions taken globally to contain or mitigate its effects. Future financial impact cannot be estimated reasonably at this time, but may materially adversely affect our business, results of operations and financial condition.

 

Risks Related to Macroeconomics Conditions

 

Our operations and performance depend significantly on global and regional economic conditions and adverse economic conditions can materially adversely affect our business, results of operations and financial conditions.

 

Adverse macroeconomic conditions, including slow growth or recession, high unemployment, inflation, tariffs, tighter credit, higher interest rates, labor shortages, and currency fluctuations, can adversely impact consumer confidence and spending and materially adversely affect demand for our customers’ services. In addition, healthcare spending can be materially adversely affected in response to changes in fiscal and monetary policy, financial market volatility, declines in income or asset values and other economic factors.

 

Adverse economic conditions can also lead to increased credit and collectability risk on our trade receivables, the failure of financial institutions and reduced liquidity. These and other impacts can materially adversely affect our business, results of operations, financial condition, cash flows and the price of our common and preferred stock.

 

Our managed medical practices and customers could face supply chain issues that would disrupt their ability to service patients and therefore, impact our revenue.

 

Medical product shortages can represent a significant threat across the landscape of public health and health care delivery by undermining the ability to provide timely and high-quality care to patients. This has been clear in the context of the COVID-19 pandemic. If our managed medical practices and customers have supply chain issues and cannot receive the medications, vaccines and other required medical supplies, this can impact their ability to properly serve patients and thus our revenue would be negatively impacted.

 

Volatility in currency exchange rates may adversely affect our financial condition, results of operations and cash flows.

 

Our international operations provide support for the U.S. operations. We are exposed to the effects (both positive and negative) that fluctuating exchange rates have on translating the financial statements of our international operations, most of which are denominated in local currencies, into the U.S. dollar. Fluctuations in exchange rates may affect reported operating results in our international operations. As a result, fluctuating exchange rates may adversely impact our results of operations and cash flows.

 

28
 

 

Risks Related to Our Acquisition Strategy

 

If we do not manage our acquisitions effectively, our revenue, business and operating results may be harmed.

 

Our future acquisitions may require greater than anticipated investment of operational and financial resources as we seek to migrate customers of these companies to our solutions. Acquisitions also require the integration of different software and services, assimilation of new employees, diversion of management and IT resources, and increases in administrative costs. Acquisitions may also require additional costs associated with any debt or equity financings undertaken to pay for such acquisitions. We cannot assure you that any acquisition we undertake will be successful. Future growth will also place additional demands on our customer support, sales, and marketing resources, and may require us to hire and train additional employees. We will need to expand and upgrade our systems and infrastructure to accommodate our growth. The failure to manage our growth effectively will materially and adversely affect our business.

 

We may be unable to implement our strategy of acquiring additional companies.

 

We have no unconditional commitments with respect to any acquisition as of the date of this Form 10-K. Although we expect that one or more acquisition opportunities will become available in the future, we may not be able to acquire additional companies at all or on terms favorable to us. We will likely need additional financing for such acquisitions, but there is no assurance that we will be able to borrow funds or raise capital through the issuance of our equity on favorable terms. Certain of our larger, better capitalized competitors may seek to acquire some of the companies we may be interested in. Competition for acquisitions would likely increase acquisition prices and result in us having fewer acquisition opportunities.

 

Depending on the type of businesses we acquire (e.g., RCM, practice management, EHR, etc.), we may have varying cost saving and/or cross-selling opportunities with the acquired business. However, there is no assurance that we will achieve anticipated cost savings and cross-selling on our acquisitions, and failure to do so may mean we overpaid for such acquisitions.

 

In completing any future acquisitions, we will rely upon the representations, warranties and indemnities made by the sellers with respect to each acquisition as well as our own due diligence investigation. We cannot be assured that such representations and warranties will be true and correct or that our due diligence will uncover all materially adverse facts relating to the operations and financial condition of the acquired companies or their customers. Nor can we be assured that any available insurance will cover all such losses. To the extent that we are required to pay for obligations of an acquired company, or if material misrepresentations exist, we may not realize the expected benefit from such acquisition and we will have overpaid in cash and/or stock for the value received in that acquisition.

 

At the current prices of our common and Preferred Stock, we may be unable to execute accretive acquisitions.

 

Historically we have used our common and Preferred Stock to pay in part for acquisitions. Due to the lower market prices of these securities, we may not be able to use these securities to execute future acquisitions.

 

We may be unable to retain customers following their acquisition, which may result in a decrease in our revenues and operating results.

 

Customers of the businesses we acquire often have the right to terminate their service contracts for any reason at any time upon notice of 90 days or less. These customers may elect to terminate their contracts as a result of our acquisition or choose not to renew their contracts upon expiration. Legal and practical limitations on our ability to enforce non-competition and non-solicitation provisions against customer representatives and sales personnel that leave the businesses we acquire to join competitors may result in the loss of customers. In the past, our failure to retain acquired customers has at times resulted in decreases in our revenues. Our inability to retain customers of businesses we acquire could adversely affect our ability to benefit from those acquisitions and to grow our future revenues and operating income.

 

Acquisitions may subject us to liability with regard to the creditors, customers, and shareholders of the sellers.

 

While we attempt to limit our exposure to the liabilities associated with the businesses we acquire, we cannot guarantee that we will be successful in avoiding all material liability. Regardless of how we structure the acquisition, whether as an asset purchase, stock purchase, merger or other business combination, creditors, customers, vendors, governmental agencies and other parties at times seek to hold us accountable for unpaid debts, breach of contract claims, regulatory violations and other liabilities that relate to the business we acquired. Disaffected shareholders of the businesses we acquire have also attempted to interfere with our business acquisitions or brought claims against us. We attempt to minimize all of these risks through thorough due diligence, negotiating indemnities and holdbacks, obtaining relevant representations from sellers, procuring insurance coverage and leveraging experienced professionals when appropriate.

 

Future acquisitions may result in potentially dilutive issuances of equity securities, the incurrence of indebtedness and increased amortization expense.

 

Future acquisitions may result in dilutive issuances of equity securities, the incurrence of debt, the assumption of known and unknown liabilities, the write-off of software development costs and the amortization of expenses related to intangible assets, all of which could have an adverse effect on our business, financial condition and results of operations.

 

Regulatory Risks

 

The healthcare industry is heavily regulated. Our failure to comply with regulatory requirements could create liability for us, result in adverse publicity and negatively affect our business.

 

The healthcare industry is heavily regulated and is constantly evolving due to the changing political, legislative, regulatory landscape and other factors. Many healthcare laws are complex, and their application to specific services and relationships may not be clear. In particular, many existing healthcare laws and regulations, when enacted, did not anticipate or address the services that we provide. Further, healthcare laws differ from state to state and it is difficult to ensure that our business, products and services comply with evolving laws in all states. By way of example, certain federal and state laws forbid billing based on referrals between individuals or entities that have various financial, ownership, or other business relationships with healthcare providers. These laws vary widely from state to state, and one of the federal laws governing these relationships, known as the Stark Law, is very complex in its application. Similarly, many states have laws forbidding physicians from practicing medicine in partnership with non-physicians, such as business corporations, as well as laws or regulations forbidding splitting of physician fees with non-physicians or others. Other federal and state laws restrict assignment of claims for reimbursement from government-funded programs, the manner in which business service companies may handle payments for such claims and the methodology under which business services companies may be compensated for such services.

 

The 21st Century Cures Act (the “Cures Act”), passed by Congress in 2016, is meant to improve various aspects of the healthcare industry, including interoperability and information blocking. The Cures Act’s interoperability provisions relate to Information Exchange and Certification administered by the ONC. The certification involves complex and specific requirements related to various types of requests for the access, exchange or use of Electronic Health Information. In addition, the information blocking rule aims to resolve concerns that individuals in the healthcare industry intentionally prevent the exchange of information between multiple stakeholders. The Cures Act allows for penalties for stakeholders, including but not limited to, health IT developers and providers who do not comply with same. While we remain committed to efficient exchange of information in the healthcare industry and continue meeting all new certification requirements, failure to comply with these regulatory requirements, could create liability for us, result in adverse publicity and negatively affect our business.

 

29
 

 

The Office of Inspector General (“OIG”) of the Department of Health and Human Services (“HHS”) has a longstanding concern that percentage-based billing arrangements may increase the risk of improper billing practices. In addition, certain states have adopted laws or regulations forbidding splitting of fees with non-physicians which may be interpreted to prevent business service providers, including medical billing providers, from using a percentage-based billing arrangement. The OIG and HHS recommend that medical billing companies develop and implement comprehensive compliance programs to mitigate this risk. While we have developed and implemented a comprehensive billing compliance program that we believe is consistent with these recommendations, our failure to ensure compliance with controlling legal requirements, accurately anticipate the application of these laws and regulations to our business and contracting model, or other failure to comply with regulatory requirements, could create liability for us, result in adverse publicity and negatively affect our business.

 

The federal Anti-Kickback Statute (“AKS”) prohibits us from knowingly and willfully soliciting, receiving, offering or providing remuneration in exchange for referrals or recommendations for purposes of selling products or services which are paid for by federal healthcare programs such as Medicare and Medicaid. In addition, a claim including products or services resulting from a violation of AKS constitutes a violation of the federal False Claims Act (“FCA”). If we are determined to have violated the FCA, we may be required to pay up to three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim. If we are found to be in violation of the FCA, AKS, ACA, or any other applicable state or any federal fraud and abuse laws, whether by our current practices or for the past practices of a company we acquire, we may be subject to substantial civil damages and criminal penalties and fines that could have a material adverse impact on our business.

 

In addition, federal and state legislatures and agencies periodically consider proposals to revise aspects of the healthcare industry or to revise or create additional statutory and regulatory requirements. For instance, the current administration may make changes to the ACA, the nature and scope of which are presently unknown. Similarly, certain computer software products are regulated as medical devices under the Federal Food, Drug, and Cosmetic Act. While the Food and Drug Administration (“FDA”) has sometimes chosen to disclaim authority to, or to refrain from actively regulating certain software products which are similar to our products, this area of medical device regulation remains in flux. We expect that the FDA will continue to be active in exploring legal regimes for regulating computer software intended for use in healthcare settings. Any additional regulation can be expected to impose additional overhead costs on us and should we fail to adequately meet these legal obligations, we could face potential regulatory action. Regulatory authorities such as the Centers for Medicare and Medicaid Services may also impose functionality standards with regard to electronic prescribing technologies. If implemented, proposals like these could impact our operations, the use of our services and our ability to market new services, or could create unexpected liabilities for us. We cannot predict what changes to laws or regulations might be made in the future or how those changes could affect our business or our operating costs.

 

Further, our ability to provide our telehealth services in each state is dependent upon a state’s treatment of telehealth and emerging technologies (such as digital health services), which are subject to changing political, regulatory and other influences. Many states have laws that limit or restrict the practice of telehealth, such as laws that require a provider to be licensed and/or physically located in the same state where the patient is located. For example, California, Massachusetts, and Oregon, among others, are not members of the Interstate Medical Licensure Compact, which streamlines the process by which physicians licensed in one state are able to practice in other participating states. Failure to comply with these laws could result in denials of reimbursement for services (to the extent such services are billed), recoupments of prior payments, professional discipline for providers or civil or criminal penalties.

 

If we do not maintain the certification of our EHR solutions pursuant to the HITECH Act and Cures Act, our business, financial condition and results of operations will be adversely affected.

 

The HITECH Act provides financial incentives for healthcare providers that demonstrate “meaningful use” of an EHR and mandates use of health information technology systems that are certified according to technical standards developed under the supervision of the U.S. Department of Health and Human Services (“HHS”). The HITECH Act also imposes certain requirements upon governmental agencies to use, and requires healthcare providers, health plans, and insurers contracting with such agencies to use, systems that are certified according to such standards. The healthcare IT industry continues to experience changes as a result of new laws, regulations, and changes to healthcare industry standards. For instance, the meaningful use incentive program has since expired and has been consolidated, among other incentive programs, within the Merit-based Incentive Payment System (“MIPS”), which was created as part of the Quality Payment Program (“QPP”), launched by CMS after passage of the Medicare Access and CHIP Reauthorization Act (“MACRA”). MACRA and regulations promulgated by it change the way CMS rewards clinicians in the healthcare industry by rewarding value-based care over volume-based care. MIPS requires substantial reporting mechanisms based on clinical quality measures that highly depend on reporting feature within EHR systems.

 

30
 

 

The HITECH and Cures Acts (as described in more detail above) contain certification requirements which affect our business because we have invested and continue to invest in conforming our products and services to these standards. HHS has developed certification programs for electronic health records and health information exchanges. Our web-based EHR solutions have been certified as complete EHR systems by ICSA Labs or Drummond Group, non-governmental, independent certifying bodies. We must ensure that our EHR solutions continue to be certified according to applicable HITECH Act and Cures Act technical standards so that our customers qualify for any MIPS/MACRA incentive payments and are not subject to penalties for non-compliance. Failure to maintain this certification under the HITECH Act and Cures Act could jeopardize our relationships with customers who are relying upon us to provide certified software and will make our products and services less attractive to customers than the offerings of other EHR vendors who maintain certification of their products.

 

If a breach of our measures protecting personal data covered by HIPAA or the HITECH Act occurs, we may incur significant liabilities.

 

The Health Insurance Portability and Accountability Act of 1996, as amended (“HIPAA”), and the regulations that have been issued under it contain substantial restrictions and requirements with respect to the use, collection, storage and disclosure of individuals’ protected health information. Under HIPAA, covered entities must establish administrative, physical and technical safeguards to protect the confidentiality, integrity and availability of electronic protected health information maintained or transmitted by them or by others on their behalf. In February 2009, HIPAA was amended by the HITECH Act to add provisions that impose certain of HIPAA’s privacy and security requirements directly upon business associates of covered entities. Under HIPAA and the HITECH Act, our customers are covered entities and we are a business associate of our customers as a result of our contractual obligations to perform certain services for those customers. The HITECH Act transferred enforcement authority of the security rule from CMS to the Office for Civil Rights of HHS, thereby consolidating authority over the privacy and security rules under a single office within HHS. Further, HITECH empowered state attorneys’ general to enforce HIPAA.

 

The HITECH Act heightened enforcement of privacy and security rules, indicating that the imposition of penalties will be more common in the future and such penalties will be more severe. For example, the HITECH Act requires that the HHS fully investigate all complaints if a preliminary investigation of the facts indicates a possible violation due to “willful neglect” and imposes penalties if such neglect is found. Further, where our liability as a business associate to our customers was previously merely contractual in nature, the HITECH Act now treats the breach of duty under an agreement by a business associate to carry the same liability as if the covered entity engaged in the breach. In other words, as a business associate, we are now directly responsible for complying with HIPAA. We may find ourselves subject to increased liability as a possible liable party and we may incur increased costs as we perform our obligations to our customers under our agreements with them.

 

Finally, regulations also require business associates to notify covered entities, who in turn must notify affected individuals and government authorities of data security breaches involving unsecured protected health information. We have performed an assessment of the potential risks and vulnerabilities to the confidentiality, integrity and availability of electronic health information. In response to this risk analysis, we implemented and maintain physical, technical and administrative safeguards intended to protect all personal data and have processes in place to assist us in complying with applicable laws and regulations regarding the protection of this data and properly responding to any security incidents. If we knowingly breach the HITECH Act’s requirements, we could be exposed to criminal liability. A breach of our safeguards and processes could expose us to civil penalties of up to $1.5 million for each incident and the possibility of civil litigation.

 

31
 

 

If we or our customers fail to comply with federal and state laws governing submission of false or fraudulent claims to government healthcare programs and financial relationships among healthcare providers, we or our customers may be subject to civil and criminal penalties or loss of eligibility to participate in government healthcare programs.

 

As a participant in the healthcare industry, our operations and relationships, and those of our customers, are regulated by a number of federal, state and local governmental entities. The impact of these regulations can adversely affect us even though we may not be directly regulated by specific healthcare laws and regulations. We must ensure that our products and services can be used by our customers in a manner that complies with those laws and regulations. Inability of our customers to do so could affect the marketability of our products and services or our compliance with our customer contracts, or even expose us to direct liability under the theory that we had assisted our customers in a violation of healthcare laws or regulations. A number of federal and state laws, including anti-kickback restrictions and laws prohibiting the submission of false or fraudulent claims, apply to healthcare providers and others that make, offer, seek or receive referrals or payments for products or services that may be paid for through any federal or state healthcare program and, in some instances, any private program. These laws are complex and their application to our specific services and relationships may not be clear and may be applied to our business in ways that we do not anticipate. Federal and state regulatory and law enforcement authorities have recently increased enforcement activities with respect to Medicare and Medicaid fraud and abuse regulations and other healthcare reimbursement laws and rules. From time to time, participants in the healthcare industry receive inquiries or subpoenas to produce documents in connection with government investigations. We could be required to expend significant time and resources to comply with these requests, and the attention of our management team could be diverted by these efforts. The occurrence of any of these events could give our customers the right to terminate our contracts with us and result in significant harm to our business and financial condition.

 

These laws and regulations may change rapidly, and it is frequently unclear how they apply to our business. Any failure of our products or services to comply with these laws and regulations could result in substantial civil or criminal liability and could, among other things, adversely affect demand for our services, invalidate all or portions of some of our contracts with our customers, require us to change or terminate some portions of our business, require us to refund portions of our revenue, cause us to be disqualified from serving customers doing business with government payers, and give our customers the right to terminate our contracts with them, any one of which could have an adverse effect on our business.

 

Potential healthcare reform and new regulatory requirements placed on our products and services could increase our costs, delay or prevent our introduction of new products or services, and impair the function or value of our existing products and services.

 

Our products and services may be significantly impacted by healthcare reform initiatives and will be subject to increasing regulatory requirements, either of which could negatively impact our business in a multitude of ways. If substantive healthcare reform or applicable regulatory requirements are adopted, we may have to change or adapt our products and services to comply. Reform or changing regulatory requirements may also render our products or services obsolete or may block us from accomplishing our work or from developing new products or services. This may in turn impose additional costs upon us to adapt to the new operating environment or to further develop or modify our products and services. Such reforms may also make the introduction of new products and service costlier or more time-consuming than we currently anticipate. These changes may also prevent our introduction of new products and services or make the continuation or maintenance of our existing products and services unprofitable or impossible.

 

Additional regulation of the disclosure of medical information outside the United States may adversely affect our operations and may increase our costs.

 

Federal or state governmental authorities may impose additional data security standards or additional privacy or other restrictions on the collection, use, transmission, and other disclosures of medical information. Legislation has been proposed at various times at both the federal and the state level that would limit, forbid, or regulate the use or transmission of medical information outside of the United States. Such legislation, if adopted, may render our use of our servers in Offshore Offices for work related to such data impracticable or substantially more expensive. Alternative processing of such information within the United States may involve substantial delay in implementation and increased cost.

 

Our services present the potential for embezzlement, identity theft, or other similar illegal behavior by our employees.

 

Among other things, our services from time to time involve handling mail from payers and payments from patients for our customers, and this mail frequently includes original checks and credit card information and occasionally includes currency. Where requested, we deposit payments and process credit card transactions from patients on behalf of customers and then forward these payments to the customers. Even in those cases in which we do not handle original documents or mail, our services also involve the use and disclosure of personal and business information that could be used to impersonate third parties or otherwise gain access to their data or funds. The manner in which we store and use certain financial information is governed by various federal and state laws. If any of our employees takes, converts, or misuses such funds, documents, or data, we could be liable for damages, subject to regulatory actions and penalties, and our business reputation could be damaged or destroyed. In addition, we could be perceived to have facilitated or participated in illegal misappropriation of funds, documents, or data and therefore be subject to civil or criminal liability.

 

32
 

 

Risks Related to Ownership of Shares of Our Common Stock

 

The conversion of the Series A Preferred Stock into common stock in March 2025 (the “Conversion”) increased the total number of outstanding shares, potentially diluting the value of existing common shareholders’ equity.

 

The Conversion resulted in the dilution of existing common shareholders’ ownership percentages. This dilution of ownership will impact the voting power, earnings per share and overall control of the Company for existing common shareholders. The Company’s earnings per share calculation will be impacted by the additional common shares, offset by the amount of Series A Preferred Stock dividend that is not included in the calculation. The increased number of common shares outstanding will also lower the book value of each common share, which would adversely affect the market price of the Company’s common stock. Moreover, existing common shareholders may experience a reduced ability to influence corporate decision as their voting power becomes more diluted.

 

Series A Preferred Stock shareholders gained full voting rights upon conversion of their preferred shares into common stock.

 

Preferred shareholders do not have voting rights under the terms of their preferred stock, except under extremely limited circumstances. However, upon conversion of their preferred shares into common stock, these shareholders gained full voting rights, which could significantly alter the balance of voting power within the Company. The conversion of a majority of the Series A Preferred Stock shares could result in a situation where a large group of former Series A preferred shareholders collectively gain the ability to influence corporate decisions, including matters related to the election of directors, mergers, acquisitions, and other significant strategic initiatives. This shift in voting power could potentially dilute the influence of existing common shareholders and may lead to changes in the Company’s governance structure.

 

The conversion of the Series A Preferred Stock could be perceived negatively by the market.

 

The Conversion could be perceived negatively by the market, potentially leading to a decline in the value of the Company’s common stock. Investors may interpret such conversion as a sign of financial weakness, dilution of ownership, or a shift in the Company’s capital structure that could impact earnings per share or control dynamics. This negative market perception may arise if investors believe the Conversion is being undertaken to address financial challenges, increase liquidity, or meet other strategic objectives that could signal instability or uncertainty. Such market reactions could lead to increased volatility in the Company’s stock price, reduced investor confidence, and challenges in maintaining or attracting capital in the future.

 

The Company’s potential for future issuances of common stock following the Conversion could be limited.

 

The Company may want to issue additional common stock in the future to raise capital for operations, acquisitions, or other strategic initiatives. Such potential for future issuances could be limited as a result of the additional common shares that were issued due to the Conversion.

 

Our revenues, operating results and cash flows may fluctuate in future periods and we may fail to meet investor expectations, which may cause the price of our common stock to decline.

 

Variations in our quarterly and year-end operating results are difficult to predict and may fluctuate significantly from period to period. We may fail to meet or exceed the financial projections of the investment community or the financial projections we may provide to the public. If our sales or operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Specific factors that may cause fluctuations in our operating results include:

 

  ●demand and pricing for our products and services;
  ●the encounter volumes of our customer base;
  ●government or commercial healthcare reimbursement policies;
  ●physician and patient acceptance of any of our current or future products;
  ●introduction of competing products, services or technologies;
  ●our operating expenses which fluctuate due to growth of our business;
  ●changes in laws or regulations applicable to our products and services;
  ●timing and size of any new product or technology acquisitions we may complete; and
  ●variable sales cycle and implementation periods for our products and services.

 

Healthcare reform may have a material adverse effect on the Company’s financial condition and results of operations.

 

Political, economic and regulatory developments have effected fundamental changes in the healthcare industry. In response to perceived increases in healthcare costs in recent years, there have been, and continue to be, proposals by the federal government, state governments, regulators, and third-party payors to control these costs and, more generally, to reform the U.S. health care system. Certain of these proposals could limit the amounts CareCloud will receive for its products and services. The Patient Protection and Affordable Care Act (the “ACA”) substantially changed the way healthcare is financed by both government and private insurers.

 

The Company cannot predict at this time the full impact of the ACA or other new legislation, the new Administration, agency priorities, rulemaking and healthcare reform measures from U.S. federal or state governments, or third-party payors that may be adopted or implemented in the future on the Company’s financial condition, results of operations and cash flows. Although several legislative initiatives to repeal and replace the ACA have been proposed, and legal challenges to the constitutionality of the ACA or its component parts have been made, the nature and effect of any modification or repeal of, or legislative substitution for, the ACA, or any court decision regarding the ACA’s validity, is uncertain, and the Company cannot predict the effect that any of these events would have on the longer-term viability of the act, or on the Company’s financial condition, results of operations or cash flows. However, any changes that create stricter and more costly compliance obligations or lower reimbursement for the Company’s customers could materially and adversely affect its business, financial condition and results of operations. Future significant changes in the healthcare systems in the United States could also have a negative impact on the demand for the Company’s current and future products.

 

Future sales of shares of our common stock could depress the market price of our common stock.

 

Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our shareholders sell, or the market perceives that our shareholders intend to sell substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.

 

As of December 31, 2024, Mahmud Haq controlled 31% of our outstanding shares of common stock, which prevented investors from influencing significant corporate decisions.

 

As of December 31, 2024, Mahmud Haq, our founder and Executive Chairman, beneficially owned 31% of our outstanding shares of common stock. Due to the Conversion, his ownership percentage was diluted. However, he still controls 12% of our outstanding shares of common stock after the Conversion. As a result, Mr. Haq exercises a significant level of control over all matters requiring stockholder approval, including the election of directors, amendment of our certificate of incorporation, and approval of significant corporate transactions. This control could have the effect of delaying or preventing a change of control of our company or changes in management and will make the approval of certain transactions difficult or impossible without his support, which in turn could reduce the price of our common stock.

 

33
 

 

Provisions of Delaware law, of our amended and restated charter and amended and restated bylaws may make a takeover more difficult, which could cause our common stock price to decline.

 

Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and in the Delaware General Corporation Law (“DGCL”) may make it difficult and expensive for a third party to pursue a tender offer, change in control or takeover attempt, which is opposed by management and the Board of Directors. Public stockholders who might desire to participate in such a transaction may not have an opportunity to do so. We have a staggered Board of Directors that makes it difficult for stockholders to change the composition of the Board of Directors in any one year. Further, our amended and restated certificate of incorporation provides for the removal of a director only for cause upon the affirmative vote of the holders of at least 50.1% of the outstanding shares entitled to cast their vote for the election of directors, which may discourage a third party from making a tender offer or otherwise attempting to obtain control of us. These and other anti-takeover provisions could substantially impede the ability of public stockholders to change our management and Board of Directors. Such provisions may also limit the price that investors might be willing to pay for shares of our Preferred Stock in the future.

 

Any issuance of additional preferred stock in the future may dilute the rights of our existing stockholders.

 

Our Board of Directors has the authority to issue up to 7,000,000 shares of preferred stock and to determine the price, privileges and other terms of these shares, of which 4,526,231 shares of Series A Preferred Stock and 1,511,372 of Series B Preferred Stock were issued as of December 31, 2024. After the Conversion, there were 984,530 shares of Series A Preferred Stock outstanding. Our Board of Directors may exercise its authority with respect to the remaining shares of preferred stock without any further approval of common stockholders. The rights of the holders of common stock may be adversely affected by the rights of future holders of preferred stock.

 

We do not intend to pay cash dividends on our common stock.

 

Currently, we do not anticipate paying any cash dividends to holders of our common stock. As a result, capital appreciation, if any, of our common stock will be a stockholder’s sole source of gain.

 

Complying with the laws and regulations affecting public companies will increase our costs and the demands on management and could harm our operating results.

 

As a public company, the Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our internal control over financial reporting annually and the effectiveness of our disclosure controls and procedures quarterly. As a “smaller reporting company,” we elected to avail ourselves of the exemption from the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act. We were not required to have this attestation performed for the years 2024, 2023 or 2022. In future years, if we are required to have our independent registered public accounting firm attest the effectiveness of our internal control over financial reporting, the cost of our compliance with Section 404 will correspondingly increase. Our compliance with applicable provisions of Section 404 requires that we incur substantial accounting expense and expend significant management time on compliance-related issues and stay in compliance with reporting requirements. Moreover, if we are not able to stay in compliance with the requirements of Section 404 applicable to us in a timely manner, or if we or our independent registered public accounting firm identifies any deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.

 

Furthermore, investor perceptions of our Company may suffer if deficiencies are found, and this could cause a decline in the market price of our common and preferred stock. Irrespective of compliance with Section 404, any failure of our internal control over financial reporting could have a material adverse effect on our stated operating results and harm our reputation. If we are unable to implement these changes effectively or efficiently, it could harm our operations, financial reporting, or financial results and could result in an adverse opinion on internal control from our independent registered public accounting firm.

 

34
 

 

We are a smaller reporting company and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.

 

There are many exemptions available to smaller reporting companies like us that have less than $250 million of worldwide common equity held by non-affiliates. The disclosures we will be required to provide in our SEC filings are still less than they would be if we were not considered a smaller reporting company. Specifically, smaller reporting companies are able to provide simplified executive compensation disclosures in their fillings and have certain other decreased disclosure obligations in their SEC filings. Our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we will rely on the exemption available to smaller reporting companies. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

 

Risks Related to Ownership of Shares of Our Preferred Stock

 

As a result of the Conversion, there may not be an organized trading market for the Series A Preferred Stock.

 

The Nasdaq Global Market requires a minimum number of shareholder to maintain a security’s listing on the exchange. Due to the limited number of Series A Preferred Stock shareholders after the Conversion, this security is likely to be delisted from the Nasdaq Global Market and there may no longer be an organized market for trading of Series A Preferred Stock.

 

In December 2023 we suspended the payment of the dividends on the Preferred Stock. The Company resumed paying monthly dividends in February 2025, paying one month of the arrearage. We may not be able to continue to pay dividends on the Preferred Stock if we fall out of compliance with our loan covenants and are prohibited by our bank lender from paying dividends or if we have insufficient cash to make dividend payments.

 

Our ability to pay cash dividends on the Preferred Stock requires us to have either net profits or positive net assets (total assets less total liabilities), and to be able to pay our debts as they become due in the usual course of business. We cannot predict with certainty whether we will remain in compliance with the covenants of our senior secured lender SVB, which include, among other things, generating adjusted EBITDA or complying with a minimum liquidity ratio at times when we are utilizing our line of credit. If we fall out of compliance, our lender may exercise any of its rights and remedies under the loan agreement, including restricting us from making dividend payments.

 

Notwithstanding these factors, during December 2023, the Company suspended the dividends on the Preferred Stock. Although the Company resumed payment of the monthly dividends in February 2025, we may not maintain sufficient cash to continue to pay dividends on the Preferred Stock and we cannot assure you that our businesses will generate sufficient cash flow from operations or that future borrowings will be available to us in an amount sufficient to enable us to make the Preferred Stock dividend payments that are currently due or in arrears and to fund our other liquidity needs. Our ability to pay dividends may again be impaired if any of the risks described in this document, including the documents incorporated by reference herein, were to occur. Also, payment of our dividends depends upon our financial condition, remaining in compliance with our affirmative and negative loan covenants with SVB, which we may be unable to do in the future, and other factors as our Board of Directors may deem relevant from time to time.

 

Our Series A and Series B Preferred Stock rank junior to all of our indebtedness and other liabilities.

 

Our Series A Preferred Stock ranks pari passu to our Series B Preferred Stock with respect to the distribution of assets upon our liquidation, dissolution or winding-up of our affairs. In the event of our bankruptcy, liquidation, dissolution or winding-up of our affairs, our assets will be available to pay obligations on the Preferred Stock only after all of our indebtedness and other liabilities have been paid. The rights of holders of the Preferred Stock to participate in the distribution of our assets will rank junior to the prior claims of our current and future creditors and any future series or class of preferred stock we may issue that ranks senior to the Preferred Stock. Also, the Preferred Stock effectively ranks junior to all existing and future indebtedness and to the indebtedness and other liabilities of our existing subsidiaries and any future subsidiaries. Our existing subsidiaries are, and future subsidiaries would be, separate legal entities and have no legal obligation to pay any amounts to us in respect of dividends due on the Preferred Stock. If we are forced to liquidate our assets to pay our creditors, we may not have sufficient assets to pay amounts due on any or all of the Preferred Stock then outstanding. We may in the future incur debt and other obligations that will rank senior to the Preferred Stock. At December 31, 2024, our total liabilities equaled approximately $21.8 million.

 

35
 

 

Certain of our existing or future debt instruments may restrict the authorization, payment or setting apart of dividends on the Preferred Stock. Our Credit Agreement with SVB restricts the payment of dividends in the event of any event of default, including failure to meet certain financial covenants. There can be no assurance that we will remain in compliance with the SVB Credit Agreement, and if we default, we may be contractually prohibited from paying dividends on the Preferred Stock. Also, future offerings of debt or senior equity securities may adversely affect the market price of the Preferred Stock. If we decide to issue debt or senior equity securities in the future, it is possible that these securities will be governed by an indenture or other instruments containing covenants restricting our operating flexibility. Additionally, any convertible or exchangeable securities that we issue in the future may have rights, preferences and privileges more favorable than those of the Preferred Stock and may result in dilution to owners of the Preferred Stock. We and, indirectly, our shareholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. The holders of the Preferred Stock will bear the risk of our future offerings, which may reduce the market price of the Preferred Stock and will dilute the value of their holdings.

 

We may issue additional shares of Preferred Stock and additional series of preferred stock that rank on parity with the Preferred Stock as to dividend rights, rights upon liquidation or voting rights.

 

We are allowed to issue additional shares of Preferred Stock and additional series of preferred stock that would rank equal to or below the Preferred Stock as to dividend payments and rights upon our liquidation, dissolution or winding up of our affairs pursuant to our amended and restated certificate of incorporation and the certificate of designations relating to the Preferred Stock without any vote of the holders of the Preferred Stock. Upon the affirmative vote of the holders of at least two-thirds of the outstanding shares of Preferred Stock (voting together as a class with all other series of parity preferred stock we may issue upon which like voting rights have been conferred and are exercisable), we are allowed to issue additional series of preferred stock that would rank above the Preferred Stock as to dividend payments and rights upon our liquidation, dissolution or the winding up of our affairs pursuant to our amended and restated certificate of incorporation and the certificate of designations relating to the Preferred Stock. The issuance of additional shares of Preferred Stock and additional series of preferred stock could have the effect of reducing the amounts available to the Preferred Stock upon our liquidation or dissolution or the winding up of our affairs. It also may reduce dividend payments on the Preferred Stock if we do not have sufficient funds to pay dividends on all Preferred Stock outstanding and other classes or series of stock with equal priority with respect to dividends.

 

Also, although holders of Preferred Stock are entitled to limited voting rights with respect to the circumstances under which the holders of Preferred Stock are entitled to vote, the Preferred Stock votes separately as a class along with all other series of our preferred stock that we may issue upon which like voting rights have been conferred and are exercisable. As a result, the voting rights of holders of Preferred Stock may be significantly diluted, and the holders of such other series of preferred stock that we may issue may be able to control or significantly influence the outcome of any vote.

 

Future issuances and sales of senior or pari passu preferred stock, or the perception that such issuances and sales could occur, may cause prevailing market prices for the Preferred Stock and our common stock to decline and may adversely affect our ability to raise additional capital in the financial markets at times and prices favorable to us.

 

Market interest rates may materially and adversely affect the value of the Preferred Stock.

 

One of the factors that influences the price of the Preferred Stock is the dividend yield on the Preferred Stock (as a percentage of the market price of each class of the Preferred Stock) relative to market interest rates. An increase in market interest rates may lead prospective purchasers of the Preferred Stock to expect a higher dividend yield (and higher interest rates would likely increase our borrowing costs and potentially decrease funds available for dividend payments). Thus, higher market interest rates could cause the market price of the Preferred Stock to materially decrease.

 

36
 

 

Holders of the Preferred Stock may be unable to use the dividends-received deduction and may not be eligible for the preferential tax rates applicable to “qualified dividend income”.

 

Distributions paid to corporate U.S. holders of the Preferred Stock may be eligible for the dividends-received deduction, and distributions paid to non-corporate U.S. holders of the Preferred Stock may be subject to tax at the preferential tax rates applicable to “qualified dividend income,” if we have current or accumulated earnings and profits, as determined for U.S. federal income tax purposes. We do not currently have such accumulated earnings and profits. Additionally, we may not have sufficient current earnings and profits during future fiscal years for the distributions on the Preferred Stock to qualify as dividends for U.S. federal income tax purposes. If the distributions fail to qualify as dividends, U.S. holders would be unable to use the dividends-received deduction and may not be eligible for the preferential tax rates applicable to “qualified dividend income.” If any distributions on the Preferred Stock with respect to any fiscal year are not eligible for the dividends-received deduction or preferential tax rates applicable to “qualified dividend income” because of insufficient current or accumulated earnings and profits, it is possible that the market value of the Preferred Stock might decline.

 

Our Preferred Stock has not been rated.

 

We have not sought to obtain a rating for the Preferred Stock. No assurance can be given, however, that one or more rating agencies might not independently determine to issue such a rating or that such a rating, if issued, would not adversely affect the market price of the Preferred Stock. Also, we may elect in the future to obtain a rating for the Preferred Stock, which could adversely affect the market price of the Preferred Stock. Ratings only reflect the views of the rating agency or agencies issuing the ratings and such ratings could be revised downward, placed on a watch list or withdrawn entirely at the discretion of the issuing rating agency if in its judgment circumstances so warrant. Any such downward revision, placing it on a watch list or withdrawal of a rating could have an adverse effect on the market price of the Preferred Stock.

 

The market price of our Series B Preferred Stock is variable and is substantially affected by various factors.

 

The market price of our Series B Preferred Stock is subject to wide fluctuations in response to numerous factors. These factors include, but are not limited to, the following:

 

  ●suspension of the dividend payments in December 2023 which were not resumed until February 2025;
  ●prevailing interest rates, increases in which may have an adverse effect on the market price of the Preferred Stock;
  ●trading prices of similar securities;
  ●the annual yield from dividends on the Preferred Stock as compared to yields on other financial instruments;
  ●general economic and financial market conditions;
  ●government action or regulation;
  ●our financial condition, performance and prospects of our competitors;
  ●changes in financial estimates or recommendations by securities analysts with respect to us or our competitors in our industry;
  ●our issuance of additional preferred equity or debt securities; and
  ●actual or anticipated variations in quarterly operating results of us and our competitors.

 

A holder of Preferred Stock has extremely limited voting rights.

 

The voting rights for a holder of Preferred Stock are limited. Our shares of common stock are the only class of our securities that carry full voting rights, and Mahmud Haq, our Executive Chairman, beneficially owned approximately 31% of our outstanding shares of common stock as of December 31, 2024. After the Conversion, he now owns approximately 12% of our outstanding common shares. Accordingly, Mr. Haq exercises a significant level of control over all matters requiring stockholder approval, including the election of directors, amendment of our certificate of incorporation, and approval of significant corporate transactions. This control could have the effect of delaying or preventing a change of control of our Company or changes in management, and will make the approval of certain transactions difficult or impossible without his support, which in turn could reduce the price of our Preferred Stock.

 

37
 

 

Voting rights for holders of the Preferred Stock exist primarily with respect to the ability to elect, voting together with the holders of any other series of our preferred stock having similar voting rights, two additional directors to our Board of Directors, subject to limitations, in the event that eighteen monthly dividends (whether or not consecutive) payable on the Preferred Stock are in arrears, and with respect to voting on amendments to our articles of incorporation or articles of amendment relating to the Preferred Stock that materially and adversely affect the rights of the holders of Preferred Stock or authorize, increase or create additional classes or series of our capital stock that are senior to the Preferred Stock. Other than the limited circumstances and except to the extent required by law, holders of Preferred Stock do not have any other voting rights.

 

The Preferred Stock is not convertible at the option of the holder, and investors will not realize a corresponding upside if the price of the common stock increases.

 

The Preferred Stock is not convertible into common stock at the option of the holder and earns dividends at a fixed rate. Accordingly, an increase in the market price of our common stock will not necessarily result in an increase in the market price of our Preferred Stock. The market value of the Preferred Stock may depend more on dividend and interest rates for other preferred stock, commercial paper and other investment alternatives and our actual and perceived ability to pay dividends on, and in the event of dissolution satisfy the liquidation preference with respect to the Preferred Stock.

 

Although payment of the suspended dividends resumed in February 2025, there are still dividends in arrears and we may be unable to raise additional capital without incurring excessive dilution.

 

In December 2023, we suspended payment on the Preferred Stock dividends. The Company resumed monthly payment of the dividends in February 2025 by paying one month of arrears. The dividend arrearage on the converted Series A Preferred Stock was satisfied through the Conversion. Although we believe we can use a shelf registration statement to raise additional capital, until the dividend repayments are made in full, we may not be able to file a shelf registration. In addition to incurring excessive dilution, investors may not have an interest in purchasing our securities since the dividend was previously suspended for 14 months.

 

Item 1B. Unresolved Staff Comments

 

None.

 

Item 1C. Cybersecurity

 

Cybersecurity Risk Management and Strategy

 

We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include internal and external threats, data loss, phishing attacks, distributed denial of service attacks, third party risks, unpatched systems, weak authentications and zero-day vulnerabilities.

 

Identifying and assessing cybersecurity risk is integrated into our overall risk management systems and processes. Cybersecurity risks related to our business, technical operations, privacy and compliance issues are identified and addressed through a multi-faceted approach including third party assessments, internal IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity incidents, the Company conducts proactive cybersecurity reviews of systems and applications, audits applicable data policies, performs penetration testing using external third-party tools and techniques to test security controls, conducts employee training, monitors emerging laws and regulations related to data protection and information security and implements appropriate changes.

 

We have implemented incident response and breach management processes which have four overarching and interconnected stages: 1) preparation for a cybersecurity incident, 2) detection and analysis of a security incident, 3) containment, eradication and recovery, and 4) post-incident analysis. Such incident responses are overseen by leaders from our Information Security, Compliance and Legal teams regarding matters of cybersecurity.

 

Security events and data incidents are evaluated, ranked by severity and prioritized for response and remediation. Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact. As of the date of this Form 10-K, we have not experienced a cybersecurity threat or incident that resulted in a material adverse impact to our business or operations.

 

38
 

 

We also conduct exercises to simulate responses to cybersecurity incidents. Our team of cybersecurity professionals then collaborate with technical and business stakeholders across our business units to further analyze the risk to the Company, and form detection, mitigation and remediation strategies.

 

As part of the above processes, we regularly engage consultants to assess our internal cybersecurity programs and compliance with applicable practices and standards. For 2024 and 2023, our Information Security Management System is compliant with ISO 27001. We also had SOC 2, Type 2 reviews performed for the years 2024 and 2023.

 

Our risk management program also assesses third party risks, and we perform third-party risk management to identify and mitigate risks from third parties such as vendors, suppliers, and other business partners associated with our use of third-party service providers.

 

We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading “Disruptions in internet or telecommunication service or damage to our data centers could adversely affect our business by reducing our customers’ confidence in the reliability of our services and products” included as part of our risk factor disclosures in Item 1A of this Annual Report on Form 10-K.

 

Our Vice President of IT Infrastructure is responsible for overseeing the Company’s cybersecurity. He has a Bachelor’s degree in computer science and has 16 years of extensive experience spanning diverse IT domains, with a specialized emphasis on Information Security across endpoints, servers, data centers, cloud infrastructure, and enterprise applications. He has been actively overseeing the strategic implementation of cybersecurity in accordance with information security management standards, HIPAA, and SOC 2 policies and procedures throughout the entire organization. This multifaceted responsibility involves managing and ensuring compliance with internationally recognized standards such as the ISO 27001 framework, healthcare regulatory guidelines under HIPAA and other recognized standards.

 

Cybersecurity Governance

 

Cybersecurity is an important part of our risk management processes and an area of focus for our Board of Directors and management. Our Cybersecurity subcommittee of the Board of Directors is responsible for the oversight of risks from cybersecurity threats. Members of the Cybersecurity subcommittee receive updates on a quarterly basis from senior management, including leaders from our Information Security, Finance, Internal Audit, Compliance and Legal teams regarding cybersecurity matters. This includes existing and new cybersecurity risks, status on how management is addressing and/or mitigating those risks, cybersecurity and data privacy incidents, (if any), and the status on key information security initiatives.

 

Our cybersecurity risk management and strategy processes are overseen by our Vice President of IT Infrastructure and leaders from our Information Technology department. These individuals are informed about, and monitor the prevention, mitigation, detection and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan, and report to the Cybersecurity subcommittee on any appropriate items.

 

Item 2. Properties

 

Our corporate headquarters are located at 7 Clyde Road, Somerset, New Jersey 08873 where we occupy approximately 2,400 square feet of space under a month-to-month lease. Additionally, at December 31, 2024 we lease approximately 42,000 square feet of office space in 13 locations throughout the U.S., with lease terms that are typically five years or less. We also lease approximately 40,000 square feet for five pediatric offices in the Midwest, with leases that will expire between December 2025 and April 2036.

 

We lease approximately 14,000 square feet of land in Islamabad, Pakistan, where we constructed modular buildings used for office space and computer server facilities for two years expiring on September 30, 2026. The Company also leases a total of approximately 251,000 square feet of office space in Pakistan and in Sri Lanka. The lease in Sri Lanka expires in March 2025 and we intend to renew it for an additional year at expiration.

 

We believe our current facilities are adequate for our current needs and that suitable additional space will be available as and when needed.

 

39
 

 

Item 3. Legal Proceedings

 

On December 22, 2023, an arbitrator rendered a decision in favor of Ramapo Anesthesiologists, PC (“Ramapo”) and granted in part and denied in part certain claims brought against Origin Healthcare Solutions, LLC; Meridian Medical Management, Inc.; and the Company for alleged breach of contract and other allegations. Ramapo was awarded mitigation related costs of $117,000. The payment for such an award was made during the first quarter of 2024. The Company’s portion of the settlement was approximately $32,000 and the insurance company paid the balance. The Company’s portion was recorded in accrued expenses at December 31, 2023 in the consolidated balance sheet.

 

A former customer filed a complaint against the Company in New Jersey State Court to recover damages claimed to have been caused by the mishandling of their account. Plaintiff alleged at least approximately $750,000 in damages which was disputed by the Company. The parties participated in a one-day court-ordered, non-binding arbitration. At that time, the arbitrator awarded Plaintiff $288,750 on its contract claims, and awarded the Company $21,698 on its cross-claim for unpaid fees. Plaintiff filed to reject this award. The Company previously filed a partial motion for summary judgment on the alleged punitive damages, but the court denied that motion finding there is an issue of fact as to whether those can be awarded at trial. The Company filed an offer of judgment for $200,000 during April 2024 which was accepted and paid in July 2024.

 

In connection with a prior acquisition, the seller had alleged that the Company owed approximately $800,000 in transition related costs to them. The parties agreed to settle the claim for approximately $316,000, which was paid in September 2024.

 

From time to time, we may become involved in other legal proceedings arising in the ordinary course of our business. Including the proceedings described above, we are not presently a party to any legal proceedings that, in the opinion of our management, would individually or taken together have a material adverse effect on our business, consolidated results of operations, financial position or cash flows of the Company.

 

Please see “Risk Factor - Acquisitions may subject us to liability with regard to the creditors, customers, and shareholders of the sellers.” in Part 1, Item 1A of this Annual Report on Form 10-K.

 

Item 4. Mine Safety Disclosures

 

None.

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Our common stock has been listed since July 23, 2014 and is trading on the Nasdaq Global Market under the symbol “CCLD”.

 

Common Stockholders

 

As of December 31, 2024, there were approximately 7,800 holders of record of our common stock.

 

Dividends on Common Stock

 

We have not declared a cash dividend on our common stock since we became public on July 23, 2014, and currently we do not anticipate paying any cash dividends to holders of our common stock in the foreseeable future. The Company is prohibited from paying any dividends on common stock without the prior written consent of its senior lender, SVB.

 

Sales of Unregistered Securities

 

There were no sales of unregistered equity securities during the year ended December 31, 2024.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

There was no share repurchase activity during the three months ended December 31, 2024.

 

40
 

 

Securities Authorized for Issuance under the Equity Compensation Plan

 

As of December 31, 2024, the following table shows the number of securities to be issued upon vesting under the equity compensation plan approved by the Company’s Board of Directors.

 

Equity Compensation Plan Information

 

Plan Category  Number of securities to be issued upon vesting   Number of securities remaining available for future issuance under equity incentive plan (excluding securities to be issued upon vesting) 
Equity compensation plan approved by security holders - common shares   242,500    499,683 
Equity compensation plan approved by security holders - preferred shares   19,199    49,769 
Total   261,699    549,452 

 

Item 6. [Reserved]

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following is a discussion of our consolidated financial condition and results of operations for the years ended December 31, 2024 and 2023 and other factors that are expected to affect our prospective financial condition. The following discussion and analysis should be read together with our Consolidated Financial Statements and related notes beginning on page F-1 of this Annual Report on Form 10-K.

 

Some of the statements set forth in this section are forward-looking statements relating to our future results of operations. Our actual results may vary from the results anticipated by these statements. Please see “Forward-Looking Statements” on page 3 of this Annual Report on Form 10-K.

 

Overview

 

The Company is a healthcare information technology company that provides technology-enabled business solutions and Software-as-a-Service offerings (“SaaS”), which are often bundled, but are occasionally provided individually, together with related business services to healthcare providers and hospitals throughout the United States. The SaaS component is not material to the overall contract compared to the stand-alone value of RCM. Our integrated SaaS platform includes technology-enabled revenue cycle management (“RCM”), practice management (“PM”), electronic health records (“EHR”), artificial intelligence (“AI”) tools, business intelligence, telehealth, patient experience management (“PXM”) solutions and complementary software tools and business services for high-performance medical groups and health systems.

 

At a high level, these solutions can be categorized as follows:

 

●Technology-enabled business solutions, which are sometimes provided as individual offerings and often provided in combination with each other, including:

 

  ○ RCM services including end-to-end medical billing, eligibility, analytics, and related services, all of which can be provided utilizing our technology platform or through a third-party system;
  ○ AI tools are designed to serve as a digital healthcare assistant, helping to enhance clinical decision-making, streamline workflows, reduce administrative burdens, optimize revenue management, and promote patient-centered care;

 

41
 

 

  ○ EHRs, which are easy to use and sometimes integrated with our business services, and enable our healthcare provider clients to deliver better patient care, streamline their clinical workflows, decrease documentation errors and potentially qualify for government incentives;
  ○ PM software and related capabilities, which support our clients’ day-to-day business operations and financial workflows, including automated insurance eligibility software, a robust billing and claims rules engine and other automated tools designed to maximize reimbursement;
  ○ PXM solutions designed to transform interactions between patients and their clinicians, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services, including contactless digital check-in solutions, messaging and online appointment scheduling tools;
  ○ CareCloud Wellness, a digital health solution which includes chronic care management interactions with certified care managers, remote patient monitoring which feeds patient data directly to the EHR and highlights exceptions, and telehealth solutions which allow healthcare providers to conduct remote patient visits;
  ○ Business intelligence and healthcare analytics platforms that allow our clients to derive actionable insights from their vast amount of data;
  ○ Healthcare claims clearinghouse which enables our clients to electronically scrub and submit claims and process payments from insurance companies;
  ○ Interoperability and data transformation software to support the complex realities of data exchange with healthcare trading partners, including labs, insurance companies, and other healthcare IT vendors;
  ○ Customized applications, interfaces and a variety of other technology solutions that support our healthcare clients;
  ○ Professional services consisting of application and advisory services, revenue cycle services, data analytic services and educational training services; and
  ○ Workforce augmentation and on-demand staffing to support our clients as they expand their businesses, seek highly trained personnel, or struggle with staffing shortages.

 

●Medical practice management services are provided to medical practices. In this service model, we provide the medical practice with appropriate facilities, equipment, supplies, support services, nurses and administrative support staff. We also provide management, bill-paying and financial advisory services. We currently provide services to three pediatric practices which comprises the Medical Practice Management segment.

 

Our offshore operations together accounted for approximately 15% and 9% of total expenses for the years ended December 31, 2024 and 2023, respectively. A significant portion of those expenses were personnel-related costs (approximately 75% and 76% of foreign costs for the years ended December 31, 2024 and 2023, respectively). Because personnel-related costs are significantly lower in Pakistan and Sri Lanka than in the U.S. and many other offshore locations, we believe our offshore operations give us a competitive advantage over many industry participants. All of the medical billing companies that we have acquired used domestic labor or subcontractors from higher cost locations to provide all or a substantial portion of their services. We are able to achieve significant cost reductions as we shift these labor costs to our offshore operations.

 

Key Performance Measures

 

We consider numerous factors in assessing our performance. Key performance measures used by management include adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share. These key performance measures are non-GAAP financial measures, which we believe better enable management and investors to analyze and compare the underlying business results from period to period.

 

These non-GAAP financial measures should not be considered in isolation, or as a substitute for or superior to, financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Moreover, these non-GAAP financial measures have limitations in that they do not reflect all the items associated with the operations of our business as determined in accordance with GAAP. We compensate for these limitations by analyzing current and future results on a GAAP basis, as well as a non-GAAP basis, and we provide reconciliations from the most directly comparable GAAP financial measures to the non-GAAP financial measures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

 

42
 

 

Adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share provide an alternative view of performance used by management and we believe that an investor’s understanding of our performance is enhanced by disclosing these adjusted performance measures.

 

Adjusted EBITDA excludes the following elements which are included in GAAP net income (loss):

 

  ● Income tax provision (benefit) or the cash requirements to pay our taxes;
  ● Net interest expense or the cash requirements necessary to service interest on principal payments on our debt;
  ● Foreign currency gains and losses and other non-operating expenses;
  ● Stock-based compensation expense, which includes cash-settled awards and the related taxes, based on changes in the stock price;
  ● Depreciation and amortization charges;
  ● Integration costs, such as severance amounts paid to employees from acquired businesses and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
  ● Goodwill impairment charges;
  ● Lease terminations, unoccupied lease charges and restructuring costs; and
  ● Change in contingent consideration.

 

Set forth below is a presentation of our adjusted EBITDA for the years ended December 31, 2024 and 2023:

 

   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
Net revenue  $110,837   $117,059 
           
GAAP net income (loss)   7,851    (48,674)
           
Provision (benefit) for income taxes   160    (364)
Net interest expense   812    1,040 
Foreign exchange loss / other expense   335    918 
Stock-based compensation expense, net of restructuring costs   115    4,716 
Depreciation and amortization   14,142    14,402 
Transaction and integration costs   46    286 
Goodwill impairment charges   -    42,000 
Lease terminations, unoccupied lease charges and restructuring costs   596    1,105 
Adjusted EBITDA  $24,057   $15,429 

 

Adjusted operating income and adjusted operating margin exclude the following elements which are included in GAAP operating income (loss):

 

  ● Stock-based compensation expense, which includes cash-settled awards and the related taxes, based on changes in the stock price;
  ● Amortization of purchased intangible assets;
  ● Integration costs, such as severance amounts paid to employees from acquired businesses and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
  ● Goodwill impairment charges; and
  ● Lease terminations, unoccupied lease charges and restructuring costs.

 

43
 

 

Set forth below is a presentation of our adjusted operating income and adjusted operating margin, which represents adjusted operating income as a percentage of net revenue, for the years ended December 31, 2024 and 2023:

 

   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
Net revenue  $110,837   $117,059 
           
GAAP net income (loss)   7,851    (48,674)
Provision (benefit) for income taxes   160    (364)
Net interest expense   812    1,040 
Other expense - net   298    883 
GAAP operating income (loss)   9,121    (47,115)
GAAP operating margin   8.2%   (40.2%)
           
Stock-based compensation expense, net of restructuring costs   115    4,716 
Amortization of purchased intangible assets   1,577    4,975 
Transaction and integration costs   46    286 
Goodwill impairment charges   -    42,000 
Lease terminations, unoccupied lease charges and restructuring costs   596    1,105 
Non-GAAP adjusted operating income  $11,455   $5,967 
Non-GAAP adjusted operating margin   10.3%   5.1%

 

Adjusted net income and adjusted net income per share exclude the following elements which are included in GAAP net income (loss):

 

  ● Foreign currency gains and losses and other non-operating expenses;
  ● Stock-based compensation expense, which includes cash-settled awards and the related taxes, based on changes in the stock price;
  ● Amortization of purchased intangible assets;
  ● Integration costs, such as severance amounts paid to employees from acquired businesses and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
  ● Goodwill impairment charges;
  ● Lease terminations, unoccupied lease charges and restructuring costs; and
  ● Income tax provision (benefit) resulting from the amortization of goodwill related to our acquisitions.

 

No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes. The following table shows our reconciliation of GAAP net income (loss) to non-GAAP adjusted net income for the years ended December 31, 2024 and 2023:

 

   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
GAAP net income (loss)  $7,851   $(48,674)
           
Foreign exchange loss / other expense   335    918 
Stock-based compensation expense, net of restructuring costs   115    4,716 
Amortization of purchased intangible assets   1,577    4,975 
Transaction and integration costs   46    286 
Goodwill impairment charges   -    42,000 
Lease terminations, unoccupied lease charges and restructuring costs   596    1,105 
Income tax benefit related to goodwill   -    (525)
Non-GAAP adjusted net income  $10,520   $4,801 

 

44
 

 

   Year Ended December 31, 
   2024   2023 
GAAP net loss attributable to common shareholders, per share  $(0.28)  $(4.11)
Impact of preferred stock dividend   0.76    1.04 
Net income (loss) per end-of-period share   0.48    (3.07)
           
Foreign exchange loss / other expense   0.02    0.06 
Stock-based compensation expense, net of restructuring costs   0.01    0.30 
Amortization of purchased intangible assets   0.10    0.31 
Transaction and integration costs   0.00    0.02 
Goodwill impairment charges   -    2.65 
Lease terminations, unoccupied lease charges and restructuring costs   0.04    0.07 
Income tax benefit related to goodwill   -    (0.04)
Non-GAAP adjusted earnings per share  $0.65   $0.30 
           
End-of-period common shares   16,256,236    15,880,092 
Outstanding unvested RSUs   242,500    733,908 
Total fully diluted shares   16,498,736    16,614,000 
Non-GAAP adjusted diluted earnings per share  $0.64   $0.29 

 

For purposes of determining non-GAAP adjusted earnings per share, the Company used the number of common shares outstanding at the end of December 31, 2024 and 2023. Non-GAAP adjusted diluted earnings per share was computed using an as-converted method and includes warrants that are in-the-money as of that date as well as outstanding unvested RSUs. Non-GAAP adjusted earnings per share and non-GAAP adjusted diluted earnings per share do not take into account dividends on the Preferred Stock. No tax effect has been provided in computing non-GAAP adjusted earnings per share and non-GAAP adjusted diluted earnings per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes.

 

Consolidated Statements of Operations Data

 

   Year Ended December 31, 
   2024   2023   2022   2021   2020 
   ($ in thousands, except per share data) 
Net revenue  $110,837   $117,059   $138,826   $139,599   $105,122 
Operating expenses:                         
Direct operating costs   60,842    70,817    84,434    86,918    64,821 
Selling and marketing   6,232    9,650    9,788    8,786    6,582 
General and administrative   16,123    21,464    23,820    24,273    22,811 
Research and development   3,781    4,736    4,401    4,408    9,311 
Change in contingent consideration   -    -    (3,090)   (2,515)   (1,000)
Depreciation and amortization   14,142    14,402    11,725    12,195    9,905 
Goodwill impairment charges   -    42,000    -    -    - 
Lease terminations, unoccupied lease charges and restructuring costs   596    1,105    1,138    2,005    963 
Total operating expenses   101,716    164,174    132,216    136,070    113,393 
                          
Operating income (loss)   9,121    (47,115)   6,610    3,529    (8,271)
                          
Net interest expense   (812)   (1,040)   (364)   (440)   (446)
Other (expense) income - net   (298)   (883)   (637)   (96)   7 
Income (loss) before provision (benefit) for income taxes   8,011    (49,038)   5,609    2,993    (8,710)
Income tax provision (benefit)   160    (364)   177    157    103 
Net income (loss)  $7,851   $(48,674)  $5,432   $2,836   $(8,813)
Preferred stock dividend   12,310    15,674    15,517    14,052    13,877 
Net loss attributable to common shareholders  $(4,459)  $(64,348)  $(10,085)  $(11,216)  $(22,690)
Weighted average common shares outstanding basic and diluted   16,146,975    15,669,472    15,109,587    14,541,061    12,678,845 
Net loss per common share: basic and diluted  $(0.28)  $(4.11)  $(0.67)  $(0.77)  $(1.79)

 

Consolidated Balance Sheet Data

 

   As of December 31, 
   2024   2023   2022   2021   2020 
   ($ in thousands) 
Cash  $5,145   $3,331   $12,299   $10,340   $20,925 
Working capital - net (1)   5,220    (57)   12,255    5,997    15,795 
Total assets   71,614    77,826    136,174    140,848    137,999 
Total liabilities   21,840    36,109    34,485    42,917    36,754 
Shareholders’ equity   49,774    41,717    101,689    97,931    101,245 

 

(1) Working capital-net is defined as current assets less current liabilities.

 

Other Financial Data

 

To provide investors with additional insight and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making, we supplement our consolidated financial statements presented on a basis consistent with U.S. generally accepted accounting principles, or GAAP, with adjusted EBITDA, (previously defined), a non-GAAP financial measure of earnings.

 

   Year Ended December 31, 
   2024   2023   2022   2021   2020 
   ($ in thousands) 
Adjusted EBITDA  $24,057   $15,429   $22,248   $22,119   $10,871 

 

45
 

 

Quarterly Results of Operations

 

   December 31,   September 30,   June 30,   March 31,   December 31,   September 30,   June 30,   March 31, 
   2024   2024   2024   2024 (1)   2023   2023   2023   2023 
   ($ in thousands, except per share data) 
Net revenue  $            28,239   $               28,546   $ 28,090   $     25,962   $             28,416   $             29,280   $  29,362   $     30,001 
Operating expenses:                                        
Direct operating costs   15,003    15,420    15,242    15,177    16,974    18,260    17,476    18,107 
Selling and marketing   1,423    1,375    1,664    1,770    2,121    2,337    2,580    2,612 
General and administrative   3,996    4,378    4,028    3,721    4,946    5,482    5,916    5,120 
Research and development   1,013    800    1,055    913    1,213    1,260    1,185    1,078 
Depreciation and amortization   3,257    3,241    3,714    3,930    4,120    3,903    3,341    3,038 
Goodwill impairment charges   -    -    -    -    42,000    -    -    - 
Lease terminations, unoccupied lease charges and restructuring costs   91    67    116    322    675    8    153    269 
Total operating expenses   24,783    25,281    25,819    25,833    72,049    31,250    30,651    30,224 
                                         
Operating income (loss)   3,456    3,265    2,271    129    (43,633)   (1,970)   (1,289)   (223)
                                         
Net interest expense   (48)   (162)   (264)   (338)   (335)   (300)   (275)   (130)
Other (expense) income - net   (71)   60    (294)   7    (292)   (422)   (186)   17 
Income (loss) before provision (benefit) for income taxes   3,337    3,163    1,713    (202)   (44,260)   (2,692)   (1,750)   (336)
Income tax provision (benefit)   41    41    39    39    (568)   57    82    65 
Net income (loss)  $3,296   $3,122   $1,674   $(241)  $(43,692)  $(2,749)  $(1,832)  $(401)
                                         
Preferred stock dividend   3,286    3,789    3,923    1,312    3,917    3,916    3,910    3,931 
Net income (loss) attributable to common shareholders  $10   $(667)  $(2,249)  $(1,553)  $(47,609)  $(6,665)  $(5,742)  $(4,332)
Net income (loss) per common share:                                        
Basic and diluted  $0.00   $(0.04)  $(0.14)  $(0.10)  $(3.04)  $(0.42)  $(0.37)  $(0.28)
                                         
Adjusted EBITDA  $7,141   $6,840   $6,389   $3,687   $4,128   $3,245   $3,819   $4,237 

 

(1) The consolidated statement of operations for the three months ended March 31, 2024 has been restated to record the earned, but undeclared Preferred Stock dividend.

 

Reconciliation of net income (loss) to adjusted EBITDA

 

The following table contains a reconciliation of net income (loss) to adjusted EBITDA by year.

 

   Year Ended December 31, 
   2024   2023   2022   2021   2020 
   ($ in thousands) 
Net income (loss)  $7,851   $(48,674)  $5,432   $2,836   $(8,813)
Depreciation   2,043    2,001    1,952    1,927    1,354 
Amortization   12,099    12,401    9,773    10,268    8,551 
Foreign exchange loss / other expense   335    918    712    241    71 
Net interest expense   812    1,040    364    440    446 
Income tax provision (benefit)   160    (364)   177    157    103 
Stock-based compensation expense, net of restructuring costs   115    4,716    4,914    5,396    6,502 
Transaction and integration costs   46    286    876    1,364    2,694 
Goodwill impairment charges   -    42,000    -    -    - 
Lease terminations, unoccupied lease charges and restructuring costs   596    1,105    1,138    2,005    963 
Change in contingent consideration   -    -    (3,090)   (2,515)   (1,000)
Adjusted EBITDA  $24,057   $15,429   $22,248   $22,119   $10,871 

 

46
 

 

The following table contains a reconciliation of net income (loss) to adjusted EBITDA by quarter.

 

   December 31,   September 30,   June 30,   March 31,   December 31,   September 30,   June 30,   March 31, 
   2024   2024   2024   2024   2023   2023   2023   2023 
   ($ in thousands) 
Net income (loss)  $              3,296   $               3,122   $     1,674   $          (241)  $           (43,692)  $              (2,749)  $    (1,832)  $          (401)
Depreciation   533    504    503    503    505    493    511    492 
Amortization   2,724    2,737    3,211    3,427    3,615    3,410    2,830    2,546 
Foreign exchange loss (gain) / other expense   91    (57)   306    (5)   309    426    191    (8)
Net interest expense   48    162    264    338    335    300    275    130 
Income tax provision (benefit)   41    41    39    39    (568)   57    82    65 
Stock-based compensation expense, net of restructuring costs   306    252    265    (708)   933    1,209    1,502    1,072 
Transaction and integration costs   11    12    11    12    16    91    107    72 
Goodwill impairment charges   -    -    -    -    42,000    -    -    - 
Lease terminations, unoccupied lease charges and restructuring costs   91    67    116    322    675    8    153    269 
Adjusted EBITDA  $7,141   $6,840   $6,389   $3,687   $4,128   $3,245   $3,819   $4,237 

 

Key Metrics

 

In addition to the line items in our consolidated financial statements, we regularly review the following key metrics to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, make strategic business decisions, and assess market share trends and working capital needs. We believe information on these metrics is useful for investors to understand the underlying trends in our business.

 

Providers and Practices Served: As of December 31, 2024 and December 31, 2023, we provided services to approximately 40,000 providers (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services), representing approximately 2,600 practices. In addition, we served approximately 150 clients who were not medical practices, but are service organizations who serve the healthcare community. The foregoing numbers include clients leveraging any of our products or services and are based in part upon estimates in cases where the precise number of practices or providers is unknown.

 

Customer Renewal Rate: Our customer renewal rate measures the percentage of our RCM clients who utilize our technology platform who were a party to a services agreement with us on January 1 of a particular year and continued to operate and be a client on December 31 of the same year. It also includes acquired accounts, if they are a party to a services agreement with the company we acquired and are generating revenue for us, so long as the risk of client loss under the respective purchase agreement has fully shifted to us by January 1 of the particular year. Our renewal rates for 2024 and 2023 were 95% and 91% of the number of practices that renewed, respectively. These renewal percentages are not indicative of the loss of revenue due to non-renewal.

 

Sources of Revenue

 

Revenue: We primarily derive our on-going revenues from technology-enabled business solutions, reported in our Healthcare IT segment, which typically includes revenue cycle management and is billed as a percentage of payments collected by our customers. This fee includes the ability to use our EHR, practice management systems and other software as part of the bundled fee. These solutions accounted for approximately 67% and 65% of our revenues during the years ended December 31, 2024 and 2023, respectively. This includes customers utilizing our proprietary product suites, as well as customers from acquisitions of RCM companies which we are servicing utilizing third-party software. Key drivers of our revenue include growth in the number of providers we are servicing, the number of patients served by those providers, and collections by those providers. It also includes SaaS fees, for clients not utilizing revenue cycle management services. When clients utilize our revenue cycle management services, basic SaaS services are included at no additional charge. Revenue is also generated from coding, credentialing, indexing, transcription and other ancillary services.

 

Our professional services include an extensive set of services including EHR vendor-agnostic optimization and activation, project management, IT transformation, consulting, process improvement, training, education and staffing for large healthcare organizations including health systems and hospitals. Revenue is recorded monthly on either a time and materials or a fixed rate basis for each contract.

 

We also generate revenue from our printing and mailing, group purchasing services and medical practice management services.

 

47
 

 

We earned approximately 1% of our revenue from group purchasing services during both years ended December 31, 2024 and 2023. We earned approximately 13% and 11% of our revenue from medical practice management services during the years ended December 31, 2024 and 2023, respectively. This revenue represents fees based on our actual costs plus a percentage of the operating profit and is reported in our Medical Practice Management segment.

 

Operating Expenses

 

Direct Operating Costs. Direct operating costs consist primarily of salaries and benefits related to personnel who provide services to our customers, claims processing costs, costs to operate the three managed practices, including facility lease costs, supplies, insurance and other direct costs related to our services. Costs associated with the implementation of new customers are expensed as incurred. The reported amounts of direct operating costs do not include depreciation and amortization, which are broken out separately in the consolidated statements of operations. Operations in our Offshore Offices together accounted for approximately 13% and 11% of direct operating costs for the years ended December 31, 2024 and 2023, respectively. As we grow, we expect to achieve further economies of scale and to see our direct operating costs decrease as a percentage of revenue.

 

Selling and Marketing Expense. Selling and marketing expense consists primarily of compensation and benefits, commissions, travel and advertising expenses, which includes onshore and offshore personnel.

 

General and Administrative Expense. General and administrative expense consists primarily of personnel-related expense for administrative employees, including compensation, benefits, travel, facility lease costs and insurance, software license fees and outside professional fees. Our Offshore Offices accounted for approximately 22% and 17% of general and administrative expenses for the years ended December 31, 2024 and 2023, respectively.

 

Research and Development Expense. Research and development expense consists primarily of personnel-related costs, software expense and third-party contractor costs.

 

Depreciation and Amortization Expense. Depreciation expense is charged using the straight-line method over the estimated lives of the assets ranging from three to five years. Amortization expense is charged on either an accelerated or on a straight-line basis over a period of three or four years for most intangible assets acquired in connection with acquisitions including those intangibles related to the group purchasing services. Amortization expense related to the value of our medical practice management clients is amortized on a straight-line basis over a period of twelve years.

 

Goodwill Impairment Charges. Goodwill impairment charges in 2023, which were related to the Healthcare IT reporting unit, represent the impairment recorded as it was determined that the fair value of the goodwill was less than the carrying value.

 

Lease Terminations, Unoccupied Lease Charges and Restructuring Costs. Lease terminations represent the write-off of leasehold improvements and gains or losses as the result of lease terminations. Unoccupied lease charges represent the portion of lease and related costs for vacant space not being utilized by the Company. Restructuring costs, primarily consist of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements.

 

Interest and Other Income (Expense). Interest income represents interest earned on temporary cash investments and late fees from customers. Interest expense consists primarily of interest costs related to our line of credit, motor vehicle loans and amortization of deferred financing costs. Other income (expense) results primarily from foreign currency transaction gains (losses).

 

Income Taxes. In preparing our consolidated financial statements, we estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred income tax assets and liabilities. Although the Company reported GAAP earnings in 2024, it has incurred losses historically and there is uncertainty regarding future U.S. taxable income, which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all deferred tax assets as of December 31, 2024 and December 31, 2023. For the global intangible low-taxed income (“GILTI”) tax, companies can either account for the GILTI inclusion in the period in which they are incurred or establish deferred tax liabilities for the expected future taxes associated with GILTI. The Company records the GILTI provisions as they are incurred each period.

 

48
 

 

Critical Accounting Policies and Estimates

 

We prepare our consolidated financial statements in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions about future events, and apply judgments that affect the reported amounts of assets, liabilities, revenue, expense and related disclosures. We base our estimates, assumptions and judgments on historical experience, current trends and various other factors that we believe to be reasonable under the circumstances. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. On a regular basis, we review our accounting policies, estimates, assumptions and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. The methods, estimates and judgments that we use in applying our accounting policies have a significant impact on our results of operations.

 

Critical accounting policies are those policies used in the preparation of our consolidated financial statements that require management to make difficult, subjective, or complex adjustments, and to make estimates about the effect of matters that are inherently uncertain.

 

Revenue from Contracts with Customers:

 

We account for revenue in accordance with ASC 606, Revenue from Contracts with Customers. Our revenue recognition policies require us to make significant judgments and estimates, particularly as it relates to revenue cycle management. Under ASC 606, certain significant accounting estimates, such as payment-to-charge ratios, effective billing rates and the estimated contractual payment periods are required to measure the revenue cycle management revenue. We analyze various factors including, but not limited to, contractual terms and conditions, the credit-worthiness of our customers and our pricing policies. Changes in judgment on any of the above factors could materially impact the timing and amount of revenue recognized in a given period.

 

Revenue is recognized as the performance obligations are satisfied. We derive revenue from five primary sources: technology-enabled business solutions, professional services, printing and mailing services, group purchasing services and medical practice management services. All of our revenue arrangements are based on contracts with customers. Most of our contracts with customers contain a single performance obligation. For contracts where we provide multiple services such as where we perform multiple ancillary services, each service represents its own performance obligation. Selling or transaction prices are based on the contractual price for the service, which is consistent with the stand-alone selling price.

 

Technology-enabled business solutions:

Our technology-enabled business solutions include our revenue cycle management and SaaS services. Revenue cycle management services are the recurring process of submitting and following up on claims with health insurance companies in order for the healthcare providers to receive payment for the services they rendered, assisted by our proprietary technology. CareCloud typically invoices customers on a monthly basis based on the actual collections received by its customers and the agreed-upon rate in the sales contract. The services include use of practice management software and related tools (on a SaaS basis), electronic health records (on a SaaS basis), medical billing services and use of mobile health solutions. We consider the services to be one performance obligation since the promises are not distinct in the context of the contract. The performance obligation consists of a series of distinct services that are substantially the same and have the same periodic pattern of transfer to our customers.

 

In many cases, our clients may terminate their agreements with 90 days’ notice without cause, thereby limiting the term in which we have enforceable rights and obligations, although this time period can vary between clients. Our payment terms are normally net 30 days. Although our contracts typically have stated terms of one or more years, under ASC 606 our contracts are considered month-to-month and accordingly, there is no financing component.

 

For the majority of our contracts which include revenue cycle management services, the total transaction price is variable because our obligation is to process an unknown quantity of claims, as and when requested by our customers over the contract period. When a contract includes variable consideration, we evaluate the estimate of the variable consideration to determine whether the estimate needs to be constrained; therefore, we include variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with variable consideration is subsequently resolved. Estimates to determine variable consideration such as payment to charge ratios, effective billing rates, and the estimated contractual payment periods are updated at each reporting date. Revenue is recognized over the performance period using the input method.

 

49
 

 

Professional services:

Revenues from professional services are recorded as the services are provided as the performance obligations are satisfied over time. Revenue is recorded based on the number of hours incurred and the agreed-upon hourly rate. Invoicing is primarily performed as of the end of each month.

 

Printing and mailing services:

The Company provides printing and mailing services for both revenue cycle management customers and a non- revenue cycle management customer, and invoices on a monthly basis based on the number of prints, the agreed-upon rate per print and the postage incurred. The performance obligation is satisfied once the printing and mailing is completed.

 

Group purchasing services:

The Company provides group purchasing services which enable medical providers to purchase various vaccines directly from selected pharmaceutical companies at a discounted price. Currently, there are approximately 4,000 medical providers who are members of the program. Revenue is recognized as the vaccine shipments are made to the medical providers. Fees from the pharmaceutical companies are paid either quarterly or annually and the Company adjusts its revenue accrual at the time of payment. The Company makes significant judgments regarding the variable consideration which we expect to be entitled to for the group purchasing services which includes the anticipated shipments to the members enrolled in the program, anticipated volumes of purchases made by the members, and the changes in the number of members. The amounts recorded are constrained by estimates of decreases in shipments and loss of members to avoid a significant revenue reversal in the subsequent period. The only performance obligation is to provide the pharmaceutical companies with the medical providers who want to become members in order to purchase vaccines. The performance obligation is satisfied once the medical provider agrees to purchase a specific quantity of vaccines and the medical provider’s information is forwarded to the vaccine suppliers. The Company records a contract asset for revenue earned and not paid as the ultimate payment is conditioned on achieving certain volume thresholds.

 

Practice management services:

We estimate the amount that will be collected on claims submitted to insurance carriers which is used to determine the compensation to be paid to the owners of the managed practices. These compensation amounts reduce the revenue that the Company recognizes since they are deducted from gross billings. The estimate of the amounts to be received from the insurance claims are updated at each reporting period.

 

Although we believe that our approach to estimates and judgments is reasonable, actual results could differ, and we may be exposed to increases or decreases in revenue that could be material. Our estimates of variable consideration may prove to be inaccurate, in which case we may have understated or overstated the revenue recognized in an accounting period. The amount of variable consideration recognized to date that remains subject to estimation is included within the contract asset in the consolidated balance sheets.

 

Goodwill Impairment:

 

Goodwill is evaluated for impairment annually as of October 31st, referred to as the annual test date. As a result of the annual impairment test, an impairment of approximately $2 million was recorded in October 2023. The Company also tests for impairment between annual test dates if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting-unit level. The Company has determined that its business consists of two operating segments and two reporting units (Healthcare IT and Medical Practice Management). Application of the goodwill impairment test requires judgment including the use of a discounted cash flow approach, the trading price of publicly traded stock and the guideline public company method. These analyses require significant assumptions and judgments. These assumptions and judgments include estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, estimation of the useful life over which cash flows will occur, determination of our weighted average cost of capital and the selection of comparable companies and the interpretation of their data. Future business and economic conditions, as well as differences in actual financial results related to any of the assumptions, could materially impact the consolidated financial statements through impairment of goodwill or intangible assets and acceleration of the amortization period of the purchased intangible assets which are finite-lived assets. There was a triggering event at August 31, 2023, but it was determined that there was no impairment. Due to a triggering event in December 2023, an additional impairment test was performed. As a result, the Company recorded an additional impairment of approximately $40 million. No impairment charges were recorded during the year ended December 31, 2024.

 

50
 

 

Business Combinations:

 

The Company accounts for business combinations under the provisions of ASC 805, Business Combinations, which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed are recorded at the date of acquisition at their respective fair values. The fair value amount assigned to intangible assets is based on an exit price from a market participant’s viewpoint, and utilizes data such as discounted cash flow analysis and replacement cost models. Critical estimates in valuing certain intangible assets include, but are not limited to, historical and projected client retention rates, expected future cash inflows and outflows, discount rates, and estimated useful lives of those intangible assets. ASC 805 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred.

 

Results of Operations

 

The following table sets forth our consolidated results of operations as a percentage of total revenue for the years shown.

 

   Year Ended December 31, 
   2024   2023 
Net revenue   100.0%   100.0%
Operating expenses:          
Direct operating costs   54.9%   60.5%
Selling and marketing   5.6%   8.2%
General and administrative   14.5%   18.3%
Research and development   3.4%   4.0%
Depreciation and amortization   12.8%   12.3%
Goodwill impairment charges   0.0%   35.9%
Lease terminations, unoccupied lease charges and restructuring costs   0.6%   0.9%
Total operating expenses   91.8%   140.1%
           
Operating income (loss)   8.2%   (40.1%)
           
Net interest expense   (0.7%)   0.9%
Other expense - net   (0.3%)   (0.8%)
Income (loss) before provision (benefit) for income taxes   7.2%   (41.8%)
Income tax provision (benefit)   0.1%   (0.3%)
Net income (loss)   7.1%   (41.5%)

 

Comparison of 2024 and 2023

 

   Year Ended
December 31,		   Change 
   2024   2023   Amount   Percent 
   ($ in thousands) 
Net revenue  $110,837   $117,059   $(6,222)   (5%)

 

Net revenue. Net revenue of $110.8 million for the year ended December 31, 2024 decreased by $6.2 million or 5% from revenue of $117.1 million for the year ended December 31, 2023. Revenue for the years ended December 31, 2024 and December 31, 2023 includes $73.7 million and $76.6 million relating to technology-enabled business solutions, $18.2 million and $23.0 million related to professional services and $14.4 million and $13.4 million for medical practice management services, respectively.

 

There was a $4.8 million decrease in project-based professional services revenue for the year ended December 31, 2024 as compared to 2023. The 2024 technology-enabled business solutions revenue was negatively impacted by two large accounts that had each been previously acquired prior to our beginning to serve them after a 2020 acquisition. The services provided to them were each winding down at the time of our acquisition and they both transitioned to the systems of their acquirers during 2022. Revenue from these two customers for the year ended December 31, 2024 was approximately $300,000, accounting for approximately $2.8 million of the decline in revenue. No further revenue from these customers is expected for the year 2025. (Refer to Forward-Looking Statements disclosure on page 3 of this Form 10-K.)

 

51
 

 

   Year Ended December 31,   Change 
   2024   2023   Amount   Percent 
   ($ in thousands) 
Direct operating costs  $60,842   $70,817   $(9,975)   (14%)
Selling and marketing   6,232    9,650    (3,418)   (35%)
General and administrative   16,123    21,464    (5,341)   (25%)
Research and development   3,781    4,736    (955)   (20%)
Depreciation   2,043    2,001    42    2%
Amortization   12,099    12,401    (302)   (2%)
Goodwill impairment charges   -    42,000    (42,000)   (100%)
Lease terminations, unoccupied lease charges and restructuring costs   596    1,105    (509)   (46%)
Total operating expenses  $101,716   $164,174   $(62,458)   (38%)

 

Direct Operating Costs. Direct operating costs of $60.8 million for the year ended December 31, 2024 decreased by $10.0 million or 14% from direct operating costs of $70.8 million for the year ended December 31, 2023. Salary costs decreased by $6.3 million due to the decrease in the Pakistan exchange rate, a decrease in the U.S. headcount and the redeployment of employees performing functions that were classified as direct operating costs to functions classified as research and development expense. Outsourcing and other customer processing costs decreased by $2.4 million and billable expenses decreased by $1.3 million.

 

Selling and Marketing Expense. Selling and marketing expense of $6.2 million for the year ended December 31, 2024 decreased by $3.4 million or 35% from selling and marketing expense of $9.7 million for the year ended December 31, 2023. The decrease for the year ended December 31, 2024 was due to lower spending on selling and marketing activities and a reduction in headcount.

 

General and Administrative Expense. General and administrative expense of $16.1 million for the year ended December 31, 2024 decreased by $5.3 million or 25% from general and administrative expense of $21.5 million for the year ended December 31, 2023. Salary costs decreased by $3.5 million due to the decrease in headcount and the Pakistan exchange rate. Legal, professional and audit fees decreased by $790,000. Other costs such as computer expenses, utilities and office supplies decreased by $295,000.

 

Research and Development Expense. Research and development expense of $3.8 million for the year ended December 31, 2024 decreased by $955,000 or 20% from research and development expense of $4.7 million for the year ended December 31, 2023. The decrease was due to a decrease in the U.S. headcount which was offset by the redeployment of employees performing functions that were previously classified as direct operating costs to functions classified as research and development expense. During the years ended December 31, 2024 and 2023, the Company capitalized approximately $5.7 million and $8.6 million of development costs, respectively, in connection with its internal-use software.

 

Depreciation Expense. Depreciation expense was $2.0 million for both the years ended December 31, 2024 and 2023.

 

Amortization Expense. Amortization expense of $12.1 million for the year ended December 31, 2024 decreased by $302,000 or 2% from amortization expense of $12.4 million for the year ended December 31, 2023. The decrease in amortization expense was due to certain intangible assets related to acquisitions becoming fully amortized.

 

Goodwill Impairment Charges. Goodwill impairment charges in 2023 represent the impairment recorded as it was determined that the fair value of the Healthcare IT reporting unit was less than the carrying value at both the annual impairment test date of October 31, 2023 and as a result of a triggering event in December 2023. There were no impairment charges recorded in 2024.

 

52
 

 

Lease Terminations, Unoccupied Lease Charges and Restructuring Costs. Lease terminations represent the write-off of leasehold improvements and gains or losses as the result of lease terminations. During the year ended December 31, 2024, there was a gain on a lease termination of $10,000. During the year ended December 31, 2023, the Miami office lease that we assumed in connection with an acquisition ended and we entered into a new lease arrangement with the landlord for significantly less space. Charges of $102,000 for the year ended December 31, 2023, were incurred as a result of vacating the former premises. During the year ended December 31, 2022, a facility lease was terminated in conjunction with the Company ceasing its document storage services resulting in additional costs for the year ended December 31, 2023 of $162,000. In addition, during the year ended December 31, 2023, the Company paid $27,000 to settle a claim regarding a lease termination in India. Unoccupied lease charges represent the portion of lease and related costs for that portion of the space that is vacant and not being utilized by the Company. Unoccupied lease charges for the year ended December 31, 2023 were $169,000. There were no unoccupied lease charges in 2024. In addition, during the years ended December 31, 2024 and 2023, the Company recorded approximately $606,000 and $645,000 of restructuring costs, respectively. Restructuring costs consists of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements.

 

   Year Ended December 31,   Change 
   2024   2023   Amount   Percent 
   ($ in thousands) 
Interest income  $88   $154   $(66)   (43%)
Interest expense   (900)   (1,194)   294    25%
Other expense - net   (298)   (883)   585    66%
Income tax provision (benefit)   160    (364)   524    144%

 

Interest Income. Interest income of $88,000 for the year ended December 31, 2024 decreased by $66,000 or 43% from interest income of $154,000 for the year ended December 31, 2023. The interest income represents late fees from customers and interest earned on temporary cash investments, which decreased due to lower balances being invested.

 

Interest Expense. Interest expense of $900,000 for the year ended December 31, 2024 decreased by $294,000 or 25% from $1.2 million for the year ended December 31, 2023. The decrease in interest expense was due to the decreased use of the line of credit and decreases in the interest rate charged. Interest expense on the line of credit was $649,000 and $906,000 and the amortization of deferred financing costs was $127,000 and $169,000 during the years ended December 31, 2024 and 2023, respectively.

 

Other Expense - net. Other expense - net was $298,000 for the year ended December 31, 2024 compared to other expense - net of $883,000 for the year ended December 31, 2023. Other expense primarily represents foreign currency transaction gains and losses and legal settlements made by the Company. There was a foreign exchange gain of $130,000 and a loss of $790,000 for the years ended December 31, 2024 and 2023, respectively. Transaction gains and losses result from revaluing intercompany accounts which are denominated in U.S. dollars that represent amounts receivable/payable between the entities. Whenever the exchange rate varies, the gains and losses are recorded in the consolidated statements of operations.

 

Income Tax Provision (Benefit). There was a $160,000 provision for income taxes for the year ended December 31, 2024 compared to the benefit for income taxes of $364,000 for the year ended December 31, 2023.

 

The current income tax expense for the years ended December 31, 2024 and 2023 was $160,000 and $161,000, respectively. For the year ended December 31, 2023, there was a deferred tax benefit of $525,000. There was no deferred tax recorded for the year ended December 31, 2024. The current provision for 2024 and 2023 primarily relates to state and foreign income taxes. The pre-tax income and pre-tax loss was $8.0 million and $49.0 million for the years ended December 31, 2024 and 2023, respectively. Although the Company reported GAAP earnings in 2024, it has incurred losses historically and there is uncertainty regarding future U.S. taxable income, which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance was recorded against all deferred tax assets at December 31, 2024 and 2023.

 

The Company has recorded goodwill as a result of its acquisitions. Goodwill is generally not amortized for financial reporting purposes. However, goodwill from asset acquisitions is tax deductible and amortized over 15 years for tax purposes. As such, deferred income tax expense and a deferred tax liability arise as a result of the tax-deductibility of this indefinitely lived asset. The resulting deferred tax liability, which is recorded over the amortization period, has an indefinite life. In 2023, there was a goodwill impairment charge of $42 million, a portion of which was allocated to the tax deductible portion of the goodwill balance. The impairment charge resulted in the reversal of the entire deferred tax liability at December 31, 2023. There was no deferred tax liability recorded at December 31, 2024.

 

53
 

 

The Company will maintain a full valuation allowance on deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances.

 

As of December 31, 2024, the Company has a total federal NOL carry forward of approximately $265 million of which approximately $187 million will expire between 2031 and 2038, and the balance of approximately $78 million has an indefinite life. Out of the total federal NOL carry forward, approximately $237 million is from the CareCloud and Meridian acquisitions and is subject to the federal Section 382 NOL annual usage limitations. The Company has state NOL carry forwards of approximately $211 million, of which $84 million relates to the State of New Jersey. These NOLs expire starting in 2025.

 

Liquidity and Capital Resources

 

During the year ended December 31, 2024, there was positive cash flow from operations of $20.6 million and at year-end, the Company had $5.1 million in cash and positive working capital of $5.2 million. During the year ended December 31, 2023, there was positive cash flow from operations of $15.5 million and at year-end, the Company had $3.3 million in cash and negative working capital of $57,000. The Company has a revolving line of credit with SVB and, as of December 31, 2023, $10 million was outstanding. The line of credit was fully repaid during the year ended December 31, 2024 and there was nothing outstanding at December 31, 2024. During the year ended December 31, 2023, the Company sold 59,773 shares of 8.75% Series B Preferred Stock and raised $1.4 million in net proceeds after fees and expenses.

 

The following table summarizes our cash flows for the years presented.

 

   Year Ended December 31,   Change 
   2024   2023   Amount   Percent 
   ($ in thousands)     
Net cash provided by operating activities  $20,642   $15,461   $5,181    34%
Net cash used in investing activities   (7,406)   (11,613)   4,207    36%
Net cash used in financing activities   (11,256)   (13,285)   2,029    15%
Effect of exchange rate changes on cash   (166)   469    (635)   (135%)
Net increase (decrease) in cash  $1,814   $(8,968)  $10,782    120%

 

The income before income taxes was $8.0 million for the year ended December 31, 2024, which included $14.1 million of non-cash depreciation and amortization. The loss before income taxes for the year ended December 31, 2023 was $49.0 million, of which $42.0 million was a non-cash goodwill impairment charge and $14.4 million was non-cash depreciation and amortization.

 

We have not been adversely affected by inflation as typically we receive a percentage of the fees our clients collect from our revenue cycle management services. Additionally, our medical practice management contracts are based on our costs plus a percentage of the medical practice’s operating income. We continue to monitor the impact of inflation in order to minimize its effects through pricing strategies, productivity improvements and cost reductions. In the event of inflation, we believe that we will be able to pass on any price increases for fixed rate contracts to our customers, as the prices that we charge are not governed by long-term contracts. The interest rate on our line of credit is based on the prime rate which had been increasing through 2023 but decreased during 2024.

 

Operating Activities

 

Cash provided by operating activities was $20.6 million and $15.5 million during the years ended December 31, 2024 and 2023, respectively. The increase in the net income of $56.5 million included the following changes in non-cash items: a decrease in stock-based compensation expense of $4.8 million and a decrease in depreciation and amortization of $420,000. No goodwill impairment charges were recorded during 2024 as compared to the $42 million charge recognized in 2023. Revenue decreased by $6.2 million for the year ended December 31, 2024 compared to the year ended December 31, 2023, offset by a decrease in cash operating expenses of $20.2 million for the same period.

 

Accounts receivable increased by $1.2 million and decreased by $2.2 million for the years ended December 31, 2024 and 2023, respectively. Accounts payable, accrued compensation and accrued expenses decreased by $4.7 million and $3.3 million for the years ended December 31, 2024 and 2023, respectively.

 

54
 

 

Investing Activities

 

Cash used in investing activities during the year ended December 31, 2024 was $7.4 million, a decrease of $4.2 million compared to $11.6 million during the year ended December 31, 2023. Capitalized software was $5.7 million and $8.6 million during the years ended December 31, 2024 and 2023, respectively. Purchases of property and equipment were $1.7 million and $3.1 million during the years ended December 31, 2024 and 2023, respectively.

 

Financing Activities

 

Cash used by financing activities during the year ended December 31, 2024 was $11.3 million, compared to $13.3 million of cash used for the year ended December 31, 2023. Cash used by financing activities during 2024 includes the full repayment of the credit line of $10 million and $677,000 of repayments for debt obligations. Cash provided by financing activities during 2023 includes $1.4 million of net proceeds from issuing 59,773 shares of Series B Preferred Stock, offset by $888,000 of repayments for debt obligations, and $14.3 million of preferred stock dividends paid. There was also $579,000 of payments to settle the tax withholding obligations in 2024 compared to $1.5 million in 2023. Net proceeds on the line of credit were $2.0 million during the year ended December 31, 2023.

 

Contractual Obligations and Commitments

 

We have contractual obligations under our line of credit. We also maintain operating leases for property and certain office equipment. We were in compliance with all SVB covenants in 2024.

 

Off-Balance Sheet Arrangements

 

As of December 31, 2024, and 2023, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special-purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. During the first quarter of 2020, a New Jersey corporation, talkMD Clinicians, PA (“talkMD”), was formed by the wife of the Executive Chairman, who is a licensed physician, to provide telehealth services. talkMD was determined to be a variable interest entity (“VIE”) for financial reporting purposes because the entity will be controlled by the Company. As of December 31, 2024, talkMD had not yet commenced operations. The Company made arrangements to have the income tax returns prepared for talkMD and advances the funds for the required taxes. Cumulatively, the Company has paid approximately $6,000 on behalf of talkMD for income taxes. We do not engage in off-balance sheet financing arrangements.

 

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

 

We are a smaller reporting company as defined by 17 C.F.R. 229.10(f)(1) and are not required to provide information under this item, pursuant to Item 305(e) of Regulation S-K.

 

Item 8. Financial Statements and Supplementary Data

 

See “Index to Consolidated Financial Statements” which appears on page F-1 of this Annual Report on Form 10-K.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

55
 

 

Item 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Co-Chief Executive Officers and Interim Chief Financial Officer, based on the Internal Control-Integrated Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2024 as required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

 

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

Based on the evaluation of our disclosure controls and procedures, as of December 31, 2024, our Co-Chief Executive Officers and Interim Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective. Our management, including our Co-Chief Executive Officers and Interim Chief Financial Officer, have concluded that the consolidated financial statements in this Annual Report on Form 10-K fairly present, in all material respects, our consolidated financial condition, results of operations and cash flows for the periods presented in accordance with U.S. generally accepted accounting principles.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

 

Management is required to base its assessment on the effectiveness of our internal control over financial reporting on a suitable, recognized control framework. Management has utilized the criteria established in COSO to evaluate the effectiveness of internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

Our management has performed its assessment according to the guidelines established by COSO. Our management concluded that as of December 31, 2024, the Company’s internal control over financial reporting was effective.

 

Management has performed analysis and procedures in preparing our consolidated financial statements. We have concluded that our consolidated financial statements fairly present, in all material respects, our financial condition, results of operations and cash flows at and for the periods presented.

 

Because of its inherent limitations, our internal controls over financial reporting provide reasonable, not absolute, assurance that the financial statements and notes thereto are free of material error. In addition, no internal control structure can provide absolute assurance that all instances of fraud have been detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

 

This Annual Report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to the rules of the SEC that permit the Company to provide only management’s report in this Annual Report on Form 10-K.

 

56
 

 

Changes in Internal Control over Financial Reporting

 

During the fourth quarter of 2024, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information

 

During the quarter ended December 31, 2024, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

Not applicable.

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

Information required by this item will be included in our definitive Proxy Statement for the 2025 Meeting of Shareholders which will be filed within 120 days of the end of our fiscal year ended December 31, 2024 (“2025 Proxy Statement”) and is incorporated herein by reference.

 

Item 11. Executive Compensation

 

Information required by this item will be included in the 2025 Proxy Statement and is incorporated herein by reference.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

Information required by this item will be included in the 2025 Proxy Statement and is incorporated herein by reference.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence

 

Information required by this item will be included in the 2025 Proxy Statement and is incorporated herein by reference.

 

Item 14. Principal Accountant Fees and Services

 

Information required by this item will be included in the 2025 Proxy Statement and is incorporated herein by reference.

 

57
 

 

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

(a)The following documents are filed as part of this Annual Report on Form 10-K:

 

(1)Financial Statements

 

(i)Consolidated Balance Sheets as of December 31, 2024 and 2023
(ii)Consolidated Statements of Operations for the years ended December 31, 2024 and 2023
(iii)Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2024 and 2023
(iv)Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2024 and 2023
(v)Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023
 (vi)Notes to Consolidated Financial Statements

 

(2)Financial Statement Schedules

 

There are no Financial Statement Schedules filed as part of this Annual Report on Form 10-K as the required information is not applicable or is included in the Notes to Consolidated Financial Statements.

 

(b)Exhibit Index:

 

Exhibit

Number

   Description
     
2.1   Assignment Agreement dated October 3, 2016, by and between the Company, The Prudential Insurance Company of America, and Prudential Retirement Insurance and Annuity Company (filed as Exhibit 10.1 to the Company’s Form 8-K filed on October 5, 2016, and incorporated herein by reference).
     
2.2   Strict Foreclosure Agreement dated October 3, 2016, by and between MTBC Acquisition, Corp., MediGain, LLC and Millennium Practice Management Associates, LLC (filed as Exhibit 10.2 to the Company’s Form 8-K filed on October 5, 2016, and incorporated herein by reference).
     
2.3   Transition Services Agreement dated October 3, 2016, by and between MTBC Acquisition, Corp., MediGain, LLC and Millennium Practice Management Associates, LLC (filed as Exhibit 10.3 to the Company’s Form 8-K filed on October 5, 2016, and incorporated herein by reference).
     
2.4   First Amendment to Assignment Agreement dated January 3, 2017, by and between the Company, The Prudential Insurance Company of America, and Prudential Retirement Insurance and Annuity Company (filed as Exhibit 2.1 to the Company’s Form 8-K filed on January 6, 2017, and incorporated herein by reference).
     
2.5   Second Amendment to Assignment Agreement dated January 23, 2017, by and between the Company, The Prudential Insurance Company of America, and Prudential Retirement Insurance and Annuity Company (filed as Exhibit 2.1 to the Company’s Form 8-K filed on January 24, 2017, and incorporated herein by reference).
     
2.6   Asset Purchase Agreement dated June 25, 2018, by and between MTBC, and Orion Healthcorp, Inc. (filed as Exhibit 10.1 to the Company’s Form 8-K filed on July 2, 2018, and incorporated herein by reference).
     
2.7   Transition Services Agreement dated June 25, 2018, by and between MTBC, and Orion Healthcorp, Inc. (filed as Exhibit 2.29 to the Company’s Form S-1 filed on September 25, 2018, and incorporated herein by reference).
     
2.8   Asset Purchase Agreement dated March 27, 2019, by and between MTBC-Med, Inc., and Etransmedia Technology, Inc., et. al. (filed as Exhibit 10.1 to the Company’s Form 8-K filed on March 28, 2019, and incorporated herein by reference).

 

58

 

 

2.9   Amended and Restated Asset Purchase Agreement dated April 3, 2019, by and between MTBC-Med, Inc., and Etransmedia Technology, Inc., et. al. (filed as Exhibit 10.1 to the Company’s Form 8-K filed on April 4, 2019, and incorporated herein by reference).
     
2.10   Agreement and Plan of Merger by and among MTBC, Inc., MTBC Merger Sub, Inc., CareCloud Corporation and Runway Growth Credit Fund Inc., as the Seller’s representative dated January 8, 2020 (filed as Exhibit 2.1 to the Company’s Form 8-K filed on January 8, 2020, and incorporated herein by reference).
     
2.11   Escrow Agreement dated January 8, 2020 by and among MTBC, Inc., Runway Growth Credit Fund., Inc. and TD Bank (filed as Exhibit 10.17 to the Company’s Form 10-K filed on February 28, 2020, and incorporated herein by reference).
     
2.12   Stock Purchase Agreement dated June 16, 2020 by and among MTBC, Inc., Origin Holdings, Inc., Meridian Billing Management Co., Origin Holdings, Inc., and GMM II Holdings, LLC, (filed as Exhibit 2.1 to the Company’s Form 8-K on June 17, 2020, and incorporated herein by reference).
     
2.13   Asset and Stock Purchase Agreement by and among CareCloud Acquisition. Corp., MedMatica Consulting Associates, Inc., and Jerold Howell dated June 1, 2021 (filed as Exhibit 2.1 to the Company’s Form 8-K filed on June 2, 2021, and incorporated herein by reference).
     
2.14   Non-Competition and Non-Solicitation Agreement by and among Santa Rosa Consulting, Inc., SureTest Holdings, LLC, Laura O’Toole, Mark Scruggs, Raleigh Brewer, Thomas Watford, and CareCloud Acquisition, Corp., dated June 1, 2021 (filed as Exhibit 2.2 to the Company’s Form 8-K filed on June 2, 2021, and incorporated herein by reference).
     
2.15   Transition Services Agreement by and among CareCloud Acquisition, Corp., MedMatica Consulting Associates, Inc., and Jerold Howell, dated June 1, 2021 (filed as Exhibit 2.3 to the Company’s Form 8-K filed on June 2, 2021 and incorporated herein by reference).
     
3.1   Amended and Restated Certificate of Incorporation of the Company dated April 4, 2014 (filed as Exhibit 3.1 to the Company’s Form S-1 filed on September 25, 2018 and incorporated herein by reference).
     
3.2  

Certificate of Amendment of Certificate of Incorporation of the Company dated June 28, 2016 (filed as Exhibit 3.2 to the Company’s Form S-1 filed on September 25, 2018 and incorporated herein by reference).

     
3.3   Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company dated June 18, 2018 (filed as Exhibit 3.6 to the Company’s Form S-1 filed on September 25, 2018 and incorporated herein by reference).
     
3.4  

Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company dated February 6, 2019 (filed as Exhibit 3.1 to the Company’s Form 8-K filed on February 7, 2019 and incorporated herein by reference).

     
3.5  

Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company dated June 25, 2019 (filed as Exhibit 3.1 to the Company’s Form 8-K filed on June 25, 2019 and incorporated herein by reference).

     
3.6  

Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company dated February 26, 2021 (filed as Exhibit 3.1 to the Company’s Form 8-K filed on March 29, 2021 and incorporated herein by reference).

     
3.7  

Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company dated June 16, 2022 (filed as Exhibit 3.6 to the Company’s Form 8-K/A filed on June 17, 2022 and incorporated herein by reference).

     
3.8   Certificate of Correction to Certificate of Amendment to Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Company’s Form 8-K/A filed June 17, 2022 and incorporated herein by reference).

 

59

 

 

3.9   Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company dated February 5, 2025 (filed as Exhibit 3.1 to the Company’s Form 8-K filed on February 7, 2025 and incorporated herein by reference).
     
3.10   Amended and Restated Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock dated July 6, 2016 (filed as Exhibit 3.3 to the Company’s Form S-1 filed on September 25, 2018, and incorporated herein by reference).
     
3.11   First Amendment to Amended and Restated Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock dated September 15, 2017 (filed as Exhibit 3.4 to the Company’s Form S-1 filed on September 25, 2018, and incorporated herein by reference).
     
3.12   Second Amendment to Amended and Restated Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock dated March 23, 2018 (filed as Exhibit 3.5 to the Company’s Form S-1 filed on September 25, 2018, and incorporated herein by reference).
     
3.13   Third Amendment to Amended and Restated Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock dated September 25, 2018 (filed as Exhibit 3.7 to the Company’s Form S-1 filed on September 25, 2018, and incorporated herein by reference).
     
3.14   Fourth Amendment to Amended and Restated Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock dated January 9, 2020 (filed as Exhibit 3.1 to the Company’s Form 8-K filed on January 28, 2020, and incorporated herein by reference).
     
3.15   Fifth Amendment to Amended and Restated Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock dated May 19, 2020 (filed as Exhibit 3.2 to the Company’s Form 8-K filed on May 21, 2020, and incorporated herein by reference).
     
3.16   Sixth Amendment to Amended and Restated Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock dated July 9, 2020 (filed as Exhibit 3.1 to the Company’s Form 8-K filed on July 9, 2020, and incorporated herein by reference).
     
3.17   Seventh Amendment to Amended and Restated Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock (filed as exhibit 3.1 to the Company’s Form 8-K filed January 31, 2022 and incorporated herein by reference).
     
3.18   Certificate of Correction to Eighth Amendment to Amended and Restated Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock (filed as Exhibit 3.2 to the Company’s Form 8-K/A filed June 17, 2022 and incorporated herein by reference).
     
3.19   Eighth Amendment to Amended and Restated Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock dated June 15, 2022 (filed as Exhibit 3.4 to the Company’s Form 8-K/A filed June 17, 2022 and incorporated herein by reference).
     
3.20   Ninth Amendment to Amended and Restated Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Perpetual Preferred Stock dated September 11, 2024 (filed as Exhibit 3.1 to the Company’s Form 8-K filed September 16, 2024 and incorporated herein by reference).
     
3.21   Certificate of Designations, Preferences and Rights of 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (filed as exhibit 3.2 to the Company’s Form 8-K filed January 31, 2022 and incorporated herein by reference).
     
3.22   Certificate of Correction to First Amendment to Certificate of Designations, Preferences and Rights of 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (filed as Exhibit 3.3 to the Company’s Form 8-K/A filed June 17, 2022 and incorporated herein by reference).

 

60

 

 

3.23   First Amendment to Certificate of Designations, Preferences and Rights of 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock dated June 15, 2022 (filed as Exhibit 3.5 to the Company’s Form 8-K/A filed June 17, 2022 and incorporated herein by reference).
     
3.24   Amended and Restated By-laws of the Company (filed as Exhibit 3.2 to the Company’s Amendment No. 1 to Form S-1 filed on April 7, 2014, and incorporated herein by reference).
     
4.1   Form of common stock certificate of the Company (filed as Exhibit 4.1 to Amendment No. 2 to the Company’s Form S-1 filed on May 7, 2014, and incorporated herein by reference).
     
4.2   Form of stock certificate of the 11% Series A Cumulative Redeemable Perpetual Preferred Stock (filed as Exhibit 4.2 to Amendment No. 2 to the Company’s Form S-1 on October 19, 2015, and incorporated herein by reference).
     
4.3   Form of stock certificate of the 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (filed as Exhibit 4.3 to the Company’s Form 8-A on January 31, 2022 and incorporated herein by reference).
     
4.4   Warrant to Purchase Stock dated as of October 13, 2017 issued by the Company to Silicon Valley Bank (filed as Exhibit 10.2 to the Company’s Form 8-K filed on October 16, 2017, and incorporated herein by reference).
     
4.5   Warrant to Purchase Stock issued by the Company on September 20, 2018 to Silicon Valley Bank (filed as Exhibit 10.2 to the Company’s Form 8-K filed on September 20, 2018, and incorporated herein by reference).
     
4.6   Warrant to Purchase Stock issued by the Company on January 8, 2020 to Runway Growth Credit Fund Inc. (filed as Exhibit 4.5 to the Company’s Form 10-K filed on February 28, 2020, and incorporated herein by reference).
     
4.7   Warrant to Purchase Stock issued by the Company on January 8, 2020 to Runway Growth Credit Fund Inc. (filed as Exhibit 4.6 to the Company’s Form 10-K filed on February 28, 2020, and incorporated herein by reference).
     
4.8   Form of Warrant to Purchase Stock issued by the Company on June 16, 2020 with respect to the Meridian transaction (filed as Exhibit 4.7 to the Company’s Form S-1 filed on August 20, 2020, and incorporated herein by reference).
     
4.9   Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (filed as Exhibit 4.9 to the Company’s Form 10-K filed on March 2, 2023, and incorporated herein by reference).
     
10.1   Form of Indemnification Agreement between the Company and each of its directors and executive officers (filed as Exhibit 10.1 to Amendment No. 2 to the Company’s Form S-1 filed on May 7, 2014, and incorporated herein by reference).
     
10.2 *   Amended and Restated Equity Incentive Plan of the Company (filed as Appendix B to the Company’s Proxy Statement on Schedule 14A filed on February 10, 2017, and incorporated herein by reference).
     
10.3 *   First Amendment to the Amended and Restated Equity Incentive Plan of the Company (filed as Exhibit 10.16 to the Company’s Form 10-Q filed on August 8, 2018, and incorporated herein by reference).
     
10.4*   Second Amendment to MTBC, Inc. Amended and Restated Equity Incentive Plan (filed as Exhibit 3.1 to the Company’s Form 8-K filed on May 21, 2020, and incorporated herein by reference).
     
10.5 *   Form of Restricted Stock Unit Agreement under Amended and Restated Equity Incentive Plan (filed as Exhibit 10.3 to Amendment No. 1 to the Company’s Form S-1 filed on April 7, 2014, and incorporated herein by reference).
     
10.6 *   Third Amendment to Amended and Restated Equity Incentive Plan (filed as Exhibit 3.1 to the Company’s Form 8-K filed on June 9, 2022, and incorporated herein by reference).
     
10.7 *   Form of Restricted Stock Award Agreement under the Amended and Restated Equity Incentive Plan (filed as Exhibit 10.12 to the Company’s Form 10-K filed on March 24, 2016, and incorporated herein by reference).

 

61

 

 

10.8   Lease between Company and Mahmud Haq with respect to offices located at 7 Clyde Road, Somerset, NJ 08873 (filed as Exhibit 10.4 to the Company’s Form S-1 filed on December 20, 2013, and incorporated herein by reference).
     
10.9 *   Employment Agreement between the Company and Mahmud Haq dated as of May 1, 2018 (filed as Exhibit 10.1 to the Company’s Form 8-K filed on May 7, 2018, and incorporated herein by reference).
     
10.10 *   Employment Agreement between the Company and A. Hadi Chaudhry dated as of March 23, 2021 (filed as Exhibit 10.2 to the Company’s Form 8-K filed on March 24, 2021, and incorporated herein by reference).
     
10.11 *   Employment Agreement between the Company and Bill Korn dated as of May 1, 2018 (filed as Exhibit 10.4 to the Company’s Form 8-K filed on May 7, 2018, and incorporated herein by reference).
     
10.12 *   Employment Agreement and Bonus Agreement between the Company and Larry Steenvoorden each dated as of July 6, 2023 (filed as Exhibit 10.1 and 10.2, respectively, to the Company’s Form 8-K filed on July 11, 2023 and incorporated herein by reference).
     
10.13 *   Employment Agreement between the Company and A. Hadi Chaudhry dated December 16, 2024 (filed as Exhibit 10.1 to the Company’s Form 8-K filed on December 16, 2024 and incorporated herein by reference).
     
10.14 *   Employment Agreement between the Company and Stephen Snyder dated December 16, 2024 (filed as Exhibit 10.2 to the Company’s Form 8-K filed on December 16, 2024 and incorporated herein by reference).
     
10.15 *   Employment Agreement between the Company and Crystal Williams dated December 16, 2024 (filed as Exhibit 10.3 to the Company’s Form 8-K filed on December 16, 2024 and incorporated herein by reference).
     
10.16   Loan and Security Agreement dated as of October 13, 2017 between Medical Transcription Billing, Corp., MTBC Acquisition, Corp. and Silicon Valley Bank (filed as Exhibit 10.1 to the Company’s Form 8-K filed on October 16, 2017, and incorporated herein by reference).
     
10.17   Joinder and First Loan Modification Agreement dated as of September 20, 2018 between Medical Transcription Billing, Corp., MTBC Acquisition, Corp., MTBC Health, Inc. and MTBC Practice Management, Corp. and Silicon Valley Bank (filed as Exhibit 10.1 to the Company’s Form 8-K filed on September 20, 2018, and incorporated herein by reference).
     
10.18   Second Loan Modification Agreement dated November 15, 2019, by and between the Company and SVB (filed as Exhibit 1.1 to the Company’s Form 8-K filed on November 21, 2019, and incorporated herein by reference).
     
10.19   Joinder and Third Loan Modification Agreement dated as of February 28, 2020 between MTBC, Inc., MTBC Acquisition Corp., MTBC Health, Inc. and MTBC Practice Management Corp., MTBC-Med, Inc., CareCloud Corporation and Silicon Valley Bank (filed as Exhibit 10.16 to the Company’s Form 10-K filed on February 28, 2020, and incorporated herein by reference).
     
10.20   Joinder and Fourth Loan Modification Agreement dated September 21, 2020, by and between the Company and SVB (filed as Exhibit 1.1 to the Company’s Form 8-K filed on September 25, 2020, and incorporated herein by reference).
     
10.21   Joinder and Fifth Loan Modification Agreement dated September 21, 2021, by and between the Company and SVB (filed as Exhibit 10.1 to the Company’s Form 8-K filed on September 22, 2021 and incorporated herein by reference).
     
10.22   Sixth Loan Modification Agreement dated January 27, 2022, by and between the Company and SVB (filed as Exhibit 10.19 to the Company’s Form 10-Q filed on May 9, 2022 and incorporated herein by reference).

 

62

 

 

10.23   Seventh Loan Modification Agreement dated February 17, 2023, by and between the Company and SVB (filed as Exhibit 10.1 to the Company’s Form 8-K filed on February 21, 2023 and incorporated herein by reference).
     
10.24   Eighth Loan Modification Agreement dated August 31, 2023, by and between the Company and SVB (filed as Exhibit 10.1 to the Company’s Form 8-K filed on September 1, 2023 and incorporated herein by reference).
     
10.25   Ninth Loan Modification Agreement dated October 25, 2024, by and between the Company and SVB (filed as Exhibit 10.1 to the Company’s Form 8-K filed on October 28, 2024 and incorporated herein by reference).
     
10.26   Underwriting Agreement dated January 28, 2022 by and between the Company and B. Riley FBR, Inc. as representative of several underwriters named therein (filed as Exhibit 1.1 to the Company’s Form 8-K filed on January 31, 2022, and incorporated herein by reference).
     
10.27   At Market Issuance Sales Agreement dated February 14, 2022 by and between CareCloud, Inc. and B. Riley Securities, Inc. (filed as Exhibit 1.1 to the Company’s Form 8-K filed on February 14, 2022 and incorporated herein by reference).
     
10.28*   Consulting Agreement dated June 3, 2022 by and between the Company and Hill City Advisors, LLC (filed as Exhibit 10.22 to the Company’s Form 10-K filed on March 2, 2023, and incorporated herein by reference).
     
10.29*   Amendment to Consulting Agreement dated February 16, 2023 by and between the Company and Hill City Advisors, LLC (filed as Exhibit 10.23 to the Company’s Form 10-K filed on March 2, 2023, and incorporated herein by reference).
     
10.30*   Additional Statement of Work dated January 29, 2024 added as Exhibit B to the Consulting Agreement between the Company and Hill City Advisors, LLC. (filed as Exhibit 10.26 to the Company’s Form 10-K filed on March 21, 2024, and incorporated herein by reference).
     
10.31*   Consulting Agreement dated January 9, 2024, and as amended February 12, 2024, by and between the Company and Korn Intellect, LLC (filed as Exhibit 10.27 to the Company’s Form 10-K filed on March 21, 2024, and incorporated herein by reference).
     
10.32*   Amendment to Consulting Agreement dated September 5, 2024 between the Company and Korn Intellect, LLC.
     
10.33*   Second Amendment to Consulting Agreement dated December 9, 2024 between the Company and Korn Intellect, LLC.
     
19.1   Insider Trading Policy dated December 1, 2024.
     
21.1   List of subsidiaries.
     
23.1   Consent of Rosenberg Rich Baker Berman P.A.
     
23.2   Consent of Grant Thornton LLP.
     
31.1   Certification of the Company’s Co-Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), of the Securities Exchange Act of 1934, as amended.
     
31.2   Certification of the Company’s Co-Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), of the Securities Exchange Act of 1934, as amended.
     
31.3   Certification of the Company’s Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), of the Securities Exchange Act of 1934, as amended.
     
32.1   Certification of the Company’s Co-Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2   Certification of the Company’s Co-Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.3   Certification of the Company’s Interim Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
97.1   Policy relating to recovery of erroneously awarded compensation, as required by applicable listing standards adopted pursuant to 17 CFR 240.10D-1 (filed as Exhibit 97.1 to the Company’s Form 10-K filed on March 21, 2024, and incorporated herein by reference).
     
101.INS   XBRL Instance
101.SCH   XBRL Taxonomy Extension Schema
101.CAL   XBRL Taxonomy Extension Calculation Linkbase
101.LAB   XBRL Taxonomy Extension Label Linkbase
101.PRE   XBRL Taxonomy Extension Presentation Linkbase
101.DEF   XBRL Taxonomy Extension Definition Linkbase
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Indicates management contract or compensatory plan or arrangement.

 

The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

 

63

 

 

Signatures

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  CareCloud, Inc.
     
  By: /s/ A. Hadi Chaudhry
    A. Hadi Chaudhry
    Co-Chief Executive Officer
  Date: April 3, 2025
     
  By: /s/ Stephen Snyder
    Stephen Snyder
    Co-Chief Executive Officer
  Date: April 3, 2025
     
  By: /s/ Norman Roth
    Norman Roth
    Interim Chief Financial Officer and Corporate Controller
  Date: April 3, 2025

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

 

Signature   Title   Date
         
/s/ Mahmud Haq       April 3, 2025
Mahmud Haq   Executive Chairman and Director    
         
/s/ A. Hadi Chaudhry       April 3, 2025
A. Hadi Chaudhry   Principal Executive Officer and Director    
         
/s/ Stephen Snyder       April 3, 2025
Stephen Snyder   Principal Executive Officer    
         
/s/ Norman Roth       April 3, 2025
Norman Roth   Principal Financial and Accounting Officer    
         
/s/ Anne Busquet       April 3, 2025
Anne Busquet   Director    
         
/s/ John N. Daly       April 3, 2025
John N. Daly   Director    
         
/s/ Bill Korn       April 3, 2025
Bill Korn   Director    
         
/s/ Cameron Munter       April 3, 2025
Cameron Munter   Director    
         
/s/ Lawrence Sharnak       April 3, 2025
Lawrence Sharnak   Director    

 

64

 

 

Index to Consolidated Financial Statements

 

Report of Independent Registered Public Accounting Firm Rosenberg Rich Baker Berman, P.A. (PCAOB ID Number 89) F-2
Report of Independent Registered Public Accounting Firm Grant Thornton, LLP. (PCAOB ID Number 248) F-3
Consolidated Balance Sheets as of December 31, 2024 and 2023 F-4
Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 F-5
Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2024 and 2023 F-6
Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2024 and 2023 F-7
Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 F-8
Notes to Consolidated Financial Statements F-9

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and

Shareholders of CareCloud, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheet of CareCloud, Inc. as of December 31, 2024, and the related statements of operations, comprehensive income, shareholders’ equity, cash flows, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.

 

/s/ Rosenberg Rich Baker Berman, P.A.

 

We have served as the Company’s auditor since 2024.

 

Somerset, New Jersey

March 13, 2025

 

F-2

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

Board of Directors and Shareholders

CareCloud, Inc.

 

Opinion on the financial statements

 

We have audited the balance sheet of CareCloud, Inc. as of December 31, 2023, and the related statements of operations, shareholders’ equity, and cash flows for the year ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

/s/ GRANT THORNTON LLP

 

We have served as the Company’s auditor from 2015 to 2023.

 

Iselin, New Jersey

March 21, 2024 (except for Note 18, as to which the date is March 13, 2025)

 

F-3

 

 

CARECLOUD, INC.

CONSOLIDATED BALANCE SHEETS

AS OF DECEMBER 31, 2024 AND 2023

($ in thousands, except share and per share amounts)

 

 

   December 31,   December 31, 
   2024   2023 
         
ASSETS          
Current assets:          
Cash  $5,145   $3,331 
Accounts receivable - net   12,774    11,888 
Contract asset   4,334    5,094 
Inventory   574    465 
Current assets - related party   16    16 
Prepaid expenses and other current assets   1,957    2,449 
Total current assets   24,800    23,243 
Property and equipment - net   5,290    5,317 
Operating lease right-of-use assets   3,133    4,365 
Intangible assets - net   18,698    25,074 
Goodwill   19,186    19,186 
Other assets   507    641 
TOTAL ASSETS  $71,614   $77,826 
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $4,565   $5,798 
Accrued compensation   1,817    3,444 
Accrued expenses   4,951    5,065 
Operating lease liability (current portion)   1,287    1,888 
Deferred revenue (current portion)   1,212    1,380 
Notes payable (current portion)   310    292 
Dividend payable   5,438    5,433 
Total current liabilities   19,580    23,300 
Notes payable   26    37 
Borrowings under line of credit   -    10,000 
Operating lease liability   1,847    2,516 
Deferred revenue   387    256 
Total liabilities   21,840    36,109 
COMMITMENTS AND CONTINGENCIES (NOTE 10)   -    - 
SHAREHOLDERS’ EQUITY:          
Preferred stock, $0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 shares at December 31, 2024 and December 31, 2023. Series B, issued and outstanding 1,511,372 and 1,468,792 shares at December 31, 2024 and December 31, 2023, respectively   6    6 
Common stock, $0.001 par value - authorized 35,000,000 shares. Issued 16,997,035 and 16,620,891 shares at December 31, 2024 and December 31, 2023, respectively. Outstanding 16,256,236 and 15,880,092 shares at December 31, 2024 and December 31, 2023, respectively   17    17 
Additional paid-in capital   121,046    120,706 
Accumulated deficit   (66,630)   (74,481)
Accumulated other comprehensive loss   (4,003)   (3,869)
Less: 740,799 common shares held in treasury, at cost at December 31, 2024 and December 31, 2023   (662)   (662)
Total shareholders’ equity   49,774    41,717 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $71,614   $77,826 

 

See notes to consolidated financial statements.

 

F-4

 

 

CARECLOUD, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

($ in thousands, except share and per share amounts)

 

 

   2024   2023 
   December 31, 
   2024   2023 
NET REVENUE  $110,837   $117,059 
OPERATING EXPENSES:          
Direct operating costs   60,842    70,817 
Selling and marketing   6,232    9,650 
General and administrative   16,123    21,464 
Research and development   3,781    4,736 
Depreciation and amortization   14,142    14,402 
Goodwill impairment charges   -    42,000 
Lease terminations, unoccupied lease charges and restructuring costs   596    1,105 
Total operating expenses   101,716    164,174 
OPERATING INCOME (LOSS)   9,121    (47,115)
OTHER:          
Interest income   88    154 
Interest expense   (900)   (1,194)
Other expense - net   (298)   (883)
INCOME (LOSS) BEFORE PROVISION (BENEFIT) FOR INCOME TAXES   8,011    (49,038)
Income tax provision (benefit)   160    (364)
NET INCOME (LOSS)  $7,851   $(48,674)
           
Preferred stock dividend   12,310    15,674 
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(4,459)  $(64,348)
           
Net loss per common share: basic and diluted  $(0.28)  $(4.11)
Weighted-average common shares used to compute basic and diluted loss per share   16,146,975    15,669,472 

 

See notes to consolidated financial statements.

 

F-5

 

 

CARECLOUD, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

($ in thousands)

 

 

   2024   2023 
   December 31, 
   2024   2023 
NET INCOME (LOSS)  $7,851   $(48,674)
OTHER COMPREHENSIVE LOSS          
Foreign currency translation adjustment (a)   (134)   (832)
COMPREHENSIVE INCOME (LOSS)  $7,717   $(49,506)

 

(a)No tax effect has been recorded as the Company recorded a valuation allowance against the tax benefit from its foreign currency translation adjustments.

 

See notes to consolidated financial statements.

 

F-6

 

 

CARECLOUD, INC.

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

($ in thousands, except for number of shares)

 

 

                                                        
  

Preferred Stock

Series A

  

Preferred Stock

Series B

   Common Stock   Additional Paid-in   Accumulated   Accumulated Other Comprehensive   Treasury (Common)   Total Shareholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Loss   Stock   Equity 
Balance - January 1, 2024   4,526,231   $5    1,468,792   $1    16,620,891   $17   $120,706   $(74,481)  $(3,869)  $(662)  $41,717 
Net income   -    -    -    -    -    -    -    7,851    -    -    7,851 
Foreign currency translation adjustment   -    -    -    -    -    -    -    -    (134)   -    (134)
Stock issued under the equity incentive plan   -    -    42,580    -    376,144    -    -    -    -    -    - 
Stock-based compensation, net of cash settlements   -    -    -    -    -    -    345    -    -    -    345 
Preferred stock dividends   -    -    -    -    -    -    (5)   -    -    -    (5)
Balance - December 31, 2024   4,526,231   $5    1,511,372   $1    16,997,035   $17   $121,046   $(66,630)  $(4,003)  $(662)  $49,774 
                                                        
Balance - January 1, 2023 before adoption of ASC 326   4,526,231   $5    1,344,128   $1    15,970,204   $16   $130,987   $(25,621)  $(3,037)  $(662)  $101,689 
Cumulative effect of adopting ASC 326   -    -    -    -    -    -    -    (186)   -    -    (186)
Balance - January 1, 2023 after adoption   4,526,231    5    1,344,128    1    15,970,204    16    130,987    (25,807)   (3,037)   (662)   101,503 
Net loss   -    -    -    -    -    -    -    (48,674)   -    -    (48,674)
Foreign currency translation adjustment   -    -    -    -    -    -    -    -    (832)   -    (832)
Stock issued under the equity incentive plan   -    -    64,891    -    610,687    1    -    -    -    -    1 
Issuance of Series B Preferred Stock (1)   -    -    59,773    -    -    -    1,427    -    -    -    1,427 
Shares issued for services   -    -    -    -    40,000    -    -    -    -    -    - 
Stock-based compensation, net of cash settlements   -    -    -    -    -    -    3,966    -    -    -    3,966 
Preferred stock dividends   -    -    -    -    -    -    (15,674)   -    -    -    (15,674)
Balance - December 31, 2023   4,526,231   $5    1,468,792   $1    16,620,891   $17   $120,706   $(74,481)  $(3,869)  $(662)  $41,717 

 

(1)Amounts are net of issuance cost of approximately $71,000.

 

For 2023, the preferred stock dividends were paid monthly from January through November at the rate of $2.75 and $2.19 for Series A and Series B, respectively, per share per annum.

 

For 2024, no preferred stock dividends were declared or paid.

 

See notes to consolidated financial statements.

 

F-7

 

 

CARECLOUD, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

($ in thousands)

 

 

   2024   2023 
OPERATING ACTIVITIES:          
Net income (loss)  $7,851   $(48,674)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:          
Depreciation and amortization   14,469    14,889 
Lease amortization   1,994    2,152 
Deferred revenue   (37)   (92)
Provision for expected credit losses   334    454 
Benefit for deferred income taxes   -    (525)
Foreign exchange (gain) loss   (130)   790 
Interest accretion   592    688 
Goodwill impairment charges   -    42,000 
Stock-based compensation expense   115    4,886 
Changes in operating assets and liabilities:          
Accounts receivable   (1,220)   2,246 
Contract asset   760    (695)
Inventory   (109)   (84)
Other assets   673    682 
Accounts payable and other liabilities   (4,650)   (3,256)
Net cash provided by operating activities   20,642    15,461 
INVESTING ACTIVITIES:           
Purchases of property and equipment   (1,697)   (3,063)
Capitalized software and other intangible assets   (5,709)   (8,550)
Net cash used in investing activities   (7,406)   (11,613)
FINANCING ACTIVITIES:           
Preferred stock dividends paid   -    (14,300)
Settlement of tax withholding obligations on stock issued to employees   (579)   (1,524)
Repayments of notes payable   (677)   (888)
Proceeds from issuance of Series B Preferred Stock, net of expenses   -    1,427 
Proceeds from line of credit   -    14,700 
Repayment of line of credit   (10,000)   (12,700)
Net cash used in financing activities   (11,256)   (13,285)
EFFECT OF EXCHANGE RATE CHANGES ON CASH    (166)   469 
NET INCREASE (DECREASE) IN CASH    1,814    (8,968)
CASH - Beginning of the year    3,331    12,299 
CASH - End of the year   $5,145   $3,331 
SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES:           
Dividends declared, not paid  $5   $5,433 
Purchase of prepaid insurance with assumption of note  $685   $656 
Reclass of deposits for property and equipment placed in service  $296   $- 
SUPPLEMENTAL INFORMATION - Cash paid during the year for:           
Income taxes  $157   $144 
Interest  $677   $927 

 

See notes to consolidated financial statements.

 

F-8

 

 

CARECLOUD, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

 

1. ORGANIZATION AND BUSINESS

 

CareCloud, Inc., (together with its consolidated subsidiaries, “CareCloud,” the “Company,” “we,” “us” and/or “our”) is a healthcare information technology company that provides a full suite of proprietary cloud-based solutions, related business services, to healthcare providers and hospitals throughout the United States. The Company’s integrated services are designed to help customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. Our Software-as-a-Service (“SaaS”) platform includes revenue cycle management (“RCM”), practice management (“PM”), electronic health records (“EHR”), business intelligence, telehealth, patient experience management (“PXM”) solutions and complementary software tools and business services for high-performance medical groups and health systems. CareCloud has its corporate offices in Somerset, New Jersey and maintains client support teams throughout the U.S., and offshore offices in Pakistan and Azad Jammu and Kashmir, a region administered by Pakistan (the “Pakistan Offices”), and in Sri Lanka.

 

CareCloud was founded in 1999 under the name Medical Transcription Billing, Corp. and incorporated under the laws of the State of Delaware in 2001. In 2004, the Company formed MTBC Private Limited (“MTBC Pvt. Ltd.”), a 99.9% majority-owned subsidiary of CareCloud based in Pakistan. The remaining 0.1% of the shares of MTBC Pvt. Ltd. is equally owned by the founder and Executive Chairman of CareCloud and a local employee who is also a director of this entity. In 2016, the Company formed MTBC Acquisition Corp. (“MAC”), a Delaware corporation, in connection with its acquisition of substantially all of the assets of MediGain, LLC and its subsidiary, Millennium Practice Management Associates, LLC (together “MediGain”). MAC had a wholly owned subsidiary in Sri Lanka, RCM MediGain Colombo, Pvt. Ltd. Effective February 1, 2024, MAC and its wholly owned subsidiary were merged into CareCloud, Inc. In May 2018, the Company formed CareCloud Practice Management, Corp. (“CPM”), a Delaware corporation, to operate the medical practice management business acquired from Orion Healthcorp.

 

In January 2020, the Company purchased CareCloud Corporation, a company whose name we took. That company is now known as CareCloud Health, Inc. (“CCH”). In June 2020, the Company purchased Meridian Billing Management Co. and its affiliate Origin Holdings, Inc. (collectively “Meridian” and sometimes referred to as “Meridian Medical Management”). Both companies were subsequently merged and the surviving company was renamed Meridian Medical Management, Inc.

 

During March 2021, the Company formed a new wholly-owned subsidiary, CareCloud Acquisition, Corp. (“CAC”). In June 2021, CAC purchased certain assets and assumed certain liabilities of MedMatica Consulting Associates Inc., (“MedMatica”) and purchased the stock of Santa Rosa Staffing, Inc. (“SRS”). The assets and liabilities of MedMatica were merged into SRS and the company was renamed medSR, Inc. (“medSR”).

 

Effective April 1, 2022, the Company formed MTBC Bagh Private Limited (“MTBC Bagh Pvt. Ltd.”), a 99.8% majority-owned subsidiary of CareCloud based in Azad Jammu and Kashmir, a region administered by Pakistan. The remaining 0.2% of the shares of MTBC Bagh Pvt. Ltd. is equally owned by the founder and Executive Chairman of CareCloud and the same director/employee as noted above.

 

During the second quarter of 2023, the Company formed a wholly owned subsidiary, CareCloud ME Health Consultancy LLC, in the United Arab Emirates, which has not yet begun operations.

 

2. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation — The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the operating results and financial condition of CareCloud, its wholly-owned subsidiary CPM, its majority-owned subsidiary MTBC Pvt. Ltd, majority-owned subsidiary MTBC Bagh Pvt. Ltd, CCH (since January 2020), Meridian Medical Management (since June 2020), medSR (since June 2021) and the subsidiary in Sri Lanka. The non-controlling interests of MTBC Pvt. Ltd. and MTBC Bagh Pvt. Ltd. are inconsequential to the consolidated financial statements. All intercompany accounts and transactions have been eliminated in consolidation.

 

F-9

 

 

Segment Reporting — The Company views its operations as comprising two operating segments, Healthcare IT and Medical Practice Management. The chief operating decision maker (“CODM”) monitors and reviews financial information at these segment levels for assessing operating results and the allocation of resources.

 

Use of Estimates — The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include, but are not limited to: (1) impairment of goodwill and long-lived assets, (2) depreciable lives of assets, (3) allowance for expected credit losses, (4) estimates of variable consideration related to the contract asset, (5) fair value of identifiable purchased tangible and intangible assets, including determination of expected customer life, (6) stock-based compensation, and (7) estimating lease terms and incremental borrowing rates. Actual results could significantly differ from those estimates.

 

Revenue Recognition — We derive revenue from five primary sources: (1) technology-enabled business solutions including revenue cycle management, (2) professional services, (3) printing and mailing services, (4) group purchasing services and (5) medical practice management services. All of our revenue arrangements are based on contracts with customers. Most of our contracts with customers contain single performance obligations, although certain contracts do contain multiple performance obligations where we perform more than one service for the same customer. We account for individual performance obligations separately if they are distinct within the context of the contract. For contracts where we provide multiple services such as where we perform multiple ancillary services, each service represents its own performance obligation. Selling or transaction prices are based on the contractual prices for each service at its stand-alone selling price.

 

A five-step approach is applied in the recognition of revenue under ASC 606: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when we satisfy a performance obligation.

 

Although we believe that our approach to estimates and judgments is reasonable, actual results could differ, and we may be exposed to increases or decreases in revenue that could be material. Our estimates of variable consideration may prove to be inaccurate, in which case we may have understated or overstated the revenue recognized in a reporting period. The amount of variable consideration recognized to date that remains subject to estimation is included within the contract asset within the consolidated balance sheet.

 

Payment of invoices is due as specified in the underlying customer agreement, typically 30 days from the invoice date, which occurs on the date of transfer of control of the services to the customer. Since payment terms are less than a year, we have elected the practical expedient and do not assess whether a customer contract has a significant financing component.

 

The Company’s revenue arrangements generally do not include a general right of refund for services provided (See Note 8, Revenue, for additional information).

 

Direct Operating Costs — Direct operating costs consist primarily of salaries and benefits related to personnel who provide services to clients and at our managed medical practices, claims processing costs, medical supplies at our managed practices and other direct costs related to the Company’s services. Costs associated with the implementation of new clients are expensed as incurred. The reported amounts of direct operating costs include allocated amounts for rent expense and overhead costs.

 

Selling and Marketing Expenses — Selling and marketing expenses consist primarily of compensation and benefits, travel and advertising expenses and are expensed as incurred. The Company incurred approximately $2.9 million and $4.0 million of advertising costs for the years ended December 31, 2024 and 2023, respectively.

 

Research and Development Expenses — Research and development expenses consist primarily of personnel-related costs incurred performing market research, analyzing proposed products and developing new products.

 

F-10

 

 

Internal-Use Software Costs — The Company capitalizes certain development costs incurred in connection with its internal-use software. Costs incurred in the preliminary stages of development are expensed as incurred. Once an application has reached the development stage, internal and external costs, if direct, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable that the expenditures will result in additional functionality. Capitalized costs are recorded as part of intangible assets in the accompanying consolidated balance sheets. Maintenance and training costs are expensed as incurred. Internal use software is amortized on a straight line basis over its estimated useful life, generally three years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. During the years ended December 31, 2024 and 2023, the Company capitalized approximately $5.7 million and $8.6 million, respectively, primarily consisting of salaries and payroll-related costs of employees and consultants who devoted time to the development of internal-use software projects.

 

Accounts Receivable — Accounts receivable are stated at their net realizable value. Accounts receivable are presented in the consolidated balance sheets net of an allowance for expected credit losses, which is established based on a lifetime estimated credit loss expected to occur for trade accounts receivable.

 

Property and Equipment — Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line basis over the estimated useful lives of the assets ranging from three to five years. Ordinary maintenance and repairs are expensed as incurred. Depreciation for computers is calculated over three years, while the remaining assets (except leasehold improvements) are depreciated over five years. The Company amortizes leasehold improvements over the lesser of the lease term or the remaining economic life of those assets. Generally, the lease term is the base lease term plus certain renewal option periods for which renewal is reasonably certain and for which failure to exercise the renewal option would result in an economic penalty to the Company.

 

Intangible Assets — Intangible assets include customer relationships, covenants not-to-compete acquired in connection with acquisitions, software purchase and development costs and trademarks acquired. Amortization for intangible assets related to revenue cycle management is recorded primarily using the double declining balance method over three to four years. Amortization for intangible assets related to the group purchasing organization and medical practice management is recorded on a straight line basis over four and twelve years, respectively.

 

Evaluation of Long-Lived Assets — The Company reviews its long-lived assets for impairment whenever changes in circumstances indicate that the carrying value of an asset may not be recoverable. If the sum of undiscounted expected future cash flows is less than the carrying amount of the asset group, the Company will recognize an impairment loss based on the fair value of the asset. There was no impairment of internal-use software costs, intangible assets, operating lease right of use assets or property and equipment during the years ended December 31, 2024 and 2023.

 

Goodwill — Goodwill consists of the excess of the purchase price over the fair value of identifiable net assets of businesses acquired. The Company tests goodwill for impairment annually as of October 31st, referred to as the annual test date. The goodwill impairment test for the Healthcare IT segment is performed using the discounted cash flow approach, the trading price of publicly traded stock and the guideline public company method. Conditions that could trigger a more frequent impairment assessment include, but are not limited to, a significant adverse change to the Company in certain agreements, significant underperformance relative to historical or projected future operating results, loss of customer relationships, an economic downturn in customers’ industries, or increased competition. Impairment testing for goodwill is performed at the reporting-unit level. The Company has determined that its business consists of two operating segments and two reporting units. The Company had a triggering event at August 31, 2023, but it was determined that no goodwill impairment existed at that time. The Company had an additional triggering event in December 2023. It was determined that the fair value of the Healthcare IT reporting unit was less than the carrying value at October 31 and at December 12, 2023 (triggering event). Accordingly, impairment charges of approximately $2.0 million and $40.0 million, respectively, were recorded. (See Note 3). No impairment charges were recorded during the year ended December 31, 2024.

 

Treasury Stock — Treasury stock is recorded at cost and represents shares repurchased by the Company. No shares were repurchased or issued from treasury stock during the years ended December 31, 2024 and 2023.

 

Stock-Based Compensation — The Company recognizes compensation for all share-based payments granted based on the grant date fair value. Compensation expense is generally recognized on a straight-line basis over the vesting period. The Company does not estimate forfeitures in recognizing the expense for share-based payments, as historical forfeiture rates have not been significant. For restricted stock units (“RSUs”) classified as equity, the market price of our common stock on the date of grant is used in recording the fair value of the award. For RSUs classified as a liability, the earned amount is marked to market based on the end-of-period common stock price.

 

F-11

 

 

Business Combinations — The Company accounts for business combinations under the provisions of ASC 805, Business Combinations, which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed are recorded at the date of acquisition at their respective fair values. ASC 805 also specifies criteria that intangible assets acquired in a business combination must be recognized and reported apart from goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date with changes in the fair value recorded through earnings.

 

Income Taxes — The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date.

 

The Company records net deferred tax assets to the extent that these assets will more likely than not be realized. All available positive and negative evidence is considered in making such a determination, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. A valuation allowance would be recorded to reduce deferred income tax assets when it is determined that it is more likely than not that the Company would not be able to realize its deferred income tax assets in the future in excess of their net recorded amount.

 

The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is greater than 50 percent likely to be realized upon ultimate settlement with the related tax authority. At December 31, 2024 and 2023, the Company did not have any uncertain tax positions that required recognition. Interest and penalties related to uncertain tax positions are recognized in income tax expense. For the years ended December 31, 2024 and 2023, the Company did not recognize any penalties or interest related to unrecognized tax benefits in its consolidated financial statements.

 

Dividends — Dividends are recorded when declared by the Company’s Board of Directors. The Board of Directors had declared monthly dividends on the Series A and Series B Preferred Stock through February 2024. However, in December 2023, the dividends on the Preferred Stock were suspended. The dividend scheduled for payment on December 15, 2023 together with the remaining dividends that were declared, have been accrued in the consolidated balance sheet. Future monthly dividends will continue to accrue in arrears but will not be recorded as a liability until declared by the Board of Directors. In January 2025, the Board of Director declared two months of suspended dividends. The Company resumed paying monthly dividends in February 2025, paying one month of arrears. In March 2025, the Company converted the majority of the Series A Preferred Stock into the Company’s common stock. The March 2025 dividend payment will include dividends for the Series A Preferred Stock that were not converted and dividends for the Series B Preferred Stock. (See Note 20). Preferred Stock dividends are charged against paid in capital because the Company does not have sufficient retained earnings. The Company is prohibited from paying dividends on its common stock without the prior written consent of its lender, Silicon Valley Bank, a division of First Citizens Bank (“SVB”).

 

Deferred Revenue — Deferred revenue primarily consists of payments received in advance of the revenue recognition criteria being met. Deferred revenue includes certain deferred implementation services fees that are recognized as revenue ratably over the longer of the life of the agreement or the estimated expected customer life, which is currently estimated to be three years. Deferred revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue and the remaining portion is recorded as non-current. At the time of customer termination, any unrecognized service fees associated with implementation services are recognized as revenue.

 

Fair Value Measurements — ASC 820, Fair Value Measurement, requires the disclosure of fair value information about financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. The Company follows a fair value measurement hierarchy to measure financial instruments.

 

F-12

 

 

The fair value of the Company’s financial instruments is measured using inputs from the three levels of the fair value hierarchy as follows:

 

  Level 1 — Inputs are unadjusted quoted market prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
       
  Level 2 — Inputs are directly or indirectly observable, which include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
       
  Level 3 — Inputs are unobservable inputs that are used to measure fair value to the extent observable inputs are not available.

 

The Company has certain financial instruments that are not measured at fair value on a recurring basis. These financial instruments are subject to fair value adjustments only in certain circumstances and include cash, accounts receivable, accounts payable and accrued expenses, borrowings under term loans and line of credit, and notes payable. Due to the short term nature of these financial instruments and that the borrowings bear interest at prevailing market rates, the carrying value approximates the fair value.

 

Foreign Currency Translation — The financial statements of the Company’s foreign subsidiaries are translated from their functional currency into U.S. dollars, the Company’s functional currency. All foreign currency assets and liabilities are translated at the period-end exchange rate, and all revenue and expenses are translated at transaction date exchange rates. The effects of translating the financial statements of the foreign subsidiaries into U.S. dollars are reported as a cumulative translation adjustment, a separate component of accumulated other comprehensive loss in the consolidated statements of shareholders’ equity, except for transactions related to the intercompany receivable for which transaction adjustments are recorded in the consolidated statements of operations as they are not deemed to be permanently reinvested. Foreign currency transaction gains/losses are reported as a component of other expense – net in the consolidated statements of operations and amounted to a gain of approximately $130,000 and a loss of approximately $790,000 for the years ended December 31, 2024 and 2023, respectively.

 

Lease Terminations, Unoccupied Lease Charges and Restructuring Costs — Lease terminations represents the write-off of leasehold improvements as the result of early lease terminations. Unoccupied lease charges represent the portion of lease and related costs for that portion of the space that is vacated and not being utilized by the Company. Restructuring costs incurred in 2024 and 2023 primarily consist of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements. (See Note 13).

 

Recent Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently adopted and recently issued accounting pronouncements will not have a material impact on our consolidated financial position, results of operations and cash flows.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments. The guidance in Accounting Standards Update (“ASU”) 2016-13 replaces the incurred loss impairment methodology under current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. It will apply to all entities. For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate lifetime expected credit losses. This may result in the earlier recognition of credit losses. In November 2019, the FASB issued ASU No. 2019-10, which delayed this standard’s effective date for SEC smaller reporting companies to the fiscal years beginning on or after December 15, 2022. The Company adopted this guidance on January 1, 2023 using a modified retrospective adoption methodology, whereby the cumulative impact of all prior periods is recorded in accumulated deficit or other impacted balance sheet items upon adoption. The impact to the accumulated deficit as of January 1, 2023 for the allowance related to accounts receivable was a charge of approximately $186,000 and a corresponding increase to the allowance for expected credit losses.

 

F-13

 

 

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendments in this update require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. The amendments are effective for public business entities for fiscal years beginning after December 15, 2022. There was no impact on the consolidated financial statements as a result of this standard.

 

In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842): Common Control Arrangements- Issue 2. The amendments in this update require that leasehold improvements associated with common control leases be: (1) amortized by the lessee over the useful life of the leasehold improvements to the common control group as long as the lessee controls the use of the underlying asset through a lease and (2) accounted for as a transfer between entities under common control through an adjustment to equity if, and when, the lessee no longer controls the use of the underlying asset. The amendments in this update are effective for the fiscal years beginning after December 15, 2023. There was no impact on the consolidated financial statements as a result of this standard.

 

In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification. The new guidance is intended to align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP for all entities. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027 the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective.

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Disclosures. The amendments in this update improve segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The impact is only to the financial statement disclosures and has been adopted by the Company.

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. The amendments in this update enhance the transparency and decision usefulness of income tax disclosures primarily related to rate reconciliation and income taxes paid information. The update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect this update to have a material impact on the consolidated financial statements.

 

In March 2024, the FASB issued ASU 2024-02, Codification Improvements- Amendments to Remove References to the Concepts Statements. This update contains amendments to the Codification that remove references to various FASB Concepts Statements. These Codification updates are for technical corrections such as conforming amendments, clarifications to guidance, simplifications to wording or the structure of guidance and other minor improvements. The resulting amendments are referred to as Codification improvements. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company does not expect this update to have a material impact on the consolidated financial statements.

 

In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40). This update contains amendments that require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. The amendments in this update are effective for public business entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The expected impact would only be to the financial statement disclosures.

 

F-14

 

 

3. GOODWILL AND INTANGIBLE ASSETS – NET

 

Goodwill consists of the excess of the purchase price over the fair value of identifiable net assets of businesses acquired. At December 31, 2024, and 2023, approximately $90,000 of goodwill was allocated to the Medical Practice Management segment and the balance was allocated to the Healthcare IT segment. The following is the summary of the changes to the carrying amount of goodwill for the years ended December 31, 2024 and 2023:

 

   2024   2023 
   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
Beginning gross balance  $19,186   $61,186 
Impairment charges   -    (42,000)
Ending gross balance  $19,186   $19,186 

 

As a result of a triggering event in December 2023 resulting from the suspension of the Preferred Stock dividend, the Company updated its annual goodwill impairment test that was performed as of October 31, 2023 for the Healthcare IT segment. It was determined that the fair value of the Healthcare IT reporting unit was less than the carrying value at both October 31, 2023 and as a result of the December 2023 triggering event. Accordingly, impairment charges of approximately $2.0 million and $40.0 million, respectively, were recorded. There was no goodwill impairment recorded during the year ended December 31, 2024.

 

Below is a summary of intangible asset activity for the years ended December 31, 2024 and 2023:

 

   Customer   Capitalized   Other Intangible     
   Relationships   Software   Assets   Total 
   ($ in thousands) 
COST                    
Balance, January 1, 2024  $47,597   $29,379   $9,653   $86,629 
Additions   -    5,709    -    5,709 
Translation gain   -    20    -    20 
Balance, December 31, 2024  $47,597   $35,108   $9,653   $92,358 
Useful lives   3-12 years    3 years    3 years      
ACCUMULATED AMORTIZATION                    
Balance, January 1, 2024  $44,372   $12,237   $4,946   $61,555 
Amortization expense   1,575    10,522    1    12,098 
Translation gain   -    7    -    7 
Balance, December 31, 2024   45,947    22,766    4,947    73,660 
Net book value  $1,650   $12,342   $4,706   $18,698 
                     
COST                    
Balance, January 1, 2023  $47,597   $21,547   $9,651   $78,795 
Additions   -    8,548    2    8,550 
Translation loss   -    (716)   -    (716)
Balance, December 31, 2023  $47,597   $29,379   $9,653   $86,629 
Useful lives   3-12 years    3 years    3 years      
ACCUMULATED AMORTIZATION                    
Balance, January 1, 2023  $39,523   $4,932   $4,820   $49,275 
Amortization expense   4,849    7,426    126    12,401 
Translation loss   -    (121)   -    (121)
Balance, December 31, 2023   44,372    12,237    4,946    61,555 
Net book value  $3,225   $17,142   $4,707   $25,074 

 

As a result of a triggering event in December 2023, we also reviewed our other long term assets for impairment. We determined that the fair value of these assets exceeded their carrying value and that there was no impairment. There were no triggering events during the year ended December 31, 2024.

 

The amount for capitalized software represents payroll and development costs incurred for internally developed software. Other intangible assets primarily represent non-compete agreements, purchased and acquired software and trademarks. Amortization expense was approximately $12.1 million and $12.4 million for the years ended December 31, 2024 and 2023, respectively. The weighted-average amortization period is three years.

 

F-15

 

 

As of December 31, 2024, future amortization expense scheduled to be expensed is as follows:

 

Years ending December 31,  ($ in thousands) 
2025  $10,291 
2026   5,911 
2027   1,746 
2028   300 
2029   300 
Thereafter   150 
Total  $18,698 

 

4. PROPERTY AND EQUIPMENT

 

Property and equipment consisted of the following:

 

   2024   2023 
   December 31, 
   2024   2023 
   ($ in thousands) 
Computer equipment  $5,963   $5,510 
Office furniture and equipment   2,342    1,985 
Transportation equipment   1,185    1,129 
Leasehold improvements   6,358    5,350 
Assets not placed in service   164    - 
Total property and equipment   16,012    13,974 
Less accumulated depreciation   (10,722)   (8,657)
Property and equipment – net  $5,290   $5,317 

 

Depreciation expense was approximately $2.0 million for both the years ended December 31, 2024 and 2023, respectively.

 

As a result of a triggering event in December 2023, we reviewed our property and equipment for impairment at that time. We determined that the fair value of these assets exceeded their carrying value and that there was no impairment. There were no triggering events during the year ended December 31, 2024.

 

5. CONCENTRATIONS

 

Financial Risks — As of December 31, 2024 and 2023, the Company held cash of approximately $119,000 and $255,000, respectively, in the name of its subsidiaries, at banks in Pakistan and Sri Lanka. The banking systems in these countries do not provide deposit insurance coverage. Additionally, from time to time, the Company maintains cash balances at financial institutions in the United States in excess of federal insurance limits. The Company has not experienced any losses on such accounts. The cash held by each U.S. operating company was below the federal insurance limit at December 31, 2024.

 

Concentrations of credit risk with respect to trade accounts receivable are managed by periodic credit evaluations of customers. The Company does not require collateral for outstanding trade accounts receivable. As of December 31, 2024, two customers each individually accounted for approximately 7% of accounts receivable. As of December 31, 2023, two customers each individually accounted for approximately 7% of accounts receivable. During the years ended December 31, 2024 and 2023, there was one customer with sales of approximately 10% and 9% of total revenue, respectively.

 

F-16

 

 

Geographical Risks — The Company’s offices in Islamabad, Karachi and Bagh, Pakistan, and Colombo, Sri Lanka conduct significant back-office operations for the Company. The Company has no revenue earned outside of the United States. The office in Bagh is located in a different territory of Pakistan from the Islamabad office known as Azad Jammu and Kashmir. The Bagh office was opened in 2009 for the purpose of providing operational support and operating as a backup to the Islamabad office. The Bagh office now operates as the main operational center for the Company. The Company’s operations outside the United States are subject to special considerations and significant risks not typically associated with companies in the United States. The Company’s business, financial condition and results of operations may be influenced by the political, economic, and legal environment in the countries in which it operates and by the general state of these countries’ economies. The Company’s results may be adversely affected by, among other things, changes in governmental policies with respect to laws and regulations, changes in local countries’ telecommunications industries, regulatory rules and policies, anti-inflationary measures, currency conversion and remittance, and rates and methods of taxation.

 

Carrying amounts of net assets located outside the United States were approximately $7.0 million and $7.6 million as of December 31, 2024 and 2023, respectively. These balances exclude net intercompany receivables of approximately $2.2 million and $1.0 million as of December 31, 2024 and 2023, respectively. The following is a summary of the net assets located outside the United States as of December 31, 2024 and 2023:

 

   2024   2023 
   December 31, 
   2024   2023 
   ($ in thousands) 
Current assets  $211   $806 
Non-current assets   8,337    8,250 
Assets   8,548    9,056 
Current liabilities   (1,336)   (1,250)
Non-current liabilities   (172)   (240)
Net assets  $7,040   $7,566 

 

6. NET LOSS PER COMMON SHARE

 

The following table reconciles the weighted-average shares outstanding for basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:

 

   2024   2023 
   Year Ended December 31, 
   2024   2023 
  

($ in thousands, except share and

per share amounts)

 
Basic and Diluted:          
Net loss attributable to common shareholders  $(4,459)  $(64,348)
Weighted-average common shares used to compute basic and diluted loss per share   16,146,975    15,669,472 
Net loss attributable to common shareholders per share - basic and diluted  $(0.28)  $(4.11)

 

The net loss attributable to common shareholders includes the preferred stock dividend amount earned, but not declared, for the year ended December 31, 2024 of approximately $12.3 million. The dividend payable at December 31, 2024 in the consolidated balance sheet represents dividends declared, but not paid, through February 29, 2024.

 

At December 31, 2024, the 242,500 unvested restricted stock units (“RSUs”) as discussed in Note 15 have been excluded from the above calculations as they were anti-dilutive. At December 31, 2023, the 733,908 unvested equity RSUs excluded from the above calculations as they were anti-dilutive. All of the warrants previously outstanding expired unexercised in 2023 and are excluded from the above calculations. Vested RSUs, vested restricted shares and exercised warrants have been included in the above calculations.

 

7. DEBT

 

SVB — During October 2017, the Company opened a revolving line of credit from SVB under a three-year agreement which replaced the previous credit facility. The SVB credit facility is a secured revolving line of credit where borrowings are based on a formula of 200% of repeatable revenue adjusted by an annualized attrition rate as defined in the credit agreement. During the third quarter of 2018, the credit line was increased from $5 million to $10 million and the term was extended for an additional year. During the third quarter of 2021, the credit line was further increased to $20 million and the term was extended for two years. During February 2023, the line of credit was increased to $25 million and the term was extended for two years through October 13, 2025. Effective August 31, 2023, the credit facility agreement was amended whereby the interest rate was increased from the prime rate plus 1.5% to the prime rate plus 2.0%. The requirement for the minimum liquidity ratio was slightly reduced. These amendments expired on March 31, 2024 and the credit facility reverted to its previous terms.

 

F-17

 

 

As of December 31, 2024, there were no borrowings under the credit facility, compared to $10 million in borrowings as of December 31, 2023. Interest on the revolving line of credit was charged at the prime rate plus 2.0% for the first quarter of 2024, but decreased to the prime rate plus 1.5% on April 1, 2024. There is also a fee of one-half of 1% annually for the unused portion of the credit line. The debt is secured by all of the Company’s domestic assets and 65% of the shares in its offshore subsidiaries. Future acquisitions are subject to approval by SVB. At December 31, 2024, the available borrowing base was approximately $10.0 million.

 

In connection with the original SVB debt agreement, the Company paid SVB approximately $50,000 of fees upfront and issued warrants for SVB to purchase 125,000 shares of its common stock, and committed to pay an annual anniversary fee of $50,000 a year. Based on the terms in the original SVB credit agreement, these warrants had a strike price equal to $3.92. They had a five-year exercise window and net exercise rights, and were valued at $3.12 per warrant. These warrants were exercised during 2022. As a result of the revision in the SVB credit line, which increased the credit line from $5 million to $10 million and reduced the interest rate by 25 basis points, the Company paid approximately $50,000 of fees upfront and issued an additional 28,489 warrants, with a strike price equal to $5.26, a five-year exercise window and net exercise rights. The additional warrants were valued at $3.58 per warrant and expired unexercised in September 2023. The SVB credit agreement contains various covenants and conditions governing the revolving line of credit including a current annual fee of $44,000. These covenants include a minimum level of adjusted EBITDA or a minimum liquidity ratio, one of which must be satisfied when borrowings are outstanding. At December 31, 2024 and 2023, the Company was in compliance with all covenants.

 

During March 2023, SVB became a division of First Citizens Bank & Trust Company. The agreements that governed the former SVB relationship remain in place. As a result, there were no changes to the terms of the credit agreement.

 

During October, 2024, the Company entered into a Ninth Loan Modification agreement with SVB whereby the Company decreased the amount available on its revolving line of credit from $25 million to $10 million which proportionally reduced the anniversary fee and the fee on the unused portion of the credit line. As a result of the modification, one covenant was slightly modified.

 

The Company maintains cash balances at SVB in excess of the FDIC insurance coverage limits. The Company performs periodic evaluations of the relative credit standing of this financial institution to ensure its credit worthiness. As of December 31, 2024 and December 31, 2023, the Company held cash of approximately $119,000 and $255,000, respectively, in the name of its subsidiaries at banks in Pakistan and Sri Lanka. The banking systems in these countries do not provide deposit insurance coverage. The Company has not experienced any losses on its cash accounts.

 

Vehicle Financing Notes — The Company finances certain vehicle purchases both in the United States and in Pakistan. The vehicle financing notes typically have three to six year terms and are issued at current market rates.

 

Insurance Financing — The Company finances certain insurance purchases over the term of the policy life. The interest rate charged is 7.49%.

 

Maturities of the outstanding notes payable and other obligations as of December 31, 2024 are as follows:

 

Year ending December 31,  Vehicle Financing Notes   Insurance Financing   Total 
   ($ in thousands) 
2025  $11   $299   $310 
2026   11    -    11 
2027   8    -    8 
2028             7    -    7 
Total  $37   $299   $336 

 

F-18

 

 

8. REVENUE

 

Introduction

The Company accounts for revenue in accordance with ASC 606, Revenue from Contracts with Customers. All revenue is recognized as our performance obligations are satisfied. A performance obligation is a promise in a contract to transfer a distinct good or service to a customer, and is the unit of account under ASC 606. The Company recognizes revenue when the revenue cycle management services begin on the medical billing claims, which is generally upon receipt of the claim from the provider. For many services the Company recognizes revenue as a percentage of the amount the customer collects on the medical billing claims. The Company’s software is utilized at the time the provider sees the patient, and the Company estimates the value of the consideration it will earn over the remaining contractual period as our services are provided and recognizes the fees over the term; this estimation involves predicting the amounts our clients will ultimately collect associated with the services they provided. Certain significant estimates, such as payment-to-charge ratios, effective billing rates and the estimated contractual payment periods are required to measure revenue cycle management revenue under the new standard.

 

Most of our current contracts with customers contain a single performance obligation. For contracts where we provide multiple services, such as where we perform multiple ancillary services, each service represents its own performance obligation. The standalone selling prices are based on the contractual price for the service.

 

We apply the portfolio approach as permitted by ASC 606 as a practical expedient to contracts with similar characteristics and we use estimates and assumptions when accounting for those portfolios. Our contracts generally include standard commercial payment terms. We have no significant obligations for refunds, warranties or similar obligations and our revenue does not include taxes collected from our customers.

 

Disaggregation of Revenue from Contracts with Customers

We derive revenue from five primary sources: (1) Technology-enabled business solutions, (2) professional services, (3) printing and mailing services, (4) group purchasing services and (5) medical practice management services.

 

The following table represents a disaggregation of revenue for the years ended December 31, 2024 and 2023:

 

   2024   2023 
   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
Healthcare IT:          
Technology-enabled business solutions  $73,672   $76,640 
Professional services   18,202    23,022 
Printing and mailing services   3,579    2,968 
Group purchasing services   952    1,053 
Medical Practice Management:          
Medical practice management services   14,432    13,376 
Total  $110,837   $117,059 

 

Technology-enabled business solutions:

Revenue derived on an on-going basis from our technology-enabled solutions, which typically includes revenue cycle management services, is billed as a percentage of payments collected by our customers. The fee for our services often includes the ability to use our EHR and practice management software as well as RCM as part of the bundled fee. The SaaS component is not a material portion of the contract compared to the stand-alone value of RCM.

 

Technology-assisted revenue cycle management services are the recurring process of submitting and following up on claims with health insurance companies in order for the healthcare providers to receive payment for the services they rendered. The Company typically invoices customers on a monthly basis based on the actual collections received by its customers and the agreed-upon rate in the sales contract. The fee for these services typically includes use of practice management software and related tools (on a SaaS basis), electronic health records (on a SaaS basis), medical billing services and use of mobile health solutions. We consider the services to be one performance obligation since the promises are not distinct in the context of the contract. The performance obligation consists of a series of distinct services that are substantially the same and have the same periodic pattern of transfer to our customers.

 

F-19

 

 

In many cases, our clients may terminate their agreements with 90 days’ notice without cause, thereby limiting the term in which we have enforceable rights and obligations, although this time period can vary between clients. Our payment terms are normally net 30 days. Although our contracts typically have stated terms of one or more years, under ASC 606 our contracts are considered month-to-month and accordingly, there is no financing component.

 

For the majority of our revenue cycle management contracts, the total transaction price is variable because our obligation is to process an unknown quantity of claims, as and when requested by our customers over the contract period. When a contract includes variable consideration, we evaluate the estimate of the variable consideration to determine whether the estimate needs to be constrained; therefore, we include variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with variable consideration is subsequently resolved. Estimates to determine variable consideration such as payment to charge ratios, effective billing rates, and the estimated contractual payment periods are updated at each reporting date. Revenue is recognized over the performance period using the input method.

 

Our proprietary, cloud-based practice management application automates the labor-intensive workflow of a medical office in a unified and streamlined SaaS platform. The Company has a large number of clients who utilize the Company’s practice management software, electronic health records software, patient experience management solutions, business intelligence software and/or robotic process automation software on a SaaS basis, but who do not utilize the Company’s revenue cycle management services. SaaS fees may be fixed based on the number of providers, or may be variable.

 

Our digital health services, which began generating revenue in 2022, include chronic care management, where a care manager has remote visits with patients with one or more chronic conditions under the supervision of a physician who is our client. The performance obligation for chronic care management is satisfied at a point in time once the patient receives the remote visit. The digital health services also include remote patient monitoring where our system monitors recordings from FDA approved internet connected devices. These devices record patient trends and alerts the physician to changes which might trigger the need for additional follow-up visits. The performance obligations for remote patient monitoring are satisfied over time as the recordings are received and the patient receives the remote visit. The revenue for chronic care management for the years ended December 31, 2024 and 2023 was approximately $3.0 million and $1.5 million, respectively. The revenue for remote patient monitoring for the years ended December 31, 2024 and 2023 was approximately $779,000 and $400,000, respectively.

 

The medical billing clearinghouse service takes claim information from customers, checks the claims for errors and sends this information electronically to insurance companies. The Company invoices customers on a monthly basis based on the number of claims submitted and the agreed-upon rate in the agreement. This service is provided to medical practices and providers to medical practices who are not revenue cycle management customers. The performance obligation is satisfied once the relevant submissions are completed.

 

Additional services such as coding and transcription are rendered in connection with the delivery of revenue cycle management and related medical services. The Company invoices customers monthly, based on the actual amount of services performed at the agreed-upon rate in the contract. These services are only offered to revenue cycle management customers. These services do not represent a material right because the services are optional to the customer and customers electing these services are charged the same price for those services as if they were on a standalone basis. Each individual coding or transcription transaction processed represents a performance obligation, which is satisfied over time as that individual service is rendered.

 

Professional services:

Our professional services include an extensive set of services including EHR vendor-agnostic optimization and activation, project management, IT transformation consulting, process improvement, training, education and staffing for large healthcare organizations including health systems and hospitals. The performance obligation is satisfied over time using the input method. The revenue is recorded on a monthly basis as the professional services are rendered. Unbilled revenue at December 31, 2024 and 2023 was approximately $338,000 and $100,000, respectively.

 

F-20

 

 

Printing and mailing services:

The Company provides printing and mailing services for both revenue cycle management customers and a non- revenue cycle management customer, and invoices on a monthly basis based on the number of prints, the agreed-upon rate per print and the postage incurred. The performance obligation is satisfied once the printing and mailing is completed.

 

Group purchasing services:

The Company provides group purchasing services which enable medical providers to purchase various vaccines directly from selected pharmaceutical companies at a discounted price. Currently, there are approximately 4,000 medical providers who are members of the program. Revenue is recognized as the vaccine shipments are made to the medical providers. Fees from the pharmaceutical companies are paid either quarterly or annually and the Company adjusts its revenue accrual at the time of payment. The Company makes significant judgments regarding the variable consideration which we expect to be entitled to for the group purchasing services which includes the anticipated shipments to the members enrolled in the program, anticipated volumes of purchases made by the members, and the changes in the number of members. The amounts recorded are constrained by estimates of decreases in shipments and loss of members to avoid a significant revenue reversal in the subsequent period. The only performance obligation is to provide the pharmaceutical companies with the medical providers who want to become members in order to purchase vaccines. The performance obligation is satisfied once the medical provider agrees to purchase a specific quantity of vaccines and the medical provider’s information is forwarded to the vaccine suppliers. The Company records a contract asset for revenue earned and not paid as the ultimate payment is conditioned on achieving certain volume thresholds.

 

For all of the above revenue streams other than group purchasing services and chronic care management, revenue is recognized over time, which is typically one month or less, which closely matches the point in time that the customer simultaneously receives and consumes the benefits provided by the Company. For the group purchasing services, revenue is recognized at a point in time. Each service is substantially the same and has the same periodic pattern of transfer to the customer. Each of the services provided above is considered a separate performance obligation.

 

There were no unsatisfied performance obligations for contracts with an original duration greater than one year. The Company has elected to utilize the practical expedient available with the guidance for contracts with an expected duration of one year or less.

 

Medical practice management services:

The Company also provides medical practice management services under long-term management service agreements to three medical practices. We provide the medical practices with the nurses, administrative support, facilities, supplies, equipment, marketing, RCM, accounting, and other non-clinical services needed to efficiently operate their practices. Revenue is recognized as the services are provided to the medical practices. Revenue recorded in the consolidated statements of operations represents the reimbursement of costs paid by the Company for the practices and the management fee earned each month for managing the practice. The management fee is based on either a fixed fee or a percentage of the net operating income.

 

The Company assumes all financial risk for the performance of the managed medical practices. Revenue is impacted by the amount of the costs incurred by the practices and their operating income. The gross billing of the practices is impacted by billing rates, changes in current procedural terminology code reimbursement and collection trends which in turn impacts the management fee that the Company is entitled to. Billing rates are reviewed at least annually and adjusted based on current insurer reimbursement practices. The performance obligation is satisfied as the management services are provided.

 

Our contracts for medical practice management services have approximately an additional 14 years remaining and are only cancellable under very limited circumstances. The Company receives a management fee each month for managing the day-to-day business operations of each medical group as a fixed fee or a percentage payment of the net operating income which is included in revenue in the consolidated statements of operations.

 

Our medical practice management services obligations consist of a series of distinct services that are substantially the same and have the same periodic pattern of transfer to our customers. Revenue is recognized over time, however for reporting and convenience purposes, the management fee is computed at each month end.

 

F-21

 

 

Information about contract balances:

As of December 31, 2024, the estimated revenue expected to be recognized in the future related to the remaining revenue cycle management performance obligations outstanding was approximately $3.5 million. We expect to recognize substantially all of the revenue for the remaining performance obligations over the next three months. Approximately $318,000 and $476,000 of the contract asset represents revenue earned, not paid, from the group purchasing services and referral fees, respectively.

 

Amounts that we are entitled to collect under the applicable contract are recorded as accounts receivable. Invoicing is performed at the end of each month when the services have been provided. The contract asset includes our right to payment for services already transferred to a customer when the right to payment is conditional on something other than the passage of time. For example, contracts for revenue cycle management services where we recognize revenue over time but do not have a contractual right to payment until the customer receives payment of their claim from the insurance provider. The contract asset also includes the revenue accrued, not received, for the group purchasing services.

 

Changes in the contract asset are recorded as adjustments to net revenue. The changes primarily result from providing services to revenue cycle management customers that result in additional consideration and are offset by our right to payment for services becoming unconditional and changes in the revenue accrued for the group purchasing services. The contract asset for our group purchasing services is reduced when we receive payments from vaccine manufacturers and is increased for revenue earned, not received. The opening and closing balances of the Company’s accounts receivable, contract asset and deferred revenue are as follows:

 

 

  

Accounts

Receivable - Net

  

Contract

Asset

  

Deferred Revenue

(current)

  

Deferred Revenue

(long term)

 
   ($ in thousands) 
Balance as of January 1, 2024  $11,888   $5,094   $1,380   $256 
Increase (decrease), net   886    (760)   (168)   131 
Balance as of  December 31, 2024  $12,774   $4,334   $1,212   $387 
                     
Balance as of January 1, 2023  $14,773   $4,399   $1,386   $342 
(Decrease) increase, net   (2,885)   695    (6)   (86)
Balance as of  December 31, 2023  $11,888   $5,094   $1,380   $256 

 

Deferred revenue:

The amount of deferred revenue at the beginning of the year and recognized during the year ended December 31, 2024 and 2023 was approximately $909,000 and $1.1 million, respectively.

 

Deferred commissions:

Our sales incentive plans include commissions payable to employees and third parties at the time of the initial contract execution that are capitalized as incremental costs to obtain a contract. The capitalized commissions are amortized over the period the related services are transferred. As we do not offer commissions on contract renewals, we have determined the amortization period to be the estimated client life, which is three years. Deferred commissions were approximately $386,000 and $517,000 at December 31, 2024 and 2023, respectively, and are included in the other assets amounts in the consolidated balance sheets. The amortization of deferred sales commissions during the years ended December 31, 2024 and 2023 was approximately $327,000 and $487,000, respectively.

 

Trade Accounts Receivable – Estimate of Credit Losses:

ASU 2016-13 requires the recognition of lifetime estimated credit losses expected to occur for trade accounts receivable. The guidance also requires we pool assets with similar risk characteristics and consider current economic conditions when estimating losses. The adoption of the ASU 2016-13 for trade accounts receivable was recorded as a charge to accumulated deficit of approximately $186,000 as of January 1, 2023.

 

At adoption, we segmented the accounts receivable population into pools based on their risk assessment. Risks related to trade accounts receivable are a customer’s inability to pay or bankruptcy. Each pool was defined by their internal credit assessment and business size. The pools are aligned with management’s review of financial performance. For the years ended December 31, 2024 and 2023, no adjustment to the pools was necessary.

 

F-22

 

 

We utilize a loss-rate method to measure the expected credit loss for each pool. The loss rate is calculated using a three-year lookback period of write-offs and adjustments, divided by the revenue for each pool by aging category, net of customer payments during that period. We consider current and future economic conditions, internal forecasts, customer collection experience and credit memos issued during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data for the current quarter. In addition, the Company uses specific account identification in determining the total allowance for expected credit losses. Trade receivables are written off only after the Company has exhausted all collection efforts.

 

Changes in the allowance for expected credit losses for trade accounts receivable are presented in the table below:

 

   2024   2023 
   Year Ended December 31, 
   2024   2023 
   ($ in thousands)  
Beginning balance  $879   $823 
Adoption of ASC 326   -    186 
Provision   334    454 
Recoveries/adjustments   2    107 
Write-offs   (378)   (691)
Ending balance  $837   $879 

 

9. SHAREHOLDERS’ EQUITY

 

On September 11, 2024 a Certificate of Amendment (the “Amendment”) to the Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Preferred Stock (the “Existing Certificate”) became effective, amending certain provisions of the 11% Series A Cumulative Redeemable Preferred Stock (the “Series A Preferred Stock”).

 

The title of the Existing Certificate was amended to read “Amended and Restated Certificate of Designations, Preferences and Rights of 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock.” Holders of Series A Preferred Stock will now receive similar change of control protections to those afforded to holders of the Company’s Series B Preferred Stock. The dividend of Series A Preferred Stock was amended from 11% to 8.75% per annum and the per annum dividend amount per share was amended from $2.75 to $2.1875 per share per annum. Also, the Company now has the right to exchange the shares of Series A Preferred Stock for common stock at the liquidation preference value of $25 per share, plus accrued and unpaid dividends. (See Note 20).

 

Treasury stock

The Board of Directors of the Company previously approved common stock repurchase programs. The last program expired January 25, 2017. As a result of these stock repurchases, the Company has 740,799 common shares held as treasury stock at an aggregate cost of $662,000.

 

Common stock

The Company had the right to sell up to $50 million of its common stock using an “at-the-market” facility (“ATM”). The underwriter receives 3% of the gross proceeds. During the years ended December 31, 2024 and 2023, no shares of common stock were issued under this ATM. This right terminated when the Company suspended the Preferred Stock dividends.

 

Holders of our common stock are entitled to one vote for each share held on all matters properly submitted to a vote of shareholders on which holders of common stock are entitled to vote. Holders of common stocks are entitled to receive dividends only at times and amounts as determined by the Board of Directors. The common stock is not entitled to pre-emptive rights, and is not subject to conversion, redemption or sinking fund provisions. The common stock is listed on the Nasdaq Global Market under the trading symbol “CCLD.”

 

Preferred stock

The Company has seven million authorized shares of preferred stock of which 4,560,000 have been designated as Series A shares and the balance have been designated as Series B shares.

 

The Company also had the right to sell up to $35 million of its Series B Preferred Stock using an ATM facility. This right terminated when the Company suspended the Preferred Stock dividends. The ATM facility’s underwriter received 3% of the gross proceeds. During the year ended December 31, 2023, the Company sold 59,773 of shares of Series B Preferred Stock under the Company’s ATM and received net proceeds of approximately $1.4 million. During the year ended December 31, 2024, no shares of Series B Preferred Stock were issued under this ATM.

 

F-23

 

 

Since September 11, 2024, we may, at our option, convert the majority of the Series A Preferred Stock into common stock at any time. If we convert the Series A Preferred Stock, then subsequent to the conversion date, dividends will cease to accrue on shares of the Series A Preferred Stock, the shares of the Series A Preferred Stock shall no longer be deemed outstanding and all rights as a holder of those shares will terminate, except the right to receive the shares of common stock plus accumulated and unpaid dividends, if any, payable upon the conversion. (See Note 20).

 

Since November 4, 2020, the Company has the right to redeem, at its option, the Series A Preferred Stock, in whole or in part, at a cash redemption price of $25.00 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. The Series A Preferred Stock has no stated maturity, is not subject to any sinking fund or other mandatory redemption, and is not convertible at the option of the holder into or exchangeable for any of the Company’s other securities. Holders of the Series A Preferred Stock have no voting rights except for limited voting rights if dividends payable on the Series A Preferred Stock are in arrears for eighteen or more consecutive or non-consecutive monthly dividend periods, at which time they are entitled to appoint two additional directors to our Board of Directors. If the Company were to liquidate, dissolve or wind up, the holders of the Series A Preferred Stock will have the right to receive $25.00 per share, plus any accumulated and unpaid dividends to, but not including, the date of payment, before any payment is made to the holders of the common stock. The Series A Preferred Stock is listed on the Nasdaq Global Market under the trading symbol “CCLDP.”

 

Since February 15, 2024 and prior to February 15, 2025, we were able to redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $25.75 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. On or after February 15, 2025 and prior to February 15, 2026, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $25.50 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. On or after February 15, 2026 and prior to February 15, 2027, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $25.25 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. On or after February 15, 2027, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $25.00 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. The Series B Preferred Stock is listed on the Nasdaq Global Market under the trading symbol “CCLDO.”

 

Dividends on the Series A and Series B Preferred Stock of $2.75 (through September 11, 2024 and $2.19 thereafter) and $2.19 annually per share respectively, are cumulative from the date of issue and are payable each month when, as and if declared by the Company’s Board of Directors. In October 2023, the Board of Directors declared monthly dividends on the Series A and Series B Preferred Stock payable through February 2024. However, on December 11, 2023, the Board of Directors suspended the monthly cash dividends for Series A Preferred Stock and Series B Preferred Stock beginning with the payment scheduled for December 15, 2023 together with the remaining dividends that were declared. The suspension of these dividends deferred approximately $1.3 million in cash dividend payments each month through September 11, 2024. Due to the above Amendment, effective on September 12, 2024, the combined monthly cash dividends were reduced to approximately $1.1 million per month.

 

During the suspension, dividends continued to accrue in arrears on the Series A and Series B Preferred Stock. The Company’s Board of Directors declared payment of two months of dividends in January 2025 and the Company resumed payment of the dividends in February 2025, paying one month of dividends in arrears at that time. The second payment is scheduled for March 2025.

 

During the year ended December 31, 2024, no dividends were declared by the Board of Directors. At December 31, 2024, the Company owed approximately $5.4 million for dividends that had previously been declared through February 2024 (but whose payment was suspended), and also had total undeclared dividends of approximately $12.3 million, which represents the accumulated (but undeclared) dividends due to Preferred Stock shareholders of record on December 31, 2024. Dividends that have accrued in arrears but which have not been declared by the Board of Directors are not recorded in the consolidated balance sheets but are reflected in the net loss attributable to common shareholders. Total dividends in arrears at December 31, 2024 amounted to approximately $17.7 million or $3.04 per share for the Series A Preferred Stock and $2.55 per share for the Series B Preferred Stock.

 

Warrants

 

The Company has issued 6,603,489 warrants for its common stock, of which 1,128,489 warrants expired unexercised during 2023. There were no warrants outstanding at December 31, 2024 and 2023.

 

F-24

 

 

The Company incurs common and preferred stock offering costs which consist principally of professional fees, primarily legal and accounting, and other costs such as printing and registration costs. In connection with the 2023 equity offerings, the Company incurred approximately $71,000 of such costs, including underwriting commissions and placement agent fees.

 

10. COMMITMENTS AND CONTINGENCIES

 

Legal Proceedings — On December 9, 2022, an arbitrator rendered a decision in favor of MTBC Acquisition Corp. (“MAC”) and dismissed the claims brought against MAC by Randolph Pain Relief and Wellness Center (“RPRWC”), determining that RPRWC failed to prove any breach of the applicable billing services agreement and failed to prove that any alleged damages were due. The deadline for RPRWC to file a summary action in Superior Court of New Jersey seeking to overturn the arbitrator’s decision was April 5, 2023 and no summary action was filed by such deadline. As such, the arbitrator’s decision dismissing RPRWC’s claims is final.

 

On December 22, 2023, an arbitrator rendered a decision in favor of Ramapo Anesthesiologists, PC (“Ramapo”) and granted in part and denied in part certain claims brought against Origin Healthcare Solutions, LLC; Meridian Medical Management, Inc.; and the Company for alleged breach of contract and other allegations. Ramapo was awarded mitigation related costs of $117,000. The payment for such an award was made during the first quarter of 2024. The Company’s portion of the settlement is approximately $32,000 and the insurance company paid the balance. The Company’s portion was recorded in accrued expenses at December 31, 2023 in the consolidated balance sheet.

 

A former customer filed a complaint against the Company in New Jersey State Court to recover damages claimed to have been caused by the mishandling of their account. Plaintiff alleged at least approximately $750,000 in damages which was disputed by the Company. The parties participated in a one-day court-ordered, non-binding arbitration. At that time, the arbitrator awarded Plaintiff $288,750 on its contract claims, and awarded the Company $21,698 on its cross-claim for unpaid fees. Plaintiff filed to reject this award. The Company previously filed a partial motion for summary judgment on the alleged punitive damages, but the court denied that motion finding there is an issue of fact as to whether those can be awarded at trial. The Company filed an offer of judgment for $200,000 during April 2024 which was accepted and paid in July 2024.

 

In connection with a prior acquisition, the seller had alleged that the Company owed approximately $800,000 in transition related costs to them. The parties agreed to settle the claim for approximately $316,000, which was paid in September 2024.

 

From time to time, we may become involved in other legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of our management, would individually or taken together have a material adverse effect on our business, consolidated results of operations, financial position or cash flows of the Company.

 

11. LEASES

 

We determine if an arrangement is a lease at inception. We have operating leases for office and temporary living space as well as for some office equipment. Operating leases are included in operating lease ROU assets, current operating lease liability and non-current operating lease liability in our consolidated balance sheets as of December 31, 2024 and 2023. The Company does not have any finance leases.

 

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of the lease payments over the lease term.

 

As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rates, which are derived from information available at the lease commencement date, in determining the present value of lease payments. We give consideration to our bank financing arrangements, geographical location and collateralization of assets when calculating our incremental borrowing rates.

 

Our lease terms include options to extend the lease when it is reasonably certain that we will exercise that option. Leases with a term of less than 12 months are not recorded in the consolidated balance sheets. Our lease agreements do not contain any residual value guarantees. For real estate leases, we account for the lease and non-lease components as a single lease component. Some leases include escalation clauses and termination options that are factored in the determination of the lease payments when appropriate.

 

F-25

 

 

If a lease is modified after the effective date, the operating lease ROU asset and liability is re-measured using the current incremental borrowing rate. There was one lease modification during both years ended December 31, 2024 and 2023. We review our incremental borrowing rate for our portfolio of leases on a quarterly basis.

 

During the year ended December 31, 2024, there were no unoccupied lease charges recorded as compared to approximately $169,000 for two of the Company’s facilities for the year ended December 31, 2023. There were no lease impairments recorded for the years ended December 31, 2024 and 2023. For the year ended December 31, 2024, there was a gain on lease terminations of approximately $10,000. For the year ended December 31, 2023, there was a loss on lease terminations of approximately $291,000. These amounts are included in lease terminations, unoccupied lease charges and restructuring costs in the consolidated statement of operations.

 

Lease expense is included in direct operating costs, general and administrative expense, selling and marketing expense and research and development expense in the consolidated statements of operations based on the nature of the expense. As of December 31, 2024, we had 28 leased properties, five in Medical Practice Management and 23 in Healthcare IT, with the remaining terms ranging from less than one year to eleven years. Our lease terms are determined taking into account lease renewal options, the Company’s anticipated operating plans and leases that are on a month-to-month basis. We also have some related party leases – see Note 12.

 

The components of lease expense were as follows:

  

   2024   2023 
   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
Operating lease cost  $2,451   $2,669 
Short-term lease cost   4    - 
Variable lease cost   28    32 
Total - net lease cost  $2,483   $2,701 

 

Short-term lease cost represents leases that were not capitalized as the lease term as of the later of January 1, 2024 or the beginning of the lease was less than 12 months. Variable lease costs include utilities, real estate taxes and common area maintenance costs.

 

F-26

 

 

Supplemental balance sheet information related to leases was as follows:

 

   December 31, 2024   December 31, 2023 
   ($ in thousands) 
Operating leases:          
Operating lease ROU assets, net  $3,133   $4,365 
           
Current operating lease liabilities  $1,287   $1,888 
Non-current operating lease liabilities   1,847    2,516 
Total operating lease liabilities  $3,134   $4,404 
           
Operating leases:          
ROU assets  $5,125   $6,571 
Asset lease expense   (1,994)   (2,152)
Foreign exchange gain/(loss)   2    (54)
ROU assets, net  $3,133   $4,365 
           
Weighted average remaining lease term (in years):          
Operating leases   5.0    4.5 
Weighted average discount rate:          
Operating leases   14.2%   13.3%

 

Supplemental cash flow and other information related to leases was as follows:

 

   2024   2023 
   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flows from operating leases  $2,467   $3,244 
           
ROU assets obtained in exchange for lease liabilities:          
Operating leases, excluding terminations  $864   $1,682 

 

Maturities of lease liabilities are as follows:

 

Operating leases - Years ending December 31,  ($ in thousands) 
2025  $1,601 
2026   727 
2027   557 
2028   371 
2029   193 
Thereafter   1,240 
Total lease payments   4,689 
Less: imputed interest   (1,555)
Total lease obligations   3,134 
Less: current obligations   1,287 
Long-term lease obligations  $1,847 

 

The Company leases certain apartments which are subleased to others. The sublease agreements are currently on a month-to-month basis and are considered operating leases. For the year ended December 31, 2024, the Company received sublease income of approximately $94,000. There was no sublease income for the year ended December 31, 2023.

 

F-27

 

 

12. RELATED PARTIES

 

The Company had sales to a related party, a physician who is the wife of the Executive Chairman. Revenues from this customer were approximately $138,000 and $125,000 for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, the accounts receivable balance due from this customer was approximately $13,000 and $18,000, respectively, and is included in accounts receivable - net in the consolidated balance sheets.

 

The Company leases its corporate offices in New Jersey, its temporary housing for its foreign visitors, a storage facility, its backup operations center in Bagh, Pakistan and an apartment for temporary housing in Dubai, the UAE, from the Executive Chairman. The related party rent expense for the years ended December 31, 2024 and 2023 was approximately $281,000 and $256,000, respectively, and is included in direct operating costs and general and administrative expense in the consolidated statements of operations. During the years ended December 31, 2024 and 2023, the Company spent approximately $979,000 and $1.8 million, respectively, to upgrade the related party leased facilities. During the year ended December 31, 2023, the Company temporarily advanced the Executive Chairman approximately $330,000, to purchase vacant land surrounding the Bagh facility for the sole use and benefit of the Company in order to expedite the purchase on the Company’s behalf as only individuals with citizenship in Kashmir are allowed to purchase land in this region. All advanced amounts were repaid shortly after the advance was made. Current assets-related party in the consolidated balance sheets includes security deposits related to the leases of the Company’s corporate offices in the amount of approximately $16,000 for both the years ended December 31, 2024 and 2023. The Company also leases two facilities used for temporary housing from a management employee for approximately $6,500 per month.

 

Included in the ROU asset at December 31, 2024 is approximately $550,000 applicable to the related party leases. Included in the current and non-current operating lease liability at December 31, 2024 is approximately $181,000 and $367,000, respectively, applicable to the related party leases. Included in the ROU asset at December 31, 2023 is approximately $331,000 applicable to the related party leases. Included in the current and non-current operating lease liability at December 31, 2023 is approximately $182,000 and $142,000, respectively, applicable to the related party leases.

 

During June 2022, the Company entered into a one-year consulting agreement with an entity owned and controlled by one of its former non-independent directors whereby that director received 10,000 shares of the Company’s 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (“Series B Preferred Stock”) in exchange for assisting the Company to identify and acquire additional companies, including performing due diligence. In addition, the Company could make additional payments under the agreement for any successful acquisitions by the Company based on the purchase price of the transaction. No such additional payments were made in 2022. During February 2023, the agreement was amended and extended through December 2024 whereby the former director received 14,000 shares of Series B Preferred Stock in February 2023 and received an additional 14,000 shares in January 2024. All of the payments made were capitalized and amortized over the service period. The amortization was recorded as stock compensation in general and administrative expense in the consolidated statement of operations. All such shares of the Series B Preferred Stock were issued in accordance with the Company’s Amended and Restated 2014 Equity Incentive Plan. In addition to the extension of the consulting agreement, the amendment provided that any transaction fees due will be offset against the last two above payments before any amounts are due to that former director. Effective February 1, 2024, the Company added an additional Statement of Work (“SOW”) to the consulting agreement with the same entity. As compensation for the SOW, the entity received $25,000 per month. The SOW was cancelable with ten days’ notice. The consulting agreement and SOW, through mutual consent, were terminated as of April 30, 2024. There were no transaction fees paid through that date. Effective May 1, 2024, the former non-independent director became President of the Company and effective January 1, 2025 became Co-Chief Executive Officer.

 

Effective January 9, 2024, and as amended February 12, 2024, the Company entered into a consulting agreement with an entity owned and controlled by a member of its Board of Directors to provide investor relations and other services as requested for $8,000 per month (reduced to $2,000 per month effective September 1, 2024 and reduced to an as-needed basis effective January 1, 2025). The agreement was paid at the contractual amount plus amounts for additional services requested, and as of January 1, 2025, is paid on an hourly basis. The consulting agreement is cancelable with ten days’ notice. For the year ended December 31, 2024, the expense recorded under this agreement was approximately $75,000 and is included in general and administrative expense in the consolidated statement of operations.

 

F-28

 

 

During 2020, a New Jersey corporation, talkMD Clinicians, PA (“talkMD”), was formed by the wife of the Executive Chairman, who is a licensed physician, to provide telehealth services. talkMD was determined to be a variable interest entity (“VIE”) for financial reporting purposes because the entity will be controlled by the Company. As of December 31, 2024, talkMD had not yet commenced operations. Cumulatively, the Company has paid approximately $6,000 on behalf of talkMD for income taxes.

 

13. RESTRUCTURING COSTS

 

On October 2, 2023, the Company committed to effectively align resources with business priorities and improve profitability through a reduction in the workforce for the Healthcare IT segment. The Company identified opportunities for improvements in its workforce realignment, strategy and staffing, and increased its focus on performance management, to ensure it has the right skillsets and number of employees to execute its long-term vision. In addition, the Company instituted certain other expense reductions.

 

A majority of the impacted employees exited in the fourth quarter of 2023. The Company estimates that it will incur expenses of approximately $1.35 million related to the reduction in workforce of which approximately $606,000 and $645,000 were incurred in 2024 and 2023, respectively, with the remaining expenses of approximately $100,000 to be incurred in 2025. These restructuring expenses consisted of one-time termination benefits, including but not limited to, severance payments and healthcare benefits.

 

The following table summarizes restructuring costs for 2024 and 2023:

 

   2024   2023 
   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
Severance and separation costs  $606   $439 
Equity awards acceleration costs associated with severance   -    170 
Other exit related costs   -    36 
Total restructuring and other costs  $606   $645 

 

The expense associated with the restructuring is included in lease terminations, unoccupied lease charges and restructuring costs in the consolidated statement of operations for the years ended December 31, 2024 and 2023. This line also includes $291,000 for loss on lease terminations and $169,000 for unoccupied lease charges for the year ended December 31, 2023. The liabilities associated with restructuring costs are included in accrued expenses in the consolidated balance sheet. The following table summarizes activity related to liabilities associated with restructuring costs:

 

SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS

   Severance and separation costs   Equity awards acceleration costs  

Other exit

related costs

   Total restructuring and other costs 
   ($ in thousands) 
Balance as of January 1, 2024  $145   $-   $26   $171 
Additions   606    -    -    606 
Payments and other adjustments   (751)   -    (26)   (777)
Balance as of  December 31, 2024  $-   $-   $-   $- 
                     
Balance as of January 1, 2023  $-   $-   $-   $- 
Additions   439    170    36    645 
Payments and other adjustments   (294)   (170)   (10)   (474)
Balance as of  December 31, 2023  $145   $-   $26   $171 

 

14. EMPLOYEE BENEFIT PLANS

 

The Company has qualified 401(k) plans covering all U.S. employees who have completed one month of service. The plans provide for matching contributions by the Company for employees of the Company and most U.S. subsidiaries, although there is no match for CPM employees. Employer contributions to the plans for the years ended December 31, 2024 and 2023 were approximately $449,000 and $587,000, respectively.

 

Additionally, the Company has a defined contribution retirement plan covering all employees located in our Pakistan Offices who have completed three months of service. The plan provides for monthly contributions by the Company which are equal to 10% of qualified employees’ basic monthly compensation. The Company’s contributions for the years ended December 31, 2024 and 2023 were approximately $438,000 and $394,000, respectively.

 

F-29

 

 

The Company maintains a defined contribution retirement plan covering all employees in Sri Lanka. The employee and employer contribute 8% and 12%, respectively, of the employee’s gross salary. The Company’s contribution for the years ended December 31, 2024 and 2023 was approximately $28,000 and $24,000, respectively. The contributions are required to be deposited with the Employees’ Provident Fund Organization, a government owned entity.

 

15. STOCK-BASED COMPENSATION

 

In April 2014, the Company adopted the Medical Transcription Billing, Corp. 2014 Equity Incentive Plan (the “Original Plan”), reserving a total of 1,351,000 shares of common stock for grants to employees, officers, directors and consultants. On April 14, 2017, the Original Plan was amended and restated whereby an additional 1,500,000 shares of common stock and 100,000 shares of Series A Preferred Stock were added to the plan for future issuance (the “A&R Plan”). During 2018, an additional 200,000 shares of Series A Preferred Stock were added to the A&R Plan for future issuance. In May 2020, an additional 2,000,000 shares of common stock and an additional 300,000 shares of Series A Preferred Stock were added to the A&R Plan for future issuance. During 2022, an additional 1,000,000 shares of common stock and 200,000 shares of Series B Preferred Stock were added to the A&R Plan for future issuance. As of December 31, 2024, 499,683 shares of common stock, 33,769 shares of Series A Preferred Stock and 16,000 shares of Series B Preferred Stock are available for grant. Permissible awards include incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, RSUs, performance stock and cash-settled awards and other stock-based awards in the discretion of the Compensation Committee of the Board of Directors including unrestricted stock grants.

 

The equity based RSUs contain a provision in which the units shall immediately vest and become converted into common shares at the rate of one common share per RSU, immediately after a change in control, as defined in the award agreement.

 

Common stock

 

During 2024, 226,894 RSUs of common stock were granted to employees and independent contractors to vest at different dates during the years 2024 through 2026. Included therein were 30,000 RSUs of common stock granted over two years equally to each of the five outside members of the Board of Directors with 25% of the shares vesting every six months. During 2023, 1,098,976 RSUs of common stock were granted to employees and independent contractors to vest at different dates during the years 2023 through 2025. Included therein were 30,000 RSUs of common stock granted over two years equally to each of the five outside members of the Board of Directors with 25% of the shares vesting every six months.

 

During December 2022, it was agreed that certain bonuses to employees of medSR that were originally going to be paid in cash would be paid in common stock. The change of paying the bonuses in common stock resulted in approximately 135,000 shares being issued in February 2023. This change resulted in approximately $404,000 of stock compensation expense, which offset the amounts previously accrued.

 

F-30

 

 

The following table summarizes the RSU and restricted stock transactions related to the common and Preferred Stock under the A&R Plan for the years ended December 31, 2024 and 2023:

 

   Common Stock   Series A Preferred Stock   Series B Preferred Stock 
             
Outstanding and unvested shares at January 1, 2024   753,495    -    57,199 
Granted   226,894    -    46,000 
Vested   (513,190)   -    (60,000)
Forfeited   (224,699)            -    (24,000)
Outstanding and unvested shares at December 31, 2024   242,500    -    19,199 
                
Outstanding and unvested shares at January 1, 2023   645,475    -    80,462 
Granted   1,098,976    -    62,000 
Vested   (896,893)   -    (85,263)
Forfeited   (94,063)   -    - 
Outstanding and unvested shares at December 31, 2023   753,495    -    57,199 

 

As of December 31, 2024 and 2023, there was approximately $416,000 and $1.3 million, respectively, of total unrecognized compensation cost related to the common stock RSUs classified as equity that will be expensed through 2026. As of December 31, 2024, there was no unrecognized compensation cost as compared to approximately $351,000 of total unrecognized compensation cost as of December 31, 2023 related to the Series B Preferred Stock RSUs classified as equity that was expensed through the following year. There was no unrecognized compensation cost related to the Series A Preferred Stock RSUs for both the years ended December 31, 2024 and 2023.

 

Of the total outstanding and unvested common stock RSUs at December 31, 2024, 242,500 are classified as equity and at December 31 2023, 733,908 RSUs are classified as equity and 19,587 RSUs are classified as a liability. For both 2024 and 2023, all of the Preferred Stock RSUs are classified as equity.

 

The following table summarizes the share activity during the years ended December 31, 2024 and 2023 and the amount of common and preferred shares available for grant at December 31, 2024 and 2023:

 

   Common Stock   Series A Preferred Stock   Series B Preferred Stock 
             
Shares available for grant at January 1, 2024   493,579    33,769    38,000 
RSUs granted   (226,894)   -    (46,000)
RSUs forfeited   232,998    -    24,000 
Shares available for grant at December 31, 2024   499,683    33,769    16,000 
                
Shares available for grant at January 1, 2023   1,498,492    33,769    100,000 
RSUs granted   (1,098,976)   -    (62,000)
RSUs forfeited   94,063    -    - 
Shares available for grant at December 31, 2023   493,579    33,769    38,000 

 

The liability for the cash-settled awards and accrued payroll taxes on equity awards was approximately $6,000 and $767,000 at December 31, 2024 and 2023, respectively, and is included in accrued compensation in the consolidated balance sheets. During the years ended December 31, 2024 and 2023, approximately $45,000 and $19,000, respectively, were paid in connection with the cash-settled awards.

 

Preferred Stock

 

In February 2023, the Compensation Committee granted executive bonuses to be paid in 34,000 shares of Series B Preferred Stock, with the number of shares and the amount based on specified criteria being achieved during the year 2023. During October 2023, the Compensation Committee approved for issuance 10,000 of the above shares to one of the executives who retired. The remaining shares were not issued and previously accrued amounts were reversed during 2024.

 

In March 2024, the Compensation Committee approved executive bonuses to be paid in shares of Series B Preferred Stock with the number of shares and the amount based on specified criteria being achieved for the year 2024. There were 34,000 shares awarded. During May 2024, an additional executive bonus with similar terms was approved and 12,000 shares were awarded. During December 2024, the Compensation Committee determined that the financial objectives were attained and all of the performance bonus shares were issued.

 

F-31

 

 

Stock-based compensation expense

 

The Company recognizes compensation expense on a straight-line basis over the total requisite service period for the entire award. For stock awards classified as equity, the market price of our common stock or Preferred Stock on the date of grant is used to record the fair value of the award and includes the related taxes. For stock awards classified as a liability, the earned amount is marked to market based on the end of period common stock price. The weighted average grant date fair value of the common stock price in connection with the RSUs classified as equity was $2.16 and $3.40 for the years ended December 31, 2024 and 2023, respectively. For the Series B Preferred Stock, the weighted average grant date fair value was $6.33 and $25.07 for the years ended December 31, 2024 and 2023, respectively. The following table summarizes the components of stock-based compensation expense for the years ended December 31, 2024 and 2023:

 

   Year Ended December 31, 
Stock-based compensation included in the consolidated statements of operations:  2024   2023 
   ($ in thousands) 
Direct operating costs  $(27)  $891 
General and administrative   72    2,835 
Research and development   (4)   135 
Selling and marketing   74    855 
Lease terminations, unoccupied lease charges and restructuring costs   -    170 
Total stock-based compensation expense  $115   $4,886 

 

16. INCOME TAXES

 

For the years ended December 31, 2024 and 2023, the Company estimated its income tax provision based upon the annual pre-tax income or loss. Although the Company reported GAAP earnings in 2024, it incurred losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all federal and state deferred tax assets as of December 31, 2024 and 2023.

 

The annual adjusted earnings and profits of our foreign affiliates pass through to the U.S. as federal and state taxable income under the Global Intangible Low-Taxed Income (“GILTI”) regime. For the tax years ended December 31, 2024 and 2023, the net GILTI from our foreign affiliates was absorbed against our current year U.S. consolidated loss. For state tax purposes, the Company’s foreign earnings may be taxable depending on each individual state’s legislative stance on the recent tax reform legislation. The activity in the deferred tax valuation allowance was as follows for the years ended December 31, 2024 and 2023:

 

   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
Beginning balance  $87,597   $92,091 
Current year valuation allowance increase (decrease)   2,067    (4,494)
Ending balance  $89,664   $87,597 

 

The income (loss) before provision (benefit) for income taxes for financial reporting purposes during the years ended December 31, 2024 and 2023 consisted of the following:

 

   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
United States  $7,191   $(48,985)
Foreign   820    (53)
Total  $8,011   $(49,038)

 

F-32

 

 

The provision (benefit) for income taxes for the years ended December 31, 2024 and 2023 consisted of the following:

 

   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
Current:          
Federal  $-   $- 
State   120    123 
Foreign   40    38 
   160    161 
Deferred:          
Federal   -    (252)
State   -    (273)
   -    (525)
Total income tax provision (benefit)  $160   $(364)

 

The components of the Company’s deferred income taxes as of December 31, 2024 and 2023 are as follows:

 

   December 31,   December 31, 
   2024   2023 
   ($ in thousands) 
Deferred tax assets:          
Allowance for expected credit losses  $213   $228 
Deferred revenue   103    68 
Property and intangible assets   3,015    1,933 
State net operating loss (“NOL”) carryforwards   20,981    19,749 
Federal net operating loss (“NOL”) carryforwards   55,569    57,562 
Section 163(j) interest limitation   1,669    2,731 
Stock based compensation   (173)   - 
ASC 842 - ROU asset   (559)   (1,026)
Prepaid commissions   (267)   (303)
Cumulative balance translation adjustment   1,015    988 
Section 267 limitation   6    6 
Credit carryovers   2,498    2,498 
ASC 842 - Lease liability   558    1,031 
Accrued compensation   86    80 
Other   (46)   (59)
Section 174 costs   4,996    3,799 
Valuation allowance   (89,664)   (87,597)
Total deferred tax assets   -    1,688 
Deferred tax liabilities:          
Goodwill amortization   -    (1,688)
Net deferred tax liability  $-   $- 

 

Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their tax bases, as well as from net operating loss carryforwards. Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years.

 

The Company has recorded goodwill as a result of its acquisitions. Goodwill is generally not amortized for financial reporting purposes. However, in 2023 the Company recorded a $42 million goodwill impairment charge, which partially reduced the basis of the tax-deductible goodwill. For tax purposes, goodwill from asset acquisitions is tax deductible and amortized over 15 years. As such, deferred income tax expense and a deferred tax liability arise as a result of the tax-deductibility of this indefinitely lived asset (also known as a naked credit). Typically, the resulting deferred tax liability, which is expected to continue to increase over the amortization period, will have an indefinite life. As a result of the Company having indefinite life net operating losses under the recent tax reform legislation, the federal deferred tax liability resulting from the amortization of goodwill was offset against these indefinite federal operating net losses deferred tax assets to the extent allowable prior to 2023. As a result of the goodwill impairment charge in 2023, the entire deferred tax liability was reversed at that time and no additional deferred tax liability was recorded for 2024.

 

F-33

 

 

A reconciliation of the federal statutory income tax rate (21%) to the Company’s effective income tax rate (determined in dollars) for the years ended December 31, 2024 and 2023 is as follows:

 

   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
Federal provision (benefit) at statutory rate  $1,682   $(10,298)
Increase (decrease) in income taxes resulting from:          
State tax expense, net of federal benefit   94    7,383 
Non-deductible items   30    26 
Impact of foreign operations   (132)   50 
Subpart F GILTI inclusion   1,066    804 
Stock based compensation   (177)   18 
Goodwill impairment charges   -    5,692 
Deferred true-up   (2,708)   455 
Valuation allowance   305    (4,494)
Total income tax provision (benefit)  $160   $(364)

 

At December 31, 2024 and 2023, the Company did not record any uncertain tax positions based on the technical merits. Therefore, a tabular roll forward was excluded and there has been no accrued interest and penalties. The Company is subject to taxation in the United States, various states, Pakistan and Sri Lanka. As of December 31, 2024, all tax years since 2014 remain open to examination due to the carryover of unused net operating losses and tax credits in the United States by major taxing jurisdictions in which the Company is subject to tax. IT companies in Pakistan are subject to a 0.25% tax deducted at the source on receipts received from foreign sources with no further tax being due. It is the Company’s policy that any assessed penalties and interest on uncertain tax positions would be charged to income tax expense.

 

The Pakistan foreign receipts tax does not have a significant impact on the Company’s effective tax rate as all of its earnings in Pakistan have been fully included in the U.S. federal tax rate reconciliation at 21% for 2024 and 2023. The Pakistan statutory corporate tax rate is 29% before consideration of the aforementioned tax credit and the foreign receipts tax.

 

As of December 31, 2024, the Company has a total federal NOL carry forward of approximately $265 million of which approximately $187 million will expire between 2031 and 2038, and the balance of approximately $78 million has an indefinite life. Out of the total federal NOL carry forward, approximately $237 million is from the CareCloud and Meridian acquisitions and is subject to the federal Section 382 NOL annual usage limitations. The Company has state NOL carry forwards of approximately $211 million, of which $84 million relates to the State of New Jersey. These NOLs expire starting in 2025.

 

The Company has a full valuation allowance on its deferred tax assets in the U.S. which results in there being no U.S. deferred tax assets or liabilities recorded in the consolidated balance sheets at December 31, 2024 and 2023, respectively.

 

17. OTHER EXPENSE – NET

 

Other expense - net for the years ended December 31, 2024 and 2023 consisted of the following:

 

   2024   2023 
   Year Ended December 31, 
   2024   2023 
   ($ in thousands) 
Foreign exchange gains (losses)  $130   $(790)
Other expense   (428)   (93)
Other expense - net  $(298)  $(883)

 

Foreign currency transaction gains and losses primarily result from transactions in foreign currencies other than the functional currency. These transaction gains and losses are recorded in the consolidated statements of operations related to the recurring measurement and settlement of such transactions. Other expense primarily represents legal settlements made by the Company.

 

F-34

 

 

18. SEGMENT REPORTING

 

From January 1, 2023 through April 30, 2024, the Chief Executive Officer (“CEO”) and Executive Chairman served as the Chief Decision Maker (“CODM”), organizing the Company, managing resource allocations and measuring performance among two operating and reportable segments: (i) Healthcare IT and (ii) Medical Practice Management. As of May 1, 2024, the Company’s President, CEO and Executive Chairman served as the CODM. We report our segment information based on the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments.

 

The CODM evaluates the financial performance of the business units on the basis of revenue, certain individual and total operating expenses and operating income (loss) excluding unallocated amounts, which are mainly corporate overhead costs, for assessing operating results and the allocation of resources. Our CODM does not evaluate operating segments using asset or liability information. The CODM uses segment revenue, certain segment operating expenses and segment operating income (loss) to manage the segments, comparing actual results to forecasted amounts and investigating the reasons for significant variances. Currently, a focus is being placed on reducing costs and managing global headcount. The segment revenue and segment operating income (loss) is also used to assess the performance of personnel and in establishing their compensation.

 

The Healthcare IT segment includes technology-assisted revenue cycle management, SaaS solutions and professional and other services. The Medical Practice Management segment includes the management of three medical practices. Each segment is considered a reporting unit. The Company does not have intra-entity sales or asset transfers, however, there are intracompany bank transfers. The accounting policies of the segments are the same as those disclosed in the summary of significant accounting policies. The following tables present revenues, operating expenses and operating income (loss) by reportable segment for the years ended December 31, 2024 and 2023:

 

   Healthcare IT   Medical Practice Management    Total 
   Year Ended December 31, 2024 
   ($ in thousands) 
   Healthcare IT   Medical Practice Management    Total 
Net revenue  $96,405   $14,432  (a)  $110,837 
Operating expenses:                
Direct operating costs   49,945    10,897     60,842 
Selling and marketing   6,201    31     6,232 
General and administrative   9,093    1,911     11,004 
Research and development   3,781    -     3,781 
Depreciation and amortization   13,813    329     14,142 
Lease terminations, unoccupied lease charges and restructuring costs   596    -     596 
Total operating expenses   83,429    13,168     96,597 
Segment operating income  $12,976   $1,264    $14,240 
                 
Reconciliation of profit or loss (segment profit/loss):                
Unallocated corporate expenses             $(5,119)
Net interest expense              (812)
Other expenses              (298)
Income before income taxes             $8,011 

 

(a)This revenue represents fees based on our actual costs plus a percentage of the operating profit.

 

F-35

 

 

   Healthcare IT   Medical Practice Management     Total 
   Year Ended December 31, 2023 
   ($ in thousands) 
   Healthcare IT   Medical Practice Management     Total 
Net revenue  $103,683   $13,376  (a)   $117,059 
Operating expenses:                 
Direct operating costs   60,319    10,498      70,817 
Selling and marketing   9,614    36      9,650 
General and administrative   10,992    1,854      12,846 
Research and development   4,736    -      4,736 
Depreciation and amortization   14,046    356      14,402 
Goodwill impairment charges   42,000    -      42,000 
Lease terminations, unoccupied lease charges and restructuring costs   1,105    -      1,105 
Total operating expenses   142,812    12,744      155,556 
Segment operating (loss) income  $(39,129)  $632     $(38,497)
                  
Reconciliation of profit or loss (segment profit/loss):                 
Unallocated corporate expenses              $(8,618)
Net interest expense               (1,040)
Other expenses               (883)
Loss before income taxes              $(49,038)

 

(a)This revenue represents fees based on our actual costs plus a percentage of the operating profit.

 

19. FAIR VALUE OF FINANCIAL INSTRUMENTS

 

Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgement associated with the inputs used to measure their value in one of the following three categories:

 

Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. We held no Level 1 financial instruments at December 31, 2024 or 2023.

 

Level 2: Quoted prices for similar instruments in active markets with inputs that are observable, either directly or indirectly. Our Level 2 financial instruments include notes payable which are carried at cost and approximate fair value since the interest rates being charged approximate market rates.

 

Level 3: Unobservable inputs are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 instruments include the fair value of contingent consideration related to completed acquisitions. There was no contingent consideration recorded at December 31, 2024 and 2023.

 

The following table provides the assets and liabilities carried at fair value measured on a non-recurring basis as of December 31, 2024 and 2023. Refer to Note 2 - Basis of Presentation and Significant Accounting Policies, for a description of the valuation techniques used to determine the fair value of the assets measured on a non-recurring basis in the table below:

 

   Fair Value Measurements at December 31, 2024    Expense for the year ended 
   Carrying Value   Level 1   Level 2   Level 3   December 31, 2024 
   ($ in thousands) 
Goodwill - Healthcare IT  $19,186   $-   $-   $19,186   $- 

 

   Fair Value Measurements at December 31, 2023    Expense for the year ended 
   Carrying Value   Level 1   Level 2   Level 3   December 31, 2023 
    ($ in thousands)  
Goodwill - Healthcare IT  $19,186   $-   $-   $19,186   $42,000 

 

20. SUBSEQUENT EVENTS

 

In January 2025, the Company’s common stock shareholders approved an increase in the number of authorized common shares from 35 million to 85 million. An amended certificate of incorporation was filed by the Company. Also, in January 2025, the Company’s Board of Directors declared Preferred Stock dividends for January and February 2025, whereby the payment for these two months would be credited to the arrearage.

 

In February 2025, the Company resumed monthly payment of the dividends on the Series A and B Preferred Stock, paying one month of dividends in arrears. The second monthly payment is scheduled to be paid in March 2025, which after the conversion as discussed below, will include dividends for the Series A Preferred Stock that were not converted and dividends for the Series B Preferred Stock.

 

In March 2025, the Board of Directors elected to exercise its conversion rights, which provide for the conversion of each share of Series A Preferred Stock into 7.3358 shares of common stock, inclusive of all accumulated and unpaid dividends. Dividends on the converted Series A Preferred shares ceased to accrue as of the conversion date. Individual shareholders who, at the exchange date, owned at least 100,000 shares of Series A Preferred Stock did not have their shares automatically converted to common stock so long as they were held by the Company’s transfer agent, unless they consented to the conversion. There were approximately 985,000 shares of Series A Preferred Stock remaining after the Conversion. Also in March 2025, the Company announced that it will be delisting the Series A Preferred Stock from the Nasdaq Global Market.

 

F-36

 

 EX-10.32 2 ex10-32.htm

 

Exhibit 10.32

 

 

AMENDMENT TO CONSULTING AGREEMENT WITH INDIVIDUAL

 

AMENDMENT to Consulting Agreement with Individual, dated as of September 5, 2024 (the “Amendment”) between CareCloud, Inc., a Delaware corporation with its principal place of business located at 7 Clyde Road, Somerset, New Jersey 08873 (“CareCloud” or “Company”) and Korn Intellect, LLC (“Consultant”) (collectively the “Parties” and individually a “Party”).

 

WHEREAS, the Parties have entered into a Consulting Agreement with Individual, dated January 9, 2024 (the “Existing Agreement”); and

 

WHEREAS, the Parties desire to amend Exhibit A of the Existing Agreement to modify the Fee Schedule on the terms and subject to the conditions set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

1. Definitions. Capitalized terms used and not defined in this Amendment have the respective meanings assigned to them in the Existing Agreement.

 

2. Amendments to the Existing Agreement. As of the Effective Date of the Agreement, the Existing Agreement is hereby amended or modified as follows:

 

  a. Paragraph 3 of Exhibit A to the Existing Agreement is hereby amended by deleting the entirety of such Paragraph and substituting in lieu thereof the following text:
     
    Fee Schedule. Company agrees to pay Consultant two thousand dollars ($2,000.00) a month for Consultant’s Services for up to ten (10) hours of work during the month. For any work exceeding ten (10) hours, additional payment shall be made subject to Company’s approval at the rate of two hundred dollars ($200.00) per hour. Company shall pay Consultant monthly and Consultant shall email a monthly invoice for the pertinent period to CareCloud’s Accounts Payable Team: payable@carecloud.com.

 

3. Effective Date. This Amendment will become effective as of September 1, 2024 (the “Effective Date”). Except as expressly provided in this Amendment, all of the terms and provisions of the Existing Agreement are and will remain in full force and effect and are hereby ratified and confirmed by the Parties. Without limiting the generality of the foregoing, the amendments contained herein will not be construed as an amendment to or waiver of any other provision of the Existing Agreement or as a waiver of or consent to any further or future action on the part of either Party that would require the waiver or consent of the other Party. On and after the Effective Date, each reference in the Existing Agreement to “this Agreement,” “the Agreement,” “hereunder,” “hereof,” “herein,” or words of like import, and each reference to the Existing Agreement in any other agreements, documents, or instruments executed and delivered pursuant to, or in connection with, the Existing Agreement, will mean and be a reference to the Existing Agreement as amended by this Amendment.

 

7 Clyde Road, Suite 201, Somerset, NJ 08873 Phone 732.873.5133 www.CareCloud.com

 

 
 

 

 

4. Representation and Warranties. Each Party hereby represents and warrants to the other Party that:

 

  a. It has the full right, power, and authority to enter into this Amendment and to perform its obligations hereunder and under the Existing Agreement as amended by this Amendment.
     
  b. The execution of this Amendment by the individual whose signature is set forth at the end of this Amendment on behalf of such Party, and the delivery of this Amendment by such Party, have been duly authorized by all necessary action on the part of such Party
     
  c. This Amendment has been executed and delivered by such Party and (assuming due authorization, execution, and delivery by the other Party) constitutes the legal, valid, and binding obligation of such Party, enforceable against such Party in accordance with its terms.

 

5. Miscellaneous.

 

  a. This Amendment is governed by and construed in accordance with the laws of the State of New Jersey, without regard to the state’s conflict of laws provisions. The Parties irrevocably agree that any action to enforce the provisions of this Amendment shall be brought solely in the Superior Court of New Jersey, Somerset County venue.
     
  b. The headings in this Amendment are for reference only and do not affect the interpretation of this Amendment.
     
  c. This Amendment may be executed in counterparts, each of which is deemed an original, but all of which constitute one and the same agreement. Delivery of an executed counterpart of this Amendment electronically shall be effective as delivery of an original executed counterpart of this Amendment.
     
  d. This Amendment constitutes the sole and entire agreement between the Parties with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both written and oral, with respect to such subject matter

 

[Signature page to follow]

 

CareCloud, Inc.  

Consultant

         
By: /s/ Norman Roth   By: /s/ Bill Korn
         
Name/Title: Norman Roth, Interim CFO   Name/Title: Bill Korn / Managing Partner
         
Date: 9/5/24   Date: 9/5/24

 

7 Clyde Road, Suite 201, Somerset, NJ 08873 Phone 732.873.5133 www.CareCloud.com

 

 

 

 EX-10.33 3 ex10-33.htm

 

Exhibit 10.33

 

 

SECOND AMENDMENT TO CONSULTING AGREEMENT WITH INDIVIDUAL

 

SECOND AMENDMENT to Consulting Agreement with Individual, dated as of December 9, 2024 (the “Second Amendment”) between CareCloud, Inc., a Delaware corporation with its principal place of business located at 7 Clyde Road, Somerset, New Jersey 08873 (“CareCloud” or “Company”) and Korn Intellect, LLC (“Consultant”) (collectively the “Parties” and individually a “Party”).

 

WHEREAS, the Parties entered into a Consulting Agreement with Individual, dated January 9, 2024 (the “Existing Agreement”); and

 

WHEREAS, the Parties entered into an Amendment to Consulting Agreement with Individual, dated September 5, 2024 (the “First Amendment”) whereby the Parties amended Exhibit A of the Existing Agreement; and

 

WHEREAS, the Parties desire to enter into a Second Amendment to the Existing Agreement and amend Exhibit A of the Existing Agreement to modify the Fee Schedule on the terms and subject to the conditions set forth herein,

 

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

1. Definitions. Capitalized terms used and not defined in this Second Amendment have the respective meanings assigned to them in the Existing Agreement.

 

2. Revocation of Prior Amendments. As of the Effective Date of the Second Amendment, the First Amendment dated September 5, 2024, is hereby canceled and revoked in its entirety.

 

3. Amendments to the Existing Agreement. As of the Effective Date of the Second Amendment, the Existing Agreement is hereby amended or modified as follows:

 

  a. Paragraph 3 of Exhibit A to the Existing Agreement is hereby amended by deleting the entirety of such Paragraph and substituting in lieu thereof the following text:
     
    Fee Schedule. Company agrees to pay Consultant Two Hundred Dollars ($200.00) per hour for Consultant’s Services subject to Company’s request for Consultant’s Services.  Company shall pay Consultant monthly and Consultant shall email a monthly invoice for the pertinent period to CareCloud’s Accounts Payable Team: payable@carecloud.com.

 

7 Clyde Road, Suite 201, Somerset, NJ 08873 Phone 732.873.5133 www.CareCloud.com

 

 
 

 

 

4. Effective Date. This Second Amendment will become effective as of January 1, 2025 (the “Effective Date”). Except as expressly provided in this Second Amendment, all of the terms and provisions of the Existing Agreement are and will remain in full force and effect and are hereby ratified and confirmed by the Parties. Without limiting the generality of the foregoing, the amendments contained herein will not be construed as an amendment to or waiver of any other provision of the Existing Agreement or as a waiver of or consent to any further or future action on the part of either Party that would require the waiver or consent of the other Party. On and after the Effective Date, each reference in the Existing Agreement to “this Agreement,” “the Agreement,” “hereunder,” “hereof,” “herein,” or words of like import, and each reference to the Existing Agreement in any other agreements, documents, or instruments executed and delivered pursuant to, or in connection with, the Existing Agreement, will mean and be a reference to the Existing Agreement as amended by this Second Amendment.

 

5. Representation and Warranties. Each Party hereby represents and warrants to the other Party that:

 

  a. It has the full right, power, and authority to enter into this Second Amendment and to perform its obligations hereunder and under the Existing Agreement as amended by this Second Amendment.
     
  b. The execution of this Second Amendment by the individual whose signature is set forth at the end of this Second Amendment on behalf of such Party, and the delivery of this Second Amendment by such Party, have been duly authorized by all necessary action on the part of such Party
     
  c. This Second Amendment has been executed and delivered by such Party and (assuming due authorization, execution, and delivery by the other Party) constitutes the legal, valid, and binding obligation of such Party, enforceable against such Party in accordance with its terms.

 

6. Miscellaneous.

 

  a. This Second Amendment is governed by and construed in accordance with the laws of the State of New Jersey, without regard to the state’s conflict of laws provisions. The Parties irrevocably agree that any action to enforce the provisions of this Second Amendment shall be brought solely in the Superior Court of New Jersey, Somerset County venue.
     
  b. The headings in this Second Amendment are for reference only and do not affect the interpretation of this Second Amendment.
     
  c. This Second Amendment may be executed in counterparts, each of which is deemed an original, but all of which constitute one and the same agreement. Delivery of an executed counterpart of this Second Amendment electronically shall be effective as delivery of an original executed counterpart of this Second Amendment.
     
  d. This Second Amendment constitutes the sole and entire agreement between the Parties with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both written and oral, with respect to such subject matter.

 

CareCloud, Inc.  

Consultant

         
By: /s/ Norman Roth    By: /s/ Bill Korn
         
Name/Title: Norman Roth, Interim CFO   Name/Title: Bill Korn/Managing Partner
         
Date: 12/9/24   Date: 12/9/24

 

7 Clyde Road, Suite 201, Somerset, NJ 08873 Phone 732.873.5133 www.CareCloud.com

 

 

 

 EX-19.1 4 ex19-1.htm

 

Exhibit 19.1

 

 

 

CareCloud, Inc.

 Insider Trading Policy

PURPOSE

This policy provides guidelines to all employees, officers and directors of CareCloud, Inc. and its subsidiaries (collectively, “Company” or “CareCloud”) with respect to transactions in the Company’s securities.

 

POLICY

It is the policy of the Company to oppose and prevent unauthorized disclosure of Company’s material nonpublic information and the use of such unauthorizedly obtained information while trading in the Company’s securities.

 

APPLICABILITY OF POLICY

This Policy applies to all transactions in the Company’s securities, including common stock, options for common stock and any other securities which Company may issue from time to time, such as preferred stock, warrants, notes and debentures, as well as to derivative securities relating to Company’s securities, whether or not issued by the Company, such as exchange-traded options. This Policy applies to all officers of the Company, all members of the Company’s Board of Directors, and all employees of, and consultants and contractors to, the Company who receive or have access to Material Nonpublic Information (as defined below) regarding the Company. This group of people and their family members are sometimes referred to in this Policy as “Insiders.” Family members of any person include family residing with such person, any other person in such person’s household, any other family member whose transactions in the Company securities are directed by such person or subject to such person’s influence or control, and any controlled affiliate of such person.

 

This policy is also intended to prevent even the appearance of improper conduct on the part of anyone employed by or associated with the Company. Accordingly, any person who possesses Material Nonpublic Information regarding the Company is an Insider for so long as the information does not become publicly known.

 

1
 

 

SPECIFIC POLICIES

 

 

 

(i)Trading on the Basis of Material Nonpublic Information:

 

No director, officer or employee of, or consultant or contractor to, the Company, or any of their respective family members, shall engage in any transaction involving the Company’s securities, including any offer to purchase or offer to sell, during any period commencing with the date that he or she becomes aware of Material Nonpublic Information concerning the Company, and ending at the close of business on the first Trading Day following the date of public disclosure of that information, or at such time as such nonpublic information is no longer material unless the transaction is completed pursuant to a written pre- determined trading program that (a) meets the requirements of Rule 10b5-1 of the Securities and Exchange Act of 1934, as amended; (b) is adopted and/or amended only during the trading window (defined below) and when he or she did not possess Material Nonpublic Information about the Company or its securities or was not otherwise restricted from trading; (c) is adopted in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5; and (d) is promptly filed upon initiation and/or amendment with the Company’s General Counsel (herein after “Rule 10b5-1 Transactions”). It is the current policy of the Company, unless otherwise approved in advance by the Company’s General Counsel, that Rule 10b5-1 Transactions not occur during the first month of each fiscal quarter.

 

As used herein, the term “Trading Day” shall mean a day on which national stock exchanges and the National Association of Securities Dealers, Inc. Automated Quotation System (NASDAQ) are open for trading.

 

(ii)Tipping:

 

No Insider shall disclose (“Tip”) Material Nonpublic Information to any other person (including family members) where such information may be used by such person to his or her profit by trading or in recommending or advising others to trade in the securities of companies to which such information relates, nor shall such Insider or other person make recommendations or express opinions on the basis of Material Nonpublic Information as to trading in the Company’s securities.

 

(iii)Confidentiality of Nonpublic Information:

 

Nonpublic information relating to the Company is the property of the Company and the unauthorized disclosure of such information is forbidden. Employees should not discuss internal Company matters or developments with anyone outside the Company, except as required in the performance of their regular employment duties, nor should the Company matters be discussed in public or quasi-public areas where conversations may be overheard. This prohibition also applies to inquiries about the Company, which may be made by the financial press, investment analysts or others in the financial community. It is important that all such communications on behalf of the Company be made only through the General Counsel. If employees receive inquiries of this nature they should decline comments and refer the inquirer directly to the Company’s General Counsel.

 

2
 

 

(iv)Certain Exceptions

 

The exercise of stock options for cash under the Company’s Equity Incentive Plan and the purchase of any shares under the Company’s employee stock purchase plan are exempt from this Policy, since the other party to the transaction is the Company itself and the price does not vary with the market but is fixed by the terms of the option agreement or plan. This Policy does apply, however, to any sale of stock acquired by exercising any such option or pursuant to the stock purchase plan, including, any such sale as part of a broker- assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.

 

The mandatory automatic sale of the Company’s common stock or other security by an officer or employee of, or consultant or contractor to, the Company, through any of the Rule 10b5-1 Transactions, to cover taxes due as a result of the vesting of restricted stock units (“Automatic Sales”) shall be exempt from this Policy.

 

POTENTIAL CIVIL AND CRIMINAL LIABILITY AND / OR DISCIPLINARY ACTION

 

(i)Liability for Insider Trading:

 

Company personnel who enter into transactions in securities based on inside information may be subject to: a civil penalty of up to three times the profit gained or loss avoided; a criminal fine of up to $5,000,000 (no matter how small the profit); and a jail term of up to twenty years. Additionally, supervisory personnel, if they fail to take appropriate steps to prevent illegal insider trading, may be subject to a civil penalty of up to $1,000,000 or, if greater, three times the profit gained or loss avoided as a result of the employee’s violation.

 

(ii)Liability for Tipping:

 

Insiders may also be liable for improper transactions by any person (commonly referred to as a “Tippee”) to whom they have disclosed Material Nonpublic Information regarding the Company or to whom they have made recommendations or expressed opinions on the basis of such information as to trading in the Company’s securities. Large penalties have been imposed upon persons who disclosed such information to others, even when the disclosing person did not profit from the trading. The Securities and Exchange Commission, the stock exchanges and the National Association of Securities Dealers, Inc. use sophisticated surveillance techniques to uncover insider trading.

 

(iii)Possible Disciplinary Actions:

 

Employees of the Company who violate this Policy shall also be subject to disciplinary action by Company, which may include ineligibility for future participation in Company’s Equity Incentive Plan or termination of employment. Consultants and contractors who are found to be in violation of this Policy may have their relationship with the Company terminated.

 

3
 

 

GUIDELINES

 

 

 

(i)Mandatory Trading Window For Officers, Directors and Certain Designated Employees:

 

The period beginning the last day of the last month of a fiscal quarter and ending two Trading Days following the date of public disclosure of the financial results for that quarter, is a particularly sensitive period of time for transactions in the Company’s securities from the perspective of compliance with applicable securities laws. This sensitivity is due to the fact that officers, directors and certain other employees will, during that period, often possess Material Nonpublic Information about the expected financial results for the quarter.

 

Accordingly, to ensure compliance with this Policy and applicable federal and state securities laws, all directors, officers and employees of, or consultants or contractors to, the Company having access to the Company’s internal financial statements or other Material Nonpublic Information and their family members shall refrain from conducting transactions, except for Automatic Sales and other Rule 10b5-1 Transactions, unless otherwise approved in advance by the General Counsel, involving purchase or sale of the Company’s securities other than during the period commencing at the close of business on the first Trading Day following the date of public disclosure of the financial results for a particular fiscal quarter or year and continuing until the last day of the last month of the fiscal quarter (or, if such day is not a Trading Day, the end of the last Trading Day preceding such day) (the “Trading Window”). The purpose behind establishing Trading Window guideline is to make conscientious diligent effort to avoid any improper transaction (or even the appearance of an improper transaction).

 

From time to time, the Company may also recommend that directors, officers, selected employees and others suspend trading, except for Automatic Sales and other Rule 10b5-1 Transactions, because of developments known to the Company and not yet disclosed to the public. In such event, such persons are advised not to engage in any transaction, except for Automatic Sales and other Rule 10b5-1 Transactions, involving the purchase or sale of the Company’s securities during such period and should not disclose to others the fact of such suspension of trading.

 

It should be noted, however, that even during the Trading Company should not engage in any transactions, except for Automatic Sales and other Rule 10b5-1 Transactions, in the Company’s securities until such information has been known publicly for at least one Trading Day, regardless whether or not the Company has recommended a suspension of trading to that person. Trading in the Company’s securities during Trading Window should not be considered to be within a “safe harbor,” and all directors, officers and other persons should use good judgment at all times.

 

4
 

 

(ii)Preclearance of Trades by Officers, Directors and Certain Employees:

 

The Company has determined that all officers, directors and certain employees designated by the Company for preclearance, together with their family members, should refrain from entering into any transactions in the Company’s securities, except for Automatic Sales and other Rule 10b5-1 Transactions, even during Trading Window, without first complying with the Company’s “preclearance” process. Each officer, director and designated employee should contact the Company’s General Counsel prior to commencing any trade in the Company’s securities. The Company may find it necessary, from time to time, to require compliance with the preclearance process from certain additional employees, consultants and contractors.

 

(iii)Individual Responsibility:

 

Every officer, director, employee, consultant and contractor has the individual responsibility to comply with this Policy against insider trading, regardless of whether the Company has a mandatory Trading Window for that Insider or any other Insiders of the Company. The guidelines set forth in this Policy are guidelines only, and appropriate judgment should be exercised in connection with any trade in the Company’s securities.

 

An Insider may, from time to time, have to forego a proposed transaction, except for Automatic Sales and other Rule 10b5-1 Transactions, in the Company’s securities even if he or she planned to make the transaction before learning of the Material Nonpublic Information and even though the Insider believes he or she may suffer an economic loss or forego anticipated profit by waiting.

 

APPLICABILITY OF POLICY TO INSIDE INFORMATION REGARDING OTHER COMPANIES

 

This Policy and the guidelines described herein also apply to Material Nonpublic Information (i) relating to other companies, including the Company’s customers, vendors or suppliers (“Business Partners”), or (ii) relating to the Company if there is a reasonable likelihood that it would be considered important to an investor in making an investment decision to purchase, sell or hold stock of other companies, including Business Partners, in each case when that information is obtained in the course of employment with, or other services performed on behalf of, the Company. Civil and criminal penalties, and termination of employment, may result from trading on inside information regarding the Company’s Business Partners. All employees should treat Material Nonpublic Information about the Company’s Business Partners with the same care required with respect to information related directly to the Company.

 

5
 

 

WHAT IS MATERIAL NON PUBLIC INFORMATION

 

It is not possible to define all categories of material information. However, information should be regarded as material if there is a reasonable likelihood that it would be considered important to an investor in making an investment decision to purchase, sell or hold the Company’s securities. Insiders should assume that any information, positive or negative, is material if it might affect the Company’s stock price or otherwise be of significance to an investor in determining whether to purchase, sell or hold the Company’s securities.

 

While it may be difficult under this standard to determine whether particular information is material, there are various categories of information that are particularly sensitive and, as a general rule, should always be considered material. Examples of such information are:

 

■ Financial results
■ Projections of future earnings or losses or changes in such projections
■ Actual changes in earnings
■ Results of product development
■ News of a pending or proposed merger, acquisition, joint venture or tender offer
■ News of the disposition of a subsidiary or of material assets
■ Impending bankruptcy or financial liquidity problems
■ Gain or loss of a substantial customer or supplier
■ Changes in dividend policy
■ New product announcements of a significant nature
■ Significant product defects or modifications
■ Significant increases or decreases in customers
■ Significant changes in net and gross adds in customers
■ Significant pricing changes
■ Stock splits
■ Calls, redemptions, or purchases of a company’s securities by the Company
■ New equity or debt offerings
■ Significant litigation exposure due to actual or threatened litigation
■ Changes in senior management or other major personnel changes

 

Nonpublic information is the information that has not been previously disclosed to the general public and is otherwise not available to the general public.

 

6
 

 

ADDITIONAL PROHIBITED TRANSACTIONS

 

The Company considers it improper and inappropriate for any employee, officer or director of the Company to engage in short-term or speculative transactions in Company’s securities. It therefore is the Company’s policy that directors, officers and other employees, and their family members, may not engage in any of the following transactions:

 

(i) Short Sales: Short sales of the Company’s securities evidence an expectation on the part of the seller that the securities will decline in value, and may signal to the market that the seller has no confidence in the Company or its short-term prospects. In addition, short sales may reduce seller’s incentive to improve the Company’s performance. For these reasons, short sales of the Company’s securities are prohibited by this Policy. In addition, Section 16(c) of the Securities Exchange Act, 1934 prohibits officers and directors from engaging in short sales.
   
(ii) Publicly Traded Options: A transaction in options is, in effect, a bet on the short-term movement of the Company’s stock and therefore creates an impression that the director or employee is trading based on Material Nonpublic Information. Transactions in options may also focus the director’s or employee’s attention on short-term performance at the expense of Company’s long-term objectives. Accordingly, transactions in puts, calls or other derivative securities, on an exchange or in any other organized market, are prohibited by this Policy.
   
(iii) Hedging Transactions: Certain forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts, allow an employee to lock in much of the value of his or her stock holdings, often in exchange for all or part of the potential for upside appreciation in the stock. These transactions allow the director, officer or employee to continue to own the covered securities, but without the full risks and rewards of ownership. When that occurs, the director, officer or employee may no longer have the same objectives as the Company’s other shareholders. Therefore, all employees, officers and directors of the Company are prohibited from engaging in such transactions.
   
(iv) Margin Accounts and Pledges: Securities held in a margin account may be sold by the broker without customer’s consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of Material Nonpublic Information or otherwise is not permitted to trade in the Company securities, directors, officers and other employees are prohibited from holding the Company securities in a margin account or pledging the Company securities as collateral for a loan. An exception to this prohibition may be granted where a person wishes to pledge the Company securities as collateral for a loan (not including margin debt) and clearly demonstrates financial capacity to repay the loan without resort to the pledged securities. Any person who wishes to pledge the Company securities as collateral for a loan must submit a request for approval to the General Counsel at least two weeks prior to the proposed execution of documents evidencing the proposed pledge.
   
(v) Post-Termination Transactions: This Policy continues to apply to transactions in the Company securities after a person is no longer employed by or affiliated with the Company. Any person in possession of Material Nonpublic Information when his/her employment terminates, may not trade in the Company securities until such information has become public or is no longer material.

 

7
 

 

ADDITIONAL INFORMATION – DIRECTORS AND OFFICERS

 

Directors and executive officers of the Company must also comply with the reporting obligations and limitations on short-swing transactions set forth in Section 16 of the Securities Exchange Act of 1934, as amended. The practical effect of these provisions is that officers and directors who purchase and sell the Company’s securities within a six-month period must disgorge all profits to the Company whether or not they had knowledge of any Material Nonpublic Information. Under these provisions, and so long as certain other criteria are met, neither the receipt of an option under the Company’s option plans, nor the exercise of that option, nor the receipt of stock under the Company’s employee stock purchase plan is deemed a purchase under Section 16; however, the sale of any such shares is a sale under Section 16.

 

POLICY SUBJECT TO REVISIONS

 

The Company may change or otherwise revise the terms of this Policy from time to time to respond to developments in law and practice. The Company will take necessary steps to inform all affected persons of any material changes or revisions to this Policy.

 

INQUIRIES

 

Please direct your questions as to any of the matters covered by this Policy to the Company’s General Counsel.

 

Adoption & Amendment History

Adopted by the Board of Directors: 6-18-14

 

Amended to reflect name change: 4-1-19

Amended to reflect name change: 4-1-21

Amended to reflect updated policy: 12-1-24

 

8

 

 EX-21.1 5 ex21-1.htm

 

Exhibit 21.1

 

CareCloud, Inc.
Subsidiary List

 

1. CareCloud Health, Inc. (Delaware, US)
   
2. CareCloud Practice Management, Corp. (Delaware, US)
   
3. CareCloud Acquisition, Corp. (Delaware, US)
   
4. Meridian Medical Management, Inc. (Delaware, US)
   
5. medSR, Inc. (Delaware, US)
   
6. MTBC Private Limited (Pakistan)
   
7. MTBC Bagh Private Limited (Pakistan)
   
8. RCM – MediGain Colombo, Pvt. Ltd. (Sri Lanka)
   
9. CareCloud ME Health Consultancy LLC (United Arab Emirates)

 

 

 

 

 EX-23.1 6 ex23-1.htm

 

Exhibit 23.1 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We have issued our report dated March 13, 2025, with respect to the consolidated financial statements included in the Annual Report of CareCloud, Inc. on Form 10-K/A for the year ended December 31, 2024. We consent to the incorporation by reference of said report in the Registration Statements of CareCloud, Inc. on Forms S-8 (File No. 333-203228, 333-217317, 333-226685, 333-239781 and File No. 333-265536).

 

/s/ ROSENBERG RICH BAKER BERMAN, P.A

 

Somerset, New Jersey

April 3, 2025

 

 

 

 EX-23.2 7 ex23-2.htm

 

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We have issued our report dated March 21, 2024, except for Note 18, as to which the date is March 13, 2025, with respect to the consolidated financial statements included in the Annual Report of CareCloud, Inc. on Form 10-K/A for the year ended December 31, 2023. We consent to the incorporation by reference of said report in the Registration Statements of CareCloud, Inc. on Forms S-8 (File No. 333-203228, 333-217317, 333-226685, 333-239781 and File No. 333-265536).

 

/s/ GRANT THORNTON LLP

 

Iselin, New Jersey

April 3, 2025

 

 

 

 

 EX-31.1 8 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, A. Hadi Chaudhry, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of CareCloud, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosures controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
   a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  CareCloud, Inc.
   
  By: /s/ A. Hadi Chaudhry
    A. Hadi Chaudhry
    Co-Chief Executive Officer (Principal Executive Officer)
     
Dated:    
April 3, 2025    

 

 

 

 EX-31.2 9 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Stephen Snyder, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of CareCloud, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosures controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
   a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  CareCloud, Inc.
   
  By: /s/ Stephen Snyder
    Stephen Snyder
    Co-Chief Executive Officer (Principal Executive Officer)
     
Dated:    
April 3, 2025    

 

 

 

 EX-31.3 10 ex31-3.htm

 

Exhibit 31.3

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Norman S. Roth, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of CareCloud, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosures controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
   a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  CareCloud, Inc.
   
  By: /s/ Norman S. Roth
    Norman S. Roth
    Interim Chief Financial Officer (Principal Financial Officer)
     
Dated:    
April 3, 2025    

 

 

 

 EX-32.1 11 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Based on my knowledge, I, A. Hadi Chaudhry, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of CareCloud, Inc. on Form 10-K for the year ended December 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-K fairly presents in all material respects the financial condition and results of operations of CareCloud, Inc.

 

  CareCloud, Inc.
   
  By: /s/ A. Hadi Chaudhry
    A. Hadi Chaudhry
    Co-Chief Executive Officer (Principal Executive Officer)
     
Dated:    
April 3, 2025    

 

 

 

 EX-32.2 12 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Based on my knowledge, I, Stephen Snyder, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of CareCloud, Inc. on Form 10-K for the year ended December 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-K fairly presents in all material respects the financial condition and results of operations of CareCloud, Inc.

 

  CareCloud, Inc.
   
  By: /s/ Stephen Snyder
    Stephen Snyder
    Co-Chief Executive Officer (Principal Executive Officer)
     
Dated:    
April 3, 2025    

 

 

 

 EX-32.3 13 ex32-3.htm

 

Exhibit 32.3

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Based on my knowledge, I, Norman S. Roth, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of CareCloud, Inc. on Form 10-K for the year ended December 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-K fairly presents in all material respects the financial condition and results of operations of CareCloud, Inc.

 

  CareCloud, Inc.
   
  By: /s/ Norman S. Roth
    Norman S. Roth
    Interim Chief Financial Officer (Principal Financial Officer)
     
Dated:    
April 3, 2025    

 

 

 GRAPHIC 14 logo_001.jpg begin 644 logo_001.jpg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form10-k_001.jpg begin 644 form10-k_001.jpg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end GRAPHIC 16 form10-k_002.jpg begin 644 form10-k_002.jpg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�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

^%6@_!3X>Z#\-?#. MN_$+Q)HOA[^TC9ZQ\4_B1XV^+?CF[_M75;W5YQK7C[XB:WXC\7ZX(+F^FM[# M^U=8N_[/TZ*TTRS\FQM+:", ]-HHHH **** "BBB@ HHHH **** "OSR_:>_ M;(^*/@'X]^ /V2?V7_@9IOQV_:*\:_#C5OC/KD7C3Q^OPP^%?PO^$>E>(?\ MA$HO%WC;Q7;>'_%VNW%QKWBM9- T'0] \,WUS/<03W%S-!&L$5S^AM?GW^U' M^Q/XQ^+?QG\ ?M0?L[?M#ZK^R[^TOX%\#:I\)I_';?#K1_C'X&\>_"35]:/B M:;P#X_\ AAKWB#PK;ZM:Z;XE\S7="U;2O$VA:II=]U/XU:%I7AF;PQX M1^%6B?%#X>:+\/? WA#1;"Z@\/\ A^XUOQM+#"/VX;/X>?MK:%\)+[X&?%WXU6/[,GA?6_A)\(/"E]?6EKI/BK0_B?)JSVUG<6]TTVG7RZ=: 'G-I_P M5C\6B3X8^!/%?[.J_#[X\C]O3X7?L0?M!_#+7?'B:OIG@&?XF>$]9\8:'\4_ MAYXPT30GM?'GA?Q#HFF17_AF"_L/#EW*CWD.HK;QP6-[J?EZ=;VMV\]]=2W!^QMIJ1_Z16%>_P#!(NPU3X/^(+/5?VF?B%J7 M[7?B3]I?P9^V#?\ [7]WX,\)MJ,7QY^']A)H7@ZYLO@ZDJ>#+;X9>'O#%SJ/ MA_2?AL-3:&TL]0E UYXH+2W@PO%7_!)GXD_%_P $_M>7?[0_[8\_Q8_:$_:J M^!N@_L[0?%C3_@+I/P^^'WPJ^%_A_P 1KXKMM(\.?!;0_B9>3:U>:AKGFZAJ MVIZI\3(KNXN)/]$DT^ S6\X!Z/\ ##]O;]HGPW\9/V>OA3^V9^S7X%^$FB?M M:1:A8? ;XK_!SXRW/Q7\'S^.;#PFWC:'X>?$+3?$/@?P!X@\+:SKOARWOIM" MU2QMM:TN^U2"#28#.)-0O])R/^"@/_!2/QM^R%^T%\$/@5X7T#]F6RMOBY\- M_'7CV\^)G[5'[1+?LY_#?PY/X,U?3-.BT"7Q9/X.\5::\ MNH3;0J?F=7^#?^"9'Q(\:_$#X8^+_P!N;]K%/VL_"GP-\*>*_#7P@^$7A;X# MZ-^SM\.="O/&G@N?X=:[XK\66VB?$/X@>(O&WB1?!E[J6D:-=3>(-'MM!>[_ M +0TNUM[S[3+><=\8_\ @C[ITWQ#^ _C3]COXG_"S]ES0O@5X(^*?@_2_AWX MZ_9K'[4?A'5I_BWXATOQ#XCUTV?CGXS^$DL;X7&F!(%N(=6DADG>:SN;*/=; M2 $NF_\ !5WQ5J7_ 3[T']K"#]G^"[^,7Q%^.UG^S/\#?@_I'CB35O!7QY^ M*6L?$:3P%X;U3X7_ !&&@6=UKOP[\16]AXA\0:9XD;PW"T]GX9UD1PR6<,6I MRU?B!_P5[M/"'[!_P!_:QM?A=H,'C3XQ_%O2OV>O&GASQSX\N?!_PG_9]^,% MA=^+-%^(A^,GQ*@\,Z_JWAGP/X3\1^!]9TZTU1O",NK:DFH^'Y;C3+!KV9(. M-\+_ /!$J3^S_@-X8^)7[7?Q U[P3\)/B;\>OC[XAT7X0^$=1_9RUC7?CY\: M;NQ_LGQA\,/$GPY^)[2? ?P=\--+L[BV\,?#_P ):;JS/J?B#Q5J2>*=/L]; M;1K7O?"G_!*3XK?!GPQ\=/ 7[./[^ OBU\<=.^.^D^&_BC\&/#W[23 M#Q#J_@>Z\)?%_0OC3JOQ7\<7MY\<]!^*VJ'3?&=Y<3?\(%XETCQ+H]GJ-UX@ M\0ZB/[04 X/XI_\ !6;XS?"_]G#X-?&'5_A9^R,FL?%S]IMO@#IOB^Q_;1\. M>*_V86\-/X/O_$L'Q?F^._A7P;?V/AGPQ%?V4VC:IIWBG1[/5-'BLKK5M1CM MK>XLX)'3?\%2?VB]6T/]FO1?AA\/?V'/CG\4_P!I3]H3XI_!+P_)\$OVRKSX MG_ _P_%\.OA-X>^* E\0_%?PG\+=0FT_QC<6U]K$>J>$&\,RSZ;II\+ZDMS. MOB%4M>3;_@AQK]A\.+#3?"W[4G@+P_\ %V3]K;0?VL_$/BF/]D'PFOP,N-=\ M*?#[6?A]H'@SPG^S!H?Q7\.^$/"?A\6>L'4]?EN/%7B0^);Z'.I6A#6[VGKO MBK_@F)^T_P")M+_9VUZV_;5^#/A/XV_LV?''XE_&#P9\0_!G[!7ACPMX)O++ MXA?##1/AH/#>I_!_0OC]I^CW.KZ5!:Z_J$_C2]\17UYJL.L:9I@TC3AX:M+Z M[ /K+]D7]L;QI\:OB7\;?V;_ (_?!RW^ _[3?[/]IX(\0^+O"6A^-[3XC_#[ MQEX ^)%KJ4WA#X@?#CQI'I?A_4-2TJ>YT?4M,UO2]8\.Z9J.@7ZV-O=-+=WE MU9Z9]]5\'?LA?L6ZS^SWXX^,_P =/C%\<=:_:5_:9^/O_"'Z=\0_BQJ/@K1? MAGH%EX0^'UG?VG@OP)\/_AMH.I:[8>#?#.D?VMJ-W=1'7]9O]:OYX[[5+^XN MX3-)]XT %%%% !1110 4444 %%%% !117Y_?M5?MYC]FWXU?!_\ 9^\,?LX? M&G]HSXH_&GPAX[\:^%_#OPBO/AA82V^C?#R;3$\0MJ%Q\2_'W@6R62*'5(KN M);>ZFWPQ2@9EV1N ?H#17Y;^'_\ @J_\#_$FE?"1K3X>?&'2/&WQ"_:Y\,_L M6>.OA3XN\/:/X5^(GP(^,7B?3K_6+)?B;I&IZZMG)X>?1[.+5[+6?!^H^)K? M5;"]B^P^9?6FJV.G9\/_ 5;\'^)O$OB"?X0?LI_M@?'GX&>#OB)=?"[Q5^T MG\(?A;IOBKX<0^*=*UP>'/$4WA+PU'XGA^+'Q)\-^&M8\RTUCQ)X ^'_ (@T MW%M#==^(UU\+;RZ^-GA3Q'HNK:QHZ_#BS\%?$+Q1)!J-_):Z#I-I:^-!X4-QJ7 MC#0(T/D_VE-8 'Z<45^5EI_P5E^#%Y^P_P")OVW1\-/BO::+X$^*:?!CXA_! MS4K/PSIWQ9\!_$9?B'HOP^OO#7B6PN_$,7A^SO\ 39/$6B^(KR!=7XE?POY,&O,-:N#;Z_._]BG]TKW_ M /H8R/#_ /P4N\2>/_C1\6OA+\)/V&_VH/BOI'P2^/.H?L__ !#^*OA;5/@+ M9>!=$\3Z1?Z;#JVKO;^*?C!X?\6W&B:=I.JVOB&X-IX;N+\Z8WEQ6--1?5$UFR\7_$33_!%W)X9LK31[N"X74]-GGN(+3[;< M6?N/P@_:K\*?&7X\?M9? +0O"OBK2_$?[(WB/X7^&O%^LZJ=$_L3Q=>?%3X= M6WQ(T>;PE]BU6ZU$0:;IMRFFZE_;EEI,G]I9^R)?M'I^S#-_P3\_:R\*?$+3K7P/XC\<2:]K/[.CZ9\/?AMX^\47WA;1OB M=XC?2OC;J%Q<^%UNM*U>[N;30(-7\2QVFEW9_L+S?)CEZS2/^"H'PKUC_@GK MK'_!1:#X:?$R/X::-J.N:=-X!E_X1#_A8$[Z%\:IO@A//!L\2MX7\F?7H6UF M#S-?1_[&(\U$O\V@ /TTHJ&WF6YMX+A595GABF56QN5945PK;21N 8 X)&=_%[QOG0ZO=_#_X=^-?&]KI M-S M!W^)WPL^)?PU355T)_B%X \9>!TUQ[ ZJNC/XL\.ZEH*ZJVEB^TPZDNG'4!= MM8#4M/-X(3;B^M#)Y\8!^07AW_@M-\&?&/P1_8?\4^#O%G[.WBS]H3]J+XS? MLJ?"OXE_LV^&_C_X7USX@_!BV^/GBS2/"WCC5KKPQI@NO&L]W\,;C5HUN;'7 MO"^@Q2W;6]KJUSI)N(F;CO'W_!5K]I_2OV7OVB/VK_ '[,_P8\0_#S]EOX^? MM'_"/XL67B;XV^+?#WB(Z#\&O%?A#PUX2\1>$M/L?A;K5KK>J^+5U_5;K6]( MO=1TBVT(Z9;1VFH:H;W]U]"V7_!*CP;I?[-W[#WP1TGQ?X%TKQO^Q]\7OV4? MBGKOQHT[X&:18Z_\8U_9I\2:7XBU+0KJPM/&L.K>$I?B3)IBPW.M7GC'QNWA M^:4WEUIOBIU,& M+3Q"FKC6->\'^ ;MO$UW)'K5FV@Q:8]HAMM.:'5IC?2+;?,GP)_;/_;?^)E[ M\(/B3XX_8)L_!7[,/QM2+4],\6:-\>_#7B'XQ?"?P5JV@77B;PW\1/C%\-]4 MT#PSH-IX;O\ 2;:&?5=.\&^-?$WBC1CJ%M;1Z+JFK_9](O\ ]$_'WPM\(?%/ MX4^+?@U\0M/7Q#X'\>>!=7^'OB_3O,GL#JOA[7M%FT+5XHI[:875A-<6=Q,; M>XMK@7-E,8YH)Q-$D@_.SX%_L#?M3?"C5OA1X,\5?\%&OB'\1OV7O@I)#;># M_@I%\#_A_P"#?'/BCPOH^B77A[PMX!^,'QQL=;U:_P#B%X*T72;E;6[TNR\# M>$KS7!;6GZ=<60!X4/^"JW[2VJ?!/6OVY?"G[#L6O_L!:%/K_ (@; MQC_PNG3[+]I'7/@MX8U.\T[6OCEHGP;F\)GPM_PC5M9V%]XCB\-ZE\2;+7I] M#LY;MI+?3V&K)Z+\-?\ @KEX'\5?\%!_'7[%GBWP=;^&/!5_:?"J+]GWX[P: MQJ$OAWXD^*OB9\&_#GQGTGP-XHM-3T73+7P?XF\4^&?$$TOP\L3J=[<>)9M! MU#2C;0:S=6%E+PY_X)$_%RQ^%VM?LB>&_P!OOQWX=_X)]:_J6KV=W^SG;?!/ MP5=?%73_ (8>(=;N=&F^'6H>(HM#N+K1 M9-;N--NKBVD]'\4_\$A_A9X[U+]NJW\6>-A)X/\ VM8?V8KGX7:'X;\'3^'O M$?[+GB;]E;X93?#_ .'/BSP;XV;QGJ=WXDUJRN%L-4L[BUTOP1+:Z/!J'A'4 M)=;T[6]0NF /D&S_ ."YWC77_A]^R!?:=\&_@#\/?'W[3G[/WB#X_7.I?M%? MM*-\$?@;;#1OB;X@^&]I\)? 7Q2UCP!JEOXG^*VI2: VNMI?B*T\(:7I^FWN MF%]2N)-0B6/]&OA%^V]X]\?_ +6OPK_9B\8?"'PSX(N/'O[!NA_MA:[J>C_$ MZP^(;^&?$NK_ !0?P!+\.].UCP[I*>$_%VB6UF$U2+QKHNK-9ZA,QCT^VN; MQ:A-\J6__!)7XZ^'?V;O@/\ LV>"?VVO! \$?"CX6ZG\./&'A+XL?L2?#+XX M?"?Q[J=_XV\8^+(_B3H7P\\;_$4ZU\/?'5M9>+3X:-RGQ"\5Z//IVCV$QTF. M5IT?I="_X)(^*/@GI?[,^N_LA_M<^(/@A\:OV??@/K'[.>J?$;QU\'_#?QO\ M+_%+X:^(?&E_\3=2TW6_AI>^*_ T/AQ]/^(6K:KK?A4^'O%<4>@Z9-9Z!,FJ MVUBEQ* :&C?\%1O%^J>/_ASX+D^#GAN&#QQ_P4W^,'[ =Q?KXTU1YM.\-_#' MP7=>*[/XF0V[>'$2ZUS6)K<6=SX8>:&PLXF,\>M7#_NJ]*_X*$?MA_M8_LA7 M_@;Q'\,/@%\$OB?\(_'/C/X2?"*Q\0>-?C3XJ\#>-(?B[\6_&E_X1TG3)/"^ MD_##Q3IB^#;$R>'[N\\2'Q%_:"?;M11-"E6PC>Y\/U?_ ()#>.].^&/P(TOX M8?MAW7A[X]?"?]K7X@?MH>,?CU\1/@5I7Q,A^)OQG^)/AW6?#OB&\_X5AIGQ M*^'>@>#]&CM]2M!I^D6FL:U:6EOIJ0B-[JX>_3Z@^,'[%GQE_:&_9U^#GPC^ M-W[37A[Q9\3_ (9_M&?"7X]:_P#%_0_@'!X0T?QG:?"7XDKXYTSP;:_#"P^* MMW!X6EO]*AL_#3^)5\9:[]GG@?79- O6G;2T /F#XW?\%.OVA?V;]2^+/@GX MO?L]?"BV^)7PB_X)^:Y^V?KVG>$/B[XEU_PG/XBL?CWL]4L/# M$.K^&+N^CT6+5O!VKVVJ,+75[74M$LO1_P!LC_@F;>?M9?$_X]_$:#XY6OP] M3XW?L&W_ .Q/'HLWPLF\8-X7GO?B\GQ4_P"%GOJ:?$KPHNNQ1(O]@?\ "#KI MVBN['^UO^$R0#^RSS7BC_@D3\.=9_:M_9<_:QT'X@CPUXH^#/A;1O"WQO\++ MX(DU+PW^TJ/#'PKNOA/X5\1:E;_\)K80^!O%6E^&M3U32+G6I[/QW)J/AB33 M_#C0VW]GOJEZ / M/VI_AU\./VC?%/PP_P"$B/A^;XWZ;\)O&MCHO@X>%[9=NM-X5G^)B>*;K3FA M&GI=PWMA?W/VA^W[^UW_ ,,5? 6T^+\>B>%-7GUGXG?#3X7VVH?$'Q?<^!?A MOX/D^(OB2#0V\<_$7Q/I>@^*]?T[P7X7MWGU#6)/#7A3Q'K;JL*P:9]F^UWM MG^9?BS_@@]#XPTSP-\&M8_:HAU7]DGX6^)YM2^%?PS\2_LR_##Q5^T#\*_!- MYXKL?&&H?"GX=?M9ZUK<_BGP[X'N]5T^U1D?P%?ZTUA!!IUSJUWI\9M7^^/V M\/V")OVR-4^ _BG0_B5X8\#>)?@-<_%2#3M ^*'PAC^/?P8\=>'?C-X$3X=> M--)\>_"[_A/_ (77VHZE;>'1.OA'Q-I/CG1M3\+W6H:I/;BZ6_EB !]!_LC? M&[Q;^T/\ _!'Q4\??#B?X2>-/$ UQ-<\ 7-YJUV^G1:=XBU;3?#_ (ALU\1^ M'_"/BRUT'X@>&+31?B%X5M?%_A'POXFC\+^*='_M?0[.Z+A_I2OSX_X)X?L. MZ[^PG\/_ (A^ -:^,Z?'?_A-/&VE>,+;QUKO@75O#OQ,,6F>!?"_@*ST#QQX MNU7XF>/V\A?#\0V'A8^$O".GVGAVXC\03POK4WZ#T %%%% !1 M110 4444 ?F7\=_^"E_@C]G_ /;X_9\_8=\8?#O677X_^'M U#3?B_!XAM(] M$\->(O&&O^+_ EX*\+ZEX9?27N[F3Q+XK\,Z?H%KJ*:U;1I>^([)1:3&!UE M^6O%G_!Z-J'[>0\,_ ;Q1XN\.?L16_AJ2'Q0/'>C:5I_QI;5OC=8? /6 M;OPB1H&IVVF:!H_C8Z\-/\0-?:W::_9Z#*\4=A+%OCGI'QR^%_Q4ANM-LO) MM= \-Z_H&EQW&*YOOAY;ZZO@:/P_/)IM\+CQ+8 MI;Z\M[/:Z?+%+IE])'U>J?\ !4W7?ADOQJ\)?M+_ +(WQ'_9\^-GPU_9O^*_ M[3W@#P#K/Q"\ ^.?!OQU\!_!W19=7\9Z7X"^+'@F74M(MO%>AC[+_;F@ZOH4 M-[I>FWL6M11ZC8JQKY3\6?\ !*/]HOQI^S;\:O@[I_@'_@FM\ ?%_C?Q;^S; MXL\+>)/V:OAE\3_ EAKTWP3^)D_CO5+#XM3WUKJ&HZQ8M L$?A2'1H%:VU'4 M]>DO988[F"5/8?B7_P $Z_VO?VIK[XN_%#]K#XU? >[^*9_9-_:)_9G_ &9O MA]\&O!_CG0?@[\+=2_:,\'#PGXY^)?B[Q%XNU+7?'GB;6];T^UTO19["VT^' M3])T6U>2SAOK]D< 'JDG_!477_'=[\-? _[,/[(OQ-_:5^,?B7]G7X0?M*?% M+P7X=\>_#_P)X.^!GA/XT^$[;Q5X+\+^,/BAX[NM,TK4O'NM6L\SZ'X;TG1C M/JVEV[:W))I]GYJ0=#^T#_P4ZM/@;^RC\(_VAG_9A^.][\3/C5XIE\'>#?V4 M_&>D)\-_C='K6B6/BG6O&QU;2[VUU](-.\+^%_!FN^)H=3TZVU6SUW1Y="O; M.2&TUE+FU\<\'?\ !/K]L+]F;6O!7Q/_ &0/CE\#=/\ B#XA_9?_ &*/A1XR\6_LZ_#>P^'WA/XL?#[7?"&L:!XR\.:E9Z7;W&E/X?O MM/DTO7=+:.[U V6I!#;/\6_\$VOVL/CA\:?VECX*\*7?C'PM_P M4(L/$NJ^"_%UKXAL;.'P+I_A_P"%]E\3%?6--%C>MK-Y<0WAT&[LK6]TZ32] M3MKGSWE,;0#V+]MC]I[3_P!C']EOXO?M.:MX0O/'FG?"31-*UN[\):?K$&@7 MFLPZGXGT/PV8H-7N;#5(;-K8ZT+UF>PN/-2V:!55I5D3\?/"7_!*?]M#X(Z1 M^RYHWP5^,O[/WB.#]BC]HC]I3QY^S_-\9;?XASPW7P:^.7AW3=.T7P;XXTSP M5X?TH1^*?#>L7GC34[V?PYJ-KHG1V<-C):R?H7^UA^S+^TA^UY_P3 MG^*'[-/CWQ7\%_#_ .T;\4?"=AH^J^*_"=KXUMO@U8:OIGQ"TCQ+:7&G6NK0 MZOXS2P.@:+;6TRW,%U.VKO,RJ+)E*@'S+XX_X+!^*?@II?QBL/VB_P!BWQY\ M'OB=\._V;D_:G\$^"#\8?ASX[T7XG?"^U^(GAGX::WL\9^$K>Z/@SQ%I>O>+ MM*GBT?6_#=P;VRCOI&N+2:&WAN_H3]G?_@H7XH^)'[0.G_LT_M!_LP>+/V7? MB3XL^!-]^T=\.+C5?B=\//BIX2\7?#/1=>TOP[KLNH:YX,N+:Z\'^(-/O-7M MKR+2->TA()]+MM1N+C4K"[ALK'4?)/BS_P $>?V?+3]D3]HGX*?LJ?#;X;_! MWXS?'SX8>'OA]JOQ/UZ]\;^)(VCTCQ'H'B.YLKG5];O_ !5XDTSPW>7VD27D MVCZ!%:V5[?IIMS?6,LEA:R6W@D'_ 1Z^(_P+E_:WTW]C77/@7\/-&_:J_95 M\+_!6V\0>.$\?:I\1/@GXXEET[0/BM+\/_%KZ?XGUVY^&/Q"\+)J/BK_ (1^ M?7=*O-+^*<'AS5[.&WTS0[1(@#ZY_8M_X*L?"C]K_6/C_9W/@?Q!\%-"^#?A MM_BSX2\2_$#5K1K7XN_LXMXE^('A>'X\:!;0V%I)I7AB#4?AYJB:U:22ZHND MO>Z?%_:EXTK,N9\(/^"F/Q*^,VH?#'QOX8_X)^?M0G]EKXU>*+'PO\,_VA(9 M?!.L:G>6FLR7$/A[XC^,?@CHFK7_ ,1/ OP=U=[:6\/Q"U5+B#3M#EL-RU"U+^#>&?^"-OB#X6?%/X!^(O _[2GC_XF?"WPS\%/B/^R;\;?AU\:]3T MBV&H?LM^/? EQX?L_ WPDO?A[X"T>31;OPMXLE@\76%MXIGU&*XFM+>&/5]. MG:^N;_V7]GG]D[_@I%\#+7X)_ 6+]L3X)WG[*_P,UCP_::?XLLO@;=S_ +3/ MQ%^$7A,>1HGP8\72>(M:UKX6:%;R:0MMX&=+7Q<^GZ79ZA8VUEJDU[ M+* )\+?^"B_[4/Q _:8UG]F;7/\ @G=XA\$^(_A_;_"KQ-\9];G_ &G?A'K] MG\,?AG\5]7UBPT?QZUKINE1+XP%I8>&_$FJS^&/#-_(?AUXG^('Q,^*OBC_A'O"_A#PC/?Z#C2;^73+N[U36+V+P[86-U=PM M.WUSX%_9@\7^%?VWOVJ/VH+SQ%X;N?"'QX^"/P ^%_AOP[;#5/\ A)-&UCX2 M3?$V76M1UPRV::8=-U,>.-/&EBPO+FZ!L[S[7##F#S/SL^"?_!*S]IK]FCX9 M?LC^+_@5\=OA)H/[5_[-7@/XT?"+Q>GC#PKXN\6_ #XU_"7XM?&KQ7\6[;PM MK45C>>&/'7A;5/">HZ]::KI7B71H)[AM8MKC3[NQN]'='(![!\3O^"K'Q!^& M7A'X*'7?V&/BSX4^,OQ=^.?CKX!/\(?BW\1O ?PEL--\2^!O"*>,IO%OAGXM MZY%J'PY\>_#37=/,EIH'CFPU/2M*O=2M+ZP)CNH8X9_T&_9?^,WCKXZ_#23Q MO\0_A3I7P<\0)XFUC0U\(Z/\8OA]\<;-[#3HK%[75_\ A-OAI<7/AM9;]KJ9 M)-%:3^T=.^S*]VH6Z@)_*W]I?_@G9^W!^TWX-_9VU;XR?%[]DWX]?%3X2_M! M^/\ XQZYX&^*7PCU[1?V;8?!7BKP,OA+0/@OI'A?PS;ZCXP\<>'/#5[]IUZ3 MQ+X_U?\ X275+ZXA$]RD&G6\#_H]^Q'\#O%_[/OP7F\!>-_A]^R]\-=:?QIX MAU]?#?[(W@_Q'X(^$YLM3ATR*WU&31?%+-J9\5W9LY5UN]!%K<10Z>L(S%)D M ^OZ*** "BBB@ HHHH ***,C..^,_A0!^"_PO_X+$>/?BA^T7J7P8@^''[%W M@?1='_:SO/V9[B+XG?\ !0?PIX#^/6NV.F?$[3O -SXP\"?L]:Y\((=?\9ZM MK5I?F?P/X0TSQ"G_ F7BJ'_ (0[3==2Y?[>O,^#O^"\OAGQ/^SU^VK\1;[X M&P^&_C?^R;8>,?%_AKX-:K\1+N/0_CA\+O"WC_\ X5O+XZ\(^/Y/ ,-S$FE> M*;?4=(\;:=9^#M^(FA_' M3]E'Q)X$\5?M8ZQ^TKK&D>/_ -AK2_%_QCL--\1_$;3?&6L>#?!_QPU/XTG4 M/"NJ6>E:>=/\)>++/PO.OA;Q'+_PE5GH4TJ?VT[3=?BMK6T&IZ'J9==U]Z%==SZ:_;+_X*L6?[ M)GQ7^#'@"U^"][\2O#6K^"/"'Q=_:C\<:=XO.EV_[,?P:\>_$_P+\)O"WCF\ MTR+PQK!\8R7GB;Q3K,]QHT][X2F@TCPVVI)'_P!E[1_$0\4:WXAT=?"'A >) M/AAXMTKQ'XAB318M0M;.TUY+B]L9[BX-O;0V@DGI^.?^",&@?&[Q[^U'\2/C MG^U+\=9];_:&@T+P?I_AWX(^,/%/P9^'6B_"'P3\/]+\$^ _AY\0? UIXJ\2 M:;\8+31KRUU/Q+J*>(I+#0-3U77=7FA\.Z?=:KJUY?\ G6I?\$A/VC;CQE\. MOB2/VJ?V;/&7CKPO^R/\,?V5?%E]\YEGFMM8%E9JZ[K[U_F%UW/JG]F+_ (*6 MZO\ M&_&#]EWX97'P!U;X:6O[1W[''B+]JN:]\4^*[@^(?",^@_$5? =MX7M MO#I\)64/B'PWXFM63Q=X9\<-J^C2:KX M+/A/XDCUK_A&9+V?3->;2]=OUL(WT.\O_L;Z_:V<=/P9_P $G/VBO@5K7[,? MB_\ 9P_;5\(^'?&_[/?[,_BK]G.^\0_&#]GB]^+$'BS3_&?Q1U?XHZKJ.F:1 M9?&KP/'X4TC2;R_L?#OA/PZMWK(T'PYI%IIZZE"&UW MXYZ2/".G>,]8M]7\0W6AVD5R;:SN=$T:]U'6)/#\.J71==U]Z_S"Z[G7:Q_P M4?\ VNM9^,G[5_@7X%_L.^!/C9X(_9 U7P'9?$#7=/\ VIH_"_COQ3;>,_A/ MH/Q4DE^'O@O4O@S>Z'X@N;6QU/4+/3+=_&]H-<%E9RV3_:=3CL(/\!>)=<;P'J-VOC#XB>%_A]J MFA:[K%CI'C)=$UGPGJ.N:C#J<-GINM6LNJZ)/I\%R;:X744\-U[_ ()R_M=: M9\9/VM?'7P/_ &YO OP5\%?MC:MX&O\ XB:1I_[,*^*/B%X7A\(_"?0_A9./ MAYXXU#XSV6C>'KV[L].U&_TR\D\%7KZ&U]9I9#[7ID=_-[?\"O 7@[PUX_\3Z)_PGNH67_"'?$3PO\ $+4]>U_1 M['6/!BZWK/BO4=#U&?4Y+/4M%MHM4UN>_M[=;:W33G+KNOO7^8[H^>+'_@K] MK'PK\5?&[P7^V-\ _"GPMUKX3?LOM^U5I-S\ _CUI/[2.D>,?"9^(/AKX6Z? MX&-RO@CX:3^'?B1XD\:^,/#VG^%]'U&VDT[5K2[GU*35;.PLWN7]@T#]M[]M M71M*\0^+OCM_P3MOOA;\/W^"7Q5^,'A7Q9X>_:&\*_$4>&[OX<^"KWQOIO@G MX\:5%X+\,WGPWU3QA:6T6D:?>^%/^%EBRUR?[%<:?)%;:G=:;YYHW_!&+X"^ M&]1_;%\#>%)O"/@;]F?]L;X8^!-"UWX5^ _AYI_AGQM\*_BIX"GL9=.\>?"[ MXGQ:Q=-IOA&XU#3[;QG_ ,*RU;POJFCV'Q @_MNPOX=+O=5T._\ 0=!_8G_; M5UG2/$7@_P".O_!1*Y^*'P_7X)_%3X0>%?"GAS]GKPI\.SXEO/B+X)O_ /I M?C?X\:O'XS\3WWQ%U+P=:7<>KV%AX1/PT6^UV!;ZZOECFU&VU$NNZ^]?YBNC MX\MO^"^&AW/_ 3[?]K.+]GY6^/*_%P_"1?V7Q\3)1))=#0#\4O^$O7QN_@- M=;'@P? A)/B$=;/PY%NVHQG14+:4\?B=_P!U_@WX]D^*OPA^%?Q0FTJ/0IOB M1\-_ WCV71(KYM3BT:3QAX8TOQ"^E1ZD]GI[ZA'ISZBUHE\]A8M=K"+AK.V, MAA3\4]/_ ."&/@JRM(-6/Q=TZ7X@0_\ !/6Y_8R_MY?AY-'H$GQ0F^'5S\'( MOVDF\-GQQ)(=>M_A#=2?#I/#QU4ZA_8!\A?%ZH?*K]J_@UX!E^%/PA^%7PNG MU6/7I_AM\-O W@&?7(;%M,BUF7P=X8TSP[)JL6FO=Z@^GQZ@^FM=I8O?WK6B MS"!KNY,9F=W7<=T>DT444 %%%% !1110 4444 %%%% !112$@=2!]>!V[_B* M /C'_@H#^TQXX_9#_97^(?QW^'?PQN?BOXI\+7'A>PL]!%MK]WHFAVWB7Q/I M7A_4?'?C.#PIIVL>*9/!/@6QU&?Q-XG3P[I=WJ;Z;I\L:OIUL]SJ^G_FCX$_ MX*Z_$J#]F_XC_%/7'_8]_:A\=S?%?X._ S]GW1_V/_B7\0["S\9?%CXX7VK: M/X7\)_&3P3\6_#:>./@E#IM]I-S?/K.K3ZJGB;3[34[31M/MK_3I=_[%?M$_ M"#6?CK\,-2^'_AOXV?%?]G_79]6\/:]I/Q,^"^M:3HWC/2M1\,ZQ:ZY8V4KZ MUI&MZ=JOAC5+NR@L_%?ANZM%M?$VA27NA7TZZ??W<*/AEH_P MV\(Z=X>T+QYX=UN\NK^Z\9:I9:[J6LV[1Z3>I_9;ZC:ZB"NNZ^\S-1_;7_;A M_9N^*?@SX1?MG_"W]FB^N/C_ . /C?K?P%^)'[-?B#XG7OA70?B/\$OA9K_Q M6U7X;_%CPU\2;2PUZ[M=9T'19GT7QCX:U/2[>^FM9;*71+"2Z>XTOY5_8B_X M*D?MB?MF?\(KH7ASXL_\$S;/XJ?$/X5^)?%/A;X,KX5_:TM?'7AWQEIVC-J= MG8^-;B75-1\*/H6CB"XN?$J:!XAN;Z:R\O\ L>\DF)W?>7A?_@F5>:GX_M/B MQ^TE^UK\;?VI?B)X*^&WQ)^&?P1O_'ND_#_PKX8^#MG\5_"%_P"!O&GC'2/! M_@70-%T_7_B-K/AJ_ET>^\7:S<--9H^ MIR2S95UW7WK_ #"Z[K[T?B_H?_!0/_@JEJ'[/G[<_P"T*/ _[#6O:1^P_P#$ M;X^_"+Q-X0\-^&?V@O\ A)_&7C#]G'6O#C>/=!+)+4SQ:AHFE6EO)9VE_?H;N]BN)#=P_+M/YVQ?\ M!!KX$3?LM_";]F/6/C'\1M8M?AQ^T!JWQMUSXB3:=HL?BSX@:)XBTC3_ EX MC^%.LAI9X;/P?K'@/0/"/A*;RI;KR[7PIH]R+-S;06\!==U]Z_S"Z[HR/VE? M^"GW[6OP*^&'[*R^'_@G\,OB%\>M9_9ANOVUOVU?!MAI'CFUT/X/_L[^%4\) M#QG<>#K$>+9M;L/$(=9T/P]<^)=0\0V@N_!VN7M_I,MLDD-ITO[8'_!3 M#XK^ /VD?@I\)_@#\5/V"?AM\+/C%^R?8?M+:+\9_P!M/Q7XM\'>"=;_ +9\ M7W&C>']!\.>*?#OCOPUIT]QXAT&?3=,/C!JOQ5TCP7X1\'^%4\3^*_AWX?^$/@'PAX= MGT2?P=X?'@+Q3H\WB/3_ !+?W,_B/7!XH%[9OK$]RUIIUM!=W44WEG@G_@BQ M\%+.V^'FA_&+XBZW\>O!_P ./V2?B'^QYHGA_P <>#?"@N+?X?\ C#X@:OXR M\,^(]+UJ0:I=>'O&_P ,M(U2/P=X*U_1(;2YT[3=-T^\MVM+F-XW=UW7WK_, M+KN?#/B#_@N!^T-J_A3]C7Q#I&F?LD_L]VW[1?PA^-OC;QCXF_:)L?CGXJ\" MV/B+X/?&/5_A79/X(U'X8WFG^)9?"WQ&M-'D\5>%9-5\,7K"RNXX9=9GACM[ MW4OW^_9+^*FN_&[]G3X6?%7Q-XK^%7CC7?&6AW>HZCXK^"%GXUL/A5K4T&MZ MKIR7/@RS^(J1^-;?3DALH[>=/$""[_M&&]:/-J;%/BS^RU\!_$_P"SQHGQ/C^$GPM\2ZIXR\!Z]K%M/9OXCT/Q=;ZU MH4>M:;X._B1J M7Q>\6Z#8SVNM_$C6/#GASPEJ7BNYEO[N[2_N_#GA&TL/#FE20VUQ!8K!I5I! M \=HD[H9Y968&>E444?Y_*@ HHHH **** "BBB@ HHHH *_*;]L?]F;]L'Q9 M^V/^S%^UK^RC!^S7K=_\"_A?\9? &L^%_P!H7Q_\4/ ]IJ5Q\4GT*"&]TN;X M;?"CXCS7$6GV>FW3RF[N-,87+PQI!<1L\D7ZLT4 ?@=:_P#!+C]I;6/%WP\^ M.WQ'^(WP4\3?M ^,?^"B_P %OVROVF%\/R>-?"OPST3X,?$G_ ()&?MP2 M_#2#]D_X3_&CX+Z=^SKX.\%_BSXL7Q M9XH\.ZI\/O@V=)^$_P <]0T.Y:YM/#.L>._$^D0+%>7\YTK3Y;R);#^E?(XY M STSQG\Z3>G]Y?\ OH?XT"NNZ^\_*_X-?L/_ !=^&WCW_@I7X@UGQ/X#UK2O MVNO"OPG\._":^CUSQ/-K\5QX _9]U'X3:KJGQ2M[OPE';Z%/JOB*YAU6(^'- M6\=R2Z=+=75S)'?(EE/X=\2O^"<7[3GQ'_X)^?L$_L&6WQ,^%W@+1OA'9_ ^ MQ_:M\:AH$G[A KZCGWS_7I^E&5]1^8I77=?>O\PNNZ^\_ MFZ^*O_!([]M:\\(_MO?#/PI^T)\)_C7X<_:VN_@#\9AXW^-"R?![Q9;?M)?" M[XG:#>^-KO7/!/P,^"M_\.K#P?XS^&&@Z7'-XH\-V*>(]2\6Z+I-GJ_A=8#> M^*[C]NOV<+W]K6]\/^(W_:Y\,?LZ>%_%<>N11^$+;]G'QS\2_'7AZZ\,?V;: M--/XCOOB;\//AUJ5AKHU@WT45GIFGZC8-IJ6L[WRW3S6\7T7D>H_,497U'YB MG==U]Z_S"Z[H_F&\'_\ !OSX<\-_\$^?AK\.)?AE^S"/^"A_A76_!^H>(/VA MK77_ (B-X9N[70?CM!XMU :?XM?P'!XCNKF;X.V\?@ZV6]^&=I$^HA=.DDM[ M&./7DZS_ (=%?&N/]L3XT_'?Q3^S5_P3G^/?AOXE_M=7GQW\)?$3XO?%+]HC M3?C=\-_ EYXGT35;;2-!\/\ A?X+7'@EO$>@+IMWXETG3[KQ+=:9+XIO&M;S M7GTPI<6_])N1ZC\Q1D>H_,4KKNOO7^877<_FP^('_!'3]M'XL^$_VD_B1XC_ M &O/"'@?]H?XU_M"I^TMHWPZ\(>&O#GB'X-:?\0OA-JZ0?LP-J/QT\1_!RR_ M:(T2+X>^#-*T30[H^$+&RTG2C)JEM9^'/$5I=:G)KOU=\+OVD_ *70]:DEU2#QA?>"QKOB'3TU*Q@\./KH_,4M,=T?" M7@O]F7XA^'?^"B_QS_:UO]2\&2?##XE?LP_!OX,^'M)M-5UN7QY;>+/A]XW\ M=^)-17>CV$,4-Q+ M)/ <'B)+FS^#\D7@^1(_AG+%%J*#3T>XLP=>?^GJB@"M90O;V=I;R%3)!;00 MN4)*%XHD1BA958J64[254D8)4'@6:** "BBB@ HHHH **** "BBB@ HHHH * M_&/_ (*1?\%&OB[^R/\ &SX4_!_P39? +X5^%_'?P[UGQU=?M(_M;VOQI'P* MOO$MAXE@\/V?P9T?5_@YX?U*30?&S6;'Q1K.N^*M0BT;1M O--F.FW=Q=6T5 MW^S6]/[R_F/\:^$OVI_V0?B/^T!XMLO%O@']L7XS? 6VD\"7?PZ\4_#C1_#W MPP^)OP;\6:%>7]YJ$^KWWPT^)GA37-)M_',@OIM-D\7QSS7KZ)#9Z2MO':PR MK<*Z[K[U_F*Z[GPW^T3^VM_P40\ > /V2?BY\,+7_@GMK7@/]J#Q5^SQ\%8( M[;Q1\8?C'9Z7\:OC1+K-KJ.MZ!\2? FL^$/"'BSX/:9/86S66KZ/I]WK39O8 MH!KD,=MJ%QTG[;7[>'[:'[*7@/X!?#OP?\+O@5\;?VQ_%7@+XT_&_P"-OA[P MA;?$5OA'X8^"7[/_ (>E\0^-_$'ABSNO$-AX[TW4?$LFI>'/"WP_D\27%]:Z MSXL76-)AM;RX-I OT+'_ ,$T?A3HO[-G[(G[,7@[QWXRT+P=^R-\>OA5\?= MUO48M)U[Q%XX\1_#;Q'XA\6WUAXD?[/IFF:?;>,-?\3:I>W[Z%I]E;:-&\=G MHNG6]G##;I0^+W_!+']G_P#:1_:;^(_[1_[26L>,/BU_PDG@+P!\-_AO\.H_ M$WBCX>^'?A%X6\*+K%YXEM-+U/X?^)] UGQ0WC[Q#K-QKFL+K\S6MFX^QV]K M+$()+=W7=!==T?)'[;7_ 5D\ZUO3?$;1R02:-JJ1:E;M#)? MVJQ[)?"OBG_P6&_:*\&>-/@+X)T[XO\ _!.71M)^)?[*[?'?6/C;XR\)_M5W M'P@\2^+%^.7Q'^&/_"*?#:W\/ZBWCVRMQH7A.POS'XO\-H3JFE>*G&LFVGT. MQ?\ 0#]F_P#X)4^#?V=/B)^S7XSLOC3XN\;Z+^RQX/\ VBOAU\-/"7B3PWH) MC/@'X^>+8_%MOX=UG6H[B:[O/^%=RBZTKP_>1VT+7VE3P6MY!$MI%N^J+C]D M;PG<_MJV'[9C^)+@ZII_[,+_ +,L/PW;1-(?PR-)?XH77Q._X2Y;]\WT6KB[ MNY-(^PQP"T-H6G,GG.Z,KKNOO7^871^0WQ?_ ."O/[1OPW\$?M1ZUX?T7]FK MXA7WP,_9"_8H^/7@_P 4>&]$^*:^ O'OC#]I/XD^&_!?C"6VAUGQGHGB5OA] M%I^L7&H>!;6ZM] \3V":[EAU"YTJ;Q M'H]RWB;PW/I4]H=$U'^TH;+V_P#:<_X)5^!OVE_%/[6_B;4OB_XI\'']K'X3 M_L^_"?5M-T?PWH%[:^!]/_9^^(VE?$32=5T,W<\3:A<>(;G2H]*OK2]6*VL; M29IK,M*BK74^./\ @EG^SWXT_;5\/_MJRS76G^)+CX9^./AE\8?AQ'I>DW/@ M7XX67C;P!K?PSN_$'B^*18[VT\1'PAK]UH>L7MG+*GB#3+'1[>\AAGLI[N]+ MKNOO7^8[H^5_A=_P4H_:HUOQ=^S5XW^+\7_!.;X._!K]JF7PCXF\ _ 7QS^U M9+X$_;(T7X+?$R>[M?AW\4GM?&B:=X'^(=[J\JZ:!X%\#Z!)?:G?ZG;:!I>N M'54U1=(_=^OQ,TG_ ((J_#V#7_A#I'B7]IOXU>.?@+\ O&OA7QG\'?@[XH\/ M_"&_\2>#X/ ?B)_%?@CX>K^T _@)OC->_"CPKK3YTGP+_P )):V\>G*NGO?2 M;1./VQ#K_?4_B.Y.!^'3^=.Z[K[U_F*Z[CJ*0$'H0?H0:6@84444 %%%% !1 M110 4444 %%%% 'Y*ZC_ ,%3='\+_P#!3K6_^"?/CKX96GA?PC;^%=&O=#_: M$N?'.W1Y?&VM_"F[^,%AX0\5>'[_ ,+Z=I'A6#4O"WAKQW'HNK2>-[^XU74? M#45K!I(-].VG^5?LV_\ !9_PW\;_ ($?MV_M&>+/@Q-+C4_$?QD\(>-O"6L^,OA3>R:9>>#="C\&:S\3M+7P:/#>E)<^*()9O&VF M8U&6-%DN=']K+_@CW8?M6?$#]M;QSKGQI@\*7'[4FE?LHIX!O-,\ 37/B;X' M^(_V;1K&FZQX@L=?/C2T3Q&?B-X3\1^(_"=S90Z?X<72-,UN[::;698K)[7X1?LB? MCP[\(]$^#^B^/(/'L,%C-K_B#PKH'CNT\8'PK))X0>&=4D\=GP FIVVA:[X1^(MAX@T_4)O !BN=1TG6-&MC/!:MJ@]0^%/_ M 56\(_&[QY_P3]\)?#WX=3-!^V/K/[3O@KXGVOB3Q+-HOC;]FGXG?LQ?"R/ MQ[XL^'/B;P?_ ,(W<2ZUX@FUA_[&DAU2_P#!L\&@76D>,+6TO[35[2PKYH^+ MG_!$'5?$^@?M<>"?AO\ ME_%=?!G[8'P*^&GP]\?M^T;-XK_ &D_'Z?%7X4_ M%?0/&7A'XI7'Q$\0?$'PUK>LZ3IOP_TF[^&MGX*O8TFL8;^+58/%'V#3K3P] M'[E\8O\ @E!;Z]^W/X=_;M_9^^,UK\#/']KX.^,R^*_",O@OX4^.&G:99^,_"UCHGB;1AXHT[6_'=O]@OY/B(/"VFPRZEH>J7VJZY M=JZ[K[U_F*Z[G3?LZ_\ !4G3_CS^VGX__9DN/A!<>#/A>;SXT:!^SO\ M!W? MB_\ M+1OVA/%_P"S?J_A#0OC=X>T+0%\-65IIC>&[GQ+?:MH]Y9^*/$$.K>' M/#FJ:A^)WB M/]H_X>?";XJ?%RT\&^)IO"7C#QS\(/A!XWT2UTC6_".EZQ;7C:=/XK^)O@Z[ MU>QMC-)!IEU]KL=/\Q\!_P#!#[3O@WH_[(NN?"3]K_X^VWQ9_9:^(G@;Q^EW M\2O%_B[XB_ _7]"\'_ -G\9:1IGPMLOCO+J>O1ZW?>'_$-YJEG:ZQ M=IJ]UXINY[J^N>/^,O\ P0F?XF>&+_X":5^T?X0MOV21XQ\<^+OAY\/?B/\ MLU>$?BS\:/V>(?BEXAM?%'Q&\+?L\_'C6?&.F7'@C0/$.KVD7V5M5\&>(]5T MRP2"T>_U"=;R]U$NNZ^]?YA==SM_C;_P6&\,?VF_\ @H!X7_9@U3XA1?$+X;^'/B -0\'>%/%7PAU^+6(= ;7' MTG5O[+\0ZC';.VC7$TL3:S';VW?>#/\ @LAX'?\ :I_;9_9X^,7PUA^%GA7] MDOPA\5O'&@_%=?&S:YIWQ3TKX(:=H&N?$K1X=(O_ KX<@T/Q?IOAWQ5H/B' M3/#VG:YXIN-0TAM2NYGLX[6 W?'^+?\ @DS\8+;]HSX\_&SX3_';]EV+P[\; M9O@TL?A#]HC]B/2?VB==\'V'P;^$?ACX5:9;:+XLU3XR>$+2UFUR#09]7UJ; M3O#&FQ7,\^G0FVQI8DN7?%3_ ((G^#OC7XK^+'B+XA?%VUO(/B7^WGX:_:[% MKI7@*2POK;X:_P#"(:+X)^)W[.VL:G+XRNI-8T/XEZ/H]M-?>((H-.M+#4=- MT*XG\+:I%IT]O>EUW7WK_,+KN>$Z1_P7E^(FL_!/X3?$N\_98^%/PW\3?$[] MI[XL_LYWVA_&W]JV/X3^ OA\/AG\+O!'Q)'BGQW\4-?^#;Z=X>EU0>+I?#]S MHVIZ+:QZ;JMG96T>JW][JB65MZGX_P#^"V\GP4\,_LI>-?BC\)?@OXP\&_'S MXB?&[PQ\1/%_[*G[4NF?M.>$OA%X+^#D/PXGU#QQ:^)/"?PTTG3?&ESIUEX\ MNM;\>>%S)X;O/!VA>'Y[M+[6;B]BM8;GQ)_X(X>.O$NH_P!O^"_VAOA1I>LV M'[>W[3'[:FB:9\2?V;!\4_ "Z?\ M ^%O#_A:R^%_B'P+=_%CP_8>(8O!MMH MTUR-?ENK2TU2ZFL9K7PYHTNF1R3>Y^&/^":OC&^\=?L@>-?C!\2OV??$EK^S M5J_[6!\8> _A3^ROIGP<^&_Q9\*?M-?#;0OAT?#L_@FU^)/BC1=#GT6STN^E M\4:EJ$/B:/QQ::@FGRZ?HRVK3W!==U]Z_P PNNYI^*?^"A'QL\1>*OVK_#?[ M,7[/?PK^-MM^R_>_ OQ"_B/7OVCIO 7AWQ]\'?C!\"?%OQBO?B'H&KZ7\)?' MEB]YHUWI7A;0] T"SFU.Q\5Z3XENO$@\1Z.NCIIFI>Y?\$_OVGOCY^UU\']+ M^./Q;^ /@3X'>!/B%X3\#>-O@S+X1^-EW\7-5\7>'_%-GK%YJLGBO3KKX8_# MO_A";[18H- ^S6:3^(1J9U>\5YK!]**7?@G[&?\ P2RT;]B^U_;5\+^"?B_> M^(_A[^TY;Z;I'PU\/:_X?O9]4^"7A/2?#7C30-'\(SZ]=>+;YO&VC>'8O%Z6 M7A\1V?A:6VT/1K.QN#<7(I?#UA'9/JT.A2ZMKLFDQW93S%LGUG46@!VF[EQNIW7=# MNCZ/HHHH **** "BBB@ HHHH *3(]1^=+1@>G^>O\^: /,O&_P 7?A3\.KVR MT_X@_$SX?>![_4;62]T^R\8>-?#/A>\O[2*8V\EW9VNN:G8S7-M',/)>>!'B M64&-F#_+7$_\-0?LU?\ 1P7P0_\ #N?#[_YH/_UU]!%0>H_4TFQ?3]3_ (UT MTUEW)'VU/,'5M[[HU\!&FW=_!&KA9U$K6TE.3O=II-)>77IYQ*K-X:OE,*#: M]G'$83-:E9+EC?VD\/CZ5&3YN9IPIQ7*XIIR4F_"8_VD?V>)462+X[?!J2-Q MN21/BIX#9&7IE677BI!.>0<9''0Y?_PT;^SW_P!%T^#G_AT_ G_R^KW$PPDY M,49)ZDHI)^I()/XTGD0?\\8O^_:?X5=LJ_Y]9H_^YC+/_F,P]EQ#_P!!&06Z M?[)GB?S_ -O:/#_^&C?V>_\ HNGP<_\ #I^!/_E]4D7[1'P F?9#\;_@_,^" M=D?Q/\#2-@8R=J:Z3@=SC'->V>1!_P \8O\ OVG^%->UM9%VR6T#KD':\,;+ MD=#AE(R.QQQ32RF^M+-+=;8C+&_DG@TOQ#V7$/2OD%_/"YZE^&.;_!GCW_"_ M?@5_T63X3_\ AR?!G_R\H_X7[\"O^BR?"?\ \.3X,_\ EY7K?]FZ=_SX67_@ M+!_\;H_LW3O^?"R_\!8/_C=5RY+_ ,^\X_\ !V4__,PO9\2?\_N'O_"?/_\ MYK/)/^%^? O_ *++\)QW_P"2D^#/7I_R&^_Y>]6T^-_P7D19(_BU\,'1P&5T M^(/A)E8'H59=8*L#V()![&O4/[-T[_GPLO\ P%@_^-U5?P_H,C,[Z)I#NY+. M[Z;9,S,>K,QA)8GN2231RY-_)FZ_[BY2_P#W60>SXC_Y_V@BU5I9[B>9T MBAAB5I)976.-6=E4^I CZ8Y/([DCGOU.>0/?&,5E+X?T!'21-#TA)(W62-UT MVR5T=&#(Z,( 5=& 964@JP!!!%:V!UP,^N*YJZPBW*TKH[\'',8JI]?G@)2;C[+ZC3QT(\MGS>U^NU*DF[VY?9 MV5K\UVTTM%%%8G:%%%% !1110 4444 %%%% !5.]N[:R@>YN[BWM8$9%>>ZG MBMXE9GVJ&EF=(U+,0J@L"Q8*,D@5'O%>F3Z+XHT'1O$FC7+PR7& MDZ_I=CK&F7$EM*D]N\]AJ,%S:RO!/&DT+21,T4J)(A5U!#2BY14W)0NN=P47 M-1OKRJ=H.5ME-J+>[2,ZOM?9U/8^R]KRR]E[9U%2Y[>[[1TDZJAS?%[-.=OA M3>A3_P"$F\/_ /0=T3_P<:;_ /)-/3Q%H+@[=;T5L=2NK:>>IXSBX.!Z9YKB M?^%"_ S_ *(O\)__ W7@_\ ^4]/7X$? ],[/@U\*4SUV_#SPBN<9QG&CCU/ MYFNE0R^^M3,+>5'+K_\ IQ?F>4_]8>D,A;\ZN>+UU6'D_P #MO\ A(-"[ZUI M'_@TL#_[<"C_ (2#0O\ H-:1_P"#2P_^2*XO_A1GP2_Z([\+/_#?>$O_ )44 M?\*,^"7_ $1WX6?^&^\)?_*BJY5L/EK_/$(3?$?2EP M^_7$YZORP4CO?[9TO_H*Z;_X'6G_ ,=I#K.E=]5TSH1S?V@ZC_KK7!_\*,^" M7_1'?A9_X;[PE_\ *BC_ (49\$O^B._"S_PWWA+_ .5%/DRK_G[FG_A-E?\ M\U"OQ'_SZX>_\*L]_P#F$[]-6TQLE=2T^3&,[;VU;!_"4X(Q[$^^.)/[5T[_ M )_K'_P-M_\ XY7G?_"B_@E_T1WX6?A\/O"0_EI'M1_PHOX)?]$>^%O_ (;_ M ,)__*FJ4,G:5Z^;I_W<+E=M_P#L-7Y"YN)?^?'#K\_KF?+\/[/=OO/4(Y8Y MD62)TD1QE'C971@."5=2589[@GOW!Q)69I&BZ-X?TZTT?0=)TW1=(L(S#8Z7 MI-C;:=IUE$SO*8K2QLXH;:WC,DDDA2&)%+NSD;F).F !TK@DHJ4E3V5-5>2'M526/S"@92X7<5!&1S69_PDWA_P#Z#NB?^#C3?_DF MHO$_@7P1XW2SC\9^#O"OBZ/3GGDT^/Q1X>TC7TL)+E8TN9+)-5L[M;5[A(85 MG: 1M*L48D+!%QR/_"A?@9_T1?X3_P#ANO!__P IZVA#!N*=6>+537F5*G@Y M4]].5UIJH_=M?F6CTC[MF>;B/[8]K+ZHLI="T>1XJ>:1KM\JYN=8:E*C\5^7 MED_1JNGD<$CJ+C!Z=J=_PD&A?]!K2/_!I8?_)% M<4OP*^"*C"_!SX5*/1?A[X1 ]>@T@#J2:7_A1GP2_P"B._"S_P -]X2_^5%: MJ.76UJ9C_P"",N_^7K\D87XBZ4\@MT_?YXOP^JNWWL[3_A(-"_Z#6D?^#2P_ M^2*5=>T1F 76=)+$_*%U.Q8G\!.3^0./I7%?\*,^"7_1'?A9_P"&^\)?_*BC M_A1GP2_Z([\+/_#?>$O_ )44^3+;ZU,Q_P#!&7?/_E_^J$WQ'TI\/_/$9ZOR MP;_([P:SI0&!JNFX_P"OZT_^.TO]LZ7_ -!73?\ P.M/_CM<%_PHOX)?]$=^ M%G_AOO"7_P J*/\ A1GP2_Z([\+/_#?>$O\ Y457)E7_ #]S3_PFRO\ ^:A7 MXC_Y\\/?^%.>_P#S"=Z=9TL\?VKIO_@=:?\ QVGKJNFLH*ZA8,O(R+VV93SP M6%RMN_SQ:5OG\@;XDZ4.'7ZXO/H_BL _R^9Z'_ &IIW_/_ M & '?_3+M>J!0HPH 'H!@5AB(X-M>_OYR>SY[WES\MHW6BBBN<[@ MHHHH **** "BBB@ HHHH *BEEBBC>69TCBCC>6221U2..-%+.\CL0J(J@EG) MPB@LQ R:EHHTZ_@[?UU\MM-!.]G:U^E]MGO;7>VVI\^G]I_]FL$AOV@O@@"" M01_PMSX??*02,'/B'.1CG//K3H_VG/V;YG$_P#HNGP<_P##I^!/_E]7N'D0?\\8O^_:?X4>1!_SQB_[]I_A1;*O M^?6:?^%&6?\ S'^8O9<0_P#/_(/_ DSS_YO/#Q^T=^SWS_Q?/X.'_NJ7@7^ MFORM'!32RB_O4\U2MTKY6W?YX1?G M\A>SXB6U?A]^N%SU?BL=+\CR+_A?OP*_Z+)\)_\ PY/@S_Y>4?\ "_?@5_T6 M3X3_ /AR?!G_ ,O*];_LW3O^?"R_\!8/_C=']FZ=_P ^%E_X"P?_ !NJYSXC_Y_3Q?'CX(32!(?C#\*Y7()"1_$?P M<[X R2%36F8X[\<ER:1 MI,R&.;3-.EC.,I)96SH<'(RK1%3@\C(X/-5O^$<\/?\ 0!T7_P %=C_\8HY< MF_DSA?\ <7*7^>'0>SXC_P"?O#S_ .Y?/E;_ ,NG_7WF9X7\9^#_ !@EY)X2 M\4^&_%$=A)#'?2>'=>TK7$LY+A)'@6[?2[NZ6W>=8I#$DQC,@C=D#!6(ZRJ= MIIVGZ>'%A8V=B)2K2"SM8+82% 50R"%$#E0Q"EL[02!C-7*XZGL>>7L/:JC= M5/WKM^KAUB%1@L6\/+$>][1X6->.';YI
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�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end GRAPHIC 17 form10-k_003.jpg begin 644 form10-k_003.jpg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×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form10-k_004.jpg begin 644 form10-k_004.jpg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end GRAPHIC 19 form10-k_005.jpg begin 644 form10-k_005.jpg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�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�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end EX-101.SCH 20 ccld-20241231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000008 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 999016 - Disclosure - ORGANIZATION AND BUSINESS link:presentationLink link:calculationLink link:definitionLink 999017 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 999018 - Disclosure - GOODWILL AND INTANGIBLE ASSETS – NET link:presentationLink link:calculationLink link:definitionLink 999019 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 999020 - Disclosure - CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 999021 - Disclosure - NET LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 999022 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 999023 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 999024 - Disclosure - SHAREHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 999025 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 999026 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 999027 - Disclosure - RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 999028 - Disclosure - RESTRUCTURING COSTS link:presentationLink link:calculationLink link:definitionLink 999029 - Disclosure - EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 999030 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 999031 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 999032 - Disclosure - OTHER EXPENSE – NET link:presentationLink link:calculationLink link:definitionLink 999033 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 999034 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 999035 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 999036 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 999037 - Disclosure - GOODWILL AND INTANGIBLE ASSETS – NET (Tables) link:presentationLink link:calculationLink link:definitionLink 999038 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 999039 - Disclosure - CONCENTRATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 999040 - Disclosure - NET LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 999041 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 999042 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 999043 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 999044 - Disclosure - RESTRUCTURING COSTS (Tables) link:presentationLink link:calculationLink link:definitionLink 999045 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 999046 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 999047 - Disclosure - OTHER EXPENSE – NET (Tables) link:presentationLink link:calculationLink link:definitionLink 999048 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 999049 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 999050 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999051 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999052 - Disclosure - SCHEDULE OF CHANGES TO CARRYING AMOUNT OF GOODWILL (Details) link:presentationLink link:calculationLink link:definitionLink 999053 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 999054 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, FUTURE AMORTIZATION EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 999055 - Disclosure - GOODWILL AND INTANGIBLE ASSETS – NET (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999056 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 999057 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999058 - Disclosure - SCHEDULE OF CONCENTRATION OF RISK, BY GEOGRAPHICAL RISKS FACTOR (Details) link:presentationLink link:calculationLink link:definitionLink 999059 - Disclosure - CONCENTRATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999060 - Disclosure - SCHEDULE OF RECONCILIATION OF WEIGHTED-AVERAGE SHARES OUTSTANDING FOR BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 999061 - Disclosure - NET LOSS PER COMMON SHARE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999062 - Disclosure - SCHEDULE OF MATURITIES OF LONG-TERM DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 999063 - Disclosure - DEBT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999064 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 999065 - Disclosure - SCHEDULE OF CHANGES IN ACCOUNTS RECEIVABLE, CONTRACT ASSET AND DEFERRED REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 999066 - Disclosure - SCHEDULE OF TRADE ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) link:presentationLink link:calculationLink link:definitionLink 999067 - Disclosure - REVENUE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999068 - Disclosure - SHAREHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999069 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999070 - Disclosure - SCHEDULE OF LEASE EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 999071 - Disclosure - SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 999072 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 999073 - Disclosure - SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 999074 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999075 - Disclosure - RELATED PARTIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999076 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS (Details) link:presentationLink link:calculationLink link:definitionLink 999077 - Disclosure - SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS (Details) link:presentationLink link:calculationLink link:definitionLink 999078 - Disclosure - RESTRUCTURING COSTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999079 - Disclosure - EMPLOYEE BENEFIT PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999080 - Disclosure - DISCLOSURE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD (Details) link:presentationLink link:calculationLink link:definitionLink 999081 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION, RESTRICTED STOCK UNITS AWARD ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 999082 - Disclosure - SCHEDULE OF EMPLOYEE SERVICE SHARE-BASED COMPENSATION, ALLOCATION OF RECOGNIZED PERIOD COSTS (Details) link:presentationLink link:calculationLink link:definitionLink 999083 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999084 - Disclosure - SCHEDULE OF DEFERRED TAX VALUATION ALLOWANCE (Details) link:presentationLink link:calculationLink link:definitionLink 999085 - Disclosure - SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAX, DOMESTIC AND FOREIGN (Details) link:presentationLink link:calculationLink link:definitionLink 999086 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME TAX PROVISION (BENEFIT) (Details) link:presentationLink link:calculationLink link:definitionLink 999087 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 999088 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) link:presentationLink link:calculationLink link:definitionLink 999089 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999090 - Disclosure - SCHEDULE OF OTHER (EXPENSE) INCOME - NET (Details) link:presentationLink link:calculationLink link:definitionLink 999091 - Disclosure - SCHEDULE OF REVENUES, OPERATING EXPENSES AND OPERATING INCOME (LOSS) BY REPORTABLE SEGMENT (Details) link:presentationLink link:calculationLink link:definitionLink 999092 - Disclosure - FAIR VALUE OF THE ASSETS MEASURED ON A NON-RECURRING BASIS (Details) link:presentationLink link:calculationLink link:definitionLink 999093 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 21 ccld-20241231_cal.xml XBRL CALCULATION FILE EX-101.DEF 22 ccld-20241231_def.xml XBRL DEFINITION FILE EX-101.LAB 23 ccld-20241231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, par value $0.001 per share [Member] 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share [Member] 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share [Member] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Treasury Stock, Common [Member] Investment, Name [Axis] MTBC Private Limited [Member] Title and Position [Axis] Founder and Executive Chairman [Member] MTBC Bagh Private Limited [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Long-Lived Tangible Asset [Axis] Computer Equipment [Member] Finite-Lived Intangible Assets by Major Class [Axis] Revenue Cycle Management [Member] Group Purchasing Organization and Medical Practice Management [Member] Segments [Axis] Healthcare IT [Member] Medical Practice Management Segment [Member] Customer Relationships [Member] Capitalized Software [Member] Other Intangible Assets [Member] Office Furniture and Equipment [Member] Transportation Equipment [Member] Leasehold Improvements [Member] Assets not Placed in Service [Member] Customer One [Member] Concentration Risk Benchmark [Axis] Accounts Receivable [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer Two [Member] One Customer [Member] Revenue Benchmark [Member] Geographical [Axis] Non-US [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Credit Facility [Axis] SVB Credit Facility [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] SVB Debt Agreement [Member] Additional Warrant [Member] Ninth Loan Modification Agreement [Member] Long-Term Debt, Type [Axis] Vehicle Financing Notes [Member] Insurance Financing [Member] Product and Service [Axis] Technology Enabled Business Solutions [Member] Professional Services [Member] Printing and Mailing Services [Member] Group Purchasing Services [Member] Medical Practice Management [Member] Chronic Care Management [Member] Remote Patient Monitoring [Member] Billing Status, Type [Axis] Unbilled Revenues [Member] Referral Fees [Member] Statement of Financial Position Location, Balance [Axis] Other Noncurrent Assets [Member] Receivable Type [Axis] Trade Accounts Receivable [Member] Accounting Standards Update [Axis] Accounting Standards Update 2016-13 [Member] Certificate of Amendment [Member] Treasury Stock [Member] Sale of Stock [Axis] At The Market Facility [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Scenario [Axis] Forecast [Member] Series A and Series B Preferred Stock [Member] Warrant [Member] Related and Nonrelated Parties [Axis] Ramapo Anesthesiologists, PC [Member] Accrued Expenses [Member] Physician [Member] Executive Chairman [Member] Related Party [Member] Former Non-Independent Directors [Member] Consulting Agreement [Member] Related Party Transaction [Axis] talkMD Clinicians [Member] Restructuring Type [Axis] Severance And Separation Costs [Member] Equity Awards Acceleration Costs Associated With Severance [Member] Other Exit Related Costs [Member] Retirement Plan Name [Axis] Defined Contribution Retirement Plan For U.S. Employees [Member] Defined Contribution Retirement Plan For Pakistan Employees [Member] Defined Contribution Retirement Plan For SriLanka Employees [Member] Plan Name [Axis] 2014 Equity Incentive Plan [Member] Employees, Officers, Directors and Consultants [Member] Amended and Restated Equity Incentive Plan [Member] Liability Class [Axis] Five Outsides Members of the Board [Member] Employee [Member] Statement of Income Location, Balance [Axis] Direct Operating Costs [Member] General and Administrative Expense [Member] Research and Development Expense [Member] Selling and Marketing Expense [Member] Net loss on lease terminations, unoccupied lease charges and restructuring costs [Member] PAKISTAN Income Tax Jurisdiction [Axis] Federal [Member] Tax Period [Axis] Between 2031 and 2038 [Member] Indefinite Life [Member] Business Acquisition [Axis] CareCloud and Meridian Acquisitions [Member] State [Member] NEW JERSEY Consolidation Items [Axis] Operating Segments [Member] Measurement Basis [Axis] Reported Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Individual Shareholders [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Entity Listing, Par Value Per Share Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Current assets: Cash Accounts receivable - net Contract asset Inventory Current assets - related party Prepaid expenses and other current assets Total current assets Property and equipment - net Operating lease right-of-use assets Intangible assets - net Goodwill Other assets TOTAL ASSETS LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued compensation Accrued expenses Operating lease liability (current portion) Deferred revenue (current portion) Notes payable (current portion) Dividend payable Total current liabilities Notes payable Borrowings under line of credit Operating lease liability Deferred revenue Total liabilities COMMITMENTS AND CONTINGENCIES (NOTE 10) SHAREHOLDERS’ EQUITY: Preferred stock, $0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 shares at December 31, 2024 and December 31, 2023. Series B, issued and outstanding 1,511,372 and 1,468,792 shares at December 31, 2024 and December 31, 2023, respectively Common stock, $0.001 par value - authorized 35,000,000 shares. Issued 16,997,035 and 16,620,891 shares at December 31, 2024 and December 31, 2023, respectively. Outstanding 16,256,236 and 15,880,092 shares at December 31, 2024 and December 31, 2023, respectively Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Less: 740,799 common shares held in treasury, at cost at December 31, 2024 and December 31, 2023 Total shareholders’ equity TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, common shares Income Statement [Abstract] NET REVENUE OPERATING EXPENSES: Direct operating costs Selling and marketing General and administrative Research and development Depreciation and amortization Goodwill impairment charges Lease terminations, unoccupied lease charges and restructuring costs Total operating expenses OPERATING INCOME (LOSS) OTHER: Interest income Interest expense Other expense - net INCOME (LOSS) BEFORE PROVISION (BENEFIT) FOR INCOME TAXES Income tax provision (benefit) NET INCOME (LOSS) Preferred stock dividend NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS Net loss per common share: basic Net loss per common share: diluted Weighted-average common shares used to compute basic loss per share Weighted-average common shares used to compute diluted loss per share NET INCOME (LOSS) OTHER COMPREHENSIVE LOSS Foreign currency translation adjustment COMPREHENSIVE INCOME (LOSS) Balance Balance, shares Cumulative effect of adopting ASC 326 Balance - January 1, 2023 after adoption Balance - January 1, 2023 after adoption, shares Net income (loss) Stock issued under the equity incentive plan Stock issued under the equity incentive plan, shares Stock-based compensation, net of cash settlements Preferred stock dividends Issuance of Series B Preferred Stock Issuance of Series B Preferred Stock, shares Shares issued for services Shares issued for services, shares Balance Balance, shares Issuance costs Dividend paid per share Statement of Cash Flows [Abstract] OPERATING ACTIVITIES: Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization Lease amortization Deferred revenue Provision for expected credit losses Benefit for deferred income taxes Foreign exchange (gain) loss Interest accretion Stock-based compensation expense Changes in operating assets and liabilities: Accounts receivable Contract asset Inventory Other assets Accounts payable and other liabilities Net cash provided by operating activities INVESTING ACTIVITIES: Purchases of property and equipment Capitalized software and other intangible assets Net cash used in investing activities FINANCING ACTIVITIES: Preferred stock dividends paid Settlement of tax withholding obligations on stock issued to employees Repayments of notes payable Proceeds from issuance of Series B Preferred Stock, net of expenses Proceeds from line of credit Repayment of line of credit Net cash used in financing activities EFFECT OF EXCHANGE RATE CHANGES ON CASH NET INCREASE (DECREASE) IN CASH CASH - Beginning of the year CASH - End of the year SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Dividends declared, not paid Purchase of prepaid insurance with assumption of note Reclass of deposits for property and equipment placed in service SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes Interest Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Rule 10b5-1 Arrangement Modified Non-Rule 10b5-1 Arrangement Modified Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Processes Integrated [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Material Cybersecurity Incident [Abstract] Material Cybersecurity Incident Nature [Text Block] Material Cybersecurity Incident Scope [Text Block] Material Cybersecurity Incident Timing [Text Block] Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block] Material Cybersecurity Incident Information Not Available or Undetermined [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND BUSINESS Accounting Policies [Abstract] BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Goodwill and Intangible Assets Disclosure [Abstract] GOODWILL AND INTANGIBLE ASSETS – NET Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Risks and Uncertainties [Abstract] CONCENTRATIONS Earnings Per Share [Abstract] NET LOSS PER COMMON SHARE Debt Disclosure [Abstract] DEBT Revenue from Contract with Customer [Abstract] REVENUE Equity [Abstract] SHAREHOLDERS’ EQUITY Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Leases LEASES Related Party Transactions [Abstract] RELATED PARTIES Restructuring and Related Activities [Abstract] RESTRUCTURING COSTS Retirement Benefits [Abstract] EMPLOYEE BENEFIT PLANS Share-Based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Income Tax Disclosure [Abstract] INCOME TAXES Other Income and Expenses [Abstract] OTHER EXPENSE – NET Segment Reporting [Abstract] SEGMENT REPORTING Fair Value Disclosures [Abstract] FAIR VALUE OF FINANCIAL INSTRUMENTS Subsequent Events [Abstract] SUBSEQUENT EVENTS Principles of Consolidation Segment Reporting Use of Estimates Revenue Recognition Direct Operating Costs Selling and Marketing Expenses Research and Development Expenses Internal-Use Software Costs Accounts Receivable Property and Equipment Intangible Assets Evaluation of Long-Lived Assets Goodwill Treasury Stock Stock-Based Compensation Business Combinations Income Taxes Dividends Deferred Revenue Fair Value Measurements Foreign Currency Translation Lease Terminations, Unoccupied Lease Charges and Restructuring Costs Recent Accounting Pronouncements SCHEDULE OF CHANGES TO CARRYING AMOUNT OF GOODWILL SCHEDULE OF INTANGIBLE ASSETS ACTIVITY SCHEDULE OF INTANGIBLE ASSETS, FUTURE AMORTIZATION EXPENSE SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF CONCENTRATION OF RISK, BY GEOGRAPHICAL RISKS FACTOR SCHEDULE OF RECONCILIATION OF WEIGHTED-AVERAGE SHARES OUTSTANDING FOR BASIC AND DILUTED NET LOSS PER COMMON SHARE SCHEDULE OF MATURITIES OF LONG-TERM DEBT SCHEDULE OF DISAGGREGATION OF REVENUE SCHEDULE OF CHANGES IN ACCOUNTS RECEIVABLE, CONTRACT ASSET AND DEFERRED REVENUE SCHEDULE OF TRADE ALLOWANCE FOR DOUBTFUL ACCOUNTS SCHEDULE OF LEASE EXPENSE SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES SCHEDULE OF MATURITIES OF LEASE LIABILITIES SCHEDULE OF RESTRUCTURING COSTS SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS DISCLOSURE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD SCHEDULE OF SHARE-BASED COMPENSATION, RESTRICTED STOCK UNITS AWARD ACTIVITY SCHEDULE OF EMPLOYEE SERVICE SHARE-BASED COMPENSATION, ALLOCATION OF RECOGNIZED PERIOD COSTS SCHEDULE OF DEFERRED TAX VALUATION ALLOWANCE SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAX, DOMESTIC AND FOREIGN SCHEDULE OF COMPONENTS OF INCOME TAX PROVISION (BENEFIT) SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION SCHEDULE OF OTHER (EXPENSE) INCOME - NET SCHEDULE OF REVENUES, OPERATING EXPENSES AND OPERATING INCOME (LOSS) BY REPORTABLE SEGMENT FAIR VALUE OF THE ASSETS MEASURED ON A NON-RECURRING BASIS Equity method investment ownership, percentage Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Number of operating segments Advertising costs Internal-use software costs capitalized Property and equipment, estimated useful lives Intangible assets, estimated useful lives Impairment charges Number of reportable units Shares repurchased Foreign exchange (gain) losses Allowance for expected credit losses Beginning gross balance Impairment charges Ending gross balance Intangible Asset, Finite-Lived [Table] Finite-Lived Intangible Assets [Line Items] Cost, beginning balance Cost, additions Cost, translation gain (loss) Cost, ending balance Useful lives Accumulated amortization, beginning balance Accumulated amortization, amortization expense Accumulated amortization, translation gain (loss) Accumulated amortization, ending balance Net book value 2025 2026 2027 2028 2029 Thereafter Total Intangible Asset, Indefinite-Lived [Table] Indefinite-Lived Intangible Assets [Line Items] Amortization expense Weighted-average amortization period Total property and equipment Less accumulated depreciation Property and equipment – net Depreciation expense Current assets Non-current assets Assets Current liabilities Non-current liabilities Net assets Concentration Risk [Table] Concentration Risk [Line Items] Offshore bank accounts Concentration risk percentage Intercompany receivables Net loss attributable to common shareholders - basic Net loss attributable to common shareholders - diluted Net loss attributable to common shareholders per share - basic Net loss attributable to common shareholders per share - diluted Preferred stock dividend amount Anti-dilutive shares Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] 2025 2026 2027 2028 Total Line of credit borrowing term Increase revolving line of credit Line of credit, term extension Line of credit facility, interest rate Minimum liquidity ratio reduction amendments expiry date Lline of credit Line of credit, description Percentage of shares in off shore facilities Line of credit, remaining borrowing base Upfront fees Warrants to purchase Payments for annual anniversary fee Warrant strike price Warrants term Warrants price per share Line of credit facility commitment fee amount Debt Instrument, Term Debt interest rate Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenue Accounts Receivable - Net, Opening Contract Assets, Opening Deferred Revenue (current), Opening Deferred Revenue (long term), Opening Accounts Receivable - Net, increase (decrease), net Contract Asset, (decrease) increase, net Deferred Revenue (current), increase (decrease), net Deferred Revenue (long term), increase (decrease), net Accounts Receivable - Net, Closing Contract Assets, Closing Deferred Revenue (current), Closing Deferred Revenue (long term), Closing Beginning balance Adoption of ASC 326 Provision Recoveries/adjustments Write-offs Ending balance Revenue, remaining performance obligation, amount Contract with customer asset Deferred revenue Deferred commissions Amortization of deferred sales commissions Stock, Class of Stock [Table] Class of Stock [Line Items] Preferred stock dividend rate Preferred stock dividend amount per share Preferred stock liquidation preference Stock repurchase program expiration date Common shares held as treasury stock, shares Common shares held as treasury stock, cost Common stock available for sale Underwriter commission fees percentage Sale of stock, shares Common stock, voting rights Authorized sale of stock, value Preferred stock, redemption price per share Preferred stock, dividend per share Dividend, share-based payment arrangement, cash Dividends undeclared Dividends in arrears Dividends in arrears, per share Warrants issued Warrants expired unexercised Warrant outstanding Loss Contingencies [Table] Loss Contingencies [Line Items] Mitigation related costs Mitigation settlement payable Damages paid value Damages sought transition related costs Unpaid fees Advance amount Settlement claim amount Schedule Of Lease Expense Operating lease cost Short-term lease cost Variable lease cost Total - net lease cost Schedule Of Supplemental Balance Sheet Information Related To Leases Current operating lease liabilities Non-current operating lease liabilities Total operating lease liabilities ROU assets Asset lease expense Foreign exchange gain/(loss) Operating leases, Weighted average remaining lease term Operating leases, Weighted average discount rate Operating cash flows from operating leases Operating leases, excluding terminations 2025 2026 2027 2028 2029 Thereafter Total lease payments Less: imputed interest Total lease obligations Less: current obligations Long-term lease obligations Lease term, description Unoccupied lease charges Lease impairment Net gain (loss) on lease terminations Operating lease description Sublease income Related Party Transaction [Table] Related Party Transaction [Line Items] Net revenue Receivable due from customer Rent expense Operating lease upgradations Payments to related party Lease expense per month for temporary housing Operating Lease, Right-of-Use Asset Shares issued for services Preferred stock dividend percentage Compensation for statement of work per month Other expenses General and administrative expense Income taxes paid Severance and separation costs Equity awards acceleration costs associated with severance Other exit related costs Total restructuring and other costs Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring Cost [Table] Restructuring Cost and Reserve [Line Items] Balance as of January 1, 2023 Additions Payments and other adjustments Balance as of  December 31, 2023 Subsequent Event [Table] Subsequent Event [Line Items] Estimated restructuring expense Restructuring expense incurred Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] Defined benefit plan, plan assets, contributions by employer Employee benefit plan, description Defined contribution plan, employee matching contribution, on gross pay Defined contribution plan, employer matching contribution, on gross pay Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Outstanding and unvested at beginning Granted Vested Forfeited Outstanding and unvested at ending Outstanding and unvested shares, beginning RSUs granted RSUs forfeited Outstanding and unvested shares, ending Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-based compensation Number of shares reserved for future issuance Shares added to the A&R Plan for future issuance Number of shares available for grant Share-based compensation restricted stock, grants in period Shares vesting percentage Share-based payment arrangement, nonvested award, cost not yet recognized, amount Share-based compensation nonvested awards total compensation cost not yet recognized Unvested stock option award, equity Restricted stock award classified as liability Liability for cash settled amount Cash settlement Share-based payment award, number of shares issuance Share-based payment award, number of shares grant Weighted average grant date fair value Beginning balance Current year valuation allowance increase (decrease) Ending balance United States Foreign Total Current tax, Federal Current tax, State Current tax, Foreign Provision for current income taxes Deferred Tax, Federal Deferred Tax, State Total income tax provision (benefit) Allowance for expected credit losses Deferred revenue Property and intangible assets State net operating loss ("NOL") carryforwards Federal net operating loss ("NOL") carryforwards Section 163(j) interest limitation Stock based compensation ASC 842 - ROU asset Prepaid commissions Cumulative balance translation adjustment Section 267 limitation Credit carryovers ASC 842 - Lease liability Accrued compensation Other Section 174 costs Valuation allowance Total deferred tax assets Goodwill amortization Net deferred tax liability Federal provision (benefit) at statutory rate State tax expense, net of federal benefit Non-deductible items Impact of foreign operations Subpart F GILTI inclusion Stock based compensation Goodwill impairment charges Deferred true-up Valuation allowance Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Line Items] Goodwill impairment charge Goodwill amortization period for tax purposes Federal statutory income tax rate Income tax examination description Pakistan statutory corporate tax rate Net operating loss carry forwards Foreign exchange gains (losses) Other expense Other expense - net Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Unallocated corporate expenses Net interest expense Other expenses Fair Value, by Balance Sheet Grouping [Table] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Goodwill - Healthcare IT Common stock shares authorized Conversion of shares Shares outstanding Shares remaining outstanding 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share [Member] 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share [Member] Common Stock, par value $0.001 per share [Member] SVB Credit Facility [Member] Minimum liquidity ratio reduction amendments expiry date. Percentage of shares in off shore facilities. Payment of upfront fees. SVB Debt Agreement [Member] Payments for annual anniversary fee. Warrant strike price. Ninth Loan Modification Agreement [Member] Vehicle Financing Notes [Member] Insurance Financing [Member] Cumulative effect of adoption of accounting standard update. Stockholders equity after adoption. Chronic Care Management [Member] Remote Patient Monitoring [Member] Professional Services [Member] Shares outstanding after adoption. Revenue Cycle Management [Member] Group Purchasing Services [Member] Referral Fees [Member] Schedule of Changes in Accounts Receivable Contract Asset and Deferred Revenue [Table Text Block] Increase decrease in contract with customer liability current. Increase decrease deferred revenue long term. Deferred commissions. Allowance for doubtful accounts receivable recoveries adjustments. Certificate of Amendment [Member] Treasury Stock [Member] Shares authorized for sale value. At The Market Facility [Member] Underwriter commission fees percentage. Amortization of lease. Payments to capitalized software and other intangible assets. Purchase of prepaid insurance with assumption of note. Reclass of deposits for property and equipment placed in service. Series A and Series B Preferred Stock [Member] Dividends undeclared. Ramapo Anesthesiologists PC [Member] Accrued Expenses [Member] Loss on contingency unpaid fees. Advance amount. Lease term description. Unoccupied lease charges. Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block] Operation lease right of use assets, gross. Asset lease expense. Foreign exchange gain loss. Schedule of Supplemental Cash Flow and Other Information Related to Leases [Table Text Block] MTBC Private Limited [Member] Founder and Executive Chairman [Member] MTBC Bagh Private Limited [Member] Physician [Member] Executive Chairman [Member] Former Non-Independent Directors [Member] Consulting Agreement [Member] Direct Operating Costs [Policy Text Block] talkMD Clinicians [Member] Healthcare IT [Member] Equity awards acceleration costs associated with severance. Treasury Stock [Policy Text Block] Schedule Of Liabilities Associated With Restructuring Costs [Table Text Block] Severance And Separation Costs [Member] Equity Awards Acceleration Costs Associated With Severance [Member] Dividends [Policy Text Block] Contract With Customer Liability [Policy Text Block] Allowance for doubtful accounts adoption. Medical Practice Management Segment [Member] Defined Contribution Retirement Plan For U.S. Employees [Member] Employee benefit plan, description. Defined Contribution Retirement Plan For Pakistan Employees [Member] Defined Contribution Retirement Plan For SriLanka Employees [Member] Capitalized Software [Member] Finite lived intangible assets accumulated amortization foreign currency translation gain loss. 2014 Equity Incentive Plan [Member] Employees, Officers, Directors and Consultants [Member] Amended and Restated Equity Incentive Plan [Member] Employee [Member] Other Exit Related Costs [Member] Customer One [Member] Customer Two [Member] One Customer [Member] Intercompany receivables. Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized. Restricted stock award classified as liability. Liability for cash settled amount. Cash settlement. Share-based payment award, number of shares issuance. Direct Operating Costs [Member] Net loss on lease terminations, unoccupied lease charges and restructuring costs [Member] Deferred tax assets interest limitation. Deferred tax assets tax credit cost. ASC 842 - Lease liability. Section 267 limitation. Prepaid Commissions. Deferred tax adjustment. Pakistan statutory corporate tax rate. Federal [Member] Indefinite Life [Member] State [Member] CareCloud and Meridian Acquisitions [Member] Medical Practice Management [Member] Unallocated corporate expenses. Net interest expense. Office Furniture and Equipment [Member] Assets not Placed in Service [Member] Technology Enabled Business Solutions [Member] Printing and Mailing Services [Member] Additional Warrant [Member] Group Purchasing Organization and Medical Practice Management [Member] Rule 10b5-1 arrangement modified. Non-rule 10b5-1 arrangement modified. Dividends declared not paid. Warrants expired unexercised. Five Outsides Members of the Board [Member] Between 2031 and 2038 [Member] Individual Shareholders [Member] Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Other Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred Stock Dividends, Income Statement Impact Other Depreciation and Amortization Increase (Decrease) in Contract with Customer, Liability Realized Gain (Loss), Foreign Currency Transaction, before Tax Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Other Operating Assets Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment PaymentsToCapitalizedSoftwareAndOtherIntangibleAssets Net Cash Provided by (Used in) Investing Activities Payments of Ordinary Dividends, Preferred Stock and Preference Stock Payment, Tax Withholding, Share-Based Payment Arrangement Repayments of Notes Payable Repayments of Lines of Credit Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Liabilities, Noncurrent Long-Term Debt, Maturity, Year One Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four Long-Term Debt and Lease Obligation Increase (Decrease) in Receivables IncreaseDecreaseInContractWithCustomerLiabilityCurrent Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss, Writeoff Contract with Customer, Liability, Revenue Recognized Lease, Cost Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, to be Paid, Year Five Lessee, Operating Lease, Liability, to be Paid, after Year Five Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Restructuring Reserve Payments for Restructuring Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Stock Issued During Period, Shares, Restricted Stock Award, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss Deferred Tax Assets, Deferred Income Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Deferred Tax Liabilities, Goodwill Deferred Tax Liabilities, Net Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount Other Nonoperating Expense UnallocatedCorporateExpenses EX-101.PRE 24 ccld-20241231_pre.xml XBRL PRESENTATION FILE XML 26 R1.htm IDEA: XBRL DOCUMENT v3.25.1
    Cover - USD ($)
    $ / shares in Units, $ in Millions
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Mar. 11, 2025
    Jun. 30, 2024
    Document Type 10-K/A      
    Amendment Flag true      
    Amendment Description This Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) amends the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Annual Report”) of CareCloud, Inc. filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2025 (the “Original Filing Date”). In this Amendment No. 1, unless the context indicates otherwise, the designations “CareCloud,” the “Company,” “we,” “us” or “our” refer to CareCloud, Inc. and its subsidiaries. This Amendment No. 1 is being filed solely to correct a typographical error in the Report of Independent Registered Public Accounting Firm (the “Audit Opinion”) of Rosenberg Rich Baker Berman, P.A. (“RRBB”) contained in the 2024 Annual Report, by replacing “March 13, 2024” with “March 13, 2025” under the signature in the Audit Opinion. In addition, this Amendment No. 1 includes a new consent of RRBB as Exhibit 23.1 hereto, a new consent of Grant Thornton LLP as Exhibit 23.2 hereto and new certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 as Exhibits 31.1, 31.2, 31.3, 32.1, 32.2 and 32.3 hereto.   Pursuant to Rule 12b-15 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we have repeated the entire text of Item 8 of the 2024 Annual Report in this Amendment No. 1. However, there have been no changes to the Company’s financial statements and notes thereto or the text of such item (other than the change stated in the immediately preceding paragraph to replace “March 13, 2024” with “March 13, 2025” under the signature in the Audit Opinion).   Except as described above, no other amendments are being made to the 2024 Annual Report. This Amendment No. 1 does not reflect events occurring after Original Filing Date or modify or update any disclosure contained in the 2024 Annual Report in any way other than to reflect the amendments discussed above and reflected below. Accordingly, this Amendment No. 1 should be read in conjunction with the 2024 Annual Report and our other filings with the SEC.        
    Document Annual Report true      
    Document Transition Report false      
    Document Period End Date Dec. 31, 2024      
    Document Fiscal Period Focus FY      
    Document Fiscal Year Focus 2024      
    Current Fiscal Year End Date --12-31      
    Entity File Number 001-36529      
    Entity Registrant Name CareCloud, Inc.      
    Entity Central Index Key 0001582982      
    Entity Tax Identification Number 22-3832302      
    Entity Incorporation, State or Country Code DE      
    Entity Address, Address Line One 7 Clyde Road      
    Entity Address, City or Town Somerset      
    Entity Address, State or Province NJ      
    Entity Address, Postal Zip Code 08873      
    City Area Code (732)      
    Local Phone Number 873-5133      
    Entity Well-known Seasoned Issuer No      
    Entity Voluntary Filers No      
    Entity Current Reporting Status Yes      
    Entity Interactive Data Current Yes      
    Entity Filer Category Non-accelerated Filer      
    Entity Small Business true      
    Entity Emerging Growth Company false      
    Entity Shell Company false      
    Entity Public Float       $ 19.1
    Entity Common Stock, Shares Outstanding     42,316,513  
    Documents Incorporated by Reference [Text Block] Portions of the Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025 are incorporated by reference into Part III, Items 10, 11, 12, 13, and 14 of this Annual Report on Form 10-K.      
    ICFR Auditor Attestation Flag false      
    Document Financial Statement Error Correction [Flag] false      
    Entity Listing, Par Value Per Share $ 0.001      
    Auditor Firm ID 89 248    
    Auditor Name Rosenberg Rich Baker Berman, P.A. GRANT THORNTON LLP    
    Auditor Location Somerset, New Jersey Iselin, New Jersey    
    Common Stock, par value $0.001 per share [Member]        
    Title of 12(b) Security Common Stock, par value $0.001 per share      
    Trading Symbol CCLD      
    Security Exchange Name NASDAQ      
    8.75% Series A Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share [Member]        
    Title of 12(b) Security 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share      
    Trading Symbol CCLDP      
    Security Exchange Name NASDAQ      
    8.75% Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share [Member]        
    Title of 12(b) Security 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share      
    Trading Symbol CCLDO      
    Security Exchange Name NASDAQ      

    XML 27 R2.htm IDEA: XBRL DOCUMENT v3.25.1
    Consolidated Balance Sheets - USD ($)
    Dec. 31, 2024
    Dec. 31, 2023
    Current assets:    
    Cash $ 5,145,000 $ 3,331,000
    Accounts receivable - net 12,774,000 11,888,000
    Contract asset 4,334,000 5,094,000
    Inventory 574,000 465,000
    Current assets - related party 16,000 16,000
    Prepaid expenses and other current assets 1,957,000 2,449,000
    Total current assets 24,800,000 23,243,000
    Property and equipment - net 5,290,000 5,317,000
    Operating lease right-of-use assets 3,133,000 4,365,000
    Intangible assets - net 18,698,000 25,074,000
    Goodwill 19,186,000 19,186,000
    Other assets 507,000 641,000
    TOTAL ASSETS 71,614,000 77,826,000
    Current liabilities:    
    Accounts payable 4,565,000 5,798,000
    Accrued compensation 1,817,000 3,444,000
    Accrued expenses 4,951,000 5,065,000
    Operating lease liability (current portion) 1,287,000 1,888,000
    Deferred revenue (current portion) 1,212,000 1,380,000
    Notes payable (current portion) 310,000 292,000
    Dividend payable 5,438,000 5,433,000
    Total current liabilities 19,580,000 23,300,000
    Notes payable 26,000 37,000
    Borrowings under line of credit 10,000,000
    Operating lease liability 1,847,000 2,516,000
    Deferred revenue 387,000 256,000
    Total liabilities 21,840,000 36,109,000
    COMMITMENTS AND CONTINGENCIES (NOTE 10)
    SHAREHOLDERS’ EQUITY:    
    Preferred stock, $0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 shares at December 31, 2024 and December 31, 2023. Series B, issued and outstanding 1,511,372 and 1,468,792 shares at December 31, 2024 and December 31, 2023, respectively 6,000 6,000
    Common stock, $0.001 par value - authorized 35,000,000 shares. Issued 16,997,035 and 16,620,891 shares at December 31, 2024 and December 31, 2023, respectively. Outstanding 16,256,236 and 15,880,092 shares at December 31, 2024 and December 31, 2023, respectively 17,000 17,000
    Additional paid-in capital 121,046,000 120,706,000
    Accumulated deficit (66,630,000) (74,481,000)
    Accumulated other comprehensive loss (4,003,000) (3,869,000)
    Less: 740,799 common shares held in treasury, at cost at December 31, 2024 and December 31, 2023 (662,000) (662,000)
    Total shareholders’ equity 49,774,000 41,717,000
    TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 71,614,000 $ 77,826,000
    XML 28 R3.htm IDEA: XBRL DOCUMENT v3.25.1
    Consolidated Balance Sheets (Parenthetical) - $ / shares
    Dec. 31, 2024
    Dec. 31, 2023
    Preferred stock, par value $ 0.001 $ 0.001
    Preferred stock, shares authorized 7,000,000 7,000,000
    Common stock, par value $ 0.001 $ 0.001
    Common stock, shares authorized 35,000,000 35,000,000
    Common stock, shares issued 16,997,035 16,620,891
    Common stock, shares outstanding 16,256,236 15,880,092
    Treasury stock, common shares 740,799 740,799
    Series A Preferred Stock [Member]    
    Preferred stock, shares authorized 4,560,000  
    Preferred stock, shares issued 4,526,231 4,526,231
    Preferred stock, shares outstanding 4,526,231 4,526,231
    Series B Preferred Stock [Member]    
    Preferred stock, shares issued 1,511,372 1,468,792
    Preferred stock, shares outstanding 1,511,372 1,468,792
    XML 29 R4.htm IDEA: XBRL DOCUMENT v3.25.1
    Consolidated Statements of Operations - USD ($)
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Income Statement [Abstract]    
    NET REVENUE $ 110,837,000 $ 117,059,000
    OPERATING EXPENSES:    
    Direct operating costs 60,842,000 70,817,000
    Selling and marketing 6,232,000 9,650,000
    General and administrative 16,123,000 21,464,000
    Research and development 3,781,000 4,736,000
    Depreciation and amortization 14,142,000 14,402,000
    Goodwill impairment charges 42,000,000
    Lease terminations, unoccupied lease charges and restructuring costs 596,000 1,105,000
    Total operating expenses 101,716,000 164,174,000
    OPERATING INCOME (LOSS) 9,121,000 (47,115,000)
    OTHER:    
    Interest income 88,000 154,000
    Interest expense (900,000) (1,194,000)
    Other expense - net (298,000) (883,000)
    INCOME (LOSS) BEFORE PROVISION (BENEFIT) FOR INCOME TAXES 8,011,000 (49,038,000)
    Income tax provision (benefit) 160,000 (364,000)
    NET INCOME (LOSS) 7,851,000 (48,674,000)
    Preferred stock dividend 12,310,000 15,674,000
    NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (4,459,000) $ (64,348,000)
    Net loss per common share: basic $ (0.28) $ (4.11)
    Net loss per common share: diluted $ (0.28) $ (4.11)
    Weighted-average common shares used to compute basic loss per share 16,146,975 15,669,472
    Weighted-average common shares used to compute diluted loss per share 16,146,975 15,669,472
    XML 30 R5.htm IDEA: XBRL DOCUMENT v3.25.1
    Consolidated Statements of Comprehensive Income (Loss) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Income Statement [Abstract]    
    NET INCOME (LOSS) $ 7,851 $ (48,674)
    OTHER COMPREHENSIVE LOSS    
    Foreign currency translation adjustment [1] (134) (832)
    COMPREHENSIVE INCOME (LOSS) $ 7,717 $ (49,506)
    [1] No tax effect has been recorded as the Company recorded a valuation allowance against the tax benefit from its foreign currency translation adjustments.
    XML 31 R6.htm IDEA: XBRL DOCUMENT v3.25.1
    Consolidated Statements of Shareholders' Equity - USD ($)
    $ in Thousands
    Preferred Stock [Member]
    Series A Preferred Stock [Member]
    Preferred Stock [Member]
    Series B Preferred Stock [Member]
    Common Stock [Member]
    Additional Paid-in Capital [Member]
    Retained Earnings [Member]
    AOCI Attributable to Parent [Member]
    Treasury Stock, Common [Member]
    Total
    Balance at Dec. 31, 2022 $ 5 $ 1 $ 16 $ 130,987 $ (25,621) $ (3,037) $ (662) $ 101,689
    Balance, shares at Dec. 31, 2022 4,526,231 1,344,128 15,970,204          
    Cumulative effect of adopting ASC 326 (186) (186)
    Balance - January 1, 2023 after adoption $ 5 $ 1 $ 16 130,987 (25,807) (3,037) (662) 101,503
    Balance - January 1, 2023 after adoption, shares 4,526,231 1,344,128 15,970,204          
    Net income (loss) (48,674) (48,674)
    Foreign currency translation adjustment (832) (832) [1]
    Stock issued under the equity incentive plan $ 1 1
    Stock issued under the equity incentive plan, shares 64,891 610,687          
    Stock-based compensation, net of cash settlements 3,966 3,966
    Preferred stock dividends (15,674) (15,674)
    Issuance of Series B Preferred Stock [2] 1,427 1,427
    Issuance of Series B Preferred Stock, shares 59,773            
    Shares issued for services
    Shares issued for services, shares 40,000          
    Balance at Dec. 31, 2023 $ 5 $ 1 $ 17 120,706 (74,481) (3,869) (662) 41,717
    Balance, shares at Dec. 31, 2023 4,526,231 1,468,792 16,620,891          
    Net income (loss) 7,851 7,851
    Foreign currency translation adjustment (134) (134) [1]
    Stock issued under the equity incentive plan
    Stock issued under the equity incentive plan, shares 42,580 376,144          
    Stock-based compensation, net of cash settlements 345 345
    Preferred stock dividends (5) (5)
    Balance at Dec. 31, 2024 $ 5 $ 1 $ 17 $ 121,046 $ (66,630) $ (4,003) $ (662) $ 49,774
    Balance, shares at Dec. 31, 2024 4,526,231 1,511,372 16,997,035          
    [1] No tax effect has been recorded as the Company recorded a valuation allowance against the tax benefit from its foreign currency translation adjustments.
    [2] Amounts are net of issuance cost of approximately $71,000.
    XML 32 R7.htm IDEA: XBRL DOCUMENT v3.25.1
    Consolidated Statements of Shareholders' Equity (Parenthetical) - USD ($)
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Issuance costs   $ 71,000
    Series A Preferred Stock [Member]    
    Dividend paid per share $ 0 $ 2.75
    Series B Preferred Stock [Member]    
    Dividend paid per share $ 0 $ 2.19
    XML 33 R8.htm IDEA: XBRL DOCUMENT v3.25.1
    Consolidated Statements of Cash Flows - USD ($)
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    OPERATING ACTIVITIES:    
    Net income (loss) $ 7,851,000 $ (48,674,000)
    Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
    Depreciation and amortization 14,469,000 14,889,000
    Lease amortization 1,994,000 2,152,000
    Deferred revenue (37,000) (92,000)
    Provision for expected credit losses 334,000 454,000
    Benefit for deferred income taxes (525,000)
    Foreign exchange (gain) loss (130,000) 790,000
    Interest accretion 592,000 688,000
    Goodwill impairment charges 42,000,000
    Stock-based compensation expense 115,000 4,886,000
    Changes in operating assets and liabilities:    
    Accounts receivable (1,220,000) 2,246,000
    Contract asset 760,000 (695,000)
    Inventory (109,000) (84,000)
    Other assets 673,000 682,000
    Accounts payable and other liabilities (4,650,000) (3,256,000)
    Net cash provided by operating activities 20,642,000 15,461,000
    INVESTING ACTIVITIES:    
    Purchases of property and equipment (1,697,000) (3,063,000)
    Capitalized software and other intangible assets (5,709,000) (8,550,000)
    Net cash used in investing activities (7,406,000) (11,613,000)
    FINANCING ACTIVITIES:    
    Preferred stock dividends paid (14,300,000)
    Settlement of tax withholding obligations on stock issued to employees (579,000) (1,524,000)
    Repayments of notes payable (677,000) (888,000)
    Proceeds from issuance of Series B Preferred Stock, net of expenses 1,427,000
    Proceeds from line of credit 14,700,000
    Repayment of line of credit (10,000,000) (12,700,000)
    Net cash used in financing activities (11,256,000) (13,285,000)
    EFFECT OF EXCHANGE RATE CHANGES ON CASH (166,000) 469,000
    NET INCREASE (DECREASE) IN CASH 1,814,000 (8,968,000)
    CASH - Beginning of the year 3,331,000 12,299,000
    CASH - End of the year 5,145,000 3,331,000
    SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES:    
    Dividends declared, not paid 5,000 5,433,000
    Purchase of prepaid insurance with assumption of note 685,000 656,000
    Reclass of deposits for property and equipment placed in service 296,000
    SUPPLEMENTAL INFORMATION - Cash paid during the year for:    
    Income taxes 157,000 144,000
    Interest $ 677,000 $ 927,000
    XML 34 R9.htm IDEA: XBRL DOCUMENT v3.25.1
    Pay vs Performance Disclosure - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Pay vs Performance Disclosure [Table]    
    Net Income (Loss) $ 7,851 $ (48,674)
    XML 35 R10.htm IDEA: XBRL DOCUMENT v3.25.1
    Insider Trading Arrangements
    		 3 Months Ended
    Dec. 31, 2024
    Insider Trading Arrangements [Line Items]  
    Rule 10b5-1 Arrangement Adopted false
    Non-Rule 10b5-1 Arrangement Adopted false
    Rule 10b5-1 Arrangement Terminated false
    Non-Rule 10b5-1 Arrangement Terminated false
    Rule 10b5-1 Arrangement Modified false
    Non-Rule 10b5-1 Arrangement Modified false
    XML 36 R11.htm IDEA: XBRL DOCUMENT v3.25.1
    Cybersecurity Risk Management and Strategy Disclosure
    		 12 Months Ended
    Dec. 31, 2024
    Cybersecurity Risk Management, Strategy, and Governance [Abstract]  
    Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management and Strategy

     

    We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include internal and external threats, data loss, phishing attacks, distributed denial of service attacks, third party risks, unpatched systems, weak authentications and zero-day vulnerabilities.

     

    Identifying and assessing cybersecurity risk is integrated into our overall risk management systems and processes. Cybersecurity risks related to our business, technical operations, privacy and compliance issues are identified and addressed through a multi-faceted approach including third party assessments, internal IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity incidents, the Company conducts proactive cybersecurity reviews of systems and applications, audits applicable data policies, performs penetration testing using external third-party tools and techniques to test security controls, conducts employee training, monitors emerging laws and regulations related to data protection and information security and implements appropriate changes.

     

    We have implemented incident response and breach management processes which have four overarching and interconnected stages: 1) preparation for a cybersecurity incident, 2) detection and analysis of a security incident, 3) containment, eradication and recovery, and 4) post-incident analysis. Such incident responses are overseen by leaders from our Information Security, Compliance and Legal teams regarding matters of cybersecurity.

     

    Security events and data incidents are evaluated, ranked by severity and prioritized for response and remediation. Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact. As of the date of this Form 10-K, we have not experienced a cybersecurity threat or incident that resulted in a material adverse impact to our business or operations.

     

    38
     

     

    We also conduct exercises to simulate responses to cybersecurity incidents. Our team of cybersecurity professionals then collaborate with technical and business stakeholders across our business units to further analyze the risk to the Company, and form detection, mitigation and remediation strategies.

     

    As part of the above processes, we regularly engage consultants to assess our internal cybersecurity programs and compliance with applicable practices and standards. For 2024 and 2023, our Information Security Management System is compliant with ISO 27001. We also had SOC 2, Type 2 reviews performed for the years 2024 and 2023.

     

    Our risk management program also assesses third party risks, and we perform third-party risk management to identify and mitigate risks from third parties such as vendors, suppliers, and other business partners associated with our use of third-party service providers.

     

    We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading “Disruptions in internet or telecommunication service or damage to our data centers could adversely affect our business by reducing our customers’ confidence in the reliability of our services and products” included as part of our risk factor disclosures in Item 1A of this Annual Report on Form 10-K.

     

    Our Vice President of IT Infrastructure is responsible for overseeing the Company’s cybersecurity. He has a Bachelor’s degree in computer science and has 16 years of extensive experience spanning diverse IT domains, with a specialized emphasis on Information Security across endpoints, servers, data centers, cloud infrastructure, and enterprise applications. He has been actively overseeing the strategic implementation of cybersecurity in accordance with information security management standards, HIPAA, and SOC 2 policies and procedures throughout the entire organization. This multifaceted responsibility involves managing and ensuring compliance with internationally recognized standards such as the ISO 27001 framework, healthcare regulatory guidelines under HIPAA and other recognized standards.

     
    Cybersecurity Risk Management Processes Integrated [Flag] true
    Cybersecurity Risk Management Processes Integrated [Text Block] Identifying and assessing cybersecurity risk is integrated into our overall risk management systems and processes. Cybersecurity risks related to our business, technical operations, privacy and compliance issues are identified and addressed through a multi-faceted approach including third party assessments, internal IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity incidents, the Company conducts proactive cybersecurity reviews of systems and applications, audits applicable data policies, performs penetration testing using external third-party tools and techniques to test security controls, conducts employee training, monitors emerging laws and regulations related to data protection and information security and implements appropriate changes. We have implemented incident response and breach management processes which have four overarching and interconnected stages: 1) preparation for a cybersecurity incident, 2) detection and analysis of a security incident, 3) containment, eradication and recovery, and 4) post-incident analysis. Such incident responses are overseen by leaders from our Information Security, Compliance and Legal teams regarding matters of cybersecurity.
    Cybersecurity Risk Management Third Party Engaged [Flag] true
    Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
    Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
    Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact. As of the date of this Form 10-K, we have not experienced a cybersecurity threat or incident that resulted in a material adverse impact to our business or operations.
    Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Governance 

    Cybersecurity is an important part of our risk management processes and an area of focus for our Board of Directors and management. Our Cybersecurity subcommittee of the Board of Directors is responsible for the oversight of risks from cybersecurity threats. Members of the Cybersecurity subcommittee receive updates on a quarterly basis from senior management, including leaders from our Information Security, Finance, Internal Audit, Compliance and Legal teams regarding cybersecurity matters. This includes existing and new cybersecurity risks, status on how management is addressing and/or mitigating those risks, cybersecurity and data privacy incidents, (if any), and the status on key information security initiatives.

     

    Our cybersecurity risk management and strategy processes are overseen by our Vice President of IT Infrastructure and leaders from our Information Technology department. These individuals are informed about, and monitor the prevention, mitigation, detection and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan, and report to the Cybersecurity subcommittee on any appropriate items.
    Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Our Cybersecurity subcommittee of the Board of Directors is responsible for the oversight of risks from cybersecurity threats.
    Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Members of the Cybersecurity subcommittee receive updates on a quarterly basis from senior management, including leaders from our Information Security, Finance, Internal Audit, Compliance and Legal teams regarding cybersecurity matters. This includes existing and new cybersecurity risks, status on how management is addressing and/or mitigating those risks, cybersecurity and data privacy incidents, (if any), and the status on key information security initiatives.
    Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
    Cybersecurity Risk Management Positions or Committees Responsible [Text Block] cybersecurity risk management and strategy processes are overseen by our Vice President of IT Infrastructure and leaders from our Information Technology department.
    Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] These individuals are informed about, and monitor the prevention, mitigation, detection and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan, and report to the Cybersecurity subcommittee on any appropriate items.
    XML 37 R12.htm IDEA: XBRL DOCUMENT v3.25.1
    ORGANIZATION AND BUSINESS
    		 12 Months Ended
    Dec. 31, 2024
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    ORGANIZATION AND BUSINESS

    1. ORGANIZATION AND BUSINESS

     

    CareCloud, Inc., (together with its consolidated subsidiaries, “CareCloud,” the “Company,” “we,” “us” and/or “our”) is a healthcare information technology company that provides a full suite of proprietary cloud-based solutions, related business services, to healthcare providers and hospitals throughout the United States. The Company’s integrated services are designed to help customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. Our Software-as-a-Service (“SaaS”) platform includes revenue cycle management (“RCM”), practice management (“PM”), electronic health records (“EHR”), business intelligence, telehealth, patient experience management (“PXM”) solutions and complementary software tools and business services for high-performance medical groups and health systems. CareCloud has its corporate offices in Somerset, New Jersey and maintains client support teams throughout the U.S., and offshore offices in Pakistan and Azad Jammu and Kashmir, a region administered by Pakistan (the “Pakistan Offices”), and in Sri Lanka.

     

    CareCloud was founded in 1999 under the name Medical Transcription Billing, Corp. and incorporated under the laws of the State of Delaware in 2001. In 2004, the Company formed MTBC Private Limited (“MTBC Pvt. Ltd.”), a 99.9% majority-owned subsidiary of CareCloud based in Pakistan. The remaining 0.1% of the shares of MTBC Pvt. Ltd. is equally owned by the founder and Executive Chairman of CareCloud and a local employee who is also a director of this entity. In 2016, the Company formed MTBC Acquisition Corp. (“MAC”), a Delaware corporation, in connection with its acquisition of substantially all of the assets of MediGain, LLC and its subsidiary, Millennium Practice Management Associates, LLC (together “MediGain”). MAC had a wholly owned subsidiary in Sri Lanka, RCM MediGain Colombo, Pvt. Ltd. Effective February 1, 2024, MAC and its wholly owned subsidiary were merged into CareCloud, Inc. In May 2018, the Company formed CareCloud Practice Management, Corp. (“CPM”), a Delaware corporation, to operate the medical practice management business acquired from Orion Healthcorp.

     

    In January 2020, the Company purchased CareCloud Corporation, a company whose name we took. That company is now known as CareCloud Health, Inc. (“CCH”). In June 2020, the Company purchased Meridian Billing Management Co. and its affiliate Origin Holdings, Inc. (collectively “Meridian” and sometimes referred to as “Meridian Medical Management”). Both companies were subsequently merged and the surviving company was renamed Meridian Medical Management, Inc.

     

    During March 2021, the Company formed a new wholly-owned subsidiary, CareCloud Acquisition, Corp. (“CAC”). In June 2021, CAC purchased certain assets and assumed certain liabilities of MedMatica Consulting Associates Inc., (“MedMatica”) and purchased the stock of Santa Rosa Staffing, Inc. (“SRS”). The assets and liabilities of MedMatica were merged into SRS and the company was renamed medSR, Inc. (“medSR”).

     

    Effective April 1, 2022, the Company formed MTBC Bagh Private Limited (“MTBC Bagh Pvt. Ltd.”), a 99.8% majority-owned subsidiary of CareCloud based in Azad Jammu and Kashmir, a region administered by Pakistan. The remaining 0.2% of the shares of MTBC Bagh Pvt. Ltd. is equally owned by the founder and Executive Chairman of CareCloud and the same director/employee as noted above.

     

    During the second quarter of 2023, the Company formed a wholly owned subsidiary, CareCloud ME Health Consultancy LLC, in the United Arab Emirates, which has not yet begun operations.

     
    XML 38 R13.htm IDEA: XBRL DOCUMENT v3.25.1
    BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
    		 12 Months Ended
    Dec. 31, 2024
    Accounting Policies [Abstract]  
    BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

    2. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

     

    Principles of Consolidation — The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the operating results and financial condition of CareCloud, its wholly-owned subsidiary CPM, its majority-owned subsidiary MTBC Pvt. Ltd, majority-owned subsidiary MTBC Bagh Pvt. Ltd, CCH (since January 2020), Meridian Medical Management (since June 2020), medSR (since June 2021) and the subsidiary in Sri Lanka. The non-controlling interests of MTBC Pvt. Ltd. and MTBC Bagh Pvt. Ltd. are inconsequential to the consolidated financial statements. All intercompany accounts and transactions have been eliminated in consolidation.

     

     

    Segment Reporting — The Company views its operations as comprising two operating segments, Healthcare IT and Medical Practice Management. The chief operating decision maker (“CODM”) monitors and reviews financial information at these segment levels for assessing operating results and the allocation of resources.

     

    Use of Estimates — The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include, but are not limited to: (1) impairment of goodwill and long-lived assets, (2) depreciable lives of assets, (3) allowance for expected credit losses, (4) estimates of variable consideration related to the contract asset, (5) fair value of identifiable purchased tangible and intangible assets, including determination of expected customer life, (6) stock-based compensation, and (7) estimating lease terms and incremental borrowing rates. Actual results could significantly differ from those estimates.

     

    Revenue Recognition — We derive revenue from five primary sources: (1) technology-enabled business solutions including revenue cycle management, (2) professional services, (3) printing and mailing services, (4) group purchasing services and (5) medical practice management services. All of our revenue arrangements are based on contracts with customers. Most of our contracts with customers contain single performance obligations, although certain contracts do contain multiple performance obligations where we perform more than one service for the same customer. We account for individual performance obligations separately if they are distinct within the context of the contract. For contracts where we provide multiple services such as where we perform multiple ancillary services, each service represents its own performance obligation. Selling or transaction prices are based on the contractual prices for each service at its stand-alone selling price.

     

    A five-step approach is applied in the recognition of revenue under ASC 606: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when we satisfy a performance obligation.

     

    Although we believe that our approach to estimates and judgments is reasonable, actual results could differ, and we may be exposed to increases or decreases in revenue that could be material. Our estimates of variable consideration may prove to be inaccurate, in which case we may have understated or overstated the revenue recognized in a reporting period. The amount of variable consideration recognized to date that remains subject to estimation is included within the contract asset within the consolidated balance sheet.

     

    Payment of invoices is due as specified in the underlying customer agreement, typically 30 days from the invoice date, which occurs on the date of transfer of control of the services to the customer. Since payment terms are less than a year, we have elected the practical expedient and do not assess whether a customer contract has a significant financing component.

     

    The Company’s revenue arrangements generally do not include a general right of refund for services provided (See Note 8, Revenue, for additional information).

     

    Direct Operating Costs — Direct operating costs consist primarily of salaries and benefits related to personnel who provide services to clients and at our managed medical practices, claims processing costs, medical supplies at our managed practices and other direct costs related to the Company’s services. Costs associated with the implementation of new clients are expensed as incurred. The reported amounts of direct operating costs include allocated amounts for rent expense and overhead costs.

     

    Selling and Marketing Expenses — Selling and marketing expenses consist primarily of compensation and benefits, travel and advertising expenses and are expensed as incurred. The Company incurred approximately $2.9 million and $4.0 million of advertising costs for the years ended December 31, 2024 and 2023, respectively.

     

    Research and Development Expenses — Research and development expenses consist primarily of personnel-related costs incurred performing market research, analyzing proposed products and developing new products.

     

     

    Internal-Use Software Costs — The Company capitalizes certain development costs incurred in connection with its internal-use software. Costs incurred in the preliminary stages of development are expensed as incurred. Once an application has reached the development stage, internal and external costs, if direct, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable that the expenditures will result in additional functionality. Capitalized costs are recorded as part of intangible assets in the accompanying consolidated balance sheets. Maintenance and training costs are expensed as incurred. Internal use software is amortized on a straight line basis over its estimated useful life, generally three years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. During the years ended December 31, 2024 and 2023, the Company capitalized approximately $5.7 million and $8.6 million, respectively, primarily consisting of salaries and payroll-related costs of employees and consultants who devoted time to the development of internal-use software projects.

     

    Accounts Receivable — Accounts receivable are stated at their net realizable value. Accounts receivable are presented in the consolidated balance sheets net of an allowance for expected credit losses, which is established based on a lifetime estimated credit loss expected to occur for trade accounts receivable.

     

    Property and Equipment — Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line basis over the estimated useful lives of the assets ranging from three to five years. Ordinary maintenance and repairs are expensed as incurred. Depreciation for computers is calculated over three years, while the remaining assets (except leasehold improvements) are depreciated over five years. The Company amortizes leasehold improvements over the lesser of the lease term or the remaining economic life of those assets. Generally, the lease term is the base lease term plus certain renewal option periods for which renewal is reasonably certain and for which failure to exercise the renewal option would result in an economic penalty to the Company.

     

    Intangible Assets — Intangible assets include customer relationships, covenants not-to-compete acquired in connection with acquisitions, software purchase and development costs and trademarks acquired. Amortization for intangible assets related to revenue cycle management is recorded primarily using the double declining balance method over three to four years. Amortization for intangible assets related to the group purchasing organization and medical practice management is recorded on a straight line basis over four and twelve years, respectively.

     

    Evaluation of Long-Lived Assets — The Company reviews its long-lived assets for impairment whenever changes in circumstances indicate that the carrying value of an asset may not be recoverable. If the sum of undiscounted expected future cash flows is less than the carrying amount of the asset group, the Company will recognize an impairment loss based on the fair value of the asset. There was no impairment of internal-use software costs, intangible assets, operating lease right of use assets or property and equipment during the years ended December 31, 2024 and 2023.

     

    Goodwill — Goodwill consists of the excess of the purchase price over the fair value of identifiable net assets of businesses acquired. The Company tests goodwill for impairment annually as of October 31st, referred to as the annual test date. The goodwill impairment test for the Healthcare IT segment is performed using the discounted cash flow approach, the trading price of publicly traded stock and the guideline public company method. Conditions that could trigger a more frequent impairment assessment include, but are not limited to, a significant adverse change to the Company in certain agreements, significant underperformance relative to historical or projected future operating results, loss of customer relationships, an economic downturn in customers’ industries, or increased competition. Impairment testing for goodwill is performed at the reporting-unit level. The Company has determined that its business consists of two operating segments and two reporting units. The Company had a triggering event at August 31, 2023, but it was determined that no goodwill impairment existed at that time. The Company had an additional triggering event in December 2023. It was determined that the fair value of the Healthcare IT reporting unit was less than the carrying value at October 31 and at December 12, 2023 (triggering event). Accordingly, impairment charges of approximately $2.0 million and $40.0 million, respectively, were recorded. (See Note 3). No impairment charges were recorded during the year ended December 31, 2024.

     

    Treasury Stock — Treasury stock is recorded at cost and represents shares repurchased by the Company. No shares were repurchased or issued from treasury stock during the years ended December 31, 2024 and 2023.

     

    Stock-Based Compensation — The Company recognizes compensation for all share-based payments granted based on the grant date fair value. Compensation expense is generally recognized on a straight-line basis over the vesting period. The Company does not estimate forfeitures in recognizing the expense for share-based payments, as historical forfeiture rates have not been significant. For restricted stock units (“RSUs”) classified as equity, the market price of our common stock on the date of grant is used in recording the fair value of the award. For RSUs classified as a liability, the earned amount is marked to market based on the end-of-period common stock price.

     

     

    Business Combinations — The Company accounts for business combinations under the provisions of ASC 805, Business Combinations, which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed are recorded at the date of acquisition at their respective fair values. ASC 805 also specifies criteria that intangible assets acquired in a business combination must be recognized and reported apart from goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date with changes in the fair value recorded through earnings.

     

    Income Taxes — The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date.

     

    The Company records net deferred tax assets to the extent that these assets will more likely than not be realized. All available positive and negative evidence is considered in making such a determination, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. A valuation allowance would be recorded to reduce deferred income tax assets when it is determined that it is more likely than not that the Company would not be able to realize its deferred income tax assets in the future in excess of their net recorded amount.

     

    The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is greater than 50 percent likely to be realized upon ultimate settlement with the related tax authority. At December 31, 2024 and 2023, the Company did not have any uncertain tax positions that required recognition. Interest and penalties related to uncertain tax positions are recognized in income tax expense. For the years ended December 31, 2024 and 2023, the Company did not recognize any penalties or interest related to unrecognized tax benefits in its consolidated financial statements.

     

    Dividends — Dividends are recorded when declared by the Company’s Board of Directors. The Board of Directors had declared monthly dividends on the Series A and Series B Preferred Stock through February 2024. However, in December 2023, the dividends on the Preferred Stock were suspended. The dividend scheduled for payment on December 15, 2023 together with the remaining dividends that were declared, have been accrued in the consolidated balance sheet. Future monthly dividends will continue to accrue in arrears but will not be recorded as a liability until declared by the Board of Directors. In January 2025, the Board of Director declared two months of suspended dividends. The Company resumed paying monthly dividends in February 2025, paying one month of arrears. In March 2025, the Company converted the majority of the Series A Preferred Stock into the Company’s common stock. The March 2025 dividend payment will include dividends for the Series A Preferred Stock that were not converted and dividends for the Series B Preferred Stock. (See Note 20). Preferred Stock dividends are charged against paid in capital because the Company does not have sufficient retained earnings. The Company is prohibited from paying dividends on its common stock without the prior written consent of its lender, Silicon Valley Bank, a division of First Citizens Bank (“SVB”).

     

    Deferred Revenue — Deferred revenue primarily consists of payments received in advance of the revenue recognition criteria being met. Deferred revenue includes certain deferred implementation services fees that are recognized as revenue ratably over the longer of the life of the agreement or the estimated expected customer life, which is currently estimated to be three years. Deferred revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue and the remaining portion is recorded as non-current. At the time of customer termination, any unrecognized service fees associated with implementation services are recognized as revenue.

     

    Fair Value Measurements — ASC 820, Fair Value Measurement, requires the disclosure of fair value information about financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. The Company follows a fair value measurement hierarchy to measure financial instruments.

     

     

    The fair value of the Company’s financial instruments is measured using inputs from the three levels of the fair value hierarchy as follows:

     

      Level 1 — Inputs are unadjusted quoted market prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
           
      Level 2 — Inputs are directly or indirectly observable, which include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
           
      Level 3 — Inputs are unobservable inputs that are used to measure fair value to the extent observable inputs are not available.

     

    The Company has certain financial instruments that are not measured at fair value on a recurring basis. These financial instruments are subject to fair value adjustments only in certain circumstances and include cash, accounts receivable, accounts payable and accrued expenses, borrowings under term loans and line of credit, and notes payable. Due to the short term nature of these financial instruments and that the borrowings bear interest at prevailing market rates, the carrying value approximates the fair value.

     

    Foreign Currency Translation — The financial statements of the Company’s foreign subsidiaries are translated from their functional currency into U.S. dollars, the Company’s functional currency. All foreign currency assets and liabilities are translated at the period-end exchange rate, and all revenue and expenses are translated at transaction date exchange rates. The effects of translating the financial statements of the foreign subsidiaries into U.S. dollars are reported as a cumulative translation adjustment, a separate component of accumulated other comprehensive loss in the consolidated statements of shareholders’ equity, except for transactions related to the intercompany receivable for which transaction adjustments are recorded in the consolidated statements of operations as they are not deemed to be permanently reinvested. Foreign currency transaction gains/losses are reported as a component of other expense – net in the consolidated statements of operations and amounted to a gain of approximately $130,000 and a loss of approximately $790,000 for the years ended December 31, 2024 and 2023, respectively.

     

    Lease Terminations, Unoccupied Lease Charges and Restructuring Costs — Lease terminations represents the write-off of leasehold improvements as the result of early lease terminations. Unoccupied lease charges represent the portion of lease and related costs for that portion of the space that is vacated and not being utilized by the Company. Restructuring costs incurred in 2024 and 2023 primarily consist of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements. (See Note 13).

     

    Recent Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently adopted and recently issued accounting pronouncements will not have a material impact on our consolidated financial position, results of operations and cash flows.

     

    In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments. The guidance in Accounting Standards Update (“ASU”) 2016-13 replaces the incurred loss impairment methodology under current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. It will apply to all entities. For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate lifetime expected credit losses. This may result in the earlier recognition of credit losses. In November 2019, the FASB issued ASU No. 2019-10, which delayed this standard’s effective date for SEC smaller reporting companies to the fiscal years beginning on or after December 15, 2022. The Company adopted this guidance on January 1, 2023 using a modified retrospective adoption methodology, whereby the cumulative impact of all prior periods is recorded in accumulated deficit or other impacted balance sheet items upon adoption. The impact to the accumulated deficit as of January 1, 2023 for the allowance related to accounts receivable was a charge of approximately $186,000 and a corresponding increase to the allowance for expected credit losses.

     

     

    In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendments in this update require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. The amendments are effective for public business entities for fiscal years beginning after December 15, 2022. There was no impact on the consolidated financial statements as a result of this standard.

     

    In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842): Common Control Arrangements- Issue 2. The amendments in this update require that leasehold improvements associated with common control leases be: (1) amortized by the lessee over the useful life of the leasehold improvements to the common control group as long as the lessee controls the use of the underlying asset through a lease and (2) accounted for as a transfer between entities under common control through an adjustment to equity if, and when, the lessee no longer controls the use of the underlying asset. The amendments in this update are effective for the fiscal years beginning after December 15, 2023. There was no impact on the consolidated financial statements as a result of this standard.

     

    In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification. The new guidance is intended to align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP for all entities. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027 the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective.

     

    In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Disclosures. The amendments in this update improve segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The impact is only to the financial statement disclosures and has been adopted by the Company.

     

    In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. The amendments in this update enhance the transparency and decision usefulness of income tax disclosures primarily related to rate reconciliation and income taxes paid information. The update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect this update to have a material impact on the consolidated financial statements.

     

    In March 2024, the FASB issued ASU 2024-02, Codification Improvements- Amendments to Remove References to the Concepts Statements. This update contains amendments to the Codification that remove references to various FASB Concepts Statements. These Codification updates are for technical corrections such as conforming amendments, clarifications to guidance, simplifications to wording or the structure of guidance and other minor improvements. The resulting amendments are referred to as Codification improvements. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company does not expect this update to have a material impact on the consolidated financial statements.

     

    In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40). This update contains amendments that require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. The amendments in this update are effective for public business entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The expected impact would only be to the financial statement disclosures.

     

     
    XML 39 R14.htm IDEA: XBRL DOCUMENT v3.25.1
    GOODWILL AND INTANGIBLE ASSETS – NET
    		 12 Months Ended
    Dec. 31, 2024
    Goodwill and Intangible Assets Disclosure [Abstract]  
    GOODWILL AND INTANGIBLE ASSETS – NET

    3. GOODWILL AND INTANGIBLE ASSETS – NET

     

    Goodwill consists of the excess of the purchase price over the fair value of identifiable net assets of businesses acquired. At December 31, 2024, and 2023, approximately $90,000 of goodwill was allocated to the Medical Practice Management segment and the balance was allocated to the Healthcare IT segment. The following is the summary of the changes to the carrying amount of goodwill for the years ended December 31, 2024 and 2023:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Beginning gross balance  $19,186   $61,186 
    Impairment charges   -    (42,000)
    Ending gross balance  $19,186   $19,186 

     

    As a result of a triggering event in December 2023 resulting from the suspension of the Preferred Stock dividend, the Company updated its annual goodwill impairment test that was performed as of October 31, 2023 for the Healthcare IT segment. It was determined that the fair value of the Healthcare IT reporting unit was less than the carrying value at both October 31, 2023 and as a result of the December 2023 triggering event. Accordingly, impairment charges of approximately $2.0 million and $40.0 million, respectively, were recorded. There was no goodwill impairment recorded during the year ended December 31, 2024.

     

    Below is a summary of intangible asset activity for the years ended December 31, 2024 and 2023:

     

       Customer   Capitalized   Other Intangible     
       Relationships   Software   Assets   Total 
       ($ in thousands) 
    COST                    
    Balance, January 1, 2024  $47,597   $29,379   $9,653   $86,629 
    Additions   -    5,709    -    5,709 
    Translation gain   -    20    -    20 
    Balance, December 31, 2024  $47,597   $35,108   $9,653   $92,358 
    Useful lives   3-12 years    3 years    3 years      
    ACCUMULATED AMORTIZATION                    
    Balance, January 1, 2024  $44,372   $12,237   $4,946   $61,555 
    Amortization expense   1,575    10,522    1    12,098 
    Translation gain   -    7    -    7 
    Balance, December 31, 2024   45,947    22,766    4,947    73,660 
    Net book value  $1,650   $12,342   $4,706   $18,698 
                         
    COST                    
    Balance, January 1, 2023  $47,597   $21,547   $9,651   $78,795 
    Additions   -    8,548    2    8,550 
    Translation loss   -    (716)   -    (716)
    Balance, December 31, 2023  $47,597   $29,379   $9,653   $86,629 
    Useful lives   3-12 years    3 years    3 years      
    ACCUMULATED AMORTIZATION                    
    Balance, January 1, 2023  $39,523   $4,932   $4,820   $49,275 
    Amortization expense   4,849    7,426    126    12,401 
    Translation loss   -    (121)   -    (121)
    Balance, December 31, 2023   44,372    12,237    4,946    61,555 
    Net book value  $3,225   $17,142   $4,707   $25,074 

     

    As a result of a triggering event in December 2023, we also reviewed our other long term assets for impairment. We determined that the fair value of these assets exceeded their carrying value and that there was no impairment. There were no triggering events during the year ended December 31, 2024.

     

    The amount for capitalized software represents payroll and development costs incurred for internally developed software. Other intangible assets primarily represent non-compete agreements, purchased and acquired software and trademarks. Amortization expense was approximately $12.1 million and $12.4 million for the years ended December 31, 2024 and 2023, respectively. The weighted-average amortization period is three years.

     

     

    As of December 31, 2024, future amortization expense scheduled to be expensed is as follows:

     

    Years ending December 31,  ($ in thousands) 
    2025  $10,291 
    2026   5,911 
    2027   1,746 
    2028   300 
    2029   300 
    Thereafter   150 
    Total  $18,698 

     
    XML 40 R15.htm IDEA: XBRL DOCUMENT v3.25.1
    PROPERTY AND EQUIPMENT
    		 12 Months Ended
    Dec. 31, 2024
    Property, Plant and Equipment [Abstract]  
    PROPERTY AND EQUIPMENT

    4. PROPERTY AND EQUIPMENT

     

    Property and equipment consisted of the following:

     

       2024   2023 
       December 31, 
       2024   2023 
       ($ in thousands) 
    Computer equipment  $5,963   $5,510 
    Office furniture and equipment   2,342    1,985 
    Transportation equipment   1,185    1,129 
    Leasehold improvements   6,358    5,350 
    Assets not placed in service   164    - 
    Total property and equipment   16,012    13,974 
    Less accumulated depreciation   (10,722)   (8,657)
    Property and equipment – net  $5,290   $5,317 

     

    Depreciation expense was approximately $2.0 million for both the years ended December 31, 2024 and 2023, respectively.

     

    As a result of a triggering event in December 2023, we reviewed our property and equipment for impairment at that time. We determined that the fair value of these assets exceeded their carrying value and that there was no impairment. There were no triggering events during the year ended December 31, 2024.

     
    XML 41 R16.htm IDEA: XBRL DOCUMENT v3.25.1
    CONCENTRATIONS
    		 12 Months Ended
    Dec. 31, 2024
    Risks and Uncertainties [Abstract]  
    CONCENTRATIONS

    5. CONCENTRATIONS

     

    Financial Risks — As of December 31, 2024 and 2023, the Company held cash of approximately $119,000 and $255,000, respectively, in the name of its subsidiaries, at banks in Pakistan and Sri Lanka. The banking systems in these countries do not provide deposit insurance coverage. Additionally, from time to time, the Company maintains cash balances at financial institutions in the United States in excess of federal insurance limits. The Company has not experienced any losses on such accounts. The cash held by each U.S. operating company was below the federal insurance limit at December 31, 2024.

     

    Concentrations of credit risk with respect to trade accounts receivable are managed by periodic credit evaluations of customers. The Company does not require collateral for outstanding trade accounts receivable. As of December 31, 2024, two customers each individually accounted for approximately 7% of accounts receivable. As of December 31, 2023, two customers each individually accounted for approximately 7% of accounts receivable. During the years ended December 31, 2024 and 2023, there was one customer with sales of approximately 10% and 9% of total revenue, respectively.

     

     

    Geographical Risks — The Company’s offices in Islamabad, Karachi and Bagh, Pakistan, and Colombo, Sri Lanka conduct significant back-office operations for the Company. The Company has no revenue earned outside of the United States. The office in Bagh is located in a different territory of Pakistan from the Islamabad office known as Azad Jammu and Kashmir. The Bagh office was opened in 2009 for the purpose of providing operational support and operating as a backup to the Islamabad office. The Bagh office now operates as the main operational center for the Company. The Company’s operations outside the United States are subject to special considerations and significant risks not typically associated with companies in the United States. The Company’s business, financial condition and results of operations may be influenced by the political, economic, and legal environment in the countries in which it operates and by the general state of these countries’ economies. The Company’s results may be adversely affected by, among other things, changes in governmental policies with respect to laws and regulations, changes in local countries’ telecommunications industries, regulatory rules and policies, anti-inflationary measures, currency conversion and remittance, and rates and methods of taxation.

     

    Carrying amounts of net assets located outside the United States were approximately $7.0 million and $7.6 million as of December 31, 2024 and 2023, respectively. These balances exclude net intercompany receivables of approximately $2.2 million and $1.0 million as of December 31, 2024 and 2023, respectively. The following is a summary of the net assets located outside the United States as of December 31, 2024 and 2023:

     

       2024   2023 
       December 31, 
       2024   2023 
       ($ in thousands) 
    Current assets  $211   $806 
    Non-current assets   8,337    8,250 
    Assets   8,548    9,056 
    Current liabilities   (1,336)   (1,250)
    Non-current liabilities   (172)   (240)
    Net assets  $7,040   $7,566 

     
    XML 42 R17.htm IDEA: XBRL DOCUMENT v3.25.1
    NET LOSS PER COMMON SHARE
    		 12 Months Ended
    Dec. 31, 2024
    Earnings Per Share [Abstract]  
    NET LOSS PER COMMON SHARE

    6. NET LOSS PER COMMON SHARE

     

    The following table reconciles the weighted-average shares outstanding for basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
      

    ($ in thousands, except share and

    per share amounts)

    		 
    Basic and Diluted:          
    Net loss attributable to common shareholders  $(4,459)  $(64,348)
    Weighted-average common shares used to compute basic and diluted loss per share   16,146,975    15,669,472 
    Net loss attributable to common shareholders per share - basic and diluted  $(0.28)  $(4.11)

     

    The net loss attributable to common shareholders includes the preferred stock dividend amount earned, but not declared, for the year ended December 31, 2024 of approximately $12.3 million. The dividend payable at December 31, 2024 in the consolidated balance sheet represents dividends declared, but not paid, through February 29, 2024.

     

    At December 31, 2024, the 242,500 unvested restricted stock units (“RSUs”) as discussed in Note 15 have been excluded from the above calculations as they were anti-dilutive. At December 31, 2023, the 733,908 unvested equity RSUs excluded from the above calculations as they were anti-dilutive. All of the warrants previously outstanding expired unexercised in 2023 and are excluded from the above calculations. Vested RSUs, vested restricted shares and exercised warrants have been included in the above calculations.

     
    XML 43 R18.htm IDEA: XBRL DOCUMENT v3.25.1
    DEBT
    		 12 Months Ended
    Dec. 31, 2024
    Debt Disclosure [Abstract]  
    DEBT

    7. DEBT

     

    SVB — During October 2017, the Company opened a revolving line of credit from SVB under a three-year agreement which replaced the previous credit facility. The SVB credit facility is a secured revolving line of credit where borrowings are based on a formula of 200% of repeatable revenue adjusted by an annualized attrition rate as defined in the credit agreement. During the third quarter of 2018, the credit line was increased from $5 million to $10 million and the term was extended for an additional year. During the third quarter of 2021, the credit line was further increased to $20 million and the term was extended for two years. During February 2023, the line of credit was increased to $25 million and the term was extended for two years through October 13, 2025. Effective August 31, 2023, the credit facility agreement was amended whereby the interest rate was increased from the prime rate plus 1.5% to the prime rate plus 2.0%. The requirement for the minimum liquidity ratio was slightly reduced. These amendments expired on March 31, 2024 and the credit facility reverted to its previous terms.

     

     

    As of December 31, 2024, there were no borrowings under the credit facility, compared to $10 million in borrowings as of December 31, 2023. Interest on the revolving line of credit was charged at the prime rate plus 2.0% for the first quarter of 2024, but decreased to the prime rate plus 1.5% on April 1, 2024. There is also a fee of one-half of 1% annually for the unused portion of the credit line. The debt is secured by all of the Company’s domestic assets and 65% of the shares in its offshore subsidiaries. Future acquisitions are subject to approval by SVB. At December 31, 2024, the available borrowing base was approximately $10.0 million.

     

    In connection with the original SVB debt agreement, the Company paid SVB approximately $50,000 of fees upfront and issued warrants for SVB to purchase 125,000 shares of its common stock, and committed to pay an annual anniversary fee of $50,000 a year. Based on the terms in the original SVB credit agreement, these warrants had a strike price equal to $3.92. They had a five-year exercise window and net exercise rights, and were valued at $3.12 per warrant. These warrants were exercised during 2022. As a result of the revision in the SVB credit line, which increased the credit line from $5 million to $10 million and reduced the interest rate by 25 basis points, the Company paid approximately $50,000 of fees upfront and issued an additional 28,489 warrants, with a strike price equal to $5.26, a five-year exercise window and net exercise rights. The additional warrants were valued at $3.58 per warrant and expired unexercised in September 2023. The SVB credit agreement contains various covenants and conditions governing the revolving line of credit including a current annual fee of $44,000. These covenants include a minimum level of adjusted EBITDA or a minimum liquidity ratio, one of which must be satisfied when borrowings are outstanding. At December 31, 2024 and 2023, the Company was in compliance with all covenants.

     

    During March 2023, SVB became a division of First Citizens Bank & Trust Company. The agreements that governed the former SVB relationship remain in place. As a result, there were no changes to the terms of the credit agreement.

     

    During October, 2024, the Company entered into a Ninth Loan Modification agreement with SVB whereby the Company decreased the amount available on its revolving line of credit from $25 million to $10 million which proportionally reduced the anniversary fee and the fee on the unused portion of the credit line. As a result of the modification, one covenant was slightly modified.

     

    The Company maintains cash balances at SVB in excess of the FDIC insurance coverage limits. The Company performs periodic evaluations of the relative credit standing of this financial institution to ensure its credit worthiness. As of December 31, 2024 and December 31, 2023, the Company held cash of approximately $119,000 and $255,000, respectively, in the name of its subsidiaries at banks in Pakistan and Sri Lanka. The banking systems in these countries do not provide deposit insurance coverage. The Company has not experienced any losses on its cash accounts.

     

    Vehicle Financing Notes — The Company finances certain vehicle purchases both in the United States and in Pakistan. The vehicle financing notes typically have three to six year terms and are issued at current market rates.

     

    Insurance Financing — The Company finances certain insurance purchases over the term of the policy life. The interest rate charged is 7.49%.

     

    Maturities of the outstanding notes payable and other obligations as of December 31, 2024 are as follows:

     

    Year ending December 31,  Vehicle Financing Notes   Insurance Financing   Total 
       ($ in thousands) 
    2025  $11   $299   $310 
    2026   11    -    11 
    2027   8    -    8 
    2028             7    -    7 
    Total  $37   $299   $336 

     

     
    XML 44 R19.htm IDEA: XBRL DOCUMENT v3.25.1
    REVENUE
    		 12 Months Ended
    Dec. 31, 2024
    Revenue from Contract with Customer [Abstract]  
    REVENUE

    8. REVENUE

     

    Introduction

    The Company accounts for revenue in accordance with ASC 606, Revenue from Contracts with Customers. All revenue is recognized as our performance obligations are satisfied. A performance obligation is a promise in a contract to transfer a distinct good or service to a customer, and is the unit of account under ASC 606. The Company recognizes revenue when the revenue cycle management services begin on the medical billing claims, which is generally upon receipt of the claim from the provider. For many services the Company recognizes revenue as a percentage of the amount the customer collects on the medical billing claims. The Company’s software is utilized at the time the provider sees the patient, and the Company estimates the value of the consideration it will earn over the remaining contractual period as our services are provided and recognizes the fees over the term; this estimation involves predicting the amounts our clients will ultimately collect associated with the services they provided. Certain significant estimates, such as payment-to-charge ratios, effective billing rates and the estimated contractual payment periods are required to measure revenue cycle management revenue under the new standard.

     

    Most of our current contracts with customers contain a single performance obligation. For contracts where we provide multiple services, such as where we perform multiple ancillary services, each service represents its own performance obligation. The standalone selling prices are based on the contractual price for the service.

     

    We apply the portfolio approach as permitted by ASC 606 as a practical expedient to contracts with similar characteristics and we use estimates and assumptions when accounting for those portfolios. Our contracts generally include standard commercial payment terms. We have no significant obligations for refunds, warranties or similar obligations and our revenue does not include taxes collected from our customers.

     

    Disaggregation of Revenue from Contracts with Customers

    We derive revenue from five primary sources: (1) Technology-enabled business solutions, (2) professional services, (3) printing and mailing services, (4) group purchasing services and (5) medical practice management services.

     

    The following table represents a disaggregation of revenue for the years ended December 31, 2024 and 2023:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Healthcare IT:          
    Technology-enabled business solutions  $73,672   $76,640 
    Professional services   18,202    23,022 
    Printing and mailing services   3,579    2,968 
    Group purchasing services   952    1,053 
    Medical Practice Management:          
    Medical practice management services   14,432    13,376 
    Total  $110,837   $117,059 

     

    Technology-enabled business solutions:

    Revenue derived on an on-going basis from our technology-enabled solutions, which typically includes revenue cycle management services, is billed as a percentage of payments collected by our customers. The fee for our services often includes the ability to use our EHR and practice management software as well as RCM as part of the bundled fee. The SaaS component is not a material portion of the contract compared to the stand-alone value of RCM.

     

    Technology-assisted revenue cycle management services are the recurring process of submitting and following up on claims with health insurance companies in order for the healthcare providers to receive payment for the services they rendered. The Company typically invoices customers on a monthly basis based on the actual collections received by its customers and the agreed-upon rate in the sales contract. The fee for these services typically includes use of practice management software and related tools (on a SaaS basis), electronic health records (on a SaaS basis), medical billing services and use of mobile health solutions. We consider the services to be one performance obligation since the promises are not distinct in the context of the contract. The performance obligation consists of a series of distinct services that are substantially the same and have the same periodic pattern of transfer to our customers.

     

     

    In many cases, our clients may terminate their agreements with 90 days’ notice without cause, thereby limiting the term in which we have enforceable rights and obligations, although this time period can vary between clients. Our payment terms are normally net 30 days. Although our contracts typically have stated terms of one or more years, under ASC 606 our contracts are considered month-to-month and accordingly, there is no financing component.

     

    For the majority of our revenue cycle management contracts, the total transaction price is variable because our obligation is to process an unknown quantity of claims, as and when requested by our customers over the contract period. When a contract includes variable consideration, we evaluate the estimate of the variable consideration to determine whether the estimate needs to be constrained; therefore, we include variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with variable consideration is subsequently resolved. Estimates to determine variable consideration such as payment to charge ratios, effective billing rates, and the estimated contractual payment periods are updated at each reporting date. Revenue is recognized over the performance period using the input method.

     

    Our proprietary, cloud-based practice management application automates the labor-intensive workflow of a medical office in a unified and streamlined SaaS platform. The Company has a large number of clients who utilize the Company’s practice management software, electronic health records software, patient experience management solutions, business intelligence software and/or robotic process automation software on a SaaS basis, but who do not utilize the Company’s revenue cycle management services. SaaS fees may be fixed based on the number of providers, or may be variable.

     

    Our digital health services, which began generating revenue in 2022, include chronic care management, where a care manager has remote visits with patients with one or more chronic conditions under the supervision of a physician who is our client. The performance obligation for chronic care management is satisfied at a point in time once the patient receives the remote visit. The digital health services also include remote patient monitoring where our system monitors recordings from FDA approved internet connected devices. These devices record patient trends and alerts the physician to changes which might trigger the need for additional follow-up visits. The performance obligations for remote patient monitoring are satisfied over time as the recordings are received and the patient receives the remote visit. The revenue for chronic care management for the years ended December 31, 2024 and 2023 was approximately $3.0 million and $1.5 million, respectively. The revenue for remote patient monitoring for the years ended December 31, 2024 and 2023 was approximately $779,000 and $400,000, respectively.

     

    The medical billing clearinghouse service takes claim information from customers, checks the claims for errors and sends this information electronically to insurance companies. The Company invoices customers on a monthly basis based on the number of claims submitted and the agreed-upon rate in the agreement. This service is provided to medical practices and providers to medical practices who are not revenue cycle management customers. The performance obligation is satisfied once the relevant submissions are completed.

     

    Additional services such as coding and transcription are rendered in connection with the delivery of revenue cycle management and related medical services. The Company invoices customers monthly, based on the actual amount of services performed at the agreed-upon rate in the contract. These services are only offered to revenue cycle management customers. These services do not represent a material right because the services are optional to the customer and customers electing these services are charged the same price for those services as if they were on a standalone basis. Each individual coding or transcription transaction processed represents a performance obligation, which is satisfied over time as that individual service is rendered.

     

    Professional services:

    Our professional services include an extensive set of services including EHR vendor-agnostic optimization and activation, project management, IT transformation consulting, process improvement, training, education and staffing for large healthcare organizations including health systems and hospitals. The performance obligation is satisfied over time using the input method. The revenue is recorded on a monthly basis as the professional services are rendered. Unbilled revenue at December 31, 2024 and 2023 was approximately $338,000 and $100,000, respectively.

     

     

    Printing and mailing services:

    The Company provides printing and mailing services for both revenue cycle management customers and a non- revenue cycle management customer, and invoices on a monthly basis based on the number of prints, the agreed-upon rate per print and the postage incurred. The performance obligation is satisfied once the printing and mailing is completed.

     

    Group purchasing services:

    The Company provides group purchasing services which enable medical providers to purchase various vaccines directly from selected pharmaceutical companies at a discounted price. Currently, there are approximately 4,000 medical providers who are members of the program. Revenue is recognized as the vaccine shipments are made to the medical providers. Fees from the pharmaceutical companies are paid either quarterly or annually and the Company adjusts its revenue accrual at the time of payment. The Company makes significant judgments regarding the variable consideration which we expect to be entitled to for the group purchasing services which includes the anticipated shipments to the members enrolled in the program, anticipated volumes of purchases made by the members, and the changes in the number of members. The amounts recorded are constrained by estimates of decreases in shipments and loss of members to avoid a significant revenue reversal in the subsequent period. The only performance obligation is to provide the pharmaceutical companies with the medical providers who want to become members in order to purchase vaccines. The performance obligation is satisfied once the medical provider agrees to purchase a specific quantity of vaccines and the medical provider’s information is forwarded to the vaccine suppliers. The Company records a contract asset for revenue earned and not paid as the ultimate payment is conditioned on achieving certain volume thresholds.

     

    For all of the above revenue streams other than group purchasing services and chronic care management, revenue is recognized over time, which is typically one month or less, which closely matches the point in time that the customer simultaneously receives and consumes the benefits provided by the Company. For the group purchasing services, revenue is recognized at a point in time. Each service is substantially the same and has the same periodic pattern of transfer to the customer. Each of the services provided above is considered a separate performance obligation.

     

    There were no unsatisfied performance obligations for contracts with an original duration greater than one year. The Company has elected to utilize the practical expedient available with the guidance for contracts with an expected duration of one year or less.

     

    Medical practice management services:

    The Company also provides medical practice management services under long-term management service agreements to three medical practices. We provide the medical practices with the nurses, administrative support, facilities, supplies, equipment, marketing, RCM, accounting, and other non-clinical services needed to efficiently operate their practices. Revenue is recognized as the services are provided to the medical practices. Revenue recorded in the consolidated statements of operations represents the reimbursement of costs paid by the Company for the practices and the management fee earned each month for managing the practice. The management fee is based on either a fixed fee or a percentage of the net operating income.

     

    The Company assumes all financial risk for the performance of the managed medical practices. Revenue is impacted by the amount of the costs incurred by the practices and their operating income. The gross billing of the practices is impacted by billing rates, changes in current procedural terminology code reimbursement and collection trends which in turn impacts the management fee that the Company is entitled to. Billing rates are reviewed at least annually and adjusted based on current insurer reimbursement practices. The performance obligation is satisfied as the management services are provided.

     

    Our contracts for medical practice management services have approximately an additional 14 years remaining and are only cancellable under very limited circumstances. The Company receives a management fee each month for managing the day-to-day business operations of each medical group as a fixed fee or a percentage payment of the net operating income which is included in revenue in the consolidated statements of operations.

     

    Our medical practice management services obligations consist of a series of distinct services that are substantially the same and have the same periodic pattern of transfer to our customers. Revenue is recognized over time, however for reporting and convenience purposes, the management fee is computed at each month end.

     

     

    Information about contract balances:

    As of December 31, 2024, the estimated revenue expected to be recognized in the future related to the remaining revenue cycle management performance obligations outstanding was approximately $3.5 million. We expect to recognize substantially all of the revenue for the remaining performance obligations over the next three months. Approximately $318,000 and $476,000 of the contract asset represents revenue earned, not paid, from the group purchasing services and referral fees, respectively.

     

    Amounts that we are entitled to collect under the applicable contract are recorded as accounts receivable. Invoicing is performed at the end of each month when the services have been provided. The contract asset includes our right to payment for services already transferred to a customer when the right to payment is conditional on something other than the passage of time. For example, contracts for revenue cycle management services where we recognize revenue over time but do not have a contractual right to payment until the customer receives payment of their claim from the insurance provider. The contract asset also includes the revenue accrued, not received, for the group purchasing services.

     

    Changes in the contract asset are recorded as adjustments to net revenue. The changes primarily result from providing services to revenue cycle management customers that result in additional consideration and are offset by our right to payment for services becoming unconditional and changes in the revenue accrued for the group purchasing services. The contract asset for our group purchasing services is reduced when we receive payments from vaccine manufacturers and is increased for revenue earned, not received. The opening and closing balances of the Company’s accounts receivable, contract asset and deferred revenue are as follows:

     

     

      

    Accounts

    Receivable - Net

    		  

    Contract

    Asset

    		  

    Deferred Revenue

    (current)

    		  

    Deferred Revenue

    (long term)

    		 
       ($ in thousands) 
    Balance as of January 1, 2024  $11,888   $5,094   $1,380   $256 
    Increase (decrease), net   886    (760)   (168)   131 
    Balance as of  December 31, 2024  $12,774   $4,334   $1,212   $387 
                         
    Balance as of January 1, 2023  $14,773   $4,399   $1,386   $342 
    (Decrease) increase, net   (2,885)   695    (6)   (86)
    Balance as of  December 31, 2023  $11,888   $5,094   $1,380   $256 

     

    Deferred revenue:

    The amount of deferred revenue at the beginning of the year and recognized during the year ended December 31, 2024 and 2023 was approximately $909,000 and $1.1 million, respectively.

     

    Deferred commissions:

    Our sales incentive plans include commissions payable to employees and third parties at the time of the initial contract execution that are capitalized as incremental costs to obtain a contract. The capitalized commissions are amortized over the period the related services are transferred. As we do not offer commissions on contract renewals, we have determined the amortization period to be the estimated client life, which is three years. Deferred commissions were approximately $386,000 and $517,000 at December 31, 2024 and 2023, respectively, and are included in the other assets amounts in the consolidated balance sheets. The amortization of deferred sales commissions during the years ended December 31, 2024 and 2023 was approximately $327,000 and $487,000, respectively.

     

    Trade Accounts Receivable – Estimate of Credit Losses:

    ASU 2016-13 requires the recognition of lifetime estimated credit losses expected to occur for trade accounts receivable. The guidance also requires we pool assets with similar risk characteristics and consider current economic conditions when estimating losses. The adoption of the ASU 2016-13 for trade accounts receivable was recorded as a charge to accumulated deficit of approximately $186,000 as of January 1, 2023.

     

    At adoption, we segmented the accounts receivable population into pools based on their risk assessment. Risks related to trade accounts receivable are a customer’s inability to pay or bankruptcy. Each pool was defined by their internal credit assessment and business size. The pools are aligned with management’s review of financial performance. For the years ended December 31, 2024 and 2023, no adjustment to the pools was necessary.

     

     

    We utilize a loss-rate method to measure the expected credit loss for each pool. The loss rate is calculated using a three-year lookback period of write-offs and adjustments, divided by the revenue for each pool by aging category, net of customer payments during that period. We consider current and future economic conditions, internal forecasts, customer collection experience and credit memos issued during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data for the current quarter. In addition, the Company uses specific account identification in determining the total allowance for expected credit losses. Trade receivables are written off only after the Company has exhausted all collection efforts.

     

    Changes in the allowance for expected credit losses for trade accounts receivable are presented in the table below:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands)  
    Beginning balance  $879   $823 
    Adoption of ASC 326   -    186 
    Provision   334    454 
    Recoveries/adjustments   2    107 
    Write-offs   (378)   (691)
    Ending balance  $837   $879 

     
    XML 45 R20.htm IDEA: XBRL DOCUMENT v3.25.1
    SHAREHOLDERS’ EQUITY
    		 12 Months Ended
    Dec. 31, 2024
    Equity [Abstract]  
    SHAREHOLDERS’ EQUITY

    9. SHAREHOLDERS’ EQUITY

     

    On September 11, 2024 a Certificate of Amendment (the “Amendment”) to the Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Preferred Stock (the “Existing Certificate”) became effective, amending certain provisions of the 11% Series A Cumulative Redeemable Preferred Stock (the “Series A Preferred Stock”).

     

    The title of the Existing Certificate was amended to read “Amended and Restated Certificate of Designations, Preferences and Rights of 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock.” Holders of Series A Preferred Stock will now receive similar change of control protections to those afforded to holders of the Company’s Series B Preferred Stock. The dividend of Series A Preferred Stock was amended from 11% to 8.75% per annum and the per annum dividend amount per share was amended from $2.75 to $2.1875 per share per annum. Also, the Company now has the right to exchange the shares of Series A Preferred Stock for common stock at the liquidation preference value of $25 per share, plus accrued and unpaid dividends. (See Note 20).

     

    Treasury stock

    The Board of Directors of the Company previously approved common stock repurchase programs. The last program expired January 25, 2017. As a result of these stock repurchases, the Company has 740,799 common shares held as treasury stock at an aggregate cost of $662,000.

     

    Common stock

    The Company had the right to sell up to $50 million of its common stock using an “at-the-market” facility (“ATM”). The underwriter receives 3% of the gross proceeds. During the years ended December 31, 2024 and 2023, no shares of common stock were issued under this ATM. This right terminated when the Company suspended the Preferred Stock dividends.

     

    Holders of our common stock are entitled to one vote for each share held on all matters properly submitted to a vote of shareholders on which holders of common stock are entitled to vote. Holders of common stocks are entitled to receive dividends only at times and amounts as determined by the Board of Directors. The common stock is not entitled to pre-emptive rights, and is not subject to conversion, redemption or sinking fund provisions. The common stock is listed on the Nasdaq Global Market under the trading symbol “CCLD.”

     

    Preferred stock

    The Company has seven million authorized shares of preferred stock of which 4,560,000 have been designated as Series A shares and the balance have been designated as Series B shares.

     

    The Company also had the right to sell up to $35 million of its Series B Preferred Stock using an ATM facility. This right terminated when the Company suspended the Preferred Stock dividends. The ATM facility’s underwriter received 3% of the gross proceeds. During the year ended December 31, 2023, the Company sold 59,773 of shares of Series B Preferred Stock under the Company’s ATM and received net proceeds of approximately $1.4 million. During the year ended December 31, 2024, no shares of Series B Preferred Stock were issued under this ATM.

     

     

    Since September 11, 2024, we may, at our option, convert the majority of the Series A Preferred Stock into common stock at any time. If we convert the Series A Preferred Stock, then subsequent to the conversion date, dividends will cease to accrue on shares of the Series A Preferred Stock, the shares of the Series A Preferred Stock shall no longer be deemed outstanding and all rights as a holder of those shares will terminate, except the right to receive the shares of common stock plus accumulated and unpaid dividends, if any, payable upon the conversion. (See Note 20).

     

    Since November 4, 2020, the Company has the right to redeem, at its option, the Series A Preferred Stock, in whole or in part, at a cash redemption price of $25.00 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. The Series A Preferred Stock has no stated maturity, is not subject to any sinking fund or other mandatory redemption, and is not convertible at the option of the holder into or exchangeable for any of the Company’s other securities. Holders of the Series A Preferred Stock have no voting rights except for limited voting rights if dividends payable on the Series A Preferred Stock are in arrears for eighteen or more consecutive or non-consecutive monthly dividend periods, at which time they are entitled to appoint two additional directors to our Board of Directors. If the Company were to liquidate, dissolve or wind up, the holders of the Series A Preferred Stock will have the right to receive $25.00 per share, plus any accumulated and unpaid dividends to, but not including, the date of payment, before any payment is made to the holders of the common stock. The Series A Preferred Stock is listed on the Nasdaq Global Market under the trading symbol “CCLDP.”

     

    Since February 15, 2024 and prior to February 15, 2025, we were able to redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $25.75 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. On or after February 15, 2025 and prior to February 15, 2026, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $25.50 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. On or after February 15, 2026 and prior to February 15, 2027, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $25.25 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. On or after February 15, 2027, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $25.00 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. The Series B Preferred Stock is listed on the Nasdaq Global Market under the trading symbol “CCLDO.”

     

    Dividends on the Series A and Series B Preferred Stock of $2.75 (through September 11, 2024 and $2.19 thereafter) and $2.19 annually per share respectively, are cumulative from the date of issue and are payable each month when, as and if declared by the Company’s Board of Directors. In October 2023, the Board of Directors declared monthly dividends on the Series A and Series B Preferred Stock payable through February 2024. However, on December 11, 2023, the Board of Directors suspended the monthly cash dividends for Series A Preferred Stock and Series B Preferred Stock beginning with the payment scheduled for December 15, 2023 together with the remaining dividends that were declared. The suspension of these dividends deferred approximately $1.3 million in cash dividend payments each month through September 11, 2024. Due to the above Amendment, effective on September 12, 2024, the combined monthly cash dividends were reduced to approximately $1.1 million per month.

     

    During the suspension, dividends continued to accrue in arrears on the Series A and Series B Preferred Stock. The Company’s Board of Directors declared payment of two months of dividends in January 2025 and the Company resumed payment of the dividends in February 2025, paying one month of dividends in arrears at that time. The second payment is scheduled for March 2025.

     

    During the year ended December 31, 2024, no dividends were declared by the Board of Directors. At December 31, 2024, the Company owed approximately $5.4 million for dividends that had previously been declared through February 2024 (but whose payment was suspended), and also had total undeclared dividends of approximately $12.3 million, which represents the accumulated (but undeclared) dividends due to Preferred Stock shareholders of record on December 31, 2024. Dividends that have accrued in arrears but which have not been declared by the Board of Directors are not recorded in the consolidated balance sheets but are reflected in the net loss attributable to common shareholders. Total dividends in arrears at December 31, 2024 amounted to approximately $17.7 million or $3.04 per share for the Series A Preferred Stock and $2.55 per share for the Series B Preferred Stock.

     

    Warrants

     

    The Company has issued 6,603,489 warrants for its common stock, of which 1,128,489 warrants expired unexercised during 2023. There were no warrants outstanding at December 31, 2024 and 2023.

     

     

    The Company incurs common and preferred stock offering costs which consist principally of professional fees, primarily legal and accounting, and other costs such as printing and registration costs. In connection with the 2023 equity offerings, the Company incurred approximately $71,000 of such costs, including underwriting commissions and placement agent fees.

     
    XML 46 R21.htm IDEA: XBRL DOCUMENT v3.25.1
    COMMITMENTS AND CONTINGENCIES
    		 12 Months Ended
    Dec. 31, 2024
    Commitments and Contingencies Disclosure [Abstract]  
    COMMITMENTS AND CONTINGENCIES

    10. COMMITMENTS AND CONTINGENCIES

     

    Legal Proceedings — On December 9, 2022, an arbitrator rendered a decision in favor of MTBC Acquisition Corp. (“MAC”) and dismissed the claims brought against MAC by Randolph Pain Relief and Wellness Center (“RPRWC”), determining that RPRWC failed to prove any breach of the applicable billing services agreement and failed to prove that any alleged damages were due. The deadline for RPRWC to file a summary action in Superior Court of New Jersey seeking to overturn the arbitrator’s decision was April 5, 2023 and no summary action was filed by such deadline. As such, the arbitrator’s decision dismissing RPRWC’s claims is final.

     

    On December 22, 2023, an arbitrator rendered a decision in favor of Ramapo Anesthesiologists, PC (“Ramapo”) and granted in part and denied in part certain claims brought against Origin Healthcare Solutions, LLC; Meridian Medical Management, Inc.; and the Company for alleged breach of contract and other allegations. Ramapo was awarded mitigation related costs of $117,000. The payment for such an award was made during the first quarter of 2024. The Company’s portion of the settlement is approximately $32,000 and the insurance company paid the balance. The Company’s portion was recorded in accrued expenses at December 31, 2023 in the consolidated balance sheet.

     

    A former customer filed a complaint against the Company in New Jersey State Court to recover damages claimed to have been caused by the mishandling of their account. Plaintiff alleged at least approximately $750,000 in damages which was disputed by the Company. The parties participated in a one-day court-ordered, non-binding arbitration. At that time, the arbitrator awarded Plaintiff $288,750 on its contract claims, and awarded the Company $21,698 on its cross-claim for unpaid fees. Plaintiff filed to reject this award. The Company previously filed a partial motion for summary judgment on the alleged punitive damages, but the court denied that motion finding there is an issue of fact as to whether those can be awarded at trial. The Company filed an offer of judgment for $200,000 during April 2024 which was accepted and paid in July 2024.

     

    In connection with a prior acquisition, the seller had alleged that the Company owed approximately $800,000 in transition related costs to them. The parties agreed to settle the claim for approximately $316,000, which was paid in September 2024.

     

    From time to time, we may become involved in other legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of our management, would individually or taken together have a material adverse effect on our business, consolidated results of operations, financial position or cash flows of the Company.

     
    XML 47 R22.htm IDEA: XBRL DOCUMENT v3.25.1
    LEASES
    		 12 Months Ended
    Dec. 31, 2024
    Leases  
    LEASES

    11. LEASES

     

    We determine if an arrangement is a lease at inception. We have operating leases for office and temporary living space as well as for some office equipment. Operating leases are included in operating lease ROU assets, current operating lease liability and non-current operating lease liability in our consolidated balance sheets as of December 31, 2024 and 2023. The Company does not have any finance leases.

     

    ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of the lease payments over the lease term.

     

    As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rates, which are derived from information available at the lease commencement date, in determining the present value of lease payments. We give consideration to our bank financing arrangements, geographical location and collateralization of assets when calculating our incremental borrowing rates.

     

    Our lease terms include options to extend the lease when it is reasonably certain that we will exercise that option. Leases with a term of less than 12 months are not recorded in the consolidated balance sheets. Our lease agreements do not contain any residual value guarantees. For real estate leases, we account for the lease and non-lease components as a single lease component. Some leases include escalation clauses and termination options that are factored in the determination of the lease payments when appropriate.

     

     

    If a lease is modified after the effective date, the operating lease ROU asset and liability is re-measured using the current incremental borrowing rate. There was one lease modification during both years ended December 31, 2024 and 2023. We review our incremental borrowing rate for our portfolio of leases on a quarterly basis.

     

    During the year ended December 31, 2024, there were no unoccupied lease charges recorded as compared to approximately $169,000 for two of the Company’s facilities for the year ended December 31, 2023. There were no lease impairments recorded for the years ended December 31, 2024 and 2023. For the year ended December 31, 2024, there was a gain on lease terminations of approximately $10,000. For the year ended December 31, 2023, there was a loss on lease terminations of approximately $291,000. These amounts are included in lease terminations, unoccupied lease charges and restructuring costs in the consolidated statement of operations.

     

    Lease expense is included in direct operating costs, general and administrative expense, selling and marketing expense and research and development expense in the consolidated statements of operations based on the nature of the expense. As of December 31, 2024, we had 28 leased properties, five in Medical Practice Management and 23 in Healthcare IT, with the remaining terms ranging from less than one year to eleven years. Our lease terms are determined taking into account lease renewal options, the Company’s anticipated operating plans and leases that are on a month-to-month basis. We also have some related party leases – see Note 12.

     

    The components of lease expense were as follows:

      

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Operating lease cost  $2,451   $2,669 
    Short-term lease cost   4    - 
    Variable lease cost   28    32 
    Total - net lease cost  $2,483   $2,701 

     

    Short-term lease cost represents leases that were not capitalized as the lease term as of the later of January 1, 2024 or the beginning of the lease was less than 12 months. Variable lease costs include utilities, real estate taxes and common area maintenance costs.

     

     

    Supplemental balance sheet information related to leases was as follows:

     

       December 31, 2024   December 31, 2023 
       ($ in thousands) 
    Operating leases:          
    Operating lease ROU assets, net  $3,133   $4,365 
               
    Current operating lease liabilities  $1,287   $1,888 
    Non-current operating lease liabilities   1,847    2,516 
    Total operating lease liabilities  $3,134   $4,404 
               
    Operating leases:          
    ROU assets  $5,125   $6,571 
    Asset lease expense   (1,994)   (2,152)
    Foreign exchange gain/(loss)   2    (54)
    ROU assets, net  $3,133   $4,365 
               
    Weighted average remaining lease term (in years):          
    Operating leases   5.0    4.5 
    Weighted average discount rate:          
    Operating leases   14.2%   13.3%

     

    Supplemental cash flow and other information related to leases was as follows:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Cash paid for amounts included in the measurement of lease liabilities:          
    Operating cash flows from operating leases  $2,467   $3,244 
               
    ROU assets obtained in exchange for lease liabilities:          
    Operating leases, excluding terminations  $864   $1,682 

     

    Maturities of lease liabilities are as follows:

     

    Operating leases - Years ending December 31,  ($ in thousands) 
    2025  $1,601 
    2026   727 
    2027   557 
    2028   371 
    2029   193 
    Thereafter   1,240 
    Total lease payments   4,689 
    Less: imputed interest   (1,555)
    Total lease obligations   3,134 
    Less: current obligations   1,287 
    Long-term lease obligations  $1,847 

     

    The Company leases certain apartments which are subleased to others. The sublease agreements are currently on a month-to-month basis and are considered operating leases. For the year ended December 31, 2024, the Company received sublease income of approximately $94,000. There was no sublease income for the year ended December 31, 2023.

     

     
    XML 48 R23.htm IDEA: XBRL DOCUMENT v3.25.1
    RELATED PARTIES
    		 12 Months Ended
    Dec. 31, 2024
    Related Party Transactions [Abstract]  
    RELATED PARTIES

    12. RELATED PARTIES

     

    The Company had sales to a related party, a physician who is the wife of the Executive Chairman. Revenues from this customer were approximately $138,000 and $125,000 for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, the accounts receivable balance due from this customer was approximately $13,000 and $18,000, respectively, and is included in accounts receivable - net in the consolidated balance sheets.

     

    The Company leases its corporate offices in New Jersey, its temporary housing for its foreign visitors, a storage facility, its backup operations center in Bagh, Pakistan and an apartment for temporary housing in Dubai, the UAE, from the Executive Chairman. The related party rent expense for the years ended December 31, 2024 and 2023 was approximately $281,000 and $256,000, respectively, and is included in direct operating costs and general and administrative expense in the consolidated statements of operations. During the years ended December 31, 2024 and 2023, the Company spent approximately $979,000 and $1.8 million, respectively, to upgrade the related party leased facilities. During the year ended December 31, 2023, the Company temporarily advanced the Executive Chairman approximately $330,000, to purchase vacant land surrounding the Bagh facility for the sole use and benefit of the Company in order to expedite the purchase on the Company’s behalf as only individuals with citizenship in Kashmir are allowed to purchase land in this region. All advanced amounts were repaid shortly after the advance was made. Current assets-related party in the consolidated balance sheets includes security deposits related to the leases of the Company’s corporate offices in the amount of approximately $16,000 for both the years ended December 31, 2024 and 2023. The Company also leases two facilities used for temporary housing from a management employee for approximately $6,500 per month.

     

    Included in the ROU asset at December 31, 2024 is approximately $550,000 applicable to the related party leases. Included in the current and non-current operating lease liability at December 31, 2024 is approximately $181,000 and $367,000, respectively, applicable to the related party leases. Included in the ROU asset at December 31, 2023 is approximately $331,000 applicable to the related party leases. Included in the current and non-current operating lease liability at December 31, 2023 is approximately $182,000 and $142,000, respectively, applicable to the related party leases.

     

    During June 2022, the Company entered into a one-year consulting agreement with an entity owned and controlled by one of its former non-independent directors whereby that director received 10,000 shares of the Company’s 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (“Series B Preferred Stock”) in exchange for assisting the Company to identify and acquire additional companies, including performing due diligence. In addition, the Company could make additional payments under the agreement for any successful acquisitions by the Company based on the purchase price of the transaction. No such additional payments were made in 2022. During February 2023, the agreement was amended and extended through December 2024 whereby the former director received 14,000 shares of Series B Preferred Stock in February 2023 and received an additional 14,000 shares in January 2024. All of the payments made were capitalized and amortized over the service period. The amortization was recorded as stock compensation in general and administrative expense in the consolidated statement of operations. All such shares of the Series B Preferred Stock were issued in accordance with the Company’s Amended and Restated 2014 Equity Incentive Plan. In addition to the extension of the consulting agreement, the amendment provided that any transaction fees due will be offset against the last two above payments before any amounts are due to that former director. Effective February 1, 2024, the Company added an additional Statement of Work (“SOW”) to the consulting agreement with the same entity. As compensation for the SOW, the entity received $25,000 per month. The SOW was cancelable with ten days’ notice. The consulting agreement and SOW, through mutual consent, were terminated as of April 30, 2024. There were no transaction fees paid through that date. Effective May 1, 2024, the former non-independent director became President of the Company and effective January 1, 2025 became Co-Chief Executive Officer.

     

    Effective January 9, 2024, and as amended February 12, 2024, the Company entered into a consulting agreement with an entity owned and controlled by a member of its Board of Directors to provide investor relations and other services as requested for $8,000 per month (reduced to $2,000 per month effective September 1, 2024 and reduced to an as-needed basis effective January 1, 2025). The agreement was paid at the contractual amount plus amounts for additional services requested, and as of January 1, 2025, is paid on an hourly basis. The consulting agreement is cancelable with ten days’ notice. For the year ended December 31, 2024, the expense recorded under this agreement was approximately $75,000 and is included in general and administrative expense in the consolidated statement of operations.

     

     

    During 2020, a New Jersey corporation, talkMD Clinicians, PA (“talkMD”), was formed by the wife of the Executive Chairman, who is a licensed physician, to provide telehealth services. talkMD was determined to be a variable interest entity (“VIE”) for financial reporting purposes because the entity will be controlled by the Company. As of December 31, 2024, talkMD had not yet commenced operations. Cumulatively, the Company has paid approximately $6,000 on behalf of talkMD for income taxes.

     
    XML 49 R24.htm IDEA: XBRL DOCUMENT v3.25.1
    RESTRUCTURING COSTS
    		 12 Months Ended
    Dec. 31, 2024
    Restructuring and Related Activities [Abstract]  
    RESTRUCTURING COSTS

    13. RESTRUCTURING COSTS

     

    On October 2, 2023, the Company committed to effectively align resources with business priorities and improve profitability through a reduction in the workforce for the Healthcare IT segment. The Company identified opportunities for improvements in its workforce realignment, strategy and staffing, and increased its focus on performance management, to ensure it has the right skillsets and number of employees to execute its long-term vision. In addition, the Company instituted certain other expense reductions.

     

    A majority of the impacted employees exited in the fourth quarter of 2023. The Company estimates that it will incur expenses of approximately $1.35 million related to the reduction in workforce of which approximately $606,000 and $645,000 were incurred in 2024 and 2023, respectively, with the remaining expenses of approximately $100,000 to be incurred in 2025. These restructuring expenses consisted of one-time termination benefits, including but not limited to, severance payments and healthcare benefits.

     

    The following table summarizes restructuring costs for 2024 and 2023:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Severance and separation costs  $606   $439 
    Equity awards acceleration costs associated with severance   -    170 
    Other exit related costs   -    36 
    Total restructuring and other costs  $606   $645 

     

    The expense associated with the restructuring is included in lease terminations, unoccupied lease charges and restructuring costs in the consolidated statement of operations for the years ended December 31, 2024 and 2023. This line also includes $291,000 for loss on lease terminations and $169,000 for unoccupied lease charges for the year ended December 31, 2023. The liabilities associated with restructuring costs are included in accrued expenses in the consolidated balance sheet. The following table summarizes activity related to liabilities associated with restructuring costs:

     

    SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS

       Severance and separation costs   Equity awards acceleration costs  

    Other exit

    related costs

    		   Total restructuring and other costs 
       ($ in thousands) 
    Balance as of January 1, 2024  $145   $-   $26   $171 
    Additions   606    -    -    606 
    Payments and other adjustments   (751)   -    (26)   (777)
    Balance as of  December 31, 2024  $-   $-   $-   $- 
                         
    Balance as of January 1, 2023  $-   $-   $-   $- 
    Additions   439    170    36    645 
    Payments and other adjustments   (294)   (170)   (10)   (474)
    Balance as of  December 31, 2023  $145   $-   $26   $171 

     
    XML 50 R25.htm IDEA: XBRL DOCUMENT v3.25.1
    EMPLOYEE BENEFIT PLANS
    		 12 Months Ended
    Dec. 31, 2024
    Retirement Benefits [Abstract]  
    EMPLOYEE BENEFIT PLANS

    14. EMPLOYEE BENEFIT PLANS

     

    The Company has qualified 401(k) plans covering all U.S. employees who have completed one month of service. The plans provide for matching contributions by the Company for employees of the Company and most U.S. subsidiaries, although there is no match for CPM employees. Employer contributions to the plans for the years ended December 31, 2024 and 2023 were approximately $449,000 and $587,000, respectively.

     

    Additionally, the Company has a defined contribution retirement plan covering all employees located in our Pakistan Offices who have completed three months of service. The plan provides for monthly contributions by the Company which are equal to 10% of qualified employees’ basic monthly compensation. The Company’s contributions for the years ended December 31, 2024 and 2023 were approximately $438,000 and $394,000, respectively.

     

     

    The Company maintains a defined contribution retirement plan covering all employees in Sri Lanka. The employee and employer contribute 8% and 12%, respectively, of the employee’s gross salary. The Company’s contribution for the years ended December 31, 2024 and 2023 was approximately $28,000 and $24,000, respectively. The contributions are required to be deposited with the Employees’ Provident Fund Organization, a government owned entity.

     
    XML 51 R26.htm IDEA: XBRL DOCUMENT v3.25.1
    STOCK-BASED COMPENSATION
    		 12 Months Ended
    Dec. 31, 2024
    Share-Based Payment Arrangement [Abstract]  
    STOCK-BASED COMPENSATION

    15. STOCK-BASED COMPENSATION

     

    In April 2014, the Company adopted the Medical Transcription Billing, Corp. 2014 Equity Incentive Plan (the “Original Plan”), reserving a total of 1,351,000 shares of common stock for grants to employees, officers, directors and consultants. On April 14, 2017, the Original Plan was amended and restated whereby an additional 1,500,000 shares of common stock and 100,000 shares of Series A Preferred Stock were added to the plan for future issuance (the “A&R Plan”). During 2018, an additional 200,000 shares of Series A Preferred Stock were added to the A&R Plan for future issuance. In May 2020, an additional 2,000,000 shares of common stock and an additional 300,000 shares of Series A Preferred Stock were added to the A&R Plan for future issuance. During 2022, an additional 1,000,000 shares of common stock and 200,000 shares of Series B Preferred Stock were added to the A&R Plan for future issuance. As of December 31, 2024, 499,683 shares of common stock, 33,769 shares of Series A Preferred Stock and 16,000 shares of Series B Preferred Stock are available for grant. Permissible awards include incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, RSUs, performance stock and cash-settled awards and other stock-based awards in the discretion of the Compensation Committee of the Board of Directors including unrestricted stock grants.

     

    The equity based RSUs contain a provision in which the units shall immediately vest and become converted into common shares at the rate of one common share per RSU, immediately after a change in control, as defined in the award agreement.

     

    Common stock

     

    During 2024, 226,894 RSUs of common stock were granted to employees and independent contractors to vest at different dates during the years 2024 through 2026. Included therein were 30,000 RSUs of common stock granted over two years equally to each of the five outside members of the Board of Directors with 25% of the shares vesting every six months. During 2023, 1,098,976 RSUs of common stock were granted to employees and independent contractors to vest at different dates during the years 2023 through 2025. Included therein were 30,000 RSUs of common stock granted over two years equally to each of the five outside members of the Board of Directors with 25% of the shares vesting every six months.

     

    During December 2022, it was agreed that certain bonuses to employees of medSR that were originally going to be paid in cash would be paid in common stock. The change of paying the bonuses in common stock resulted in approximately 135,000 shares being issued in February 2023. This change resulted in approximately $404,000 of stock compensation expense, which offset the amounts previously accrued.

     

     

    The following table summarizes the RSU and restricted stock transactions related to the common and Preferred Stock under the A&R Plan for the years ended December 31, 2024 and 2023:

     

       Common Stock   Series A Preferred Stock   Series B Preferred Stock 
                 
    Outstanding and unvested shares at January 1, 2024   753,495    -    57,199 
    Granted   226,894    -    46,000 
    Vested   (513,190)   -    (60,000)
    Forfeited   (224,699)            -    (24,000)
    Outstanding and unvested shares at December 31, 2024   242,500    -    19,199 
                    
    Outstanding and unvested shares at January 1, 2023   645,475    -    80,462 
    Granted   1,098,976    -    62,000 
    Vested   (896,893)   -    (85,263)
    Forfeited   (94,063)   -    - 
    Outstanding and unvested shares at December 31, 2023   753,495    -    57,199 

     

    As of December 31, 2024 and 2023, there was approximately $416,000 and $1.3 million, respectively, of total unrecognized compensation cost related to the common stock RSUs classified as equity that will be expensed through 2026. As of December 31, 2024, there was no unrecognized compensation cost as compared to approximately $351,000 of total unrecognized compensation cost as of December 31, 2023 related to the Series B Preferred Stock RSUs classified as equity that was expensed through the following year. There was no unrecognized compensation cost related to the Series A Preferred Stock RSUs for both the years ended December 31, 2024 and 2023.

     

    Of the total outstanding and unvested common stock RSUs at December 31, 2024, 242,500 are classified as equity and at December 31 2023, 733,908 RSUs are classified as equity and 19,587 RSUs are classified as a liability. For both 2024 and 2023, all of the Preferred Stock RSUs are classified as equity.

     

    The following table summarizes the share activity during the years ended December 31, 2024 and 2023 and the amount of common and preferred shares available for grant at December 31, 2024 and 2023:

     

       Common Stock   Series A Preferred Stock   Series B Preferred Stock 
                 
    Shares available for grant at January 1, 2024   493,579    33,769    38,000 
    RSUs granted   (226,894)   -    (46,000)
    RSUs forfeited   232,998    -    24,000 
    Shares available for grant at December 31, 2024   499,683    33,769    16,000 
                    
    Shares available for grant at January 1, 2023   1,498,492    33,769    100,000 
    RSUs granted   (1,098,976)   -    (62,000)
    RSUs forfeited   94,063    -    - 
    Shares available for grant at December 31, 2023   493,579    33,769    38,000 

     

    The liability for the cash-settled awards and accrued payroll taxes on equity awards was approximately $6,000 and $767,000 at December 31, 2024 and 2023, respectively, and is included in accrued compensation in the consolidated balance sheets. During the years ended December 31, 2024 and 2023, approximately $45,000 and $19,000, respectively, were paid in connection with the cash-settled awards.

     

    Preferred Stock

     

    In February 2023, the Compensation Committee granted executive bonuses to be paid in 34,000 shares of Series B Preferred Stock, with the number of shares and the amount based on specified criteria being achieved during the year 2023. During October 2023, the Compensation Committee approved for issuance 10,000 of the above shares to one of the executives who retired. The remaining shares were not issued and previously accrued amounts were reversed during 2024.

     

    In March 2024, the Compensation Committee approved executive bonuses to be paid in shares of Series B Preferred Stock with the number of shares and the amount based on specified criteria being achieved for the year 2024. There were 34,000 shares awarded. During May 2024, an additional executive bonus with similar terms was approved and 12,000 shares were awarded. During December 2024, the Compensation Committee determined that the financial objectives were attained and all of the performance bonus shares were issued.

     

     

    Stock-based compensation expense

     

    The Company recognizes compensation expense on a straight-line basis over the total requisite service period for the entire award. For stock awards classified as equity, the market price of our common stock or Preferred Stock on the date of grant is used to record the fair value of the award and includes the related taxes. For stock awards classified as a liability, the earned amount is marked to market based on the end of period common stock price. The weighted average grant date fair value of the common stock price in connection with the RSUs classified as equity was $2.16 and $3.40 for the years ended December 31, 2024 and 2023, respectively. For the Series B Preferred Stock, the weighted average grant date fair value was $6.33 and $25.07 for the years ended December 31, 2024 and 2023, respectively. The following table summarizes the components of stock-based compensation expense for the years ended December 31, 2024 and 2023:

     

       Year Ended December 31, 
    Stock-based compensation included in the consolidated statements of operations:  2024   2023 
       ($ in thousands) 
    Direct operating costs  $(27)  $891 
    General and administrative   72    2,835 
    Research and development   (4)   135 
    Selling and marketing   74    855 
    Lease terminations, unoccupied lease charges and restructuring costs   -    170 
    Total stock-based compensation expense  $115   $4,886 

     
    XML 52 R27.htm IDEA: XBRL DOCUMENT v3.25.1
    INCOME TAXES
    		 12 Months Ended
    Dec. 31, 2024
    Income Tax Disclosure [Abstract]  
    INCOME TAXES

    16. INCOME TAXES

     

    For the years ended December 31, 2024 and 2023, the Company estimated its income tax provision based upon the annual pre-tax income or loss. Although the Company reported GAAP earnings in 2024, it incurred losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all federal and state deferred tax assets as of December 31, 2024 and 2023.

     

    The annual adjusted earnings and profits of our foreign affiliates pass through to the U.S. as federal and state taxable income under the Global Intangible Low-Taxed Income (“GILTI”) regime. For the tax years ended December 31, 2024 and 2023, the net GILTI from our foreign affiliates was absorbed against our current year U.S. consolidated loss. For state tax purposes, the Company’s foreign earnings may be taxable depending on each individual state’s legislative stance on the recent tax reform legislation. The activity in the deferred tax valuation allowance was as follows for the years ended December 31, 2024 and 2023:

     

       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Beginning balance  $87,597   $92,091 
    Current year valuation allowance increase (decrease)   2,067    (4,494)
    Ending balance  $89,664   $87,597 

     

    The income (loss) before provision (benefit) for income taxes for financial reporting purposes during the years ended December 31, 2024 and 2023 consisted of the following:

     

       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    United States  $7,191   $(48,985)
    Foreign   820    (53)
    Total  $8,011   $(49,038)

     

     

    The provision (benefit) for income taxes for the years ended December 31, 2024 and 2023 consisted of the following:

     

       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Current:          
    Federal  $-   $- 
    State   120    123 
    Foreign   40    38 
       160    161 
    Deferred:          
    Federal   -    (252)
    State   -    (273)
       -    (525)
    Total income tax provision (benefit)  $160   $(364)

     

    The components of the Company’s deferred income taxes as of December 31, 2024 and 2023 are as follows:

     

       December 31,   December 31, 
       2024   2023 
       ($ in thousands) 
    Deferred tax assets:          
    Allowance for expected credit losses  $213   $228 
    Deferred revenue   103    68 
    Property and intangible assets   3,015    1,933 
    State net operating loss (“NOL”) carryforwards   20,981    19,749 
    Federal net operating loss (“NOL”) carryforwards   55,569    57,562 
    Section 163(j) interest limitation   1,669    2,731 
    Stock based compensation   (173)   - 
    ASC 842 - ROU asset   (559)   (1,026)
    Prepaid commissions   (267)   (303)
    Cumulative balance translation adjustment   1,015    988 
    Section 267 limitation   6    6 
    Credit carryovers   2,498    2,498 
    ASC 842 - Lease liability   558    1,031 
    Accrued compensation   86    80 
    Other   (46)   (59)
    Section 174 costs   4,996    3,799 
    Valuation allowance   (89,664)   (87,597)
    Total deferred tax assets   -    1,688 
    Deferred tax liabilities:          
    Goodwill amortization   -    (1,688)
    Net deferred tax liability  $-   $- 

     

    Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their tax bases, as well as from net operating loss carryforwards. Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years.

     

    The Company has recorded goodwill as a result of its acquisitions. Goodwill is generally not amortized for financial reporting purposes. However, in 2023 the Company recorded a $42 million goodwill impairment charge, which partially reduced the basis of the tax-deductible goodwill. For tax purposes, goodwill from asset acquisitions is tax deductible and amortized over 15 years. As such, deferred income tax expense and a deferred tax liability arise as a result of the tax-deductibility of this indefinitely lived asset (also known as a naked credit). Typically, the resulting deferred tax liability, which is expected to continue to increase over the amortization period, will have an indefinite life. As a result of the Company having indefinite life net operating losses under the recent tax reform legislation, the federal deferred tax liability resulting from the amortization of goodwill was offset against these indefinite federal operating net losses deferred tax assets to the extent allowable prior to 2023. As a result of the goodwill impairment charge in 2023, the entire deferred tax liability was reversed at that time and no additional deferred tax liability was recorded for 2024.

     

     

    A reconciliation of the federal statutory income tax rate (21%) to the Company’s effective income tax rate (determined in dollars) for the years ended December 31, 2024 and 2023 is as follows:

     

       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Federal provision (benefit) at statutory rate  $1,682   $(10,298)
    Increase (decrease) in income taxes resulting from:          
    State tax expense, net of federal benefit   94    7,383 
    Non-deductible items   30    26 
    Impact of foreign operations   (132)   50 
    Subpart F GILTI inclusion   1,066    804 
    Stock based compensation   (177)   18 
    Goodwill impairment charges   -    5,692 
    Deferred true-up   (2,708)   455 
    Valuation allowance   305    (4,494)
    Total income tax provision (benefit)  $160   $(364)

     

    At December 31, 2024 and 2023, the Company did not record any uncertain tax positions based on the technical merits. Therefore, a tabular roll forward was excluded and there has been no accrued interest and penalties. The Company is subject to taxation in the United States, various states, Pakistan and Sri Lanka. As of December 31, 2024, all tax years since 2014 remain open to examination due to the carryover of unused net operating losses and tax credits in the United States by major taxing jurisdictions in which the Company is subject to tax. IT companies in Pakistan are subject to a 0.25% tax deducted at the source on receipts received from foreign sources with no further tax being due. It is the Company’s policy that any assessed penalties and interest on uncertain tax positions would be charged to income tax expense.

     

    The Pakistan foreign receipts tax does not have a significant impact on the Company’s effective tax rate as all of its earnings in Pakistan have been fully included in the U.S. federal tax rate reconciliation at 21% for 2024 and 2023. The Pakistan statutory corporate tax rate is 29% before consideration of the aforementioned tax credit and the foreign receipts tax.

     

    As of December 31, 2024, the Company has a total federal NOL carry forward of approximately $265 million of which approximately $187 million will expire between 2031 and 2038, and the balance of approximately $78 million has an indefinite life. Out of the total federal NOL carry forward, approximately $237 million is from the CareCloud and Meridian acquisitions and is subject to the federal Section 382 NOL annual usage limitations. The Company has state NOL carry forwards of approximately $211 million, of which $84 million relates to the State of New Jersey. These NOLs expire starting in 2025.

     

    The Company has a full valuation allowance on its deferred tax assets in the U.S. which results in there being no U.S. deferred tax assets or liabilities recorded in the consolidated balance sheets at December 31, 2024 and 2023, respectively.

     
    XML 53 R28.htm IDEA: XBRL DOCUMENT v3.25.1
    OTHER EXPENSE – NET
    		 12 Months Ended
    Dec. 31, 2024
    Other Income and Expenses [Abstract]  
    OTHER EXPENSE – NET

    17. OTHER EXPENSE – NET

     

    Other expense - net for the years ended December 31, 2024 and 2023 consisted of the following:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Foreign exchange gains (losses)  $130   $(790)
    Other expense   (428)   (93)
    Other expense - net  $(298)  $(883)

     

    Foreign currency transaction gains and losses primarily result from transactions in foreign currencies other than the functional currency. These transaction gains and losses are recorded in the consolidated statements of operations related to the recurring measurement and settlement of such transactions. Other expense primarily represents legal settlements made by the Company.

     

     
    XML 54 R29.htm IDEA: XBRL DOCUMENT v3.25.1
    SEGMENT REPORTING
    		 12 Months Ended
    Dec. 31, 2024
    Segment Reporting [Abstract]  
    SEGMENT REPORTING

    18. SEGMENT REPORTING

     

    From January 1, 2023 through April 30, 2024, the Chief Executive Officer (“CEO”) and Executive Chairman served as the Chief Decision Maker (“CODM”), organizing the Company, managing resource allocations and measuring performance among two operating and reportable segments: (i) Healthcare IT and (ii) Medical Practice Management. As of May 1, 2024, the Company’s President, CEO and Executive Chairman served as the CODM. We report our segment information based on the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments.

     

    The CODM evaluates the financial performance of the business units on the basis of revenue, certain individual and total operating expenses and operating income (loss) excluding unallocated amounts, which are mainly corporate overhead costs, for assessing operating results and the allocation of resources. Our CODM does not evaluate operating segments using asset or liability information. The CODM uses segment revenue, certain segment operating expenses and segment operating income (loss) to manage the segments, comparing actual results to forecasted amounts and investigating the reasons for significant variances. Currently, a focus is being placed on reducing costs and managing global headcount. The segment revenue and segment operating income (loss) is also used to assess the performance of personnel and in establishing their compensation.

     

    The Healthcare IT segment includes technology-assisted revenue cycle management, SaaS solutions and professional and other services. The Medical Practice Management segment includes the management of three medical practices. Each segment is considered a reporting unit. The Company does not have intra-entity sales or asset transfers, however, there are intracompany bank transfers. The accounting policies of the segments are the same as those disclosed in the summary of significant accounting policies. The following tables present revenues, operating expenses and operating income (loss) by reportable segment for the years ended December 31, 2024 and 2023:

     

       Healthcare IT   Medical Practice Management    Total 
       Year Ended December 31, 2024 
       ($ in thousands) 
       Healthcare IT   Medical Practice Management    Total 
    Net revenue  $96,405   $14,432  (a)  $110,837 
    Operating expenses:                
    Direct operating costs   49,945    10,897     60,842 
    Selling and marketing   6,201    31     6,232 
    General and administrative   9,093    1,911     11,004 
    Research and development   3,781    -     3,781 
    Depreciation and amortization   13,813    329     14,142 
    Lease terminations, unoccupied lease charges and restructuring costs   596    -     596 
    Total operating expenses   83,429    13,168     96,597 
    Segment operating income  $12,976   $1,264    $14,240 
                     
    Reconciliation of profit or loss (segment profit/loss):                
    Unallocated corporate expenses             $(5,119)
    Net interest expense              (812)
    Other expenses              (298)
    Income before income taxes             $8,011 

     

    (a)This revenue represents fees based on our actual costs plus a percentage of the operating profit.

     

     

       Healthcare IT   Medical Practice Management     Total 
       Year Ended December 31, 2023 
       ($ in thousands) 
       Healthcare IT   Medical Practice Management     Total 
    Net revenue  $103,683   $13,376  (a)   $117,059 
    Operating expenses:                 
    Direct operating costs   60,319    10,498      70,817 
    Selling and marketing   9,614    36      9,650 
    General and administrative   10,992    1,854      12,846 
    Research and development   4,736    -      4,736 
    Depreciation and amortization   14,046    356      14,402 
    Goodwill impairment charges   42,000    -      42,000 
    Lease terminations, unoccupied lease charges and restructuring costs   1,105    -      1,105 
    Total operating expenses   142,812    12,744      155,556 
    Segment operating (loss) income  $(39,129)  $632     $(38,497)
                      
    Reconciliation of profit or loss (segment profit/loss):                 
    Unallocated corporate expenses              $(8,618)
    Net interest expense               (1,040)
    Other expenses               (883)
    Loss before income taxes              $(49,038)

     

    (a)This revenue represents fees based on our actual costs plus a percentage of the operating profit.

     
    XML 55 R30.htm IDEA: XBRL DOCUMENT v3.25.1
    FAIR VALUE OF FINANCIAL INSTRUMENTS
    		 12 Months Ended
    Dec. 31, 2024
    Fair Value Disclosures [Abstract]  
    FAIR VALUE OF FINANCIAL INSTRUMENTS

    19. FAIR VALUE OF FINANCIAL INSTRUMENTS

     

    Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgement associated with the inputs used to measure their value in one of the following three categories:

     

    Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. We held no Level 1 financial instruments at December 31, 2024 or 2023.

     

    Level 2: Quoted prices for similar instruments in active markets with inputs that are observable, either directly or indirectly. Our Level 2 financial instruments include notes payable which are carried at cost and approximate fair value since the interest rates being charged approximate market rates.

     

    Level 3: Unobservable inputs are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 instruments include the fair value of contingent consideration related to completed acquisitions. There was no contingent consideration recorded at December 31, 2024 and 2023.

     

    The following table provides the assets and liabilities carried at fair value measured on a non-recurring basis as of December 31, 2024 and 2023. Refer to Note 2 - Basis of Presentation and Significant Accounting Policies, for a description of the valuation techniques used to determine the fair value of the assets measured on a non-recurring basis in the table below:

     

       Fair Value Measurements at December 31, 2024    Expense for the year ended 
       Carrying Value   Level 1   Level 2   Level 3   December 31, 2024 
       ($ in thousands) 
    Goodwill - Healthcare IT  $19,186   $-   $-   $19,186   $- 

     

       Fair Value Measurements at December 31, 2023    Expense for the year ended 
       Carrying Value   Level 1   Level 2   Level 3   December 31, 2023 
        ($ in thousands)  
    Goodwill - Healthcare IT  $19,186   $-   $-   $19,186   $42,000 

     
    XML 56 R31.htm IDEA: XBRL DOCUMENT v3.25.1
    SUBSEQUENT EVENTS
    		 12 Months Ended
    Dec. 31, 2024
    Subsequent Events [Abstract]  
    SUBSEQUENT EVENTS

    20. SUBSEQUENT EVENTS

     

    In January 2025, the Company’s common stock shareholders approved an increase in the number of authorized common shares from 35 million to 85 million. An amended certificate of incorporation was filed by the Company. Also, in January 2025, the Company’s Board of Directors declared Preferred Stock dividends for January and February 2025, whereby the payment for these two months would be credited to the arrearage.

     

    In February 2025, the Company resumed monthly payment of the dividends on the Series A and B Preferred Stock, paying one month of dividends in arrears. The second monthly payment is scheduled to be paid in March 2025, which after the conversion as discussed below, will include dividends for the Series A Preferred Stock that were not converted and dividends for the Series B Preferred Stock.

     

    In March 2025, the Board of Directors elected to exercise its conversion rights, which provide for the conversion of each share of Series A Preferred Stock into 7.3358 shares of common stock, inclusive of all accumulated and unpaid dividends. Dividends on the converted Series A Preferred shares ceased to accrue as of the conversion date. Individual shareholders who, at the exchange date, owned at least 100,000 shares of Series A Preferred Stock did not have their shares automatically converted to common stock so long as they were held by the Company’s transfer agent, unless they consented to the conversion. There were approximately 985,000 shares of Series A Preferred Stock remaining after the Conversion. Also in March 2025, the Company announced that it will be delisting the Series A Preferred Stock from the Nasdaq Global Market.
    XML 57 R32.htm IDEA: XBRL DOCUMENT v3.25.1
    BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)
    		 12 Months Ended
    Dec. 31, 2024
    Accounting Policies [Abstract]  
    Principles of Consolidation

    Principles of Consolidation — The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the operating results and financial condition of CareCloud, its wholly-owned subsidiary CPM, its majority-owned subsidiary MTBC Pvt. Ltd, majority-owned subsidiary MTBC Bagh Pvt. Ltd, CCH (since January 2020), Meridian Medical Management (since June 2020), medSR (since June 2021) and the subsidiary in Sri Lanka. The non-controlling interests of MTBC Pvt. Ltd. and MTBC Bagh Pvt. Ltd. are inconsequential to the consolidated financial statements. All intercompany accounts and transactions have been eliminated in consolidation.

     

     
    Segment Reporting

    Segment Reporting — The Company views its operations as comprising two operating segments, Healthcare IT and Medical Practice Management. The chief operating decision maker (“CODM”) monitors and reviews financial information at these segment levels for assessing operating results and the allocation of resources.

     
    Use of Estimates

    Use of Estimates — The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include, but are not limited to: (1) impairment of goodwill and long-lived assets, (2) depreciable lives of assets, (3) allowance for expected credit losses, (4) estimates of variable consideration related to the contract asset, (5) fair value of identifiable purchased tangible and intangible assets, including determination of expected customer life, (6) stock-based compensation, and (7) estimating lease terms and incremental borrowing rates. Actual results could significantly differ from those estimates.

     
    Revenue Recognition

    Revenue Recognition — We derive revenue from five primary sources: (1) technology-enabled business solutions including revenue cycle management, (2) professional services, (3) printing and mailing services, (4) group purchasing services and (5) medical practice management services. All of our revenue arrangements are based on contracts with customers. Most of our contracts with customers contain single performance obligations, although certain contracts do contain multiple performance obligations where we perform more than one service for the same customer. We account for individual performance obligations separately if they are distinct within the context of the contract. For contracts where we provide multiple services such as where we perform multiple ancillary services, each service represents its own performance obligation. Selling or transaction prices are based on the contractual prices for each service at its stand-alone selling price.

     

    A five-step approach is applied in the recognition of revenue under ASC 606: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when we satisfy a performance obligation.

     

    Although we believe that our approach to estimates and judgments is reasonable, actual results could differ, and we may be exposed to increases or decreases in revenue that could be material. Our estimates of variable consideration may prove to be inaccurate, in which case we may have understated or overstated the revenue recognized in a reporting period. The amount of variable consideration recognized to date that remains subject to estimation is included within the contract asset within the consolidated balance sheet.

     

    Payment of invoices is due as specified in the underlying customer agreement, typically 30 days from the invoice date, which occurs on the date of transfer of control of the services to the customer. Since payment terms are less than a year, we have elected the practical expedient and do not assess whether a customer contract has a significant financing component.

     

    The Company’s revenue arrangements generally do not include a general right of refund for services provided (See Note 8, Revenue, for additional information).

     
    Direct Operating Costs

    Direct Operating Costs — Direct operating costs consist primarily of salaries and benefits related to personnel who provide services to clients and at our managed medical practices, claims processing costs, medical supplies at our managed practices and other direct costs related to the Company’s services. Costs associated with the implementation of new clients are expensed as incurred. The reported amounts of direct operating costs include allocated amounts for rent expense and overhead costs.

     
    Selling and Marketing Expenses

    Selling and Marketing Expenses — Selling and marketing expenses consist primarily of compensation and benefits, travel and advertising expenses and are expensed as incurred. The Company incurred approximately $2.9 million and $4.0 million of advertising costs for the years ended December 31, 2024 and 2023, respectively.

     
    Research and Development Expenses

    Research and Development Expenses — Research and development expenses consist primarily of personnel-related costs incurred performing market research, analyzing proposed products and developing new products.

     

     
    Internal-Use Software Costs

    Internal-Use Software Costs — The Company capitalizes certain development costs incurred in connection with its internal-use software. Costs incurred in the preliminary stages of development are expensed as incurred. Once an application has reached the development stage, internal and external costs, if direct, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable that the expenditures will result in additional functionality. Capitalized costs are recorded as part of intangible assets in the accompanying consolidated balance sheets. Maintenance and training costs are expensed as incurred. Internal use software is amortized on a straight line basis over its estimated useful life, generally three years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. During the years ended December 31, 2024 and 2023, the Company capitalized approximately $5.7 million and $8.6 million, respectively, primarily consisting of salaries and payroll-related costs of employees and consultants who devoted time to the development of internal-use software projects.

     
    Accounts Receivable

    Accounts Receivable — Accounts receivable are stated at their net realizable value. Accounts receivable are presented in the consolidated balance sheets net of an allowance for expected credit losses, which is established based on a lifetime estimated credit loss expected to occur for trade accounts receivable.

     
    Property and Equipment

    Property and Equipment — Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line basis over the estimated useful lives of the assets ranging from three to five years. Ordinary maintenance and repairs are expensed as incurred. Depreciation for computers is calculated over three years, while the remaining assets (except leasehold improvements) are depreciated over five years. The Company amortizes leasehold improvements over the lesser of the lease term or the remaining economic life of those assets. Generally, the lease term is the base lease term plus certain renewal option periods for which renewal is reasonably certain and for which failure to exercise the renewal option would result in an economic penalty to the Company.

     
    Intangible Assets

    Intangible Assets — Intangible assets include customer relationships, covenants not-to-compete acquired in connection with acquisitions, software purchase and development costs and trademarks acquired. Amortization for intangible assets related to revenue cycle management is recorded primarily using the double declining balance method over three to four years. Amortization for intangible assets related to the group purchasing organization and medical practice management is recorded on a straight line basis over four and twelve years, respectively.

     
    Evaluation of Long-Lived Assets

    Evaluation of Long-Lived Assets — The Company reviews its long-lived assets for impairment whenever changes in circumstances indicate that the carrying value of an asset may not be recoverable. If the sum of undiscounted expected future cash flows is less than the carrying amount of the asset group, the Company will recognize an impairment loss based on the fair value of the asset. There was no impairment of internal-use software costs, intangible assets, operating lease right of use assets or property and equipment during the years ended December 31, 2024 and 2023.

     
    Goodwill

    Goodwill — Goodwill consists of the excess of the purchase price over the fair value of identifiable net assets of businesses acquired. The Company tests goodwill for impairment annually as of October 31st, referred to as the annual test date. The goodwill impairment test for the Healthcare IT segment is performed using the discounted cash flow approach, the trading price of publicly traded stock and the guideline public company method. Conditions that could trigger a more frequent impairment assessment include, but are not limited to, a significant adverse change to the Company in certain agreements, significant underperformance relative to historical or projected future operating results, loss of customer relationships, an economic downturn in customers’ industries, or increased competition. Impairment testing for goodwill is performed at the reporting-unit level. The Company has determined that its business consists of two operating segments and two reporting units. The Company had a triggering event at August 31, 2023, but it was determined that no goodwill impairment existed at that time. The Company had an additional triggering event in December 2023. It was determined that the fair value of the Healthcare IT reporting unit was less than the carrying value at October 31 and at December 12, 2023 (triggering event). Accordingly, impairment charges of approximately $2.0 million and $40.0 million, respectively, were recorded. (See Note 3). No impairment charges were recorded during the year ended December 31, 2024.

     
    Treasury Stock

    Treasury Stock — Treasury stock is recorded at cost and represents shares repurchased by the Company. No shares were repurchased or issued from treasury stock during the years ended December 31, 2024 and 2023.

     
    Stock-Based Compensation

    Stock-Based Compensation — The Company recognizes compensation for all share-based payments granted based on the grant date fair value. Compensation expense is generally recognized on a straight-line basis over the vesting period. The Company does not estimate forfeitures in recognizing the expense for share-based payments, as historical forfeiture rates have not been significant. For restricted stock units (“RSUs”) classified as equity, the market price of our common stock on the date of grant is used in recording the fair value of the award. For RSUs classified as a liability, the earned amount is marked to market based on the end-of-period common stock price.

     

     
    Business Combinations

    Business Combinations — The Company accounts for business combinations under the provisions of ASC 805, Business Combinations, which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed are recorded at the date of acquisition at their respective fair values. ASC 805 also specifies criteria that intangible assets acquired in a business combination must be recognized and reported apart from goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date with changes in the fair value recorded through earnings.

     
    Income Taxes

    Income Taxes — The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date.

     

    The Company records net deferred tax assets to the extent that these assets will more likely than not be realized. All available positive and negative evidence is considered in making such a determination, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. A valuation allowance would be recorded to reduce deferred income tax assets when it is determined that it is more likely than not that the Company would not be able to realize its deferred income tax assets in the future in excess of their net recorded amount.

     

    The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is greater than 50 percent likely to be realized upon ultimate settlement with the related tax authority. At December 31, 2024 and 2023, the Company did not have any uncertain tax positions that required recognition. Interest and penalties related to uncertain tax positions are recognized in income tax expense. For the years ended December 31, 2024 and 2023, the Company did not recognize any penalties or interest related to unrecognized tax benefits in its consolidated financial statements.

     
    Dividends

    Dividends — Dividends are recorded when declared by the Company’s Board of Directors. The Board of Directors had declared monthly dividends on the Series A and Series B Preferred Stock through February 2024. However, in December 2023, the dividends on the Preferred Stock were suspended. The dividend scheduled for payment on December 15, 2023 together with the remaining dividends that were declared, have been accrued in the consolidated balance sheet. Future monthly dividends will continue to accrue in arrears but will not be recorded as a liability until declared by the Board of Directors. In January 2025, the Board of Director declared two months of suspended dividends. The Company resumed paying monthly dividends in February 2025, paying one month of arrears. In March 2025, the Company converted the majority of the Series A Preferred Stock into the Company’s common stock. The March 2025 dividend payment will include dividends for the Series A Preferred Stock that were not converted and dividends for the Series B Preferred Stock. (See Note 20). Preferred Stock dividends are charged against paid in capital because the Company does not have sufficient retained earnings. The Company is prohibited from paying dividends on its common stock without the prior written consent of its lender, Silicon Valley Bank, a division of First Citizens Bank (“SVB”).

     
    Deferred Revenue

    Deferred Revenue — Deferred revenue primarily consists of payments received in advance of the revenue recognition criteria being met. Deferred revenue includes certain deferred implementation services fees that are recognized as revenue ratably over the longer of the life of the agreement or the estimated expected customer life, which is currently estimated to be three years. Deferred revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue and the remaining portion is recorded as non-current. At the time of customer termination, any unrecognized service fees associated with implementation services are recognized as revenue.

     
    Fair Value Measurements

    Fair Value Measurements — ASC 820, Fair Value Measurement, requires the disclosure of fair value information about financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. The Company follows a fair value measurement hierarchy to measure financial instruments.

     

     

    The fair value of the Company’s financial instruments is measured using inputs from the three levels of the fair value hierarchy as follows:

     

      Level 1 — Inputs are unadjusted quoted market prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
           
      Level 2 — Inputs are directly or indirectly observable, which include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
           
      Level 3 — Inputs are unobservable inputs that are used to measure fair value to the extent observable inputs are not available.

     

    The Company has certain financial instruments that are not measured at fair value on a recurring basis. These financial instruments are subject to fair value adjustments only in certain circumstances and include cash, accounts receivable, accounts payable and accrued expenses, borrowings under term loans and line of credit, and notes payable. Due to the short term nature of these financial instruments and that the borrowings bear interest at prevailing market rates, the carrying value approximates the fair value.

     
    Foreign Currency Translation

    Foreign Currency Translation — The financial statements of the Company’s foreign subsidiaries are translated from their functional currency into U.S. dollars, the Company’s functional currency. All foreign currency assets and liabilities are translated at the period-end exchange rate, and all revenue and expenses are translated at transaction date exchange rates. The effects of translating the financial statements of the foreign subsidiaries into U.S. dollars are reported as a cumulative translation adjustment, a separate component of accumulated other comprehensive loss in the consolidated statements of shareholders’ equity, except for transactions related to the intercompany receivable for which transaction adjustments are recorded in the consolidated statements of operations as they are not deemed to be permanently reinvested. Foreign currency transaction gains/losses are reported as a component of other expense – net in the consolidated statements of operations and amounted to a gain of approximately $130,000 and a loss of approximately $790,000 for the years ended December 31, 2024 and 2023, respectively.

     
    Lease Terminations, Unoccupied Lease Charges and Restructuring Costs

    Lease Terminations, Unoccupied Lease Charges and Restructuring Costs — Lease terminations represents the write-off of leasehold improvements as the result of early lease terminations. Unoccupied lease charges represent the portion of lease and related costs for that portion of the space that is vacated and not being utilized by the Company. Restructuring costs incurred in 2024 and 2023 primarily consist of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements. (See Note 13).

     
    Recent Accounting Pronouncements

    Recent Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently adopted and recently issued accounting pronouncements will not have a material impact on our consolidated financial position, results of operations and cash flows.

     

    In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments. The guidance in Accounting Standards Update (“ASU”) 2016-13 replaces the incurred loss impairment methodology under current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. It will apply to all entities. For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate lifetime expected credit losses. This may result in the earlier recognition of credit losses. In November 2019, the FASB issued ASU No. 2019-10, which delayed this standard’s effective date for SEC smaller reporting companies to the fiscal years beginning on or after December 15, 2022. The Company adopted this guidance on January 1, 2023 using a modified retrospective adoption methodology, whereby the cumulative impact of all prior periods is recorded in accumulated deficit or other impacted balance sheet items upon adoption. The impact to the accumulated deficit as of January 1, 2023 for the allowance related to accounts receivable was a charge of approximately $186,000 and a corresponding increase to the allowance for expected credit losses.

     

     

    In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The amendments in this update require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. The amendments are effective for public business entities for fiscal years beginning after December 15, 2022. There was no impact on the consolidated financial statements as a result of this standard.

     

    In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842): Common Control Arrangements- Issue 2. The amendments in this update require that leasehold improvements associated with common control leases be: (1) amortized by the lessee over the useful life of the leasehold improvements to the common control group as long as the lessee controls the use of the underlying asset through a lease and (2) accounted for as a transfer between entities under common control through an adjustment to equity if, and when, the lessee no longer controls the use of the underlying asset. The amendments in this update are effective for the fiscal years beginning after December 15, 2023. There was no impact on the consolidated financial statements as a result of this standard.

     

    In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification. The new guidance is intended to align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP for all entities. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027 the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective.

     

    In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Disclosures. The amendments in this update improve segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The impact is only to the financial statement disclosures and has been adopted by the Company.

     

    In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures. The amendments in this update enhance the transparency and decision usefulness of income tax disclosures primarily related to rate reconciliation and income taxes paid information. The update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect this update to have a material impact on the consolidated financial statements.

     

    In March 2024, the FASB issued ASU 2024-02, Codification Improvements- Amendments to Remove References to the Concepts Statements. This update contains amendments to the Codification that remove references to various FASB Concepts Statements. These Codification updates are for technical corrections such as conforming amendments, clarifications to guidance, simplifications to wording or the structure of guidance and other minor improvements. The resulting amendments are referred to as Codification improvements. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company does not expect this update to have a material impact on the consolidated financial statements.

     

    In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40). This update contains amendments that require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. The amendments in this update are effective for public business entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The expected impact would only be to the financial statement disclosures.
    XML 58 R33.htm IDEA: XBRL DOCUMENT v3.25.1
    GOODWILL AND INTANGIBLE ASSETS – NET (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Goodwill and Intangible Assets Disclosure [Abstract]  
    SCHEDULE OF CHANGES TO CARRYING AMOUNT OF GOODWILL

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Beginning gross balance  $19,186   $61,186 
    Impairment charges   -    (42,000)
    Ending gross balance  $19,186   $19,186 
    SCHEDULE OF INTANGIBLE ASSETS ACTIVITY

    Below is a summary of intangible asset activity for the years ended December 31, 2024 and 2023:

     

       Customer   Capitalized   Other Intangible     
       Relationships   Software   Assets   Total 
       ($ in thousands) 
    COST                    
    Balance, January 1, 2024  $47,597   $29,379   $9,653   $86,629 
    Additions   -    5,709    -    5,709 
    Translation gain   -    20    -    20 
    Balance, December 31, 2024  $47,597   $35,108   $9,653   $92,358 
    Useful lives   3-12 years    3 years    3 years      
    ACCUMULATED AMORTIZATION                    
    Balance, January 1, 2024  $44,372   $12,237   $4,946   $61,555 
    Amortization expense   1,575    10,522    1    12,098 
    Translation gain   -    7    -    7 
    Balance, December 31, 2024   45,947    22,766    4,947    73,660 
    Net book value  $1,650   $12,342   $4,706   $18,698 
                         
    COST                    
    Balance, January 1, 2023  $47,597   $21,547   $9,651   $78,795 
    Additions   -    8,548    2    8,550 
    Translation loss   -    (716)   -    (716)
    Balance, December 31, 2023  $47,597   $29,379   $9,653   $86,629 
    Useful lives   3-12 years    3 years    3 years      
    ACCUMULATED AMORTIZATION                    
    Balance, January 1, 2023  $39,523   $4,932   $4,820   $49,275 
    Amortization expense   4,849    7,426    126    12,401 
    Translation loss   -    (121)   -    (121)
    Balance, December 31, 2023   44,372    12,237    4,946    61,555 
    Net book value  $3,225   $17,142   $4,707   $25,074 
    SCHEDULE OF INTANGIBLE ASSETS, FUTURE AMORTIZATION EXPENSE

    As of December 31, 2024, future amortization expense scheduled to be expensed is as follows:

     

    Years ending December 31,  ($ in thousands) 
    2025  $10,291 
    2026   5,911 
    2027   1,746 
    2028   300 
    2029   300 
    Thereafter   150 
    Total  $18,698 
    XML 59 R34.htm IDEA: XBRL DOCUMENT v3.25.1
    PROPERTY AND EQUIPMENT (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Property, Plant and Equipment [Abstract]  
    SCHEDULE OF PROPERTY AND EQUIPMENT

    Property and equipment consisted of the following:

     

       2024   2023 
       December 31, 
       2024   2023 
       ($ in thousands) 
    Computer equipment  $5,963   $5,510 
    Office furniture and equipment   2,342    1,985 
    Transportation equipment   1,185    1,129 
    Leasehold improvements   6,358    5,350 
    Assets not placed in service   164    - 
    Total property and equipment   16,012    13,974 
    Less accumulated depreciation   (10,722)   (8,657)
    Property and equipment – net  $5,290   $5,317 
    XML 60 R35.htm IDEA: XBRL DOCUMENT v3.25.1
    CONCENTRATIONS (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Risks and Uncertainties [Abstract]  
    SCHEDULE OF CONCENTRATION OF RISK, BY GEOGRAPHICAL RISKS FACTOR

     

       2024   2023 
       December 31, 
       2024   2023 
       ($ in thousands) 
    Current assets  $211   $806 
    Non-current assets   8,337    8,250 
    Assets   8,548    9,056 
    Current liabilities   (1,336)   (1,250)
    Non-current liabilities   (172)   (240)
    Net assets  $7,040   $7,566 
    XML 61 R36.htm IDEA: XBRL DOCUMENT v3.25.1
    NET LOSS PER COMMON SHARE (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Earnings Per Share [Abstract]  
    SCHEDULE OF RECONCILIATION OF WEIGHTED-AVERAGE SHARES OUTSTANDING FOR BASIC AND DILUTED NET LOSS PER COMMON SHARE

    The following table reconciles the weighted-average shares outstanding for basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
      

    ($ in thousands, except share and

    per share amounts)

    		 
    Basic and Diluted:          
    Net loss attributable to common shareholders  $(4,459)  $(64,348)
    Weighted-average common shares used to compute basic and diluted loss per share   16,146,975    15,669,472 
    Net loss attributable to common shareholders per share - basic and diluted  $(0.28)  $(4.11)
    XML 62 R37.htm IDEA: XBRL DOCUMENT v3.25.1
    DEBT (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Debt Disclosure [Abstract]  
    SCHEDULE OF MATURITIES OF LONG-TERM DEBT

    Maturities of the outstanding notes payable and other obligations as of December 31, 2024 are as follows:

     

    Year ending December 31,  Vehicle Financing Notes   Insurance Financing   Total 
       ($ in thousands) 
    2025  $11   $299   $310 
    2026   11    -    11 
    2027   8    -    8 
    2028             7    -    7 
    Total  $37   $299   $336 
    XML 63 R38.htm IDEA: XBRL DOCUMENT v3.25.1
    REVENUE (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Revenue from Contract with Customer [Abstract]  
    SCHEDULE OF DISAGGREGATION OF REVENUE

    The following table represents a disaggregation of revenue for the years ended December 31, 2024 and 2023:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Healthcare IT:          
    Technology-enabled business solutions  $73,672   $76,640 
    Professional services   18,202    23,022 
    Printing and mailing services   3,579    2,968 
    Group purchasing services   952    1,053 
    Medical Practice Management:          
    Medical practice management services   14,432    13,376 
    Total  $110,837   $117,059 
    SCHEDULE OF CHANGES IN ACCOUNTS RECEIVABLE, CONTRACT ASSET AND DEFERRED REVENUE

     

      

    Accounts

    Receivable - Net

    		  

    Contract

    Asset

    		  

    Deferred Revenue

    (current)

    		  

    Deferred Revenue

    (long term)

    		 
       ($ in thousands) 
    Balance as of January 1, 2024  $11,888   $5,094   $1,380   $256 
    Increase (decrease), net   886    (760)   (168)   131 
    Balance as of  December 31, 2024  $12,774   $4,334   $1,212   $387 
                         
    Balance as of January 1, 2023  $14,773   $4,399   $1,386   $342 
    (Decrease) increase, net   (2,885)   695    (6)   (86)
    Balance as of  December 31, 2023  $11,888   $5,094   $1,380   $256 
    SCHEDULE OF TRADE ALLOWANCE FOR DOUBTFUL ACCOUNTS

    Changes in the allowance for expected credit losses for trade accounts receivable are presented in the table below:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands)  
    Beginning balance  $879   $823 
    Adoption of ASC 326   -    186 
    Provision   334    454 
    Recoveries/adjustments   2    107 
    Write-offs   (378)   (691)
    Ending balance  $837   $879 
    XML 64 R39.htm IDEA: XBRL DOCUMENT v3.25.1
    LEASES (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Leases  
    SCHEDULE OF LEASE EXPENSE

    The components of lease expense were as follows:

      

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Operating lease cost  $2,451   $2,669 
    Short-term lease cost   4    - 
    Variable lease cost   28    32 
    Total - net lease cost  $2,483   $2,701 
    SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES

    Supplemental balance sheet information related to leases was as follows:

     

       December 31, 2024   December 31, 2023 
       ($ in thousands) 
    Operating leases:          
    Operating lease ROU assets, net  $3,133   $4,365 
               
    Current operating lease liabilities  $1,287   $1,888 
    Non-current operating lease liabilities   1,847    2,516 
    Total operating lease liabilities  $3,134   $4,404 
               
    Operating leases:          
    ROU assets  $5,125   $6,571 
    Asset lease expense   (1,994)   (2,152)
    Foreign exchange gain/(loss)   2    (54)
    ROU assets, net  $3,133   $4,365 
               
    Weighted average remaining lease term (in years):          
    Operating leases   5.0    4.5 
    Weighted average discount rate:          
    Operating leases   14.2%   13.3%
    SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES

    Supplemental cash flow and other information related to leases was as follows:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Cash paid for amounts included in the measurement of lease liabilities:          
    Operating cash flows from operating leases  $2,467   $3,244 
               
    ROU assets obtained in exchange for lease liabilities:          
    Operating leases, excluding terminations  $864   $1,682 
    SCHEDULE OF MATURITIES OF LEASE LIABILITIES

    Maturities of lease liabilities are as follows:

     

    Operating leases - Years ending December 31,  ($ in thousands) 
    2025  $1,601 
    2026   727 
    2027   557 
    2028   371 
    2029   193 
    Thereafter   1,240 
    Total lease payments   4,689 
    Less: imputed interest   (1,555)
    Total lease obligations   3,134 
    Less: current obligations   1,287 
    Long-term lease obligations  $1,847 
    XML 65 R40.htm IDEA: XBRL DOCUMENT v3.25.1
    RESTRUCTURING COSTS (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Restructuring and Related Activities [Abstract]  
    SCHEDULE OF RESTRUCTURING COSTS

    The following table summarizes restructuring costs for 2024 and 2023:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Severance and separation costs  $606   $439 
    Equity awards acceleration costs associated with severance   -    170 
    Other exit related costs   -    36 
    Total restructuring and other costs  $606   $645 
    SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS

    SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS

       Severance and separation costs   Equity awards acceleration costs  

    Other exit

    related costs

    		   Total restructuring and other costs 
       ($ in thousands) 
    Balance as of January 1, 2024  $145   $-   $26   $171 
    Additions   606    -    -    606 
    Payments and other adjustments   (751)   -    (26)   (777)
    Balance as of  December 31, 2024  $-   $-   $-   $- 
                         
    Balance as of January 1, 2023  $-   $-   $-   $- 
    Additions   439    170    36    645 
    Payments and other adjustments   (294)   (170)   (10)   (474)
    Balance as of  December 31, 2023  $145   $-   $26   $171 
    XML 66 R41.htm IDEA: XBRL DOCUMENT v3.25.1
    STOCK-BASED COMPENSATION (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Share-Based Payment Arrangement [Abstract]  
    DISCLOSURE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD

    The following table summarizes the RSU and restricted stock transactions related to the common and Preferred Stock under the A&R Plan for the years ended December 31, 2024 and 2023:

     

       Common Stock   Series A Preferred Stock   Series B Preferred Stock 
                 
    Outstanding and unvested shares at January 1, 2024   753,495    -    57,199 
    Granted   226,894    -    46,000 
    Vested   (513,190)   -    (60,000)
    Forfeited   (224,699)            -    (24,000)
    Outstanding and unvested shares at December 31, 2024   242,500    -    19,199 
                    
    Outstanding and unvested shares at January 1, 2023   645,475    -    80,462 
    Granted   1,098,976    -    62,000 
    Vested   (896,893)   -    (85,263)
    Forfeited   (94,063)   -    - 
    Outstanding and unvested shares at December 31, 2023   753,495    -    57,199 
    SCHEDULE OF SHARE-BASED COMPENSATION, RESTRICTED STOCK UNITS AWARD ACTIVITY

    The following table summarizes the share activity during the years ended December 31, 2024 and 2023 and the amount of common and preferred shares available for grant at December 31, 2024 and 2023:

     

       Common Stock   Series A Preferred Stock   Series B Preferred Stock 
                 
    Shares available for grant at January 1, 2024   493,579    33,769    38,000 
    RSUs granted   (226,894)   -    (46,000)
    RSUs forfeited   232,998    -    24,000 
    Shares available for grant at December 31, 2024   499,683    33,769    16,000 
                    
    Shares available for grant at January 1, 2023   1,498,492    33,769    100,000 
    RSUs granted   (1,098,976)   -    (62,000)
    RSUs forfeited   94,063    -    - 
    Shares available for grant at December 31, 2023   493,579    33,769    38,000 
    SCHEDULE OF EMPLOYEE SERVICE SHARE-BASED COMPENSATION, ALLOCATION OF RECOGNIZED PERIOD COSTS

     

       Year Ended December 31, 
    Stock-based compensation included in the consolidated statements of operations:  2024   2023 
       ($ in thousands) 
    Direct operating costs  $(27)  $891 
    General and administrative   72    2,835 
    Research and development   (4)   135 
    Selling and marketing   74    855 
    Lease terminations, unoccupied lease charges and restructuring costs   -    170 
    Total stock-based compensation expense  $115   $4,886 
    XML 67 R42.htm IDEA: XBRL DOCUMENT v3.25.1
    INCOME TAXES (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Income Tax Disclosure [Abstract]  
    SCHEDULE OF DEFERRED TAX VALUATION ALLOWANCE

       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Beginning balance  $87,597   $92,091 
    Current year valuation allowance increase (decrease)   2,067    (4,494)
    Ending balance  $89,664   $87,597 
    SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAX, DOMESTIC AND FOREIGN

    The income (loss) before provision (benefit) for income taxes for financial reporting purposes during the years ended December 31, 2024 and 2023 consisted of the following:

     

       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    United States  $7,191   $(48,985)
    Foreign   820    (53)
    Total  $8,011   $(49,038)
    SCHEDULE OF COMPONENTS OF INCOME TAX PROVISION (BENEFIT)

    The provision (benefit) for income taxes for the years ended December 31, 2024 and 2023 consisted of the following:

     

       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Current:          
    Federal  $-   $- 
    State   120    123 
    Foreign   40    38 
       160    161 
    Deferred:          
    Federal   -    (252)
    State   -    (273)
       -    (525)
    Total income tax provision (benefit)  $160   $(364)
    SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES

    The components of the Company’s deferred income taxes as of December 31, 2024 and 2023 are as follows:

     

       December 31,   December 31, 
       2024   2023 
       ($ in thousands) 
    Deferred tax assets:          
    Allowance for expected credit losses  $213   $228 
    Deferred revenue   103    68 
    Property and intangible assets   3,015    1,933 
    State net operating loss (“NOL”) carryforwards   20,981    19,749 
    Federal net operating loss (“NOL”) carryforwards   55,569    57,562 
    Section 163(j) interest limitation   1,669    2,731 
    Stock based compensation   (173)   - 
    ASC 842 - ROU asset   (559)   (1,026)
    Prepaid commissions   (267)   (303)
    Cumulative balance translation adjustment   1,015    988 
    Section 267 limitation   6    6 
    Credit carryovers   2,498    2,498 
    ASC 842 - Lease liability   558    1,031 
    Accrued compensation   86    80 
    Other   (46)   (59)
    Section 174 costs   4,996    3,799 
    Valuation allowance   (89,664)   (87,597)
    Total deferred tax assets   -    1,688 
    Deferred tax liabilities:          
    Goodwill amortization   -    (1,688)
    Net deferred tax liability  $-   $- 
    SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION

    A reconciliation of the federal statutory income tax rate (21%) to the Company’s effective income tax rate (determined in dollars) for the years ended December 31, 2024 and 2023 is as follows:

     

       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Federal provision (benefit) at statutory rate  $1,682   $(10,298)
    Increase (decrease) in income taxes resulting from:          
    State tax expense, net of federal benefit   94    7,383 
    Non-deductible items   30    26 
    Impact of foreign operations   (132)   50 
    Subpart F GILTI inclusion   1,066    804 
    Stock based compensation   (177)   18 
    Goodwill impairment charges   -    5,692 
    Deferred true-up   (2,708)   455 
    Valuation allowance   305    (4,494)
    Total income tax provision (benefit)  $160   $(364)
    XML 68 R43.htm IDEA: XBRL DOCUMENT v3.25.1
    OTHER EXPENSE – NET (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Other Income and Expenses [Abstract]  
    SCHEDULE OF OTHER (EXPENSE) INCOME - NET

    Other expense - net for the years ended December 31, 2024 and 2023 consisted of the following:

     

       2024   2023 
       Year Ended December 31, 
       2024   2023 
       ($ in thousands) 
    Foreign exchange gains (losses)  $130   $(790)
    Other expense   (428)   (93)
    Other expense - net  $(298)  $(883)
    XML 69 R44.htm IDEA: XBRL DOCUMENT v3.25.1
    SEGMENT REPORTING (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Segment Reporting [Abstract]  
    SCHEDULE OF REVENUES, OPERATING EXPENSES AND OPERATING INCOME (LOSS) BY REPORTABLE SEGMENT

     

       Healthcare IT   Medical Practice Management    Total 
       Year Ended December 31, 2024 
       ($ in thousands) 
       Healthcare IT   Medical Practice Management    Total 
    Net revenue  $96,405   $14,432  (a)  $110,837 
    Operating expenses:                
    Direct operating costs   49,945    10,897     60,842 
    Selling and marketing   6,201    31     6,232 
    General and administrative   9,093    1,911     11,004 
    Research and development   3,781    -     3,781 
    Depreciation and amortization   13,813    329     14,142 
    Lease terminations, unoccupied lease charges and restructuring costs   596    -     596 
    Total operating expenses   83,429    13,168     96,597 
    Segment operating income  $12,976   $1,264    $14,240 
                     
    Reconciliation of profit or loss (segment profit/loss):                
    Unallocated corporate expenses             $(5,119)
    Net interest expense              (812)
    Other expenses              (298)
    Income before income taxes             $8,011 

     

    (a)This revenue represents fees based on our actual costs plus a percentage of the operating profit.

     

     

       Healthcare IT   Medical Practice Management     Total 
       Year Ended December 31, 2023 
       ($ in thousands) 
       Healthcare IT   Medical Practice Management     Total 
    Net revenue  $103,683   $13,376  (a)   $117,059 
    Operating expenses:                 
    Direct operating costs   60,319    10,498      70,817 
    Selling and marketing   9,614    36      9,650 
    General and administrative   10,992    1,854      12,846 
    Research and development   4,736    -      4,736 
    Depreciation and amortization   14,046    356      14,402 
    Goodwill impairment charges   42,000    -      42,000 
    Lease terminations, unoccupied lease charges and restructuring costs   1,105    -      1,105 
    Total operating expenses   142,812    12,744      155,556 
    Segment operating (loss) income  $(39,129)  $632     $(38,497)
                      
    Reconciliation of profit or loss (segment profit/loss):                 
    Unallocated corporate expenses              $(8,618)
    Net interest expense               (1,040)
    Other expenses               (883)
    Loss before income taxes              $(49,038)

     

    (a)This revenue represents fees based on our actual costs plus a percentage of the operating profit.
    XML 70 R45.htm IDEA: XBRL DOCUMENT v3.25.1
    FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
    		 12 Months Ended
    Dec. 31, 2024
    Fair Value Disclosures [Abstract]  
    FAIR VALUE OF THE ASSETS MEASURED ON A NON-RECURRING BASIS

    The following table provides the assets and liabilities carried at fair value measured on a non-recurring basis as of December 31, 2024 and 2023. Refer to Note 2 - Basis of Presentation and Significant Accounting Policies, for a description of the valuation techniques used to determine the fair value of the assets measured on a non-recurring basis in the table below:

     

       Fair Value Measurements at December 31, 2024    Expense for the year ended 
       Carrying Value   Level 1   Level 2   Level 3   December 31, 2024 
       ($ in thousands) 
    Goodwill - Healthcare IT  $19,186   $-   $-   $19,186   $- 

     

       Fair Value Measurements at December 31, 2023    Expense for the year ended 
       Carrying Value   Level 1   Level 2   Level 3   December 31, 2023 
        ($ in thousands)  
    Goodwill - Healthcare IT  $19,186   $-   $-   $19,186   $42,000 
    XML 71 R46.htm IDEA: XBRL DOCUMENT v3.25.1
    ORGANIZATION AND BUSINESS (Details Narrative)
    Apr. 01, 2022
    Dec. 31, 2004
    MTBC Private Limited [Member]    
    Equity method investment ownership, percentage   99.90%
    MTBC Private Limited [Member] | Founder and Executive Chairman [Member]    
    Equity method investment ownership, percentage   0.10%
    MTBC Bagh Private Limited [Member]    
    Equity method investment ownership, percentage 99.80%  
    MTBC Bagh Private Limited [Member] | Founder and Executive Chairman [Member]    
    Equity method investment ownership, percentage 0.20%  
    XML 72 R47.htm IDEA: XBRL DOCUMENT v3.25.1
    BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
    		 12 Months Ended
    Dec. 12, 2023
    USD ($)
    Oct. 31, 2023
    USD ($)
    Aug. 31, 2023
    USD ($)
    Dec. 31, 2024
    USD ($)
    Segment
    shares
    Dec. 31, 2023
    USD ($)
    shares
    Jan. 01, 2023
    USD ($)
    Property, Plant and Equipment [Line Items]            
    Number of operating segments | Segment       2    
    Advertising costs       $ 2,900,000 $ 4,000,000.0  
    Internal-use software costs capitalized       5,700,000 8,600,000  
    Impairment charges       $ 0 0  
    Number of reportable units | Segment       2    
    Goodwill impairment charges     $ 0 42,000,000  
    Foreign exchange (gain) losses       $ (130,000) $ 790,000  
    Allowance for expected credit losses           $ 186,000
    Treasury Stock, Common [Member]            
    Property, Plant and Equipment [Line Items]            
    Shares repurchased | shares       0 0  
    Healthcare IT [Member]            
    Property, Plant and Equipment [Line Items]            
    Goodwill impairment charges $ 40,000,000.0 $ 2,000,000.0        
    Minimum [Member]            
    Property, Plant and Equipment [Line Items]            
    Property and equipment, estimated useful lives       3 years    
    Minimum [Member] | Revenue Cycle Management [Member]            
    Property, Plant and Equipment [Line Items]            
    Intangible assets, estimated useful lives       3 years    
    Minimum [Member] | Group Purchasing Organization and Medical Practice Management [Member]            
    Property, Plant and Equipment [Line Items]            
    Intangible assets, estimated useful lives       4 years    
    Minimum [Member] | Computer Equipment [Member]            
    Property, Plant and Equipment [Line Items]            
    Property and equipment, estimated useful lives       3 years    
    Maximum [Member]            
    Property, Plant and Equipment [Line Items]            
    Property and equipment, estimated useful lives       5 years    
    Maximum [Member] | Revenue Cycle Management [Member]            
    Property, Plant and Equipment [Line Items]            
    Intangible assets, estimated useful lives       4 years    
    Maximum [Member] | Group Purchasing Organization and Medical Practice Management [Member]            
    Property, Plant and Equipment [Line Items]            
    Intangible assets, estimated useful lives       12 years    
    XML 73 R48.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF CHANGES TO CARRYING AMOUNT OF GOODWILL (Details) - USD ($)
    		 12 Months Ended
    Aug. 31, 2023
    Dec. 31, 2024
    Dec. 31, 2023
    Goodwill and Intangible Assets Disclosure [Abstract]      
    Beginning gross balance   $ 19,186,000 $ 61,186,000
    Impairment charges $ 0 (42,000,000)
    Ending gross balance   $ 19,186,000 $ 19,186,000
    XML 74 R49.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF INTANGIBLE ASSETS ACTIVITY (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Finite-Lived Intangible Assets [Line Items]    
    Cost, beginning balance $ 86,629 $ 78,795
    Cost, additions 5,709 8,550
    Cost, translation gain (loss) 20 (716)
    Cost, ending balance 92,358 86,629
    Accumulated amortization, beginning balance 61,555 49,275
    Accumulated amortization, amortization expense 12,098 12,401
    Accumulated amortization, translation gain (loss) 7 (121)
    Accumulated amortization, ending balance 73,660 61,555
    Net book value 18,698 25,074
    Customer Relationships [Member]    
    Finite-Lived Intangible Assets [Line Items]    
    Cost, beginning balance 47,597 47,597
    Cost, additions
    Cost, translation gain (loss)
    Cost, ending balance 47,597 47,597
    Accumulated amortization, beginning balance 44,372 39,523
    Accumulated amortization, amortization expense 1,575 4,849
    Accumulated amortization, translation gain (loss)
    Accumulated amortization, ending balance 45,947 44,372
    Net book value $ 1,650 $ 3,225
    Customer Relationships [Member] | Minimum [Member]    
    Finite-Lived Intangible Assets [Line Items]    
    Useful lives 3 years 3 years
    Customer Relationships [Member] | Maximum [Member]    
    Finite-Lived Intangible Assets [Line Items]    
    Useful lives 12 years 12 years
    Capitalized Software [Member]    
    Finite-Lived Intangible Assets [Line Items]    
    Cost, beginning balance $ 29,379 $ 21,547
    Cost, additions 5,709 8,548
    Cost, translation gain (loss) 20 (716)
    Cost, ending balance $ 35,108 $ 29,379
    Useful lives 3 years 3 years
    Accumulated amortization, beginning balance $ 12,237 $ 4,932
    Accumulated amortization, amortization expense 10,522 7,426
    Accumulated amortization, translation gain (loss) 7 (121)
    Accumulated amortization, ending balance 22,766 12,237
    Net book value 12,342 17,142
    Other Intangible Assets [Member]    
    Finite-Lived Intangible Assets [Line Items]    
    Cost, beginning balance 9,653 9,651
    Cost, additions 2
    Cost, translation gain (loss)
    Cost, ending balance $ 9,653 $ 9,653
    Useful lives 3 years 3 years
    Accumulated amortization, beginning balance $ 4,946 $ 4,820
    Accumulated amortization, amortization expense 1 126
    Accumulated amortization, translation gain (loss)
    Accumulated amortization, ending balance 4,947 4,946
    Net book value $ 4,706 $ 4,707
    XML 75 R50.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF INTANGIBLE ASSETS, FUTURE AMORTIZATION EXPENSE (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2024
    Dec. 31, 2023
    Goodwill and Intangible Assets Disclosure [Abstract]    
    2025 $ 10,291  
    2026 5,911  
    2027 1,746  
    2028 300  
    2029 300  
    Thereafter 150  
    Total $ 18,698 $ 25,074
    XML 76 R51.htm IDEA: XBRL DOCUMENT v3.25.1
    GOODWILL AND INTANGIBLE ASSETS – NET (Details Narrative) - USD ($)
    		 12 Months Ended
    Dec. 12, 2023
    Oct. 31, 2023
    Aug. 31, 2023
    Dec. 31, 2024
    Dec. 31, 2023
    Dec. 31, 2022
    Indefinite-Lived Intangible Assets [Line Items]            
    Goodwill       $ 19,186,000 $ 19,186,000 $ 61,186,000
    Goodwill impairment charges     $ 0 42,000,000  
    Amortization expense       $ 12,100,000 12,400,000  
    Weighted-average amortization period       3 years    
    Medical Practice Management Segment [Member]            
    Indefinite-Lived Intangible Assets [Line Items]            
    Goodwill       $ 90,000 $ 90,000  
    Healthcare IT [Member]            
    Indefinite-Lived Intangible Assets [Line Items]            
    Goodwill impairment charges $ 40,000,000.0 $ 2,000,000.0        
    XML 77 R52.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2024
    Dec. 31, 2023
    Property, Plant and Equipment [Line Items]    
    Total property and equipment $ 16,012 $ 13,974
    Less accumulated depreciation (10,722) (8,657)
    Property and equipment – net 5,290 5,317
    Computer Equipment [Member]    
    Property, Plant and Equipment [Line Items]    
    Total property and equipment 5,963 5,510
    Office Furniture and Equipment [Member]    
    Property, Plant and Equipment [Line Items]    
    Total property and equipment 2,342 1,985
    Transportation Equipment [Member]    
    Property, Plant and Equipment [Line Items]    
    Total property and equipment 1,185 1,129
    Leasehold Improvements [Member]    
    Property, Plant and Equipment [Line Items]    
    Total property and equipment 6,358 5,350
    Assets not Placed in Service [Member]    
    Property, Plant and Equipment [Line Items]    
    Total property and equipment $ 164
    XML 78 R53.htm IDEA: XBRL DOCUMENT v3.25.1
    PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Property, Plant and Equipment [Abstract]    
    Depreciation expense $ 2.0 $ 2.0
    XML 79 R54.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF CONCENTRATION OF RISK, BY GEOGRAPHICAL RISKS FACTOR (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2024
    Dec. 31, 2023
    Current assets $ 24,800 $ 23,243
    Assets 71,614 77,826
    Current liabilities (19,580) (23,300)
    Non-US [Member]    
    Current assets 211 806
    Non-current assets 8,337 8,250
    Assets 8,548 9,056
    Current liabilities (1,336) (1,250)
    Non-current liabilities (172) (240)
    Net assets $ 7,040 $ 7,566
    XML 80 R55.htm IDEA: XBRL DOCUMENT v3.25.1
    CONCENTRATIONS (Details Narrative) - USD ($)
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Concentration Risk [Line Items]    
    Offshore bank accounts $ 119,000 $ 255,000
    Non-US [Member]    
    Concentration Risk [Line Items]    
    Net assets 7,040,000 7,566,000
    Intercompany receivables $ 2,200,000 $ 1,000,000.0
    Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
    Concentration Risk [Line Items]    
    Concentration risk percentage 7.00% 7.00%
    Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
    Concentration Risk [Line Items]    
    Concentration risk percentage 7.00% 7.00%
    One Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]    
    Concentration Risk [Line Items]    
    Concentration risk percentage 10.00% 9.00%
    XML 81 R56.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF RECONCILIATION OF WEIGHTED-AVERAGE SHARES OUTSTANDING FOR BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) - USD ($)
    $ / shares in Units, $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Earnings Per Share [Abstract]    
    Net loss attributable to common shareholders - basic $ (4,459) $ (64,348)
    Net loss attributable to common shareholders - diluted $ (4,459) $ (64,348)
    Weighted-average common shares used to compute basic loss per share 16,146,975 15,669,472
    Weighted-average common shares used to compute diluted loss per share 16,146,975 15,669,472
    Net loss attributable to common shareholders per share - basic $ (0.28) $ (4.11)
    Net loss attributable to common shareholders per share - diluted $ (0.28) $ (4.11)
    XML 82 R57.htm IDEA: XBRL DOCUMENT v3.25.1
    NET LOSS PER COMMON SHARE (Details Narrative) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Restricted Stock Units (RSUs) [Member]    
    Anti-dilutive shares 242,500 733,908
    Preferred Stock [Member]    
    Preferred stock dividend amount $ 12.3  
    XML 83 R58.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF MATURITIES OF LONG-TERM DEBT (Details)
    $ in Thousands
    Dec. 31, 2024
    USD ($)
    Debt Instrument [Line Items]  
    2025 $ 310
    2026 11
    2027 8
    2028 7
    Total 336
    Vehicle Financing Notes [Member]  
    Debt Instrument [Line Items]  
    2025 11
    2026 11
    2027 8
    2028 7
    Total 37
    Insurance Financing [Member]  
    Debt Instrument [Line Items]  
    2025 299
    2026
    2027
    2028
    Total $ 299
    XML 84 R59.htm IDEA: XBRL DOCUMENT v3.25.1
    DEBT (Details Narrative) - USD ($)
    		 1 Months Ended 3 Months Ended 12 Months Ended
    Aug. 31, 2023
    Feb. 28, 2023
    Oct. 31, 2017
    Sep. 30, 2021
    Sep. 30, 2018
    Dec. 31, 2024
    Oct. 30, 2024
    Sep. 30, 2024
    Apr. 01, 2024
    Mar. 31, 2024
    Dec. 31, 2023
    Aug. 30, 2023
    Debt Instrument [Line Items]                        
    Lline of credit                   $ 10,000,000  
    Line of credit, remaining borrowing base           10,000,000.0            
    Offshore bank accounts           $ 119,000         $ 255,000  
    Insurance Financing [Member]                        
    Debt Instrument [Line Items]                        
    Debt interest rate           7.49%            
    SVB Debt Agreement [Member]                        
    Debt Instrument [Line Items]                        
    Upfront fees     $ 50,000                  
    Warrants to purchase     125,000                  
    Payments for annual anniversary fee     $ 50,000                  
    Warrant strike price     $ 3.92                  
    Warrants term     5 years                  
    Warrants price per share     $ 3.12                  
    Line of credit facility commitment fee amount           $ 44,000            
    SVB Debt Agreement [Member] | Additional Warrant [Member]                        
    Debt Instrument [Line Items]                        
    Warrants to purchase     28,489                  
    Warrant strike price     $ 5.26                  
    Warrants term     5 years                  
    Warrants price per share     $ 3.58                  
    Minimum [Member] | Vehicle Financing Notes [Member]                        
    Debt Instrument [Line Items]                        
    Debt Instrument, Term           3 years            
    Maximum [Member] | Vehicle Financing Notes [Member]                        
    Debt Instrument [Line Items]                        
    Debt Instrument, Term           6 years            
    SVB Credit Facility [Member]                        
    Debt Instrument [Line Items]                        
    Line of credit borrowing term     The SVB credit facility is a secured revolving line of credit where borrowings are based on a formula of 200% of repeatable revenue adjusted by an annualized attrition rate as defined in the credit agreement                  
    Increase revolving line of credit   $ 25,000,000   $ 20,000,000                
    Line of credit, term extension   term was extended for two years through October 13, 2025   term was extended for two years term was extended for an additional year              
    Line of credit facility, interest rate 2.00%               1.50% 2.00%   1.50%
    Minimum liquidity ratio reduction amendments expiry date Mar. 31, 2024                      
    Line of credit, description           There is also a fee of one-half of 1% annually for the unused portion of the credit line.            
    Percentage of shares in off shore facilities           65.00%            
    SVB Credit Facility [Member] | Ninth Loan Modification Agreement [Member]                        
    Debt Instrument [Line Items]                        
    Increase revolving line of credit             $ 10,000,000 $ 25,000,000        
    SVB Credit Facility [Member] | Minimum [Member]                        
    Debt Instrument [Line Items]                        
    Increase revolving line of credit     $ 5,000,000   $ 5,000,000              
    SVB Credit Facility [Member] | Maximum [Member]                        
    Debt Instrument [Line Items]                        
    Increase revolving line of credit         $ 10,000,000              
    XML 85 R60.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF DISAGGREGATION OF REVENUE (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Disaggregation of Revenue [Line Items]    
    Revenue $ 110,837 $ 117,059
    Healthcare IT [Member] | Technology Enabled Business Solutions [Member]    
    Disaggregation of Revenue [Line Items]    
    Revenue 73,672 76,640
    Healthcare IT [Member] | Professional Services [Member]    
    Disaggregation of Revenue [Line Items]    
    Revenue 18,202 23,022
    Healthcare IT [Member] | Printing and Mailing Services [Member]    
    Disaggregation of Revenue [Line Items]    
    Revenue 3,579 2,968
    Healthcare IT [Member] | Group Purchasing Services [Member]    
    Disaggregation of Revenue [Line Items]    
    Revenue 952 1,053
    Medical Practice Management [Member]    
    Disaggregation of Revenue [Line Items]    
    Revenue $ 14,432 $ 13,376
    XML 86 R61.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF CHANGES IN ACCOUNTS RECEIVABLE, CONTRACT ASSET AND DEFERRED REVENUE (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Revenue from Contract with Customer [Abstract]    
    Accounts Receivable - Net, Opening $ 11,888 $ 14,773
    Contract Assets, Opening 5,094 4,399
    Deferred Revenue (current), Opening 1,380 1,386
    Deferred Revenue (long term), Opening 256 342
    Accounts Receivable - Net, increase (decrease), net 886 (2,885)
    Contract Asset, (decrease) increase, net (760) 695
    Deferred Revenue (current), increase (decrease), net (168) (6)
    Deferred Revenue (long term), increase (decrease), net 131 (86)
    Accounts Receivable - Net, Closing 12,774 11,888
    Contract Assets, Closing 4,334 5,094
    Deferred Revenue (current), Closing 1,212 1,380
    Deferred Revenue (long term), Closing $ 387 $ 256
    XML 87 R62.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF TRADE ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Revenue from Contract with Customer [Abstract]    
    Beginning balance $ 879 $ 823
    Adoption of ASC 326 186
    Provision 334 454
    Recoveries/adjustments 2 107
    Write-offs (378) (691)
    Ending balance $ 837 $ 879
    XML 88 R63.htm IDEA: XBRL DOCUMENT v3.25.1
    REVENUE (Details Narrative) - USD ($)
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Jan. 01, 2023
    Disaggregation of Revenue [Line Items]      
    Revenue $ 110,837,000 $ 117,059,000  
    Deferred revenue 909,000 1,100,000  
    Amortization of deferred sales commissions 327,000 487,000  
    Accumulated deficit (66,630,000) (74,481,000)  
    Trade Accounts Receivable [Member] | Accounting Standards Update 2016-13 [Member]      
    Disaggregation of Revenue [Line Items]      
    Accumulated deficit     $ 186,000
    Other Noncurrent Assets [Member]      
    Disaggregation of Revenue [Line Items]      
    Deferred commissions 386,000 517,000  
    Chronic Care Management [Member]      
    Disaggregation of Revenue [Line Items]      
    Revenue 3,000,000.0 1,500,000  
    Remote Patient Monitoring [Member]      
    Disaggregation of Revenue [Line Items]      
    Revenue 779,000 400,000  
    Professional Services [Member] | Unbilled Revenues [Member]      
    Disaggregation of Revenue [Line Items]      
    Revenue 338,000 $ 100,000  
    Revenue Cycle Management [Member]      
    Disaggregation of Revenue [Line Items]      
    Revenue, remaining performance obligation, amount 3,500,000    
    Group Purchasing Services [Member]      
    Disaggregation of Revenue [Line Items]      
    Contract with customer asset 318,000    
    Referral Fees [Member]      
    Disaggregation of Revenue [Line Items]      
    Contract with customer asset $ 476,000    
    XML 89 R64.htm IDEA: XBRL DOCUMENT v3.25.1
    SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($)
    		 12 Months Ended
    Sep. 12, 2024
    Sep. 11, 2024
    Dec. 31, 2024
    Dec. 31, 2023
    Feb. 15, 2027
    Feb. 15, 2026
    Feb. 15, 2025
    Feb. 15, 2024
    Nov. 04, 2020
    Class of Stock [Line Items]                  
    Common shares held as treasury stock, shares     740,799 740,799          
    Common shares held as treasury stock, cost     $ 662,000 $ 662,000          
    Common stock, voting rights     Holders of our common stock are entitled to one vote for each share held on all matters properly submitted to a vote of shareholders on which holders of common stock are entitled to vote.            
    Preferred stock, shares authorized     7,000,000 7,000,000          
    Proceeds from issuance of Series B Preferred Stock, net of expenses     $ 1,427,000          
    Dividend, share-based payment arrangement, cash $ 1,100,000 $ 1,300,000 5,400,000            
    Dividends undeclared     12,300,000            
    Dividends in arrears     17,700,000            
    Issuance costs       $ 71,000          
    At The Market Facility [Member]                  
    Class of Stock [Line Items]                  
    Common stock available for sale     $ 50,000,000            
    Underwriter commission fees percentage     3.00%            
    Sale of stock, shares     0 0          
    Treasury Stock [Member]                  
    Class of Stock [Line Items]                  
    Stock repurchase program expiration date     Jan. 25, 2017            
    Preferred Stock [Member]                  
    Class of Stock [Line Items]                  
    Preferred stock, shares authorized     7,000,000            
    Warrant [Member]                  
    Class of Stock [Line Items]                  
    Warrants issued       6,603,489          
    Warrants expired unexercised       1,128,489          
    Warrant outstanding     0 0          
    Series A Preferred Stock [Member]                  
    Class of Stock [Line Items]                  
    Preferred stock dividend rate   8.75%              
    Preferred stock dividend amount per share   $ 2.1875              
    Preferred stock liquidation preference   $ 25             $ 25.00
    Preferred stock, shares authorized     4,560,000            
    Preferred stock, redemption price per share                 $ 25.00
    Preferred stock, dividend per share     $ 0 $ 2.75          
    Dividends in arrears, per share     3.04            
    Series A Preferred Stock [Member] | Certificate of Amendment [Member]                  
    Class of Stock [Line Items]                  
    Preferred stock dividend rate   11.00%              
    Preferred stock dividend amount per share   $ 2.75              
    Series B Preferred Stock [Member]                  
    Class of Stock [Line Items]                  
    Preferred stock, redemption price per share               $ 25.75  
    Preferred stock, dividend per share     0 $ 2.19          
    Dividends in arrears, per share     $ 2.55            
    Series B Preferred Stock [Member] | Forecast [Member]                  
    Class of Stock [Line Items]                  
    Preferred stock, redemption price per share         $ 25.00 $ 25.25      
    Series B Preferred Stock [Member] | Subsequent Event [Member]                  
    Class of Stock [Line Items]                  
    Preferred stock, redemption price per share             $ 25.50    
    Series B Preferred Stock [Member] | At The Market Facility [Member]                  
    Class of Stock [Line Items]                  
    Underwriter commission fees percentage     3.00%            
    Sale of stock, shares       59,773          
    Proceeds from issuance of Series B Preferred Stock, net of expenses       $ 1,400,000          
    Series B Preferred Stock [Member] | At The Market Facility [Member] | Maximum [Member]                  
    Class of Stock [Line Items]                  
    Authorized sale of stock, value     $ 35,000,000            
    Series A and Series B Preferred Stock [Member]                  
    Class of Stock [Line Items]                  
    Preferred stock, dividend per share   $ 2.19 $ 2.75 $ 2.19          
    XML 90 R65.htm IDEA: XBRL DOCUMENT v3.25.1
    COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
    		 1 Months Ended
    Dec. 22, 2023
    Sep. 30, 2024
    Mar. 31, 2021
    Apr. 30, 2024
    Loss Contingencies [Line Items]        
    Damages paid value     $ 750,000  
    Damages sought transition related costs   $ 800,000 288,750  
    Unpaid fees     $ 21,698  
    Advance amount       $ 200,000
    Settlement claim amount   $ 316,000    
    Ramapo Anesthesiologists, PC [Member]        
    Loss Contingencies [Line Items]        
    Mitigation related costs $ 117,000      
    Ramapo Anesthesiologists, PC [Member] | Accrued Expenses [Member]        
    Loss Contingencies [Line Items]        
    Mitigation settlement payable $ 32,000      
    XML 91 R66.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF LEASE EXPENSE (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Leases    
    Operating lease cost $ 2,451 $ 2,669
    Short-term lease cost 4
    Variable lease cost 28 32
    Total - net lease cost $ 2,483 $ 2,701
    XML 92 R67.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2024
    Dec. 31, 2023
    Leases    
    Operating lease right-of-use assets $ 3,133 $ 4,365
    Current operating lease liabilities 1,287 1,888
    Non-current operating lease liabilities 1,847 2,516
    Total operating lease liabilities 3,134 4,404
    ROU assets 5,125 6,571
    Asset lease expense (1,994) (2,152)
    Foreign exchange gain/(loss) $ 2 $ (54)
    Operating leases, Weighted average remaining lease term 5 years 4 years 6 months
    Operating leases, Weighted average discount rate 14.20% 13.30%
    XML 93 R68.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Leases    
    Operating cash flows from operating leases $ 2,467 $ 3,244
    Operating leases, excluding terminations $ 864 $ 1,682
    XML 94 R69.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2024
    Dec. 31, 2023
    Leases    
    2025 $ 1,601  
    2026 727  
    2027 557  
    2028 371  
    2029 193  
    Thereafter 1,240  
    Total lease payments 4,689  
    Less: imputed interest (1,555)  
    Total lease obligations 3,134 $ 4,404
    Less: current obligations 1,287 1,888
    Long-term lease obligations $ 1,847 $ 2,516
    XML 95 R70.htm IDEA: XBRL DOCUMENT v3.25.1
    LEASES (Details Narrative) - USD ($)
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Leases    
    Lease term, description Leases with a term of less than 12 months are not recorded in the consolidated balance sheets.  
    Unoccupied lease charges $ 0 $ 169,000
    Lease impairment   0
    Net gain (loss) on lease terminations $ 10,000 (291,000)
    Operating lease description we had 28 leased properties, five in Medical Practice Management and 23 in Healthcare IT, with the remaining terms ranging from less than one year to eleven years. Our lease terms are determined taking into account lease renewal options, the Company’s anticipated operating plans and leases that are on a month-to-month basis  
    Sublease income $ 94,000 $ 0
    XML 96 R71.htm IDEA: XBRL DOCUMENT v3.25.1
    RELATED PARTIES (Details Narrative) - USD ($)
    		 1 Months Ended 12 Months Ended
    Sep. 01, 2024
    Feb. 12, 2024
    Feb. 01, 2024
    Jan. 31, 2024
    Feb. 28, 2023
    Jun. 30, 2022
    Dec. 31, 2024
    Dec. 31, 2023
    Dec. 31, 2022
    Related Party Transaction [Line Items]                  
    Net revenue             $ 110,837,000 $ 117,059,000  
    Receivable due from customer             12,774,000 11,888,000 $ 14,773,000
    Current assets - related party             16,000 16,000  
    Lease expense per month for temporary housing             6,500    
    Operating Lease, Right-of-Use Asset             3,133,000 4,365,000  
    Operating lease liability (current portion)             1,287,000 1,888,000  
    Operating lease liability             1,847,000 2,516,000  
    General and administrative expense             16,123,000 21,464,000  
    talkMD Clinicians [Member]                  
    Related Party Transaction [Line Items]                  
    Income taxes paid             6,000    
    Executive Chairman [Member]                  
    Related Party Transaction [Line Items]                  
    Rent expense             281,000 256,000  
    Operating lease upgradations             979,000 1,800,000  
    Payments to related party               330,000  
    Related Party [Member]                  
    Related Party Transaction [Line Items]                  
    Operating Lease, Right-of-Use Asset             550,000 331,000  
    Operating lease liability (current portion)             181,000 182,000  
    Operating lease liability             367,000 142,000  
    Physician [Member]                  
    Related Party Transaction [Line Items]                  
    Net revenue             138,000 125,000  
    Receivable due from customer             13,000 $ 18,000  
    Former Non-Independent Directors [Member] | Consulting Agreement [Member]                  
    Related Party Transaction [Line Items]                  
    Compensation for statement of work per month     $ 25,000            
    Other expenses $ 2,000 $ 8,000              
    General and administrative expense             $ 75,000    
    Former Non-Independent Directors [Member] | Series B Preferred Stock [Member] | Consulting Agreement [Member]                  
    Related Party Transaction [Line Items]                  
    Shares issued for services       14,000 14,000 10,000      
    Preferred stock dividend percentage           8.75%      
    XML 97 R72.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF RESTRUCTURING COSTS (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Restructuring and Related Activities [Abstract]    
    Severance and separation costs $ 606 $ 439
    Equity awards acceleration costs associated with severance 170
    Other exit related costs 36
    Total restructuring and other costs $ 606 $ 645
    Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Lease terminations, unoccupied lease charges and restructuring costs Lease terminations, unoccupied lease charges and restructuring costs
    XML 98 R73.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Restructuring Cost and Reserve [Line Items]    
    Balance as of January 1, 2023 $ 171
    Additions 606 645
    Payments and other adjustments (777) (474)
    Balance as of  December 31, 2023 171
    Severance And Separation Costs [Member]    
    Restructuring Cost and Reserve [Line Items]    
    Balance as of January 1, 2023 145
    Additions 606 439
    Payments and other adjustments (751) (294)
    Balance as of  December 31, 2023 145
    Equity Awards Acceleration Costs Associated With Severance [Member]    
    Restructuring Cost and Reserve [Line Items]    
    Balance as of January 1, 2023
    Additions 170
    Payments and other adjustments (170)
    Balance as of  December 31, 2023
    Other Exit Related Costs [Member]    
    Restructuring Cost and Reserve [Line Items]    
    Balance as of January 1, 2023 26
    Additions 36
    Payments and other adjustments (26) (10)
    Balance as of  December 31, 2023 $ 26
    XML 99 R74.htm IDEA: XBRL DOCUMENT v3.25.1
    RESTRUCTURING COSTS (Details Narrative) - USD ($)
    		 12 Months Ended
    Dec. 31, 2025
    Dec. 31, 2024
    Dec. 31, 2023
    Subsequent Event [Line Items]      
    Estimated restructuring expense     $ 1,350,000
    Restructuring expense incurred   $ 606,000 645,000
    Net gain (loss) on lease terminations   10,000 (291,000)
    Unoccupied lease charges   $ 0 $ 169,000
    Subsequent Event [Member]      
    Subsequent Event [Line Items]      
    Restructuring expense incurred $ 100,000    
    XML 100 R75.htm IDEA: XBRL DOCUMENT v3.25.1
    EMPLOYEE BENEFIT PLANS (Details Narrative) - USD ($)
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Defined Contribution Retirement Plan For U.S. Employees [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Defined benefit plan, plan assets, contributions by employer $ 449,000 $ 587,000
    Defined Contribution Retirement Plan For Pakistan Employees [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Defined benefit plan, plan assets, contributions by employer $ 438,000 394,000
    Employee benefit plan, description The plan provides for monthly contributions by the Company which are equal to 10% of qualified employees’ basic monthly compensation  
    Defined Contribution Retirement Plan For SriLanka Employees [Member]    
    Defined Benefit Plan Disclosure [Line Items]    
    Defined benefit plan, plan assets, contributions by employer $ 28,000 $ 24,000
    Defined contribution plan, employee matching contribution, on gross pay 8.00% 8.00%
    Defined contribution plan, employer matching contribution, on gross pay 12.00% 12.00%
    XML 101 R76.htm IDEA: XBRL DOCUMENT v3.25.1
    DISCLOSURE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD (Details) - Restricted Stock Units (RSUs) [Member] - shares
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Series A Preferred Stock [Member]    
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
    Outstanding and unvested at beginning
    Granted
    Vested
    Forfeited
    Outstanding and unvested at ending
    Series B Preferred Stock [Member]    
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
    Outstanding and unvested at beginning 57,199 80,462
    Granted 46,000 62,000
    Vested (60,000) (85,263)
    Forfeited (24,000)
    Outstanding and unvested at ending 19,199 57,199
    Common Stock [Member]    
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
    Outstanding and unvested at beginning 753,495 645,475
    Granted 226,894 1,098,976
    Vested (513,190) (896,893)
    Forfeited (224,699) (94,063)
    Outstanding and unvested at ending 242,500 753,495
    XML 102 R77.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF SHARE-BASED COMPENSATION, RESTRICTED STOCK UNITS AWARD ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member] - shares
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Common Stock [Member]    
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
    Outstanding and unvested shares, beginning 493,579 1,498,492
    RSUs granted (226,894) (1,098,976)
    RSUs forfeited 232,998 94,063
    Outstanding and unvested shares, ending 499,683 493,579
    Preferred Stock [Member] | Series A Preferred Stock [Member]    
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
    Outstanding and unvested shares, beginning 33,769 33,769
    RSUs granted
    RSUs forfeited
    Outstanding and unvested shares, ending 33,769 33,769
    Preferred Stock [Member] | Series B Preferred Stock [Member]    
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
    Outstanding and unvested shares, beginning 38,000 100,000
    RSUs granted (46,000) (62,000)
    RSUs forfeited 24,000
    Outstanding and unvested shares, ending 16,000 38,000
    XML 103 R78.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF EMPLOYEE SERVICE SHARE-BASED COMPENSATION, ALLOCATION OF RECOGNIZED PERIOD COSTS (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
    Stock-based compensation $ 115 $ 4,886
    Direct Operating Costs [Member]    
    Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
    Stock-based compensation (27) 891
    General and Administrative Expense [Member]    
    Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
    Stock-based compensation 72 2,835
    Research and Development Expense [Member]    
    Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
    Stock-based compensation (4) 135
    Selling and Marketing Expense [Member]    
    Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
    Stock-based compensation 74 855
    Net loss on lease terminations, unoccupied lease charges and restructuring costs [Member]    
    Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
    Stock-based compensation $ 170
    XML 104 R79.htm IDEA: XBRL DOCUMENT v3.25.1
    STOCK-BASED COMPENSATION (Details Narrative) - USD ($)
    		 1 Months Ended 12 Months Ended
    May 31, 2024
    Mar. 31, 2024
    Oct. 31, 2023
    Feb. 28, 2023
    Dec. 31, 2024
    Dec. 31, 2023
    Dec. 31, 2022
    May 31, 2020
    Dec. 31, 2018
    Apr. 14, 2017
    Apr. 30, 2014
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Stock-based compensation         $ 115,000 $ 4,886,000          
    Liability for cash settled amount         6,000 767,000          
    Cash settlement         $ 45,000 $ 19,000          
    Series A Preferred Stock [Member] | Restricted Stock Units (RSUs) [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Share-based compensation restricted stock, grants in period                  
    Series B Preferred Stock [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Share-based payment award, number of shares issuance     10,000 34,000              
    Share-based payment award, number of shares grant 12,000 34,000                  
    Weighted average grant date fair value         $ 6.33 $ 25.07          
    Series B Preferred Stock [Member] | Restricted Stock Units (RSUs) [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Share-based compensation restricted stock, grants in period         46,000 62,000          
    Common Stock [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Weighted average grant date fair value         $ 2.16 $ 3.40          
    Common Stock [Member] | Restricted Stock Units (RSUs) [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Number of shares available for grant         499,683 493,579 1,498,492        
    Share-based compensation restricted stock, grants in period         226,894 1,098,976          
    Preferred Stock [Member] | Restricted Stock Units (RSUs) [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Share-based payment arrangement, nonvested award, cost not yet recognized, amount         $ 416,000 $ 1,300,000          
    Share-based compensation nonvested awards total compensation cost not yet recognized         $ 0 $ 351,000          
    Unvested stock option award, equity         242,500 733,908          
    Restricted stock award classified as liability         19,587 19,587          
    Preferred Stock [Member] | Series A Preferred Stock [Member] | Restricted Stock Units (RSUs) [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Number of shares available for grant         33,769 33,769 33,769        
    Preferred Stock [Member] | Series B Preferred Stock [Member] | Restricted Stock Units (RSUs) [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Number of shares available for grant         16,000 38,000 100,000        
    Employee [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Share-based compensation restricted stock, grants in period             135,000        
    Stock-based compensation             $ 404,000        
    2014 Equity Incentive Plan [Member] | Employees, Officers, Directors and Consultants [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Number of shares reserved for future issuance                     1,351,000
    Amended and Restated Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member] | Five Outsides Members of the Board [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Share-based compensation restricted stock, grants in period         30,000 30,000          
    Shares vesting percentage         25.00% 25.00%          
    Amended and Restated Equity Incentive Plan [Member] | Series A Preferred Stock [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Shares added to the A&R Plan for future issuance               300,000 200,000 100,000  
    Amended and Restated Equity Incentive Plan [Member] | Series B Preferred Stock [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Shares added to the A&R Plan for future issuance             200,000        
    Amended and Restated Equity Incentive Plan [Member] | Common Stock [Member]                      
    Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                      
    Shares added to the A&R Plan for future issuance             1,000,000 2,000,000   1,500,000  
    XML 105 R80.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF DEFERRED TAX VALUATION ALLOWANCE (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Income Tax Disclosure [Abstract]    
    Beginning balance $ 87,597 $ 92,091
    Current year valuation allowance increase (decrease) 2,067 (4,494)
    Ending balance $ 89,664 $ 87,597
    XML 106 R81.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAX, DOMESTIC AND FOREIGN (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Income Tax Disclosure [Abstract]    
    United States $ 7,191 $ (48,985)
    Foreign 820 (53)
    Total $ 8,011 $ (49,038)
    XML 107 R82.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF COMPONENTS OF INCOME TAX PROVISION (BENEFIT) (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Income Tax Disclosure [Abstract]    
    Current tax, Federal
    Current tax, State 120 123
    Current tax, Foreign 40 38
    Provision for current income taxes 160 161
    Deferred Tax, Federal (252)
    Deferred Tax, State (273)
    Benefit for deferred income taxes (525)
    Total income tax provision (benefit) $ 160 $ (364)
    XML 108 R83.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2024
    Dec. 31, 2023
    Dec. 31, 2022
    Income Tax Disclosure [Abstract]      
    Allowance for expected credit losses $ 213 $ 228  
    Deferred revenue 103 68  
    Property and intangible assets 3,015 1,933  
    State net operating loss ("NOL") carryforwards 20,981 19,749  
    Federal net operating loss ("NOL") carryforwards 55,569 57,562  
    Section 163(j) interest limitation 1,669 2,731  
    Stock based compensation (173)  
    ASC 842 - ROU asset (559) (1,026)  
    Prepaid commissions (267) (303)  
    Cumulative balance translation adjustment 1,015 988  
    Section 267 limitation 6 6  
    Credit carryovers 2,498 2,498  
    ASC 842 - Lease liability 558 1,031  
    Accrued compensation 86 80  
    Other (46) (59)  
    Section 174 costs 4,996 3,799  
    Valuation allowance (89,664) (87,597) $ (92,091)
    Total deferred tax assets 1,688  
    Goodwill amortization (1,688)  
    Net deferred tax liability  
    XML 109 R84.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Income Tax Disclosure [Abstract]    
    Federal provision (benefit) at statutory rate $ 1,682 $ (10,298)
    State tax expense, net of federal benefit 94 7,383
    Non-deductible items 30 26
    Impact of foreign operations (132) 50
    Subpart F GILTI inclusion 1,066 804
    Stock based compensation (177) 18
    Goodwill impairment charges 5,692
    Deferred true-up 2,708 455
    Valuation allowance 305 (4,494)
    Total income tax provision (benefit) $ 160 $ (364)
    XML 110 R85.htm IDEA: XBRL DOCUMENT v3.25.1
    INCOME TAXES (Details Narrative) - USD ($)
    		 12 Months Ended
    Aug. 31, 2023
    Dec. 31, 2024
    Dec. 31, 2023
    Effective Income Tax Rate Reconciliation [Line Items]      
    Goodwill impairment charge $ 0 $ 42,000,000
    Goodwill amortization period for tax purposes     15 years
    Federal statutory income tax rate   21.00%  
    Income tax examination description   the Company is subject to tax. IT companies in Pakistan are subject to a 0.25% tax deducted at the source on receipts received from foreign sources with no further tax being due  
    Federal [Member]      
    Effective Income Tax Rate Reconciliation [Line Items]      
    Net operating loss carry forwards   $ 265,000,000  
    Federal [Member] | CareCloud and Meridian Acquisitions [Member]      
    Effective Income Tax Rate Reconciliation [Line Items]      
    Net operating loss carry forwards   237,000,000  
    Federal [Member] | Between 2031 and 2038 [Member]      
    Effective Income Tax Rate Reconciliation [Line Items]      
    Net operating loss carry forwards   187,000,000  
    Federal [Member] | Indefinite Life [Member]      
    Effective Income Tax Rate Reconciliation [Line Items]      
    Net operating loss carry forwards   78,000,000  
    State [Member]      
    Effective Income Tax Rate Reconciliation [Line Items]      
    Net operating loss carry forwards   211,000,000  
    NEW JERSEY      
    Effective Income Tax Rate Reconciliation [Line Items]      
    Net operating loss carry forwards   $ 84,000,000  
    PAKISTAN      
    Effective Income Tax Rate Reconciliation [Line Items]      
    Federal statutory income tax rate   21.00% 21.00%
    Pakistan statutory corporate tax rate   29.00%  
    XML 111 R86.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF OTHER (EXPENSE) INCOME - NET (Details) - USD ($)
    $ in Thousands
    		 12 Months Ended
    Dec. 31, 2024
    Dec. 31, 2023
    Other Income and Expenses [Abstract]    
    Foreign exchange gains (losses) $ 130 $ (790)
    Other expense (428) (93)
    Other expense - net $ (298) $ (883)
    XML 112 R87.htm IDEA: XBRL DOCUMENT v3.25.1
    SCHEDULE OF REVENUES, OPERATING EXPENSES AND OPERATING INCOME (LOSS) BY REPORTABLE SEGMENT (Details) - USD ($)
    		 12 Months Ended
    Dec. 12, 2023
    Oct. 31, 2023
    Aug. 31, 2023
    Dec. 31, 2024
    Dec. 31, 2023
    Segment Reporting Information [Line Items]          
    Net revenue       $ 110,837,000 $ 117,059,000
    Direct operating costs       60,842,000 70,817,000
    Selling and marketing       6,232,000 9,650,000
    General and administrative       16,123,000 21,464,000
    Research and development       3,781,000 4,736,000
    Depreciation and amortization       14,142,000 14,402,000
    Goodwill impairment charges     $ 0 42,000,000
    Lease terminations, unoccupied lease charges and restructuring costs       596,000 1,105,000
    Total operating expenses       101,716,000 164,174,000
    OPERATING INCOME (LOSS)       9,121,000 (47,115,000)
    Other expenses       (298,000) (883,000)
    INCOME (LOSS) BEFORE PROVISION (BENEFIT) FOR INCOME TAXES       8,011,000 (49,038,000)
    Operating Segments [Member]          
    Segment Reporting Information [Line Items]          
    Net revenue       110,837,000 117,059,000
    Direct operating costs       60,842,000 70,817,000
    Selling and marketing       6,232,000 9,650,000
    General and administrative       11,004,000 12,846,000
    Research and development       3,781,000 4,736,000
    Depreciation and amortization       14,142,000 14,402,000
    Goodwill impairment charges         42,000,000
    Lease terminations, unoccupied lease charges and restructuring costs       596,000 1,105,000
    Total operating expenses       96,597,000 155,556,000
    OPERATING INCOME (LOSS)       14,240,000 (38,497,000)
    Unallocated corporate expenses       (5,119,000) (8,618,000)
    Net interest expense       (812,000) (1,040,000)
    Other expenses       (298,000) (883,000)
    INCOME (LOSS) BEFORE PROVISION (BENEFIT) FOR INCOME TAXES       8,011,000 (49,038,000)
    Healthcare IT [Member]          
    Segment Reporting Information [Line Items]          
    Goodwill impairment charges $ 40,000,000.0 $ 2,000,000.0      
    Healthcare IT [Member] | Operating Segments [Member]          
    Segment Reporting Information [Line Items]          
    Net revenue       96,405,000 103,683,000
    Direct operating costs       49,945,000 60,319,000
    Selling and marketing       6,201,000 9,614,000
    General and administrative       9,093,000 10,992,000
    Research and development       3,781,000 4,736,000
    Depreciation and amortization       13,813,000 14,046,000
    Goodwill impairment charges         42,000,000
    Lease terminations, unoccupied lease charges and restructuring costs       596,000 1,105,000
    Total operating expenses       83,429,000 142,812,000
    OPERATING INCOME (LOSS)       12,976,000 (39,129,000)
    Medical Practice Management [Member]          
    Segment Reporting Information [Line Items]          
    Net revenue       14,432,000 13,376,000
    Medical Practice Management [Member] | Operating Segments [Member]          
    Segment Reporting Information [Line Items]          
    Net revenue       14,432,000 [1] 13,376,000 [2]
    Direct operating costs       10,897,000 10,498,000
    Selling and marketing       31,000 36,000
    General and administrative       1,911,000 1,854,000
    Research and development      
    Depreciation and amortization       329,000 356,000
    Goodwill impairment charges        
    Lease terminations, unoccupied lease charges and restructuring costs      
    Total operating expenses       13,168,000 12,744,000
    OPERATING INCOME (LOSS)       $ 1,264,000 $ 632,000
    [1] This revenue represents fees based on our actual costs plus a percentage of the operating profit.
    [2] This revenue represents fees based on our actual costs plus a percentage of the operating profit.
    XML 113 R88.htm IDEA: XBRL DOCUMENT v3.25.1
    FAIR VALUE OF THE ASSETS MEASURED ON A NON-RECURRING BASIS (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2024
    Dec. 31, 2023
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Goodwill - Healthcare IT $ 42,000
    Fair Value, Inputs, Level 1 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Goodwill - Healthcare IT
    Fair Value, Inputs, Level 2 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Goodwill - Healthcare IT
    Fair Value, Inputs, Level 3 [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Goodwill - Healthcare IT 19,186 19,186
    Reported Value Measurement [Member]    
    Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
    Goodwill - Healthcare IT $ 19,186 $ 19,186
    XML 114 R89.htm IDEA: XBRL DOCUMENT v3.25.1
    SUBSEQUENT EVENTS (Details Narrative) - shares
    		 1 Months Ended
    Mar. 31, 2025
    Jan. 31, 2025
    Jan. 30, 2025
    Dec. 31, 2024
    Dec. 31, 2023
    Subsequent Event [Line Items]          
    Common stock shares authorized       35,000,000 35,000,000
    Series A Preferred Stock [Member]          
    Subsequent Event [Line Items]          
    Shares remaining outstanding       4,526,231 4,526,231
    Subsequent Event [Member]          
    Subsequent Event [Line Items]          
    Common stock shares authorized   85,000,000 35,000,000    
    Subsequent Event [Member] | Series A Preferred Stock [Member]          
    Subsequent Event [Line Items]          
    Conversion of shares 7.3358        
    Subsequent Event [Member] | Series A Preferred Stock [Member] | Individual Shareholders [Member]          
    Subsequent Event [Line Items]          
    Shares outstanding 100,000        
    Shares remaining outstanding 985,000        
    EXCEL 115 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

    ZH/)^>\?QJMMH2=*<%B)E!7"ZOFH- M[(N;0.W7&QY2^BP.UJ \63'V35V,DZN6I0RB&8VETD#PWQ,=TBQ3BM",/VN= MK>9()7BXWFD?:=_1EQ41=,BR7]-$;JY:00L2NB9E)N?L^1=:^^,I?3'+A/Z% MYVJO[[<@+H5D>2V,%N1I4?TG+W4<#@0"ZSL"3BW@:+NK@[25MT22ZTO.GH&K MW:A-+;2K6AJ-2PN5E(7D^#1%.7D]G@YG7R-8#OX7+:"])*N,BLYE5Z)JM:$; MUVIN*C7.=]38#GQEA=P(B(J$)F\5=-&FQC!G9]B-X#85<<9$R2G\-E@)R1$:OQ_SN=+H'M>HRN5";$E, MKUI8#X+R)]JZ_ODGV[<^G["WU]C;.Z7]>C'\);J]GT0P&\%M-(KF\^A6I0D> M!I/[P7(\F\)@,IG].I@.HV.VG]1^W/8?.=+X/R6\2C9@JFB^HERERU#I4CES MC?89I 7(#2L%*1+1,6[H8UH4:?&(=921(J9P!D'?],(^+D+'M$+;&):= RTZA^'A*;O]_:G MG4B/UZ3'>W=ZZAIJ3V:+10=NHM%L'L&^L$RXQ=5B.1["8'H+ZNGXR_18SDX? MN=Q0(ZU0W$;XB@ZL*+(RA2UG3ZEFR?:*%G2=R@[@ Z@W2_)"A;ZQ3@N,2$HR MI-,MXU)%:5OR+1.X(2FYNI8;JH,O@/XKN;H6 9.ILNQ"S)";A<1-;*WEUDRE M";5ILF8AB42'SJ!OVJ&-_]N]P P##Z&!3(X\74#@6-#V M7+RS9!+C@= P+;O:&YJ6&T#G!$C\!B3^NT&"WM[-IM%TN3B C"JNN_GL8;Q0 MQ=6^B:;1:+P\RK^G3U+8>#<,WI5B^*$4_XAW'\EL30L7QH@FE.N$G:L_0^<: M;$RGC7*[]/8L< ,#F1ALWS9NZ9JB>+*7/H>VXSF8_4I<7?85&'#A.5Z#BGWD MCM;8&:@3$#(NDLLIO/0;O/0_QOF#Q2+"T*KRF(P'-^/)>#F.%L=@?_XI<.S^9Z$F'1W$MW B>O\) !'D)R)JV(@]:-[I MHO%&]7O1LDNXSAP1@DIQ80R:%J)J@+YL<2[$+=A#DE2"(E3-&8[MJE\GV&OA M](D6):+,$QQ;*H/ A>)Q /;#%VWAE>!L[42(9IP MU4G05G%UK,_3V42O[,\=B GGKVC;,^&)0,^0LFRP0[/?"QO@?DB5YYF>'X*' MS<]WC$4]#]N^V_ZCHQR@" 6,0)JGLNJV-K;+$+MJW[71!19_TX,OQ@HQ@?-X MM:EMJY+!$APLAA#T'*RB^>R^B@*6D1?BP[9M6HZ/]72'#8>D6D.>"E5':+B# M31OWN)8JO6&9EQE1(WK3N'$P*T16#P#)'S@,YVHTL'6 PR!H7%&*#LSWP3>& M55IU(-@31:YS<#H(JM\#DR=ZELA2LDJS%'/J>8$Z !T?Q#$O_^ETX$-@&3,L M$(Z=PE?F*T?W0>WW4$ @#'IF&/H(AGX8&@]'YIAV/92@AGHJV;%.\F_THJ&8 MDR!XB^R=U2E%>']A+'E.LPQ(KCK[7]5YYRH%*(C*IYB6Y)CXZXY,3\U%04-A MP;LI+!J-HN%R_'#8[&$^6$8PCX:SZ1!K7$^5QWCL]"D#@U-L33&:7_FYZTYU MF0A$0BD9?SVD<*YJL8T%#A\Q\B-=:U>UQYH'D0=6:M/.=(X=U5!LRW1"E;3Q MD6D7SWC#P5B]^ JJ^&#-67Y1DX[R6)%<(:A9T<:Z"4]M!."TW#?=P#6FK#A' MQTH$L6(RG*)R)#(+"\L88QN(*^FZN=;\HTO8=K&+@F<9BW*U)5S""+Z,)\NQ MLC K144FEJ^JIG>22A03V,$>Q2D>FW)=[_&&\$>J:L S_= YJ &LS_-RBT1B M]BV,%O0\[VBMN9:W?SOXCUI[]^"=.Z=HH/JR(-"OLI#5ZW=SM_EX,:C>V??; MJR\?7]&_%*.9T36*6I_Z^![ JZ\)U85D6_T&OV)2LEPO-Y1@+M4&?+YF3.XN MU '-)YWKOP%02P,$% @ M(6#6G/V9Y_# @ \04 !D !X;"]W;W)K M&ULC51M3]M #/[>7V$%A%II(R\M4$H;B98@D 94 M%/:B:1^NB9M$)'?=W966?S_?IP[^_%C^^S^4L@7E2%J6)4%5P,G MTWK>>=NB7+N1/V[=E8AGVQ MT$7.<2Q!+\..L;<&7W-A\X!&N'P/*N EF65TRSL"_%$J2Q M)C0CV%2M-Y'+N6G*1$NZS:PP@P^P/0#N!-<9PHBGF#R'L E@C7+8,-R&.Q%O,+X&-K^ M)PB\H+,'KUUGW;9X9Q]EK3.4<,MC42(PGD"THE>N4,'/RZG2DM[*KUUY5ZCM MW:AF?GIJSF(<.#0@"N4K.N'1@7_J7>SAW*DY=_:AAY/1373U_"6"AVNHNM9< MMZT%M_>CA[L(/IO&[>*]']E6HX%5"0B$TRZ@<0_"_Q!L6TL U?E#4ZO&\"[IET3R$G%,D ML5!$0K4:-*,T@1QP%6>,IP@I;20%S4(HZFL+#L%O>_1MGIU[T&I4+V"3<[,3 M=*$%S?/V/U=5.<@O.#[6&)8H4[ML%-5FP74UD?5IO<\NJS'^ M:UXMPSLF4T._P!FY>L=G)P[(:L%4BA9S.]13H6E%6#&CG8S2&-#]3 B]44R M>LN'?P!02P,$% @ M(6#6D&V&MO_! >@P !D !X;"]W;W)K&ULO5?;;N,V$'W75PS<16$#W%C4S5*:&,C%FP1(;,-. MMET4?:!E.B96$E626J?]^@XIVTD!)]TMMGTQ;S.']YMS 4UE4 M^K2S-J8^[O=UON8ETT>RYA6>K*0JF<&E>NSK6G&V=$IET0]\/^F73%2=X8G; MFZKAB6Q,(2H^5:";LF3JCW->R,UIAW9V&S/QN#9VHS\\J=DCGW/S4$\5KOI[ ME*4H>:6%K$#QU6GGC!Z?1U;>"7P4?*-?S,%ZLI#RLUW<+$\[OC6(%SPW%H'A M\(5?\**P0&C&[UO,SOY*J_AROD/_X'Q'7Q9,\PM9_"R69GW:23NPY"O6%&8F M-]=\ZT]L\7)9:/<+FZVLWX&\T4:66V6TH!15.[*G;1R^1B'8*@3.[O8B9^4E M,VQXHN0&E)5&-#MQKCIM-$Y4-BESH_!4H)X9SD=7=Z/Q/);J7Z^Q3IOL8)7L&@ =[(R:PVC:LF7?P?HHV%[ZX*==>?!FXB7 M/#^"D!((_"!Z R_<>QLZO,%KWO)'+"@#,UY+943U"+^>+;116!N_'?*W10L/ MHUF^'.N:Y?RT@X307'WAG>&//]#$_^D-6Z.]K=%;Z,/YQ?7H\N%V!),/F)V/ MH_'#:$Y@,AW-SER>1K],1^/Y: YGX\L7VS?CB\G="+JWD_F\!^>?MID].T>D M;;(/>?IUMGC?W1;OFK/"K'.F.-S+G@:E\A7O<=B K,6C::54O=^V;T,;9!Q;_PJN'P#K*$1'Z,$QJ1 M* R@RWIV07V2A@-O4G/%7!'Q)^R1FNMC[U(H;#<@]T>YU$9#E)$LBL$J9@-( M<(@";XZMR(J@I(53AA-@2&X"PY6H[&63$ST*@ M)*,4;2*^'WDSK$*F\K437Z(?A:R==R$9I!3>MZ-WR;%><\':OFB12TN'/]L- M&I*4AA &F?6;HJ574BXWHBA E#43RB'F:Z8>N?9N.?9$,%RA;4Y?$V@JF>=- M+3!'A3O>"KN[D"E&-;EIU'-\XBQ!X_#7BFV!U[ MWL2LL5[W6MT@2W'WIC5ZP?$CRWVG:0G6HT;9;UV#86R#6Q<-1AXP1#F*8[U;I]&.%U%K73TZ3!?X5V0,OS<9 MJ1^2) WM+"0AIG;'Q@'QX^Q;V(C\"S%3R,8(PS] -M+!*VS,2$(C"!,[B?VW MV(AH619@M:5Q9(LOC9+7Z1B106@KWHW_1,>(^%$"89RX-N2_24>( FP$OH5V MD^]#3THHML'W[?@Z1;%5$%OFZ/T@PB#$,8GCY !)NXY3SUSMAAFA2&Z;SP3[ MK-U),3D#Y,9_Q]<4O&.56IUVI;4*@W6X/D *E6Z1"$8'>P^D>3#(0:QV;M1UH__L= M)RG+[5).=[I[:.,?,Y^_;\;CH;-3^HO)$"T\YT*:KI=9N[GQ?9-DF#-SH38H M:6>E=,XL3?7:-QN-+"V=MZ3>]U8<;7F74+?J^S86N,T2XV4TTS?X^2\AREX4J"QE77BYHW_;:S+PV> M..[,P1BBX=7J*$*?_#KK*]_.1!4ABK\MJ9 M&.1<5E_V7,?AP.$Z>,,AK!W"DG=U4,GREEG6ZVBU ^VL"K]"#]] ;X8P5M)F!H8RQ?2O #Y1W?,-7_GVPY.(MYA<0*MY!F$0 MMD_@M?;Z6R7>Q[?T,Z[AB8D"X9:;1"A3:#3P1[0T5M.5^?.8Z JR=1S2E=&- MV; $NQ[5B4&]1:_WZR_-J^"W$X3;>\+M4^@_)&Q^/X0HCH>4I?$PBA>SX2T\ M3B""R>/D?#8<+&:ST>0S]*-X%!]3(W,13\%5*$@ESS4F!5D2 M-E4;)QP#:@64=\R7J/>Y=_@-&K0N8(8KVK *)LHBA' ._=*3W*:.MK2L>@&( M4 6!33K;UA_6S]C-MZ_ MJR2IPE#XS8?&9Z72'1>"LG2/3-B,[@7": [OH/GIK'E]18/S^N_[PC\1TOH? MA+3^(R'M\"P( CCV#O@'CWB.>EVV*BH;=T6K]WR_NN^&4=4$OIM7K73,])I+ M P)7Y!I&ULM99K;YLP%(;_BL6D:9.J<,F5CB#ETFZ1UC1JVDW:M \.G 2K M@*EM0BKMQ\\&BI*)LJ5-OR38^'WMY_@<=)R,LGL> BTB\*8#[5 B.1'F$2:ZZ3SRV8Z]!4A"2&!4,\ MC2+,'L<0TFRHF=K3Q W9!$)-Z*Z3X TL0=PE"R9'>N7BDPAB3FB,&*R'VL@\ MG]AJ?;[@&X&,[STC1;*B]%X-9OY0,]2!( 1/* "=@Y:G"S'FF*!78?1##&U M6KJIASPVN5K2D%C=XE(P^99(G7"O;SZ/YK,?H]O9]1R-YE,TOEO.YA?+)?HP M!8%)R-$<,X95L#\ZNI!;*J'NE?;CPMYZQGZ4L!8RS#-D&995(Y\TRZ?@M5 [ MEQN=0[DN02M:JZ*U071"MBO.KI&.U5A MYSS!'@PU64(;LB;S>27SRD1#RB"$1 ?43B+7 A MBU$@FL7 >$"2,Y0 \^24+-ZZ4#3Z'QN*PLPTJK$:3 !/Y08@;$Z%QXV/I3V1V$*-N%:/N&R=" MH_^QH>C6)8)AF/6)T*L@>_].A#'>!$<5>Z/GL6 G,CO [U?X_3>^XWY]?0ZJ M:RD@&X_Q0LA!!3EXY1V_KN(;=S\V&TYD=A HNPJ4_<;98-<7J?57-C0>XUA( M?:^G4?WD%68;$G,4PEK:&ZV^_'*PHD9NSHD(V3?EC(-M:8&J!?+^F M5#P-5.=4-G,O C/A$D2<.0B;<''L3K^X;1>#_QQ5\L97ZB MV;];L06?N\0E'B/SY?)WNO23Z4 MESC^EA^,9O>-5MXC'G!/Y@B6_7GE0QX$.2GKQQ];:&/79EYQ__4[W2D&GPWF MA25\& ?_]6=R>=^X;I 9G[,TD%_B]2]\.Z!.SO/B("G^)^MMV5:#>&DBXW!; M.>M!Z$>;O^S[]D+L53#-#RJ8VPKFN16L;07KW KM;87V006K]T&%SK9"Y["% MFP\J=+<5NN=VJ;>MT"N"M;FZ16AL)EG_3L1K(O+2&2U_4<2WJ)U%Q(]R*4ZE MR-[ULWJR_S"8CJ;DR2&3+W1*Q\^#Y]'3F S&-IF.W/'(&0T'XV469=R<-/;-D\WS9L?-&^8Y#&. MY#(A-)KQF0IH9F/9# M$5%"=\ZF[SGU,<_6T7UET M15K:H2H!M78*M0IN[P/N1&3SKI!OG\DD8-EH630C](_47Q5C__VWK#@921XF M_ZOH\\.&;56S\WG^-EDQC]\WLHD\X>*5-_K_^H?1;?V[2C)(F(V$423,0<)< M$$R13GLGG;:.WA^GX0L7))Z37$+9'!4M2+*Y:1+RU_O]4R4;+;>N;) P&PFC M&UBG@.4/+:]]\Z[YNJ\%9',N"*9HH;/30D>KA<'L-9M%_"37@!] B MZH8=";.1,+J!7>^'_::5_SL(_G&Y=JNBG OJG!+7[BZN76U<1Y'D(F+!SVG" M21+/Y3I+7YL($X^M?,D"_\_#)XM-M+7@NM%&PFPDC':/;O).KRK:Q^6NNU71 M!G5.B79O%^V>/MKABOFBR/Q>]IRRJ'Q0>= RZ@86";.1,-H[NCT/0]H["NEA M,$$=4H)YO0OF]9GI6?!5+"1["3A)(_]4C5=H++6UDG5AP?Q$1_CV+9[3@Y-."^=%/)(B3I#JX>F#=Z$)I-I1&M[1] MM?QL6!69N:)@[Z8BU*CNJ;'>LY(,_2-V$,1K%GFR%3&WK?/ M9!B'81R1WQ]YGOXK71L]L;8BD#0;2J-0F@.EN2B:JIO2]S,N:?P94.)&*[/DCR;+17Q\;W ]Z6FW-0'T_*(T: MQ\[?T4/'R2(NJD]J=$M'S]!;>K]P%LBEE_L]HV=]/H$:>U":#:51*,V!TEP4 M395+:10:W4OF$ZA;"*794!J%TAPHS4715 F5[J.AMQ]K^A3&L4.W-= /9M)A M1_:^4QX M(OV0Y1Y:FO!Y&I# ?ZW.-/H&ZLH(2K.A-'KB4EKDC3-1O1@*V0\715,E4WJM MIMYK/4Q/V>?:+_R51RDGPSK5'*Q/_'H\A9T&2N49D-I%$ISH#0715-E5-K0YO4E M\Q;4H(;2;"B-0FD.E.:B:*J$2H/:U"^N!;B+4),:2K.A-'KB4NH^GT$-:11- M_<5E:4A;>A?UD7T_^>67'E%7%%":#:51*,V!TEP4315*:4-;Q@73DP4UGZ$T M&TJC4)H#I;DHFBJATGRV],N#?SP]Z1NH+2.H 0VET1.7LO-Q>H+VPT715,GL M[0B@MTD/T]/?_?)+WTQMX4!]9RB-0FD.E.:B:*J82B_::E\RA4'-92C-AM(H ME.9 :2Z*IDJH-)S:"H)ZRU :/7$5-'!^8-P.BMT:FR5FL^GE(Q,+/TI(P.<9LG75 MRY*TV.PCN3F0\:K8QO EEC(.BY=+SF9_P @ O@@ !D !X;"]W;W)K&ULK59M;]HP$/XK5C9-K;0V+T#:=1 )"*5(;:F@K)JF?3#)$:PZ-K,- M=/]^=@(9I2&B4K\0GWW/Y1Q H9>4,MFRYDHMKFQ;1G-(L3SG M"V#Z9,9%BI4V16++A0 <9Z"4VI[C^':*";."9K;W(((F7RI*&#P())=IBL7? M#E"^;EFNM=T8D62NS(8=-!)!:,LN6&*2 I.$,R1@UK+:[E7H&__, MX0>!M=Q9(Z-DROFS,09QRW+,A8!"I P#UH\5=(%20Z2O\6?#:14A#7!WO66_ MSK1K+5,LH+K&]CH:1B^B%.9_:)U[GNA(T9+J7BZ M 6L[)2Q_XI=-'G8 ;OT P-L O'V ?P!0VP!JQT:H;P#U+#.YE"P/(58X: J^ M1L)X:S:SR)*9H;5\PDS9QTKH4Z)Q*AAW;WKAY+:'AM>H>].^[_?&Z'&(NNW1 MZ.?@OH_:=\/)_:,Y[0^'X=/@]A:=A* PH?(4G:').$0GGT^;MM)W,8QVM(G; MS>-Z!^*Z'KKC3,TEZK$8XM<$MA91*/&V2CI>)6-[F9RCFOL5>8Y7*[M0-3R$ MJ(#72^#A\?!:A9I:49=:QG=Q@*_/>;PFE"+,8C1@"K.$3"F@MI2@) J)C"B7 M2P'H5WLJE=#_G]\EM^[D46KE44Q/N9(+'$'+TDU#@EB!%7SYY/K.][(,?B19 M^$%DK[);+[);KV(/.I 0Q@A+4"*XE+IS4,PB*$M@)=%[$YB3769DIB&O O>; M>^D[CM.T5[O)>>OHNWN.KX0W"N&-2N&#=(&)T&U;H6B.10*R3'/C3?2]^W4K MHY1G!96]!#E/8R?265U/+.>@4+\0ZE<*U5WEJ/)6LKRWO/ZQY3W",5=M[W3V M%'2]S(24*.)+IO+66.SF0[BKAW VK/;V]7!N9S/)_D^33_8[_1H0)A&%F:9T MSB]T-40^+7-#\44V/Z9?Z P.$<=#G,\[5UC !BD^6X!]02P,$% M @ M(6#6B28J78+!P T2P !D !X;"]W;W)K&ULO5IK;]LV%/TKA%<,+=#4XDNRL\2 XZ2K@:8MZJ3#,.R#8C.V4#T\B4[2 M8C]^E*R8ID11EB+O2R+)]QX>7EWJ'C[.'J/X>[)BC(.GP ^3\]Z*\_5IOY_, M5RQPDW?1FH7BE_LH#EPN;N-E/UG'S%UD3H'?1Y9E]P/7"WNCL^S9EWAT%FVX M[X7L2PR231"X\8\+YD>/YSW8>W[PU5NN>/J@/SI;NTLV8_QV_246=_T=RL(+ M6)AX40AB=G_>&\/3"<6I0V;QS6./R=XU2+MR%T7?TYOIXKQGI8R8S^8\A7#% MOP_^2@O5V;J>/^]3/Z^ZSSHC-W;L(FD?^'M^"K\]Z@!Q;LWMWX M_&OT^('E':(IWCSRD^PO>-S:.J0'YIN$1T'N+!@$7KC][S[E@=AS@':% \H= M4-&AJ@6<.V21ZV^99=VZ=+D[.HNC1Q"GU@(MOL*/ MCV:3#U>7MQ^OP.?W8/KI9OSI]^F%N!O/9EW$R_36_^!*\O&7<]/WD# M3L#M[!*\?O4&O )>"&Y6T29QPT5RUN>"3@K:G^=-7VR;1A5-0P2NHY"O$G 5 M+MA"!>B+?NPZ@YX[MX1F!('LHL#,:&/)E'"WX([MO3"T N78MCY;CAG MNCYO@0894/H%>A@-;!L-S_H/^YTI6SD#9TAW5@I+NF-)#V#I+A9>^GW1YO,6 M@.ZU2QVK2*YL-*#4TG.S=]SL [CQV T3W\T^?TOQA0:O_2A)WNB8VB42R"KP M+)N<.-#6\W1V/)T#>+)P4?.:G5+;0X3IH,"P;*4F@T)QL*,X,%(;8".B M*,:D&T0Q]WYF$3TP00H*H_,X'=BDS-&:(6@ZI("CK M)#26G]$DTSDL!E_9-@V2E;<6!?*:!7] M+LH!]F>:T*9%W::QP@A5R#8D50&JF3:;51'X%UP+W1!L J-0,C?25!QTA::& M1(H#1(\IE)!1>C2.14=H:BRD_$!F^7&;L/N-#WP1"ZWVJ'''X =S8YWGI(VG MV@FI+E"-NJC/I/L=;* 7#>^T(30V)%!]H<-0<-TJ;QK'H"$V-A50XR*QP M:G/<[ Z1(.VW(S2U M]U(I87C49? 6TL80BX[0U%A(M83-:JG![#9'VE<5:(B=XG*SS@Q24C&YP'M[ M%S5K,O6SVQRA9CU<8S6@9%#!3ZHC?,BF0@.MG>,9U\0U-M6+XEC*%GS(FD:] M'LYA%"%)H55.&D.$=7%#]" MN#@ET9B1(:Z8D6!9^W';S8E#Y\2XO-8 +8J*DWJ-F4-05:++>HW;KD@T&:CE M!8=2^,LFU6O\1-9ITG9)HG[LDO(R T*.;1>8:\S4_%*IRR)+S,L1]7-94MY= M@ B38F;HS!Q(*E*;R,I'S)7O,U\)F:\I_P899(9L6OJ[0E,#( LJ.>II -+I MAD=7:&HL]@X$='D]YTO&%!I @W9Q!(.42KDNL&BN5I"STQ%SHZZ16C;M!:K7Q5#LA MJSTYZOY#CJYJ*%(JF!JK :HX3T-EJ:?'WGV@FDI>/ JD*_85(HO*4D__AYT' M#Z&I^/LE&I?PFP/^UZ[ ML1CO"?#9O8"TWCDB8O'V_.SVAD?K[ CJ7<1Y%&27*^8N6)P:B-_OHX@_WZ0- M[$XQC_X#4$L#!!0 ( +2%@UKJ5#_ X0( (D) 9 >&PO=V]R:W-H M965T[?ST[2B$*:5FA?B(]SWM?/.22QVSO*'GF"D !/*6E*50R)"M=+YF""YR44ITRS!H/+SA&\8[?C>&*A*YI0^JF"XZ&B& D($Q4(Y0'G9HAXB1!E) MC#^EIU8MJ83[XV?WF[QV6B*2C^1I8H"7<$#&ANSM4UN,HOY@2 MGO^"79EK:"#><$'34BP)4IP55_A4]F%/8+9>$5BEP'JOP"X%=EYH09:7U8<" MAFU&=X"I;.FF!GEOQU(DPZMT-^K.O _!P X:C:7=T.[R6 M43>*!M/H MS,IK.)#.\?)M/AS^YT^# "@Q_CP2@:@/,^$A 3_@E\!K.H#\[/ M/H$S@#,P3>B&PVS!V[J0B&HA/2YQK@L ,NP6C7RWOOE]DNY M+AM3=<>JNF/E?MXK?K>4+G:8$""K <-,P&R%YP2!+N=(<-#'/":4;Q@"O[IS M+IA\*'_7%5VL8M>OHE[4*[Z&,>IH\DWDB&V1%G[\8+K&E[H6_">S%PVQJX;8 M3>ZA[*M35V"A\G.5^G!L0].P K.M;_?)&[U/)&]5Y*VWR-TZ\D+E[)$[@7D( MWFA](KA3@3MO@7MUX,X1N.FUW /P1NL3P=T*W'T+W*\#=X_ ;<,XX&YT/I'; MJ[B]M[B#.F[O'=R-SB=R^Q6WW\@]39#&PO=V]R:W-H965T*'7 $H\I3$J1P9*Z76YZ8IPQ4D5)[R-:3Z MR8*+A"I]*9:F7 N@42Y*8M.Q+-=,*$N-\3"_=RO&0[Y1,4OA5A"Y21(J?EU MS+;WQERY7*;ICCX9HN80[JV_I6Z"NSHD0L@50RGA(!BY$QL<\#NY,) M\A+_,-C*G7.2->6!\Q_9Q2P:&596(X@A5!F"ZL,C7$(<9R1=CY\EU*AB9L+= M\V?Z-&^\;LP#E7#)XWL6J=7(&!@D@@7=Q.HKWWZ&LD&]C!?R6.:_9%N4=?L& M"3=2\:04ZQHD+"V.]*E\$3L"S6D6.*7 V1=TWQ!T2D'G4$&W%'3W!>X;@EXI MZ!T:P2T%[J&"?BGHYV85;S>WQJ.*CH>";XG(2FM:=I+[FZNU(RS-4G&NA'[* MM$Z-@R]?O/O9U169W'AD=G,WN0EF%U<^F:I6DOAI!%$= M8.IF5&UQGMMRX;02/0A/B>W\31S+Z314Z+)=_B54IZ1CORGWVN63S;)5[A]0 M^5+>;9!/#YU:GYJ< MQX1YF# ?$S;%A 5(L%K^=*O\Z;;1QP'GT9;%<5-BM"J/30Q,F(<)\PO8((=E M XK'L7UF#US+LH;FXZ[IAQ8,7A=T[;V"-;-ZE5F]@\PB+%E3)O1 19%P1<42 M9)-_K;!C_<.$>;U7+VCO%?J_$8XT?:@%I[<3J:L'C]9KSY#:5_/5K7QU6WV= M)%PH]A_-QXSPI$>_$IH,;:4<:R@FS,.$^>[K[\RQ&SR;NJ_,M9UND[E(U:N9 MVZ_,[;>:>Y\/TB$ZH8\@]*2#T%VWUR 8CYK,;J4>:S8FS,.$^>TOKT-^ 15- MO=L4LQ8!$JR6((,J00:M;;R&B(4T)K0#1 M.'YKI1^;*)@P#Q/F8\*FF+ "59+GK,J><[^]/C_##-_,&$>)LS'A$TQ80$2 MK)8_MO6R+F']]@R@77IL;J#2/%2:7])V!QUG#2..PXH%6'6K6[JSU&2W6OH9 M:*Q6(17ZL[]K_>]H!QUM,";-0Z7YJ+0I*BW HM73Q7E)%^=/_X>4$;#R")/F MH=)\5-H4E19@T>IY]+(4:;>N5!V[/%'2=OO28O*VWYU>-I1LG,1[[14\VFK4 M)4-46H!%*ZPV=_8U$M"&95M6DH1\DZIB6Z"Z6VR+^?;Y--\]VKL_L<\G^2:1 M^8(I]MJN=1ZP5)(8%AIIG?;UM%T4VU?%A>+K?/?D@2O%D_QT!30"D170SQ>< MJ^>++$"UB3C^'U!+ P04 " "TA8-:(\^!\PP$ W% &0 'AL+W=O MW4U[8,;#B5:$F>V ]N_GQW2O$"PBA2^0%[.>?*2W4!7,T2,@SS$$\)C,F MS\P"91E$$/. QHC!:FA8+] MV@0G3W"R0G?,LK(F1)#1@-$M8BI:HJF#3)LL6U83Q&H8YX+)NX',$Z/Y^.MT M\G@[1??7:/9P/YL^+/Y'5]\F:/K/X\WL;OIM@=Y/0) @Y!_0)_0XGZ#W;S^@ MMRB(T6)-4T[B)1^80E)1@*:?/_;+[K'VD<=.P+] #OZ(;,ON-*2/7Y_NU--- M*4"A@EVH8&=XWA&\&9/S@HD_']$L)+% LB@T_94&B32L0-]O93BZ$1#Q'TVE M[K"=9FPU#R]Y0GP8&G*B<6 ;,$;OWN"N];FI\); :C(XA0R.#GVTH(*$*,G% MR%2 %Q6:"M^A]3(TM5YL1I((M@?FIEI10Y33]SI%5(UJIZ#:T5*]!<[E&N"G M41H2 4LY=:4@?D#4XM#$=0?G5EA\PI9G[Y-M".MU7:^9K%N0=;5D9XV*HG=O M>C;&GU$,C>JZ!U1T7=WAE7 :]-&5H"J\G0*V3HM;H*] XMV.\Z>SYM"'*QU>S3?D&T MKR5ZOUH%/J#KE,6!2!GL#YC&LUK@4P>K);":!M@J7^#6&5V;@[>D1%MH=2DJ MO0QNU;DY7-65MM/9?R4T1.%^SVWV+BY;#JQ]E8\6C,0\H4QDKZQ7^E:/>?)P MG:/9P&6W@9US.E?;RYPL14MH=2G*;@;KVYF3G7O8IV!<\61>5%.4W3_BW+*; MP?IVYA;D=].:ADMT$TG*&U LN=ZW6L23!ZLEM'K]97N$N^?T;:O]4EMH=2G* MC@EK.Y'3?>L=.++KN+U]WQY&N8Y[I%O 95^#]8W-%><@?1I3H0;.EQ\-\B-V M+C517836O5KL);2Z"F73A/OG=&^KG5-;:/6/_K)ULK7]R,GNS>'J'[R= M/?/JG]E<$VHJQZSLZJ@MM3O"GH.8HQ!6$MFZ\.3\8+M=JMV)H$FVT?-$A:!1 M=K@&L@2F N3]%:7BY43M'15[A:._4$L#!!0 ( +2%@UJ(PV_M< ( +0% M 9 >&PO=V]R:W-H965T39,=+BR38PUXL4>(YY*%% M1FLAGU6.J&%3,*YZ7JYU>>/[*LVQ(.I"E,C-S5S(@FACRH6O2HDD\_KMFV''^CN'[Q37:F=<>9#@G2Z:G M8GV+M9Y+RY<*IMP7UI5O]\J#=*FT*&JPR:"@O%K)IJ[##J#=/0 (:D#P'M Y M AK0.B$5IDY62.B21Q)L09IO0V;W;C:.+110[G]BP]:FEMJ<#I.IE^3\?3Q M)_3O1S#^]G273,;WCW Z0DTH4W!/I"2VTF?P"9X>1G!Z<@8G0#E,*&/F1ZC( MUR8/R^:G=22=LBAHZOJM#196FRZ1^/8>$$:Z!\ S&+TM:FN>OX5=_IK0T M[_?WOM)5S.%^9MO3-ZHD*?8\T[0*Y0J]^..'=K?U>9_L_T3VI@B=I@B=8^RF MJ(8TI<1U*V[,V%&X3W#%UZ+OSLU(ZKM.]/_25/-L0N2"<@4,YX:R=7%UZ8&L9D1E:%&Z M-IL);9K6;7,S5E%:!W,_%T)O#1N@&=3Q'U!+ P04 " "TA8-:>9-Q)PD# M ""@ &0 'AL+W=O[V>[)AV!U]N0 WW\'];?]^V!X\=(/V8]HZ M G?M8-P?@O,.XA!'[!.X!)-1!YR??0)G "=@O"1K!I,9:ZI<<,K1U#!CNMDQ M&35,'11> 5._ (9F6!7RX'2YN2]717;R%!EYBHS4GUGC+UA3BA(.(&.(5X:S MTWNI7NZ;C6]8GJ8UU4V1NL+*-"PSM]J#,W,X\RAUSU9I])V=[L3IY MK,Y_KF#G(,>&KI?FX=#&TVH6BIN#N6].0O@FG'LXL&FZ);H*(\.N62->CN?] MX^;R#D>S+:^$=&C4T.R:C#5RI,9[;*U&Q=8R3:<$6&55FS1=^WNE:"?/ZAN< MF:=]!-&O%?D,R)]] M_A]02P,$% @ M(6#6OM2KM3" P RQ$ !D !X;"]W;W)K&ULO5A=C]HX%/TK5KJJ6FD[LT_.<N:X,0DBHO.%;8/K*BHN$*GTJUJ[<"J#+-"F)70_CKIO0B#G^(!U[%OZ M[U0<,7@62.Z2A(H?8XCY8>@0YS@PB]:A,@.N/]C2-5@.'6P800R!,A!4_^QA G%L MD#2/;SFH4]S3)):/C^B_I>*UF 65,.'Q7]%2A4.G[Z EK.@N5C-^^!UR01V# M%_!8IM_HD,=B!P4[J7B2)VL&2<2R7_H]GXA2 NE>2/#R!.]M0OM"0BM/:*5" M,V:IK'NJJ#\0_("$B=9HYB"=FS1;JXF8>8QS)?352. [YB2=9(SG'Z*8_Y7]CXA MMQCC@;LOBSD/\SJ=@V6FD.>7LT^LK(GK=+L73=@O MR/4;R3TP!2+@R9:R'_KM%T"TIXL8:JGVS\O PS54S^,(KL95J-X65&\;J4[2 MEPX(]*1]A)0\C&]P#U<^Y(WOK\VJJO%. M:KR?JX.7 _\?ZJ"9S=5.L(16G;M35T2LMT7$:E]D"ZVJ_]09D>;6Z/I*:/^G M2K@RJZKFU$"1Y@[*O @*6Y>L/H,]L!V@,; @U(O C94ZL-J,V4*KSMRI'2/6 M^S%BM2&SA5;5?VK)2'-/=GT=].H;[VBA\^\;H;FE9K)VX3G<+)$K_OK,5 M9S&:[4B,S8Z$65:_&1^1NU&Z/G=/,-DVQR,5ZXA)%,-*0^*;GO:;R'8.LA/% MM^GB>\&5+H?T, 2Z!&$"]/45Y^IX8FY0[-_X_P)02P,$% @ M(6#6E9T M./-R P 30H !D !X;"]W;W)K&ULM991DZ(X M$,>_2A>W=;5;M2."B#JG5"$R,U;-J"6Z\W!U#Q&B4 N$2X+N??M+ L,Y%F/Y M,/>B2=/]3_^:)/3X1.A/%F/,X5>6YFRBQ9P7][K.PAAGB'5(@7/Q9$]HAKB8 MTH/."HI1I(*R5#>[75O/4))KSEC95M09DY*G28Y7%%B998C^,\4I.4TT0WLS MK)-#S*5!=\8%.N \VVQHF*F-RI1DN&<)20'BO<3S37NO9'T5PX_$GQB9V.0 M)#M"?LK)/)IH79D03G'(I0(2?T?LX3250B*-OVM-K5E2!IZ/W]0?%+M@V2&& M/9*^)A&/)]I0@PCO49GR-3D]X9JG+_5"DC+U"Z?:MZM!6#).LCI89) E>?6/ M?M5U. LP[ \"S#K O RP/@CHU0$]!5IEIK!FB"-G3,D)J/06:G*@:J.B!4V2 MR[<8<"J>)B*..X'WY,^VSSXL'V#M>\N%-W^>NYOY'+7?@#+[2;8N(O9?/$(#\LU3-U@[H$PP&S^O!4!L/ W\+P, ECY:_"6 M+R]"4 7#UQGF*$G9-[B#;3"#KU^^P1?0@<6(8@9)#ML\X>R[,(KQ)B8E0WG$ MQCH7N#)I/:S1IA6:^0&:8<(+R7G,P,\C'+T7T$6=FF*9;\6:FE<59SCL0,_X M#F;7M%H2\FX/[UU)I]>\NY[2&WR@YR.:)_F!P0I3"&3YX$]WQS@59^.OMGI5 MVEF*01IDQL,W'.D["M(-4J0[6*O.^.SIUE]4=C M_7A.VN)E6SUKV+B]8^@W#/W/9(B2M.27N[BBZ-]$T>)UA<)N*.RK%*_JGL31 M'3IB*J[]=]DS*!F.:J9"I%^]B0J[$)M6>;4A58OVSY(U;,.R1X/^!56+8]^V M1]; ;.<:-%R#S^2JW\X-9(-;R5H&PO=V]R:W-H965TLFEII M)2$!VG40B;>IDP9%9&P?IGTPR4&L)C:S#73_?K8#&700M5*_)'ZYY[E[[I*[ M]I:+1YDB*GC*,R8[3JK4ZLYU99QB3F2-KY#IFP47.5%Z*Y:N7 DDB07EF>M[ M7LO-"65.V+9G$Q&V^5IEE.%$@%SG.1%_>ICQ;<>I._N#*5VFRARX87M%EABA MFJTF0N_&GRGN)4':S!*YIP_FLV7I.-X)B#, M,%:&@>C7!ON8989(A_%[Q^F4+@WP<+UG_VRU:RUS(K'/LQ\T46G'N74@P059 M9VK*M_>XT],T?#'/I'W"MK"]\1R(UU+Q? ?6$>24%6_RM,O# :#>.@/P=P#_ M.:!Q!A#L ($56D1F90V((F%;\"T(8ZW9S,+FQJ*U&LI,%2,E]"W5.!6.A]_@ MZT,4P60XA?[#:/0PANB^.QW"Y0 5H9F$,1&"F&1?P37,H@%<7ES!!5 &(YIE MNA:R[2H=BB%TXYW;7N'6/^.V[L.(,Y5*&+($DV,"5VLHA?A[(3V_DG& <0V" M^@?P/;]Q(J#^R^%!13A!F=? \@5G^*8HE:"QP@0BQ>-'F#&J)%Q.HYF\@I\C MS.@R M1:\3FJW-MP,R)=K%*<$%2].RF*:S"?V&W_2\MKLYE/*_V4T0?/1N2[.C()ME MD,W*(">Z:Z 099FJ*E/)]-K*O!'9D>A6*;KU0M'2BD[HAB;($B Y7S-U2GM! MV#C(?MVO!<]*5.GUM9K<@Z:6HUC:7B\A-A$6;:$\+<9)3X\3VW:?G>LQT[7= MU?U'4\RH$1%+RB1DN-"47NU&%T44?;_8*+ZRK7/.E6[$=IGJ48G"&.C[!>=J MOS$.RN$;_@502P,$% @ M(6#6IRN'3TV P ,PT !D !X;"]W;W)K M&ULM5?=;MHP&'T5*ZNF3MJ:."D!.HA4"EV12EOQ MTUU4NS#!$*M)S&P#W=O/3M*$B<2@J+LA=N)SSO>!S\'I["A[Y0'& KQ%8 J=6230V25A.T+([$ZE>9"":?$HD3WN3F;M"?W0_ XRT874]GX^%T M.)BHV?WCPX]OT\%X!/J#WA2<][% ).1?P!D@,9@&=,-1O. =4\@R%)GI9Y*] M5-*ND.QC_P(X\"NP+?L2S"9]<'[VY5\:4W:1MV+GK=@);[.2=R[ ,.:";>2V M$>#E7BX 0X$C_JNLRI3-*6=3;KCB:^3CKB&W.\=LBPWO\R?H6M\UM3IYK8Z. MW9.M-\IJ2E&M!*4,M?4<:'7,;8G492YU>4S*+9-*48T]*0C+E1JY4N.84K-, MJ7&@U"H7#2V2HV7P4YP'BQB"^IS MJ])[\#"YG"JU(KJ@/KOD1MXPZ;M]_^FKNYV+ (3NAYH/:@.U;KE%C$)] MCE:Z[S!'[7:[XK"E1UD53[C&6GM#3B:#K MY%0\IT*>L9-A(-]J,%,+Y/,EE?^^V40=M//W).\O4$L#!!0 ( +2%@UI9 M)&'TN@T ):_ 9 >&PO=V]R:W-H965TF'=/V89E_RJ92%^#J?)?E-;UH4B[>GI_EH*N=1 M?I(N9%+^RR3-YE%1_IG=G^:+3$;CNM%\=JKW^^>G\RA.>K?7]6,?L]OK=%G, MXD1^S$2^G,^C[.F]G*6/-SVM]_+ +_']M*@>.+V]7D3W\I,L?EU\S,J_3M?* M.)[+)(_31&1RV(L)]%R5OR2/CIR]8+.*F^4SO+Z_^+Q^;D7PYX8+?,BG:\:ETLPCY/GG]'7 MU8K8:% ZW0WT50-]J\'9Q9X&@U6#P5:#R_Z>!L-5@^%6@X&^I\'9JL'95H.A MMJ?!^:K!^6L7Z6+5X&)[+>U;K9>K!I>O;7"U:G#UV@9:_^6=Z[^ZR?K-WGFW M]S9Y>;NU[?=[?Y.7-URKW_'3Y\]B_4$VHB*ZO<[21Y%5SR^]ZI>Z&NKVY>37V/J8DP38II+LQD+,<=[4UU^\&A]O:!_G4%<%JNH/5:TE_6 MTGM=*;Y;WI^(@?9&Z'U]T+% ']3-+7EW(O3+OG5S[;+KS5 W-^1HO>J&'U=S[\#[OLA. M1'__POOJYF&4*5][\/I5U_6Q"5_SH>UW-6\5P6 ]5 QJ[V+OXMP5PDWR(EN6 M6^Y"_!&43Q!N(>?YOSN6[OVS-NC6J@G)VWP1C>1-KYQQY#)[D+W;?_Y=.^__ MJZO 2,P@,9/$+!*S223FDUCPC%W66+6K_'"K]9__ MNSY]V"QBJ-=6$9^MB_A,7<2M&GY3[G97._9Q"NZE;*QU8W MB1DD9I*816+V,W9V\!/FD+VZ).:1F$]B 8F%$-8J\?-UB9\K2_SGR22?IIDL MZSCY(J+1*%TF1=Y5T$KGV((F,8/$3!*S2,P^W]UD:%>[Y4SVZ9*81V(^B06[ MJU8_.]O=%D-]M@KU8EVH%\I"+7>CEUF4C*2PXJ3\66U[_PCE_$YFG?O22NW8 MQ@,1""&N5_N6Z]"_1PVB79.F3F$%B)HE9 M)&:3F$-B+HEY).:36$!B(82U2O]J7?I7RJU^7?IQ4LB2+D06%9W[VDKCV((G M,8/$3!*S2,Q^QJI3P.L)9/^D?S&\O-K\;VNB3BZ!2V(>B?DD%I!8"&&MPM;Z MS6GTOK*T/_WV7M3E_>X^D_)YPZZ8SZNU8XL[IYI,M%,+U6Q494_51KRSTM'0&ZH9VFXFJ7,;C@;:4,U&-0?57%3S4,U' MM0#50DIK%WH3@=/4&;C5-ER4^^?Q%RD663SJKFPT\(9JQDJ[VJCLP/ :SL3 M3S+*NHXBF.AR6*AFHYJ#:BZJ>:CFHUJ :B&EM:N\2Q.N[6S"T3@JOFH%J!:2&GMXFYR<9HR M>[/U_10QB4;Q+"Z>Q"B=S^.B/IM6[H>+:%Z%VCLK'HW*H9J!:B:J6:AFK[3- M P_#X6ZP'>W4134/U7Q4"U MI+1VR3=Y.$T=B%.D9L1?XMVX' ?B-(EFXF6_ M79FI08-SJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6DAI[6NO--DZO8]F:G0T7(=J M!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%E-8>")IPG:[,[+SZ#+R:.7H 0$-U*VWS M#+Q^.;SJOFH%J!:2&GMRF[2 M3MW^Z(HF->/ :U.#3;O'C-3VDA<^7A>74O1]<]&JE#-1/5+%2S4JAFH9J*:A6KV@7=SL/?HAH,NAXMJ'JKY MJ!:@6DAI[6IOXGJZ.JX71E^1W0(TM(=J!JJ9J&:AFHUJ#JJYJ.:AFH]J :J% ME-8>'YILGW[%[A:@\3U4,U#-1#4+U6Q4P#[^;Y_MT"=#E<5/-0S4>U -5"2FM7>Y/1 M&Z@S>E6D_\/S-WBLEV_PJ.;_:N[HHD>S>JAFHIJ%:C:J.:CFHIJ':CZJ!:@6 M4EI[(-";@4!'Y_\#--J':@:JF:AFH9J-:@ZJN:CFH9J/:@&JA936'@@V;ANK M#!]M?Z^WN=GW>]K*"R37TKK[QL4]WCOKHZV7PYBZH6>K__W=_*GYE9%V6;NR<1):O+F<7_+1^(BB*KOU%9WWM 1'EUB_MR$<8B M3D11+OIJ.:*7;V-VCE[D^K10S48U!]5<5/-0S4>U -5"2FN/7DVT<:".-KI) M611E">ZMVLX1#,TX#G8OY5=?LW/G2_4&VJ_9U6_G323EYK"SA-&XXH'%JQ?GL=P>UXLT+C?( MU85(B\?T^6!;N6W.TN7]5/P\*M([F0EM\*:< >AGG3,4-,OX_RUXYQ;_6\1J M'M-<#:*R.P<.--R(:BZJ>:CFHUJ :B&EM0>.)MPX4%][;VOGY65"_^;P;;Q6 M<'4;@F+C-E);%_GZH.[_Z-T3-+^(:A:JV:CFH)J+:M[+!VGK?F3:6?N3Y+_N M Q>@"Q<>7KAVX35APH$Z?O;RK8-9_.BVJ8..S??:,00U4Q4LU#-1C4'U5Q4\U#- M1[4 U4)*:X\+3>QP<,Q5 M^(L740/)U4?Z7EIW$UTX^[[]ZEYH\>5M"P(JJ9J&:AFKW2MF:\YUL38P?MU$4U M#]5\5 M0+:2T5L4/FQ3B\/ ->O?EDL1?XJ=R?WXJ@C1*1)B.XTD\BNJ-RNMN MYZON^]CA -4,5#-1S4(U&]4<5'-1S4,U']4"5 LIK3UJ-&G&(7L[WR&:9D0U M ]5,5+-0S48U!]5<5/-0S4>U -5"2FL/!$V:<:B^0.$WQ0#4YM&C 1II1#43 MU2Q4LU'-&>[>&UGK#$6X'<_LCFUXZ!+ZJ!:@6DAI[2INHHA#=3SOP$[ ]I6. M.FN:##=]0#4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)*:X\-3=!O.&2G^FC&#]4, M5#-1S4(U&]4<5'-1S4,U']4"5 LIK3T0-%G!H3J!]FU3?30NB&K&2MNY%?C. MS<#1;JW7=FNCW3JHYJ*:AVH^J@6H%E):NX:;V-Y0'=L[--'?NG919T6CERE$ M-0/53%2S4,U&-0?57%3S4,U'M0#50DIKCPU-LG!XP4[TT:L5HIJ!:B:J6:AF MHYJ#:BZJ>:CFHUJ :B&EM0>")DHX5,?.OFVBCP8*4BZS>_E!SF:Y&%4W!K_I5>?T MUH^6M3VI[IC[UM)ZISN/O]/>OM.KQT\;YO9Z$=W+,,KNXR07,SDIR?[)1;D_ MD\7WT_4?1;JXZ6D]<9<613JO?YW*:"RSZ@GEOT_2M'CYH^K@,&ULM5A1C]HX$/XK5JXZM=+=)DX@@3U @H7NKE1:!+N]AZH/)AE( MU"2FM@.M=#_^["0;"(1H6847B)V9SS.?OR3CZ>TH^\%] (%^16',^YHOQ.96 MU[GK0T3X#=U +.^L*(N(D$.VUOF& ?%2IRC43<.P]8@$L3;HI7,S-NC11(1! M##.&>!)%A/T>04AW?0UK+Q/S8.T+-:$/>ANRA@6(Y\V,R9%>H'A!!#$/:(P8 MK/K:$-_>X:YR2"V^!K#C!]=(I;*D](<:/'I]S5 100BN4!!$_FWA#L)0(YB,GS]-T)>/:/RX M&-[?SR?WPZ?'+Y_5S'SR=?+Y>8+>CT&0(.0?T-_H>3%&[]]]0.]0$*,GGR:< MQ![OZ4)&HS!U-U]YE*ULGED9FVA*8^%S-(D]\,H NDRCR,5\R65DUB*.P;U! M%OX+F8;9J@CH[O7N5DTX5D&ME>(YY_ "3M9K!FN2"I:NT!RV$"> OGV2INA1 M0,2_5Q&7X5K5N.K!ON4;XD)?DT\N![8%;?#G']@V_JE*NB&P$@6M@H)6'?H@ M3[@JQ\RQDSJJ=\UV@+'1L9R>OCV,OLK,,=K=PJP45[N(JUT;UP.04/@N87(7 MGM"W*41+8-_1?^@)7#^F(5W_EJHDRQ \-$JX].8<+6B8J)WDA4-57K4+7[IW M#8&5.+(+CNPKR==NDH*&P$H4. 4%SEOEFSFV#W3I6+9C'JFWPLJV6T:U>#M% M5)VWB7?&Z$H*5>X6"=%"FUPLRT#-.L%BP^*#+P6R4;Q"*(UTC6$&@J2PQU M_2KIUJ]XZ<8UA5;FQ]SS8UY)OCEP4S0TA%:F85\PX=IBI%; UHDRK;;3/=;O MJ979M3MGY+NO8G!]&7-6OO>,)ALT2YCK$_YZZ=:N=O&>-816YF9?2>'VM:3; M:*G4%%J9AGVQA&L+D5KIVB>B[+9/WKRG1MAH6V>4NR]@<'T%,P4O<&4U,&/J MO.R"?,?&\G0NS^&B7J*UL!?O34-H91+V]1+N7$NBC19(3:&5:=B72+BV_*B5 M:/?TF-5J62Q$%82TKAQY(/#LHY--A!TDS8]EE0(&J67/A / MF#*0]U>4BI>!6J#HFPW^!U!+ P04 " "TA8-:!Y W%NH# #(#0 &0 M 'AL+W=O M*/O.-P "_4QBPD?*1HCMO:KR8 .)S^_H%HB\LZ(L\84B/2"74\W/IK MF(-8;%^9'*FE2A@E0'A$"6*P&BD.OG=Q/W7(+-XC./#*-4I#65+Z/1T\AR-% M2XD@AD"D$K[\VX,+<9PJ28X?A:A2/C-UK%X?U1^SX&4P2Y^#2^,_HE!L1HJM MH!!6_BX6,WIX@B*@##"@,<]^T:&PU104[+B@2>$L"9*(Y/_^SV(A*@[8O."@ M%PYZW:%WP<$H'(PLT)PL"VOB"W\\9/2 6&HMU=*+;&TR;QE-1-+7.!=,WHVD MGQC/W2=OLOCJH9='Y#XYT]^].7J>(L=U7Q;3MSF:>:[W_.X\?/5ND/LR?9LY M[AMRYG-/_DXG:.(]>K.9-Y%V[]YTX:&K"0@_BODUND6+^01=?;E&7U!$T-N& M[KA/0CY4A>1.GZX&!>-#SJA?8,0Z^D:)V'#DD1#"VX/\GL;.E MZ)5+T>M2'SM!0'=$<#2# **]OXQ!9M(4Q UZD:4K(NNV\'--.]-,"]=^C+%M MVT-U7XVKQ:IG649I=0;<+X'[G<#EZW(X!\$[,7.E?@6@KPUZ-=O&8#!1NV5N-M-3+;>:V2U_H@;TS)&@E@ M23>QU8#1^V8-N&EC]/1V7KODM3^;M1$)9'OE,H00\BL9 0'11F\WR&R[3M^T MN=5MN]_./RCY!Q](XIL*:\E_$7K0!++,>I(TCK19G4AS7&E^^+_D.@?"@*W?(>X'D/3Z/;2MXKU4Q#Z9[/?C2F_\*D6 MHF? NF75RV&;V5EM/X<^M5S&ULK591C]HX$/XK5EJ=6NEV0Q)(8 \BA'/W<"^)[Q2I@G.AQM>P[*=D*R M^NBL&-2$-F_\XQB'$P2@VA^A17DJNO1/G)>)7>S6?K^SE:W*+'93*;H^3^?O&4?$KGZ':Q M1+/%>OIXN[Y'29HNUI\>5^C=#"0FE7B/KM!Z-4/OWKY';Q&AZ+%D.X%I+L:N M5,PTOIL=64P;%OXK+#P??614E@+-:0[Y[P"NDM3J\E]T3?U.Q!EDURCP_D1^ MS^];"*7_W3WHH!.T80X,7O0*WA+V0'> "LYJE"JI7/V_ZJAEB5)SR,#1Y^19 MF/4OM@ V^($=7^?ZC=CB#":.2F8!? ]._,<;+^S]91/_/X']%HI^&XI^%WH\ MA0VAE-"-2K\*TPQL:AN(H8'0A6@?#Z/1V-V?BK#8Z+/:6[@-6FZ#3FY)SK:F MNK "):L4!7YH8]<)8@\?LAU#@S,X4> -0[N"L%40=BIXX&Q/=(FU\0XO]@N" M_EE4+VWZ@[Z=4]1RBCHY+2%C>^ $A(OSK^IW5UU 6JM$=+&Y?T;OTL+K179Z MPY;>L)/>$R<2KEA16"D-+S:\"J+A&2N+43CR[+1&+:U1)RU5"?\E24:7"1!$ M9\PL-B>)U!!S3]J'*D0;TU4%RMB.RJ;BMJM-XYZJQFT:W-FZ:NB)Z6/N+YCF M-O 1=:1BQ9L.VTPDVYHF];$/P%02P,$% @ M(6#6MV(T5O4!0 1B< !D !X;"]W;W)K&ULM5I=;]LV%/TKA#<,+9#&HN2O9(Z!Q$RW#DL7)$OW M,/2!EJYMH9+HD73<#OOQ(V59,BN&K0WZ);%DWJ-[CW6IZY M.NK6*$F:0R%25B .\ZO.-;XD41E0COB0PD;L?4:ZE!ECG_3!N^2J$^B,((-8 M:@BJ_CW#%+),(ZD\_JE ._4U=>#^YQWZV[)X5/!"0%@% MA%\']%X(B*J Z'L#>E5 KV1F6TK) Z&23L:<;1#7HQ6:_E"264:K\M-"_^Z/ MDJMO4Q4G)P^W'V[?/]VB5P0D33.!WE/.J?XM7J,WZ.F1H%<_OAYWI;J4#NC& M%>S-%C9\ 1:'Z(X5!-=RH)JIICTJ\X4OII((N%AP6M+S[V1P]P#,4:T!__ZZ& MHG<2"H#-2SX/,$XV 4#8,@&'>?]]FPC1P&_8O62.),YLA2^W6I M?6>I!.; .21JUGVQYBU"?Z^2BZ!=QK0]3%$3M,MU)G1DN8.ZW(&SW.N<<9G^ M6_=)LBM?T P$BEF>IT(_A82-B$&KPBBT_/+M8;U1>QAQ9GHD#\.:AZ&;ASA> MY^N,2E6ZXB"-4VDK>-BJY,U@,(C:/^K4,G+8ZXUPNVQG8D>6/:K+'CG+_I/3 M!) JGJT+*=0L&4/Z3&>9FBCO()\!_XC^VWV=%@OT*&F14)X(]+1*%%EJPL:# M-SBJA]M(KKDK$AC-*49'S%E4\TX@O-)+3Q&'ATJH[T M:AV\HA%?:":IC7O 3C'M[,B+5J,-AY;U")6M>ZK'7I/>44COM!,IAN3$.(3-6KHU2IX M12.^T$Q2&ZL0.E6SJU&K2./1&8W:C5J-,URAK5'=F1Q;::/?0[=^W]TLTR]Q M]MU*UHUY\)WC=;RDHEP-_OIA;.7*DYJO"/6)1GRAF80V3B,Q1)M4+JMW_, 1U>N=5BI'[5[&MH>P5_?@"\TDJ7$/X;?< M@UYJ4WKZ+7RK?;V^;?"*1GRAF7L,&F,2!:?:9>#5@WA%([[03%(;#Q*Y7U0< MVKX5W+XV[@TMB\'NRQY,DE=/T=W;8*2*790;M?3+=R4_MEMXZK/;S6 W^'): M[IGZZOPUOKPNMT9U&YCM#K,[RA=I(5 &WF[:V!Y*MRFU,,R85 MX^7')= $N!Z@OI\S)G<'^@+UUKG)_U!+ P04 " "TA8-:89&9=4(. !5 MP &0 'AL+W=OZ; MB\26.0\IYQQYQB])73TGZ>=LKE1.OBX7<78]F.?YZNWY>3:=JV68G24K%1=? M>4C299@7GZ:/Y]DJ5>&L&K1A\&4;QX.:J>NQ#>G.5K/-%%*L/*:4W3199]3=YKK<=#LATG>7)LAY<',$RBC?_AE_K;\3. ,L],L"N M!]A=!SCU &=OP-%#/4 K^N 43U@U'7 N!XP[CK@HAYPT77 93W@ MLNL :_CR/S>L*FCS7U[5BQ_FX*3'__QT]5Y7NR]-,ZG]9[\S9[L(WNR;/(^B?-Y1H)XIF8Z<%X<]O;8 M[9=C?V<;Q8E:G1'+?D/LH>VV'-!=E^'6T>&^>;BOIF?$.3X\Z#[<:1E.S<.I MNB\.WJN&CUN&L^[#1RW#>??A7LMPT7UXV[=.FH?_ECR=D:%;#1\:ZLC9]H!3 M>>,CWMTBS#*2/)!)GDP_DS]_+;Y.1*Z6V7];#N[=!G/:L?+GV=ML%4[5]:#X M@96I]$D-;G[XWAH-?VDK423F([$ B5$DQI 81V("B4D0IK6$NVT)UZ3?W"7+ M93%[R>9A89.Y6LQ(F)&\F(%EZ_0;R5-_N:U'C'K?'D%B_@;S*JRM:P]0U],DR]NJVFCWK6HD MYF^PBYUR'8V*)=)PKZJ[;4:1A\:0&$=B HE)$*95]6A;U:-.5;VIWJ+[;U?'&BGI.I4K.,/*3)DD19M@[C:?7J.5%I5!3V M.]*4_&13\K'*RPW4UY6*L_9UA'&G?0L>B?FOP$C;3X&+@RF9Y=KCPX9 'CQ# M8AR)"20F09C6$)?;AK@T-H0?/44S%<_J5_:?RU_BS\@J_+8L)@>D_(UJ_*C* MCXOE1IC-VXK_\K TK);7RKN6[9R6[?S+@]=>SVU[C38^L;X3$R3&D!A'8@*) M21"FU:TU;!*!8:?*S<@ZGJGIHJC>ULF(F>G[X@S5_%K;K77+;FN* +I?"M48 M5.-034 UB=+TDM\)P:R.)1_%Y6NS"M/6Z8B9Z5WR2,VO-:WDQ^/6DD?NET(U M!M4X5!-03:(TO>3MIN1M8\F+EREZ^I/N6L:D[.8V)[_/%7D?II^+!2<-I]$BRK^1/]^KY;U* M6R->L]B[]*$A+U0+H!J%:@RJ<:@FH)I$:7J'-&&OY2)/@+"@Z2Y4\Z%: -4H M5&-0C4,U =4D2M.[HXF,K6Z9\2;=>0JC17B_V 1+6;A0K1T"38JAFF\=AL#> ML/5W]=#]4JC&H!J':@*J292F5W\3+5OFT/53/%/I#9W]#H!FM%"-034.U014DRA-[X FJ;7, M4>VD>)&O3@,X==*;V>E=\-!\UCH,7@]>[D]N0J''Q* :AVH"JDF4IE=PD\U: MYG#V]Y?SV^KYO6GE"TU^R)CO M#JKY4"V :A2J,:C&H9J :A*EZ9=7-4FP;4Z"-TV1JM4ZG<[#3)5G2CZFX;(\ M92$V$.K[>*J 'HX%*HQJ,:A MFH!J$J7IW=&$QK8Y--X[G\TXK3)3O;L!&AQ#M0"J4:C&H!J':@*J292FMT83 M+MLV_9"T6">M8?57I-,J.5#XT=89J/E0+[,. VK+LBY;*A\;4 M4(U#-0'5)$K3*[^)J6US3/VR+DC6>9:'\2R*'UL+'AI10S6_UDRG69S>A$*/ MB4$U#M4$5),H3:_?)DRVS9?\3C97NM_N7^EN7NA"(V6HYD.U *I1J,:@&H=J M JI)E*;?:;&)E)TAZ/^E[!P]VYR=GP8NQ>[O[9NZT$]!@"J$:A&H-J'*H) MJ"91FMX'37[LF"]./MH'X3)9%RN$E4HWH5EK3T#3Y%JS[)V>L,^LB[&WWP;0 MH!BJ4:C&H!J':@*J292FM\'.?:E[!<5D$7U91[/->7>KZFLJGK;W #0LKK7= M2\;L@_)'[C& :A2J,:C&H9J :M+\_ZX7=9/^.N;T]W5G/YC1W@4-S8.=PYM% MN]ZHY>P'Z&XI5&-0C4,U =4D2M/KOXEZ'?/EQ ?U7WRHEJOZ13V:JA.S&VCT M"]5\J!9 -0K5&%3C4$U ->D<7BY^]&= $^@ZYD#WH >V$WQS[4-#7JCFU]KN M]^G@Y7^SR:6VDMA?1U#H83&HQJ&:@&H2I>DEW<2VCCFV;;N%W)L3Y0Q-;J&: M7VN6LU.LSMG0W2]IY$XI5&-0C4,U =4D2M-+O\EM'7-N>S+W(G^1.Y7FT4,T M#3>WU+]=%JU2W0G7E(V9]]N[0:!)+U0+H!J%:@RJ<:@FH)I$:7H?-?FQ [T8 MV8$FQU#-AVH!5*-0C4$U#M4$5),H37]#LB8Y=LU7Y?;.QLQ>W_ZHM;T[!EG6 MWJ]!H3L-H!J%:@RJ<:@FH)I$:7KA-Z&P^\I0N$L89K9[-X'5807K0_<90#4* MU1A4XU!-0#6)TO0>: )AUQP(3XZ\B8QQ^6 V>]<^]+)BJ!9 -0K5&%3C4$U M-8G2]!YITF+702X?7&A$#-5\J!9 -0K5&%3C4$U -8G2].[8>4/CGK%SO]C- MK/?N%NQ;&D.O1X9J%*HQJ,:AFJ@U;6[L'4R.)6JG>ALTZ;/;,WWNEKR9U=[E M#TV=:\UTS4V]B;YNL0[>S!L:$4,U#M4$5),H32_I)DQVS6'R*Y(WL]B[G*%! MLMN6$GO>?D5#[TP-U1A4XU!-0#6)TO3*;S)G]\2=J4^MBLE?A":IFH:9.6@S M[Z=W/T"3:*@60#4*U1A4XU!-0#6)TO2^:0)K]P*Z4H;&T%#-AVH!5*-0C4$U M#M4$5),H3>^.)H9VS9W<+-+"&:@%4HU"-035>:WM3MKT9FX#N4Z(TO0N:(-HS1GF= MYEBO>%-F\UY[=P^8<^_5O2VN&>S<*-,JNM5-O2PO=*85J#*IQ MJ":@FD1I>@E=\-"P&ZH%WN&ML;W+\7BO?2ATIPRJ<:@F MH)I$:7K!-VFW9TZ[/Z3)5*E91A[29%G="CZ,IU4+'%MPO"%QL;@H-E!?5RK. MCK0'-/N&:CY4"VIM-V&PW)9WZ:'0W3*HQJ&:@&H2I>D-TL3:7J?KL/_.NKO8 MXGWX-5JNE^:E.#01AVH^5 N@&H5J#*IQJ":@FD1I>F,UB;@'O3#;@R;@4,V' M:@%4HU"-034.U014DRA-ZXY1$ZF/S)'Z[?;&?233UR1/X6+=N@8WBWT[!*KY MM;8[2W*\UCW=OGX>!B2-'N?;3_)D M=3TH?D+=)WF>+*L/YRJRD$ #.%@ &0 'AL+W=OE87;NGTS'9\S3)X9XBML\R M3'_<04J.$\NU7BX\)-L=EQ?LZ;C 6U@!?RKNJ3BS:TJ<9)"SA.2(PF9BS=Q1 MZ':E0+7X*X$C.SM&1%)F?I&Q[)M MOV^A:,\XR2JQZ$&6Y.4O?JZ,.!.(@;8+O$K@O1;TWA!T*D'GO1&ZE:#[7D&O M$JBAV^78E7$!YG@ZIN2(J&PM:/) N:_4PJ\DEW^4%:?B;B)T?.I_62SFCXMP M^;A"LV6 _"_+Q_GRCW#IS\,5^A QTG*T!)3BF5*/Z)?T=,J0!]^_CBVN>B MQ-A1%-U[[Z7W=YX6&$!T@SSO$_(OFLH&]%;YC1J5/94;S!&[S/A#'D M"X.3? MYE !#7S^+-FC.(6/_M'3PK@1VVH%RCAJQ DP)K^\I/; M=WYK\]HD+# )"PW!&EGIUEGIZNC3 &=BPF6HP$F,#CC=0ULBM(QK$V$2%I2P MH8+)M\YA.N@YXC.V#^<6&XK9L+A76]Q[E\6,[,5; 7&*Q7N,EV^R%'.(4408 M9VV^:\'7^MZ[L&KH7%H5E,UZ9\V\X5"8^LI10UUK.-JO'>UK'7W*U=]U ]#J MFE9\K6LF84'_(@6>V[\=OK+64,B&M8/:VH'6VEE\P'D$"&=DG_,V=[7Z:]TU M"0M,PL+!9:J:3TO#WF%M[U!KKUC9\A3$2I:C*,5)IO%9"[K6Y^'%:#JBZ<6S M;S)F: C6\/FV]OE6Z_.#F',+@F8Y,+X#43:D9)N(2?83NO?1UP5D:Z"M2PXM M]EK73<("D[#0$*R1&]H=TTO!BF@H,49I@5%::(K6S,U9P>5JGYR%6)IL M\?N6)Q7J?%IQW<'%M.+K0UYMMTE::(K6M-L[V>W]_XD*_8MF443W(A?A 8Z"R@;B_(82_G,@ ]1;V]#]02P,$% @ M(6# M6B5WRONQ @ DP< !D !X;"]W;W)K&ULK55= M;]HP%/TK5E9-K;0V7Y"P+D0JD*J3VA65=MNK22[$:F)GMH'NW\]V(*,TI'O8 M"_[(/>>>V+=(<2BPN6 54/5DP7F*ICGQI MBXH#S@RH+&S/<0*[Q(1:<63NICR.V$H6A,*4([$J2\Q_CZ!@FZ'E6KN+![+, MI;ZPXZC"2YB!?*JF7)WLAB4C)5!!&$4<%D/KRKT!'PGL!%[>Z2=S!E[ MUH>OV=!RM" H()6: :ME#6,H"DVD9/S: MP V. +PMP#L$](X _"W -T9K9<;6!$L<1YQM$-?1BDUO3&T,6KDA5/^+,\G5 M4Z)P,IZ-;Y+)TVV"[J_1;7(U2U#R9V) MVNN,.DH<- Z"3@??,2=X7L [^H,W^KW!@8&W(;[77MVPT19V:GMD$A>J)5 U M8;KEA2TOP, _$-@2%#KN@41[K[^5P)>F[0N5>$5EW2J:VWJRC-1D,1WXX%Y- MG"O3:.V_-/6XNL-\2:A0EA:*TKD(5=H)G#\1]02P,$% @ M(6#6D1E90EV P U@H !D !X;"]W M;W)K&ULK99M;^(X$,>_BI5;G5II:9X#] ")0JI6 MHH!XN'WMA@&L36+.-M#]]FLG:98F)G=[NV_ CN<__LWX:7IGRK[R/8! ;TF< M\KZQ%^)P;YH\VD."^1T]0"I'MI0E6,@NVYG\P !O,E$2FXYE!6:"26H,>MFW M.1OTZ%'$)(4Y0_R8))A]>X"8GON&;;Q_6)#=7J@/YJ!WP#M8@E@?YDSVS-++ MAB20=-W[ 4$<00">4"R[\3 MC"".E2?)\4_AU"CG5,++]KOWQRQX&R$?N^T3'0!K;X&(L%/3]! M$9"O_$4TYMDO.A>VEH&B(Q"R5$B=6*P'#V%X_4D1+-' MM%S/YY/P)9RNAA/T,)P,IZ,0+9_"<(6>IX^SQ\9PH)JZ8THP+L(0=SKH"- M(;I#KOT9.9;C:>2C_RYW/\I-F:(R3TZ9)R?SU[[B;P)RKVC#R'6N7J=.X3T_ MX CZACQF'-@)C,&??]B!]9C5>]'S^B6OW\@[I6DK^G_,O@;'JS+7 MC1S?#O3,0"6;=H^5=6U[9^O%76 MS]Q0_#/ZDCW3L$'X)(-1O^B]'(E"E!" M4['G#1>S??%(V[\:^(;PB![EU2(-M=NKF$+AEVMBW=E>=>6NV%U\4B&KFJRYEX4G,&4@Q[>4BO>. M*FW*4G;P'5!+ P04 " "TA8-:-)7LM;(" "-!@ &0 'AL+W=OP9L.8;8<^0MXFC[.%A-O^32;PL(?>TM_",L9C'TO\ .X'J(@2L@B%<7]W %20Y+&.ZY22/>-<44K+:V PK>?U2GG5!7M."" M$YC2:VW8.ACN6Y\R#C&\ [MY"U;#$+9)"F-E M^)4300N='R]4R#32PUA^+Y"I!KF^IE0<)FJ#^@OD_@502P,$% @ M(6# M6F*H;[$V P 3@P !D !X;"]W;W)K&ULK9?O M;Z(P&,?_E89;+EMR&Y3?>DJRJO>Z8E4RH%Q;=?OOKP6&#A -N3=" M2[]//]^'EJ?V]H2^L0W&'+Q'8NE?2_4ZY$M#X,8OU# ME&$Z,<##LF^KT#EL^,U M6&^X[%"]7H+6>(KY/'FAHJ46499!A&,6D!A0O.HK][ [@(84I"-^!WC/CNZ! MM+(@Y$TVQLN^HDDB'&*?RQ!(7'9X@,-01A(#25K.VZYP&TYYG31&;LGM%-S..>Y.';=3X88=H\3=&+DEMUMPNXW"&:\M;EK%S2VT+*MDIWF^MGZ. M:CR\^-6011BLD3Q"U5=K6-W=T##+?F"E6)BF=ACUE?-0?&%CXLR/<\@>T;I3KNB=(#S44-A?1"8G7MV)91!=FM::XNF:%M3I*MZ!=8E6/ M#GORI/V,Z#J(F0!9"9EVYPBO-#N\9@U.DO3\MR!*8N_$-X_4$L#!!0 ( +2%@UJ)]4=HW , .X* 9 >&PO=V]R M:W-H965T&8\XZW2CR8'L.1G M(:291+FUY64<&Y9#04U;E2#QS5+I@EI MO9Z.U=H*+N%>$[,N"JJ?KD&H[23J1,\;/_@JMVXCGHY+NH(YV(?R7N,JKE R M7H T7$FB83F)KCJ7LY&S]P9_G2+K]DD2APA$,"L0Z#XMX$9 M".& D,;?.\RH^J1SW']^1O_LM:.6!34P4^(OGME\$@TCDL&2KH7]H;9?8*?G MPN$Q)8S_)=M@VT5CMC96%3MG9%!P&?[ISUT<]AR&R1&'=.>0OG'H](XX='<. M72\T,/.R;JBET[%66Z*=-:*Y!Q\;[XUJN'2G.+<:WW+TL]/?;Z_FMW-R>@.6 M3EZ:D#"81%IT!O8%H^O%#IY]\JA/U/X&]DMBK)/::T(-$8D$7+:P+ MPS0O7>'5:7X'D,&\MCFA'I"HY8D 8XC-J228+$5(%JJ!2&6Q.S"E,6\(EV@" MA"EIE. 9M;BWH()*!L3GO&G7A:V1SR^&[:(*VT6CV@>I&%N7')D*'T&64[VJ MSY6 -/1(KMUNILDXWNPK.;3H]$=)\F+VBF._XMA_Q]'RHJ1<8T>V==P:$?YK M'@>PBUJAKQ0,*@6#1@7?\'Y;X1U%3H4RYHS@A2"J?.62NDRM#?G@,*#)?CP# MW\$!W_-TU#D:]V'%>MC(^GL)KKG*U8[LOY15,]@62$XSD@X#6$9*C7>[MAQ, MZV2)'=Q5SQUDG%%![K6[+[%J[JC$R]D=.J$2O;O.Z@M087/FRN_K'ZU0J:[N M-+@YP/%U835$4[ERJZ56!7DI8"6!/ '5Q"J"]_,&I%^:]LGWM=X[EU#@&80S M0L:6/CHX+M&1,J;6R"J8:Y"P1=[*!\>T/)V9PHR53Q\_#-/.X!.B293$2]\5 M5!7:$MN#\>(\E#E!CM9_V4T-H=6<6W7N']P(P.L29=88_%_L(:,J3T:-1SM? M+T(8N&2J@+K<&!WD\:AWF,>'5F\S.-X;'0K 1N4F*D/\683;N=H-0]LU#FU^ MN'FSC\/8, G>8?_C>"0"E@B9M =85SI,5V%A5>D'E(6R..[XQQP' M4M#. -\OE;+/"_>!:L2=_@-02P,$% @ M(6#6C16&ULM9U;;]LZ%H7_"N$9#'J TUBB M?$LF"9!$U UM)TC:F8>#>6!L)A:JBP\EYP+,CQ])5BPK8ABK9[D/B2_<'ZEF M;7E3BZ9.GU+Y,UL*D9/G.$JRL\$RSUIC'E>/)4/ MPVPE!5]407$TI(8Q&<8\3 ;GI]5KU_+\-%WG49B(:TFR=1QS^7(IHO3I;& . M7E^X"1^6>?G"\/QTQ1_$K]0/&4[CTEY*'=I^K-\XB_.!D8Y(A&)>5XB>/'K45R)*"I)Q3C^K*&#;9]E MX.[C5[I3'7QQ,'<\$U=I])]PD2_/!K,!68A[OH[RF_3)$_4!C4O>/(VRZB=Y MJML: S)?9WD:U\'%".(PV?SFS_5_Q$Z .7HG@-8!=-\ JPZP]@T8U0&CMP'C M=P+&=&X#CC>-\ T7O]R1J6@S9^\ MTHO-([L\GUQ1AEY!N7DI?:_8U\)C]N;?+I[[^=#O.BRS)P.*_Q;(.G[^!-\C5- M\F5&6+(0"T6\]T$\U0"&Q;%N#YB^'O EU1)OQ>J(&.;OA!ITI!C0E3[<$7=' MQ*3OAMM[A&MZ9_KP@"='Q'H_W-FC=SJKPBU%N/M![^NR=Z,*IZJ_I3[<%G/M MX/W]PU6##_8/IQH=6=O$L2K>]+W$$1'/Q8)<;KB6FEM^'IYD*SX79X/B R\3\E$,SO_Q-W-B_%.E5B3,1L(8$N8@ M82X2YB%A/A(6@&"M[!AMLV.DHY]_*RH[*1Y%LA:J%- &]TT!),Q&PA@2YB!A M+A+F;6"S"E;6XX_GIFG,K*EA&*?#QUU]JUI.C?%QIV4 &F!+O..M>,=:\=Z( MN0@?^5TDR&(MR+U,X[H8$U*E9BVMKYJ1,!L)8TB8@X2Y2)BW@8UW-4JGTU%7 MS(J&YFPVZVIYW%7]:#JU=ANV=#K9ZG2BU>G56DJ1Y(1GF4+6:;K+$P>5++6XOO*&@FSD3"&A#E(F(N$ M>=..8"?CCJJ1/08@6$O\LZWX9UKQ_ZO0.\\+89,J#7XGU27*S^G]YQ]%,ER4 MIW:5Y+70OI)'PFPDC"%A#A+F(F'>K"-YR[2L[KF\VVYDEBH.J]'(;\+HS!_(9_F=<%2G-'+*R6JZXF76GA?82-A-A+&D# '"7.1 M,.]844S/%!-#13ME*0T:7$O8IM%<*S=^3=HJ(>M9?94,I=E0&H/2'"C-A=*\ MFM;6Z4BA9T5#.E;5W:CQM16]X_Z86D6[(BDD'1&>+ A?Q&$29OG&]GFMQY72 MUD)[2QM)LZ$T!J4Y4)H+I7DUK3U/-*FB"%&TI.9HTKU"$J!&V!8W;<1-M>+. M>?3SJTVNBM?#>&)^F MWOEDSV*^KJK_JR4/9 M[3.EI*&&+)1F0VD,2G.@-!=*\\RNW7H\[:Y5]!7MS-*[ZFKZ$+ZLV1BSIMZ9 MO>8O<7%FSDB>?KQ43,_J+6BH$PNE,2C-@=)<*,V#TGRS:]I6:Q8ZJC^$:4L; MTY;J3=MVU:Z;SNI!?24/I=E0&H/2'"C-A=(\*,V'T@(4K9T8C?=+S0--9RG4 M_X72;"B-06D.E.9":1Z4YD-I 8K63I3&1Z9Z'_D7EVCJJ;VS!&HH0VD,2G.@ M-!=*\VK:;LTS'G=K'E_1SK*ZL^$ -;JVLAL3F&J]L[^Z5E-/[ZUPJ!,,I3$H MS8'27"C-JVGMR:SB.HZR'54H_!#N+6W<6ZIW;WLMV=2S>NL9ZN)":0Q*=#.+2T<6BIWJ&]7KYDU6(V_4P6:LQ":3:4QJ T M!TISH30/2O.AM !%:R=%8\S20QFS%&K,0FDVE,:@- =*F+-6;LN4NCT*2;VGRV4\68B6*'TE.[%"*>9[*YCLKY'_D*DVR=53-9B\> MI!"EFZN?!T!-7"C-AM(8E.9 :2Z4YD%I/I06H&CM'?D:J]+,ZOE;-4V.UE>)$[U<9+> M5SL:-]OP*-,%:@!#:79-V_W85]2Q#-JI Z6Y4)H'I?E06H"BM?.@<7:M#YS= M?%G(O%ZIK%S760-::NJ(Z4K1JEMIVOK!]#Z10TU7*,V%TCPHS8?2 A2M+>"= M38CU!NZO[=^@A_8^?4-]6RB-06D.E.9":5Y-VST%3;L?>SZTTP!%:ZN_,7B<2U#"&TAB4YD!I+I3F M06D^E!:@:.U\:\QG:WRH^374D(;2;"B-06D.E.9":1Z4YD-I 8K63I3&D+;T M.S/?+GF!)6&6K8MTJ2;811_A_)TY!M2$AM)L*(U9BLV(N_M&.?LU@A^%!:@**U==KXP9;>#VYJH:RJA1;A8UB44(ORZL^\*'[X@WK^ /6)H30; M2F-0F@.EN36MW$%PJW_CR)A-1\>[_]YF W(,/I06H&B;;!CNW!6KF"8\5'=A MR\@\72=YV[2/$_CZN%2\(6098/B_?LTS5^?E!UL M[Y=W_G]02P,$% @ M(6#6JA&EK=: P L D !D !X;"]W;W)K&ULO5;;CMLV$/T50@V*!$A7LN1;MK: 7=EI%DBZ"\MN M'X(^T-+8(B*1"DG9F[_OD))5.Y&%+5#TQ1;)F3/G#"\SLZ.07U0&H,ESD7,U M=S*MRUO754D&!54WH@2.*SLA"ZIQ*/>N*B70U#H5N>M[WM@M*.-..+-S3S*< MB4KGC,.3)*HJ"BJ_W4,NCG-GX)PF5FR?:3/AAK.2[B$&O2F?)([<%B5E!7#% M!"<2=G/G;G ;38V]-?B#P5&=?1.C9"O$%S-X2.>.9PA!#HDV"!3_#A!!GAL@ MI/&UP73:D,;Q_/N$_MYJ1RU;JB 2^9\LU=G-F%V,M<96AGP[CZ,-RL?FX)(_OR6H9KU>;:+U9 M/?S^&XD>XW5,7B] 4Y:K-^07LHD7Y/6K-^0589RL,U$IRE,U>80.X=@;S]S#N:(?;8;!N];F@NBH)3KJ);K\ M6C']C= CE:G"YR7!I^:<*J%*B839;3PRG:&61EF7B-Y8W2DG75M7XXS.A XF M7K?0<2MTW"OT46<@"3PSC<]P?2RO[D4OTK^0,?Y!1C#N5C%I54QZ5:R%ICD* M^/ZF":ONJJ#)"PY7A\UPU,UVVK*=]K*]?!&BC,H]J+CG\Q'P+I'-$BL)Q8#F51< M)$E5,CP,N5U.:HXVIY=9OI;;Z/^.6N^$>U;\,"E[VQ,HM*^XKBM(.UNW'??8 M=MCR_-T\MB-WM@J[_\#4O!"= V:>'?4$L#!!0 ( +2%@UJ2P1QOK 0 /$7 9 M >&PO=V]R:W-H965T=/BBV '=MBY4$)/^^LNS8&(P:)\X+V$+WZ)XKZ>B@ MWIZR'WQ-B !/81#QOK$68G-EFMQ=DQ#S"[HAD?QE25F(A7QE*Y-O&,&>"@H# M$UE6VPRQ'QF#GFJ[9X,>W8K C\@] WP;AI@]#TE ]WT#&B\-,W^U%G&#.>AM M\(HX1"PV]TR^F1F*YX:3T1_PR M]?J&%6=$ N**& ++KQT9D2"(D60>/U-0(QLS#CQ\?D'_ILA+,H^8DQ$-'GQ/ MK/O&I0$\LL3;0,SH_IJDA%2"+@VX^@3[M*]E '?+!0W38)E!Z$?)-WY*"W$0 M -MG E :@(X#FF<"&FE 0Q%-,E.TQEC@08_1/6!Q;XD6/ZC:J&C)QH_B:70$ MD[_Z,DX,G-'U9+RXF8"[;^!F:@^G-]/Y=.( VW'N1E-[/AF#A^G\&LPFSGRV M&,T7L^E??X#1G3-WP.#QGK_B&^R2OB$WM4(T!K_^ MO6[V7,:P(KU*&9U:&I0Q\,<8 C MEP#, 5V"/W&TE2H"2NN<,$_@+A5<+$Z[ >S GKD[)*0=LIP0T'!I95Q:6BZV MY_FQ*)6N]R2T=9!WVVH?Y5W2I]G*^A1R:F-GJ;:"J]5%Q9HP@+U_ MI:"HUK)$VR=)?.UT.D>9EG1J=IKEJ7:R5#NO7PK) DL^Y=XCX:/,O'S_)6EK ML5\UYPFSS@FSP_55(':9$;O4$G/(CC!%S9:3X) -9E@=7O&VY^#[K6)7NL^U MP%7W>4U@A1ITLQIT/U+ONG76H2:P0AV@E9^T5KV*E^(5EN2!+"2<](-6USQX MX!S@VU4OC=7+7DFG9J-;ON<@RO-"-2M?"EB4OM;QX5+6"W7/:!_,_0#4'K/O M5#\]> 7Y2X'.+;8BN?R0A_I3?O)SZXMG8.\Q\SBP75?Z]X(&VIQ3U\>">.#! M%VN02Z9.'?6C5I6%NM"*-I7(N:T(JUR$T+U+N6ZAJIQ:NR M_M\/5.2^7X#1:CG-W[@8K_EG.;@O0VY4[-XN3)%U*" J7,_V]7]9A51:@NM&(% M=&IEVJTRX4)Y58*Z:U4=:E- 8N&]60N2CK!,RJ*8D'R&[Y!_\!4$L#!!0 ( +2%@UJBQ@M]5 , ( - 9 >&PO=V]R M:W-H965TXY]CI7KZ^Z&\6>Q!)#D-0IC MT=.64JYN=%WX2XBHN&8KB/'-G/&(2NSRA2Y6'.@L!46A;AF&HT2!J$@CQ0SJG:ETMR129CCUQ\O.SJ$J=58-W/I^AG M4U@GIC MM2D8/_&O2,#\3R[#LD@4-W@]O MEL"]]\,;%6H:Q18T4K[6";YQ,A7PDD LR7"MGG]^8 2YDQ")OV5V9W2-S8V"QN;5>SN4,@ \P#,,!T) MR1-?)CR(%P1>,4<**#.RDO!<(^LD\S*R=DJF4O?:-1NV@;^NOB[QR"X\LBL] M&I4Y0X+83S@__#(SBRKYSK7(/E+E&,ZNJ$Q\%F;OAC7MD]J=0KM3J?T!#]$% M'H3D(F1"7!(\=$+ $X-(X)A8J3J&1)D%E;3G6N <:3.-8P>.HZZLCGG2@E9A M0:O2@DG,?#]9!?B-9-+])>4+*%5=R72NZM;1QA\J/HXPGU"<+M2\'%J MO8=H"KPTK592G:NX3C*O)K(]"SN%A9UZ3Z=.G3;62>;51+9GHVF\%5I&S;DW M)VP?)HN#;V=0/?&Y+M7%EMFD[Y2F$6"R426^(#Y+8ID5?,5H=HWHJVN$*FT/ MQO%Z<9L6U?H;378WN<<<%L0"4]H<*8WK%N9-GI7[64>R55H 3YG$5:VT1UZ M);L%I.6EZDJ[>VCIWNE4W0<3!F)M$J>V@?+OSTY"2-C TBKM%["=F6?F>1@[ M'KH;QI^%CRCA6QA$HF?X4L;7IBD\'T,B&BS&2#U9,!X2J:9\:8J8(YDG3F%@ M.I9U:8:$1D:_FZQ->+_+5C*@$4XXB%48$KX=8, V/<,V=@N/=.E+O6#VNS%9 MXA3E4SSA:F;F*',:8B0HBX#CHF?$ 7I20Q#UM<8A!H%&4GE\S4"-/*9V+(YWZ!\3\HK,C @"T3R"9O4MN,8X*V$9&'FK#((:91^DV^9$ 4'USKB MX&0.SHJ;:H9DY-!.B:68)K1&1I-_E; -<6RLT/4BT2;P5&QKIGW$JN7I* ME9_LC^\G=W_].Q[#8/PP_GC[&29W-P]3>#="26@@X(%P3K32[^%/>)J.X-WO M[[NF5)&UO^EE409I%.=(%-N!>Q9)7\ XFN.\#&"JE/.\G5W> ^PQGR_ZHD/1E1;^]K$1,/>X;:OP+Y&HW^VS?VI?6A M2HZ:P$KBM')Q6@EZYQ5Q!ABI42;&B HO8&+%$;[W_MFL!* G5R@3H_ MM>P[=0I1$UA)"#<7POVE9>^^+/NF^[+L4[-VP:QYU3I:]EN8W<^Z'L/]7[;XX?J4BC(D=R')W/_ MP=*QK?W]Q*KGF)ER>D>B9W+F,7,Z[/=NK[K0RB(5+G'V3SUJ,OBZQ*@)K2R& MLQ?#^:7'31:N>-XX%<=-E=GQX\;>WRSM\ZZ6Q9PS3KN-K1H"Z?DT6I:,+D 9 M+CD3 F*RK6261K;M0LY6PW(/F;UF5F:VOQ;:)R];9S#C/\RL596R[1PR>\TL M9686^JL0^3)I.X5*:17)M&7)5]/6=J!;6]V?':RKEON#=3S!6-R-]$!\C\"^O\# M4$L#!!0 ( +2%@UH^:2/&F@0 46 9 >&PO=V]R:W-H965TIT>^JL0GK=^E: MQ%%*)@SP=9)@]CP@,=WT#&B\#$RCQ5)D V:_N\(+$A!QOYHP^606*&&4D)1' M- 6,S'N&#Z^&J)4Y*(NO$=GPRCW(I#Q0^I@]7(<]P\H8D9C,1 :!Y>6)#$D< M9TB2Q\\8!T3% 2.9X'8LIW7PBN2 G MPYO1F*M?L,EM+0/,UES0)'>6#)(HW5[QKSP0%0?H'G! N0/:=; /.+1R!Q4Y M<\M,R1IA@?M=1C> 9=82+;M1L5'>4DV49I\Q$$R^C:2?Z(^N@^'GN^!^.@9W M'T#PR9^.+P9^,!Z!X=W-9'P;^%^N[VZ!/YWZMQ_'-^/;+P$8?*\93OSOV3CP MO_G3$7@W(@)',?\'7( IX8)%,T%"$ @Z>P3W:20X>#<-[N7['S2#L/VG( MEY@1WC6%5)3Q,F5H*KW4 +R L(ASX8")7-V&LB.1+\)IBIH7, M\L(57^$9Z1ERXW/"GHC1__LOZ%KOF_2>":RFWB[4VPJ]?4A]MBPN!G*7AF!( M$YFZ.%:;WV<,IPLBTXD #\^@:C?!SVK8WV 6@A^?)22X%B3AC:&RSQFJ,X'5 M0N44H7*T"^5N+;C :1BE"R O8)T^RKU?U1+@2QN_.WRK2.1RA[.TY-6;M0UM8J^ZJ^7Y,PK=\1PMZ.4Q/6 M*81UM,)D^9V3Z( VK>L1VMZ.4]/F%=J\D[446/J$+T*25,Z'5 M59>=!>S\Z2Q\0F.A"=>9T.KA*IL5>'JWHL_"WMZJ;3LMVW-V5_>^G6L[=MMI M7MZH;#B0ON'0Y.'X-=A!R^MX;?< N;(70-KBJ4G%N6,MV3FP M!;W=;-=DV/&DB@/)&)65%^DKKS89H_VR>8&0[>ZEK29#S[8.U0I4%EBD+["G M)5NT7U21C9R](M)@M[-NM[3-RH%:0MA"G3-R,*/K5&S/DHK1[5GF %X-U9'? MSK@/KWQULF>6,-L#TAO,Y ;C("9S"6E=MB4IMCUSW#X(NE+'=@]4")JHVR7! M(6&9@7P_IU2\/&03%">__?\!4$L#!!0 ( +2%@UIDAE)>900 -@3 9 M >&PO=V]R:W-H965TW#:+Q#;,X^?>6R/ M1^[L"'UA*P".?H1!Q+K2BO/UG2RS^0I"S&[)&B(QLB TQ%PTZ5)F:PK82YS" M0-84Q91#[$=2KY/TC6FO0S8\\",84\0V88CI:Q\"LNM*JO36,?&7*QYWR+W. M&B_!!?Z\'E/1DG,4SP\A8CZ)$(5%5[+5.T=38H?$XJL/.[;WC>)09H2\Q(V1 MUY64F!$$,./O#%3*YXP=][_?T#\GP8M@9IB!0X)OOL=7 M7:DM(0\6>!/P"=G=0Q90,\:;DX EOVB7V2H2FF\8)V'F+!B$?I3^XQ^9$'L. MJGG"0:XUZ%DAVAL+=#BCT2;Q%M$XT?Q,KJ< MBE%?^/&>Z]P/!\]?ANCI,W+O[GHZVCZ)_HX ([]@/V.&F@"C%-_SL%#+B?S M%_0<^9RACQ/W68Q_?X!P!O0O8@T=/5\9/<'33^ Y M) S%/D_5>Q.L2J=:F#@-W+$UGD-7$N>< =V"U/OPFVHJGZIBO!)8*6(CC]A( MT%NG]F*\%1I]<2@])*(7F8KAY*S;E.)H"2)[<#1[1?MV8_R:=-L[3#WT_8N M1",.(:N4RKBF5%<"*TG5S*5JUFZ.IPUG'$>>'RV1^$.;:"L.G- C/4XW: 9+ M/XK$<)4,*78SP8[S_+9G6'JS977D[7Z QV:J8;4-2\OM2MS-G+M9RSU. 6@I M5I0?'MN4G7DT;4/3S+9E'-"KL%,5JVVUS&I^K9Q?ZSP_<4$NP#_!L'4TLZ9K MEM4^('AL9AF*J5>S:^?LVI>M/"1C5;3;%N/-7(!D[YY/6 J=CM# 2P$I'+;$IQH^HR4-CA9 M)R\Q,\(Y"9//%6 /:&P@QA>$\+=&/$'^F-?[%U!+ P04 " "TA8-:#F#W MO& $ "T% &0 'AL+W=O[JK[L+$G8,7VNKL+I/?K;W9-#.;%+2=+ M^0)K>^;QS#//+L-TUHR_B 6 )*]1&(NNL9 RN39-X2T@HN**)1#CDV?&(RKQ MDL]-D7"@OG:*0M.N5!IF1(/8Z'7TO0GO==A2AD$,$T[$,HHH_S& D*V[AF6\ MW9@&\X54-\Q>)Z%SF(%\3"8-BHH(0O"D@J#XM0('PE A81S?-Z!&]D[EN+M^0_^LD\=D MGJ@ AX5_!KY<=(V607QXILM03MGZ!C8)U16>QT*A/\EZ8ULQB+<4DD4;9XP@ M"N+TF[YNB-AQL!HG'.R-@[WO4#OA4-TX5'6B:60ZK2&5M-?A;$VXLD8TM=#< M:&_,)HA5&6>2X], _61OYMRXP\=;EXP_$_=N# M_LP=$F=\-W'O9_V'T?C^@O1O;\>.7BO'J>N,O]R/_D:SB3L=C97U[&%&/@Y! MTB 4G\@E>9P-R<%:E:%\2NV+4C 3F_[EXM"*>:5:2J\9JG M*K*@'"X'*$V?3.@/W#*2]#FG\1S4^H*XK[B'U5,DD#@T"20-@W_!QZI$;(G6 MWVX1DHPD1.*?8P2G[Z\>?[\Z-ZY%0CWH&G@P". K,'J__V8U*G\<(ZIP.)9TBM322.IL6_4LJ]XQ5[NY'-K46JU& M9I2+L9[%6"^,<1AP/+'(. &.L<5SXC A!?EV!]$3\*/U*00\MSXE@>5R;V2Y M-]Y9RHTRJ2H)+$=5,Z.J69J44Z3ZCDPO[>:>E ]M6FWKN));68BMPA"_0(P: M#G6M^C[^%@5"*DVOX*V.A:HN!#^W5"6!Y7AH9SRTWUG5[3*I*@DL1Y55V;87 ME=)TO8':%6W3WM/U$1N[5:T?5[:UTP59A6%.,77*O84NV1!6V-XFNK"_HNQB M['/K519:G@E[RX3]SNK>!% 6726AY>G:-FM688-SGKZKAP=W;5_?AS;627EO M^R3K)XT2_DU2O8U2>[>RT/)T M;;LWJ[#C.4_;C<.S^T#;AS:M^BEM;QLGJ[ASN@=)0B8$83$) 8,E$CAV)SI4 M<4&6,?.\91)@$NEC#U4P!Z%KC+1)OO3DDJL-X?VT-2^.Y>SZEH269V[;SUFM M]]X.I39]9:'EZ=JV?59AJW3>=O@?71LKTQ*1DD5XN@/K E0$^?V9,OEVH%V2#RMY_4$L#!!0 ( +2% M@UK*S/PM+PX "S1 9 >&PO=V]R:W-H965TF9JJZE5Q Z+&M4G-/^E+M],Z+J7T1\:A4 W&2J./6?OA- M,!(.B4?H^??Z9EKQG%_"R&,.X2$%-_4BZF<['(I^E"R\3E^]ZQ_BX>#*L)RQ'_FHK[?.UKK;HKYVGZK?HFN'C? MZU=[)&9B4E1$4OYS)T[%;%9)Y7[\6:.]U3:KB>M?/^GN\LZ7=^8\R<5I.OM] M>E%MJ%N$QN9\67]-X7]1T:5-XDG>7+_VKW]=A^3YO7>S"? M+A[_3?ZJ_T>L32B=[@E&/<'8G& ],\&L)YC;3K#J"=:V$P;UA,'FA.$S$X;U MA.&V6SBH)QQL.V%43QAM3C"?F3"N)XRWW8+>?_K-];>>LOIEMW[;STYY^G7K MR]_W_N,#:_FHM),B.3K,TGLMJ\:77O7%\J&]G%\^&*>+*H5G15;^=%K.*X[. M?OMT&KT].3YS;.WTTX?/SL>SX]^"3Q^UGVU1)--9KGU,LBRIHO*+]E;[>F9K M/__SE\/]HMQV)>Q/ZNV&8[NO8A7137N>8L+L1%QWSWA?F& M@O[_3J MGAM/]_S$4(H?D@?-U-]H1M^P.O;G]*79V9YJNJV>_FE2K*:;'=,=]717G.]I MQNC9Z:YZNBTFRIWWMI_>M75_^^E&Q_1@Z]];OV-VN/7&]5'']$@]_?BF_+7K MUG+Z0(OI9G\YW5(\ALU5>LVE=_!<>J^33+P]*8]"%]II.B\/S7FR/+@= MEYE=7(GR<%EHYP_:^KC/RQ@,1"$HM(+(8P M*=_6*M^62C\Z*]+)M[?GR]Q.UO+=E52EM&M22@;;PZS1:-@:YY/[%I!82&(1B<40)L5KL(K70!FO>)J<3V?3XD$K MG\YJDR2_UG)1%+,R;O.KD@I@5TC16(VB3DDY@[;QZ2. M(U=[E#YN1XKQK_LMJ8%<:E=O>-8TD9I.8 M0V(NB7DDYI-80&(AB44D%D.8E.W1*MNC5SZE,R+S36(VB3DDYI*81V(^B04D M%I)81&(QA$GY'J_R/58?NY>Y;9_2T;+F@)U7!^PWVE49^/*0/5UH-^4!/^UZ MU>1$N;%=PTQB-HDY).9^!Z9UY1AR?/+.!206DEA$8C&$21'6^\V+IOUM%N G MSR[ .U\@59J[9A75;%1S4,U%-0_5?%0+4"U$M0C58DJ3\[M6>M!?>9%=[P 5 M=E*S4Z/W6B5ZG8YAIM8:YZ+YYJ.:C M6H!J(:I%J!93FAS"IJBD*WL2.X5P^;RW,X%F^U%NM!Z^IQW#.A[EMGJ/=SX, MHA4B5/-0S4>U -5"5(M0+:8T.8%-E4A7=XE^7Q;2JVK#GHT5W+4"U M$-4B5(LI34Y=TS#2U16C%\\4_:V7:M4;WSF9:!L)U1Q46Q1VCS#UK8U&,[EB :B&J1:@64YJ%*<,=7'JXV8[*KE+IK/D?":6 M%ZUXMBNE9G>.,*G9J.:@FFNTRV/6>#P<;=8V.L>9@X/QY@*Z/4ZWQB-K;,@# M _1NA*@6H5I,:7*BFB*4\<)%E=@7;]1;VSEH:#L*U1Q452O7@UZ?/?/),V+\M9">Q!%N0*? MI%>+Z7]$^8/GK\"HWH>=\X[6I5#-036WUJ1KQND=?:F.<;K9;[^=T$=W+T"U M$-4B5(LI30YITY@RU(VI9Y\ ;X0SUXJT2&;RF&?RVIE3M'"%:C:J.:CFUMIZ M_EH1;0\Q!WI'0M%^%*J%J!:A6DQIG-XR?6/!XQ MQ9^WT^*A,W!HZ0G5;%1S4,VM->E4E&4,V@?&]K@#TQSW1YNI0XM*J!:B6H1J M,:7)GZ71%)5,=5'IR\;YW\? :9-9DN?3RVEU6,RUV=,UP[L"J-[ K@%$-1O5 M'%1S:TTZQSL>C#;> ^MM-\Q']RU M1#5(E2+*4V.7]-9,M6=)<6)X+,?>L%C M]7[MG%JTVH1J#JJYJ.:AFH]J :J%J!:A6DQI\M^ IMIDOG:UR42K3:AFHYJ# M:BZJ>:CFHUJ :B&J1:@64YH<]K4/K_LQU28UNW.$T6H3JCFHYIKM*I)I'@S' MFZOLK8;YVPT+T+L0HEJ$:C&ER6EJ:DVFNM;T\O+Y!UV$1KU?.\<1+4"AFH-J M+JIYJ.:C6H!J(:I%J!93FOPWH.E2F8/77CZCQ2I4LU'-0347U3Q4\U$M0+40 MU2)4BRE-#GM3K#+5'ZSWW:CFHUJ M:B&J1:@64YJ M%*+,_^NGYJFWMG.RT:(4JCFHYJ*:AVJ^V2YGZ6;[([$#=*LAJD6H%E.:E%FK MJ5-9+WQ(7I7'CLQV!5)-[1I(5+-1S4$U%]4\5/-K37J[0;_].2P!NM40U2)4 MBRE-#F13L++4!2NCKUN:LVP/:\%B4BZ$IW="^SQ+%NLO!#T]#\[?:)\N+Z<3 MD95?V=-,3(HTR[5D42VW%_GMK%@>9U7/EM7[LW.JT6(5JCFHYJ*:AVH^J@6H M%J):A&HQI72^J=Q652^JJ?I549[%>7)]O5]0J![K5[$^W M13Z]*/\$/-Z>5W\4BFNAG:3+8[IJ\8[6NE#-1C4'U5Q4\U#-1[4 U4)4BU M MIC3Y#T53Z[)>N]9EH;4N5+-1S4$U%]4\5/-1+4"U$-4B5(LI30Y[4^NRU+4N M^*4N]=9V3C;:]D(U!]5=L-\]%]"U M1+4(U6)*D[/8=,*L+2YG ME6O5Q3BFBZLJ9=6J/+GJ?M*,=L-0S48U!]7<6M/UM0SU]XS!9M*V&N:C^Q:@ M6HAJ$:K%E"8GK6ES6>IK4GW?<^&SEZX+T)E3M-:%:C:J.:CFHIJ':CZJ!:@6 MHEJ$:C&ER:EO:EW6:W\.H(4VO5#-1C4'U5Q4\U#-1[4 U4)4BU MIC0I[(.F M#S9XH0]6OTOIHCK.%^GR-/3Q3\G\YM&'>.,CG%1Q[BN]VK%U+V0 ];TNP;J?M??6D,_?W& S@RB MS2Y4LU'-0347U3Q4\U$M0+40U2)4BRE-3GW3[!J\=K-K@#:[4,U&-0?57%3S M4,U'M0#50E2+4"VF-#GL3;-KH&YV86MHM."%:C:J.:CFHIJ':OZ@753J6LT& MZ%9#5(M0+:8T.:Q-OVOP(_I=G1_=W9EAM*"%:C:J.:CFHIJ':CZJ!:@6HEJ$ M:C&ER4EO"EJ#URYH#=""%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%E":'O2EH#;8H M:!%K<+29A6HVJCFHYJ*:AVK^X+FK>K46X>V!1M? $-V_J&O_!IVGLM'BU7Y^ M+41A)T5R=#@7V94X%;-9KDVJ3_BK-K)VJY:)RS(<^CM'[^VW;G?U=W[7[O.^I_>T\[0H MTOGRRVN17(BL&E#^_#)-BZ=OJ@W&ULK55=;YLP M%/TK%JNF5EH+(80T78)$0JI62C^4CV[2M <';@(JV)EMDO;?SS:$)2G)]K 7 ML,T]AW,N^+B[H>R5QP "O64IX3TC%F)U8YH\C"'#_(JN@,@G"\HR+.24+4V^ M8H C#>F=>EN4@3 L\,\3S+,'OO0THW/:-A;!?&R3(6 M:L'TNBN\A F(V>J9R9E9L41)!H0GE" &BY[A-VX&KJK7!2\);/C.&"DG0^ZAF6$@0IA$(Q8'E;PP#25!%)&;]*3J-ZI0+NCK?LM]J[]#+'' 8T_99$ M(NX9UP:*8('S5(SIY@Y*/RW%%]*4ZRO:E+66@<*<"YJ58*D@2TAQQV]E'W8 M#?<(P"X!]B' .0)HEH"F-EHHT[8"++#7972#F*J6;&J@>Z/1TDU"U%><"":? M)A(GO,G@;AC,1D/T=(N"X>UP/!X&:.I_1R_^:.9/[Y\>D3\:/7WS'P=#=!Z MP$G*+] EFDT"='YV@&FYFL?X;LG M(II3G#- /?\X%DS_QS[J6%8S->D:UL6_X"H?0,^3.Y<#68'B? M/S5JEK5?I:)_4-SNNZQR( MJZG:^PB%.',G:3)@2QW '(4T)Z+8H=5JD?%]F?$Z"P_69?;[.O+,/S3%P?& MF?QG.$IA(2FMJ[9L&"O"N)@(NM)Y-J="IJ,>QO+\ J8*Y/,%I6([42^H3D3O M-U!+ P04 " "TA8-:SDYO(,0" #U!@ &0 'AL+W=OW.1" MHB4VLPUT_WYV$C(* >UA+\0?]QR?F*<(8 M,R*NV!*IVIDSGA&IIGQABB5'$N6@+#4=RVJ;&4FHX77SM6?N==E*I@G%9PYB ME66$_QY@RC8]PS:V"R_)(I9ZP?2Z2[+ .5L^.\9_3M MVV%;U^<%7Q+OC/W4DW'4,RPM"%,,I68@ZK'&(::I)E(R?I6<1G6D M!NZ.M^QWN7?EY94('++T:Q+)N&=T#(AP3E:I?&&;>RS]M#1?R%*1_\*FK+4, M"%="LJP$*P590HLG>2O[L .PVT< 3@EP]@'-(P"W!+BYT4)9;LLGDGA=SC; M=;5BTX.\-SE:N4FH_A<#R=5NHG#2"X;W(W_V,(+)'8R?AI/'$9P_3(+@ @:C MN\G+:+LX[7^[!%^-@NEX"/TG'_3N^/,3G/LH29**"VC +/#A_.P"SB"A,(W9 M2A :B:XIE5)]GAF6J@:%*N>(*MN!1T9E+&!$(XS>$YC*8N73V?H<."<9?0RO MP+4OP;&<9HV@X;_#W1-RW*KM;LYW?81O3$.6(4S)&_B)"%,F5ASA>_]52*[> M[!]U+2L8W7I&?=MOQ9*$V#/4=1;(UVAX'S_8;>M3G=W_1/;.?+,RWSS%[LUH M(C&"0!*)M2]' >_DD7M2E'[I*(IDR2MT],^:$#'LO>[=%C4:-Y8 M;F=/D[F3(!GR11ZL D*VHK*X9-5JD=T#E=UYQNVMJTSOYU%F_J4I/@B/A"\2 M*B#%N:*TKJY5EW@1LL5$LF6>4Z],JM3+A['Z+B'7!6I_SIC<3O0!U9?.^P-0 M2P,$% @ M(6#6@PKJ?Y5 P "@L !D !X;"]W;W)K&ULK99K;]HP%(;_BI5-4RNMS8U;.T JEZI(*Z!"MTG3/ICD -82 MF]D&NG\_VPD94),-;5]([)SS^GV,+Z>Y9?R[6 )(])(F5+25W-33*C3;IJ^,6\WV5HFA,*8([%. M4\Q_=B!AVY;C.[N.)[)82MWAMILKO( )R.?5F*N66ZC$) 4J"*.(P[SEW/FW M7=\DF(A/!+9B[QUIE!ECWW5C$+<<3SN"!"*I);!Z;* +2:*5E(\?N:A3C*D3 M]]]WZO<&7L',L( N2SZ36"Y;3L-!,87;?-8ST'1 M6DB6YLG*04IH]L0O^43L)?BU$PE!GA <)U1.)(1Y0FA ,V<&JXAR/AOWA=*);@Z%J M]]'T[@L:/XT^#2:#T1!==/K#_OU@>HDN>B Q2<0END+/DQZZ>'N)WB)"T73) MU@+36#1=J0SJ8=PH-]/)S 0GS/@!>F14+@7JTQCB0P%7D15XP0ZO$Y0J]B"Z M1J'_'@5>4+$8ZOY]>EAB)RQF.S1Z]1-Z QJQ%- 4OZ >$5'"Q)H#^GHW$Y*K M!?W--F698FA7U+O\5JQP!"U';6,!? -.^]T;O^9]L.'^)[$#^$H!7RE3;W?7 MG .52.*7]^@>8N XL0&7JM@](AOKO^L<8%8+S.K?8TXDEF"#S#2J1D,?M1NU M^+VFN]D'L,6$1O0\*&W5R],%48[ >*?77LU0[]FJ+\>UF&X791JG9'LQ!&8SU9BY= MSJ4R9RSGQBN&JZ :V"%N"HB;,R!.+M92D3,0;BP(]1,KVO=^WV!>*40'*,R) M-(LFW@']:=64:Y[!E L=0%6#Z@FHO6O9+X6:,HF3/0JT*C;'Q2P#OK1R9;*- MTNU@";H*:Y4CS^Y>59$"7YAB2Z"(K:G,;N"B-ROH.KJ@TU7)4;\J].Y,>>/^ MELFJQ$?,%X0*E,!<27K7=36-/"N\LH9D*U.[S)A4E9!Y7:IB%;@.4-_GC,E= M0P]0E+_M7U!+ P04 " "TA8-:83^%YU0% !&0 &0 'AL+W=O=XR477^6,,86> MBKR4)\Y,J?E1KR?3&2NH/.1S5L*5>RX*JN!4//3D7# ZK9V*O$=<-^P5-"N= MP7']VY48'/.%RK.270DD%T5!Q?-'EO/EB8.=EQ^NLX>9JG[H#8[G](%-F+J= M7PDXZVVB3+."E3+C)1+L_L09XJ.$D,JAMOBU:.V\AWWT 64ENIGQA:3E5![W%.151>^EZQP^KG(@ M;^20L/00>?@71%SB&]Q'N[M[!O=D=W?RVKT'9&X8)1M&21TO>B/>69GR@J$; M^H223*8YEPO!T%_#.ZD$[/*_3?RL(GKFB-6C?R3G-&4G#CS;DHE'Y@Q^_@F' M[J\FMKYGL.0[!7O%I+=ATK-%'PQSJ$JT3!F"^H;8TQQJ!9NB5+!IIA 0*YEQ MMZVB]NNH5=U['! ,&^-QFR2##>F_MDFLV77$[F^P^U;L";MG H!";7UDY8*9 M<*XB!%L8L-O&J=N$;9C61#K"##8P RO,*P$=3*AG!)4#JHBBY4-VES-$86V5 M<7$##9#GXJ"%6C?"L=>B)K%FUA%WN,$=6G%/%%4,E=#7*_Q49>5#O:'1GG-Q M>>[LHY0*\0S;?DF%N:2&&D3BQGW<(D*WPG'DQRTFK+EV9"+:,!%9F3AE4R @ M_U]<1!K*( C"%LJ1P2H*0M+BPIIM1R[Z&R[Z]EVQ%D,X]/:^[%?/ X.;0*G+ MB@PV#%PRH>_K:QQJX'4C$GFMW9)8L^N(/=Y@C]]Y(GCZM99P4.%Y ;I6OHDX MUL NO0=.1JCO$U!;UY>WJ[)H%%BN3DD0 MM#>!R0J[)&QM WM*72%O*5+\3D]@P>PKN'$:RF6+UO7YTH M/J_?0-]QI7A1'\X8A;F_,H#K]YRKEY/JI?;F7X_!?U!+ P04 " "TA8-: MGJLGK_T# #J"P &0 'AL+W=O4%,61 M:+47O;%%:>;G-T-R.*,#XR]BARCA+8E3,;9V4NXO;%N$.TR(.&=[3-67+>,) MD6K(GVVQYTBBW"F);<]Q CLA-+4FH_S='9^,6"9CFN(=!Y$E">$_+S%FA['E M6N\O[NGS3NH7]F2T)\_X@/)Q?\?5R*Y4(II@*BA+@>-V;$W=BYGK:X?5H(HPQE%J"J+]7G&$<:R7%\723$:<'8!K:Z6F'_+< MY-XJ&IKJ97R07'VERD].'F8_%O/'JP7<+F&Q7"YFZ]73 E8WL]OK!:RG?\#] M=+V ^\7L]F:VNEI-UZO;&SB;HR0T%E^A X\/)&PR\D?UZ'&'3J.,Z MWG!0F7UB[U7LO5;V!P6'(-6ZX9NJG@*_0:KJ*]O"MHRJ#,7$74CWCI"&W1IU MTZ3O#WPS($9KE_!]5OA M5HG:9T4"&5=U-@5U*ZF%5]O""-EO$'18\8<5)B#]G7/-GO")2SA M^^IJO5+U+8PSO7=-C(/&]*X3!#7&IM' Z9HAAQ7D\%\V)PM?\HLL E5?]/[, M$VEB'!KRV._7&)M&[HGSXSH?=XS3"OF=L>A XQBH6GG*51<@(=P1_HSFBZ)5 MS5RIP%3Q2J%/FR(8>B?".;HRW=9PYKA%SE7")<^PD^V-,;C-8]-W!K5D&ZRZ MO=X)/N^#SVOE>R)Q1HHF*59M&DE#8TDM53X?_EZ=L&G4Z7:')W:M^W$9NJW7 MS63-I"J&PO=V]R:W-H965TJTCZ<4:;;GX)-< "MU&82Q/6FNE-L?MMO37$%%YP#<0ZSM+ M+B*J]*E8M>5& W2H"ALDT[GL!U1%K?&H_3:A1B/>*)"%L.%0#*)(BKN3B'D MVY,6;MU?N&2KM3(7VN/1AJY@ >K=YD+HLW9!"5@$L60\1@*6)ZT)/O;(D0E( MG_B3P596CI%IRC7GG\S)/#AI=4R-( 1?&035?VY@"F%H2+H>GW-HJRC3!%:/ M[^EOTL;KQEQ3"5,>OF>!6I^TABT4P)(FH;KDVU\A;U#?\'P>RO0WVF;/'O9: MR$^DXE$>K&L0L3C[2V]S(2H!^+$ D@>0!P'#SB,!W3R@^]02>GE +U4F:TJJ M@T<5'8\$WR)AGM8T%$OHNTW%J/#^?_G$V0U>3OV8+],H# M15DHT3D5@IH7\AK]A-XM//3JN]>CMM+EF:BVG[.G&9L\PL8$G?%8K26:Q0$$ M=4!;5[2H+;FO[2FQ$B?)Z@!U\8^(=$BWJ4+V< _\(KS7$.X]/;QK:4VWT+Z; M\@:/\&;+):3='LUCGT> KN@MNJ0*T"7X//99R&B:'!_>ZD@T5Q#)?QJJ?9H5 MTVTNQHPPFKR]0MZ>C3[^A?-@ MR\(0L6A#F="#E4+^FHH5-&F8L88IRPR6-^/.J'U3%<9:6G-;4),F7Y;4TZ.T M^2D*K+6W7[2W_[3VTH@+Q?[-^LX&!.,!TC,$4KI[;1*QX1)DDP16_*[=R"7, MLS<<]]$=4"$M?>:PT/#0BGH# 0@:(JFH2A07=XAEJ6FTTT-B8]>Q(G?5+8-A M7.V(!P37^Z+GJ,B:1H-"HX%5HWFI"-Q2/2=E'2T Z0NV,<=-(EF9NXIDKZ!: M YIRG?2Q?GU2+VFN/^IQ%BG^C:[S 9I?(3^]RT#JUXLNZ">FW[=>@PBH/(PH MTL+WOT\;JJ>OQ%<0(*IO:;SDB? !I6L?'W2K979PHQ]9"AZ9?--+CCA_4.I9 M7:U1S-$R$3I>F)J@:V#Q"@5)4Z?R'.E5>\/#X@T/GY0%'\X@N@;1..=8";N^ M3Y7&G7*YVK%WS7%LA;7K,ZE3G3LBE M1+Y>K-Z9A-M2$31.;';FKFKFM.H$3@[[#V;P3"M7!=?%JJSM\4YYC/Y#4SW( M34.>Z)$L#M"97AP$3 ]]$_]SPB0S75-:T]Y>XLY2NJ1YKFAUM4FI-ME/[N?E MN-+8)E_"FH+ M$&L'V\7I"* /AO:$?X;ML8CGDN:YHM7U+?T6[N\IX9TZ+Z1S DL5,=\JW; GV5'?JT9S2 M/%>TNK*E(<+#/:6Z4]_DE.:YHM4U+JT3MEJ'9Z:Z4Z.4TZJI/A@V9_I+V"!2 MVB!BMT$+9?J>+9GM@%V%<4KS7-'JXI6VB.#])#-Q:H:X,9M=%5P7JW0UY"NN9O8>_3:[7,S^;E3%J7UQ2O-K" ME0Z']/:4R4Y=CE.:YXI6U[AT.<3^=>5YF>S4T>2TZG_JRE;Z%#/:4QDX=C%.:YXI6U[AT,.1IWW1V M^K)I9^ZLY_!)WS:_^EA=@=)?$+N_*+[SE1+X7&RX:;Q=!:<>(Z<];-[10Q6< M&HQV98=0!&*5[K32 SE/8I5MORFN9KNYIOC82S<]/;@^P<>3=&]3N\1D6\3. MJ%BQ6*(0EAK9.1CHH5ADNZZR$\4WZ3ZD:ZX4C]+#-5#=*\T#^OZ2&ULK55=;]HP%/TK5UDU@;0V(8% .XA4(%4KK065=ILT M[<$D%Q(UL9EM/O;O9SN04AI0'_:2^..>XW-N=!E2YFE M%,<U;#VBT\IO-$Z@4[Z"[('"XEKLC4$[F3+VHB=W<<]RM"#,,)*:@:C7"@>899I(R?BS MY;3*(S5P?[QCOS'>E9X]=/2?!'+A'G" MNHAM^Q9$2R%9O@4K!7E*BS?9;/.P!V@< [A;@'L(:!X!>%N 9XP6RHRM(9$D MZ'*V!JZC%9L>F-P8M'*34OT5)Y*KW53A9# 9W(;#YV\AC&Y@]'0;/D(M_#D. M'R9A'>X>!J/[$,[A(7R"VA E23-15_/GR1!J9W4X@Y3"4\*6@M!8=&VI!&E: M.]H>WB\.=X\VX.SM]]R3C$*,+\!I?P'7<9H6@ MPJ%)3A40!-U%" MZ!QAKAJ+@%K&A,I"O_SXE[>2BO(JC3 M.=1G[[63'/G<=%D!$5M2691BN5HT\KYJY*;A':RK!G]M^IK]2E/<#O>$S_6/ MD.%,43H7;94Q7G3<8B+9PC2M*9.J!9IAHBXIY#I [<\8D[N)/J"\]H)_4$L# M!!0 ( +2%@UHIT7RB? L ,YK 9 >&PO=V]R:W-H965THA()47$=J]JZH?W&0@ M49,XUW:@N]H_?L>.R23X^)#I'NZ'6TC./';R8_SRS-@^?$JSG_E8Z\+[-9O. M\Z.]<5$L#CJ=?#C6LR3_F"[TW+QSGV:SI#"_9@^=?)'I9%0UFDT[W/?#SBR9 MS/>.#ZO7;K+CPW193"=S?9-Y^7(V2[)_G^II^G2TQ_:>7[B=/(R+\H7.\>$B M>= #77Q9W&3FM\Z:,IK,]#R?I',OT_='>R?LX#P498.JXNM$/^4;/WOE1_F1 MIC_+7RY&1WM^N49ZJH=%B4C,/X_ZDYY.2Y)9CS]KZ-YZF67#S9^?Z6?5AS2ZT_I])^343$^VHOVO)&^3Y;3XC9].M?U!PI*WC"=YM7_O:>ZUM_SALN\ M2&=U8[,&L\E\]6_RJ_XB-AH8#MR UPWXRP:RI8&H&XA=&\BZ@7S9(&QI$-0- M@I<-1$N#L&X0[KI*W;I!=]599P4R?%AECYY65EM:.4/U1]$ MU=I$.)F7?[N#(C/O3DR[XGCPZ5S%7SXK[_K,NU5?U=47-?C@7=^HVY.[BZN^ MI_ZX45<#-?!.KN*-ER^N/EU?*N_=Y^O!X+UW^B_3]N;Z]N[DU) &JG^IKNZ\ M=[$NDLDT?^_M>U\&L??N;^\/.X59YW+)G6&]?FJU?KQE_1CW+M-Y,-SG EBA3WCSZV'QT1.LM7F,-S]9/J#- MU0XK7S>70//^[LT%\EV*]5^/J'C=MK\>_6"V8X5WJQ=I5DSF#][%?+4]+;=+ MWSZ;)A&@B W/P50:1S$=F[YS] MU&4L4" HQC402EA,"5-A,Q N@#R:=;TP\%OCZ*[CZ*)Q]/7<=(UI%4H?F>!'G1\ M7(.V>DH91WLB&V?*#$WDLTYR[14Z,_N3JH/D'[SE/!T.EXN)'GG3ZNTZHJHS MF34MLN6P6&;H,1J^6.?H*&DQ*4W5M,UP@E[8[%5 G3G&#MHSY#9#CF9XEQ;F ML, >..M?"SW/6[H4BG+.A9(6D])43=OZOGW695 T0&DH6;?]Z(!9F<#0L]?C M%KT$9D/J#DAI,2E-U;2M0V3&@4,$H'!?=AE#NHT]\6?XF?]U,=89WEE(S_Y) M:3$I3=6TK>^9]R(@$* PBD1['/;TG^'G_R_LJSJ[OE7>S>WUUXO!Q?65]^Y4 M7:FSB[OWGGGCN2_=G?RA!F!RI(Z E!:3TA1KGOU'/H.Z4K-P7_9\$;5G9T4! MPTW!]7K?4\O3W/MVJ6<_= 8Z4ISFG ZI,2"E*5):GXJVG;+U#ZS[AF*\>-X:^=42:4&*4VQIJYH<^1@*2K)F94;[!6[ ML;,FQT'.T9"*#5*:8DUCT:+*@4KUINQ07'Q86+.\=1 MSM&0B@M2FN)-&P'[C<2@N.2PMGA8[SG-,A51>D-,6;1J)%HX.5F$?G M5EUP7%TX>G23*=IL.D,-NY M89HM4M-]--YY2"4#*2TFI2G>- ?[ 6,]("&@,@I9N\WE5C%P7#&4RFIP2%T&*:U/1=L.Q_H. M@?L.>)/K_==SG#J +\:Y;Y+Z#5*:(J7UJ6C;\5M5(L*WW""3RA-26DQ*4Z2T M/A5M.W3K8 3N8%Z9.H"W=DZ5U+N0TI1HVI1>*+<=9)T88&A\$6)G+-:["-R[ M[#YS <,4= M4,C\7J]]_%-:^2)Q^>(R<0!'.2=#ZE9(:4HVE0D\<0 H1"<.2&M6)&Y6G"<. MX#SG=$@%"RE-2> B$Q$QJ., E=)'9MQ(*T8D/K'#\1P9ISFG0VI"2&F*E-:7 MS:D?^,0!N7&["MQRO-7$ 7RQSE'3WNJ"]EX7S5D=X,0!H Z=.""M#)&X#'&9 M.("CG',A%1ZD-"6!*UF$Y,#8)U#))'\Q(+>=C345\I5+67:?.("3G*,AU1*D M-"6!F1J\UX4Z3;-R7_08;S]/DM8G2-PG7.K19&@ZSDU6WAQNJ+W+9)X\Z&HG MACE#'.N<$ZEH(*4I4EJ?BK8=M_45,GI#9RA)'08I+2:E*5):GXJV';IU(?+U MN2?8[;A(#0@I+2:E*0G>A0.Z> *J%*+;?KH06 <2X YDERVN^Q@.OE#7$$EI M,2E-D=+Z5+3M/P8K70+VAMOC@%3#D-)B4IHBI?6I:-NA6Z$3X$+GE>TQWMHY M55)]0TI3 21EH.WQV2O?Z#<&]8\^Q'^Y%:\JSU_C\^]8\E85!;@J:<)YSNJ06B)2F@N8D$@%I5*@. MN?@JL.8FP&>:.(XRX33G9$A5#2E-D=+ZOT-#.Y^U- %N:=YJ$ I?K/-? JG> M(:6IWZ'!6^#_'[1]HOI MTFQ:/=/[AJ8\>=!>>N\58[W1(1=9>C\I/G[C;[\,:(/2V7B STR;74'Y,*?< MH)?S8O40@O6K]0.C0GYP'E8/2GKQ3M^\ ;VN^,$9]+KYVI^?/?6R!3LX9U + M=G!2D3IV55=/NKHT>[')/#<[M7NSVO['KNFPV>KA4:M?BG11/8KH1UH4Z:SZ M<:R3D<[* O/^?9H6S[^4"U@_PNOX?U!+ P04 " "TA8-:?'?Z27H# !E M$0 &0 'AL+W=O+,Q'!__()^D9+79)Z(Q#%GWZBO MUD.C;X"/2Q(S->?;*\P)I0YZG,GT%[;Y7LL +Y:*![FQ]B"@8?9/GG,A]@SL MSBL&K=R@]:<&[=R@G1+-/$MI38@BSD#P+8ADMT9+!JDVJ;5F0\,DC*X2^BG5 M=LJY&,WF\#BZ7DSA[@(>KJ8PUCR6)/3EP%3:Q>0@T\O=.<_< M:;WBS@2]8VC;1]"R6IT*\_&?F[?+YJ86IE"G5:C32O%.7E.'4 &/A,5X!.>$ MD=!#<-/JNA0\CFBX.H(+&NIU2ABXBBC4*:Y@3*(D225\O]:(,-/+\M\J-;+C MV]7')R5\)B/BX=#0-2I1;-!P/OYC]ZRO5=HT!%92JETHU:Y#=RXY][>4,9T+ M5TB86GM$:.(/5:1KD:K]A"J^&4X_Q4E>5QNGH]]>UL#<5!#I%$0ZM43V0SX+ MHUC)([C*PX?L-!D\H*B-9BWIH)!L"*PG0+03HOF_.=YM4JB&PDE*]0JE> M8SE?BW1 SO\]3HGJ24'UY(U5T:JMBEK40V/=$%A)@'XA0/]]JZ+?I%(-@964 M.BV4.FVL*FJ1#JB*O\(&R)65,O/<*GMK.,3#2.R.WTV43Q*K\5/7.E+ M=CI<(_%1)!OT\R7GZF62W+2++RO._U!+ P04 " "TA8-:F%FL&5P$ "C M( &0 'AL+W=OTYSM N<%9:LXD^]\AF$UJ)/"O)(T.\*@K,_KXC.=U/+=#9A=(^8*BUI:D?;I=6R@[-2C:R%8/)J)G5BMGBZ6T2_/T7O_T#11[E= MH!]"(G"6<_0>,X:5[S^BGQ%/,2-\8@M9IU+:JX9_5_.]-_@N>J"E2#F*RH0D M7;TMV]HVV#LT^,XS A\PNT*^^Q/R'"_H:<_<+/\5ET9Y>([<>5,>F>4A6;6U M#WKD\?ERW]"7?FN^KWFCM\ROEIQ\KD@I4+13VT^_R1+H7I""_]7G=8WS^W$J M"-[P+5Z1J26C'"=L1ZS9]]^Y0^>7/J,@82$D+(*$Q4"PCL&#UN"!B3Z;TZ*0 MX5M&D=5S\P@C7(F4LNR?ET]C[;"1=ZG#D+ 0$A;5L$##U,MW-_,#1_]-[-VI M>V<4[#@3M,X$1F<6A&72C%OT*-^DA#&2H(5VZ=,#*9:$]3Y^1N2EYD#"0DA8 M! F+@6 =DX>MR4/8^#J$-!@2%D+"(DA8# 3K&#QJ#1Z9G^(ZI#*BYO!9N4%R M[LX%+A.YW^>OD7:IOY"P$!(6C5X%S4'@#3W??1%( MJ4;4I99 PD)(6 0)BX%@'7.O6W.O86/J-:3!D+ 0$A9!PF(@6,=@USE^DCK MLU8S\%*3&]II7!KWS@[#GI+]\\@(M(4Q%*UKT$G.P/VV (O^1=\TL377=[%_ MD+00E!:!TF(H6G<<>,=QX,'&XH8'Y3,D+02E1:"T&(K6]?F8)G*-20H9D,L= M83J93->F5&"-4:G+-AZ.KGP_&'>CX=Q2^3JY7U-J3@U9N)#,Z\._/WOZ82WWUQK/W MDW(H\*8:.\PQ_L,8]+)MO2J M^ZG1:KFG&#EUD-=,C-;K'+@ ^U< &U(O= ^IEMNE!TTN#ONY%.N4C'S;8/1) M0;T'P@?^B' V5@Q8.2D87]KF+C1,))?*TV8OF( AM%2/%@YM#;9)HU,P(54= MVT:P?\=-]QU@50.#C//68->W#<-^2;2F2ER;2MVY;GP">4WY;ED:AU-%EF'W MTE\3ZIL),I8JHZH-$_JKIF&?TQSL*#:=P5W+,@!0:UF80L;(5 I2>U@QFH*1 MG5#.;^$9\CW?TE[D&RM7IX5HB\904[0RM@+ZFVI6>U/V\H]TO9(]2/UI;H8C MZCID&[U1-&>+NK[(6P.8>HBKD[+DRX^<345![> /#CCLDQ7/FTG%'DTT2)6) M::#*]QZHTFRRV?)3D?*.+O0JG18Y[KG[W_-O/$^IH(KP3=,F]P]PW+S"7L)S MO4EW'3M-1KWC]]B\LH_;Y(L]!_XB/^/CG];F\'/L)I/78#)]!29[+_:I&VO&YB(IM>Z_ 6&%\;ML=_$8B*C M"YJ-FJJ:CNNB9PHF:G,!81>YKB\W@G$LYD8 P^)@#C".96%Q_J7Q).AX+(9Y M2YQ(@G(2E&-9+F14?[ X;DYJ+O=(TS2*XAB;T='(Z6"$S5LMAGD#!A8' M(CUOKO'5QC-D?QY@:[HO0["1XIF(C12?:T#<\P:,-'6O-A8'&-@J8+D#\=UQ M(*?-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0 MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( +2%@UIG MY#L7! < "TZ / >&PO=V]R:V)O;VLN>&ULQ9O?;YM($(#_E96?4JEW MCC$_W*JIA/':1H>!8W':WDM%;-*@8HB I-?^];>+DW1PR.A>ACPYQ@[^/+O, M-[.+/_PHJ^]79?F=_7O(B_IB=-,TM^_'XWIWDQZ2^L_R-BWD*]=E=4@:^;3Z M-JYOJS39US=IVASRL79^;HX/25:,/GYX/%=8C>&3LDEW3586\J Z<)FE/^K? MKZNG[#ZKLZLLSYJ?%Z/V[SP=L4-69(?L5[J_&)V/6'U3_EB75?:K+)HD%[NJ MS/.+T>3XPF5:-=GNV6&A(./DJFZ/-,E5E$B0BY%Y+D]XG55UT[ZC/7\B&>]3 M^>;CL[NF7&9YDU:+I$E757EWFQ7?U&GDMQB#K]'&X?'Q&,3WU?\)8WE]G>W2 M1;F[.Z1%8*L*AOLMMZQ(KDD%Z,G/(^K=3WD1_@[H_?K9%0(%+5^TR^ M4+G[%H\2I:C+/-O+3]^S>9(GQ2YE;0AK *@A@-JK ;*S, &04P1R.B"D4!#J M'VI67K/@MC/4.@*IOQJD4QYN :2!0!JO!BEN$AA)$X$T7Q'RJP8@+032>KWA M3NH; #E#(&>TD&'RD]W7+$RK]M_5M;W(ZEU>UG=5"A#?(8CO:!'=HL[V:<7B M*ME+83"[JI+BVS&8,(>?8TG\G'BL?UZE59WN[BKI6Q9E]7>V28KD2,E@DIR@ MKB&631"M;-_]QX[=P&>VOV#SK7!]+@0$Q%PS(9;-W!:N8,&2A1$7W(]_DPIW MY;L0$[/-A%@WJR!8?'(]KR5S)::_9[80/!8,8F*^F1 +)XR"D$?QEQ:3 M_[UUPXV,*:3#1#.A-DW@.Q(G:L>X,P,QLTR(U>+SF'F!$$Q&CCG!9B/GGUC; M$8> F%4FQ%I9\'EG"#%Y3(CM$?%+[F\[H<%$,2$V13M.Z\!;\$A\;2=\_ 46 MT9@A-&I#R*GDQNKZ$^WE*&=_[/HK[CLNAY-?P_R@$?O!X[;HTJ"-![$,(N[9 M,5^PT([BDR!AR5\C3O[23'&T=>)M),=/CJ.(.VA8PM>($S[?A%[PA7,VYSY? MNC$+/;N36C4LX6O$"5_$@?/7'U+Q7$W_39^R(>E?HTX];N^I.(LMC]W M)QN6[37B;!_$:^DA_ED%B[.O3.H)HF')7R-._H*O5#IC$0^#2.4R"(9I0"/6 MP-)V(W9I>UNN*LFEZ]LRR=J>+-34A;N!*Q:8$:;$1A#;N9".4B%4&NUDD2EF M@2FQ!= BO--=3S$]3(GU@!;A74QT98I8%_U%.#N+$\E1OX&8F#JFU(M3G6J\ M%P]SQY38'2^6Y4=2B(DI9$JL$%6<]\8.<\B4V"$/57HO%R:0*;% CM5F+Q:F MCRFQ/GKJNSY&'7.'3NV.%TJI!U"(B9E$)S8)K*AZ8XCY0R?V1T]IUS&JN7$-W3(/8&6FQU+*QC_M")_?'BRB<[6Z0-7*#5,7_HQ/[ 2Z\IQ,2, MHA,;13AKOMAZ[9 [:UEXRMM.#<-S#D&L7-@-'MJ;XB)V<<@ML]+;8'*1ED.-[8, M3$ &M8#@E0Y;!'4@@ALR!F8A8^#NY2&*S$^J2KX;8J)[Z]0K8"":$5?0KN<^ MA?,3Q,0L9+S6'L@S61J8A8P!+;2Q5;VNEHG5,R_P5W] 3,Q"!K&%CCWAR8R\ M3V$%9V#Z,0;4S\(5]FH5\=7O:QS>\8'IQZ1N>7IJ#E?61HX3;+N+9R:F'W- M_U@30>6EBZC&IU=.SFP=X(2:F'I-< M/V)Z\AB(FI MQQQ0/1U,QQ9KMH28F'K, 1N@$T.J*0 Q,0.9Q 9Z7 A$3BUQ[+HO@-JJRDPP<%_;E%B8@:_B-?CCP$!,3 MD/4JF_Y]G:2%"<@B%I L+1W95&RC8])47;JRSA1KB(D)R*(6T(O[%.WLA)B8@*PA6R"^Y%$D>6/[<[NP;<,[ M+F:8A68#MD /6RMGJD]_(R_];F\QPRPT&]!":M #ORV.'Z$A)F:AV8 6Z@SZ M<>$58F(6F@VX L>72^[$[B5G3SMK$!.ST(S80MVMOF>5',3$+#0;L TZ;@"> M/?1!;U1,(29FH=F %GIHU<5;IE:,[9,[K6:8A6;$%NIN_LEP/NZM;&1%O^TD M)/0W+M06.KW3JCM!(29FH5EKH7'[YOKCAWUZG17IWI&5R?[QUXZ/O]3\^!]02P,$% @ M(6#6CAE:^>: M @ 7]H=N6'R>CN=A7>W'L?M5U\-F7T[-\-!VY7RYLFW[4S->EOVN M[IK->[,KM2R75O?W,ZJGQ_N9B]>OKOS/Q':[/6S*[W;SYU3.XS\&UQ]M_S[L M2QFKQ6O3[\JXKNK/X^WT4%\/X>$RN5H\OZVK_ODM5/7<00)!,G^00I#.'Q0A M*,X?E" HS1]D$&3S!SD$^?Q!&8+R_$$K"%K-'Q26*..2(&F"-8'6 ;D.!%X' M!#L0B!V0[$!@=D"T X': =D.!&X'A#L0R!V0[D!@=T"\ X'>@GH+@=Z">@N! MWC)YV2;06U!O(=!;4&\AT%M0;R'06U!O(=!;4&\AT%M0;R'06U!O(=!;46\E MT%M1;R706U%O)=!;)Q]+"/16U%L)]%;46PGT5M1;"?16U%L)]%;46PGT5M1; M"?2.J' MB4#OA'HG KT3ZIT(]$ZH=R+0VU!O(]#;4&\CT-M0;R/0VU!O(]#;4&\CT-M0 M;R/0VR:;30CT-M3;"/0VU-L(]#;4VPCT=M3;"?1VU-L)]';4VPGT=M3;"?1V MU-L)]';4VPGT=M3;"?3VR69! KT=]78"O1WU=@*],^J="?3.J'"WR3Z$Z:,0OM[;OO+I.-DAKNQ&UUK3:>.K:N@IQ73P, MS1\IZZ>$-)Y<]OA]._FKN"$1KR;,*W\/>#KW[<$ZUS9V=5NY\+7JXRYQ[(0/ MCYWUZ?D2K_0X[G9M;9NQON_CD=1/SE:-WUL;^BX]%;TZGQSB#=O39W9Q_E+F M7&#<>>O&R<>).?O^N.>1S*?74RQD76C/O^)+8BQ]\?O9>=J-;=Z8':_WY^@. MRSR\6!Z7W_'O,WZI_\X^)*0/!>DCA_110/K0D#X,I(\2TL<'2!_9AM((1=2, M0FI&,36CH)I15,THK&845S,*K!E%5DF155)DE119)45629%54F25%%DE159) MD5529%44615%5D6155%D5119%45619%54615%%D51=:<(FM.D36GR)I39,TI MLN8467.*K#E%UIPB:TZ1M:#(6E!D+2BR%A19"XJL!476@B)K09&UH,A:4&35 M%%DU159-D5539-44635%5DV155-DU119-4560Y'54&0U%%D-159#D=509#44 M60U%5D.1U5!D+2FREA192XJL)476DB)K29&UI,A:4F0M*;*6_U/6'^-X^,?Q MRS/MJW9XSA?+_UIN?@%02P$"% ,4 " "TA8-:1L=-2)4 #- $ M @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( +2% M@UH9#DR!\P "L" 1 " <, !D;V-04! !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#% @ M(6#6IUZ=VH2 M#@ ]UH !@ ("!)@@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M(6#6M3?7M_=!0 I!8 !@ M ("!HB$ 'AL+W=O&55P, )$) 8 " @;4G !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0# M% @ M(6#6J9%0CVW @ '0@ !@ ("!8#0 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ M(6#6I$B%]E? M @ R < !D ("!9D( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M(6#6NRL/&>Q# F!\ !D M ("!*U< 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ M(6#6C1::W"D P I0< !D ("!/&\ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MM(6#6DDQ5;J-&0 KDD !D ("!P7P 'AL+W=O&UL4$L! A0#% @ M(6#6B<[P".>"0 MC!@ !D ("!$:( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M(6#6NQ/7HR+ P +0@ !D M ("!]K8 'AL+W=OT;L3,) "%%P &0 @(&XN@ >&PO=V]R:W-H M965T-V5^PH )8: 9 M " @2+$ !X;"]W;W)K&UL4$L! M A0#% @ M(6#6HK\T*EG P B0< !D ("!5,\ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M(6# M6MN>G1H> P S@8 !D ("!8^$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M(6#6E ;;=\A P G08 M !D ("!M_@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M(6#6KP'?2S# @ \@4 !D M ("!E0(! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ M(6#6MD8CK>. P '@D !D ("!+! ! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ M(6#6G/V M9Y_# @ \04 !D ("!JB ! 'AL+W=O&PO=V]R:W-H965TZ6PJA , "\( 9 " @=HH 0!X;"]W;W)K&UL4$L! A0#% @ M(6#6HJ.^7O1 @ - L !D M ("!E2P! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ M(6#6B28J78+!P T2P !D ("! M)CL! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ M(6#6B//@?,,! -Q0 !D ("!*$H! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M(6#6IRN'3TV P ,PT !D M ("!Y%X! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ M(6#6@>0-Q;J P R T !D ("!BW0! M 'AL+W=O $ >&PO=V]R:W-H965T&UL4$L! A0#% @ MM(6#6F&1F75"#@ 5< !D ("!&H(! 'AL+W=O&UL4$L! A0#% @ M(6#6D1E90EV P MU@H !D ("!VY&PO=V]R:W-H965T 0!X;"]W;W)K&UL4$L! A0#% @ M(6#6HGU1VC< P [@H !D M ("!WJ$! 'AL+W=O&PO=V]R:W-H M965TJO 0!X;"]W;W)K&UL4$L! M A0#% @ M(6#6I+!'&^L! \1< !D ("!>[,! 'AL M+W=ON $ >&PO=V]R:W-H965TF[ 0!X;"]W;W)K&UL4$L! A0#% @ M(6# M6CYI(\::! !18 !D ("!$< ! 'AL+W=O&PO=V]R:W-H965T\8 0 +04 9 " @7[) 0!X;"]W;W)K M&UL4$L! A0#% @ M(6#6LK,_"TO#@ +-$ M !D ("!%&PO=V]R:W-H965T&UL4$L! A0#% @ M(6#6@PKJ?Y5 P "@L !D M ("!A.(! 'AL+W=O&PO=V]R:W-H965T MJR>O_0, .H+ 9 M " @9OK 0!X;"]W;W)K&UL4$L! A0# M% @ M(6#6F4((/;:!0 !R< !D ("!S^\! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ M(6#6GQW M^DEZ P 91$ !D ("!B 0" 'AL+W=O&PO=V]R:W-H965TI9-P( -\R 3 M " 3L; @!;0V]N=&5N=%]4>7!E&UL4$L%!@ !A &$ *GAH *,= @ $! end XML 116 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 117 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 119 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 304 449 1 true 99 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://carecloud.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://carecloud.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://carecloud.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://carecloud.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://carecloud.com/role/StatementsOfComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://carecloud.com/role/StatementsOfShareholdersEquity Consolidated Statements of Shareholders' Equity Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical) Sheet http://carecloud.com/role/StatementsOfShareholdersEquityParenthetical Consolidated Statements of Shareholders' Equity (Parenthetical) Statements 7 false false R8.htm 00000008 - Statement - Consolidated Statements of Cash Flows Sheet http://carecloud.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 9 false false R10.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 10 false false R11.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure Cybersecurity Risk Management and Strategy Disclosure Notes 11 false false R12.htm 999016 - Disclosure - ORGANIZATION AND BUSINESS Sheet http://carecloud.com/role/OrganizationAndBusiness ORGANIZATION AND BUSINESS Notes 12 false false R13.htm 999017 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Sheet http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPolicies BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Notes 13 false false R14.htm 999018 - Disclosure - GOODWILL AND INTANGIBLE ASSETS ??? NET Sheet http://carecloud.com/role/GoodwillAndIntangibleAssetsNet GOODWILL AND INTANGIBLE ASSETS ??? NET Notes 14 false false R15.htm 999019 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://carecloud.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 15 false false R16.htm 999020 - Disclosure - CONCENTRATIONS Sheet http://carecloud.com/role/Concentrations CONCENTRATIONS Notes 16 false false R17.htm 999021 - Disclosure - NET LOSS PER COMMON SHARE Sheet http://carecloud.com/role/NetLossPerCommonShare NET LOSS PER COMMON SHARE Notes 17 false false R18.htm 999022 - Disclosure - DEBT Sheet http://carecloud.com/role/Debt DEBT Notes 18 false false R19.htm 999023 - Disclosure - REVENUE Sheet http://carecloud.com/role/Revenue REVENUE Notes 19 false false R20.htm 999024 - Disclosure - SHAREHOLDERS??? EQUITY Sheet http://carecloud.com/role/ShareholdersEquity SHAREHOLDERS??? EQUITY Notes 20 false false R21.htm 999025 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://carecloud.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 21 false false R22.htm 999026 - Disclosure - LEASES Sheet http://carecloud.com/role/Leases LEASES Notes 22 false false R23.htm 999027 - Disclosure - RELATED PARTIES Sheet http://carecloud.com/role/RelatedParties RELATED PARTIES Notes 23 false false R24.htm 999028 - Disclosure - RESTRUCTURING COSTS Sheet http://carecloud.com/role/RestructuringCosts RESTRUCTURING COSTS Notes 24 false false R25.htm 999029 - Disclosure - EMPLOYEE BENEFIT PLANS Sheet http://carecloud.com/role/EmployeeBenefitPlans EMPLOYEE BENEFIT PLANS Notes 25 false false R26.htm 999030 - Disclosure - STOCK-BASED COMPENSATION Sheet http://carecloud.com/role/Stock-basedCompensation STOCK-BASED COMPENSATION Notes 26 false false R27.htm 999031 - Disclosure - INCOME TAXES Sheet http://carecloud.com/role/IncomeTaxes INCOME TAXES Notes 27 false false R28.htm 999032 - Disclosure - OTHER EXPENSE ??? NET Sheet http://carecloud.com/role/OtherExpenseNet OTHER EXPENSE ??? NET Notes 28 false false R29.htm 999033 - Disclosure - SEGMENT REPORTING Sheet http://carecloud.com/role/SegmentReporting SEGMENT REPORTING Notes 29 false false R30.htm 999034 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://carecloud.com/role/FairValueOfFinancialInstruments FAIR VALUE OF FINANCIAL INSTRUMENTS Notes 30 false false R31.htm 999035 - Disclosure - SUBSEQUENT EVENTS Sheet http://carecloud.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 31 false false R32.htm 999036 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 32 false false R33.htm 999037 - Disclosure - GOODWILL AND INTANGIBLE ASSETS ??? NET (Tables) Sheet http://carecloud.com/role/GoodwillAndIntangibleAssetsNetTables GOODWILL AND INTANGIBLE ASSETS ??? NET (Tables) Tables http://carecloud.com/role/GoodwillAndIntangibleAssetsNet 33 false false R34.htm 999038 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://carecloud.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://carecloud.com/role/PropertyAndEquipment 34 false false R35.htm 999039 - Disclosure - CONCENTRATIONS (Tables) Sheet http://carecloud.com/role/ConcentrationsTables CONCENTRATIONS (Tables) Tables http://carecloud.com/role/Concentrations 35 false false R36.htm 999040 - Disclosure - NET LOSS PER COMMON SHARE (Tables) Sheet http://carecloud.com/role/NetLossPerCommonShareTables NET LOSS PER COMMON SHARE (Tables) Tables http://carecloud.com/role/NetLossPerCommonShare 36 false false R37.htm 999041 - Disclosure - DEBT (Tables) Sheet http://carecloud.com/role/DebtTables DEBT (Tables) Tables http://carecloud.com/role/Debt 37 false false R38.htm 999042 - Disclosure - REVENUE (Tables) Sheet http://carecloud.com/role/RevenueTables REVENUE (Tables) Tables http://carecloud.com/role/Revenue 38 false false R39.htm 999043 - Disclosure - LEASES (Tables) Sheet http://carecloud.com/role/LeasesTables LEASES (Tables) Tables http://carecloud.com/role/Leases 39 false false R40.htm 999044 - Disclosure - RESTRUCTURING COSTS (Tables) Sheet http://carecloud.com/role/RestructuringCostsTables RESTRUCTURING COSTS (Tables) Tables http://carecloud.com/role/RestructuringCosts 40 false false R41.htm 999045 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://carecloud.com/role/Stock-basedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://carecloud.com/role/Stock-basedCompensation 41 false false R42.htm 999046 - Disclosure - INCOME TAXES (Tables) Sheet http://carecloud.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://carecloud.com/role/IncomeTaxes 42 false false R43.htm 999047 - Disclosure - OTHER EXPENSE ??? NET (Tables) Sheet http://carecloud.com/role/OtherExpenseNetTables OTHER EXPENSE ??? NET (Tables) Tables http://carecloud.com/role/OtherExpenseNet 43 false false R44.htm 999048 - Disclosure - SEGMENT REPORTING (Tables) Sheet http://carecloud.com/role/SegmentReportingTables SEGMENT REPORTING (Tables) Tables http://carecloud.com/role/SegmentReporting 44 false false R45.htm 999049 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Sheet http://carecloud.com/role/FairValueOfFinancialInstrumentsTables FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Tables http://carecloud.com/role/FairValueOfFinancialInstruments 45 false false R46.htm 999050 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative) Sheet http://carecloud.com/role/OrganizationAndBusinessDetailsNarrative ORGANIZATION AND BUSINESS (Details Narrative) Details http://carecloud.com/role/OrganizationAndBusiness 46 false false R47.htm 999051 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies 47 false false R48.htm 999052 - Disclosure - SCHEDULE OF CHANGES TO CARRYING AMOUNT OF GOODWILL (Details) Sheet http://carecloud.com/role/ScheduleOfChangesToCarryingAmountOfGoodwillDetails SCHEDULE OF CHANGES TO CARRYING AMOUNT OF GOODWILL (Details) Details 48 false false R49.htm 999053 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS ACTIVITY (Details) Sheet http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails SCHEDULE OF INTANGIBLE ASSETS ACTIVITY (Details) Details 49 false false R50.htm 999054 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, FUTURE AMORTIZATION EXPENSE (Details) Sheet http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails SCHEDULE OF INTANGIBLE ASSETS, FUTURE AMORTIZATION EXPENSE (Details) Details 50 false false R51.htm 999055 - Disclosure - GOODWILL AND INTANGIBLE ASSETS ??? NET (Details Narrative) Sheet http://carecloud.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative GOODWILL AND INTANGIBLE ASSETS ??? NET (Details Narrative) Details http://carecloud.com/role/GoodwillAndIntangibleAssetsNetTables 51 false false R52.htm 999056 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 52 false false R53.htm 999057 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://carecloud.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://carecloud.com/role/PropertyAndEquipmentTables 53 false false R54.htm 999058 - Disclosure - SCHEDULE OF CONCENTRATION OF RISK, BY GEOGRAPHICAL RISKS FACTOR (Details) Sheet http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails SCHEDULE OF CONCENTRATION OF RISK, BY GEOGRAPHICAL RISKS FACTOR (Details) Details 54 false false R55.htm 999059 - Disclosure - CONCENTRATIONS (Details Narrative) Sheet http://carecloud.com/role/ConcentrationsDetailsNarrative CONCENTRATIONS (Details Narrative) Details http://carecloud.com/role/ConcentrationsTables 55 false false R56.htm 999060 - Disclosure - SCHEDULE OF RECONCILIATION OF WEIGHTED-AVERAGE SHARES OUTSTANDING FOR BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) Sheet http://carecloud.com/role/ScheduleOfReconciliationOfWeighted-averageSharesOutstandingForBasicAndDilutedNetLossPerCommonShareDetails SCHEDULE OF RECONCILIATION OF WEIGHTED-AVERAGE SHARES OUTSTANDING FOR BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) Details 56 false false R57.htm 999061 - Disclosure - NET LOSS PER COMMON SHARE (Details Narrative) Sheet http://carecloud.com/role/NetLossPerCommonShareDetailsNarrative NET LOSS PER COMMON SHARE (Details Narrative) Details http://carecloud.com/role/NetLossPerCommonShareTables 57 false false R58.htm 999062 - Disclosure - SCHEDULE OF MATURITIES OF LONG-TERM DEBT (Details) Sheet http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails SCHEDULE OF MATURITIES OF LONG-TERM DEBT (Details) Details 58 false false R59.htm 999063 - Disclosure - DEBT (Details Narrative) Sheet http://carecloud.com/role/DebtDetailsNarrative DEBT (Details Narrative) Details http://carecloud.com/role/DebtTables 59 false false R60.htm 999064 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details) Sheet http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails SCHEDULE OF DISAGGREGATION OF REVENUE (Details) Details 60 false false R61.htm 999065 - Disclosure - SCHEDULE OF CHANGES IN ACCOUNTS RECEIVABLE, CONTRACT ASSET AND DEFERRED REVENUE (Details) Sheet http://carecloud.com/role/ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueDetails SCHEDULE OF CHANGES IN ACCOUNTS RECEIVABLE, CONTRACT ASSET AND DEFERRED REVENUE (Details) Details 61 false false R62.htm 999066 - Disclosure - SCHEDULE OF TRADE ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) Sheet http://carecloud.com/role/ScheduleOfTradeAllowanceForDoubtfulAccountsDetails SCHEDULE OF TRADE ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) Details 62 false false R63.htm 999067 - Disclosure - REVENUE (Details Narrative) Sheet http://carecloud.com/role/RevenueDetailsNarrative REVENUE (Details Narrative) Details http://carecloud.com/role/RevenueTables 63 false false R64.htm 999068 - Disclosure - SHAREHOLDERS??? EQUITY (Details Narrative) Sheet http://carecloud.com/role/ShareholdersEquityDetailsNarrative SHAREHOLDERS??? EQUITY (Details Narrative) Details http://carecloud.com/role/ShareholdersEquity 64 false false R65.htm 999069 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://carecloud.com/role/CommitmentsAndContingencies 65 false false R66.htm 999070 - Disclosure - SCHEDULE OF LEASE EXPENSE (Details) Sheet http://carecloud.com/role/ScheduleOfLeaseExpenseDetails SCHEDULE OF LEASE EXPENSE (Details) Details 66 false false R67.htm 999071 - Disclosure - SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES (Details) Sheet http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES (Details) Details 67 false false R68.htm 999072 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES (Details) Sheet http://carecloud.com/role/ScheduleOfSupplementalCashFlowAndOtherInformationRelatedToLeasesDetails SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES (Details) Details 68 false false R69.htm 999073 - Disclosure - SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) Sheet http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) Details 69 false false R70.htm 999074 - Disclosure - LEASES (Details Narrative) Sheet http://carecloud.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://carecloud.com/role/LeasesTables 70 false false R71.htm 999075 - Disclosure - RELATED PARTIES (Details Narrative) Sheet http://carecloud.com/role/RelatedPartiesDetailsNarrative RELATED PARTIES (Details Narrative) Details http://carecloud.com/role/RelatedParties 71 false false R72.htm 999076 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS (Details) Sheet http://carecloud.com/role/ScheduleOfRestructuringCostsDetails SCHEDULE OF RESTRUCTURING COSTS (Details) Details 72 false false R73.htm 999077 - Disclosure - SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS (Details) Sheet http://carecloud.com/role/ScheduleOfLiabilitiesAssociatedWithRestructuringCostsDetails SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS (Details) Details 73 false false R74.htm 999078 - Disclosure - RESTRUCTURING COSTS (Details Narrative) Sheet http://carecloud.com/role/RestructuringCostsDetailsNarrative RESTRUCTURING COSTS (Details Narrative) Details http://carecloud.com/role/RestructuringCostsTables 74 false false R75.htm 999079 - Disclosure - EMPLOYEE BENEFIT PLANS (Details Narrative) Sheet http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative EMPLOYEE BENEFIT PLANS (Details Narrative) Details http://carecloud.com/role/EmployeeBenefitPlans 75 false false R76.htm 999080 - Disclosure - DISCLOSURE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD (Details) Sheet http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails DISCLOSURE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD (Details) Details 76 false false R77.htm 999081 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION, RESTRICTED STOCK UNITS AWARD ACTIVITY (Details) Sheet http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails SCHEDULE OF SHARE-BASED COMPENSATION, RESTRICTED STOCK UNITS AWARD ACTIVITY (Details) Details 77 false false R78.htm 999082 - Disclosure - SCHEDULE OF EMPLOYEE SERVICE SHARE-BASED COMPENSATION, ALLOCATION OF RECOGNIZED PERIOD COSTS (Details) Sheet http://carecloud.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails SCHEDULE OF EMPLOYEE SERVICE SHARE-BASED COMPENSATION, ALLOCATION OF RECOGNIZED PERIOD COSTS (Details) Details 78 false false R79.htm 999083 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://carecloud.com/role/Stock-basedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://carecloud.com/role/Stock-basedCompensationTables 79 false false R80.htm 999084 - Disclosure - SCHEDULE OF DEFERRED TAX VALUATION ALLOWANCE (Details) Sheet http://carecloud.com/role/ScheduleOfDeferredTaxValuationAllowanceDetails SCHEDULE OF DEFERRED TAX VALUATION ALLOWANCE (Details) Details 80 false false R81.htm 999085 - Disclosure - SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAX, DOMESTIC AND FOREIGN (Details) Sheet http://carecloud.com/role/ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignDetails SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAX, DOMESTIC AND FOREIGN (Details) Details 81 false false R82.htm 999086 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME TAX PROVISION (BENEFIT) (Details) Sheet http://carecloud.com/role/ScheduleOfComponentsOfIncomeTaxProvisionBenefitDetails SCHEDULE OF COMPONENTS OF INCOME TAX PROVISION (BENEFIT) (Details) Details 82 false false R83.htm 999087 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) Sheet http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) Details 83 false false R84.htm 999088 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) Sheet http://carecloud.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) Details 84 false false R85.htm 999089 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://carecloud.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://carecloud.com/role/IncomeTaxesTables 85 false false R86.htm 999090 - Disclosure - SCHEDULE OF OTHER (EXPENSE) INCOME - NET (Details) Sheet http://carecloud.com/role/ScheduleOfOtherExpenseIncome-NetDetails SCHEDULE OF OTHER (EXPENSE) INCOME - NET (Details) Details 86 false false R87.htm 999091 - Disclosure - SCHEDULE OF REVENUES, OPERATING EXPENSES AND OPERATING INCOME (LOSS) BY REPORTABLE SEGMENT (Details) Sheet http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails SCHEDULE OF REVENUES, OPERATING EXPENSES AND OPERATING INCOME (LOSS) BY REPORTABLE SEGMENT (Details) Details 87 false false R88.htm 999092 - Disclosure - FAIR VALUE OF THE ASSETS MEASURED ON A NON-RECURRING BASIS (Details) Sheet http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails FAIR VALUE OF THE ASSETS MEASURED ON A NON-RECURRING BASIS (Details) Details 88 false false R89.htm 999093 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://carecloud.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://carecloud.com/role/SubsequentEvents 89 false false All Reports Book All Reports ccld-20241231.xsd ccld-20241231_cal.xml ccld-20241231_def.xml ccld-20241231_lab.xml ccld-20241231_pre.xml form10-ka.htm form10-k_001.jpg form10-k_002.jpg form10-k_003.jpg form10-k_004.jpg form10-k_005.jpg http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 121 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-ka.htm": { "nsprefix": "CCLD", "nsuri": "http://carecloud.com/20241231", "dts": { "schema": { "local": [ "ccld-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "ccld-20241231_cal.xml" ] }, "definitionLink": { "local": [ "ccld-20241231_def.xml" ] }, "labelLink": { "local": [ "ccld-20241231_lab.xml" ] }, "presentationLink": { "local": [ "ccld-20241231_pre.xml" ] }, "inline": { "local": [ "form10-ka.htm" ] } }, "keyStandard": 393, "keyCustom": 56, "axisStandard": 36, "axisCustom": 0, "memberStandard": 38, "memberCustom": 60, "hidden": { "total": 182, "http://fasb.org/us-gaap/2024": 167, "http://carecloud.com/20241231": 12, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 304, "entityCount": 1, "segmentCount": 99, "elementCount": 806, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1174, "http://xbrl.sec.gov/dei/2024": 49, "http://xbrl.sec.gov/cyd/2024": 13, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://carecloud.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R2": { "role": "http://carecloud.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R3": { "role": "http://carecloud.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R4": { "role": "http://carecloud.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:InterestIncomeOther", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R5": { "role": "http://carecloud.com/role/StatementsOfComprehensiveIncomeLoss", "longName": "00000005 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R6": { "role": "http://carecloud.com/role/StatementsOfShareholdersEquity", "longName": "00000006 - Statement - Consolidated Statements of Shareholders' Equity", "shortName": "Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R7": { "role": "http://carecloud.com/role/StatementsOfShareholdersEquityParenthetical", "longName": "00000007 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)", "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2023-01-012023-12-31", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "link:footnote", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://carecloud.com/role/StatementsOfCashFlows", "longName": "00000008 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OtherDepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": null }, "R10": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-10-012024-12-31", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-10-012024-12-31", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R11": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R12": { "role": "http://carecloud.com/role/OrganizationAndBusiness", "longName": "999016 - Disclosure - ORGANIZATION AND BUSINESS", "shortName": "ORGANIZATION AND BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R13": { "role": "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPolicies", "longName": "999017 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R14": { "role": "http://carecloud.com/role/GoodwillAndIntangibleAssetsNet", "longName": "999018 - Disclosure - GOODWILL AND INTANGIBLE ASSETS \u2013 NET", "shortName": "GOODWILL AND INTANGIBLE ASSETS \u2013 NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R15": { "role": "http://carecloud.com/role/PropertyAndEquipment", "longName": "999019 - Disclosure - PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R16": { "role": "http://carecloud.com/role/Concentrations", "longName": "999020 - Disclosure - CONCENTRATIONS", "shortName": "CONCENTRATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R17": { "role": "http://carecloud.com/role/NetLossPerCommonShare", "longName": "999021 - Disclosure - NET LOSS PER COMMON SHARE", "shortName": "NET LOSS PER COMMON SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R18": { "role": "http://carecloud.com/role/Debt", "longName": "999022 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R19": { "role": "http://carecloud.com/role/Revenue", "longName": "999023 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R20": { "role": "http://carecloud.com/role/ShareholdersEquity", "longName": "999024 - Disclosure - SHAREHOLDERS\u2019 EQUITY", "shortName": "SHAREHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R21": { "role": "http://carecloud.com/role/CommitmentsAndContingencies", "longName": "999025 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R22": { "role": "http://carecloud.com/role/Leases", "longName": "999026 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R23": { "role": "http://carecloud.com/role/RelatedParties", "longName": "999027 - Disclosure - RELATED PARTIES", "shortName": "RELATED PARTIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R24": { "role": "http://carecloud.com/role/RestructuringCosts", "longName": "999028 - Disclosure - RESTRUCTURING COSTS", "shortName": "RESTRUCTURING COSTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R25": { "role": "http://carecloud.com/role/EmployeeBenefitPlans", "longName": "999029 - Disclosure - EMPLOYEE BENEFIT PLANS", "shortName": "EMPLOYEE BENEFIT PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R26": { "role": "http://carecloud.com/role/Stock-basedCompensation", "longName": "999030 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R27": { "role": "http://carecloud.com/role/IncomeTaxes", "longName": "999031 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R28": { "role": "http://carecloud.com/role/OtherExpenseNet", "longName": "999032 - Disclosure - OTHER EXPENSE \u2013 NET", "shortName": "OTHER EXPENSE \u2013 NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R29": { "role": "http://carecloud.com/role/SegmentReporting", "longName": "999033 - Disclosure - SEGMENT REPORTING", "shortName": "SEGMENT REPORTING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R30": { "role": "http://carecloud.com/role/FairValueOfFinancialInstruments", "longName": "999034 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R31": { "role": "http://carecloud.com/role/SubsequentEvents", "longName": "999035 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R32": { "role": "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies", "longName": "999036 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "32", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R33": { "role": "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetTables", "longName": "999037 - Disclosure - GOODWILL AND INTANGIBLE ASSETS \u2013 NET (Tables)", "shortName": "GOODWILL AND INTANGIBLE ASSETS \u2013 NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R34": { "role": "http://carecloud.com/role/PropertyAndEquipmentTables", "longName": "999038 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R35": { "role": "http://carecloud.com/role/ConcentrationsTables", "longName": "999039 - Disclosure - CONCENTRATIONS (Tables)", "shortName": "CONCENTRATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R36": { "role": "http://carecloud.com/role/NetLossPerCommonShareTables", "longName": "999040 - Disclosure - NET LOSS PER COMMON SHARE (Tables)", "shortName": "NET LOSS PER COMMON SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R37": { "role": "http://carecloud.com/role/DebtTables", "longName": "999041 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R38": { "role": "http://carecloud.com/role/RevenueTables", "longName": "999042 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R39": { "role": "http://carecloud.com/role/LeasesTables", "longName": "999043 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R40": { "role": "http://carecloud.com/role/RestructuringCostsTables", "longName": "999044 - Disclosure - RESTRUCTURING COSTS (Tables)", "shortName": "RESTRUCTURING COSTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R41": { "role": "http://carecloud.com/role/Stock-basedCompensationTables", "longName": "999045 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R42": { "role": "http://carecloud.com/role/IncomeTaxesTables", "longName": "999046 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SummaryOfValuationAllowanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SummaryOfValuationAllowanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R43": { "role": "http://carecloud.com/role/OtherExpenseNetTables", "longName": "999047 - Disclosure - OTHER EXPENSE \u2013 NET (Tables)", "shortName": "OTHER EXPENSE \u2013 NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R44": { "role": "http://carecloud.com/role/SegmentReportingTables", "longName": "999048 - Disclosure - SEGMENT REPORTING (Tables)", "shortName": "SEGMENT REPORTING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R45": { "role": "http://carecloud.com/role/FairValueOfFinancialInstrumentsTables", "longName": "999049 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R46": { "role": "http://carecloud.com/role/OrganizationAndBusinessDetailsNarrative", "longName": "999050 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)", "shortName": "ORGANIZATION AND BUSINESS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2004-12-31_custom_MTBCPrivateLimitedMember", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2004-12-31_custom_MTBCPrivateLimitedMember", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R47": { "role": "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "longName": "999051 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R48": { "role": "http://carecloud.com/role/ScheduleOfChangesToCarryingAmountOfGoodwillDetails", "longName": "999052 - Disclosure - SCHEDULE OF CHANGES TO CARRYING AMOUNT OF GOODWILL (Details)", "shortName": "SCHEDULE OF CHANGES TO CARRYING AMOUNT OF GOODWILL (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails", "longName": "999053 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS ACTIVITY (Details)", "shortName": "SCHEDULE OF INTANGIBLE ASSETS ACTIVITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R50": { "role": "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails", "longName": "999054 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS, FUTURE AMORTIZATION EXPENSE (Details)", "shortName": "SCHEDULE OF INTANGIBLE ASSETS, FUTURE AMORTIZATION EXPENSE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R51": { "role": "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative", "longName": "999055 - Disclosure - GOODWILL AND INTANGIBLE ASSETS \u2013 NET (Details Narrative)", "shortName": "GOODWILL AND INTANGIBLE ASSETS \u2013 NET (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R52": { "role": "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails", "longName": "999056 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R53": { "role": "http://carecloud.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "999057 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R54": { "role": "http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails", "longName": "999058 - Disclosure - SCHEDULE OF CONCENTRATION OF RISK, BY GEOGRAPHICAL RISKS FACTOR (Details)", "shortName": "SCHEDULE OF CONCENTRATION OF RISK, BY GEOGRAPHICAL RISKS FACTOR (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:AssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31_us-gaap_NonUsMember", "name": "us-gaap:AssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R55": { "role": "http://carecloud.com/role/ConcentrationsDetailsNarrative", "longName": "999059 - Disclosure - CONCENTRATIONS (Details Narrative)", "shortName": "CONCENTRATIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31_us-gaap_NonUsMember", "name": "CCLD:IntercompanyReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R56": { "role": "http://carecloud.com/role/ScheduleOfReconciliationOfWeighted-averageSharesOutstandingForBasicAndDilutedNetLossPerCommonShareDetails", "longName": "999060 - Disclosure - SCHEDULE OF RECONCILIATION OF WEIGHTED-AVERAGE SHARES OUTSTANDING FOR BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details)", "shortName": "SCHEDULE OF RECONCILIATION OF WEIGHTED-AVERAGE SHARES OUTSTANDING FOR BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R57": { "role": "http://carecloud.com/role/NetLossPerCommonShareDetailsNarrative", "longName": "999061 - Disclosure - NET LOSS PER COMMON SHARE (Details Narrative)", "shortName": "NET LOSS PER COMMON SHARE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R58": { "role": "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails", "longName": "999062 - Disclosure - SCHEDULE OF MATURITIES OF LONG-TERM DEBT (Details)", "shortName": "SCHEDULE OF MATURITIES OF LONG-TERM DEBT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R59": { "role": "http://carecloud.com/role/DebtDetailsNarrative", "longName": "999063 - Disclosure - DEBT (Details Narrative)", "shortName": "DEBT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LongTermLineOfCredit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R60": { "role": "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails", "longName": "999064 - Disclosure - SCHEDULE OF DISAGGREGATION OF REVENUE (Details)", "shortName": "SCHEDULE OF DISAGGREGATION OF REVENUE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_custom_HealthcareITMember_custom_TechnologyEnabledBusinessSolutionsMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R61": { "role": "http://carecloud.com/role/ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueDetails", "longName": "999065 - Disclosure - SCHEDULE OF CHANGES IN ACCOUNTS RECEIVABLE, CONTRACT ASSET AND DEFERRED REVENUE (Details)", "shortName": "SCHEDULE OF CHANGES IN ACCOUNTS RECEIVABLE, CONTRACT ASSET AND DEFERRED REVENUE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "CCLD:ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R62": { "role": "http://carecloud.com/role/ScheduleOfTradeAllowanceForDoubtfulAccountsDetails", "longName": "999066 - Disclosure - SCHEDULE OF TRADE ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)", "shortName": "SCHEDULE OF TRADE ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R63": { "role": "http://carecloud.com/role/RevenueDetailsNarrative", "longName": "999067 - Disclosure - REVENUE (Details Narrative)", "shortName": "REVENUE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R64": { "role": "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "longName": "999068 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Details Narrative)", "shortName": "SHAREHOLDERS\u2019 EQUITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CommonStockVotingRights", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R65": { "role": "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "999069 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "From2021-03-012021-03-31", "name": "us-gaap:LossContingencyDamagesPaidValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2021-03-012021-03-31", "name": "us-gaap:LossContingencyDamagesPaidValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R66": { "role": "http://carecloud.com/role/ScheduleOfLeaseExpenseDetails", "longName": "999070 - Disclosure - SCHEDULE OF LEASE EXPENSE (Details)", "shortName": "SCHEDULE OF LEASE EXPENSE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R67": { "role": "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails", "longName": "999071 - Disclosure - SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES (Details)", "shortName": "SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "CCLD:OperatingLeaseRightOfUseAssetGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "CCLD:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R68": { "role": "http://carecloud.com/role/ScheduleOfSupplementalCashFlowAndOtherInformationRelatedToLeasesDetails", "longName": "999072 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES (Details)", "shortName": "SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "CCLD:ScheduleOfSupplementalCashFlowAndOtherInformationRelatedToLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "CCLD:ScheduleOfSupplementalCashFlowAndOtherInformationRelatedToLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R69": { "role": "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails", "longName": "999073 - Disclosure - SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details)", "shortName": "SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R70": { "role": "http://carecloud.com/role/LeasesDetailsNarrative", "longName": "999074 - Disclosure - LEASES (Details Narrative)", "shortName": "LEASES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "CCLD:LeaseTermDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "CCLD:LeaseTermDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R71": { "role": "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "longName": "999075 - Disclosure - RELATED PARTIES (Details Narrative)", "shortName": "RELATED PARTIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R72": { "role": "http://carecloud.com/role/ScheduleOfRestructuringCostsDetails", "longName": "999076 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS (Details)", "shortName": "SCHEDULE OF RESTRUCTURING COSTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SeveranceCosts1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SeveranceCosts1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R73": { "role": "http://carecloud.com/role/ScheduleOfLiabilitiesAssociatedWithRestructuringCostsDetails", "longName": "999077 - Disclosure - SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS (Details)", "shortName": "SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RestructuringReserve", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "CCLD:ScheduleOfLiabilitiesAssociatedWithRestructuringCostsTableTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PaymentsForRestructuring", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "CCLD:ScheduleOfLiabilitiesAssociatedWithRestructuringCostsTableTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R74": { "role": "http://carecloud.com/role/RestructuringCostsDetailsNarrative", "longName": "999078 - Disclosure - RESTRUCTURING COSTS (Details Narrative)", "shortName": "RESTRUCTURING COSTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R75": { "role": "http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative", "longName": "999079 - Disclosure - EMPLOYEE BENEFIT PLANS (Details Narrative)", "shortName": "EMPLOYEE BENEFIT PLANS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "From2024-01-012024-12-31_custom_DefinedContributionRetirementPlanForUSEmployeesMember", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_custom_DefinedContributionRetirementPlanForUSEmployeesMember", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R76": { "role": "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "longName": "999080 - Disclosure - DISCLOSURE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD (Details)", "shortName": "DISCLOSURE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SeriesBPreferredStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SeriesBPreferredStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R77": { "role": "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "longName": "999081 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION, RESTRICTED STOCK UNITS AWARD ACTIVITY (Details)", "shortName": "SCHEDULE OF SHARE-BASED COMPENSATION, RESTRICTED STOCK UNITS AWARD ACTIVITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R78": { "role": "http://carecloud.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails", "longName": "999082 - Disclosure - SCHEDULE OF EMPLOYEE SERVICE SHARE-BASED COMPENSATION, ALLOCATION OF RECOGNIZED PERIOD COSTS (Details)", "shortName": "SCHEDULE OF EMPLOYEE SERVICE SHARE-BASED COMPENSATION, ALLOCATION OF RECOGNIZED PERIOD COSTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_custom_DirectOperatingCostsMember", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R79": { "role": "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative", "longName": "999083 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)", "shortName": "STOCK-BASED COMPENSATION (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "CCLD:LiabilityForCashSettledAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R80": { "role": "http://carecloud.com/role/ScheduleOfDeferredTaxValuationAllowanceDetails", "longName": "999084 - Disclosure - SCHEDULE OF DEFERRED TAX VALUATION ALLOWANCE (Details)", "shortName": "SCHEDULE OF DEFERRED TAX VALUATION ALLOWANCE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R81": { "role": "http://carecloud.com/role/ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignDetails", "longName": "999085 - Disclosure - SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAX, DOMESTIC AND FOREIGN (Details)", "shortName": "SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAX, DOMESTIC AND FOREIGN (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R82": { "role": "http://carecloud.com/role/ScheduleOfComponentsOfIncomeTaxProvisionBenefitDetails", "longName": "999086 - Disclosure - SCHEDULE OF COMPONENTS OF INCOME TAX PROVISION (BENEFIT) (Details)", "shortName": "SCHEDULE OF COMPONENTS OF INCOME TAX PROVISION (BENEFIT) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R83": { "role": "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "longName": "999087 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)", "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R84": { "role": "http://carecloud.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "longName": "999088 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)", "shortName": "SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R85": { "role": "http://carecloud.com/role/IncomeTaxesDetailsNarrative", "longName": "999089 - Disclosure - INCOME TAXES (Details Narrative)", "shortName": "INCOME TAXES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "From2023-08-312023-08-31", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R86": { "role": "http://carecloud.com/role/ScheduleOfOtherExpenseIncome-NetDetails", "longName": "999090 - Disclosure - SCHEDULE OF OTHER (EXPENSE) INCOME - NET (Details)", "shortName": "SCHEDULE OF OTHER (EXPENSE) INCOME - NET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R87": { "role": "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "longName": "999091 - Disclosure - SCHEDULE OF REVENUES, OPERATING EXPENSES AND OPERATING INCOME (LOSS) BY REPORTABLE SEGMENT (Details)", "shortName": "SCHEDULE OF REVENUES, OPERATING EXPENSES AND OPERATING INCOME (LOSS) BY REPORTABLE SEGMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } }, "R88": { "role": "http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails", "longName": "999092 - Disclosure - FAIR VALUE OF THE ASSETS MEASURED ON A NON-RECURRING BASIS (Details)", "shortName": "FAIR VALUE OF THE ASSETS MEASURED ON A NON-RECURRING BASIS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:GoodwillFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:GoodwillFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R89": { "role": "http://carecloud.com/role/SubsequentEventsDetailsNarrative", "longName": "999093 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-01-31_us-gaap_SubsequentEventMember", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201613Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate201613Member", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2016-13 [Member]", "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments." } } }, "auth_ref": [ "r345" ] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r92", "r98" ] }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Billing Status, Type [Axis]", "documentation": "Information by billing status of receivables." } } }, "auth_ref": [ "r92", "r98" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r79", "r1039" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://carecloud.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF TRADE ALLOWANCE FOR DOUBTFUL ACCOUNTS", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r1230" ] }, "us-gaap_AccountsReceivableChangeInMethodCreditLossExpenseReversal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableChangeInMethodCreditLossExpenseReversal", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfTradeAllowanceForDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "label": "Adoption of ASC 326", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable from change in methodology." } } }, "auth_ref": [ "r357" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r966" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Accounts receivable - net", "periodStartLabel": "Accounts Receivable - Net, Opening", "periodEndLabel": "Accounts Receivable - Net, Closing", "verboseLabel": "Receivable due from customer", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1225" ] }, "us-gaap_AccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionExpense", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest accretion", "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations." } } }, "auth_ref": [ "r1003", "r1262" ] }, "CCLD_AccruedExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "AccruedExpensesMember", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses [Member]", "documentation": "Accrued Expenses [Member]" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r82" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r39", "r212", "r808" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r16", "r17", "r99", "r220", "r803", "r846", "r850" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r13", "r17", "r650", "r653", "r732", "r841", "r842", "r1199", "r1200", "r1201", "r1210", "r1211", "r1212", "r1214" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted-average amortization period", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r380", "r979" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r1126" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r93", "r1039", "r1442" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r866", "r1210", "r1211", "r1212", "r1214", "r1381", "r1444" ] }, "CCLD_AdditionalWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "AdditionalWarrantMember", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional Warrant [Member]", "documentation": "Additional Warrant [Member]" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r1132" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r1132" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r1132" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r1132" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": [ "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amortization expense", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r7" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r201", "r202", "r203", "r204", "r205", "r206", "r257", "r258", "r259", "r260", "r270", "r337", "r338", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r391", "r392", "r401", "r610", "r611", "r612", "r613", "r614", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r689", "r690", "r707", "r708", "r709", "r727", "r728", "r729", "r730", "r731", "r732", "r756", "r757", "r758", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation, net of cash settlements", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r61", "r62", "r536" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:" } } }, "auth_ref": [] }, "CCLD_AdvanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "AdvanceAmount", "crdr": "debit", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advance amount", "documentation": "Advance amount." } } }, "auth_ref": [] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advertising costs", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r577", "r1027" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1093", "r1104", "r1118", "r1144" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r1096", "r1107", "r1121", "r1147" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r1132" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r1139" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r1097", "r1108", "r1122", "r1139", "r1148", "r1152", "r1160" ] }, "CCLD_AllowanceForDoubtfulAccountsAdoption": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "AllowanceForDoubtfulAccountsAdoption", "crdr": "credit", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Allowance for expected credit losses", "documentation": "Allowance for doubtful accounts adoption." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfTradeAllowanceForDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r221", "r340", "r356", "r358", "r361", "r1408" ] }, "CCLD_AllowanceForDoubtfulAccountsReceivableRecoveriesAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "AllowanceForDoubtfulAccountsReceivableRecoveriesAdjustments", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfTradeAllowanceForDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "label": "Recoveries/adjustments", "documentation": "Allowance for doubtful accounts receivable recoveries adjustments." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfTradeAllowanceForDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Write-offs", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance." } } }, "auth_ref": [ "r360" ] }, "CCLD_AmendedAndRestatedEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "AmendedAndRestatedEquityIncentivePlanMember", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amended and Restated Equity Incentive Plan [Member]", "documentation": "Amended and Restated Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDeferredSalesCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDeferredSalesCommissions", "crdr": "debit", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amortization of deferred sales commissions", "documentation": "The amount of expense recognized in the current period for the periodic realization of capitalized fees that were paid to salespeople, distributors, brokers, and agents at the time of the conclusion of the sale. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r7", "r102" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated amortization, amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r7", "r377", "r384", "r1002" ] }, "CCLD_AmortizationOfLease": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "AmortizationOfLease", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Lease amortization", "documentation": "Amortization of lease." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r1100" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://carecloud.com/role/NetLossPerCommonShareDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Anti-dilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r286" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r640" ] }, "CCLD_AssetLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "AssetLeaseExpense", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Asset lease expense", "documentation": "Asset lease expense." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r136", "r144", "r216", "r247", "r290", "r299", "r324", "r328", "r344", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r641", "r643", "r692", "r796", "r905", "r994", "r995", "r1039", "r1064", "r1271", "r1272", "r1399" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r209", "r223", "r247", "r344", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r641", "r643", "r692", "r1039", "r1271", "r1272", "r1399" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNet", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative", "http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails" ], "lang": { "en-us": { "role": { "label": "Net assets", "documentation": "Amount of net assets (liabilities)." } } }, "auth_ref": [ "r12" ] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r247", "r344", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r641", "r643", "r692", "r1271", "r1272", "r1399" ] }, "CCLD_AssetsNotPlacedInServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "AssetsNotPlacedInServiceMember", "presentation": [ "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Assets not Placed in Service [Member]", "documentation": "Assets not Placed in Service [Member]" } } }, "auth_ref": [] }, "CCLD_AtTheMarketFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "AtTheMarketFacilityMember", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "At The Market Facility [Member]", "documentation": "At The Market Facility [Member]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r1100" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1076", "r1078", "r1100" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r1076", "r1078", "r1100" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r1076", "r1078", "r1100" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [ "r1155" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r1156" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r1151" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r1151" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": [ "r1151" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r1151" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r1151" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": [ "r1151" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/NetLossPerCommonShareDetailsNarrative", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r539", "r540", "r541", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r563", "r564", "r565", "r566", "r567" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": [ "r1154" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1153" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1152" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r1152" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r400", "r1410", "r1411" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r69", "r70", "r400", "r1410", "r1411" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r113" ] }, "CCLD_BetweenTwoThousandThirtyOneAndTwoThousandThirtyEightMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "BetweenTwoThousandThirtyOneAndTwoThousandThirtyEightMember", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Between 2031 and 2038 [Member]", "documentation": "Between 2031 and 2038 [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r378", "r379", "r380", "r381", "r382", "r631", "r1022", "r1023" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r63", "r64", "r378", "r379", "r380", "r381", "r382", "r631", "r1022", "r1023" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Business Combinations", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r130", "r131", "r132", "r133" ] }, "us-gaap_CapitalizedComputerSoftwareAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareAdditions", "crdr": "debit", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Internal-use software costs capitalized", "documentation": "Additions made to capitalized computer software costs during the period." } } }, "auth_ref": [ "r979" ] }, "CCLD_CapitalizedSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "CapitalizedSoftwareMember", "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Capitalized Software [Member]", "documentation": "Capitalized Software [Member]" } } }, "auth_ref": [] }, "CCLD_CareCloudAndMeridianAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "CareCloudAndMeridianAcquisitionsMember", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "CareCloud and Meridian Acquisitions [Member]", "documentation": "CareCloud and Meridian Acquisitions [Member]" } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r71", "r72" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r149", "r800", "r877", "r900", "r1039", "r1064", "r1195" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "CASH - Beginning of the year", "periodEndLabel": "CASH - End of the year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r21", "r109", "r244" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCREASE (DECREASE) IN CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r109" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "CCLD_CashSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "CashSettlement", "crdr": "credit", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash settlement", "documentation": "Cash settlement." } } }, "auth_ref": [] }, "CCLD_CertificateOfAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "CertificateOfAmendmentMember", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Certificate of Amendment [Member]", "documentation": "Certificate of Amendment [Member]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r1130" ] }, "CCLD_ChronicCareManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ChronicCareManagementMember", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chronic Care Management [Member]", "documentation": "Chronic Care Management [Member]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical", "http://carecloud.com/role/Cover", "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/StatementsOfShareholdersEquity", "http://carecloud.com/role/StatementsOfShareholdersEquityParenthetical", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r161", "r217", "r218", "r219", "r247", "r275", "r276", "r283", "r285", "r293", "r294", "r344", "r424", "r427", "r428", "r429", "r433", "r434", "r463", "r464", "r467", "r470", "r477", "r692", "r857", "r858", "r859", "r860", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r878", "r892", "r915", "r938", "r959", "r960", "r961", "r962", "r963", "r1179", "r1206", "r1215" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r217", "r218", "r219", "r293", "r463", "r464", "r465", "r467", "r470", "r475", "r477", "r857", "r858", "r859", "r860", "r1010", "r1179", "r1206" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants price per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r478" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase", "verboseLabel": "Warrants issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r478" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1131" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r1131" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES (NOTE 10)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r88", "r137", "r799", "r891" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r122", "r414", "r415", "r967", "r1256", "r1263" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares reserved for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r91" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/StatementsOfShareholdersEquity", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1055", "r1056", "r1057", "r1059", "r1060", "r1061", "r1062", "r1210", "r1211", "r1214", "r1381", "r1441", "r1444" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r91" ] }, "CCLD_CommonStockParValue0.001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "CommonStockParValue0.001PerShareMember", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, par value $0.001 per share [Member]", "documentation": "Common Stock, par value $0.001 per share [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "verboseLabel": "Common stock shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r91", "r892" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r91" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r91", "r892", "r911", "r1444", "r1445" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value - authorized 35,000,000 shares. Issued 16,997,035 and 16,620,891 shares at December 31, 2024 and December 31, 2023, respectively. Outstanding 16,256,236 and 15,880,092 shares at December 31, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r91", "r802", "r1039" ] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockVotingRights", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, voting rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r47" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r1136" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r1135" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r1137" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r1134" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/StatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "COMPREHENSIVE INCOME (LOSS)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r18", "r225", "r227", "r232", "r792", "r813", "r814" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r28", "r29", "r73", "r74", "r336", "r966" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r28", "r29", "r73", "r74", "r336", "r852", "r966" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r28", "r29", "r73", "r74", "r336", "r966", "r1189" ] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://carecloud.com/role/Concentrations" ], "lang": { "en-us": { "role": { "label": "CONCENTRATIONS", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r114" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r966" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r28", "r29", "r73", "r74", "r336" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r27", "r28", "r29", "r30", "r73", "r135", "r966" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r28", "r29", "r73", "r74", "r336", "r966" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r142", "r162", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r253", "r290", "r301", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r330", "r424", "r425", "r426", "r427", "r429", "r430", "r431", "r432", "r433", "r994", "r995", "r1192", "r1193", "r1271", "r1272" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r142", "r162", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r253", "r290", "r301", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r330", "r424", "r425", "r426", "r427", "r429", "r430", "r431", "r432", "r433", "r994", "r995", "r1192", "r1193", "r1271", "r1272" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r68", "r984" ] }, "CCLD_ConsultingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ConsultingAgreementMember", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consulting Agreement [Member]", "documentation": "Consulting Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Contract with customer asset", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r480", "r482", "r501" ] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Contract asset", "periodStartLabel": "Contract Assets, Opening", "periodEndLabel": "Contract Assets, Closing", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r480", "r482", "r501" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Deferred revenue (current portion)", "periodStartLabel": "Deferred Revenue (current), Opening", "periodEndLabel": "Deferred Revenue (current), Closing", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r480", "r481", "r501" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "periodStartLabel": "Deferred Revenue (long term), Opening", "periodEndLabel": "Deferred Revenue (long term), Closing", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r480", "r481", "r501" ] }, "CCLD_ContractWithCustomerLiabilityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ContractWithCustomerLiabilityPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue", "documentation": "Contract With Customer Liability [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r502" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of shares", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r23", "r24", "r25" ] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lease Terminations, Unoccupied Lease Charges and Restructuring Costs", "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation." } } }, "auth_ref": [ "r120", "r121" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r423", "r1269" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r423", "r1269", "r1270" ] }, "CCLD_CumulativeEffectOfAdoptionOfAccountingStandardUpdate": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "CumulativeEffectOfAdoptionOfAccountingStandardUpdate", "crdr": "credit", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Cumulative effect of adopting ASC 326", "documentation": "Cumulative effect of adoption of accounting standard update." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfComponentsOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current tax, Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1190", "r1209", "r1376" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfComponentsOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current tax, Foreign", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1190", "r1209" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfComponentsOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Provision for current income taxes", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r609", "r1209" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfComponentsOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current tax, State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1190", "r1209", "r1376" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r115", "r336" ] }, "CCLD_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "CustomerOneMember", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer One [Member]", "documentation": "Customer One [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r65", "r1244", "r1245", "r1246", "r1247", "r1249", "r1251", "r1254", "r1255" ] }, "CCLD_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "CustomerTwoMember", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "documentation": "Customer Two [Member]" } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1086", "r1170" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r1086", "r1170" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r1088", "r1172" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1088", "r1172" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r1081", "r1165" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r1082", "r1166" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r1082", "r1166" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r1080", "r1164" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r1083", "r1167" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r1085", "r1169" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r1085", "r1169" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1086", "r1170" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1089", "r1173" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r1087", "r1171" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r1084", "r1168" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://carecloud.com/role/Debt" ], "lang": { "en-us": { "role": { "label": "DEBT", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r123", "r245", "r395", "r396", "r397", "r398", "r399", "r422", "r423", "r435", "r441", "r442", "r443", "r444", "r445", "r446", "r451", "r458", "r459", "r461", "r706" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r84", "r437" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r253", "r436", "r437", "r438", "r439", "r440", "r442", "r447", "r448", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r460", "r1005", "r1006", "r1007", "r1008", "r1009", "r1037", "r1207", "r1391", "r1392" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r15", "r47", "r52", "r77", "r126", "r127", "r253", "r436", "r437", "r438", "r439", "r440", "r442", "r447", "r448", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r460", "r1005", "r1006", "r1007", "r1008", "r1009", "r1037", "r1207", "r1391", "r1392" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "CCLD_DeferredCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DeferredCommissions", "crdr": "debit", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred commissions", "documentation": "Deferred commissions." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfComponentsOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax, Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1209", "r1375", "r1376" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfComponentsOfIncomeTaxProvisionBenefitDetails", "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Benefit for deferred income taxes", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r7", "r158", "r1209" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfComponentsOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax, State", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1209", "r1375", "r1376" ] }, "CCLD_DeferredTaxAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DeferredTaxAdjustment", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "ASC 842 - ROU asset", "documentation": "Deferred tax adjustment." } } }, "auth_ref": [] }, "CCLD_DeferredTaxAssetPrepaidCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DeferredTaxAssetPrepaidCommissions", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid commissions", "documentation": "Prepaid Commissions." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsDeferredIncome", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Deferred Tax Assets, Deferred Income", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income." } } }, "auth_ref": [ "r1373" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Total deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r601" ] }, "CCLD_DeferredTaxAssetsInterestLimitation": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DeferredTaxAssetsInterestLimitation", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Section 163(j) interest limitation", "documentation": "Deferred tax assets interest limitation." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Federal net operating loss (\"NOL\") carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": [ "r1373" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "State net operating loss (\"NOL\") carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards." } } }, "auth_ref": [ "r1373" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1373" ] }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Property and intangible assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r1373" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Credit carryovers", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r1373" ] }, "CCLD_DeferredTaxAssetsTaxCreditCost": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DeferredTaxAssetsTaxCreditCost", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Section 174 costs", "documentation": "Deferred tax assets tax credit cost." } } }, "auth_ref": [] }, "CCLD_DeferredTaxAssetsTaxCreditLimitation": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DeferredTaxAssetsTaxCreditLimitation", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Section 267 limitation", "documentation": "Section 267 limitation." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs." } } }, "auth_ref": [ "r1373" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Stock based compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r1373" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Allowance for expected credit losses", "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r1373" ] }, "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Cumulative balance translation adjustment", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions." } } }, "auth_ref": [ "r1373" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "http://carecloud.com/role/ScheduleOfDeferredTaxValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r602" ] }, "CCLD_DeferredTaxLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DeferredTaxLeaseLiability", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "ASC 842 - Lease liability", "documentation": "ASC 842 - Lease liability." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net deferred tax liability", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r1368" ] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Goodwill amortization", "label": "Deferred Tax Liabilities, Goodwill", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill." } } }, "auth_ref": [ "r66", "r67", "r1373" ] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined benefit plan, plan assets, contributions by employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r505", "r508", "r521", "r1018", "r1019", "r1020", "r1021" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined contribution plan, employer matching contribution, on gross pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": [ "http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined contribution plan, employee matching contribution, on gross pay", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "CCLD_DefinedContributionRetirementPlanForPakistanEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DefinedContributionRetirementPlanForPakistanEmployeesMember", "presentation": [ "http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Retirement Plan For Pakistan Employees [Member]", "documentation": "Defined Contribution Retirement Plan For Pakistan Employees [Member]" } } }, "auth_ref": [] }, "CCLD_DefinedContributionRetirementPlanForSriLankaEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DefinedContributionRetirementPlanForSriLankaEmployeesMember", "presentation": [ "http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Retirement Plan For SriLanka Employees [Member]", "documentation": "Defined Contribution Retirement Plan For SriLanka Employees [Member]" } } }, "auth_ref": [] }, "CCLD_DefinedContributionRetirementPlanForUSEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DefinedContributionRetirementPlanForUSEmployeesMember", "presentation": [ "http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Retirement Plan For U.S. Employees [Member]", "documentation": "Defined Contribution Retirement Plan For U.S. Employees [Member]" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://carecloud.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r7", "r38" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 }, "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r7", "r38" ] }, "CCLD_DirectOperatingCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DirectOperatingCostsMember", "presentation": [ "http://carecloud.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "Direct Operating Costs [Member]", "documentation": "Direct Operating Costs [Member]" } } }, "auth_ref": [] }, "CCLD_DirectOperatingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DirectOperatingCostsPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Direct Operating Costs", "documentation": "Direct Operating Costs [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative", "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r500", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative", "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r500", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://carecloud.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DISAGGREGATION OF REVENUE", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1277" ] }, "CCLD_DisclosureLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DisclosureLeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases", "verboseLabel": "Schedule Of Lease Expense", "terseLabel": "Schedule Of Supplemental Balance Sheet Information Related To Leases" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://carecloud.com/role/Stock-basedCompensation" ], "lang": { "en-us": { "role": { "label": "STOCK-BASED COMPENSATION", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r534", "r538", "r568", "r569", "r571", "r1025" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "DISCLOSURE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r10", "r59" ] }, "CCLD_DividendsDeclaredNotPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DividendsDeclaredNotPaid", "crdr": "credit", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Dividends declared, not paid", "documentation": "Dividends declared not paid." } } }, "auth_ref": [] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Dividend payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r82" ] }, "CCLD_DividendsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DividendsPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Dividends", "documentation": "Dividends [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_DividendsPreferredStockStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPreferredStockStock", "crdr": "debit", "presentation": [ "http://carecloud.com/role/NetLossPerCommonShareDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock dividend amount", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock." } } }, "auth_ref": [ "r4", "r128" ] }, "us-gaap_DividendsShareBasedCompensationCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsShareBasedCompensationCash", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividend, share-based payment arrangement, cash", "documentation": "Amount of paid and unpaid cash dividends declared for award under share-based payment arrangement." } } }, "auth_ref": [] }, "CCLD_DividendsUndeclared": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "DividendsUndeclared", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends undeclared", "documentation": "Dividends undeclared." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r1078" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1076", "r1078", "r1100" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1076", "r1078", "r1100", "r1140" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r1077" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r1065" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r1078" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r1078" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1125" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r1068" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://carecloud.com/role/ScheduleOfReconciliationOfWeighted-averageSharesOutstandingForBasicAndDilutedNetLossPerCommonShareDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share: basic", "verboseLabel": "Net loss attributable to common shareholders per share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r233", "r261", "r262", "r263", "r264", "r265", "r266", "r272", "r275", "r283", "r284", "r285", "r289", "r629", "r639", "r666", "r667", "r793", "r815", "r986" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://carecloud.com/role/ScheduleOfReconciliationOfWeighted-averageSharesOutstandingForBasicAndDilutedNetLossPerCommonShareDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share: diluted", "verboseLabel": "Net loss attributable to common shareholders per share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r233", "r261", "r262", "r263", "r264", "r265", "r266", "r275", "r283", "r284", "r285", "r289", "r629", "r639", "r666", "r667", "r793", "r815", "r986" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://carecloud.com/role/NetLossPerCommonShare" ], "lang": { "en-us": { "role": { "label": "NET LOSS PER COMMON SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r271", "r286", "r287", "r288" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "EFFECT OF EXCHANGE RATE CHANGES ON CASH", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r698" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Federal statutory income tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r250", "r586", "r615", "r1028" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Subpart F GILTI inclusion", "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)." } } }, "auth_ref": [ "r1028", "r1365", "r1366" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationLineItems", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r586", "r587", "r1028" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTable", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Table]", "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation." } } }, "auth_ref": [ "r586", "r587", "r1028" ] }, "CCLD_EmployeeBenefitPlanDescription": { "xbrltype": "stringItemType", "nsuri": "http://carecloud.com/20241231", "localname": "EmployeeBenefitPlanDescription", "presentation": [ "http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employee benefit plan, description", "documentation": "Employee benefit plan, description." } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Compensation for statement of work per month", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [] }, "CCLD_EmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "EmployeeMember", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employee [Member]", "documentation": "Employee [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r82" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://carecloud.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-based payment arrangement, nonvested award, cost not yet recognized, amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r570" ] }, "CCLD_EmployeesOfficersDirectorsAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "EmployeesOfficersDirectorsAndConsultantsMember", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employees, Officers, Directors and Consultants [Member]", "documentation": "Employees, Officers, Directors and Consultants [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r1071" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1067" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1067" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r1177" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1067" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1174" ] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r1100" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1067" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1067" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1067" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1067" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1175" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "CCLD_EquityAwardsAccelerationCostsAssociatedWithSeverance": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "EquityAwardsAccelerationCostsAssociatedWithSeverance", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfRestructuringCostsDetails": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "label": "Equity awards acceleration costs associated with severance", "documentation": "Equity awards acceleration costs associated with severance." } } }, "auth_ref": [] }, "CCLD_EquityAwardsAccelerationCostsAssociatedWithSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "EquityAwardsAccelerationCostsAssociatedWithSeveranceMember", "presentation": [ "http://carecloud.com/role/ScheduleOfLiabilitiesAssociatedWithRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Awards Acceleration Costs Associated With Severance [Member]", "documentation": "Equity Awards Acceleration Costs Associated With Severance [Member]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/NetLossPerCommonShareDetailsNarrative", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/StatementsOfShareholdersEquity", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r203", "r229", "r230", "r231", "r254", "r255", "r256", "r258", "r265", "r267", "r269", "r292", "r349", "r355", "r392", "r479", "r610", "r611", "r625", "r626", "r627", "r630", "r638", "r639", "r648", "r650", "r651", "r652", "r653", "r655", "r665", "r699", "r700", "r701", "r702", "r703", "r704", "r708", "r711", "r732", "r812", "r841", "r842", "r843", "r866", "r938" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://carecloud.com/role/OrganizationAndBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r341", "r342", "r343", "r621", "r1183", "r1184", "r1185", "r1377", "r1378", "r1379", "r1380" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://carecloud.com/role/OrganizationAndBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity method investment ownership, percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r341" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r1133" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r1093", "r1104", "r1118", "r1144" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r1090", "r1101", "r1115", "r1141" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1139" ] }, "CCLD_ExecutiveChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ExecutiveChairmanMember", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executive Chairman [Member]", "documentation": "Executive Chairman [Member]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r71", "r72" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r449", "r508", "r509", "r510", "r511", "r512", "r513", "r668", "r669", "r670", "r671", "r672", "r681", "r682", "r684", "r744", "r745", "r746", "r1006", "r1007", "r1018", "r1019", "r1020", "r1029", "r1033" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r673", "r674", "r675", "r676", "r677", "r678", "r683" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r449", "r1006", "r1007" ] }, "us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueConcentrationOfRiskCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative", "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Offshore bank accounts", "documentation": "Fair value of cash and cash equivalent subject to concentration of credit or market risk or both." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://carecloud.com/role/FairValueOfFinancialInstruments" ], "lang": { "en-us": { "role": { "label": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r677", "r679", "r680", "r681", "r684", "r685", "r686", "r687", "r688", "r790", "r1029", "r1034" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r449", "r508", "r513", "r669", "r682", "r744", "r1018", "r1019", "r1020", "r1029" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r449", "r508", "r513", "r669", "r670", "r682", "r745", "r1006", "r1007", "r1018", "r1019", "r1020", "r1029" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r449", "r508", "r509", "r510", "r511", "r512", "r513", "r669", "r670", "r671", "r672", "r682", "r746", "r1006", "r1007", "r1018", "r1019", "r1020", "r1029", "r1033" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r673", "r674", "r675", "r676", "r677", "r678", "r683" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://carecloud.com/role/FairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "FAIR VALUE OF THE ASSETS MEASURED ON A NON-RECURRING BASIS", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r673", "r678", "r683" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r449", "r508", "r509", "r510", "r511", "r512", "r513", "r668", "r669", "r670", "r671", "r672", "r681", "r682", "r684", "r744", "r745", "r746", "r1006", "r1007", "r1018", "r1019", "r1020", "r1029", "r1033" ] }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Federal provision (benefit) at statutory rate", "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r248", "r583", "r585" ] }, "CCLD_FederalMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "FederalMember", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Federal [Member]", "documentation": "Federal [Member]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets, estimated useful lives", "verboseLabel": "Useful lives", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Accumulated amortization, beginning balance", "periodEndLabel": "Accumulated amortization, ending balance", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r214", "r362", "r383", "r1002" ] }, "CCLD_FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated amortization, translation gain (loss)", "documentation": "Finite lived intangible assets accumulated amortization foreign currency translation gain loss." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1252", "r1450" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r385", "r979", "r1002" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "2029", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r385", "r979", "r1002" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r385", "r979", "r1002" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r385", "r979", "r1002" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r385", "r979", "r1002" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r376", "r378", "r379", "r380", "r382", "r383", "r387", "r388", "r755", "r759", "r979" ] }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Cost, translation gain (loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cost, beginning balance", "periodEndLabel": "Cost, ending balance", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r362", "r383", "r759", "r1002" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r376", "r383", "r387", "r388", "r389", "r755", "r979", "r1002" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r376", "r378", "r379", "r380", "r382", "r383", "r387", "r388", "r979" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Goodwill amortization period for tax purposes", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r755" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Cost, additions", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r378" ] }, "CCLD_FiveOutsidesMembersofTheBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "FiveOutsidesMembersofTheBoardMember", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Five Outsides Members of the Board [Member]", "documentation": "Five Outsides Members of the Board [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfOtherExpenseIncome-NetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfOtherExpenseIncome-NetDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange gains (losses)", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r694", "r695", "r696", "r697", "r935" ] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign exchange (gain) loss", "negatedTerseLabel": "Foreign exchange (gain) losses", "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r913", "r1063", "r1389", "r1390", "r1443" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Translation", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r693" ] }, "CCLD_ForeignExchangeGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ForeignExchangeGainLoss", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange gain/(loss)", "documentation": "Foreign exchange gain loss." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1097", "r1108", "r1122", "r1148" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1097", "r1108", "r1122", "r1148" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1097", "r1108", "r1122", "r1148" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r1097", "r1108", "r1122", "r1148" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r1097", "r1108", "r1122", "r1148" ] }, "CCLD_FormerNonIndependentDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "FormerNonIndependentDirectorsMember", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Former Non-Independent Directors [Member]", "documentation": "Former Non-Independent Directors [Member]" } } }, "auth_ref": [] }, "CCLD_FounderAndExecutiveChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "FounderAndExecutiveChairmanMember", "presentation": [ "http://carecloud.com/role/OrganizationAndBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Founder and Executive Chairman [Member]", "documentation": "Founder and Executive Chairman [Member]" } } }, "auth_ref": [] }, "us-gaap_GainLossOnTerminationOfLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnTerminationOfLease", "crdr": "credit", "presentation": [ "http://carecloud.com/role/LeasesDetailsNarrative", "http://carecloud.com/role/RestructuringCostsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net gain (loss) on lease terminations", "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term." } } }, "auth_ref": [ "r712" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 }, "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "verboseLabel": "General and administrative expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r103", "r917" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://carecloud.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r103" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative", "http://carecloud.com/role/ScheduleOfChangesToCarryingAmountOfGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill", "periodStartLabel": "Beginning gross balance", "periodEndLabel": "Ending gross balance", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r213", "r364", "r791", "r995", "r1001", "r1031", "r1039", "r1233", "r1240" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://carecloud.com/role/GoodwillAndIntangibleAssetsNet" ], "lang": { "en-us": { "role": { "label": "GOODWILL AND INTANGIBLE ASSETS \u2013 NET", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1231", "r1243" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r363", "r375", "r1001" ] }, "us-gaap_GoodwillFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillFairValueDisclosure", "crdr": "debit", "presentation": [ "http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill - Healthcare IT", "documentation": "Fair value portion of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r1029", "r1031", "r1382", "r1383", "r1387" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 }, "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 }, "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative", "http://carecloud.com/role/IncomeTaxesDetailsNarrative", "http://carecloud.com/role/ScheduleOfChangesToCarryingAmountOfGoodwillDetails", "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "http://carecloud.com/role/StatementsOfCashFlows", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Goodwill impairment charges", "negatedLabel": "Impairment charges", "verboseLabel": "Goodwill impairment charge", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r7", "r365", "r371", "r375", "r1001", "r1031" ] }, "CCLD_GroupPurchasingOrganizationAndMedicalPracticeManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "GroupPurchasingOrganizationAndMedicalPracticeManagementMember", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Group Purchasing Organization and Medical Practice Management [Member]", "documentation": "Group Purchasing Organization and Medical Practice Management [Member]" } } }, "auth_ref": [] }, "CCLD_GroupPurchasingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "GroupPurchasingServicesMember", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative", "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Group Purchasing Services [Member]", "documentation": "Group Purchasing Services [Member]" } } }, "auth_ref": [] }, "CCLD_HealthcareITMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "HealthcareITMember", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative", "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Healthcare IT [Member]", "documentation": "Healthcare IT [Member]" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1076", "r1078", "r1100" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Impairment charges", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r7", "r37", "r119", "r1030" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Evaluation of Long-Lived Assets", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignDetails" ], "lang": { "en-us": { "role": { "label": "United States", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r249", "r584" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignDetails", "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "INCOME (LOSS) BEFORE PROVISION (BENEFIT) FOR INCOME TAXES", "label": "Total", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r100", "r139", "r143", "r794", "r810", "r988", "r994", "r1218", "r1220", "r1221", "r1222", "r1223" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfIncomeLossBeforeIncomeTaxDomesticAndForeignDetails" ], "lang": { "en-us": { "role": { "label": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r249", "r584" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://carecloud.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r393", "r400", "r406", "r674", "r678", "r683", "r836", "r838", "r922", "r979", "r1032", "r1412" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://carecloud.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r400", "r406", "r674", "r678", "r683", "r836", "r838", "r922", "r979", "r1032", "r1412" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r243", "r586", "r587", "r597", "r606", "r1028", "r1372" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r243", "r586", "r587", "r597", "r606", "r1028", "r1372" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://carecloud.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "INCOME TAXES", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r250", "r580", "r586", "r594", "r595", "r596", "r598", "r604", "r616", "r618", "r619", "r620", "r862", "r1028" ] }, "us-gaap_IncomeTaxExaminationDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationDescription", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income tax examination description", "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings." } } }, "auth_ref": [ "r1367" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfComponentsOfIncomeTaxProvisionBenefitDetails", "http://carecloud.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income tax provision (benefit)", "verboseLabel": "Total income tax provision (benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r148", "r159", "r268", "r269", "r290", "r307", "r328", "r583", "r586", "r617", "r816", "r1028" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r228", "r581", "r582", "r598", "r599", "r603", "r608", "r856" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r591", "r1028", "r1365" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Impact of foreign operations", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r587", "r590", "r1028", "r1365" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Non-deductible items", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r592", "r593", "r1365" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill impairment charges", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss." } } }, "auth_ref": [ "r1028", "r1365", "r1366" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred true-up", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense." } } }, "auth_ref": [ "r1365", "r1366" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Stock based compensation", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1028", "r1365", "r1366" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "State tax expense, net of federal benefit", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r589", "r1028", "r1365" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income taxes paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r22", "r111", "r1205", "r1370", "r1371" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r22", "r243", "r605", "r606" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable and other liabilities", "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other." } } }, "auth_ref": [ "r1204" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerAsset", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueDetails", "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Contract asset", "label": "Contract Asset, (decrease) increase, net", "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r1204" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r750", "r1204" ] }, "CCLD_IncreaseDecreaseInContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "IncreaseDecreaseInContractWithCustomerLiabilityCurrent", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred Revenue (current), increase (decrease), net", "documentation": "Increase decrease in contract with customer liability current.", "label": "IncreaseDecreaseInContractWithCustomerLiabilityCurrent" } } }, "auth_ref": [] }, "CCLD_IncreaseDecreaseInDeferredRevenueLongTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "IncreaseDecreaseInDeferredRevenueLongTerm", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue (long term), increase (decrease), net", "documentation": "Increase decrease deferred revenue long term." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts Receivable - Net, increase (decrease), net", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r6" ] }, "CCLD_IndefiniteLifeMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "IndefiniteLifeMember", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Indefinite Life [Member]", "documentation": "Indefinite Life [Member]" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r376", "r386", "r389", "r1002" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r1097", "r1108", "r1122", "r1139", "r1148", "r1152", "r1160" ] }, "CCLD_IndividualShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "IndividualShareholdersMember", "presentation": [ "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Individual Shareholders [Member]", "documentation": "Individual Shareholders [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1158" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r1079", "r1163" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r1079", "r1163" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r1079", "r1163" ] }, "CCLD_InsuranceFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "InsuranceFinancingMember", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails" ], "lang": { "en-us": { "role": { "label": "Insurance Financing [Member]", "documentation": "Insurance Financing [Member]" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Intangible Assets", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r751", "r752", "r753", "r755", "r985", "r1243" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails", "http://carecloud.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets - net", "verboseLabel": "Net book value", "totalLabel": "Total", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r376", "r1251", "r1253" ] }, "CCLD_IntercompanyReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "IntercompanyReceivables", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intercompany receivables", "documentation": "Intercompany receivables." } } }, "auth_ref": [] }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseOther", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Other", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Net interest expense", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r994", "r1202", "r1220" ] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOther", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r239", "r241", "r242" ] }, "us-gaap_InternalUseSoftwarePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InternalUseSoftwarePolicy", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Internal-Use Software Costs", "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally." } } }, "auth_ref": [ "r390" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r222", "r983", "r1039" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfLeaseExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/ScheduleOfLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total - net lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r716", "r1038" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://carecloud.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF LEASE EXPENSE", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1395" ] }, "CCLD_LeaseTermDescription": { "xbrltype": "stringItemType", "nsuri": "http://carecloud.com/20241231", "localname": "LeaseTermDescription", "presentation": [ "http://carecloud.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease term, description", "documentation": "Lease term description." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r118", "r725" ] }, "us-gaap_LesseeOperatingLeaseDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDescription", "presentation": [ "http://carecloud.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease description", "documentation": "Description of lessee's operating lease." } } }, "auth_ref": [ "r715" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://carecloud.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF MATURITIES OF LEASE LIABILITIES", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1396" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r724" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r724" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r724" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r724" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r724" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r724" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r724" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r724" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://carecloud.com/role/Leases" ], "lang": { "en-us": { "role": { "label": "LEASES", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r710" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r15", "r81", "r82", "r83", "r86", "r87", "r88", "r89", "r247", "r344", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r642", "r643", "r644", "r692", "r890", "r987", "r1064", "r1271", "r1399", "r1400" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r97", "r138", "r805", "r1039", "r1208", "r1229", "r1388" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "negatedLabel": "Current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r83", "r210", "r247", "r344", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r642", "r643", "r644", "r692", "r1039", "r1271", "r1399", "r1400" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-current liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r15", "r86", "r87", "r88", "r89", "r247", "r344", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r642", "r643", "r644", "r692", "r1271", "r1399", "r1400" ] }, "CCLD_LiabilityForCashSettledAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "LiabilityForCashSettledAmount", "crdr": "credit", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Liability for cash settled amount", "documentation": "Liability for cash settled amount." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeeAmount", "crdr": "debit", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit facility commitment fee amount", "documentation": "Amount of the fee for available but unused credit capacity under the credit facility." } } }, "auth_ref": [ "r80", "r85", "r423" ] }, "us-gaap_LineOfCreditFacilityCommitmentFeeDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeeDescription", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit, description", "documentation": "Description of the fees for amounts available, but unused under the credit facility." } } }, "auth_ref": [ "r80", "r85" ] }, "us-gaap_LineOfCreditFacilityCovenantTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCovenantTerms", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit borrowing term", "documentation": "Description of the conditions for borrowing under the credit facility including the nature of any restrictions." } } }, "auth_ref": [ "r80", "r85" ] }, "us-gaap_LineOfCreditFacilityDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityDescription", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit, term extension", "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity." } } }, "auth_ref": [ "r80", "r85", "r423" ] }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit facility, interest rate", "documentation": "The effective interest rate at the end of the reporting period." } } }, "auth_ref": [ "r80", "r85" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increase revolving line of credit", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r80", "r85" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit, remaining borrowing base", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r80", "r85", "r423" ] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mitigation related costs", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementLoss", "crdr": "debit", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Settlement claim amount", "documentation": "Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r1264" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r15", "r797" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r253", "r453" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r253", "r453" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r253", "r453" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r9", "r253", "r453" ] }, "us-gaap_LongTermLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLineOfCredit", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Borrowings under line of credit", "verboseLabel": "Lline of credit", "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r15", "r41", "r42" ] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Notes payable", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r15" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r15", "r1257", "r1258", "r1259" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r15", "r43", "r1257", "r1258", "r1259" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r416", "r417", "r418", "r421", "r576", "r1004", "r1265", "r1266" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r416", "r417", "r418", "r421", "r576", "r1004", "r1265", "r1266" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mitigation settlement payable", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r416", "r1182" ] }, "us-gaap_LossContingencyDamagesPaidValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesPaidValue", "crdr": "credit", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Damages paid value", "documentation": "Amount of damages paid to the plaintiff in the legal matter." } } }, "auth_ref": [ "r1264", "r1265", "r1266" ] }, "us-gaap_LossContingencyDamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Damages sought transition related costs", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": [ "r1264", "r1265", "r1266" ] }, "CCLD_LossContingencyUnpaidFees": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "LossContingencyUnpaidFees", "crdr": "credit", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unpaid fees", "documentation": "Loss on contingency unpaid fees." } } }, "auth_ref": [] }, "CCLD_MTBCBaghPvtLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "MTBCBaghPvtLtdMember", "presentation": [ "http://carecloud.com/role/OrganizationAndBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "MTBC Bagh Private Limited [Member]", "documentation": "MTBC Bagh Private Limited [Member]" } } }, "auth_ref": [] }, "CCLD_MTBCPrivateLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "MTBCPrivateLimitedMember", "presentation": [ "http://carecloud.com/role/OrganizationAndBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "MTBC Private Limited [Member]", "documentation": "MTBC Private Limited [Member]" } } }, "auth_ref": [] }, "cyd_MaterialCybersecurityIncidentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentAbstract", "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Abstract]" } } }, "auth_ref": [ "r1111", "r1112" ] }, "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]" } } }, "auth_ref": [ "r1111", "r1113" ] }, "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]" } } }, "auth_ref": [ "r1111", "r1114" ] }, "cyd_MaterialCybersecurityIncidentNatureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentNatureTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Nature [Text Block]" } } }, "auth_ref": [ "r1111", "r1114" ] }, "cyd_MaterialCybersecurityIncidentScopeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentScopeTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Scope [Text Block]" } } }, "auth_ref": [ "r1111", "r1114" ] }, "cyd_MaterialCybersecurityIncidentTimingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentTimingTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Timing [Text Block]" } } }, "auth_ref": [ "r1111", "r1114" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r163", "r165", "r167", "r168", "r170", "r199", "r200", "r417", "r418", "r419", "r420", "r528", "r576", "r672", "r749", "r835", "r837", "r851", "r882", "r883", "r946", "r949", "r953", "r954", "r956", "r977", "r978", "r1000", "r1010", "r1024", "r1033", "r1034", "r1035", "r1036", "r1049", "r1273", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r1131" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r1131" ] }, "CCLD_MedicalPracticeManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "MedicalPracticeManagementMember", "presentation": [ "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Medical Practice Management [Member]", "documentation": "Medical Practice Management [Member]" } } }, "auth_ref": [] }, "CCLD_MedicalPracticeManagementSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "MedicalPracticeManagementSegmentMember", "presentation": [ "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Medical Practice Management Segment [Member]", "documentation": "Medical Practice Management Segment [Member]" } } }, "auth_ref": [] }, "CCLD_MinimumLiquidityRatioReductionAmendmentsExpiryDate": { "xbrltype": "dateItemType", "nsuri": "http://carecloud.com/20241231", "localname": "MinimumLiquidityRatioReductionAmendmentsExpiryDate", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum liquidity ratio reduction amendments expiry date", "documentation": "Minimum liquidity ratio reduction amendments expiry date." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r163", "r165", "r167", "r168", "r170", "r199", "r200", "r417", "r418", "r419", "r420", "r528", "r576", "r672", "r749", "r835", "r837", "r851", "r882", "r883", "r946", "r949", "r953", "r954", "r956", "r977", "r978", "r1000", "r1010", "r1024", "r1033", "r1034", "r1035", "r1049", "r1273", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r1151" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r1159" ] }, "stpr_NJ": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "NJ", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "NEW JERSEY" } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r1132" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r240" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r240" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r109", "r110", "r112" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://carecloud.com/role/StatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows", "http://carecloud.com/role/StatementsOfComprehensiveIncomeLoss", "http://carecloud.com/role/StatementsOfOperations", "http://carecloud.com/role/StatementsOfShareholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCOME (LOSS)", "label": "NET INCOME (LOSS)", "verboseLabel": "Net income (loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r101", "r112", "r140", "r208", "r224", "r226", "r231", "r247", "r257", "r261", "r262", "r263", "r264", "r265", "r268", "r269", "r281", "r344", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r629", "r639", "r667", "r692", "r811", "r914", "r936", "r937", "r1063", "r1271" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/ScheduleOfReconciliationOfWeighted-averageSharesOutstandingForBasicAndDilutedNetLossPerCommonShareDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS", "label": "Net loss attributable to common shareholders - basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r237", "r261", "r262", "r263", "r264", "r272", "r273", "r282", "r285", "r639" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfReconciliationOfWeighted-averageSharesOutstandingForBasicAndDilutedNetLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "label": "Net loss attributable to common shareholders - diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r237", "r274", "r277", "r278", "r279", "r280", "r282", "r285" ] }, "CCLD_NetLossOnLeaseTerminationsUnoccupiedLeaseChargesAndRestructuringCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "NetLossOnLeaseTerminationsUnoccupiedLeaseChargesAndRestructuringCostsMember", "presentation": [ "http://carecloud.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "Net loss on lease terminations, unoccupied lease charges and restructuring costs [Member]", "documentation": "Net loss on lease terminations, unoccupied lease charges and restructuring costs [Member]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "CCLD_NinthLoanModificationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "NinthLoanModificationAgreementMember", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ninth Loan Modification Agreement [Member]", "documentation": "Ninth Loan Modification Agreement [Member]" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r1131" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1129" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1128" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1159" ] }, "CCLD_NonRule10b51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://carecloud.com/20241231", "localname": "NonRule10b51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Modified", "documentation": "Non-rule 10b5-1 arrangement modified." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1159" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative", "http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails" ], "lang": { "en-us": { "role": { "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1446", "r1447", "r1448", "r1449" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "OTHER:" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Notes payable (current portion)", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r81", "r82" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r995", "r1219" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of reportable units", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r989", "r999", "r1219" ] }, "CCLD_OfficeFurnitureAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "OfficeFurnitureAndEquipmentMember", "presentation": [ "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Office Furniture and Equipment [Member]", "documentation": "Office Furniture and Equipment [Member]" } } }, "auth_ref": [] }, "CCLD_OneCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "OneCustomerMember", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "One Customer [Member]", "documentation": "One Customer [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Direct operating costs", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "OPERATING INCOME (LOSS)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r143", "r988", "r1218", "r1220", "r1221", "r1222", "r1223" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r717", "r1038" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease expense per month for temporary housing", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1394" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [ "http://carecloud.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease impairment", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1393" ] }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncomeLeasePayments", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfSupplementalCashFlowAndOtherInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating cash flows from operating leases", "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r291", "r726" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails", "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities", "label": "Total lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r714" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails", "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease liability (current portion)", "verboseLabel": "Current operating lease liabilities", "terseLabel": "Less: current obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r714" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/ScheduleOfMaturitiesOfLeaseLiabilitiesDetails", "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease liability", "verboseLabel": "Non-current operating lease liabilities", "terseLabel": "Long-term lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r714" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "verboseLabel": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r713" ] }, "CCLD_OperatingLeaseRightOfUseAssetGross": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "OperatingLeaseRightOfUseAssetGross", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "ROU assets", "documentation": "Operation lease right of use assets, gross." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating leases, Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r723", "r1038" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://carecloud.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating leases, Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r722", "r1038" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net operating loss carry forwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r607" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r322", "r323", "r324", "r325", "r326", "r329", "r994", "r995" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://carecloud.com/role/OrganizationAndBusiness" ], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND BUSINESS", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r78", "r134", "r853", "r854" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r215" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfComprehensiveIncomeLoss", "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r2", "r812" ] }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxAbstract", "presentation": [ "http://carecloud.com/role/StatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "OTHER COMPREHENSIVE LOSS" } } }, "auth_ref": [] }, "us-gaap_OtherDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "label": "Other Depreciation and Amortization", "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other." } } }, "auth_ref": [ "r7", "r38", "r102" ] }, "CCLD_OtherExitRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "OtherExitRelatedCostsMember", "presentation": [ "http://carecloud.com/role/ScheduleOfLiabilitiesAssociatedWithRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "label": "Other Exit Related Costs [Member]", "documentation": "Other Exit Related Costs [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": [ "r103", "r104" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r1002", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1251", "r1253", "r1254", "r1255" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingExpense", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfOtherExpenseIncome-NetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfOtherExpenseIncome-NetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other expense", "label": "Other Nonoperating Expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r105" ] }, "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeAndExpenseTextBlock", "presentation": [ "http://carecloud.com/role/OtherExpenseNet" ], "lang": { "en-us": { "role": { "label": "OTHER EXPENSE \u2013 NET", "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [ "r235", "r236" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 }, "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 }, "http://carecloud.com/role/ScheduleOfOtherExpenseIncome-NetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/ScheduleOfOtherExpenseIncome-NetDetails", "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other expense - net", "totalLabel": "Other expense - net", "verboseLabel": "Other expenses", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r105" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1131" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Current assets - related party", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r1078" ] }, "us-gaap_OtherRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringCosts", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfRestructuringCostsDetails": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "label": "Other exit related costs", "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r7" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1095", "r1106", "r1120", "r1146" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": [ "r1098", "r1109", "r1123", "r1149" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r1098", "r1109", "r1123", "r1149" ] }, "country_PK": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "PK", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "PAKISTAN" } } }, "auth_ref": [] }, "CCLD_PakistanStatutoryCorporateTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://carecloud.com/20241231", "localname": "PakistanStatutoryCorporateTaxRate", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pakistan statutory corporate tax rate", "documentation": "Pakistan statutory corporate tax rate." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r1127" ] }, "CCLD_PaymentOfUpfrontFees": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "PaymentOfUpfrontFees", "crdr": "credit", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Upfront fees", "documentation": "Payment of upfront fees." } } }, "auth_ref": [] }, "CCLD_PaymentsForAnnualAnniversaryFee": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "PaymentsForAnnualAnniversaryFee", "crdr": "credit", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments for annual anniversary fee", "documentation": "Payments for annual anniversary fee." } } }, "auth_ref": [] }, "us-gaap_PaymentsForCapitalImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForCapitalImprovements", "crdr": "credit", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease upgradations", "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use." } } }, "auth_ref": [ "r106" ] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Rent expense", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfLiabilitiesAssociatedWithRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments and other adjustments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r405", "r1203" ] }, "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Preferred stock dividends paid", "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity." } } }, "auth_ref": [ "r107" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/StatementsOfShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r20" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Settlement of tax withholding obligations on stock issued to employees", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r238" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r106" ] }, "CCLD_PaymentsToCapitalizedSoftwareAndOtherIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "PaymentsToCapitalizedSoftwareAndOtherIntangibleAssets", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Capitalized software and other intangible assets", "documentation": "Payments to capitalized software and other intangible assets.", "label": "PaymentsToCapitalizedSoftwareAndOtherIntangibleAssets" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r1130" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1130" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://carecloud.com/role/EmployeeBenefitPlans" ], "lang": { "en-us": { "role": { "label": "EMPLOYEE BENEFIT PLANS", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r504", "r506", "r507", "r513", "r514", "r516", "r517", "r518", "r519", "r520", "r522", "r523", "r524", "r1020" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1129" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r1132" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1128" ] }, "CCLD_PercentageOfSharesInOffshoreFacilities": { "xbrltype": "percentItemType", "nsuri": "http://carecloud.com/20241231", "localname": "PercentageOfSharesInOffshoreFacilities", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of shares in off shore facilities", "documentation": "Percentage of shares in off shore facilities." } } }, "auth_ref": [] }, "CCLD_PhysicianMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "PhysicianMember", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Physician [Member]", "documentation": "Physician [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1361", "r1362", "r1363" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r1129" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://carecloud.com/role/FairValueOfAssetsMeasuredOnNon-recurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r691" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r1072" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r1074" ] }, "us-gaap_PreferredStockAmountOfPreferredDividendsInArrears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockAmountOfPreferredDividendsInArrears", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends in arrears", "documentation": "Aggregate amount of cumulative preferred dividends in arrears." } } }, "auth_ref": [ "r51" ] }, "us-gaap_PreferredStockDividendRatePerDollarAmount": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendRatePerDollarAmount", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock dividend amount per share", "documentation": "The amount per share used to calculated dividend payments on preferred stock." } } }, "auth_ref": [ "r464" ] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock dividend rate", "verboseLabel": "Preferred stock dividend percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r464", "r947", "r950", "r952", "r957" ] }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendsAndOtherAdjustments", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Preferred stock dividend", "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders." } } }, "auth_ref": [ "r26", "r1178", "r1217" ] }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendsIncomeStatementImpact", "crdr": "debit", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Preferred stock dividends", "label": "Preferred Stock Dividends, Income Statement Impact", "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders." } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendsPerShareCashPaid", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/StatementsOfShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Dividend paid per share", "verboseLabel": "Preferred stock, dividend per share", "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding." } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock liquidation preference", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r47", "r48", "r90", "r1206", "r1274" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [ "http://carecloud.com/role/NetLossPerCommonShareDetailsNarrative", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/StatementsOfShareholdersEquity", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r1055", "r1056", "r1059", "r1060", "r1061", "r1062", "r1441", "r1444" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r90", "r463" ] }, "us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockPerShareAmountsOfPreferredDividendsInArrears", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends in arrears, per share", "documentation": "Per share amount of cumulative preferred dividends in arrears." } } }, "auth_ref": [ "r51" ] }, "us-gaap_PreferredStockRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockRedemptionPricePerShare", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, redemption price per share", "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer." } } }, "auth_ref": [ "r46", "r47", "r50" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r90", "r892" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r90", "r463" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "verboseLabel": "Shares remaining outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r90", "r892", "r911", "r1444", "r1445" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 shares at December 31, 2024 and December 31, 2023. Series B, issued and outstanding 1,511,372 and 1,468,792 shares at December 31, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r90", "r801", "r1039" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1198" ] }, "CCLD_PrintingAndMailingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "PrintingAndMailingServicesMember", "presentation": [ "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Printing and Mailing Services [Member]", "documentation": "Printing and Mailing Services [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of Series B Preferred Stock, net of expenses", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from line of credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r19", "r1207" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative", "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r172", "r173", "r174", "r175", "r176", "r177", "r197", "r332", "r754", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r981", "r1011", "r1048", "r1049", "r1050", "r1053", "r1054", "r1194", "r1267", "r1268", "r1277", "r1409", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative", "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r172", "r173", "r174", "r175", "r176", "r177", "r197", "r332", "r754", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r981", "r1011", "r1048", "r1049", "r1050", "r1053", "r1054", "r1194", "r1267", "r1268", "r1277", "r1409", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440" ] }, "CCLD_ProfessionalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ProfessionalServicesMember", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative", "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Professional Services [Member]", "documentation": "Professional Services [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r8", "r725" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://carecloud.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r117", "r152", "r156", "r157" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Total property and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r118", "r211", "r809" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r725" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment - net", "totalLabel": "Property and equipment \u2013 net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r725", "r795", "r809", "r1039" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r8", "r152", "r156", "r807" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://carecloud.com/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF PROPERTY AND EQUIPMENT", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r118", "r725" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property and equipment, estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfTradeAllowanceForDoubtfulAccountsDetails", "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Provision for expected credit losses", "verboseLabel": "Provision", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r234", "r359" ] }, "CCLD_PurchaseOfPrepaidInsuranceWithAssumptionOfNote": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "PurchaseOfPrepaidInsuranceWithAssumptionOfNote", "crdr": "credit", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Purchase of prepaid insurance with assumption of note", "documentation": "Purchase of prepaid insurance with assumption of note." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r1127" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r1127" ] }, "CCLD_RamapoAnesthesiologistsPCMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "RamapoAnesthesiologistsPCMember", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ramapo Anesthesiologists, PC [Member]", "documentation": "Ramapo Anesthesiologists PC [Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r163", "r165", "r167", "r168", "r170", "r199", "r200", "r417", "r418", "r419", "r420", "r506", "r528", "r564", "r565", "r566", "r576", "r672", "r747", "r748", "r749", "r835", "r837", "r851", "r882", "r883", "r946", "r949", "r953", "r954", "r956", "r977", "r978", "r1000", "r1010", "r1024", "r1033", "r1034", "r1035", "r1036", "r1049", "r1057", "r1260", "r1273", "r1385", "r1402", "r1403", "r1404", "r1405", "r1406" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r163", "r165", "r167", "r168", "r170", "r199", "r200", "r417", "r418", "r419", "r420", "r506", "r528", "r564", "r565", "r566", "r576", "r672", "r747", "r748", "r749", "r835", "r837", "r851", "r882", "r883", "r946", "r949", "r953", "r954", "r956", "r977", "r978", "r1000", "r1010", "r1024", "r1033", "r1034", "r1035", "r1036", "r1049", "r1057", "r1260", "r1273", "r1385", "r1402", "r1403", "r1404", "r1405", "r1406" ] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r92", "r98" ] }, "us-gaap_ReceivablesBillingStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesBillingStatusDomain", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid." } } }, "auth_ref": [] }, "CCLD_ReclassOfDepositsForPropertyAndEquipmentPlacedInService": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ReclassOfDepositsForPropertyAndEquipmentPlacedInService", "crdr": "credit", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Reclass of deposits for property and equipment placed in service", "documentation": "Reclass of deposits for property and equipment placed in service." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r1090", "r1101", "r1115", "r1141" ] }, "CCLD_ReferralFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ReferralFeesMember", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Referral Fees [Member]", "documentation": "Referral Fees [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r339", "r515", "r736", "r737", "r798", "r806", "r885", "r886", "r887", "r888", "r889", "r910", "r912", "r945" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r251", "r252", "r736", "r737", "r738", "r739", "r798", "r806", "r885", "r886", "r887", "r888", "r889", "r910", "r912", "r945" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments to related party", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r76", "r736" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r736", "r737", "r1398" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r339", "r918", "r919", "r922" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://carecloud.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r339", "r515", "r736", "r737", "r798", "r806", "r885", "r886", "r887", "r888", "r889", "r910", "r912", "r945", "r1398" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://carecloud.com/role/RelatedParties" ], "lang": { "en-us": { "role": { "label": "RELATED PARTIES", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r733", "r734", "r735", "r737", "r740", "r863", "r864", "r865", "r920", "r921", "r922", "r942", "r944" ] }, "CCLD_RemotePatientMonitoringMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "RemotePatientMonitoringMember", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Remote Patient Monitoring [Member]", "documentation": "Remote Patient Monitoring [Member]" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of line of credit", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r108", "r1207" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of notes payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r108" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 }, "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r579", "r979", "r994", "r1407" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://carecloud.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r578" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r1091", "r1102", "r1116", "r1142" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r1092", "r1103", "r1117", "r1143" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": [ "r1099", "r1110", "r1124", "r1150" ] }, "CCLD_RestrictedStockAwardClassifiedAsLiability": { "xbrltype": "sharesItemType", "nsuri": "http://carecloud.com/20241231", "localname": "RestrictedStockAwardClassifiedAsLiability", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted stock award classified as liability", "documentation": "Restricted stock award classified as liability." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/NetLossPerCommonShareDetailsNarrative", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://carecloud.com/role/RestructuringCosts" ], "lang": { "en-us": { "role": { "label": "RESTRUCTURING COSTS", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r402", "r403", "r405", "r408", "r413" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://carecloud.com/role/RestructuringCostsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated restructuring expense", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r404", "r407", "r410", "r412" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfRestructuringCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://carecloud.com/role/RestructuringCostsDetailsNarrative", "http://carecloud.com/role/ScheduleOfLiabilitiesAssociatedWithRestructuringCostsDetails", "http://carecloud.com/role/ScheduleOfRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total restructuring and other costs", "label": "Additions", "verboseLabel": "Restructuring expense incurred", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r7", "r409", "r410", "r1261" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://carecloud.com/role/ScheduleOfLiabilitiesAssociatedWithRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r404", "r405", "r410", "r411" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://carecloud.com/role/ScheduleOfLiabilitiesAssociatedWithRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r404", "r405", "r406", "r407", "r410", "r411", "r412" ] }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostsAndAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 7.0 }, "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Lease terminations, unoccupied lease charges and restructuring costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://carecloud.com/role/ScheduleOfRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges." } } }, "auth_ref": [ "r1180", "r1181" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfLiabilitiesAssociatedWithRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance as of January 1, 2023", "periodEndLabel": "Balance as of\u00a0\u00a0December 31, 2023", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r405", "r411" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r94", "r128", "r804", "r845", "r850", "r861", "r893", "r1039" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r203", "r254", "r255", "r256", "r258", "r265", "r267", "r269", "r349", "r355", "r392", "r610", "r611", "r625", "r626", "r627", "r630", "r638", "r639", "r648", "r651", "r652", "r655", "r665", "r708", "r711", "r841", "r843", "r866", "r1444" ] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameAxis", "presentation": [ "http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r1024", "r1187", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337" ] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanNameDomain", "presentation": [ "http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r1024", "r1187", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337" ] }, "CCLD_RevenueCycleManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "RevenueCycleManagementMember", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue Cycle Management [Member]", "documentation": "Revenue Cycle Management [Member]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/RevenueDetailsNarrative", "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "NET REVENUE", "verboseLabel": "Revenue", "terseLabel": "Net revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r141", "r142", "r290", "r300", "r301", "r322", "r328", "r332", "r334", "r336", "r499", "r500", "r754" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r160", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r980" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://carecloud.com/role/Revenue" ], "lang": { "en-us": { "role": { "label": "REVENUE", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r160", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r503" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue, remaining performance obligation, amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r155" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ScheduleOfSupplementalCashFlowAndOtherInformationRelatedToLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating leases, excluding terminations", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r721", "r1038" ] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1159" ] }, "CCLD_Rule10b51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://carecloud.com/20241231", "localname": "Rule10b51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Modified", "documentation": "Rule 10b5-1 arrangement modified." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1159" ] }, "CCLD_SVBCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "SVBCreditFacilityMember", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "SVB Credit Facility [Member]", "documentation": "SVB Credit Facility [Member]" } } }, "auth_ref": [] }, "CCLD_SVBDebtAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "SVBDebtAgreementMember", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "SVB Debt Agreement [Member]", "documentation": "SVB Debt Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Authorized sale of stock, value", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock, shares", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r336", "r1188" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r533", "r1191", "r1213" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r198", "r270", "r533", "r1182", "r1213" ] }, "CCLD_ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueTableTextBlock", "presentation": [ "http://carecloud.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CHANGES IN ACCOUNTS RECEIVABLE, CONTRACT ASSET AND DEFERRED REVENUE", "documentation": "Schedule of Changes in Accounts Receivable Contract Asset and Deferred Revenue [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://carecloud.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF COMPONENTS OF INCOME TAX PROVISION (BENEFIT)", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1374" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://carecloud.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1368" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://carecloud.com/role/EmployeeBenefitPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r11", "r55", "r56", "r57", "r58" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://carecloud.com/role/NetLossPerCommonShareTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF RECONCILIATION OF WEIGHTED-AVERAGE SHARES OUTSTANDING FOR BASIC AND DILUTED NET LOSS PER COMMON SHARE", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1216" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://carecloud.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r588", "r1028", "r1365" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://carecloud.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF EMPLOYEE SERVICE SHARE-BASED COMPENSATION, ALLOCATION OF RECOGNIZED PERIOD COSTS", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r60" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://carecloud.com/role/OrganizationAndBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r341", "r342", "r343", "r621", "r1183", "r1184", "r1185", "r1377", "r1378", "r1379", "r1380" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://carecloud.com/role/ScheduleOfIntangibleAssetsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r376", "r383", "r387", "r388", "r389", "r755", "r979", "r1002" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF INTANGIBLE ASSETS ACTIVITY", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r1002", "r1250" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CHANGES TO CARRYING AMOUNT OF GOODWILL", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r1001", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://carecloud.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAX, DOMESTIC AND FOREIGN", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1209" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": [ "r376", "r386", "r389", "r1002" ] }, "CCLD_ScheduleOfLiabilitiesAssociatedWithRestructuringCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ScheduleOfLiabilitiesAssociatedWithRestructuringCostsTableTextBlock", "presentation": [ "http://carecloud.com/role/RestructuringCostsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS", "documentation": "Schedule Of Liabilities Associated With Restructuring Costs [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://carecloud.com/role/DebtTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF MATURITIES OF LONG-TERM DEBT", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SHARE-BASED COMPENSATION, RESTRICTED STOCK UNITS AWARD ACTIVITY", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r129" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://carecloud.com/role/OtherExpenseNetTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF OTHER (EXPENSE) INCOME - NET", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8", "r725" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r75", "r76", "r918", "r919", "r922" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://carecloud.com/role/ScheduleOfLiabilitiesAssociatedWithRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r404", "r405", "r406", "r407", "r410", "r411", "r412" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://carecloud.com/role/RestructuringCostsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF RESTRUCTURING COSTS", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r40", "r120", "r121" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r34", "r35", "r36" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://carecloud.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF REVENUES, OPERATING EXPENSES AND OPERATING INCOME (LOSS) BY REPORTABLE SEGMENT", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r34", "r35", "r36" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r535", "r537", "r539", "r540", "r541", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r563", "r564", "r565", "r566", "r567" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r44", "r45", "r47", "r48", "r49", "r52", "r124", "r126", "r127", "r128", "r217", "r218", "r219", "r293", "r463", "r464", "r465", "r467", "r470", "r475", "r477", "r857", "r858", "r859", "r860", "r1010", "r1179", "r1206" ] }, "CCLD_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "presentation": [ "http://carecloud.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES", "documentation": "Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]" } } }, "auth_ref": [] }, "CCLD_ScheduleOfSupplementalCashFlowAndOtherInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ScheduleOfSupplementalCashFlowAndOtherInformationRelatedToLeasesTableTextBlock", "presentation": [ "http://carecloud.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES", "documentation": "Schedule of Supplemental Cash Flow and Other Information Related to Leases [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF INTANGIBLE ASSETS, FUTURE AMORTIZATION EXPENSE", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r1002", "r1252" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://carecloud.com/role/ConcentrationsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CONCENTRATION OF RISK, BY GEOGRAPHICAL RISKS FACTOR", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r27", "r28", "r29", "r30", "r73", "r135" ] }, "CCLD_Sec8.75SeriesBCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "Sec8.75SeriesBCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "8.75% Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share [Member]", "documentation": "8.75% Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share [Member]" } } }, "auth_ref": [] }, "CCLD_Sec8.75SeriesCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "Sec8.75SeriesCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "8.75% Series A Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share [Member]", "documentation": "8.75% Series A Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1066" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r1070" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1069" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r1075" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative", "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r141", "r142", "r143", "r144", "r290", "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r313", "r314", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r330", "r336", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r389", "r407", "r412", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r991", "r994", "r995", "r1001", "r1052", "r1409", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative", "http://carecloud.com/role/IncomeTaxesDetailsNarrative", "http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails" ], "lang": { "en-us": { "role": { "documentation": "Geographical area." } } }, "auth_ref": [ "r164", "r166", "r169", "r171", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r334", "r335", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r879", "r880", "r881", "r948", "r951", "r955", "r958", "r965", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r982", "r1012", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1051", "r1057", "r1277", "r1409", "r1413", "r1414", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://carecloud.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "label": "SEGMENT REPORTING", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r144", "r290", "r295", "r296", "r297", "r298", "r299", "r311", "r313", "r314", "r326", "r327", "r328", "r329", "r330", "r332", "r333", "r336", "r989", "r992", "r993", "r994", "r996", "r998", "r999" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r331", "r334", "r990", "r991", "r997" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://carecloud.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r103" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expenses", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r1364" ] }, "CCLD_SeriesAAndSeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "SeriesAAndSeriesBPreferredStockMember", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A and Series B Preferred Stock [Member]", "documentation": "Series A and Series B Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical", "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/StatementsOfShareholdersEquity", "http://carecloud.com/role/StatementsOfShareholdersEquityParenthetical", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r1196", "r1197", "r1275" ] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical", "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/StatementsOfShareholdersEquity", "http://carecloud.com/role/StatementsOfShareholdersEquityParenthetical", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r1196", "r1197", "r1275" ] }, "CCLD_SeveranceAndSeparationCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "SeveranceAndSeparationCostsMember", "presentation": [ "http://carecloud.com/role/ScheduleOfLiabilitiesAssociatedWithRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "label": "Severance And Separation Costs [Member]", "documentation": "Severance And Separation Costs [Member]" } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfRestructuringCostsDetails": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "label": "Severance and separation costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://carecloud.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails", "http://carecloud.com/role/StatementsOfCashFlows", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r556" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Granted", "verboseLabel": "Share-based compensation restricted stock, grants in period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r554" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding and unvested at beginning", "periodEndLabel": "Outstanding and unvested at ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r551", "r552" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r555" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r535", "r537", "r539", "r540", "r541", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r563", "r564", "r565", "r566", "r567" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares added to the A&R Plan for future issuance", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1026" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding and unvested shares, beginning", "periodEndLabel": "Outstanding and unvested shares, ending", "label": "Number of shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r59" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-based payment award, number of shares grant", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r547" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/NetLossPerCommonShareDetailsNarrative", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r539", "r540", "r541", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r563", "r564", "r565", "r566", "r567" ] }, "CCLD_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-based compensation nonvested awards total compensation cost not yet recognized", "documentation": "Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r534", "r542", "r561", "r562", "r563", "r564", "r567", "r572", "r573", "r574", "r575" ] }, "CCLD_ShareBasedGoodsAndNonemployeeServicesTransactionShareApprovedForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://carecloud.com/20241231", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionShareApprovedForIssuance", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-based payment award, number of shares issuance", "documentation": "Share-based payment award, number of shares issuance." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1338" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unvested stock option award, equity", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "CCLD_SharesAuthorizedForSaleValue": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "SharesAuthorizedForSaleValue", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock available for sale", "documentation": "Shares authorized for sale value." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "CCLD_SharesOutstandingAfterAdoption": { "xbrltype": "sharesItemType", "nsuri": "http://carecloud.com/20241231", "localname": "SharesOutstandingAfterAdoption", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Balance - January 1, 2023 after adoption, shares", "documentation": "Shares outstanding after adoption." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r718", "r1038" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r1073" ] }, "CCLD_StateMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "StateMember", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "State [Member]", "documentation": "State [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative", "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r141", "r142", "r143", "r144", "r207", "r290", "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r313", "r314", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r330", "r336", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r389", "r394", "r407", "r412", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r991", "r994", "r995", "r1001", "r1052", "r1409", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical", "http://carecloud.com/role/Cover", "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/StatementsOfShareholdersEquity", "http://carecloud.com/role/StatementsOfShareholdersEquityParenthetical", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r161", "r217", "r218", "r219", "r247", "r275", "r276", "r283", "r285", "r293", "r294", "r344", "r424", "r427", "r428", "r429", "r433", "r434", "r463", "r464", "r467", "r470", "r477", "r692", "r857", "r858", "r859", "r860", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r878", "r892", "r915", "r938", "r959", "r960", "r961", "r962", "r963", "r1179", "r1206", "r1215" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/DisclosureOfShare-basedCompensationArrangementsByShare-basedPaymentAwardDetails", "http://carecloud.com/role/NetLossPerCommonShareDetailsNarrative", "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/StatementsOfShareholdersEquity", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r91", "r95", "r96", "r203", "r229", "r230", "r231", "r254", "r255", "r256", "r258", "r265", "r267", "r269", "r292", "r349", "r355", "r392", "r479", "r610", "r611", "r625", "r626", "r627", "r630", "r638", "r639", "r648", "r650", "r651", "r652", "r653", "r655", "r665", "r699", "r700", "r701", "r702", "r703", "r704", "r708", "r711", "r732", "r812", "r841", "r842", "r843", "r866", "r938" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative", "http://carecloud.com/role/IncomeTaxesDetailsNarrative", "http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r164", "r166", "r169", "r171", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r334", "r335", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r879", "r880", "r881", "r948", "r951", "r955", "r958", "r965", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r982", "r1012", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1051", "r1057", "r1277", "r1409", "r1413", "r1414", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical", "http://carecloud.com/role/Cover", "http://carecloud.com/role/NetLossPerCommonShareDetailsNarrative", "http://carecloud.com/role/OrganizationAndBusinessDetailsNarrative", "http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails", "http://carecloud.com/role/StatementsOfShareholdersEquity", "http://carecloud.com/role/StatementsOfShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r254", "r255", "r256", "r292", "r711", "r754", "r855", "r878", "r884", "r885", "r886", "r887", "r888", "r889", "r892", "r895", "r896", "r897", "r898", "r899", "r901", "r902", "r903", "r904", "r906", "r907", "r908", "r909", "r910", "r912", "r916", "r917", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r938", "r1058" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r198", "r270", "r533", "r1182", "r1186", "r1213" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical", "http://carecloud.com/role/Cover", "http://carecloud.com/role/NetLossPerCommonShareDetailsNarrative", "http://carecloud.com/role/OrganizationAndBusinessDetailsNarrative", "http://carecloud.com/role/ScheduleOfConcentrationOfRiskByGeographicalRisksFactorDetails", "http://carecloud.com/role/StatementsOfShareholdersEquity", "http://carecloud.com/role/StatementsOfShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r254", "r255", "r256", "r292", "r339", "r711", "r754", "r855", "r878", "r884", "r885", "r886", "r887", "r888", "r889", "r892", "r895", "r896", "r897", "r898", "r899", "r901", "r902", "r903", "r904", "r906", "r907", "r908", "r909", "r910", "r912", "r916", "r917", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r938", "r1058" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r1094", "r1105", "r1119", "r1145" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock issued under the equity incentive plan, shares", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r14", "r90", "r91", "r128" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued for services, shares", "verboseLabel": "Shares issued for services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of Series B Preferred Stock, shares", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "presentation": [ "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails" ], "lang": { "en-us": { "role": { "label": "RSUs forfeited", "documentation": "Number of shares related to Restricted Stock Award forfeited during the period." } } }, "auth_ref": [ "r14", "r90", "r91", "r128" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://carecloud.com/role/ScheduleOfShare-basedCompensationRestrictedStockUnitsAwardActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "RSUs granted", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r14", "r128" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock issued under the equity incentive plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r14", "r90", "r91", "r128" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of Series B Preferred Stock", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramExpirationDate", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock repurchase program expiration date", "documentation": "Expiration date for purchase of share under share repurchase plan, in YYYY-MM-DD format. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1276" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares repurchased", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r14", "r90", "r91", "r128", "r860", "r938", "r962" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r91", "r95", "r96", "r116", "r894", "r911", "r939", "r940", "r1039", "r1064", "r1208", "r1229", "r1388", "r1444" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://carecloud.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS\u2019 EQUITY:" } } }, "auth_ref": [] }, "CCLD_StockholdersEquityAfterAdoption": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "StockholdersEquityAfterAdoption", "crdr": "credit", "presentation": [ "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Balance - January 1, 2023 after adoption", "documentation": "Stockholders equity after adoption." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://carecloud.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS\u2019 EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r125", "r246", "r462", "r464", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r476", "r479", "r656", "r941", "r943", "r964" ] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [ "http://carecloud.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sublease income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r720", "r1038" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://carecloud.com/role/RestructuringCostsDetailsNarrative", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r705", "r742" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://carecloud.com/role/RestructuringCostsDetailsNarrative", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r705", "r742" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://carecloud.com/role/RestructuringCostsDetailsNarrative", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r705", "r742" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://carecloud.com/role/RestructuringCostsDetailsNarrative", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r705", "r742" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://carecloud.com/role/RestructuringCostsDetailsNarrative", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r705", "r742" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://carecloud.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r741", "r743" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://carecloud.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF DEFERRED TAX VALUATION ALLOWANCE", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r1369" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://carecloud.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL INFORMATION - Cash paid during the year for:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r1138" ] }, "CCLD_TalkMDCliniciansMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "TalkMDCliniciansMember", "presentation": [ "http://carecloud.com/role/RelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "talkMD Clinicians [Member]", "documentation": "talkMD Clinicians [Member]" } } }, "auth_ref": [] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodAxis", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information by period subject to enacted tax law." } } }, "auth_ref": [ "r1367" ] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodDomain", "presentation": [ "http://carecloud.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Identified tax period." } } }, "auth_ref": [ "r1367" ] }, "CCLD_TechnologyEnabledBusinessSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "TechnologyEnabledBusinessSolutionsMember", "presentation": [ "http://carecloud.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Technology Enabled Business Solutions [Member]", "documentation": "Technology Enabled Business Solutions [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative", "http://carecloud.com/role/OrganizationAndBusinessDetailsNarrative", "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": [ "r1224", "r1397" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://carecloud.com/role/ConcentrationsDetailsNarrative", "http://carecloud.com/role/OrganizationAndBusinessDetailsNarrative", "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative", "http://carecloud.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1130" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r1137" ] }, "us-gaap_TradeAccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAccountsReceivableMember", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Trade Accounts Receivable [Member]", "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business." } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r145", "r146", "r147", "r1226", "r1227", "r1228" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransportationEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransportationEquipmentMember", "presentation": [ "http://carecloud.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Transportation Equipment [Member]", "documentation": "Equipment used for the primary purpose of moving people and products from one place to another." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r1161" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r1162" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r1162" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1160" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r1160" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r1161" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://carecloud.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r53" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://carecloud.com/role/BalanceSheetsParenthetical", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Treasury stock, common shares", "verboseLabel": "Common shares held as treasury stock, shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r53" ] }, "CCLD_TreasuryStockOneMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "TreasuryStockOneMember", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Treasury Stock [Member]", "documentation": "Treasury Stock [Member]" } } }, "auth_ref": [] }, "CCLD_TreasuryStockPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://carecloud.com/20241231", "localname": "TreasuryStockPolicyTextBlock", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Treasury Stock", "documentation": "Treasury Stock [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://carecloud.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://carecloud.com/role/BalanceSheets", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: 740,799 common shares held in treasury, at cost at December 31, 2024 and December 31, 2023", "label": "Common shares held as treasury stock, cost", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r53", "r54", "r91", "r95" ] }, "CCLD_TwoThousandFourteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "TwoThousandFourteenEquityIncentivePlanMember", "presentation": [ "http://carecloud.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2014 Equity Incentive Plan [Member]", "documentation": "2014 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r201", "r202", "r203", "r204", "r205", "r206", "r257", "r258", "r259", "r260", "r270", "r337", "r338", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r391", "r392", "r401", "r610", "r611", "r612", "r613", "r614", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r689", "r690", "r707", "r708", "r709", "r727", "r728", "r729", "r730", "r731", "r732", "r756", "r757", "r758", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/RelatedPartiesDetailsNarrative", "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r640" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://carecloud.com/role/ScheduleOfLiabilitiesAssociatedWithRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r404", "r405", "r410", "r411" ] }, "CCLD_UnallocatedCorporateExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "UnallocatedCorporateExpenses", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfRevenuesOperatingExpensesAndOperatingIncomeLossByReportableSegmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unallocated corporate expenses", "documentation": "Unallocated corporate expenses.", "label": "UnallocatedCorporateExpenses" } } }, "auth_ref": [] }, "us-gaap_UnbilledRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnbilledRevenuesMember", "presentation": [ "http://carecloud.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unbilled Revenues [Member]", "documentation": "Unbilled amounts due for services rendered or products shipped. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions." } } }, "auth_ref": [] }, "CCLD_UnderwriterCommissionFeesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://carecloud.com/20241231", "localname": "UnderwriterCommissionFeesPercentage", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Underwriter commission fees percentage", "documentation": "Underwriter commission fees percentage." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r1157" ] }, "CCLD_UnoccupiedLeaseCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://carecloud.com/20241231", "localname": "UnoccupiedLeaseCharges", "crdr": "debit", "presentation": [ "http://carecloud.com/role/LeasesDetailsNarrative", "http://carecloud.com/role/RestructuringCostsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unoccupied lease charges", "documentation": "Unoccupied lease charges." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://carecloud.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r31", "r32", "r33", "r150", "r151", "r153", "r154" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://carecloud.com/role/ScheduleOfDeferredTaxValuationAllowanceDetails" ], "lang": { "en-us": { "role": { "label": "Current year valuation allowance increase (decrease)", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r600" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://carecloud.com/role/ScheduleOfLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://carecloud.com/role/ScheduleOfLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r719", "r1038" ] }, "CCLD_VehicleFinancingNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://carecloud.com/20241231", "localname": "VehicleFinancingNotesMember", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative", "http://carecloud.com/role/ScheduleOfMaturitiesOfLong-termDebtDetails" ], "lang": { "en-us": { "role": { "label": "Vehicle Financing Notes [Member]", "documentation": "Vehicle Financing Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r1055", "r1056", "r1059", "r1060", "r1061", "r1062" ] }, "CCLD_WarrantStrikePrice": { "xbrltype": "perShareItemType", "nsuri": "http://carecloud.com/20241231", "localname": "WarrantStrikePrice", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant strike price", "documentation": "Warrant strike price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://carecloud.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1384", "r1385", "r1386" ] }, "CCLD_WarrantsExpiredUnexercised": { "xbrltype": "sharesItemType", "nsuri": "http://carecloud.com/20241231", "localname": "WarrantsExpiredUnexercised", "presentation": [ "http://carecloud.com/role/ShareholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants expired unexercised", "documentation": "Warrants expired unexercised." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://carecloud.com/role/ScheduleOfReconciliationOfWeighted-averageSharesOutstandingForBasicAndDilutedNetLossPerCommonShareDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted-average common shares used to compute diluted loss per share", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r274", "r285" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://carecloud.com/role/ScheduleOfReconciliationOfWeighted-averageSharesOutstandingForBasicAndDilutedNetLossPerCommonShareDetails", "http://carecloud.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted-average common shares used to compute basic loss per share", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r272", "r285" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://carecloud.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r1176" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479910/205-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-13" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-14" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "740", "Section": "25", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479172/805-740-25-8" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "740", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479172/805-740-25-9" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-40/tableOfContent" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10B" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r980": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r981": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r982": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r983": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r984": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r985": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r986": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r987": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r988": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r989": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r990": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r991": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r992": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r993": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r994": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r995": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r996": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r997": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r998": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r999": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1000": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1001": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1002": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1003": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481639/420-10-35-4" }, "r1004": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r1005": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1006": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1007": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1008": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1009": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1010": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1011": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1012": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1013": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1014": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1015": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1016": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1017": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1018": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1019": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1020": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1021": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r1022": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1023": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1024": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1025": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r1028": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1029": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1030": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1031": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1032": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1033": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1034": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1035": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1036": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1037": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1038": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1039": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1040": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1041": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1042": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1043": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1044": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1045": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1046": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1047": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1048": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1049": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1050": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1051": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1052": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1053": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1054": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1055": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1056": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1057": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1058": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1059": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1060": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1061": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1062": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1063": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1064": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1065": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1066": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1067": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1068": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r1069": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1070": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r1071": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r1072": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r1073": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r1074": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r1075": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r1076": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1077": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r1078": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1079": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1080": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r1081": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r1082": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1083": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1084": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1085": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r1086": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r1087": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r1088": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1089": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1090": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1091": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1092": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1093": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1094": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1095": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1096": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1097": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1098": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1099": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1100": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1101": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1102": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1103": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1104": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1105": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1106": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1107": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1108": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1109": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1110": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1111": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 6-K", "Section": "General Instruction", "Subsection": "B" }, "r1112": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05" }, "r1113": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "Instruction", "Paragraph": "2" }, "r1114": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "a" }, "r1115": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1116": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1117": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1118": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1119": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1120": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1121": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1122": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1123": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1124": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1125": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1126": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1127": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1128": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1129": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1130": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1131": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1132": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1133": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1134": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1135": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1136": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1137": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1138": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1139": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1140": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1141": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1142": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1143": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1144": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1145": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1146": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1147": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1148": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1149": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1150": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1151": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1152": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1153": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1154": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1155": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1156": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1157": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1158": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1159": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1160": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1161": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1162": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1163": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1164": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r1165": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r1166": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1167": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1168": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1169": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1170": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1171": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1172": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1174": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1175": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1176": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r1177": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r1178": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r1179": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1180": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1181": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1182": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1183": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1184": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1185": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1186": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 122 0001641172-25-002589-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001641172-25-002589-xbrl.zip M4$L#!!0 ( +2%@UJQU:6K[!D .X+ 0 1 8V-L9"TR,#(T,3(S,2YX M %_$N4-V]86J9!T<-'( X^' Y%^#@E[\];1WI@3"?>N['LZOS MRS.)N)9G4W?]\6RI#V1]I*IGTM_^^I__(<%_O_S78"!-*''L#]+8LP:JN_)^ MEF;FEGR0;HE+F!EX[&?IL^F$F.)-J$.8-/*V.X<$!#*B+WV0WIY?O[V7!@.! M>C\3U_;84E/3>C=!L/,_7%P\/CZ>N]Z#^>BQ;_ZYY6W%*M0#,PC]M+;+I\OX M/['B=]2WTL+O?[S;^3\]:?2W-7'?A6/3??2_F->W^_O%^W^__?V=3KYM'KX, MW]_KWTRV_QHLU_K3FO[SWF';ZU]MY3;ZY"^^M2%;4P(P7/_C&?(7L_=X<^ZQ M]<7UY>75Q6]W4YW3G46$'YX],G M:L'IFOEZ.T@+9 E?GL19>9(:27ICQ$I34AM4J#SB76^]AXN( /H MKW]("$-_L#;-74J\,OU[7FF<420.]COB5U+SG!RY'; "?:X[(/L"L[',]>#R M9G!SE90DEEW=?,C(?<+R0C=@^VKB.#-7P&=!N?60F*]U7_-YR,C7%NQ8-27F MY/LN8+6CXOT%Y":$H]%TG%):)B.6XX4VSE%>W]4U=A-QR):XP<1CVS%9F:$# M7/TK-!VZHL0^DP*3K4F D\[?F18Y5ETR=4W7]6"&PS(3IV#:;D=A"J<)D(1# M_@/S'&( >A+^@"6FYAN8>S'R8)T\DRCT:O0S4UM2GTU6U*7\V_&:NW_EOW>,^%"<\S2%A+A\3-)0VU(L:6X/BFJL$=" M!(D%Y+O!A@04>*B )9\OA-&-.$;2FUS]W_68U6"6]J<_7\UW*(O!Q^-I5),G MA-4/35@=*I:\E72HND=) "44C!G9$->G#T0%N7M+IIY? 5D=H1!^;\7QRWU' MBCXDO<%/]=-.!%!] _D;S[%!SU'^%=)@7\:R@D8(QA_%8OY/P MJ]C[VA000O:GYR';;Y"G++VFOYDXWF/58IMF":'WKL7R"C5+O.H>HQJ,YFQM MNO3?O+6R:P]#G[HDV1+K,IMQ>O_^_>45KIYCZL/7_) 1^&.NW%25V>*KO?0U.H$/H7IL2'M. K7ET44 M1O/9"+I=XXM=OY+5]3XL1:C&+@@#'7?KN5R0CD"HSA+ XJJ(!2Q(TG2NZQ+, M"P#F[@ZV'_V3K"D]+#6PC,E]O"SQ7P*=?EWL]+$R[!>=NO[5R -QPWB@)W\( M]/)-L9'Z00E-(%8"CIRYJB&]IR9$ K9K>P[NA&#T4= M%,IVYWA[0H;$A6\'"\=,E+'*' $X2HJQ8SK\JBC149LI$-:3%5.Y5LP:S MO&=]&^#Q,QO]C\3U><,3PWQUYG%<;DJJLF[,1W\?#&&CP,WY;J',=*XU]\C4 M(!,Y@ WS*=DRL@D"")049'4&_:Y(AOQ;OUG4NT""#6'*$XYUDEI9BXD"O5_2 ME.?&)T63E-]PX"N]%55D:2)KU \TLO,8:@?QFE1,%0"CI%#KRBVJ"K!W+^8: MZ@D]"#4@3$S*^''K^6I"71,4---1712M#J9DYX[Y-_A<"K\G! J90J $M)S]:70UWY=8F3 M!XU2/0@OZ;%]MN>VA0?WIJ3%G^S!E=XDW^V/OYSFS#5,^,L7<>G&E +XENP% MXHY=Z4WTF1[.-A[>+(@-^0+0E6P,U=[>'J9V;M\L0)4Y M"4[ UY%W /R4F^ MX"PR303' ?JA9'BH]0OW6(DXB+/09/X60*)D@$!G<=_I@E[C;+_GDP2ZOF1] MB#W(?>^+><2RG9]+$>C[DK$A\H[U7=_>3Y.? S6Y I"4C L5/IL>GQ-=!5F0 MFDD$D"K;&VKD5><)(%32XDM>AQZ99[H?LD")D0K@5E+Q!5P1/9(GWBT;D\"DCC\S M&9IB'DCC7;,2\7$TWY;L ;5WSZ0WSA?T;E1#_1(5"0R#DC'B&=Z. M?IB([ZS6AMBA VOR:&.Z:Y YO1'TVA[0E+<(ZWR5^#OB7HUWW?;E! 9!R2RB MCSXIX^64K^NC3_+L%N UYM)(UK2OB+E\A^AC;NH\2=#O,3^.>=%_)5LP6VBP MKX'Z&+D PN63'AF$RSXO>62HGU7C:X_J,U"=A 'T-4Q+D(^C+3O69P1A/EI> M /?RG8TFW+^7)DMCJ2DXOT$0CV6!1'7JQ\+SG-G5^WS+,@*8EVQ%;1S<_1Y^ MPLRO\FK73/(F4@%L2P:G['RN\X;W\_:$4PO5LU6(4@#'DI7J"';]?&PE4VWQ%LS<[?!<$28XD],*_!8G7A]0A4"N)=M7UE).WMD A,T5?_[ M]]+PJW2KS&\U>?$)E*\I3]6E"/?_23^03)K)& M+$"&.C2>AE\(76\"8@_,!\+,->%G8/QY&&#D9XP//O$8&DXL6)_'U F!M/+8 M3,VD?^W/'1]'/Y;O!V46"$W!4:5.U72%^**HMY\,93R0/RN:?*M$)WAT:;XT M=)#SQJBL3V"90*O.B.\M8W6ZQ-N1#<=_^B7EE+-:U2N+&*G P!"/Z]&O-2>M M-7]9RLS!% JV1$RR'1S[8VLPWZT5RO&5DG G9TE*]FKAVA%L"N MT1 V5G7Y]E93;@^2=W(NL)]F;3T9JAM[IGP0IPA]0/\OQC%AH"MQNQ8*2V1% M&"-V,^K/KU!@8)1/5E7X/M19XO'240A3U,_R<*I\SZ.I:*"(1::T2+Y2)HJF M@8#5#Z'V0\A@IDUDQ_$>,=8^2-=C+[P/5J&3C(":D2)<3F! -)K8 .VQ(LG3 MZ?R+#/H=EZW'\^70F"RGAR'20RYXF+MZ?Z[+% "O(AA,?A;VN[3 ?"R%!ZO& M28!. +*R2:PVK%B/8BN[5VTDL3HCF'@! 5PK+&(-H+7A@SG>Q[1?B8']MR=N(0:(87W;"I@?7TB@3 M+QF;LN#KR\5BJN \EJ?24)YR04C_I( K,Y (+J+M*@D#)LQ3V_Z]./DI'&2 MO/T JS(_%O^LL=*^,H'QTFC'RHV7D:Q_DB8@/O,M(#J;WX^:5[%A(HA3:MY3 MAZ>(F#%KB@B,@,8#9@5+)M\\IJH\5*=18@^QV/7+:KFM)D\ M))1K##E>EE, M1)/-!BRM4V@;:020*EFI"D%.>\A.]"\7+\_6>H;K" 7 :[0H55ZY[==#<0WH ML%W)ON]9%&?:%QILA+$]H08!T$N6J)S^E-G\9%V?CU0^F;^HQJ=^0)PT(&JQ M*BW%1^D$P!4)=MPOR2W@JPIS7 V@$*4 A((!DGL4V[CTR4'TUFYQ;JEZ[T^-AX5[)]C55]-)WK>#4"%5HT4%?%7I U M#?V%D8ES^#5'N)"_\A.]\A=9&_<+>AM32#7H?"6G%NS5/+K&$IKGKZ/-A%UA)( #^\A+6]U/F\T#\U[E)!8H%Q4+:VU88#ZL674TZGQ<>)#/,)0V>D M\Y@?+ZD[HR921@#;YI-JR>DB0_Z-A]Z(!8_T0$H_9]MTA6'B-I M"*@Q_,\/^+'^":33M5N#^0DU"(R QB-I<82I-WCT^SO0529S$$H/8:>^E\;P M2S?BT_Z8J][.^F'1ZO;8=N>YT;/K*: +YCU0']H3ZYVUU\9:E!48"HVF0USH MYS.N;!P&!BX,"VW^6=7Y\A\KL]_U(^"TY3^.N.#:QSUI@J4$4&^T'>:V@"1> M TSUWJ%VHHZP6A%4\0Z+MV8&)'\5K$X!:%%4 /;&RZ'*9**@"IA=["5--I3B MK; >^Q81(*LE]28" 1Q+IL5\5,A>(C]AEF;C04;P# [A,8KSLIGX.(+O&P^_ M18=6WL2GW[Y+T!WD FCTF(IX7_DY;W^^(S@1W'4,&6Z<:5I&Q-Y'P2;Q_D<< M?;+66_M2%0N,E49C7WS\7/]>PO .,@^8%@^<:-<^)!<$^Z]Q.$R\:))&R.Q' M5XO F)$0=D=,Q 6^.//< ="'#%U_/+Q>;OB<5%)@?)1L=OFPF;"8)%+X<@")*VS"R^GAF68X]N+Z\_N'J^N;J'\#V^=/624CP M"RGJCX^/YT_WS#GWV/KB^O+R)D*^V%/QAY,J3&:5:GF\X75< 9X7G HJX?%] M0%V[2!J?5!#0 (MG W)*^!U8/BY>D'/'O&_+.10ASBNR/,7Z7X-7&*!M>2V, MZ5?B>'3XRFOP#;.K+=_Y"?E*;(_3CY2Y_N7"W.VHN_+B%/C;=;UH'B1)P#B( M49)K;HF_,ZTFIJB+,50L:($/8MO6G,8^LH8B^-<@*3? I,'5]>#FZOS)MP\M M;=.(0S>T:T12[H1&\-I\8IVOO0< E5[@H*C^OE]'CC_X8!+]Z,KT[SD+H3]8 MF^9.Y*.592Z($_A)RLE-P&GB/[\-O)I6CF)$:7FU M((P?2[@CVWO"SGA+HYN>0M34<5 I_G@6L! W"V@E_;#C1Q<,OM?9810S[4R* M]CZ8&M&\_&![6Y.Z:D"V2 F<@\@-VTR(U+?,"WMWI$@-!T0S2(+O&@_O$[5G>NTX2OVVLO5W85N MNS.&HP6C#V9 IG0+U':>]8;\+C1_ JNR31@&)WTB5HB@C#8F95O3S?,A0M@% MAK"_A^9ZLW@(ID$%%A5Y76AV;'\<[2V'W)FN&1U-S3?_"$T7V.#$BY!9&].G M[KKP^,@=L3$.Z@+#\%"KEL_G5M*%COA$3"?8H+5)-?+<5>9THK>*G@LBS<-!%U@8+Y:02=/0@:Z-D;XS\22SC,B0M@% MAN)P]1[>QK"(K;KQB=@\-T>INL#**/0#;TO8W"T.JHJ,+C78>/2J&YS-Z$*# MH0.3IA5&>T5&%QJL?QZ.0(2EP<3$4QW!OB .UV9WI/$8[E)>,U*Q.=?F=J'I MLFUS6Z3I?$'W2;'M]=E=:/R,NL%FZH$\[=G\P2XN\%2C($C;!;8^DPT%@742 M/23HKF$U)WZ>FV:2+C"ANCY\! ,%)FW,<]"0WX7F&\3:N)[CK?>*BXU)GP'4 M/8?75@"D!7T7V%LP;P6-XS,[EA *##52=(,%RH.GH8)CPI[@KNL8.4K7!78* M*EPU+\>(NL"(H,KZYU!*1QOFN=0:H793PT@S21>8T,@6MH<%? 9;!HT-/%9: MCX\1=8,1-'2:SH04)T9E3A>:/$)G,!> M#%)2L"$@:8#T1/W 7XP*<_LH61>8D2T+/FXGAV +0ZPFLPL-7VSV/K5HT7M1 M3NY"8X^X7+KM:)EX;$O8S'-5UR8P$FP\ TT9P>?-"@-&C+0+3(U M0D=+F!7 M*]Y-!%U@P#"=;W?C$2@&?+@7];JZW"XT72?X9!;HT'RYWYG1!WF\@^*N<)RP M"PQ% 'AS1N]Y>8T$L'XA&4:3@O5MJ2>A/0KLG5KXS\+XPOQ&\7SE,]BOK^+/T@DZ MHU/3_68^HQ/JJ^A")QB/GK'Q0M_$X 0A"PAQH[5)Y:]@@HR";!0VFW9ENL!F MVOF1&Y7YJ902/6^ 6[_I%E>PUJ6ZP"K7S(D-+<0P5KCP'@6T79$N,#F!1N'; MF]1.YI/OK4 _'GJPHQ9D5"'2+C"5#+?J0=BIID83(;T_6;'[-U)T@87X-(1]*+,U&1O*@OW<166BE*S@8[YYKIY50Q>Z '5P?F>'3.FJL(C4 MY'6AV>B1&.'%37X$D%$;]%?9@OW'IQ4.3&'J+K"FXUY:4'%S25UH) P-^D#M MT'2R;WB5AD\331?8.)P]CR*QS%>R[>VP&O@5O?R'KDA\K!OV_>7.!AP.QZ-. M*MN"[2CO/GJ;Y^.9Q0\));T196X]EP0FV[_(N/.L;[G'V.150%C"U&$L'B/K M+H?%U]>K&3Q&U7K@1A0^K_=%9'6/!?$)Z/C)E8-,7I5U.B VN7]%/.+@RK[A M51RX/3PO!#"L*;0_.OZ9VO!/+-S9T3G&Q1)4*G],+ =XL/&@JTGM@VQ[V2.B0J\O[MU^]Y M#C%?1/GSW&/-;R;YPSDXA!N)WGR2H1X\I'188^KRS?A7TO:3=\$ ==97,B8L M/(=:>X,\!4,'I)0FJT*9]!GR:)!4\]*G46H8.D+3$4[2#:L6EMK\CG"0/!*/ MVTYRLR )R+FOX:IEF8YPF@E N\&7,'S535X^ATV(T =L9,(:EZ5@_TGBE<8W M$0VD*?7'J]3D/8H9U&LH.#_6D:>Q#;7!Y3I\PHL7"\KLWD#O#;AMLI!=T/^FVO8:]J,,TMK"H]8.TK3SO*]N.,O?*DDB=* M^6CK? GS 6"#R_HZ>74)A(?Y:N5O8$C&QYGI 4MA:G%HBPO:+OK$R]F^YJOE M;L5 ^L'#_0735C&OLW,L,<7!2B&[;F@Z\"\L,,R'ZJ'M18M=/5EG.8POB.J@ MO'XC"Y8QT53F/&N \:'[(BN?A6HB&9/H_ZK;J)I$ZWMP6!A/+-U58W.9H8*2 M,?7<-7K?ZWN@OD!7F6X2A [;';XW\!#=K;#_"FJ&+S$"%./#,C8 0K< M"P\;?<*A&.DS-)F7V_A3JQ>V.7+DE QBN:RNKBWQSA?)B\1>NN0).HGZ!WX: M*?YH+RHJ+KBE@=Z+:LW214=35@IK(NCLLB;;#_PJQ!;7YW0)+R1V="E+#?3< M0*/A42D0@?U(.X6:#DJL$&5'N>1MY.V.;\RE*%5D=)2'V"2@/%GCHEO,9HS)M7D_='^K^K#H8<-L2:WJ[O)*7>;GG,OJLM=47Z@OF)8 M'J7ZHP B$GR.0_53C/IP1$2_0UB[QTB)7TA38(-!1HY,@<+BQ.2.L'"/J MZA9R:.LV8T8II7:U^8>Y=>MY-EXR@'E%\N^3^]SV;W)[,:>7=SL&:C\JE*KO MA]DU^07K^Z,UA=*SG-QI -..1W VLXNR&&E'EYYLXU,C3A5GV;!0)Z_<'MQ"QPD[8;E;NJ;CX,,;*'_&34RBWASTKD::KJH< M,SQ7%.U4!:M$9D;&M__<4!28GB P1HDD!F M[DZW:6S@\+QP7C@ ?OO;TYVG/* P<@/_]Q>7KUZ_4)#O!!O7W_W^8FV-5&NB MZR^4*+;]C>T%/OK]A1^\^-O__O=_*?A_O_W/:*3,7.1M/BK3P!GI_C;X55G8 M=^BC"I5)<'?OH1CA7R0?_JC\_.K-SS?*:,0 M]S/R-T&X-O4CW-LXOH\^7EP\/CZ^\H,'^S$(OT6OG.".#: 5V_$^.D)[_?0Z M_5\R_3?/];]]A'_=V!%2,+_\Z.-3Y/[^ KZ;?O;Q[:L@W%V\>?WZ\N*/Z[GE MW*([>^3ZP#<'O9D8]-VA^9!Q(5G X@> MD+9N\>]O V^#[:/VY]Z-#SSXUL\>!%4N=6T!J@\EL:/;F1<\\JE%<5(;Q(@U MC9#S:A<\7#B'36H #S>8!\C9AY@)IAM]N[9]>T<^K/H;*\;+!NT.4S?"-$7[ M$)VCG?G#$FP@!?Z#T)08T98?ZH[4:_R%T+6],TSP(G,W&(<.*.2$WY%R&>'. M]MW_$.N&&3G>1ZZ/FJU.P[3.G$OD8OU=ABC"/,@^9KD[W]WBA89%[SC!WH]Q M#+@,/-=Q$8,O; VR(Z*N@F#SZ'H>_JR.,?!W[HV'U"C"7G"!XB;\V69WA.HR M#+#GBP_X8V#F[F&U-2%(F],16I, QPU^S.C(JT=WA KF.7C8)0JQ[[T+?.(9 MFC"B3NH(L2FZ:115?DQ'GS71 _+WC1PH#.O*4?('(WT'("!@-R9^&"\(K(I@ M6'#>RF"I&*9VA.0[H/*XG8NB;L&*=WQ;O]383^W&/(V@,+=G7C MQ07$/0;&0@+DE8W_UD@-#XP>@V4V9)MG]A(XLR%'F]-G$,V&'J9%\-D6LD ?)"WB753MHG4NK*O;G%@P#D!Z3 M'%[.\\#HWF+ETQEC"SN)X\,5"G:A?7\+F[?PDVAF.W$0\ANO]L![R?!X)<,V MNW.9F,C!'W8]-^7;%^3N;F.T&=D/*+1WB"1UD;&/27,7]@FS( 2OZ& -FKK> M'@^MS .YY3<0(GVFS;PBYP+2N>2O;4C"H)AO;.>!OQO%*+R#_)E;=*R0.JP& M\+*:-J=SSD[=R-[M0K3+;%%2#N#F*QN0^0/X!.V$A-J'$ M5\/"0UL4AFC3EL+./M4Y$U:AO4&JYP6/T"B';+)#Z']7F=_E@P)FV5Z^?16: MM,,[8B'3+>I5D-0]N^C/]!BCPQ;EKW^ ,79; MD,@!K--"/:]-H,_JI?.#WS6PS.XA4RGN'+3(,1I =&]>3UJ& YG <8%S7]SX MM@-JVL/N;0^(7Y58(?38U<.+- ^,KE*>8PMRV@!?WIU2\9?]I"D[&A]R@Y;V M@71J/]KAAE''>OI<]^ZQ&C>B5:Z#5P/9R5O[+@ZP )_6]>2./M0Y S)5M%#X MX#JH3E8XZ7"..:03['SW/UA0*'2#33O3T\]W^]W[Y.DO21OY; :V';9'L.-08X6@2'?>PI_B/*"8U/)P0(W?GV[ M^\!/SOT-W;S>T6@8D^:8N) M@Z?S$C2_4>0'VGT3":^58YC:.??SW2+)]T>G;3]V?C.!Z2$-(86Q*#V7ZN]2 M#$"#CS_+&:5#TGH")TD6\35.7G'0N#'\1>"/0CA'!X$] MZ:)@I/HY,'OJ.^8.'!CGT]!U;,_9>\1DS/'?SV:@IQCY&[3)X #2S ?E8S>& MT>GE!9?*"&XZ(!U&^#_3D?VA4GT:_@RE-QB/XP%:@I,?!9Z[@>162>84>BSZ!P1\#9J="M'=V0:PKVT6AGV_?)T5#DQ5'VD],9T?0'_TK4 MZSK-OD$>^^*]T7&'8A1!BEU% M[%R027BZ#VXT" ^YXUEE*9V/8A/'3T+%44673'PG\?5IA4N/1+X:IHB-)9H$QLT$FV6$M"_=\,J-,$1U2 M\BPN.MDRR>@\%LYP/C07FAKFB0XGF:7%Q@"91%951F87'-MLT<$HL_AXF"&3 M$!=!C)CCCB9=, \DR22='$U-& M(54P7L/^[R-"@!/%*Q3>Y9$+GH? M;30[]+'#CU3'V=_M235ZBK:N0PM#6>:*#G:89<;.")G$E\.2;"9.JI]+6Z#8 MV*[L)VJ%G@^0Z""(?3&V8Y%,4EZ%Y+3.@<6;58T575-DEE4]H17B&,E0M2(O MM;%'K,TS1<>!K+35%[UD7$$,+P]5!X:UDT3'B"WEQ/P$4Y/.BE#*22 M^=M%D1Y:(=DFL0FJF6R8I72$?DP67JJN;.]=WHS@Y;]XHJL:)HETJ MJ[P8.2"3T$P4(8S)+;GA]@%Y 3FKT2BRAFFBBQFL F.B7B9Q31%.R9WD+A=0 ML]S["Y1&#=HDT>4)5E$Q4"Z3H+(# _K=O>V&H%50.Z'8P)KQHBL2S*:/2J], MDBG?^0CJ!&<+3KA/;NUP1XL N8"([H?BL(:\G)%)L!57$3&$\/G!HA227*\T MPV*KVHX^'O0"2>!_-M3R="M@TB0M9WPX..F47.>(%T Y+^Z'Z,0FR:ZI6^UX^* M7AP#<+1.TRIT4B)[GU&18$FVK&@J4C%8].(?7K04GLDHVM34,A-T4Y16,4&T&V87;BVU4IG7,WK4!]OUX#3'*L@U0:8;O>0! M0\9%R )(JF7*3GGQP%ZE/DBT],X[BX^GV(Y7CVW^C?-ALBE<+UL>&%(MT-9B MY>=:PZH>N/4AWS-0TYM7W4#P,WL#P1E<)0&LO 30/XCI**@@M+E'DSI) IO\ MW80]#-S_WFPGK;4U?:VD^XXD;^EO#^:BF9=[.M[HFTROVKT MRWFINM3RIKK\0FBUE?Z%W4KG0?[5O@^B7Y5B5^S0-#&TXKWK@$!1/7K9JY0U M'O8]AX?%D)0$E"A'!"B0!WPP,\:'=80VNG^L^:9/AU'[?7E@_+^[Y8IS.67S M77K?5DTLS3-%>\1G2X^5.1T*M.)1Z,E\^J_\5]/W:BLD T,K1XHNO;>71"U) M\BTEO-#A$!":HN1/W:<>9J?6Y?@ B2ZS/WNAM62=3-(_/L"'(^=IL+^)MWLO MN]625O2AS1+="OALN;(P128A9J\0*;AM\MB@962.3-.MSV"O;]2$B M,Y'MP1.T]8+E@2&ZK?#9,N9GF%3;+'#/*0)L&_>MRR/99/=>7MG5$2_3@ARV M!_N#O,+Z?IJS2>%G7'SSNEYD=>,9,_G7\LJ,S@F99%:.ILO/\_%D'U6S&>4I M<6F&ATM2N3FV9*GAN1PN((S"EKB2TX)GDLL\>RR06A=NF,8H5QGK0FP$?A>2 M)%7&$\D-K\"QSF>4[7=5%*)Q2G(A%QXXR7I<3O>5LEPG_4RPC"HA<3VI$[[* M%*K5< 2,6/3,S;]*&()JH_:!;+>N M7Y<^^&J/9-0DJEE .&I-N&%*D6ZZ;< M#.O2_-7L09V02F^%A$*0%6SC1YP890NO^#!>S2Y52UB2[B@R"/891$OHWVKX M,'-]VW>>9[8J88@U6\;V]"[%6-[3,L?$MXDG9O<*SG9S%2IG0L M3\G<]5'4_*(-98JD[1OM!%O)#IEDE[<]C+*C3)&T7Z.=*6:5G3A;#+3"_R&O M?;"])#J(XM!U<( O\#VX_P'N9%+%+K!IEP;2J^>T9Z<6YQ2(1,'&]IVBQS: M2SH#XR$ZP!?#]W*3-&]94,JK@V1F)JU$(>6MV3(SDV:%)?*("6G&-D^NX3^+ ML?66LY>/B0Z-I5#"'L4H[HP>$4N$G%>[X.'".6R2$UZ3PPT*\4_WH1L?3#?Z M=FW[]HZF3_\=0GWLY_&P.FO/%@%X"HGP(KM MPY&P!+22A]W12;9J4J_Q]T+7]LYPP\H!1;*XB<*?BQ1FT JD9O#Z(*OB@)X1 M[FP_/:B!Y37>1Q!X%H_H??CPX?7E+T4*#/-*7>C_5%>ZL5#4Q509KRU]H5E6 MGPC#[001254CS*4,;\O=^>[6=6"K)=E>Q,MU&7CNV5L3.6+>%8D9JY9N*<9, M69J:I2U6)ZHL_6JAS_2)NE@IZF1BK!&,?VBS^>$%!W3M;C2QW--42U+6UG*7__R_LWEY:_*0EOU24BV M&5:Y#Y9#_T,1_:5I+#5S]96@K_UCK2^OL7#Z1'42^ [RX^KG) #)-Z]+QLI8 M3#!6)M&97A4"2QW:3I?D$#C%G$QM<_:8MTK7QK/LQ/,2DZ1R.N3 M,9]JID46[KM?R9I8?>UW032_XI/#NN3H0-GT%2Q;BZQBO%K @&J+OJTG.798 MB6/)EH7F73G9&F'<0WC2B[)U.;J2ILJ2]5<]4'6""SHI*/$M>1+M>SHVOFJ:,M84VTU?*>;0V*;5$-O3?5CWYQ=VY1 N>:"9JIO* M9W6^UB!4GND+%5MQ=8[5 0P!L?&],GE_$Z$_]_"^R$,=SB7_8ZW'%O:2P&?P M[/UBV"(]H:0I;TN.JG6:HKS,OM/KA2_TC&4%.\N5A):<'WO>HKQ,P/9*5U4" M4T]-R5%6IS'Z>S]3C7'*:YUG-(+A6IC>U*/]4\IRU2CUR):>9Q.H#<:X8%M?C6?*5%<'Q($C7A)[U MF)<]9DT .@CZN4BT'N627\S'HX.@60A,ZU$M>;;:\'08[2C$J?6(EYQ8*5H= M!.&&L+4>_Y)#8PA>AU&=ZIK[%,6VZT4+.TQ>/*R@Z>>2QZNMP2LO4WC*$6"O M1+4(?%D(+GG-9P3 PS+$<,+99L)PB5D5_ MR35;DT_:=#TG*CSYA*-B3-G*4":J:7X%XR@,\('(K<8]Z<[[@<* ME>7$.$=E.?A7)RO]LXZC:<&4S?8X,D#YN\Y2AT AM5S4I9'ZHS);XP!" [%B MDYNN\\QWG,@7]<),,<$[/AZ6J79]]P';;$'7$+F^&Z,Y-A&E++9"V@NL4:M' MY#V@Z\"/;RD=%\^%*[KWC$?BQ8N*.F&I3+TZ?!1]17:X>@RZTHTC.-$==(.I M1(&!W[DFX"]3SINT!BBZ!7!8;<@S\?O6AUFPISS.UA:>Z%Z\0;4AS\+O7!ER MN5 GRD#@B3[:,JPRY-/)[U89U&V,PJXUH@!4]*F9P=2BDIE2O7A!WSMCJ9:4 M*KD\NVBBRB-56VN4!+I4^LTGT'7[;&(3Y=JK0!:T^][HLX2=MJS&Z2JD7@O: M-$]T8LLBH?))2P96R.1\5,?9W^U)&UK^A03\WQY*Z[5YN]GBQI_NOB ZK6VA M$%VS5ZZ7\RA6FNJ22MM?#29Z^.I\OC_"V,)1D_'A"@6[T+Z_A0>2X"?1S';P M@J2XI?)N6;Y0GV^E@!^8NO7W'Y7Q5^5*,ZY,=?E)GZAS\E-+F:F3E6$.4]L^ M;PYAD6=CFX@H.9K(P<2XGIL*\@M9,V@SLA]0:.\0Z26)C'TGL\M++]I%[FOY0[-W,R-S7@C#[7CT+_HNE7GU;:=*1^UDSU2DM:4RS% M6*\L')E-8?MFAB4/6UP3LCRF^GP-'<"4OI8AM(3&%YJR_,)^"D&.JNW+4*+1_0L0U_FQN+J]%*,Z_3?A^QD2@0N$KI M@V;^Y%(STH)CW'CN[OS02]G!L\X7$^#DL3N)-7^MPC)TL8VXAPX"]EV;9X(5 M'=ORR;P0U'3"4IF"8"Z"&C=MVD$3'=P.IQ$2;]KPTT'?LVD+3_26S<#*(.N> M#3[GJN MZ*S3%UDKH04)G:9_5L=S[4=RAM7$>7I22$]R-6VFF29.U@0Q:17:&Z1Z7O ( ME_E5O-Y'X06UIHX)G6J*.I\;7U2G[BSB#4GDN5NC0K3M.> MBV6HU5DZZLV"?;F:5'OT>VB"*,?!62BKJ!]1CH>+LZ7$YS6V<[ZCEH#(2159 MNC4)07"&A1*TG(:("<).;T T(ULU5GBJ742[^#IU+7TRA<+6;1#&$,@Q2*%J MK/#TMD$*]?3))(7/=NA"A,,@A(JAPK/*!AG44B=5'G!R!];^_MXCEX_9WMCV M(,2R;A&*=7\;A E#CG>C)R<:*4ZC5!;/.PUKO5S.-?"'ZEP9JW,2UTGT7AV.:)_4(!>J MAZKC@DQVL@;C1> [+467GRK:EW4BO3(OO@,K"_=?SG V>WIEIX6EI6[4G5G: MB6I]4F8XQR5)2')&E]7>#K]/F1>O2^4 ]6A=8:N2I"MS71WK\^2'PE.6*$*H M1JFS)TFF>UI1GAF"H*HS(WX30\Z5)0'^UP$ZF.@SR4' \A>*A1 M%,#!)K2!YU^/.%:( &"U R4Z!V414GOJY(LX2'FU_@;XBKIYW031V2/'\FH@ M6JH8(->5OLE[HT(9'N"+JEL5L MA5@H?' =5*=5'G&&:9^S$^Q\]S]8I<@#?@WV[SUU5_"XKBS-_*Q/- K[H"=V MDFN.GAA7"_V?H%Z:J1O3(0UDS:7/#);E?7F'L/;Z9V&-[6E7]\I^@JN CPI M6ITI@J:WMV<-VROU#W(M<&HVCHW.@]\N"A=?PT';,=H&(3I>A#W%?T0Q.:@\ MPS]W=SZ%9&I;>WI+]DLX@OL#=APS ]O0T]79/RI3_%_6*CU]#+_5KQ:#=_MC M_0W\Y,#(D0?D/=<(?RCUFQ0.4/-PT&=C05S"B1^@ $O3^*Q;1,M3A_K#T(3G MM#R]QGZ"GT(N]:X% M;3;3P'/E%5LQ<0Q;/)$_",VYV^Q9;'$IRCN_UUZ4_5[?HG5X/ULYXT+B"B"VQL\BM>),?/)NGJ-WF:^;6U5D\'[W=L M([\F!LAUDU)^>X$<9XN, M[@^(US!A E/"2O=D#??/J,!\4$4U/"]#"<]:," MES&IY*&$U!XGP<'IQX68\6OZ_ ><@SR^""+::!?YQ]#R>QHJN&TYJ1;[&P[< MRU.$F]TZ"=0U*-=1+9-=M9#GP6L=_N;:#K\A)LM*FR/N[49R$QHVB:IPH>C>#55Z,')!):":*$,;DEIS8?T!>0.X3;!19 MPS31S6NL F.B7B9QY>^S+%QC62\LZB31C6:LHF*@7"9!95=(ZW?WMAN"5LVI M]_+6C1?=_L5L^JCTRB29\@XFJ!.4^4ZXW:A5X_*GIQ#,#1.DVKT,G>FQ[7OITT%,#^>7@?8$P0 MI2(#<^A31*_P >77S PI+49"S%E].5]#IK[-P39;= %A^#7,PU6I@KB!MOV& M?X%M<"O.MH$C4WMM[H7QI._B&MFP9[(Q?$S("(_?AY";D">N*3LNI;:R\P?' M5Y^TK/WB6E.A?7&J0+^1LC 6(U.;K$W2E9H\<#U,0\;^)D)_[J'V](!\II[: M#^5NL?78TOZQAFT@V%2B==2F*@24CB%$6H^>*R^M%:AH-=]+>?7/S3__N___M_=7SM?#2>DO\&WMH.\3@^O-PX*$/E# M_.%?.^]_OGG_U+FZ$ACW*W(M[#U,!_MQ5T&P\7]]\^;'CQ\_N_C9^(&][_[/ M)EZ+#3@+C"#T]Z.]?7F;_%_<_;\6OSM)]-T+#+\S2_7-_'@_W'4*-ANR"3V;3H'?^J\ M*?OAKN%0*.R=ZISLS8E!7Z M0\13O(F6_%!UK-Z3+WBVX1Q10A:9;1$:*N"PX/@53:ZQMS1<^X]H=R."[(:^ M[2+^KL/I5IER\6TR?R<>\HD,=A^;V4O77I"%1J W31RZ 3$7)]BQ31L)Z,+2 M0U;$U!W&U@_;<('7F@&1.^ZRQ[V^>RC=)F=TJ(BX^]LR- M%_YTRFE:E55%C@*>_D)Y1 )*'6A>%5QH27>1*=I@C^XA7)R ]A61=8/>J9!<^^>CWD(RL/XM0![679Q#7:!A+,9#G M!OD7EYLB8]1H+(L1R^]9B^$L1ARK3YU&M!AU ETK-*C%:,JVK-:X%J,BMW&E M!J,8'7EM:[/81$7#[E>OF21&HU#GZDTF,>+ #O683V)$,3O59$H)8LGLU8Q9 M)49IH4'J]4#V46#8CC\R/*IZGKDNA8+#R#/(BC)6X2>J6@7F"EFA0R9);T5, M*[()X![YU)90H*TI*>/%SOY**.&ND-(C5L[2J;FHF42"=K MS(G@0+4S(&,G>$R^/9),\FR/1D1LY%Q1=5N5&JQRM/-N_,# "@]1XR"DJ^2)C5+]C MI8\SXP6]2>QN[Q!>>L9F12]OZ6_\6\,,L%=\\RH_>"TGO*+(B/6N'),I,LF' M;<=.Y/8-VH(LLIR6-FG*A?"W#,LI#D._D$#YT\?A4[ (G1VEA7DM.F*UCJNB"X;3 MK;9;XZ)TBH]0_ZUR<95?>*C*YWGD(BQ[*&%TKIS06;@A0U%A&4XZ?)7&)3C':OI<]>HQG[9H5MDF60W13=Z#:Q,#B])3VI]N?%" MKP7W$HV.C\5]"05&J^%:9/<RC* I!KL\9LZ:XX\*&@V#_LY]'(C-Y'CEYWAQ,=GH"U"S+IMN-X23B M.Y%[[M-(.EST-)+\<'@:66#L2AF*XIW.H?IH@$I)TZQ_A7[LMYUC^!5&,7*Y M@U;' I%,Z!C>T/;IV4U_(6N*SLL>?<:+O6UI+@3'K861L^N93_;5F@XY]$*C%,)H9$_8TY&.HO" MW%$JW @\@X:$I)U29Y%[-%Z-$X <3)?D;$?/",_(R[P4*D Q.%)UQ*9B;RH@ MF#E:=41'$\_O$?,%S?&]N[&I,7/>-(9&JW)?\&T+>3FSNKLE:_V,?2)_7#\X M&KY ]1/]_YC5Q9>&W9! MHK.]&Z X^M+5&JV?:+JQ0N0>=ZV?5L-QBE$8=:B?+A<'6E'2=GT:G9/QEE1Z M4NZZ']-,?FV[=KS]N-^/Z$9TD[+0?GNF [(CE-(Y[^R MD[R&EYWKF@2Q.A% M$?DQ;IG0L:/$P>;1YZ,['.R5WA#I;P[[8?*+QWV.+,(N&I ?]SNN8SPA)_KL M8](XK^T;N50?.1<8%"?M3JD]H*UY.[J3J2*X'N/Y^:N)W8#,#SV.WB%S//;W M[2A;>'C-%64B-LSD("U;0LA/'>P12^)O/UV_/=!"S2+K;S\%7IC#]F*+S*YLETIARU6F/)B.I0] !/&:@Y8L7-(D]A.U# &2U[92)+(6 M @\&4,*82SD$Q)U#>%5P['3CN;M;:;PB[B#(WI6%+"?TMS?L/R:O M/NC7)T9\Z_'V9Z*D)\B+(BKN$YLP P[M+=:Y!K2.[54 "<9*P*5X '>TLEL: M@,D,F9]^_OA^%KDC>N$Z=*([FRFR$%K3S9C0MD%!:#@3+[G#+@E@#5]ZS-M4 ME$&[+H;!';;.J=%M;FY4]*G'O.U+S&@<K\SD&;-$FW>/PD!R3^N2"/4$BVE9@V?-%JA!B+$G3K&,M\V1XU45JX M64IK->(+2+>/?-.S-^F[:$#(J9;MD/4IP: J:7:OF**E[2=/P?<,L3>/W"Y* M@\"G'-RZFT5#*8*C8(Z9:MD'V&8$CDOS0K\G^$AA<@S]F*2/VD<2L$ MGT(_IAD4?D,GX%[H>4>D,7<>J+72XF<2#=F:;_(WEM&T+ M!)]+,BCYADZS,6ESXV5 RQA&&:NIO/@ %U:@ .+F4[,L#_E^\A_*US4+EISF+0 #HAJ\ M &OH_ M1=U,,@IM60G##AJ"A\R]$W;MB$+QK)03OV! T= H^HJY'?AQ[<_P# MN'T'&K='_"X2 6C1Z3=_,D-A=$ M5D''\C[WA6:=Y[=LC_RS9( H-G9J3&4'=*%#8 MU5$3I66=I104;T-'8ZIS- \9\+1.MU!;N*>$@K)MZ)P[Q/169X5=I@_YM)72 M,LXE%I1S4\?5^/$ZM#WL_ZRT9(^IA$1:^N5-09%^\^R T$/?I81NXD$";OYR MFRHM:IAB4.P-'3EG4>T\FL7NGO#AV8:3+_-L.Z4%#I +2KNAT^7$0W0.(&+D M1\%P]'&Y-UXLH)T:;J^T]#ED@R@T=,P\(6_@^R'RBF*1Z=4F1/*)!W%IZ,@Y MHQDFB4EU??,TI[D3@)WHI)72=C8ED)[];)->_528*]NZ*2Y(VI?17W\Y-C+H^RT^2+/Z= *Z4-T0T#\TM2+ MU^B]5JHDURWY(1^"W*9*"Q^F&!1[4T]A0\L.D!43>&N[AFN2P]R>*G S= MM':Q_8SZ1F D]+*PR._1 BP8A(-8-!IX'"W4TQ($T'.&?<,62#Y++RCP1N.- M9VO#<;JA3QCPF?O/4<,6"#Q++RCP1B.*]37REF0;O//PCV"5/.1E"3ZW0PL M@.D&@6@TDT#TRUG&JGM.P! M.MA@VOVI9BV0]2FUH*@;/?EV#?>[%VX"XA_2_4=9./U43B.FX8/1K 4Q<\D%T&DY%Y1^> M["&+5A5=((\&;\S12] E'_K.-JZXW97&JA@7(&0-';T'YL*+7/;8TX( D>D4 M7:" 015P>Z5!X9 -HM!PPJI;FRSO=:!['O9ZF&R[)AL-?C^E41$D'T2GT4,Z MK>Y%-MI=VNA=QFB6O@&Z*(T)GW((C@]-W67'Z_C6]M8#X)A^U$1I<6G/"!OG( M]]W?GR^5VRZ5VU)+^5*Y[5*Y3;5J M855KO4OEMDOEMB8KMYV_K44%C;3CFD5@[:>=-.!.ZI;X$J0=7%72=KBDYE09 MB'([/>9%@ZL'$4P[!%$UX=9E(,J4_!I[T8YA\7PXR0!B_1\_JGI**\X&A*&T MC?"8]OCB0PN#%?;L/U">_R>7Y]-^+8,LEWSE3+X\FJ,P\X(PQ7U:"5&*=%!A MJ00/^^:4P6CZ[K&-0)W2#UJ TFSVHQJW!?660&?E41/E ;0Z%$!.7%TQ.K4) MJ4**JI*@D4H0XFDIH$/[D!'03Y4$BU2"BI!R8D;%M X?4;5427A(&9#F'C+\ MT-M&-"?D1Y3#"(%=E(>'33F$S2=)5UV'1[;CQ7B#O.,L9,>W1[^P;H\. W7P MHI,>JK;;KS3M-"C70ROJ(7Q&-(IJC8;8!QAY+\[(T;B=>.#.G^C0?VZ(LVCR MK+!#IHFO_Q[:P3:?J0_B3*6'_$]C@_V_=I*1+Y=\ETN^5W?)%\]MNI*Q2Y> MX$5??K>67/:Q>%;(^W-")N^>"6@N^=J/*6LLPH!ZMW]5 -.*.\!SP5/T*K#8 M!5/N[8P<.YN]0E@^N@/9RFUSJ2,;#XI,4UF7L$6 R"=:O=M7S;(BH1G.Q+"M M@=LS-G9@.#Q,F-T>\Q:Y8OCP&0!W,&E835% &$*6;G@N?5O& RF_O:S[\2+H M,"@'_=3REI!IANO0H:?*Z#URSL&;NYQ$AWC,>]*O&'C%F &]VM+PS'%7\? # MNSSF/>=0#"\V\:!_6U[ T"54E75RE78Q?@E55>>P>@E5O82JMB(,$B1=N>VM M\CC5ZA=927#:]O&SXO>H ,G*^78*A!UDK^N5!R&7 MXJIW*]-TK$BPUS?OKB/A]GK#_F,O/EB1FS+35@6S$7X@M"O9(47N6NCW>[D3_'P)UJQ-D3X<.B6Q_9 M]Z)];(J(/>C; 9HA[]DV42R%*3+Q,D8J6@2L&^AZOZS\/&I$ *!O09$PGK[] M;%O(M?Q8D>Z%-UAOB/(4#>]ACZ+\3"C,#(BJQ#L]6!%&5E,YRR#JJCQ^8APH MZFZ%-%DYU%)]VPK;*0L@;M+>Q++F6_QK &!%;:DUGF MC#P?66"'D>]_L=1E[ RI6Z3 M+V%EE["R2UB9.F%E[0A;@FE7T/E1=619.Y)4PK2#&Y^\G&S&=F=\[PX3-#-X M#_NYY>=WCCE&+UDO \2]BCSB(914.%O<*G Z@/70$^!.P] M:0==2NBM@W\ 24L^%4A:0D;J)$-5DZ/DJ%R%N;5BZGM; B#Y;>B1X_+4]K_? M&ZZQC.C07 ('+6.UW/9MGYYXPD/NN2/&KFE:F4,;REEZV X=MW,8N&.XE-UX MZ$YZ[#HYO2>?\VS#.2)MX)ITJ@4\!M^?,K@;[833W7@U<)4S]<;>TG#M/XPD MZ.*TB';"PN?/G]]>?SAE8#R]TT:#_]'F@_&HHXWZG>[#;##29[-::UWX-EDE M9+7[1$8[LF?VTK47MFFD"]5.R+HP;93+R\=37KK:;##KC&\[DZD^TT?S U.S MP=UH<#OH::-Y1^OUQ@^C^6!TUYF,AX/>0*^3USN,K1^VXQ &!X17=VF3TZWF M^RCP1RC(8^O3*5MWXW'_VV XC#@9$+9&=X/N4.]HLYD^GW7^\S\^W5Q?_[4S MTN9;6H\ZA&BIM&$J7,V$,AIS-0DBJ;:I1/+(_'ZE$2";FI? M]=%#G5+A9O&*",NHP@BL+^-A7Y_.HB7[\:_1 MBEQ@1[W)J#A(^ M,;P $%M&$4WUH3;7^YV)-IW7*Z@I\@,O-(/H>NCH5))Y&[X+ N.E)D;+[GS\EU&B0Q& MA#"],]?^6>NDC&((]!Q;W9>ZSB,T MHV!F^AW=#\D2FHRG=#.LD>K-GS0J65\.QAI9//6AF0NT"T@VMKK%''XY*/?0YJ=ZQDB.:-U9@_=&5&- M5,I4F]=*8(FS".-,\BZCGDJ?23I_VGVGSO2D[.-)=!67RV=&Y8D?4CI_BH>M MDZV\TPK,3$8]YI]9FB#\^/ "DYQ1E<='F"9(S3W+@!3_DM&7X(FF">+IT0:F M-:,XZ0&G";*2DPY,649O)N>=)HB+C7*8MHRJC$WS9N1V:@;#9&8T9(XQW 3- M@*T)$Y[5DX#%V03U*=,3ICBC#=,&:!-4GEBB,*49?0;:HXU,C1/#%*8[H[HR MYFD3]'+L5)C\C!H3L%8;F3?Y'O4^3>_G^"/#\Z+W^CDLO<_H.=##WOE3,EYG M/^ E,O$2F1B)3=W(1-\+4N"0?QV (?]XG)DK9(4.V0EBW^@]"E:8G"V>4?SF M*_M;A$;&&@$!BV3(\T94-)[Q;+[ *= DV!")8(@=Z<3KTW#88U5 8&$&(>0J MCHYL'#HEHR2;AK>>8$H@-/8SV6B&]MH.D 4&W]'V4/.F$^Z)KQ$L M1GS5>R%#W%UCN9H\!\. +^K3IHU'-Y:6ZDXH653NW^Q@%=V,4C_ERM[,L>Z28]"6I3\*#]*\+<#&@(&5 MF#QD:WT9,*IJ%]0$=:,6P"T.73(PO>9X069(70B]E6%[:P-._4X[22X>40'D)6*09A;TXD)9Q*V8N9(ZXV)9%;?C[I:6!@0%Z:M: 3>D2%]);LG]>1.DD>>P%!Y! M&5>F.)2GKLV"TE+2Z3DUW"7#@YGZL[S31U$YXSSRE? Z1O2 YLV.X%V#YL\0 M67GA?-+4.!,4$:>JMKR@R)M\ZLR1^CT1V3I6JXB.Z- M%ZYDTTT:K_K'EVR&/'#.RGM8#&F1[G9./LO./R+4N76JL@ASS3CUJL"3TLQ+ MF2'464X^DR)H".*8E8A*J4[J!E))$Z )L!7-DT)C!\, >7N*! CUI M)CF)*E.VI[D%<_A3R<8I X#*]LG9(#5J;WQ!AA.L:+S!8,[46-F&A$Y)$1^Y M4QKS:86O>N4KCS@ZA?H>L%M >>1W:[WR8$DCQ^*3&U^U)Y.WAP'-)2L3IJSS M0J@ ?E52*E4 TPHENA.\A; ,&7;M@\?B =P(4F[9XLK4]I_Q.DZZ,73#"^"'\1XW16Q9*PHD=[M M T^<*]#R4.Z:_,%'B] 9V@O&PA/HW#XPA9EJT96;")@BO=N'ICA7RGGZ:,%7 MVXO>?"R&V%U&3,3NZR_(H27O'EA:4:A[^P MP)9RQ^^=$18G-*)^!7$;--NG M?=CQ>($ ^R +L%U:R,.DHZG^8+#RV[>*$\0D)^DV2_80_;2[86>AUQS._<,UZ)/.''YR22/2M44X M%6,)OMV1]&3WYM::7'+/[6EP MB$;6U#-]7P\SF4V'GF(RF_99Z\T'7P?SWU*,*79"]#.3NE!0WE"=U\8,*H7? M&_/'4.;%<1%(P3?'HC*3\^JXF@G^>J/+A=&K(;Y62 MX\O/OY@*_0"OD9?.E.1S'X'!G9I.!WGF*L5%^*IZ-P=.AJE[L=U]&#-F#VPO MJVAY!1'D;)Y (*3IU:A40(99SC)B=))5S+R:=<1C#%21S6>":4O>G:+6JECF MG4:S@%XR[UPR[_S[9=YI/"RQ8.J=1@,/JTZ^C[>J/<6E>?1$^,)@E'RL=[)(ULS?P]M#UG7/"#9O=L+I@A?;7+.Y5UB MQF?4W25FJ27+'[:]4^ LAILQF-6*4GQ52)_R!0$J+4Z1P;5FFN$ZC.K&:VM: MP^\/ X@&X$L0&.MU@6D!CFL3L/3H,,[M?&R$5X0B"KVQX(U0,H?#L M*J63HSH#-7RJ5>C7*P1HPD@+M3SE;X0"_<5T0LMVE[O0('C5B_1N%?J%^8( M347D28KXRIB781!Z*#UIDV=IC*"H3$5I9E#47SJW#_.'J4[COZ;S76'87:7A M)B+ =MAH;@9R J%(-8I,*>I]!!LM0)&- SNJGZQ*^8F!F\B4?XF<60EYB[S, M:+*#QCA4"P>.B8VC3/#8.="#P61%9*E\0-FK3995"*5*4F;)RUES29EU29GU M[YLR"\Q2F)#$KN JU%E2K!0WL98X]55O6C6D+Y,42%,F>UF#H3$%MB'^"75_ M6I.4L;1">^R(%>5N_"IZ6/MZ8,IA3#D[2K/^%<9%*&^Q)^;/![N\ NC8O"EW M[[:[,V8XNKXA>[FBOLIGY!%%*7(?=\ZHKV$.G,L^: 1*]PCNGK^F7[XRG'\? M6,Z_R70\T:?SWR*WF/Z/A\'D7A_-9;^&O-1=Y;FS+G57,PE@57=870K2U5*0 M3KT"@]FZ4)>"=)>"=&HZS"X%Z5A^MJ0'5,=-L>PG.:M,K!Y=&C%7:LP7KCX>=(/7!?CS(Z/:J6^XF+&H\9"+,/%>^!21P+#@@+)O5* MS)#W3.] 6!L@N]/CI]: (<@,!,8G]=>RX7X4>Y6XU4N&3I&M(F,B#WLFH05+WG.,+7][]WM'<)+S]BL:$0% M_8U_:YAD(3#N!#XQ4T&.1SW"XS2.^R6_F YF?_]+I_M;YTX?WTVUR9=!3QM& MOYUU;K7>?#R5?6&PC_O)S&1&!.!0^H7 CA*>V_^DG3+.?5CL4&"B BY[3H* M/:GI506G<&$TE^>.SY=VGJ0#\L90=NWGR*%[YLL0CA#;G) M&P)"21=X56 IZN8>8?>!Z^%)-6K:G2TT_S&+6N7."K%C(WX]R#HKIIL]2CH, M".ON++7J'>\3AY)KBHG^T+(ETC\A6-&)SQ-[2X3-%+&T*,&A;3S9#A$4XF\P MV;;*BQX@&52K"L @LM_D-F\3&(([C[0<)_M7P=P]'ZDO]V-*(5F_E^13._(] M^2+>M,^G;J8CU]),G9?61ZQ1%YJ 'XG51U9@RPE%'+\2U%X9_Q(?EDR$"TL" M2OJ;YG2]1*]^[6?;"EF^)J"I-#\31]J81[@2OJ8,;=_L8)7.SC['NAO0HD,, MQT?A09KW2[$Q8& E)@_9GBH9,*KJU:H)ZD;?1N_J)(Q=3F6"TW:-1P*>L68P MCP]P;55=#R+Y^OP'%I+VOEWC)G6UTC[F YS;54?!NFA' #OJ];1=XT%WU4@[ MGP](VJ7C[:JWG[O;+G+-U=KPOK.?Y_![*FZD"?.AG%\L2_*.8-[3#7Y/.0]P MA$'@89WM0'GI*V6;T *WH/N:NQ.T4FLI_IYL.[E(1ZR'KD(;RR,H&1 M,!O@6I2VD0.-$(3TG\&R8V:FU)@G_ M4;"TZZ$L:P)O2)F=E+%!..]!!3A7VO(X$ZB6V1OEP534RM@=,#.4BQ8:!3HJ M8W/P7_<*, *NPVHWS-&K;WU7!"E/,HJF?X*\VUZ'_H^Z]G'TEI.0FIA$W;L9/M=9=>],J(\XO.5J2W M/PX#/S!<6H'H%GM=P[=-LO_V;2J MTVC+P7"P?\?[31_=\<-\-M=&_<'HKG,[GG:Z MVFS0BQX\]P?#!](A*HLS',]FG8D^[?3&]_=DP*AS(^6 6&)AQ9]^N#Z5#Y\/ MZ:&HEZ?,EZ?,=0)$S;Q@2U/!81>)E\O)[Z;H$V:2R^,P M98U%&%#OLJ *8)3TRU0-GJ+^F0D9!GD>LF8!-KDW GFM)>7Z9*^0TR0]^60K MM\UI/PS/XM]=GS136]7D\J10E%QD,I/3!K+H9"(<&['D/,.-ZR[YW>VAS<38 MTM]%3!TXGJP_;-(92TL:Z8IJK2GR \\ MVPP2A?9 $/*GLP>>]F9VJP%^L1? =6X0N"#_H$$@S2+HTZ<%R+7\8QLF^A\8 M:58O64FEA=T(7.*5NWW1W,"VJ)_2?D8S9(9>E!\@KJ>.K%LBB3B_?.+^U W/ MM=TE]=I%,UM;TV!8AKE7Q?#*PUX=EP)FO21'^+T1)'R-%T/L+J\"Y*W[Z(E1 MI.K##@6@TD*A\6SX:MT=?\7]'*-AUT:[N&:Q*#9H0#! ?, MT2Z,'I)\L9S9CX5IKWH# T-&B"E%"#C0P10XU%S6D5ESJ-RA MNA!+OR JRH: XDH[U"Z-.<*6DM%N.$?)AQ)BLWWFM%?<^;%DXJ.N=/!\*E3V39\'5J%=R]K5[3 /300:TEN2- M9,YU+$1U,UL4Y]G[E$; P+D?4G]661$<4]K,V5-$L."$WA&\:]!\\H:LO' ^ M:0WMWQ6*4\G=65SD3<8#N.TVNCW<&R]< MR::;R$BKS9%LACQPIY#F]*,75^-%*LZ3??X!FJNL^=B4*^>02X?<:JXUPJYQ M^,V<_.0;9N2'XN8H+3J0G+,3&Q=\'DOJG:QDP:NDQJ]_"C1]6HM3P M#FLYC1^O/\HYK95=6EB,(]"D^%AQ3,F(L+\:8L.]QY:]L,WX&8,0(B)='V\D M95NL !]Q_F S1=[SP->5'4#<;BF9(D!:N<-+B@!%?;J7% &"X#5J,VB6%8G. M<+Y%&SI;10&MR=E2X=?_7,+AM2(U%N;R?N$$C_>JH'%YOR!=FUS>+X@QUY0> MJ?;]PHVD>*UJ7C#<,,,K?U'T%<.-I,HT%3QCN&$5I+F15RYO:+MHO#B^7>[A M9T2H#VB@'TNE\[H^WC2=(KM<3*,8'Q!X\O1+#MW)?4H7>Q[^069?S]B0OP3; M8BA"H[084#9+H.]-)6S[R#<]>Q.D[%HQ.%,=6XQ@A@MP-U4)M"@/,O*#*3EY M:\$$>3:V=-]L^H12P5XH/I#IRYW"EG+MU]V8A/0_9I[#3UJK#Q25=/7=%KLVU M7ML!9?06H=+*#AJE+1@69@G"]D.UN^6A5,5X$6?!'[CCQ<)?80\EA-I@+0.Q MSJI#5)03")F/*JVZ*:(2(A;QF6<&>!S583V#*0CA3Q6OO?C1Y'CQL"%,1ML MN-)RFJH. )MN2,:?I;W\< S?'R^26YJQ-Z4E0D8AE039$_;YX'J&XR"KNTW: M^4E#ULNI\P96'>8JN00/[!7[C)-IZ=]B3W/=T'#(_]K/R/,-;WN;^Z(_-9FA M7JH#)&_C]50=IT)L@,#)*VF>M^GJ+\28M?UXRNW_N-]I6>7XR@S7$HC/X W$ M79[O@W>JP0 *L<8GPU2HS'&7Y#A!"MJ M9@SFS!C7;$-).8CR)S3F45KUQ@/%Z)"3NFDX$X\^W331O>$:2_XS54ZO1TF6 M-5?4(G2#5XZ-9GR:>)@& HV]&?*>":EP\J?\EJU0P2#UX*XO 0+JBDZ(\\%- M_\!)7O/F\T8QQ9J1/LRB[(1256&@I *N *=&=>\7A "HL>M.P:86, =9*2P*B1^#NF@ MQ"L7.>'3=I>$YGO#)NV7@H)G=VL\2WEQ\0LP ('P2\4@W'DXW$Q"SUP9OB@" MS#Z/33^ *RI^/O60[#]("VI(3,"X;B>]+S*#;W:PZH5^@-?(B^MZTBGE^V1A M(VMNO,#GZA*#/5[G:<(F//WE/(NE682@?RO=]=];T3Q!_L#53)-> /M39"+[ MF:K/'8N4&UKRH)]4^N7?#KQGW0[TOFBC.WW6&8PZ6J\W?AC-9YVIWM,'7[7N M4/]+IS<>S:=:;][19C.=_.^HW^GKM_ITJO=S[A$.\JM/1G//L)#F./A']+X5 M>WTD<;#L??M%%/[]R.IYW^^*$[OWT8'H33!+/' MF#*K1'P\Y>@4%/F%(B[7/)=K'LA+U\ US\6#5,*#),.)=_$@73Q(%P\2/:_U M5AYV;;-'+ /!FP9&#]7]1!S2&[K@F:(U#M"$[*7TZX0@TI&7'X;91WD'$9]Z M<&>J6/95NN74]PLQ20<]0I5/]\A8Z&U-1W2+8751WA_$)1YT!U4L^.I=<4UG MH:[6%;OJ!/MC1NL93\ M]K*J4@NN-BS*0N4WOF?CTS4<>H\R6R$4#'%2:8*I9^$>;=*?/+ZK2_M6"T2\ MS9/51XX^Y J1^007;=SE1:CT^-U MTV4DQ1<0+L8$Z(HMG6>EL=-D=WOXN;J39/ZH;=*"5[#'-;2U*0I22?6U@ZEWN5-.+Y*"FM$6M"4E$5>.!N1A/T&9[E/VPL(T W M;Z\_7+_C%H\6Z2Y-)3)75.Y10X016#7^&S_.>/_Z'V>\5[&\4<+)/@7W!'D+ M[*VI;V7\Y-BQ7+A8L[NW%%T1IL"U+"T%:0W \KBK^K8+B+W:/5>+LIQ&\8]0Y8"< MEJW!@4F_GL__\CT\WUQ__VM'_\3"8_Z;.Z] DR_DLP.;W#)Q@ MPO?3YI)2W.W?)$?T=+<1=9QGH,Q.RKP"9<)RFN6.+X;V)/A,,RZ8W#/;19I' M6P0*(*\GQ+A*)[<4B;QKPKRVDK-[@A+.K?N0PZ5*+NKSL%#9/7T^7HHZHF?( MLY&O3;R=24LIYKF?&9TD)0IEK(_3[*M,TI7;WF)ZNV7PR>TD+?*L($(,XD&, M2I>> MP3R5R)GUH50(%V%NK[>/U953 *\@!B\EG:RDENH6@MI/AA)]MR YJW MR&IC,JR0VS9%(0U[&F'7./QF3G[R#9.=$7/GE"DZD!Q;CXT+/H\E]8Q 6?"J M;#[6. 6:S4&"O,!>V*0#98<09/&3D#"Z2#(6RRXR+,Z5+W! M;H%B)?G=6J0=A02@T/NN$S)YQVF@N63O!E/66(0!]?1;%<"HK*LJ Z_9_.H> M,OS0VT;;P=B%@\FC+.2YC1\EA[)4M+A6 @/'MT0 M(/+.PTE98!X21\T>;YK.X50"@QR*0:U1.G/3^098^.3;EFV0Y6OL[1:.\05W M:9/AQ6-"7%(4C8QWGE=Z=!KA%RP3Z2C+'N C@PIRH9Y?5BYW2%EOE^#9J MNFG!?(7N#>\[VI<]9UIO8/M'28%(!=8+%F4#$O[[1I,P3ZE7!$Y^G?IS&Q32 M,<6@A!L7,#C;=P1+\E_GR@OGD]:0/JA0G$KNZ.(B;S*>@"/U>^/%7H=KEMR/ MFC1_!PW,5LRB#[S2O);F$Z2*'OT>4M_,,W55( ^J 0/%S# M$^XB[ZS DC87&X4/"!7"HZ3RJ!9"50/6CNGEAD+E-7^\EN36XJ\7)CAIZD'U M5+&+BZ/[][<%,Q.YAF=C^+0 -&V#*H*IAV#XV"@("4D/KK]!IKVPD<6JT\)H MWOP)@RU7+$*T&F>/JD!04K54 91")Y8=C;?80Z;APUHDQ<]QV\=K"246^&L@ M"T,>V:#N*%U+KPK[];%O(M:9DRDW(ADYFG;%DO)\2Z?WX3H'(YR'GV90X M(Q"&T@PS)NE][#B&IZUILI>2,*:':#^666[ 1:D&H$/[]]"VHJ>V\1^0:PJO MR-S.+021P0=HA#1KC1,BIV@3%]9!$P\O/6.MOVQL+T[U2R8?9)SS>ZH-6"$F M0#-$7D[,5&P/32F W>C!-^O% M1%;9S$J(< DA8:<$3O5\,)&9M?MFW[($F1 M7?5-&?3<*H)?"X,5]F@J&F*YTIM52-;1"R5&%[5%+D9]U2YN0/(/+AGUAV<' MR#MD,Z%%PYBV-^TJT%-]'(29:,;94S+F):3"(/^()M7 ]T-D#=Q4)()8] MO M%+71+,T0A.PG>;G-(HT8[<28YL>@^:S&N>AT$Q<] M$IWV:P50(BR YU@5(@-[V/7),3P^#L0IV)$U+KQ-\H=I!9PE. +1E>BFP"9" MED^SRM+]/J9IK'<[KT6]8R[3,>*W ^QS60."E/6D\IGN*++3>Q)X9 MVZ0NMFA[$MV.@>XM@568$Q!%:8Z/?"^IOR.[9_BKB6$+JU5P@!8BR>$%Q%*: MCV1/<$1MU_"CA*<;1%0(%3$E'\91H',K,!3F \2O8K_*GB!ZSC4=0E3>:HJR MU&9;JBUR)M&@?*4%")YHVNCR)Z5_]YP,B%@]9'B,XU[AH=0&\CRNX/ML-9#> M[=\Q0WXED!<9LX78%V37V#BEDAAZ1/O)[!JT+W=TF M[?RD(3_A;=F!6S$=*N$1G!-EG4> BMU]/;IJ1-:#BUZ09]H^J&GA#FJ#(T([ M>!,N.R_I\5P:AX%/:P[9[K+@2DOU5!NM0DR L,GS[!C;*$=3PN;.8]'#/FMS M9/5J!5Q\!D"H4KZ81G/31]=FP2ZA%JTX0J85\R@+5%[;&B 14CD"RP"+D YJ'&F[VI (+JX3.$-!$$^_^&I!^V$0XJPY M'A,%ZD7:EG'T+3+,HZ0D \6/OX6Y@@"6MB4>\[R-IJ;A:$'/\+PM^27GP890 M]_;@*E]8MTND4]C7HHA>-JQK=CE\J&P$?NDZD,BP@ $D+32U?M,2T-D^"@Y,22W>#D7 M@A_?9JI6][[H_8>AWAG?=H:Z-M,[^C\G^HC\=W<9^.<4;_71/PLWFUC8AI,^ M+0W.)R&\WQQ&O/H/+:Q:7LX?)9*C3*U!MV.EJ0VW4TSNS+[H^[PQ& MM^/IO38?C$>=J3[4YGJ_,Q_'/Y%GRHEFGLC2(*4DGD_M(TGFN?99@K@'4L A+6'Z6!.;\'W*V$X MT+J#8?S+)C@\@I!UK__QEU-63G!(7^#71V_*D2X6C_#Q_2G=NZDTT:9SI2(0 M@ N;C/80OO =RHY&.*P?L&4B640!?CT9=\Y4I03\,!);3.GZW.\ M&+@6C?^E_@PPT2305(%$DV7 P#R^FG'B%(7GFQVL(J8H?RM[,\0-4'=:-749/5UK=-VW"9EU GK9H.>#AC MN6 F$U7OC("0;\DI!WDC[!+RT8;:IF[0MXD=2@9@W_X)])12+*$".(19 T&2 MEU+@WR:@LA++I,)X2VDW&)=XRTN\Y27>LK#FTU^0&5+W1V]EV-Z:8V8 K1]_ M43G DD4T>+&DA.;BE<;(MI55<9>/!)MD" =YQ7;WR?+3#[\XM9K@+J_"/N"* M1*%LO&D2>1HGKZVDVDU<">>^"\WA4B7M?QX6*FO_\_%2M483\FSD=XN5@&=T M:OX,S%\AN!CQ\"E7VIF'5I\:+S3Z*'P9QWPR]1/0_%7H)J8H%$I"GJ*0/K0> M8=8TTTIGZ^@ MCQ#D7B4U6 =<*JNXBB%M5*W-#>?[?;]'&D9WK^SKSOS&C]>?Y+L=X86!Q>@' M==O%4*V"$G:*XTBQ#V\@X2IAFES8P3^5,]/D)!+_0\Q"J_R.K5-BSYO( + M5G:ZNUOL39DXG31L&S2YY(-6B )H](R-'1C.8+WQ\'-\_A$")Z=?B[$"N5'N M]@:RIW:IA(6JO108I&V@%F9-.3]H]+SHL+7[(MH-[M,V_'B<*'?^'F^BPD+N M,OW\CX%47O/6@00S >$CK2[!,:UQ>N#%@X^HH#:7YE')K\PU)0)AUDC>':,$ M>K<-5W&>X&L]66CJZXV#MPAUD4OD&UUGYE?K@B$5'J)MN!9D# 17FN*I!Q*4T0F4&@&D3$5585A9)/Y MP,HF,]5G\^E#CZ:4&=UU>N/9O.D<.:F4..2@C4V; A@_-BW Y$=FNJA4>AQM M-AOW!E$JEV^#^1>. "0YKT\8)]L&^1TQCU%F(N=YK45ZR\_LDJ(RHC!:N!', M!?*Y< =1*(N+.*B,3"Z"4FM!P1I0'+S .DY')8+K1&$ZO941$HI"%]9Q:.X1 MW;P8+4876>%T8E+/>R_ X%RE<+HJ85([C*Y2*!L-HYNA9W)$H&E6R6D;;0PO MKA5.]PQF1!VWGZ3B-?P%@@LR4?7N![UH_SVT@VV4]][73!,Y*$7-L8FZ)YO] MZ+WT@+*J0!3"[DSV*G<- K F_A([2&MC)FZ,'H]Y>[EJP/#H!_64Q'#5%&/) MQBUH"B:M'V\D+9DS['N8#P@AB7'Y:2Y7AK=D^5?S6K<>H",^E#/(CR(K4U0+ MAI*F>K01*#8OX'XGR9\'.KB8F8D_93,3PQXLZ=F)9^&3CWX/"2CZ,\U/S_=? MP3TD^:R.Z>$YIW);*^.%XL%QZGEB\*Z\B^F4>/(I3OH=J(,\EQ)+_FRH3KA5 M2$7E4,IS1C"Z2,JSPY$V%QMU?455PJ.RKZ@B"%7-OW-,+S?S3E[SQSSR&S M^! 7-4ZXQU<#-!; 3'Z^%CQ4,49X?*\$>H7.5CQV7N-YN(4PI4E7 MSKRX(\S3,EAC=XZ\M>U&OLBD_ XCWHC1JR40<5D0./]6X6A]<+%IAAL;6=&G MX55!6^\ M?V.* MN+I$?Y&!EK;N1,?GL% F:*P')JE["$H)!9DB64G\P(ZB$K3H8I:AXN MZGH\JH-&97]')? U&A&3[ I1(A[[*:02/*;K%GL/LYUQP[[++S66I,@9[MK! M%?!5]09Y!H83X[OM!X9;'9+ B+*B-JH&E,4>N+U* ';FV4/#_6Y4!RPPHKSZ M(=4"RV(/ E9>I9&LU99FSN]N$S88?F?A(1X_RD'XG&-',>:J]FU"T8U97T ? M^:9G;X#'KE&('[-3J[ 19$>Y\T/.]D'IOC=>['6XUEPW-)RCZ35!WH[/Y#4V M=QF>,WBK)D'%;%?M6*UKLNSVFWLC,%=1S%'J[R7GB,"8KVAJB'*KF@?XP/AX M$3WEOWHZ?W:8:)4%U48 W_ +ST]M39W%_,.L-Q[.':?0&<_9%F^I7 M76VF]SN]\?U$'\VT^6 \ZFC3J3:ZT^_UT7S6Z?YVU'"B_49_W]&^:=.^[&>9 M^2D04F)+I-8]%9J Y[F*L66[I;D\^! 3PB[KLS^AC#N[NLD$^KHKPD-Y/WA, M,C>Z[Z29 E[OJ@#"+#Z5,V3+:2'AP(R1J+,*">,J\"&)75 M:67@*:H?"95K[ J5^,TTE:0'V6L#\VE6;G=[=?7F:U9:EQKT=:NJ2PWZ2PUZ M^37HM3(UZ',[R."2I[0BBKME(,KM)"O"JR!$,.W@QB4W"9N^=)3CUO9&WL?XW6KTS!9>J> M)SGU?!&UL7^+O06R)<_>#!&7"7RV\ 2<+Y**+0#Q(61>,6Y4%4]NHHCF=+]+BO/1NV0_7R+?:BL*$:;BN_0>1 M8"2$=/')O'BE&U:\TKXHQ$R??AWT=$8 DS8CP?_01%_Z M=##NGQ2OE!3 E"?.[(3D23,S'7,:II^8/Q3 M#: I'PLU<,DVBO8.A&'"&]OKR.RD@-^Q#B"QN 24,Z@ :GE.,$XW.;Y)$S<_F '21>;8LL#BW*@W.9W MAUQ"J:.YEF:MB3#)\28JS$9K:KH^XKDJA;K+-\1W40$(>3U?)3D MJBF#GQ O$'@?*JYA,T)!7# UJN"9JIKJYQ?WC,H3I^O@A5]X_-0"E.O@ M&9H-GQ1[FU'T8NCQ6E)]]88\# RF!6YHFO6E4J=OUF4J4"/WT[N,:Y2^S,PK M=*!,E=S+"\W+"\W+"TWUO))B97R5*]Y;3[RCXN5\19_$J?$D4J#BJ_IO&*V"]1L336\:?($)(<@?S" MG469J'JO N#1UI&)FYR>R.G,*HI.@1%DA9#RT2G*!(A.M:K$]X+4GD;^==C/ MR#\>Y_0$,5X,7,M^MJW0< "=3]H"35^?XH=Y!7615,B^V<%JBIS8M;&R-W.L MDPD7;$']E,<@;Y"&[04N!@RLQ.11NT6A((Q*VB#U0=VHE;(OE3U>+&P3>7Y\ M48<]ZE?L$?*(<&BR1Z8F+#9(TY;*&8LMI^BQ.(]5;[L,;W G;G$= ^B/-2X*'2X*'BBT,N0D>6I!5()]H4(&U.+CD>'A5.1[:D4 IAU<5:^G M-M7'5D $TPY!]%$:1)>JQ4WV:9LQ)>J)H;83V[C@='NUQH:0N'+>\$B' M=T)3G07I6(@3^WE*O )G_2QE+%DO5VOXW.O=%+6(R9H!DH+ :HH M#:$&:$@]]0<$@5PXA;KNN3 MKV\JU2RJJIWT@ ^JUDE%OW"90CE3J [!@"% K;."$E-O+XKC\TL-=A#[@Z]H MWC4A*/#VN-J-*Z\L1.0DMA8J]G M^*L9"@*'D+/&8:[SB'9B]GEEJ GP"OH2*[ZU.GP^?;UW@LUQHU<&1AYSH/0K M3BUS(/<.8XN^#R>;,3HV1?TYX<\W3,IKU%[;;#P4M/K=%OB#KGB%9\1IZQ1)$( M^D: ]A$)#1P=N#2\TJG:H.S &9SRMDHJ]]9/GN?,C1=*\#Y;\P^Z^3.*N/W" M*N+6UV_UZ53O=^;:/SM?M>%#G+.8%FS[IHUZ>JHHVX'_^GB,DX[3-.)=M, > MBO]-..Z3__B!;6HT&9]'L'09'+]G<3P8]<;WA*_A>#;[KWXZG^NZ71 A_ MZ?3)3[/YH-?11OT._>O@;M2P& X9$G8B(2*8$(5OT^BX+G+)1P.& #ZP!$"3 M4X]'^F@^2XF#PC^9CK\.9E'*ZJX^TF\'\S\WS'=JBFN^CP)J#*4BO1@ MY-ILIA/6*;C#@=8=# ?S@3YKF%%]L4 FS5*X1W=*]J+C #4&MY^8=1EO;_7> M?/ U/:L[4VVN=VCAQ5&/<'R8F?WYC4?>UM8\B2?QP02W[Q./E[#CS)'R=_?VRZ5(_0 M1,=Y5()"E5R(E=KR<61RL!4IM)MMWSZUP6$(W*_404JL_&I>#YF%JA*_9]W7(HH5%V2_ITFT>FTY=+#K9,8M@2)REDQ1#5X_4N& * M,]5"5I;&(J(\)1>,=:A$/>]L'C_8>/&N0G]*V:?D7X^C_\ZS1,E?1O]-EH[: M(DV3"9^5I9DZU#T;78:Q+9R39JTU;'+95>B-Q)X^GJ[,-)1CO>3+$Y"YNK9* M6;&K;)F4@*91.Z2+@A\(N:EB5?.5[07;L4N3]F1^K=-;4*:>+3^@K'K4T,K ME3$%@?FAXI(8 S<1%QK:"[8YE-=45J9) 0! X&?X$NLJQ!GC2YV.5*P&5+(4Z85/9FJ@8 MVD8MC9[AH1Z]W2<:\YYL]Y9MN"G*V)6VQ#K+RI HOH9P*98@B#Y)4W(TU/B' M[3B#]<:P/3IGA\RXVOSVTO) 57$[SV() DQ>(KG$=GI&UL -#'=I$^T=QTA- M$968[2ZU-?8"^X^(^=@>NX8!+3E@JQ$_BV?0ZZ1R8(X6)"Y=ZHX,"0W;H\;G MA>QP!F_U5*F,?W7O^O078VV[2:BA;WKVAIW&@=.QU7 +\5:UFQ.PLR;&=]LG MN]-^5O6PM\$>X0E>M;0CMU\[$2K FG*GTS$YLALTLPNU+(B]Z&T7V(O>WL/+ M#.[33OP$V0(O&J6_NXBR1.DO]/%)(H"K$6)$WW]^RXK.'L^_Z-/.G_1_3O31 M3/_S+L#YJC/2YPT'H4_1,W)#Y.^A29BD4??[WZ5>9&RGB"RZ@/J-DA@EAA"N M64*8ZE_UT8,^^TMG/-&GVGPPNNLD$HDC\P^_/GFN\1OI.QE/YUJ7C#33[^[U M45ILD@H&1<*(I1.)C$SMM6@0N%AO2:_G#KGD82J[V^2/G"CP4H,I$P]>!.33 M-VSEI2@G(+S(#-D%A>Y<* D7HB6C\[NI4#RA,%1 34>68!0Z3>YV=%Y9G.-F MDJLY,F5[6N0LAS^57.)E %#9U7TV2(TZM[\@PPE6U%P:S)F.[&S#1TE/KG,G M-.916O7& \CS'EDT<'WBT9P5)KHW7"-^K\T4+J>7K%K97%&+T T*OM'70CWL M^MBQK4B1148+_)(+:MMF[<54#@9*J MN0J8%"W8MW=8[,P,7JD^H$/3VEQD00">M"SARETV)"ZF6\(NX3*@^O&;':QZ MH1_@-?6JF4YHT5LWWR<68I3X 4:LQ&"R(N+.\!:4Y5*Y*^O]/*5I9:E/<>=> M%%B3IUU:B".;%P7/_XY#9Y5KW1O>=Y1R![/.HE"?%N+%84:YK?4.N?3NF="K M66LB5S^(4Z)P4>-T;"%T(AQ5?7E;185A1 A9$:K[9,MW\(:RST6/V:V%V/'Y M4>Y6MX\V'C*3&!#72D<,P;@Q.K40-1XW K>YK8QW;!]2#$8@D*25:H[2AX=F M$'HILRF*SSM0WUL9WI)E0Q88I(5P%N4.PEA:X89,L(' :> UG *$K/^R90RJ M0^40[B& RZ%QFY$YX0+"IN*B! ^NX43M:6;;))B-L21H'U:7-@$@Q MX0):8 MB25 'ME^X_F2$#O"+MY-I!%BE"(5Z=TF$(NRU=#U5Y$]C\;UI4D]XH&Q_3'[ MM1!# 89 ]"2'L=-=>^Q*^&[I%!HUNM,2VM=D7: MAQZUR[N&;S.257^^.8V-O=4&TRC[>A0=._^B[[)4W^O:[(%FKJ8YV3NC\>AJ MJO<>IE,:&=O59H.9[-C7O4BZAD/ST,]6" 5W'@XW1 ZW!&;7M.,',M'=9,^( MT_)GIE;. [6S1Y;T4F]/]S:/ 1DJ'R*;8B;9+Z*H M.+I'L(-DN1VE!>(4P@>$EB4-A6[&)E0Q1J_]=J3O?SALXKQH@T*#R(FJ%44& MEV<,O$23=JAK&EPEPX*:F@"*A@Y%K]%H^?7(!MX5/BPQ#PH.)"EPN,R*Q>?R MJ=RNGIKL^Q^_V.3@XIFK[9#>1 HK9V;_ENMH =DH%!.QIS:U?_E9%GAO+ H. M(UU=BX $(%Q$4"KI;1E(MT1WUSP;%%7B>W('[B8,_(CE:Y["9G22]=:DW,H$ M\ 384L\7GT?Q31GTDDZ/DC(EU(5>FBUP,U8*O7=ET$LZ-5YUI6;TTFR!.Z.C.]'\\T/0:-%G'7*'JBR?\"=PEP#TD!=L?T\-+G)';6ID[ !XU,*%1V(]],&<=P_?'BUF S>^"R9>R M75JAE7@<*^203I/(V_'RVDK.KP1*&',I5T\)G8>%TFKG;+Q4U3C(LY&O38,TGU"(C0$#*S%YR$XS) -& M)958?5 WFD'P0-1L97AHA1WR&791'%87&97GRZXD7( E$ YIB1AZ>+W&;J1I M(YK]I!3M'P>/>XZ!"'>25>BYH!^6QX' K4;3.+G/9"X1$2:65$QV_.L L8K= M<+NV!C,1/M3S4414CL. UG"@N:L8QOMITY8@DT^WY&4PC62!DK=_HM)]/*U;I;KA.7M@-;3_PY=S"QJ_Z]JX'[HFI0V7L.MNJ2JJ W]6L?X5^$,4,U?^]@YU=[\&ULY+U[D^-&DB?X_YG==XC3[*U) M9IF2JJI?ZI[9-2:36>(TD^20S%)K9&LR)!#,1 L$V $PJ[(__44$'L0C7@#) M",^^M=E65='=\7/@%QXO#X]__]]?=A%ZP20-D_@_OGKW[?=?(1S[21#&3__Q MUK0>3Z=?H33SXL"+DAC_QU=Q\M7__E__]_^%Z/_[]__G^AK=A3@*_HQN M$_]Z&F^3OZ"YM\-_1A]QC(F7)>0OZ),7'=B_)'=AA D:)[M]A#-,?\@?_&?T M^V_?__X175\;V/V$XR A#ZMI9?V\^_JK48E9$>N]^^.&'[_BOI6A'\LLC MB/?MES3XJGSY_ V2),(KO$79]XBCKQ"3I/R0^O5#PU:A])UML$M,PB28Q,-0 MM[4=P:=MAV0G.%#7M^[")LF\:!#XNJ9UV',\[(T?]>R_:1KG\; W7=.\".RL M"[GWZQ6_UXC]XXS^J0$1?\EH!X:#$B0SH8C _ F\8RAL5]83OV$W8M$\(5W? M6<_(;6Z]])$;/J373YZWIP]X_[OO<)2EY;]F MB^TZ2_S?1E_"M'P.=_(_OC*0_Z[M -,6& C_&CU6]O.73"%('&F($9PF!^+C7M^X[HWI6RT0[B*JP09L M.+Y^6'_UO[@82K:("Z)?F.C_^??OCJ:'<,GWHX 3Y-W[O'O_M_%X=OLK':<3/VQ=FC% ME7-27:&]1] +,X#^!S>!]G1HGS(CZ)?CX,%0]#56/ ]8*;RPUP[,]QTT[//-K$C?$,ST$8$L\ MKV?*IG@#LBF>/I[GWHV:KTK8]HPTK([I]= ;HWJYN'-FFV-L<[3J*%KL@\:P MF]X,DVC89Y@2>I=A0G%@#%-AE##L!C##RMGPY!^','MENPE)3/^:FJQ+B'6< MK$VHX O7)T0*<)AF@++-M5P4'67/M%1Q,L5Z1"_W83+U*8=;)TA, P189,M5H%AR.C( C9IBN=KGAA,(W'WC[,O$C)%XV. M3>X8P:_S2*D AE,F*-O\.NH@IG0=QJA0@\.V%&UJ50*HU(:#H-&OI^O@^!@D3UCPL9J!#_C. U?\#3VDYUX MZ6Z OM4XUM>M1DPS50;#QKZ(.[%N,9ZB49:1\/&0\76P+*%1C] Q.QRJ;@CV MT@-YY3U^WOLKJ:F0MTE%+>PZ]:3"8*BF0]BF5BE?KJ(6P[;+LBHE68U1]&]' M-M&__,K2]X)#A!?;?(9ZC[/GA X+7G":':>X]7_%F.42"A8@3C=G@XOG>)#EFG?V2RR(L#M$Q2/N&\;."X2PYQ@,DH#B9?L']@^Y_C9R\D.T\\FC)5 MLA9*C!VH8HI6PSEI>L%L,ZC0XQRJ-%&I>NDT$1;C;KRGY^5+-LLTG5!7SFH' M)(/9Z'S:0C"XH4 F['28+*R>9T4QR@;0M=]L]3 =.&6O4OW@_,.+T'1VE MYS)NV_6]]T7]N9N_6_O<(EC5YZ[_".-S"Q!U/GB_ MAVQ]>)2F^++=3+^-^?TAPZ1R2;<]+Y:VO$FO@MS:JA>)@B&6&I]@VYY+HTH< M3D"[HQTJ6]FA3)_&64%USO3TYO7>^WM"^,DK16#K9<$FWP:X5N=@#W4PO.R/ MN3.SYA:*T'>TD0>_%#V^(FX&Y>?Q+KILL\(O.#[@\:L?X7LO]IZP-,X9R%N; M=IO KJ;?*F'GK#)%V-W[YRJ(ZZ"CTJ7793Z2Y+!?4L^?O32,GQ;DR8O#?_*" M$+3SO\?3R:,1HTXT:(UR9W&\XN1)UF"0]APNM%G-;:*C452WRE_8]@J<;>:0425D+?W*(54SKBCC_]&I<[8]]%$33S<4W.&0!LJ"< M8LO#4-/>)D@O5X[;(D9J,#C4"VMGA4W19Q7Z9MQ>5E%&'Z6&S>AC +T>?13BSHEE MCK'-+JXA6-.ZT7[T[D#C,#@37MR'D81D (\SN+8$#"K(8$EG]%003F>=1U25?O5J=M-ES)QHYLVH=9R3JR?0;B9-30TQ/52I0+H* \ZE&D2 M394:C@.8*K%4(0Z&67J,!A&+:4 )5F7_W7',:%=%JN5B9T7C@FAW1:("AVY& M.*5C,@'W+ W(-Y\3_8"\)F1]0-X!V!F05Q+.V:"$)?WX5/#B*]LQ+A^G6,GN M"ME;N98!/*Y4MR5@?&T9K,Y*-)UU55\49N:RULC(ZN%7-&)F@ M<]*8H.LDP-;$H(Q?YTG\H-YF:$C8#"L":/5@4OO9.1ODF-H8RVE+@"&!R)4G543)@-J+KO":49"/RL*+C_$89:NU@_* MZ*#1L5LGU !^LURH0@$,ETQ0=HU4MR0D$K2Z12($V5D4Z4F!()(76F?YR051*7O9HQ/K331.8?!8L%;5W:9,: M[/'>);&<5NV"A<$3\DLE:3L51P&TE8 M(D'G[#%!UUVZCZAV0O(+LVHZ/-^O_O<\LS1[]F+45+IT^+G%C]GHB6#-.5:9 MI,W@HX!:CST",>?DT6,311XFC2KQBV=25:7[?_(8,Q5LD(K:RYU2@STF38GE M8!!"#4YQM4(A?FE&S,,X>YXE7GR?!.$V]//3S_I@8:9GC2M]W*B(8Z($@T4] MD';68I@J8KJHKGR!F'-Z=G 2/V68[%A,U*S6B$6MY@,KP#82@05RSDEE $Y8 MZVI#97F7=77.-1U):/J$GT,_PG=A[,5^&#_-DPR+5W'UXM8"D0'H*OXH9)TS MQ!!@FR6%!JI4$->Y="\VC=,#[2W](U0Y3^2RUDBB@ULQ1"8(@QX:=-U[ KQ M&CN<;B@N21(<_&Q!BD1TR5ZB6,S6-J(*9+F#*))Q3A$-L.[EAER4SYJK@P&7 M[%XVV'^.DRAY>IW$+)LSJ(JJ)-&!'SN7QQ!S76LQI:\[58PQ571.J"%H.T?D M*G54Z*/2 *HL7+JWHE3?T@?R>5Y!=0775-+6V*6'7/%)+@J#05I\@LA4*92A MR0)'Z+R-]I"L$)D74ODG$Z;H="SRQ0Q^C35J!2C<,4+995"NEM=_RQ6M,:E5 MY4Y/(XV"JWJ%&@(II6&PQP2BMIZ@+=H,*(0)I]1EWV*6;Z)[K\>]/$4@%P6!F7T #O;F;D&8BH6J;+"NR3#2R\+ M&4"*@"HJ5W$T"A;K.!L KQ5R5DC#H(P)Q&XF%M-!A1(Z:L'96RB/;_+E2+8; MDM(Q7+4.=3S3F=Z\WH01']EE7G9(=5FC)YMU<7[WU)<@.N<[U*9SUI_9D7;; M*&11+GS6?9.3&\5#_$C1X: XZ*%.D9<)VR2P&G"=EF)),&13PFM3J!1&I?3E M>^,M)L2+[K!JGBB2LMCORB#6.MNVB///K\;5[59S0<0DX72E-U[$=G'6SQAG MLZ3(19!WD7)QFY%#![H>.V2RSNEC"%!T%V(^BD^VY=X;FQ&6U^J6)JY081A* M_\0S)N?TXQX(85F8AK5491K6:ZFJH7=JJ8K%P;!.CU%<2_6HO MQS^?:48@-@EQ-J!R?LA,0&0/#,G/X$2W&Z\*!D$:_&^(%^">9:@T.I;KONKA MM^J^RA7 \,\$I:#N:X 1Z )5H^#OAS3CU4+O$C+'GPNTM$TM21+3/_I8=[]0 M3QM60^D0]QJQLX\!,&0=@EI25ZU8(HD#CP0I>M@'['YV()'R"+%"F -\__V[ M/[S[H(R8AKH.^GTS=P0=O%H1#CE[H.U#2J9^_>[#Q3?/,,GR;'UV%(VVHD"S M>Z:4M[=]9@#[N'^F$';.(U.$G1VTHPJ;;U=*ER;,AF O/9!7?A9>6>M8)FDO M5U$)]9B9*!2#00PEMNX +1=<.+*,$Y/-4-CW)YJZ6X M=+ ;Y;ADPLYY9(JPLYQ'I5AD*^0T;5"]0"-L[,ZH#?#PU M*I-TS@LC>)T12X:H LHU !8R8"3'_SC0?G#R0O]'LX@FE;8=9A20VT%&(.J< M2F;X.@&FDD9<'-2R51+(NN01/+)E5 0*H'490W:](%1-7+MX]@C8:*K M&-F4LUXM4@2S4RFR+N2<(SID'7X4(A>-*#I6%!CN$H)]+Q6'$96@-5XH@5;$ M$$K!8(8*6IL:I="EY\IK3$* MD+O9 UR,Q[!Y$I/BKTR-Q;.++O^LO)VW3T8Q3K-GG(;LW'289NERK$@*U:G8 MRQ U W],%U7+.V=4#Y =#G$MU%&[0LOQQ4O.^3XYX&#R98_C5)5.+!&TMW2H M GI<-A1)P>"&"II@@Y/)HE+XXL?9GU_3T ^]6'%ZO2UB[["Z&-SQ;'KS=QA? M6PRJ<_*\E+KT!YY\P?Z!53,=/WLAV:D^M%34V@?7@*T^O$0.!@'4X-I$J*11 M*0YSM*N<_8@$78U>Y?.@KI1SPFBAR4:=7/+2L>,N(3N>63Z- TS[HP#'V6U( ML$\-* 8,1FK68DH/)ZKX8J#CG#H]@0I6]';Y&8#KFBZJE"^>1D7G6H>(UVS1 M%[55"-M+H-(!/F9/R21A<$8'3W ':B$/L3:M9![??PD&S)I+ST66M["J8K", MDG=H-9T+%QGTHM_N;\=4D(_"524%)9+VDO*44(])>4(QY\S08VLS(N/"Z"@- M*=BD&3GXV8'5T!@G:3:* _IOF+RHDF:T6M;OJ=*[T+FI2J[BG&+]< IOJRJU M+%3/7N,7S*OM\JVSO9??[\S@*H*0@9+%K4U#!VK;FAH-YQ3J!;.[G5GHH1'? MSRPU$5>]^ +//P[L4BUVGU\Z\GTCB%E%1_9?^KYR=FA]\B7,BB&C M)F0JQ>W=8:X'?;S-7"X+@VQZ@.)" TP%E0/]\P;%,PSILI#P.>V2(I][._5( M3BQL=P"G MP!O&C.-Q1L)'7H"\B?@N M(0_KR6X?):_*%K90W1AJDY?:0P_?KK]% ME__]N]^A8AVGTLKCTZ77(LN(M]AN0Q^3M$HG&,5!L8_LQ:I5F[X6 M[*TY#G+MN,[82QT&%0=A[JPGED:N4&GFJI9EPK+G:Z8NGO3,BK[@(-\88DZO03I_DX=TZ;-=6&0LC_@3HIU;H%3K[1QX7!Y\KCMS@O))R\ZX)O7 M6>@]\AH2X\A+567Y-#HV1W9&\.M#/:6"PF M)RG$G3/('*/R#H)<_6+W#LA6:_EL8+'G>09YYI9J,58A;6^M50OYN)0J%77. M&C-\G850KH J#6@[^A]Q3)%%=(8P"G9A'*89P_F"BR.5RH-,AKHVHU0O=^KQ MRDC1.0>'H.W$FT::EE.) M35UII1/KU,"PTARK(*V8:W)2UG3A,7*-^45X_.IL5J22_MF$CGHUJ^7\#)UH M5/;3Z(!AH2'0;EYR?L-A?KEYH7AV_DD&=7-V U::+N(9]E*\P82&93ZH3!_B MQ/><%HLZ#7R]Q6CP+.:MS9LO,!+J<:99[3MG/@7/_CI=;T9SYSUS/AW? M>%]&A^PY(:&RLIA,V/Z*B@QP=S&E+>F<&T;PVGPI5DVH-/I/&@W2(+1P@/4. M!VS.HUC$;PK86ZX7 3LNS-=_=?ZYI9 ZB^VY#)Q!.R7;$I,P"101H25C]1(X M$;S&I6]U ><\4*'JW!E"FWDN=-D&?H.SSQC'M7R@S7-(LM=%S,XG=OYY$CX] M*RIHG&+-6N@XW>4JS@PWY9R,Y\'?N>X^-XC>?__A'1^_TC_\Z=*30%999AO& M889GX5:Q3RB6L\8[%7JR$W+BX7BSJGCQF^3B@II%%-_+)]X=@C>!PE!Y;V=4_[WB#T MXMK#%>M$IIKVRDCUMK''^#P8 N(&':P677R])L3_*NA_VI=LT(_=NO\_]LX:[^U0G])^3U7KRLY/;85BF>!*% 5^@G69X)\I_50G: MNAU&#;2\'48LY9X".FBB"H&5,.+24&XEJ[)4UOB)WWBMW-.42ML<5VH@U\>5 M$E'G##+#URD64F44E>)PYB>U5.][?F5FR2 M<:"+=7+V- &&K,-P=_.+P0_)U& 51>[J.5M M;M=J8=>W;:7"SEECBE"PC5NHH+H.G*!4G2K<>(\1EK25MI#5\P)"@(W3 0T) MYU11PI(?ZOR%BP$BQ"R,,5\AUOE7$W1"C Y0(3DJ*7@$:4-3D(2)YNOVE]F* M"W"8DX3^X<@-^I=?;Q/_P-E,+;8K \H(F';;)$#;O.E M*PF*,5)X4LYP#52HP*'-Y(6-SNDPR=#9FKQ+\G1@J_A3"8.E4!NA(8NX&F)Z MCIB4GRFEPVRBXU!'TC9[)%#;O&F)@6*,&)N4*\6!7R[OGB23.#"B2"7GAB M MF&)Z%$( R=%$IJ/&A)7Y,NS#UO2C'EHPN2=D&1\(*2!6M[C MR$5MT40'MN2)3 X$433@.B>N!&K-?+EK_A5ZE='SBXG)#";I&@) 6*%&)F$%H4PXM*( MBCLAQI*$.X^\KD-?TU5T!>U20P:TR8VV%"!R2*!)V%%(H_5T[+(GV7A?I@$E M:K@-\_LG-"R1RMLEBP9VDS,284#442.4,(@5Q6MJN202*\A)]DDMW6&:U%*J "*8"4X)S1JJ5WE."DH(*@P@9L$)XT9!0%C]K/P_ MLS#&[Z3^"V7MLDL!M\DI@2 @)LG12?A32%Z5?T!,!RUB**1YW\/5]^Y)\]Z4 M-.]!D^;]$-)L/B= 2/.AAZL?W)/F@REI/H FS8=!I*$?WFFL&=,_+L@F^2Q* MSI9*.J%,%ZJ0,$'3I8-.1A2FP\0Q3<4D3/K!:D"5)7L+8EP^99>)."",! M+61-2Q8>=<0 =?RI!L2EGM-8DP_*M8VD%',399H@Q2&FN# $'$F:P+3!)9=V M28EEDF9>]-_A7CD1%PL[H8<0L) D#4EX5!'!TQ$FUT%4R<7$NJ KV] 0'B5K M_6YMMUD$J]IBKO\(@@0B1-WRG?GJ22YD^S,SCA+L22)"\V=K'UD JOK&M=]@ M?.(NH,X7YNV:RKAHR.PVZ6CYG,3R!(&NB*TO+0-7?NWV[R"^N 14^ZMS,<3E M'*W&?\EPG(K#=^TW:SU[&T[5D9<_@/BZ;32=;KK\W?+7_(F$&7WR.-GM#G&Q MRR/*&Y3(V?K*2ICE%Q<*@?CZ*F1M)A2RJ"ELF1;K) K]D)5MOJ>33Q)Z(J]$ M0K8((0=8LJ$K 8(*4EB=2BZ5("HE+9-@23 C(:8?@A\"Q'& R6*[%?;V*F%; MI- #+LDAEP1!$BV\SNVF!%_[-0V4JR"NXY8VTS0]8-*+/ (51Q22@I<0J2,/ MD4XRD%I2Y8HNN;7&_H%=W/KN_>,FS#I%Z,0BUOHD";BJ1VK]#H(;$E"="S+9 M;RC9HG?OOW[\!I5:EC__/-D0+V!73[SN'I-(4GU**&6+! J()0\$(B"H(,?5 MN3$H084HRF5=5*=J@!6XT_K=%@&$L,I/W_@1Q$<7(>HT_L:W=A3R)U_\9PH* M2PXDB,5LAWX1R';XK\N H( "6&=24HBB4M;%@81CE_6D'P0\.1L$/&D& 4\0 M!P%/IH. )V>#@/*Q>8D0&I<6CU'XY$F*$RJE;9-" ;G-#X$H**K(\4EC1J6" MCCJV*UKR$F?3>)N0'7_^'?V#P$N)G+6:EBJ855%+D1 (CJB0=2UW:7DK/$S!^PE'TUSCY'*^QER8Q#O*U%-%.D5K>;L:,!G8S:48B#(). M)@@EJ3-,Z?HWIH5*M6(ES F3/B71(L 2,6MSR<6TEZ-:I;:$L(,XH 4?4DK++!2'$)A<:(H"X(,(EX0(71:6L$RY,=I@\T>[M(TD^9\]%?5:I M;Q)IN]Q00FYR1"@*B"LJ?!+.E"HHURE+ZKHASY=C0?&\RJ+<4X&H9=I(P;8X MTY!@9N Y;(NRS]99YDJ%-@AY2C+)GC'@Z:T#_O58)/K?CZJ81WV<'(O)1 M>1QX1$0AE;#U6T>D@#MWCW0D01!)"T]^#TFE@4H5RZQ94 Z3^CR.@V!WZ4E/ M.^A5;#'(%'S)(YT\"#89@FQSBJLU)]=*UB>4PS_W5)$A]CEF655M%*M_YFJ&V7,[U<:K+)2!40S_K@ ME3#P: +5;%S5>BR7BWDL:9Q5]RB^:3U%-V]'\+#U6 <3!S>L*;S%AYPXV^$MV0Q_T MFV*&8:!K>_9F[$Y[,J=5!$'"OFAE4[T4U0V@1Y8C5IA OS CB%NQ?7_YU-\2 MGDB2D%&68=HT>!*3^+2!2M@6[?2 2Y[))4$02PNOS:3I^&Z%"@U44W%Q(.%X M+PB-S+ML0DA"Q@GMOGT%?4R4[-_-HG.@>TV+3 ,$K8QA*BYOZ222(6X&'>V@ M7Y@EV\$J[]=G8:HT M>C A-+UU\YTE1ZD:OUK^QJ*#4[6?('U?Q3&I\NLZ.!Q5/)J5"9*=X^_^XXRM+R7XX$*/[AUVJ, MLMA6 Y=EDN_#CA[954)^>UFQGZH-R@QQAG&ICYYSD@T VSE?50U(DVUMG%IJ MHU]*_?..3(?P2:&&"=54T),/P1PNK$J?5ZLED#84&QL&U$ MAHZL?4Y(X':IT1($QA Q.ME-E![7^;-SQHR]]%GB5OZ333[4P=0_/_MW,%^[ M!J;S<>E/SK]HD>.3KK"/PQ?O,<)SG(DW/,U4K$8$ _"-P*"0!\,8 Y"=_J10 M0:320=?PNQY?$BS9(<)#X!:EAEI6@TWYJXTHI%>#0SU MS+%VJUSGFGE/Y9QVT_B%8DW(*P4N\;4I8I-((G!UQM1_!T,- :C.%E IXOSS M%TF*92Q,M<%&I6"3&GK@=:+(I<'01@M1/>*EO1C!$=^3WGODS!5NAC!K2?#> M"X/)ESV.4SR* ^Y@8T@O>1-&FC:YUL.5.ND,U,"PSQRKH.0FTT0X5TV1%P7\D#F=0L*S6.[Y3/L MI7@5/CUGB^T#C;&L MD M>WV@?P$2SZ9Q1B&'= "9AV3::"9?_.C \F0_)DGP.8SD\Q835;O3/W-GFM-" MO1X8)O8 VYU&EJK'20"$D*3J2Z8&-,3<.?.O^GH M9CJ;;J:3-1K-;]'ZQ]%J\N-B=CM9K?_GO_WI_;L__@5-_NMANOD9$E?-$CQ4 M"H[X:)#J(9>&R+E^21_14=%]YD>YQ;ST7ME"OEF&0%O816Z &+ H*Z I"88_ M2GC23(!]+NV<-Y/=/DI>,5[EVSC=QB#QVD#/)IN,W:@32ZL$AF.F2 5T(P<< M(#_9L7T2&$G7!2ACJBGD+0Q6S!(+@Z&4#J&,2N6.FW,:-1=32S]>U5S2 M*;E;Y)8Y(%_E;FN H9813-TZ=SFZ>D5?E[MWO-1'$G_CG'JB/"Q# IJINLZ; M,R&CB1X82O8 VSG:S"HM$!KY"'[!\0$#Y.,\R;#9R%\H:9-M"JAU<@G$P'!) MCJU[_2.5+(?Z 'ES&[Z$ 8X#,^Y(I6WR1P.YSB&)*!@>J?%UPE A#6;F:#Q^ M=SUP-QNQ.QZJ:Y?AC0?JS8RGVB*5>\8D\=,&DUT]@,J\%8I:98T";(,W CDP M(48!3ME7@:'*+(SQ8CNFPZ]0&EZ$HBZH(@(KHDI=#AQ5!.#:5+E)"$D^LP*, MZ,!ON*?V^'6G/M=R3A[)_%.?*Z#7 [ ^H,DAT"F!(9PI4N.% N>\4TXRM>PS MU@:S.*!FHJ$J&#[VPZM;)7!.QMIX43^B=#8@UXS$P0[!E6-O2&-N5L8VS'@- MT5$<,([3R(EC7TX+I8;=V*.%WHPW4G% ,4:'L9-LL+B_GV[N)_--GM(R7LPW MT_G'R7S,DER^GB\V$_3N>_=+2;VSK:#D5_7+J'H#.52]LZ;D65+NTUJ6I.A7 MN5>\Z*/$;:&DY?.:,JBM\YEM,3#4D6,3G+\LQCMI7B#]?WS_[???OV.G@-$+ M+\UYC;Q#]IR0\)]4Z(]7WW__/?O_*.6%U+]%:TQHT$.C*Q2R*Z*#_ #GL;PZ M^MW5[]__X>K]AW>%"O(R=(M]S&ZB01_>72'&%:[5_M7?WN#W^Z^N,/[_L_ZXH.^-(]YK>*1A"F(%6]>U5CZ8K9[MA%(-N] M>5T&3!N1 .L6W.#7!QBUC@^_[S2/:4[;=W^X^N$'VG@^_#[GZ1^N_O#^^ZL_ M_3"@432)^FW]*@-F]_WO66/[0_Z8WU_]Z4\4S[] >Q@% 2_NYT5++PRF\=C; MAW2(+LN)D4E;S3-20VYD&8E%P;05-;Y.AE$EC=C9_NLP1GZNX)Q&*YQY88R# MB4=BMNXY\OW#[L!S\>C$/_2EB],FBC;)9>Y(G6=Z+3"4,X8JR&\K!5&02SJG M70T3/U'%KF C^!G'*8VN[$:0'9XE*3N\N=ANO"^R5MC7BN6LRB$NMG(M^Y@ M0]5AN%6\+0J@U.V@*#GS3=9#B+PAV$L/Y%4[,!4)VJ2C'&B=<5TI.Z3Z(2=5 MC)]X%KB"6U*$G2-3.$W_C/[XN^_I].<'1AT^:LU'?<\X"A#MA;/"V!4;!_I) MFO48#SJG7G!&E@FNF-8'K6)9+@V98 Z(IN_+]&9#,DE_B;*SEFF.2:YP-54"S M37^1LXQRR84N<3YQOZ[GD,Y(T]&N7I_!G($:&!Z:8U5O!\(9PW7N1]<.X)0: MCOAF,G13B$/DE^&@K".VCD?*X9I4VBFOY ,UB2A3AU6P%9";A:]%HJ"X9(:7[>T-9-& MQXMB 5T)N\K/%=W1+R4ZJ515[V;E6NG_!?)\D$&6["8I#7:UF;74VPP8W@[' MWCG7/=F@U>339/XP<<[AZNAF<>./[H9CA;R3@[@RV,(#N&UA,-S2(>P3M?MS(94/XR3E9ZE*7W0^=^6=,$D&6\BDMC \)DD0=FO8 M$.QG**E.<+-D(O=#M#6.(A9+X^#>([_A6M.0);DH%*RF#&F!-U*'I-)@"*6% MV#F[EBOPW+-=J>*<4!]Q3!D>43=&P2Z,0Q9>V8$(-:NT6E8O+C%SH7&?B5H% M#,G,<'9N/\FU.-.\AIYSNJUPBNF[?*8>W=)Q8Y3PF\C49-/HV!WN&\!O#NP5 M"F!H9H*R3;)2A[,L.&HYI]@MWM.N.^0%I%G#V;$2AO_D?Y6XK]2P6C%0#[U1 M-5 N#H9:>HS=\B1'C3R$U72^-C*<04#WG4(QY.#.E?KDD[XTH4J9,Q1 M#"AG.@#E2ZC3^7AQ/T%?SQ;KM?NJ3?,D3II.%/37+,P;Z-DM*F_H1K/$O$8) M3&]HBK3#NLV/DY7[M?II3+MAVKOFT/E19^ENK4#2\MW/,JBMJY[;8F#((LGEC=XFY"B M9,?&^X+3R1?:+R:#^3[**OKIN- M=I''P9IY7-[13N"OSUO0S>1NL9J@Y6KQ:;J>+N;HZYO)?'(WW7R#Z _E)&*5=I@XE1OR)K3QB@H3#CG:*-EC5Z\,&(W M/&V2V@&>HF#.C9>&ODG[-+'B+/"9NR@-C7H3@(.G,7A1>&5A%8TVF]7TYF$S MNIG10=P"L3L(Z!BO7AS).:O+^I[EN6L5=R6R5N^G5\%MW$DO$@03)57H.G3" M&2\^B?9Y3AVS Z9-*SR5)IES1J0581J1 %2Z4FOAYD"G)% MYW3Z"8=/SQ3(Z(7.P9_P_,#J8"ZVG<.QJDC5TX9-Z@URKT[(7@; T'0(ZC9Y M2QO77FZD56;UD-)!8Y;PNKV4R7ET/+*=2T%E=]%J3<_D][8"@.$Z%PTX+C,! MG>4:W"?RO COIIPF>>H$EYEQ :W^+\\G7_=4.\.*4NYBGX_&]1 MGI!?+15I[F6XU,.@4/[T%V;:0H8_Z4TTJ)/=:[>_PB#R"XLH.QI!7F7%>7,4 MO ]-FU)J6*[YI(/>*ODD$X>UU*@'*KC!M!;FC0];YT#_Y?G+@UR*O&52/! _[ MP,O:F7PGV+'!H)/=9 P;;,3YH.94Y)TNI#*%,+>%DBT=IS!K\1,:K11L,>B8R@'SFD% ="(1.,0QEDTGO"6$GNWV4O&*W9?VZNJ'N=N99?0TY#R/G0-\I9L43QXH;ZP\Q[=]0]HR+ M^_ 8VW',QT![J@65[GEDE7HNRX,<; T Y4U=-B"]SA1TVAOB/X7XYYJ;GMP M:BFAFT1RTSE_'X_4^X"MF^$XY4NL*^98&F9XC AF3*YJ;/D_WR6D&-/TG(K*; !@J=H]T[#9,0"=NTK4 MG4%I_3HSM$T('8#F"E!)6[^Q;3!KI48 T%;CH'&@?7/$5<,V9Z[CC8;!:31V MMQSR%(E)K)PH*% .2**!EY/B(G-)]\JE("^7IR+&7/K-UNW[K'%UM M/ M,I<,UIS:JG#XUPMO]UJD7![MJ0R@,W_5 MEBRSRXBY+/NAO;U"IV!YUZ\,UQ MBEP>#,\,0'97X\O++.D$GBDAK@7I:LLYSG@+816? AS5L#P=S!T>4'MT7@S_33=3"'<2MC8<&.[9;$? M1KB1T+1)SD/URSS*V=;OF5^6=+OW3,\!TZ NZ%R[R=4>Q4YQD_)A?%>WD8K' M?F;_R/=Y]\6#T>-K[=H$KWJJ^U;+5[_[7W"E5[-^$+/G55^AMQ7(-VR$NMFK;]C$!+5P-@]^-7L5.*\FOA'?.W659 MF/\RJE*Q>Z:E!Y\6BV[EX\:N="\@%2I H9U9C@[>SGYKYQV01G: MPJKL-P#6R:MM?/3"F,VH5MB+PG]**T7V,6"3B_T=J]/27!M:$FAOY+)R*?B+ M_TS_G4YSGZCB-SQ,.J<4,*N)/BT)$$PQDE/-,#$V NV>K.9*KEP^(8B6:U MNH\!MY-4G6/J^:E,&PPO>T/NE.+@/6!*AVSUU5QV,W-^C7)43&=!K.QVO2VG M12OLX_"%5B>6%O)Y_ 3(TFG\@F/ZH%":=J[1<02KP"IQ??RCIO0? !A/F81*CL>."HJ]LM%!>^57Y-CL.:7L/5XQLPAA%]G#?;'AI8!#PO*B_%]*1 MZ#XWP>='"6\+M5F2\P9AGI-WFUHP^7>R#OY&475M)2=VM@7RGP M@4O-"V4N'J$7"\)L8W2=;+//'JE&0=,XHVA#-BX2S=Q.,60M^_$D1ZO\R$%6 MH-#U9 \Z*UI'"R@M3-2&O6%E![)]AX*LT!(#%!HX:L%EA!?K 5P^]D\,TG8_F8Z@#7W;5 M9'EFNG&4FO8_^3]@RA7^+YH15R]+;NHN]'957([!V R4T<;I+AC79N0GZ<&P M>X4C]DXVR<;[PO8&69T9VG99Z9\^"5K#S;G@^5"G163O:PLJXP?ZTXZ)E%-6CL@3AHCBW^U',"N^K2#!/,EPNM4M> MHES<)KUUH.OTE%GL1TZ MIAAHS/*!IA,<;AUU&F )S$CY)/B"XU'<&&(OFP=/?0G4HKAYD;/K/KS67\@L MC#%MW&-^O,O@!;;D71%:"%O&V88P2%J*$*J91RURUN7G\IQ3JMY1F%!*(>^J MS]922BH,N='J32S#RG%KEV&WI2JD9=CR M7M-)<2YP19OL(F:>L__/MOA>O"B?]Z49"=D):_8#'84T_Z$F*7FA%WF2S79P MP5=5;S 7> R8D<3E?&NWOLG=W62\08L[-/G;^,?1_.,$K4:;"$P\ MB@/![)?Y'"7I@6!-GL[I9FUW&^=X">U&=XI-,-.X,SG2V1-^6"YGD_O)?#.: MH?EBSMM'+=M]?HLND@(DR2*N,COHR#/R" [F22:XOT(C:RT76 >W2O>5"3JG MEPDZV;T3*0H*^2NVG7N6Y!E9=GF1U\YWYO;\(F)*;K:YQO(A1FEZV.WSBJYL M(UJ8KMS3@KU\\D&N'1/)>ZG#X-L@S+*C#OE)!VX&A:4=GMG"DL4+2V7&P87H MN6+M(&69:9@.3L(LO4M(>72C?FIC&7D^6]$NKFX3O9O!IJP1]D1G*^8.M .# MPJ>![^ZQ<6N,I4%ACU>Z%)_@07MNE.UO%%?Z.1^_K@_[?9Y:YD7E2&4:4Q=V M><%US>T_IMI6:\KUE??EV^ M[#>"I.+F3S8^M @,^[KU?W?^205@.L-U[Q6]I&B)">]7V!C]N$B!?N&JY[U2 M3O^1)U^P?\C"%SSV,OR4D-?1E["]6Z.0L_7YE3!++@B%0!!#A:R30E#*HE(8 M_<+$;3-C&O,S00;CED.2#?Z2W43= SL2&=O#N@Z\]OBN$@#QT66H>HWX MKM#F[ >_](08)VL<\2N+"E[.O9UHB"^1LT4,)O6,M[MO?@5 ME1JH#!A,QS([V".#:@2ZV&Y#'Y/T+E:%#P,=6ZPQAE\R2*L @DVF*#L9B$P/ M'2<4I>85NDN2[!R;07U[(XP)SUIAQPRUQ%)*6^NA])"KODHN"H)&>GR=_HMJ M(*Z""AUGU,EOSP@J']3444I;Z\/TD*N>3"X*@CIZ?.+;3@)TI)##J)-L6,8X MGY?MVFO80@E[T44([1A1&C^#H((84R=R3!:(BS4GN*,=J^ML__N/_.S@1=$K M6VA7TD H:)$-"J U4@BDH'!##DU$D5(:,7$ 5.'K-]0+AD3=PT@EK:Z,R:$V MULBZ8B#HHL:F6#?;)(BQI\X79[W+/(FI"W/*_)9%$CD0 MM-& Z\R"DOB:L67.XLT+)MX3!M,UU5WA7M2BIYY#0@T75%) %S%*( Z.6'*, M)OQJ,JO1R;GKURKW#'LWN;S5/DX'N]'3R81!\,L$H7JWJ,ZU!L<<=7XLR3-[ M_>1%ASQ-KLHVO@VW1;$H-='Z&K"6<##(L2H3H9!&4&4%', 7D&2U8#$9)6IEY5Z&K"W6S+$L>,V2A]M$&P=!%FT\2+I MI%_2;XLQ8LTD6N'L0,Y[-_D0TLYQ5B23]J*J2,T=0>5.R&G9U0%*1BG0GA1D MQ9QR0\Y)U]G1[$<^E;H[$NJ=DI-1K@N4E%K /V3%5!X/^45AL5*I8: M:]HB:$]72FX:JH&@93^L;4;*NF3T*:UM-#F/E?S>GT%A4J+I+D(J79$'1Z$: M" +VP]HS).;7]3J*@][C(?+(+$PS;<:?0M9:K-/!K:*;3! $G73H.A$LET=, MP4T"H" "BU>:98(.>T/!NK)8"@8W5-",NS9'6^9ECVS*%JV&]80M,_YHQ$$0 MR0RC(GGK!')=X"O5:AWGD]M9DLJ*.!\%?OV=W1J3F*1X)O@@:G"B WKM.]Q:U7+.8LV5O03D4R(!JG IAQIK>3&,\'J^QH@I(90BE;Q%! +'DA M$ %!"SFN-BOR24/]C$BAQ-+\V?XYP"X%ZK^!^/8"0.:' !U]=;8G M+3X)5/UB,0U2=-JG^&<07[B)1939Z.#PCOI EY-C7(K#6]".;.D/:KDXCY7$ M'^E@L\!VBU.?A'P[77D@RT#)8I:8H0.U1#&-!@BZ&,,4I8M]'(V6U>"OIFN] MIP]"]E@O^MWW[U^.)U/5F6%:'7MC D/XQX&"1@$$LTQ1=H<4I1ZBBE^_?%,[ M:VQ[,!&G\4V\S5(ZS-&<\9-)6AMLJ*%6@P^Q& C"J+%UEX7BE.U>W. 8;UF5 MQ>-0U-WIO@DA; R\PG[R@LFKK.Z46,Q:3J "9)7Y)Y !01(%L$X6'R%)C)-# M&KVBT6>/!+AU-*"+!IPTC%*BRR%NF6ZK+/?EL1?D$U*)FD6YC6C M[W'VG 0JZIBIV:)1'R=*2IGH@*!7#Z"=XM[LDGJT)"&[QIZ@S7J%CB90;L/V MUMTAHSUFS"Z#TG97"EEKVW@ZN-5FGDP0!(=TZ#H;>T=Y!+.;J[DQ3[*?<35B MP\JX9:;F8%RD=4(P6I+J@.!<#Z"]1U;4(*(6T=&D9?K=T7= @97+"=,XD.Q= MR01M44P-M"256,HJC>AS'Q-QWI(6(8#MKA:^VP/>)),OC+%XL9VPZSA\/DL4 M]W2]M!U1Q\0E"9]4JB!B57^\;?E]73\F.SQFL,CKS/MLSE2U"9=T-7%.Q5F5/ECB&H V96]EBO&7&4.%-43- M 2+Q;9C^X^!%X3;T"\\WWI=RF\B^ABQBSZRODN;X'2>9"MVN2JIXJFJ8^RC[&(/WVV!]0"O[BJPO;$6FS1QL=-> MXET2'&1D%P=WD?>D\*LE9YL90IAM7C2$0+%"A$S)":;@:O>R'O/&<1H0'3?: M@B[ZF"Y040=SE )%#R$T?=6B("BDQ]>Y M^+4YKN4SI0!M$]),PV'5LIT,>H6S/FUXTFFYGX&K Y5:!035S'$.G9R[*3TG M]$N^D:$6=\HSR6:&2A;2=H8!3@ ;&ASE0QR0Z/5IC?T#";,02Q(1%+)6B:*" MVV")2!!.\%&@:Q.#BF(JRT;;1W$73)E\(3[/TIO+H39HT!6#PP M!?T]'\\B+V5Y$US3Q2G.9@![O?\MXUP=/\=/2U_4@>@4;''&#'A)';4T" 89 M0=1W*J_HWB._X:PXB)5?+VR95--\XK\A'C\#1,@LC/$TPSM1_0&5L"TRZ0&7 M1))+@B"1%EZ;0(4"*C0056&$X55.T"],&W%UV]N3]QF)-ICLTL5V0P**2C7? M5@E;6\'1 JX6<*22("BDA==9OJ&]%@F]"'$MGMO:)9/MXNT"M8FS(3Y+VT!ZU^Y :SSF?FO()J\$%*G\#[[S7;V MW2'"[[Y__/T["F\4)/L,R_8.I9+6\NK44*LD.K$8"!JHL772XZ@T8N+7[^J! M'A6:]@N FI-%)6RQX*22(%BCA2WGY' ;'8U&X E%57( M.M,9M]43J,-&O]02EZZA?W_2C_J._>?WC'/^QX/+MM#'?NDR#< MAL(IJ4;6QN#WR&=3 $6Y30HAQ+.S0JMV*MY MDA5P5-D!/73=TC\<>4G_\NOX]9'= M?YQG7JW"]+=[+_;R$<$ZHW,+_/0ZBH./K%1$S*XL'3VF&2N0U'I9IYFRP=IS M.,M(?(H=YYP^ _A.A9NZ.<3LH:/!*U2:O.*4/UI%OY1V+]/K#V(\;Y%IBM.[ MA(S8?U/::*E$%;.N$IT%O: MZ:[U:H>H>AX_E5@]\0K5GIDWT?*QJ'@N^H4]&?%'0VRJTYB&%Q9C1"/VH48@ M-3&Q@WV:3]/"FVD:0MA#:7\TAGYAYF!3^=1N16@))JE/ZA@$9MX@O<\5VNL< M!QFT-\\AG4EY)'N=Q$_TWP:$;(D) -Q6.F= :J$^=#:K0/>C,;>$N"E4V (2 MJ8\^+NCL)0V?GC,Z/"L&3D5![.-XSI#1 XPZX_C@%R!E?6^+,-O!4#<,6D:] M.53&^0"]:;X6_F&TEO(P3?0ZVFZQ3SNC!5EA+TUB[S%ZG86_X>AUD[2E5O@I M9,L!<6;>)9SC.0[[C?.])D7GLY.S/>S--M8^E?L]D.FBF=J^T"FE+=)!X)%MO;D%"0 M"4FK$4*OIFEBQ5F;,W=1VICT)F"V$F/G+&)HL8&[V#32206D$IC;?>G,Y,<' I,T ZE0$H\BC M-^=H0R<^ -*,^-C2 MA4]+,>"^[,RM@(V0:S_9#V=I6QL$2<4N&7&TJ0J?HD*\?1G*C8 E:'X=VF"& M=M1!4%3BE!%'6[KP22H&W)>EQ06+4&E:_CC=[>E(I)M.TOQ],)T'/P8$[4]\ M24;-8^ SX#>CTQSKV]RJWW-SXEREMA#4QIG/9GFB,CLT_^*%$;N-;D'8M1_E M;;Z#VV1?ZR":XK!78M0"^YF&W_ &^=.WO=4>DI=A*!_#6E[]09=K9%LO?>3O MZY!>/WG>OB@A$F5I^2_')E?\PZ\+\N3%X3\Y;G9/;1*% ?_+* Z6] M1U_A? M%]N[D!VXIV]@3?\EOQ=%LCIS9MLVFMM%7@=K;&M% MN9.C?;8E73T!'1]QJ24EZRWL> .KK'>[W&/>3+M3O*2S-4'!,_XU6J/+QX MF&^F\X]HN9A-Q].)^\#[,4F"SV$4L=/*]&7$3VPSF54%JOQD 0_$AJ-N<+FWD1\TK*R@W@XYV($5[(\=U\;VO$7"$5L;P?A;>%J5U M(V.:8#7>>53!8,ES0 .[>R%>*(RB.N "F4M9W1Q2^%O$M"*2.5 M5!@LI70QB4Y2T6RQ7B,Z%$/CQ?W]8H[6/XY6$^=\NL6/F?'BH4S8)I/4@.LT M$DN"X9 27IM 3!CH,E[3#UT\DDJ[XY R%DE$@;)(%X=N)S< IG[X!<<'?$<_ M"1WF<1;_%&;/XT.:)3M,=)- 4VVKT\%^+C4FAF:J8 C7#V]GLIAK(_;Z4*F/ M/E,#J+0 *;9IG-4%.W-U0&15AD-3W;="5UW 7$T^3>8/[H=I;.$O>]7-'5M" M5@?X0H"-47U# @Q!A+ Z^C9IU-NM M.L.,E<&0KR_B-B_Y'/+'Q>QVLEKS#=$__H6O\6]^=D[0O/1!GH(\-3!R?P<>8.^'^6G]]Z]__".LY+? M(W]$-\->*MT\UOF;LKAF\V&.VH18_Y:AT MX4JG9#,\F3E0#T=J#>=DZ@6SPZK): T@'WF%(W9M';_N:$.\.*7M@%6@E-TMW,]>URLZ=; M368:*@/B93_$W5A:T^?SW3*Z'DW BJH:?_N$UR&F0''9..#VM_-V&-XG!*\W MJX?QYF'%#LZ-%^N-^S!,)_A[3+N3XNS@"F]SYAZ MG?+@!C_V_J_FL3+T^U"K)MJ%_!H,8A-OGV6H?2CT[SV"S&?[V^&:TG M;//J?CF9K_GY&>>-81K[R0YOO"_&HW6EADT2&T"O$U0A#H9\>HQM8N4:B*H MW=D7N*0+I6H5QQ13!D&5/&22Z<+7=$Z#U@1M1G\#L.[+1^VY$^S(]A<6HK6+ MO3HEJ^4!C1QH%/M3:H!AEA',3B$^IH2*.,9K/Q1ZD*(8!SE/XJ3<2&Y[J2UH MV<. =2[V2U?>F1^VZBZ9)CIOGN>C6PS.N1 MXS[YR!(KT6JR7*Q85J5SYMUY(?GD18=:HKYN>*=6LC&9K.V78Y3QMWSK;UX3'%_SC0&#UY,=AID8M;[3@UH!N]I406#+,T #O] M8B6.]7@XIM"A7+E=JTX%L5VJ3R8#AE +);0#6,_7 ?T>%5LFW>,>.<8.UY2>Z1 M&=,,=5W.))7NJ.:20D4P).R#5KNHX9R##RE>;"=I%NZ\#*<2E]M"-EDE!EBG M3U,"#$^$L-J$H$(L+E5BSOF@J5EB%ISZ&@%4@<8@7/6S (:/@V#+:BBML)\\ MQ>$YNE'I$6."_:PZG,AS2]3L,U>S>/#8V(G:&62MCG-.]03:*07'-5&EBKBN M\]BWQA$U]_01QQ07NT!B%.S".&3SVBQ\P>7>J^D ;9@QNR.V4QQN#N&&6'+. MX[/ [P[RN#&^7W_OD=\PIWAIPSG+5SC%]#4_4R]O:32/$E[4OX"7>RCM00PT M+1^A,G6E=6)*IP:&F>98!8?_N";G84T7#A.G<89)[$5T$+Q.MMEGCZCYIY"W MF_BF@=W,>I,(@V&8#F$WJS*7OV9SEU(#2 ^^(5Z R\,KQ?5\*1VKXO"%7="M M9)>AKDVF]7*GSCHC13 ,[(-65V7Z9(!?UR M\^I-]WS;[;V0,.HOR&V8[I/4BQ;;61(_<6]RE-/8CPX!SS5M^MUG-^0B3[+* MZ1/8U8J\2MAY^#-%V.9%J8*XCO.8=3PV7#]8O-@7M5:F_$H^&F39B#Q51J]! MEJRNN@]WM;'DWM^,<[*>CKVSV,[86]16J-MR3NB;0QK&.$TIJ,BS1)XB4,DR4[>$)\UTRLYI.12QXK1CS8+[ =5=0G#X%(\/M,W$?K-&?1SP MOT;UT:*6KPMF!^++R\((W:S.JYZQGLVCT<=:;7T#Q!=:)1,$WB7)X(+R1"&TQV MY:3Z"CW$B>\?]B$=M>0_CY\]\H33HEI]O7X]C!2C.?YD?_;Q' MZS.TZ6_&9@,9ZF2]/?2U 8;^ X%W\R]]7NBU,H6:MIPS>>T_X^ 0X<6VW"/2 MYK2K-*PNH>NA-Y;*Y>)@6*?'V%GZ'O\XN7V8\;H.XQ]'\X^3-=HLT'BT6OW, MKD 8W2\>YAOVZ\?%XO:GZ6P&B'*UK);VMN:&)?&94[&')3<4[>VJF+K&9@!2 MNB]V%=6G\PWE^O2&_FVT7D_8K9?CS?03A'N'2X<3E<-WAXR5KMVQ \#_Y,.@ MLKA>']Z?YQ$N&L0Y7XZHI9S#/K@F=$:G>K6M*W3WL'E835AGLMI,_YL7YBX+ M/#IO;](TW<$IUM"2JX>E5H>9L P>3AVY?A] M,1]3+J_R^$K_835=__4*W?R,/DX6'U>CY8_3\6C&_W6-[NB 9[$"P_O%=N*1 MF*_^8%)F]H0^.[$81H<,!ST']#VMN1G4#W)9/+#O90I<.QB&7]465A/6&J:S M:=48?II,/_ZXF=Q>CSY-5J./$[3^<;2BL]W%PV9-!RRW;+9[MUBAF]%Z.N:] MP^UT]L#N8YU/-FBV6*\1[3C8Y2+WU"!7!M1Z[CVVP,E74WFZ.EL@O<6/6<]F M8VK&37OIYZ2XH9C9 -A">@%7-8W[$;O>DMTPS/XV6\P_7F\FJWMT.[EQ/PZZ M#5/OZ8G@I[(_S+,0C&ALJ&OY'BAS=UJW/>D5P;"T#UH5-6^GZ]''CZO)Q^,0 MAM5Q?#@YTDJRGHZM:_S,;E)+IW'WZ'"95,/GR;R$0IXA8T+-BSW%6@;5Y5Y1 ME6=U_DK]E@:#+]-+J93:[8)('.$,:;?&TF'^=, M[B:K%1WHG*FQG=P)=-_2*(J2SQYEZEU"QO3MA-DL2SD+?%6SH)R_G:#1;+;X:41GR7RD?[MXN-GG&M%6SM661_V^XCO_WO1C1>QQK%^QCB; MQMN$[.J7:6X2[I,Z4)[=NH.QR;E>B6!,2]SX?WJ\ELQ-97-HN\ 9T1=O4&<8T=&:# MJS*M_"549U**1:U7P_'. $MVQT*#76V.DWJ;<=XT3L?>8\F2C[9FT]'-=,;_ MT3G'CS&AD6U,@T']5G/S97A#*VY6X7NY*%Z$-S(!AM/#<*MWI]B]66-&ZOE' M-%ZL3Y][:L<^92L,<2LMO^%4[DJ/ <\)9AV,4,^1C MM&8KCXOQE ]3?IIN?KQ$:SC'/E1Q.1X=YPD+C8P(88NZ/ W_YO4HL_1>V;^- M/GLD,-BQ.N]3+.]M7>(5M7;!SOD(YPWNLGYUCG)/U^/98LTR+]DT@F4L7-_0 MH=,M2V)@2U7YE&&T6K$M WZ+(TL6J@LN1S_SNVM'/XU6M\X;Y3%4S9/XA08E MMDU"0U/HTS_Q(CX/<9BEQIA/V5$"UEC@'2A8;">[?92\8KS&Y"5DRW["R!-Q&,4^ M/K^AYY\T[F 2)GVG,6=_GJ,TOW"]GBY\G$[2> MK#Y-QQ-%DV8[A.-:]LEX\7$^_6_6$TY6T\4MD-'I^K#;>>1UL?U4%I&MMDFU MK=-(U>Z=M>;.-*^OU>O!H;\Y6&6"5)FJL1G]C5_(70SARGUM]\RLFGE>N>P& M;Q."JZ)GM_0_:<8S>XL:%ST':0.MNNDX3GH%XNYAD$DXK> L?J@/G]%X/D%? MLWSM;]#-Y&Y!9S_%/](V#5%0!HAP!S4W&RW6*V>G'L*5=>AMFT*/;I&^##R;[GXP:8=#3['NR\ M9(+=VQ[ ]C#8">4T^>YNPA:MZ@,FM!IM)JW3=(!:!L^UF2=Q4B895%\7*;S?E"W@FAW^!,3W-7YBVS\KO&=U M.IC359K9S6OQHSGA>UISP_A!+HLIW\L40,X/P:].0^'G?=97B-7$H+%]_K%, M8L^'0\=_;LVK?Z:ZR\5JP\X4H?7D(X@:&E6-X=K(L"@6'"QBVCD>"$M@8$?+ MTX4PQX4=,IO'^D+7Z3DT;NLRCG-2?OL#+$I:J/N-SP#3-"SK7*0D\FJ[X MBF]^G.G'23EMN9^,V!8_;:QS-$+SQ?R:CM8>5CR7AM4R<#^1875ZLM=[G#TG MP93OT/(+]C['F*3/X7Z)":N XCUAR5ONH6^S!?5VJ]XLC)7!<+TOXLZ%AUP? M[;@!%%864%*:N$+[RHASTAY[77G9*=:4M9VV3MW-J,K,*?$P2JT+AK ] LZCAA5KZNTP-#1&&I/ M(C)UQ/7=LW%^V#UB0B?GY:2\F)3(2*B0MUJI7 >[49)<)@R&:3J$;8+E\NP: MXFHQ!:6%BG-*C8(72OXPI:"*M1V)UR)!JS4_LP\R*6(L:V3 \9)NMDFWWV"!X%0WP'U*\/42S<"L+94::( 9G75>, M1F='-3"$-,R\D?$F)E[?D[N:Y'C_BB.4# M/DB'?H:Z5N\L[N-.XP)C$T4PU.R#ML/-2A?Y^7U=SDE8SISR'3:VPF,X@14I MN)C!RH&+IK!=:3#$TD*43V))I8(.[."7=56]/435?T& M153Y]"Y*4J:C7N7R-CD\9G1@5M;"' 7)GGG0L]/)R.<530VX=<&045X5* H(Y6^VFGOQ!?9YQ,T\DJE: M>P==^ZW?X*^PV&K%B/XL)7 M*#=TS2V!R:I0>#?3Y%68J<)8(^TZ8[9&>M0#P\P>8#L#_CH#VP1-8258*-S\ M2&J#"?.W4Z@!(63#"4,R0 M3F7>*=^$3M4^!\V*HW"(S@IWDA9GYVE$=L_0]]S=9HE 41WEJ/Z6))1S._-<8L_F@X MG_VZ7>6Y:$J"W6_V@LECHEEP[X.Z_=4>("4@*+@W\OW#[L!+?8]V[.CE/SW! M@OPIAH#T)1I'#<.+Q,H;&Z*KO>BL[Q^ED5<3ASB0K[O#Z@HU_9:\*9V2U51K M(P<::==*#3#C&2.8YM2K_XWO.<7IR>R3;&#V;TB]A^T7?(ZU#=)+OJ9J0_42 M#W'>1"[MF7FK>C-3@\OVYF]K^J#SPOSS@YADM-V;XVSRQ8\.#)IJ<]-$#]XD MHQ?J3F(@SM!CDOR&7EBA!N>#+Q5':SPK3F#-\9=L\QE'+_@^B;/G 2M91D:A M3#_,7X!I\-);=-ZSG=6--OLI_W[_QCC_,_;(YG-REK=4V8++\):[PXE=&'JC M?&ZB%]#X#V^1QO3)_0]3::P!IW+=Y1/)S$R]93K7\ L(_<[_5P8\"Y7'/X1"Y3V;?,Y2-\ 9=_ M>&-<'FTS3,Y*Z)9%N*P6NCZC^K4] =Z>FL1O9L35E4WF#LIN:-); !-;!L'6)_4?C0%+ M[-=X>?-Z[_T](>/(2[6)_L-,6:U!<8*SS:C;WPX8AI\ OLOS%JN!'Q88!7\_ MY#5V[Q)BD+BDD+=;2$\#NUE/3R(,AH ZA)V=QPLD;9Q.I2)=7#$6_0F'3\]L M>_4%$^\):XM)G6;2*B'/X'R#LR?8@T/KTYUH,[^4O_9RA6;^4IX!X+PE2.O$ MJI6\Y8PH[9*2$5:S,J7H?_[;G]Z_>_<7%&/W\:[.38GK31&;<4<$KDZ@ M^N]@^D0!J#8OZB(F\XU+AG8^;,QS=<7QN2Y@N54J!\-"7)U#:OGO1256YZVM M6(ZFGZ7YPH6^U<6L]O82D%U6'&6 T:(#K).AFL37OC$W+OZRY:\87(N3IV^[ M?(VUR^ 4L:PK!:^^EP*C++A%1Q7G$:X&7QOF)+(V8YT2KH0ZMJ/>(.[TBH"0 M"%3MV*H#/';3*8HG,M6/P&+U$9'HA :0,=&8O?PX(WPTO K3WU0[VC)AJY?% M* $WKH<12H(AB1)>M]Q#31@Q:3 [S!T_9II]9)6"4R9U@"O9- .W\ZN%:,*J M&:#]W.JVX0;0Q98A'7OI\R@.V'_8:M"+%REN+1ABR,G=U+T=%=X\;6P%#'4' M0V]3>K'=IL\)P>C1BW]C2[2\5K5S)G>:YO'V8%D).;6*TT I *\,E35Y,(PS M *D.EX2%R_/=WRPI,\'O?O.3W=Z+7U?8QR&_3EU8*4(J:JW8@P9L5:]!(N>< M&P;@A'?S%=*(',4=K<30F<4TIG P*_0P>O'"B*'9).-DMTMB?MO'8+)#3!\=#:1@-FN:CLTT M.S52:7=TZD"64VH&;H-&C:^;I]@@$:RM&<9U1G4&\M[+B@"\PGOOE3-^L5V2 M,/;#O1=-8\.B?B?:M)JY<@[W&QDNIQB$-E,ZAS,@Z_KUW:_N$$]^V8?LC!SV4KQXC,(GOK!A,I!6*;OBJ]XA&4'EFK .+/;" M#+,&%IMM+K9C@H,PN_-\EJ'^.DY><.S%&7--2CZ]GMTS!H9N-,\;:)3 +"F8 M(NV<8&9K"F%DC1HL!DG;6YSZ)-PK3GAKM5R3 M4^""CH\U%= 4[.)4!\HK'A\1_I+A.-74>G!&.9Z3B--LY65XE"W+BX1ZO!:I M!==4U+BFHZ5$'31%U9@U_?JV,'*%PL(,(M3.A9*5[\.8!?19^(]#2)_^NF+# MW!4.#CZON4)G8@&?C4V^[$/R>DN!M-[#8"O64IR'NUAE/_%1HL>7Y1.DT M+@^>%4Z$XC,ZIIK6^K-^KE1]F)F:SV#[LZ5?EP5T<(X5R]B*B N8Q_@F$G)-%AZS-AT(";3& V,4+TB^V/WF$ M>!0^6;'2R//#[A$3&K:K%-^Q%T4XN'DMY-)"4%IKXE2K5L]9G^<5-(YBGV;2 M.:7/ZT>G_G8AQ@[E["G[/U(EZ_Z;3<4ZNGD#E/12$;7EA+SSY0J?(89HWFNK'JNN5EK<99LOY>,S4 M7>TH3&<(#'5/02_E,X^;QU//SJFM78=4'C0UUG:]6*)PJ==2,K#CH/WP&NZ9 M\G/ZN04VK(-R8+IU-E'>NXL$'9X#E?3@72DPK))"TYS4NT(;"+UU$WX]C6"= ML5K&QZ5M(__5!MP1R\0Q.>%4VD"): !92-"S9H"(B>O#-XB)R>3@LTX/L\*JAPOK00@G.@7>Q4S/=R7>M&@"Z=9PP MH%RE YUV;: ]J#@4)]H?O;#EZK:8HIKPL2KH'&>JRYL4\I:_4WZ7*!TMD$SU MK8P0=^KE%$KHJ(6NT9Q=B[[88[:_[.A[B>C&KV90?S8#-9A?KP]P06UCKEO< MZPWQTY7WJ[SV_'9MO;?S\:3(N^/[HL9;V0=^75PN\PWH#ZF^],=0]0U^3@%X M_1>-DN)TGMDWM3*Z+H]DW>+\O]-87J/<4,?FN-H(?IV22@5H]U&9@.W1EX?E M\;NO@\(@):+F$E6KWT[:_9E]2:DZH KG0U"K>_JKVN>L/K'VNYYTH8&)"[*^ MOKYE/]22Q>L03G&U=EO"$#-0HM'I+O09[ P)4FK\.T>"+VKEM((J2SQZE MP%U";I/#8[8]1-W>0];-&"I;O2^@ET.-3MY($^+:6B_D;9[>X*1$S MXIZ3'>CC9XJ8#DGOF?$NIAB--1\'?:Y?.#3:+)\DGFK*U=G,'I:C7C!%O.(\J9 M'.CF7I2RWWE'8?>]IY&C/Y$PPZSHPTE#BIH5>&.\CHO]!WN5"2B+QZ?![QP^ M8;]?)U3 U3K--[7B&L6ZATT M7@GN6( VJ1V$7KHB3/19VR?,=:2JX%D,N9FUNJ@!9S3D%,LXCF :8 M])/[1U'GT6JT2T@6_K,X7E)"7'L13N64W>=^\\I(+JJ.02@V;7#2 7B>@0AP,Z_08.Y< M,SFVR4GE&-7XW\$<@2SJ=W!0,\VY1XFL@ZHK8KB"JBI-03 L4J'K#/9;Q)D! MNNAW2D]'I@F-<#;'=?JNHD.1.# M0AE&R0"E8[=)%'E$6:6GASX84HK<,F9F7?EMT%. V)BC^?(;H)I234_S>S/X M<#3_ <>=$HZ]--UQ5.F*G)U"-:"\5&'5,3+Z_\K[UN;(<1S!O\*8O=OHCDC/ M=77W//8V[D/:+M?ZPF4[;%=W3$Q<=,@2TZEII92CA\O>7W\$22DE\2%*F2DB M:R)V>UPV $$2((@".QPR;9!/HXY%GG9,D7VKYT9LG_\QF5YH'5QV_L\>\F# M#>_0POG3].!Q1YO# ,<* =;GBN/=]$8RJCUVD+S!9<;&D47/'&%_'OOF/,'# MARI_YVS">3U+1?L%W4IA!,:7\3/,JAK,!Z"Z>\2:)FRS*D@IZ8A58R'_C$%9 MOP1)I5W/52A$CR,MS$U32)@5QWHX)@QF697K+(<0^E660UBK,_#M$*P=?K8P MM@O;33S;!NS=:%PY-%D.7WJ#UR!.^,,AJ 8.<<4CF!3^CL M8#R#NZ/-9CPCA&ALR $'ARFY,ZITX=AAMH+2O"D'G&4DLO?##$P,&UVEQVX+GE:*3B(IT'!4\4 M@R>*?%D%&0VCXX0Y;YUE9U&ZI98'T="L,>Z\J@67!:9T\\^@4RBS0]$/C?"^ M+B]4M#\(&95C97O6_,.Q.4P8(_W\8C/8?-F>9B9WV9XJC'>XMJA!AX-@0 MO%J2PKC5FF[0/!L83Q.NV,1Y! (^93N"Z;[F?&QHDIPF45^+9C/YC&]TY M^+X,P[P*DF5YP?;^=_9+70;D2%Q_:^2 ..;ETH"(QR1'<&LQQ:*Q9[@W@.T9 MFSU>!IO@A19P*3?"$E4LCS9H$L%B?7T4K'9GX%,)<@DP9F-QA"0A0R_(8U:Q M@]%X0^O@^3Q"O]&KU"63OL,6@'6.[ M T>2MZ0#PW9FYL*KJ057_(W8IP M%"+K['N?UG=;GJ&"<4]G,:'L2JU!HIJ^1M;ZQ-( DX:9R MB)>B^S]76&=Y"2WKANQ$!SCKPP,CHYW7!0H4&CLQLJ8L*@!X!CV0,!G*+T$> M0_!ER$XT<'.:B9'-MI4H0&B,Q,19WT9J.$P6,F09GBS":@E^+*#,RB"QY>T, MJ?\)") SZ [J: %X7:V=2O^,>T:0, ML=DNER(G;O6EH+P3Q*=<#=0Y8\T6Q747H7$6AE&\>^SC^%0:Q-Q]$6TYCA;3 M!^*<*QF1TH:K5:#Y8OLF!G?Q_3X$#IV;V%+B_ GUPEZF*B@0==764[CE_3C M6\B;?WX*XE03P;>#SJ;W 68;[1O@<-B G;F^)4AH9@4"G+PP^/_U'3MH%-\C M\T1^I;"&T6C)O+3@9=?\BO\1@EMB M06I2)!"T6MW.Q+(',4S\$ _^Y3L-L(WZ\%T463!?YKL@>CY@# EE.G 9,I!8[P*[93J%D M!EDEV=>"P$#VCZ?^PQR]$]'=<\GV!Z@26'M.S#4:%PK9B^*L75+W%[W3.W4Z M.316O[\,PTLV\[&3BG?_!>:O-+/ M65JNC5E8D\G->_.VG]#=B[IIM+"%MO>4HS\!F*']Z62,^V\TR)^^9GN.3$,% MHRGW1)QBP9+$J1INEWV-O?[YM.R5?=/XSF(\';0VVQ9SLM4"D9.VVY8 &LO] MRTE9[A4;S0.,B2"#U6[;0DXU6Z!QRE;;XE]CM'\]+:.-7P^QV@HR:(VV)>1D MHV4T3MIH=_QKC/8_3L9HERMVSCR0Y?9H831?K;A3;+A#Z%0-62>$DCBRICD- M /!D;'K/4<%IN?L8*Z[$I9%K8[DF<+([G53Y5,+ MP]3 ]1M >[=F>\N;]>;;1#G V5%["C^2I:U4 M8=39.F;WQQG+=X3!X!HYHJ Q.S<^AZJO'-!UVK\(2_6<[') #6+W@68MOJ)E ML%-XI0.!QE:T;"F/^"40B3F4?W.0107N5K)6 "_:W&HP6YR_=_YBZ2XPD=:L MQK6/N!T;G$((CZGNP;WRO%36F." I$4#38,#@XPW VT.AM%FS?%V%**3R#V M@\8>'1D=87HW;ET0CJJP5YI6](K]$DJP0FF77^-R?5$5)5OX\X]U\CCDI[/_ MBYZ"-[T.1Y/!%H+<1P2=4Y\+>I[TN@SY#5$AVK'#"L=XLL3V;?"__8PM'<&) M6W4>UL DJJAX'Q1*[7I?_>M;ZJLL?S _N52@9FTKJ6>QTRNR"X)FY=;SI1I( M6AZJ,,$A#>(BV,9ED%QOMGGV2FU/&(>0/)F+10"#]6@P,!J3FY[ZQUA9.RJQIO; %MC!41C43;N]+M(7;]M]S1LK M7U8YX_">YG$6\2[>A?@]VXP?:?X:AU3K6HRC@$^C$_E7"VD#O.Q1S:=D(5$\ M:;;;F;UNJ]ZJ3!*\:-=+%SQ\6AS%M;(IU\BD &P227188R6N]^WYXV:;9.^4 MGM.4KN*R6*;"1,_9>A)=9!O8% *+&SD"?\YM?+18;5-U1D:SW8_E6"D7W (1 MBTS)3)SW9\E6Y&N6_[[S"[R;+.\!*ET:8RY.%V96#U+'7L+-0[U;Q2*$Z M'=,,-(PH3 4Z%:A9K_CU+';.+%T0-%:AYTMMRB:A^/)1T&V0"X?@F#T\/_ZS MBLMWWM^[6(8A3:CX*.>4G6"S,(9@%MSK-?SUI-R#SFQYW?N(V61]3R'BW0;W MY;QOI8(4"3@M$K2("3N%DN22'/G*Z#%#E@2]+W+E\K/[]WW??(ZT/^L\Y;6?8MJ14'MWSM;A8<'U%;P93I%U0_7DR=F',GHT>#XTYCF#6 MP0[!YY'8SGG3\QNFY-!E1!I0;X;78]9H:!)N5L/:BOOM,LA+9T>ZRV??INK^ MHT$!._;_#=(*$E$^+ C3Z$_>LN_W.-'@*81C94_I A9%,8ZTQTY6<$L"T^V] M$=Q;%K:&:6,Z=@L66[FK 3Z-Z8F[F8)^Z!N9-\AKP;K M<63>Y[P.:4]6+NT1A_KY0BPCR]X7C%UH[Y*NH$68S,V\9T(4T- QR8J*C:-; MJ-:)AI]@[0CQ].%:!P)H%I$I7/<-5V(2B4H %XW;I(JUDVK(AW+$G=-,1XG3 M-D\G1#1F.89;)W/-RPU1!>>6'^+F2U65D)KRI:] (?+]F.B"6W50-R(C- MUW%AH]+PV[,%9/LA[&')/,10:!;3?$8([3!H':MCGBKL(XZ=(?A)3 M9'?BU;\H7>8YM#WG%WGG[SL8>>7'<_[=8AQ[T_<3_SC0L.AC(WL21S.]#BV1 M[L.H5+![Z"\!="3^L@O>-GP^(V M2U]I4=+HMH+\B4/K:?SW3V)^3AW6@TSCL1_'F$\YM_#*0[FJ+,H@C>I73I5$ M(@%;%NA+G*8#5<-.?-I_8B3*XCH5Y9UF5U+_\]_&I-(+H/8Q?(UB!,(%+/IQOWC0^MD\',GL9\X#MI!IO# M[ZI (Z;K,[3 ML^!D%IB"-K82VCS].X:L?0[&1^13;N[./)78K%-L+X&=JZ<;*:%SI/:10GDO M\/BE("]8PAAC)6L\ND,-58L@:A-7!-_+S!MJ>.)Z^XJ@M?/5J1X ,#D+WY)[ M[RKK:',J&%%!ZZ#?\I.^ M=(3ATJ!;O(TIG2\1H$BQV$W]!9''XB,]3V><.Z"^(:"2&)JOI,&-U M,Y#B=/"O^.A?@,^8JEQG.2RI M1SXKM;YSBO%V99B.<79N/H)F;AU+,D.#QB"*V'0K,U*N*5G^>[#9_N>#>$H_ M<@J>@$5Y#IPMAG06)4R("G3C.-5S*=#[TAW!M&D>2SN":O HDC%V'K3&:)N%(] WC;77:?XG? S-7#RVA+;=%= MW;HPAAGE?4><[!?HLW/KP^6AO9"AKYV$1^HV9 ?Q2>V?\CYAYY&O/X&_-#DD M<#0D&:=1;WF4'TV/M+/I\JDNDJ HXE7,EJ;B)@Z>XX1]7[>PC4">;5\:+5"S M[3AC>C?22>QJJT6W A+"W$C8D(!.&$E-Y$CFUS!YE>470;%^I&69,.ZY,Z>3 M>@!A-C-S8KPQ+2LT#G-R8;%O0@T.C[:&#(L4 NVX[OB./UAV==+T(6:S"SUK MC2%T_XQ#\UJ>^JJ^V"D7H(Y^SOJ495&Q3".VC]+NH;1X8GMP$82P17+XY7:; M9^)NV'#W?V#:'LY8AQD.S0EK/\(X#/C TC@%*81KEO;OGTX_I4![W6%]1G2, M+YU$6L'P4!WD4L[\&>_3[_BR[3,9!Z]_3RN.\2N%2P[FDKW2/'BA?,PN@Y)> M!7'^2Y!4![]JF\# 248[G ?V* &0P:_CFN5SBMR?_#4>"02BF.$D8JADQ7#) M*R![G_&7=$6AX])3\+;DS1= IB;)^JLE.=4)<^:JV*ZB],I?#Z%A?'CNSK;2 M/+1^(DZ>11M1[T:HLMZ7[F(-\_8ZU09;II.9TSRG"MFVU;$TT"S'$QE73O;0 M'2Z%ZY] +*#B6BBHB4(#N9RR)9U\%U'QT_>> 2%>=TE>54P#&!:7')?BC*.#0,SEX4 MYURB#B!ZVY;W((=FX=I?!O7^#%[V$[;!E]3:/!VKM5^Q?\8O_:Y8AR"(W-9[ M@N]IZI+:*5MZ5P1-&3OXJZ?]=X(X']_*/,ARMAL%^3M_VLE.@;RY2Y:P+[Q< MIR6%U.@#&8#KYV;>[P]L(Z.E[)L13S;RODY*S_.*1DS2A$DF7PC+'G6&\1K$ MFO6YIIL(G<>9=A0T=NG&I^DT409O"R)QL1@:=P^6S.EF'QEK;D.X'HS.31R- MZ=D1L1F@$[=6,^04L!BAW,''KG9&+!^KW8 (NM7.@(+-V ;XM*]VP[[9G(;6 M^ MC[,R(Y,',!@306)D! YN1V=GLV]A]GKW&!83D>)*5M+B8TP##0W#@K2-5 MX[V6K>>L7D MYQ:?_5#_3LHIJQ)!QN$R#/,J2(KF:H9Y@Y=9]5RNJH3]#>[?3 ETQ_B0UQR! M@PV4]1)O[Z]@FT5'D[ __1H4[E%21IJ_ @G9=^*2)!G[.!Z?LAF-^A=BL7$= MPSZ6UXFA%\%JY5T4]":K9=>X&>?TE:88$[;8F6M+\_(=RE65;+)!=9BMYJW) M% )>+7!0,*LQ&K'1N8K.+&M.VQR>%RF-TY+]+89R4@&GAL]2Y2U1^@(72!=! MGK^S-9V_]>YXRZ[#Y4S.JQ6/%-IJTXZT\%KX. '4>J^0/)O2DF0U'>X!D._^ M<'MW\X?O2=BF>$KV/Y! -(D24JNW)0Q-('.*MCZ0("2#4[,9NN%]HR)0?5-_ M$V_BLE-K6@Z%.]ILKQ)'"-$\.'3 \6YU(QE55E+*'Q>2#W_^Z;M_? ^^ \.S6=1$VXWO=9X?$LFZ>)F3O]CB58S7E:%,E;$=[ MI?7K'E)":8M$/MMJEL:YCC#LAPM^(L8AA/L5HD+P;VEA.3>>8 M'__\%^QG%R%1)PXPP@'58OL^85A$&CHT:%"]&^,T?I4U3]Q,\@A-]DKS&<(S M-_#.U5K\T +L8Q73,ZQ;NKJ0WDW$B3VS@\_!#U>GT&.,Y>!G9_^KV3C!#Q,5 M07]'/E82Q?8A\P-;>SXU5 _]4YSC^@+8[_5*FV'[#0I >E\WG=A3FE?#WV8_ M&6CBQ$X8"$X#_:BM [AWRW#GT7B'\9>?>5UXJZ,UY^0\7*&/F;JE[1$;MS#= MU]9&'CRW&JCP$Q+:"T MZ] M"IK-?C+KIM0XS1LL$I2D*(.R8H;Z3G(,510:>:$I5AJR6<>%TS\--"ZAHZG, M7T5KM(C:EX-N)- 8]32^]3G-L#!3,2D6(N]S15;2UJ6!8[7FVRR-:%2QLSAS M:^3$'C=B>@H(K-@FFH,%Z]"Q6Z^%9\6SR-*S'2R)H;075B.5Y4YV?V63[C)> M,;>(LKW'^.1D,C4$QNLJLH,A#Y'";M2._/<-_'JS#4*Q% L"=38^A@2KCXS] M$#)K.E)UY?X4)V5LK9@]FLJL_9*GB=CI@CR.!!I#GL:WXEM4S]L@+\D5^71] M\W0-10R2JL 00QBQ^XS.YC\0;01+^+3AF.B9^$[0/ZS/@B85?\ZI AM6G$,^ MI36W=B^*2*>%2?2)DZ%/#EN>QOZB&&/-<0-/0C:)7A"4UQ@A+10=8:I9LP/X M)7VE26:KA' NDBG@WT8)DX*/=%3W!VLDA@K@)1Y1<^J+=;I4#=0&9&/X#:" MHP@CF! 3!L)A1HR@BGU*C!?E%'(Y7,Y,3P%;!/8X;LI B7!25GL^HIKKXT/WM*'3IQYRKE1']R/6 )_NYR?O*\Q5#!VG M;I@A*0E(#W03Q- *(_U?9 RMGW8<2C&[LX#9-', ME,/)8DI;VN4GM>I)XTI5^O@6;.*4RWI)BS"/MYI'\LY87J(!=A$,1B'>*1'E?=![_'S-339HY<9&Q# #O7+ZJN2+,]L7(6H'EE M-8CAW99&L:F4F)%XK14LK#'Q+&+FBHN&>65#F'/I&F:\O6J9H;T;F3.+NC3U M7JU+7D&!H*GF*I.(ZKHW3U#')N O$#\Q)QKD%*TOV40R>>)C*,QZ6AHO6N>$ MY(Z.QD#'\VSH;LNVUI"'T\D+0RS(=Z(E@?^6(/SU]&V6-K/*GIMK!I]U(1Q@ MNK,,&F"Q/=<9X%/[ZKU.!O<4S5-8%J[D&&5T,&;N E3"<]%1*M%S:U4-.8-$ M?>_3_#%(4S' MD!WP\%BN.[-JH0^+>3I??NT1S_B20I9#"!M]X6V8JX=?K8HA@O;30## M!HS%HW)EM&] +916V$+NX_Y/EG75_HX3TO9.V.'8&!AT09TW"NLN3#<4.XR' M9C$;P:PNT-&T6_C&O'QT=_B._%K]?/_KPU40YY!P1\_?ST45Y<6G/*NV M3":;3^^&.FNL:80PG2"3 QZ:]6$$LTI8B:$2CLL=;XE..#ZI":#QPW>":L2\ MBE/VNUCW*?11#@5]A+$-DWTJLFF:P+N,B3+*BRDT+NQ5C3N-W8%V7_:.0@C_Q+#@6"1HT[[/_(DNA3CQ;ENY6+<'$K]F9U92)Z8 WYTK@+$;7]@:0 MT*P*KIRJQE?C0:A56)^G=4%P?%>5D,H1L3U2&U7L \U\K+,&$8V\*3%#,J1Y3(OS M7?.B!QI1QB,[<=W3?$O+*DBZ(M\'PE'XX8\__/"!P7#!/M/-<[=(^]$^\EN4 MA;,9!/M6!;YTH$D,/;:$?0N"[_Q/(KY$SDFKW]3N8Z3Y&FD^1_CW%F0;Y.05 M/DG^!_\H9+*+-9K\77QX[@K20BC\@+Y.]SWO6:'R56QSG(J+3/6 M7,V[H>%2\"B>E=<&#?+NR$QB.#_#OQ@%LFI(^%%D\ [2WZV^;-EOT_**ZM2F M 4*F)#.'Z@,0#@KZJ 0P65%/H\_6\TOZ7"Y?6_3>&4%>0OS-+,LT'$SPNQ;@Q:Y@E!7\)'7 \^)\: M$::,EQGS:Y#G05H^EGG\.[W/XU#5C@J"2R%&_OHZD("DX)!D"Z!>!OTV3LOU M31:DG[,H7L6A>#\\L&BY(.%2S B.E5PH0"6 2]K(2-:W7^@Z#A,J;Y'3E]NL MI(5!;1987-H:9E0I]24P2(-".(Y7U5RG197#G7_#E$$O)D!<2AG@4GW7+<%; M.O$:)VKB7:*"PMUJ&64\S8+]%(90H)JQ^ B!_2"/OFPCW8EV"A%<6MQ# B6B MM(L@4DX+_.Y 4N,_-_1((0DRO]S;P9:'OM99$C$_YR,[B)?ORU5)\UI^U36W MP^/2JQNSVGK2$HM0CD8"P&OTZ$53%VMV=HO#"XAI!BD[85M\$0LL+@T-,ZI, M,(%! (7L<+PNHP]TPS;6>R8E<,_8*[/H1D4EW(&^53.N"T$4F/XO=KH)QP,;#Y6<%S:<>)U M./<%P\[S0%]I6M&+=W:8&-QZ;,"X-.3 J;JV<13"<;#L/CQM^IX-SSHHP$VU MKVY6:%P*<%'+)#PK'./?"T@2"!,+UQWO1!<"G#R)\Z1P0@ 4B_NTOS MY%Z432^N4WF:*QYH2.-7R.Z %J9Y$):\KB;O*B R/.14YZ]UGNA;>9ZP4X&Z M(QW\$[BT?C3Y;$4-Y*?@WK#^&-E]C=2?(_Q[A.V3I>4"_0XI45@:\2_EE/ MP:XPIT%!+ZGXW^NTYOW7N%Q?5$69;6A>=X)^%R6-2L7(II'!94A[R: IC\B) MD$A2 U,):[/XR@B24%+<-]#>Y MRO++K'HN5U6B;DE0^O>59W4NHW^PI8#?[2KZV8,6+CWN+TA?WPU%?B$>29IU M]!HR_YO].&_(LF-J0]=/C)3FI;B,9!Y+DXMF"I):@'&IUX%3)4RZ0P&7JD'R MZI _P4I>Y>\\PGZ7FM*0]6"X5&+EL:^,&E@D&B.(N.U>7K(%XS%(*,^;-L3; M],"XU.' J2'6MGM-RE>Z@F&))' _NUOYM*:?@_QW.I3M;83$I9@A-I5]IR0, M@0@,'$G?7]*(YE_SF+F:.S\)@AN[9%=%.PXXN/3DSK!:HJO!;#F'/,<4'E!( M9#^SJ=7IY&YU \<(=1ZI,+@T8V90F3OMQBYLTT\ UF>6=?&4703;N P26%\? MLU7YE:VYRS3B99KZ/6W4B[@I5' I;Q\1C"FJ94;"'3522'(\$I;Q EAQ0Y$$ MG*0?*Q!1>.:SWN=T&\11D_X$,1\F:[6123:0EZ:J?Q0Z,KU/X5U1N"0"\GA'J=PJF!>B-)CSNJ6TF1SWI:TR1;3A3BH84@ MZR>K3$09F+3R*7GWG:[Q7;,#%BY=CV%9+8XK7QV#!IN'\+TGQEX]W\OX-8YH M&A7@XS$SS+M5B$PPN%1D9E")<=:0I&I _2RGP2;89LN4%FPW9]YTDKW$15G< M7YCNCNWPN/3AQJRR#'(LHJ"1^PNO4V09AGE%H[J,L>FPKH/"I18;B\I!0\"2 M&MBK!GB?HHQG5$,_F"\I^$G:9YU&2%R:&&*SKPV )YFX )4X; 'CWJ*WAY[+ MZ!6<5'8BK307VIV_XAI\'6N*^0L8:*1:>;I/YF$ N#XUM$DT N$:;0N'BI7S M2V"X[FVW0?0R^%_2+ RK;4PCSM0%[Q6MJ\NO \.E "N/:J2O!A:A)=DEV]-3 M\ET_E6J[37@:9I"T2]6V6DT\T 1:"#QE7,K".:EK7]*XE'UPN:R=:5J?Z-7Y M;?< D9^!F);X$)+4K5T;1.#J(7Y90[&%0D3H/N5LRU7,9A@%ESDX\ZL4V1>( M3'MB&<@!E=>7*.IXXX*\ $_O@=PP&72]$/00^!2C(D]Q0_A^8]"![+E@9!$4ZZLD^[J[;SCHQCB5/"Z] M'T4VYPT2OD/@0SP8*+J8G,(V^?GI_.(^CU\9:%C!,W3FTL?,BE*#7@8Q<"G(E5UUG>9X?'8U MF*1&]5M3D!G1>?"ROG\M;TK;].D#X=*,A4/MM %85'/G?OU>Q&%LG"F]O^,: M?3USRH5R#>5UH%V7II-8D,8M0\B6'N:];GB7M6NV.++S0\0DO8QS&I99;KK* M<,#!I2%WAC7./;P@8JAG+5S2('LN\9P650+']Z'"9$9(7'H:8E/3G4/"(ZDZ M)NRBB:I<9'"KF25Q^&X^43G@X-*2.\/J[3I@D@:5<%SR=X'M^R#S%"2_?[Z\ M8+_F&Z1I]=.#X5*1E<>^5DH.3';07J?0K@77]9-! RH(KM$W\MPH:=QTQ#6Y8-&)="'3@=>JF%8W/:Q2;K M!_*0=-BQR =:E'D5EE5>[\K.L=S)-'%I^W "&:.V=RO2HDUVQ E0)QWRM7N# M(DS;K%<\474;M!8V8R[N 8RY3NRJ^;@2CRRY$FX-6:MO1/;E4V1E,FD<&EY M;SD,^[2@2-HDI0'TI_C.7E#D90\?+_6 N-0ZP*4Y31O)]FRM9#.DHC'(N-0V M@7--#$?4[.&3JR;2;++O6#1LJZ]AK%;I@H1+HR,X'ELOQ&L!R\\TBD-H%LA, M+0Y;Q1X?Z8LE<.J&ADN%HWA6+N8$,JFQVQ4N);[??8^NXA2J%;%5(WZN1!9& M&>=4/J=+F=U^>?RXV2;9N[G2XB0JN+2\CPB:RDY B[2)D1TU N0(HT>^_/'Q MCZ2AZ=Q4SO@]]C M*'9\B%EKH(5+P?L+,GD&UV21S&*7D7C,XYL@_3TXA'D8:)V>>=@%F6P>-5DD MYJ&IF&&ZX39!XE+M$)O*Z:A5Y*-&\)LO$J)'^ @N.SBBA$H*"_\42>!;:E48.)[5GX/7C+OJ M02N9UQ[*+Y)R]TG/.>Y/7[.G=58501I=,=V4E*8BC'>=0JTI)BDL:*;[^Q'( MN(QF N=]8_CQAP\_$QGR;+#$\H_!F2_N5BMVZ,R+)L%JF48RRR=(C3<5X]!Q M*742[R;GOUB0FLRBE:0&*<\M4GZK)4 94K:TI1'WN)1/@FR7N!987,,_S*CR!I4_ MD0*4YFV4_RO;^@+#7-I8@<"E!Q-[:I=+>5/# %&,./..!D:\@< YXGWVC"/. M /VN/RFM>3&M.GT(7"-N8D]989AI-Z/NMV5R2?,PVVR#]'U7S%\].!O@<(V^ MG4FU"\@.NM5RP-/C:B@8?AX4O%T&O+;G0MYFZ2MSR9A_QY-(GC)X-=SZ.^Q* MMUGY-UI"^X67%*(Y:K;5P4CCTO;!Y=(6<2?\"Z1-@C3?J)-[^%>Z,/ =:(E. MV)?([E.>*J@691Z'I2P;$W"A@0)BEWS)S]%NNJO7V4Y//!_I&69\,">KBB:%1J7[EQ85>IW-3D] MD" 20KV#0J#YK*.VXQX$UEPLM/^,2PE:WM0KA&:< DX>T(>LD2SG\R..Z*"KMDY-#$<:EUP-+I=TQSY[YCKD5%>7% MTKD@:04^+M0F*41OE%B2\I,\H'EI:+K\-8+B4NT@GZYO)CV>1FYI"?=-=VE3 MNS%.N<"%OI:@#'MVGUT8]'A VK@4?WC!^I9R"Y7 9"'8I"F567]E02I#[48> M4\X[#U="[S96-QM\"M[$M2@_!S(F>9V0SB@KO18M.+ALPIUA8R_&,GBK;W)C MB+OGQSW_! MML;)%C\NG8#-*+@59>17*3$E^Q1=>&X3W!:@:4IK54L#A5<3?1;MFTT#[:D% MG,@U?F2B5666OU]D^39CQQC*)'D(=/V^AC!P*<:57;6-FTS"+FI$Y@5(3*XX M^,%/'5\:L7-F8BK\U?XK+E7H6%,R(06,YYN\"'*Q>?+GRI0BH /"-=P6#M4+ MO!J4 *S?UL>0-V4J=[#[&ZZQ5AE3'". \)RHG].+)*L@Q>TSS>,H#M)E^,\J M+F(>?3!F[;N@X5+'*)[58+Q$YD&7&IVT\?U6HC6]'1W[/A:CYMR8'?,BUF]/ MZB!)LE#DRDGGH>[&I>C)!HQ+20Z+?C<14)^M,$0"_E65,Y>GXAV>FW:OIFRY(0Q<*G%E5\FFXWBD M0125V)NVM5X?)?!(U&W6;\AK>H=@!<>E+2=>M6UE"F@F3>Z;;L(2T:NBGFBX M3J'QY_O'%-( H_.JB%-:%(]94MD\35=$7,H;R;52RK!!)Q*?U 1(0\%OQ?T\ MYATKP9<.8O;7ESJ]P52"?P !E_XBB)^2@F27X,\ M#XQ;F@$.EW;L3*HM/VMH(L&]:N)3GE7;>S8FZX#-Z)>[_"5(Y=-=?C ==X[; MBQHNK1Y"E+[N.4VR(TK:5.51'N)<&+8@$F M0%S*'>!2R1"&DJT ?_:!\#DK-;*1J%X."+=9ZJP5"RPNQ0PSJAS8LO0LQZB? MIKCD)0V3(*<1.,]!K#[9, 'BTLP E^;2FI&$Y\< N-'UH@VYUQ;L]!\S9KZD M](WF85QHGM"807%I9)#/ODYJ!(AK :I=BA^K@GC5WI7E06S%.G)%MGJ:4W/ MLR W]2]SP,&E)G>&U9(KKY34J$3B0E)UN::$HWOU"/[_ M.DLB:FSQ90/&I3D'3C4WTA*%M'%\::H5J,; M817JMY_1#+2%.7TO@059EJ+*(N_[46;D/L!AW= 9PTDA0S@XYX&=5=^EN\(U B-1@YDVY!FQ>LM6@OL?\.@VS#>U7HK2 81QW#7?FD1? MY#L _][3\/>N]7DU)]WXZ^ 0*<#*GK:8"20H2.@%X?">- "5,)CWRQAAYU5A M$K>TO%L]!6\Z15C $>G#A4NU!TD+ISLY%@022]C1G>$CV]CO])FXG MV.E[2$%JFD5];3>+6NRZ17G2N:XXMRC-41?G?J"B MBKM.W>[8B$(]$YA6ZS?)RO: T>RWDC"I*9,6Z05YIE"7''9C--.[;H^UJV7G M-J=5/-03V<*NX^RM*9 ="31*O$Y?V5Z?Y888H!4!M=IT?#KJJX6*1D]\WV\. MLB)/U4UA.DS4FK,R[*A"X2;M#OZ"BB=MLI,4%".[SS-PMJ/S]R\%)"3O1&1K M_*LQ#.^.C4BK$YC6/6S@-=QJ(N3YG7P'=)B"OV_KMJ'EZT J:HD53QE_SY93 MQC'CKGR'LO1E^YV ]CCJC(U(OQ.85A^#"Q(03Y!$2$UEP2OZEXON4PD_;_EK M034MC)B9/:1U'#M7!?\_JZ4Q=N#3:BB3V!Z9$+ M=T,*S\)]M]KUX>Y$V9@]BE^P QGEO[&MX"/((-+X/MP;U_1L1>[R*$Z#_+T= M8^R''V%YW]$6O_1L"[*EQE/&CMH0NX%+56:LT'I06]';9A!C:2&TBLDB&$QC M 2$,TJ*T$+E(9Z*0N80BRUU2M"=[>*#;9F+<9B4M&&NF&(<)%I$^!UE4@U3; MUF3F*$3B(-#(#3SFNUN) FI#*ND (]6)GD>[4C@._""P<#E)5VSQ3\.I3I(& M&Y'B)C ]TDEJ2/EWDH!+^'\XAKT&B=@4Z@8$\(>Z8F_SBQ;D/-O)+J,BVU6! E_3LDPV+_9M]D9J**1C&/U M*F?Z^#Z">(-7L8]G]CO3KEDBXF4M8+:Y(CNV9C9X&D9PM?F2I13: ;W2_/TZ MC6Z#3+ EP4L.#JIHW$H#I00OP?JIDAL',94 39D@DVG!@ M4,EOV:&@THIHI7619 5]RCZGVQBFK4$O-E@DFG%B4:D$(=J)<2RX9'N*-SP; M\//M_35?QM@?JIP6&/3UE$?+/#H2S;\51.0Z]#S(_5=(L>AO3<%COM[&'V[2\L2/,-);-[@2M!0O,4\99!.[WAW@$B4KJ=/^M+[AV\+R5D MZ0MT5[NDS^7G /J9 6/M*P:HKA?&VR"Y3F^9__#TE2:O]'.6EFO]\^]]"&)2 MZD'D4)3/J)X!60)T%T129A/S;S3(R5WJRPT?)2[P^O0UVUO]DLZI:KW/_DAE M,]234?8ZI]HK[&F43EKA'0'&JAR03T7I5VR@#Z)S('3**N_P/U+C@(M XRU65 MN#US=,-$H..)#&O"%_TWC0O2T"2K+)=9:>3&7\#33<9?V2Y/[U8K[3(\D@2B MA7DJY_MI>D$XQ6RU\E; E-3U+'TK='DF4!QJGJO B83V7&?B*LL[;.ET8()%-*,&6326 M"(' <0?%5ZL.;1V+U@.+\_<=B.2>OX01C1.N4Q!!Y!M Z:*G=9#>;?DU]6W& M2]W0Z+;J-QN:_>.(IN[\,O=ML%UQI,U#^UD-O,?75B8!3A:R:P9I,2-K#I:, M'2+YX6FA@B/V(^?IFS/R7[AXUZEXVCVOC7>_C6A5G%UD?Q8N&(+D#<'2-V?@ M;&=;T=B;C2N?_Y^^O(%H)CBC4\BF#^-A;>Z;L*RCVH]_ VF]HW8H MJ3)@'^.(X32/B3)8K:/S6+U&1:5[=\6BU]H$E=Q27TNU\%H80Y#,G8:,([Y( MW&9I1*,J+,'BY#("'2'C'"(DX)@:WZU-)8=(KX>00NF2S@N9MCJM@A'P$J?= MC_!;@]UG=FOX[DM$?&KA]RJ9!\D8KUFO![;.+$RPB'0^R**^%V<;H]:5C\>+ M7]* '2%#*"ASD>7;+(?"OIJNZH/ "*X*W7GLZ\2&I-%*^U&UL[+U]D^*XDB_\_Q/Q? ?N;,3&;L3VF>F>]W-VGQL44#7$ M4L "U7UF_YEPV0)TVMB,7ZJ+\^D?R39@;$M*&9L4U6S<>Z:Z2I*5^4M)J52^ M_.?_?=VXG1<2A-3W_NN;]W_Y[IL.\6S?H=[JO[YYFK_KSGO#X3>=,+(\QW)] MC_S7-Y[_S?_]__[?_Z?#_N\__\^[=YU[2ESGKYV^;[\;>DO_;YVQM2%_[3P0 MCP16Y =_ZWRTW)C_QK^G+@DZ/7^S=4E$V!_2#_^U\^-?/OSXW'GW#C#N1^(Y M?O T&Q[&74?1-OSKM]]^^?+E+Y[_8GWQ@\_A7VQ_ QMP'EE1'!Y&^^[UN^S_ MTN[_Z5+O\U_Y_SQ;(>DP?GGA7U]#^E_?\.]FG_WR_5_\8/7MA^^^>__MWQ]' M2;?2\^2E6_][_^^NNWR5_W34LM7Y\#=_^-[[_=3^L;SK?UOWPG>5R+LW7A$2A:@*5C=N8R)3]W8O6 M)**VY6K-JK)G0U/DRX9LV/#A9#G9\J7.9$G)-'FO%J;&-YN K(D7TABB%:F/1\S?Z^]EV'[8^#/V,:[73F*^Y]D:EJB6N-H=H0$BM5__*MO7.R#7#WS'A [#A@3)C1\/.CY5FKY,-=SYE' M;-F0U:Y/0T93& ?D=-K[\[ T-B>%_Y#0E&ZB-3_4'*F/[ L!M=R3F;!%1ATV MAP8HU!R_(>&:!"O+H_],=C?&R+LXI!Y1[SJ*;HT=+B%E\CL-2,AXL/_8G*X\ MNF0+C4%OVW[L14P'G/HNM2D!G(6UAVR(J ??=[Y0UV6?';(9>"OZ[))N&+)3 M<$PBU?QAO1N:ZC3PV=SVJHQ>7'9L>JE9)I=T:FEQZ[5E8KVIQJFC:E%;%K@+!X)732 "'NJ!Y M4W"1%=]%9F3K!WP/4>(D:-_0=.XM&B06K,GRGGH6V] L=^CQE93L=:K9 ;LW MQ;OX.21_QFSDP0MD=J+V> IQBXHQBH*\L-B_E-3HC-&BL@R;K+IG*XHS;'*R M/FTJT;#9 ;HVJ%##YE1NV:QR#9M%9>-&%4;8/*K:MJ:Q05DC[]>NF@2;(ZAS M\RH3;'+"#NVH3[!)23NUI$H!L93VNHQ:!9NIUB#M6B#[)+*H&XZM@!\]+TJ3 M@N8P> J9+F$-?J*I56"OB1.[3$AZ:Z9:L4W [[%/[=@,NAL^E+=[(/XJL+9K_GC+?Q/> M6W;D!_J;5_W!6[GAZ2(#Z]TX)C-BLP]3EV9\^T3H:AT1YYWU0@)K19)+73B) MH\2YBYT)]W[ 3T6;25"?NC%K6GD/U,;O0A-I\]JL"[G6((TC_VCQ2Q@WYD^6 M(]];O8M(L.'W9VWHH",U: W09;6L3^.<[=/06JT"LMKO1:DY0)NOL'':4BR' M7J;S76G2=\A/9?E?6/?.VA&I?SQ$18 M]U(BZ=SX1.?QE@W%F66Y>?=5[J0=;)(=,GNB7OBIW5.;G+,_T2K1>T]")BJ) MN:TEPFM_IET%A7]Q1*UGIB!&M :)&H,U:JC7W1/DO5KQ_- _&B"]6[BI%%\. M:MPQ%$,TO[T>I8PI,KY-.><^T6C= #7UQV[M#4A?E* CM.C5HSMIG3&:NO(< M7) S!_CRZU27?=E+G;+#NUVNT=3:)9[:7ZS ML/OL/V&4V/#8A9C0E:=-6/VQ6[!O;[:^E\;]'*8Q#?P7RN-7L^.BAF%;?]0V MA3%[4?.<<]1QO?&:WS>72\*WZ*.TS)CR=&J"UM\4]0=MWHE$=Y<#=&V<^WEO MD?3[[X[/?G!^@X9IX1J2&,;"+"[56V4SX!)\^%UN4]JEKB?;=7M)%_,@NKTQI=";>V/?>!3R.CBOVB1<%D.ISQFS)[UA;<0#V/SL\DMA9 M>.3T9:L5!,D[)D&0[(=C$&3E*,U-EH MS4UZZ(74(0%_:.#..[D;6NV9JX=L:_H'1_? MQN:?M60LNEO0YS]0)P$<+J*B$:\=99"Y'WG'<\WDOCYL1_3EME,]G-A-ZF3SRW>!TYE9P$ GVXPF8 MY7PF68MOMTGF@7?VFKH'.5@&_D;$ONR#OG36?L D]K^^>?_==^C\9D)/ANS' M$,#S7%MDO@OX*F=^;OH9 !\, *#G6B'/><%-$=U7"L&AW.4:X2A3<5@66*#D MI]3W-Q;UQ&A4M34,!I%H%1"IHB2#HBX2%0_AO5'_C\P'BG]H:J5W@._^P@[' M*0D2^^(CV3P?3] UWQ+[Q4*TY[L.-261:1*/.;%_^3V,B,.(1N^AMELMB2*+7<:9-:7 MDXO&/@44C!\,$HR&V7RN9&A>,_97FP4;L?J6<=H""%!;^(BUWST^I1FCL+7+ MON_P.=R[UJJ:KX4F0,:^1^5L)5E8K.V3T [H-I\J0\#ADY;86H8>HRN(1-HA M9F1%PRP$XD"#?,L0=,$^_;4V$2G92%!T/8\=+>E#@AR!TY;8IZL6XZN(1.+W M_\16$)' W4%87FH,Y/J/1G!=0"J65A)87DA3;QXUY\NM@:S_R0C6BXA%XOU\ M35R7/^58'DCNJ]H#^?^S$?P7$VP LEK99]1 P MXUYM5=1>F/D#+Z+1CA>6&<<"@S-K5FX%93;N=59$'0J3]\8,+^*%]L\HI16'[PGH=\HH<2?(USBTU]X5=H"#@7EA!=*-@P?W-@ZV?LUKW M>!:+8-?S'>FVK^@(Q07W)JO! Q1TNH[#^!9F_^&4O)=A4MD<_(IE !(2>@WA M_P<]_G^ \Q_WAJNDUQ#^?Z_'_^_A_,>]Y2KIQ>1_C_TX"1;^%\'SN; QE/>X MMUP%K9B<3^8_"9(XT;2DIXK]I1Y0#$RX_,JI1ET"J48 D?]]2RCC3;@(5U.) MR?"I'T:6^[]TJU)$J]M#F6_"E5A&\:7-FZD <+N(R%>JT 3*:-Q;<"5=E^8M MASH@EEB@3UM .8M[M:VBZL*,'?G\46;M>U*S<+D5E,&X=U01=9?>G'F@9"C< M%7)_!COMX6Z]17HNS,]/ 8W8#'B,2.QE]B#! YZ@*93/N!=+*9T7YOD\B1SF M:1;VE8*K&5[5#LIMW&NDF,(+LWH:$ XY8>I[XK'&@ZR#R7(IVIUE[:&LQ[U% MJBG&A6 8AC$)=(&HZ 6% _="":7^TEM05I7\_8?G!<\>(-B 2JV@3,>]3(JH MNS"3QWZ6*F*^VSS[KCBRIK(AE-6X5T<)C1?F]LD\JOE<: +E,.Z=L9(NI.UB M\&HG.?;%SAC5+:&0O.EPR.3L*E<8OA[]D,U_P5-H9Q'#D65T7EIGL<.C8B33NE0 M'_) AL H.X%10(Y5A5(/F60/3T(NT#A,.'= M4T$W"A8??3=F[ H2;]A L"H$3:&\-^&]4T GC@-JZNM].)\X&:*0 GD/* (F M/'S*J49RR8L(3S1'7TC?BJQLAC(@1#V@0)CP""JG&BW0(.@Q"E:^_.6_T!#* M=A,<@RMI1.'V?&.Y[K[FM(S;A890;IO@ 5Q)(PJW!QL2K-A^]Q#X7Z)U%D,K MX[J@ Y3[)OCY2FG&0>'U&,J?1A5*(:AH#4X980+_A=1B94Q&&4H]S$.>R*DC/X9-V M4,:;<.6MHA G "U^=JE][_J65+\_:09EM GWVPKZ4/A\9WF?@W@;V3N>-)X0 M_JX3'M8?X(8%' "*C0DW7RV>X%@DCOES2V7CI78):3\H1B95QI9P]-H)R%_>F+*"M@L/_^6V)##;PY_U?*_]X M,IIN#:X[R^7E;MDMGN1\!DYJ<7WHO.L=K'\G&^!L03FK M-M!D>7"$F/JI;512RZN(H+3W^4N@#F59(5@E#<5VP&71^J( %(HKE--<:-[ M47T@LHL\%(]2A ]*QP+>9[^E=PEI96V2SBH%\Q8T.8 MF[UHA#-B$_K"*ZJ,222VZ.W)E?8"1S : :$?G20V/&;T/")1NM>'$;^A@0) MD1"L0)W!3L &0*;!#73DAA[/J^T'.S8W,42GKWH\$P#LK6HDY5OY]7;^9Q/B!3C!.H,!*PUR[<.8!K<0$<. MB%$]-%JS>FNI PJ^;_=5YD8IU<(9)M.+_,ARDY9X:\W?DB#:3=F5/6+"-?@S MIEM^39.>1_)>0#Q;,YF#KC00PM'7TX1-T>(FY!&Q0C*CJS6[/C^Q78!3*#FK MY-W 5TY4@$"THR,T9'SS5I2=I"E13'H&K[8;\Q?D!]]WOE"W*F;WH!U!>D/Q MPK41Z' "'38U-/KL;]EVH&"_<2S.J2ECW[-!^G6Y.93Y+=L*($JUB%9T)-*) MJ=0Q.*];ON2#-+ WH'J-J/5,71I1$C+](W%"6OLN8W'(=9%HIS8IPT> 0MN^ MXYR^^5^73^CK+3=A\.N K \4O-;L"]H(" $T]0EA;^6=6CMN%0';MXOMH5"U M9ED \+K:OEU-.3HP@\W6]7>$S(C+WY;+Y(DQ G2%PM6:Z4$;+C _T)%C@A7$ M>HA)ND"1:LVH4&=AR>E'1^CTAKV?Z$YM"E?T [^U&H,5C!/H@%4];,%A@_6& M@M>:L4$;/!VNH$,X]B,"UC(J&T,!:LT T M2N*,&3.X]+']A'BV%$]I)["/LZ'X CB"ONKJO)DU\$K67L67,S&[@K>QZ7YC M2.::A,6*L:IL# 6IQ>!)35@D-*/CDUQ$F+9R4+R)J7IGLA/*7, MAHS\D#LK3I8+ZU7Z-JDW$!36%O,@Z2[$>KQ"QW@1L(M_'.P@IUA56RA2+29" MTD1*3+'^'>S7] [FD57B4(!Y"ROS04>/AP/98OZDLS7V-W"95MUB0!8204\H MQ%=@-I'RIE'X<3.(3!.VKDE$[9Q6=Y).Y'MX.I'.OYV,]^^W]"(M4;:0O],5 MVZD69DFL6]J :[L9%PG*1T$A0S$JYA&2P)%K:Q@D)P(E8GYN^GDW,60 >JX5 MAI-ELEUW7RD$AW*7:X2C3$4N'PV2Q2HWI;Z_81=1BT\DQI782))N"H\J16OFJ(.YO2MZWDA(C?251\<,P^-+LX=TX6OL! M_>?QHJ2"K=P/.Q]<3;Q$## 2IZ0"HR9&^S[8B>3.PN>4<".QD=<@D-!6IP@! M8@I8*"6&0)5[.=4_JD"=L3/,@2'38(5)L,&/*&DG;!VP#DS&'DZE.:I.)F$' M[!1T]6$Q[$S2+(HCHJK.:818: 5$AB$(G3Q^9C-.)@M\]3WM@IU\#HR-DFP3 M4L=W%!(6;ZX\\-A3NH7'F$'+!>F%^+% MY)X)7Y5G_2%/%\^MP_Z?(_6$J348LA5" 6#)OZDVN]!WQT,T3)8P%% I0-(% MVQJAAYN2=G/0Z?EAXEB_GRD G7(7;%N$FM\"?$34H^,S)Z[+%[;G/%K!9Y*C M368R%_?!MD/H(J2F'QVB!^(QFEPVQ:ZSH1[E]$3TA2AQ4G;$MD#H@@7D!#IB M,\9&]ODUFVB?G:RNG^395>*EZ(9MB-!%"\0%=*SZA/'1IBD7F6!M>+G:?XK* M;V6]I)VP+1.Z. $X@([2/MGK<+.U:)#<'OU0HD.(VF,;)K1W/"G=Z+"P)1X% ML1W%04['2?*5'B?<8W?VE4S?TQH$VWI18Q/4Y1 ZJB4:-6Y2^,GP:^OH$MW\ MVAS2#S0=@U@ &.8;HZ?,KWD1+A-\Q3".?<\_)6Q?%$5IX@!T1<^RKPFV NDC#&&+ :MP?U/M7!^K%;+;'EZ\[LO2#+ QW8;V2 MJECZ*7G) [SR] !7K'H=J,[6 MS1WQR%*6^$#8 ;V801VQ$!*.OF^,202YU!2:H9+NCRZ;N'G'*JR,.\[*Z0V<*%" M!D(OC'#&4H8SZHH7^SY)SMXW6"$ @N;H-17T8)82C;Y:B[/K4S>.9&ZWP@[H MU1+.@Z5 .#HPGP@O\TF<[@M3NE=D'/.(OX,B]>/;X8C>.]'[#MW$N+N=B[16!Y M(9M[ZEJ4_,M-43C<:=69*-OZ'KHWL2;N<*DY'P5T(:N@3"TITD[HKLEGP0W@ MQW6GT,OK4HG25YTF\$2-^@FN1N6'_%=KZX=_ZV0C8^?3JY?4']3]EE'OK(QZ M-;*;WE+JM8K)%:?42P6(;^.^QSCI]0K34F78$S0W#!"9 ML!5-I-4$Y1RI37@S5*5Q.RM_6_NYI33P,#J'6^[52H5(15-L#;P.'$**T;$0 ME!%1X:+HAAT36 C0 J!*)<5? CL ,%: M2TR70^B85J2/46$HZ8(=.%@',R4'T#&ZY1L7YAO_<,LW;DJ^<;P[$%K"\?9O M1$!8;GG')2BUGW-7"R6STX]?J-86?I[J%FHL;1F^/D/5"B+<>FEPKZDS_*+P M$03X/*$ :-NNDZ#R_L/W[Q-D>KU1_X]>>C7@F7B62V)'DV77\;>PGV_;C MI);VG!-C!<[3EK_/52#'QZHWE#&&)2&R]6EK9OL4(%?QPK6,>,1!.B\!2,I> MQAB1I'@ B6^+]<5%#N*\HI,QMB$YXT&DHVL,K3H*XB>F;C;([(4$SWY(\&/! MOQ['-/STV6_#S=;U=X2D91'BP%Y;(9FZEL18 M4G,X[)17>A>/NNPR%>STK!).7VJIK#D@=@:M*Y%2 KN@IQ!I1&\S*("8] M[^I!=M(7/;M8,R?_58"6B%?Z:W93R0X0?6U.- QZ^K!&EI^0/Z:BFJ^P=0ZL MPG'0DWPULT0-![;V,]T?'PQ(N'7&2QV??R-//0,/6;DYXZ5.!T1\&UCE]%O" MT+"@O&G"R#6)J&VY!Z)/(O1^;B!"K_-O)Q]"2GMPB]B[1>S=(O:^IHB]FU-J MT2D5+TKOYI1:<$K]^GQ26[-4B67KYHQJ0-2>)CQF>Z%.K=U>G=[?SRW/)DEE M((G-7]H+.345W,(/H!T?H.IGB'T"R9X5KOG+E/;[3'F JW$HUF2)<8GYV/SN M7?^+(!7?+QJI^-A(G70H["OH@2BMFV=%+S37ND1L I\+DW.W>PJ),_0.99RZ M=L3$+**0:LYUQC)ERY0 6?;6J\DQ]"VUW93]K=5?J<_PM^YG>>*QP=TM/)NZ MY(3.A=_8^F[G:]B7CL;$JTTPT+>.Y"FY5HE>=4_L>TVKP%7XZ>K5^;WXKB0( MD\A/<[(<$:NRJ!=O6MD2.Q+E$B +B3=D$3-2>28"TB?I?X<>KS;%*?E$HW6/ M\8=Q(AA1ZYFZTO=>[8&PPV$NN,1K,OFJ]9"$:R'#\MX/^G[\'"UC-PNDDQ82 MDO7"#M^YH,A V(>^>?0SH=0NR*;LB!UE?-_Y0EV7 M^_O3(+%22XU'HO;H83 7!%/.,W1(]W713F-X%'Z!%>W10UHN"*F<9^B0EB\= M!Q*SP"U0=2#P&.A!+:@7.A5O#12'_76"L8K0%[ES(:PW>HQ,#5Q4P(JY=-4Z M&,PDT0U#HK4]2 9!C[II03B4/'MC,C+T7AB??>[*HR,5)]W0HW1:D(,*OKPQ MY)-7BN-!R65<2P2J^Z.' [4@"S).O3&AV)^-4VO'#\9]3?0#\7N+MN9VH34L M>C!2BSJ'!E_1]4OXFWD3WD)PW%NS#S;I@Z+)N4:+R1DA)OP #1MR+I..!16; M]A/XG.U>!N 9^JZP=RM>^%W[SY@&A!'!Y#K:\61#$=O8>"#8EC>1O EJC 'V M'+KPK@#!JMHA&\XY3.5"X"!R)"(["OD;QMQ?1E\8+_?'VI#AXZTH/^A$:B4? MK.984(FXM*^BAD2<03V^9%SPQ&CBI( +S*6]#_6W$'W.O3W%XIYZEF,)+6S%O[">N667)ZC@/&/9^#1?!:M/R)4FEJSBC8N376Y M>M4B-2/;PV(:^Q'9FW#$(B/N 16)UHRCC8F$BBM7#3ECCTV($]XS]NW#9B?+ M,PZCFN-!Q:4U0VAS.\A9',5737+3'U&/\#!7-FV9/ZRD"Q362]LYSX.UDB_H MR.7W*2!RDBY0Y%HS-;:R?ZN0N[X-',ZF)FZ,&K%MQLN%/N>NV,"PKPLU>+77 MEK6^Q#X\9;U8/^V?5Z*+R9.]D#NR^J\7'864,$VR0:,@1-VJS'X\/AIY3H=MS9KA^& =$_;)V_LA0 M(6P_R;^>$#;!SY:JG1Y>?9AFXC(6.&,_$N31X^W%S:'8M&:Q;HS1/H3<5D'9 M5V5+#)_;I-X6FRDWA?+'E&X8QINL/#&WJ(M\9C0'@0+8F@VY#0#K<;(E6&=< MB'C*U#YA)PJ->"G.O6=7WJEKZEHVMZ5D-4 $^-8>#0IT:U;E-H ^D[?H]H!Y MO-VZR=%BN7O^#+VE'VQ27-39)*$#0.$WR0M6DSOH:![R>?#G3NJ,%8%TI;;@ M[%BM8:3)\%)4@X!\ Y")"&-F!("ET!"*27L6U#,QJ23\XDF!$P:$Q/[+RG_Y MEMA.>O>9OFR/^_QA;FD^X%]__9$QM?.NOCR0%0EA/4,?S5P> @I>MJ*X,G^;AK\@U M&J L.Q7[$PJ:K1ZCYNS@E=@Q4V!(CQUU*S_8"%)158%WD/?)9+Q2;'?SD=318B4:,P]!Q^28XM5RSCQ3;X MG)8(=W&RN83#%Y+JXPQ4TES1$I^WU1)Q*KX5$[^LV':=?RQ\[H(JEMI"$WS& M2H2V,-=QA @J)+;7#9VNE*)R*:VG6EQ761V(E]@^AJ)XTP.>H1%!/ M9II+\GQ)?7?!+BAW;K4C;F[VN6;PT-+&+W]G:[\E:AN]@ZNYWO/GQ"7\A2W# M?FQM!%<.05,P]YN_>DOYZ*LFCL)O_NFC)CE9+JE-@O#>4T@]H!L8A^:==Y0\ M]G4(0<%E2DB0O"$G-;X!B$@[@+%HWM]$ PL S9?>C1)OJ^/$E"A(.X!1:-XM M0@,% ,T77PO^@GNI)5K7ILH*FPA/H1&8V\V__VO)?"5ME^=PUX[8_AW%J$C<&,;_XM7H/Q"EHOK?;X'IO+ MF G#RTJ]MXA;@WG?_/,X4-E448K(^&0FN<4(XG]E)S ,S3]3UX!!0C?&!G28 M&GP;$G>!)]%I PDHEWTH.2BH3:/?1_HSY=9G&L2IATQP#CULJM M61^W>CRZN#'CE)2/8;(#)UD->)(#$LPBY8U"*U MX:OJ"0:ME?MY$Z")^8$.54E#U89,-@(8NE8N]4U I^;/A2&LV "X13NS1RC0 M W<& ]>*?4 ?.$VNH"^[),]@W14GZ S&K!4;0Q.+3AD5MP1BT8HIH9#_#-(#N]U$-))2=P)"T8I;0 MAP3(!72W[)-*3178')..Y)O!T[6B&(FJ)UWBN&9T/PD:K.Y;X_E>N'BJ6X(Q M:C,))M6HDMP3P\5KRL;@EG=9OIB*:LE]&'82:5/!*%N:ATDZKE'-5"]EA2US7- "G?>,@K98:/V7Q,U!B/2SA-[/6]:.>6&A%$.@H!K M -)0RA]*H92\7NX+"78=?]EA(_@>\>/0W76Z7RR&A-,YR=1] 2G;SV>R+-%3 M@NA4Y& ]+_+BFWY_/R%)G&5U2WPG?AT4\L^XE>1<.@"3IW7*L@STV7_%D1.5 M#?&9+Q.?'+,K9W_A,,SK# $,O@6#/@U! /FEQ&)2+"A7L(BOJ;4VT:Y!VZX M4,V-&\*$2U\*5JLHHT%LIBFTP0T6 C'1%TX>A?IX$]"19A, @CFN9P>231VG<4",!ZX@8(*='0(?_21O@X M8HO8X[D_(1N0I#EN>) 2 R6A>-O]V(]^)X'WM1L!M97[0PDX^" M&^>DJ2?799(!6+++UY_L9DN7U,YFN[!>[XA'EC0*M?!4CX0;--4 IE!FX>+* M-A#7\K()#C=;GG613?B9NC3:*325FD/A!F&=!940<3TVXET"0%J/K#UN)%9# MX*D9J3UN>%9[Z.+>!?.'B4]"=B&:D3]C&APH5>RS.OUQ8[4: M0E"?88:\62>OS NZ24NM2-ZMOR^^6R<].VG7"R?_32>]268\DK])"YI>Q*#" M/QWV&%N83#UZ6\KG('F*EK7'?TJ2\CQO1Y%0<>EWZ.M\'%7+C?J)]()9@&]/ MI!@A&^ER9!\02';6KM ,G]UPX:ZFH%$7@%JE0G@4SYT5$B?OF-4- I[E*ZG4 M?+<[MIFFU9L3(HZ4>,Z4W;VX]M[W-Q;UQ/BU\S5D,:A&MA+]=NB_<++C[.0\ M2+OB-47<'->S04L#D-%[Z8>M_7P@S[O"QKB>#=J\-^(M=S^;:4"<*-AXSKUK MK>1\+S1%]FK0Y'HEG5C2SE9?SPN= ,#T8EMD[X4:^TR94B2V_^9_.( M^B [,&C"(*?\TE%<^[.';@BW\7#MX:/EBI>"M .RZP(0" #-&(NB4MF'K Q5 M1V27AK/M(=AKI')FTF<6>0]D9X1S\+C>MY2$G"?/"=S=:D[L.$BJ=HK]=<7- M<5T2M."3T8NQB :O@3T-JHO%[N><:X/K**#%Z1)E&.Q]8+?]),+FWJ(!3U$I MXW-58]SW>RV&BVF],.=/U]CN\7.4R$%O[:VFE95P62=5']RG>"@.,,H->;\; M>B%E3%L$5N)(G#.,53WB_5A\Q,NZ=[+^G9,!+O)"4YA^"9CB:XVX_47N%5'@ M+DBP"2?+1>"P[RL465E[X&IH8RFHV9Z_5RAIOG1VMV064DVUT 3(ZE:V'2U> M5Y)V1>KH8?X+ONLHL,G:@-4A8\ Y(>[2KCFQ2]Y_]_SC>S:5KN-O(R(Q\ D; M WG>BGU/B^<*UI0: F&F7_3^8A#1.N:@?D>BN&O!J; M3161B!O.(MAX$7"_R;<%;]0_.3(??84I*4,GLEH*.EW&)SR;BY">AO,@"NAECSI3"_U#<&D^&[?!Q.\>!D_UQ/W0K$5JD4AB2\]X,N_V_( M9'WHL+_0Y8Z?\9Z3-&8_+MBWK4B:_TO.B;.^A;5YGP7NZ>[0(G=:/ ;.$ZNA MQ]C#>20ZNH%,*8Z#=C"T#Z*>M%0SV&A):& 'J1P,[9G.7)DP>(M8K"G3D:P@ MV@V\%?M=O0U", K:ZZ$AHB!E+K8,'"*&N.B M/7&BRDEM + EYY'M:0'E)>VZRV52DFL2S(@5^I[U[.Y&]#-Q=PN_V&I&5I1K M9%ZDM<4T\2FTQUSD?:@YF*Y=Y/25G<:^A_:F?=7"9YS*=.=;@3-9]FG YND' MX6'/UA4MR$!H[_"H,@-GL1'"T/,W&QI%A$R">?QL[_\U(^'6]T+Z[!+&IO/$ MI/8GT+P)\ 7H3%BP12MC$9OCD">^Y5FS+B!MC7\5S;,"50!; @];)F>,[9-E M[EZK*5V2_GB>(:B"HN0H-N0Y3OAA4N4PG 0',0[SDEO+H@P:%,^MQ1 #D@[O MKT=BSK \PT?&\]"Y$MDQ;LNI.#R/U#0D2F=^ RI4E[9HG_T V@CO#?&AV!L5 M3H@<>C;EBTSE.E&*?-V/5O"AV(]W87\)*6URYPA@UTLL?>E4QE:DJ"BM(J8T M J+7@A9@N15:AT47WL"E4YS;_O8L$(L#8+H:M )B-8=,PC#-V7T.B*41,)T# M6D%1P".38-S_<;C9,@++9OC3OY\#=^TO83H*M"(69_+<)/%)%<($"NX_^V)1 MEV JT(2ST.7US;MAESF*H;.W^Q_4VJ:D^"E>71 M?Z:L]YR[F%UFV36BH%K_^NNOW[W_J:A83V8/W?'P?[N+X63KFF.9Y/E/>77*P;F?%_*(Y1HWMGX#0V/D\O\ MK,D?09=M$DVPJ?)+6+I_L[B?;BBM,7."FDX6>;)X $0=.4EOE%LL[5M M7DLP%Q-2M>N4@L3NNO/AO#.Y[TQG@_E@O#AN/_/APWAX/^QUQXM.M]>;/(T7 MP_%#9SH9#7O# =*N5*92O=7(^N#L'S7 !.P5YXV*O"^H@2TL]B9X:,+"?O!] MYPMU7>[JR,;T5MR4R WA43@F4=4:_J6XAA\FD_ZGX6B4+-LA6\/CA^'=:-#I MSN>#Q;SSK__RRX?W[__6&0\6.(M60N*1#O4ZUAP&9VF#)@E8S+KC("_?6A 7 M5G0]UIFPAJ>!OR5!Q)\;!G_&=,L5BJJ5^VMQY4YGD^E@MO@]6;F#_WD:3A_9 M&8RS2O=$\*(O49X2]4_1M-EB: MGZ1*Y_WP72GZ=S+NL64V2W1=)$66/S*&C,U/;/9!9%$O NFRBFXXJ^P$ CY# MK=4%ZXV\JD!P%5:4#EM,6$E,W1SY83@ER?.V[R7UP:H6U/OB@F*:96GJ'.]$K7'60&GLP'(O[ #LO3+82C( MOH)J$R1_1EZ(%U>>"Z52U[/!Q\'X">D4R"9ZSP!A)W'"]4\T6O?B,/(W) #H M6M !<%:(8GJ )0,? 5O[TH.RL*AT&67"*DM.OK7O,K:&_"86[:H67"FO4:)T M_389]0>S>6+V^_EOB5EA\3N2)I9,':!_%=HAE2B.F!2<,'WL1T3K%-(8 ELK MJX2F6$98ER,FK)W4.3=],/0Z0 M:Y2J)];]J7I>6H>,UB#HMR@8A*7KDS:?S%AHC*K8CN* ;0@]/ZPH[,<66\F7 M8C:8+V9/O<73C#L[]2;S!=J"R\V?G>89#%W&_!<*?"R"#X&U!!43U%R+=49# M7Y2:,)=69WT6FK!,!YNMZ^\(N2,>6=*(OSY7+M22Z\3@<3J:_#X8=.X&X\'] M<-&9CKI8C[F\8CQA&V/FA#8C$0W(Z=LYZ'(&'P3)G8+-+YW=)%J38,IVU> P MS0Q!O35;?T3\ZYHNY$6'BS.9:<+J3>Q#[YZ9MNWD&5*Q@+\O>6',%Y/>?[^[ M8YRL%XK[[;?ESQ'AF.V] >=1??O M6!?;PXQUSFII)YPE6S$EP'J4]T)>; !H"BL)P@03EDERX@]>^4HGU5[^WY<\ M22:+WP:SSN#O_* HBDMD, _13^DB#X^J['O^7L38G&&D%@] MC3&PH_! X!7#Z[1Y9,)2FY,5/RYG9.L'?-)5:ZWDN#(?//#WO\YL,)W,^.,? MSAHKSEV]NL0]D)[4"_/1>TR'=$9>22J(B@_J<'Z8L'CN+1I\M-R8Y$)FAQZW M."4J:-5:*OFDW'>'L\['[NAIP,-,[X?C[K@W[(Z8ZL M?%]R(:F=]*#S;_OO_/LM_\%9 6/'Y!S)I':P0#%)KVO+7P#A0:-IKYI0W]-Y M@A$#=D=+95@7.RVVH(/X%#+U?1!&=&-%I*K.=M:PV XM-V%=6*H)1>>_(OX MO)ITQT%+(E@7OWJ,.A=?H5,HK[IS<"E,'F'44*6^BX">:$G[M,$!DV3(B >FRU/)M)U-M1+RFA%](7LC9T:AUB]\="*[-4_U]ODU MFWB?;22NGV2OR&:=3EKJ.Z;NC%:YKOZ&"F8).GR\.G#@62X[Q.?^,OK"&*(" M3=(%K6!<7:B4Y*,#M @LA^R]E3+ZPAFQ"7WAV5E58 &[HQ5JJPN<%EO0011F M^0$?A_ 1T$J>U852ESGH:!;3I-VSXSHB(W98.X"]4]45KQ39&9LHC!_XR&VV M%@W28C)]&F[]T'(GRY'OK9+9IM,?>K8;.\E#^RE=FF:85CZ&5XNLMG2TQW-T M>9+D3MS_2;4C: R!5TNL+O;:_,DARJA;DB @SBCEF9"$9/XO)'CV0Y*T;=8B ML0B(%<;!+G&ZAIDBY%WPJG?5,D) Z$=?B$<_W;PG[V2;O6$-DY1P;+M) EU4 M2[+68%!4#3 MG4.F(7CO2SRPF3]3+TU"J8)5U@>*GCEF(S4'T$$ZN 7#529A M#RA YEB!5-2W9D!_X=5<'+#57-0"JP,?0 M&P(*BP&F&GWB#-FX#@YMCXGJ0X[&"/!.IC$$%%%S+#;:_,%'U \(77F]F%TH M//LT#X/G)/]T\VLTQ@_T25C3+[DJ ]\C_UHI]6I-#=]_9&@N)MC MTJG++1,<7.5%?Q;\X:C2D[64&PI>^J?S;^FP2(ZK7U,-H+F])D[LDLER/UV( MFXFLTQNH[@-@"OH&?)QC[N6H2'&RC+0 U1@,VQ6V6:2UN6B,!/BRN=_'O-Q\ M=\.=?]-JD_L 6$W1:.8KV'ZZ3BJZX,A'^5?5:&P M[?C M_WO/YN=#RE74&@P[O6.-NF%G,,V$55A91DRX&'\HY843%A-#7I?77U7LJ)@7 M9\8#;FWN)4[=."*._A5'VO)6)!QZ MY?"9/6V) 2@)8TM=<:&8\B^U\2%L.VU-^-MBAR'6VS(=7=?UOUCL$G7O!STV M?YK<3:!;0=WQL"VRYVT.YW'1A),YJ_\C/)A+^1[3FE+GG<&7_@Y68[;[[".-61*#^1]!.NF;$X%SNHFL\587O#E[-V95Z M!]^Z:PR&EF6HH3*!0&Z9H-:42YJ)59Q2&MZ*PF;H=HBW7^'LN.T(IIK"J&,& M! Z$;I\XKZY93<:U?C;OMPM.P8G/L6!QP@_D,T;&MT;4!+LQ#IBS20M*8HEW MZG*>9T%A+.P'F5N%+ $WJN.7NT' S6O);.]VI?I-W2]6X&A6S&KD0]C/0VU7 MT&H0#73U_K@WCGWOA>V"W ++.$%M]E.RTSQYE'$GW6C!BOZ9PV(?-ZV(4".L M-DA@]H55YR1XH=S24;DJW&0:V1N0[:\\^D_&,1)0OX9FVO@GL>WH+0M:2Q"9 MH 7EZ@"*-9]27OY\-4!D;>>ME 6PF2QXF?1"HY#$'5/8"TOOJR@3J M,,6@+3TE](XL_8 [TQ8G<6"4>+E60H! M+I4B1EZ6;Z F\=$5I#"SG/O'W2[[H]9:U!P0NW2D9NWB\_AFPCI4U#,6+\M2 MR#"@JC'R0GV#Y8US2GF6\,^9>$Q#BP/^,)Q4#7WR_.>0!(G;\M#;QE%!@=-( MF-CHUZZXF'(+7#=A+Y@$*\O+\H@P762?QKA/(HNZX=@*TK)7%;O!CZ68Y_N^QCNS=TWPX'LS9'I"-USD,B*5.Y\@]J3W*:,\7VLWMC'/V&P)\Q6]H M>"2-8#^39,.6'/2%=JI%71+V=G3J)I$MGOD%BO,U7Y"Q8AL &;(?)15-J]J: M@5FUQ(F8GYM^/B-K@P"$091C/OO7D?'L'WE;TY\Q]Y4ET=IWALD[>5)2KO1; M0L86N^.]TBIXV)#GC7@-()Y-9.[YY')(BZ;4]S<6]:JQ5/5!1NML($JXJ@@^ M*G--.J$^+NYZTX"^6#P]VH9&Q'DDFV<25(#"VXN;H[W; 5AWRFLY'YS#ZRG$EBL^2P1-K^20 M$,P^]V"*R/34^SK+J+ZFVX4_\-A-:"<[#K0'P3\?I,(FPTI%6CLGP;T?LYMN MD%C0V3VV@I7'FVNF&!)2DQ@DV7^KLT$<$Y7'EU2FV?.+.6VAUB9 M2EFY[KKSX9R;FZ>SP7PP7AS-3?/APWAX/^QUQXM.M]>;/(V3EZ+I9#3L#0<& M6:'46?Z%63@J^V"_((D3I"HL2> 1S-!B]&OZ@0G$-RD)9P@P,4'ZF@&AKM!" M4P&C&Z=F/+!'?#O(_?FZ@3BE!<4ZE'Q?J&+N)PC5)=O7ZTNB4>3E?JIGZNFU MF/E(/;J)-S)V%II@FA0JH,\QLY(6%+O!H_6JY.II$S2G1357JVA!O[D(=ZV[ MW8)]5K 3JXZ1?.?KWJ=U*&W'RM,$F'R.0BN/BL1\9S/ U!!:< V$')&MG!\: M,/(0AC@BP6%RPOTOZR'L -P-6ZL_K2&0I4* 4AZ@[YN2RC9WNT?K'W[0U*,YI0,:!?)RK]$%537;U0&: 74/(X7A7$]Z.C3W+H=K; MV2YYM#PKS1TA-:_+NP WUM;JQM>4S+QU'<*3EIYC'P(_WD[CP%Y;(?56!>>] M1^)0VW*GW"!%;2A>9XX)!+2U^N<- -H(5]$/UL/KPMZ',W-!5QREBFYF[*=G M'IX*&G-76R3HTNFH#L-",T.@@8A=$8]30MHYNGXCEANM^4/5<"'= *L:0IV# M6HOJKQ2)_*8E)L^_QA6JH=2=#< M$*@@8ECY\EXB"-NPL0B2D)-=DH$K+2BG,FU(ND WM];2%$BEK("(DG3T[6X< M\^E,EH>,ROL34 R.I(NI-5)'"I\5)1?0<>HZ+XPRRE7\+%1:XFU1T18[T4]M M:,2$HV/2L[8TLER>S&UON)S[R^@++T?H.#1Q>9.8;T&]L9/RU,9-ASGH2 JI M? K),G9'="E9;J#.V,EU:N.HP1IT&,7F% B.L-[8^7%J ZG#''0DAYLM=_GE MCJ-)*? M%%1(E-BIU7^P7D=JXP1F#CF&6F+07!XPA]FX16%[(WV=\[\&B'A>W M&4DU9XFRHC$&$--?C<-4GU$Y;!F5:4[(4(*5S[(IU=Q]]RF@06?EA7\/W>')#AQ G7[>6SP!4K[R[\GA4$ M.YYZ:\-G/5GN#Y L7NS MWWD44/>1QP/QOSY,)OU/P]'H$ ^$% 6TIY(A77RYUDFWKCD,KDZD)@/= EH+ M%H$&5']/_3Y=+-OT\(VL(#IG2[TVG;8U&VJ3X"K5VUK'IQ$PJX']XP.^8;5) M,#D]C:S5@5>$$/&$+;)E7[=',%.UN$=^U=W/A\LYIUN;S'\ M.%S\?CM,+WB!/> K<7X#A]ZJQS#C.;^)U:Y#-7Y$KF2.I1N!ENOTR-RH7*A$ MP]VE1ZU'YC8#Z5<2_= \P,+XAX:C@IN!^1;_8&3\P_F>#'$8^1L2Y#/UA,KX M,UDG[+O2F9[U$!*;L28+#(8Y]XF]VX34#UC2'ONFTT"0@Y(;Z#;]K"I&@3S% M"I)VPO88:68% ?B"DF/@>C..Z.H@E3E'+IN3\)9SI$%FMI9SI 67Z5O2$<;6 M6]81]<7B(9!:Y-4]L8MS:%@[X)>%$ZY<_3-,2JA;16C7_C.FC)[W*A%0]3;X MV@&3 QA[3%[*54X;Z>UI[[11:YU#AC7XIG/&+@!GJ,EB<>8.K_%DAW$C.G>3 M;_$%SQ0)>#LN^*W(@=0)7T\27DCP[)_GQM;F3M"U[7@3N]Q?H+OAU0?3;!6U M]@;A6-BN_>WL%0K67;V*F">J[ @EA!5/^R(@3.D <:2EJS0^J)82_M+TOZW M\BGL,(0ZP+?'#?.UQ N<#1J:)$;>I^9/AS>C6Q;I'9-H\&J[L4.]E=KY#]8; M.U;B#,G084_#NJ5!7H+W<<1=J7+RGZ4-D+@-_J#E-O@?G?NGQ=-LP+WR9XM] MR=C!WZ>#\7QP+0(T[AN( 6B&M49K&F4R M?B=6L/CB-R48A^&PC=*7%X@")Z]1#MB7:QFJ% -BFZB19"'/S2N4AGL_EKCQ MU!T/VYZ-(PMY7EZC*.1*O34B"LEXV"9M)%'(E\V[+E'H+B,2-"T/A4&Q;=B7 M%XI*KJ)+AD%VA]8LU$U@?1$#1.1'EHMM?I!PBQ$-J0SZ8]'D< CLY\5 RZ&* M__HOOWQX__YOG?%@84XIT*_)V)"W.#EDV4#L(FP<,]R/FXU?A%&.'\.HF&<^ M&JADG*TZ".J,9@;^]:2_=#[480!^W./749SB#&!A)2KP(AIO)2I:*%$A+"V3 M?5T:K@;MC&TZ55:RT.-"2VX:EZ@6TIH5ZIJ+A5Q19JAS=!EX@JA;@B?#,#(T MC6G7^4<<1GQ:]WX \_21=,%^5&D0-R5C\*'+@E$DEKU/A*[6W OIA03L.(1X M?I\W*O89UJ0 -,!>LS)E[C.#YI."2IQQ?I(YXTQGD^E@MO@]L9(-_N=I.'T< MC!?83C?"W*=JVQ>@*[:]"U8K3&;I4HU@QDT+C*+0KJ6B$]^B!<_2JR&J!ENK M:M6Y@Q"*;Y42SO)NMV"?E=NF0)W?-IAY2M$M5&+2V$=5=BM09S/ U!!:*(YY M(M'S:&65K@Z34^;0$G7 OHIJ"&0Q9Y:5F++6( M ?IA7RYJ0 &DS) ;91*KE%3$25Q!H&M'T0W;>Z;^"@+Q QVU$;%"LO9=9[C9 M!OY+8O169CR3=L(.UJN/&( 7+>U[F=.)'[%)V]Q4,"?!"W^(D&UZJD[805 U M=SP8+] 7CI Z18H,5;]K+;X+XPV$\ES>\2.69XO)#/N9*J&: ?W$N,,NE]2+* G5:T[1#=DG4_4(56AG MAAD4A(3(R=*8QZ3#C$IGMP2'D7&/1962)&+^J/4G($6>XL-,\ON9.)&YI/DU ML%].03O/-BH 4G_%_&R$#S1\^N+F^(G.E<*4QT%,"/:SR]CWGI2FQY-&:!=D M.2,K]YX*ZO"-(8FI+4TV)K-HG#9#5GC%YU71"E%%G2$\9])@P]B>;XEM$-)D M?9E(0[BOXCF^@463T\;P=T2M9^I2K@@KMY6JMMBOM&"^BPF]:F-ECBS(%B5H MCIT'HPZ*TLWJ^H \A+$KSQ<->W)KK^RZ!TNEL1C-9'5BJ HAQMY?BS:I$SO4 MW!PC[ULR-IW Q&>H,#J)VIMQXZYC?!)1A&^$*LT,8(R2]3$#([G$J5M>V![9?U+N=5UNA^;\V0RGA92C&U9*9]C=[HYX]GIC!9_E04+JGM=T M2H.):J=$[EF([2>HB@12]S04,8%,*K$KDH?]$M6U;3_VHG!&;$)?N!BJGJ7$ M/; MFE Q++MP2EF OB'.+9>PV;T0+R9CH@PS$33'#E:HB8Z4>'1H*O8%=2RK MM).A^YWF"56*5/W>G,,)$J$J[60H1,J(5"E1V ?17ADM35(9D:KJ:-RQI(Y( MA?&BG=WO*W/G EO,U&Y=/]S*?#"%$E/YA!39RQD!S'U6U*QND%M?J%#7:)U2@+^"VM%WFLH] ML+W,M/&#, $=J58<,EKS/]/& .*8T81M>NA%#%Q_L[6\W=$V(2I'+&QMG/HK MY*^4#"&K$<.VV 09<=2EV2ZZSW/XSDH3'<[7K'5.3>#^ZLD-IL MF^U3-V9-F1CQ/*=3KNQO-KZ7=!&'>/WTG2S$:S;@SC7#T? 0X_5I,'SX;3'H MO^M^',RZ#X/._+?N;##O3)X6\T5WW!^.'SKWDUGGKCL?]I+PR_YP],0Z)'4[ M1I/YO#,=S#J]R>,C&S#IC!T4-K "C[&2LRQAEMI%1]P#24TDT=!CXD0X\MT7 MQDLNXPL_DX#(MS_SU!PD"!-AD:B2N@,AJRLJZ(H*9ST^H9]_\'EGFT 3"!^& MPM9I6@.YP"QTF M9;<J\(.V.$! M9T(J/B.; /7B5RW9[4@6=?#3^^(U27V=00] N/Z+S77GN-!<>K?T%NW 8%IZ MBSH [1EBJ*4'/6EZ8ELH+1-#<,$!DPE94%ZH)PGXW MG>YUD^2ZKWI K6Z-;O:0B58I-:"87O2K4?>+%3AJ)[9",\/6A&R3*LPXH49TP++2RLSAG>[8YNIM4M2WG$BCI1X#D^*-[8V2L^V=KYF!OR5 MHEL\HEJA'WL'G1&FJU([RK:4)X]&X6S^I-I*%=VP;8UMKHR"6( 8B+XW]WFX M#[M!AZ M)94&?_H@>_Q_["Z>9L/%D+_NWW=&D_'#N\5@]MCI#^[0ZPTF=!TFKC9LB=IC MI4I^CH8>FT,,L&U5-C9#/9*C4$J:7$$'OHWK=%H 0Y>P@SF8"&1+"HA1=B^^ M?^VW+_7-L;KUM<%1306ZA:LX+=5U4-3>##AD@J7 H]U<&!_)FMHNN:>>Y=E, MY1C[$1%[_O,NTA[8"IE<:O+^F0#"6W.'9:<6^^CQVU)^BYMCWVKAS%:1C'[= MX:0L,E*."NV,;-.K>,A+H%(V\:WE#KTQ4Y877XC[0AY]+UHK3H@SAD6^T2I4 ME(I]ZVP67K7SAA8'?B<63P[3D.P<1L/>@%N4F0+'OC)181^67-;JCH=]A+0M M+GFN?5T"<^_'LFJ@]8;#=NIL65SR/'LSTI)$0FXI+[/&:Z5.GEVZ2M-KP<1# MUA_;;[2^/*BY4EL C"AIES/ 2OT+OR]:8D^LK.BNA#=[JPG6BYN]]69O;2<4 MGNVI-+JW>.AIM%,DFZIH>VU05-& ;FD]G90RH51E:S. $(N3%(=V+:SSCW>G MGY-:^X2ML2_V,BG)F_H4Y**D>IIQ-QMQ:J?MH$,\&[@JM5M* _G/!WG\DRY\DH5^($S:]FVY63@9XB-.]1VO6]9Q]\L MV$\AN[=Q(X+HFMJ8>)/6H5D.3+*NVPLC%4.?RE+>VP MIN 5%$<)(UIZBQ]3+UJ/?,M[]!VZI';*,1 6L*[04[HUDWD#R.@P"?U >LNA MB_ #"A:_V'">5PV4;O&+;<0O"C:YKL.NXXPEEOLI6?OR?4W8&KJ5X48F2DDP M9(^ZN9D6W$Q_O+F9WMQ,FWV0O0B+(;&YO,;L8Y-B-.G)B:NHP8)S%(#5ZW--CUV=P$2DF= M@:[$*;$N>:8LQLR9,B]T\FM3N35VCLIZ[J-5%%^WMW"E(K;9T(BSY9Z0VH>B M>!0@]#\9 GT-#K6TM1[KI.R33P^]R7(9KOV 9%.CPMH:T,Y =%J[\&ELH7K\ MP-\V*R1I1OAUEN<./^\R(1L'B&AK#X3GKSE9KDNDBRY7?()?0L2;F;HG M%")#S!I05J!C5KFM#EZ9@DK#5+P.?SSLI;**C_6&@Z*+;?\XCTI#(%=>#%6) M$,$#0&$UQ5BBQQAT(*^D_NY[0PPB5UQ^M^"R(CU+J]I"D<(VCDA(,!*)_$M% MXE+G'$T[4(3D8Z![29^#'(0]9B6&[=/06JT"LMKO#>2%>+&L)NP/LK2P_>&\ M^_ P&SP<:L+.!A\'XR?T.JX976D27R\)C?]$HW4O#B-_0P)UT@+P %BYNBMQ M5*4SD/8RPUU.$[E2'F\9A09D/*B>7VG; 6.7ZVD&?A#)A(&6(PT_*\+!H?PN M#MF\PG!.5AN-$(;J;E<+F8(N]/P)V724]4I.FYD!!TC4BGB<$M*.P_!OQ'*C M-=Q=2UY9##[N&VY4[Y<49M\FAYUDH=XJ;LA?VR MI60TD&Z4X/1IX'-'GTDP)\$+FYPX045U2S-V$)T-74@*2OZ*;"K95S7'SVTADZ4R]ZMH:&<;7Q![[?FNO]H-/"X1SN&<\7DQ%%DD.N\/[XZV MYU;?ZN M&,Z(3>@+/V#W3.'T\[2__8Q0M3GZ1YDYNO=;=_PPF'>&XTZWUYL\C1?SSFS0 M&PP_=N]&@__H]";CQ:S;6W2Z\_F _>^XW^D/[@>SV:!_,UQ?AKZR+(Q)U(L# MOA;%1,E[(>\1YUFL(0RIO2=LD]BB>60%$6HT0R5?^-J'@ _JC&U>.D\(-/CS M)F5A1*WGU!VECC"4>V/'>C8O#2(.O6UQ&/N>?99$Y ? #AQM42C*?+IZN1AZ M=L"K0/1)^M^A=SPA)0]NBF[8<:CGR0"()_K(_YHB[_%;3M;6'-2%1Z..#$@& MP8YW;5HBE/QJ+;,-9": @SY-&5-O,.P(UII@GD,R_J('"T3AEK^/W0;+@+ _ M=FALH[ KN(1N$VS^!O_'!_Q8V/8N\9RZ1G2R@8=[-K=]B=<0@]:<%UJ_QK]I M:6CV&J\A#^T%\;9_D_\Z)*+!F[R.7%R1O4] :4NB@?@NM @LAW1=U_^2)(7T M@[X?/T?+V-V?HI+GGY]DSS^+6;<_Z'1'H\FG[K@WZ-Q/9IW^Y.ENU2.)H@CL?]V//EI,NGI;7L4#2;3VG30D=>2'/*D: M\4+"N1N$EJMSGP />=U/16?S$OT".0W\%\K]O2J$7PRXO-=U/_A .(*9S4Y4 MPP"TB[&??#8'2L*N\P_&CXT@4#LI$G#.B%?ZOG,VW88L:Q@-GP(:$9X+[EP- M(#?0=3_JU.3;53_S7$9)U+@H&OJ\ Z?SK5P33ST #Z7NJ^Z"/Q?O@D47OLZA M^^VN=XM"OT6AWZ+0C8Q"OX4D%@!1A20V'%9^"TD4![U.ZQ^0/# MH*4]KB;P$$!W2^XZ,[+Q(S)E+.%?9)-@'575J!1]KB;B$$3[&XKQ-"'0$"G& M,SMF>CO;A>XL\BY7$V (H?S-Q74V[QYD9%RG4-CYC=]R>8)XA8B7&Z)YWN@+ MMHA*?!-H9II)ZDGRXMR<;,. MHO;X%FJ(H&]TT+/W M;G?\N3EMLWI4,Q9CBYIF-=DY+P-L+9-/"JY;YEN;@5T34BW4)O/D8F^SJ2MT MZ4%?M=$JNJ%7FY%)8@$7$ ?PM]FCO]6]'XS)EVS&3!JG@>^Q'VT"R :M.8P9 MB['.1JI'9^Z&@[0,V=B39=?QDV*QRM57V=H,L&H):G%)5M*'O54>"9GS.F-6 MX(1/6\>*R(?OWO_T_GL5:,#NZ%NG3!2KU1481]"WT%LJP6M/)8@B+X<*PU,2 M+/U@PZ]PDV>7IEQ42HBJ.W8LR'E" 6,.^M*7A46+$93WP@[XJ DO9CQOQ3C8 1P-8JIFEX'Q//O,(TE-R,1;0Q2G4]D2.PQ# M%SXA(88LP^[&#R+ZSXR:_4SGEDM".4)[_1#8'_L!JN:RTV,/.IHS'I/@$6=@ M!?S$#IGV'F]BEX?BL+E3FTK# -1]L5-?U=9DH&RI0/#R20S6['=KWV6L#'D= MU6@'"53YI92TX+?N;/#;9-0?S.;_^B^_?'C_\]\Z@_]Y&BY^-R=V)25/':)2 M;(=4[^N076(>^?;GNUU2PEH1B"+M9(8]IQJ%8O$O&1WXT299-?%D;J7M0%AB MO=C<##P Y5G@D)*$7,#!C6&K);LB8E=+[PT*$1^Z N:&W*X:!_X M G+0?<1S,^+>+F/?LXZ_6;"?0EXN55:<<6\7T1W(#"2E4EDT_>B2V%+4*@DB MNJ2L Y\Y^[:C#EN5=L%6"FK*X$E$*X GZ#O@025-K]<]?[/U/;7[CJ*;&>OH MC"M0-5GHSN*%::EN0H+FAJ #D;P"/@*"6BH.S+/0Q\$N$9Z))W9%3.KF"AIC MOP1))>:D\*^46O1]2N]"<^9%$Q4,*0F&H/$I.0S%YWO6KM ,>H5IK3B%#O\K M241G_#Q^#JE#+;9.KBA![D9C:U-FN-[KRRJSFM( M7T,P4\EA$3$ 9>V6G3BB2 ]R27OL=V6X:)TD5%4QH)U- M39%*:L;O4N+\7;D_&R+P\$WJ=/KM>/1#N"L4\_T$#;%ZG/*KFI>MNMXKF/EH MO=)-O)&QL] $SV1>Y%>)FY7$&*'6D#]C?AE\X?8595BFL,/5[18J@G*'BC'8 M*/48<1=#\)'+FQH;8UYC3Z>F?.BK;@[=KUJ[F"EE3(Z( ?K,P9HUMXEG!=07 MZS:"IH:L#"T]1T!*+O/;!1'(IO#DA5MBTR4ECBPYJ:0YOCXDE:8\_\5$8&A* M^^G<^P&QK5"\'>6F7FP+W8M:R6^GE*$*WE<3BZY2G=H/^_2%.L1S9DRNIB2P M.4=7$G]06&_D,$*I-Z74G"IGA]G8]7W7M8+NA@>\U@3P= CLI];&8*SBC&%8 MCNB?,742UJ9_()X-7H:"SMCQ?_7QDW(#28UCTYJ1;9JUE$P#?Q58F\'KE@9I MEB0F:2*M#M(3.ZX/A!68&D.6V,G3)0]X\KTD.D7FR27N@OUBJ[.6[)15;;&C^6HC>4)K6RZKB9QTXVCM!SP8EZFQ_'U!Q.;$MU/:!?MU M!,1M-1FM,OW)8SSXPNN7!KE7.-C3KGH4M!SO-7:N.OQ!!S4[*Y/-UN=Y@V9TM9;57!5V M0$L67P,J!=7HJ)S>#HK[-/2:5.Z'[OA5_XHD8@(Z5KEEW_.]D-W#TYM!FKB0 M.!/M?1$R#!1)(XP5M5B$#BR[Z]F$."%/L\6W\"23TO)4*KN><[RP)[^1+M.U:XGEH4?(1*!D!/"WF^N5C(EJNVEARH2TB[L\(DE=.6L .&8\-I%<,/ MZ@R%W@B#B@8[6KKL'V; ;[NVRV91M?Z2U%M5+:'H2 @U;&-,WX9R!_-A MZD/&TX!8@>0*6&,H=,>:^INE!JL, WF_NZ<4A(V@K3:@9-AJ8SG,_ MU>0!DSA/'GDE@4U#X8DLZV!4)@[IP:PFV\RE.XFCD.=QI]Y*](0"982Q M",H(=,2FUB[)BI#1M;=V]/Q0MI/*>T&1,L/6 V" "1DZDY>U:)_!@J=F9F)$ M/)MMX9!4G;\64W7V)H^/P\7C8+R8=[KC/OOW>#$%@;DZV3AG9!W+4 MR3PUA\%9BR,_#$^FIDCS*6IOAN]Y+>0*BU-$(7[NS]+,2OL, *^1:5E Y1*H M F=D4A;0&4ER+4^M(-KE,_SPTFK'O\CCTG3&N$( =%00[]DN%CS^P.[:^H ^F#EM, ['/])X5";D;A1Y\ MY8[8V^BYP(E882ADK:-:H)UTQ8YI:PBV"G:TY!A2^/Z3MV42PZ,?!%J' MI#UVL!J<]PI"6F5XUWGA^I$P9CK1BD[;8,>.Z3&VDD#\;:="2>%TZ6EM:0_L MZ+)&-+0\\2:\$!V3O8R(%9+L1I ]Y%2\"?W\7:E\6^^W0?]I-.A,[CNC07<^ MZ S^/AV,V7_W[T'U7H&$+G7[;R<3#B7/.*ECFJ@YSH*8;),( &^53(<_&(J7 M0E5;K%N*G)>5XB\F%7U;FJ_](%J08 - H:HMVOVB!@QB6M%A^&@%E!OJ "A4 M-$6[*]0 04@I.@8 WNOSO'E%OP;/9;S6\TJ+_,AR"SYIB"?U/-YN4VW">N.^J.>X/._+?!8-$9 MCN\GL\?N8C@9=V:#47D(YJE5 )I2MO\&JO>7K^!XMZ DLH;RYLC68%U>6O@E[#]+Q/A*\R MXG39666MR(QPUXG]'[GUY#WTI(",A):EZ^PC!,XGLP'F3. O);GTOS4!KAP) M+7M7TP!+^&36\T7>*,(C^^]=_TO7QQ>3]?*MUWOY?MNVQ'?9H-%SS:\/#< M/!IV[X:C])>WC;7JA8?)$Q&(SGX3Z<=DS*!>?"'N"WGTO6@M\]&H/>(5;;[G MLNVJK650XG\G5K#XXI\O*H>!KFG+KLFEKT5O+AH4X7] -RN"#QY3F:XYE&N-FNJJI97<[AK>LDYBV/ZDO)K M*BD>67&+^]?E_&'@PP[$6F@$*I?RM&L^X:9YGG;LW#?3[^JR?G8ME'4QTM&N M"NZ+OP"@:)/0CN@6T'-G"2&MK+I M-9C6Q;-OYD@2UMSS;3O>4K:*DIB0M16LA*'6HL9789B6$6#DJ3_<;"T:J,." MY;VNR2P,H1\=I+VWWL3C*Y5Z"2>S9UPQ2/)>UV2=A="/#E+5?4Y^>D@N@G7. M$F-MI2T<+>?'',?/[MPQ.L=TU&22K:33!+267P1&6_/KG'XO*Z=Z-;]J= M+8Q*=RW*#ZK.<*WNB;16#DY$L-RGBIS7-8J>9B!ZEG3#TC&/6L^J'091#DWVKR.2[!]_+/A..ED./8?7#.*Y[*H3S+*V M@J9O""LQD>UDR-;%YA.-U@D1G)XUW2[\@<>.0G'*["J"5(,@XRG&0(V5BK1V MLM).U[N0VM3RI/EH2ZW0[!1U.%>V7@BH;B\H;T."L>^Q*9,MURB]J$^9]L@& MD.)NV$IW5+V%R]0M2TH^]R"S;V9-GE-4E7:9$)Z0XG:&[(>FEP=Q,0 MFGL:P\$K-R->0Y%=WJSC;_*DJM:8]D!F8"R5UP*&VB2VHUKWV!=BE[]>=E^E>Q WQ,%NT48AJ&-)J.AF!HH MZ81AU:Y!86&YGQ_[/=8PL??*S:VBQM#]KGEG;QCKRKN;G&P#MK87XL7DGM') MBUWP%V9N-^[%8>1O2#!XM=V8%Z/G24K8_W,6UJMLN=08#+D0&_3]N;2$:O/M MBKW[NW82,A3.B$WH"S\-QB12!G#(>V$7;ZLI !!67'7,Y3Y\\-X/9E)X2PVQ MJ[K51%1 ,/H6G9M7S]K2R'*'FVW@OQ!%AC15/^PJ;N?#)&$'.FHBK2R)L@PG MR]SO].\0E8-@5X:K?9)J,PH=W"3-Y''G#R&GH*R/2:]D&M"IV8"/U(FCN#B] M]9ZBZN;8M>CJXB,CWC!H+EP@I?D(_2:A4A=+N3Y]$CG\N_D0_28!!T2"&X7: M9>.Y+VW-J8F=-+(;RV?!MS\/PS F3C\.V(RG)*"^,U\S[H3I[YD>/2?!"[4K M0V0/+\]ZXQCE<**!;#U^7?6^?/H:W>?.H\1S<@G@K95$88+UAHJ#:48>'=Y< MM1 ,-EO7WQ%R1SRRI,E37B+S=VQ_$E@N$Y:NLZ$>Y7%\W-=4>1E5=H3B9)K) M!\B1J]Y1TYCHA?5*PJE%'3'*I8905$VS!@DH-B$/5@F6U M"7Z2U2:8#>:+V5./%R@8/W1ZD_GBW'H$#=B<<\2QU94!V67PO21U&" AXN A ML/Q'>:4BSTY*/8>2,EVEAN@/S9K@E)Q'*PEO*5)N\&?,;K3=+U;@A%W;)FYR MX_6]Y./=,/1MRF?/W[P/$Q/XF.3\@:IG9%ATO?(0:$A_IR MA6L2\)MG0-9,=68Z=/K+ 5>00OKLDH$7;[+=!R@:C7T-_T&Z0=%J& .SM.)< MJ:[3TTE+7?Y9IB[GRW9UY_-);YAD5_HT7/QV4Z7QTRY53C4!7"/9DG(04QRF MS]3$=4@V(<-280TG$PU)\$)*5WJ5UB#J;0:P-01:JDV(J&TIQU(SF*JB4A0= MOP(DV\S%I(%A&KEV,D]5/(JDBQFX >6R,K:RDJQV8E$.EV[^@D,89C_$8MQ4S: ]L\ MH04*@':S;$;9U@Q4%PZM3;*D*Q1:F590H+ZVM6B;^@A%5A"98S-JUQQX&;/[ M&=B:5@;A)+@H-T^)9Y6P!_9!=09&*C;HKT&#RHZ=O[7^\0'_Q&MX=^4D-;*_ M#KPBN@A9Y0764&EF^5_*F>7%YDX#LLM_!8;/^#DD?\9,+@8O/$V)PL)9V=K M^W8=4V8E;?@VR\*\ '9*<0\SD)+)G!P4HPR/13+8IQ0I$$4=KAV6(R7HEL2* MF:DLB9(N9@)3$#0U-L8D/#R=FC+5875S[+=TI8C) 3'9"'+ZJ,!]D.WL9XEW M(7P$9&.)ZB25J? SI@%Y94:/<[!J"F7)Q-\YA'+$+9F+-'$]A*5" THF]J: M]0+*[EJ54R]N<"@$G$U=RP.9''XMFAP&C]/1Y/?!H',W& _NAXO.=-0=&V1U MR ?/):=.1(/$P^Y(A=KNH#4(MLM5GP'J$><$V<,TX4Y7H&',T.AK8"QTO *1 MC6_&*$\S5V%3;=, =C<#WEJB70 82#"^&>0HO'R28VNC=+NJ;O]VH!-1B&X< M*4],G?57U,,,N.3"I\2E7=>J3(*2I*CT.>:<.9W"O1\\S?>*C=PSI.98V-]VV<0EEFF-(9!MGEIJMU(%53"J+=?8\M6_3T([ MH%M!*%_B%:KHA'TRU@(&0IA9JRPO,7RJC]8KW<2;KN?%EGLB3E,2[$G+,DHI MU]]Y@V.;0QM8FDUPUU1)V6\NCU;$^,B=C')_KRD@H#&QE:P6Y$*#ER;8>H_T M3I9)5K%WS\6T8OEB2W>[7*/,K3()!Q 'Z/[R7=$LW!_.>Z/)_&F6A.C.?^O. M!N_NNO-!O].;/$X'XWEW,9R,.]W9K#M^&#P.QHMYY^[WDX;3[N_\]YWNI^ZL MCQVUF^=AGG%Y?_R$;7FN 3S:SAT7V]A*?$Y$EB14?O)H%,[F3^J2]M)N MV%:--E=&E>N7BH'HE]M#?J0T2IESQ?<2/4GN*B[O9L;B;?U@ES,A9Y]!RA1^ M.BW5/BYH;@B6$#DMY@"O)@A[9V43VOA>14'Y2C>I8E/L'50J5 4 A)2:L^WU M7"L,V0;!YPC<\LI=#%DBE]KNR@S(F1R1UE1N2JI]KJJM(0BJI+*XOBHHP=[= MYB3@L8RGY3B4D32R3MCO(&+9*J5]5I*.O_$E<[RK X^@$_9SA"8\4M+QX:EK M*TJ/Y:''PTV2'3Y)<+-86]XD>7<-Q[[WPFXDQ!G'"K O-P7L>*O&S*--6?SJ MHGCU^7#:X]@#&R(*AUY:'0Q#[(LSP-;@KU#LJT%\P[OUQV218TIM<0;86M@5 M2FTUB%>=-ZD]9MW[P9)09*&OF 2V>GN%JIZ[TH>S-,'53N+L]EY6C4+DZO8?:7*V88_7II@O)KW_ M[CR-AXMYYM[6[2V&'X>+WV]^;C<_MYN?V\W/[>;G=O-SN_FYW?S<;GYN59)S M\W.[^;G=_-QN?FXW/S=L+&]^;F;LH&_#STW/S\-,_QL=),QV[K@Y'=Z<#F]. MAS>GPYO3XN;.L/NR\6=?E6?N\'B<-."T95Y1=O+H7U,+I^ M#T*^L(9A&!.GGV1;3UT/4K(+-HJ$,0^!'THUKWKC8=];VI/ LQA\W:X?NJ0? M/& :E*_8"="B),!_,/@Y[ XE/4'839)1/4)68E=>H2LK _D&-?LX,8T[+OD*- M<@S?;Z@9NIEF([VHT]-A12P[VUU$V=?F+@+33 MUR<64G:@.R@)9J=Z+%!T,P-E@/3"L&JYR 5E>FTT84HU^UA6"ER>*U_2 =NX M Y*GDWSX2NK1+\P/Q&.S<[N>TW4VU*-<%>'ES7@-2R\DJF<"8'?LBZP651U^@7@ C_ M:@3"C5-ORA*NU+!U;, ML3R\LJK<@#%5:6\FU5N8I=&FTUN8Y2W,\A9F>71,!]7B-;L";SOX&E:3%QH= M:69<(Z#J[F5J[2Z^^(NU'X>6Y]S[<1 1XNW3B?#J5DQQ2NJCR6YK>D-@FRK5 MM3KKL*2EJW9WDZC6V0V/'_>ZX&B-@.V_I<:F!D/:N?N&093;I=B_CCL4^\+)?4)D&8OB/Y 3>"]=A,8C?B M&3FE6Z+N(&@G5AV^E[?,>CQKZ4#;3P8$D"X /QF.@&DVV5OJ@993#^"%@-Y2 M#WR]J0>,"'B_I1[8VT31H3 [QO.6>Z"%W ,_W'(/W'(/8.4>,"6X_99[H!*> M7PR!Q^S< [=TF[KI-G\T]_WWEF[SEF[3Y'2;K?D>WM)M%F"^MVCPT7)CN9NOP6Q<\M^3:OZ&;&XFU[VU.16-QSRIEX,V+' M 7>/9313[DG[')+@A9,[]+9QQ!TU/9OU2EA5I%!U)ES@TV;(&&C]B.2F/>:T M\]IT3U_()(Y"ZI#L=23TEXLUN?/92I&^8(!Z0HU(K=VG+K9@\H\A&DQ%/RUR M1LR>M:61Y1XROC!6$)[EY3Z.&+MX:AC+LR5NJ36&>JLIPVIS%5T>FDK.$D=K M/^!! 6?<,O0_A>UY97S.G!(L;T;@\),VX;]>&2]^@!2(5R:%;[<(\E>46.S\ M(LA-A*DA2'PYCUB)6<^59A->7Y?IS3.Z6D^!<0I*>UU!S-2T_3'#+IP*IS'%>7I]Y?B%K0 MEU0?Q':A,$]C@D'4TG95E5D[,2_3)65+)3S8G 6[D49_XU]J:VTVV@QL"%ZSF)(I=-8./'E<8HWDG1!]T%MQW$0)QJ":7C]_AR\DL%8D MH;EO1>3@LG"!RP%@#E I_8I,K+61K!!>Q,HB_^2Q3ZEW7_\+W>4F] MD!]D]4+Z@_O!;#;H=Q;=OW<^=D=/:;(Z7AOD4W?<&V#7_TA353*2CQ2H,]%) M.^%L0SGPNF%(HK ,H9@>4&=DWQP 4(7UK,&2JR^Y5[5@3ZGOK?DV-O2$%]!L M*/V1L)UL]"6C+K?0E8VV5[E&G;'6[CNM+/2W60LL917/G'Q'EGY CJQC_PDC M:G=Y/J^ J2.>Y/S^479^#\>]R2,[I4>3^?S?.W>#^\ELL/\E.]+_H]-G/\T7 MPUZG.^YW^%^'#^/;H=XD'1S?>[9*>KX742^FWBHK(L%TS@+N)-PCKZ*SYJ!7 MIP0TP$+T7;\&#=FJ;U0*#F->WX%_/@>O40@&KXPG# SJ6<$NN?FR*ZK->C)6 MLZFMAEY$&'3*/;&ECUZ?HG$!#,PR"1P3#^V5#4;4-/!?:,@C8(A'EC22J!8_ MR50+GKU^,AZ,%_.^+P MG&0!9@;[Q9_-,\K,P?7[$/E(#.%7WZSO3M?AB"HJ9 M5E%CX0D[7M\Q"N2%*9@="-2$3-@/.^"B-F(*3J #MC<$97NZ-G#0_MA1!O5- M9##.& /DR>9>&T[8*-BQ _5!U>&2,=#61O-< %MSO:\/H.F8:6-U+D8MUY[4 MO_-#L+G.TG15S__I*PK?48Y9,B2W_)_!#@#=^7S KOO\J6 T[-X-1\/%<#"_ M7>Y;>AWDL\M^ETEOEG""8]NU[2"VW/#P1L;T\;X?/T?+V&5_X^^>$@^X-KYU M=2:$]AA^U1%]);:'U6"B OWA;>T\#?DB#:\2QZ$9-\'D^_%3C8 MB_@D&>/Z+![Z'$+7^4I3SAXYO!5__^A90;!;^D$2NG=R_]" &#SB]1E,SN7> M-<&O=CFH-=CU&EEJ\*RE*)O2C/;/C2.ZH9$HR0+O"NIY1283,$VFKK^R:GGB MI>XYV<4TK/:/Y]'49VGS-;YVO0:9-KBNK^+]FJIX'EGQJH_GJ'B [<'Y1QQ& MDB!(0=LK,NA(J+CH)CP-R-:B7$XV-.1^%%77[*K]JJHC=OC^F5NPF!?F[A2)_#[!T_UF5)&S2&P [&;V"O5/'G4CH.^Z''_DUK*#F57='#[L]5 MCCDB8T_X"&Q&FX:A2D$C:HP?3UU]*U:0; MN7Y@&FL;MP$#@M@OJ?2_3>MMDNQ4QYB3MD+ZBN".+C_3M:[: M[XTUQ50RP;S=%2NJNH5"W\VMFB;CJINS>30/OB(IC*@]%&(3;"0*4LQ;ECD/ M%9[(Z MU779 #QE[O15]=DDV_>Q/(/!TAX3B:X(-YGQJW];"SE&O*QMPX,TT MVE20WC"JB,YL@^62V!%].8;BS=@$3PLX23S:?I%YM WN[P>]Q?!C/@Z^,^LN M!IW9H#<9]_[_]JZLN6T;"/\5/28S==LX3WF49-I6:QT5Z;1]RC 2;&$BD0H/ M)^JO+\!#I$!6P)@['Z+!;#X%I@]S-)+;G[2VKIYY$[*6>=E88K% M:]+6X&AIS14&/K,7P_5BJ/(9[C*?7;NAX5'+&NK*5(P7/G7U,?':9-61F6QM M?/F-#(\PUD!'IN*:I?E=3,0WF,S/5'%81AAKW.#P^&(M=0>.O##LY+9X>CB@#)P5$2*5HT.CX;6 M@0X'?2150WZ:7T.DW)$%[PUZ07M?D6?00=,#HKQU)[39WB6_KK/5>4T7;0^( MCM>AU*89QVNE*1L4V/W!TY3+US.F0=6%&]#@U4MA?J7X[0D"%:0\0RI=1<2!_8!Q6:P5IJQ@QH:YMS M Z!+0I^CC]V"'091"6CR5P$R^>-3$B:F:[L[Y#\'[G&'-^Y^_!WSP"3E)<4' M#IIR/ HCL@T^K/SE:S[ZDWX$%(.4*NU1NJ;^F+=;'<;3S QR=!,Z' MG6^9\@/W/@KI2B=3IL D]$1"40QQ1@I5:^+2D4,2D(.SH_LYHD_.&GKDR-:I0\]GR# Z!JF7H+^5%BGD MKT^+/WC+$?(-_<*<;"N%.O,.&S(MD@ZGKQS*9T.FF!F>M>TDR A5.J4'QD(U MY54*FH$'UY9$.N]W7IN@Z!M"GO/-=W9^'+K>UMGA(#HM/4I5JGQLT0<4I;Z[ M38/0!S@"NRH[^/;ZZFE6G7E;](0]'*$'_"2?7OE%H4](-)0ODQ%\@IC$(?90 M&(XW7V,[\\#^F2]B(> M2*+RP)S^1JL)=E^X6; !\%MT%5633\BM"9!5T@K:F=GC:0*_<+#HD7.IO0U ^.?D"D M$(]56E&C'G0J0"MP-&4T9(2);[85#RY9'6C6?A?C2JT3#FR .=+)93B-]<_*6MC6VYQQ=S5:6 YT)G0B:2HBO6L]%3E4 M4^U4]8!6QVE26'[)HA.X7DBZ0[.&R&*N> V>&+%D15RG$>#=DAY\[*JWOI;@ MO2H5=.%[?NY)E&FPXAK0.Y=&H*D4,.AK1RK"I=JICS%3#WKWT0W27&4TCF)$ M?N3NH4GKQ52[1B_(BU'Q(,!92]YV>:F!Q#.=UHBL^R(:]LXH7I)I^9UL6EY; M'ZW%HV7_,EJNK/78F2WN1MDI;I6UH/<-2D5KRMW/MEV1HC/U MO=#?XVVBK61.$N=.B-]GMJ?]YV[@9?D-9!@JR.(0O%)F"I50&.UAWR**6& M/A"_/6 /TS@8/8E60J:L"$U6:8&;IE+ P>-?EZ6$3E$-FLC2:G+44 @X;#>( MJ'23D=J(C978CV+0I)6@"2PM(--0!CA@K\S[[BU9NHU+U.5[@WG"*(@W41R4 MED8)R[CH\'3G!L^R%6.M1J#3^-IYR;K* @>X#O+>VOBP6_9*'? MGIT !&9!.M" LUP8.MNI"T"KPL-!*HC]/WKN/BE/KWS.R,"2 4CKR*N WW/1 M!#BU6$WA,X@?-O,B1,"(+IA098K4 DFOA=2I#7XM1XMA6T<_\+,E+-FOOQ>4 MV_C=?CE_)F0N%C-*'AYFGUI*6<>E^VRM[U'@$MBPYP:G1'U$11L:6/:3V%5N M]K*AW^,_U34X$Z-(KX#&L!FJMV2O02_T1LNG-"%TCEQ*(MTNZ>7P5Z1\'- M MRL0-<2BAH%ZS%-3;\6P]^CA^>$Q(J,Z]-1K;MN78H[DUMA_7ULUHN1B-1XOE MXFIM31_7:TI G8SMF0U-,3VKI)!'(U-$7@LH3R3OT^0THB4>/(.TZ">GE[?$2WD;G.;C)LR8J9OD<(85SR@# MN&G+AH&O8>9"(VBJ G@::DG\S'DGC$#JL.5$5&7%'PA>@83@[-,57=(D>?5Y M5SFN3,67J=6(<:#*C);!LY:@T+2G) &8&&BZ;D7;]#&W!O#6;@B:6]' J!F@ M&^H.?--?,NOSK_>8[#6"S>[T0(]#M5VRM+YQ@[B%9Y8*"G[]];EW)3<55KNL M2A^HV8QQ^&I8LPAA/8FAO?6Y9S/O&$=A(MT[E6>65H(F336R7!&(8JV8XW-+ M?;QN@MQU3>1Z"WCUA=SU )![WP2Y]S61ZXTWU1=R[PU#+J>B<%9D:DH.MQ(P M&[RK*(N LB/1DQ%7 L6?0_0UICR]%VJQ&B_L?7A?N73@<6);?SW22P+HE0.. M0<_LL?)IW!H@K '$Z+[LC^I: &YI,Q:5*BQ8_C97%/BP+-,OC7"KN(:1P$AS MNH6BP(=#63'(OU+DXXLJ#!V60A+P,">G9\J$>W$5,X%A#$V-C2E;7Z9KJ@6X MH#ATT%%I8G) #%M@%RO-O1N&RR<[\C=?-.\5J58Q<\#H7!I2E04\(ECNDLJ) M\% HS"\2JGW22=4[HO627HR(_8MBIIC4K106[%<.@. MHJ(6SI#E MV-0_''PO<;))+\/L3M6=(LW_]O6?/MX30+1 @@2#M M-IGQE^?GC]\W/SO-#[V/1ZW-C>:';KN#_S+Z:_8.>T?=5K/N_L6W]?1U<_^D M\P<[[_UQU'U;&2@9[['M1A2SG@C!L&,8LS,5BF"R]W>]V;)& M_ 6.N$KK9]DWT9MFG1I$;IS>>!PQ?(NW>""&WY3K.^WUKPP&@"?G!<&6-G.[[CWN'Q>]9^?];MT@OV^;#W@1T>=PY_/^Q\:A\UZY]:R\*5 M+XF)Q6#RJ&<^'>,;UN?>UZ%6B?2W/!4HOL M/=0 (6*0C44\8H?2%Q?"3WA093Z/P6?<,#7 =J,8PCYHMEME.XV=%^Q9/ +V M<^#_F:@W;6S IT9^UO;[+ZP/\1A L@.NX2!0B5_%IKU:E7'6@8"/\?'FAJ=T MI#2/A9*N=Q$;%FDA/1'Q@$4!]X Z[R=&2#"&!G7,<"3-8K-2UR)F-17BZ8TU![ M:@!=F/&T4J-&F?3Y0_>LVSXGH53%Q8G 21'#1OP"F-4.0)C!=L)>SUFQW6_"3+>2(<]"]*G-PQI]E]#G@Q$:&*&.I#O+_($V260J>!E"5#A4 M/I)O"[P#8.?>"/PD0#$N[3,$@?+=R5G7PA)%'Z'#"!]26R$%($($AHH02'A2 M^$BSH5*^_7K!@X3W YBN6K45-7@@D'D.AH.!\ 1(;T+MXJ"\$;/6"6&OC_K9 M^RK5. !_"+ZKGJT03K@G^VB JE^-S=Y3F["_@>E#%"T=-.NRIWGQZE7*&,&7B3#J%;&%'H]5SP)\]'$>6F[=/79Z[?VC+COH M'AV=G[8/#H_?OZTT*O;[:;O3R;Y?>ZQCX<\]M :M1W; MZ.(FB!=2:QZ%MUKOY6:?Y0GZ-[Z^C+?%RGN--@HO,.K)J/^(05$4,6CTF*J,30 MLO=)6VC#GOUSI]IH-&J-QB^,HY:6Z/RB?\/*D49#\1E#)%T(#XQ]GT380RH? M0+)GVU@?V];6>A@K_97YBMC2]R'L@>?1U =C8X@'D5:H1]&X5IK]V;F"S)@A'X)A;5*XT]' M'Z$71Q34LD;37F>X:,="X5-D8NFQ*PLA%]BM(R,K*>2%0KY9MA$Y$2T92C.C5/A;2'0CB8 MMZ[KUAYIK1W#E3?EGZ,ICPB8MLRSJ=]O]:8=O[&PBP;1@59 7F5V7V5[7I1V MJH-\;P -$ \H?H$+#;Y%Z$\:Q#-01.!L!4.>[7=">@AN M6]@.0M/"DM3!(,&ON)(\^Q;)L)3:DE0CM84HZ$+>AGWN*3D0.G2F42F.4F.? M!4.3VTA D: 2)LYBFXCW.Y>&%+X5-QYS<;A>U$=*12_YXWT6 8IVX MO2PNBXJTXE$8C#ER6%,O)&U<'"GGS7=80V(4&RS5QR?4&;ZTVVS4W"#1MD%\ M-4CBA+CIN2"6<_ C9 )5!6&+V4T@?($B6_YG8."R6S3K*>\F(4T7= M&CN1;AH&.-,NI#L-HRH#CN:GA@&R2N($SH0:IN.Y*1(=H'*?,]O-RM_"U2]I M1E#8@,Y>;&Z4WJC!O/)"5DO;=*BH?(O10'Q%XS=24L5!RJX!MX29RB%VUY8CY^BU [)E:1J[0*38<$+]_'O,HE MKSI84M#'MHG8Y 7U%C)7K4)3]BNF5_<3C0<]R."6)+*P.!?A-E&"%[L_W74J MR\LTQ? '_Z92 A(T:E"E;D]E!_SFL@*F#+1;L&#GISMV"F]#VXL[GY[3D9)P MO2EZ^7RGAA-0V]U^OL!9F)^YMJP3\_+.)P:-T_%X7,O=F28+(=3\L!9 MAO>EO'!X_]C:8N\$!/X>FFM#>(,-_)F0]L>*;&LKBWAT#G_/R)@9S*\TF%0U M9,_V W3IV#9RRJA ^"35<_U4UD>S^BKMX4I%,Z.0+J.L4$-SE,OE=-\I=3/5 M].62I8C5%%";=>3-'#;U-?"O6WT@)V$/K6KB;1D8OSJ"5XHO/\B%$J;J!"J' MH_OQ#&X%,L\?V90N./CTHK:Y<084]4&SP27$D#/YF6N-7JD 0R&H M&NMRM\<43_)H3%;)A7_&KD*^$ZUF A /LRW\JO9ZEQX^"!X>]X;Q+<.NT_O- M][KMLRC*G^JN]F'L:!MQXR*I%+VU7E*516H,VD73>!*/E*:(*XH$ZY.XM..9 M1"8J2MM:H-'8"FW2ONKC**TLLED82W+6P722M_161KKU1&@-S&P;YIM&4T$SWO(JC/VP\4@88I7UR MNR^$Q8O$]W3+G!+O+[>%'?1AQ(-!.9F5,UEIO;I MN):?T):Z4P-_.8%,6X<2/#"&SI+,W[PJ&ELOK!4 [&K3NH;5DM+JK8R\%FF& M4CDYWS@)>,6F[Y3$M.^><6.2D+9I_01RFA!S"D@WP7R"_?M=$GU8&]%:;VC/1'96$3,FR6$A]RVLHN$TU;X)Z' MWB>GK?+\O*W-![G"SK[GS8%7VP_F^:]D)&BWMKGQ41@/@H!+4(F+_#RI"-XZ M8K..V#S&B,T\'84F_% A<&1JF+NZ=1X>CL^!DSL(#QK[]M6B_3!&NN5CD4*K>%">:B&TB1HE\YF M-[#$9O!2MG3B')+R M"+/L#WHK40]>@$S@JAS==61I3>O:4UE&I?"D(TLCX+X])WSY6#&E6].1AB(+ M5LGT7(2O; HT=[G9+OR$YGZD(>;SPU3W'F]?&E:O$GQ7F]8UK):4UE6.WX1\ M0D9B'KVQ2?F)E79HEIKTS$-^P8>@^VT@M&$>IK1 1Y;"+7TTA-.C,JY<$99! MJ0IY:-WP$(I3!#5'3*<4;^>E0%*)CCGV+="E85I)PG0P*G-!X MCM]6=FY _!U/1'$CL*.7K@6>JYUNVN?W5?,M6(-<>"2+H;@P8[E6>T;%\L7D MTQ7]^N;G/7_(8LQ.UC;NIY];'%]=<&Q^M?F[7%B-Z.8>.+1[#G6.R9@H3!_C%.S3W=:T&WYOE80(CQSR$>D_$ =SS B_)W:K]-0PM0G;P[F3YA/!ZKG)! MS.KL(Y=\2.FB% B3%"1:R^9E;?3Q\>M)R6:Z4^W:*WWN)1"W6/NOZ[OUG1=K MJ;R*L[1D-X0N-$E]J<)+CSN8O+X4;O[?^E*X]:5PZTOA5O)2N+4>NH$>^OXM MM>.O?PUZT]B42+.OUV?,O^F#S]YOS_ 5!+ P04 M " "TA8-:<--7-+,- #-B@ "P &5X,3 M,S,N:'1M[5W_<]JX$O^= M&?X'/>;=33M#@"3-M4UIYA$@;?IHDDGH=>ZG-\(6H-:V?)(=ROWU;U>RC?F6 M)@T$$YR9NX(MKU>KCW97NRM1_]C]W#DI%NH?VXT6_$OPK]X][W;:)_6J^1?N M5J/;]=/+UE_DIOM7I_V^U!=><$SV:WY NMQEBERP$;D6+O7*YD*9W##)^R5X M$!Z]>NAS[XA+Y8![>X'PCPDT3R[T1! (=_J:P_I M58"MJ^>^(5GEQ?=]+OV M^M3ESOCX9V_3;17_AQGF2B>_>SWEOZM7D>"C^A&P'\$>=?C .R:2#X;!QKM6 M/SUI_QCR'@^*A?U:Y?"P7CT]64%/?ZU;3_.BZ7'X%JJ ]\=/#M!E7/S:T*X0 MI,]$HGAQI3/E_/,'P&0F5?ZCQ:GMQ(:'-)%O)IA8I?&K?SFY:3[YQ0?2^'#=;NOK7\^['\GY1>O\S_/6ET:G7OURLCESN5K[L5@Z\2S( M5!_?D1ZUO@^D"#U[SQ*.D,=D-.0!6V7GYT$1"-(4G@J=@'L#TAA(QEQ )!GQ M8$C./9O?'?# M+.'9I %D;"3UN]277Y(>"T:,>:1))6LZ(K3+Q<*Y9U7*A )%AX[@.K&$](6D M 1>>X8$'BOB2>Q;WJ4-\AUH,6>B%BGM,*>((RW 6D->DZ8QM!K*@-LA N$PJ M%I2U?#[AYS&IO7GS^I"\B%A-.(EX+!:$C+O1%*Y/O7'"/84^_5=(#X02,,=A M%A#N=)H36D:*--7A%S",V)#?,F=,4B*ZHC+@3$4--6F>B-H9%PLTW3+AH;)K M<,V.N7K*7H.&^OJQ?=UNW*"*@DF"R(D@0[2U8(@7F+GT07/W$_5"*L<+)VW[ M!U?35&+0:7CNVA#DP/L)\+R)?G^H";EA?F"LQ]$"()YQJ8)YXU$LC(;P^IY1 MHS%/%)L!R6BM3QIH&;#!/)QS&.],KRB4-23@*1<+D0J&?GMBY#![P.SRM$)&W.,BH0^>KQBIXUT;L+7$U),.;#ZJ MOE\I%EJLSSVCERH$\=BD/@^ UW_ %!ME%BIF,.>) %0NM->> V"%JWE=.Z2W M+$*A\LUZB;B,>H!C@)12( 2DK)6B:\@ &.>5;9;61SFH[@^J P#5-;O%A7RD MRZXDAY5X@A!509B1ADH,;;\?X:0%/F5\=1981C?->)3+O%!0JBK1#7PQ& WP(()QCK;M1-LAH&V"K.6.GM%MOX:Y!8X@*+[8?)I5BPXV M:=^0F\#:9FWF^B'4;9QVVJ39[G1NKAK-\XL/[TNUDOY^U6BUXN\/[NN(V\$0 MF]9^ Q,O)#@V:-X=ZBM@*/Y4TN4&]>[UPU]PR\"YL:@38QFD6HJ*%^K=UB\S M7*L<<6^-4N^V5L+DP8JYI)45<;AF-0@N+7BSU!\:%@]QPD\6?,N7AW/SG,!' M&XR);H+%I$FWV9""-HM\^F83+)J MI#L2Y".LW3$(W4*K+A5Y\>^#6JU2J[TD/GCR0Q%*#(&0="Y.8?P8%YWREEM M>!)C,UPD>;ZHH61_ATP%/Z-3(4;L,=MJ2!UGEF47NC]TQEJMIRZ;MLREW"'4 M(X."W-=OZQ_#V:NW#CWO_;VR!EGCGT,7L6 O0,"X!AY%CY(]O9B'[-U_F?,QDPO_\!>1L8DOG;J M0(?(/HA0"8?;: <2BY:V8+,6+GK#4M,T8\+F<3DQ7 O,T<)"W\E$FR(]WS(6 MX"RTZU60S0(Q]22CW_=Z#'-UQ^ QHFS3B/G#,+Q5@]+ON,BNU8P&]FIG(NL<9'9W0(9[>.K"G3GR\ETBA,==Q.;FWK7TMG8 M75C<,>*.0WIPU66$)?3-/H*X(GE?I^"/="%HL1"7)$\QD]3 D_8/BV&EDB+L MAR^94LZ8^%+< MOJ@?PE?PXBQSUW3.E ?" U$2"(NL3((7K@-/?2Y=DQ-*U4U5R%<>#$48$(>[ M/$D4#9C')( E&!<+LP5>)L],)WELH!U076=C*@0-MUA_TS,57X$,39Z9>I/G M,)XH)!E1D+-$&6 LT]2-);*Y2S3P+%),$8 K^+:(-I+KAU(3A#O], A1F)8I M]##UCSX( 9]D7#?36Q[@!@7LB-"Q=416UVQ"V_@]R4L2R8C)PQ5RZ9EQZ&.) MYWSRODP8M89 N ^B@B5-5%.TI'XSPJ/&57*C'&_>2.ZRE%QF[^*0P(1AR EBEO3G2%5^HO6'8J$8-@N$KE1)@!1H1 MK0[8GGO9G38U.730&K'2C4D;+3\R9)-:GY2J0)C25/I\ [)]4WE[-+OS]\G0 MD]?DY#4YVU.3,"R&!L=#>2B!8:XSM92S^H-Y#T\&P!.\1R&Z/__S$J&!?^L#1A M2F&H87[I:?A(U6(&XWPB/0>V4*5"%UU3.V2)1M0^;7G& I33Q,:QVD\MDE^:^"'6I#/C>#ML M@!OZ;T%DMGF\AV8"WC9QG:=5:AD,@XZ5ZOI$.J 89IHU 3I$95FP7L3]5Y/S M7W3 =BZZL\G"Q3?[&UNR;V7 YX]*L?"9*XO!RM]C(C0!GIT*U.6AECS4LCVA MECF3-3%&X) /!*#"B_QKD]B*\DL+-+@V&'24I-AN@FC_)')CSN4JZY:8 )-@ M662\V9NH0*?^3)F[80=S: ZW=,9(4YWD\"JDFSJ+@$NI]Q3WG&A3@-_T+=:T^;A\(368K MW=&X*!CO>F#R;ID7ZBT0V?0B\S#+L^$U2[#*Z*CL=$AHR*BMC]R(BRCNMTJ9 MTY%1M[$( K2QGL5Z"->D87<@DH*-K:$*M!L&!55&)4G+^%L>CZYBK(S]$ M2 [K6>I$D9P>^,U1>9MI/ G7@,YE25Q=49=-"G\J>.AN$F>GJ=A2BH]'*N%H M&$V7&9Z%*X6'T\*)=\SV9JH"[6F>XIZN@[F[ TKYI-\NMG(+D<51625;]E98 MB#NV*]P14YD-L&-$P91WZL-B)EH[.44]?>RB#K-$A^ M')D.<^",CQ$)&PBA1O9U["**Z@0,2TU-R-84OZB ZD@_""!=0RJGJOE4.5UX MQU%:/0$\CB0';DRQ'Y"-#=@L_SHC,-V!)7Y\)K:1/I>8_\\V 3W3"';S$OMS M\;YT\ O,KQD.Z=]*0'[Q]Q(6:L&5_<+2E&I]A&@VOF=P=6.0G-R2S6F9-5<\C#MU83W9J2^6;+:SZU$9W)IF ^_Y*=_N>CH_O ME/$J7Z_/WZBJ*KD0$FY"DV 8BW_Z#(XUL[%2L#_' 3K%/5#X:T++3^+:_-Q8 M#P"VA^CSD]=3H&O!?#&S[JG#!1?49=4N#QSVQ!,\I7W+^M?")'=)\^PR>THX M'ZM$$5<_4X\.L((1@RH>D[EFSB[1YR>OG=+,N 7_P?-\A8?RZ)F_?U!]6SUX ME2OEK1RF/ *\BQ'@_/S9Q7_Y^;-IWO+S9S,Z,/GYLYD\8&_#I\D>O".7ODX: M'Y,.54%^N.Q##Y?=_+&J.^'\5$\O6W^AQJA^['[NG/P?4$L#!!0 ( +2% M@UJ<7$0YJR, "4@ 0 * 97@Q.2TQ+FAT;>U]:W/;1I;V=U;Q/_3Z?35Q%2W),;=D22,Q2>735A-HDFV# ((&)&M^_9Y+=Z/!BR3&BB72 MF-J-;1)L].7TN9_GO'X__'#\IMMY_?ZH?PA_"OS?Z^%@>'STYO4S_A.^?6:_ M?OWV]/ /<3'\X_CH7T_&65J^$B^>YZ48ZIDRXD1=B?-L)M,>?] 3%ZK0XR?P M0_CIV;J_VQ[T9!B^:W')/WGR7CDR^__H9#@B[OG[U]L_D+?4Q'AA]^P4)>#S[\(B[.#_[U M),DFV?\^?_YB[V,^>2+ZQ\-_/;GC.D=9$G^=Q48J+57QU>_>)B_P0!;J(,FJ MN-?M#-)H;^52%Z?!H]T;'=\S7^&3&Z1&QZKH=H:%C'4Z$6=9HJ/KA^,S][[. MLU_/STXOCAYN1?>\GH<\FN9E^UB94H^O[W-]PZDVW4Y.-"CR(KL$XC1B4L$? MB4[AKV4F9)((-^2^,\JVS_(9KE,K[\KZ%_=3E8(O#+\)9Z M'QL_+OS'3\65+J>B4":',7&V92%3(V'\+#5"IZ*<*N%'-_@[F)"*JD*7,)W5 M[&5C2/3!)<)7(-.ST^/!P1\/36"=P!#&V<%? [#X1_=SND[\8!>)KA6O M]=29'CP2)17=ZRB;S>"RFS*+/H'6EO,0P 4:WQ 706Z5P"VU,I<2XR&:BA"61N@5_]ICU2(-,;JR* OB-?>V5+& !)4PLS4IE=48U M D8(/ \^A=]<*5BFI 6#8:0O):J&C8D4*H$/84GPR$UKOYHJ7(2 )<+;>+:Q M&%V'FU;/57V.IC*=J%UDA/"3 +_@!FRLIVF?4:HN9JFL$N10IV M#E<_E?"GC")E:.(?G!PY\7)D$(B#'=B,6(U)3(Q4DET]A;$F,%?:\OHM>V"T MXM9,BJS*<1VYRO)$.3FD"\$7P.\#J.S"9#-5TGWPI $S(D+VNXRG855]:QZ; M/:OCBW?-(>&M,!.P6. ?,'6F=N5>#"2E:=9D%-!!\X.]FL2%_VGX@#^D:0;2 M= J2(/Q)8UVXV48U+B8H HV;&5 E;0);24R+P4OQJ, V^F@MEV73 ;&=5"J- MZ%B) K*DY^^L_2"!D2409J+AH,%V&H=#?2O2>]/9O]4AX5+(Q. -*54:\VUQ MJB/^E\@,F)*20'\1Z7UZ!H8['#:20UP!+67\5"Z+TEZ8+%6.Q1 1 C%)8[(( M"2;FV]*\Z/THRH@!H(V.I&8I%AD-J+1&X?_=QEB6Y";CQ2(+5@4O08NXZ_#&044W@7KZ+];W@5&XOH@'D7"[D<6'KVCI,%/R[J03 MX+KD):# 0.TZ &/G,DLNYVRD6SQ[_/*Q*L@XK(IH*@TY"/R'1B5)3\3P6_LX MF&\ZB\GS!YHL711O]<5 ]? 768HIC6+@#[:VP%*[DAR;N,74@^V";4WGUL&> M"K!C:1HE?87Q#AIQ5!F,,(/I:Z_A6!<&R,R&)0[E-1QFDF17;E":)[J=^/7- MV G-/[ <^91*]H20LU(:_L?R8 J:X"G;H;"%/O)2I0DYT::J>6H&MS)/%)K/ M< *F0K)!'Z&X@O,"TQV-]ET1PP/%C#QK+MP"MOJDD#.>\(Y\"K2B2GY# 78& M4"J<$/K\8%$HL(&,1R]W7SBGXD7@68*]/;).3-&/R-9_\?,//Y)7%0P:=!_L MBYW14S*YXRS'R<*/GN'.\-? 8%:+9W815H'6AIG5V+'^@6['>L8Q'=>36%Y M-:G$.B8#W;H%;J,4.&7QR)=GL)P?MVBJV(^M+F6LV&U29)0 M2.[RX!!V7^[38#LQO0T>F^5E<@V3T>B JW*ZS? ['YWS&XTGNN!E\9?\%Y6J M O;K(*M2N+AB!U:LD%6,82.=8S0DA6'@>K1^TJ=[W8\'TRD(2^9VCV8"5.W<^R\.9@NLG M@:%?"PY'(UNF:P,4P&$I%YTQ+KP@3MP#?>NYQ%L&U%-SQ&[G4,F$Y"[E'_7! M-)N1A_/?55;R#RZN3:EF8N>D?W'8__=39:#N%VS"3GU0]+VEU0; 9/X-:CZH37"7^C*N+"D[":Q<=:F2+""C#F=XJ+(5S7O]>E946VU MAQG*=^MR&.L4EHUZ"PE;]'Q>*E/2:B5L.UAPABI$K'Z@T[F?H=BN4N L>X)] M(GJ69P5Y=LE;X<6_?3!R CZ%J8!R,)XG*#=!\I:5TR*K)E-.O9YSA\ +QT$N MGTO)J_>!!H89@;6+E AC7+M3BU6$)3?61UNRX4M)_;/)G[RY/YOLV3:?-D6C7_P=7\R\>HY" 15?4L([*.2D4!0F1OT=E] H6A'T$E3#8?K3[ HLDJ+GO'U&)K9$@*M_ M(FMVP-OL@;F4 =*0[0OQ-4&4F[QPBQL9Y"CTZB'PC56DWB\:EJ U31&[S"B:D_I8NUDB$EBKEHUW &E@_10A M=#W/Y0@Y*[%.%!*K0OAT-R.TJT4I/\,NQ!5=&(DI#_ Z]WLT@LDM/@YR(>QB MT-P%-N>B 'V_'1>P'3Y)P+J^1RO974OY]U2S_W53P^\7:F%X=#(<](^[G8/! M;X-CT3\Y% ?G@P^#D_ZQ.![8 F/Z^)DX/1>'@XN#P=DQ?'T.GQX,!ZY+E)N[;^\]S_18RY%>/XZ&FK,+?]M$+0JA MB6TSNK=>%786)^S MOP+]-=*7.H%YI3+A*%V5L_D(YBLE9?LXWA@!-]>9Q81A;8"(DPSL1GF9:4IW MAI<6>J8Q.H>9R_5+___+WO/GS_'_Q4Z:V;@8FL?"S AHPT_DZ?YZ4Z%J?/%1 MPE(I^[%>YQ4Z(?QYHS&!-"H8#CNM0&C1=_<&! CSDF-(;1UIL% MO@^S5BB7%XQ:3)8'VSHW806Y3A(U@:W1]N+;1)3>XO'-G][:07J[ZR_\KF/Y M!2QO4BC,D>FMH((5!QO:0VM/A>Q]:\IY6_!29XG<:FN_512^W6S/+U *VD31 MS5<)'(P.9V=26@9P]P2(POI,/69(0S<@!YC'^MAA=QGAZM30/<2(ZV33'%FJ M]2Y1_B4YE$""$0:12T\%%>,O8850]=W\H)2*L3HYDZ"3_K)F2* M8SA-9:4B:E TI9%2*669&%<)Q'MH2!7SN[ D>Q9! BF-I/S\(56+"BM[\[7;&$,8'5]&"QIIHTA;WKMOO=5%@PQ=;@.T$-DF?14*K!6P*YUFR3I_$ZC)(&WB! M; "I!A ?QX>K9-Z-OWN9Q??AT<'AT/3K8>'VW;X]PM#MQ&,\<6!^ZAC=]':/I^<"F!Z]F^ M#JKD=\8]>@?&QJF%>N_5>.UD6=B\=G&H#)P..;R\H=6:RQML+E-*J05*&REX MNXRB$/2LO,I"1#-S5T@S;['758T<_#0VY5F6[G4] MPKX2;%5C=6B"^/.IT60ZV_7@:+!ZAW*S1DL)![;%-:D>Z,XB+R2:G+QN9X*;E9HW&M.<[7)Y&,9V=K,S-^Z.+QUW4YDKQWG[-8UEEC1UZSMP>24-#;HYE(OMC98RH) M'+)NYK'LMOJ"])ID:9Y<1^P3W1>O ,+)+#246FSDP6[!0HT+O('$#VRO ;IT MC5QV6]*.C&8N"YW&YYFL3(7O=M8!IUL HZO1-$-8S)M* D(P&9H:L!!L.U"# MU2U 9ZY$LG3AQB\$L@R8?K<3/H713]AH*=B!Y^<0XECUG.6%^$46]EX7$<1.6M=UP]4++?O.TE0J/7RJ\ QX&TD"'3:R:L!DV M;<+G&;!NL83']Q!MES6&FM-[5H>@LZ TI7&=:[>,0W8[=V:1B,TK;$R&#!R0I!@5MU(! >M]Z"VZB< MY?I"-A/<%TP[#_F-_$.IJ;=^CG)'NSZB$4ZY@XI&\HE]1V/P2D41HX53+88 M@0+C<&==G[U5.GJ(_F<\F2"7)2CICU4\8?PA1@^BK.5ME?,W!WM_;(.]]Q?L M_;$-]K;!W@>7OIM=8_K06_:U@TTK9KCML:;'&&PZ V4B\2Z!=>)-H"ZADJ,H MY_ZV2%,;7MH&\X/"2Z$N'3:'<;"4*\(?PD4_:@]#7(5$7W1M>7BHB9=W=X@>MVX_\2TVAT")KF@4]6@U&;=C?2@[] M:]_]>=G$K($0;HXU$+J=O,C0Q;XGCK ;B3V'^AALYW*_YS6@%&\;^EPYB'5[ M@Y>\T%S8$OJ4>6]C-=]+>FD1RG#.536&'1&Z%*G"-<@";+HE7=K+S,',+HE^ MJ ;-^/VPWGY+?M+7L-:4V M;E<_GWFZKC?0UI?ZW).0?HY0?I+&^U'$EUZS( M/E9X,A%YQC@B3L&<+9$1*U#*QIP\H" M$%]+8M%8$&_*A9)]# UZKQVHD\YQ-^^QDZ)&29OSJ_E,DJ -1@VSYVI(YWSN M+'Q\L V=98KD>SEE?2"8>A$^2.C9/1=;]Q@%WK56NV8=-A^%?"-$1N!@G(-3 M;[8#6JG=4^;F5RNN' M3H94IB8(38'DPX&L^XL]W4'Q8FU4 MCX/NAXA[F;(KF@+.\ZB@[)=#SSMWQ[27Z>9L)*[&M7%G!S;O;^D([A-\9X)9 MH YH*NK^*<%(@#N3S6!(0M# RBN[;ZFMN\*FE;X9SY74Y38W/7MH']J&=X7O MGYT=#PXLZE^W<_I.4'?X/\3P5 Q.+@:'1_#'N]/S#WU$_A/G1[_TSU$?%J?# M]T?GXN#TPUG_Y*%ZR3]<<8&CQ4="A)M+?Y@YVNT$B7EE0_U FSPJ],BWH:R; MD)!:=4O:YXY^VN@RPS+"]Q0+NRZ7@?^F1I2%!64Z$*XO>S=7-;DAB%(K3?+$_"]C?5-R=Z$^P"5,,4'+[ MXU)<.1TJB)(&W4\R2EJB=BK<>PUD%GL?PB8KL4(8:.[?YC(P*,LEH59NR,\L MA.Z8-PPS&I?LV,*B*;)-W5XC3.JP6!?-QLVXS&Q4,@J4EB^!:7H)P;2N'&T:B[<=W0I==48@\(W(H4=8<7YC$]6$E=66S,:%D6FS?L M1+P<<IZJMZ?"_LTI[H)X%_Q7?U0>"LM;LKUVKQPGMJSX^1,P3*+E3=AHB^ MLXW-N97/?#>]>%4GFFW5)&Z.B[]LX^+W%Q=_V<;%V[CX8_$P/61IZD8>V!V. M:L.-HM_?]X?=SN!"@-5S=#[H'XL3L'W.?GT+EE%H#FV^)'SX^_<("L2WQIC" M%%A;Q9%;C"A"]U&$E8L!:$1PFV2N5^',:9N!^K4:RXQ=Q;V /].Q9GA)L#J9J@7 M"3D>JQ7Q8C*N, (+]HPW<*@6:L3=E( \]!B4",+76]@-EU= H7 7%5AG#[Z% M!M1;RH*JJ9JLHHEJ21<$GEU1E0R3Z3&2Z,3F1A15HGP.BDRNL%:ZR0#< M5/;$T6<)QC&_=A'0$[3];27:QX-K@8;&?:8BD-GRI>D(?W^)S/_[^: O&S9<]Q0*QZ'8%-HA$)&8WSP$LB01RW*M9FG/-@9F\U3W$D MTT]%E9<1'6J-HY-HN-XQYFC"S1\E:M8>[T8<[R^^];SK).7O+CH1\6A=[D:8 ML=$>[B8<[H%K6H(31(\GIE4CQDI.:4+M(6["(<*3/#FG)\!0>,T67T:=B#;D]Q(TZ1,P-P>@;L ME=;7L!G'=B"3! O,. X7JUENT0W0H6C3,JS&&ZTN/FO"/+0GOPDG[XTP0;@,[FW*,"](3>*^>D.F">/$,WFSQ["5%\LCY/Z5>YUC(4C_?'O@F M'/B\A\FH%#%;X*=R0@Z*NO!H)C]F#CHR5WCH$F[[H4YCA:_?O7<\ MC\=9C/NWY?G=J]"HX?GGTO$81:+^B/+L$.4A)6Q4;'=1J$O,SDNN%^&>7:Z= MK1M#FTZ'2/LXB+R4.I$V+SCX$6(Q$UCTMN;6?6W*O+F:[*>VFNS^JLE^:JO) MVFJRYX^CFJ4M[GI,DA8O*=9I]8^[G;/ST_>#MX/AT:$8GO=/+OH'^,V#]?AL M 23^#MQ-5T]@L!#'=V\A32@-4:G&%@JKAO>RV%]DP3M,R+FNZHW.&&::%>4N M5EI0?D&NL H"BQ^HFT0#0_,FI,=!R947A")D-<#YYSGJO;)!20!^5(,V,L30 MLFY/#&^0+K0X<%V"ZE9&P3+:DHM-+[E8:B/>_25?M\_H_<[^GN=[@3>?9TC@ M8X3\*.A3:F(SCZBW'&@,$UHB17!>U)"0#3[;80S+JMPH6,VG+) ?_]N/@KT1 M>2*QBK@U5BHNT:Y@B!."#4-$V\19>T!VGU09#D:#LXF)W'-LY]7$2D,6ITL3 M,CW@I00>0E64'CC6.L%-L!D,IA)7D7M;T-8NPLY=C/U&S/I2+6> C/B"]9![ MU+L5'C+*5IF:7N-UO&L\C1L.@(K7BFRJ1]I#+'MDP^:2@!88Z^W%3SO14W(0<(7,OJ9ZSZV:0,BB<8UWE0&>.=@)RI[O32 M6M,CG='"4XVD85"LFT&D]AJXF.'Z@%7S1 AC;9Q%E6F\V*\@F(#_3)8E]6$D M(18*BIIYN\Z:*/%2!OR:WYLD2R?T.\LX1Q^Y(3&B9@6=7A=PZO.JA,.),!!; MN^[!$-"7I)0W,.NI%2JBB3+7YJKZ&A@W*R8R!9J)K;2T,NUFB?'-LH"66V_, M4:V"8'_4,WZOXHFOXA@V35+@U:Z'"K(84OZF_#QGH*:JU/^QH91&VPDJH@6E M]S^JR':CC-I+)(FT&AH,=H5@"M22T@%]&^H"G=EXOZQ[=:#VFB!'1Z22*O+] M=DD1IREIXDF$8DBL'X$Y,#G ]3#7 370"L@SXJ[8 QJ^J7+TL/U$:[)MAGF/II7#JGQDL : G9JZVNJ MTO?K(#="!6LHM/G$.UHHW% Z(!@*-.&ISO?$[QX@,HM@/-.[P\38>4%R@@P7 M:S(@Q.&\R!!RN3_% DI.@:/C21 DX]!)8N[U'72_6*&[S_F&FM*!9[*HWB-U MA,?1BHU-X$*MV-C1EYLE-3Z0>XVGB'ICY7K7G"4@'[S/IK;AIRKA#O36,R=@,O5&1?;+-EI#=N4SI&C08;C:J_XR)Y;^W3$'JA/N7*\R[=J]# MS75/7&A8,6+I]$)?14YSCJE9^?0Z1_:%V#SQ4V1P)+=*BOMS#_DDDVECUBP= ME>U!;U->>&JCK"BR*]*4QY+ZT%MK!@?9$V]M)VH_2^[17(3C\6?X/N+AU$&5 MX?TM_*_B^:.6#4=PA8P26R[C+&X!NVU 8SE8,X0V*DN;]+"D3T1#T[^CMWRI M@D_8!:* C7+P$F@ MX5K7U48REY%M?5*H7%Y[LO+W!NQ;]':Y7N66R,/@2#^U]JA;V33[\M7-X#IB MG2B0$2'5_5DIPTTE*$!T63M+Y_IZ62IQ;9;+*YB,4I],W>^+NVQ9 'U&2;C MJLICL*6Y[LUZ?AUU^,=Y-:U"L D"IE4(=C9,'S@#$V]W6".^KS(GAT%[(V?_ M$+/Q#0=N:)#88#]@V!4U3R;IY8P6*W=0G_ E[!+$4Z()=GV^O2'Q03]02LB> MUC4(G.46&4I"&!;UK!9XY)ITZ/>*X\$\#Q2PM\C4FSO31Z#GN/1#%OCUJCV^ MW^/(G-V^C,.;\@W_T>8;WE^^X3_:?,/-SC?;=<':D+!N>G&ZG M]LBC=\!5V])R" ?]ED0LW!7RXAC]>7<&NSY%35MG,6]@K,TD*R:,G<\]%]$>&[\1#CI7"YEZR_H:G6]/9OIBZ M%@4<^TG\%I-A0J$=PZT(\,MN9WZ$;Z7,:W_P-2#7M2GA_] M-KAH$_>W0*0U$O?1I5WGX]1N?RQW-+;MKK(A_K ']4(W878X8_=MVPS!0_.2 MNR:15\1.K<11)'_J:6!&K2BQT6\*',T8! $UIO 8F@)),&<+W\^9ZCE08^83 G!7KM9BYH]*U<\HVPG;&\RQ=OWXVN$L9Y.9>!-H!S%*R"0UO,\QV [+W5N8K M\=/NBW_NOOBQ)=_'0[Y]-IG!JD(59YP@$TNIM2\I&Z_$C[LO=E_\O$5+%3>M M]/L76[32QJ%6>4R10"[\A">_Q^5NZUV\.7+USWU?G"&.,>^B#5]]8?CJGW\U M?/7P@9N_62@\>WMZ^ >&H)^]'WXX?O-_4$L#!!0 ( +2%@UJ?$!;A+P, M $(F * 97@R,2TQ+FAT;>U::V_:,!3]7JG_X2[2JDXB!+JUVR!%(H^V M2*&-2#JI'TUBP&KBT,30=K]^S@M82U4Q!\\]=IQK]N9?94)3_RJTIQ6=5NC#MPW#O+/).Z\ MUTM6-R&_<7Y3J7=$Q\F\JRIIA]Q*NPI\76#XB$)/IK%+(JM8SGV9D M3-CAP4F[V585K?=_&5 IV(I=6P9$A3Z5630O_%H4C"/&HG"+KSU,&8XS(#J* ML1Y$"[\! ^HU0=5&J>HJL]59C!/B$Q0_'QY8)&$K<[7]A-'*M"K9VG?L[P7T MVR'F]C7+!-VT+,?NZX/KRW.I)67G=M\PRO.=S7LD/INE55N?NS".8A_'LA<% M 9HG'%?Y3\K&?-4=[7Z#)8X9\5!0NHT'O%3,(*IK[-[?)@4!GK"5":WF*:%5 MTM%NKCAPC7^'7"6DE?!S-%<8!6Q6# +'!@[0(Z_0@%OGRR9T_C,2E\ ]3MFB MT/8:UL>AY$1X%=DQ\K@[,0P115,<\G&] 7H4SVM-U9H2DI*OPFNJ[STL2$(8 MB6BMI5I+ E/R33PM#7DY7WW1',P0^ZDO_YJ=Z@>^6E"B4G(JGJ!"[#NC1@ZE MEDXM'5$I.1-/.D-7T\ME$EDBAL$B(6'8AV,;W9.$(5KK1R3"/K)^OHNL'PU- M9[6(:A&)3LD/\40TTH6]OP5E:5B1[RS(M0-X]M+D;DB@@/L>USCAO M9IA?9J"+6[Z9.GZ18GYM_EK[6Q2]599KX6QTO2:ZC,@R&E6%NZ;TTH9OE=2Y MN0.%"HBM ?OZ*S9B54GW@.6;PM*]8W\ 4$L#!!0 ( +2%@UKNKO)+&P, M #\. * 97@R,RTQ+FAT;=57WX^;.!!^CY3_82Y2JYX4\HO;[#9)5R) M=KEF243H57UTP$G<@DUM9]O<7W_C -OMJ:>[!WK:Y0',V-\WWXS-&,]NX[OE M=;LUN_4=#Y]@KEDM8OG]C;K[IG\Y7W 3;QAZ7_IK,37$]@."@TQ"RG M"D+Z!2*1$]XM#5W84,EV'00B=%WCDC_R;8Q'[D>[!^-U\&+CBNNWH7QD%X XL@NC/SU&RTSVLV/AZ59KM3 MDZ+?TW;K0.XI,*6.- 5QE"!I(:2&E&@TW!&9'&!H=V$T&%UTX0O3!QRA"IIH MT +T@4(BN!(9*P$[Q@E/&,E :33DN((4,)YDQQ1[&3\C',Z/."(J/8E=N^42 M2=U,'-,N!#SI@>"P$#)'F=;;OH/"Y1EXHD0"Y8;*HPG-MU2"/3R+^ZT'[TLM MZ+*6AHZ%1"=$,V301&6UN&6RMJMB.Z9TA5@\RT$'/X/&A5L MK"MXM6 9PD/1 ]NVK=' 'HVNNF5[>&D/+ZOV:#R^NJC:]NO+JR$0GH(!PP-V M?'%ACW_M/;.U]#,^@*>[KS:IK*_Z$*VP*,[]Z :BP+V%N?/6CP#?[YRP"^N> MT[3Z>K8:HMN(G$I%=1>:2PN.;+=^-[2GISMW3B%9!E5]?+HRG]G'B=I^L2PL MBS1+)[ F>SI%Z.>CJ=P3>#V%56$*M)K DB@-EE6='&9>\,?W?_F6%D55_RK# M5F@M\@F,C6TK9$KE@VV>D>03##$-YQT-=<7.?.F#ZR^7:\?S\%?D36?0.;]O MUHY;OUZIU"PA65VI4?_WI3NC MNS/"JQ&/J+]-=.R9XU-D;B8"?&)JZBP]RFW?)+=,X)-:$#]VC21QP&VS6-CM#?WVO M\S$S*^UJ58FIV#S$CG//N>>>)'8\N8OO%S?-QN3.=SULP1R3.(@7_LVD6[9X MMUO=GDR7WD=8QQ\7_KM6)K@>0;]WT!"S/540T@>(Q)[P=CG0AC65+&LA$*&K M_XH;PY[(+>,CP- Q:/JH+9*S+0XDE&LJ6S>3^3*,7_):&=FS_#3Z'G,1J]@_ MM!2"3-.;G_E&'<:3[A0K-[S8K,XO7;+M3I]9N?^X8QNFFPW;Z=BO7<"3]Z]* M_N,]V%>1/EN&:S^,FXWE'(+0\U<^GI ^\F^#=>Q'O@>K]]-%, -W-EN^#^,@ MO(5Y$-W_D-7^SP_J-R*3'=C]-M@]^]$8@F9D! *3:$_; -1H 4\[!A&ZATMD$A88?M.@;UJ MPP/3.V17!YIH@S"QB>!*Y*Q(UFQDC!.>,)*#TCBR1S<5,)[DQQ2U,%Y 7,Z/ M&!&5,D4&,R+I+!?'M T!3SH@.,R%W&.)UA]=M]!J<"=*)%!NF#R:T/V&2G#* MPIP.?"BU8$:4UFP8 "86$I,0S9!R5LHANF=)5_/JY M@F]K5+"VAO#+G.44_>R XSB6W7-L&VTM^OUKIW]=]>W!8'A5]9W?KH=](#R% M+[&#JRMG\+9SWG?\G&]<_1U>JKZNZL)MY");?+>,PG@9PF*QNER]E^YGH&C. M>+O9,)#?J53T=+EBW8-D>;-1S5B7J_.K#QT5OK$LG ]HGHY@1;9TC 2?CF;" M&L%P#,N#F9C4"!9$:;"LZI]\X@5_UJI*O986AVK]J08V0FNQ'\' C&V$3*E\ M&IOF)/D;^FA&,9-CG;$[7?@P\_'#<3T/?QO>M7JMXGJ]3U];U..HYOA,I68)R>N5$O5_N73F-"L07HUX0?UL9^R9 MC4ED3J8";-&:VJ47WG:-N:6!E_Y2/.M[ROH<685TSU<;6_J.!;^7JG_ MP8LTHUX)"FVGNQ)PD2C0N6C9@F@ZFOO1) [Q-HES[03*_OH]QTZ \C)M=>D4 M2EJI-(E?'K^U+]UFFWX)/A3M[I6K].HE\TG/"VGC^LW M_?9W2NP7(:'[K@[?F MK9& RC$/JP22UDC,GN(2]?D8;D@^]N)"HW[;O[.6BRVY-.#^K/I2P3JMXO]C M!D>A\6LX4E&M7L8"H?&#QOY#KM\T.D\>'_'X].3JXORB7KYIO&<#;!;&3*;W M>.@P++%R?LW#/1Z(4BRBM"WIC9&(8Q%L;=^.1ZC5&5K=VVZK:77[=Z=%G8 MN:I<0F.)]:U#[IO#F^9=Y[[4_[/7^4Z:+0N?7%8JE^\]D?^;J)B[LSV>M1KT M+O%UBZ)JW\4B,C(1TF2[;P?1HI )3]5]#NLFX- MWU[!!#O=IGXV&\%,"ZGSK5OMM_O7W?7SQ?F\CZWV$J16'[OX[FOA\LW]N=,Y M;!!Y=,*(9!/.ILR!J)G'8S+W=O5NSNT&ZJ88Z""/04S\AB*J<^< M,2L:FY/&V!P!Q88B!F8,8\I#0L,92<)8)HRHF,8L &V!5DC!.X#(X&"G+K7A MEB0BX#$,DTFWEB!D-E.*RIE! >D"^LB@\J6"%=QS !'4ZZ.\QHHP@?OGM /G%\EAFU9D=_BK5CT345,H@Z7H8O;]P70Z7 M9^J+-M(N@46$I@,P;S[R&9HM84!$(Y\K#W-@L@ 4$*H@O':XLGVA$LB'VD@* MW_!")(7-'+BM#)HSX *' ;D8CNH\V1X-QXPT078,$Q^:>'%%2Q?79\Q N;AV MS)6YY!BZ"0TI824$9,64SV+#SG(3@"DA,\=&FNT(\4=3B7'5G"S.-8J.L22$H5K5>WI4M>#2UPM MBX5B@"H&38LY(XI&DO@4]3$T4"-9+'PAAUE++\0P5AX DP*WF/"'>1VJD1(<4E!%?@% M#%DBX5/I9+P+[H#3$?=Y/,-0PJ:ZT1]IBM;L:[S(LZ2+D(F!HY1#1M#DRD1^1R*)7\#QFC4(G:=F&.!V7W[S1$88/\?0N?9;S'0*@*H9.%!# M;F#[-7$/&VL^@SY^5)P#H>BVH;R,HE=(%/<,I%%O_60C5;]!B&-@1=AV(I$E MEP(8ZZ4:.(%0,3S$;9!0H()927XD5$)]Y&P+&A>(']3Q2NH4O0U,K/<\X'8( MO37)@/MBH'E4S>,^J*NUCV!.&B "8:Y[)ET6S(C/'QE\Z T0*YF*/]U9M=PO M[)^U'#;6SSJ#KH_NG:?>:NEDU%U<*$Q4O<0 M:>+P6$@UCV_H&U!N$/ X9NPOE/U(4*F%L\,!I"[D3*0H0$TO$'F40=R M*S97>5O9,8T)0Q:@."&!H74(04$/J"0(J(2FZQ:E.GOC#KD\//"Y8.6:Y_2;-&LBGDX$?Z$X=(XI./TW(!,52H+ M(E_,&#R=>L+H4OJ,Q(%T_R)XD$4=7LG2YULT7UF?.6ODA^..\'#< 9RHPN/& M\[-N!AT>>"//SM,>*5WOR1!]C.^,J(.;">8'P"_P1/2;K?ZZ\LO?[%QW@_MJ MI[!O9M44Y_LC_^U?.X5>[S;J#XVR*J=;OE?.@]?+#]":[M%310YK3)V0EN?2!]$U^ M4R4#.F8U*.!'PD(;,E[62#_2[RBKI$=53$JEK._;W3\R5"]]%]@_\5X:R:S M;*GH17=FXYZ->;T,79/UTE+?EK%S30>N?EGA?, 7I:8QMC)^'Z+Y@D3\'L7_ M U!+ P04 " "TA8-:48CMW:4( W40 "@ &5X,S$M,BYH=&WM7&UO MXK@6_EZI_\&+M*N.!*4OV[T2,$@4Z Y:;D% 5SL?3>* ;Q,[8R=0]M??<^P$ M H6=5D.W4.B'0A*_/+;/>%I,'E=N.XVOI#_XVFY^SGE21"5R>1%&9, #ILD]FY*>#*C(VQMYTF>*>SFH M"%6[KZU7)@%5(RY*!(KFJI6[SOT@VT;!HP'W9Z7OM6+*:OXWLYWFJK^(H0[+ ME2(V"*/L;@-?F43L*2I0GX_@AN*C\58A5VZKS:B$,DP&4MR8RBC2 8;Q[?E%:HW>X/67:M>&[0Z M]Z#TY-! MA_2;=9P [^974Z@-\3,=;?6:*37KQ[#E+O1&(M>_%PF0ZE@H@J.]'T::@"4 M?LL9@UD9]%[?P00GW:%^NM:@O[G$_%8&C==;V.W-\^7Y?(X'C0RD>@>G^/YS M[NK5\[E5";:(QG3"B&(3SJ;,!='EFM2$B*E/>BR4*B)2D#NI JA5^(-(C]2I M8G5?QFZ>M(1S7LX.$O[U/N)2KJC,+B[GLLKD2FA4R F84$>6"4#$CL8A4S(B.:,0"L,*HA12L YAC M#GKJ40=N*2(#'L$RV7+/"@CF,*VIFED44"Z@CPPZSS2LX9X+B*!?'_UN[ @+ M.%PY<0#%!+0!<(#$R73,G3'1,?Y;U)\RQ9)&2\0^% #BD4 ,ID]M0#E4CXGGRZE.64FQ$=>1HM ;Q9L6 M/$#-9WA%IX@,Y)1UCORR#Q)\./SRZQ[RRV#,4JU.]? 7I;_%LJP3!DGB8;3^ MTO,X7)[I3T9)6P2""$,'H-Y\Z#-46\* B(8^UV.L@<4"\(#0"\)KEVO'ESJ& M>N@;*>E;7@B5=)@+M[5%7M/"Y\2F-0 N.Q MTJ[*_#R>?^L$YI(6_!#(=V"I'T!^9-0#7!6Z@?UW#6>#:6@Z=2I-Z/=]5LYC M:.K0&)S1EU;!X'3(@%QM=TG *6,%#8!7-^$:?<5Y',N$:0RSKHN8-^NS*N93 M0]E0>)EQ\XD_BP\YN)T 2$N?NS0R:(>:NYPJCJ/@-C@V7K3 EF*-L:JQ=(GI MP1#7N,52,T 5@4^+-4.*2A+[%/UC&*!!L@A\H8:-I;-Y /@V9%@0O%>HS]RC MTNZ8,NPWUJ,$O?^J#/>7]E_L)3]C_Y?[UYN,0 IC80FP*%B/"7>1VZF6@F)( M0378!4Q9(N%3Y::\"^: TR'W>33#5,*ZOM$>&8HV[&NMR%+11/&.AGD>[G( MR2[YO>CD0T7PR;7-_ YE''T'QTMB$#HOS3#![7W_S1,98OX<4^?&;C$[*0"J M;.% #T<%VRW!W6^L1PEZ_U5Q]X2B&Y;R4HI>(5'<,Y!DO+&DNG$VDO;7DDZ0=UF5< MGF6YYQ!I[/)(*CW/;Y@;T&X0\"AB[!\\^Z&DRCC.+@>0II$SF: /UJCLPZ? MF'1/S0/[%G,8B+$"L7#,5HY/)7((LGW<<;$?*[1%RW"(+P1K?K*Q"W.T'-@. M-S'@G@B',Z"E)-B?OY.;,OJ(@;O-C)K0W61WS>;5=+?71L9;ZYO:-V=4S6EY MC9M'7:BMV=S+V\B.24X8J@#%204,;5((&F9 QT% %0S=C"CQL]?ND#NF!SX6 MK"/G[N*J'.)[N)I(]NY[BN+IF^F8&9<3V-/LM4]H-F^C8BXFTI\P#(T%'27G M!E3BI;(@].6,P=/I6%J_E"Z1.)#N/R0/TJS#"UGZ?(//5S1GSJK'PW$'>#AN M#TY4X3GD^5DWBPX/O)&ETZH'2M<[LD3O8SM#ZN)F@OG)\$L\;_QJK;^Y^/E? M-J[;P7V]5=BWLU*"\^V1__J?K4*OM*J5AVI1%RW(#C*5U\$1QA+4* M*Y&31&@283D*R1%6%E9=%NICSCP+IOG$G!BW/9".S2F3LZ[=*09N]K.'GX[B M=(2U"W[2>XRT@1N72GNP #L*ZZ/*12U4/$E67^?)U<75S1XLQH["VL,,#B#\ MJ5 @=YSY;HETZ8B5H8%O,1,.5BR33FC>3Y9(F^J(% KIW#=:?Z:H5GX/[#>, M09*D37KOUJ?.(T8GQ!PC@F$M,D?93-%J)BGI86,*:"55]#P462CK&A5^DRITM<*<),I).2F]9I?R>)4)?)52G29,@#IDB7SEDDI5_L]'*FH4BWVUXJ\M.D*R1J+=(5H]ET7J,_'<$/R M\43G:M7[7G>XW&S!HP'WY^7G&C9E%?\_LSB@I;M:Z_N$C[@^/[NYNKRI%N]@ MBK#YVD\9@,-"S>0N1Y#.]HXP%[2($MS)C9'06@2_9"RP&HW68-B^;S?JPW:O M>W[6NR?]0;O;:/?K'7+?[M;A*WSKW4.1UF"GJ_76(^]_&3Q\J7>'YV?#'GEH M-7 "R$WI&@9+AI];Y*$^N*MW6P^%WG\[K:^DWACBD^M2Z7I'T[ YPA=-S1X+ M\\[QM?/G9UTAH2AYN(0Z>I*'J9*:>W.B)U27]Q?Z]JD=UN\Z+=)H=3H/_7JC MW?WC4ZZ4,]?]>K.97K]Z##/NZ@D6+?U6(2,A728+CO!]&BD E'[+&=M4'0Y> MW\$4)]VA?BJO(*"YQ-)5A\W7&[/=S?/593;'P^82I$8/I[C[*7?]ZOG=(. MG?^+%?+X+C'?4<5<"Q7T*9B3 MQU#,?.:.6=[JG+3*Y@IH-A0:F#'4E(>$AG,2AUK&C"A--0O '*,64K .8)RX@@GY]]*^Q(RS@ M<.G$ 10+H0V R1.9A/N3(B*\=^B_HQ)EC2"HPBX\AEU>3@&0Z G,$H5,0=1 M)BB@\0A "A<&#!('##2:+T_(40CT3V*7GR[4QT,Y-^^. CZC/RPT-\\ M\(U+P)D%!5\\YZ&'GJ[FT X/'3]V04^!(Y;T- \DPZ4_)Q&H.%(44I?O9QQD M<23JK];Z!ZYS.;:>QQ*Q#P6 > 00@^E3&5 .51/B^6*F4E:2;,R5EA1ZHWC3 M@@>H^25>42DB SEEG1._'(($'P^_?#Q ?AE.6*K5J1[^+M6W6%14PB!)/(S6 M7W@>A\L+]<$H:9M $&'H -2;CWR&:DL8$-'(YVJ"-;!8 !X0>D%X[7+E^$+% M4 ]](RE\RPN1% YSX;:R:"Z "UP&Y&(YJO7=F=!PS$@=W(Y![,,0KVYHX>KV M@EDH5[>NO;*7'+,=H24E[(2@6[+$598V$- 3'5D4&[UY*[UYT!N.>)W&H 3& M8^5]E?DLGB]=WO+P5W'4#X%\ Y;Z >0G1CW"5:%/L/^^X6PR!4VG3J4)_9YG MY3R&I@Z-P1E]:14,3D<,R-5VEP2<(I;0 'AU4Z[05\SB6!::QC#KNHAYEWU6 MR7QJ*!L*KS)N/O%G\2$'MQ, *>%SEVJ#=J2XRZGD. IN@V/C18?84JPP5C66 M+C$]&.(:MU@H!J@T^+18,Z*H)+%/T3^& 1HDB\ 7:MA8>CD/ -]&# N"]PKU MF7M2VCU3AL/&>I*@MU^5T>'2_HN]Y WV?[E__9012&$L+ $6!>LQY2YR.U4B MI!A24 5V 5.62/A4NBGO@CG@=,1]KN>82MC6-]HC0]&&?:T562FZ2)E8."9\ M^9X,+8IE!"9 F22(XPCI&A0F SIF(9/4!TL 3UB$=@:+Q*&V; _VB$<0-YRT M=<^TX+"QGB3H[5?%.1"^;TVI'Z,'O'A'PSR/.9I/@;S4EOQKEO=9^/;J2>?> M7BYRLBM^+SKY4!%\RD M *B*A0,]G!1LOP3WL+&>).CM5\4]$(IN6LI+*7J-1''/0)+U-D^V4O4K''%, MK C'B26RY%("8[-5"R<02L-#W#D(#2J02O(MIA+Z(Q=/H/& ^,$[7BN=H'> MB!]P.8;8F67 ?++0)55G>!_UJ8R.8FR2(P#$W,Y.$!7/B\T<&'V8#Q%JE M_ ]/5N5D%_9/6PX;ZWN5H-NC>^=IMEJZ*77G%QXF>KW+I+EP-I'VMI)/DG;8 MEG'9R')G$&GLSW)>%M]4_OFC,J, MEK>X>=2%VHIE7MZ3[)CDA*$*4)R0P- FA:!@!E0X^KLHQOH>KA\G>?4]2/'TSFS#C<@)[FKWV"Z1LO2=+]#:F,Z(N[B7(3CY?X6GH5VO];>FW M7VQ;=X/[9J>P[^;E!.?/1_[Q7SN%7FW7JE]J156T<%+7V L[:,GBA.L M=5A63BR43%A.0G*"M7(V'UUK'E@LC0EG'KG/_.J>S2N3B[[=+0:W-AY^.,G4 M"=8^.$MO,=(F;EXJ'\ "["FL]RH7]4CR)&%]DR?7I>O; UB,/85U@&D<0/B/ M0@%L)?/=,NG3,:M ]]B%CI0\6.%]"+SCK),.E1I4BBD<]]L_R=%]=RO8/T3 M[R6IG/3>G4^=1XQ9B#E;!.-G%=*;KGJYYM0A3D\[2TMP6<7+M!.Z_4!C!*.(O']J?0L1?3/P+ M4$L#!!0 ( +2%@UJ'6=T/1@0 (T? * 97@S,BTQ+FAT;>V9;6_: M2!" OR/Q'Z9(/242QA"27@L.DK%-8Y7#"$S5?%SL->S5;UVOFW"__L8V#H3F M=$)'>G ''WC9G9U]YF7->*S]6*H.GY"]E)LTQX:/44N/G%67D\K M?4N_AZE]/S1N:UX4B@ZTFK$ FP4T@1%]@$D4D+!>#-1A2CGS:K@0EX[W7=>% M@/ %"SN HK6>,K!&]K8.R2,!\U>=O].2RR;L#UIL6NO]$LZ3N*O(F4*T+Y6%A^SWC<C M6OG0?(='!.P[ Z;JI*^.C*ED?1D:]Z!J=C9SU6Q>G9Z)KW\Y^SU-!/-6AX3N MDX2ZU4H40K""KV'TX%-W0>M@UD%MP!UQ&6A+DKI+OJJCSWBV?QWBE"7'#4@"Q(UB0=UGXJ50E@21!V))84KXG(0TD:Q'GZXPX1V1 M36594$9'J8NTH=, 5#J(>("&29_04)ZO6E'" M@88N4NC4H<&<_G$3YV4,Y&I,!Z=)0D72%O8T/K0O@82NH49+$2L@.2J'(P$ M82%RL1"2U%ENPQ/&$2SF-,D04*):(;Z/B8$IR] ).!$C4I)O[[&0A$XVC#I= MEFO/MD2AU$<9Q(ABRO-MDQ<<=[SUV,LGRE;[0P,T8SB^Q MJNOE[[UM>&"N6&:BS;==F$?OYF=;W\+2K,S-H]O:U=X^/73=]92V!5U^Z)_]32 XODW. M(3H2Q)\1C)BX+@L7TCP2(@I0<_:GN?>IOVF^_5G1.BAW^Z#8_55GS?GZY->_ M'A1=,7O*K" M 6,\8LDOV'<*ENL[J=$PC MD6+]5_-"C3GS"Y)VWHZY.8%@'"G6)D?DO#G2.X$NSO'P[9 AVQM)@@&COMN! M,5G0+B[]EM+0P24W7;#BO)/6@2%)!$A2F16Z^;GD*4@E/&WK+NYZH+QE>I>- MK7M,Y5C?)\[7[&8*DLAG+G)M&EW;C:W=QM=ZR[_L6.UTMGXT?W-=>>%J\;P! M[5,O7_&4_UNJ-X$N,[+,1D5&UY1>VO*MG#FW<. _3X=-],;/HX "&[1U\LG9 MX_3B^7KV&/Y/4$L#!!0 ( +2%@UK0>$MU/00 *8> * 97@S,BTR M+FAT;>V9;6_:2!#'WR/Q':9(/242#A"27 L.DK'-Q3J*$395\W*QU[!7LW;7 MZR;V<0N.>SLVKQM!Q&4/.NU8@LO6-($)O8-9M":\630TP:&" M!0V,]P*&-@3JR)^ZV#24@:Q9N>O]D)1^;L#]IL6AC\ M? M)'%?;64&TMSR;8(^PV9X>7 M$?1N.I\YF@28.(#(?I7&>DA!F-(Y$WJ\30?4P2GUDY=X9H-%1)-;HEO([NBGR M61M*!%#N(X5!/;I>4 '=3A.-GU] D(;A!KQH'8<,8W;'Y"J?).BWE FZ1H$D M&)E@R[,3<@IHNG-YXI\^\%,O%4QF)LQ[;T7X$FD+'SH?NQ= N%^XP3ABK4EN MRL,\$,:1BW%(4F^U#4^80+!8T"1#P!'U&@E#E 4*EF$0L"-&I"1?/F"<<"]K M1IL^RZUG2^*@-,0QB!'%5.3+)B\$;K]Z??W]Y&K#L0FZ.1X[4TVW)K]=-]J- M_/=4,XSJ]\X^W#%?KK*A[?=]6$0"%:]X41B2.$&@ZELC/P^K[FSW!;YGN\-\YUCNN]3UX-L"[I\TS_YDT!P M?)L=4_1&$']&,F+B^XPOE44D9;1&R]E?YLZ[_K+]_F=E:Z_]DO/U MR2]^W2NZ:@W4^:"5M K1'+&VL?1( MT5>,!@6,>8_'?(PG\!\Z3X]R.F*]A7/2O^&I@?>K M?N\ $O!&L?ZKNM!BP<*"I)N78BX/(!EO%.M1(ZV\,#(X@ K.V^%[1H9L[Q0% M1HR&?@^F9$G[./5;2KF'4Z[Z8,=Y%:T'8Y)(4)1*%8;UN>(I2!7<;67]MFRH M;I>NLK:ROE2U#4/B?-#_ENG'1%>*K-2HMC T592V8MO*@EL$\*DD'A+]:+-432M[ MSEP\>,Z>3_\%4$L#!!0 ( +2%@UK]D1:-000 %0> * 97@S,BTS M+FAT;>U9;6_J-A3^CL1_.$.Z4RL1 J6]+Y BA22LT1A!))W6CR9QP+LAR76< MM>S7[S@A%'H[;95 *AM\X,4^?OR<9VE?4ZVH7NV,ZG7G!$8=[8U@I$]T2>&K8_!&6&W M-3N]C*!WT_N9>Z]/O'K-NV^Y;:,%KB6(7,$G>Y-NWF2SNANO::; MSM2S3*@R R>:F$TVZK4O[8^X1,"[L\#59T-]8KF*\]O8>@#=\&3/5;M]=7HN M'G\[^SW/! O7AR0])!D-ZK4DAM4:OL;)8T2#!6V"W81)PA$!W!9"B643(\;E M[$U(R2VJ@B09$%%9Z'.16OPDU4:,8S9(Q/+8A"GWW+& MZ0H%DF%DPAW/+L@E('3GYB*XW/*G?LZ9D!#6D[\D\0+9ECYTOG2O@<1!Z0:+ M0QG1 LK'/! 6(R\60Y;[RUWRA'$DEG*:20IH4:^1*$)9H& 9!@$[4J24%=.' M+":Q+YL1,V %NIP2C?((;9!&DE)>3)N]$KC#ZO7XZ\G3AV,+#&L\=J>Z84]^ MNFVT&\7OJ6Z:U>\W^_#( K&4INT/?9@G/*!<\9,H(FF&A*IOC>)(JGFSMT_P MAUP]/HFJM2R2M+$YX&J>^?8S[-'B[)D[M Q'AGERV[AZK:RK9D5RSZ MO3\))(YOLW.*W@G%]Y2,[0*_D>L[)4' XH4R3X1(5CC^J!O77K8V^*\P*('> MY$SWPT&/ NO>AN?QF5]_.BAUS1YH]P,U4TNZ^R<73;U'7^S__49QIO625JF3 MDLI6+&>1G&GMTK+E/9&M2B[&DM$01MLSMQ.&#.]%<#'E#%M2;/JN\_*LJ3.M M4SHL'=)3$R^M0>\$$O!.:?U7=:&GG$4EDVY1C[DY@62\4UK/&E&+ZLC@795Q M3JS A Q_4!3\%Z=1T(,I6= ^ GS+:>SCP$]]<-*BE-:#,EGYVDSYMR6K M%Z6M[]/SO*^\LEOLUY\C&A8CMOK?@7X.9Z7(2HV:BJ&IHK036U4&MPS@(63Q MG#]5/A4N'Q/+I\E_ 5!+ P04 " "TA8-:#GY!-S!( #2@ $ &9O MD>6=4$^O[;3P6E"H@O41%0.G202!'.[_G=FO1]F MS;O>=_;,?O:S]YJ3B9,%T.7[^H;ZH#-GSH >GYZ@DVF0[G^N_K^._RSR_[O& MF9-6$.=%$/2,S-DSUT%_<9XYRWGFI ,$!H'.G/\?$T#_\SCSU]ESYR\P7;S$ MS'(Z 7\9]->9LV?_.G?V_/ESYT[OAI_>!YWC/,]U[?;="]RF3DS7 ZXHOGSS M\:+8ODE)64553U]#4_4=/W^!?P_OF MCRPLK:QM;%V>N+JY>WAZ!08%/PM!A#Z/C(K&8%_%Q+Y-?I>2FO8^/>-3WN?\ M@L*BXI*JZAI\;5U]0V,[L:.SB_3M>_?0\,CHV/C$Y!29LOAS:7GEU^H:;6=W M;__@-_#G\#^XSH#._F_H_U=X_CIW[NPYIO_@.O-7R'\F<)X[?^WV!:Z[ MIDQ. =S7%5]>O'+OSG@\R\-Y3)XK3_0/OOR/[?@$7\EY#] M;V#_!]<4B/7LF=./=Y83! $Q&#<_Q8+^JP-^/+:HQ9ED3XME!)Z X)#IQ0/, M\2<=]35T5=W&G>//RNMVFP;MO^<4J19],32UQ&!9.5UP3' XN$MQIC,?D"1O M86\$3A3&?AB1<1LU=1MU&??9"&:3FH)-PZ9*NP1QQ.W)S(.7M*[HGVAO +HP MWQ&.OJ^FX_>Z$9-.EK7<&LS?D:A[+]4GJ.J<<^L,**_T\?AB&OUR4ZNC )J= M'@IDJF"GD&XM5W_HB+25SE3U:>.BD__%T_264K(2P%./PV$V&4/;=JX-M]>@ MGST2E%&^F:P)1R&84!3TK7^N()"?]1.0NUY.Y-GQ3L)4(?N96ZSDKO6OW??O M#7P@[>GL_R?\XKU'1=\?195TFSW*MWH;A$Y'>O/'00U- MYR9D(0Z,YXAU0)HN@A-A[*XT5.62E^;/P[X34!+2HDS$=/ ,?/L*U$F\OS*8 M/_&&SWU]]VO<3!=3H&T$/'BS_ 1T;AIH^$!7/RX6IZEUS$?9XJ8J+H[BBYL# M5/,_0)^N!U-@T;F7\0(W1B7&D!IHR>PBA%!'B*ZJN8C$HN$/<$U(82'BXJQYYRAE'[]X;SW"- MKST!&;;/*;@UAW4(&%Q )+VCGH"X_ TI':= /IQ,@18O5$[R MJIVY:-4VP.18(!!V\SXGXOE#_ZBUAPF")R"!KA.0P4QR^]R5 2U=*E:'4L&Q M*,K94XF$6K9(QNQZKTM3LG2@ABZ[PM4QBAM=YL3%XF5^+\3XICMS@K-TG_%P M84P*4GXU!--L_!%!(DXQQ2&52FS644(T_;C/0!QQJC\S@&TKN_37\\WHEL)\ MKXSPI9JWTPX3:[Q\JK\MTU1WOI^C=K_MO/%J#1YL]PQ! L5'SD/(#)4_X:?? M $OSK::@)_+:4J=J5C41=SI;U*EN";>X_KSY]=RM)EB:)0S[U@8YCD^V;JQ] MT74]5OJBCZQSC%CM0_3#RRXZ"Z(FT'4&VI8N'UME2"5QTYC83:HZC,3ZJV7* MG;GJ:C$L/);9@N6R8IKO1$6#KV?&>S4.Q@7$^QS?;45"1947*K@HOQXBK&GR M[$L"PT1M%,Y*H76P_%4>[[3OEWO,I=3>.Z9U>1?VS/50TB.15\Q_?O\ M?W$(;\?15?(1 ^TH"2JF"=0PB#3_L,80&?V@,&T?VO@,[Z23_?P3RW18D\;[ MZ9GO57=*[>)"O&5^] @\@?0D;>!IN1TG(*H1>BJ9$M(&27PF*N$7S;B>*@)Y MU%*)60NZ5#CSC7$6^$Z&"VQ>C^MXKE/YZ>M8#$5Y<+'VJ]M[XAV=Z@4;Y&VU M?4?]NZ)Y7Y&K1[J,'O!9@A>8K9,\$"]Z"3^>TRZ=?\JO&)D*N2 8/\*6$I[H MIZ5-T=8@?ZTY ?V+$8I+4-W>;&0O_QGGXVG0E;B6(W8K]J->(Z]3!WG M=:UO7HRH)[)%$U?4O5O*-6UR'.);+8.K9G9O9?O-'(>\*.10>*/&8XZ(NIZB\$\3D M?_(4S,87Q@0;NUE?QVQ;#BGG#Z52NMO7#E=69:T8%VVH+>%F6^%\B]L=QFIZ M;Q>T,9E%"#NB8/]'3\]:!9^MX%>%@^26W.L/'"H2GM0']U68RQZ*'"FBVG*K MDS9*;XTR1!!FZY:T'F*1'90F3>(KIL@+L4BOVO^Q]Z]L(RH$F>%D'*4Y)"/+ M]VTHM_0+I*>1*J>5G'V,@[CWY$:AF(_3QSP80G13ZE'_:QM$KMD0%T= &G&1W,G( BH @7BD-7.2WDX(D=!Q;&R[5N0;,L7YC R=7,LR". M.M >FAU\ASP;=;0INB8M:BK^P<'X(7H"*1]68F\WOW;[5YKS40<7W8>J=M!R MNEP&HF4!U=ER:6CO,S!(SK:<(UD!'VEG#>H::85$&/.JU8%/,2%)/GA@DW#) M8=IS$ I_@M1#DY,X$4GF/]Q][N@.(0T6638E+1*K^R^0Y[E=W]-60 %R3/(I MWGKVXXGJ80F!7@AA& N4S\RBKJ\-'4XI \-@;1#"GJ,]<,(@?FXQL WIDC_#-%28M#<*C-+)JU&KOV[MZ*/ :H;J0SN.W\"PWE"9/7MET MST?]T-R/5=G"4W.[-(WWY])PUOKB([X;2(@/Y5:%;/[7L/H\?%W58# $FY'? MGS,T[=EX_"[',B7D-VDCY.@QXLY!.2!=@#2.&$6*5]BNI3E>H>$POA6H0=$$ MRK$$R:AEQ&G8CR=NSF,\-:,VN\13C>^VG>-Q!.,B3O930^Q#M$(_(%AKEZKU M6WR@2N?VMU7G7ZX 'HWC08 GA9JYN=]I]@%/MV9D98#$2_@)$IRVF, /" MWM3]8O/R^S7:<<=-6"W3]N6&(7+.#7+B#>KVJ]*%VQH5-JFTB.\NF '%&1%; MY^:&%=TD3G"]&&59@Z MW>>X NWN-SEQG$M9Z91G USLPKB+IA#&OF K6LI^I@'BH.XRPLH@\<@VB(O*QL4$_3MQOXV+W>Q%):'?U*V,&?YN.,H*_R9(ZVHX *QH\3$.?> MO@\_J; "Q_=".<%L]PC\8-QUZ)*D#0W3A!JWS %1=VWG;8R+;(Q*$1%#*R81 M)'V:?#3C^ZF<&Q(X'&0@_ 3OZ3YW2FXG^@I4E!"V$ Z#M33]4&[*+*I9_8 6 MG<<*SBP0TN#^%#O#;^-XS+LRZH'8'9R_7#'@WF% M[T]ENH,]J7.&R4Y?ZG-N44C8Y$0QGHC"Q&(H4\K/=U)Z/W("$Z/_M2A;$I9E M+KDT^B?Q)LT@)I!=OA,(((OJI03P<2]=*;*@;(E19"R5+K797Z[T3W@@QZ)0 MFCI=.P&1=]!?&,].0.VFM',0Q 1 MRK4-?G@-TM]2 P@K*:P/*T=K^80_:O%/"7BCQ(I)^C TM7ZECNU8;T MYMME)-?BN;N%-5](Q;.>_O.3JSLS=@8A@=RS=C&RDAOA1S*%T="(M(,PX)Z6 MJE.82^'I3BP?TK7JWO5VJXAY!#_LTI==#J]7/U?TN)[G3^61*;KM&E*@M%=' M O4M(V6\;3M6!UR/=1BB7\]8VB1$^.'+;ZYI1N=O1P?SR]W_S>TGPM3$I4H$4+HZPC%>*!2"L2*-6 MI]7V D\B4ND%Q82=8F-N2Q%_[;R;-:#>72UCP7]+2X=%2/@<;>AX1.16?3%C MIM1W,ZDC!)3T@_$X-A@Y>R0^C_J1=@(ZT\PAOVGXT;,%#(RR"F8GQ M8!B5^JA9?1W>$W&W3FYO+&@@>^"/ W5K*T?QB&:-,@=/MN!GXY=M?SV%JF&# MT)_A.[W$"SL;J#ORJ9+G$Q#"CI(7:>F^$OPS!+Y]K^&\_2QVN2PG5A,NPO52 M+.YBEXJG"9>A%VH]V4U:O?MI[^3C:F&\FS6KA+;K9!=[Z#/XR\,YT6QT\;(U M:G^H%__T\.>I/(D_0I>?[+@'?N-^[5 MOR]:GQ/'',^ ZF&D,2(?BOC?2'-/;*$Q#S(CGMU=;6 MOC7C&J) @*Y+(8!G9]%O,*SW'&P96A9ZU3) M^>*\3T ?$/)MS05()8.D9E.*H7\(LW.6:XK3K7OOJLNVLA9O#97>4[E%D;R? M*J>0]>610CVKKVOL1Q/K>=>(UD;KV/GO+=>/KRL! 3EB[=OG@'LZ5P-:+CW" MA";A-'NP]<^^:MS+?JX>\Z,T*O]5\8L46]/> ,3,L%RW@G7&ZYZO%2[I!IS1 M'X_6AMW:S^7Z952JI7,1J*.^ M"5[W"3,8F>K,LH7;/GL'MJ=B2H/A$A\]6=H"BSP:.[/Q&^ZF; &J[W)UHZC; MK2;*Q3*9$.V".U+EJ9H5V9KU&S)>98_0N%Q!Q'Q[+GNS) ZQ3M+1HNN0!_/@+ MZ@)C3- O9I\CLN7J"%Y "QSFXHY;M3V(+@(";:H=3$9F/1M?#._?S'L;+K?7 M&0IGVV"[ 0\MG)ONO8Y85*1KT,)(!.Z6FZ>T!VM!%^?C,\(FD 8T^;8CEH'+ MEVHTFE4"BF506L,;>WZ7'3S,_L +9X',N[5#S7K/4E/'-)_\UOR<9FN2GN^9 M/+5:2[AXN@QKQ"E#J !E6G\;L! $S?P]6P-T7]>'/OSWW$K$WXO\N)@>+?F> M=02L;$>F496I]ADI1 M>XK4E1*IX.SGE86'EH&+SP)TNR 7ZL6DNJEOR&@NX+Z]7D)IYF/:A./UM@&% M=C?KYMJ,S^OMB7\5,.? 3-1G1,4X'/.])C+V"BTCB ]38*M=L3=Q'0.KCS_% MW@3]KU%V#+48#G+0.0%9CLEO['V5OE_5-((WAIHV8'J@PS7K+*%RV[AMG)SC MG3"C.W>L\QL:&W+^B;TH]M;&P50 $XV>G%_TOQH?P=%^ M N+^>1EQ]64$QSG!M5;RF!(X;6%)PSQ13:'U<;Z9E&**^N+M"6'A0O[NP7T+^;\7-=R3,M;[MKOK_61GHU"YU[-=Q3UM*3U'YTK!C),E@K5:B=2>M01^ MKE"L=>Y6MZF):;1A]ZWNVP;21]J,F?GJD$U=BA\7<(?,EU PBC0@9[J-2 SM M9_.94Y?F*O-DYR=&;ZZ?^.S6QR*8??.SL53+ MU!\]@2'!6C&LE_5N5#5^2@7G SVM#>[8YF 8YNE]@.YVR3541S6^7U2*QH)H]5G__.KF1X85.D*Y5HV==*J.D_#ES):M M(NR76%Z'*P:\&:'EA._./#PCL'+#U_[);ZV 1(28QL_'@?%6/]/H6ID4JZY3 MUGN>RAYD(VV1,,7=/A6\.9H_WH'C6ELD2T;@.:ILRS8RW/(HFZI#+"R%SUSC MC&EZ<]'E_1'JXP:)^W/]4HTA=)ZZUI:+PW2#3ZCA^?,MTL@S0#7Y^/K0(8E\ M_!N[G_ <(@PS9M$:R^$9(U3N]1BQ>,39?6O$Q1(J@SS+*Q;#PLW6UGNJ,WL< MKP0<'<_*1*X+1%D(C'WS;R@PC*5XBVCN1-T:)5&[P.K%N8\]BQ\5;B[%MMZS MMNZ96BP^O1XIW""((&6,1W =VY=2U%X58BG(9X8="%'67BFRYVBQ+<:B2[T, MD\;F%ISQT<)I,;*W1!=LR9YH U,NEPHJ87Q9%^Q*_K!JF]-0 5L]U,%^FG#T MFNJO+'6P79VR3,GW_-$36N1EFY.'5N;-0&6[>)ZK4ZNK"]2%PWVN)-L;"?_; M#V%#+V1 N%$B T?NJ!E1T68:)FEQ6Y!N2"L?B-4113#Z9+=EZ18+7YDZ4)*Y M5D-!VL]_E1_WM>3ZE &N;X?ZG@RKW(&PUY;ZR-2.\3XEQ)2!:\?I/*6VABNR M5*8# SPAU,?>4*91_XLLS"C1+E3V[;KA>(L<(M%#SE>%A>5[N?(\YCFW;H!' MFN5A[]U]= /2X31IHHZSEZCR$37H:%$QVN]34SG/45$1#.&@NPWCK56@?'#; M_#XZGWSH8E!=W>"UD;E^]1S9"U#6[PM_D)I/6 JK5S&_#48@?[?^S+K6*J#& MY9\F2/.KHC@JMSY6["5>(JHS:]V-6G!-CVH.>;Q;6.%+]K,NFG\98Y&':/FFJ&E6?E^M ML+C?FK+'RW7@J"D/%1R//4 TWMDKQ41]DL%^IH&*S M0DR[:?O2>R^5$HL.RCIE=3A_N@LEZC[_;Y:C'F;1EW< J;BPQ1-:H!,?H#'. MX0ST:%-8>UAT9?*9E:M8+>&I2UJ0M,?%SM)CI?&]THO52#>)* 5 2Q1\UA*/ M7MD]X!OV@< )P"TP27X*T@&7?$57H:Z8C2.-%HQ*RR&/O@XZA^)#D7S4G"?U MA(;)?(?5ELO#%BBJW8G6 E/_"?N.!-,X#LH /8JQSM$#VM?75(?^_,)OLNZ1QHU & ZQTL:X M.2Q7L>GK%HW;P ]7&D77-6=(%_S[20G]S^7XOQ25VM0AL-787638 MNR( :R61M_63KD%LEGQ+75(W42*>@)S-R!L$;DP'>53:U+17BE*ZZ-7_SD5P MOU!JM7XTTG%ET#E;RR *0%WK@'CFTD)X PB7 UP]VS_?EG\%#S#QB>Q\3'.< M[*[.L=(]']53;%XJJ:4J>H5:KA_D==V; XHFC656:FXZ'F,U^#7V%Q,]1Z)? M7!4MG*;BNJ"_CN1ZJO[L_:G(UG];= $$R@H@.8>Y@%>^HOQ18Q"J&2X*7 V) MY28_2_J$B%R4[SK*G&6"U@'N"^E:+SV+$+%!QI)&X\';E6OE\/(UN,IG6UCT MGBQ?!TJ*T#@:9-T?Y^=>+$Z'Z*/&YX7 !V''F0P9I%U51I>L7_N<8+J67,8[ M"@L\EP]NKOL1L)WQK1HQ"X79CY1E"!F6+=4UO^$=6R">JX+RK5C1N< 'CP?W M8!@U"!Z6L#G<,<_;HK0NR*C.6S\4Y2OKL^3OT[;<:\ VF1[DKKH]+![=8RKC)5J9*7DD?* ML40WC8/03(M0%-0 ;,;/JDD<)SE[4HJ'#^ YX#H"_4K.M'YD5QJ!"CTJUN*+ M\S%Y4E-%:Z#)9(CWC=ROU/V4/[KR*MD<(?X/,X,G-2S4L"'WOK58ZK4#CHV M$]!Y/D#MR'$@D&RL./X("*6Y/ZAL((R@A(&",<$1$S*^M"- M_?*_0#>-/(-F^3H$/=PSUN\EMBL]1]_]&QD^9W#/>FMO_>6TUIM#%W TC&I% MF#Q&BA0 \@?3@+%X;H3.+;HFC8"1U7*BL$D>GS4?<_G:6#OWU_430VIAP"VZ?V.RO*PU4SR3T.BMN_%)F;F2BJK@91)50WA];T_@#- M]R8"%%&1/B6Z"7.JC[IE<=H273?%'3'3S3_#ZV3[SI^K5\&"JMXLXJTGM99P MWWYOOIMFP7&%?OW[.FT)?'DWZ8IZR-5"(Y$NY*W.='F6A6K!21[-=[>6)^N8 MW9$::4L\BG2B-'$\QU48=YOH9BV,$KIDQ[8?&]P@E7L:_=K^/@%Y;\(/%("P M!7G^7XX7AYL#PRBG FU +M[ &UNNW\?7#&W4Q&V&6:0R56$\\T(!\= 7U#<+OXV/6+R^**(%PSJY225H!UFM/Z>ICG\;VCOSP MY[,WO?&9X?>'^D-;PN*L/V8WI!+,( NY)Z"J@9<0-_2+'';!\RGY*XG-:#*! M X&C&,1/6AKKPD;Q/MK!_RHWV6'J\&]/]5\XR3092MU*$N:4X5V5^X@:/]QD M%)8Z'OI_0[!$(]7(+1*4%N$NMQD+N9N+R.B?0;M:;G81?0$:$JZ1[74YBPK# MQ:_RTIZ8YMFF:,E90%GB^@+4ETQJY5*8 XN:+P6XQ]H'+W+P^_O]1<,P75] M^/MAM:"BXL7)2W]:G-XL(+ WNUPT$'#YKO9$(8:H'FZT2+S=&?MM-K+E@R:#506O88+3[1YE.AJK#G7BRK[E+C81 "E" MYPDH051B=$]^(O/ A(;N[ ,3QZ]ZM2C0GJ[QJB;?DWWW/O/^X!0+F'7@Z5!; M:+X=G"&G>9!7:+AB3,[6=$VY1H8LE.;(C^DHTT\5C>"LS=(I",,B-2C&<'U: M88>#\7ZXQH7L@!(OO@S?-Z$5DXY]^7=Y"!'-UUPI2?R>ML;+3<*B-T?V'6Y9 MSO68#N[!)]$PE* ]:H# 1&,^8E]@ER)%R3M]0 MLKZ^/L/!Q"AST\BT.6/QX:B*T60A862?)3-S?76Y(@NYR\(YH8N M/K;HCR8%$D^+!2>>/]Q3T"@4HAEPKK2 745ON3P5%:'.M0C=I"1=KA:6O.", MV(U'E-[^4-W8H&,E["9TGF@C84>T>:9V)I*T_$A1YIF20$RQ$=-%TQ16"]O< MM-53@;H/T*A&-H,+QS4$EVU^NAPUZ56P$5Q(7ABA,#]KZ[D9Z%+^&BQ"Y;V*O'/Y0W[A=VH:CCV\(N'<#QM241IR%_KX,L&<4&3KE^'EJDM,7GS<,'$SP0W_48G3T^GX(-2T\LM$6&A M&\NUB3M\T?ZH:UX04(L4H-0!X4"B*7Z8'$DJ.C;HCW*?WS\C2"ORJD_%YF1> MJD!>\,@07/M>]]I-OYJO^H,++<,J0G8.^ET4EAX/5UAKTB1FL0/"KK(-W,31 MN:>)HF)H,!#F".C1IA87C+^,71U],H*\*QFI M>6FQHPKSW5R3OL>8L)S3W]FF$E+X.!6#XGWM]=+HU:$)!!_\J-DOZDORI!/(^8K163NG<+V MX;R7 U6.-W+,OF@\4\RQ27.SEADTZUD+=\M1C$KJA[X0O30*\4Z:.FJ=XZ/U M[68.).1RJ0QP SN4%8N1^,T\F]7#WQTP0<]:VYHX='%<$J!?PV:G1SWZ?NTU M]#C]7%VMJ6]++6,FR$'RP8^];#6]P8V%X;V$Z^T]1D-[1ZZ3/DZ%GK6#-A.3 M=@8G()F%FEK,S6L/Z)7Z+W8S&&J$A=2IN>Q\QBRA>K-OYC!(-:-L_G+0*WD5 M@;>S5YO&=#@16R(BWLL9UBX.1A8C?:G8PM9EJ^9<*SL6#]&MK7F_@\>)?\5' M*"6W#ICFA)^ ..X?0?+=I+F-X@"7ZP6SPLE2Y /Q3B_A=OM0J9EOL OS^YE=M5Z)?#E;(&.X7%+SG7WQ]Y=9"^[CPK3M ML63G0_9C]?7Q?+4^Z %!S&1.*?)U..,%(WUE_F4RK",!?G$"BNJ27SIDM=HPH%_))Z*(L!IS]CF6FH7]$]";4B*AD ?P.XUH M<;1C;'MVR$$#D%M,NM$80L1-UAZ1^&AZOK_-OGN2?4RV[3)N;KZU%B7/RCCP M7LGA2]Z*<9&I((SDB/PHCSG4 "JCB.T6TA1$G#3Q8=Z5=R7C'3H7^9O+$GE/M]NTZ_$8U,H;L06E?2*O\S8 MJN?9(I0#@S.[KY;\:,JP-OFX_;@2[4>( E?.IF87 *EL5EWS7,VZ+J>M$=LB MC'!<[A(Q.%(7<(ITI.F4ADM.-M\F-\6MA\I<)< =H!8CDD8%@S6REK(0\S#H M-S8#!DL^[2->:'RHY2)=MF9HZL!MN&P?&RQYG^.\8N+)Z7X<;F7H.@;] >/-T#(W9;&1-HFK]UQ6#N#>\CJ:2X'0G/.;>A9+=;%&UTB M*W2@?_P^2)9WF-CHOO&;ZJ9]O7NV;)/2#(20C'I3U+ MU5>RGS=^JL96E1!7]V!7G(INRT^ESO-2:R$=)HH=KH ]2;N8 MX4/B0G&S'O/3QOQ7C])DO8V]^(-CNZR(S8Y@)MU,3'WRZOF]Z-3 +F&FKDGW MJ#FPDY*]KSGQBBC42*-OEY36Z-]!J18D6'1:&H9YRY3V03DBB92 IZT+"O7X MEYUN_$G))Z GN8 4NDU^RL5QB"&*B'PPPN"@6X[Y%M3\:%:AB.BSP8F.T@T0 MC]2IGO8YY=J:X4^95JECY] ;D,NKHN"6G .G0@]9"M]=K5Q#U"2A9HFPD4F5 MA &U)+Q\(>ZYM'@BPL) MOKX^,A(U^ RAN%<%T)40!O.;(R' Y< :2%G(%4%>_9)+S&5M$2/=KAS,&^F; M0DA3)#$2B3MKPW^'%3\971@,%I'=ZPN\'[NTSSN$CW-X=G/_IO*?&@<)TAIN M:G>Q]N.1/KI-G,&!?#"^Y>.+=%#K(/P%^)$4[6;M3'8!0KOT(H3#ZS#[)V]J M[4//-)2XLUA)\\(+99:^G+WP4I[OQQ9_/T8]024 M6)_)ENPVR0OAM+2>R17BP(WATGH$+@UP"VN'NKXO8_MW@-/R*_/>^&@EG@K0 M9:A3"\@ FKPX>5NHGB5QS16!YM%26MCPN_S$WCB%[*$K/[#S1Z8* U9*A)EQ MM@UP8S !D;U%HX71>=A.IU)(A>N$MZ--/$9^7^W@TG&%+\3;+V(*VZ%MU7YK M89X+ >MJ3'NA95HPZ:AR$!U29NV! M-NV!9B?>7$PPV5F\K%.J:XUT5W\QZUA@]/LVA622Y?'9$+LR]1>-8(3!G%*@^%0[5$U#R$P!_ G(7 MJ!#>"3P!\>:1)9D$VO8/$TTNX297 S!"F>I'E=$]@@XR)--*"SA1L1UH&\&X^@KVN09R2DE4B:RC>A?*\.E]VC4Z\'^>_] M^A%M._(E2-QJ8C#_TEBPEWZ*FMDC,K!2>&KNK3\U'M?*$]QZ2?,)Y@ MR,LOB.Y%FRQ$I59H'J)@O:U.D'ZHG="2GV](UM;MJ%5:/73,%/ZQ=@*:3'N. M?J5RY^B2WF]L.>2^CO9_?B4SH]T(9_IH+)3Q&/V7'\MG;)]EP\\W3R4V4-@L M@T*=!NF0SW9G0TJ\N'19AQL_&,&-/#XWM33@:Q(-Q_\HOW!G,,<4G\G*!6Y" M8AJ#_Q \M>TB3"X\-;CZ]+E5^>GCVJ 4@;C3\+$97()4&\9K^-%O4Q/9.%IU M^*ETV5#WQUKPNU:B/EN9A&9P'>R#Z,N_SV9!IG#SZ MDQ+'*8?5%\%L.\B2%&2:. D(-(JM)_ 8\-CBO0CFH18:HWGF@K0KU/J9 <[T M1AZIHC(5P: 2RBWR%>K>ZBC#J+LE&>E"I)^A,,)SG/UG##HT_.)4 .D7"M;Q M/*S:S. I\#3^U@^@GC[3UK'T,=;S0[/4WZ=YN5L+5?;&E0FC43G M,^_:@;]%M^,!;G("A'A1/'&"KDO3+RQ").[RR[[UN4J5@4HY M/U9?F^8<'&?_-3KO;9.V&H.Y;V%[2GI!)%_T\ ;-%HJJ5UP M++?B>PE"J$N33F!'.O%39V!^=?@1I'R%0]?8;0_>QNBY.D^*]'RM-:EX=:KZ M5Z-^Z2';D1RZ[4X+",D".) WA3H(K'0!&@=%FY%4.$._2\,F-6M_1+3L_.XP MO]8\(A,4%V[;?P(R&@QB$]P)K2GG&C"L,WPR["-;H0(_=K=(W;9H^M/#8(:< M%L41H$*!O9Q3 SJII#8=8<"/!B:K88+]!/MSV(:5"6P>.G)4'-:;SY2FFD1A MX^UB<1#?4CXU(ZMUC17119-VMJ>%]\SGB6MC[6C%YM(?ND[H7FAO/?8L40!] MWMU&A']%G57"@O2N^CE^[3B,+7TAE4DDH:?2NG&W/-6E\KV7]FB_= M=1(%CV@EW_K1KSC3Q/>J'%L872J%=NA9?[Q*JD$),#!FG#_&B6)%P%I9UP; MV5N/*<>DD'MZXF8M_^SS1@?*I93/_CH0O=)4F[X8\1,1?>UU97 L[!L:N/X; M4NM#/I<+5,Y!;CSE^,\..290U//'HIH!QS*H0?1?=/FC?^F"-$(;CN^[=D[R M(INBNNP^W,.YH>D'OD?H/5[V+ Q?EYZ7N!PN9%53W<*+DS$*$5:T3=_LG4.& M,U16^%FQJSS$R66?>Q8[&R5I9]TTHL6-+3*(Y/7E46F3*[FTPNB51*D4OF#; MB@O9MSS-!KH/U?P9[IW@?RH4R5E8KB]_6D)C:-Q2W>O==:.KS8[2Y]\,G0:D MZYKD8A<-\8A2QUN:5ZHU\2E?D^$XP)VZW0Z[Q #4')AA')3N%@[ZM)@V2F# MNF_Z? CT<6(V$#\U8I.RY4Z-8RIW[%#L)E+?F%[$ HH6[4 M6W[S]"4\&FK6$^_*^S!+E$@OGO=\KMR8@-_$Q^ S^QC\2/_C^A.02RZ'QPGH M;(LZJ@=\^03D"68'+,<6]8% &O;@>:P?[XQ7#L\/ER'O/6.Q3D&VBK2 P(*^ M@DD3I^I1Y+](E>(UU8"V@K8"!&91=ZS9*-1VESR_:7J:Z(1HOXG:1HN$MM,M MW,&3\F1"_'#7)G6Q)T9("SUZ)2P2JR%9[7$'_0([L;K":K?'X6C MJCN;7=_12-C0)*R&Y+D "W9IBE:BEBQF88,445U6?:D-F#1M?4Q.[%?*,C$R MBJ2&RE\T2=$:PKBGK*0G: 4+%X*JA.7$N!/S[F'73T 1]I H+:D>3[]":0!. M_.EY<%#[[+7U)>4X*[BZ3Q"P6(G'S+QA?79@2O+D^F 4=+GDYKH8,9C9OSCR MY3RD\(K>.87K!JRFG5?NQUPQU7]#$M1_*?;//VKC??KJ,]P'>K0LCZI#VDQ0;I_?YIT"^#S5! ?+%Q&V:@(TY M@OOAED<=![9Z.5E=B/VQNB3*[VB?,M/R,3"G'50%US'/W-13@/;S8C]@LLA@ M\>-YQ\ P1("CMODKR&L?D'>!<(J(6B>*E>:8R5OZ 1'Y;W9!Y8BLR,]HJHA8 MQM36T/*MC6 1G:V;\GM]^E/;)B.RY;AR7Q_*2HLRG0<(IAV1QU^A^.C0'\[C MS=(4H:=57;!O(\KE]Q26B8X_5$!)JDFX527"5-"LR80?QIC:G3PY$.P#(2(1 MA/7,FU,(9X#V$T7NZLAU-=)@X<:*.=N;)W^>\5K'/],LDV0.95GQPUQ>^?E M"5U5>QV0(.-HM7 "8@E(>B5LU[/A#PAF:<>29[ R.+NIX;P$BO>1:M1!<8155#2DY,;2(,=%,0QF#6.Q!E3.8)4/B*8![ BSC-M M(*\MRK,CTAZV5([X-ON ,S2CXZ'*,*_ONY%(Z M79QAZ)->H7/JRB(>T"VIN"2""QH$N.BUU.I7%'7GNW[E4H5)N M9S>(M\M4GW2O&:;?+81E)DAY)G_/+L-]Q(1*5#7]BYH&)*FZ9,)I^%OY&W"@ MUMU-^IO:$A5%SMW4+*@KF;GA;DKC>X7G>M-3"D1:IBIGG( >UC]D_LS[[,N4 MY]@S5@A-D2NG $FBJ8 R!J= 3$->D83Z09%D_HN5*E;3*U1L,>C>\ MC1,\-&8Q$6SYF(]P@5&?KO%-Q6?HOPD+(8?#6W]H*2#\; @)M5/;V#X$.*XJ M49QZ)%M1+R9[ K)10!J3M^1?5>+7%]86BY[\(-,'9"E:G<,E56MT7KQDKDFYE$!.Y;+B"STG%* 83[@1D4,_Y;\034[D"#D73X(HF: MK@WX4/;5"B)'G:,.0%Y#<00SJ(446,0/$<< MW^DC"NS!6&S@CN;VR?TSG(B9(O$8M1N[E<@=YI6(41I>9JSF37D>IX M7O<,V@7% CE^9%4%-T?:D8?34_&X#C+->F91Q([MKI-G&/,C1TE.?H-6FGQ7 M+T<,0S!@@ ,!>1L YJ-4VJMD.0%):AU/!##&;Z@55E#YTKC^6XN5-J4?S04Z M EN=;JMKU5WK*7*F*799'O9Y_^/_WN91;AIJ'#@M=BM4:^Z!X&CKW@GH30@) M\HT=0E0Y5D)>)=&EH-$D;1T1X.K",TFBIL>YE5I%Q)ZV-)7CH.@XNT5QG4 U M]IO MFGZ12*W>1#P3D?P$+[O&EV7; V&M@")4Z0HI)# UV0[08NAM<834.P> M"]_;_L,U;2VOZ]MFJK7/ZG:G3D#W^^,5,;0W!0A7_A MG?&YD$/'.'<7Q)O['V0J93N;2][>9+D>'0P2W&E^1%H(T!(AUB-5U5A>=9C1 M[G0U&]]7A@^56O(CH=Q.9"/)(Z=].>2Y#EM9MW8U1/ M0*^#$4I8*()P,(0!\X.=XQR&&-+K1R$-T@:)/93#?D#LM._:M5#W(ZP! PL= M 9HP=8TAU%A#$RG3N3)$MR,G":XY3\%#*Q:A&]-AN5++P4E[SZ89EW1/8\3N MU[J(@X$%E?+9[)';,U..=DA;8%H;/YHU^+GV][-=/9KFOP5U.9*&5U,EWVI\ M>O)6[8FKY&K25-.!,]5@TX6*M@&@BW?B$B0,*V3W"3AX^@Z\]Y?1"P+TSC:&<9#A65E-:'ZPM1ISC_[&OW]1"\\6"PJ6F M&$9LZ%:4VG!-Z=_*7Y4)8*1" M?:80\;VO7+>H:JV2).G)Q'M+XE+*;MF5VQ95O8ZPV%)LI[/_'C69:%':HP+] M3G'D(X-93WM@OS2-FQB/BT.J+Y:AN&.=NOPBJ[9D._WE4%_XO0G:/8A(%G.V MN'Z%YCL9%NT_^J@:!>PYDDR1G8](IIWD7]T/@U&GC#+T R1_#=!=-D))4,"6 M( R]VX6F+.VV?1=^"M4X-QY.%3I0/(Y!L= -Q[3TJ&IMIP36D41(&Z,Y@ @6 M^5A'+5IB/CD,PC?^HF[ MF41"'79S]BA@>DV'YSB9P09P+QR\>SOU"W4+2"BAZPXW6Y4C3 [),#.UQO"Y MAD+ [EOBBN'+\HYG8#:D4_"5LJ'.8IL'OTZEV1#B#)D8USU^J\5',53AX(;1 M_P8(-*.'PT@C6B1%-"\@U'_N.NU\\:AO>=G>;I%6W:YGAN]''!"QJ>+@;+A_ MC#8;4S&&6Z?>DG\\K#Q_-LZ3-L[QQ*: *9%N*_7 M"N)MS4F6E/0?O6NNZ?I_JR5LJFNZ=X=!Q80AV'MY)UPXM+#SP/DU/U-6TUWI^A6M3R*$3T/WYRJ3- M[U3" 9YJ^6Y,L^4_/2GN$)7BUJ(%N 9J3JU9VC;:&1]_+ )LYW;QTXY&+'N(S F()W0RD@S9-*4>0+$$'N72=!^GIB13Z@GH MU9YA^8:6#9G-@?EL"0)NV5 ](E:3@7@WM<:;]BPDP['TR:9G\<3L/Y6AL-YY M$@X0M]K4HPH]:J091, ,@92%3:[#1G* O-,<[GL^Q6I5_IVG.# M5\'9HN%J%L.R0>\K/J<1!?OQFEYLEX9Z,1!5R*!_^N\SP$I[.@<'+2?<* JI M3^Y5?DJO@W3=DS^?31[*,[R7?S^Y\%Y3EQ2_[?O>E@I)IOB/Z?<*G%(I 5=V MF0')/Q(N1%')<'Y@,0; $?OY2TDHS@!?19N*@': N3H1@KVM!<1N^>>;\ 3P MPS9^QW0][-FU5=$D$?XX%HZHF\9TYL*B%R*<&IU M3(W#A?YIU]F6UR):NA2CN 3% 6AM]5#%-MTP#RU]Z$Z:GPKIF$K-_K Z7\.W M>:8$!B0>]OSS97@)6*1=XS9K'ML2&]Z4<86?@/ATGU3.]02+U"2$*UN6B+L$ MW_!G"CB4/5)&MPGKJ"#_&5'N"UPL9V13T:V7_(=@'H=RQ1\1I13V:K:(T%M&%S_:XNW#3P,6OUFYD5R>?KXKQ$6+)!]]/R49 M?1_"B;1KHR#\VL LU;$:6[+AYMP=?PIKH1%C^&$F["DK>P"RQ@ M=@2!V )&<[ Y[G;D7#WUAAV"%_+@;$M=:;+SF/*@$Q#;+%$\GM<\CH-SLOS0 MWKAJ!YV)7G@_=VE,1\)CO@Y"Q''P7R L#DR*=3I>'D3]J./P.RZGR&\:2[2: MR"PT-MU6F?UY7:^V-B>\\'*;3*8%(01UA]']W 1[Q(0T/3[=SQU]:6)U WE& MEH ),O3;]/%MUBV;@*TVSFZ.5>+6S.SNAE'\.+,5_6K@MK.S-7R"*1U_'1Q! MA_.L\/3]4Y[(T,\ :0O9Z$7YSEQ>CX-#>4RPK"8$8_L 6N+)]_LP[15=GC)[ M%_GP.WLR&GU@)\MD.N0VY):S-YUP;]EZ*RBI;K5['%M]MFM&VKQ]7B!05+C= M-4O^7IT ]4 )6^\SDL]<^4B\_6GK(^N+(T6?=F6@'"X!*50@M(<%D]%)+AZ) M4MA),6$=)R:J%2ZZ#R[>H-")ZHO"#F .==R93B1,T*+4++FCXDZB)_3H7KFF M8K%P)E-GNN\%C#2?"7^SL<;";8M;]Q%%YODT")U+:/$"EIIV4)U+S%'Y*G@A ME^;2.D4B9FK(#QOC8WLH;+A72$@%PHMDU3)242XYO-AB+-F1(Q QU;,9PC=W M:Y2N[:(2I^]X9,*H(=VT\VR=']6'JFMQW5VI4#!!3'_#M9U&,"8Z5Z0-D+S( M<87N?YSE.CCN0%.:!R))IV88OWDWZ,@GK".$C].X"(AL:^RD,GJ'_52BWNX^ M'-LS]ETC_9MF&H-3GCXR&)&LAG:+V!U4'']MX7%<0_^UCTN/[+O'Z2=3J5&+.04!F M>'UFQ([?9U67Z$44,Z4Y5Z:_Y,D$*X2'VA\L;-NY%/SERI+!^J,QKG=K4 [^ M\6+=Z<9@A?*O!1U;Q_P"+7@F+1:!!XET^'2?# M^BWB+ 8O[3U*UM+O6GMUO!=V.F'3+BZLT@US3+B7 \2? S6O#_\ P1/T'4Y; M#57U'5/'/A[]H6>T M&CM?#GB;Q2-'TW5282?^)'OO @US2/&OC#XE7]M?WS MWEOXJ\1Z=JNMZ1I.CWVIVUI>:U.+WQ%K/B+3;J[TX_V%>W%O#W MB/POJO@W6](L+_PMK6AWGAO5-!D@\O3KK0-0L9-.N]*:W@,0BM)-/DDM52W, M)ABP(#&P0KX?%''_ WX=Y7X;\!\'9M'BN'!/%&%XLXFS?!R5/ YAF%'%8FM M6R[ 5)1J4W[6698^HY4*M:A@X0P6&GB<3B*N,J4?HN"?"OC+Q=SGQ?\ %'C_ M "6? ]3Q'X*QG!/!F28V/M,QRS*L3@\%AZ&:YE1@Z57V=*GD^54DL31P^*S" M=;,,92PF$PM++Z=?\,/^"&GQ2\*CP!\9O@K/=QVGC6'X@Q_%2QLI[NRCDUOP MSKGA'PSX1O'TFT,POKJ3PUJ7@^-M=E%N+>VA\3:#LD=YK@0?NIKNK:3X=T;5 M/$&O:E9:-H>BZ;>ZMK&KW]S'::?I>F:=:27=_?W]U.1#;V=I:Q2W$\SLJQQH MS$@ U_+=^U#_ ,$T?CU^RSXUU3XO_LXZQJVK?#;PL=3\6Z!XITKQII_A3XE_ M##3K/3-4OM6L;Z\O-7T*[URVTG1X+RSCU70;B[U37](N1I^HZ)<7,M^;KY@L M/B?^W/\ MU7J_!-?B/XT^+<3I%XBOO!]]X@\&^#?#\MC8ZMI,2:KKZ#_ (1+ M3M%\K\'.,_"SB7&\=9!#%Y/P:LHJ82KE'%6'^NXVKE=:C62E MB\5AXXC&2I2Q644,7/&854W/#Y=F*Q6&H=!^SW#;_M _\%+/#WB;PI!J\6A> M-/VJO&?QHL3-9P2ZII_A.'X@^(OBG:/J]M:75W:6LJ:?%96.J207UY:66D?LFZ+<>/ M/'=QIWB?X[^*M+CLM4U"S5IM%\ :/,4GNO"7A6XDVO?3W,Z1GQ'XE:"UEU22 MUAL+"&VTF!FU'NOV]_V#_#'[8G@RRO-,O-/\(_&7P79W:^"/&<]CYUMJ=G() M[L^"/%CVS)>R>&;_ %!S/:WL1N[KPMJ-S=:OIUC?QW6JZ5JW9_Q''A+!^+>6 MQP]>M5X R[@Q^'E3-W3J3E4@ZF&K_P!LQ2HPQD\OI8K!T<-4J0I0KU\-*MF- M+"QI0I8>IPOZ-''N8^!&<5<5AL/0\4LV\0O^(KTN'U5I4X49JAC,.^'I\V(J M8"&:UL'F-?%TJ%3$3P^&QE/#Y36QDZTZ^*I?8/PI^)?ACXQ?#OP7\3_!=[#J M?AGQSX=T_P 0Z7GW#;(WBU#1[];G2=5LYX8+NRU*QNK.[M[ M>Y@EA7YK_P""A?Q4\+?"O]D'X[7OB:Y6&?QO\/O%/PM\,6 FAANM9\3_ !%\ M.ZGX8T^UL1*V;E]/@U"[U^^BB!D32-&OY5 ,:;OY@]7E_;7_ .">WB*Z\)KX MO\4_!NZ\4#4I4L?#?BWPSXI\*>)(M-OH;6[UVTT5+GQ#I=K=--!;PPZIJ>A: M+XF>S/V=EBMI+BWKZC^$?[%G[8W_ 4"1_B_\* MM-UQM:UZ^T=H?#FGZ#X4T*>^LO GAF^URQTFX\;7HT#1]5O=,TJ:*UTF[U2X MLM5LOG'X&<-\+9CE_&V<>(_#\O#>CFN'S++L5AXXNMFV;T,-CJ.+PN5814%/ M"8C%.="AA\1BL)4J25#"XW%?4\/-5:6&^OC])SC#C;)LS\.,@\(^*?\ B+^) MR7&9/FV"Q3P&'R3(\3B*P^!QU*C3^M8S 8'Z] MBX.A4Q>9_P $7./VSKL$]/@=X_!'N/$_PX QSGGOQVP:_K( P,#^O_U\5_-/ M_P $@_V;_C'X*_:>^(OCCQCX3C\/Z'\.?"GB_P"$GBB6;Q!X:U&:U^(5_J7P M^UY_#]K;Z'J^IRWGV/2%@O[G5H5;1&2\@MK34;F]CNK:V_I9KY'Z2F8X',_% M+%XC+\;A,?1CP]PY1G6P=>GB*"KK"X_$3I^TI.4.94<=A:W*I-JGB<.W\:2^ M_P#H:95F64>"F&P^9Y?C*Z]&AC\/4PU>>'6*RW!JK[*K:;@L3EN-P M_/)*];"8F*O[-RHR.>N#CVQCZ#GN:EVC).!D M]??_ #B@ #) Z\GWK\"4;:JWI;]>WEJ?U7_75_G\_P Q:***H84444 ?_]E0 M2P,$% @ M(6#6L43@YK;6P( G$" ! !F;W)M,3 M:U\P,#(N:G!G MI'MI6!/I]V44D4T,BX*"$!40E24_95.61$1$I!$5%0$A*B)+&M(J2Y"0*,@N MI-$66FB(B(#*$A$" H$(":1=$-DE"%E062-5"J$TE3!Q9IZ9+_-A9O[AJ2Q/ M%9?WWGONO>>\158^K @06DQY&K%JU"G%>\8-8&4.X_?KT7WK\,O)?M;%J MY25"6W65L](MI57;$:NU5REIKUKA(% (Q"KE_W$!XG\^5JU66J.\5D5535U# M<0%#"[%ZE9+2ZC5*RLIKUBC.)BG.(]9H*^MLV^.Z5O?$!97M5S;LO9E7JFIR ML*YCX\D^P-3FXM5D-74]_4V;#![U/77Z MC-]9_X"02Z&7P\(C(J_%Q,;%$Q.NI]Q*34O/R,RZ<_>O>_D%?]\O?%CVJ+RB M\O&3I\_K&QB-32^:6SK9G*YN[K^O7OKX7Q=HKU'>MF>MCNL) ME0M7=+?OO:FZX6!>:5V'FHG-26#CQ:M]ZGJFMD(S\)=K_]VS_SO'DO^_//M? MCOUOOWB(=4JK%,E3TD9@$7+YSH=9B/_;0^VE^=V;_ZROG%EP)Q5)24'C'\B= M_,9[2ZGC0ZE+!?-%TL-!H[BS'[W#$D/CHX#$;IO H-'Q,6<_O:8SW[=[$ZZL MR>M9\_@.9WJV&GL3_0$IL94]7T$(RARY')F2(%Z\*DR8N'#K.C9YB:KCT$6] M3=G=]/#3A;@4J=-"T8*]QI5V45[S,0ZU44Z.+!-C8#VKZ=/<>+U.%-,/[21XU2 M8%TOR$["\_Q1G+M6.MQEG>Z?U*RJDG*95 )3CU2 MV]8Z[!FX:0"]->=!87A(UI?QSS\I@EXN(07;X)$L)F\G:4 T 35+KMYZ7^S' M"5X+KB\6:1CBI^\%3'H-MK.=ZV<,NA[$Z+?85VF6/+DTK_.U7_]'N-+P3KH. M!$J/P&ME?SL;KB TE"3)$%U OS6A(3*X@U7%D]3G)* M5N;L,$G1@SPZ2M8.V1G9=+;4M@E1&8[&^2N(3>U&$=_P5<+QR %VL$WC>U[@ MB\49.VF0D]2T)RX?G?3E8_5>!'D%T8?K1<&&?B*D%O&NQ!BZGRCRT<)/F+1E M2^Z!]QK\VK<-,URN?K.X!)BS$W1X3FUG9K^*G&+N^%\ZJ^.JP[SC^"#L(N4, M);P7VJDR'R8UB\R_KB+6D!XB.4/71(ESX80'0.R0>"'#F2 KOL::YSV:4 ?N MY;)$K=[;/W&WC\V.7'=VC.7D,?\8=\YZC<"PRUQ<(%0>]E^#'UQ)O(R.O8SC M<0\/VO6.]DX2;I M>=-R#XF8FA;[=V\&T]':JZ:,>+A<8U@(.\6G6L.N3<&.3?MBAEM(9*/#";0H^!R7^-AAMI^&U=FC1 ML$BFZL3#Z^\4H/IC*^H>S>IZ$RX\C1@9T?LA/:07WSAB)%')TN3=!TPAS>,> -8\7\H80L9M WRG40-H0-G M07G:<>&EE+(1Q@XU1"%/0WG8-*9_!*C/+HSOI&M!Z4<&R3M7$)W^DB!]7$O# M"X A:[]7>:[7ONRGW0IBK83\>DZZ?UP^Y'>&UHB=;Y8>#H!NP^BLJ9>LYY7= MD;^"168: MO&X%D=Q$Z7 @;X4/UD&!0BSON_!8V:21WZEL]_ZM+UJ&%RG(N0 &IW.BUZ?/ MF5 SW1*?;%=4?%A8UM0_V0^[Q\1Z95Y(.>:PMT=GG\KT[66M +95SR P%O@R MQW2@=[O;NCV/WWA:/M_[*+PL/^S\@ZM''FXN;4ZSR$YX^**IQ#9_LS#/+"W\ MT7'PS8;'_J8Y@VD>AW>_=CWINI9EAA4TTM8\@I:E:L2JEWR@3U':*XC+1:?! MA1M+V7QM4C24$@6PA2JYPH9!\\84864N?"&F9V-J?G-B KXZ/.Z[_VQ^P805 M(+])2*A,6,]+*\;)U4P$? WR*PK@O8+0=)MD\>B"@JZ%U42]!5'8;:8KF/(2 MMV&1NI&D!.&%15'!WU809X'V;-#^V^S $9PZI!F%KHWM.0B$_R3???IQ[HI5 M304M2N.%RES7QF^_\9M8\Q[Z;!]=."1%PI 5,PBI[>N&+4E.(HH1,5ZT?)/I M(Q2;<%K*BR(-_%*GVH"OC*>6)3N'JD/N+!P%AI[1S@V*^S[7/7OA?G$_?W1, MKNX@U2(/R2U> .8OD3R'EV0,R-1K$P#?!3=7I][!=X+>4A/DNQ A]RO 3$#S@Z)]DU"BP4M+_R& M$7TMXFDXH@RZ/M!UEXV/NI)@:FSP8B@L<-..MCVR.PY_(Y(6W(DJ';V\5@E. M5KIDA/. 5*2'2>N@L:IP@ZC:NMH(FAK9 M(7[2@MB] ?8-3D/GDZ"GD%#=7: M2C5:[^$3$UM?B)I*8O>XF^RS"%Y!'%#>"-^G=)RE"!KX&\GKY/T4=1@E5;RN M()2<+P 5RR\+8[FG(T:6D% .^/%1@!^$@?K(B4BD#(_"4X*N5V!.%5X%[CV M[A,B74#C+*PGOD-I$F^YET?N.7N.F/*R9>)AX>':WZW%](LWZ59?>XK?.NRA MW]WKA" WG<"]QL):2,D3* QPD&R7/<28DP?J7!\8C:! M'LT7AMVH]3L \/!^(RV-C,=-]ZT$[YE80N+UBU)O0?VW.PE^RV62*XKJS9!W M81E-&70F2NHB?R]7AE(G-3&OO8_A5"HE(VG.@5T2,#QJ. MF=NR:Y#0D*TQ%[3/.YI0WJ1O_^4XLF%G-6H#L9*-404D=:*%S5"V*T"]!3M5 M?HR5\FOO$TWG@*6QI:TBR* JLB0DHF MOO!B_,\K.L:.\(JT\/NF66='[QP*C;GX2!?[8P5A@-A)+VH@C)E(#H.H7*8/ MP&:O(!BH^>\U\!' !]Y! >Y#2D>A'N#K"J*;K+."2+UF]@FKA<,DPT'H]XI#Z6U7JN<"%AM\&53RJZMJ >#?H7P#N@5 M0)OD)C07VRCBJZ)^O(:Z0@E2"_*7V'UG:^AV)O M0W(!T-W8]'8+D(D#\A-Y(C@-O/JKTS9:\.=7A50WN(*0J]>4RWMQ]07) ML?P/39(22*4:O@*J< AIR]^A:X=!!S8V*W@;$S*?Q*TF#G#R)VP8@&_D]?(9 MH*3>CI6R$--KX%I9O!+,)JP]Y0J)"J"*,/E%I>D3>IB?,V2"L'Z <'TQC".8LH M Q^D\[L!-GGCP+9!YQ,BD\NI #OKE+/:FUQ$Q%.U(BT?$ M&&(M5[2N1'^(M!^5$>L7Y'" YE_WO&EX@3H:TQQ=\?JXRM@IOQ(2&FH&JB;C M;XF924"8R.]&NR5D\$TQW8XU@ 5L@GZXL0/ &"XM/V?H?:R;CP.&Y.7EWO&5 MXQ:!_$!NS$# NXI=>5LVTN^O(,)]H%TJ\W92"^@O(GJ2)=X%S'48VYY]6#+7 M\D0+RDXD__-TUGG\ .4:Q]N-2E<@9%R2@=&@>A>HPEX#\20^I+L M@2EJ3%7CP%+ONIEO^/;_##K;/7Z4LZ&%D(U,MB5HCT$^)YMBL)$#L >F("$\ MU:PY>>>GG+%Y:CI-FZD$$CK(QA 5:.T.W@RE"% ;1^W+A*Q-$#;@&:B2;M=J M^Z*P/R)&'/A;R9=WD_,CC2-G'/(>MD]4,Y0S^,3[FL^Z\4?'&;Y5B(^D5 M\BOL\_\,7)25D5U@+!3T9,Z^4WH$&*8_Z7E"[#TUP'PE<*PH%E"1 7/&Z+9^ M/1$O\?)038.G[:>6V[RV_H_:FVF2*[)&2BB2]\5(P87"T+ER!%29\#"PYBM# M*-/US7_3;6"7TF/$O)Y/%]1<'_,$X^Z7]URQ/?,^,IYGJJ?[\453UN?<*0D]N!CD(^XE_36M48E[8 MZH%Q]8^L:V-"AQ;SAY1OOK#7>/+!D+XS./#'/[%\<;ET)P_VAP*!W5@J17,) ME\TR:'B3=$U8<(.YG^XF*H[G_-1<3B4PKU004TV _MG&GW[I#+I:Q$BA_"8= M?W>F\#"KLC.TCTZXG6=Q(\G%G=0D=9./89_'SY?DNTDR("DP*0R55ZYJZ6>Z MT/&9UR:- GH,+Q6T^"7'$)?0^I%Q>]I-[DC8[B\868=/W3E]^70T5D)4X""; MS,$QXC-H'7P$18&+]!(,^'=3,S.]X^"4+\"ZO3 __S!A@6Y+52/V_@8L9#"* MG%1-(A:^+A;;2R:ZMWC'6^YY7H>0GJ1^_S'RR0?>*)5(&V2YV,MT(W>@8+*R MTT=9/ES'(SF"YC?(!L2" .!P/:AQ%@C+(&]W%[;A."T^G6W7EY9JXEWOL#W MU.=S<3_MNFE1F)2JEH_5/T__FYZF6".&TG'4EL;C2BB <9[TD+R/LL:.PEON MDN^#RBI&8?,ZT)S=JTKZ;=C921A8@SO;7SE UHDHS&G*,&]J L[D)='?/ Z8 MSBTPL*T0ABK_M;S;;Q]1>B MZ.IK/8^<$]G6_5=WCU/,*<]'YD/1*5C!"V,GB*>8G">0H]>XO%M\'8S#K -% MG>DD/> /I4BJP..##7S=L3= ()>E-NA^K8('6]]2&:DI\AVLCDFRZ6C9,Q#C M@KG4W 1P%V6@GTBALE@W2]8-DK?#H5"FH#=U0KD_8-\24H^XP+GNEV:[T]I< MQQ!O-FB'+SIK/HAV?J+#/=840:"7^VJ6,_O_O*74]YC^#IN. _Q\H!TC7;A- M_A"R@\7@=\XP?1Y/[*!5!!!S8#=!H.89>/I,O M,2CGC%SS)&@^][(:>N[]$UD[UV*>NN@2QIDP&UKL14+7V"UGRFJA%-SP@CBF MS="MSS9[/T/3[^P0PVGT_/.!AA[[[HG$,>E<Z8EP' 0BCT;07E6;S893)# M;D!"RBJ<5TUB41_-!@L)MW8$43JO2YB-Q]NZIF 3/6.[/M)^AZR X>']!.L0 M0#!DFO9.;<'T-",YXKC2UY:=#V^H6WRO%!'@C?5RM0X@I5N?K 3VBJ\!S\>Z M').F)'%/*HE7HQ*YS\)_9ES9,&PP42,PTN7P[+,3(DS6L!A#L1J>BU_\]7XZ M7=M2A'D%>8!E0C2W=\T,7UNN3O( PKJPJV=SW_.(E2_E6P>8;H^R_Q4F)RR. M-2_.3#F2Z6%&0RQ)&I7GS?=*#1(]NK ;_*%B0(7=R M!T)$EZDB)V]<%X^08=F 7 >[0.F)@IIH(,!5V-2_)(N4=@2,9D8O&?:8G&ZO MNQ-EZ'4'_1X)F=!@75_)21E-ON,C^3VEGB[FE\L'>/F90(\S$C3OH*B2K@G> MK"#2"AVHS#")YK$I7]"(SJ;J\&6-[XRP7JU- #65F4A(N!(18PZZG?.I.COC M=@@ASWW\_[#;^?]R_-"7JRNO('9LED:M($8?ROMQ/RN88;@I< 6Q9DK15PI( MORF>H_ T/6=78$3(O=&^/8B$ZW-6>S@+0+/+G+@3$5J0\?>N^.&],^GL$7NQ M96$*]'P&K2S(.QX08'CU_@L=R@,TO&'C/>QY^ECL^#UM["4L[T3QQ]33IR&; MR8-OWQY1?[K*] X"<><*[JT/;/"$$G4--)?PLH8E&JG&JV0EP6?%7T/NN5FW M@?="$G0D_ M1VZ3'(C.K+70]\FHWBQFU&0V52-2O5I,$2+3Y:AAIH60K\6S]:40(B1DJV?V MN<]1#E'H>#_)[2<:"P4_ L'/6W?>L!U],O]I M*^BF)K=0_[2J"0$FZ 21Q0K"Y$A]N!X*0?SB8GCLMD-Z>3-NFBH9 W!I+$$] M"CCJY&,H?SO2R)O*L$ND($G7(._2CY%Z7C$8$P@1R2-DD3?,^:DNA(:(NNM8 M8!.[3G)?W#"'VWCN['AP\%BX//3;#8H#"C@V;BY7/5%*TBO@L!3-.\MX!U@I M5A;)"+CF06=UTC;I1>X#DOW[BX-3#?U6#T?DJM!A%XNNB5V@65LKL2H W"+? M-7QGR*[52F]XS'LPIBU@SG<:>Q[-TQ4H5$6.(C\W .XMUD7T[> =4)G4@-P7 M; =4=K:^<'8M)?+9#KR*>Y,UMF/$.#8GP)P*6PAI6D%0ME"?T^81G3*Y]OUV MYB!LLJ/TDMW>$C-P[1<%-:-$XSY@)>>@)!%J](U-TB&=:&QB#AJ(I"]9^K;(S'2VL=6S$=*N:OO*B/+(RU_@]DSKXM*@ M&8-3A6J#L=11&K1C2AST"_RR1FPD:P,1+?"#=6TZ^!J+O6G7UV:"*D(N=Q=F M%6QKD'9?-(X\58C_P Q\#.FR?W9G G<##!?Q"^DVK)PEBS;RPK&1OK"!6(TH M^]?S2N""I)\!CL ;;>0:\8_);P/2;].='00X-?CD$'D5%,3L2" (?%;!9@/H M6'1VR[N4BB"[MK_D%N#A9B%??V+,Q])R1+\>PONP"J5'WEO=(\\I\%E&Z4"R M0A2%&R\QA^Y*#Y%6#V$LB5@N3:6!NJ[GL4(= M[LDTU'S1V-]V0^U9% W/LO!,.]IH+6E_/.$/3 \8#V\HZT09L 3Y?,!O$RN* MI4H\$Q4B7.:@,PE@_4M>SU+QH+$6Z#)UVW8TIC<'J[I$UV)'7 DK(SZ43QX' M3TFVJC$LHG0YCBJ9498,E>=M33X$Q4)O43IB83,I0%"IR_SGO;!VH&18]L V.Q'?1A$6_#(7>\-*^V^/S+P$R[ZY1 M9)P#3MW&["7]VE1I)D6#]*SV[<2R+M]SQ,0.AQ)#V:,E]J2A.*I##VN@< M.HF^(=\P6%L;'6T7.&.+1$)G*#HS_XFH>C3K5U"H^:[HBK"B0?:7PM9VDD8_ M*W(!,FD2ITNQ7E6CH^9=M"R:'@E5.>_WN<*$L"[,7UE78PY."H%=2!TK'<>R%(*3(J:=Z M#,>++%SN1*=/8*!T04[\T30&G[=5- A?T2ILB()D.E4%W\#5""LR%8=DF\EV0PM MHG,P6ZCNC4V#^2/=.,VQ4]"8D("<:[<&'#@XU:"C,?^BHTFGXX5H[8C^618O MO\!^8I-495Q! *_HSWL"B8+&-B&6M]QAL$"-16>@&'[=1A>85RKG?E;%_2+U_V=3%F_#D?8MXT_=U>L.:1CL/'UHDSL"@7BPGB]76U+ 9!;:!BC) MU823V#%L!WDK=#<)])#\J4A,)/0 6O C9M*<40+'XH!O)69+$$:=IVY?TBX#ZQ[5&W-Z]F+>U80;.>/C>!6)_6HJ;BXR7]$K,U8 MP:#&&Z\V'\D/J=506V_! S*W/2S/]NK\^!6I;Q3_X"Q F@B/L4_=@#^@X8BM#9,$Z(3;\#-4GN@[TY8E@WKH5<-QF$[,095'." MUQ:K:Z3Y&Z]BK!IE_&6']R_RX,S__:G0^Y.A;X+M3C=M>>43=>:_D'<9R>AP48G8O%X@"6QQU<5)892,FCZ!^]_ MR=7B$-W8F]4OA:X[?/C N[T[E=XK,/,XV'J$F;B"6/L35@5I6;$:Q3A.B1E MGP^KPK;W95DK MB,\!/CPO^;\%XM851)ESDH(E=!SZ6G-102D5C>-R:Z;U^=QQIIITX[WB+SG; MSG,[QX[<^WN;)KPO.O'R7\^1>A4RS[,C:,AH!7C3"]5A"J^<5@B.0,E"-4);D]=9&W M/IP)=H)N5D(A763U00;TL)$6T,^P&R!YATJ>G,\%%*WDRO3(]TC].-_9 GZM MHMKQFD,U(R_YO,\UT>>;3T-]@C]ZUO2]?>K#GLY8%W(9D?=NO28)I4!=>?OS M=+G&/>E^5[O/U;XV9([T0KYHY^**L$:PE:RE71-*Y&!V#C W"I+,A:PN"\K:&;]";@93 M31'4^$S8:Y*J!)](LCE6W]IR]P"#Q@EH+! %197=X;-[*J#+(OF^Q5=TM-4^ M>AH+^&-!["<]!#L]D]':->U-,[ZD<95 R M')O85=AU[K$/1OUG9A*K9O.O3^7:+F@0KQ]*\C@Y0CO<4.#SM](;BF!X5U,<216*W9=#GK^(,^#_J_T'HC.:]Q\5I03>C_FY[#JM"<8WS/E:KH6'X$+?TE?A.D$5(6/"K!DUQ$"PSY;Y'K.WKVZA^A;$BJ&V9AE2T-PU@,+T44K'(0P*UAEIWS[' M0W&PJ_%RQZ$O$+5FNO!+.?ZI:QDQD9T7&+'LB$J#;=;$;6=[,N)R\9Y?\/F% MKGN[YW3()RD=O0&H3%LTCRO!0;=_NG="D5)!37=FZ9R?UML63)F(I@Q[#I'< MJL.MXFYLG_#_0+S+5NAGRV1A-4/;=MNMJ[:41SA%7ZW@JU $90IH'T5"NU"9 M&$/(IQN+I).U8:OL0R N'4[ IINRU$0]Z[E^ XRB_3!6D0>N!^WT,Q"3&6HW MZ3\^CD2ZP(UQE-_UXAZ@_D(!AY"0&6Y^27J=M!^J @,E.VM6=^/M\N* M%,TL\&M4+>L2G[=?7+OUA;OLT>MZ5\MKNYO@W:ST*;SM[R_M5?>9[]M/[UF M=HXO_84#KE ZJA*BQ2'%[0[DS@,'OG/J]R3VIDL/9/ZS'YW7H&SV?,\_68A% M-*2@')('(%:A!R*QJ;BZ4&Y.!6#^LE"9MO-^\D&D,&FV!P-=J.>7WQ30$5-35M-SM<*6[>H3M@#H,*&V*?D M7D<6FY_&-X8IPMY$W6HHPGOO3< ^N]1OIVK%4&U/5T3@-N4B+2L.IR\W)O-7$.M( MAN949]UR8@C;6!OB5K@)1YG^$4+-D)<&PT]J(;]NC-W[[6F"8)(M:$PEDJQ$ M5:W_EO79)L1X&7I?_;+/V2\ZY!/LH.A_<0J,[_0&V-XCI @%Y#N 5&K7E;)# MO(44V$;J2'ZG/[&6H&.I'LUZ!E][/.<8]!)H:'(OG)"> +HJZO&_;[[TOI)8 MAO\36845C*)X-"Y61ZX.A\ON,Z\\'9\SH,RO(!(%5!W2GF96&\H!M]:8HT6>C=WD$Z/9HNO$/-YF;W^[BU:_ M@NCN'6T]*GM$7D_F&NO*J$L+&4V.!>G,$"$+2=K3#^NB,DR M#J*7MZ3:NO+RV=W8H]/*\'?,>KRU\:;90S% M$&Z@-4S-@Y/4341Z1_MJT$_L)(V:P^POZO#3]I^;, 5&;K7;$+\'%W1J!W_\ M,7S&ON5=%;[<*S8^J0+_AYM1YIZ(RXL\G'^28H@IOU&$TH_\EO^LDKV"N+F" MT,6&'8%#'XP2%[JOC[#I^A"V"[-K$,97!GOJIX6!:PM$+FC?D?(70XMO_EU! M/%_2L/+SP;]IV_L#/5]9U]@?>*S8SDI!938N_<4"KJB(]0D;/U<7:( *;;FU M9DV\MO/K5Z ;MY1]J/; U2384!7@(+DTX-[)>^.A%%&J0K$9B*9NAI[UG/EJ+P/55PMY5#ND5(R=/ M5/G/8JRB(KM%1F=4T0_@&MF-& *TU2<=&S:^5U%9WZ'[(LIFA;2VNNO7"CJD M701PXH+*:93Z/(41JY!E!X"OY8!/I][$%E"OZEH9MQ(?,)49-LQT4P0OL.E9 M_T0GK_\S@170;DKN)N^1-6$%?-R'*39*_7=?'%0)% GC.[$Y?"0)&PUJT#8' M0=9S#SXO%G.>)$;\")4B*!T' M6()B'(*\GGH#U]0[OTK8NX'D!^&J\87>+$XB871 Z)-%BJV=&0GX4OZT6$,T M40#J3'9.6/7!>.%F0A$[?UEWQ\,FGE%:T?JR]?>>1 Q@'J^J5!10C>PAQD#^ M!@OXZ4%HJ3E\"41UT3ZT2OX$G6G(AL0VRD&0FOJ5$3=$VC%A JRMJH$"N^2; M@.Y6_9QV(V(7&F/D+7JB(.FN(C3RW&S+DT!OF],W9EAG*!U7*2$^6\A<5@/J M)DOPE/(\J .(&F1IV0;YB&[TUUCFL%(P-EY7KA@7@,9!COX*7=.SPK"6E%6#U<0#054Q9MZ2E/3#ZEH M=63KP>H%^'3E!+N*Z!$ ^J2;L0;(IG#2\%?;[(+Z00R*A.TK;P86V/GZ>[M$ M08=GO\ZYM;V@B=;>C(I7X&V %]NANB6X)A;;A=H0WKX;=,AE'GS&"W(O1^F8 M^D9<]11(-2C5BH5.XC[X";@WG'5#I00H;KE;C[;!^1KH(5!4AQ-+G4LI#83W M],'Z#V%KL+@F*SS8L!X0-Y:'4-89KWTO2GW79G5+V_#?TH$ALQL!\%W0K1.G MC15,H*"=K.3V[9#],J?=3I8G1T<\J;PU''W^KB\XQ2:N+T)2F4CZ.#NB='JO M GTA-1/NDVCE!\T"AR5 M\T5^G=U0#T 5S1$'.F_'>ANCT@U8*?*MT/6QKGC=P"I&;=%:ADBLY#U8\GE[ MTO:OX,/!_CYQ=+Z6.A]PI4+FN XT C: ]*7DZ8FM$!7;C4,%9E6PZC"IZ9T\$*ZEXVWM>:$%@)_CU[*O"C/P_]( M4BQK':7C.%D':A(NS__:K?W2"H1E-V"SC;4!;)=A-FK3QX_A>R']+GN>2@:# MLB5P-+S;Y0337=:,38LM/OCU9__3N02C^>#[_1&NN:)-0_N"Q$K2J"4JD M4SHN4 0,E Y3&<1Q6[[F"9Q\4+!?_YVIH^''Z$+6#/ESKY]NW9(0. M+/ &+:,(L8FEWIC"QCXH[IVP>LG;X3-U3*4#U5 ):]?+U;-%!)[T9;MR03#D M.4G)*'&!,@4TK8D97BO)!G1((5OS(WGT7+(&5,21Q UT" D;P_7U6XK;\XP^ M?9N]$A"!V0S6,'(9EYH:3_=1.MPH CIJ"T7P"/M<_S9S#R"5_,:"<%)'HA<' MM9[!S\'I+>%T@HE?>J6_0VR/1@!UB^0BV@3;"%&:'X+X4'N@4U'V/A3'V'2P MH:R/)9@G)I)V4+2M(TK<7H/7P ]V,9K!Q]E M[1HY!%(XU.P6 IN%A#*MICRCOD8[.SPF/C2ZWC\\NWG^Z]?%:2OZUOQAA0!_ MA8;,$;]N^P5-XW0P.Q0U33DUC$&W E-BOYJS'PUY"9:0? M7X=Y8M(GV5B?>;<+8P.F9]"7ID/KAYW]KQD7A51R'P?/7(TL?'[NK/RMPI0C M)53*'S.7:TH5N)H'RX(#SA(KNR=V0^Q$06*-*URSGT01]&8V3C@ +NU/_E J MWK@P%YG(^E!\AM4'0K>:"Y4Z:)! M.WJ[*7K0I"0(;&\6X-;#!X'\^@>P/S#T[JZ0MH5XGVD^N9!F\)QT%NA-)WE/ MBFT.,/+9(O,;2W-S5L'?CPV-_390.;2DB3ONQ=.RTK(NA%QA8\L3+S+QR.QFS&[1@-GCS_RY;WN_^#M&,2I"PH\TJO^ M]-P!SE%6Z0JBKD"^OF9/0-MOA1M\( M;9=+-H/4M,FFD9C[SH&E1)0[Z$YC]ZH&!\ZT,"JHD\5A79T)\ 7LK<4S?8NO M8L\T-\$_%U@3'1&=/:H^?379% MW$QV52I]@&RF1-&@K83Y) MT8+$O_X?81M4GP3R!=Q.BAXN62:1@;;7I",E)43!WN[!ZSG8/SHT?^]-ED*8B LU6$.GB MK*^!&MZ$0.#MWE>FN_."WN1?Y"XK2%;*=G=%; 2RUDMY_?L&)$>AG^^^ M=FAO(.T%MUF^Y>Q^C/AT![%$GQJ1:[Z%"$(6%5=7 &_ "K[4/[[U'K-K3D)9 MS\B6[7_0VCQ0S0P!TD^^#V,UNF[-H5N:L!P:,TT>-@ >SV]^Q[&(47XJC7&4T.7[AK7]4^]E=1@+A3*N-Q>; M U@)36%X'RD"M&NL%/K'1H5T858/D>S [^[]S,W5TZS1J@CEBF:PEQU@W"RB M*I%.]Q&6%I#$-QWT:F*:AD6B15V1B].YNN=U,ZS0!5U(0Z[F)CT&GX60BEG\ M'UDVTP&L[+S^2<^^\7I[,]#:(;Q\-+K<^@IV!,\63;2$<8\.!V(*! M,/!=TY-@*!JE 1VS2@Q.&SAK$'-F>>L6%7@+=S+'0>33N0#M&.$4[U#;UN^< M),3F8O8-6$4[)/1%M.\&>N>7Z*,=V/L;K+Z4U\!7WK2K%A&C^@Y?35G@0V9< M6#M>H-)I92+!R1J9'J"^J(F#Y1DL=$P80NRP)^?F]!P=;BZ^H6>R-&HM0X$? M0%_=4&S49?Z1]\ZA\>4*A3DK-R^:Q[;PGN [:;M08KH&&!DZAL/92B9:<9W)-7"=F3?*0"/+2731CGE Z6CAU5 MCX?7H^D_ GIZRH?+1%@D-,9^4W6.>*W[YWJJ2",SROE$2.W,GW8Y2\-/0KHI M';]3(M ?N)([T!,!,A-7MX)@VP@H:VEKB-_9[9:0@LZK,TG; 5;WPH:(Z[E4 MQW/$Z-=?1HXT@W9\MC1P:L#9M7;6\3"MNLLA(V;<<29L0-R0F:'R=1G6[Y78 M0Z=!#\GE KFZ3N=H X,:A(:N!Y,JH M"E>S\9ZF-"9:1%@UAS$9_DW+XK7$T3@[*J%Z]N[#OY[W5]-C-=*\ OT_^[Q! M0UO1\$8-(5HA>35(>HH6$P>5=;1;IG I6F1KTO$70"4G.Y"&;+JAW)01XTT1 M&=\/K?K!8Y*W>U\[,1QS'S:KY$7PS#[?'IB][O)Q!-C6=O8 )D%V>P7Q.125 MR9=HMEX*OY(SS2VSA9C-^AL PR\9.FB,:J0/="[ERTFL.ITE\SO@LE+_XFSY=_,!LYOG;F^Y MF1)( 4Y3DE<0QA1!X0H"\*U!RM7= 7JG/F8K%"CB9\1A-S8L:,L*3M$ZKSM0 M[7#('85ES-[BP3&>?%BPS;-'Q?W-FWY.+05?A/P.;F0=CF2<"! M54M3\ 8/N28LNT?>(.?2=.26Y)X"OK:S"^@@H"3;43("ZD#6[5HFO@SV!KBI M5CN&F/X7:F>6GP5\F#98D&@REKZD/R$>&W'OOR,?LF08K?TVL2RVMZ<(\E@, M&K7=A=*A&'71_!2<3FR/6YC"T#:37"%<3&B("HI9ZW%:AUGL*>]?M$V>XY4S\&) K1E9)!LI-ZD]^T M[Y31*&$KB)LT+7CS)#^'MZ9]-=C=/!FXL#XR_SHR'3Z@3,UH\$D?)NL-VKGX M=5_G9RR.1MM:&(H]?@/X'[:Q"B56VW\N18D+Q 1H!WU^/XB4_+K-X$4>PZ"A MH8=E?VD(-LF M^4[0FE'Q[N3480:X]EYI9/ZPXW#>T\#'*I/QL-8;N5H;$"97UZB!8VB3RQEP M@CF;GOR,M*LM15B0LC1'7QGOT0 M,/W^0^3(26)^@DK&[Y96])BV:ZF*=3XDOR*O5;R&_OK*4?NZF15$_;%648^- MFU2EDY K5V\ZTOKF\M@_ M6\(V=W#=<'LH':]'&N,42#S>>T/[7-"8JPFYE[_^-=<6/#R/[,9E/-"JG>7H MJ*Y9IZ,Z=P#UL8>\6K%$#HY!S<6&43Y,L2GK,0;XELI4DI_T*'&6@(AL-^M# M[QA@)-D(VU/*SA%3N&<*+Y=&F<;;QV/,S%V!>_/O'5]/H$9B_[U(K,C?)9+] MI'/XD/7"O-MD[YBYY$!=.^1:&D2L$BV\Q&ZB,(:BNI[B;7#"NY3@ ,+H_C) ML'D",#!9*4;'@DB.L2.T()@FQ0J+;3K:;5X E],!?L>$J=\+X%#+*4?'WYQ= M18%\I$MZ1JP3;8-U:5G ^&Q5*74=;?[^PI)/.B4DL3>3!GCB(*MUE.>AZ3D+ MS-, 763>A56%-X%)_]3:RIRZ2Q0C*:QB C8":^F/5 I^&X"O"(K=.!.&21Y^ M#9EF^'!F4-E9;WP9?D%'Z@'K3LG7JP)3\_>D>X@$R6790XP*Z2@8GX59.Z-/ M7@>L;Q;,U2AYM[:]MVV>(JR'L"+C]$E#F<9Q(*U4J!%&99N<'! OO3+MBQ'O M&Y_6BHP;H5)>*K*S#[.!]$M(/_DEGSXIWJ3 AX"DD5MR+1(6*JN$ X9);E'X MQ^:WTEB I+MS0+#<05]#3)[MWT3RJR7&>6,['2MO$VKNA:0?[K110_P>V "Q!=0-I$#P5+OST&)2<")! M9Y:E;3>6(&XXW.^,?6!6DOOG7]H!0>6RSI9ZQER5ZH#45F$ID=+A2/ZU:XAQ M-IOLL1#0,S"F^&&6/H&Y2T31<> $$0X.5S:PWC:4CO<[83=C4VW#$Z MJA"8C]KRBB_NVJM\GO\V##8R3PS#2\_(>UY=BX^*[I4Z19;K)8@R_Z9TOAGN M/GTIUG*OZK]K+EUD-?:L22F=YFQ)*8_@:+^GUK%[$)%][AL0)_Y+QUY/DRR' M?+\C#S,-/$WS[IGDVIY\]W7^X,/MR6_?'GR:[(DXKC1-_]PD@14NC\"^D(WT M.FD3Y"#=2SHC^YL4*[6#FEPA\X1)UI8.:RJHPS\\" >"@5WRS5 JX0JHP:9H MB9EVPB]]I&V/IGF/&GGEK*('[+C"X0+FDK;U.!%TR690 7 M"D)$2[=D[%H,[-4B[0<+TDF$AP%XO?>!0>=F'!SI:;%6QSHUCTX,2]Y]252+ MUIG=:2VNN&.62[S_TF5U%K2LZ)#P!EV)*:0B:E;,\71)&60EP!H$O-KBF)YJ M1S6<08HT=T2<,,TRNN995_AMV2W_R*-GL74%+F8=QELY/3MWBSV\^VKI5N=E S^FYD0 M8IH9'V:1X'#<;>=.A--KBTPH%;003G7ZJ$=B'*'R29HJO!\(_M-$/@#B[>OC1\]9)__A8"9C3MB-9GO=PJ+AFT4$:>2._B; MF!="!<@T&H/VDK\1&O!MR_;N=W8(FVS;/G)J>&G7EV]6BV)U_LG"-U+"\>8B M;=YHA%5"[%5.@O8155,E<:3%CUC%I"J4[X9/04$"].CZ*2&E"YU)61=M1]T$ M7T@_^P*Z BIU3:RF^26_89/7Y;\S"B"HS3DZM_QE?[7'MC$ON $<\[3M7=W= M_V_@XG>!BOB5U(Z$D-W&AA31>.F2 D#_)@DO6ABE"Y8SRG&9)9BL*6ZPB6-Z M\B*V@9C[<^0XDP4>>UR8.O_<]N?2O(V9>(1G[/4JU'/T -;W,1T-N8)-0B1W M!;&V ]004#ET9?@T\-MRD\%Y$'V3Y%8!97NEGVK(FDALVR%)\8=YCD=R2YB3XYIM4\>@,\ MYXH*;M;*3=R?3CN&2ABU$7>(V_E!=SFO'H?S,/>?1/(8=R.2IXX-V$KGI/\* M&0TE9U^Z9'WA37R;2/1ZL>W75YX"\56!?]])3"Q*Z'M8J":\%["_M- ^_'.6 M^Z6\S7F#3[9^CC#>#$RE\^+?,[$/PY\'67K&_#Q\]T)%V^N#YSKK&<7,':$9 M;W9E7K(TV7OD^&HQ+8 M?=?XYF+L8!L!F7WW:N>'SM@#HLG_:)F=<5U6=SSR=/KU]&QM[NW-09M65U>K MK:M6W?WR3] W MG% SW;IYRXZIK7JF63]\)AW$R]*-\EZ,24$'WX 2L9""13)Q4?7B]@W#S*A' M38K1;F]:@A)'K>W$]_AYVG287@O,.=H_^/'@G"7FTB6[Q+!.7 Y+1>Y"]"=% M ;ZB^)ODW=!O']ONSLE7@Y@\49(]3V[F5^#31O-L:=$SN'5DQC1?_^'$UWV? M%=?$743BR"Y#H8927\ MONYXP 14S_[9-JCE/N7]N6O#XXS0NQ>3Q;3#@(^"GJ^";=]',2V R0Z,-D01 M)NX51PA9:R#"8: B);+?R7-;8]^BA84F1LFDM?7OFO?U=2%WWOJ 8H5 W0;C MH2%@0-(!J961;*%>D")LS'E,[G6,+G\%QAV#%COH%KGE9"Z$8<\8/FX(K0KLIW[,#O'P2C^5?^FFG MGGI.W?]A38OX^[W96$W2KD8C'U4QTZ#]1E"UEX)[0 M]_+ ''W60(-1N.($'J;,,6(A']_7]6;*_5(E7!F&&K];S,;F&:'PJ0XM$3F' M]KN(]F/H%7QUNT":S:$ILRW1IJ[<&KA?"TK<)FQ3JV(.>/:6YC8U(^0A%_?# MLZJIZVG)CT628H\48P6T%GLEC[NP:<[/%8<>.1SD[)VJ[:6?2NM[&R( M>_N-ZRE"(9$3PF"P^H-^TO)G:3'S5>IFIVD)R21=LF%!KWJJXL0 M$8X@ [5G,5SLX?%6*BZVMN+XL*OS'N>"A,2'H,,'5^NB]YZ;8,8IAUH-AY54 M% 0$OQO[O6QA?TK#]]CPN:RG U6V_]D;OG4]9I\1XZU?AAV'5(\_8B"%@&4O M;B$6M- NQ%Y>O@LH]9@U],#QD:A8C)]F'%$.P59$(RBFN6IX6[84@.4.]WIZ MJ?QDUY;U.@2Q48;'(7ZLK?A6.'-5V(9M$VL\ Z'P%-ABK_W*_55469O%OA7^ M'O//2LYDN2A6II4MUDPO;N>^CN:;:MGP<5M]]RJ#Y!O\#PK]#.VN4?UYRXHO,:O[TIMFB@0 M3IZ?73#;G_1.J?.?F1PUAZH1Q^&I"/HMSQC??4?OHC83.(_T&'($TZR&S]$T MSS+L,+TF\Q'[(.1)]CI?FZMDTM2QO?^0N]KEAXG?QHQ(8OY\ M#CB1XS=ZVR@:-K#MV_34\5ZUU]24S=W#C:\NN9-MSU+ M^>)2FLD@]" MT\W>U8#CYOCG1?A[O6Z>'!N_?KF]U%K(W9:M[Z M<=,*>YQ?A(4*O[G][.\*UJ 9-.YZW[ ,/33JV)QB\IFR?E4U.?11M_G*,M4=>HPE.>\7JWUZZE\M_0_.?K M&^NSC3.5XC53LK6N91YU]\DV]:>9N+HY&\M/0!,]2+S'BHH$JRYYR-,;R*+\7,2J-:>=_:*SIAE'6W8?\QAQ M:LCV?Y?]7?V9],,HIXRW_A[[0JWR_)N=DF3(Y0T2BV;!N:^5*24MLG;I _(N MKE?^.+\Q%/ASME=&8"L6<[*4WOU^R5OIB['R);#:QU%B;31LC0>I_L^W_B=1 M3_=;8]K*SPQUI9LJ_SYIC7*;;[\$\/.O@#@W#FL _)QBX+IV053B;%H*[#!R MQCCU!<,+TAMIOM3\_:>0_%<@4NO'8[@XS2 MDQ?RPFO6%A/"D9GB'<2Q\8RM!)X(1HD/,-3R+N@ 3 /8!5F36 WQG.A97 Q= MH0XNZ>D9>-?.KW0:[6#7SDI-"\A;OC?EJ// K+VA#'CJ7V,_D?FE+TJT[AMD M&,9/> )_U[&$+M#48-*C\&#PY*+Q"\+*2B9?ZVK-N:>/_E*/+UNNEYKQMWW/ M/A6A=$GB[9Z<,7?W=AKK1P+4?$Y4V(YM\Z2.*]<-4Y@H?SM:"Y= AUZI&O^M MZ^?4A#"8NC <%FT050&_6-UX3D6XS#SA[0N8_[?K_2"L.*[S (Z?LR5)UY%Q M! G>40ZFJH:UWH-+%6*D&,-4J(&*V"I],A*$ABY5+WJX-)0M;)DV6] 36VU* M@^04*VL""NA+D2$9Q?R9[#&?']M?MP]),N:XXSH-2?[@Q"T"RU,_;5N0@DQ# M2H>!8V&R8Z1@4>MU,LT<:)DSWP7%T92&,%K,Y4E=5-$7C@W3CJ/Y;M%;?B3O MV6J(Q\#XB&55PF=P $JA=T. Q;>*1W9$,-[L51(?4OP<$-Y!5T#SMK=V3!U8 M[6ES7#$OFZNC#O'#9')[\&<7GEK;J[1MX\I86)[%I[CT&0VK6R"(#<<*<&?U MS0G&S;-0W22\]SZ@D"&)'CZY=NM+JT/Q4N35C,ZF MSX869782#[[V-?[09*QWK#\F"4%/1LRFQ<(%>7(8 Y9WH?E,(-]%1?-#6Q=6 MF-7-_?RL !$:]18=:CMROZR4=FPNX7ONL)VBT?E;QQ^"!Y" 'CZ)@YR% QJD M56TF:0_0T.TMP'9Y]9XW&%"$+N[T5A]OU6 &GS2&4'&S[2]*BG*88# RH+G[ M\9*B\\9:%K8^ZVG2C,GFSZYO#@%A4 -T,4>I? L5[0$PO3X\MEQ+V?:3B_KJ@<65N\V#"AJ[K)4]AE^Q;]=5RYZ@S1:_R M$D2J94';-B8+T/_X) M\V997Q.;J&\/3L!D6&UK1=EC/^)^*[7=TM+]GN;2-/3[S\:I[[7'@F\Z_ FF M+:K7G\QK"'MNI"'5IUWK\V,]E5!/7'FQ8Q@HFVW:.TA58YAVM3W8IFGW(<4 M8H^9,R'!M^K-?Q\"X:Q4*^@V,Z"FU=!F?_[1W,S+=B)5O>;0D+(%R'Z2/^01 MO1:!/\H.[R F(<$\7?2#\?MUI%'.7F:.&N79HNN]!$5MW5O*)DM1.8J;;LQT MM_(--YVUPE@,P/1WO_HP\EN5#?2>I5& D:%:M\ZE=Q\/5?U7J)YJ.RUS/TS# M2U[&5UW\K&J[;]JF!C?A&S>2.JI"-_\-7> MX=S'"']FLF\C,:< M:9=6K&HQ>*1)=:3GM.ZG-^[UGIQ;C\?N!9P9NGZ])"FH+R,-A-8DU]-O3T!= MYT113JQU_.^R>UU&Z5O.8R&ZMV<-/GT4D6CMG7#V;6*GM' MDQ/!?8,+; -OWN&68!4 .A..Q_DA4Q4'"$5HP=[Q<9II5>,05@G(9@7EJC0T M-'^8* Q6#+K?JCCPN#K%Q);1M'-%]+OM&;BC6NJI?-MWYQ.//?-)/36J?K?G MX7%5U8P].=+7+58T6CM_&F+Z=7):R"S6B5E2F%4\M77:(7-7X5DVW M#,FZ9!>NUC+=\LDC_$& 0XWD[26J&)YH):VXEE(8=.'LD>P#_R^\*=C+?ZZR MB1#Y>"A6X6GSL1O)KJ?470G\#"DHF+(+8GCBNJ;^2H^P.%U9!RW(D]H%"?$+ MTC\,7O5ZJ!A\4!FY@UOM&54B5:5 IZ-?*G#R9;WS@5!V"T._.P798\:GN7B: M%'L^;]8\QV2B^PO:U:-V0O5+B'%H:8J)4E^_Q8\J Z_ZE/>JNFV?=]0_-,4A M]=PFM>N^-SWW'Z7TZ7S.B\NWCCM:?S0""Y.//(5Q=K84CB_S+CJ8(W^=;4S- MCR,>'\J+?S]V7*;,\:?*OZ'3Z>CW\L?\3D/9+\N=M 7BNB[W5S,IX2H70[9V2_:6E591$SYK]C5;/C+HS8:PN;:%V;BP,FR8VO5I M7./Q^,# @8K@X+RS3Q)I-&G;ZPF"PH?\2_(?@HC"0-:.%K:/H&A#+W/_I15]M,?++1#_>LJVO> M&^5.5](J3.]B^VBKN=-Z40^>59N?DQC-";HY.0#98V-,N?FG':)-.54.\T,> M_USRO1$/"[&RA'CN<1#PI-[KF]R!7AUSW7Y2'V@C$(=K?1^OR,ZD^U*,S-N9TN^6^" M:+7VM[5]V00[%B&V5H&V;,D:?Y3O9;>G/OV'W5#MJ@G3X0'ZF[]*D+G_37\/ MVW=/*6X]WJ>F*[]=.H42QMP'=.=0DG8,L"#F.N#%I,MT-:R;QG*,V>!.WF&V MM%VAK>HHU5'*=CQDX[R7&2*=F_M5V/2/GKVIS#0ZOQNKP')Y5 +D]ZBH?\%H M,-J.GBH8@YYE>ODX?C&R,-8+>5O=$,5%NC35CJQD!K6\CK+UF&=J9"XQY<5K MJWM2^BX+)>=[Y*K4"RO92'E.-I\*_ KU.N3HZUYH-40>Z[I$<79^;9]4>.Y] M.?5*CLNP^<)\1(BFJ*<"_O.]%6NPV+*.M3[XY;63\O9@43F=<\2DO%1B[%L6 MV\DM%BECQ6"^*7LOX61/JWB[D/W[0F?E O5__[GX7Q^K77:T/N9[[$*?2/C3 MSU7_77BN]_:DM:]Z3&(J0A3](/C@N(/O3TT1>?E&&12E]:\S1U]5H0.NY1&3ZS]R\$[&^%^, 1+$-$6UCV$/ 5B=! M_'X_;&O'9.F-7XQ- AGW-9=5BHG<3YR8_;GO^LG*..=UPS^_:&<3+8A2,1T?EXDK\@LDWNS;O^^J5RG/$F7R#N53;M5Q-FR"4R2Z+)X=+$]6Q ?YJD< M9#6:)_"LL'K,:'%-I])'+#7UR^=.=>N4KN;J5!,(GU7W%[/+"6*'@196#RI> M ND54 U(ZL?#)#-Z+B[)9@Y[>P7\1'L9AQ(U5BL*+DU/>]0]GCZ+.I0E95V5 M;_#31C#Y.5MZ[G&/4Z7$E4R]YR?036-=ULEOCO?).2#XK<>J1+Z('] \26!O*UTWG@ M&1,%7J(=1 DOTB!>JF3W\6!4W2:GZN^58'\$<#R<(T,FTZ2Y+]L/8;NP1P!] M5CI<9I&F-O;;R[PS]R0K\]'[H&RW%[_[=D'Q<*EVU45O,59]&L/K'W?-L=5: M!U&]X:5=D&OB. :(N5(W9+2 J[3;!87@)L4F**L,80+5@:'N\9.6)%4DP>%GP*\S8;5KF:24(XH#&=WLKLHKQZQQG9IK$ O]X MX%5@0W-6_ ;7QVFH5M>LGZJ>NK;C-EJI6SOEX*Z>K>&0L*86F^WV[&J6E87; MYRRSOL+8.)\,/P4,FWVI@PQY<@>/,75BC..1([6UZ5#+C8??_-O)X''0'33!G>7]HC10Q9!M M7&!PUI>(7NYNIN4SB;*T@"K$(5.A=Y[+9FT#60Q&N(@KF;R-S>*^+=I9%:$- ML2]OAG$)6#/N$TP((,,*G9,?'BUZ"3N..S#GP]7,PPW&8X 4TY4\F) =MD9D+?>VBP"/"@,F5@OI2U@AMG<,\DA M**AGA*B/@>-*/*CTBL+OA4,UN5>:9"=RE0.1@ M"OZPTTU-PQ6ZK3+EG#.LS!?,OM<5J(^\WOH8D[]ZVA?\X1AGZLD$U]ZZH$>!#OT)2QH02WU&#', H(@M20>NQEQ/='\=5G$+5MFIIU&BG.'G7+!!86O MKR/KB84+D;YK-16!+HJP9T74_JC2I>;"U?:5.5S(E3(KYFPND&.:G;2KMY\":@NY:A1XCE3D^3[MYLE^@N_43VU&DY'.ZE:J!F61Y@>3Q MN P&5_A,JG^MKIS=T(VF9[Z-:;8CMW^/YIY7NCCO<.JZNY?4-]<[G^6^[Q/3 MMM:ZY#9L.VV;KOI?NIIV?L^2@KKU)>>AYZ4B0I>4[J@?>%NB:.L.AM^OC[ MG]:^/\:[H'^V:.-UY6LOBUX[F12..?WHI M@S'( S"CA2%T^)QF%S&.+HN![R-"%>4H@WO1/KW91H9V2N=^6?%3IL/8[?Q, M6_=W$9("#U)>"1VW+5^/)8%X ABQ^M9J0(OER3#MW+&P\=N,+>ZBXV%B "X8 M]SW=9^>FBM10[ *_ RM]\S\UI-UGZ MN0 1AAECX.SVMD.25W=!U_RWN7D3-QMBW8N;&H9">'VE,YX=[[V944'NUQO. M51CV5,:VV;L?#4?JE[Z^^#$T>])1!16/%U 5WY1X:OFZWX8BC1+83\ORS;QH@9*H=2P*W"[LK";[265*= M?&UVE5!#Z%S4,K!-C#A^_>3SP!'R>*?/,:;V\9!4E7JPG(V$NTN@D=!!@KZKTX^+XV^Z\OQ+X0Z=.C,)9OL/ZD>L5W79_Q9YY$8\A[^(??\4F9 MJL9L-TP8QE@0GWBOLHSI;R;AY#PF7ZPQ3Y+>!=WB^Y>Y'-H+'+MA%M*)3';= MEC3RT-CJ1L3F"@ QX?F4X3_]LB]"F3/"KJ\1*87<.8W\KB($38*4O1J,5<*8 M5PW5HL2^ L*=+E@5UO=G(QAXG@?@>JZ!+W>GJJL^#-7^5R[9YU"M(?W:4_[P MPQ>7?#XEELTB$^ABV*/NR"6X&/8PH,D4(Q1Y::3F1\_B9!=4=&L^M*5+W,D, MS_*&D$:OU;0$A:,*'J6+"K:6<0DDC\J=MLT M_K:?261<.N:B7W18$4U[7Y078D=_M6JQX0*ISZ*-D_G+\\T?=L^>RM:C=CGS M\N^_ZNRW>S-7U8C^Q3SAIE-LU.US@C5"HUP_\2?LMI,*['?T$A I],NZ_Y?V MGR:\S)V>BX_(\Q%$R3N;[IG,'RNL5W'7"3<;H?OUBMO6KM_]^H::^=* M)E :?SJ\?F;M&.VHV]9"_>C/.K-)W.O95D9)N;VYJI#RUM_^)54V_N5G*Q%? ML:Y")^T.Z-Z=8[P^G C'QY2B'T>O0:SL@EB_>D>,^_KGTO9B%(%0AK[\OQ.E M1N$5F@FU8-'%[:DZZM5IC3Z+7TI/J M.UO@QV.H0%LCT$#U8(:SX)[MHDE*Y^DP54?H>:?0W-%YM;T,V$*MT_M+[KL<.(C M^Z7.[;M?/S55'I5W=A)S>G(B[$1&1ECIW)WIU>[. B M5\H3<.W:I.8O9]*4O@1OE&KDAH_-#OU>"+/)73";^7?[R8.^!R-7R]-U*2DG M(V(:G[TTO[56E1^@<>B;=J;XY^]@O[9YGVJ>^8Z5XHY":K5[E M<\OV@",[H\/;?&QE-JCTMR.88G(O*"% XA_/H;SINO8*C>>^3QTC9-YD5AGV M5']*4;_>;I#K^&:\K_CU\,>:R";'HW.NQL4OYIT-/EU*2K[Y_I812ZJCL^MR MLM]@4N*30OG^+D?)A<[R:B^2>3MY3XEW5R/S=5$*F%.<+-V07XXO(J! MN\=U)GT/1QH(8H"EA%[=1(.P!G+>)]A/.Q6=#6\L_Z6E;O]G6\S_<%-< M4-#+&XT-C8FV>H=SC;(5&"]$[I&-+FFK5SDH:*F'E*<^*?NG(!%]#2=FN/P% M*ZCYC/I:I\JS6^=7WZ$3EDI]1L/-O=(7K0N_9;H?>F]SR+]P9CK66>#E0R'B MJ:U_*]3(N2JL71 5_N&^LM+Y'>2+3>)*BEZOXP[BV7P$Q']'6OP/#9&C_V(^ MY"=GTB28-IETA46,W6AYN6Y,%%TP:YL^J7/2*S ;1BBYVGW0W/Z9C<5,:W6! MG79KDN('YW _D*$D]O@8:;:$SG+J!W=+ J:7N34XOT9C0,]C&*T&I.1Y?;6\ ME[RL?FDY,UQ.43I8JF=1*]K.1?-2NDR(]BI.%""0L09?:DG2@"7%#)+(,:ST MT. E,>&B2^.*:['E;O_9]T84+FU[=8\32CQL.YXTUC9FRQYYW-39L?^[S"_7 M7L24VN85[JO*VRLP&.\+\B!,.I":4AX^KBB7#/4M"&A7:QV9SW13':UH/;V9 M8#Q9.Y$K-.ME;6%1GLSJ Q/FK3^9M@MB^2@CKNH7!2J2.L I.-%VO M7=Q-DBA.QFIC/Q-J?E#HD M&NX5?OOEY9<\KQB5J;< [BRK,J6(+\F*>L\8@V#_\6=N_MMB,463"]LF&3[_ MK#[NDV;?0*K W9!4N@P'SO#4]=RTXV:NM3JPU9A;:?>Y M*LJ>%)X&<'KV54'+!"=@SLMC.M#["%NL[*[1SYG R#?;N54E@T;#=J%AAC6@ MZ*HRM"=9\??0U:!MV?_3N%);]^ M/-IPIN-_&V?L!W7T@.1!8AVND%EX/ ',.XZ^-=A#$(&&S:['\\1&-=OK/[#] M'G(0[]!DLNF$F>\WZH-"E!\1';ES<7C-;V1#."A):2&O.4)7_W#V.,,G5].* M>?]O 6RBQ]I5^UDX!^ 7R^<24!=F/5J'J7:6+!QJ3)&GG2/EVN#YIS(X1.*<12$E8$=IQP']B[&UZKJCS!OUEN%F[X*"2#%8 ME?$I!C[^ON=@,DT"(#)T?,*$$F"DAT\.:1#P8;D M,/IT/2]$&%N<6QIQXKX ON\X8_M)-18YL7\OMZ?"1; 2E172-0&R[:?8#]+> M!393Q.%9=^_F+V3)J;F-!5=\H_#K/SKEL\E/ QNC^)^J'P1)%Y&G,0?YQ>6[ M3KV]),$;W 6I\.0P'JW#A^4\*E_,#LH%>!2U%$W6)AU$(A>$S8)<'H -=4[2 MK[K9!*CW?K++/N/2IL]$= _&PO?7.D D.=> '-86 X$WMK@!!@[_,>R+\TO!*RD91B:#M6)V_TGV;ZIJ>R_L66U/T-U4WI MA\'GWK5[ FE_&V<1A* *#%0\3@(>0'JLHLAR3:U80T'!3/.T>)Y@V*#,3/;'7"J9JSB%4U1AE! M'K,/X#O%I-Q#52V>H@Z769H)]_NCC5[_43.TNEX^-8G0F$^),MJ[*DX-S-S, MDO*4:4HT?31\;L_*J.MC3"BW%.<'F7SM-+(!I^Z=0Y&13URH'8W!BOJ'@!J[ M(6-E7UV0Z3U_JE5_QUB=_ZJIZHQ#L?O5WI"?71D&T"%M!D:,6P/W!5,]UGXX M L)\"&@ I>7N9(VQ\4<,B*+_!$_]\;">1EL&^=:\;MAM'[@V71F^DDC7>FDJ MO>=WM_3%,P+_OP_G]CJ'9>T^+85A\S[/)%?TYOKYQ@3&+<=/?6W.'[T^]3TU M*+CI_/[87LXWTNQ;OF%SHL>2JNBK7);GIB7+-)6G"I1UPJ5^0QXKCM2?A\LLA!Y(,9Q!'HZ(+J@8C,EXABIL4ENF.89<:&7 M*X(=XPF,D&9CX2Q[ON?(%>!F\M0QY\9"4P)&HX)P? M,BK3EUTVLP00Y':9*H<<2 <$;$P$K(BQ&1]8W@RYU8F:8FMFD*YTJP'SNDL#P0JSFN MLS^G?&$SJ[>^MV^UP#HP;SV>]BDC73OCDY;FB,C9I4X^;WXK* MXY@XE#UZ3RTJ#IWKUS,"HMXO*SKRDAAE?@">M=P;ND@3'VUU1C%FH$L\\:;Q M?ZQ$(A][3MXEL9Q05#)/R)4UR+#.^[MR06;GT$(DOAL) M(H+N-(&26&$IJ, M9"O'TFJBHN%Q,+4 T0 LV)O3Z[H:"41 Y=$% [Z'HWU*7;W^EBXY'%S? M7 M16 Y(5(@+%LB=6NS:8*S=\>$UY%M2AZ4Y"A^J=5/AHCP3@82P$9]YDD5H61O M]42ELMYJUL[R7L88+27*%%\'%PQ441^?(W0;P&H"F[$IN'=4ZO(92!:RH3@! MJXWK=.,/055D^(J=SUQIJQJKN ,IQ;%AX3KJ#;-:AS#Z02QZEP@_A6 M?5]6UIQK+^X?=);]1.U^-B0>ZE6*MNS]P/<,)^@]/#6) )-<*=9S#[GDPJK/ M[8KCOTL97^ZW61^;NLBJK-A7_!_G;Z,@/%I_SI0CB><=G"O&SM .L>R!8@8J MC:>Y3)*%"K[W?E6!,:VD<TI!7UM/,G_@*;23!/+EJV?O M#>8O9=O$W]:I\7/ 93*C&.S,D*TZ_ K4^Z>GUV3:,AUYI(H^]2 MIQ M[-U\R'W:KLCQ!SK997/U->R6.7@71 A-'>S.AI'>>J*#.H8":3(UC2PX?@5J M6H$.\ABM6]7LRMXS9*1L+1I$R1#>"=9S@Y["J/EHI-03>G&=_3#C&O:/#OV_ MZXC3I&S8D"<5K<'1;/UN$YH2>_PYQG1.>;\RK@,'KG.K14HO& Y"LTWC:_]; M&Q_Q&/:(*!C9.!"BZ^WZ\U7:;]==T#[ %_55;A/N>^T3[I9^S!.#IU=B6%N6 MG?ONV#2>>@O^CN.)QK$1B??UJ>N;+X KV:WXKFQ21P3'M7+QA%%9$0UH86Q1 M=D$' %>KB2/USZID*)'(%(R-O^]QS:K"J]CRLU@[=O'*ANFJ^RY(8 GH MVS&;PIQARW65\'2QPZ1:!+Z.I )8!@*O_V7%IG4AXW,UV///"EKL#JFB% '( M.3;XD:9<7T1A759"I:O;\$:..FW1E.[ 9X#:+''^BX 0]]VXUKMG^)4IMO@+ M.XF78,";)/1(74L=9+OO6>>IY0N\@(9T;^KW/C?>V@7=&L7]%5[$PT$L!MF-1-AFM/*"&9F M"HO0G:L )%0NY&I6C;UE"S[A>#&5S2D>P3TY# *XOV#)Y3+Z''/D0O5ED[3H MX%+*9KWB[7&]"5+>)JX!V0V>I/-$)P M=IHE6Y0%?&3J'YCD#1#$.-?#S+T# M(P6^L >3H0(%Z%2%XIOICGY=$!'.D>CPMPCSJW\\QC,*:=XV)5;*W76]E7P( M_+21^]L)DM'BH&I-8HW#Q?8O*E^\AU7 ^'?TB1O<00^@C6=QPKB;.&DLE<0* ML>D"Q^Z"Q((98["CZ'OT;H@,5C' $7J"&(^Y/(M,YLO#&H%LLG790;FPC2]1 M4/,H(A!EG_W3K3Q_K,Y<+V@$ MVWYM@HE*XJ!\9T7!G=Z:5<-URMYP82##@T5(XD3/#4HM1\K%U_6CD*.M$85! MX]MAY:8N=]XM#"]E?]O^%13@6XCY042CF!".>!KO8,,L70P# V*):,+L1.(Z M]M!2-L6LMLJ3ACG/S<7@F!$Z.V5 M\Q8:Q2B_6\P \KLFO%79*F5,N#SG-'OB<>O%,L#UXM"&J'FO1RJIQ&-).RS4 MK+]R9M&L,JOH:)K ]UU0G,U[SA4^8MBXSBNMVG.X@QSH&$:3A>Q4Q).CX-(6 MTU7T8C*"[W4[O-4)%-?\;NKJ6]Y'9#Q24C^DU0Z,_VTNI"])=Y_@IR>S=CPC M.H@BLF<5P@IM$MP8>.!RS8Q)P7OS> ;@<-/+LOCMGE46CF_@D9<#[V@X# M0F?78PC5%[''4MZG+N#!^?QW??I@T;$P20R]1/^T+>F6$V+?L0CN"[T[9YYH^ MN4C3JIF83^VS8O%:, \5_JXPY@_0Y+(W]Q74.)2-9)*Z6\!4_1X5@1&.9001 ML+S,:D6"H7N8;7Y6J=N]Y.WP&")&VZ(W$6KXUGO:;^NG6 ] M!CW4,/XL '><7\+[L%",#_<2H,_6]N;F0Y5F<\S)-R:ZJ@$OF#S'F>J.) 7-=D:L3^/[N:0\H5BU1V ?^!-?Y#\D/E4RJ35NM M82-X!Z^SS>T(#JS'RQ#Y5JL"]+-RW^KA]L.8 &"J+"AH3A@IT'V"NPN*Q4@4 M!/&.U8X2=6?*5XR5'-WH(3L2*PB7V6=QS#9T\\ M=(]ZNP6[@CO_XJX_[_!??X#'JHY@CLRB\#C1BK H783ED+'V+FAU4$QX^>/O MUQ4P;:YE-\]X]+9Q&W:)27?9]N$)*_&E(A*0V=G'&VB&]((G?S#AW5_OXR0X M#BR^\8^'B$*CB &Y&E\PM@U4OT1C(AC(GK@P8H02HWDN92PP8 M/EJFVY/$UXN5S1J;,LPB,\=A+HTC'LH[B&/N@N*%66R.':NF6Y% $48(6+Z? M418F0Q3:_T'_CE.'D;=_^;Z;4\1J=O9?8@O%ACN:(5'8M2FPQ M,SPKZRWDQ@*AVIXWR@=5<'C7:0S\76_^&SC!CSTI6QE6#/U4NJP< M0A=3MG.FUXBG '#Y(N\PD/(V4%Q!3R6J,X^^R#-CM5747NQ53GV= MCPY%/!'(G01/T5GG#C )/"&[G1-DH[O](J7L=WPME+7]EHI(PTFGVWY+>>1J M<\EYZ)'+)NW42E&3T2#REYG@;@G M^0RHSC%F"ZX._FU* 2SOX# >P_VT-!;9E8WK$4I9T8X.#F;[,=OFJXHY9JS^ M-^'P +ZQ_-&1P'1(@7QJ3)\[2R#G'O#T4:V]3-X)U^0'LG$4;X< M,1#L[2 EZIR-?76SAPX6OW-E3AD-?:P]"I]-P%5[_&WZA:#'>>#BC3*K@$=L MJ@G 9A^G_33V7 [BP\D#EIZKP-I8V 5YHC3Q6)5%FLPP\??XG MI3?B7QR@ULN14G'8ON^ M.:?L#M7/6XST+IX#2Z(]UJA!T9-- 4X]1_:O%MACY@>IL#@OV# MWYP_3-;7QP#5J$"NR"#BXA]O?.NH>5=V%@V0[+%X MWN=VS0PD$K!]32B7H1L8?/Z!'5C$'AVJA#J*MCJ4$/:C MJ^J6115_D">RX@)J7[7:A3.X]L)0FU)W2P.UJZ!H.7Z<&,".MT/9#3'84]C_ M8.83(1RK=QCE(>AIMN#L:O?TENG/!17IB0T+OW/LXIB*]9"B6TED1:<&N;@Z MW(& /GE9-8KWD;KXSNNHXLFIO]LW=JK@KB/^MF0X _^:H<8^-R;* M8K38.;%X?'Y#V.?653%IR>>V.J%PWU8I'T$LH1^Z";B3,LK82D%=8 M==^VY+(/937@'O*9XK8(RV''GS>DJO7N*7%E!F.;>OZ>($>7M#?Y:;FMPIQZ M&.?8WN]$0->5(U7&P'.D@IBX3CX?3])["!)29X%GC#1I].M_&]BW6H)*@.*. M=A, 5;:0;EG.ERHS6 9CI[&\4'$^!5=8,3P3Y&'=4.CMW5W>%QSNXU>$NT)@ M74()<>2X!;C95UA("[<4[M]'F$SJ4M$8;A?DG)F J7V=1NA6YA-IG@&*/7FS M'UN%BA$^?/'7 =YU;5UM&(*"!0JG1+'*$$I]\\U!1ETBB3^ELTM_&/AN7-67 M3/]WNK.D-*7SZ:I^_,]%:U(H?BICA7]W!$7K,UTJ=L1QG<:MN+RI0%.($$9B MMND^*=[U04=?P:**(9M$1CQY0#JXX15PZ=SA.(=@.:88_GJ)XYYZ!^X]9=/5 M"UY+FP^VWD+,S[*$>:)+0 MKN1LNQ!/D?=D%*4#E=LY8,G"2"-8$TZ9'U+(' M*U?']DLUFI%EXL06%5MAQUA^>)[,S"+M\%BP;H62UV5)TKI'O QL=1B-(X4-*DIU\_#9,?=T9,(NJ/[.SGDY R(9^1!V M_ZEM:LH1-K@[9<#DD,"#Z4]W#,#_/(2;\T"\_[:1JWP=$@CEOH7[(231NZ!N MN%BK#!.7C*O;WS*WZMIY:PQC5XF&=Q$DPW0]=D%=BO>SDUVS+5JSU]YF7]RY MU5"P3/6*<=?E-,N6W@T.#L'RT]#CO\ODI;!@'H4$,DJC^FP&LHF4B-\X8:"W MBZ8 X!G@^-S#P\9E29Y(B:OM.6_1Y&<'O%^5THU#& M]27&.;)SYZ+W>XKZ,-,>TNM&(56:')F&S43NNTJL\C)!!F,\NYZ$JS/)8>\E M\Z1:X^C((:@P4S_!+/-%.3#0OZ::A1B,0ZD/_\BDN[W^=Y@H.?MU9ME#JRGM M,')1# MW;/.-&7^(O/VL'!Q4'@9D#N_%$62;$\K]5YVQ 7?-0^XX._A_0JG0@P-O[UG M4[ '28WJP=6E<91TY];C"9)U441QCCV+UL;R8_BE8FRBM:\B@8PK0,3.+8[B M4&V:1&#X)0?=_K6&2C04'72%+<,=\N1C37PFL"&Y/*-7AT_)LYF$VM3"_VWX MO'\7%("B@L_6U[6P71_"-#$W4?O.1DM.!_"9(P=(I3/68Z%2H:4>+13]^Q7P M;L7YK)*E>F$= V1 ?=:#I_TB(^I)X%[]R9AN4C6$HV3(%F20*&TF2##&=B)L M/08BQ<'ET5Z^:V2M-;#!FX. />+B*C3)M+:\<'5*ZHT4()+7 MI=%:QDJQ,YO!)CCIA6;'RM)[9>J9U+#NT47IRB2EA]CSN$X81I=?#N/ 1"GG M&K#!GQY/;@G4\B[;G,([W1ICS;(N?<^QQ[NQ?68"LA\0*SF7V,6)4!E&SF7G M42R]= E/YLD,54!M"CP"+,G4B:G:UWVG[\M\&,:E(FN0'"D<[^!I5L,:Z3]&B89H2 MQGATPUP7%11&R_?E2>TQ7Z]>82; 75E)VV&\J%?@.UYD,TO M^M](^?YPGSGE<$9_0Q+V,,9LHN+^CBC$DR68>%]A73=,FR XDV(P1?&6'.>8 MA'GZ-8]N.'Q]VSZT,:7K/;71L,DO2/Z4XW%UIJLXULZF)V#*'Y7U+W5*".5% MV-'&#T!I.>;HAY%RG58$@VMAW ]'9'4V1RW#-.I88YNO_N]W?4"?T$U(Q-7)<:1=9[=61!GZXA9I3S#P<8O/0(V0/E5<6%(/^MY/]S 2C>4LB M79N;L<,7RLYF0HU^)V'2E3_I=#Q$"0M=I"O#1#E:;#P%#CAM*/N0#="H;@]B M+/1(22#OR' (%%*(1MFWLW@Q3"5S1T_;X7=#4&>5LG=3@1=PP8&T$X_'-Z=< M@!V>\!8+Q6Q8(?.!L!>P^/O,NI6V23BPO$WJ3)->P&JUU*2NDYO!O<2'U(K4 M_'S E3*DUI2H'&[)RHK=J%"GZ6@1;8*84<)JZMD:/=BBOY 2E,.( S]V=(%E MABD9/CDU!\MG;\UI=A$4T0>W.OE6AI4&C\%HF,:WRI2Y 2T469[.T(:%I3?; M*87A>-3+!UDCRQ,>UC/65M;NGY#K2V*IQQ]L?YQCDK MR]ACAS1L0F+V?KDO+R_#C?!1_O5TCJ5"2,$=@;,";W^PQ:%D'J.+W1C<%Q/W M0RI/\FGMH-/PW98 M5,#8J>(R].;%NVA?W[S< 09@_:3H;+6.OI_.5D+?&A[I0R_/KGKT4K*]GV:%(V3J M8H"'BR/H"-2:YN/QH3"7S)^^->Z_N%5,&]D;)]#T?/J!'TTY_\+QKXH% +]7 M[%NN9O>///Y\ KC=I^54&>""#F &S=YY2KZ^9)](&2$/O:NJN^[XJ0*+^^7: M2=M'OJ7@-]R2=@JE$:?=7?Z:HB]_#[MO(.^R'+3W..7&S_(_/9DVY^0_H:$P MWY1,4P7K7(UK2\R[\@G7CGTJ][$!?^1,8GMX![B/,:%YZ%XF?)7,YG,M6XKB MK3W:G_;$<9"R!UJ?WNV+BYI#2@)99*S*:)V7'W)B(ZK-7IZ9Y2W>B;JUM36$ MI"]=S-'W^=OO(HY0-;&Z/KM,GT0RU\K84IN1;!Z1(2K<+3MQ=WF\&@(&2!>S MR-LD/,91E/>(45,6"-L[6HE/Y&A7=!>VLJAVUX.-9V;Z!^/S1T_B?'!)R*H? M7<)(18XFEV\Q;M6.QNKRL]Y/U M624!6W+4Z-&[,W;2U!0>(2K 3[FN8JQW(6UEDFW.$R+LG.$--^MWTF/I53-Q M;X87M@D)K89LL OK:&& =/.H MB>(AJE?=>&%Q&WV1@WHU'^$4S-2]/1?+\6)6"G:SZJ\[2,2YY>ZI8(2))%:Z MQJ3N-6)\)9;=N#/RZ8>9?+DJ>3SW5K%]A?WSLN'BAZ4(-DKT)R;+XB-4GL1Z3*8<)QS'3GA8T5U9CN_>W'D=6>WMZ$]OW!@[./67W5!CE"K0U.(#_C[WW M#&KB>\- 8T6D1'HG/T% J:(4I20JT@4$I(42$1$"(B(@ 0)1D=Y4FH* 4J6+ M]"(! D1!>@D$(20(2-\HX HAW/B?^_7>._?KG3N3L[N9S)S=/>=]WN=Y-LEY M)IPL.+\.5FW&O3^B\=:]']UH#-@SA&*XL#_H7QN(L[FI?_K7;(-I?H>Q\_=U\OY8$%CY5] MKWS"RBV+Z8&LPD%YJP3X7K<6UII*%,54;052%25"@G$CIK$84\2M$<& ,(92'[/.G$=!?FV7H%SO2A_YE!(<0)N+A M(8[JG-/]$]&F%#ZD%55=AC4AK>4X([I$[XJF15;%8%V+]/Q/-31^&E>;0=P" M/ @&;9%W6NJ&U?:&C^A_Z)=\#QTX@-08=N!!F?OX8VIB@^2+\_4-FMV; F@Y M*Y)B@"H=:EP+!BJ_%\\;O#KR;AC+XU_HA:Q,]-H9+'7QVJ1)7 A[H!VS1@L3 ME4G:W(YFGMS>NP#BYS?7#B#OP"KJSLM0&DH$*T3:AO&QU._EHDX2LJV!RN75 M*:8BH%> S-_\/*:V-+KE$X">H)N%AKD7S)*7JP=Q2G5IE 6VM?=[1K@.C2W\ MJQ;Y3)W1_#A7G.?M_*6,3D6/4WCV/H[H]N$.9WW7)=&7Z;PYRB]=S@"+1R*P MV+Y&BS@TB(ID04<*2(Z^ ..0F;\G%.\-\)]_\T (&DV38]E/6[FH]A':F@O: M A;WS4\D;O$M_6;V9:*8XS&D\R:#]_>\"N-QG78PL\PI!OH#TKF8EI#Z:3NYN.%-%UQP;'[ 0Y; M7 9+J*@>E0MG9^=MAI7JE,25AM._#N3I[]?-Q#;6Y6[7,-FWYY,GO>T4]TP3AISX2DXRRZ1)^PY*Y3/\HZMKF\\:,LP#[V #:8^R3:%.19LQYU=T) MH1C5L0N:\5_=8WIN3S@Z"IG?6A!Q>[AM*\>=)CSBXA+4B=&G0I^\1230*F'S ME=R#;:DF.5>MH^3INIRY2M3[ P4/+VT(]M&=],6AIXC',N8+,V]VV.R\>'N! MX2SBJHI:YRU=QW48X^>RS,KK< MT4NP>2":IFL^;5>=8@0,1L\2+6N;AGC)M+%8M98LTQ$ .67AB?=B.2(#.KR. M1@%/IU=\6"4U"/V9@'%A]:BOE3?J*3FY3#QC:6"^K#3_->Z7D$D0NZS?Z3*[BX M0^6D=_B_A0/_\VX3 \8+FI/J_.&0KJN]\LG:_C(E] MW*63]F\YL[5>?QDBR)CS?/B[),<>>O;JK;.2Y M7&R)*&M<@&L)!Q#"9:R[G*(%,?Y%T-L7;/_^Z]YXY,GYXP_/.T:0WH,1.]\1 M]$;4H82W*EV^4\YQKS3XED!QR*T2'8$O7P?\$OQS3)GLQ2RVX0-]]F @'PWQ M)%P6@^C)G'A#PPM>G>]G6@-DT:M\ZS+IFO"Y,XG3]*QAT.0@9 MME_1W[/\H.Y$Y7Q#DE@PY4NK!YV\NI/V;Q4NQAEP$/&L3B5Z-RB>J+OO^,=&DSI$M087GDRJ;@;8!I0OV-'3N51S@_: MO6?7_A:5!B[-VPF[_7)R$8J^F 2=%TA;$I ?VA%)J'Z+2!_(UCGC%I^NW+IL MJ-S=ZA1>)DP5N-1J9M13QV9'3UCJVC@ZP$S &^*@O]K^ZW1K))ZF6V!89AG4.?44 *?:J>B)'.\G]N=,Q323 N45U2^'H7@_[+/<[K&L M_?>MAK2J1)=3^ZE;F_R:S]LD/+6"GM<=0& 69S+R3<88IK0]JG\1!5/*!=>. M[S?4 Y0C);,JIY8_(IV>!I504/NO#B#6-<..YC2=($":R_FX91" ^8(":(1F+E<6^6' O )+?]J"QMLIR!?!S!/QG54;D57)LUG>6X[FWD?$U) M;*>:-6G7OF,D2(>K<2JWP[J)ZI?T$S>9V% AKFK&3W^"\V6CZ<;'.9L9I M$8OX^?A\Z_/18M2:4E^AV,*8A[<^TLLNW4;4R%LE2=VT;J>=W8>*#G?2= +H M>\=H/7(=W[A51*RYN/E[P&F]Y+?HAV=^K6Q]>@/ZQ5-+XU4Z202#TJJ8 /2M M;[.^!@6LKN2#TT4;QE# =3Q9K ?&T\;/T -5Y[GT;D[@J3><0)/5#G+4>T62 MD*TD!SVPK<[;AWHU4"=A9'E6?%Q'*5S-,VKAX^BVS(C/-^3C[.)I1^:TEVAB M6T:QRTK#B,SGI"R/H ^SWTU6Q1^2'=K_"%WX*OTI[\S#ZQL;/Z2>V*?=-/N? M85EMW7^K$P;<9]P'V0 Y$U "D:3B 2PE!IB*B14&!\*.HU <1O^1W&NK:^@& M+_E#QDCI6CUO?"1*G;PT=YV'(NQ' [45+-H".3A\3#I_FWU.]*@>4U*^K[Q> MYG]&X*H5_R7 FWKZHPM?8(A9)97AP#%>\ M_;4HPBWK@*W&B/GPQ[A-3K=N2.F5ZEN8D?M'HMK]X7BN]#O2>&3CK^OO!#4&4W9&, M"7NR&OU\\=,=Y54N_=POR>V^T;/*K(BI9DXRU>A"W3B1U1"VYVL!WJP06ZE> M3NE0+J12#G=73J)G!4'?.8SZ)74S3/.,90H/M3H[M@T;D"3"4,BL"$3B :L/IY7\O1@S0?@P.(J?V&&GNK MS+R9D-%0((+=*) ?,5TC'*C]M9P]_DKST ,+LMVOLKD_":W!K EYM5_-L,O# M&@#F)31?MI5FC7RJ0D_-K_5-'0=@8M5EM(Y%(_J _DS7UV+4BD:$0<.>049H MH$3S]^^K3)%Q9;6*.\?PHWB++0JH9$$8%&:X@BA@C]K0 8V3/ -LQF_[O0>? M[=)(%LG$4Z@5DX_+JJ!V!UE_XU/.:<$&S@>!?L&ERRS@>\0B.]GO1I(M5F%\ M[^?-;O0=L>YHHN%HO"K0A\FRZ7K6T52"7V_^2S?IMX:BU>MZ>X93_J4*/%ZS MXS:WWJKF.B\R>0$7G*&6@X&[WC*[Z4E&<+C"/&[B6-<8IK)8:%#K .+PZ\\+ M4^5TA^#R_.E'.HX=!Y!/+/M;]GO.Q64>R%BO>[^"^YC!X$_IR*U%1-TOJ 4\ M$K'ZQ0S'^MJ/T5^B%CF:A @'$#$=I0.W\1:X#A>$QP$$=,K]5%0U+R'57\EP!>3IS-/+ MB\*VCK$,*5=3E1C;.H,+%N-87/$-=.Y9-'PJ0-( M770[BAUD[OKR@'9SQ.=8C>92EQZ9AE$F%"N1,MNGTVLL MZ1X,OM],]F0 1S5\7JG2>IH>O9,PH5R7"UO=N3!8#"9?C[,#(]SE%.!P"ZM%(/11! M[)5D))A5 .7!>%P!-$K>>3;[1NLH_:]0AB/0+_[NT) ML.:8<02PGM.,@I_">@"PI$!G4VK;F_VG5.@ID'?:<*RB#L^%[)=>%G6I]BY; M%55 (]-CCW07&/H_^+,3U!R85M'5,T!_()W2\\6_ZA18U;'V.(RJ?]_,XE1- M+M_%\NFNC%<6QY@U.AI:@0IW;Q+ZA&?<4Z@??W6X>NH;]P@KRB Q09(W.J$_ M,;G1.F?G? NX'3J96JY *D..2CD.^DL#D7XRBKU.XM5O?+3X+Z47R8I@!066 MP-:[_HH/9&VD^ZW/$ZU*8A=3?S55C<"FXG>XAG%W!\ MS(#17)OO6A7WE0W_W8-S>VR&ZW:4$C)R'=EJD="VJ)'Z M_?L(\X1>J'Q*'MDJ4Y,FVYAQ;^_EG$Q07DDR.\=U')>(/N\7Z MI)M.?BBHAHCNJ^VGX7T%]NO">9G#%[\"-5V2D(SV9I6$]Q%6OU%((+TPSPLI M^=[O_:0Q3=K'35SR\J>/Y%FI(>F&S*/U>X(-Z,?UY-)E,F[1@W$J:H3\AP9; MYW,+YC7S#@:(';89&K]Z/AGZ>6O@*XAJCPSE^5]=EGZ9EZYQE-^G_/SXCY%H MD2HN9@J"SB,13'?RDY14_&45'&92(M]D\=$RQS[GD+$[L]_:N,>D2G-"JM2_ M>'T>%OV+[O_S/N-TDJ3X*2!'"5>&)F@4ZY%#=5;4LXT\;+_-7+Y7BMW #F4? M@Y9^';5L^ *'@F^ K!W2?GFK&1VU,PNVE(%'J/[H/^2VB'P'V<_^#]4:MQ4N MM9X&:JYJP>-I(CJ:>=/HAHR0*/P'I".2@OH^Y=(O\3UDHP7>X#T4/K$+7?,! MXF^"OO30G4/@9A5A/OM(U[!^"<9=ACZZHB5&< L-+<10""&;<3JJQ4Y=MUOJ MG(6Z1/4W:G ^..Z*VTJU/VK,O+1;N?C:X1S[3W'>/J'4S74? Z-QYV4[+,: M48L>"V@,%$LT[+0337P[RP^6S3W572_*+7/N1M^^KUYQNDY8IB',T''$UZ-N M8JMQ?7H=P1<^#@.,5G51G5H6SQ!NN: 9OJ'5, \=LC -LC%YMH<"P@QOQDWL M[A LLFZ-;2?SKTX,X;.*,=XW1M\Q26^):,$*WP!ZA]S&FTIMH70Z].2BCL@+ M3&$7 ]*(4$FR3GGH'GXT-[*1D;PG)L#Y&*K>><^O.";IPLVE=+@]XX:JNNK# M .#5@TIMJ/7?#)F^\R+$D_0!&QJ,#Z/2T2;?U\4YX4#BP43H=>W"U=VQ!F T MF[7RMPLZ]TQ6;Q=G7,M[_NCG @;Y6NL2>VGC@H"IHJ ME .C?;5V#Q[Q;OGQB,,DNMY.B \E7+%^[]N08H:0M3G=-%;0X>YW@5@!N@J# M?VF'!>F3^Z_588F/&+#Q< VE/_$,]3GO7'8]@86&R-LC.GHR8VU2XSHXFF> MY3H AXS8H/WZUM3+9*E?M;DF73;M?O?\/ )JKB M62]=),<5I=1!DV$G=2QL5S>6-BK*.(P^*I9_[:2$%$:;\*8ZOL?TFHQD[*D2 MQB[>4+[ZDEKSS4>\3XMP=\H6IOGMX?#;\W^CT'K*'9;?_,9.V_*O]"1IBIGR MQ!>+OG@^Y@??.BU+A?[[F"D0MM-R_$W1,O+$J*TC3H2AXQ@U;G?+84.]ST%))F/7 M?#\G #5%8K+[L(32.Y!.3]ZQ!+N]]\PP%XU&F>=8_%S'!]#FT MH+A!-@(?$D2N4/1'E!BZ(6T"K+,D!GR6UY5B'D"Z + &V302H.1H'P8U8]P$ ME_9,YL+*5&5:EG>/\9:54./N@2OY>KB.F3Q, 6*L@(V?_ M,E*4N%R>NL]LAG0:)M2^"=AI:R9G3[S4HM] D'(TF!A*I4&X0 MYS1$K1Y1$W-D_Y%B7?=QI*K63.Z*-Y<>RYD_BPO_"O_WNZ+_PDFP0TQ-YE<4 MOXX]4X*>F!S3:@8L^@K-.LZ 22,'D'9-%Y%HFB8!!AM\9X_QO4&O(E!.D3%E M5Z9\U1/3Q@=22F?0&30SQ^LU=.7\<5R'$DLN%V06,WB%:&S$JBG'G6;PZORJ MQ!$;>I?6GUBU*FXD6E-2"_2GRYF,*#)4/[@DBMF,U29J=L]RTJ.C:Q,/.W)Y M&Y&P*;X%R[L#3YH7WU3VZ39([P4SQRB\B+EF/,O;=B">Y7XB=0[R+.<( [;9 M- 24@6B@&]5IS11(:K0"/PX@O'!EK*F64D]) 4:E4U2_*HJA>QBI7%QZHYY\ MW<5Y83 &:^Q.[;L"Q>/F?J!B0E#=@U,-3/9^NMWUAO110S!=QV=^77DDV"TG MU!0JQ+@,!M(X3(T78Q0?#7H??_?B!KTTWU0LS>;HH95VOZ?5WY1^5;GDHW?)NQP#._YW#2A5CS-3<- MG8I;)81@FPO"V??3\;=Q,9+_.=J@[]8"N=&M1X!OJYG$#.%[H692(UM>(0F] MG(^1-G4;^0^'R4@+>4A8]@'D^)9\%8.W;Z[1Q@8&Y&##J%]DA_\1A=>6B MZG15K"=4 O[FF'KOP\,TM!4FE5V6-^Z[_B4RV:6E_F[P>OGBO1T0-JB%II#=&!YWQK]R5W: <0BX^9X\H; M$YKQ< MSR"_X7PQT*>7AWDV3S2TU+*(-HS"ZE*7^:[;T8]U757W&%>72 =4QT02GAQ M#)L'&7P*5!4&GR^3O85UB;)#< 'L53!C?L\B'G>(X5/I;<4P2>D8^8Y. 1VI MFW&UJY?4\JG0DQA;6,WW[K(;?Z[MBGWE?*G_XRMO<-P!) ,%!"*BMM\PSS&_ MDJ>GG/3>><-.MBF#5J/(5Q?4_JK_W#Z <*(&"\MGN'YHA:W7+4?$2LZ0KW-* MI_BNP&+P<\64P[BY?!Q@C@+/EN>R;ZF(8PQ1H.&>BK7-%"<7YCS3Q=RA\N YO/'J3++;S9+\*+H\9;]6FBF!UR\&-U4YR M=G95O,Y5&D+R._C*]SA6"PC;:"KRGI#D KWGLF&$S.>RO42S"\N[)IY:DL_J M:RB4U1"/&13P((A@)C1?M89FC;D$J%+NU(K/)$Y7I7T 4D&G<*S@5F M=(8\7Q:<>Z6CD5D[ST/3?P#_-$Z-XM+!8\MF?+.$MW MWXS"WM71+L+,$@CH8KG8^^K0HRZ8.,01K!UP%-G?DUN$(;6W*8^HKSM(G@VL MN#3C\!V=L4/*MP$V\JG[5XZ\8P&@%-=Q>>-?[1D^)H0YFEO]I]LB!HF(KMOD MITQB0O:Z1#_7D1+;1!D&P'Z"Z$)]+G=+_K*6N,L90"ZAUBC0J&K+^3&9YB ] MNFT&=8)_U8 MX\5!EV,(7F3!HUUE*F+G&BOUME1!/>$R8RH,A0),%)<65 Q[C;X4$[!G=IIQ MM6P9:9M?N@SG %2>U-J.DS?MQ]5+?.8^C07B3H%1/I($\_J$\ A<1T#;<7)X M7RY@F#PIMQ.F55A9(M<)2Z81[U_U#P'F **.LN;.TMI1^^_A2E@,2<>; MKMWQYP7F&J&#>6XH IEG -<(FD2_M>!I6@=!+H2=.S.T$K=2?0(_C"#\YS! M=:I]6C'S+@*1O495ZKJH!3SXWQU,\9PA0R":=>\L%O:FR8VK79WS349QZ:!D M/IFZ%8*9OZG0Y !]X$^:\9F4Y707F8G[^\%[@BJGY5'E3$P)L^TG(MR302D8<9-,V0D%6_:$&3AZ,J$J%G82:S*K MC:CQB*NC\'MJX;O$UJ'Z;\W5Y?YA@*L#F @'+0;@MRT+S'&HD52B?W8[:]*=P,<7I/V1PB M&B&X33F2Y_NQ NTLE,'3WE[E[+P*)3#,Z[^6L>0&J9W M9;RJUEG!,M:CB:$(+E&KIH)H^/4E -J9"QCLL]%F(G?J:-#CLS]MF\?:5*_F M86U&L#?5"^F(9P<0JCJ^B;Z3.#=XXN=C54QR=W-N;.#9VGUY#BZ7Q2_V/],C M%UB9RTCK;-Z3D_\OFD[\O% []"FE5CG"G8I+HIQH$V>@@)TLS&Y45CX+LN&1 MM#T)#::166M#)E9T(9$V^;WOT"_W'%+O*_MJ\80O$$$X#X,#5 4X"*\P>G/1 MG571%'8=%=UA?--0N 1HJ =$901AOTAK-J1G2J2E!F7D6)5?6_QIIM45R]N8 M:&-8.GP%ILI [L?A[ZHDP_^#*X*C>Q>P'& A+=U(.J6K[3+H2H7RK/XN+%?P M\TI* M#( MVSW7_!2)[DIKK/U:Q7NV62:]+">KILME2LC&+U.PGSM *T%G=&\<\0R8QB3[)RBKMOT7((/,W=IQ@= M\B ;S=OA[5J\O..GA_9P]SE\1F.G'B >594BBGO%\7L.7Y'TGMN,0+ Q)59( M(7]80CT2QH7EJO02]$>3=DD1K1Q4'.<*J3FL>TRH9G)F14LYPRW8WT-]O:+N M^\3H#>!KH.\Q0KXIYX/"W([D"#(N$=H5#V5U<3]<2GV=63"K6P.H1*ZW>I*3 MRMP#BU:"EKK/+Z,KQ69,S3]__HAOUIP-6TB;&:_H>G753]%W^=9--IEY! 3D MHVFD<4?2.3I<>.F+L;XX[A+??'"0D(F(4_N@KHUYX%.Q+1RP_V!@=T0!5-I4 MGHM:/^T8\[ZY*?;,K1P;;Z8H4!6E(Y0WB?'NF!4?PLI1^Y7NF5V\ DR\+/ZI M)?LV@Z\O\&&]EFV&K[>K9\V,A>ZWOF.M=TQC"]\0C*6K9_.>P+U _)YH^%=4 M[?'Z'%EP9D\="P4K:+>BQ'"@46LPT-<)ER'ES)+//"//.KM9CU2JB\S5/U.+ M(HM4WDV:E>'I_! AL(K@A@LRU$%=:CR+O>0 M@BX* 8^0@MMP7%B^ A(1*2: M<)7R6_OA,;*WDMW*'*09*D;73**R!UNQ>CFP 0>\I2]O0.2*%"7G99=:SE-)D]WBPL"AN+G>U[F?6C1 MA^"4\0U5#'X<\^21/:7P<82P#H(>M'-T)%R720A)I$2O,067134><(!GT[D3"&^0B\NC7 M!9%M$<7>N:?"Y67&7>;Q/%JNQ7 MXN8:_]5TPT?C),,U&-PDN'CX ).W$?"I2E#YP:+D6ERT**(S.9I9& M,1QICEP7EHB2*F!TV>R*:'B97SZ[/R.G7 MS8_FMY0B\EN6%OCUQ E()_(?NZY_R.;6,1L(!'(X5Y__D/A0MQ]__1\>0QV^ M'J"?\\NG;C6K$F.I=$W.5X92%Z7S2^RL;)X>C0/)FTSVX;TC*#"-X1J\)Q+^ M+0,N\VJYZN[X(G@.^+M1T()&/L[N&,(6ORQZ_#+>(.@B[U15C>>[DZ(/T@I_ M-OLDL%+GO7>QF+(2SO$OWI4^S$ZJT9W% MQ%IFH*;534TUFC<)CWR*TN8N=HMW<[[,5RE@Y;.P^>3GN2?#9;\6]]'EJ!D$ M2LR%9=49O4+C^>1CH&_W*_2+V=?('27=[76-_?+Y%N_0Q\VF;J+?A4]?B%:5 MG8VP!9(CU3$B%(5/ZD_SX/35KAKVB^_WP@RVQ%G1 M2^(9'LV/B5KLI)W#WH"P#Q=5J M'>K[P>$[&-^!Y\"*O5NU0GI]-/8N12::6HR<;HF;MJQ+=W3\*94FU<(Z0(\8 MW0WP=0(0G3 6O7"ZC\F!/@"!2B%,;7LJ^=0YM$+GJK@PYCXFY([B4+&P:V9' M;HS._N*0:VKR-JJ\$?N Q%.?X8T;RC#9)F"VD"5&5WR M\_$:[TI,A 482E70]476T259>L?(I\['=MHHZ0!B&>'R^PQS*NH7S7/;0I7Y MO6;C_M^@)SA75N:@4%'_%N5VQZKOIX=#,'RTPS.FH="$_S&=J%Q,^::*A*9^ M;76-9@8'IX+NU^B!-W<2C-9X_,8MKT@>HV?LV.R_.8!XOKFO#-?!'@:OTI]M MFC8XZFKLT50(% ZPX>;'&H>")D<%73V'4>5-G_+NKE$G#J-B4YR6@_NOUJ\2 M6;Y4Z-IO +:#&WVPE?P4?[Q-F"$U6@=5V#,@40>?,B[/;8UAHUZ^8P[[<)A_ M>L6X,M)[6\CW_/.O!;:BNM=&XTD:Y2D5\GO&/[QU2[-+&$.XXEE57^5= ]6[R MLR#)TZV@_IX:EA/T"Z;-:.T9T-4I$4PA4%NOF53K8WY1L#C?*T-0Z[JUB^=N MZG7B![2UMKW+.YNFAC2;*[O(.,@<%LJ"6A !MJX*D%B0"Y=,O&^?Z,$\A6/# M!'7BR/,WA-S,1'-WCF<7[[>B:4S0/KY*<^W9SN8:$T6^1YF=N^U6C'^_NFO% MDE3LH#,P!'[ 3#)T@'/TUZU"\]W%G9*2<#DABL?>^<^2_VD%[320N_&[EQKW M[-]>P;Y;@)ML]'Y@@W#/%I^Y'899M\BK+$2.-^G6>=5]?BN@%3Y1@2S-/LM0 M6RZM\]K3\MM36_[?=O[]H!Y'%"$45>;Z<1+G:VNS&H:"1A/VO$;!,MO=-LGH M^@J5!F05:UMG:QB)O;&?]:^":8(=L'( $6CCQ*J#$66./>E#7K.*0'ATN5>L M[PE)&_Q.VL+;C'Y?P<53[;_5;D8]C'F:I8LBX)[C.,)YT*-H&$>X).8B=3'C M\5>EA8R(ULL%8(C"U)T+)UQ ]./Z]= S4@[8C!9T#H]"N;[ :YC)?Y+O8!7" M1]YU!PZJ]Y?.O4^WZ?>,#1[EGW/I6(_HF$&ZP /-X4I*<JN2+;31I3>R^&!,O_0^[0DTU2K_C+_0M&D2K2%8O'KL<#3 MPCWY.5I6;^_D7S8_)V.^VTFT^O1Y=%O,U'&/Z]H$K9?9LS.K4*8]K? !R5%F MVN?X_!5'EF.,I)%'0Z9FE.==3*%!8EP.HA/'!1<'11*(HF)AT[-SIL;\5C5$\>=?2H5_!*7>#@E8=JJN M<.%?L8P,&/DT[LR$NEI53KOWK>.MEGXM+#PJ:'0FCVRS"5) MME*(PXXGVLH>J^^D(5DDS5T<'AA=90VU^GQ,NRW0X+. =IN[0DMUZB.#BT\N M)KW^+X)8=&B'*%R5Q?#>DV;VX7ETKOK3!B68@Y03K38T[[]MHV&5JY)'@/79 M$MQ#)VTGRNQ7MR64D_9"06-+<&'JTK?' EO9LFSO&)$!MVO$B8IE\G_ON27W M>0](]@9^6GNLJ5*A%62UXU_VM.?VRD#V2/A H Q'H;*^"F:^_]&-+-WWG!I! MJ>Z7!T2S]9$Y,,W>7VL3D5I?+Y76_KQGSQDF'WC+,;FNV%S@LF-\5KP?-C>B ME8_%7A#/Q[/"@&9DJR[K#;>#VUHF-$HM3/O:B,]7H_&"9(O1_^KK')S=KBK. M6F;ZE+J_?'VOY@X+-2,P GW]2$S3.#6 MJ$$YR?K*('^# 3!XYL9P3>H=!7S[5EXUIMRQ!%G33[TQAI6;^BJ&^R4I"5.C;5W/<)'.ZD3AR!? 2%S.8>KAYY=NN\><(M MSU8)6$GSI@N&1)CFL/+ M.;)#6_TX"]/I@,RSOKQ]-G4M]:8?[C3F7*H\>LUS!&TIKI@D2HQF7*8>0$XN M:V0*16[IP@@A2D\SUD(TGA9._B3;O&EJ3%^97R,_SO;U]O!=FAG4_=9SEJ^_ M,1/]5NW510FRO&Z%G?'-P-+FDP_RWJ][[1VSK+2SM-RIC/LPD9275S21Y./I ML^UTHHS\(GC?RMR(4OJ_6K=[7]^9N MIM'4CQ>UR4UO8K<=*9$HSD"SQZ/=HLF$9,@*7/:3C_I:JW[8W";WK'=]%76[)OKF?MR"UV0NODYVC8VCMP=4'Y;K(4I-QS_%0*G\)D'RIOD2#745IG; MR)MD(Q^]7="RJ[?-F&@0M*NO__/8[H693S ZB#-(D/28=.).#GEQUAU3_ SS M)C]3Q)*6KA'P4L0^XK)X??,6H@;1P3_!^].YXB?H2[T?GY9VS^$Z MF]G>>:GKMN33)T[TS#0);)L?6KEH_/0G0CY!T#MSH;3VT7?2Q3[76)-+,0M_ MTUV?)$F=,SEG9R_^^*3Z2$(A?YE!1?XYF;ODD'MO=5]X^!-N#7Q23+F4PVV. M,5Z<@MMD6G#(G>VU(IA>Z//[16@R.96:S6ZUF"I][IR)ZJL25P_OXBGRY.2T MX]240X= 879V@>HTV8$\+47P]?;Q/4GD%-RA2^D?Y9$RY/1BJ<^9STPJV<=_._5I,':42J$>U03[J2Z_=M9);@) M%[(.XA+^]_;_W!3D\[=NTF"=^*@#B*":.TME=!U #F$,:<=C.2O\N3/F85"T MR^E/#4WNDW\T/JX\)G&@'P[G*A77J9K<_*06=<&V"1:%J\EH1T0$L4BH,SD" MQ\647&EX45&9"2]6+\L>O+^;F/;*93_3X.2(8^SS"VEZ9WP6WJ,> MM>OJRT)^LBTXC_V^,9%^LLC15.W;LGN=4[93<[K[:ZN^E2:3"REE3XJ3BI]^ M^#$O)&?-IBF;?\[?Y%R55 /WCTL) ^E!*.FO"DOVF)Y+6%J;69IM_X>S!C>+ M/BRF/2*_253Q$.E5V\_1$G^9FF\VFE H!/Y;TT9AO[E-'3S2P]3=3V7R82_$ M.Z%$L&JC:O')HE/H'-EQ'4M7E62U&20%-8I%L)Q@C8.7'4L//II,A.]*2R^3 M,EY5U[4TU\?>V4: 9PS7<+3!J25J4#S\#-8:F!F,9,I@D:VC5H,$C0KGRJ43HPWI'0N/]GDJ'.-K:;V@2&JGCC M_>.2@7 I1=DN- &+@U<:A%*'1GX^/88 MX5)KC6+[W;<\SP;EH.4$-AU-N,J%;JN\TN'\A.Y?-HO==E56C]X^'/M@P"\@ M7?5--<L-:VIX*XSK]*%.!3FF'/@]7H*O_H* _DP)S#X&/ M?]NV-5%:UH5(K^R#_Y X>SD& WZ;GMY;&]^*_$='9;]U!%U?+Z2YHQ2_^?WU M";XZDHUMD4CL6S7/\C)_NS+G]UKK4]&/RN7> FHHW'0EO#_S[AN-X&O"3IMG M>VO>JFO%U>G ?=,6IBI.!K[RLT$/?_MX:??6RH<& 2M^JG5:X^_&!J$^3%!' M&Q^0$:W$$L@XSI^2$D!1KH=LKCLUF\_HXZB:F+>(-2^YNV"*()#PT&+1R,-" M^O["3!'WR.7+3%[0&UAMKYEU N7:)4\"@3WO^6U))$D!H/(I=6K39WUFX1G' MUX P>*_I:]?@,Z_.%J&E8V=F^"_R.8\+I%9?*@D-Q]K*HI!9)7&+733W[=(D M\P=%$/]4FA-4$J_)QG=ITS?8V7OK.LY2P M(EWI;B9LA''5[=B7F[GHA@CK^D93QQ01A9T8G1*DAF=?JF)Q!!BXIQH^@&=7 M1ZT?0*)@1\.%0#ZGFW39!FKN,4^M>U6B-RK$2WQ+'*>4UC@4[P_W?AP43M=0 M;?OY56!S4C*"<0#9C5[X7][[69BY.'8^\,**2"5:3[EB8-5]ZZ)B3]+ALNRF M&2#Z^92E3TO6U808Z@"L>_&6?[FMWDN:?X+6,\+BY-N,.W D&W%6CI5KN03U1\\&6EMTN,WX[- MGPQ7;?M7=2Z\O3DW)CE>Y0#B!IM*6NTR>-SD8XMZAH,F]IE_6QOY*'HB-CO3 M4!%Y\17QO\4V_*C:YXO71P/VQ0Q&RP,2I8UKZD>W/BN8UC:,;LUH= X(--16 M?ZRN31)SU-9V##!2JO"A)9TX?3WN[#C_6;S^>1VY>;FUSWN7PH&F3YW1#? >%H/49.%7- [>6CE8X6).W5%LRY(9%@>NECCHX5$BYE"K]N% MBZI3X%7@R%S0VGZ^"TL">73"HB@G G1-'(.WE2Y2!R-T$'-[SN:A^IG:QMMG MALH5D]XKE0?Q$7UDJ-GK(^AT0?TT0L@Z_R$"AD+%$2QB7Z*'L(:L?GQC3GG^ M^FY10)C'L7M**L2;9JY+)VWX:.F&6N!-SSW(CQ+>.%-OGW,W3NW%IYYW 4A< M]):$W-5JH#XM#RWJ$:76+S5-V/6-5MO7&.B[.KHEIJ V6KYE*B%%%M[:,Y,: MM4C2YO#1X,"LS=4D*MV)_$__:A7+_J=049-B.ZD=_R!P:2* M*CNK6KIM/!#:GAE>Y_Y!FBUIMV>'HF>LZ'OZI:V1L@_GQ:M299T_YWC6TW./ MPZ'VF%Z+F'K$2;CH%/9JYJ_?EEE$VYQCP.>&A,(Q]1/N#7A\2A>PC*[XO+#= M.GHU.(#4$_K:/?U<]HB!];_GJ&^QUJ ND#^?_'P)D.M!13'9P)*YOOA&E04 MWP7E]&0J#27NE_9+U.VBFV<*%\KM)NC?G?2/_; L_';SN]/U5^7^O57=6-7] M-/P]W+-98;K*,R8O%@)J TN=+A>?3X,$0@X4#*2:<1C1W:LR_$_5TM43D](X M1; BM8&@';IG$0V#LBPG<]0F M1ZS"BM0AR3>$/>=;XC3==;NA$1]]]>/'I%^8T_>B1!X(&DO%O!Y.8Q?HP][> MSVD[&CX48I,>31^=6R(@XLGF;\[\6DY'\# $J)O">D7& =45H\OXZ[^KYUSQXKLM0%HHHKGE/6"%$6NO?TPX?V-E-K&K'/:6_F&-.36M^O@O:+=ZEJ]9O -)U,TGX6>6 MTYM5NE!'0 21K)Z4+UCM7@"2"$B5N( ^7:28:=^)0%-'KD>]S F*91S12A<$ZL)% 5I]SJ M2TW^]ZS^\KPI:>SN9WIXQ!R*XR?S;$O8'13"-K0"9S&RONT8/2ZWOY,W,M/4 MEO$G0];N;]G(AW=07K!C3SU\$%$K+IA^ )& LS'.@I\EMTL787$7I8 M=V0M*P?XN 56+#=DV#[^I3/R]8S@J#[?ET6#:Z!7!>"]X[*?=0#QH& M'_K!U[-58G2Y=2@@U\$\E](!5P"[ 0(A7#DJE /-T*P$-PE(VR8?OU+#H^0 M(2WWC7RNF5;2QQE'4V_^8>E!@2[>G@KQX9;04_>KA7]>) W-"S.2PNC.ZA]? MMZJ=W_:[=,-%-$:W64X94>X M%.,UNX8/W.A+&[MU[\8IU8XS?"^?J+X(ZX"E7=(PA_P9;*BJ* M._O.59__YJ'_VW9:[N/@?)SKB\.7YK8O+_>$7=Y 0$/L4*35J> UV9&_KRPM MU5H,_%*6W_)MS3/.46N&0OZ(;XML?H<./!^=*E[,]-XTJ^I2KC^ (,P)']Z% MTO55(_\?5RN^=7_/X%J-^-,GT'#&D5V/O^X:Z=3]0-PS,^;1U%MP[P/(H.SF M_B93.OEWG(4Z?BF%:?8_-Y23[14\/W-R=9!EC#(.(%(6^NKV+[,+ N: X-47 MP<)_5LW+FD.]SN?%G87\/[87;SVDW\FML/V%Y8;\]HTY@ BUB3*D1HZWT"\2 MX3R ;-KINW6?Z;XQ6WAH=YB\ED*'VWZA#C142Z'\E=Z]E&\QO?W"UB_K85RQ M/7:%D1W4ZDO?;()+ \XWZL"EA6*K+&>'\J,ZA[IH"F93=2=OR1L74)12O)-A MKV]?*)>5/O^-/JG3<.AYL?QD^6/7.,+MAQ@O2[#TCBKFFP$?U[7,Z9QZJ=0' M(V:]E@F?Y>/^)K?CZA%K_705IPB"RTF0 M2@2)LB4J-;WC!QS\22%;L+'XU\ MU*9%%I\MW6Q.:S0-O;24G6S4'W8!]M^K$\2K Q:6/R_/%R/>5R80%+_]RAPF M+$[=0K&' M_8BNN0"C^R%<%=J%;I9?Z+A0[^: MQK)/84>HSH591*Z_SQ'A6T1QDL:PL92QW^&OA:+JU>INAEP&]5*U8]_/4G]. M=-F^*F:_E94HSU]F\RKRDGG!=_37:Z?>_I@_86*YV#U__O5)OFZW:OO[DJ)9 MSTIBNFEG71]NS2!3EZVMJV(KHO/9K"J0MTI*)N*S35X4'SOW5?_/EETNOELE M>ABDPX6-69?83>=V5E)_C150_EQL2(NM77+X(73S9_*%%5[B#_)WI_"-X[A/ M!)GAJ_>+O#;'-B#S(MLL\%"9,DCU#WL('X,ZF(^):^WJX)-<7 MFI*'2KXB/) 9M?G6KYS2//H4A+'W^(36F25Q!%IX64S9\ZY]E\^B!Q#;[J$? M.Y-.AM45CI-WT/X$,G4U5'[K[_R@@7COJKZ$9_G B_\K2!15DPMV0T9+7MT] M+1U!7'B9._)4-S>?Y5VV0U4TDJ/Q#Q#3T>V4ZJ G:NL>MJ,6\7 I3->*Q@&$ MN_6(P/QROF/8Z5IJQ:IH3WE]!GY*4F(HPV8TTTW>G MJ7!?,(/)@9^[.F=?#$2W^PKVT>5#S[]:SI&ERT:S/:W-UG\?Z!@YL97B3Y,( M[YWUJ:Q' >,:5FS(4G4H ; M%% V)V//8#F1/CI?@"Q G5@/=,S6[ICE^=B<9=H*)GY8%N+I+EU!YA0>YNA# M'$/_>3GC^2W3N3NGHF)5H^&KX/MB--D-YX-S!Q !?(E(P/,I8MU4X28_X%]-%22KZ,E MW2.I;L:P2VNAZY12P>&EFR]H(YW#;+NR6<7DO\CP+$BP)+F33!;,04NA4;L1 MK&'U.(!T&.L8[EFN]@$JM*"(= I-,RI<<@;,8@H:I(57%(*]@X1FEGQT,:WP M%!(<=O+,.=W$G*ENR0G3^&T]$B@6L\V>SL7QK6:T8 =&QNW<'X>+,92!@=P] M'N87W*<#2&RKS0&$7?=S58S:I@A#'>!?15-]U[(-C-6-BDGJ"([ZDI+^\JN% MTRZS*Z(#A;@S?/V:4Y6R*D%LW7"A$<12QIC%U&(3Y!?\I^DE@HJ%%EFGC M!$-@#O><*3%.'G 3SY-K^0A6GVI,4OCPOCF)_$N[[WACP],-)>7#_ CC'AW? M#A=U0$()C808'$'ZZ2*5F/'@ 20#^K@%-#3'" MDE# +A%3:D12Q2Q+:^1B2;0/OI7(2.]_ GS89'* M#?.HGMPDG"#"$TJF$#)]UW%%X5^8$OMI:MK:R8=!N*/9886J&-+JN^^K*9@, M5--$9?FFNH3LKGW%NDS2!%=([TB?(T"M!_9FLU(JF5GAW2@1ABO] ++C#%ZF M^Q,S[X:@XAG.U&DBR6IV:)+LI1FB$J.>S*T2U<6*(.YFL@$AMA?&WR6-RD;[\WAI(?(RZF=M: M\PS9:18]RS:L5%X7!J<09W7I7*3INQ,;RI5RP&1#')=6KX(*-P9G1:K3FCVR MWXJ8R\>=8B@58_X/OOXSJJGT^^.&<1AEJ)'>B8J(TD*O(1EE% &10:27"$B7 M#A(@)"HUU+$ @I1!!$1*J((8$R %I8C2FX0$ >F)"!P@A(=YUKI?W&O]?_>+ MO4[..BLYR96SO_NSS[7/MK!;*WRWBG?8C_O MPT1H%;T49#N?(]K>PY^[ M"$78:=)K-S. H(L5&?1-4*E0V/<&J&)2=]A,&'!CJ.[>[?!A*H,IE6EY>,3E M*'L9*B>0*<>!HJ.8EY<1O4L9'#4@@V$_OF[*XMXA'5;"U-%]B%90=SS_)0XO M^Q03@HV&GP0MKJ/*\%B[(.L<9J7O6*S5-C6+I5A^LB]DB"L$M_Y,*+_S98QJ'YH;W M%;ITLD!I;#C=6B,XDB*SD4,?$!DPF V2V:GP*U^^_R8NH>IO8LG4$-IN+>O>:)7A)(>F(H)$1L)0]>'.HI<^T=W>*VOAZ M,+ARV4%+6&ETNU\K)(O_>FGZ/@\%#%Q<8HM=86R1B;_K\2,FS7L?AM+9JN3<*%Q=+TP('3]5T9\ M?$VQRN+BE+R9&;.5F!FZYE4Z-.R@+>%-S->+M]O=%[>]RCP%+@_YB#AT*!B%AH<%"IR5>SZ@Y-_6YQ?)(:3 M>KCIYG\P-R+3Z?CW^BS1K(!%HQ*$@EHOFI@?%B.PL)?E5LZ/K2+M%?$AFE_4-FKE_@@\%Z#9)LK<'[5R]X" V%4%0!;/6QGTH2"UD $_ ^\<+!DW8X%:%Y9ZVVB36GXVO@>YL#G_H5ILQ#D5>*DX\Y[YAW M]L \0&G]5WQEJ[%O(NOWZEEF MW09I6S,_U&X=<5D5U-^+3@O6@PA]FZ%9G<*J?W[W?#HX]>-/N=_=M2ID$GYO)+A,J[;7*@G=^[D.O/O%2'8R MPFQ$^9#IT0U.'795E^S&C9@Y6+RV4X@*$V+ P).D'U ]E8H!=PHJN'")#:$6 M7'6SYI/.$I PR&!-YBDF(S,$K^!9>^CPQ'[%I.(;ZH%2;/&X:&^^TH2NUTXS M)I30V&!HHXA2MG1Y[OR9N;T,6:V;L4J-JX7MTC="'NCU)#F2IG8R!)K/J;H[ MT59 P0J(-<<*"8G-_^I\IC;G82]83\F81LEUK)@%"]>=%^F&Y.]Q+9]D@:\. MUUJOFD5&RX5=KJ-Y^.?MPI2^H*X*UCWK^/PT^/74ZMO[)6>'+QCG9.4PEY1Z M[KXCQ-)W9>G YU(A.II8^GT"GZI%SU;L\K$M-K9OQBL@LBG>/WSW'$0J7# > MU0\IAZ$G+%^I,AK>/"J^GB!D/P\664!9_!/6D^$AZX4RJ::TT]8($@PH2-0' MY==ME!UM'*WJV1ZC.1"QIN"._=C<'ZVBAVD.\#6$O%Z,7AX43*3B_ZH>+ET3 M%Y="[6RN?@R_928[56N_\NNK:=P-Z[._+H7 M7A2-6]K<26*!4@F7T%/P%D0RP1"E=(A#PY%@NE);]Z806Y=ILS9=!3PYZ)[E M#ST-7.@CSYX;0WF5R+(@*1NB9)F-"M01UZ2DW8")F]/TBL1P[#_+4Q$NF#]O M)2RP,4_]V+NXSZ&36#/T#)AIN]ZI><25E+H3=$:V8L'E3]09D8A8*9XA MXBTF22\5-#Q/../D\KS6P:Y;3/E1KD"/^--YS=%P-H)DY!,XH3;-G42=;]H? MY,?67(MNB+(/?![8VE#?JF*8OH%Y""P]'F5T<"28^3O)T%,\:= _J;;]#LHJ M77X3 NX"S0\,>XQ(]"V!#!WJG';_.$@N1"C[7 D8[$Y?]JK^FTI-1EV3!$FA M(X^XNM\=_M-@SC89Y/ ]//ZZFY103APQ_\8M3'?'X3_QQP1K"I^KFM@\)K1= MBN=>*>!"Z^,9+@G:7MWI.*8U')N7:9Y<2Y #/$C44ADT!#EO 2"8QV]^?/?K M!LJQ3FW(JAZ)?=G1U(X0 $)Z9ZT.G5^^;]76S=,?\G RB]0[Q#TZXB)IH;]] M>H5+MUG?/ /D*7*^/"59,V.ZM5%@SA>3N\%"JNJ)CIP>!W7_PK8=S'1_?&AV M7ANX'5Z]@#ZS:(BOX2]:DAZ#)( MTR0=%0"*XTVOL>)QU>M1009X?7.1"I1ZYQD>60; XNFGG/.7D+-@^EH&;X]T MME5RYSPR*^R(ZR'ACSGF.W&YSUEN#NY)=9D,F&'O15_I,9.3J77/__[X<_(V MU?R$C&&1+^2$7,BI$N4!^-P+!3UB*J-JW8P98_:58X TH$,>P>D.0!5]D(29 M.C>U/\VP(8VQT%DUQR-O\:HEKK+L3>!I(/(V<7AN% H/A95I9W"+?Q&,C7W] MS8-#,#^KU'8:]D-*ZGP1,_[IEQ/;JXC/NUU$*EA$S& QH.,[RH5XH!0 M7BRA9";F&C#*,K!M'H&:S1%39> /HV0'(#8LY0>Z_.\V[%Q'T.>G:=.!'(&A M[9HZAXD),\Q._J.+(='%HNM$*?;YP_<<;F3DWT =\V"GYOUAN1ZY!MTNL?QN3%+:.4*]3*KFN/^F& MVL2B))/[#:FY*',))LR\D'7*O-NP]H*=G5&_3@YN4>JS?%_ &-7;,$/]D](S M^MFB13YQS4EJ/%3);70\.S2'Y#.BI1<>NLZ69(&U/N'AN"024QGK9O,DK$J4 MM<$C7VI'9]>D$IM^%A$S= *?HTYQ)T6B%5-BLZO_6;@9Q7*#D\0:1[3M4ZH? M'P>Z(ZA;'9ZC3P =Z:0Z8E\W-BN_FA\;QY*#@ 77.4]_N&<0%DZ!O M"^NSXKZ*\B/\.UKK=A['?7G*[SYIZ>6;60YVQ'5I/8E4.BJHR2OL&WOF+Y;67'B =;*2@,\ 98:VOG;*:[/YR)1Q!,O M?)Z_,5QKT^WRU)$CRJ;FFPIX\,BGE&=T>[W^_'6Q(HWD=7&TT-.FT";1 M^]9[Z&IT53^B%=$S8#.7^C#*'R]9$4 X![2Q3"@.""&""!#CTJ[O(D90'JD+ MP>'PUHSWK[^[9H"Y =D_&T>A=HR!*V=^UY?@#5*BI!&L)N"@EU_8]HR#34&4 M74,'2SF+[<]7I< D4%='4-)SI7*L# M5U%8K&U"@PB4;?M<)C\#?+E=/=%4>!A]QG33J^)!#&=*-,;"5 MY]_1/ZR,Q@A] C_O[K,=V]Y,41!F+=9Y]W)7!]#X]1 BWW@>^6MXMF5V?/RX M*/WJOZ=]V48 C@XZP?E\Q"5YQ.7'JP<71*K.04B0-)C4./LJ<\OYZR^,.-*& MCLN(PB3O\,?3^X*M1]PG*'3,'RN-&3F"YSD7AG"G#6[88 ^L_^:GO83S<0L-ZG$GLG 6!6W5+?R/ZTQ)G+[(XN%"]JE2V( Z8 MIL>D0,&LR+GLI-%[PYOU8XTW6FJ=4W^-IX3!=1F*-O,4>4Y/3* MV.1 W9E]' D-7#0SM#.8!2(;[%=E8WQMT&.5 M=AK?QX$ZI3V M.PK,H"6#I= J;NR_1_!27P"-GJ[C?PBEB@N0"<'-\[(A=(@,4+]O"KX\/KMI M,32V10"?W,;6[6+F7LY"F8X/X($V8BX!QM07P8SU>+KRVK?YT:^Z MSW$:V^]+TXE\Q( Z=;8I^NV^KDORC,>Y5D"G!KE0#YT614&U_/R#S5[MA,T< M4N6]PH&UC"2M"8$:V<)%Z6O>E!%-IQLYFN4P>>J"] ;"ZEQ_9(@D0TT>ZFN3 M1J&_&>YA-!1DJ:!I/'G>%T=[%HV$HAUY'[![1*$:-D]8-F ?YQ),_G=GAX3\ ML L06YELXQ#8M,[^%.9O4&CB#=>@S[ M:K[V::.5/E[RWH+7<$395L#2@1 ROEOAU&%#<,L1UVFV[)C>NUJ4Z<&?@#G% MXR*KLICYZ( \1$D!!>'A,D !OY7+-@W M,ICF9.,J;$NP*YFC"/ R9*]'@TZ9U06LOAY@7/1CJF\%EG '.SH,114;<^05 MJ.-_9?OK[CECBI#O(91%PQOW8XN9ZR&@>0'30*>9>=6:/*^?;FU8[362^+;- M>G^^!GDXJJ&=W0Q>\_>;N-$FBH!0Z%K/49L@ 2$-H[>2PH>/Z;/1#SZQ]OP$ MP@8E/=E7F >2J75YWZ4'H$O<9.<>GB5G!_[5FI3V#(.N,?OP=ST9I$0U*UQ"/5N#^RD(BW'5^M;3J(&SG?30VK'!>5-\'CVPGHP_B5 M_X67_X^%P451SM%SD-19*.M#7F(\(V/P#R2<3+C0S)S-%^^?ROX06>;?5EA, MR/*3K_LPLAY>/1 D7X2^6M=?5BDH)FHHW/:Q(V)U:A=;S@I-9\/GP-D*$(#( M#(\:$.TB_)XW-$WW?$P]@#-O&2YS5Q"$V#8V M#<\W#ZW=NX>_S.#/J>=<<$..#=-WPFU[4.*),)TO%.ZQNM-FO$1OHVG_--N"A?E'U,>DU23?I.;L!(67)UWM]U MR2D0T52B)PA"J8^:X3GLC)P"*QVD;AE>P'] M;/YP#YW)#[I2IW835A*.[9Y_LP"X>8@0>&"?F6RC]/X@V][&5B]F^]6,8_I= MH\FF)X7=7F3ZYNOE)!(4D'YSVVUKTS7?D QX.N(//>=?M%- AF4I _RP=FK5 M=AAVQE]!8$SZ#)$%2O0>4_O'"[&0AMI9-,6!:9;,MY=71WT&.FE;CENQ_)]HS'<7?([,_11J1MRGJ50I[=3 M5[UBW/JV@/Z^M%FA@"%OT$50:R8RE]*@.G0M%H2ZGT]2AU +77Z@]3*Z2LX1 M,RB.%@QWO9"0?O70^>(8ZGT/\),?KBN."B*MS$-JM4!A4IMD6]QB)+(H0]A5 M6.8XT-0\BM*Z11D_9F=VB&=:2:C9B4(&*YKEG(MX<^O3BJ_3;58[%'8NDC+4 M\Z5:VE-+[MWOL#(*4D[_%+)(3\X#K.-4)*#-UG!9]9$.L7]409KHGU;LG N; MN)'^;(N/;69SH.N#K@^71V M]2@+/HXA'\;OCSJSQ\V_14W_:WM5C.O_,L=<=M08WH9.?%0JB3*;J]9XR!;;C-9$6S0F\QKD*/F0A$N4@*PS5"YUC>*:2Z:N# M@H[F![5_7>P#'6\[MG7C83=((*@O-SBQ EOSJ":C-S0W0CO[0+WG% M'>O#%VI0_;,RVFQ1P"\R<*[.N:CIM1.)+Y_1WA?E!>?48.M M_ ?_Q 3<8P-HP#OA)R=^8 0Q_L5\/99?49ZO@9)Y.BW+8\HP& +U"XY]^6T5 M)CNZ.29U&Q'H(95#FLK+WUFVF:H^G_OWP8 5SAV8D \G3J NLJK30NA::8"!!@=!A48<_61.X.WQ5Z/ARA=SZ M\#ZC>VC60J+@C?\M9R1:NBXZ6*.7YL:ALR+>*E,1O[4;9!FJIJ[,A4&UBGP? M?S:T4R^7:>S]\:5;K4K8\41J)SWL"^5.4T<&R ,B^##+TOF^M_$PZ>"&/CR? M36$*I8!^L'[]RQ(E#8H85J;X%;!*+C\=/#-?-"]LK/,YW+ 6U8Q7$AB6+O"5 MJK[3+,=XUF@8T"-=8)F+&K]4=25/_1;%!W_$%8_ILH8:,1,IX%-XZ4JV]^%+ ME/6!D;\52V)JR9+%DQ)E>8R,1)B5>?Q 2YM5VX2>?)9OW.*8O1SD M&>DC]B3UB9,$41C419MP+,)T_4VXR/UT>*Z'L@;*17:NMR1FI][?V#[X<,S& M/*,:=1PAP"%!><>JX;!Q;*M''R29N,3<*6?TA0I-%X.@MD/RX!4A\.5 MUT-GB$UOT[_:V4_&WF_X_'@ F ]GP$]/F>D-]+"%^4G+H;]9F))R$C'B8?^0 M4RSN&@+W>OC2OXEG7]X+1\C.C>EHE7=)Q3FY>21<*]UY&QQH%",.\#[SW%M( MZZZZ!THSNJ^*G;?]=/5VR;E7#;F5+YFGDY5N07X17^F[/V/@KU.]M)XK2.)L M[SI+ZMT;?\AYYKRC.DGBS7P6VPSGVT*!3XV42QD91S6TY!DGR>4%&(T77]+0 MZ2;R8N8*XFS2=1$B*+O##MA9]CUF3XI?@@A73684R!6+FBV5[9-QWWM.#5"+0;2:82RA] MZ3H1H-_F:.Q17F]V*E?B73^ZSY'(M,1-)79V1 _L=@Y.]M$=R>Y7]A%\JV!^ MMJ-R4A1$O#@B*'S!XEA5-G2S',D=(>5B=1HY-?X[88'ZNW_/.,],302^%:&6 M?)C# 4JC)?2?;VO,,1_V$OZ$"0Y44V\-OJ7Z:5Y!<0X?HB.=B\0FSW=( M5YJK>0CZL&/-^)7-3ZII^&P3MT^5IDK'"(3-2J8U.H_\--[ZO+6F$?G,6_NC M(=[=4J52H9&^] <2FS<7P=[J=@M-D:K-QSIP:^8%T5-494\BM+(-E/=SV'_M MSZHOSOA1@,]B7[^/@ MC4D5N*ATV0)D8<;P.TXJ.R8&I M(;O-;820/*1\SMD1Q=2,FOD !;6H&E.:\O1VPC57:XU.(Z?"GS]/Z)A+[""Z M!Q^!FT&44D#E5 5D'7[@BIPF$V0!T]C:P!T:+PP$6/Z8^'/?-&MM+"NF\EN? M['2 L=ZK[EVS%ZY/K3I8CAF;ZI#0Q0]#48 N"[.;RA;O[7$A'B9QU#!>6 \3 M]2!Z?7D=Y8^(]7^G4'\QA]W?KSF+3(TYGS<1[MI7W5$;09F\ MX7P"-_LL)0OP7$$D@H76@H21 MN@W\_!*OZJZ0U("6&S?=/42/WLHGAR 7!671_P@7*;M&,$EN?,LV5>NN;]Z.%M#2H 0U1 =\,XA:"\^Z^<-Y?02(SI>;YXOMQ'* MW<61]YG!."8YJ(HF]R>YKK+U*_/W?9VU;30ZG?H%V@W]-W'K2Y5.WA)%-0 MXG.38)QE+V.QQT,:!"Z8KSUF_@=JL(LHTV.899LRCKBX DNG.JSG6#1LM)7K M^\%&=Z?W@6,RWQ8K0L-E2;$ZNO=K[KQTN)7\]SWXOV\>1F;F_#0ZA/<4IBD< MPKP28L^ >N3WZ0^_SRL=#/Y[B*$2+PVVEZ8!Y<)FDN1WB\&E7LP6!4D0=H#U M/#,ASM#1!9EZ)3=P>21+V>/5RAO44'K1]]&G"XCWS+9389C?/;4,%83HM3G) M3,.9V^'M> 6S?,^F?@U%:3FH9B-YM"SE297*JJ!EL:1=GG:NX56K@OH8=7&) MK1]P!*L\]A<8!XQCHR4&H0T(W,0SW)8AT$L50Z? M-_-@7J'@P)+S"=-BT[F9I* .O&#DI&"F1(-6Z0FJM]^G+%DR-]-^??.V9'(: M$RHF9P=\0M^0:H"7%/E_LTX*O.=_035"1^8R?M8FN/D("'GF+Q4XJ%[L\0RWU]20 MRK=$WK.WN-AMN7W6>E9#^!D&RH*3V! L7@F17+,(;(!?;X6 !S6E9QW-3F#[ M(VJ'4[9J%6+SYC5O-XO;G:HQDTRLXE'Y)[=ZY,T[WRI#FY_3.X''[% *Z# & MR:\)/*@@((!A,_E^7FEAX$-*#ITFY?;MF__^8E483N_M8XF*ZA\PB9%?";X< M^9R*B55C]0_UU>^H5_?]7Y]7H 9^\.\&M8*_+E,![4GRSI4. Z-(B90]_%;H]' M3VW6!*'%AJ(%K]W_7;!.[QNY^?1O#^Z>.5&XC];_A$1(=A<9,23_\'F>+=_E M)TT-)TG3!!Q[&#IN^HZEWR?DA/P;C31\LFQ[O+0S^]3Z+XW>UAJJP_:QGKWQ M7$BKX;V*2V,.8MO'(?,$"#,G)[)(6=+7#?[/7:@?J<@OI4_SG0;$F'[OB$NS M7SLFD:%6!7G6-*,1_VQQ,MA2F^+SM3RIGZFW[%6>6N$@:O,-[G))\M]]T((5 M(K>4\+_FCT]_VLUG[P2R5PZ?8[X#\+ER//<1ESAH;;3KUQ%7LAD,<^B^[_BC MMC06,^B+^XR;Q'!L$CE\QO&@TYR!A/!QCK@ L!9)RS;A@".[,3]O(HOV-4!] MIO#O1#H8MO2=('\&W]&QA_10:XM M+86,DTY53[BRU/P?7>G6Y=\S8RWMP(>(/B"L#&[=]0"&4O@"#6:.VS%WZNC$ M;!IWU*!0@ Z02H*)C+>\H(%69PT!;I. S7!Z_,>68%>'4%$@YF9[\[!&5%_6 M%>FSG*[W[XZXDN)_Y?!O<7@I#G/W]"/-P##(7&U(>#8=Z;5Z%WE3DJ$"U'8; M5=IWO\M3%K4=[_ILU'K/P?-!OU9@EIR#<51[W(=[>@+W^75('+/Y4#[@:6(9 MP]<@-=SYJL8)%EB#SGZ?^6;N8KB$25:['>AAK]\3OZ*@9W,-+1*RFJ]^WH#Q MJ_3_K!5@&68JN/*Q;5/*L!2?R6R[]'5,0,ZTU\[@CCW@<\3%QTU%*XP0 TMS MC#%=6:*D$GGF;!G=/:@G3J)J/HNOA[R[7U]%?U]!#+IXQ-4TMGF]^?UXRT&\ M;#SQ=, 61?<&JS5D!<.TLTET45Y+IH,S]JO2V5IU;"^6XT/=&D/"Z67CL0(# M; [%:D!M,C#N?G,Y!3(-U:*_@)SNBH^/J0]Z.R:A:.8:&PP;CL543GQCKQZ8 M!F :2]=\#C396D ;W9^M=7 ;=1_ UJ\HSRVVE@/F-]H!W#P&O)+6(9$_1^-= MCC%W8AD\:-D4F!ZH^C&KE:6AH?QE6W9U)RA^W=7E:XOKX,LC+E\;0!G\0#T$ MY5):^!Q-F*S6-5+I^9Q*3V9KW%H9P>//@ M@W:H&6.2.I/0N$39@95F6^4.QCV7Z.\+B8;?,/BQ"\LAVSDK3V'$\R-T"@_*]YD5E1X4ZHSWEP;AE['>B* MF#8F_^-6CH)AJ5Z732HRX]$;OQE;>KWYP\&(="G\/'R.R*^IIYV.7"O-TG*> M=3>>](UF*$LL2A6-"RLH].4I\F _K2X49*Z:7:3O/\_<789/@.EK8'[,7<1# M#D\BF2/#0A7:I.JI?K!R9V:W5@ 9I">K<4=B8!Z]:3!!6G@U)GY8>ABG,V OXP(69]9G/E4SI1 M8%G?^$)J9<7H-\KAEZ9AW1_J:^N$84Q,9'R8%_;&KJ/HC%6'L_MT%6ZIY.R M4HG?WF*,T5@U=-YP0,?91MA&\!J^Q#.'XBU;8\YSB7[I]MMS6KE0M:74RKDR MR\BDVTN'"=W28H:(), [IEX;)(W:1=3?%99/X+K[$1_YX]+_J:\L?F[WF 2,3YJ2\BYC7UTL" M+8,$YN*W'I?T[,_OQ91A:RISDH@AF,2.U"P4/YV(G17]VA(JC%R:JZ^I#60" M9J[X1,OA8YXQ9-5GA,_1,C \&]NJE4$FO.@SP,TCKK4.)?:7 74<]MNEJN^[G0DF.Z'.K5G>.X^9" IXRI5>F?T6)@:$LAR=,GH\3//GE).A1B]= M@ 38'^Q@0)0>>W><((3LZVJ3:-/71M;;\*X:VV1K?-L>! 6&N3J;DHD$HAQ: M =,] EC-TW[K\:2[V]P:A\)CCKC^6"=F_3()%4$Z@"4#DO5R3@4:+Z;&/7$) MU(\S3_]U"':,CV7D:>_8-E_5T#<@8_C0LBB!PQ:4Y$L4@H5+B@:G@EO&DZ_2 M2(.9A4ND4)'C'(J@@C1A^"6[ZV+$_#L6J^GR9C<)'4WOW@\_=6)^&1^VXZ:&Z<-Y"D<^5R\@U;[Z# T H5+,@DVAKP.WF^4(876) M-69&I(6)?FI*0%*VYP/*UR0M<2WI4]Y) TW]W2FR)]FYC)Z441VBZ,^U^V9F MJ2I^SI7FASBYC RF,)4Y*.D5H?*X5R?0_N*BF)8;'#L0L58E^<177+MH^ 2V MQE70BI_I&(.PSV7AW5 M(P_M^D_9'LX O <&J/.')5#8E V))OA7X2AG.D><_>>X3[X'D#S_P?,KX9J''F:ZWO^Q)U\,V&UO 0XG/.^:%6S,3NSC-@CY'# MLT(3(>@C7W0?<37X;.:@Y:;9=UE$+.'\JNV )&6YCNT:$)00,6\7RH<,FT!Z M>XQ'9YSKUR.NP-"I_$Z"!)-MAU0E'7&U#K-#AW3[<),] MC-TN4S$@AK[=DZDG>]>X+0D-F7 +;!,!=*XQ/^;8L01@BJZY3VV_M 0CK$?+ MO^H-F-R6,?_0<[N]+5,;7R[X3[@Z*E30F]DNT%O.@"E6Y7E'LFD&G6.?M0A? MO9A[U^P2>PU#+_3YCY"^MS8Z7Q,JTL2;%\U%'(.-854AXP>J*EFO790TLP2E MA/N=HC=M:/4V%KRU!FU;)07Z.?OQ?L7RI,'P;06=Y @Y$IR>^8A@D4@^U#EP0CD#9^G?('\"UBP#^H%@BR4Q.S<:[,P3A-U(L6DM%KKY:$9V<\G>YB0V6VS)(P^G):SO5W_DG M0-0Z-L#H[1[W#HR5FHB68=LR%8KI?B/0RTS9G5SF_??EZ$$%"&NC\!/+FP[' MHL57]EMF+QT^8[OB B\9Z\C&N2%GTEO?'6CK(OW_$M2[.K.FDG82!.22X $%A M>5PFH2H9'HQ[D$-X#1 M[OT(23 2NMKE/*N*UOKRU:(02N? M'VTT'V)IY('H/J>-3:OY]NS_8P('7*'90(TP5&R'^G%/1&#(PR_*/G5V?3+E MD;=&!;!<&9MDD#S*?)3H2YN<#4I0IG9HE):M8*31FBMOM69_8+C9.HP:YU \ M7 C[RN,$*)-S"=E\\]'*9G>AD3ES$1O$'T2XT.%/3[Q.^/6SJ%RTB.%W)>F' MYP]ZP[;6NQ3/S-<_YB+PA*3E*P0361>MZENZGL8C_L,55W)1'CJ2:=UW- WO M73.0OO*$:9B1%N9F]*@*2[$C,UB&_?9J[R_V1NS;X@K]8M^>*XY[[H93+[LT M5*5VU05Y[VK<*$N<.2%'/)'Z@$CYF M3(_5!U5&#@F4)4,M"(ZE[S(=&ADV21[GF6_KJH#F+M' KT$Q,GRKI7?&*YD[ MKS6FO(,8.7_0?J O#I43WIU&*'UL;&]:AR.T[*B/EF!^:.6\>_-) M;S,#A6&TMK'@9(S"JJ2GRQ&7&XN8%6T5&YV%L25$;UUP]LVP;LT)KG_AZ>TI M(-$(;%)M)JUV8MX.HRQ8-C< ><8G=K#\!WS;&+PY-"V4(\;^D_6J+N9D_9B- M $"CEZ;J'0#>[X)J7A!% A_/9,'&P@5'FE[I/SD40FA(E.>D@-4&#,OY,YXB M58P^W,.EA"/E@BC&48%7ZLW3J?2:.V'M6!6='"SL"X M&1#$0$A^ \8M6EEU*2\PE=-!?E287@X9+GJ^(5O^BFL+LYKU$@C7N[RST,![ M_FU3PMGH<,&6B '=1ME^92"Y-I]BNNTCAJZ&G ME:H@^344:L.4W(G^[Z8] &*4/.8=02F__J^I$%YV?I#/8V4L[6[+5U3L7(XX M9[A$<[B5]L>JZ,GF\3O6TJVN\N^;MK2/KP:^L9M53J6#IUC[P*;9U%CPP M- =^=SAT&SY90S(P4 =9F'\3*]QIF0_:L#]ZVYUK[J/0'UJ?]RR.!]*IXFM M**BP#+"*V9?II2DN'B_N1[<3RH6[##-G;VLY$31(#*:ADURHL7FOI]L!.D.]%;77;%& M0*#Y0:,3=!SLR(,XM>RM,U4$SZYVM^^ZT[2FH:-/1]6DL0I*9'3?D$YTL2'= M>P3% UB%VWU94=(>5.?&^,D#:>_(D]_P.M,VXOVBUYZ0H")J7P9D!6H;KV=^ M9+4I.3OG=O8V_BX:%;4"4JYZ-[B->P[WP4Q^!D_V=<:UI:2FV3E\8-FD1]O( MK.S#4W\]AUYB#G;+U#>=.W!,X8@!,J.+J5T$WF:MLRW#@@L+ PN#4WI6GYXP M6.OT_6A)?\7S6R7HQ)DCKM)NHO: )B!WP?OX@GF^6^CS2]6R1%(+&3#':;.^ M]B(:AKMUJTBD6F5D'GY??/Z:8>'M95O*K7+SW7H%JN\$.U^-ZE=P(T)M6C0Y MRPUM)Q<,[;H3U!M]JV+[C6VF[X*E8=S/*HVX]@"&7R+.@:!X,HWLF"!FZ\;3 M\G\*Y9CT+1X,Z8-Q.A?[OR4*BCADM/9A TP>:;E%[TF[^Y:UV]V7A3[B^I/I M6_WZF"0A,B2&_=>RD;D/[?F[,G[8>V>_OH3)CX7$./><7&Q\-9M0(G]G11_\ MCX?R\:>=Y8RXF#]49 EE,&@I,'46LDG2.)7T7AYA-ZQQV3\SIRK X_S8KU5K MGMM$[N#WYJ\)R14M_7.!$7_60(FCVW]]?*[\>W;Q36UMHRYY0'%\EN@W1P3C M+>8$,KA)1?#G/N&??K+O*\N:"V9_:D!.?C;L37^K>!)ZHRH5MVW\/-7N]#,E M.3>5L=?5\_9*ELF0Q?]6W4]'"P%5Y,DJJ7 'NZ+!-!TW''^^(W4!;_;<9V1Y MI/-6'IBGX%;W%:E:@YUD.>V*Y)!7/H]JKB3# _(/_!R%70%N^&F"(1OR?A0E M*)G#44'^MDJ*JRQ[N:H@TLRJRF!KZ@:[6KTO[+LU7/\KP<2QZ>UQN,8_8O _ MIW1(?4^_W/ZPD(/%S#TC-N/6'])+Q:Q9F_-567@$B$239.N]'T9!YA RJ,LL M1ZS>ND="I#.3@RM'5AYQD1SWL\LJ_35= USLO^>)!-I=99R5:'ER @ _^(Z(^ JI=2Q_WUK9([UR.1[^!?' M9;1ZPKF($%VZ' 3$)/(O[/F:0#N-44'9/=^ES=O*7/[NO%V=2%^+-A8EM]^F M?B5_=JZ+O=5C+B@C5GU%O,:K!IR)Y/UUC0$1 @[ %&@H=8\0F1?VV7\%&9GG M4V1?FN HGIJY9:D;*:32%^AU-M'>WV-.RMS(6Y_#JAV>#+FBA M?![-BZ[.(ZQ^8!_,V:Z4L P8/]8@K"R$,]61 )H.H:"YFQ489W2(J1X*& MH"&ON9]R%XIN'@KY91VRK(<1,0L*J V42;*"IVR[6EUKB7R-^0O3;)"*5D1: M[: 53HN(^8IC6WYA2,#6%FQBBFC0X$&&?4N 1)?W:8"99Y81RI453L]R#/. MJ\QWS'A-FYKQJ/LV]5GC_*[RYSD#.?V-4_%+IJ#0FT:#>OIQ0I&91UPW,<>< M78=(9Y5B#3=T>[4S<9(/HY3RQTA>+*G"=V]]"JB5RKRD283 4-4S3ZWEK_3^ M-Y7JV4/'09F= M=,W;VM"J"\5J"O#TK1)MG"N\9^&)4[;&YQ^+L1LZW \'(P.E4!Z@& MGV;%C=H:VJ[2VHR6TJ/E+^(&!J?^YP.FCU,NRT=RXA/9U?[_"IGWP'B8XV0, M#[*\TT-KV',,I3XOSW^+N4BLO,EUS T.+7F?-_3"#$C&/9""X$AIY_40[_3% M;T^0Y=%L&6;KX'KX$=?O+\?P5^=V@=@ZSA"F<:.LSF.5(#.NJU\$I':9WWJ: MT%,RIE_XBB#S08+U:FHVOWHY'#!Q'NGOH&+K @SR]T>B#WE'U!.?\$IQ_TLU M^J&I4^3-'/Q3"Q'3Q8ZV2]$LJ+N/7UUW[-[,!*A5KF!!ZFDOAWS@+L'.!NEA7^#BQZ=^;J MBS #,+-%ZYEA?.9/8R"C,^4VMS=&N\N\72E]@E3V#_#&E.*J M($H^*(*Y7!&:#]LN+H'''-\3S"[-7AILJ#[Y$+SF71E-6^EHLD6*A8 M#**+=OYUGBSYQ^R("^U]Q,50_8$9PYSRP'5KG,O:;D'9]\?:;[?$MEOT]OG< M_U9W_]LT,+@MNBS3@K@N)!'@7\06Z8V=E+_?B-\+MW"=L^__C MY.4<<,:! >8K!!@\XGJ@P'O$M?B6&,BA!!QQP9A'7+371UQ .NS_O0L?"ST% M_S$4#N:HNQW_\C)AS&O:]/CN"IQS[I])E^]>LV#$MFWB/Y>E M]LR/N'#2Y8>^3&].EK+P\7",]F/VA4';LLOR1USF!\DP#]X%Q*%TZ>=C-8"Z M'AP/6I<[WFYN,)4C#(0RP(_ 3?!4O'DH R*#'";?&$( )5;^TL*,=BW7@"E" M31 _8A*()\TJ&!.*JP*-'XY#K6J@]]\*.V,NSRHP-W+IP?Q7F9^3 Q1*RX 8 M\^$H>9GN[!N7" M3IBF"&GU+-B-#[)*YD!F-&X;XWMM5!;Z3 M]0%9MI3%22I\XN\*5TF'8IFHAI%+GF'M<;KGA@_@@FRM_),,(!6KPU'N;U_* M078X_<&2E%A$0B4<*A[T>KI(7[OZY&Y!9 GWN8\1@[6,H+\[OU1[U-WS./=6 M1Q9+]CI?=+D3;'GQ)4'@T.U_%2*G7-[B'@S]ETXL1JLB,3O(8;0)^ANMK>+# M+A6>?<3%AT.9O$%QO7M$FB.2WY>F-@7MN."Z,_X>[]AND4E8Z\"[H/+"KU;. M/)9SN+:_+%Z\P4*T]KS^/7QU \EQ9E_'/288<\BES?GKO(P:L +J&M/C7U2X M9Z7Y2T@&7IE!$T^;:PTJ^GB;I 8"KR_ZWB_\8WKM!LE M$)IW<,0% JI )*GLL]G*FOU-R*5WH!UKN265/NVU5?$\QZJB!6FRJM6E_IFP M]AG8!>E@MY/(:NJ'DVDI%W)TJV\J?X=I,!4@64R4LB-O[H+-##3LE2BX/2$Q2D3J^4\O4UO.K$1"CXP)Q:HC@Z=L1EWS@< K8)/>V\ M;/RWN\;4AKO'+S=:]R*5.N=Z?O?"1==F!*#L^XRO_;".&"KFF7+$]31K!&N7 M;?ZI3/CQD[J&IJ>E:AWRHU+'".7"^00%K0VFLR,'C^-=^E]QDX@<:J7'L,* R#+G$N1;RKN?GO2USJ#U#(Y->74 MS$!'\CO4PH$ IQ_#2^#CS!!;\U/8JB>/N#+A=%MD*%U.091EDP51@YHQ((*! M-%&\Z>N@68-LDP-501.;EM%M(W7/ML(-=1C-(>=&-J-SYD7\P&4->"#=B]*< M31O_!1[#6\W!UY:9\3O!S ^[2000< 4N$%!(K=S?>!\-JZI9G9HEU@Y(96W+ MAR+&-[?5/3AW$H/QVM\.LP?N/E8+KGL2(/YA6&J0N(4;A/[%^,2J$ATT1,Z, M:U68JWS\F6ZXMG"KZKFW@\TS>H/X%M_$#=- P.WW+>@]K=@DIE/@DZHK]O.# MQJ,+'C6'^5V<$SFIWZ@CM&F_K;#.X-:L7FBETB+ M4D4P6=G"X4]-RW--KWV=>O^NP69+'QA'A360AOB._?#,X?7_Y8?_CUW[@2Y> M_:_G)K$Y)KL6=L$=/53:M)06%==6F'1?, ]!PD"1*,_S"C/.9NZ .1TP_E0:&#Y MP!&8W9R'/(3QN "N\X@U;$+,?0ZH<5ROIB]4%N"GC._C4C@JZ'Z.P0C[.)\$ MN0;0Q&=I)&-,-E0^OJ*R\=_+1D/].SL&^5X.VX@DF%0#4 ;)WH![YDRY#,]! MDF&*;@/*5.+D+IGP>X)Y#XV;C=$;"4=.VP.1=-?U2#,\X,K(*%.GYE>[6I0' M<@1R7+!Z&%#_I] *\PI.9[U-H;93R#R4XU:BJ=.Y6;@W/ ]:*SXP0:%&@J-Q MQ_[$R]9AE)Z>N(;U8;2XF__)2GYYF6""_)<5D[SYRT:D]F_%ING.J>J4$SDJ MNI\&5[18.HIUMRI%\D$C=+>74BA]4=6R!RG\F2FE$KJ%E^=/[(_!]6KVK:'&[KA#E[K_+G]]F=$!#R>*L MY_TAL>D#;WP5%.:;!7S/9?Y\O>@L*1HF%^0+UJ3O: M[&;)K*X%H\_6SY9NN_^[C#F!\<8D-@0\6=F7)(%29B6L,@;,R0IJH_./MMS& M-IUF CLV/M0A.FC(@Z%C-@VL5KV?$WS:U2C"GG,VV>KK3H.8'+NQP M9L^Z0>V/XRR9Z$=+VK_YP?/ P%]!N:EC&&7&DJ1XJ#PR-4$ ZV]^&+Q4+18E ME3*S97.$V,;#T4Z*8_7J(9NHFZSE1@^ST,CE6?[#1\2[I;\!A7U4%_.N+) = MZVK28XQ?4(GA*-N9=6[WAE8Q"Y9_Q,4O2H:II-Y\8L2%]&W,GD6^ZNLY1Y!* MP"K<_[X!%;K^?2YN6[F1IVQ_O-<+R+C8J483? MU21W^S9$;?G[%/A*@E^,Y?D5?,F](:1JW-]L80/*=Z1X1M02^=7Q!'7WM M\+3(V+M2L//=842!L!C^\;[& D=N9HHBN.!+SWR3L\H[N:W:)=F\NT[([WOZ M%\2:U21!/D8J*1!]TIWPR;'@S)3?4D#BY[+>U/SX%VTFUF*+.(5^_[:XY>!_ M3D4=V^\AJ3\2WL>Q$&*<(9=3C2V!7G-,G((3DFVN"+NETA1=>P>*?+W-;JOJMO;B)JX\;DC=6F0E).*$,4$ MN/,A@ FKQN+: MX6P^*X.^4Q5=9(^!2&XX4'*YT1+446 GS#[2XUP? MLAS6IQ5+]7:PPV52&3]W"_RD)9MJTNL<5][%??1,ZFO0;9 .D=R54K(39JXO M/23>0V1\1V(8/%BT/'KP_\?6F8-2I8*0*E4(B"E52H20J AA$5/E42H4HB*B(D8D@+(DD@32UBI+@$A0LCU5 M62(S*N%()L,[/M?[Q_M[K]\?_!&N7),SYWS/?7_NF3-G(&)E"GVNY.F8(ZNH MG3L_>/NQZZ<;#_ -^.>3TK0 695WQS7?NFJRK'$LS^7UA;3P]UF_5-U1*2$[ MSCQ U$X1SH\V$^$!J9I^'O4_O$QE$UNY])J0^3[9]#SN8,^)925[52G&[;W' M>OU?'_E@CNBIM%C&_Y%+_-/"G=^^V8@%K)8J*%FK7"*N;+Z?3.[?2%V@_% H8/QQ^8%__X/4%\3 MC1P[_29][_F'@H%76R\>O,W8,F/CMI///GR^[V$UX]\_?-5S_BO]ZFO4J"*% M6^3?#]C!_V;)WW]/]W26_*H>8> M/PLI0M+M5ZFJ2W2G[&Y6^FT8\_GTV;]TL[J;<5]T2](TLZ]MW.W?><^9OIL: MZAGGE40?U[H5UXD*R7D!O)>ICM!3%,1<:#J*)XWIGQ#2&0HV70W"O@/F!X>P M;IQ]@[)Q/;="=E5UMJ="7";,B6O44;'LEU7G!\[Q\#PZX7 M:V:\*;5<2LY8]"AOS\^_=CQ:CW9;+D):OL!13&319)*96! ;SV?GTA(%Q&5@ M';).J^*+ ]B+03I"VF81-F^YQ=X"TW)1[]-WU.SMJM'#G47?-='FV@7L;VGJ M_J-0UEGR3=TU:?F9C+MP [(T(S>.50'< 9;BL$,<9LL.<2<@I+U)%%)_N^ M#[;1A_4HQ]V"JJ8(]BR-GB\ESDZ,%!9@SNP Q*?T]Z)([H7Q7'\W[_2@:N_= M/=6C(LO>P?=/W"C >TSZ3/C2:Y^EKB/SU!W_EH!#35T1I@QN?LP\:G#C>LE\ M/0@W_?;@Q>\-BYXM%,!%/A)T*6U%]W>*0O(DZ[6E3'*,!E:&2@^*K5$/A&9, MARD'+-?$5M1KMVZWZ/AG&[,JC=9(E:XCV^_N*;H-Z@^RO/+\IP@.[&#X:%U] MJ:4T[CY0/NV[#"KW\;;677[]R;+--$787?@?6P@LYIZ_B7<@=UCRKQ/H4K/? M(>REBK.LN>^XA)&IK:IOJ:L3&'Z,"3Y' 6%DW/-^]Y%3":'P3_W'CQPXF5!I M#BE.()C)K5,$^ #EO'BQY1XW$>IW.@3'5.F(N9):SB5]"[-U;P)GB?)VMSAD M )!:UP!#>R3]?(6+R\=X\7+85'CR*#?E.LVC)GGY67]-SN%KQE/5VVPY)[?B MK:K6L'=V0G$^3B:6I1!;AIX&%F0$)VBZ<<\#]F(\T/.#K75T>[8+.&A(CV_G MGT3<])H+M[O]-J1D1.UGG)+,&7+])2LY0YAQ^?WDMZ>JZ(_<)*M!#3Y)LGK% MZR(YKXNS)0CQ2YT7(#(37PG%X^4?H>>>5\;DMW&GLVD5Z%?PA.Q9%<4A.L=O MX)J?9$$4(S#[K"'$ZYMFB7*U'_>X"K M\'! K+/J;(T'!J7K;KTZ.*+>=N,_&EG%H:T_39ZQOALO@ ^,6;'.J;2[!.2G M> X:G _X",FD[N(>IEP@SP[.N!=/=4<$HQ:$O@?.OF%P*XWZ/GHU* Q#%.=O M*X]?;X0?U%VG]P]A%"73[I^*?ZX,"NX.715\P^F9(M3KT>F@"):8V" *#E-P M10HC!B*9'8I,$0K\W=QMGV(NI'WU MA3=?/TNZ%SV"++W=C?Q"@P>_UI7+>:O:6:D:-1I,0>>66L6(HC=D9XV_Y57)",X_U42LPGKV!'K84!SN9D]AK MX @Y,U.\$;8(SHF7CTP1:HGME$P/7^1XS&)8P_/_5M@<>AA9VHHMA;/D#JP\ MLD/\VSU8)T+ .IZ(DFQVGIC&XK9&&-UF(Z<$QG:YIWNL^VMS&-9_K[N MI&)5:)^O[VBU+I.60>MD^YL96&]C$4^\>HM>")9+%$0K=AAL+3U-I;"LI45? M+N^[@_*G&M)]G_'Y22?$"_&"=&Z>+?94-H<@-=6<@93;Z,:>YI 4TT1=]KH' M PW0J%IX M3$Z9CWZ+N%?FXN/+5$0*VSIR8KXJVJ'R?5]]-$_16F;;*>JP9W0-$FLULXQS M2-<])F O;#8#UICN@B8X5%9OBN_PW MOC]%G\4B*8K9O[BVM%<@L7+QZBYTCZX/7I4:&-)79)U=1Y[;\L^;"\&?+&N$ MS\G]/--TLO4BB]B/Z9(8N*OT)N>E1)0JI^2I=U7"H=\CH3**.XAZ&K.Z^_ZJ M3\]MFIFZ?\.*7':0OL#%;$[=4],3['5_563X8.WI]%L:V>GT]&6"GU /L/\Z M.@^D7T?]X1=-B*V\F,*3B K*:A":/K1 [ />C)DC]K?TOG7%?6A)(F%!FCOB^">M0WA0I5Z$E;F'Q.+RJ_[?]3-$/EDK)<7X>=1J8T!+[O4QT ML. V^HOE9G,B;#@ .AYL-=#(0ADQBVN+.0S%+,;A: >%Q!IH^V60C/S2E)PL M9%7_V.GG3OP:?C[^]\1<6O))/X?[#H>P;-5;C3'4[ 04>DT[E\#I(=0LV^X>>[E D02/A *%ENF!+NL=+]20V/.C M_VO; ]W-X3<2BJ/'G_^=G7X[:J;R:7 YS=(R18CWL=+S1L/@= -WM-RZ5>". M*04NDGABUN"Z&C&X<8LEV=EY'[-EK2<[XV4]%UN0('9[> V-TI'=K[6U_$Y= MHT2MA0RI[5WHD? X5)L2'M%DN!2.( MTP%< A>B*\!6^)FN;B(W#N;Q(B*0K;SL9H9PA+H6V29)/%4>#HXM^NX[W7<@'CO_25N878O M*H/AX0,_#1R,W/022#";C^9O$\H"0+)Y.VNI25<+3IL3X^DV%/%,=C3HC36O M9=&CP'9$H1.@7H'"B\TAE8F2VOIR9/D&]AH]<3:='ADY1/VJ$_/ZLRJDKK2M M11E>2? #Q*1E:6JLC=;PLVA$GS 9=R8. M7-.%Q+6[DML@7MGJ+C^O.N1M%KKE)N,2'1RS-1/MH__BG[:_68^TQJ;?G2#7 MT]!YPC;RHPXY62UH+:9+Z40@[3"E6')%9+5B5T\*D30<&:+(\T^*TM_7V+^! MH\>KZ\_>450,]9E^FB(D**H'.C)2?%K-;HR[Y,FMAV-PY5\RZD_+Q!;5]G(9 M@IS((F.JGJ:FMPKJ[:8(1FZJML.FOIRD$/!,CO$Q]D\>@<#+E9D^X@6L=!DI MD,_[),B6[8M/6C5N\[6J;(6/CU:*1*".<7I:&RYSF*J(*X*,?*B-KW8RW0-N MU[$7G>SOE=B_AB"BF,S^"M!U./H(\XPB/@X&G=CRF/#JF 37MR5W$M1E=Y&U MWDWYN5#7,J5V7=2+:>^F"',@)E/M)>,N@.*$65!]W*A*2S]?[&5DN-PX#+OI M):T=%QH@9Y0,73P>O'QP/4_W5NX3(*=:P]8YP3[W1\0+&\0EFWM7)=55^YJ_ M.V>WW&I#X6Y)]\^0]CH$[X7<.'_01:16XMD84B=T+,J;F2^P0U,, QVY@KI0 MHZ.F5B#CVM.TS^D[E3<[/9$?,7ODP._JLL;BLX'A=8K^-\V-YP9BO0 M]37I)2Y1\8*YV")6?OO@,OK,F.'(;04I 3E^Z4DSWD\11'Y-4>D=HF>G%>Q8 M7.&I0TKV%D TT%Z.Z;G2COZ3FX&SEI_'(79C[F#$E$BN(Y]/86 ^@!>&$'/& ME7$&P07,,TTWY(IPHQHY$ %/F+F3F[B M+"@.^&)KV%N!,[!69E(=K@%D[+':5GXN&6?C4MY@ 8A MSBV\'/:FVZQ+S0&VM#A=Z8^A&G5^KY22'W*?DM7M*MTOF=8% MU#5H5+PS-XR>\$KQ,.#RZ H?-HJ#8C M;I>HUTVZ=EA].8%*OFK8^3"Q_[)]@!1GV&_N0K68%2M6'V%,1:QB8)J4EBOQ M$%,!;RO8HG,/-?WE@AFR+8 M,!IKJ95ZHG/"=GTIM2,JR575 E>BCH7ZAE;!'/8IF#1J,">#*MW8&;$/.UDI M#AJBNH%R.%:F$142YPYCUHUP49O%UK"K"J$K2 V"A9_(>>H;2G;0 =%&, M9W=P6'G_<$#,(L3^)B2:9Y4)*O'>/@:>XP3W$_!'>!'@H'GI\AKDI*F$>2:0 MF3_*32+;X\Y]F&D'98ZA8=9MG\5!(**UP41= ,LC3/OBU;=+]:4>'=]UZ1\U M]M;--U:_7Z6]I.2V[N7&MT1ML11_HF>3B=S#'1>Y\Z8(#)K:22]HI1#_A,-, M?S4# 0S)$'8@"->-Y?V+/A>-@ 72UYN3H/8 %Y5:GE9YWDVVMN/V4*5T\O*K M%^+%W]7]9P";E2Q\R=[P4,GV,>]EV>*]1OK14HWK38>J]@K M8?-!D'&=M4[*K9W)0^@R\5Q8P&LK>Y@2PHGB.[-^!5CK@>^\VO8 ,KH7MRU&J$TD\R MM2.5[<)W[-I$+]O=O)C3 MUM@Q.F'@7_BRN>4'H?<[SJLT'<2WGOJUNW?:+@?UE42!=HZB*, M;Z!CF@*Z]10A;FP.YP79E1O?D0>YLA<;)*Z +I/,$E+G?Q_&+&<'E^RDS:V_ MD8Q0%(,S'AU\V.F4?[WDHV!N;G.8W@:;R_F+6V^M$)PM MLP>Y*7!3&UTDD)*S&IEYXH5;]*7>ASP6(O,&'>$>CA=/KY!_V?OP^X\^_GQ' MEA7N!CE^KZ(.O68([_3G1^4_)/;F>7^D*+CPWB@ND55EN@VGXK_5SS1HVEN8 MIJU(D4QCQ]Y3#]N]E48'%U@K-+;C4X2\+0HU$_6"'-#E=!G'37F*,IITHL_P M)^(TXGKE,J/1QR(4),_AVDJTMV,\$.%H*1)AZL1CTN@0(M-&/-40V"LZQ6M8 M =&@( 6N_S!BB,L*#KTYK&Z_*+%?A:<*VS;'37'UI_5>SG,2_ M>B" MWZS.SY!ZW_<$SN][Z%>NXM9/SR0)'N(5+DGJ@I7ZEMOY6EH> X[5DUN?[^B0 M!::VX5*TC9Z31I&-C-FQKDK'Y&M8G!=3A/!">20E1[@H^N?MI&]ZDDSE])I: M>N^BGZT?6[M_OC[CIF3M*1KXBBQM.8G9O-4*P(H6B0S*?8CZ(^V5.HNO0H?B MXIC#E;;6%,KI;B1MBD@U2,^E2[&=KA_M$K0#(Q\EII66;IP!)^?_@5,1.J]) M7@:!+B111Y'27C)-UX'P%ML1?+S#Z?A"?E^!J.^ [5%MM)-\7WAJN%R]^O+[,[;$D,/9T\L%GG*VE!,[M+GHI-'>*H,4]Q0I; MR'G%F6;)JDNR4I &UR'_YC@IQ[FY:4E7BR 9F3<8 /)O )6ED75?W-IMM##2MO#],' MKD;N%*@/FI<<4A-%G=8]HHC_3!%D&K!25< ^;0ZM')4%H$X?38_@2KE/H.HI MMA21%YMJS8'4:_"$KH'?O"=#E^2F3\W1[ #=PX= M$G1-4Q[]\HO\Z,0%;] M4AS=CTD_LG_[9\2/#[ZREK;$8C8C][FM6Z\#!K(6RBY>7_Z H63-I(-O(-T/ MNR9)[7?%LVC!;L$[!DD?XE0WDHX1U]%#L?:ES[^1/+].L/C=O-%P[422]O'^ MHP=U>4W%"S'^J[7RF8P;^& M>N_X]:\_'%H<'Q/S/:RYN1I;JB?J'[[_E!?(TA(7L-S]%0\#[[WKT'?8#T?. M'JZNR#>N'@ZK=/\ZNNY,C^@C:_%Z_63GGV_;IWV>H=, GX!6P7S4P<)#]VG' M7#@O!E=9;D )E N:1Y5222ZWEIF-08!^"&3"1P8,;_/]<*4W'&B$VW_S;4X, MT1 XV"5OE[\><\37&L/#K[FR#3U':-)4P3;#[V^T'$B[ANNF,\6A((Y MKVHG\VP0;EL:,;=0]@@L0VE$0P"L?W>[K>[?".]\T<& S4.GJI=]G51)F#2T MN$ &?=\ &3WB4]B??R^FT,$4X1((+S)E3Z"%=D^P9N+ M'_?YCUF#F<;F\-1E:;TE\6L8_/CL@5WQ*8R"3_E)'[V>"@8@DP9<2X-UU->O$ M%&%[?79&Q"Z86< .UQ?,'W;IZWK7>%MHRE@R1?A$PZ68O1BAZ6CY'#OV9J4* MIW#D[=D4+D],43;_.6I?I3.F;\5A7)^7SLCJ/:]R275R2\]//'ORZ)J+\5Y. MWUPFON@XRWT88 R'RP^ /=H.9V[K-O%B=)NE2#Q[NUU#)C9[*PSAAI')/JGG MV[Z;]%3QFGVTY ODA<=36B*G"'K2.5'T\G^23GQJHEBQ=GP\Y-)WDI[ 2*T< M4KE\[3$/TM[3B.KOPK1(RQ/V2K-]FQ![&CEO$C<@MW8(;CQEIJA##P$?7<&N MC[OZQ!OC!3/?P-?@!G3I@;Y?2(-+\V5I1?(2G[0,^Q=1]9=TU;F Z=(LH.=N0SX'@6'W&;7]AL4'F<9J-+'M4KLV7'=;#M] M?CAMJ]*'3=8SYX$XN5,8_$$^G-K@X5FRJ<>O/&EF;0BMF,"X.J$O^5FE07U2$Y4<5U8 M+[=KIPCJ/G)_WEO=+SR=Q)JF&W/ GI4MMUP1+PC_\N*'COQ@-\,QI*PR51^> M\)?NN']84'XTI=51_0Y.\'#H\>S[9&3N;OR!^.MQ7/V?#/JK,#+G#Y(ZM55R M!B*R,\R[.!V#BX#EY%U.%UU4SG8 ;L?]F+GB18#)@(N>TN?5\0D)5S$O4'UW M^_7UC6IZ3G7PXHJAR:3WO]'W/B[42OKSV\FSV.NT M^7P/K+61;,QZ,)P&R4>(.4R=P'%XBC"/_-01#5+6X2BW4@>1XJ_V'?;_MCGQ MYO#SN#L[VT.HZC=/V^Z$?ZB0H(X1!B&/>VSLS!2A-NX<-TDXG3B=O0)$W44W MX#-1O(HC%\P1;V![(>\KN0;F?/ (R@TDR3KH@2P3B7U7**<[O M/@ZI0\XKME\\4$JNZ)1H+U-7 *\*[._)L5&>&9<\+:]=V#^AI=:8-PX+')I3 M8*Z,ZX92D#"=,(?-X"(!>Y5XW12)O6$_ZL(,2.]2?6^$XTSU0 [M>1?X8U_: M]#_O#7Q?(;_NZAJ .KNU35;RL87 EY99YI9-7,AM#<=6*)L# M8$5K:HQW+;AFU\1*=APYU+>\P265.O_TC8>UN1>0D0BB^=XG(5@1:N29O\?^ MB,!F(F09\0Q]NM@+78ITX*F1O:0&L2[@^(&JIX-^//U8F\25#D*W*Y?!XD)8 MUA9X!*R7_ZDS-W4XDAVX\5X#=?/"9^]_6/">#47@\V$+:VP7B(67AH'#YL.O M6>D&E92K5NFMC3<,9#[=@3J#07=:#$H0@9[&2Q'8@^R/F'/V-<1;-WA6:W$- MRMC1R9C<>KNF.C(R:NCNK(+W#SPLU.N@U>S"/FJY(8FC9PIF80$<)0YR<7*\ M_KFB."F=CT__-@M1N]!C;A<:AQ>6?@=XNQ-.$LILB7D-/[$BHRQ?N4%V4&Y$ M>^18_]NSX_U^MGVE(A'A< M_DE3J8Z8+_94X7B9=E1O.T7@I;E_:G37\*@R?:+$X<_R31F) M]\)/EM_F^XML[SRKA6NQV68=/U^\P'*A[KGU4YXF8S2O/(#Y#^V?S#(*EL0O^! M_=T4(:MLLIB] [XY4O--ON7L%&%6X)#:NXEL9(*=OQ)':Y^SRC$;)_CM04L5 M]VB'6K$)G OVU_,SJ2Y=S3Z(1/I,F^M/L<.ZRV7DV>_%3B!"'GE%@BZOGPO< MVB+IV74A^[Y]TE=9B[PJYFX<>*[:=/^_.]MOV*LFTXZ#)*1JE;- M(_*955.$'P7Y5-\P(D^MXD,)7![='HK7S$._;'J< SC,@DFFE.GZ\IW8WH-4 M']VH9!W@YN;J2ZHWWG!-BY:E'^:>-/&,9G,TCF_.[!DB(/'(U87'9,3I4V6T M+).:)R>37@&23I+Y'Y"O_]9O/=(AISL-I1'SQBU!K1Q2P^EQNR,T.]8^>=K M/>E#AN"8.=HH>$//A[29G4"V$PYHK8XUW>'MMUSFN("RI# =708Y8G]+Y@3O M-W^->L/A;_-&V8?OL%>"%//!D;9I:>K(H> M0DHBS 83;#FWW/+(GW8&6]F)>;)BGPYZ KN3R%Z[H*_!#3@;XG-G!J?H-!<& MI]-X,7[=['2X"7/"1TREOEB1I.L*!*%R->WBJ22:="(R^V[(X\:HST<(Y$W8 M'QJWYBCS%M0*#FVCD=D;!#JO@N"O_>6JX&DG3U=%BTM=2O4^45^D.^>X2LXA MP_Q\GU/D'(_YHB[.8M8!51OF $MRRV%)WBFN$3>S=X^Y%=X?#9B-SFP_(GDH MP--6#H?0)UY7J>""\."D"I9T0!$Y=C:%:8_N7,,HFP%+SMS_1%S(:MH/KAE, MR(MKNA;;UDF/+!C=+XRO1+YPK9B:W=0VZWQR-LD$ULH>-9R3[=V4K+-D=3RF\GP^1 MYX;BS;+B=,:X@+>WV#\#.K+7K7K]LS_K.H,#A.]<#Z6>9!3GL7+*8V2,XT=^ M;V(W&31@"5.^DNK,/@[VP#(])/,)V 'RS8[87Y+:8_R[X*JF;8V&CH8#"J(W M&"+::+EE?M'0CIXY]5,$Q[KPL(,]A]?OTR385"?\O.DDDW%;9KMMVB=> 5=; M17:FNK!G@@KDF9X[FG3XQA8MTX'M\&73 !\=I![1JA#VV^US*69<3!B;[&[/+[WXML MIW/F\;:=C1S8TS,^1#F:'?2;)^TP*,*/.F(1LPTP7X)UAPD>,)FN0QOCUU&@]6253?)W,T M96N9=(#&HW6?BHJX_,)MQ!1*\+CKA3J3Z,CK,1G="OL;>D21:]01!G(N-XY^ MGBRJ;*/, *D*"1&UT8Z=+7,"2ET0TYE%D6*KP0U#4_6Z'3W-Z=61'>O><=RZ M3\52JRL&ZAN6%6<(BG\]!8F(Z+QAI98Y6@[S3=G41"SLJAUT,[R M;S3NEI>,6] U$NG)STL1NKE'A;74J;KM@J08"3[6I(]/"0D2$EOIN(S\2+Q(M\+Q,(>ZV(+W4QSE#%W$E6DN MELU!%'G4>:QG;9):H2R=R!MT C6P.1K.KKG.>B8KOE)6Q$RN@'ACHL]^+:EA M\>_'K8[>G;Z^ V&B3HFFAT"'5)J20>&7]]SH$?( ]YCP'!;4Q:8@^[1Q6!GC>J-&B<41*NV$8W)%3ZBRNU M2B^Q48.^ 6UOMO V>W-W9OO]&0/?:.UH^+ M-4G/SR6+[ 5F/ZR36VN=#QW5Y%)7 :<,CA<[&-S544CL=5TI1HJL M<;0Q^XGV67ZBT!IDTII[C<(EW?[&Q8L$8?4])WS]O6T?'[^?0EX&:O&"/6T1 M^$ _TM1>VLK1N_" 3M*JN: A4^>STG6F*@2*:4$DN4OC/_$=WGDL??+H2>]X MTQ3!F56X$W[]C^F2YW_4U+/.U5>,DXR&@+ZU?QY.]&PXMPD_:AK@P[YTM2;< M4I""!TJB'U-=9=H/2UJCF'-9NN",>^QO@):E>5?FQ4C_O\61V+$QSOTODR+> M6Y>'\V^UO!>03!6&'7\_$P?543+$=G]8CI_1/LKN MY)[NZM$ZV[V8G4X EC)S<%_8!ZSU%"NLNPP">(J503.H2[$_)6X<=W9BSZ?\ MPW"-XK:P9J9->C5%$.'(=3[& MR6-;+AS;ULW*C^P3N\0?^,"P3=(]I^E#LT_5(2>')J/+;L0F';T7GK[JN@W< M@,VFF'>C7UMN^POZ2P[AW)C*XK52EP(N$ZZ2:Q:,/\%SK>9\FD4@(V=SG<$6A K"Y@(''GP:Q_-KN5Y;SU*GL%MI:^B?L5> M8ODM92P3#WC61!1J/%C!CD!"<12.(]L 1:OIN0[O3C*N561>C!8S;$YBGX)^#"%028,KJ93AYGR_RK> MZW'2$;6!UE33U/5ZX9ET:_D8^$HA)V?'.( 5*9J7L?J.+.I:-!J\-0C/T&"> M7B-G3D,]'RK985KFK,H+MQ%F-L=GY%("V1['466T\N^KQ=87C_N'>.]HZ:FF MW+>Y.#Q?)_CD9J*#YP;A18G=,D0BA[("(UH[YGKEUA78L9>6HT= !M+^?-3O MW?T8%1X'SP_H*MHZLONB3(W7EG5%THSN0:-_322X#/^+Z\UE<(%7G+'5' X" M3+_TBM>R8RR%G!#V=R#,O.G+E@,>3[3,//JL<2/)E,1KC?D*7@O"O@:46RRZ M;/TD_T)PLJ[#+L92&5,H%T.]4P2=9R_EP6*G5[=<4YJ)DR%F!]0>X8Z:X1CF M-)9&-S': JLBN:XL'IUNA_TQ2$3(YZA.)3Z[W-=Z9VP+)[6M4E]#HOMKKZ0T M=6ZMEN\>&IGU]]X?K48F_\5J)>NJ? M0;8OQ"[(0@E\Y>"[?3L$_<__T>#@H91N@Z8C[15ZV@)T!1*:N02!6Q!FIK^[VSZLHR<)TJWIOMFH M$AD#Z'GJOLZ$-(_;T:GT-&?5R2'A 6;71-G7LZ. &NTMO1S$Q+'9O\JL%1* M)G$3H(6,04I@M&14 2=[\CN9R6KEMY MO3MXO?KRH8[$]&3?(AFG'_JR< -[#M7MJC6O!Q$ZQ:@LXV@Y:@\7M>=@B[$N M03V/-T4X:B3+M[2Y:G).I<"\\]:YN%,U[$#(.4?"77PV][U0QH3E#RQX[VO7 M(EI_;OL0>(O-:KW./H&,&4.1I0:!,0SIRV":LC,WPQR!3G..NAJAM0IXD10I M>3H*=:-.6H@GF,NV8^B%C@S)?!^_Q&?1-'EC'BLOS,YJ7V_*ZYAX=E#EZX3& MNG^F"*4)=/A;FGJ]H9UN+U[&5U>:CB-%%YLIYJ7H&LL5]L$,Y)G),]-P+%?_ M&W7^L/J?-IX\&I)A*X%QQNU,?6GL]N;N52D,7[>HQ/RJ\)@W!]_4]\VX4MSX M7CR.'4YY-5EI.H*7R-5A7-&9[<3^5-T5Q5/W*%V%T.AN7LC*-U453[11O1]3 M%\,7)HGR_;![0Y:Q.9#M>928PP[0)QZ@D5AQ"KNJ=]T)XH62;LH^&<-]4A3C M9 [EMD:S4^"3IGI\>IO7@'1=QVAZ13_;-E/WC0;^G=-#;U!D28Z&\1Q4E82IF'W2@,XQ"M8^::G^_12Z '?]WRTW MQ3,2Z;7D?%S:B0,14JH[(AF=,*\#5::38@2OP7[]A%[NL4J)QB&A$:#\WG#@ ML4M'D:JG"-CW;3>3,LH.TD'VU8./_,CV#)?BM.&(->YWT_76J*/2E(]0C"2$ M;[K0Q8T7]J_;AY 53%NVM9*=4H$F63(_:0KZ#E"7@XUPY;<@XU[BX*RD5$/9 MY>"EE:R.[QMZT2TI-]1;?TZZ__Y4N.O$GKYE,!I8T97R.F,$E8X\4262X3TX M$H\@P15H*%;#Y!685\7MF&'NJZ_OA!CY:F M6F6=FV7M!]J,&'&VJH_Q(U5U.Y0;T( FXP=F@M!V#1SN$X;92.!TQ5YT#=S( M\GX:8P^K^"CM)E>:?N<@5^J..$FG"'/K0M+I7:,I_)F^#?>!<$_G^(+QC:O& M?5S4/ONBRK#!UTG5RET_CS2:59\OOONL5V"S+??9WDA$^]@,[*6&@*Z$&R)! MN)G28-Q_ZQ5J!<9O8=V!H1?8RSF+0*+NA$ ;^[-X%F! /,XR5F&[>#5L$N@R MR'OJ"W?U5ON^[;G5>WQTU> _ELRO<0Y(BG;;@1#SQ4'B$E(CF67Q&G@;Y8S8K8=[G&[%VLNG9DFY(A=GCNP@; M>"CAA;7TG@J:(FSJY![A#D0<[ [>JITB7)3 >[P%>62B2BMHHYWW<(8K>5"< M<#8[B.K9#/*U)5,$JR%. $"J% ;(2VM/LSDCU$!X^K'."NYAU+UTFAS_' MENRI[PE[,#)&?^-=;GC&!)1LWLDOZXNXZA>4_L]1AK_00Y -R40G.WDZ;C_E M9X6$88[C2!.P2ZG1ML*+EX'S*;7P?Z+JRQ=T[:[_-_+%/U,P.V"BY4EF<9S1 MW24[^)M+]*$RKA7+%.WH_:9'WW4+X67[2>:*KWC<,J6E#SL,==RINTD/RN@]/@=ILZNQ'HLP#$.G4$&?1%KQ1XT\L%R0-1;K_=+US9.\N MT?5VM/XA82R'^Q'Y9?UOXR!/ + "]7*O)-E,&VQ7,$6 MHZD@%6Y_JY?DL7V2=>FV(=.C$B?2EO.2]'2GH1AR#SO5L"%X966BQ\K"5NJ, MFIXX)"!7*6N,'KP]>4*P*F$RI?;5\"3W#?\LI'T@<;QN*<&6HOM49%.(Y0X[ M-:"-FRFQ@N)>DTT0*$+LI1WM=!?J!GJ"&LI"O9#"5L@%75^V 7C:EV3<>J6A MUE;1[E7FBLSANY3;E$;AIZ%4K(W3!2**!RLUJKE1THA"58IR,9!7"#*5[\&/=0 MO6) Q"8\28;ICDF0J/V B<3*Z(Y)J_Q'FJ+C-G4=RR"U4UU[/C6E#U4??53T MSX1RC@JU!CKOD85^I]@W52WX$ZK>_05^*4S/%$:%GB.<(L;F(8 MW9V5VA[YRP5U:2F_X(1GKS]Y-C6K/,?7E[VCV#KG!//VHP]3A)JQ9;^5:DZS MZ)C-E=-W :;4*XR>YDC<<.YREK"\=0UR039W.A--OX5"L#";:M^/1L!94X2S MS0R#^])6;$:G7S1$!P7W00(6[6%N4S^7A9^\[7>5?XS87RF:-)NV6XK1C>;E MV O)3$G<HDO8#&NM@ATJP7-9>+"Z\/53\_DG2#ZHY%.$/#S\NJBOCBC9< M=CM=3*U<5GOT"Y%-$5;CP/")0WG'A7=#X*NK-\Q4SI<0N *&1OV%#/)#/*PR M^9)9S>$ZHAV(,YW#"5?0'K/:\GN*T#Z G_+^I[)RW^P8)R_$*^'8<70C$F&Z4*,,IN@.4F>R RTYXQ0^=Q9UT;!$ M[? *W0:0&VP_@D4JW:WJ$('WE]Q MM(,^Q9FXE@OH G@=CL)U$6^O9\RP:6L MUD :%1PVA\5+<-M(@IQ!0^N@3=\4H9Y-3RYG<3?!;_/800:)'4/YBL7;) A7 M^14$F .QR3=]FH/BL*+Z>H?03]9R+EA6.:I!QDR90&?>Q.EVY5V@KDZ0.)_B MSP"AK7@[G8!0I^%ADR_ MN";D622CKS/Z]=: JRPO;%8-O/?%@.X-#\G7^S8@(_C@V4,_"G*X-6]R=5.$ MA:P Z3F]YLOS[-1%"=A:N"/G4TO"IGO1K'0\Z\P1%>R%K%G>]*[%HB=*T>L M6G-#8MAO@P&IT:I!R=^^38(Y(!.S/6O>DH#-LQ2PM]QB"![11B>2S%O1Q6#@ MR[W?$E-N#7BK%_[K)6Z($^TA=%UT(5BZ!\2>K@17Z;;L;:*N_R 163_VLM>D M2?]ZO^%H7UQV4/KKL FS*0SL)127=C[D8 \S)EEB$:N\E+O#%.]P>(X M0Q0Q*[*G,S'MP>]%U#FU(.\2Z-/L^O9X>4-I\-?GQLS;W/KXZV^_$G0\IV$V M=,0Q;(K03V^GSK<\QCQ9^_0=HW4P63Y%J&W/1:C0>8$M.^P>Z]G3-%--4D@) MX&]!4L1U-T*K&>*%2C^:7<>]J/ZZ%W?4B2-[0ZHMXU)!#Y0Y. =ARC398B(&KO8ESK^2X4'V8#7D5L+WACF] ,DQ_6JR2<6W0-TJ0'KPYU6.Y618;_4*2NO,#>CL/H-LXK1]0OTT0#-*1<*RXU!X(@ M!=EA')=8R/4!MA)3:F;C;<>_648"M?HV)"XO..@>FPK6GQ*ONL\;DD]_8.O^#OMVA_*R#OC?N!I;KG48J?PRK#4E).+DO]X^H^D"H7 B^2<2-"QFP^ MFZ=CK5\Q6_JAL#CILN5$Q_.M@@NMTP>.OA7?>:B!5Y="V MB![.D2NJE GA1]LOYU(BS)/ WXX-1'Z40O43,F@VIU-@@_D#//PUX;+S&TMC MV/PGG-YV52,JDH[EJNW&"AZ,=TQ'YP!O+CPL:\76@)M2EG!D$#PRF$=-/+99J)AO2!U@>L->8 UGTMN212Z$Z6V:_0@$YHBFZ M$>$<[C&UGQ)<-.N9L@Y>Y)7L1O_,C'D'THX)[KQ<7WRUMN7#Z^ ^)(-T:1A: M\]_FE_[?YK_##C>3IP@S47!2QH5I@FR)O2B)-^HHVB7AH.7L.:IT5E M7EW^44E+-\%3A"S,]A#+LSGTNF])JC[:B]:(^/1=H^0Q7?L^QF2LKFB3?"KY M[TF$WD';O/]+X:3HCC2AA\/E4NT[HL.7D4ZA.<0$ZQG5B M[WB$0.U$_GK.6O@[KBUF#X)T'?+X8(>*(8A0T3E^U[-W$9(U<:Z]2>\>XN\] M/WC#Y*OBA1.35QY<,V_YE[ZL=O/%_I@BN%'GH60XO.@I)8M#0C2RECA%!%W$-S(3D5OL MV6+$AY?[ VP1M):2(\!&G65'N'7[\V.*-M<73?KJS3YNVSHI?OT72U*34Y*< M-:-]G[ /6"R:J*.H!28<:,U?L^J?M8FG66HXZ]@SZ@N?%G'MF_?!AE!X N]3 MR4STX(T8^F""T_"$QHZZG+7O4'<2>G*1N"2\L WI\!]Y]VO_D#?3_?[::NE_ M+Q8=:7S/#C!_@ZDU\!XB 5>E[> )+%5A-L9J%M%T'8D81> #LXS->Q">P;VL M"*DR?-/X_$%Y]3NR(]OF/M@B]5@%0F[3#A_OBQ3S*U^/A)>\O.[ZGS4#"21W M+V.=F<51DQ\5G<&FL8-@KG3L+-V->YSKS+(UT+[LS2?V@+,:Y = J(Y_CEZ+ M3ZX*A%B ;M+E!PGGOF2-A?>PPY97Z#ILV5"AO(C4U]B13_J^^W!=\^/UOU(Z M:W #\>/,>R>IC1O--:]A!2DX:SN;W:PKBK#>C R M$'S=Q]X]2$7L:Y,?)-H*_^ZK/T%5,!-7;;;Q>:TZ18KN^A!JK,.=[4=$(>6Z MSEUKN07%C#N@I$:@UA[_3D%)*9[:_Z&%%FJ63^QO0E:7) MXV[IUYQ^*#98;RIY5G"8O@W\@Y!U?'2)P*X:A>XT\(]7MV?I@FP_ MDO/1]>>'BR/R?D]/2JI[?WW9W=SFQEY25)3,BLK+^Q*LQ1AFZ69VZ@L MS2N5F1,WS^.@6.PYIKKF<_S?KTG:\ZI^4DU4(VN#H9OBUE7=_O@PJJ+6BYA?E$6][]E5=2Q&^A_ M!Z+_%*'47H^-KR+SZ%J3/$_C+)VI]G=VG)M\*SZAO4IY#WPR7<)9 L M"Q^.3\<9@\2LS=6IOE!ANL0;3C!@/@N(,%W.J:WY@"6$;N.0=88BC"TJZ:'@ MB,( [PGA6 N8\4C TZ(I?W6=F#=H.B?O@N,JQ@8:1"WX:V@=_%E"TAJJ.^1V MO:IA1TS[EF'-BB^I1UYUE4"FC,O#6\!/\\?EJ?M[Z%4/7\C53RM*I>DC)@\0 MF_$<7CH'DZG:!EY2/J/IJ3IXFK.1]F[@\/5XDC@!+Z?!V<74_5TQ@:N&.O0B M4*9FK[J*NMCE&&]+DK%[/FEGUZ/R&-R>G^\HJSIHMDH.%;\0T6;7QY1X,%)H M>]06*A407 VZ'24FYA@$[097U(#O90)33,:!''FWP*W)2-F7^BRHOVT[)?&/ MYYU3,K.4^&W?9/^9]'$L^D)/%H''& -%_E#L9*^4G@G1&_=R5RN,E$]#0$9Z M_5(0U8KGG.4N4[ZP)=X0Z5G4<>!8R'V*&I8?>UUE-CS^O2)?XSH5^< ]H50T M?F5@15Z%R0F[ UWXV EHUT\>VZYP2B3"+H\I>>K7Q,>MN[_<4[D+S\LGZCKAE],6CM Z05M[1GIE@_?"8'U,I1T)*+0JW#K56\<@FY*F!IN"5*/;(* ;H@UDY(U2;B=L%?\EKMQXJ&5 M^!4DO%X5!PP#A__*PVV]X5L?61)\--?6UR::3L+ YD.I4[[04GD?]/X55()< M&4#KR?>9?%3X2WTW]A>[CG2N!LR01QJUW'M&N=%*Q-E6$728:<-Z$#I-81$5 MLIH)-'?9ME^8*KGGFVL996K13(;-SQ+7S+*S"PU!66LCV"J/AR&(+=\+\3)5 M*-BRT2'GKB2>F$1\8?&:L5IAWHE#CG*QB:W_- ;OYDF0*T=-':N@Z^"S6Y3+ M$_N[(LTZ[;3JO'M#;%"NV6S%VL%F Q%(D VDRME0WF0O^IK*B?:6YMBI^$7M M5(D02C F3G#T@C!I7%-GH. 8P82)V,**?$CBZL"9IR7:^"/W7J^P+'!S[[,E M!6,-RI\BC\!>ZB?K#3):9*;T1CQU,S@']+1K3#&>J;JY*V$F24+0;7\$#\K# MX8*%'50K1BO7"HZ2D#744;._9,.1:')252VW3'X>TEK9^" PW/0W3A6OJG?* MRO(K(Y,)[C?Q$2*Q&7VJNQSK MA'Y%_?DCS!'_"5$-/I5^0=2_(+5CO^Y #\".TITPNRF*8D W@-V(<">$%/MD M<;5@+VE*08DOW-'4YV"17G5:DNWH#PWQ/F(^PVE8ZQ*^3?'#\;R!BE=7_E,* M*^H*[",) F,TB2'CIW-5UO9.165W.)8$)%:V$:?0O MZE@@JV2)5_&3F17434JV"C=(]57FS[/G?4YC_B$^M(S^:I!7<] MU4%9Q@MC]U?R1:OIP9Y&?#$J#6<\^IS2*K^G#OHU"E%^JA=G=@#2 GBIN W: M+HW#^I!/DPG-^HS)+YS6KACR)&_-^(Y!QS"AGH<>:6 FGV=\#K9]#KO(TY1I,\P!BT P(;61ET1;!Y\H\0_C6O7B=E+V=?5% M7M9>D4#TNW<8;+FW]M_IL0_WSH>?\AV2/80A([.?4LXC+\;MPSV 7.*QJ5=Q,I-[;: M3GAHNWE^J+ JTL-"IP:QO[WKVJ @YL"E2?94@D2 'M!74=_,$#@JPW)826+ M:Z5Z'SN ;A$-5..35$M@*LY080.Z"=0UUD1Q1*C2YA8 8S'.DC$J/JHHXJKU MLZL7RD)#(DW+Z/%/-]^I*847$2HMLD4C897J79 =7 3FB7E96&-H6F+1(EM% MW0_1)TL7CHTQJT:2N#H4C/@S?K5%#_:2NLQH*FR[HD5& 6-]0=C:/D4<$&61 M(L.:/*30XJNX?1+)W:C:VJF=BQ$A.6' M"IC]_U"]P"5CZJQ$)M?C 1(F664&6HN:&Q<9)A M.75OD4>)VZ;A$8 !;V%GD>MC%C90A%(- ;M_3I#+J_1F+YQ$KZ,@ <(DNX2Z M'B9#H4W,*B$_4@OH!"=5FASXMB0;Y<(\4-DE*X9.C;-;-2(FP?FM>9BXHH"QX(,/LQH+WD?>;BU^2HA_4+]0:Q; M445._KGB;\2?BA O'9F* >D>L!0BBY'7<1H4/0DJ2:$M)2?NA-VD(:+F=I_F M833D6?@\[NE;28/#!,#@\^!]Y*J3#S[@VL_=AI,B0GWJ??(;9Q[ET307#-7) M;E5%_L@5RGM!W@T:9AAF +*IO>22,;0VU8D-T^0)7N*\I!FF-J7[]TZ%.:XA M1C+X%:K.!C[6!^4&H77Z83__2*1KY?.7]JC+;70B6?4&_\LW>HBL/UY,F)3% M2^KHZP.I1G XP$@5FF*J.L^"7VK2BL'9I"N$,I>''F6D%^$[AOZ:-G@[6W#@ M@49X79YQZ5"L2RV.\=^GT1Z_F4476*\S98ZPI[]>P[:U_)PDTE0[BV%E,[L"-9AIG:^/?@V]A04D7$E5T!@VZ_?0^BZ$A\G;/_ MQK<%$!1V&I.]BPBWY:#+(F+U"%^F"L,K8V9TCEQE]'2=)Q)ZU.XJNMLW=E," M!]O86\,=%;YVO1=+7Q8!A!ZU]'<_?'@N_'%74.#5.,'3=J#LRV\/!N27!*=W M^=VY]25;^1B$YX^?_?$J_R)K[3M)_N5CY*9@Y6-Z:/K1LYG2FL92\TNO-A$R M"I>>#1F[$R+,^/-PG(;A^NB]=(4M>7)N$7&@6SRB,L$OH7^?;Q#P-??N<'4? M/[3-8OS@)I5MX7[T= MF0SRPE7Z0@[GYI6WD4LKG ? EK:;'X"_LG): MUWMY;.-657K$5)M;D3\7:F,$3GEK9MA_$CNT"HOAX'L*0ZD(Y-&6TSO/P@2U M);5H9"KJBU0HV6OVO!53 M)/7@*Z-E/\ 7BXC7)_'PT DZZ6^]E)?V[=ID^^_?TYO1O[ILZ MVV[3MUS@?;-18\^]O-'7U3?82D,5?OTZ_O5XRO#PP*\<[]SX]*_1&>O.>-_R#0S.]NT_/O^G M^5@.P?R5>:'R<-Q2T;KF$$SJS++HF[9.9INR^PX.10]NCHX^]6:T"7&B\UI( MR(8RA/,R[VJ-@%7SDE=ESS9>FG_4_*1_@5#>IK4M*O#R]P1O_2YOGKW3T-2[ MKEI'\-*_9YXFT"B:[B\7,$^Z6_=AJZG#P@G.=O>ZP;S^?C^%,-*VZNB!,U?^ MK]-\O1KJJE]<_W;AF_74*=<#<=]8&<.;SR4\-?(M,#_V[[XG5EH&*W<>7'OY M.>?G[G+QS5?/SF,R;$V,!?EV;?S-+;?98U<<6NY>VEQ5ZE37O'2,:5C[O*>BG%7(RI*(Q5=#\R5T8)]"#0&/,"!S$:$M3%Q$_" 0B-?1 M2[L=<=K4;7_,#H+339;W0PU;'EN5 MS'-X)9GM/?U9S4S5ZK83]\G*P]&P[3_XA8M;_^?G1<2#OIN+B$0/I.I@!4:E M']J(F3?G:>%!$<5C$7%'G]Z4!6]>1.R/!4)5QC)-^O='97EJ@F#>9:A^;>/] MH!#3>"/#ZCQ+G.Y0G74D3"E_G>FK8BB,3M*_'_!5#70M(D8MU?T4Q[ 6$29S M%5HJ?>+_U4+F?VLA/\=7_O1KD#?_"WM:8&8O2-AV<6%6,%+VO?&@C%X=S9M? M.<:#3<(7$:WAJRN+8WNCWR=%T<,<&/,3 6C%UHX;Q!DWF@$=X()YBXCMZFXF M&X(>JC194X?"?EAW$?'E .Z/,A7M*Q/VO+.(F#["%M"G)]096>:DSD@]GJ?_ M'^?O]%3]V)$UU< YCV[RNK%CDL#=[ E\YQ)WN,<_=>_-L>M?^2W]1^@/7K=;T.78B)?Y&_)R&KO>Y MFX]&A]'=Y;8)&N[=T8$;FW9IY^0]_C@8/A#SUQ^R;1E=+>^W1I9+=[IO2C9+ MUZ^KO/DJW>'4+UTO-STJWNSYMOMKGGE^QKUDD65^XE_ZG\Y_+MIVP)UCZ+Y) M])PP$+\G/L3SQ.=4SO'[7SR/?PD8O__4=>UF3X^[^TZ8&[[L?[_C=KC^T0/F MO_\W^5IJ?[2G2KEG'UDV^2SWW&G4(,9Z:MFS:RB=NU\8_VXU]$C^=%SG9OLY M>I,GL(B87SW*A/=TTW]L>03AKU-UI-&5C!;::I"=6=1=&&<+*XX"4^9$#TT; M;]M7M][:^3MR./%)*6L+'NA4E>F?V=>(6L]0;"5>9\X<^+F>"J@%Z8N(;1-A M+BLD!;Z27L^X.]LI>[U$AWW\(HKF(FDA15VXJ;M?)?AJIV?<)R_R]G5^II1^ MO5DAVOYUY&3$L2*(F)=+^%1C5QQ]94)BLOROW_IF+J^.,ZHH=%N6\TBJP8J( M56PR0BE7_.\!?,D#M!1G9&$:.Y(/.:$ 6=+OLZ.VUQQNA=,!5ZIZ)#UR!"O5 MR3F7Q/MQU._)E[Z^DI^3OSMEJB#>IM.TC6.$#34$T4@F.%]6,_R^6Z6KK:5* M]'-3:5OA?VR\$S.E\_?RONA; L7#&$<#"U#O]H^EC.)+1+ (]Y]AI1Y#"TU$ MQ9.B_SLK?^PP]@.%5'UQ!-"'Z+BIP6AZASAO9&MJ"S^Y?K3L9>+ M"/8$0>7HH:PL7D1\\/%4*\7/SP$HQ5;>_W^6^&PYL8C 1Q$46]ZIB\\3'[5J M3/-%L%>A.FDTAPM"/;#TB/]*Q(FG8\\>5#P\U?;F34-U"!:\O'F#M%O!P/\_ MKFOQL_5 .G!8H2XD?#J@[L?+_ A#S]GR_.(OR>\&>1T&=[CT#>1TAR. <"*S MHPA^ME3!#7VH]D+AHNE%Q"D-^DS;)?BS>R%3ZF?^8-[G#OHZ?MFZM>1$IM;* M/YV]P(6FLVNNWEA]^P;RXE7AT^4K?WOPR^B*Y:?33OZ0Q45]'[#WV_KHU7OQ?X>Z)\6Y6XOBSD7G;)7&G;WE=CQG3Z>'XYO) M?8^VW_!]V[352K J/S?#=@)VI =2J[N='?L'A&,)U?&#@5/5K Z6G*G,;S3C MA6%N(&XXH\$:')KZ6/>W*,GZS\'WIR<.,^3WE?>^7EJ/1W,UVRR7-I9N@-W-3F6/S3.CQCH?KMO_JY'(9V;,^,3#W'6^D+_QG M%$(G;B@))ET=L]46&[]SM1P4D7?Q;^=-C=4#V'@!I\8J5(=85*,(Q"R!U$-, M%:8>?ME*=:Q':ZGKU7%BB0DJHL_+N#7TCG4\V0 ]V?2_\.W "_:/V7QU3JB' M[+_TOQORUJB)1Z%6+,U='2HR%DOK%%6*\!!5M1J]\#1HN2I_SNX<9D!#O/_) M"S>H"+!Z7GVHENH!>IDU;E SY*_8+%/*!L;I2=5_-7"DFGEJ,G"RW.3]SO9( MK1VO7[?I;Q)?W$G1[WJ'D7FU'ZLY],,_]@> &OF.JI1LYM#0M)].^,^8 MPI5MN/OXW96]5N\/)]SMO^?H[K%^?5;;_N/C[SCW87C+LAE5KTN\F MJ$7$\BMXQ9F<@'L_=B4O(BY=SOL!?(C'F:L%J1Z[B/A&Q'FK>\%2)GP-35:$ MBA<1ZS9_+M2%""F*HR9)?[8F6*3&3%D&>.RUT76[?D'D45?K'UMPYD_![77_ MWK _NVIMVL3V@I("UAC0G)Q=D/97V4&KJ5/5NOK+C[PQV[_Z^(Z5_H[.&X+M M+K\-BT=&/!FZO/W;[3*2Y72M3O:6'Z_*W^J_BO.:JQ"5I9Y,=M4R +\+ MXH<[@>"@/5=^%+=-2M/_FBA^V]8^M4F$M[=^^.[F ?WCQO\=V@SS6\J*1Z^& MJ"K+QW<;N3**^S\1QZ^6E,9%LL8&8K*?>=KU3BEG/_TYT-\_^/LM#Z=>P7/^ MJHBN@^-/3U)B%7;(R;XX=!7Z]>2:7Q<1F:] >'JL-8TQ,3_+?O!&XXE<7<=& MA'VWS\S36 I2A,>O/5S.^H#BF+>S$2\/73I:_92DLZ_J/OOII4L9?K9#^4 S M?^=?8O#$B_F+1ZD3QJFMWK?S[+H3F\[\ V7%14=<^NL^Y]C1#^ >>CBSOP7( M<(;FQ/??_W+Y3\5)<%66WH8+9M3?#QXYN#RMY:#)P3(\V,FK%"E1A$0F'*U0 M>X:V\3GS]>=_>_/,:=T*=,#ZK(5N:AI^)(LX-X5OJJY6EUQ<)4&QM0W_(TL: M_3*QQ-R,1M8HM)BS:F0+0/6 #1/URU29K,8.A0-MF;J$TO$(SQIN8)=(L.+G"&ZU;;_#N7=SR@\+?G#5N[!G96/#_3)N6[BKYF?;@ M<_\*R^68TBMPA7"?]G/OFTW8YAW1.I>/_+ ='_XX!PQ 6U1.V. MLU!@1->),[ZXGQ+_%@Q=1&"V'Z0Y4G4+WC5"B<#9?Y^>?$S4H9J8(Y##9G8E MIW;N^PS$?1:6+2+.C8FF@9!%Q+5_Z%!M1J"QV\LCM\?\SK]9+7[Q<>#-PW]< MQ6P]Q,6#;PP;S1O6O[+_'HJ&';>INQ[R@]$/H14J0*:PZ. %^"L8N]4ELA^, M8L*UBXA5'>MO0DN;[L^/J+8L(I3DXEB<$>26HO!AO2V%B0(C=+KMZ+?BRGCE M4I_NV;)-=>GFM_Q#Z[HOV$1V2?:,)'].?JS;>6+E*])=<7![B M&_(IKZGUMQ.OBLC/.G[9'E [;7FZ=-_3V]UW6.\X7PD>T:?-[CT5MA*VW5GM M'GAJ[-R?[ [6EI>UW45O"GX(,4ZOXHPJ&YZJ58KPQ__<]_PK.9M7;3$YN. MW^,'K8;;('\7$)].]5V&JL7=B6?!C./,A9V2;U^;M(.];_/G;=B10(,NJ,!$7%D5]\R\(=![2T-M M6D)KZJO0I5\_N1$T)*@UY];;\=F_,,JLVJR;ZKW-)V:>-)U8/?A--_QWR<[9E2D$5>\*(CZ^_X/8:[JZ9FP1(1!EX9%<)+R" MG#[LV((EU!D&BQ M=2EUS86FG3-PE9/QD2V>ARU+Z\M^_6;SL RLD\;RF5D$21UYZ?A5:<3P\M[S MT<1U<&B+Z0IHA(\WA",63G19VTV9S3*6J=5.F$0-#&61_ Y,VM=NJ;3)L,T^ MMZDNT&;^FR=.:?9]?:X5P]@O=>UK6D;JGMFRH^9^!_]Q^/7Z 1O MR7?MW2-2'EKU!HWFG(#*8 9!R+6/4*L&9T6ZE&E*81.9XA/?. O>JHY<_"IL M^ .%!7@7)K,'8((XAR'!]Q<)5';=#VZ_-K4"F7Q9BFA-#&8),NN?<2%>EQH8 M8WH7BCFQM:_<2.^.GTZYG^WV]Z;O8\)F^E.T4*A8ZONVXO&?T3.B^),@VO.]28OGAG(TGU;QT MV66@NVAE_9_R^C^5]XN8'V@)$Q#;5YFI^BV\<"D<7T+=UCG;KLW]C4)O15?B MI[2*X1H!?E4T48]JIFF;1N=,C3EPS#(ZLHA^;=BH1[5)80OC0=[K MV*M?[XF-,3E1_7"\H/9]NOAO\M'[*,)9VA5ECP_ =XPQIV4':*B?[ZTKU9B5I%I&M0=%_(X;P[^" M'=FM"CWY-,!K\;#6.@(>3HZ2RA@X%,2>[)>B-2ED0?Y0\4<.%%1C9:H-UY10 M?%H5Y$W*%GZG!JCON"/=GJG!*==K--VJ M?$@SH#I#J-?MM&EY',3.PFV'E_+1E;:+B)6G/%WXPYL@8@9N642^\!K7*F"4 MN_ZX_6,9#PI85C5'V8+0FT:#)=#2'36G@2O.:XJ2.8S,KDKE-XP>1(J6CY MF+V1276IA)WJP!:0E\->!^',!V,,"7V5YY.(0@VN<'+R6;T',+3OZ\EG=D/; MO\I&9I5_*9S9JD8:1GGW68QU*/^J,&.&:/H6B'24Y"G,\A^;:N$V0-\JI3Q- M*E9X'J<_R$JO@?E$^? M=Y\?:P!K+L5HC[?(7%_VG#_EP) G-/_K5UR@O,/^+$I=1*AU-"T(WXU;H^H2 M&='/M=&SHZAG&N!B*$I^79D7H\7X96B\5B-#90[[ *P47BA)W;5L-6HBN>LI M+"]E 7R5;E&/-H\(,"O?6J3/X%>$YW_0&">VD+.8J_&A'N3;ED^WO1FGZ73$=.A%N4_;>4&:"A3NW M%G<.TLC-F;@I(0X@Q2-)5#)H#[QOD,9;T@U577E!VZI@\R*_\/GA"NH5ZEIQ M)B]MV**NJLGI'+E]=;7=*UPE3FDD66HV)SPF$)LG9==^]([8VV&VQ5&PZGS>J7L&*BX M2KRVH8N&IAS=!!:F%HW.^>4R6&$XT^[ZO26DX:TY?8.^O5C[0TH&SHE"E\B: MD.L^AA<:\RJ53)HUS 3F7K>5$X@Y,G.ZAZ6VCT >LO)=S@<6+8 G1.X8;G M8,VDE/P =@L AUC\$[< MK%H-!]MG3ZGL.R!C EB>RX!BL&[E,-D;;+@C3)FE&S:6(FC=JBJ?Z:-0%-#W M$$ N%U$WPTIPD$\WHDY&UQ:HJ!!A$R%#\!8&TAYH#@)STD'B0RY'%*F_-S<01-V740<3@3:3M+&U/.CAL+]D*G:7_.#Y?$U7=A8<*2E5;**BX!]U45*;URG M8\%]O-8[&< 84%R ;#6A*MT.I +#Z1;\!J2 JP-Q[C!2L)M+$,@>D3ZEC$]; M^4%&]91,D3W!D=29KU7^RM"3=1FMAZM("X.1N]\$!!YN6W]NXD@]I_+:KJ6; MFP5'*WQ;8B? 4#5;W(B";WO >F+T"@I1'@-?C#%;6*&P!G_N+J[9WPRV[*'& M+^RC;H.$C73],;\KSY6E\1JI5"^I1X+Y89A?#(>VUDZ-AQT=FIC;?34O:Z;! MTL?_#>]R_6]/"HW [VY #7@^_.'8]L(U-Z-#;C<]J38 J+LG@+9V-_Z[>:/K M)3M'_9)56=JE1H%?>M-NQ"(^/2N(#>BBVA5%J,R$[*F9:A7/7U[ MMV=759T[FZ.U4'JPR=]WP-E.\&VG]YZ/UPXVDWS,U3(41M11K)4B$93";1>P M>Z6,523N&F'YU)?=<[JCJDU=WZ(3#CG&)R]_4# IV[SFW[7UI2O?YU/&O_9\=%]=I;\E1,?3M[]D/0IV.$#'[M_M,G3->:AJVZ$WKV MC_UGI(G-;1C6O@KM$\I'WO@, MV@[872Q*Y!G0MJC5;BKU1@S2.*)PS3W ]#:@5@<7Z4+"X3G^\[8HM>JU7K.S M/A9N%9VY4-?\P;; UTJ:?N:62XRMM^R[QJ2/FG*X(&:2#KD(1/H2^&8%U4U( MKO)T:QI>F[+ KPY:5P/V)3\=]AT:=SNR8/J\C+EF(M:#%2YO>]*2;\!0%?M>$XG?^Q2UZ MZ9?TJ7O^C*@&Y?M>)Q_>ON[Y.WO;A4[_!U!*#R9 M<5'^U]8/Y3[3(DV(NRT8QFNG08E; 45>UG!P_CZN5@JD(SAEX+OJ#X,3?H=S M+4U261GESGTQX1]:?!B5*0;EA)!T=AJ_:S[50UG$U1ZF7)YHSN_(H>+%GBN0 MF=P]L&'D$^J!OBKBLL'Q182N8JD4KPNC3H!?4W>_>C+H7!8T[B!,XO1C\>&A M5GGS+07GA-5R9^_CF1S(OIF0@M,25N%7PJT2^VL*"PE=SW=\@)&BV"LAH^!X M9V&]"VO4@)U0(0J[BBM],C#NP"G,#%F?E\]I3^8(C&*>D2_%;5I3>NG'S6>T M9GR5:9YD068,AS:;FO2<$<;@!W?Q!T:NGX(PB;8-..(26B>ORIL#,5WJ XF2 MU,DA2/3'=(P(V59$\9"T)I^GFA=;3X3/;Y*KMD+6C!3KF2F/3UQ=6KOI7A@E M9>@,A)FN@LF0(R!B%"G_!IA$.!-:ZG]/@N0G8.0)H,8-Q2_!P)?":8"1YB4) M,%W+!8\S4=SU)+T(TQ6%Y SN7JC@BSQ/O) ^V'R5V8PN9NY7[%$^P8?2,VDH M$)/%-557OB@) :GPK&<>!I?WX+9V6]DH?$L'W>G:+6HJ':B2&_7V<<@V=Y]L M;LFRA9ZZR"US;W4>0X5,VK*SZ+]RIG8)KO8E0P2 RRFB. K08#JESKN+&@5D MNWFJB:Y]JCH?NTOBN.!TC!2(%&@&O01VD+DI,W%XVIM\>P%Q">5V(.2693O(4!M/\&O= ZIS MI]Y\S!32N9KAU7MK*R<0Q\RDGR%GH?6KU.G' MT('MY30XBB3N2.95(AL/=9:JE:B[V$J M0] ^"6="8?P.;Q:3LE&"3!.1H,/PX_@\,\7JPMF&GM?X_3/L'*8VUB,&[*&8 M"_+) D\]"61'@ZG ;+)?!IXTO7Y[KR$XI:^ M[+@:W^LS$S%8:#O?NQ>W'IYN9*ZQ'5KJWP#VO:*+&?IA-,O* M3H4;RR4RB@XHCTTX7408\,1,^DI\R$>[T$[K M&0\M7\Y'VC;813 @KV0-4#*ZIX+TZZIZR^L/H--BC OL/1<2Q=79T@+'PPVF M#K S& ^X%H6H:YH&Q<.= > SV5A_4NEH(:H;-/TU'22DUZ- /;DM6%"2"LYW2U&O&2:J]^HG<4=" M(NA0*B)17C5PR!/?(KX)3" M+.!;X@(&C@VLJ88?<-%="B)D0#96_ $W*Z]#*_O:_!,L)<.L$'1ZP-(9"Q_E M4[4G46+40 %QV,WXY92\U[B]4 I/G.TH0251O8 ./0KR4&^]-2AMY:VE'HB2 MX W&_#@MZ47A5S%)N/646Q/'&O*G5*V7Z^VGHMAZF1,>-1]^N,TL4C\Q@J]PIQ"ZPAMX/;@R&\2J_=#Z]-\7>K M53["HB'/F6PW*4/ RZ%9_@/V)2X848.4A7:H6C4(,Q2&Q7!1LZGYO1::/:A4 M)K/38@I^;P4L/>X0]'W=2L(*]:L_VV(^>DECU-0\!\6^#K+IIFGW4UVA4(5> MK-AM\H1XH@UO0%)MZ2K'^H(WR ,6GGVS=2(=$757IUT"NG%X]W.(W437>[N: M^6C<(9E;63+N$"AG7J6:/9S(%VN,CC1WY#@0FQ)( "O9[49]%*35@C?@#-'Y MJI4@^SJJ\68$2J@NE!5E4L\K\>V$5M4NT"+%=M #C1P5SCG+[&!6;:YMU8N: M5Z_NF._EZBM9-"T*X[4101#ITS)@P2] '8?FTG Z;:$0P:<3J_DTG(Y2;)8X MQ3>JML(^5^P2CD8WN+34VF=0K26>)N<5>Y^2:J\T*+.CRBA>7D(%WKJ0'?.: MUHVN3&%#"ZV\RHIB5-HL3XOB#S#2518DG'4?UA#2:Q%IXS;VNTE$23AK$)_* MQNJP*6;E-E]YSR'3&M9PA(%1=7GHPT]C?[ZOSF&/*7&]%%=()8\5OEP MY'8+ONI(MS75<^$ Q75$;:+1S;6?+M4(V.D&-)WJ6N$U_'$..QV-Q.Z5L%=1 M] 0X+!B4**4;6T]3=C76"C.BG3#-03:!.W?8/!Y>!\[.SAAQZVNIQ/H&AQ,% M'ZL8(R]WL.T.\26BIG+OB59OAU"!*'7@CJQI9(?BC\I_(&8JQH9KXM :NX-@ MXC\X?LP#0*T9F_M^!UH2_MDMY,KGR.J_6:V\E?ASY/4*),1,G[1%:E#WPG= MF605OM*N?M@<3E;K9YX$PX_$B#7XHN54IW\^Z,;+4DS-">F7*(?4)>48E0B3 MGW4\H6P,YVZ'1UI\\N:)239;R&O'F7:43/E*6"IA7G= -FI6R6[D(Q7;Z1_9 M\GSE'86]9 *M!V=\(^3DU[1TK(!#&W/]Y@2>&PFI?]9<5^R0%+@UY=(-5-M& MITJIAWN^<;=XEL2A5)L"5XP(\F&-T50!3ZE6W?5'3S\:NS+O6@ *6ZNO MBI)L/3W\B6FX)4:1[Q/C %&:44?&A>79-^MJA!UEU*VP%D1ZC:XZ7"?)=@C4 M:F+^0K:C,TPM\UY74M3NBQ0$BZ0:V?5XR01##];F\!)5*$C6Y"PI/S?8K):B MF\!)G VE[C4>S(/O'>FFX@'CLBO=V*./$ F=_]_&$ED[?Y7^Z>;D$"M_@-S8 M2\/]/'-I\QA=PXZ>48CHIFV;..K?5JS -T"';Y(E;4"<<7OP>B/;/(\K%S / ML[^^X(3UC7^WON7'W_G6D-;1PG4 0_ET;2+@P/!<$&123 MBL>>!Y$<"@K3'XU-1,5N"L>Q*DCY.04/1Z\&\NX](3D,%['&C (YP\4)I$@, MP&Y!PYMJFCO2B-75#R'>(?@A0"(D%VZ%[Q93#_=AR#'6-'S:_+*^@<*"LF&8 MOK]3_*&DR^X7,NY^KJE);S'D^G?ME4(Y+B:1>\NW*[+)WU]H10X#5_B^VEXW#R$W:;R@?@Z3ZU(RR+U1T5D[(K&R6M>&&8 ';SQ_HE4<^W7.(.Y!U\:,? M;P#OS4I./E^G=ZRF O:0SC423=X^;@20Z:I50K9=AP&)MJ0[>M#D0BP622JTQ[;/UT6$ M +D\2 WCZ^BA[+4!J@Z5/91*#/19]9N0ZJD?I"FDQ@&9]'ZZ!)]B2UP' ML_D#NY\'2Q:(*WY608D_.75@RW5(US@R],2K%Z]Z;+!H$F#)6$WRZ[BF]NL^ M4_Y18D+ZY8%6".D,-P"$CXF><-S"WHG"W^#K97:,5-IO!R"4G/MA*A0]D"], MPSK%2NL(*;7LQHE-<+K424O@]Y59%''U;.7$+F6-X.(0U6S^X8)30+-:F,U+ MX!J^:DD/UOU1/T78G&^?IG !F%H!XP8?)FKEJ>*%["7"9H>*VR5O-PX13\*T MD>8@XU3OES79TN<)9$^]OQ:.^_/,9\F)/!VL3ZD[B[I!?6/.5 =EP2Q9E\:? MIZ=A-22+""/*!-_4IA9"IW =/)XJ8H4/4#1L+51TKNP5R_Y6[YA%&!4ZQX;HI>\A;2:*)K3N&VP/&N73.+B,$Y=SC8I(91 MW%E^VQ5BY?#.8?04EIT*IXH(U89]$W*]/T/:Q1UI03\4)THI#'ZDEP29\G.A8Q*Q4GYGP9R2 M@LP0_4K38R5-/;-S?A3&7*9"4^H 5I.C# D3!+15<,WJTK.UU8E2S!J;/$"T MG$AU#,-M":O5R*C@8 Q'Z4A,-%[_9/@&]&-;'X!X@[:*FM"[B*C"[EI]'5(W MQ=W01Q=%Q$Z"F\7U;604&EDP[X)OR JU#^J+Y6:"=;$W;S(S6^.X:) M@//X>"ULO"1!E]Y_SY/#N>T)Q^,%NQ8.4:( C62L%=5"S0!.$#D1ZPSNE+;H MP.-?B1DX4U"613T1"\@R?!!HUC&U]8C3$-S#)]ZF=/./4KU[J'IT: L?^)S? M?(O"G7MMY/V*!8=Z0=G525V9/Q2.+#CQ1+@E?$ _,8.??I6O(A A\U?N%DVSET-K>QO MV]:E.% REB_/C$]X/!07FUL]7W"O73?N'7*$/.4$LJ3.RJ?&\ENP&S@PW5)H M">\"]8!9&?]OFH@5;D3/B9E5&^I@%_@>6.AY[%LTY6P?%P7/)UP='OZRL9O8 M;.1V@Z-Y ==9W-2WB'"B1,G/PF4@@P Q^ 6$)MP>HU"'8!;L)QDS> MWWX,A\LB:9M@VZ5S#AD*VT[5Z+I(7Z*\BU5'^QB$SZ)ZE<"9?_1BPQ]33:"<5T GT!#4!C R'JKM:0$@ M2N&:?,#8LM.NH:MM?:9GG=A9V,AX"7$5[>U5MY:$)5];Y9[*^[/DM%J--&RD MA+TN<&*)3)X.-LPU&V\-291R,]%IJFVP4!W/9-KFL$JJ^P?=%)S;R:;C!#DKWT;H&4':] M'(M&I6 /E%ZC-702DPUX2_ D]BJJ,1Q[6AQI+RG(R\1Z+J!4_^ZB?4@5X'9! MQ*QZ9PDSPU07+A>;$*2,E*_WCL//@88(F>1"&<@Z"C.!'@:?MT:AF5 ^YN() MGONY@^2JQF+*OFG^,$^,N<;3KW=^1EW7K?#""] Z5*-:)8N:("F/;=H&(--X M"(4Y0$2X+6 HPGTUW<37W,TP!.V2+!_A6\=*/<8&"EC)V*C2\/Q#<)]DY%@G M]1,IWU?/:[)6*7.5MW&J%"XAJ922K*TB1VCE.3T2I_E6S M,9X$:06\K(6LWV=@ET/=DJ"'0+ME*\WLI3!&2U#+A7UCQ =G/(/]40.,=*,8 M=.1+;E5?H7"VY-J:^ZL6$IB[^4CE9C<2! 'LI]23D^IPD(>OZ M#HR/>(*RE!BBKOL#^.JW[^--Z#64:V-CF1Z:%\Z3DPRJZ0-&7_Z]XJ/G-SHM M>/(](7]\750.THN8*ZIF*G077HNJD=E7L*#D7??HE M$B6HV@K?_'O$D*A5;XH[\3S.Q-"[Y5ETF/.7F0%62LN)Y)5W"DX<7+U:< :+?K>'[B ]\/>7BP^O2_[8?_%'?)M%>GX[ MZ4!O\ZFPXX*N!T]JCT^<&6T^5KB=@XE,?YC"[UVH;"&NIRX5,Y;!%A*;XH38 M4HI%Z[ U[ -H:PGRE[/DA;DU:$.%YP/8Y;71\,.+FY-\*:$GA(JCP,3>F%SD MV@>]4UOR=VC>E$[7R0:7BGO_AJO^&:8D>KV$[2 60'^-UO<=JS7WC'JB<(4; MRJE.8&N2E>(WBUR6LG4B"E?<=NX2!L+, MA:,PK<.WC^US$IXNH=R3X@6B%!Y887ZOJ9;JUYHTP\X0<5 M2+T)HZ^O,$DQ MJ>0EU&TW?^[09W^TJI.+JWWP?%UR3S+;1DA-S;4[^L>GYAX<$8RL;@Y,#E/#W%::%NT^> MW]7BQ>\I7==3FLK*HM12KM[."O5"KER[W757Z9[6F96#DM:FP79BJRFZ$KXC MUFJ(!^[=R;#]R4/5@P?UJ@^GAYBBV"XN_ M^?ZN@+*_S\0&[2(H'^.T(OQ$#-LZIYM\8TB(286[NK'NX9 MM8GWT('EW8I0"1X5+C+$.03Z43(E5OG"9N+*L/Q<1O'XQ67 M)&EL,M<6UC@*;NY+!UG R&3S8Y@@IT&FQ5O2P50).9V["JZ4)@^7,-=LZ,:A M)_Q24Q_#EQY2/;O4[G_/Q+R%O)H!$#,&J*:;(0Q_H0\4)LMF)G-NCS*6JP:9 ME8SL/$E..0E"-UU%7:/IP^/XE*N\9KH^+/IY2/&@/R0)B-AMQ$Z>L;Y,7->6 M0"X;K2W,NQ1BQ\RH8J[J*&^VSGDEGH$P*79:UI?I#[]1X\4DC-Y8H68]I&8L M;&BY[^[B(MAU1' 5:VK16_6YIL>&>:0[6I.L=X+WPB/0_,1+4IF_^ZF3MNW[ M@C?DO/OR"#9W5M[EVE)QT$_%L1PSPJL9,*V6EXS;3ON4WYYW7>$F-8GE7TW@ MI> CV!GY2(;"0IJ ;M9XC=L6:-^JTNVD;J'JE(<%\U<,*9P@^U92,:43^"<2 MW1)$!'BP12JCBI=$7,LU#*)D DW#L%"^!?YEP3XLOZ&\^KG-[16E8*L$/V4N ME>DJ['JBI<7]X__0.KS"B2CL-K#U8->47?BLDPN@S'D>&@(,^M1WB@E[OI &31^(*BY=$7].U]8W2!1XOF,R;R MY'ADPI,QNMT<+8OBL2C,/X,OIQC\&]5MU'&A:YWYW_%QH476K M7:)7WA50MBZH_\'&D(( 0:?.AC/WA2/VS<1KS"HW 7.M @TW R*DP@'>)94E M<:VAI$I*\&OB&JH=&Y]913:D8KKJ-9'97JWH-?@0-6:&U:(86*0)MUS,0_JW M@8,^A=- ;!K5@^5/:6MJ+Q^B1-;*=&C_TG"$CU?P_6Y L^JN>,BMQ<^*N!H; M7C9>:&-J9KH<#H M1V58@]DX#M<3]#NHR>Q 1=F9F>6"[INX/>=EQWG2D<^IWPQ2_94Z'"$HGJOD M6^#GPK3FVUO_K@_K'B]6,?-)FWFFE:1$76W< 5>$7O;%*EOZQNGPOCQ%NH;E@@.GL6(BWZP\_!I9#!E S' MG@Z"T4*@9<\AF %Z"F7T*QIJV$5];9UR+$+)$*T09EU)1X8T6)S/WW+D"_@9 M2%(?8*P<@TA M;1'<:ADOL3J.;HKS=NHT\A7^&CI-,)Z?LPH%&6+=)T0/@-FQEW2AI^HN6E(C MO[Z&,ICO#1"%NU5")&45JQ9X,4%\ F;?3E=S#&4)47MYPQP/'\(Q+CB6U5UM M)VV[6"V?;&TO9)$KNRBN<^]N5X]&[+H5&KDK^ +>FVK2"&=8=;4)KK,VU]&V M]OTJ/8$$/H49RFUX3"!0\H=LO\Q/?9!" =\4[ZF-.!,?N"[A2/#0W1+QW=9< M%>EO]#768Y)88*)]8>EU1* @9T=M'>+%KWRA[188W@.)^:Y5S<] KF C/9Z5 MS]J.D!5CZ4?MC7C,HZ *\.WA6TFX&2:'=MV$;WW/&_28TQ--54:,'WT__N4J MDT\X!)4&PZ.Z"-R=YE:$.(9]UOM%P@4\72 M(6=B."$;"88P'31KR"J'0D3'E6RXHD);Z4!9VM2;V-68T*S=.NB>X7QRR)73 MY!,D_CCI]<;>_O&3J^GM"4FVP?F!V6_G9[H8_\X+9*.+/PW/XG=/ZPYDK]T: M$4\PP/TJ,*)]D6C35Y"B^^9Q0TA\(^)O \9"002I3>(^^=[MS=,5NZQ_/?>' MDJ8OE53=BJ7@JRNFFR^1C"/74)T$)#(6[%F\"A*R77'Z\9YBS,M41?'L**C3 M.ZQ%%%RH$9:[@MCK]'B,-< ^-H0CQH("D7,\N/AB2<7Y+0EQN*@4&$PEVQ(- M_1*M?J-^%:NL6R>E<<2L1LS@&S#F8'M/!*_<&6W ONFER:M13+G:.' M#7)+G==0&X''>M,:FRR1%H1HU^!@@E'M M9"M.NES(2K9D5X=%A!TU6OBS^F# 0^LUU![$=64+K5]K T?<1SS.P0'4XC54 M(W/V#M@B3NWI*7 #7J0T!FWD7WN=\1VC0=.^)!@57"MC"E4 ]Y*0&?:>/:$UE$=.' @;[,#./9F!+-])SC"I'Z'RU#5!$:+2&A7LGOO MNDVXX)B[,$IOWK]38*ZU0?Q*HYIA.F38,>[U#*Q[RR]3Y=,WP"W?0#BM[9"; MZO+<>8]);N#AY<"=']YM?%,R/GHBXO*[/,^;[C^?=GC&N;:&.J=YQ>B2Z_,2 MP8J(=F9'LPWZ*OTL\RJA\4C36>7!]^IX7"+8$CY,L;;]O@%O-WC^+1A\S4;Z M".=]V:4Y9.!YM;P:7"PO#O)>??7_>;S!HO[]W&S21%MKB7-Z8ISCLZ?EL9NV MFARR#7 ?;%!&YWG$7L+MK?8IH/VJ[2. IXBOY#K,?TOHX.B'PNI J2:[=7PS M9)#C7N U^@TT"%\2+H4.';GITI2^&A&8VC\_LWKA;YQOY92K3]:?T+^N39B] M0N) S?.(]-'+=6[W"E6R=]9U[S^_K=?E;MX=76)]"AQX;KO/ZT;V#X<4)?64VZ\[#$::HPO?5_^W$9)W+ MV=)L8&;',HGQ8QC9X+?Y-=3UM)9L7"3XR!_D9T$;7+$BIP!(+H)Q7U9$P+X+ M0;-D"^TPJY%^A4=Z".MU?>I89P>D=Y<<8;/C2EJRF[!FH:*:J9+W36B7\Z1E2;[?3M=V_\7RU7(NTQ .ZBXI M[B:@PH"@[D6OQ1IE01K=Y)5;6?6DUNQ92R-4V'QNG":Z!^S]\%[ZO%OV[KZK M.VO#>&1$.%S^\5@Y4$$NPIFO;)Z6HUU2Y$9P>H]TI'P;.-%#>A6D(C!&(YIY MK,CB3GDCO0.;1="O=R^[H!K]J_$IY)];"5]8'EG,XIK&#]3-?_4<==-1KZ]J M#74U Q@-&'J/.UD)2S%FB5&?-\)K*"7='* B/Z[>HVV$D]TQ>72NO)L@,^B0 M(6DLG0E:QH7WY%U =D=#F1$@YSIBJ$H_)^&="PK@@?("FIV1Y7_4TY\MZ_** M:I$!]IV"O2NGT\YQ:OZ&*E253"$=?29.*(S(V!\B F%O,N6#;4>8PL51D;N M@L\23@\&L%U7-:/8\YO#/*J?/6MYUT24^2I[&#@Z=+%C_*MVLOXH8@NF=@JV MPFJ(W&'6]JTBON1PR M,2' Z)SV:ZXA*\?>$Q)TP@@:S ]X.BR(15L#SATLHSK=X2*.\2!R9SI!AA%I MOVR!0G)IFTG _BZ;[5$^(+WGLGL9MHMOWI9$%J5U9U8F+'??5KOJ!19WAO<; MR+S86 M'I=0T6G0E/;K(B(L&".'BD4'BFC60XA'@G9G(ZQQ*N09J; %+*X\E^J3 M!.FIYEJNS#,W(@GYJB,MJKD050@320=+1;2-&<;=?2?64-%C2U<7 MR-=LP+?L(G1N504Y5(4?][L%*PIH MO3I-O.5!@)W>MZL(F6NH==JM,P2SE%)'F+CBA@3"%ADJ0P)Z+&%@'*[IBMJ_ M6O9I0*-9SUVY7"G<4E=80VY<]M MTGZ)'-0.#O+M9$CDL)ID.?DD(DZ^F<-=]3TMT>Z:";^>FL2.TZX?XO8ZG!9( M<&'58[+)\-M5MZO[HC.2[5F7^A?&U\%W%-@\FPL5CW3"ZA62.SN?$3SO&A?_ M\4M>_P+W\>/AXS?JXULV;:B\/TU^D" [WF!46!T?3\'?>#255OO54?;T@9#] MVDM JG:34O4U7@]N4;QH@XYW#VJB5N\0?F)EVH3D(0?90(G!(')QQ2%B>F1& MU58#X(CW@;P)4=07D'N)^^!4"?$Z%VU)/^O[*/R0:LXIK+SO#'>Y=)$,FV: M.EU48?)Y1]FREW"/:GNY6RK\V>=_786(=] UD,F4XG_Y81^/\>@4 J9C5[(A:&2M9L/A3K M"Q^M1O 026QW(=)6YUCY]5P[XG>#=ZMH"#E 8D'$@8'&P M\M;A0>G@Q^_EJMWE[X#S:Z@3,\H^69!VDV;E@'88CP.7Q/2\$JN\C6[VW[FRAQ8L\H,&W@Q0CQ0MD6(BST>$ MO^Q)7-3:CRBV>)I*:E2G#;S^_3IZ^FNX#_W[\&T7\N*UAUT_[@V4<++K]IH\ MK+FX-WCJ@[3(IBXFQ.A8NPWK#M"2!059=RY\ 7O?^64QN)OH_L_$EA#SDUGG M!2N.%M.XP3\LSN.QZ"W?3ZU&=@<_'K[\T-?J2&9%?@V#$U"[>E^0,*/+DD^Z M>N8.*>2?S="MYU?^QS>*! (ZQNV'DN8Q)O#@B-I?C$8!&%'#Y))-0=D;T^DJ M B8LH2@\YM_-%._2E &M)&:W@M?2!6'G&L&/1^&Y%1_$OK^V6#QN#T^ (V*6 M)8?FZE.9J\C;88/0X>/W$HSO&8@+G#KX^*>#;U:B[EC>8 .$ MX*$%:YO]6[#3+&N^?J@.&XA*31;>;G@6^:P*B%:A9R%UH'UZAL'*A7]ZOH<_ M@QJ5Q5VC6$/9U)Z:R9]L,RX]5XIIILU\J]G6=0G),TY$:==?JWFT5'!&Y'!:=+7([Q[ICXQ;6]QX)W'#YU]N"Q7_ZL7# N78G2]GFQLZG! MJDE>>O+9^S#A&-@MJ'83*#@Y]MND340T/'.Z6+2&0O-\%1Q#^):P->03IM%5 M_CG*8A'!R$/.D!%RYUDYXTZ^2L'Z\429TM*@E_K5RB^P;1?&Q(-IZ/@[;K^R M *VJ:@%'?X#H8MO56.780IF (8A90QG3!I='=#2M#X\(O>R?*6_=>YG8@K>% MC'/5UKB#E^^/3BZ5ZY@A,35R#W4B8/5*4P[BZI(VT:73;<)6J@\%3 V&8Z$? M)$JV.$S#=0U13#!3F+D'3 #YMY!\SAPRHD8H218 2]2Z?=P)Y&1ZT+,L>]>' M#$Z.E!RI<[OU:#(9J-%N6GF$G!JB[90C9^&>RIE\*+I;8$KU5R<2&?(M9$0/ MO8@5$UY*_%>9[U,P1D?KJ2?@W.2*\:F22S=QJ98MU0&JC194%$B'45\>$ Q]3'^Q=&YZ4%];F/GL>3E>PY:T5? M/LO4 [L1,.GB GHJX+-6O?)<>_&]N38NGB!.7(6NB@TC4NZ-Q8JFT[#LY4S MG&M+!;6''KE[9=4M5KKE/YP*/U=Y?[S+*8_JOUI,.X#$@"-7N,Q\EK76 /GF M&9P!&1R!*K,+.-KG:>T:(L,L3?_+5"AR2?8:[\@Y+AV]17@(MU/M^8A%P+7&1G'U[,E(\*>H.*HH=(S M*\:_?\:Y1QLDF2)TQQJ5YIH<]9Y*!R,.P;?JD:_:H&CJT7[J5Y!#5\BX$=35 M(V)BX!YEB\@N]HC-AF<*]'I80(3T;R\L%=+V4O=#S%P7G(6J-[$#OP&BW4D% M56H5(8.M'9)_YD&PFB[?E*^RJ*QB5Q+5B9Y2CSKS+GM[T+BFFKK/BJ$ZG:\D MYWDMYE8A[E"Y )Q9V1^N2S1+WX#,?$I[;*<<+ 0> C=%@7@+R$2"&_G4RI?1 MC7M)OUP/$U M5)?)9-3Z_@62R51JE#6\1]6&-85;1=UKJ,VNE$ '=>S<9TKTE2@[0?]\WW8$ M_V1X8503[B<0^V)>G(,;:F M9A1X)S\,&5>F*O\H#&@/'Y?^;?^6:A"ZFJ=UA3]&27 !$''Q&DC2\;BMB-#8 MDNU"$I(^\\#J'TI&=S!E 4XP4CYZG[E?11YV.\IGZ>1\R] MQ"AGHJR$M(TD>S79FMV@:EO%B+Q85]]"NPXTI[;^Z[5X0V5;LZW>P]G'BOCT M:>-UO1E,%HL;*R1<7^ZN46YW-346+H;:%K,'=H!OQQO 1,5(YYQ9MT;(WP0>>58;!1N*=1S'2^3\ MG\$>N-5[]'B-<=CD$A$B! [.8<_!]V(>C<^$A^0D,:YP PT#^WG^:JS@B__? MY(MZ!Y5_X3PGFX!&*)!M5/;[#/,.O GD='T!.+_3G!18!4XR]&3D@HSMYEA)./VZ\ZUWBO MV+Z,DKU_\4%& 6*;GK44?>?V^6W[/?=OJ'^W.&=1M^E$M@,:%WA0*O(U990[ M%NS-NQW^,B[DGDN@3?"9<]6G:A@%::>FG_[]0_7I,G_KO1?VO>T66009Y+.O MU 6@"\O-+;98[FQWBLK&6./<'+=Y+3S< S9H"<;3?"Q85%$)%-)-1\>FTCQ6LZHJV,!O MD5,VA[A#4KO3W2KI^ZYSC:T_\[._<]URJ3=Y4L#%S VH2)E\G]7[7-OUL$O2 M&BI6_AGU:TAZ1X&Q@G6UXP]SH&EUMU=(3E,-\S-DK^3NI1"(7[N\'H^&Z56C MDU%[;HG'#XZD)-G-S94H3VJ9,'IE.ZV7WDC/P1%5S$R,(5>^ <[L^JK4-2+8 MIB>/>BC%_>/%15%E/%95=C&"A)["IC0$'KASM^" \&+BSXV=.T/#Z@3W@%B% M@('LAU)5@N[U[6U#3:Q\2[J1"V=^="7RX*P[!C[M%26HB@^:E.Q^)-_4M'[D MO2,OL33WVR!?JU>XV_'!6I%X>\_5_<<=Q2K$YZ]&-SME]8\?EE/VO9:80-L> MJN//OMTN,OT7 I:.%^UL?# U"/PC&ZR)3+?(+;1G3-!,W^(=?^;99G? #>+_ M_"VAE(O;I77G1QV%+FYF84GGP\O#LJA/79H]:I0/'_U3&:?X\DA0\C^>&6!)0D3)Y/6W-,!4A/D ME+_ 0L-11MXB3]G)IF%J8FUB&E'T7U/^#-I@S?8C? M\9Y @FQJF#*":/CR4 W<)U[NR:1&&UQ%#JI">:[U@='^)U9_G\^LB/L%IO>D M==]6$3?1) (S>@)Y\TQ:?:9.ALRFBJ++%9<=G2?6[%UD[QY+E1FNHLWWP#U*;+^&#D* [ZC,(C>R4 ML:[@$E7>1'WD2P'1"CA.SB>8:;\$XL\C3LG*[Q"T8HZNG,C!?TGU?PSZC#"0 M@YBL.G>2151\ZQKJ*N*7R 9^M3-4,24Y*8+1BF]9H4^?0HRL^["_@KF%>F*5 MC7RF3DI7.7+47AN\?>M5GE-3&-\@VW ML6TLY+FKCWB[[8L?G)$CWO!(!<#H*GF?=1?0ZPB?$"7Y^T/%8F^. M:9P-)V^V"FRO6QWRZ+WXAG@Q]:**,'M&;D/U5MJB"UA; MUU#*"T"FDG/=G6A%/3A$I8 ,I6.C,M)-0P3+VQ4%5*!&B6AMO# %;K@,I69K MHD/7K;'>*EE\JSC-L064!\(9&179;:@9OHMV2(JW6[U!^S]S=.;]H*R1*[@= MZG;_[W6)WBH$Q&G4=-2,%^?:PAIJ'=QY@?N\@"1<+LI4!UH%Z_C-@OO\[Y31 M52_H;N&'K7EA/&;4*L\:=W3% HX0\O4:ASU(LB#Q[U-RB[H%U[3$HS2#,%$E MS#PR[.[\OSGN<\8P MT#,]"*^BNS!/N%:+X]:@()_GJ8HT."7%Z2OH*"HA[P7=&#CJOH5Y&*PODS 52SN\ H]O2 MJ[EAY1LX6CVT^'N"R6IV)V^_0F '9.#MX_8^[L%G*E:)W20+FC,U:FB7)(81 M1<_1E0$UI,;_T0.K2XO-=S?+6^0=MNFD[6>FL>I>/'F=4]8%)Q=#Y>& M/-:=,V7[E6X%!YA*XF9"#NY8Z[]17TOGDYS/@!M:*N-T>7>?C/\_G)^BP"UQ M)N[G*0_,J*VRZH:RCAXYS/.!](X.\W9#=ORM0$MGV@OFO4G:YV!/ 3&32\\Y MG49KJ)G!.SZ&Z1;\1@7'%$@G@6,+@H+Z).J)UG>L!\"EP" Q\0 3G0W0M9LZ ME9&.?4^\)B.W0%-",X6$%3)GS]>O_ M\1E$R'&C$#;(XL+':U+.S[\ZCUWP\??O=X\DGQSB:-K)W9B&Q3OUR/=2/%:G M%\OU5]0%1%5A';07/4?: E_LCK)JL'=8+==BM"_*=_2'B&S^-1T-7.1LH7H- M>K1[BPGQ^6*OX^P,3MS?Z11%GRG $'D]U:.LH48%"OP-92G'-IX$/N8E*\:L M%*PL01QY&WRK0VZ,'*T/ PR5Q,+YLN@P74A0K7@V/9'64K!F\+RWT&$"=E+.-,\4#%:I76YKGZ(<]R)_33U)+]UZUP2!+D2-Q" M8@O;=&[B..W=E]T/_+6&JO#,2=+,DJE?RZXTDS8*F$E.\%FKW#=P"0MDC'24 M'US-Y.^!""PX#$E,9T(IRZ:Z/B= M4+"TAMHV[^/=,4TAY*;U=!O6V$4H!$*B"3 XTE/^N7: )V7YPH(Z^/22RKA M^;S/?'H?/&B$-SI"-)DL>3_G*8IR':!:_@C>?KJ!4HQL#5+$+#%4T,\T*WC, M(-L1#JJDIMLL:(1)M.?'\Q5^"V/#V970I? ,=SV7!5K=HKV^1BR@Z'R!GZ=PV_KA2X) MK1^TP4F8O#O=E+\N)$U\>E"Y\[']YM*>WXD@7][U*W+\*MG *1?]$M,A4L:, M"&^HY=9KJ)@Q6M=^K9CYJ#1#;\4/9^U1-G8#>L1>)+]"YZ]/+9S1^R8E\*]G M$C#4EK]]-9-F#A#5M KHEI^$9_;SL/:+1+HUIX["NKJ&VH3S5P.TS^'KD>,S MOT[JEM"C;[,<6$,= =].Y)&=H'8^*Y$V[C" \_7I9BG[K"9UO&R5.?O-0:;9 M&JK3'V\52MT^0L,"(4IYE\9LE--INX:2&2BEF;7 8?*Z2&H8G'0_41=K)_(\ M-)O'@*+O"FZS,YN(=L 1HIF_RM 5>RK)5NSEG\/SK 2*#P_5>ABR^HV\W@>L M&-J^.D].^9OL,E?_0$(Q/=^RB$[>?&PQ1/CBW6)_5'CCM@M^=6^'G][9[IOL MGOXS.7)13U"[#C&\65<] M6Z+V#^TL#K@IAIF^;;"U\C_WE:]=50/UT<,+.>3:2E)#4\MK+Z/R:O9D:V!A M2RW&9,8R+>EV7NCOWFLPV1J>> MVO*-Q\/[>:@O_N^7$XIUJ.0+A\^9)_-0R!NH!]%YS^)/('K.%C,[5M>G/HKS M0^>D: QF\)X-_?-WM/9 8E?X'X_#>^[-V#P8W]D"697&9E 2SSZ2QY=;#:6T M[_L0[] FN!XZS8Q>\.PF%.KJC,*Y5KZ-B (^JCSS:.YP7R1(R$S!K#NJ\+XL M.05.B/JV(8'#%Q9*=91A?Q!T+(BNZE)R]&8"MOZ>$-)R*R$I.JX(?^K#ZU$D M6:V!=Y-F-9#!8C&&>Z&N&A".IZ^AS,, N9AE//O>_8828P8\^>>=[<30A7I' MR:X15Y>FI,-2V1HJ8G!V87W 3$7&F]=A(CK.88HNLUW4"5+61S7FE>3DD(?_ M$U"W,SG\@Q ]?W9>8P8(.K6.4O>^K<@6F TV_S,J''<$\??NS[0>J$ZL@S7? M#SNU-4NY[,A]W?]]_BRQ*'L/?N9ZA7+H%^HNV)AC,M3]_/,'\-^Q-]Y6&._@ M8V0]KDL_M6=IGU$.]6UX6&M8<7*D:-^7"$<4#[?C>IC%>>[ Z:((X[T<#)ID M] ^<]^>>\P$5+N.26\L]3HMTAZZ]ES/%N-X0]G:77_:5(JXK9Y$MP[S-VH-0 M2[Z[_.K)5\@A:$E81Q;)K7&'%)K-B>$8,2;;JZJZ"I:(+HZ' :P(L*I^^?OP MP!=/9.PL7@!G\F:^C@J-G/XKMF+EKJ'C!JY[.\ \ J1MCSS<&(L1,\OVQ M D,QQHR*>9!0DZ@*",C7&+W^.YI>>RC92) SY^HV $/V6E?L'J^N MGF!MF)0_+NXBZ<<+UFNX222AUA5"=PKTJ#_"3JF5,FHB+%_!=T(ZSO>&LY0" MVSB"#34"TE,Z,JN!.WS/1 R8/;5$VHXC/(JSWP/*NTC6<'$$5 *+1",R?"GY M86J1X'%SW=VXM#74-61W'1!P#.25+"'F+XB;IYX$J%V_C<=;KN8CZ0J2^4R: M1YFJOC MAB!9C,UI3%B6EE;%\3$@HU U5-7?5$UI>_XPY3\7I "_I\EZD.QTG!D&_O?L MAG$+.Y5= 9A:TK!.>T8+DQ)S#D)MRDW5&_(]60@6/5W[G$R MA=Y\WS&XYM-2\O6'M0[P_BXOIT+$H2)L9B3$BY/ID8$E-1>1C?R2'1NJ#EV, M3SN?71>[N[:Y\>7KL8BC29?6>YY[_=[Y(TFD&2U63N1'PTD9:O(ZJB]L>I<: M"3O4T?H):%XP1#\!^R4IZTC*I>Q:1+\:*(P," +1760,.ZLITCP +E;:'9N6 M=#E7A+T>C8IRN_-0_EJ'+B"%L)&OEQ!E!).A--')P7FY$;"D/EY1.Q/E=%6N M-M"I59%IPAH*_"V.L"7%L-=7A>W>DX3XJVP[E9Q- 'VNQ89T%3&L>O7J4/1= M_[O3+6F[QETAI^MP^J(5HX/^1).EM87U@I[T:W$P7<$6(>B"0.(S3/ M"]:_!FQ/P5G@Q"'HSY*N/J;6G(J#7VB-2D7VGTMIULWY*L*6J>7R.VHCV^_; M($(F]6#2A<_F+=90S0RRK( :NW5;E@S.4;^JCP\?:^:H M28;P!=V2+[^;N--7%'I)L]\=S8OFZNM%5^J=! MFKOZ^>8):<5,'D910%9[7J-:J;'Z@&T7#0\G8_,T*9J<=5]3GTCOT$K&^IGSV*4:^A&/0&3;=<'ZXY F<7T[?, M46ZLQ,_0N5%LQ67M+FH(].).)94 T6=S*[3/EU]DQ4*>W7AKN@5Z2"8P:FHG"L?-X#24K?G._*UZ.)]KM )3P%EM/- MX,/R[B7[W> PB\G#7E;9;4,\FGCM\)7$C/NC";\F'%AF9KJZKXQRS..?1-1I M<\E)'MT5Y*0M29]_Y.1@FCE"K)[VK^J5^*D#]OOA>V#)1Q$>!9TNJ*3N'^0F M1?2T+C#%9!,@5A3NR*J V$,WC/B#D?L=A_("[S<_2$K!-:;_@X1Q&) M[:$;_K1:S$T=F2\($-OT9%&2L(N_P,5@C?AF A28KARS"N$.\6*4FNR/8SWW M^7>2$Y5CB>$,WXS4J 8)25SRFP$;R%QL@T_>1Q)62[4;XJ=46"N8L7A75_;Y MU @%R0PX,OKM$-7B+D 2X0V&D(RJ&;[G,(>RZGU2">7V$":?JV$*-FAP>Y1Z2HF*8QZ!' /3 M8;JH 1:$DM'P\8DPZ9&&U3)V*%P3>=2=9$R*/.,74S_=0#Q;^3IR3.1^%&R2 M(^;TTX(A5]<+M%UAGBU8( MLA9(U\;U8#OPEK 9@SX+^75?49.-J0=7*S]=/2NDN4,]N3N&W5T=2?K/:Z?H MZ\ZG8!@8@_F_D.0JJO>S$>0(6>L"=X]$AKG_B+Z+%>CJ\E6$$I/EB@M6]!*5 MLP(CCU)YGB=M-\00MLA1*D\@;>Q&"\1DD%DYDCU'#^[DZ0\<-4NC6 M MA%ET@#A,' 5R%I\ 1H0R?+%:DR^PP:4;VKJ&?_QAD$O/(SQF7B/\O(K?XVKJ M,L?Q2'+NXMNW0<&SFQZ.AK^&TP+B=@@" RL+W0BG5J]K?6:T^C!'83@7H'BK MVW)_D*,L%I&NMZH3Q[&0XS.0KK7@9*%%SYJPUWX] QOZZG):68R*:. 77PN0 M_2"_'F$HWASYX2GD69CT'K]C%"ZGHU_^EM%039-@#'Z$W&XI PV[^190.8<@ M'I5?TSHSA%H?.,F9NA\Z7JJ0Y_#=AWZ"YJH:U8%6/S2SCG/ALRI7KS64*,JN M 7(JG"5O22L;N78?K"]6,,E1/:7KY3/R]8Q32FTF"/>B"V0VLGP9'4 M&),IDAD/0[\'1PO3!L?Y3%59ZNGFX3>/);B#-4;>)VS./:,DV]^A+EHUR,8" M=M?.8%ZT8)YX7G\[B".P>U3DS0]DG^;8^]$&1O;]%_XP@+D%B0;]YTR528:' M#S>?[LA*S$2X5U[!A'$F@2I]&1"D;VISK_.:0Y! MF!S^V-T-#:B4/K;U!+*&^GV?_QOBW*LUE+X?Y@FF:PUE3-W=3]LJ4J]\O!LW M[@+1*A\!11.BW\/C2WK?5>B7W[[KVIQ?XS'^4-H:V?5Z::0\.*OQ3-CH+JM? M#;N;5E,='+;U_3<#ASRGVZVAHIFO&A=_URDU-1AB*6FE:H()$/YU+;C M.ZU)9@-=,./&N3-^HI.=T5/#SW^M#1#]5'Z@;J/_9Z0[/X'&E7LM@D.\$JV. M#%8?:UL<$ 6@(SYBK?:QS#[6;Q'_2'54G:^X]I0?5A1\NI!<=M82:[#]2:%K MWWYAI8MEC(T'Y!YIL?E)A^J@\@C?&H=K2.XZP8',%TN:P8G9 85 YBG$VR61 MOX>&1V;E%ROBTN:>3UE]-8G!Z!SZ*Y":ZCDH$SV\[%6>>1_Q]7K8]&V1;9G_ M\8 ]3GF;RM]^Q3.$HM4O!"O?4XFP0WTX=0=#1-^,V(*9*DMV_=2!<7>;3^V2 MHJ4TC[CE"[=BXB\_Y+,J9^SMZ-=VJA:7XRG>KI$>'W3KGU3U;F6$YH:8Z=*] M(*L?<2J9GM#]+"Z$$=)-IB9$ITM2,*\&$ ?XAJ(O9WE#04QL@C<6#/EN9QRXYN6OO2:7HA\FG$JHBWW;J&/4^"!Y&\TER34C-3# MH7D?1$%E+NXUJMW9E3_]EF#^@7H?)>/N=8_A]C-L'0+UTA M%7[_',^R&7KXK'?P8G$^$@,W0B.=I.WX+!(]N?]/.\:^*=IZ4QW^>?2>>)Z^71K]@W%JH$XK8]YX1Q8V<(&1I26M]7D M7(&^UBDJ8;FLJ!(,"8*D[(JIHMQS,EH3MA"QRE#4O&R*+=_D5E'8_4(;,+H_ MVJ.MZ75NC$5[3LCL2*:!\3JQMI$ F!IK L@BTOM,$"]= M6AN7AX(:D9S!MX:S<03(2=G>)W+JIY(@)]^!\Q1YSK@!>(E)ISR""9WVKE<_ M$C/%)?1K.%_.&)P9"D9E9J#T67HTV;*^(#LEC+9OLI7!P!V*,?@-HY(*E'9Z MH<-X*\1JB/9E4_,]D",BF? "*"ZWIJ)V#*>XI@JMHIPROV>*;>A7[D%XAHID M.VV_#3PGJ$AL\;F\RJ5M^[Z5M$C,PKLE2N!BG?"3KY1O:1JDV+&*W9ZD7,+E5:Y5>T0I4AOG7GG ;1B[4O^%=[2F#,+,! M=Q,UJE5]_&Z@)Q".A'XB9BVQ;/';#\7<[46+ XG*D&RJL^*Y;2G9G/B33'[- M!4E6HC\#K(0$,V[[CG=-4NI!Y?\JP!YD1\G[!A7&)*&])9L>P]P"GYM0&KV. MVR2TFI00SU8"_T&>_FLEPDM+L@,S# MI3T8HR;;ERFYB*^R-"G<^6C=[+SKI>F^[R%73=Z(R.M<5G1ZK#I@!>9O?RU2 M.[UU6&U#K%48'+E$F'+CC!B5"TDM5-V@2PQ26[W]]R8W+F M(+*P#STZ,V[5VDQ$)Y88O:MF\RQ;]LE(K^+B2(^KRN[-I,7FUVE=@*M8JRZ( MK6)V!Z:>D/"L%8$.WTK/P7^#*X?@5+5\\RB<\/R[B$"G[WD2JD\LO6IFS\7+ MJCC*'HVFJ8 4)6A_VOZ['KF3U>(O'(L6VNM#Z)R0X!5\I4)P1:81KZ&V [XB M[>YAK0GU"\B@AVX$QT:!404JIE5B"9%!J3LP\@.CJQPS[.9&P1B.GH$QG5H' ML.\ZWUD&Z(E:AYOO9^AU"II8(K0MO$0$+>]4(H#BHG";V):HT1,]6^UUMJ!3Q?N':IZ<.&A@40Q@;N?"B31126,V^>N MMUHQ!,J,&<'+FZ/NX7^P7GH1%@N&1^[0%W_;TINJ]NQB65.#X4J0I7#*HNK[ M]'7Z[!>*>FC[X+I:F'F\'XNDJNE&1U4:(\03?%&J#'3Z8>C.'&[_1:7&!!CM M+KD.C0(7^KK*;;G].%=UZ4P9!;=OS'>1#WI>JW<8Q.\"Z%WV5E($6T'%/X6G M,NZ_%!3@[6E]VMUP?G3TQ8I/]RB* _=Z)_F\8P=$=RV.VX.< M170IP%C+;"MNX4=F;K@JY@E@IT09(6!N(G(9@QN'^I'<@#[\)VCV\ALJI_\8KGI D MN'HIO*C&OK4<#_9DN[-,J;^"Z8@?A/ZM:07]F1QH64QN@9HKH8O?#%+\KF;X M_U LDJ%%')N9Q?"FYM_';2$[9O9"#<9X)IR=DU(6X,>=X3FM' N8(XU1_' MNE)JU\V]F7!8_<,](H"^PHXV9]6GE';^]60 M155CC%MU?/J;<8O5W[B$=>.A *MCG- ,H@O=Z?DR>K<16FN"R;;?##*%=;8A MS? A->9J>%,!HW/.->30;W!-)]]KQ(U*Y/A5]ZA\(L26_.W\TB ;.F-V/AO5 M#7&0K;[?@MJZZDB8H&3DT1R!?2/'X8,6#\HQ12/?02G:'7#Q2A@PLA@DK7LS MP#NRG)$77[X=PERS60KX7\(&NJF<]'(*'N2.=H_4MF_&C$:+; *ES^[#F4+^ M'HB45\<+7CE^Z#Y,5TQD42/4>TH[UE"-5M>ISDJF;6*4 V^$2]H47^(FJ.(4 MXKYL\?K6 M?48O>V)C8ZM>$W?_L\S.%$3KY $(Z-*H27 @$E23\/$5;4@ZDD])O!]VW MU=MD'3%9OG1ZR.AGQ;"?WYN<;9@0MF(XQ MQ]$3TA2)6F ->QZ6:+?*X8H>[2;0K84#$X0 #"^ MA?RSD*,/9?$EIRO74!N)60A1*3!#OKDE+'$4/)!'9621;MKO767P72;3=@GT M\.C$I?!8(='J)>V?9GMO*#:'>E0925PYIEZD#6IM8:=PZ-JX32MHGBBSRN7Y M@1*EYS6J9X:2OB71BF8%>8SG*^<"OAO!FR:,E'\UXD&4+O\_5YWN/2)5%;/E M"?M\DY/MLFZ/S73&8\HH^\(C>'-&W&\?WE2=*-UQ_;%\1_!?+_R5S-F3.K3[ M$;ZS$D ;+B%WTBUU*GJC$%*DZ]BR;3[P1UA5Q:6:U(>5>1&. M%;_D^DR6GSJ-215>GM"/"T19'SQSQAWD+>[1-*3<1IW\(Z?]%WW MB^+F!]-.!_LYO;RO_X7W,^-^X1C_ MHLT(LNVY;'&F(=JIZ]FW?,[?Q8/BC*B6)[07Y4Y;[IVNWURV1[WCCJ]ID&EF M95;-!\^Y@ROA<(_2J:SE<=*Q)L V8BH#XQ M82OU6TAP):5O W!.+B)LYUN>F=X_/A8792OA$C?!]&\@_^O40)4=S<[I<)[F M9+O$_1G7E:ZHD&]!?!*51IZJB2P/ 8/FGB]B;4#WN.[5=&&V),UJUR/^<(N2 M; #<)#/2WM]0,3&ZK!I['?LKJW)_3)4UZ1T+JN5CV$(5L9'BP7W,$(:'Y%")JC+GD'Z9 M8?!0"LDFWDN3IVERQ719AE^-BAN1AN,K*G<75;+]@%]<"#$%AM]!=8+">7(> MR2JE(#:8A#J#G"H4!8%[(ZAD""TJ0Q\%QQEJ3,Z^0%";1/2%3E?>BTL[S53U M!B@W5(!/,%9QRS36?>#JX!K*;W"^#M^C1 \S6>HUU-5L.*"S)%):!GE^QPR! M,PT*Z/%-3T'-E056MM8XWQ\^"X8LWH0KP !A^0X!O0!CB5@GUI',#:$"RZP"A%TDL=;1C8UFAV1J-T; M2:.;T7K*]2%,X7O80'ENB%O^*NLS/UU6S M)8RMI>X;YCOSKZCJG$2GQYU P14>(:D:;E%\,8(CJ@66T\O2_XNI=PUKXMS> M_U%45 SA(* @"8J*BI!:.2B$I-8**L6H* @(V98BAXBI562$(5&1A(.8;6UE M%VHB(B)RB,BI8D@(2M9 MZUZ?.WF>-8+XH9 6+X7AP#^X!WJWP#>;2R^@!J)CC!L:W?*#E"K)J:(C#?&NA3M0TT02D@$'MXES1>LV#@3S< \DZA]5(]UQ1>6G1T,=QZS8R[%O%&JG M/YKF3(;&!OBGK:C_9R1(7 HTOAIOX[BARR*0Z?[/NSG[8S260[S7 <9(YQR-BU*_"DY;C.K=M'D-YMM$V\C7^N MX=ACFBC40E5-5#4SDP8MS9]*(WM<#]6 ^^'EHT6X'M/]P3 MWWV^^(#@,%*>C0<\LMSV4GGWAS%-^MWR]"5H0KMX<%#)L<8NU/AET\S!KQ%N M^[U@A7Z-Y!BBEXL2GX M2631+ )=-+N*QY,J8,;J-[$NQ /]DY)C#^8LU&1M5CNY+E[=MM[H]F9$Z-8E M:&5J ^!AM;-@%7;$DRRV^[I5!>[YJ:M9,^A;.N&"LS+@+%C?Q5#0-#JHDY2.3H*T1F+ MFR"W^I[;_CLA4UP!O?BCM(=!TX!E2);+&-\+.;(?!)%O@5J"S_&\]<$M?^73AN<3E$9 6I,&90^(< M&9+'HB/UU$"(GJ^]G#74X@<-JQ;-7'![1'"+&FU(\8"&^9NQ"IB80W-I0+?^ MA%3"G%ID;!CVO5,"9,3T@ELV!1L\;E=COO,JX4L#^4TI-'R+F@1S22R_6'=! M-)HR^:'CAY?Q;D,UL3.[=5_(.NX93(#YJ)2W:=]L>_X[!<-3WLI#=O\V6LY:OHJ/+H$$"FT9<,W?U"K M9'6%O$6S^(EC5=.5Z\Z'0;)L<6K'A.]8SR'O*S^0UTITKC+']#JUY\/:ZN9' M/]L4%!VBALUOQCQBL*PG8%27J1695E(Y$0*OT5L;4'&6&'>YF/GHW1AYI<0& M"6,B?]T5& 3+L-ZV.R;%XEAA:9!'P9'>",18\20*RP\11'6E%CA][W:46.Q# MQK9MF MZ"W+)ZW15+/=NNH[_N/]\HJ/OG8D=F.OA%$YEIZ0XUW@(6^F*SO/%LX,8VFL M/Y,U,J+10PO2- V"F['.6!H:.K5HMO0T1H$%N9R5 %O-V8F>S8FISB']_[U M:V]9WL#?VI%.QUY[ VT59C\D-L->A*(U?%K+UMHR29ES- M,+72S0OWN?$RK=T76#32] 62S>=[ZY=_.L-14VJ@6\6.31I\!Z8].3KXU:OW MGG%?AY"M(H,?$&B14]/Y)U).^EQ-W79NQLOZ1*G5G]N' YZ'AEW:'F[R%/RX$"$ MU?I]Y O0L,UW,DMT"U5S<\]A@=.?:.O[=0D_:)3[B<1J.#%(Z+CN'OOMB;M. MAQ_\68D$26K7>N:5\%G_D!WWA!3\JLD:^Q9GX%ICB,DAS1 MV9R=EV+\R016Q _8=4O?K'U]'VV\1W%]*[U^MCW345T+TJ5(@H"S';L(,]MC M=D--K3UFEH)"PN\@72=/T\;N-U!]([ M8ES(ZZYQ:S/Z^4AX>NPSXYH!,*QB 4+)D/@&;2?V#7DE,'Q$=*++%361^@8U M*Z4BV?]$J9)K27,%XF#^=3'A_4\7$RYW)TD_1RY?JS@=N=ZHKI"SMOYTR!>BY$^>@8?K<\/&9#L&Q+;XK3^ M\^?/37B=J>^/$[7IO#3GC@^>X'W4ZEB/)R?@6W,# S EOW+/B<6=V;,?:X2-Y%73.@P?E=,Y%>G!;;V4P@5<6*ZD] M.7H&F:J$RXZL+G"J,B!16ZZ M7%:.A1S!"LO E:A[+L<)W\_.'V N20UT5EVV!=3PHSKDHHFOK*4;3R?-ZBP* M#Q3@SHXJ]E)P&W8-%EQ/,S^->G;F>%YZ20[!!.7@-M0QI^K2B4K48F8"X?V$ MDMNV0PO'#<:UG7P\])S,FK-YM.BD.->;8G\JF5F;IN[4:B>_Z+'9DG6JM_.& M*7(4B*D\--WB0#@['BF R3S)WI2RG8Y1JHGR;J'5PET: 7-L=V+>E 26CG=W M0"T7VW7;$0;/A[P>$$D;P=9EKZ795N TI;YRRR M)/L6RB"N)>!+MP+B%$7A/S\ &(KPJ-BSP[\;/18D>!K2T5Z4D$/;!>[M-3KC MO@.+9@F!SC"33_7PNP62*Y+3=!3L#EH'!;?)>,V, O!B11-/0D?&3_6(::[J M.#1H_4>?13.>T*Z^SU.RKP1DH"KIS]7!#^<2LKGG!^FD0Q"1 %C(:7;8-8/> M%D\M'CK99UR._78?*!]2-4QQEX,Q* 2R2_!_]8*!FXWNR(U8&X135C(6?EFW MM!8=N&/(H7A'ZU<\NDW@YTPS@WH_'2:YZGN,&G&9:R/YJ@LS_QJ+N_\.J#20 M50R;,1H!2>-+(J%.%RR(N"RY2)Q_WH>RVD2))D(3\"1A$"7'*;"_21GJ&--5 M'W.8:%]<[7SP!W5?/?>JT*+72T)XK$\F!:+GZY!Q=;I>*5C-$N[%\@T,Q['T MM+S42;[4%8OD;OJM>CPB?+QTT:S-#K['.M*(_.'0A5T>/-;R*[HSZA0:J!JH M_6[),-V>XPI^98IH(I$OJN,J9+91H'^^2?4-[)M2*E:P4/"(9=R9I1 24,%5 MR98R+ 1J+(37I1)7!U>-%S7E;RU6";>BM"PX@TP +K\://(4^:"=S)^2V0#1 MM_NYB102;JF9,F&K8VF7=%/,*'D5YW,P#=6TI^SP11QN/\#M,3\Q$/9U<]\T M<[DV&%X(9F+5W(> [&M)2P_HGE"">43VU[_C?%3AEFA.*^!&4M17C#KZ4IMN<.,GLTAK7CSM\UXTLTIVDI8D M#0ERZ,3)23P.%M@!NDF5OX6*;8-Q52*;Z/8[@/AD_Z!**\Y/G5R3Y!JKNK"1:&+%WR]ZTL4S?S1%8T/&#-WHU=WR6)A-V1_ZLL:\R\3;:* MM@O?@S70ZOQ4@CSA:FS7$'TI&*P!?3+(?*D=&,(D@0>1+4WY]<4MP2K2RM[Z ME//ST0A#R#KYSFDMSJLQE3=R[$L.Q6@_NI%(WHKZXK)Y5FU\&367?4-C67$ M#Q>0L^2):%,$;/Y".6*4I(;[9#8?.1[@OE^Q_#.&<:)9DGYU[ZEN:H2O=';. MOD"O*/A\4%XDSIX2U6(AX=U.8X20?=)*?+6VHP/Z1WTWG_7ON7CY7V_OI:$B^DF3=TH,[0V*S$7V# M3-Z9)21J0+\+F7!!6CMG%58P_[D$\.,P01R#N5%]T<\ 1X4KXH!RENY5A'0UJR:=\"7AE-W M%$T1G0CL3%\UUC[,N$M("'W:8.R^#ALF[%XM^?N0*8XWDCE[ZNM[J61H#[BE M6@_H9SQ, -OP<_D ]5 )4#>4-K%^_C0>@#E7CCG\C?'ENF5YPR?ZJ#[5XXP2 M0 9]$-E*">.L3'8U[H/)#*^G,AD??DAD-FGRIF1+@46S:!%4MFBF5&$^B ;F MJKEYI)VB6*13(7"'!-@NM^?C3'7HJ7)'!H MT '7FQJYM0AX]*G)7R7C2;5BPH3+NDRFG%I5? ^,,]#PA73/U M(J-\(&K\\/,7:'"[(">M.UE[>J"H[*%_2W5V]9^^_K3;[&^7M+$6S1KMC<5P MZ#>ASA"I1 SN-"7]A#,R/'.JG^9*OUE_SRV2G6OT1\77<9L*EC_S6LW4&^8Q M+ DBL-L;AJI!]V+PP?P&(A@ M<1QEY*9('09#JT8N?S;XVT.5 ;N/W2/J]RR:T458U_\W5"7V"AJGI+DCA0I* MCG$'$L[3;4.Y/- 2?LEMDSJ=>G2OP53#(W,K2AXG-OO+SQWHE_=-K_.L,G:> MZ[A(+_[KB[:(PU/^K#@+C2LQ;A#_8G+PSJOZ'6T\-V)4V M+-@9ZN\STE_!J]SQ?<'!'F58&37P4-B/R3M2Q_;X^*QX?J%^!_P=(/'9TGRJ()AWW<=IR_ MP.W4X+9U,X,+5?1$IB"6CM!5+?%&5VPK>>68T$W:S[@!TDO<%9W6;\8='+3A M OMAGG?FUCW5T_^=3 WXMH?ZI9;W:*)T5=7YHV_&1(ES+(-(*=9&G\ &YZ,P MXI ZG^/[TL T P,PM]3Y0"R@54?$8AZ#'EDPN^ 2>7WL8'D[T1I[(8_0S A7 M#(",LA$F(NSTR_<>?^?7>H%U$3AN^'K@99E\82]24SL4$SZN7#7TCM&67C @ MJOB-#5]"5#/Y5RXF5;T/1<8['G;L;)R[.S(<+CAN\^Z'9]>?V\:]G)0DS?O@ MGV,58I<$V**-:0Z>P_W=MA_.QY>R;1C_B.PP ("A\ZO;ON3 M>@!V2(#/QC$^?XD* MS[20HX(AAH*=(]P]X.ESC\G$(AX T6$]YZ;%V;'^2'G.I4X"4'BJ?TIOF_3Y MJ(YL(DR=8C\J;8 8GR&S$QH3/!\%OC>HBWPK# P2?ABCS%N%0++56')GE$9* M>@-^A?UUW]@K]#$I=/TD$?3%/&%FP=TN61;'ZO184?^-7?CAQCZ?E-T*DC/R MD8_,'R'M0*6U]U/#:-5/?FJ)3:>_ MR9@Y@Z1E;T1N&-=T7[IG%U&/L8=2=F2R5<8M=YB':"Y H=+HCM'+@>AV?WWN M5O3\;9B]!!.IC*Y]'*?DV V:G1(&%-U1? *IGKZ>..<=Q562'PN)]XVO]>LE MK"=8B)RS'K.,ASHWC.DL%AY2SU2;(@Q),#E2N#^#_69>*5M2'Q(:+?=G%- L M1DETE,RC;9*C'4=^4)PQ1V1KPKH\H=<+ M:0_H^0 D]2V:G66_H1CX5^L3ST]^Q-DE8TSR)8H+EG6\E[HO_5)E("7LUCJ) M_T"*9]5_[V9]W5OC>?_V]+T@PNY1 0%?@T5" ?>(1WNH.\HCD%D>G@EY^L7T M-XAM@#O*[T=$:U,[5V/%\&9_=2XUN#*Y>3)'C,>) 7);4LI\'E>]UOM/68 MXQ_,%=CYR6!C;PKYA"EW8M=_K+[DF7#R:8MF:M"Y8]PR)CS 8_S%E:NTC0O% M>.;\?OQ 'W@&CIY:*,%/#)!=9"R9!99VNF^:^R;BBX6?!QE8$MIKH"@F^;'D M >\%!X/1R;_WJ^Y+IC?.;IN35J0,I00K_6B;:E]H+M0DIED^T;M?731C?_I6 M]'072*G&J9C?T @=VK90XDU\D^0)1J#?[PTJ1"-"L22#+$?D./VH!:'< ./C MG^!^R ,L[:7JH]%G5*.1^CZM0P2*EXQ6SF>H0.,@>M8DKZ8-*X^/ MAC.MIZ*)#LDD:K])M]VXUEB2>@8:C.3G^@2(; 8E3E#,/G!Z% M0?1\-KYKR+D1:9F>O,%QP.BP6"'.&J@X [UD')0AQX&]DC/5,A/SYM#6Y1]$ MP[,RAUZZ,9 9&9N<7?]ZZBK1VI0Y;/UZ.;R.8W\*WW#+8/ 25($IO=2DA(?1 M( O[>B)>-DHLE@\MM)#DB#YD9U2JJGHZJ7A8YI?_G[[>E3HW->_(PU M3G^2__76^+MHR4=J "0@R(=[<7"VO!*5$_MS0F>M7),H7>]%%V2GH#O@C.N%%&(B7[-"8KYD9T;_S[57, MSH8WI_&F)O;N+-T=RBI7K%7=OWZ5%HI,3AA@IAUF.%G7P[$ .HYB%XD"62*1 M-Q.[\QGBIZXN\BU#[(V;DPIC/T/5-\6A[KQJYR-8;16K M:&L)3#8[->8$ZC8-@ >@SE7?C'*;"I7Y=,O$='$!;0VVHU=)MS5:UE-=K3DV/D.G9K"_- OJ*H24%>DYQN+U,0W(94TL+'T:$9"18*"E'W M9BR=F/U-WGOXF(LTOV)4RZEXJ'_TCAG:]^%<@W/@EY:#I]QOFK_7Y\D:^"K9 M#9T'$MR6$@3ZR/.-GR+"2F_,9>5GP_'[P:^1;)A&WJ !V*V;2'&MQCX5[ MDE3#/6>EB6ASP;2RI%G?IMBU+Y!R_E2^Y<0W3)--;YG)A3QPMK;4P%03XF8. M8!34?8@JW(S9H1D&=R7]31:C1Q*(.K8Y7.:X(=5Z%64]%NX2#94KR6N ?Q1I M=HEINUT.LY<#S__J/N?S;GU\G]=4<8'?T>L#8Y2'YV7Q]&M-14&"LDY(9)W_ MTN*49GHBH/W?8"A6GH1&SS-4X>%1"7F;9=AO+,-!SDZ6@W1S3WVUW4%-_;NX M]C3M^=J'0)K"Z4A)TH5R(.Z+QM[,W:>P,R8=9791MT Q$6U15*,SXO!\2&8+ M^.W/>_LF2>@\P-DPYA!5?DWL71SBV,A[#9R=_[IWN&?B)$=-?',FMUIG__>( M^=^%)Q>D($-L[":M1(=YU# +GBQ^DLAY15_?H'<$_)27HS)_X6S$U!";1[&;/E+)-U@E.XT]/K@*:E!P7Q%A0 MGO[Q]OQ%_%1_ZCB%9QCB93_"C\BPOY!.:,Z@4K\*1B\U\Z[K"=.95@9%HW9#DJ!_&_<]FS6S1?U#/TY,= M*LY<0>[((_R3*>TY^I#"@P7UE3\N//"Y8M+5@O',LH_&SCX+9VK13J*;K!L?>"&GKTDUZ:>)UHV;T#0%F6#LT6W'9$-T*]:GZ0^AM)]*C7_( M'$RE>2>JOSXT0<%2:#1>;Y!%"(@"P2 MF:UBT1O42I\!25P5E@"QLQJ(-XPK%AYSK(P=S5)Q%7Y@P'LRQ[&H4REP CFVZ3_5,8;ENWN+F MHEE5U9'_ZZ7$S=^S7H$I\_:)I #L#0NE MGT0/5!?R_H7=1NK@O]19]4P"6J#OJ-B:2A8E?BTIY%LZ&'PBW]^!*3$\SW3_LP M;8A>-.,G#"6T,PJXQ(8[$%'@3RJV%RLHYLDR:^JNA_A1=#;7N&Q$O\I[&VWS M2-2)@1EMYU6I*_AE4Q?(V%+.F^K@.N\#I!OY76X+3SD^B3I?U(*/)R'Y4/RC M["%1/OW9L(+ID!R[#JN%)Q)."BE:133"OB%Q?PRP0_MIMB.^A6$ 6:G;_IP2A0T&55VJ2G?C7+U46ZVT! 926W]#!S^C>6@HSKC=+"TP.M__] M]DO7SDL<*[&, [(>25K,F>I-T8\42@7D2ZY>.F(V<(U ^ 5R,4=3E!2;/$U/1S;D1F1'4XO#=W@ M-'P-3#7\EQH Y^=3+$?#A=1&"=,NN L,7JA:-$M\Z1C52UV2,"2XP7%"/]"M MN6<6$H[^VO3IM[!H*),!$2*%\-JK"@MYT.VM.8.\#U1;#<3CEDX80-O..16+5V TPTR2XS?]@S(4OV M.1&(*89*?J MOU[^^8*V>^&>D0#N2SG+M,WFK,,XBV8GZ_I]%HBG!:'8+EAL@^FA M?_4T3%B<[/6YMV*^5>>!IN6FMIB?ZA+73\0.3$:V$#(W>]UVM6A8,Y2P7KUG M5(B-JJ&#[XA=BV:4\TDV#MXG]C4<.WGB^^^>+'W\YYU6L^\OJKT_MB2:(X6P M'K?O;)=9+9J=ZYB\=IF^WXDDY%'CGXR(;&DN6*G:5[A=_ S_'73]WP3WW1^O+"6Q;SV>R'>9B2[Y^@=F%#%E<;Z'G:D#>="8:, MEU:K4E.EO<>^Z6F(OF%@R :F'O^PN6?ZW9>OQB-['7H9,;2YUTDS]+/C'&]\ MZZ>QW3?TUC0"UOQ/5"].0=W:M.4W4@?U5J??1+(:F\]6+VEZ7GRXN>_21%2; M;MIML\)SX.>,I7X4MBLLG;SY3\VJET_!+2$W]H39*TY5U;F678?!(#?R].OA MYWVQ9.U9[]*)RHP]30Q[O^,7VOHJ-L3[V\I[>2ON1>GO A<4PBU_[N63(E#S M6]^!9ZZ^ AY(X^2GOO:*7!!Y.4&C"ZPW?YT(>Y:[!\US>,%(I7Y9@_51P,3 MY'\W+;10/>)@;LY<_$>1XZUS\9^&4Z_ S7NE&W1 6$B_T178?7SAKG$UIVM. M?S.5;8,?1TV=A49Z/=I\'#_VDV-D'Q@*1:__T$"T #AM'2?0(V(6J7J"Z2B+ M9RX#H]'W]U"ZT9;MB-/1Z:8LON)EM)*SYAEVX0D#YIKOJSZ-Y7^-?*P[@^Z' M)I4%FUXG^NM*J\=(9)/L>4^8J[0[A1LUT%-TK:^V3$GX ^N=<<>B#40[EG1/ M?BPJYE$O/L$/Y\.7[\#5ZZE+*M]B^T_<&1)?-2X9CR5WU9-)V*?.T"?9:'+$ MH#\RR(IR+P!WPSW"K8U9*BVJ))+SKUU&ZX6O_ZF.,ZX^@)SO^$J@HI$0 M8CL]AV1?B\6=05GMTDU(K QOE= FNQHF)UGM,:*]"H'[:3RGGE$GR1XB+$! M(ZNBF+FXWU#@[O:BALX93P,0I%=]'OP7R:3$,V/(BG\WWQ54X7NQXE(PM)?C M,;9HMC(>"WPR)EJVDYJPM:4$]$+8[2EAITF;?\5>B2PF0+R=K)+NA24= U(YB/.U@*'+R46XY5A>F :,K::5;> (VE#-!ZTAZB#%# M;BV1TITX*JXE'@^S[; _649O9%8 'D YPX8#HIM3CXUDEG]AMF1_!4[$,N=I MXT92UQ3;Q11OQ-"BV7HL0<4WVKZ.0\.+KY0G:^G9[Q', MXF?,8%R]' H09 L_1[FM8C-L%M;D4G4-M9]W(UA^0XS>?'F MLR+TNW&1#95\,2,C#25"7*5@30@DR$X3[D4](>P"/)^_[K@*WULQGD%;N_!L M^/D & PYZY<#^3!;F0NFW "CM@6I^M[%3YHQGPH'[3V.% M:-R7R&GA.J2F GWT:H#KR-(NFBD&+Q5_VD^669Y(VX1&O$D5.TZ3?!;R\(T& MPHY91AU6B0I:FSC;,'=Z*S'/7W.=PED?R<1CL'0]\D-(N=K@06!#EV50BV,, MLK!H=HOFFDS;H.&L2R03*9>2P%38TOG+HAV)1>$%R8S7BM:[Z?V=-ZDNICZ< MQR5RW,AK!S'1(4P A4PN>8L5?I%MM,2W8/9BX$@G ^4J)NTQ2@22D&]"J;#6 M]$99"2!KXVP]@=846N1[.Q<0C_?@5*VKA2OWW.B4R'D\UJ'/Z( ?1GUKJ\&C M6!PB,ZV+@KD:"_NTY\7%64G;L_ ?'X%VO^FVC"I 9O 47#][)[B'N@7.=PD. M;Y0A Z('R;(W1O)GK('NTT!;NI:/KV4,]8OX]3'?#[:1[5(]WH ;Q<"X6K?V M%H571,^C66'L-N,NE*^8X##)6J 29O/K)\(BZ]!"A2AGSKXPF^:0++,%(^$ M@1DFY*X>2?_KIX:R_LDG([)G"=>\!2Z)9)L::C1*9J)GLU%+NXT??:9[U'&A]^24L7.;,LW'6D.M4-@P\$UQ-I8V MGS X+K5$5O5\F!)I*]4ZWQZ:&Z8(I3];5F0^XB@B<$C8 TW;+,='LY.V&_\* M214K.FV"*\>=B*;*1#C_J'6[T/?9AC>2?="]G=@CO5SJ.7")^5BZ&?0J5#=' M\,Y=8N;2[:1VR;'6 Y[3!40ETW+Z':EMJCXJ_F.!5Z$XD>:%S-Z4K#($KAC_ MNL_K0:9CN]0:M<^^ASU%'>Y8W8,SG;\:J)\4U8M?9\AIZ^9I34/L/-EZB05* M&SZ!53P!U 8_WC29UX-_@>6[MV=>/(!2!!,29AQ,X3G-*H#JC]/Z-4"4*1<[ M(0I?9]^"?(YQ+(GF[["TD'Z<$2?=[S(2S""L^,KP?8 M*=[WXH)O%\W-'X9IF[GR?>>G!KDYP:W<56"T0S;$?M,Q\Q9[3E21UP8/I43O M[P8CYUW +V189%62EJ](V0V+^9(X6$08B_7L]?+:-&_U'(K9?[*VG^J>Q,YX M6%,.+R1 DX]5\^;@QJY7^7X*T5HP! OC#LWKL]+TQ ;RBC&A=5\Y8@[:8/$& M1I9T/?^K1BQW2. RFMX7U:GHS(GU[,+#C0&]^)G4BLXG+I=_-X2@A(9'E58I MP[C=.)0]G-5Y?1".:/_QJ0Q+F#^%;T7#'Z3*EL2R8GV1PHD"0X ^A[LV.$>< M2N<[=LLK$XV?2P312% E5,DFGAX5Q['BQ"*[I.-C#HZM+G\R&QVO\6^Z(;B. M@/U;MYJ95Y30FB&ZU944NY9]8Q5:%_:BOJL$ V\*?44PM9",%.NCP+W%*M]% M,V*-E!2)'[@GL4\UG-3L;+#,8'[6(QLJI5N>ERPG*CNM\9V8?HBR@D5?1@U& MY^5.G3>G9#R'[X!_6J4V&JHY)+9UV57/S=-J 9KAP(!T&[#>QX4)=^#^2,S= MW*K30,^PZC;@N ]USZWGGE@TX]$0"WQKEM*BG6S+A2SH]O63M_[&K6+"VKKQ MK<6&(X6I255:/"CQ&P3D6C]HH5&>/L.R+T ![)S/P#W-6+XYH#/(CP-Y'XUS M(]WT;XGF&%-!7DG="[$WX$>0"76K"5R,7IC+$,/V]5BL5;/F :*YV2"Z,?>^ MK&I\%XNTLI^ZMQJX;BG.$JYOXCGKB;)LRJ5WP[&?LRXX-)8"+N$M49-_#& //N?TT_"YXBZ76:-$RN3FKJ; M.U+2'@!-8:?>AL:#C>D_5?_UD^R!)@]B"5SKJ_-&_;_16UKM^2+OYO9O)_1GM\@2L_(4N1:64S5[#_#9GP M8/- <2MM97%;NGONSE0*=L!DF):@CLP7_=/1,6&'[DXJTX,>;V[H&5 ?>7IG M?Q=)$1XD]2N,^-HGT/V_QFN"_8)AP<"O^K7C)(N>CR"=?+.!OFITUF].XB!U M9-@Q$P?2'--'7V]LZHH(O[O=R^>;3FN>YYY :&>Q]5\',F5\\-"/2+E=UZO= M4JO6"P-+U^U4$[S(?T3XK/ZI=D_\ZE/_E0_]L_K[RNLSJ3L.G) /W$SJ%X=; M92>?N.!-]T*SLNIT_D-51_8II*[O.>O/[O[CV^( ?G[7OJ>PSYNN8H!Y9E=Y !@T4PIJ^?GT[]U<5?)"-XL M^BI.=^P6Q+V-:1.+'9F9#.JBU+\,BY8@Y\O1$'GLNA94=Z\:2/@*NPX&IL*3 M:_ ]Q>KTRR50!H5,YS-N6B?^5L$@_R:T7"@S4A2H'>2G*#!7BFP>:5([M;(0 M+ TMA=@3+(AHAK'@R38]OVCVPZ(9F@$S^!-4/YA\+9U6BO2JYRP*HB%.M8&Y M$A@^@-)S>WK^UACM7[54127[<_//4=WG0M!HN=Y2DCF4&=RV:+:NGKMZG&,A MDW8[O!]4O4QBEP^.*Z)ZU3>F/?V.-]_59MJIBKAYY(//D?,M#V-/88(@]'1Z M4 GT8CXPG4"#Z9\)9A(7BB?^:D"J=,Y-$O1KX>X>HU]->17^!?JH ;UX"N5G M375PEXT* _LY&UFTG2U8.4S_0%XSYJNW^F'\%+JUM$R+N1WE0V]KB:MT7MGN M[9J*U?WC_>5!0J=[YX(V-5 #MQ\Y\71J/*(Z2DCZ\J35=/G"\M M^[+X\5_'7AU?<+/XLL9YU0W3VO2WARN@[WY-__5WM-SI=?.OH*]3]NF8Q)Z; M24&-7M6K?VWN+E_76W#NY*E>TY5?XOY^V33Q!MU_% M$U+"+H$VP]#2@AF4W M.%OP8\BP(I"HU#M*TFJB\<^PE/@'^])JDL5#HFM%]3.>%V&7M*][?3)^JXJK MZ_9*[;0:T9'X\(K:QR]=RC>:G/[RY5AV_$64V%XH7='3(%Z*_= YL[J]4YG>VC\O"9=#9.T\7"X 0X%QMW1(,QV*$ART4SOFB5-_W&7-EL 6Z3@CI#%CS:-JPH ME'4*,YCND%>6Q>"T[DO59&54L"I4N%USCFIW_RTVVPZNG[\"S"IU6[L^]LI) MC'R:)TA9^,^48"GH(<6R2_W:N 3\.%:&LF?:D(&6RC&2#_.&/T-0\JP.D;7F M3C84Q,X,GVI"CX_HK)'RZ\;U0(@J_9:X"F@:-54"IT.W#!V^(;&W:&/8CZ9[ M=EZCIAD".1W_MQ-8EFO<]!P],)?M@;KTWDT";7_M#G]J38L MJ?^UNXHB)0&]BKF9K+@SI2/:6.+"O[EG13PN0;(%*9I5F$HT6;<<2T,N'AD M]V>FE&*5R@N@1Q\>C]JUUB5&.)D#EXE66&^;< =*O,5QPX*/8BEQ4$&8W*EO MUK_S.I]?C0<^)+B:=X-Q:/K\4'DKG00F8_\KQUB*88A[ TPQ,!U/ 19*)U'> MI>)[SFV*\):>!UT^9!L@35Z4_>H%'$CJ#%U5TOGP_C/4ZQ$8$/>$U14]R$H7 MO._\,#[_/?YE-XT$AB)I2D$NU_+34$-!442N[.RX>,48QP(5*Q*EI$>E\]\ ME0K9FBDFWVDR3^H0Q7((CUV'$>:_B 44\N;WLGA3EP:Z<)XR[E2H"O4E6_N65+\;OX,5JAS^=CDP'7#'.[0"5)%NRI-N[\0B8L62\J"E;XKY6.R#@5HUU M?]K,;C4]L=H0%"VP 2)4S6G\5+'ENQ'MA[N:[Z^"99!^T!SV:]/G+YHYUT]J M8T#G,M"SF^,[1B?VJHK(N2_;KR$%E]BOU5#$!*%$^W[1K%7HT.\C(F(S'O3\ MYFQCJ3C9T5_$PR]2^%3'APS8)<"4R3-'MN;.?PNFU9M*:U#IU"27.;L$<6UQ MJWJ4/>F/\0_^L*0?C?0SU@D*TT\;,# M'Z:O'2?;4/=7@T%(^[VA0=G*<;VMC\ 6XS/1^$6SW EOQDK _4,3:4O?G](^ M;X+;X:9?YV-_@+>G9\BRF$MI.ZOU2I<=6_H2T!KQ0TR"!V,QJ'L[R:Y_^E[P M5T@'YGRDKUY,QC]#SV95;KF/-,OX'R?J,Y,]=X<]R_U7W\0D:>VV)?]LK9R_ M.#X.B($N=20&(%R.BW:H#&"8YM/:\CDZ,>"7^:9['F3O87 MWJ3M!-Q:I6:8S6,\8Z&"8_X;2B+F%-549$(!BV9OAI4R^WHV$2M7.\66#F6: MA_34=^9>UJ^0Q+ )=XMKDGM&.-O[)#901H#>+IGD<:"WA2YGKN+&T7/3&XMA M-L^)V\9V6#1KJR,3\=U;BY&F=H="H45/#Y M\#?^WC0[1+O MIG\LY!3YY>\TLA#1A*P&N'BXAT-*G&.K*3F?A@>+G,%3I(VF?YDC N5EL@UG MQ:B>*-F+1*O\3?;1993YC-'&S'N*=1YO;, 6D!='$?9-B?O]9-** 2H1[JX< M$]E-IS"#>O^%-HTT%4C,D5*#FK^I6Q+]*)'FWRVAPXJ*T8@9_U_RGP"[88LL ML7A*I:%NAV56^B@@J]5(1^Z6+%0\.B &6!'=DC!HO+'OW#?2NI\^PNR]TH4B M[MD%]R^1V6PO/)#(_\BFN2;KMB/ZO']A? /;"H_IYVP'^/NDIM1?SF^/9CB> M L\,@&DP<<5HX5S0BPJ!]-1\.Z!QDP1,?KQE, MG35AAOUK4ST6,[\;W+-0:G0%'-5%D[>H]BC@G@?&HZ4*XW:$F(TOJ<2W9QU[ M/N!=8#G$SP7W09;ZM:+53.Q59D2;-D;-H_J1&BY6)&W0J^B#K\@$0'8,?2^( MKQ[3+S&N.PUFF,I2?YVZ'\I8H!A^X5J8>@@6;=SU:VU6).*R:*:]1"$ #_ZF MF&%I48A(*5H3Z7<+WVO83HWD7H 65M6/=W:)5H&>6,90Z+YI]DH@.K3+QP)A M9M%(AU*_\7((0IB*<=E:)N;W1?P/2=;:Q#2I-QK3+\FF:;SG_IIJ*G2T&@G[ MHU[_IG,F#HM )MM(C@T8"S'(9:N-5B-&:A,BS7TL3TH8XEJ,T*VK4S.8.9^= MCAK3D%]7EP+"CMB!!QIHX.[[W]^['/[P]9-G#6: 6CFIS3!$R&/<(95 *PU.@-U<,0M"AY6CKD/.90:HI]3]\8/ MO=M_J,L-*>2EEL(=U8?5)_K=D*"L# M.[BVT4"GFKMNBB&(78U0^)(#$/NF';[CU]Z:AN>?@ZK??%MX?@7HC^<(+[+?O-3*^"".V16%[67DJ?Y%.# M2\?2:'NP[ P#966RU*KWO#=[ABW_#FF@%W%.E^ MV?4B:ZP\M.N<]SS9'KA%8 2'+=PUKF"%-Q-X%4,OBEL"OJRO?U8]R*19_KPFO)>YV6K@PNF#*[P^1&OI5AM17 YZEH)^[%) (=7_57 M@QN'_!JZ4HME:Q;-SD0R3T4GD:R$C'7['B1%A3;>2'$\W5TCWGJJ(>14D5$_ MM]\8LVC6F9Y][,>/W_C>_/>2N";J=T2SN+WM 0L>DWM""K[[9==MM"8T!]J9 ME9.,G@]C[%2:<"!?<69'A]WQ;/__ M');]=&&8]]KH#8NL]@A6J7\YV5:_ATBK^,7P/?66K*YCS[,?C34#S'O[OGGZ MML^3?]?I?/6&]A^?KOLC9=V_1K])[E8?Q1>P09AHC>81?Z+E$L>-TZ[PTI@HNH%O3[)+)J^K):_&MJ$1$>%C@PUS->(!QX9@Q M\*#&YQU%,9N>*S,,S#Z7"T2^C'5!?*?N%Z=>Y&>E>OLV M$66U6 HT>;UW1$I$F]H\+:!\+!,DQ$'L)5@EI+L#G2D+1MZ<=^OSGB0 85'( MQ#.M:N@_DQOS_N[]JN>\W5>WQM8*/4X6N78@"6/EK<;-"T\Y_N N:9>$8EAO M7/;I# 'K/N=W$KW+U-S%!]!,P36<#@ENZ1NX;;(WDRK2AOX[85@VG"&SZ;A2 M@G_5C!+ES-S+Z>6\^DF2#F"K=C-!_]YSN(>/L&& 1:__=%#8EM.57MXJXCOQ MY2(KUX7[G$WXEEXP#M:O L3J$'8I0)PYACFBVO [BCD+%7%)S7.XU,#()6U' M/I:Q+7*\/6+H7_2DO)F@-TR%'APG1RCYB8B^O2EBT,I&VHO@$RLV*1ZK; MBTV>B\X#*=#"[B^D^Q)2RZ,2YU+NA%PH?QWYIG7)W\/M;($T "M8-%OVH1CN M_[5?$F H-BF_R2TLJ0Y!(MK313R1\N\1>8NV'/E8<1^;;=,OXR9. M%FCI"O$R/, 4RQT,5 9/7M?+1<^&)[:C<7!"_M2BV88H,!1[6!148&#:@WNP M8V5 0EM4N;+313L:'D51QIP-M&MKTNUZFJ?X:!+JU6-;*6_F8G9#96-8*,DR:R=F AW<5MBV:K:4N&1+GDM8+CM7U]RJD-*0FVT!8Y9/B MO_3BQ['/ELR?]^+C&^,X%)0PC9&=,; M;29Y6M$UHQUHOO"8%HB)]R'OL^%[P>UTZRKC"O RID>:VG26B-5CJ4^*\[X6 M-/P:H@GJF\1#'H]R/'-3U9*&7JJ/YZV6%/?L>9D+UCGS\(=%LYD@OM%AN/4* M> C=;^ 5;"V^@/RC(%N?PRW)/,F!^6V!^Q%=1[O.%7EWYVT2S<;X2G R:WS"G+'P"^W_,?:F84U=7_PO=0 5 M,YSWUW7^3MR7GV7GM]/]^]SU[+ M.)9NTLVS?4PS19)!^\@S@P1#JOMQZ.U]A4!W0BI[R85UVGV2@;=9T>4A0Z'. MXPT:DF.!]&H@Y(@^\7X-E3\A:A$/H$4E^LAWD/5KQ]9X!3F5M08UBH\%M\.) M;$DZWP)Q$=X>IM;:8\(@7IA-:BCVZ(L_L!LE ,N(>E]8Q3[:4;4S W1+/A9R MJW+2/*/EMB[>(3]H_03 < MK*EW.Z"46'I.?ZL9[-DF6(&D=G@W M(_=J?$!LCDEPXF/VPY'6B'A8A_SRY2!*<:N_X@VV7 #C2*')JJ&PJXTV4W/0 M!LI&I%I<1\,@1%PN+PDH#F^EN\!. CV\B4TV/D(QLW%HO(G> A"-)GT>67J+ M"&:#4TYQVR0!W8G)]SMQI^MZZX=CAX. Y]QCOQ%<^AC1RUH%)U%W[6F"$0EB M>2]Q>(=4=J'4:S1'Y0'D3DHEM4RQK)6!#ZE 'S*%7@%!7/X:7387MCI@*S@ M!E'8\7FN:T/(&RCV.J%VHM-EJDMU"HU#ZD#.4.I"^[^H$4%GZ2GCHCP76W\T M#^"LBJ+;<^%*X?>L; M;^Y)Z#Q$ZJM!3X@F_1L.'+CZ>UA%2\VFRBZBCN#"3 91F[\GEF@V&])Y.ACF M5U4@PJ.I\ZHVLC9^NY,*AT7R?H2)-R^V\!!OJ!)H:%2.Q(;UH_9 8Q-,%.>3 M04SN5G5'"=@5U-!/\P G9S9JI5S[_[3B?;NLA1J%S/LOO2 XJGM+5L",-K(> M4BTI65$/<3+KNU9IW)HC.WKQ9RP&'QWY-+8NUD4:&\\>MP>6?IS^,MMYA K< M-8P]4-_'\L]2K3 U6-S"*>'OI0]@ZR2O-3,>VR8W4=LCAUX3ML*G/.++HET_ M3H'3L^.UD<_S@OKOOI6-.UFN\&[V[C@#:_,7PS(CG_.9*O>4XE[QHDW&^P 1 MS4+\9UV)$8#B##YI_.>KQQM*SN:^V7>OM\3"(),Y"!M"]U)VO_L?2>\HL[XX MYN2'P.@+NRZ8"R_$V*K=E5DK?\G*INF0LUXJ<^$'9K\S+GVXEW%B1H<5@>*! MFZWAVZ'OC[][W\O'XJI(9F'-%21,6.4AL:=N=AN'?=[VN!5)Y8X>05Y!N'FW M!N:Q9H:9NH]O#;&$\E06QK?0N/!*(LB168.K&VXI4ES(+QJE%*=08[#C&*SW MI0+&!+L.EI5]'BPQAN;KGL2Z9MZK&!H-'59?19T&U5O5_P3OD3]W$?JX@%U3 MPDV;FGT2?]J_U\JC]H>S?_>MZ;4]\]3^;M_J3QN M>_3!J:60M4=-+SE8Z/E6'*^'D$L$J^+@@8ALMG_Q>H)5ABOWN<&O=ZX/V'97 MGF)?.WZ*XU\1W/MG1?"IP@^&BX5Y#Y$J)6/E*'KU&XY&/Z*/$DV!WB]X4B7- M8I"_A8:%!F90 Z+R8@N -:41&XGKMC$!9#"153],30[*.Q)G'=C0FQBWL]?R MJ/PH/H1C$C#+6JV'*&J"NEM&;F.ENT;F M:&Q^B4;Y52>1LK.P/&>A7BAEZ$AK+2<"NB.8?X,&< M[*V4C3%6UK!_J6K)I8!F1U&R#P'E,I&M,C^D[7I70<(,YJ_+G>*N#+Q;392K M-K=FQYOA^ZM3)0$P(>-GR#NA\ ^O)^W0\-^KXO_&A*@)RF4MJ4:8?(>*=4 F MD_]]#$$;EN3S0A6,FV2HY!V2IK"9R@#<7.8?\U\@UHJMVAJLD%7.5_3,H,E* M>=Z@H&Y9ZR:J&PX-DWIF^[OK1RX/ Y[9],VDITC6"5@G8Q:WW@->>0K^* A7 M;4&]8('X6^WZE6BTYH\WOJ-*PYXCV&6MU0;0]C"7WIT]L':^:^E9XCOK8R@YUK.8"/KC?O&7SYAH*A_5F]__E&A'4"&KP7^X3-8U0. M"@SY6/)DDTV6$\?VAW:-_5TO^C&YX,* M[,W9MACP&]X/7$NA)2G^XV]!B58X)!P^#=QI%%%6!7N6=J6 K,R% M92T#O!&@B\D.=F#%@@R]L(D _OI7TFU]&J@JE^7!];UF+/ M/L2\IN1;."08T\8PXQVL1)3S#7T$2T351M\#18HLW4]VR]5K MN2IW;\YXF"U,;!-D,M9K<,QET2:?,I>/\^K'ZSY,N9>0H^%B/>3N4;CV!H>4 M\I[J A;FH"8P)@#BE\&GY/.1B!O(N$DW;H3')*%V;>0UL_=;01R&T>I&O.#C M#C0*&?K4#I!T ^^CZ-!&TI+8B S$62 +7H,\[WBLD(RA[8(JLYVROR18[L:\ MQXTM[;^"3KY5;T,=();8C>C;1SNCQM69>Z@F7"]7*4C9FM2HF?"BWFN7ONRY MO"5/+-?EG57,&"YK70P+>?],T#,<&+=-G9RLV]QA]F5VQ#7Y)$84BY6IYBL& M\;;0PC^(\A'B,<>XT23)XYNCWO ,NIN5P=<,"_P'MD!@P3.[HN#H1X]N0RR4 MVO!FJTU08RI_ Z$*$BCN<(3,/),BDFCDU*>WFH (>=6#<\)4#8/2Z4W1L(N( MO[N?L(>:Z:8KQ#:.M74-C9+3_/G&2'@R!"H!J8B4RM+>(65;B&8@H2_"24D$ M.):T([!.'N\0^%*3XOZ.3WH<+?-OJ7B/T,*BXA8C-0"TAAK^VLJD&V^D:-'5 MA%$ZBJN01?&QW4[)9^KZG-C[VW=DRGI[1_>N*(]Z%7FAMW/KM2G/ MDUNH#=!5T)=;H/PF_6 /'4NEA,)9F;35%;'FLX6;AD:I=>(%):G;Z4XRU<$< MQSU11TI,^>56M,RW,%HC=^*/F;B.[NIUU3<)"3=",I^G/1 MT0KXTU4=S0=( AAD5)PF0L;)NMUD9OI0F< P0#0 +R9E876X+Z4=8+,F9ON1, M6O'YXENW=:&.0OX6.R5.#RD OTXNMO?B/8%I>MQE^6%I?=QEAE[L?B1>]$NT M>?'="I=;V3,?RZ8>'NO\>^ MJ_,P9+#&U(P[6H8!*T%!+A&#ZA>-H=OIN_K8#JAC)34D"-9F7HP:[ MP'K?D'5';8R563?0SW./>T1-$[GZUE6,-_U3]%.?#>M'J7S:>T-&=4>$_/^^ M]9L$A[?8D9>S%X MRP/_?K'H[,:ZX?_H!CV"9X]W#CKGXW[HY;I10@3XA_[KE4E\ M^Q(FHW$4SHQ#A)U12T5QS?[WYWRL5^6:CGIN/7.+;\R.,:VQI^'/P(;[ H/? M45V/-]W=5F"#"<'H_.CW(+8*W-6=5[H[T3K(J^>7HAJ @)=@,L4?$=3AP.42 MC-&-=N#Y':-KYR/6[[36R1."GY[[%=L"Y_9R82!76PHVS90T'%(3ZIGT*BOHR^M[A_./GGA:O=DD1= MP2.J:CX7\KQ!"TI6V,69@#HBTN8HM5&:)&P'5-G6M2J6<'" 9Z-0#!=FSK@$8H*U-OBN\(5T?)IDHPT&BS=AJ[LW)I62OW@4?[@]/M MW]<,,U\DWKIB^"]:K1=BK_Z?Z.>"$HQ>1M'KLU3\F0D0.VCK7Q4RW,\.D-DF MN_Z:L=D-[X9Y@U\'8#=0[8135EX 9:-W#N)[L"$IK_0^3[-R1<=KS^>VNZN. MITI^ CS7KDYG_YB/>=HC/+]4:--0O8[[/'%?("O3 B2V+V'%C7*]CSWJ@Y]E M2Y)ILA"WU-(3!X'\RF,2=YFMAB;=Q9;?7$GL.A-?Q+R@I@;>9T9>%Q[$#T9Z0BL12E+17P/$%2/GU+ M#]\-@T'^_30#%A:A6XW7J3KIU/;14DL5!CT"4;V5]D#)%UV_3 M,T[_J_= 0N=#[.V"EC(@@8BYDBII:W+)3\#H1R]864CK*7JQ\R:-C^/T03>7 M=N.[A27F<0%>&MWDYFLO^&S0.^1?\.5\^)5PO0FORP\$!8PH3"I1 M+X%D3,V3$(UHNL"T]>LDV89[RI \SJ;HO@[ QU-L_B"8F%7#55G8UE)FJXO) M?O?BIA[QN#D?UUXAK&YA__.<_BN]G4X:_Y4N"UN+V$-",5VKGQA%,49_0KZU M"4)@*9-@,X1ZW!U\OW5 M:Z"P>XK &<+V6)G-O%2,78U>@/TSJN1=O??4CG+4#=8N/:^4YUA9(N=UQ(+, M3"&0\:E.E8P(18MSA>BVDH,LD)C.$417J;41G?F'2!)@>7W,#[(IP+N!H28G MX+>W &QVR=J72 1[\@5B 5IV"7T00K\>J7CZNZ$[SAUN6QT*2A/+FNUV3_P2TG)[_S.#/];44)!@N>["^TIT#U-K MID[0XU3][:A7(FQFR^SW=_S7@Y<$H&U%@7G__] MB<['F=_PT? @.4]0MY"#NC]"Z0,[8$ZF>L7X G&=\F0R\3DG&& M[Z)=&J[^749SA7<)8-'O)QK##*&&YEC.A&/4O/2N>7&*FN"*.G";I34T+["% M^#K)W"2/2UD=A^3MH:_P89SM<>)LF'2](T_[ )\>]P*GM4?[Q*[X2#+TGZ W M_T-?X%)Y: A)/REV-C[]=SXW:Z77>?*2$ M.<^:MF!OZ5S5HW=<-^G%?O?=:Q>.*K3H^R=*-B"M&@^8S\+,B7OY;M077P&, MF#.,!3BO+"7+%+4PC@^H"?)HV^>X+LTP9Y9'Y#; M?]=KA<,)9]%6-!D MN[W&4A^#,ZO@$OE\$;*U)C;,M1= B./,JCSWT> MU?P[Q-39)9 M:]:'G9B^#?)IR(V@FIC@QGW+Z&N M3((#U?,'/AP@>:XDZB-$H/TEC1()U;7+H0!&3I-4='\FJRG=RI0'[Y#GS@F& MOH;THP& +DF[MD)YJ&O]Q.#H022H@HP\(JV;.!4](=A(W[^LU>8'.[;),3-J M_+<*H+] @FF?QXBUN&%T%]PU;:<@YHP:0'>ZII(ASW86AD9,5,IUT?WPV/3I M4F3=&"C/=BY."H%W,A^W@L7)IYNA/Y .B92LBR\: MHMX_"9&SU6941Q'=!&*(UA*VC\OB!+\Y).(V(BN!K';&NCK!S?-Y1P8N.? < M82*@KGLL?U%_PW#@T*#HZ(D*OEIU(820FP_ 2\T%XM M3^^=-'>GZ@"%V82=M%/=/$PES:V'YZ' &"-V)$V6;Y[,X3*-4/.!2URR[O!X M6%\DB,EKU%C ?1-6._KYA][1NP==/PDP4ZV*84L,R,/6A34K=!![JU)(+6Q_ MAB0=>8G8NM4*E%_!:E8VP1ZYQRC7^'G.S;(&J($%,G417TS6]8B9$;X;,@Q) M /9\3CFU6GP]@M\"8O6I.D)S2N94[=9^FO>.,1''XK, @[=]XO,PZ&^':@J@ MXA@A:=Y]M7/_Q9D9K#ZG)HC#' M'IYN9>B[J.N2[!WF[1R-?:P+"PN.NILD]2=806.9L]A-5$D[P;HYU]ZB+4P/ M&LO&^]6.!D7)/.;>;\%BU<(F2?L(0^PX$>;2C[]6,>Y(V]U[F6!#)8*7.?"" M>'%N3&(QXO\Z%&GV[.?O05;@MN_(VV M51&G+PN1F]/_DCI64Z6M31LJ*C_+QO)HCH\FS;F?[E5&!_NR.='!5RNJ)LS[ M&W^/&G1-R?_XWB6@L*A>=K5TP[VX.,/;Y([P:Y9/C\_7I4?!@M1AT17J01H9 MB ?'@9WVG:A MC2]ZEK7J9\=IJ]GGJ(6>JLCYK,P:AWK=I8NZWN2-T?M'KNMJ_/OU/. HPQ+9 M9R*):WP]I=[58T3[65\I1G7WA?*/$"K][7SL'] M1S'R=ZZ#I>=!-ZM_)<>D'N*6TIY$[^;DO^UGEP)#0V7#EJY?CG$(/?$4S.U/ M/N;/=((\?GE!\T,B,9FS/6DR_7, M2GM^2WSL_(CNF=!3PR>;6(=] D)<_!>,NQZ]]Z!4XED"'=.#XP6Q'W RDWEP MZ3[Q(M&(2FEEF:#7'#) LD'PX2K9^/7+-VJ13*5/CP/%YEE:J#0S+YSJQ':( M;0[YW_2'EYV=W2]XR2%!9=Q[A;.4=2_S\K\/N?G+?XU:'['#/,_-S4Y"OPY_ MO^RW(R>LK'57%SQ]1O7J%7D XWX5(9.&DZ?F8PAORY_ZBH<#C*%Z*Z+9NG?!>2;!+9>( ['G M8:N>KN%3^>;OCE-K7.ZJ^[&Z]&W!ZK:P38*VG)B,&RUEH7IG9J0V.2>0;WCZ@BSLVYR);& PU-$15S\\_FYXT; MXST 5CTY=5DK6KZ&=O45S$SG^<%VH'8%9JH8S%^+:EQUAKFA^4(:;]\3=3^Q M+E$J/H1;D>_BV=)-.PQ'J@T'*IDT$C39UM@@JVU^&JLV:8C3$39]^!2REA$\ MJPG@J*+:C @PY5! 'X=VZ,FX_^)<03/E&L7A=E+I:-#CLNCJX0G=K=S;OBS2 MW4/O.*OX[K*7#XAWDP(*T#5+%6J,ND>PUAJ10UVBVW]#7Z<)UMR6?EY V42) MCJ"'E%'[96M_+=[]$5(K]1IPLK"M1WZ"'>Y=JPZ6A4R4;!I((!L.>1W(J7X7 MUO6?>B<[&*GQN?2CG\A?!%9?V%*U>YW1)'C%Z/FF,]9K=J_[/G< ?/+D1ZGGU_2< 1;;5VA<_XW7P+/XQ+U_T8QU]=*?3'883IS_Y1U^)U;7)>?.<8[^ M6(80> P[5'A=.#>Z\^QN[XT3I*^4=O-"L9G3C(6'@F*B[HY6':1&@M+?<'3+ MS_*-RJ6Z6?)FVIE4E6?B# &&;$J2T,XS(M(!"WP%&K)ON?'XWWD5E>0[5 M1ZTGP:!YT7OKQ4+6/\9M%'^))E4W9 MYTGHWS<+?O#E')-TIZ73H#8[,KP&R6RSM^HX#6<*'@;[/'PWOMA0L4*<5#M9 M9'3W=ORCPQ'7G =+*T+& \POB%<$_KTJL#@2I,D\Q3@M9 *3=Q6KMZP5I4<" M];*$),2.D\4W'U<;]:D=HIKPZJVL^7<#>&^HJ,\/^I3Q "4:;?T5[$;NF:MJC1P&9U!."-P\991K%^T>87N8^\V$.(R[&ET]_J;#)O$*QZ4!QH&0#."#_78\RI MPS[(%2#N\K#8W+^B/#;LX(#0.2LSSME^_Z=_NU3'?R;O/W(W2MF0_X=WU18O MZXM#/00<%1/8/>MS?2%0HS^N&'UJI5(T5=4N^@=1 S!9KR.I@][BEBF2!?PI4S)DE4?05JO0-LFAMM+ M+*"N;+HM;0\2J]0CM1L3-WSAV<,;)D6R:7G:K'\O^Y,T8>10V"P6,R['J#=2 M&[]M_+K1K)%[< @):>/K/D>2V96M DO:KY2;V+J">] A0')CEISFXF+NDD4[ M7A1678:H^\!]L(YPQJHQ0S$PQ[&(P>J/>3V$D[*Y;BZSM61SY !F4Q#R(\,8 MN8@UCL$D6F9E?)36/T$]4G84L(PYR98EN0OAIUXEN^VD)GJ79P[)Y+Y%=D.I M(MG[_B(";H>XJ(4+VNE^GYFZ?#V07WBJ]AG1(Q84U/?7-UL97T M'!>V+\[NWS.5N(-/&OB,#P6\.?IDZ@&I2&WU"J;?.V]5744])0_NNPAK5/MX M7'IP_I<,RXZ8NPWZ]X?W67Z8?S[\JKE!=ZNCN&4GS$AGHSZQBE>H'_ .'YY2 MV<". YR6_83#<*BHRX;S=F%KOX2<.9E7P_;X0YG&S7 M:O ^-MG_",R(%REZU&4MX$LIA)TG+K'E[7+C'ZKS_>5 SPR9NY^OA^Z[PK8N5\H#CL-DSU@ M+)-FPAY&Z%_GQ?#8:SG&1[66=@8>Z331*Z9!VMP8UBRTB@>7Q> M;8FT5+M'0#'VX>V$0Q!.>,@:Z@"NLK_UC[=#@@"B#E5FT?&$>(;NA%*0LT"' M0)]F#3/3\*%P6*P\8Y%SDVZ-$B&&T/XT6.[/6.,<.A>WNE'4>HU?37XPV 7EG&!>OL$)$WG_:#!5 KV672),V1;V"9;7=)2.M[$ MRDE8X\Q9BQR=CZ(1P9 9C.1G!_UDK$Y,.$FJ2&U_>\#D*KN\U>'.!Y^XY-4U M#7T>ICI*6TB![^7BI.*'N#)L$,8>@A96$K.;NI*QM/JD FVXM*;FD8HG J3>4K MA&^?@N0Y93VUSA3M\>=4R0DHU>$&-$'!1&G,(QGT)NE1#3R@/.ICB7"!41.< M=).WM29&&KSA%LC1FRB:OAGOD_)H7/;I7DIUD)BR9^-[[\3*D%#O:Y3-!J$A M[HZ=Z_:<>G_8XLZU,KTW@;0+"(-&2\;+9)]E6&&QNT:ZA MI?3SXG3^6!8O\FD>>0,USZ? [7+7<7Z_4_[1"2D)7I]4M/K#[Q-W;X=HW&! M^IP\^WIA:XIG:(\S0\82FB>U=Q6,FH62A8)-I.EFI4_L?#!B@4WCQ25#0WA/ M72KSAZ6RN64M0T1^#I)GSM!Q031;I%D12\J2;R)LBZ9O@IFY7%P&$9/8B0-= MTB=E6 EQ$TIL1M*4#%UZCY4U(@9)[QSGVY$(14<>1X>6/'!IKCCIM=P"[VTB M[#018S%S1(P'\([FP:9MZTN(BQ4ZHL&0+PN;#FF%U,ZPB:^";J]HHI\J50TA+LM+M@L0+^0H4QRM\!)G3/_?QO,*U\Z'[ MXC^B2ER1>^>3%5T; C5YVR3X\ZE8PNX>U!/$KGL?.[^L]23A__VPY-O/ZQ;R M87W2MU/%KKZBS$^?=(]%O'I59)><3"TON?;IUH5,TZU'_PB*N/7FJ:>YW:'F MC4^>!CY8ARX@FN6PVG&IB!@ESR\4K,2OQ!7$\4Y,LHD97,$FA.'=A]HI/T)S M%:-E58PVVZ1PT"T@V-V*&9%<\[ID9S?->I&OBW9O/[_BNFLEL/4HH/5 VPFLW[\G>?C3W^ MYZY3U6&L?R(?1+>=<[X'S7N+-GO>_C#4:!Q><1<:#/U+>3Y3/$9%=L6?_W7Q M5/I(3-5 F4^\-\;W;+6?L*T>=GX"/)TO.="G";D,.7=:(NF,?5UB#TN%+%-U M%\$*.1P.8K]#8D_#8SE\0VI9&X$(5^9S\^P$JY#+'2?A_*Y,^MXA*DOHU\6A MDH\-QLTN)0$7F;'*K8^C%ZPL!X,6=9ZV(.7==%'&K=RKRSVGTB MU.8=4)C4]SG$KP*QAM18TG,]V%UI(_3Q/ FO'BP#+ ,EY\O'FS*>OAZ\&/KC MP2]'UG(5,[*N^2A8FEX&UZ;!'0"UQT"3J@GVL;K5U&%ADW$U@,WBVT&-Z6C< M(^I]2?!.SI.AB5&=/@V.* 7:DR2;W#BGVY1P,$[_FBBZ*JA^=.OLF+(Q,Y&$ M?3\N6.M$S @FM3,,T4C!4AK?+8:X>7J.DDO?!1L3#U[HI^^F<@!ERMO2#/ MQ.JH':A,B941].E5)"PXB:R-5D4ADG//XJ[0M]&PF5#[T#J_T1 MN7(-JO.!/$683>H^N8$S:Q651$)6/J5M:NQ7;T4$;8ND;-0#S'<_)9V36W[; M,!+QS>\.SGCW]RI%TM$=%&-JH1?TI;B4?O(=?-5U<@PI ^PD$: MMC^!G-4 A2(+ <^1.XKA%L?6 X4! 5ACV_[/D8(\@ABQS]X J<_"A%("YT4>9GT2"/+]54,X@[$4*JZ-/DS6D(%9K M]26H3&L39PS.C<_'_8]V"0F!*W]$/($9'71#XU)%8B-D,M5QE?6=VII,)2OI M=?!I$#>]6;")YI&L'.)OBP[;!0O2[-6K0X/?1X^:P4FIB4S#ST7T###%0KR8 ME<4C/AFE8H%/MZ .$9%C0.\5U%7P64!*L%(I;\UV$EAT5_R& SO^_E5"BZ@F=N'$[=,B_82CC"X)JV6 M+D(_I!+$B' KT2U]7]!X./:U:S#-%[D%-1]Q?5L%14I&K9%DI6[+[F4M;[C] M5>E(<.L3)&;L-(ND'F2*1DV>\33(O 5AM);@ZJ5X7-EO]%]CR#J,*(PN>AP9 M#H>LVP@N$":?=E;U,QJ$5#Y&)D ?#[K9Q"+VIB:Z2HC&-%NH6B0;^=CYI;J4 MFB:\[C)M@LO*% !#LRF^>B8B+)3O]?3SCCVS$8WM@P1C])(4=2HBMF'7J/M& MM2$?^0T-KV'02]V\1%@'/% ,KQ01337^75:I>%NM#"6UC>YY"=?S=[[LYUE# M5SN4>\CF]#WH?MB(F:K>-1YF"_T1Q<8IEK0$V:?X&@GF$# X##<_A M.F#G;5C_ZZGN^A#2=S'D32@V7'FH.%QL/-](-^L]#XG?/C=NW%D!'@J9M"C6 M%N_)'ZQ;_;&F*2' ]HHNT40Y(^M3V-R@V<+W15>7M3;1;)33(0KB#?RW%S41 MP.39I_8J M"&3D7>R^\1(=9*&6Z@U(\Q_RH4]/G%*NM_D09D2%1?Y/$X:'[-<.\'!LS>P7 M9616/9HT)W"??%X,IH.6A$\FK6_C=E7D!W-10MT&% MXKVZA['N$IH(LE:?0^J$>T,0@U:"-=S(Q$>[,.GF[@!II3M@'^#=A_KDY?T,(TG4$B2>*F9G/-$G(OH4]EH77LRF@ M[2W9*V7C9H>G+[:/'86&8]*"^A4MO4Z=WF?KBMZ\C?I2/T)87-3^8[ 7#'SM M=N#_V: 4F @H7<@.0>ZR5BRIH BK\6JK::>[\=9&RUJ9/"* -1TGV/4YMWC, MJE)63 90G6=TE[4BCIWOWU[2?QO M/.).%.]Y;^F<-/B@^/CWAF4[TA,V3[15MZ<$&Y[U>GNF$LGJU<4HYNV$0[VP M<.,SGO[7J3_\JLV'.M=-'LJ_1)K_^9>O_XL"'8T_FA0$WEEG\.@9,:1D:V^Z MM3_67=W+TJ*%U-+_YJ]#S* B\L:88&D:+T5E.CS>)'Y-\G%/JX+8?TTO_/ (2*/ MOT/=T\1(HZ^F6BA9&3R\>D\OG@'*AVZ[=\^R/?TH>N_U3.9_1R00!TBYRTV\ M8E7,_L^EQ**/L%,"NI?K7O0Y-7E<+4[Q/.$].%"#JD3DQL;7(S;"$F=I_7U& MM@PM,8(*)13]SPT2@"'"8<;E&W&,2.\6T@GD/L!XJ;Y;P8%C MY7_&[#DM>GK+:U?_?,[V/[SG3[3\I/SMM027,!KV+'!'8=/^7Q]!NCII@29' M3UT^]0BR6S5^W.?-F6);KU?'?5"W2)4#[4C=(-ZZFN:_]+NS@,E:;T\PHP\& MN]Q0:TM ^6\+C:R5]=@+8.R25D$[P+8.DP\UJ 0=UJHF0'RJ"N M,)B8H5[ON9IU@V].S5P0FF.R$D,^M"S]R8B&@>%ID_91W7Z^O;HG..LWP<]+ M6$!G^IJ)B+SN;XKJX*3F,9L4. SM[#5GHC&U^@A2]Y,2)&?QM]$"X% -ZZY& M?J=WFV-$WJ05Z ]_A!+PDZP>D*@4Z.MCEBY#A=5\T=,PPJD\AB5V3LGD6T&@[ M<4-*-6@OSPC7"$LBQR2F9$->(+20P7,NCR%82[EY>A8G!G![GKEV=;8O,=7$ MSX-D?=H.B 2<(:_@AG!,&:V>SN0-M*.0-)MNCA@(92UR"> L?4TTC)8R]-"S MRERKB'8QOYA3=FZ47J#N#%L'R=-06_ ^ M9BV]P[5QBA.9O//WA3!,?R(VP]$#++Z VQ L&Z$6V)'2R9LTX'#5N]^#VYU( M-I@L;"+G\4['E[/?/E\]<.?N[2?G3KYC1_F)B7< B39F7=0]L*G^H3\\UZ>%N3:JC>9"@@!W4O_QS,S$ /1UH]@>\F6'JU:#BLX]ES&;4%G.&K=ZJCBL1_Q!95/"BZF@9B-/:=[&,M5&_M M2?2&,%T^A^;7(B7+6L^(0LX&:O-9I$(IESD""U-7HB'&:]8ZO"?(2&W2. U# M:IV8OP(B9ZBW1=$-I7PS)/FU^8'JJCSB!M:Z<34.9HDP%EV/H\I.J]M@DHQV MF!TCZXJ Y?,!\ >U'?)W.ORJ M?M"D24.3;R7(VH!\.X@;DF_:T8Q(P- A20='UJ%1O9P=]$M$-"XCX=[%-0Y M/XOE,MJJIS$B^O;>/7R;V.NX3,(V:B'@\ZFL@K85N>U6O%# ,P$YYHB=6.:? MEV236+F:3S%=M%A?DU&G<$=@L=2[&G6CZ]Z"&[!XRUDSC MSS\5.[# YF6M=']B':M-@V4'Z0[4^%;R)KQW> 4U0#*Z'VD&4JZ@UQZ.$]:6 MC %?BA6QY(S)ZLG&$FM^6F!#P8+(+X:^N?'Y1A1?N4(8)4@GFA*)A2( >TIS+$)O6 MQ;%4NK$8L,!DZ5,#7JNW0/'(9%M=V&@T 0L[E+4.J]\0'/MI*Y4OF:V8'+4V MI*X"F:G7\UE37Q4SJ]3_TUC:%% CCRMCK?8-)I+U-4.D)Y^VAPT4"TRGZ>M= MHF!RNMH!EX-/^=84AMI(@B1IZ&&@_R5<*%S6TJ46\;.16ZIK7@I[;S E0V-G M5S^5T0B]C.B6T$05$XNH.]PSL4-?@<961Y_;+6C<5/W)]&=Z6!XSZ^ M%*THEN&>63W<\;XY/>/)]N#'["=4AG"T!QJ;%R!7E#,YFF3B=:TB!\@A0,R$YLM=21%@C:Y+A+>;F7]"IK)V?# R:@H=*7HU\E@W[SD)\*: MF%%L-Y>S,7JP,3B,E>3V4D=89#(U!\LZ)/(ZG,B".:0\PK"BQ@M9JWA;P>8X M3P_$,1$B*J0W4$O86YPDJ^AJLZA'X$18,)^,%(9#$O\_D<)6UKKMR#3D'M(? MTHI=QZZEG56P#<+@JD6#^>*E!_1=ZGZBA5/*RI-I;5:;D=705T4E%KI5MN#1_NG7/0QB7W3_>U*3N M+AQ46S2VM$"?JE+*ESB0',1FT/<@)M\Z4.I=2ZQ"7-J+SKG.9'!C6W"G>]YR M'XXZ%N-"7[P8M-]#87D.3@W:A_S8'SP4Q\TW_E<8T/>!1>)S7Q8V/L1HILV8 MYK#4.,=*9Y@Y$4UH&+A1A,TC&R]K_<1:3?\GB6X/C8G(-Q;#[J3 # "3SXB. M6^F'W.-@-J$_]=JOD@&212?0F2S\=_O( MY5+5;JKP"'(+)GR@OVG@[T/ MT-SG+,!2+PK%$D"G/'2Y'H.J 5 Q-#DI;Z-OM;DY:PQG+*G.496M1:%O!4_.(>W8=[F[ M5FI\MOR%SO3*7 LE9DD <: #"-4*.E M1[1PD&Q!=1>'[;\/[H*=9FK070.TU=$5(XBO2CQJVC\K7RD!1LC!];=_A#HK M%EZ)52YH3)YD;YB,9CUPB;]'AB8LE=$B89?YZMMBLIX/LWWF!OW['OI^"20! M5O (!V^#M8W1CS]K)FF?(@[W&KL1Q0""+,8Z+C'C](1F'&NG\ ;0LE8(3)D< M,?SNOTJ5A?H?]5YDM9*2N7 %_;X!PF3-X=XE*0K3"/M\*F.MS+X5VDB;SX>. M5EU9XL2#0$6LK*0,7-;:'#1^_6WCAC)X6\3@3]+IB-Q!LDG,HSY2+K;WC8;I M7\JSP];T\+T MN@HRQO_.=:/S=H2@7O:/^8&'#OD^L"RN@<3GGX3_\NZ!U>X_]YF>"\-N2A>? MGY 4W:$=V)UQR6%G1N!(_&EVEDA:<U!+IS)KY*'K\+%EY9 M$>5_X TNPOP2)U[G';V@!;)IQZ63-].=47\D0I&R$IS)HA_ZK%[9CT.)*8!2MT*15O)N<79L=BG%]H>%+G+_V.QTV+*6(9RT"6ZX$D $'[RMC;OO M+SS_RVUQ?UF&)A?4_33^ML0\?==/SY!+SM^?/KO[[W_]\HJ#!V+Z_YPX\V?A MWY!-UONMP./#I S$9D?IK9\3GO_U#VWOF5CE/A^EX[IGU7FB,Z)/IC47'6HF M7,_\U%*19)X0=;+L^-Z*X[9J?_3HDH8>HKL,)QA&/[%:&>NY&NXK6*R<\E.2 MC:EE'O#TISL 68>:I?#,PV.?HF=Z$D9LSD$M73ES*C]L1M@"\+&_.[@RVWYN M53V\?G1C\XN++0 M4F6._C(XB[VIUH<*TWF''B.. 7UH1"T2J\FGF_!!D*J= MC1-A].D]:FT$N!8)58(7[T%E1Y"*APBF70 54 6GX='[<-DY^#S)*&992V]6 M(V71180;B@Y5%3$\BO. \ _*)0TE*W=6@AU_X5 +18O#5Y&@P:5-+I.-*7N1 MIQ;+6A944IM:_R54\)Q-VZQ:-VY7*T/^EO^JKV2:!?2@F"3(1)RVV M#$RWO!X@F$Z..N)0@SH)C*ZQTGD!>;9^QE\Q00U8\VE+#]@SCT(=3!\A'V'' M<[V)G TQ.4\K,PF]3><*)%7OKN;1;6?3A0T!BQO6D-GE:DTLF MP;B&L*=W>G8RU +,8J)F>*SQ]K0@$PS4)709Q:3*_E-O+2:U]8:H)7+C\J52 MVF&0G706]JU2,#?1>XD88M2(3D /S1.R$3Y#C@^WN7IF*/)>\[K7AVK@)5UM7=@6X+J0FC!-$@TZJFO\?L#>)=8)INI@ M,M EP@P%T;R@86#T7K3*!3%1-J;B(^%";]CMSD(N??\$:]-.Z,-=*]>\XU:; MR1LK%D26WD?X\()X#>TL:-C21TNL_GMUC?H0R5&<,R-I(UJJ-4"_5,H+A22O MK38A+<",S$!$-T/N/QZ>X+MA]>:P*VF^WQH3?=L$7O7%"6/T_CW"$/W-@/K\ MNPE&5)+H&5(M/. JN9G@*Z,2IEOS]5"N3!YJA$.FVQOFF?%07)@ M)H_-E0]S%))I3W%F;R^X58*,!(K\I2$K8<$Z7., M#/X&;J_S(:SN!%'W-"D>3%GQ!52]=KP^)I$/58*X:1V8WW%Z8*YK]6>&-L\( M(K;S5T'JVR!V/4DY3@M58@O&_*!&<8NW'S1+WP:Q^=EX9ZC.O9=F"?B$Q2Z% M^1SO BM%S;8)U:9Q[,M<;/.3AYBV_$/SUY?*G$?'@T4;5 M:O5;3=HZC'0HB1M]=+)*QHXA%:I8:J10;O01-M+(S^5$-U_5:2@7T215,6D] M]<BG?) RY>Q8:$Q>3%9[9Q$NZ @,DX'3_XQZ^Y'*):3,R WT%"X7>TQ??3+H/ M$+8CNL>?2^UG[4PQV3412V6""")S6ASC@F64M,YH&H#=1JT$ZNQ)UODD[T8"D/9XL,80C^/Y,PMKZHKB/8Y4 T0$ 9F" M4D3$$)5)&9):*V,Q"@(:A*BH#!'1(A+DD+0BDX"I4J&"$*T,(H0(,@DA$1)( MU6*$,)1027)2999S%,(IA'#C?;CW?M]]N8_W8:WO?/MIG[/W7NO_.]_>:S\= MH;:]9&[V(#^*#>QN7:XFG_@G8O+ZA3K#P7*;5W#H=#CL"EYCGGL.8!!/B,Y? M=$TCG"-DF YUZJ+#Q1Q?&3W[&F;MBE;L;#IYJ\J?-5EW4![NZEO82= %-LA$ M1@A=5LL$+4S'!->7 %^85=#VF+I^U3

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�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� .J9J2CQ C_8](I>AQ69B M/I%D3O@VTK6@..^63(LV0-@YT^52;HH MRN1]H@-OZ2"K3<<++*EY,1LIT0*M9\@JX/:\8BC5>Y3F+F-=D'PKI^'&K"49 M-5J<\HN+/\20;;R*@"@"2\@"KI52<0L]H ?)1=W!L)_":40!EAU'R%O'B'(L M/RB5-X=)I:I'5!DS5IY8?P"K.V+668+#"=2 JO%51!N:@X-'IH;K\^"5:\;F MVN:6 U]<;\_3 ;?>#&RCBTCMH4!9_!).$W-Q&>T,AY F63]"7G>>M$5%LVS.&NOPJ+9M: -[V[66 @3WYD?B5A%W"OB MHFN[#:N&J^JR5Q$AL>UATJXR:.OS)A_LP[!Y% !7FDAS>!I$K:\C;P66DT36 MU[]!9]2+YB2HX7#BPDD=C%J'84<\=N(@>FM:K]2_C/'&WVK'3MTPE_I3 R?V M+?&_F!!,VBJBWJ6S#CH@/#W'DEU%<)Q$CE!TE2@JYQCHS?!3:K'](:"JT*[@ M(DMG!XC>9P9]SYR;!GJ3IW_97F#FTZJY;^]].I;E[X+U)8^S&@/Y.F"C9)T- M."'P!;OXDUPLM+WW/3W>7W^$M)4=7:TX!A4Y-8\NU/T;7E2*\S<$T;%;7H$1 MOTF'7Q4@=68BK1N3ZQ;DB)&MS$=W-0264;31J.HDVU&!'#0)TB5K[\!AEA&7 M2+1)!\6/['=!LP0FBOLRAWV6$%ZEP\A6"8IRHG?0-?V#6"KFIP=)5EQ?K!9T M=!7A .8+Z@VL8R;3Q]V,=6S<1IMSB7-S'M .-%^7386",]/LU<6P=&!G3FV' M\@&6*Z@2Q%K3LA_2_KS@ =UY"2FZ#E8M\JU.C]AB.7>VW^,*W?T%72? [0]* MNKFI5H!&?CD*B=,.%- B-6IBR;FKB-:=X6CFZ'$:5,Q2I1/H]UB-V/GQ#0\+ MT6TH;:*;7[\MA6>#5,'V"OC^HQUZ^QK>/NRP/CLGZ3Y?.1=H[6/K-9JNV_HZF_B]@#GRH\,HQZ*#=NK0X(0+)L>T MISA2^4_*:Q)8_EOUCRI<8.J27KHZ'G.=GH&IH[=AXUB:]$#6&(&!1=HZ\KN273/40/]R?];WHYIO,]]^I=K;'(DG^MPUWUY_UBOWFIY!TR#I,&NCK9U9XHM9'\/G]QJ3%FQMJHBJ)Z-1&F[2 M.)_T[*?)E-O1)JZWC3B1\U9LPK@\QS\9E&:C^7"OD/DD?D6V)@\S2S,M= A* M/L1]K2W;:&\;7Q6TM74?[?,:(>B*[&/V8>M'^1&Z#C37P$">;;S;HC[3X.5O5#CFRL?23#DQ :TY5&42'CS%1678AG)9&WRQE7S\JIL& 5:_20,-Q_9H;<>I"8?*S"M M'5@B*,WMGICUW]34$NU[VT(1U_"J<6B^Y"T> UF&M3?]O,.C0#O&1L.1RD&7 M>!VHVK'7[O#7G^^ICS6.4H+']7R-FAK.5JMJ[NZ)W.QNT+ 0NGGYFQ*_UMY[ M?A7QE!B'A@[D"5)&OP*LI*U]+TUHX0 4M^ TS.FOOH*%V\3Z:T6XF(AK5P?\ MF<;I)F.?O 0'3OC&_--N\."+(2)T%:&]B@C^>VTN4P2SB&3=3C!5<%"<*K&% M$@77( -%7*UDF]"$PP^B'%CJD]8&F*K;%N8X9%C M(U =MSAYDN7FMXLE#)RW4AG#6;5SL1,$#H%?"+@)%F&_A8O,Q77D?5"D(''$ MU@XT9B]UM56G^H1'*A,S?0'+0J$39$=81.I,^9\]&^(S4LWAW]*Z'I[NYITM M/)$[>#KH"OWM$4?O?HD]IIXB4HZ4K,/]?30LU^H]5E5T74R%#7&G<#7>-$9M MUJ8U>2>;HY/UK"C)^X)O$(M M0KN/!U^>8^K!D)B-OJ37F-/GJ\QBCOK:^-GC%I _!)K9EJJLL2_8)%U]A&1Q M#H)+.^XKQ'* 8#_+AHOS[;=!Q9.9ZR'5=M0:D2]7->!ZHW>1]V@T+OK_5[JF0N;]!3D M4R2[_SZ;O7-[GLE)IR*I@JE0X04V:X^Y]%N@8>13*Z_$Q M]78=OA[0@--TJS N3OG^.5A_I\S\LJS^ 80>#'2RAO ^.9)6:EWU_&VPB)W3 MMI"XBM@H\N,1DGQLHYPSHWG8Q%QL @G#,9Y3.MI]*K5C(.1W"#.OHSSHD]*W MQ+'"QA8E\Y-?SOOZ%/?Z=\/]81SR%(:*D/"RIA"=@95:@LG'".H!/;C^A6 T MAUP.IIM4T>PX]'BRXC+ MQ#7JJ8U<'N7'D[] ;I*U/4(%HO'Y>A"90+^,'9=T^0S^O-@T&+%3HDT,]&X> M1)N,&]0WU<5<97GZXII= ^*B#_ O9;@=X&80+[N>/*#Y&R?98 #I"P^*KHC3 M249XP*-=8@QV)8KT07N4.LD'\+B+7S+U/35,VD=X&A(ZXS.YD+#8'-W-4OE! MUAA=;YU06NJ NVU:O,^IK#7DU''D=:D_2N#TT;_/JL(30=[VG!!+^NO0,1C& M2UL@#PK'U(5+B;-7)X4W0,G%Q)!N/] ^D6-C>H2H5(]5)]D/+7:;1F/KZH;- MQ6YMVN[YBWL[3%9B/B!EZ3,H/DZ()P5#M;!/48 5_PZG6AVBLI<[,9L\V&[X M: 9%D>91333RBO?IMS<.*4" X4PSN'J.=WD/A%-4IZ";OT1!_:RDRGG"H/N# ML[ZRJ$2LU@7Q/?(V,L.Z($^X!Y[2EG1<]1KR@#\"F+Z3R().[D+2*P-MYO,?(H.UE)/UZ MLE 84F0DL: D24Q % ,31]>VUQ!AH'Y0W[__ D,%&Z_?OE)UURJ2_I#^FC5_3Q@@A'G1(=H4*K0^1Q$YR90JT3'ZH#>%))F %?'>#+29=C4ED!!)4688IV&C3PV MSEIY^NDJ:?-M63NLEF :EXFL'3+OA;9'SM\++C_+"FYLH&^(0-<'CZY$3.64 M^1XCX;GC3)L\XV]QW+%>91.5K\Z7_]NWV9E-_?Z[8Q6A+K&DM.[&L&NI=:L( MOO1+,EP_JN3=4"3W.2MSD2XW3KS5[CUP :0DM&S#$HT9V7I;@<2D:W5H]>"F M_)&\F&?,8)^$3'-/-[7J,D.&(&?C^[O2DQ1V"4J70B"LH[3Z2^0DO:S7O7Q% M'FL#])"!6B=1""9O!BR+0$6&@"ZS5+UY3A'<,.$%HM-)BJ'1D?^#O;<*BNL+ MP@<'=X?@DC"X.T-P@@P$AZ !$B!8D,$)KD$&&RRXNR7!W8;!)4@(+H,$ F&& M )D$R?+[;]76UNY6;>W#UOX?]N&[3_?+-WG9*]@#MK7I- MA>4KM%.B'\7[WV8V#.X\AFBEV(=;8XJ ;?HX(Q4G>6\^IIF?*++-7];'NS]>AT,A)PK]QP1SC'8 MTXB7#A+,/PRW$,'PLX]ZKKX?5FKY/:2T.OP/,'*/C_EQ8Q#X;@5^<:N.UIU] M?Y>!2AH*^+TFG.P>[A:ZMP[J%<"OK/\AUW964<2#EFI#).RZ\XS\S?X44-DW MNESPM3@KG$;Q<=AJ^"?/R(<)7GN_.W?[$/KMO#]S1Z:2;WUG:H;;KD[^OHY' M-8_J,K]L6_)CE5[X!]!!>4;VJB'/PLCLP>TYAFTM2^]C+P=( JNF=#,Q[U6^ M^B;UO!GHN'E_3^+Y/XI<,',WJK>*=UD#+N>1B@092/PNE,QN4])N>$(Q[E?F MJ4*W41O\#]_#>!?:1"B^^[OC-SG M>$[7A G?PVT$Y@5[.5$=]X2LR 'J^R]UV=ER[V/7S3!CH;M/R< _33:GV_^^ M/=OK&:EY[B2]IG#67BA/;;NFZ=>XS7W4#;@YOR<^>] 5+$PJFOV>J.N&YGXY MO.6_'RX3!UKNCA B+*X$H]/14LUM]"[XE>" T[ZGAAFI5NZG)WM89$D=I2!_IK9WG4. M6F;XGO4N*42]_I;M[H,OJZ?YLN2Z"*5N)8;$&J69V&M?X?(WM# U_FK_BV^R M\4LT?7S;G1.<35JGT8T)(4!TC2AB>@=-@U.*.R) ^ M98@4JBD9+6#VU5V1QD7Z76J"WP O*R7 M@?2[F>Y5+AF!27"J6[EY]YU%IU3S)GI0M%V#7P(+ZTKNLNU8S)HU"3Q\? M[[1QK-ND^YD!]G\ YW^ =0)P/Z81F8H1+CP_W48CC5?:P*WAT?TB:(*$>Z9; MJ3C:HM%;&AV2_P.+ZK3QL9+!97\D3/V]3.RT:W2 +^[['O$5_96 MKO>G2%17N&LJ"T9M3W/,*I6\\G?RK?V.NX3FXJU,_52H#\2OHB_SGC5N;N3O MB'KYA$.&6QYW5NEQ7CU6@%NY1?FA_EX^\A]@5&E5#4D?V>OVP!ZL#\S">B]R M2W?7T;9)8[GHFZRYL_D>*O]XYT=XXLK7.?S4/4[4X9'NIY=/==O1>C.6OX-IA@K;[(2I@M15(NVS^ ^?MA":[6+69=+0OK-8O- M_*2G7A0K)[QE$<3_3^&4W9.$)-4@(F!YY^ #O0#M7("JORA3?1@2# #_PB.@ MEL7Q5"VAI"W>X\3K9DGA%>,SJ(80#V6V2(@Z@G#%@$<=-B99(-Q$6"(@H4R# MV?P3BY\_,&)R%,S#95Y#7G'F.)G>FJYUC=8J9:$W_<[X(44B2D7^XZP:^P=* MT<#:FA+\4X9!(#G%I/8%$0C)"O[3(Q.R^-SU73;G? M5^OQ. 79UFO*X'7,- M+E@=H,%IN#GGX> 3&4'("&(G5VSW6:"NDI_.BJYJ%HYJJ+PCG^Z%9!:.?=.@?K M!YKOT*?#\\%>HOQ6J@5FWI^J((B)))S-U9 M;,@!+_DZEP2[*.*A?M]2'EU_O"M3Y,$PC]FBC%/7O?53BLA0Y.5XA^FHL<%% M3(8I$UQTCFYT%B9ON%?(.93=3[OH!W(O#Z><*@L4_F6SW/K]:-%=*ED/V>-4T%7>:7NGK^;HZ*^7D#X_7B0BFR%=R M<2C!=AKXIHDH$K)(,9U&A*/X[XK3_(;RR![5Y_0S8M&,.VW[* @,?\;3[-Y!'3IP@ J$66.QG MDQ:JJ#%.->;8+9*W#$9PF*Q FO[C1%C#5)R=UFM72UYL3F*:'@+(&@FVFNB+ MK9*/?^()2N9P(D<5TJWIGGY4(2 =X;@B("C6>^<_*I<(B%=A^N2(1^+0CG D MA6=T17#Z.%R!9 >_ \BI8HEQ0&LU7<+PM/<W(BR6@GU4$ ^P0-I; M0K\LXLF%013Y'J-_P2<@NO43:,*[]Q&//X!Q&/ID'=XP7:?BM#7&D[.6T$,0 M 6&Z !SQ8%+>E$4P?O02OP4HWEP"H!D%&7-"*QPLA[TC2*4HSY!P5-)>3J1O M<)* @BWB'X"BUWY70?JWB5OI@Z8]^%:'Y>5K+T_(G/"6=UKCW%J#VUO;BW;6 M$Q[QYJ8(+-42QPW:D1.^2B^@ ^$&1XE3V"NSISR8)XUP#$_.Z "&1VF(/\T4WV6\3LA" M=^O[GC7665N%%AO$8B64PXL_5@&%>E,+[ _O!7'22JY("@XTL"9FO5UVL.:Q M+AF.B]&2K5B4"6;ELA.XMV<39#U%P9>*]1=%LJ6E&H@ :HGHOL\X ,)9;TV< MZ**@$W"MPKJ M'QEW3;A/CO&O;DA744QVYB4"[)29_:TB(WI2YL7U-PD\0[!5!@'DT82?GM25 M;+89VS'G,T,Z<)T(<"+3("G\VKS8..Y$CM[5_).3,NU8+]<#9Q6-9C5[VGT* M3'H(6#H( K8\0E,H.+_MDR^=\&)+4!=V"6L7U H?1 XQ;N@%X49)1)$32@;I MQ.)^6J/'^] 24@Z >0<$\-2^!A]6E$4PV!/4>DBD?BAPR$C3T^*4IQH'8$7@ ML9E/L71M!%":I\DB ,"(OLE(Z"_HKP>EX;B1#SH*)F7/JO#N$F3V7X#T4L5Z MU'49J,+X[HWL(KM4GJ8@'+E:8& C(IY2T$TG*P">:8#[9$M4[!?+Z<;HMY8_ MKU1S7@>(,6N 0:"W=TCM><2(&_8X+?W9^ @0'!;\F+51>)CP_Y M#E:L* H% __FV:LQP\R=%%1X/#1$U]_A ^S])5JSY*E)6PUPI,D5G9 LYQZ; M$K,4 RR_9R15([+_?-8""8+'@5>SD EDM<)_#XP3U>3Z%27.&@V %%!J@ !' MS3@=M'% 1_Y5NTG:GR NS=?A\D75P"+=!WLO8<OC!5OS6)GQ_(*$LLP MR,@P)%EDY"#S.(+3"RA-A/MKA5194"*.OS)RK?.!@F)+DF?-^_UIQ_W)6INV M2HXXSW$*WO\9FYE1*'_!P-7W\91PG%\+-.NEKWA$^Y<76RK!X-7S#\-01I8( MVA: ^)BGH,IZE D_31LM?@55V9GJ"=&&5OIO"7OFW):N#Q%8P((=)]D'SB)\ M3B5Q[BBX2B X[84U;D T:+ M/2\-P^+8,9)J%<;^O,^W 1J3Y2PV;,N%+)*. M=-5^+R%+DQ[)SMZUO0Z8;O"6B M)R/$1>LL3 SN;PEA%!>^*,-N ?BD(=Y,ANAS^Z+=;<1 E@:@-E0FK*,S-0'48=>P G %';X M?-AX.TXLZ,XK'N#5B>Z#24Q^_>P;+1U1CS,NDJP@&@9F! WML+"5&'43L&2S MB.*9US)GUG*DJ *J,;E4_XSAV\X5)@KCCK3AU@[1TC#'EPF)OF*[<.0]:@8 M I_0>?"8[9[LYMU9?<]3]8>Y5G9'VF=O;(;]ZG%([P@ WJZ##49(:;,(3/6C1DG=3X-O M$V9V&V)V.#AI^%J(L/.IA=0G"NOH7_:,\B@]?9O\5$%-064A6#F-H3(I(?YY M[KU'E[_L=T4;K[ZG &]]^?D:&EE!;Y]?8F]#Q?4(0LC%=17_SQWS_G_\__B_ M!S35$L!?FJV\"3;0VXV=F)!%T)?8J)RGA.HVI!K^23QJ"W73G6^]N3-[L?2V MM5%&M[VGMV^IC>2#N^#IF9"]2W5W3W=7-G.PFS.G65!U4>!N'%<0-XPW6C;' M?P^6?^@J=J"G9PI<"%)/D)*SE $IO%0!+D\J!/[F>%_C@ MU@S93!)(K]F%9D^6-RP)-%9NFRBV0),W5[LP.3Q^DOVZ[/!>QR$(J&5=P7LQ M"1=+9K1_99NPW69V2W?S;-YQZ9;F1G2H&E-N&KN&0.XU=;$T[CX-_L#$>ZX? M>QD40QT8HR%P0?":KW8]W[_S%HBI1 ?LY2 :0WMUT$YC17SH MK6XF]:APJFU=J:)L'MJA/GW.9AT%TCD%-KJ;YP]0MQFS&JO!>9 MA\G-5H MS"0:-0R-ZM7X*DGX--BMO+VA2E7;B4HHL]15_=W+1&=P8Z)^$?8*=+\4F0QQ.4YNFO*G7/ MZ&LA-802I8=#E]_$.A9\CLQ-LEE\H.U;>Y8I$VM1$80OPU]3Y:R>%N1!,#,[0L>RCMA M><=9_@D[GX*6V&/MA@-B1F[3.)]*Y@L$ _0%Y/V,ZQ+8TGIBE\OIG$M@_"X] MXY[$[0;LZ<,^0A&57LKSUM,1F3")-<^8,7J]YR&^'F/HL*MZQ=.-^@>XI2?9 M\^NIP[1)I5?GQKK0P M1@](VLM(1@"!+ ,C0>>0O%W1CI>8=L7#J!$'.ZSYC)Y%K_%]NQ3 "-_8%U,4 MP3"+JJ_2DC4M<-$UT/I-L%Z%\0L]XS@7WBT9/3UQE\[VBKT_J1^J+S/1D[%^ MIH')N=VNLP9%.%P(X_QN/>V"SR_*B;1O:_4,M<$^4LP#Q]O_9<.BK\/0$A9K M#V'^,#NE(L/&# 279GOFE=/>W2,LP21F7:&M2+Z^J"\RV+\ECN/MC \G<#12 M!"XS=IW.L%#12/?2?HP^6F*X")3( +.J#Z4W_9QOTJH[+,9=639U[6ZOI^EB MCV]53_C$22S>BJSM'R!.GO(;/S,#1V%%$1@7%NBE(4/NC4\H*U5?]B/O*,[/ M2C=\)._PTVY?L&ZZTZ+?&85)_Y>K)+XR?GO8B-%B54=?1UH+7>I45P?IA;L3 MKR5(26POO,R6X(U8_N[;P$>4+$N#=4H@* *7OS^CCVS212%4)KK]',+L'U& M9\H(P]D89)O#9VW@@^=JZCWQ.5IG][8[/&[ V8KQGCM0E;"THPOME[JZB\FI M5/W\9$2ZE/S5XJT&2H,BKSM3[DVY9/"!KNI5GC_[%Z5AD:0!\GXIC(P.>FY$ MA,%%40CUM9[MNZ=OE]5LU-%K,,2^;G5#,."O7J,K5[*G;Z$VH10)CR/-,QS$ MS&WD6#\=.CP.4P?9(^WW'MS;WXV>$S6J3YJ ;/1N)!;QK [+6C\KJQ2IVW/> M%9C+]J"":[ <_3:+LQ%'B21^ R_M0A&&TQ_3C,;V0=!239G!'LTUD'$L>!>- M"9PTM+6:JD?R&A\F-@K*5S.P-:I+F5,^9?O P[-8].Z^]>3V\L[\?[7_&1Q^ M'&&2@-;W'"SVLK)SSZ_G.AJ=;$]>Y/GJN_V(Z,'6;"QSJ^:@6A; M^(T"/WZ>NQXK]U+YF0NMPJ]=/>68NV%DS*MQ+O\++ ZV 4C-FF7MC3H<0HFO ML=O#%;7#-QMF/X>+-:'P([\+795+M^:]2HY;V>+#@F?_DSUVL%.^E6+)PYJS]E+Z1^L M^!LC"OX5Y'__%D 5.8GX+KU3G,.*TO!VQCFKO7^L0@/(_D[/CZVZ*RM=WM!SX&3\[MRW+^IB64$"$W$@1'!.(>"^1]\TN W%Y"$,\7'@31= MSE)2%IP!$NN"S\JZLYG/HNJHN^Z0#L(!,L3..)>O08^4&8%@^IM)E9V,E (* M_<&EM@N*Z'ZIXQSQ,1Q7D;*-B2<":ZX^4Q W3ONG3V!./D2OI:L&>W*S]-3V M^A,7>JV< J=H3U$ZG(Z,"+MT<^Q&TD(B69Y7.]A:LB7D"XG)%((D]5A0-B1( MEJ?*2^+R=CH38*A.^S\YI#[P3OR$8"["*P%R=7.MU%JSM/B#N)$P'YB&V/I& M@5,:]R\3:M$->XQ^R*4"A=Y66TZMS;HE8D7&""C=CFJ#_Z;1^K@^2BV0'9S@ M(, BAB@]2-]_(HM,WD]K<#;G4S6V_J3;OO BM;6G^_.^MI['F;6^V_D'X#5P5-;_H:?DP[S747?*X"E&*2[*.*+*>4?HWJ&MIZ@CU+: M\FW) XU'7E"[RB$:@X&&FG2=JK5TG0%J/L%!LHD+LZL20C-+Z2.4_ASL!__M MLP^$^-R8G'38T*'VNU.C%0F. ^ N811.JW6!;<8^8WM*C-96/>6ZG!%O;T$> M"Y;.F*G\5?/MN4__ 'A4=^TB_P N VP=4;?,- M@'GKP*9_@%?&H2ZT=5\PH6]4W%U!U/MF71VB^$:U M;.$!2FTH$IJU(FWYPSBVK]61/_S@]X+.,7/"WNF8Q(XPZ9C),"H.NWSXS6H5 MFW&U5:*89*5(PZO=^-+[+_H\8XZ0=>33M1@%6:PJ =0ZW (8/ '%@RYZEE"[?:6VNNQ6M^%_# MCO+O769?.AI9+S/=R&]TK[9@9E]XW,X:N?AT$*KSM#[&PYLZW=6'T2Y\I4J, MZ3MX+*J )XQU(J%.&T/[@=5+XD>B)2^@8O"2/4N(%F#WSJPW;(Z]]?VHR&K2 MV(LM$,:Q@=DO.]@/K1GGR7B$.DIJG0K"E^P+?JX)G>32\&U9=K=1T-?L%/!S M@A!2FT4OO%(&X;*@1GB:?,98Q;V"3A2SQCXX6G@$1" <+1 D1!\. D\5M!E. M'TD7MY?&C\P*:;--'FN7>8A7+"9K^W$R+?&0ZC+1I%9GO%DM4L_;\8'F2XPZ MK%:]C(_CP[OSM4,8PG^!+;D;8C#YXA^F;,ML5LE(QF+SRB:6RMP>JT MZ/%\I?AH5># 2,MX8]#NF8WL/HE"^7"C4.O/1S]TEN%,V<6/TW,;PC\W1VXS MR].AUW<#8A3Y OE16\Z*_(OJD^O9;DF% H8M7=)R3>FA'>(J-2YFZ"G' $_^ M^@ITN;U#_-F]6^#FSITGF<0'>^^.!(17=L#+W@X:2^-Z*R&$GOPY<'0JJWG3 M2#N0]%F78V))-?'YCV\AVCE_5RX#T.LD>PAU,\&9 S4"Q!\\YL-.;1>-;)?( MF')UIRY?FH*^+.WN-PQR(>C!O;K:WA= 1KG)=A&^Y'&:DV8]'; M\O;RQKI+:LS1T)\(PT^QI/!]!P =^&@1!X9U*^&_L#RVI^-7>756U7VI5!%4 MOEQYLF2[R4./"6MO6>A*#G\9_5S]&53?AS^=B9M$&.O-ZZYQ8G$X$DHS*V;D M]F[_G5]'/C..0')\ZD5D#\^T1Z6IZ7.HUGBRCGVZ+>.M+GKF;+94)"Y$24*W M?GI=2D&5)W/LP9VR8)KE _!R.?@]4>>(P "-6U8TRWH6'3>O;\\:&VLRRZYA M[T:=%[^ZUYP%_Y)<:+O2=V-25,+T'@<)YY8V7R.:.0*W[-2^N5SP/8UZ N/I M(8C#(8B2W3'CW!V([0>BL_Z>K)V-3K6F)'Z_D,67MFMHJ@Q2[:4#1O2\?VM6 M?2N.4:+K3MI\M68%F^"]4:V7.17!%,2#C?Q*' M=*Y@UJM997Q6./Q.^/PZ7C3E^+E]OW[G^6;M)*/;Y-)=@0G<>NFB8.S2,RKU MIB#3T\]MTW:B5P05KKGP2E_\*_5W/4(@1;=)TP8E!$9$\-UMZ4P>5&4!3Z!K M4$[I'&I5I8.+O?MV/#>S. M&[S=Y5%\;G$;7K36I0YPU*^TM.8SZTA:!%[H^101<%P3%)!'#XC48@C4EUH. M+A9!X_G@%ACEN?.)10IMVXHZH? J^3 MX0$MAP1;8 08>+N&XYU9 :9E]SZW68U_@O9Q)5GA>"Z/"R,!;E0@ M#^.MG &!P$YJ?+M<95\O:K/M9[$X M=8KFTS,U^9RO>T\63A MQ^_;Q#D.K,^86="$["4#3[:"V>*O=OFZ7S_+20W-+>2K9M4U/N3_4[ M>SMSQJ.V."&"!^GV<20&7'EF;\:Q*+-!XP Q>9&96^.PY6U&X7OY^_EPZG[@ M!$3H:VKH'I%O*N&HXDY[/SD*64BCTYZL TH].W8)#@_\\O$?0'=9A+OMXLF- MN-H=UJ7WCC:+_9CAM ^3=KO^L.'(D92S28RC)LT'C69A8]7/+G5+E=!J>75+ MX7^ [J$M0TC6RL7OA1;XNUZ*7?A%0WLKZL\1RVN!?4DQ7U=MJ8\@%N?))DC" M2*>NMBQ4C]AKRF4E&OKQ"O*S+&O7_LB;%O":\(FZ:;)]ZH1)BB0O)Q5%%XL= M(4QFBL, R+64I_Y==JRCA"<20RR^D>T^K4,-)RTH0 *P4G(5P ;P;& 6VS_ MT3_ LNVQ=?W>[?'I-0?S M8V=R8>-:N-JFPU",OK!=F\=XJO>T1AUIHE.RT]?67.M9;T)3)MFI7#1(%-YH M[>2\,U^W 9/^LN+PG.,7#^^.\..OHV-YGY[Y&2MB',C;T/D4^PCXII>-=[<@ M!^K-$DZ&QJUVHT MG&LW\- 9&M7 LJ2X;MR1X1BAU%&2/^<[&#]4^- [UL1,*^8YFA],[5TUB'[? M\!^-K5>+0BP?LN8;C#7J>P(>2Q?C_W?*Q7#8MP-NOQZ,CB-VQX>H[=WEQ;9. M7,>.C<"\_= %S372MR?:+1J3#0*_B, O\$R5 =FF&SJ\+YP0^MM\G1IB'8$V MA.-*+^[A['@$8P-KT;OG,9Z-L>=QO2"A,;@2T^.$P\A>A5V2J:!'"PZ,%IQ? M_29\&_%Y@;BZ/C7XFWO^D'@[B?$F0Z?FOPL^QJA03% M<5=\['2T^B9W!8%DWK7YQ0T;9D2%+70;)OG1#;P:OW5 ;\/)!28"@PGV>"AW MT5W7;C%3'R\ONB\_U]&R"5"=_CF(&]PYB-,ABD;QC]\H#S/T"B1^I..-;QFL)<[.6FY(G'W]B:KYDE@^BE,FUM_(Q,^]**7#K_:4P2A%-U]772H M'CP3/-@]'?9$)Z"86A>X)G1KZ; 6@P]F:-'THUD'O)#J6J/NQWJ0>_IM0,8U M[*ZIU\JEZB7)=MP_ 'Y5-^;53GSC)MOPX='S5Y[([M)/?FQE,+ M"R-]"N=N$C!CMENNTY_V!?:6X0B /Z""3K_P-VD/90$U.$28SN(#K^%H6/B@ M#18J@!H%]]'C'S_>A=RJ65'!:8\=I7XG?7.CZ7LY]S7D.=_M2'GQ)#H"8Q2@NMK\7YJ MS_SJ=;=^+GIE>YTMQ["L*LGOHTG!;_IDH6V@?3M2J4W_%'VCQ.#$C[&+7 M;$BO;U)AKD@55N;5D>;\,XOS2!#[K; :);G<"DK OL95[N5=]JNU6NR62'5%$'R>= NQ$L^6_12C1NCQ"1RM<35O)F[D[ ML5P07G5-^\_]*8ZW58?^X"Q-FI&E8$S8*R G%Z[BY(0/9[$]*0['KK@GU4<&#[JQ/=?A6&&.(;TV M#W;X5UAJ2W5JK*T+=,*A:R_+\A=BYT#@(IA83SCGLD\=KG=*$$TC9$[&)W\CB\ ,^A&\UOZG+4N4+FD*YS#KC++E65V,/J<>6 M!4L\VK[[!4Z,HV"PU.2:__UJN4W*DP(!@T;M/J:/U4;)KA+)EE*UR]5,K2>& M];JSA=H^,4C>67&(R\_6WE9#=4Z#LD1>0-7G. :._SJ3(SG9F\,-_ZMTV.VU MW=41"M;/8W1'NE0D9\RL7]3,'F[D8JU&#/)LUQRCLQ(Z,?9(@D^%^^]'Y#:_ MM'>+"R\M'MKGNWT'_.'TLWO%I2P$ _\HGMP<2H<-HDX#_.=CU*6O_9,_'<.=;GG 6"+ICT_#AR8A04M*3F8 X"O M#VI.JD)5CUJM1[H$U9T$2+=_>Z!?3HTH0BVMI08PVRV';6XDT&].]ON9(B&F MZ#?^]:&&^V3)G\^4Y)JHSQ\'O_L480'MWD0HYOT#Q#8[>REN[R(F&+"O-X/F M7B)V(C1YJH+)VSXYH9F(/IL<&]OA) EI?*E >,EP!!'A7MH0R6,'-N>L7X=] MC0=U[OC\SNG@+'OW#_ WV6'SE@'MD5>E8]45J?M-3$L-(/XN!I":$YD2B'P2 MH;C_"1V7ZTWUQD5PQDN$X#H^"*&1!W8_VY+/5! NZ(#MP MGRQ"+@W -?#\>B;,6_@36F38%GVY0G^=OA_O,3R9W'HJD"".&02Z._XHB)YY MUQQU+^7RFUYL?=-COCEEZ95@SZE'!2,9BUV+O)6>#"-#+3!K3=$2<"-+J7\'E39)*."=N^O>0*&&FJ=)$(_$U'O7D,G:"/.G/=WD1ZQYKY- MG:"UBJS7T_1\L-X"MFH%"0PR$0!+Y"W!_I\&=6><6B?,KVL)Y(]^XBLPL/CM MA.K*^$3"X+!W^)S1*4% ^XP43<5EFKR8H$)8MV6/QVG_E-6?!$6W=2OIHCN9 M&P&GJNL?P?3\?/%KXEXD=K]21,%'J+]+KR:L64=2F(&^LQ(IX*-B:VPO_EYX M$6F!4XDW MQ=K_HOM23'_Z7;LPCO*X;;@MG,6UA\Y^_.X;/S9,M7X".-ZE\(7+Q*,R,>>U M18+2@N?M(TWXX=R.9EPKN]C8+;"8NE>A.@WH9T%>6.'V]][! ,+!OLH1A63^ M8A5%SSY3JMQ@#I#?F(J0OGBY"+3SB6&8>ZQLO4/\#Z!VGVBAQXZS^],IUWOA M[VP07#9K;H;>ZMO^DA=&SG!S8C$?82]@$5QGG"K3FWMO?B?E4]=Y3BL>4JI7 MO2PN3#N%U$N5#^)#2M1U0N<8C7SWUOQXU"AR%J$Y?0RJX)N61&+>LH%J"N3. M?P;H?X^*<58M]F0A'JP(61!H"$>>CV$"V7^.H>"4K8,ZF"S>"(4)VO?4*A^%D<_Q\ M.UT7#S)GC>YD*?X =?@'(#J&(N-X6!)9C"#6DT;%(PQ56\7T.8A0S8 =1]C@>EKE#<.@#\^;-1=U(GJPM8X)'B7]Z^$VF?/E7 6O>I M10+@38)'\#I-37&9(SKZ[T/8@/MGR0[S^(;_?DVIK??$V&2Q=4*>?3<7:$^B MQAY[R5FG*P0M@28;CX:)SF>[^6T,N*-:!>,IBH"W:;V#7VA[="!!VN.=!(@1A19WAC;\"(A32?GD2,8\S( M7K8G=*1+XZ)6GRIN4,^44X\/9!"=X768<$=RZ5U.2D$#T6>84=&/"E'8.[TA M -4W-^]Y_P-\7>@B. VGMED3WKF@KG^1#*< CC2Q$U2P.R&14^OJN@,F+E, MX4*4?OQ03D; N0$Q[8]>[*DH;PCL''[G[;,^8#-RP9:);1)GW!:-S4!-"&( ML12PA7T_!D^1SG=^R<\C,""<\)Z!)&ZY)+?T75O<_%VZL^U M^BFN*4MM/4,_%UEMFAB^:D+$I+[)9L7:'?E=C)*'+4W89)&$+7E@BM6FSXY3 M@A1W.-5WR,#:SQ#.8*]A,20[B89)Q/[G_JY7C)2N[65[ (-9DYB@;_A$KJ>D.M"SUV\Y>I'-- M9?(O" M9Z":>&I.31$2)8>5CTXSU (A:T%*"0IA?7]74%F;ITBWJD5=L%2HE*6-H>N+ M32&VFG\ ,">7+ +2 \U:=!FM;DH1,5DNO%P\?/]%G4[MORIH&D!:,!39'#9@ MB_B &N-X/"_J49(1C9!S8L4#JP/>A#N8O]_B4-[8V2G ]IF'D8N".(I YV:/ MUC8U'@%9.]E7&G7:]$UMQ\-CY2(>4ZK*:0PQ>X7AN\NG\6ZKS'8-(.-4"J)$Y K%@?69#:<H(->LRNFD'"WQHS 1\?X4GO12@IF_ZND[O[NG\GNGTCS7 MW*0DS_+NNF[%:(Q&E9TQ7)0#-*V;RO;(=_W5%'&$S!S-G6NJLR5/S8FT=NE8H@+SQCQSL#!."'747"+\IC1]1!G4*N*[7NF-U%GK6,;V9_P M1^-1LJ G^Z%?RUNK&)Z[+)AI8]2DRZ2A49:@ACVOO(W08H:7]\@(A49CY00/ MD7'^/X!"[[._KA!R)2KH(,8]>^?"NAOF%>=7L%N+;*D[7]-FN10_,K7SFL^D ME[=_:=8,;IO=..XL;NB7?8C[Q^Z7PKBR T/XRD- &(BK _?74!&-7C1WQ<<( MZ%F,X;,K_2BXR?>\VW>N.]I2&ZU EHRD2-]9<-$GR7TRY#/77%9GI MBT2WK7V5OE2,PDS<&(=X8N[*79B41@>8*!ZM.\OE+E\BA=]76]B0*9M;NQ3Y M=EB&%E8IM_9WF;J$G$9MF662]CO-5;S:'\'7/3O FZ5^$@ ,3MT6B^.?.2$\ M4Z>[[GICENW0R7O0I?$R:DI4\F2I49\DLI1%BMBGX=P4D25=VQ3$Q?/3!OW" MY24[4<%1UQR5O5.N4U>VA,PTOVJRW(>-,2HS^J0"TUKJDE.NKP!R:&8A@>H6!ICLA M+'AB-<'9%\T\ TJNU,J39A/0M2YXH.JO(@K7%ZXV\8GB-#V+JS.J#:CKG*PTG*TH9U'\Y M;^6.<[J,4(MBX0!I%B,SAA $"WUJNTY#Q8E*3&V0DEM1E&+?WLV\^8:NO4N+ MYF+&4TM=';->KV/DH=VOI_@\PHO2M8[%<1UXZLOL@HSQ23.>E+?E-7M%#(4^-L$8J(9'E)$$BQC?MGN)I# M&+'C'S8<$CB;B--RIS%!TLB8Z)2L$O_(XAAD"Q*I3;92&UW_(IL^[OM74[XI MLOB9>HW68VV?OXT@WNI3Q?^ZRKS %(._E*(US^C0B[LK0^ZLNR)L^>Y^3LTG MXMU\+AP9<*:^[=A>)1<(M0_0,N 6^.EV6V@JBS]CZ_:_@\RT;B4"/J*KSYXV M!1[>BS,9E[FM6-8-3BMZNX>Q!X8!D]SP02+ :'F)CNEP\E['/<^D 8:VH+;M MA")Y='.RGTX94.:>:\6/[-V;7'+,D+NV!39\YI=6+8.F;1I<>6*F Q-V6I/* M\4TS5]+9D@$>V2$\""6Q0P+VQ**DSYK%6;CVPGS.'(L#"POM-K6&C0>]/"QR MO.Z-\6373&I[U>5MG R'K4QK+8G.&:KY-!2G.Y%#]ZS%RYB X5GFZ7+]C3BG M,<9L"-PBV8Q9=MD$]:V@7B@ZTZ&O478>;AS[;)?XET'/74_Q?YTWHD M_=$U+R[]]>((]2!W?X>9P850F(32R/BF=BY+E-@02,EFD'U/ 3"!9&P4H#?P3UXGL:A-,CQ]0'(I4B8;#G6+IL62.A5Y1?X&)3\C\<0LY%3CE@ABNL_K'X!F_X\F#DI8 M5Y%[XF3_V\8(QZ#]YU-W>;KG&B2/CA<+Q#!UWHEP.UX3D[J159G@IN8%=RK[ MCECL]';>(9["_3%F:87TU46<3GFL>$WU; MC;$$I>=G/]1I1^_<.N:FRB_>.DT5!*=MZXG"_<> 1;G':6[5*-NDJVT IF,D M3 :U/+;:J[9+]GH*GB=XQ)\06C&= U&7B$SW##AH*UR(O)D*SN4<)%?W\?WJ M'O&)7-E(NF1CIBZ^OBM6Q+-\*XS1(/-UU5@L8BI MC;BU_E4U;EZM7JNKKJ(?'Y\VN@5JN4X6#W\%D10S?W?%NU?SV@O3(,V=?]#X M'K'[XTMSS*@AS&6XDGB)5[)LR9&AXWXL4 M5F&FAO^RQPNER?6F%UH];^_M:\LD%91Y%/#KY;K?4AWM.!'OZV MGZ^EXS7AD\<-KFQ V"(@_LPQ:EE1BY9B-;Y360Q*+7=4BLR8&$06:_\#< 3^ MB-LF0#?3HN#&)N+61\PQ(WRN]_7\5V*R?#R-2$%\$>+"]=;:-9$L]I_%<1LF MG4<1@4I)Y_3R_P#OO7M#PW0N&H9VD3$SO@&0@^F/LN,(.4LIJ15U+EI#6_[0 MSO^K"J4QY1UL2'2:IH%7^,35L:U(B LFK*/;=RTVDTH3^':!TWUV#/I(DRW? M')\C17K'&_07]E'J3DY!%>$,5.%PGZ:\M#-VP?T%S99_ESXFB?6K8R253B>\ MZILK3=C/BZ^O'.LUX 2PG]^27'XR^)$(N.>"!]=(G& "QS_ S] )D00SQ(.U MXP*ME)HVY,CH>:B]@CXBC+DM0Q7ME- *'%MMYKA?:C6ST]ZPFG4'$DL7!,7\ M:'KE_Z>9.US[5IH5=F3*:@V3-WY(RV\PR(^!@[J\J.=3A(:7'N'.TF>G5P(1 M&N1:0"\5!4(%B!K.^UY&87O'EEJYTTW7&A:8B0*Z_A+!] M0=**]0_^N>G24>OGB#2X_.@@@,4M;F1/[,,T-PZ11A,/8W*S/EG,B&%TX7,- M[C9M7Q>C1)V]+.W6L\;3JNMHD!CF5-HB$G%HOG;I]4UP@"@!@12C.^'W_?[J M8VNE39\+N+51+TLN16REJ+P:MUFR>)0=94BQ/J!_ER__)(1L1Z!'5Q_I!#T5 M)D]_ U/W#2$K$W]6C; \*$A\8K 5MHF-.'P&NS@$"1-+]?76\ES4-OWX>Y[H MYVX/M^'^ZO?2!V[#T9-CLB+59WEAU:=CML1M+['I*@-KT0\29*J4V3$'\ M^9P4$VI0*"\5]F3:Z]*I&+DL.]N*]D^VS TEGI'+1,DRPB,5S0>OGG3F:D]6,D.JN+44D:@GHJC/SB0>S2&ZSE&!,6.H+T"/TG:05 4AO3_.BHL5T*2&D.O)[5 5&WY-?N>Y MN%*U$KSN&+;VC5YJA;^WJ/ATI_C?:#]]V7],>0?H'>3U !QY@=*X7U, M];1^PWKR<6N;;[S6 CA8/LGSFO%>\ORABQ_2YQ;CV\- MRRPF&J3[_*U^/Z' <[E&NQ) X:0IL_\V;PQ"?O")G;7$B;G M]@] ?76X)!C"6?URVWF;[)8]7-!&,TY>"&]=G;)HT+.=J;_5/M3>JHB#6F?J M:ZN?XZ>.=[6R;KL;W M_MH:L"?KE+ZG\W6VUR\YF9B&4R,A-%\6^>&T*^TGT&,3KT0P@0M/X=DO-K>R MA=8:R6_EZJ9&Y!?DHH$D,,#0:SKO5=(18K"I8"HR40;T#92G3Q8WL0&H2]F)2 W,+HH>Q[*5NZ.267*=E%@XI= MW!H$D8;DD\0OZ^KDS^Q*<"-H=T@A@SA+89JH>IR4R/#S]+F51 6?C8P_L/!& MNDMBL<16>]J<9SE';G=G?\S_,&H;@<&UP ,!R>(^GB %3R?A]H-4Y]+U@57C M2P;%;W.E%3P*G\::0?O4D&V"9MM]H\2*M2\6(3E_:![MG3,+"3G =(/&/ N; M<&$:P=@$R-1QR'J7I*&ZT,C?M>VH+_\C6GO\6@)*"J79($TQV[@YW7' QJ=K?>%U5D =N M8PW*,_K2QN;4['&M]/(?8"=S@+6?^98#30]?%TE0H@SA0MV/6"O2]RP>H34^ M.95;N8I_FZE9/[O1/?T$![:W]Y!(CA%!'7A#4K_[#+&WY@Q2L.VM#[$SW=-B M^@]4\:-'BI10_X^@HE0ATB$T:=([2( TFM >@>17D+O'4*1+KV7A-XD <$( :^_.W._ MW#_@WIG=,^?C[G.>V7EVSIFS3!%;F@M]'Y2VYXT!#]^_TNY3>6[(NG-95AS/ M T,J&TGE9%@'//GP(4DA!_;Z6G(7Y#_P)Y(&&=, MJJ'-&LJI0.D;A0Q:'&K"&;3BBHX6D0OE@A#=^6^[$/?871>#ELN@\+\ -?P- M4I-R!"J;3K@+G-1+1E*K$T779%O5,IRH#7XT[/2V+E2GB"E\.V28Z?':JR#2 MY.@"_BW_]U56F,+YHVVO6-1.SA_K,' %03F0P2Z8UIP MWHT3:M(%MVH$G7QA$B0M0>J8*. XP,CSV)]5L"? MNZ7L%LR).WW*UXR7[?.XFGLNY)EQ\7?V20LD=C\OF=+G8%SEYJ839$W%\77R MI45$G'!P3-;'&]D@$??]Z;&$5C&*F/%:X8+!3,G'8I7F5,E:@_RK))'ANR!- M/@X$;?1UEZQC%@+&C-4]:!W1C>2+V[S\':F@MDDA?0P,';D0JG*SI;1BD35T MHO/13[C2%Z/74;%P6_[%03GT M"I"S%?^"HEC52+*%C/.+:)F(B5!&$N!FF?3=T4FX6V(J+ZA_U*>=._6F=QO2 M9CDT8)@C,7/1NK\2S+'D%QN*2JR5-Y4N-O*F=NIH^>U9 >%4VQ M(01RE_U3A70T6F\!_\=IF0N?#\>%6Q(!^X9;%"+]DD)$'UTR?*5([32V2S-_ M["77]$#_P-1XG);$Q>BI!^5GHB<33=%/@J\7"Z D[^EJ@IP_S1@_^KEWGO9! M#PAQ>63_GY"9<9*F[XLI(#8+:12UZK#"[.#:>#XS,,60*?44:/"ZU.W)%Q6D M'Z6[N=02W@A[VB'JD"61VO=Z<+FJ*+(JI_E-9])#P/YBWEM X!>N]0:/Y-Z; M^@'^[\.? 4,S?L'Y^_HD94SU*I-$@!SWO)?[;)'N2WO=!+-WTHBJ1(D[N,0W MV\=@&X74NK^ J$91(M4_*I9(7.![Z1HW3,+@J9R>G+.$BFNQF^(R.*/Z&R"5 MB(J# M(]YW.^OND\)6_5\ \T\7PVT_UC8Y!!SK&'<;JP!++7F6:)!'MT==*4JHA11XTU#@V MOSN!'N<@-A.\TFV%O(3CS%ILMJG44,L=T2P+2\AP*92F)0)4#.S_NL#OG6D% M?_GR0ET6,"NF\,M\.C*"QW:#2WM"A%BTL#\SP&F;C&A04VS"7=3WHS%T%+-7 MK-WD\&N7GBU?O^C?>[I]Y[:4K[7TK?K: :![83])4E>$&^'NQ MJ2G)O0)9__>2\]Z/;F7BFQGH-2BG4A[VRI&D)E)FXC,=5>!_Y\XA"H]V]O@SJL:#K0]H1+ MSR&4UOZ#:UMZGS^.)C]LT1;U%@E4\?AXTF2LK.)2E/15Z2_ MWXWS17&$H$4M4^<+/,:+K9QWM3Q>YHBFRCNI'15+=OQT[[CZY!^;G\#&T/D* M&WOUYA9A_ X7B^Y0;YRY^P_V-N08:3 3,6.NT8/)#Y7P$85:_@4HS?XB(>$3 M(E\%%TT6G**;YB1,)?F A;.!@FQD@0]AG#AC3.'@)N,O"C;HXM FPZP95MR, M'K,?1=VGWTV$68R\1("1[56R*5.VWN6.\CSY^M-G\/G.D@UI+4Y'&5=XK7_- MR#D%32D\%+GWYTU/"Y?!O9!^3,FKD*D*K#PUK0%1SK:[HM2P6?^C_? MUD(C!_V*>R([^5"G08/R3[J-X&FQ*#B]/I:US:-Y9'_=Q.C@6J+X]'9-/^WH M8CT#84-IS+$FZNMP/FRL/WUI2J(SAU>H/EQ)C^Q4+GKGU!3 9%+;,=MDRO@G M232M/0\>Y&Q?MKSQH+4A<:LMGDA@8F;$W?'*2"#/?$$AX@Z (3PY1/>LS"K' M(P=9!6=GK\P;<<4H, T$!\<+5/T%]+=B]-B^@)$%[7\V6B4WT:?V#TL_CJO MIL@1TC)80VM_*%GZZ5K\#,TCD1\ENCK&NXZD'BQ='W'V"8NX/@5=;XC.W*TX MDB&-(KC#\YC(]--!^#Z_."D.Z2W>Z=6FLV:#9@J)AP6"=1/\5AQ,]'ZC'(2!.YYB>)U;YO> MN8CF/?.%&T[WS?5;\6@CIY%SQ43#YPQ?!N,'8_<4V-_9D@1'P*VEUW3W.3V_ MO)R"N!(V/WSY_:.,#(@YN3'.\S /^L1@8^2&N9&M(3*F$UPVX4]Q2E4(;?^M M-8LG77R-[M]'Y8?#_.TQ/8-9=;.G=+Y[L:I8^+7#Q5'S['B2?2#;'/_7NK:& M?"F6^>&3-DS]\/!? #W^Q3<LW)\-S< ^8VJID MX!5-/=%!":68$KBK?&)E$Z(G%"]0Y.!Q+-M4U#YX5U :RT$': M=IWVN# #?R+Z@ID%]L!$X]%'(Q9H>?O\9. [>Z7G'DJ5G%QK+F]PU;7 MU7*/1S=*:W^J$ (\@_-R/F!#K\VK[T9ZB#IEL-M&F,AH#NS/U"V=&PYHY%6, M\\-9LVEO,!U.&3*#?U%AN@YU;KH5)>EB&W _;%DA.UGQGAEX.ON3J78;1-J_DI*4U7 MF"U_@$-KF3))\NW'G-J4OX 7[:R%]LS,YV"3<^A6_9&HJ>AR$ M0C:H<>H54!(=C//)IVN#!)B(?X4YCO%X:(,"%UH- RW^@ALAF@3H;@99">J/,X.N_4T48,PY*N%W?4M[+Y]/GCA7X]SS@'_4*I4\REKB.J$NT&S2A# M"QOF*-$A&.OQ%]&M/B(HT&]AU,E*KJQ,A*EV3(UFKBV$*IZ/)&+HAX-VJ5*C M3"VN0L=+Q! F*4:ZAUD:%V2B56HB=CQ/''ZO%$"N[I[0:XT-_A'O"=DR5:E; M/;PZWS#?4$MKEG0G%#/=6&OOL[=]I-@SWMZ6) =MMAA/")?[7$G\DOO)[_NG M#$.JAZ')7UZ^T'0/C;GVN7J*$5=X_!?PKXL/"62:<\;?2FE@J:&SNLV]=AMC M?0MPA+'IH^\\]61F&QO*K^7=&;A45C/0L+T$O_&&V"AR,$U;42VD^5LDK$D/@2SETR6FG// MX@T?$' ^T7H*JOLH\*7U25(1^W^/X)*W_S)\0(X+5A@,6DW?9MF9]6U6(#^K MZJ:V^P$[^<#ZJ"%^<8!=8]L^+8AN_;AJ)NY/['\N I\=]VFBWC([ !C,0@%> MQ\&;I2]4Y.?_G(4RO]#AW5I[9ANOE>8^T"3"#,[5=1 MYT=&.4X)I]AJM6DZ M4D14!A>JJFGK'L[E2GOTG>=70O\"!AK%S*3&SV&5=V],N!2%MO#)9."U<.;L M2"MUGD*S][%PN;DABPO9\]V0?82^7O&$OF,##L??S7/$/[C>6,*!N MQH=,BTAYIVQM!?0.2'-"(T#_^(Y88YD2:T[ .O5C'<*X57S;U/G?9NF%E/];5P"5;C M?7)VW$XQK[.?P%] KT("1"-\K[P"3X3;++:7=:(V<6BO1F#RAZ_\ E,?M)^E MH6^T6S%[^5:EJP]VJVM\AF*"YFU4Y;42\W:VJ$8XN+F!#/.!ZQW'BKNQ!2G&',6&75G1V=' M#E/^*7YAX]4ZNW^J8/U?,)8UD69TC^ MZ[-SAT!>E*A3Y+U<]Q31<8EW*]V>S T$R":1>8=.-M(]HS0"L?+8?,IMMU^' MHXWG4]7*R[H#E@X_AF;Z+3#G.4)"*XY0B;@I:"1;LAOS!2T]ZCJ1#J7_GX#XC/:7H(.2*"7]_\EH"YY5K=J$Q+P%74)ZO$8?3[6O6 M+TA$G;AD*T]77T:[/DRTK72(IJJOFY/0JYO31FJTY?'=9/SJB,UPSGW2GA*0 M*M6G$/870!C(:HK;W&:8O^,Q.?X+H M\"A/$"*9O*5 KHX+(-P_-R5RM?EQ. M14GY[0@?)YM#H(F"7^<[I0I?";>8/L^&OVD:G("/;T1B]L#!C*Y]X%7MHZ$I M-$5L-U5-3)!-N5?NLWW=F5]"])MK8Y5X[:PIY'4>PMG1W=:^Y& E[MNT:V&] M__&QRFXK=,$V_NVEF-!CS"_A*6 2YLH[^[W1@D&R,M-MOEF:*:19C"5X3&0) MUMST3H]928A%J=GQU5;9-L;W!3$N2B]D2!?.Q8!K,PAG6%EJ-R2]B)(.XAJ: M^^[Y;J^$N-M"J=LQW:*V3=,J*OR AI:E= G4(%Z=N'[7CU);S>!E4+!SF MQ\HT-3WPN_U;E)KT]T(?5RDJTGS?_]&2I1O\^?Z'+1=+HUX@1[R?'.MV<.B2 M;BF-,B\JZ+*E!*SQR MZ/ZOH3/D3MW9XZI_^1(!,EE&G*^8&[YN/G/V+3YZ*/?BV&;'&>.#8AM,",MC MQ>;W!9%!>WKSGK?=?NVDQLCOJV$CXP3PZA95J[@+E;DF4RGC5L\*7]NJPI\)> 8SQ@WS- K9YMEF_&N@PSYCS_ )-21C;B=)>;'6&L-UY %+]H=2MR:Q5#U M5K:N]%+E.?Z-KO?]+P#ID1UFG_O7P4-^UE:Y*P80>81%Z:%LZEU"Y;+]RB^# MY /(X%YV@&,1-$1 _O!$J.2'!-#*D<5R9?A]Q-&P5CXX#RUG/*8?H?KTSV!@ MF!&,\#:K4QE;8W2;*DZ!,_0S&-"0/F*EF987/FH_#?^9@ Z*8F1)GN WR+O? M,LO5,@V2J#%?.6)\K4'VRT 6)O8VT(B5R;$C-ULH]%,0?3?#W4 W$58H*K_? MC!8SU3^U,CQD)K%XXKS=N2"^20[EV!:*D9AZ'&1E!&;^?!_ M,1GS?>+X>0 [AS5X7LC)()$2,H(P/:?3XH>B?-9 MEG],',<:P813#JU$I(VDH@N J+*._G0;MH>>RXHRH4.[AB?ZM.![$;Z2?6=];$ZK,%X<'W8*-37$ M1@,CQ.S#Y=EP/2A2B$*T\2NL;2P'-@*^+41XO,$>J9CDV@0NL4_/8UUL-.*F M_[$">59L56GT9\6FJV[.NM'K"DYQY7^;X16THORO'3LI0'=1H_6[T%UJ-R^G M0;98 A5L;E[ZASS!.:=T@XZ9QGS2D5(0$KF0[] \2UY.^IN^ 0)A.MQI:6^% M%AT/0DN_;#VWLN OC,FS3[>X8 ZT2E9_5GK;DK;;]M'@\T2=X=I'LCWWOMF^ MQ=X]0T:HFEMPK-Z%O3S' MTM[MSC'OHV^>'$^?]1)D\%Q MCB__H[J?1_-8SNE(WN4E<[S8GYGM^[]VK$*@' )?E"1S'C[QN4_PP^ID;'.Y M!8S]"T!.!6N,EK,@O-)7B&U9I4*!X2_ ]NE? %%^PL_ >\OV[5/]Y@0.[9$1 M!B98A<&SL*R/765'@=0M-T(Q32H@.700(\Y\B)XN>?.5]Q7#"5[&(]E7T^O" M*]OD6MJ<"JK9+,M@;[7Q'\(@0<\FLU_:[D=-\(1%LG:_%0O,ZT!K8 ^:\[HR M25M]91M3%_YQC4.F1HX6E?ET6Z7IZM#E!1>.1HWV,0 MY>OFAM A3+-)>=:PK)94FHZ>*:8G*GN%_TQ<-ZFYF4$U!!X5]5#R6!HB! +B M=R)=QF6K$IT>.:^Q"102V)/&*!U"V*<;^P)_3#_.LS?C4>;#\[[Z\]()&Q?: MD:>Z[29]FB13(BGLO^-^_./G\>2&\"N"T,^/9&I:556EUU^IQ2(KDAISBN6- MJNU>:Q=+&Y2L6?_9RV'2;J\/RH%Y%-O-Q'I$<) QM#>$OU7S_G X,9:(PI(7 M,7\]>DV1E\+,Z/;N]G\&K+K_!?2]O?P+('#<8,)18(<''"OQ"G,++-R]@7(+ MW$KS(.J@YXVQ;S![=17MG+(]84T,>2BG,\$\];\ BLD?45SMTYRMD8IWR9;M M2:]QN9SO*R/B."A114:2J:/U/YEHO)5B3,>7'O1\GB&-4Z1;>TG>/OGJJ,)^V.AYNKS MKM;4IM!T%.*PN>6'-TFTO&]Q#^9T=@QU')&8A=Y^FX!LCULM:O]2BMF?,>A; M8S72[(EFYOJ,W,*8;:3*\XZZ:8-)PFO,?F'^K#,*OR\.+S2FW%461FJ5$@>N ME+!1C?DE*U_S_-+ KK)E&Q2@?!BLZC(ZG>SFTA_N+>>^U>Y^)@TM1TM[TD>G ME(+T>>-9= =M)/CF;[VR244GLL+3Y^\&%9?P3RF2($D":H954:/W]K M?3^WR,-#4U,5R)D1R8=10$0[1T7Y]Z^]BZP!$F M^HD^ZF]L-+QEY2KJ^D>57A>2VMJ]WH2*T6G36XV5[H[T%6_ML*!0M"K$(?.&J3R+EQDP5OWQ/['KO0@G'5"[FL5K U9XNM MY"/ -*!K!K(O.QO"@V:SCF9&^]"D_#5G0>[,W:>L; ,&AN207S(B;4H*$AYZ M!S=V_*2>,A7$,8/#E*7:1K8<0?J=A4;2_>XF\_( M:[[?##A41>?4#=/M-\.ID]\A[XO!DIX:Z,T&+UO??BT'ME(EU")3CF?XSM C M#@*?=Y2J:V" +0%(FR23"-1,SV]8$5?&\%W.[:6+!\6[G"U&?%WVU5WS/%X! MK1#=S81EZU/"? Q'..AG"?7G.@XNZN+P[JZJPT7(#U.AU3N.P)GVIK2NK_;R%-C(7H7_[#>>X7S^ M%7@6J/9?P+9"[!FU,3:M$*TE_HF5H1DCG^Q?<+Q!W5BG53Q6!BW59VRD5JV& M&-NO\/_V"RQVB:7JS[RC[<_C)M%.Z>J"ZGMSC!:"!/@%(#BP=5G[:)4%'*G^ MFX26H6V$=]Z&$8.LDHK*X8DOA723B!E6B-NCCI6D_6"S Q;NJ75+3JRR.<7: M(H7!Y5&C%\QRY?"\AXT.J#]U-.5(VO0QX-7:HG;YHWJJ,-N-;Y+\#U^MI_)F M.)&B>E:(Y2WN=654D_:+FG]P71=F\"(U]E*\3Z=+TGBZ'F**,Q__+L\[@MU$ MV^*I>]"+D54"^!S<:AFL+#E6.-BI6#E3Z<3XE]_5NOJWJ[WY"27-?R M-T4&NUM#^H1:LK=$M_,D"R+3ZX$YN@?IJ$-.5'C9Q^SOF MVQQGSX\>ATJ$3..Z[4 >1S>6:]SO0=>.I'X>0U/]3"@TZ&V,.E=+ETCOR,\/ M.'JVJ%Q^>3YZ9<$!1OL:L2_X-62!C#>-HL9V\ MR>LKU79OYDX01]1)N5BB MCQF:_,5*(061Y>!5"U[9G.X%"9Z[A:+?+ELN]_1\J&_JQU7X6NZ)-&DRM#GEV(5DC=5P::3NR6RSML M[9Q7R>M_']DKQ;!&RF^*]A/>%]U-=A^6[NVU?+6BJ;+-44>(ZJ&Z6]K@P*1' MLV<;SQK\.R8LX1JO ;67VG6.X%Z&2J[.2" .#3@^:J!,'2 MI%:75T/?0/V(Q)W%UXS5JUY<-E^<7)L/G47)M@QMQM]1)+_#Z(=B\J^".C&P M.W:LZ3$T4@^KWU/BV$.& +E6*5J4&*H^2$MU+Q*_^)Z5F/6GI"Z$CW-:T%40 MW8781)5-JVF!+/M]D:$\4SQ;<&T4(0_U"G!KT3\:KUKOT+T*XXTH+F"-IF*#6]E;D! M/:-+(^0=KX.66QY]P!I"H&]/[5"[.B3A@WYYY1@?Y")JGA^Q\(I*^XVIU&,E MF>TGE[TCD^3D?+UX XRBSG3D543,&=/+DX,?Z4;4"B)/@_GEG4X)I0&)GQ^" MM!?OB,G3S2AGY866'3<:SQV M91S\AV?,1>][*"SJ%\KW*P279>KLO)?]ZV[Y5 (NNH &/AALVFWJ6M,6U_QF M)VAI]-6"^2CI:=(SG69K5:M#3I71[S(-_,EB(VT $C;<'4TM#A[? MUF\F$8W1[&E"6CU5TBI@56DMGN"EX1+Z"%/>^@N(OLX+#J*+1@\9>U*3^+_P M+I2!;]W^4$?3\^L6D+EYG#<;Y8YPWB:BIAZ7?*M\,) 84,J4/LIKT:HQ +2R M 8C(,"SW,6_'L7'BLC'?AHU#T-=ND_N4SXZ ML'?,P5Q59*76\KOSPRA51TX\OU"XQUT1,).2QV?T_W]X1TBA@+T=,SY(?T+) MDJ9%:960>UX>AYT/!O[T/37O3XCV!GKG4^.R#3/3U.%6 UEW39[/.8N2CR%= M&R5+3\BII^2B?FZL!7F8TZ[/(AC,C#[))AGDH_IZC_OCKO\"2*_7 M@V" M9$:42N>E;1-;KJQB)XJY-]<]8UT63*87?@YCA&:K];;3H8[?%VL-)_FNRD\G M^%EUGBNT0JV!UTZKNG;Q2X)#[#ZL:F)7\+VUKZK[)ER\H6.IFF3_X3(%B M('\Y=$TPI M)GF>2!_CK'(3R(\I4*<^*HMIDTB][%?SXNMJJYKS%L9=0N];&])/1=Z60P:T M!,67-CBI7_$,]&5)]7H:WF:P5>2%L;9R>BB]O YYM:7-'&[F=R^/4)HC9[OV M:K_;]R'W(]VPP[F87-DO_\Q%53-7Y9])/2Q*.9S+80K547/N*W_>-*M4C_3G M;=QU:-Q7JS*!I!3JYY3/AZ78 -^V:N9 M&-C4W1M@6]'16_ :K=5(%H4&&@" M,\((G: P-WV;P+09]+8R-B(7'<0P@3(E&#" @*]L?G:5X*6RMJ!J_?95G2-6 MD> 60_&QX\H19Y76U-U Q5>W15Y&>))_PN8_O#4._!5O4X<1K"D[#GPT=YE/ M!0U%^NU%DI=Z>@95V!FT=X=ZN[I7X3PT-/><7S6>@D^)O:$+GB0!;3NQN\T$ M))VGK[_72Z^( #_4G.?P"4KM%\KN:J5&<1S^!43^!=2G#[!%;?[7_10&_='T M@I6,KU=A5<@6%)"D%/]">[3A9$IDI-:( M[BU8(.\Q"4&&K6^>E,#=1/\N=!3C^XF RIP^JL"/(UEX@Q?6^#<3=-.,#G; M0L/^7@UWPI6B/*=P_='Y[AA?"8"#J?I'20OGZF^I.2XLJ MX$_&HS=)]4 B\(:*42[C6A7ED_^,C!(EQSB><$45\(%L[;YT+Q@1/\I%I_L7 M0(>X5)^:J"BN/6AY/0NRN_LES1=2)NMUN(7!^6ZY2S.[L%$HBN8QE@!M9#1, MOH5#)G.#7'7(0(6T,7V6W75*-,?M&+C1@D=*\<54@O0^%:DF'U4&VOWQN/UB MOP$BJF\:P5L_V< K,U=[U'G>Q(!FM5T#+6%&/QNDNI_D"=%F MC'X?J32N^/YSJ^T\GS1P5EL1M1FS08[+WE)GB]YXA$-L9P1R';&R=6#!43 ) MWP+SJMJ-<1@'8HF M6)2R:N;1P#N:!KXSFWON>Y3J[(U6;O>_GX,X)M*C7-M=?A0K M=.KK6X6;=*6W_PL@__7BOQ7PI,(>\C.!O.VJ,M9" MSO1P(6LN&?S1FN[W?\\RIMP]^1,("3 ]VS-0MMX[?ISZM@+@X"^ 5IX>6G$# M7OP)XJX\6LF/7%3&:N8R1,P.M#]$?&OTFTR&77LM,@;,?1(;^FTO,-C8\)9@ M3-Q,?4N! )>,MH6#N#!G?0N)YKC2H?:]?-0I^:ACU%93UIE6CC%1S<]G$5XM M,UM*ODW ,'IZ$AM:),08[%4[=#>%3;AR[<(9H(P56.U9Y3"; PE$"@DP'6PFBN- M31"BYA/Z7:FA_LB\![,?%_#&$G\!<5RS-3J*B]XO7/7FQ;LTMP?JC])Y)/9Z MH!<3SO865K;,4L^8'"O^O A^7_"928M#.RDZI[^-1)UG/_J"9V9@>K2V 6GECAOOCV=-,U)FTX2_NW\!4GKVOCSV M^HZ]6[:J=$)VSDTGJ7&;,8@DQYV53Z(@%&F)R72R#1VTE=B.[OT@VDEZ/"4& MM=?,D[N1HWA-B_EEQAA/SUO(P)6FDV=AM*%7M+,EO!;'Y^+T2<&+/&SKW/V' MYY2TQ+767\#]T-DGL1I+.EIWH7QCU^9NU9)-&#;^MQ4^N1DC4S>JSX:ZJP6%8;FXZ\U!*I:7-C--!JWNWR+ MTW;5K\+_!4B -,K-<)'HX<&_ .HC3\1",5HHIH=:XB8[C"MLD7$_'J98-CGJ M'K&ZKQ06/"^6F*B=MWS?<\V*C6=J>_9X(1]Q4(K,I[SCA'Y2O$M&;4:;4X*$ MI'+4\J64L7D-Q0I9*FO<-QIURJ8=L6+/UW9XRER;F'K4U#H&7YLB;&B!68(U/"\]Y=,M5DJQKE^K M)B8OAJ04 #WM:7F4,_'D!@;X[9@T;JJ!S&N'$FY:_DU);Y[I4NTFPQO0JHBW M<:E:KFK/Q_*1.?>P/S*0Y/8ZR^3[$2. AZ_;]CG9,DB_/'RA!#:[Y?#=4HS( MVY0C^"+(OD;OY+(S9*CV[?ENA"K)MV#F:97PZ;GTWC%Q#Y4D)4L#O8^B;Z(X M/[TQ[%P&$@*\HT,[>\B(@2B_F7VRSGEZ[/-IZ//Y&6G$';2-: MWGH&).T:$]IN[U,<9"H$#.3MM2JUR;7"#6>S= -K41!Q^RDJS8JB?9UE7I]/ M9:DRNK$IA;(NO%5<:O)M6#DT8G, 08 2A =\0Y8J8M)1@S5(8Z:H4E\FP^;( M ;_F]O9LDK!E5X_?LDT#2M)O/C.,\!-R+[L&V4\1XV:$B!V"Z+OOX>30^0-@ MX@.Z/*9&;'PQ&DQ]D Q-4/KA="+^%T"AO)U ;O>;,3 6?78"%; *YYY'=[:V MS; WA.SIQ_C'.IJG=$J5JJ(#?%[^\!K+-CP#J5;9R])V+5]P2)X[K,#C"D#V@RS,Z[<#:03SB&6453Q'4S'BVNN!170)D&LS;# MA01/;/+X_#O6B2]/- 8;J==4RU>6Q[]T"UA;$27"IH3KGO8*=(GJI MQ*G/VZ$RLD%?9]$NLOW:DPUSQ?S/Y*A3;#+7W'WEJ=E"(H2$QMQT11EQ<0UB MO9:'6\=;'N,]#_2!.0?O*T.08"J'N;L6AJDE//7-2WO)P >M.&,L-\HG0IX7 M^I"">A.ZB)25F(IJ^@L@,L,I## 6&B,10I%X9=1@\_QI8X"W\[?FKIF:K*/) M5X]OZTF\X][RL[+?%M@NPB2P/4A]L_\P^>%>FW'7B_T3;P[OF&,"N,&8U/1^ MJ<6B&>?&8SGQ+Z;K1U]PGU_Y>'L<>EPL:8 2GG2^:=F"N6*&]3'*8?(TN&&M MN<;C=3GT8H1$ JW=C]6SD #6*36L?C%*]>M"20>T:G!^XC)N4>4J@L]P8KSL MP#KZ&:L!#68JF#11357NDTJ\=:_E+JUI]/D/\8:O#U4LR?B&RFF1BC*VI!@E M&[,T[_3ITICRJ D^@V)UJIP]S7@.F9&+=E=J>$&ZNEAQ1&6L;YX!+7P0Y781 MSTU/&U6Q6@ZJ!.F:O7+\)<*IMI;+^&K_V%/0I^%.C^T MHC,'E8J6J_,7QR$8M NTI1T;]ST_X$4QSON#%"PX"M15NJ=MR5$@"*L?B1*0O<)J M_QS6G/,>RSAQ7L$,U6>. M6@X3-='%0A?Y)ZO%PCWX-=D((XJ.+<5(>R)%UYQ)0?,@$*V))H' 2($B$XG@ M.W';4Z98C^LTUU4Z!ICROV+.J-"7_\A>@;53N6#SH'UJ\'L3(M##Q5N=Y(70 M "O[3">M'!F!"E:^SEK0LGV^"F';FF0\UQWC_[@49!#QOZ=A2FYNR4$AP\JS ME^;![;8#SKQ,ZR_!E4NX423:)_92B X:,C4@ZU1LU5H?YS#U[3;"-E&0O3GD MLDP6[WL@KA*E&X3O5='-,=50TC[J.&IS:FBL\] MX-NR(V.8?KNX;-4/@1/]!K/ZVQ*4@.5&<&CI(&F)7.:I]8!/6KTX_:=ZD+J[ MK;@&NX9K $']A*U$QQOL9(M[[PA[!6E#F:M8I*@"J><2VFU9DP[:%%$< HT3 M="8]8CC87PLPMKOPJ#< M0_*/&G'EF,*K""P.1X)6KR'!&2"OIZ*ZI99@;Q<:>ZB/KJ[I(KER9&T6>Y=_ M"MKDH[DZR?-HFQ=UP',"UDFT"WN+'.Y,D+MG3!FTCY72% 0P)!&*P3.OC=W@ M[J,/[47K144?PAG?_A(B@4J]P])'@ +0C@DL.,?^ECRR&2<)%CXD9'VP#TN8 M8-O1Y<\]"^.B$>'EVHT9NE!K:0T]<9DITEPM:CYO;4'FT0Y^L-=&?L3%Q><< M6;EE1HB11=7DV!JET2O$$SP+)_TH87G\\4??%)$Z;R^*!^V(]HC7TWX/UWMU M(P0. ^END\K;FY4(<4=26G*12LIQCSFB:MLT5=/VF)^:RT[MRQIRI.N'SO&WD\.^XW5@9ONA6=D/"KI1FG MA>+LJ9\#Z93"5-KF\*]0[MM\43FQ;6X),^-*VK@1KOGV(ELV MAPO^<;7AQX0MK9F*HQ/.7,6S7W:7?WZ&4]4B.&>XNK<]V5_KA6E:\Y-HLM"] M^:,7EJS$><$MG,FAJPKXE$AJ^U/:/T*TFW48*^BIS!0^L-T:29NF-V3%P4S^ M.(^$(-T&\Z^7;VXRD1?0@MN]+SVM7!R:"W>RKGA=O! 31#*88Y2)%33J-U$ ML0JF$48*RV2/82[-A&@-1 ;WVN#O/CEG3<=SD#&>QU6.BO-8U*8]_'ZXG M&"U-+C,RI>V7[_G3[\;K5#UXD?EZUMH[1CSMHZ'V:]IWJX5 _I$+L>>Z \%6 ME@/W.,N^)G&=%])3TAC=Q]!X&=&&3=&8*F35TC[7BRBU*;9GU#$<;;<%D?)66#J\9;+WOIL_X\.P%$#5R M<3Y5O4I>FC6[^12'Q=@5V3KJ1#P?G <\_[A M4$#[=2"TID3!JB:./O^^@MUFA+R4>J;%C WV04U$IW:B])MLI/RSH)-$%S78 M,6!X'B$PKD_O3I :&(O4:V_0<\/EO"6.KD[(BJ\LN+OZ(**+72(EETW'U"WQ MLTJFM=QNB)%$#/:?5:I3<_X%]"?D@VPP%IUZV$V4U% ^3H5N)) 6ZHHVB"2, M,%;QS_1&8A]!/RFT#%<+(EQ9D]JU#\0([*[ERV^_"A6N^Q?=9E1=RG/AJ?\" MPL.QBEN$ W4(^#.V8%9V['XT&_+\4-3!$3V''49V^?1J+S47W);:W$;QDS?= M5K@P:2YRSG$T.8N=7+NNP'?,7WY?_JB3.')']9U4223>3U!F1+X)Q4;98T=! MBI?';H9W,ZJBS-EPR*$\<*,.'T*P>&AE.?^4B!Y W4R8ZJ$ M?XAJE3)H([?=:7>.-+B(XPWFN=%[*5!_0:05W\?D@M"^C\O5!N94!E3FE.5H ML80J"[M=6&U(I*Z%0V; /FN8L.EPP5/QZ"&_(330$&8*JX0LXGV">^4HA]R)<6I M(_,?-YJSP7C9J*JY8_NNZ!EITPJWNB#(87.*$] +S[(#*9WJPB)<)7*3$L3O M/12K'4#L_Z!S^NP6C)H:GB+$JV+!<:![SJ70TCYS2CR1XS>';G8,?4)CAP#U M0#1JBG*8[^".>S9M3'?!:\(6^5L'*9\O6%CLD*Y>>B0"3__J87%YQVULL2N\U#N[)=/_CH^$AK_3:)\;\12Y(&B/M M!2,T>JNNMC+:X5MI3,0S*.RA8*J*;CEQ4DA9J8R:P?98O2;#\&ZK]*Y8N3E_ MKQ4W?[TA3%.RF+F2-M@HSSBJ?^O/83]492;>(A,E H4T[FK'EI\<:<=9*&GA M6E!2)W!WS-#BE59]4)3Y:LV-\"$;;6-V; 0F9(F"A7M@E<R41ZUF$;,T[L+N5>LBCAT3G?!DE%B)"8&;5^\# M<^T\9%Z3T&K-A93RNL?K;$U2?:T?+S$R>7Z^N[36(-0_6YF0(&E\FYBRFW'" MGD+S[5^"-M9MLF6EO-K)O;->;4=##F:*VT++/>^P4T/V=\^@L3H)6IBA2HSB M8- #V%O,W;:R<][3F4[CRML6K/_77MMHP)NXE.^"@=9>G'1/XJKG2=,W<*PY11]._V$BL-XT&+5$AE6#Z* 1\$%WQ?L#J>:?!(E8:I"]$%KV# M4*.M;:K+#*0KLM(6/]R(6P>]?3[:TH2_S+[BPZ+Q4IB:WF.VN VRV;O'4&YT M1"B6HY\N"4;3.A?(T=_-@@L62OCVH_/5MDSW3_[JP"'3X.\H MIM^)P \#N_5&/K3OU1]:TNK2ZO?]>;-II]44TVT:\ZWV/FD+:.?G V-"%U1? MGZ6P$' @LUDVK,Q*Y*B*"^3LU_043*'D-FCEWLJ,I(])-;R86!Q UY]T,)WR MZFG2NGD=O>+F>665[N;R*E6WU/A!VBCM<\4'2BF.>@-H7;<_+H2B8[72!DI5 MO@X6PJVDB\)]-[SN TI>[DTT6 D!(!LG7@)'@LU&T244X<4Q],,!C+-;4Q&7 MAH01XC64L&?.0>CFX*U6(8/WYO?M_P*H2G#1]&&")\[;Z]_LVR?;,+$&B_QX MV2EG3W?_:J[2*$1W.PF[$FTVT-;'_4)85$Y:VX=R5TF7$O"!YK-8>K#K2S=K/5;_^ MXZ(3/NKVH^^#%22-/.6I4@0K-&LIBP%"J:%3$ SWF5"D4!/0*59?D5#[5\;( M7J=*]W-_-C%FEW1OM)+FC(.U#0.?D"8.PPR^]S#@@9+9+TJCQ>NGU^TOAGVH M5N^J'4TTVW90\>/6S*&A0R]KZF@L7OX"!+YN56 YP#BT2PSH"*)!0T[QA6-. M?@2)<9\!W',+]-T=YL:?NIL/-^M_&0MI\7%V<';OI.>[G,W_Q-_TWG'$[PD( MZ80GCRP@M/7W>9/&XX8(/LM#6:7"(Z3=E$%6&]N\WXL?\07/EG(H+$I@>T($ M.6LQOV+93^_ZL>0%CN$[L4II0_@'A$R9=+BAK\[;;J?FQH?4P*IOEJ_D:';\ MA-<46(JL694]/)X#R__O[S?^'SAA%EZS42J/L>LM0"I5-.[S:O;GKEY [9/D M'X^'X_9Q3;:,]$^'DJD!,:NF1&L* M:10XGJG^B%%2[J6C>UWE,,?4P3>D!*^T>.'SGEVV$K9'ZM$PW@C'R&+M:K[0AA-6'YVE4MZZ47?I=V;&65-) M/*->/#KE$0.+[O6E(YH>LRA\,T?BD/2+A_>X[:59VG>N.+%Y]O8R6^<$(:-Q M'@<5&^:3+_5&O&'.>EL CU=EO/^5X?]JXJ\'G.H^T M-/-N8+;=ZJ_,^ MBXF%%ZD1-E5N[F!0+] $C\]WD6F=$_Q9'+,QM$:UOS9"\^I+]^[M_R+NO:*: MVKZP[R@B"M*E-Y4J57HG1SE2I(3>(0)20I&.40(H)710:=)%2NB]5R$A'.F] MEQ1!:9*@X!8"O/YOO_'=ON.]6#?[;J\]YS-_SQYKS5D[]Q=@PTY> ?4D#GQ$ M,7G%Z/KL2^I@6E M18Y7O$2CB_$VV,(?*4H7Q7*V_K E11M!4$6/5F7 M()-YOQ]NA2='IX&&O]M9M@S;&<8[>MY\ 4LKO4?A5!:CO /Z)&3*4L91T5]( MG+P$K6%&Y"B9U,EG)7?2XH@]*FRIKDX)7RG"W.<29W)-KDVN1* MI[6B3B-!\#AM]!B_-U3Z"\S]Y8;'AV?I(3\EK6 &]'$C+2+F OJ$6JW+@7G%]_?#(VZ!.$^GM*@)<)= MSZS1_%+G><=^UW?[!&:+;.;O .%UWN#;(8Z"0[F&5J2U#=L!]J1(SX65^1CD MR9>[ MC+QP:_SD4!&#<87U;^D;AB0H\XL V2&XO>[E.BF_ MUGYUJYZF7E);Y2.\XQJAA\S^IK01SA\ /RQ\39G- MI1'N4UCN_2A5SL80?9VB_Q7!0!<';G*BJZ-5I$:!J+/4UZ2[>3I8!9#/&+AT=4C%*K]%[[DQ:Q/1S:HDC.,]1/GZ?-\]8-B$%,QL-R" E&D]>'2H8^]] MK][;[T0BH315Q26#PX9PM*"K7OK%8G4'?!,>!:>(!,0A1#,6T-^X0K60EMG# MI_Z;/4H[ST=A"S(,.BK$67'RI9J3 CLNU=-=95D&^*[-AOM(5\/&*,KK$L1$<<5M-F]XYDH&/KH$>849O&%<4912FU/$%GN\U,SL29#FND # MQWAOQK1^4&O:2N I(P?,B9;T[?5A30OCZRYHK+2&D 8'>1;#+S6EX.LZ/&V_ MNF,77MZ*NY$5MGK@;=[=6&35/2]=6UL?8OG.<";B(? "\^H2%*.8Q,@,V-O. M4<#UL&>MR.92I[4E+ROG**2-M&]I\J<'%L;?GL%^ADP6;R!> 1T0Y W-!LR M^Z]Y+.0)< KO(N/WU5&O$>IFB7C*3/Z#I3%SI'@RFX#@%:8;Q*>6@:ML^35N M60IW:"SN=W[RT6V/I1/99JFP_)CEOK:D>N4A;9721]K7U"!?*I7/UPK&5@MR M$J"-(XN^$B)?B3R/Q73,\DN, F>*N70RW+@#BIJB\YVYOJB.!&;C9I[(O%/M M&'P0XVAPILMICKK1N6&&F#$-A#V!J79@@V*<1=;<+(+RR>)KG4A!,5&K0Z=WE[POPIRE;@$>:^L MMG@J-6MB JJOZWC\^>R&G)[BV)DCY@<-C#+_XORFL&>U@VDAFB*^W_W+.G]]/I,8(8]D%4[024%HYN.-Q\&%_E\Y9-TGM;954P MC9F4%?G.0G]8<41VB=8+\MB<(WIH *KKB>V?MP_U+1,5>/FXOI7T+;[*OY[; M?Y/IX3A$:$*N9W@-.$]E?8!VD1!3FOF6Q484Y.SE+?_TR^=,_N0KZ78_0Z1/ M?]KILZQI>VU"$?<&X]Q^CR5923/, MU""-$6%89-K<,>\78EZRA&9_]VDM>_9ZT4EQR4JF?KNS'*)H@_%/G78W1;0/)GW (E@PD?3[-'-N5 M//@A?2?V6:[$GJW 3\C YO_D4ZV]IXDDFD:QQ)TY/K+H[&LF7;2'E:^NC9&J ME//86K[P#K"YQ:9N2K'K;=Q.?*9/0[3E=TPB0P8O&(L/&N::&9C'O-UX'V:Z MDE61U"[-DNG20Z1]DLJ:CJ,VFY-TYBTM:"ZNRFJ X,IIF;?U+;N]Y*R(U3TG M,B9"*F MSR!,SPL$VZ8TM(MM M=R+NDG2Z7Y0!?3*LCG8VK5W+<*A%]T*>V5R-T'36"I\Z9$YH-K@M:F[#SMH4 M7^WH382F_.\B;,*&R(+D#XH?Q_XAV1M;*$-6'([UT7 D@MDB!ZD($#:XZY-F MTG;L2Y]I> F!/1,%U>=X(SPG59=26.MZO?96X+A/<;]PT5"$V'NTPZSPXK%^ MR_^.#X3F#B=(?NLM#/-]8=X0EB-YJ*@G')JX;?^R7D8TING-K<5L,QTJAR?V MCR8)-*G!9VFTZTOP9J?F+I*\W@9]1^N\GV\Y:3@O+*A2+Y?W[5@*2G"7XX5R MLE2B^TN;HHQW3JV1-QJG!RU?1L"RG9L3>D;B3OKN<67)\%B+8TD,D$'_$;+- MEPF5Y,=J<$H_:U*)6:F%YU0U,G_'S/<0 W]5/CQ0D7UW,!\:=7L *&T\J*, MHK>03F#:TX;@C)1; F<+>=6:,Y@1V**-=82P<3JR8(MK[8Q[UC <\" E.Y" K27W$Z_W?G2 0VV /**1 3H[ M?7W=T7/QU?$QMBA 7)OTV3D5)#9_]M+3^O^V$GEZ 1CUCAI_>P M:-@8WD/(BXT41L:6.?4TOVH%_.CS//ZP^[W!/NMHCQJ8+73+,AL1GRJS@B,^ ML52F5$I'^,$@ @>6Y&'D+G'CWFUX,YTQ8YS$(OJIE7X<:DBQ*8)K\L@A@DX5 M%8]Q%8W[O W/W\[TFCV=<#5U]I^W?%9EA;;X?)&#N$%:?(,PKXO <$>F^#Z= MWVH]S]%2WRT$34G7[DOCR**I^Y0 PKH&XCTZ,^&Y*_)8 02(QB!=-(9E#0YI"EPDDE>'T=A(J_20?DI'J1AY*\Y M0.'WA1#[AMB4U/&ZNG%SW\RO(I[OIXY;O;_C-EY*''_\)@<-G<8>51V=;FXZ2RV&K368S)N+S&=1FQBI^&ER#Y MZH0OE7C_8];*M+*"V<)[G%6=AE4$4G/%17<<9@:- Z I+V5.1, R)>B@T=T% M%+5;IAOG6K=BL;G$?W*Y-@X3Y3(L9+BDDNEYDG#VPF>SR3):2QBVC%<=);YT MN-1/!9\DSJ=1;@NBBVZ8Z\T%1[Z^X%F4D>IAQA4(H$D&I%4(X.:+6S>E,!/I MZ?87)DMJ6]V[WEZEYR7FJ%K>4.4EWZ%3QI(^!E6=M^&&1Y74B62A0K M$!?PX^>]C<%%C)*4K)Q5QJBXE^]&@):'VCNVC?QJ31M\V?K19ED8E3'_,*='R^,N@ M:7&M4LHV4W[/@U.@>AUMG;.*$ERY=+U:]G+ET_M?S2+&3L[87-\+Z_<]WA1L M<'4ZI(<'I([X]^C'5%O'-83(%S*B_=OXZXR;V7B?*U/%$&BA>]?]&TT*+!/' MMG*G:G.'Z3TB;R@&$3B+Z[YRY+L"CR;*87<#63C D(D+4Q^IRO)";[C1S$*>HF/KVWY MJT2GT78V4@?H=[#2'K..MY0"7_VC',(7T!C30X4J3_3AO\S_A%F MS?VAE\Q?34[\NG/JNFKS+]E^?2\TBN^1A'>.E&7AUIT$6SH:$A_T) GX2:"7 M,)TZ[D_J9PK1%+1)M G1E/N).:UI4VYKITOPW4XZX#RR2=F_0M_QEF=TS+60 M]+]C9(E]=-,R&HIX<+R3).D2%'>[48-G,+S1&4IET0]M> M@ABW;4:6V\33Q_Q;J_ LM!56[SD#=+T$9S68J[$KK0*_$*-_"+V9R)\GUV= M'F-3PZ[5]S+U]$"R/[:I!TW/"^'P+[J-"\QGIZ))/$5*T-"NJ=K3)8]+N+H5 M6:(^6-1:,3(:O#V/);78- MIVBP2%&X/NIM,/4U9/UE.E9=O*_G!YEE29_:Z=8EGXP695DL%$MQQ,LP \Y@ MW$=_>/M0+C2MM< /)S X>7L-:$*CNR)CZX_5-N8$\G:^($;C%3]%9D2R8%0K]]S$IOJ$P86]Q*"\>U MZABU@KZ2*DZ71$ZGBX/GU]K]^'J85B4,)\9Y ^2W;=X__O8->$,,^Z)A&A)& MZ W]L8=M$&Y/^B$=PI.PB6D8$%)FTJU^6?80NP2?S#KXXDAS1JS;(=-*KP*JJ]-#)4&\#+ M'LOM3R\4WW*RS.B2;HWHF<0^9\?BQ:93]?/GJF.'/(X;_.LE2^CC!IU_CO4G M^EN*=3KOS@ZZP_?([-P]9'CR[:!;7B65[[@)[E@*YL#WGMY%1J.L).PV(6%'5^SV=&YDO?4 MK0DU'WH+YN?D@6]1TI2[)(\3*$DYJ8_W;_9P460K=C=9>GQA9-V_ 7KE+ZS0 M>VF)I#E,'SZOU9#"%_$:5:U"O:T*N:(?V$!!DZ\3#F6!F7F6PYD3CUB0TN! MQBASHDU94FV\9:1YL$!\'V\#D$#>PT:P /+D$KQE:B,.',-MG7IQ#U >O&"9 M[;N/$"?KH (JC6K@_<:DLL*"DP.P'I!26JHVF>!*^I&F6;M03 5U<%B*]+Z; MNQ8(H/"30Y%\%.TY148>Q--92MB9"AQJUP1\PVW>^A_)_\6J[H&_6"65C>RQ M)TS2[1F\>"F3R(/N"DGI3T"8!:^N&UA/';CV9ZWJS>ZWK/) 1L8%"9.8\C CWT-.-DDT"1^(M=^]6-;3&2UZW7T@J\;^KS?O(GXAN'Q?9>35-;C ME8@.RII 1=N.>1,NZG/=^JV&2"<"]^L:57KV6)-KS3(E6Q_%2J*9'[6!J;3I MS:DL-8PD=01OIJ"MRY 8TF1SL=A\KI/:LSJ55T!RO0)2G0[S@?*-3H/='KWD M(\*2)=>G9"ER- )/M+52J_52273(D%6X[T)B(YJU\<07/'GO,7T):JN/:\V+ M9*7(D_M*R")[A/),XB4(% F#6V,NQ$FE3LQ WGFT6RUTR>XA^>J,X2[W%L5] MX^O27F[^NXVZPA,UW];8UF2&2;*YK\I/>T^B5-2J7B#G6_E!Y(2BQKO]"N%D K"Q-A9Q\4]N"8]JZ,*5B;;*R[S,N*L:RLZM?:;&?_5LSX?O-$L*G_Y5D\ M;S,;FE%>/U+IJ,4L MMFH3_)B3, 0^3Q.D*-/'\TSQD*J*2H$E:PHK_L>]\]P(NH=:^'L(.9+?C\W# MA[Q=U/FDSV&R4??-KOYC@M7$FZA8GBUK$2Y!7?W_68^ FU!Q-,@(;D#[89JZ M IC>LTORV9OWN3K9OJAJ_593NO]\-W3$WE5:.5;0*!X'AO_5CY#(M_5'RII# M:(%"#_ANZ E\;$\9,]/4%%SM#O\S&[JP-K^IZ;,Z^W[[:;NI%D=T^R[^=DF+_JNCQ5T4)5# M!&G*&56Q#-X_JXGN.00IZ,G^>>$^18JP0 JMB;A"\>EH7^30GJ'\D^!3*$QZ MVM6:;K0@;*"3&"DW]SB NZ(+_?31VG:2 M4PD469%?8,[2EC:?D"?>D*W_Z?:CV>._0;K(K #2=)(^1RZ=TA\4Q,75%]DI M;4A.'Z?&2MK?J;,^1%.XXC20P)K4*DT7WK_!G$WRMQ'HFY#WM,#R.Y@??CQQP-<]MA^,CGN24KQF-^C9)0(\ :5S0( MI8)=B,Y0A'&.=-I-Y Y+,N+!\G"0:((9#VOI$$-[0 7/:NV3F4TC.9O5%8=) MX=;>GMD;SBE;[BI:G.>Y?5?A$!O212>^*#:"?4:QZ/I&ZV9LB&(C[$>/8GI\JE:0 48;DY^'V:^ M):TN5JPMD%]!>2C0'G([9I,>Z"9TVWX7:)49!*\(VI&A;Q37 M@X8*U8H&+ZZ1K)/[/0X,3&9;^.C^Z9H1O1@BTP("C\BI!<6.-@^#O"M%*@-> M5NZH;,C_=6>M4%J*]LPL@2/M5VOG_Z9E[VR [/_B';S?L6DA.(T:>@D:!/,M MQ@:/D@-Y=*>Y];^F!->B])(.I'WQ=S"LO[PAY_D7U[]?B#:04S-)HX-J?O$^ MBN6+O\X?H2%,(D7UHYXKP;D3>2@=XI/98VBC_*/,AS&F4F5=Y1]E[]UX;7(= M]Z($:^M[:_AFCJXT9@YC4LAN^4?,+8GQ_C3697>JD$.J^I85W4T?)6$U\J#! M;F#PCAHGKZ9:P"<2!AY>Z"*7'V%^7IF-_[Z8*L()[]'Q5ONUH7X%^7%#7!7R.D;:=9!T.FL0>F3=@T@RQW $ M/U#RR9L;^2Z2<,YH!;B&DU)EKJ[L\@O-%O>U3OW:I#$J=H ;V)QIMN54&;AZ M5RSO0E%D@&<01MBAA#'$EJ&2MZ8^D0;(:JOW=H?1)*A!E4CB(EQ:TNP"YH=X M"SHSK+]S-]5[7(%QN1T'1H9T"S!_%[BE(5.RI_:\5J0;Y6AG$_]QMO6%O/QN M5T3FME(*RDM"^*]5#7=U]@NXUO1%4N[?'T.='+=QXFY+7@;2[\=@N":*M(Q< ML/^'3O?,!SE:8,DAL[$[N_B=A6*KMGM(N_6IT>)CIOL3=Z6NM+6"%E'(FM1ZM/9941"BQ MW-:,E;QEQ$QK1?@FY'B$T291+_LN-AA+RWDL?[3Z*UQ)R )/QF0H0,L?^GX_P M4"E^*MPA$^5&][R" ,W>)+[_MG98V>[)2OAPDN*ZU^"NK>(DO8&\=%8$!;(\ MC(N&EU&>]]]""!4*A[MO0M/-+D8355"+M=RJ4JU?6OX+A;'NDO1OR3^N,GCZ M>Q ^$YH_>CM04+%HN1]GU4^PK^?PAM+U"(83-"$6T79S]>4S1)L07[N-+9FG MBG%M0-C\ZRAND+V%PV[C EY]/]9+OC[;94\YSL;0I\)\ MT,02?\N1FP2'N#DM:XD7"%NQU&8K)BK%E?LJ\XSA5.NN2454JG' M6KXNY%AK^=(WZW?R=FN!Z+/3*900$W3O"R?^KR^R FU^K/\XR#YG3R0S/;#Y^=KL5K?OT7W%:W.L+8^:%(-M M:X2M0'Y6/L?8>T*GS]XJ?4L%BR_6A+L\:V_(6?JJ4W-CY^A#O.MBA?G;5QZ@ MZ'%3W2^[48O&Y X!(4B='ID7]SQK\6&:U_%.>M0-XFOJ<&7<%SM??@Z?KU4A M=\CM5.\68WEQO$R,=Q;'^.]F/IUFGZ*T<__H$=)\*%NS$."N%2CK[<%*OYH= MIO=2YS&DHD> [F'):C5IP\*53P643YS+\BDLH#$)O#+__S>DZ/_RNN*T*RO5 MTYB>\I_UG:O^<.?)WV_$PU-U&.@C_C$G'[ZV=#(W9=PH9YJ2:Z$F@E&I_J7OWF%UY-_JT:25^?6PVZ58U,X;GV:)>#6N\:4E!0%7L]*'HZ9LCE 6>/B#J-5;#L!UXK M :Z8^IM/Y(H3T)8HNQ0O1*U=J:B1L.B)J!G8DS F1Q&!10]M :!207QP^Z>LZA"9X6R25B$_D[M1!]W5=]VQKZ>I5C!@MB).+A=]9/[_F!*G3(\G&0IF_BKGLO_MO!L6I5%5:#W]M.Q[] (JZA:RO P- M$TC0Y'',#C0+'I(O\U+SEIZ]7-PL20!Q2U7&5=-.Y4JR*C+\7 B M/2BM%>T"6T O1F58%(C_JC+-2[;4>T*K?X&D.,:=($C9GR&OP2S!D.7( :6+ MN\!R&<*.8\,#4Y3&,H2OGKR^N\*06;JYP[Q!,>EIZUSF;W)_"UW96&W[V.9O M<*WM,,!/&0G(G!@ U<1PCD&UKQQ01HJ,,H8N+&DSSHF7/)E42U$F3,8KF?0L MA'*W(Q7RDF"$=/W%U@_2OAKRE=Z+IY:H^!71=(..(CUF2$@[N7XX@HE,LS]_ M=@=0UUVL.>PQP/$I$RW[4_;OZ<]\>Y@WQ"]**BPI+OUVJG*QJ[\/5# M693^%09<$91<-CD8N2+C /"0M T%N$67ZF#]#960;!B ML67B%F)/*ZVJN3.K=&K!.X964/2:-293JQ'YGRQX.5\8GV+8+H*G6-.1^ 7D ML0'LYN\-DIOS=;RSGBWY:$FPHH^K7)KOXV1O;R7 5U+3:PT8C6:S1R_H_B+@ M??C(WG#H[,XKZ)L:+4Z'NG?$0Q:$[OQD3(\B/I))BC1[CS0T47J2&[,2E\"O M]^R]E+)!<_>Z*^]I?&CCD;O6(FGTQ*E[*D)A%F]27T@B'I(B M&O&'+$[K@/70WRI]=6_QE"8>H4S0O!HN$K;JJ.S8T.Y=*_U].+2](VU10RD(U2T_#Z M&E3*2(II&#X/PN*=ZU2GL 5EVOG-_+UKJ*PE23$1+\_W'( 2)@)1#'^QRY :K MQ;:HA:2<+^1X:P[D$@_8_9_:,Q@N)@.7(-D!UPJ-KCIH&@;7F%']5=7]<=XL M]NL2I_\WANVEYR*#9,5;_Q:;,R=.RL)[JKAT^%F"*^]UJGCC8%MUM'^B/WZ1[?B& MD"4=#M4G@J]K"2'$IBAW% [YX%2$[#>MWR/DX0P_EOX:#=V7^,,HNTL0LD>Y MPF$WUPH5N**9E5#A"! '/G;W_,XR\N#^SGSAX&6V<^2EEIPKUF/$[JMS_*L[ M;($%:K=#FA0]<:LK\S>CSCVBNYYXCXPYF6WH[&[/$NJZ<0EZ,:"ACU&]\,/: M2/YD5+M-LEFR_#R/-+"7&D SFJM/W-?)#X 7&KJ+LO&*L-*I[=9X&7LS+2BOD>4$M%9)LYS 3USLUY\'0JE8BA.-L52M=S%N7B/\W6(_1A?MXUGO+#X@:,\11U'U\[*>.SB;PMO[3-*SV. M9PH(TX4^-F!$(F<\'U8%AT(+UP]J*8ZXLVQX"Y1IJ5KB&LL-Z9H0L?>X^!![ M]>H7;R+&1+*W9#@]T[/3S)I?WNEK[F[[N]JE^.9KSUNW>H=J?[%@K"RZVSJ1 M/!]*$__]8$#+^8SEQEK$-\0U8)DT>4'[AI2(/@D!R!5+@/9)$Q"&6MN@:)&W MQL11PTCLLMF9XTRYLM44='-M@"]&@!G!>M]6^H#01':/.@L^L.+C^4-4/3V, MZ?%()=1H<; EX/I$JW7/X:/^GN?Z,F*):P?YTE99LT$?-]>KSSZ:YQ M7I!9%.H^Y!0E6/:&7/_Z:./:D(O_DA88+V9=C?_AFEA-:P&/$\_W@/(-Y*2J M!<:(N5K=4]SU/Q8_ULQ\TK@5E5C+$P&6J\IU@T='?:>>#^.0:IIG^62RG M. +*9 &<;K(?A8H,1O]6$^GTM/.6(+QO2R 82?9GPVKA019AWF&^]L;!#QE7 MI'2 C;O\)=2%=3(U^)\RF-'R0GJ>/& MFL;<>02RB?X M@T6&"4=CDS<3/A-)EKO.C9P:;K0=/I:2C[FZ0BKFT,9R]<;!*/:R^[,IUPM4 MM5G-5P:N? \?8/O];?^ Q/HOV6__-YF&R%]$"KP$G:223V*)>9%T#TEU:(R6 M2"/D%F 4W*OT(Y+'$09FZ'E8#)_%_,Y%E@4$E-G8PE[,VJ^>Y^*SABT,DM2_ M7UR]N#N5'/0:=$?VVBVJO_1:A+([S<,MQ): D2)D@9A(6($ZKA^;(@I=6X$D MS0Y%") <-Y$7X[Y^KN'E\.%!;H&D8T&"C6A87L(O(^V!Q5P+*[G'Y4E#J9\W MH0B_^.FA2U#UVU0.^:&O2PG;?ZR5[J4*@#&F];&QL,7Z;/=TO!/B)W7F=L9. MN%.;<_;]Q4'+E)L*Q:J/SQ=CWWW6$JDB_]%BU2R13%-!\0J_HB@:L,55F\6* MRXX=C3%R6I:A7V*=,^!G0IJ(/BD2J=_,Q(#H363)\XPH0T_%KK M&H7M;PQIW=GEUG@';.)?Q+=JNH0K#VK=G9'B]S4WB?J3.Z-'$<[:<<844 M. ##=G,R^]L=GE]!9M\)YM+F)5LZ'HL,#[ MI )PN5 //";_/"3;]@(X70LA:"?C1:BEOFXMY WH! M] F[VB?/MS9?0B^$^L+.'L?]1.2EP*=-1DBF([(YP=]NH:BSGRVG4L4']1#C MG614QOUMRYTAR0&D0<)1ERK[]63998UF/8,'!3=,44F9<$LT-GM/=?@JB5]0 M(-]5N,#--CW6<*$-5K %_R& WZ]'NL6.J$2RO7=3! 2I-(QIE(:^+77.C_Z\ M\6S6UL)+P_RS&M,H^3E*_YQV]<4-=?OOPLG M"Q)D/H\K$[3*/(H!&J)H7(\W8?S.$A"U"B%;598#X#-=@W3#V3MY^G-LBO4' MJ_;V"?LN[?WT^/^.C?36[49=GOI]O+A#,0?TR6!L?]MD=,MD0A\#B2+ 51/! MM &G&HZ0"OUJES(K"O%6S M\X..- .T -O%+80L^?<^&PH\!&&$5QL#VBB*[E2$()"'?O6\FR'AD]>&9W'HW MH1"0=F^,;-LB-Q+!XT*>DZ?^8%$TO^=:39;T?DIF<[.R^;"86/[]/E;<*46+ MFD1 !$B>,5M3V<==@A;$+#!/BS$YSZFD;7LAK U_^ 4EX5X*EC9;%BJ/>@*6 M7@4_K7B2=_(6HV)D^(=JJ)]FOT>&E(0YA.%3&(=.S^,.I&@&SP4(]7$:L-I= M^8TA<)3+H@_EIC-N'HDV[$D-O>K=S]+W7E&E]U%_\)<"DX M2F"LI2Y!-T0:"6G4GC<),CP(%=)DJL*X'P$+ILVHR=]BCC6^D[LVOQ>\] M$"0CU#CB%56#1Y>VHV;&3YIE>FTIQD D2?WSJ59>.; Y*'#[?\TM+E:=^("- ME1?(DOE[,\=%-$5(M93>+6QV0.U.KML<\P[W^JHG]FC/N-E]KC9:ZM/@V6K8 MX(8XH$LJ(O[&^*T,KA*+D#V.I5YH@FA2!#]"99IUJ)*L[K38)PA;*>W2C;T0 M6G+T]/?DYD_'5Z\_#Y."6K20&7K/J[HBLNM6[+Y7A@@I1:3R)*O,TAD'#6JS M): 2L-L=^?6L'T@+ 1]TDP+FY2/H1TE_^&CA.0/^?1PPO3^# M7BQB=O&'CTD;O9^\8A4P+"[#L*&T-!)L/:9U^SQ=2QBHUP;""(_)'(-0NO^U MC5*8K41HI6,O04P'/>HO"+II=GU3'@UMC;YRVS_'6CK;]0]%^1JX5W?U6LM:%#-\ZD&1"8D0;R> /4[8!&('/@^"7=)>TD?=WP]=; MTTXR%Y&_9MU\:YV\U(;*T@?"%$RUV5J4@E:-1,CRQ'+R84H/7]5W<*-O84'= MDI,!Z>= Z*E'$,(;;9V&E;DD_40_%HNH>+Q4> M(H"%T'D),$=Z]O[-'*X+ZO(WA*(5*BMRE:+!= M[/4PW"&741F '7FQX*.HJ<4GLJ#OL]\#WH+:*03\YR> O1#&R97E6)3%E6BX M\3K:X*M(Y?=*FVRV*,Y0P>J8 L]Y[-00039'>;[:I#8)[2QF<+O2.BEXUR3# M51P'IOW).\@58NO^()6&(V:0T)B6["]K.V\X^J:XT'Q84I+4P;TS?PT7&CY(M(\5U-W\-PEBZ=BVYHGEVM_WT_J6SMO(Z>0AZ8FC?.2/YBQ M-DSW@$-YL+-/$?Z+PM*"',4'[JH]T^)L;T6>;(P^\+0S:NL-0.F&!87?@[U* M2RA>:)6Z+]SMW1$\.JHB(U53^F\;A(U+H_"#0X2CYH1L^GD0M/WK4KZ.LN"( M+% 50@+RT5>00P3_I1[P?$!&]4*Q3ID>P3^P0/^I4)F50T:Q-?.34DNBRM!C M@=WL ME"J_2S*+R5 M4YDPL[O/X!^PR!ONB?67C7KERB44\ YXYIHE2E-'_8K98<9T MX<=I1=NGK*,\*+5BR+CI66-7UPM]@&SMJRHFS&60^\+TMZ^G2$9>I?K%#UJ6 MH);6E#H:&JH[67>N[&+XDBY!5WVN0CB_U-=$NH*1Y@A=8!'_9[OE94O:C?5E M[].XD?'GOZMV5QY_>.N(VE(HBD9@>I+">G@"@UZ!A\X8=#AGF_;T&D'- M^H\X@A?EL?$^E/'8$YLK0K+(NY:.@R#>'Q2>'1J""$^TB@3'^RG,["7(1J6> M)FFTP<9+R@(S/1K !/>9%%!F+WN2X3D1W##/7;YK50UW4JB"GOI][\8;RZ>I M_*3!V*P)78+FI1FQSD$:H7(]#OX?UF9B]0B!8TUI^F MIOD65>8>>WZ#YUPM:8PPDEI%EKIG3!J_X;,;,T(V?\2L1Y B&U?):JF:3Z=E-?8("Q\F/./ZU^[L!-YID61:R [Y:^P9143(OD!>?Q0 M6@+"5:$!SO&9!=@T.[M=Q*01HIF;%(V/O+&B_:(2NCJ@V37Y=8#O_"+'56JB MVOO8H'UBF;;;,=Z%BBF00\6A:(Y)/O]Y/2UP4+\&A VLI@T8O2!.(D/H']=0 M_'"7($8[N+9M?PLI=]E+.?NT"ZZ-Y3AAAO\:B*2.[>%GFEHXM)][[N>2BYW8 MVM_@ZC[RB"GTS0I_064N\!J58(YY6A)?D@UA-L[%B#>4)6*?%+*PY59R32-E M1^FFZ\[6]$"(YU1#*XR)4H<*9TGA_WBM:,-NECN-WK9K ML:LML>T26$G')5_;_%Y3(DFZ M^+YF7%'BPB6HA7Z[&W<87W2CCP^.\Q&0VGJX;T@RONQ'B%]_E MD:)@<&9_2'\)W7NFRF9G00Z1U[>LM-R:VW,#)-D9;^8_?0!O M+WI2YY;[M-(]T[]I")]%0Q^'.A9?B5F MY+:@<9LWMVJAVP?7QL[KL.1![3ABS,B1PR17AN2+N6;.;7C7466*S9@1K[MM M[E/_CAIL&T/[?/\CQ,,S4P0[:3(>X8CG@V YTH$B_$',:7O*+R@#((_=D)Y' MB)8^+-&N+PAR:B:AD(I9LRWZP3ML=Q;J8M2,3DIGOBM9S^ZUS<*F3[J^8=.0 M&[RDHMB>%]5 U03X!K!H2HK(Q/NZKZRY7!7_"$W1FBKO[YM'O 7#47TC0 MQ?9?HPB2-Y$AHS)O!)I$FHGU/ AELN.1'D*=S&-"'EJ#D>(@3>]0N2)Y>(%8 MOQXHRND1?\BL>]^L)"I6>D2?45$C_4[>L,&9I0G2\O5HD-T(O.;6KBOIPWXZ M77QMW$@QM;@?E[;F$"[P6URLW?Q]O+B+Q%S)>"S&F+^T(R\)IBL#78*_^CG9 MK+%Y__,(I\.(PA'"B29^[REIJ6=KXKCL=>W@DD:$!^^_YQE>KF)39=I,Q8DE M-\\]<)"T5SK9I'9,$=.%),681'^164PQ(@]'NY!E8GXQLGBJV>;ID!]OQ@47 M42]]5UN>T] G1/*N.MGKXQ>CT:%=R87BY-O_POWT\@VSO%<]-UL@ ^L>C\E9 M/0A?UX]V"/5X(S+#Z#"[73^ZX,7GMJ-_9Q]6 &BTEN9LCS(!S #+)F$.2G=? M]>7!RG8';&#M+R94* I;; _X8*?9#UXR.=$4?UK-F"DR!/,>:F6$+S^,S,L MK,>W&A#%.MTCGZ07PR<'5Z1+@GS_ I70BF5AKQNA5MVX$7:<8JV?>="CZ5RY M]^XA]7#%Q30W)/D2! /']LE#8\%TB$C\(JD]]8(9&'XR'[(N!XYUN@-\\R"= M8:SZ[B[T2)1Y;J@T3VO8?E**\Z5=A[M: .\^KL"A9F2CU/@LAKZ98TYMU7 MSQL]\*M0CKH48N1->#\^J[X2KC].\F/S5(-@ZAD B F9$5F[,1'#?3D&^^[._TA+B&QYKB%:N=L'(O_O[Z@, MT2:X+-?Q7SC=7[--FLC$0_G^L)_\=$*24NMK7W8%LWHQZ4HE:A(HDY\ \( M$\*V&)X(9HA8@K(<'U(#RL.YF<@$8JW9 F;>2?!J^T)RA*\1@:"9CT;5_0:),%!_N9^EC@NGCS MB^FW%,DT2.=TA!A"!/B#>XF-)6FC([BF0JH=I5<'H.RMCJ*&+>105! A^I-G MEV9]M(8E64!O3D/6[[S$]P6L7)+C_,&8VL2!&;1+(]LNCNB4\@10R^S5(T.8I[!N M) SNB*+#RI::RJT8V&63/,R3@++FRL#/QM(N.713ZV1RNI ->"!7TFK31AL M.]54$:0H(W*\$M\/"5Z@9VU0;W_@/S"-KJYX]NX)+VA$Y\&#?ZAM!S:"O47U M/HS?BGV+'?G.Q7A'.2/F[:-8H?<&OB^O0Z2Z[[56$W?&YV+<9XQJS1S:O'4Z M??(E9XU9'.96_#.WV#=WY@Z^\*B7UX]=+,IGY/_H70YJVQIG7)_,,E'&<0R*M7#$;V,ABXSUW.F$OQ*U_SOMOO("09D4?\C MF"3YM6X9840>>MJU!*+W]4VQLL3F1\UXI1,O9^]]5UON^G7_R%8H>G''H MQSR$\2*>__O8)_0S+D03?#K\#JI 827%3*%%6B.[?+7-Y9S6-^[N2$D9YOPE\$:@ MU6/?D6_]_**^;*DNIQK4K!M^];\IIQN4*:ECE8=55"#$ M>>E7O4<<$*>*=UA AJ#_( 4EQQJ.HI'W8O6%5; !>25.21&CS'$5)5\T-#TG MTKMS$RLK?ZZ9#N9K8G-$9.(ZBNX/NO\QECNJCALR-\]4&\FOG,8^W;-??=H( M6(MJ\"O3JUBCQ\>'C(Q-P7'0VW!E##]]9YACI%%'D]N[$M8'FS!E57[+SU<> MO;4T%;XO_J8E[DYWX#]97Z\&I?[S6;A)A\XU/35']-U"?P4X%=R8DE7I^VH* M%MINHL?):3?NH<-PG:DXZ5G\\IT^=ASO)STVB[0OFPG01GIL=H P-MTWO$3A M\?3'UK9"[ZMRH0=M^?)B@[@#MV!(%[HVTL;&Q+J=I] MV5+5-;#3W,JT/NDSZKPZIC+>N] X5E*'S;BV4N>VV=8E2+/G\2E[P'5'>^9D MTJHJ^MNRC^"!8+J'Y=WL[:67QL;&6:QR+4TUTV;)F5J&#D=K3TRV"[SF[)^.RT S=9 3HOZ5T;C@17.!D+ M"LW4GY"[2?7FS48_8@0!(:UJ)A="L6N:]IDH#4V'B51H!SP4B,:2DZOWO+@_^N"%"&;J;VYN'W/9XC)_O MY=CENTK;*XY\3;VE_/!M"=A8];/*)(I/=E5CYA!$*9'4V8CX_JLV:E* M;/>^!-$>$FC.:;M0YV?1EZ"TZ?_O@\5^+7G\_4K1(8IF?\]HYK^NK;! MJ" B)=*D$Y7>>P]$14! 0'HGTKOT)B5*E2Y=NHCT)KW74*1+ETX(O4A"#1#" M\'\^/'._S\Q[/^_,AYDU:\V'O7+6;^5WLL\^^US[NM;).F==77(PG\Z^-%4J MFC7Z;?*T=+W0$9(X4GL#"/5&W\.%FFCAKKMN /W;__7!;@Z=B[>XB$]I^+.F8I6Y MLD.>9$DI7C4NUVP^Y1^2DQD%%T_6)_S'0R6Z*H$^N)WV!VLIR?*: @:/71^P M6XV6J_,$NY:*[*E*UAT8IJLG*Q@K)R\%^:R2_P'?=2&@[5LL1C;2]M*',]X9 M52/LI-UZXJ9$N^YE\46XW^F_#=N,FZH6UZF95@^<99KTSR]790RPT2VO*-3,YFJLC MDY!^#3UW"5BBZ[WO_'[D J#95F1>..9N"X#)X:@68-TMF$\W@)<5Q3> P%OE MACSY/SZ1%5C=7/ W@(^T&:7XIBK5GT\CG=\/V9:R?G_5 92XWL5P1V:,0Z\( MQ Q9K>IU2JN5VA:F=^=Z#J'0W[?1IN^W&&-4!,4&<-?_MY-Q^\!80M*^L29< MR_"?>_QL9VZ=:#^Q@WSI6&-$GU^3@75N>07/P@T@2Y'(E=@]KWC(&<\)24Q( M*R.Q,)5YPF"3[^N$BZ_ 0 TG6_40C!::OST/J+5JISVRH*_;TN&:DYY$G('3 M#KXV ?:W']YV8-?%%[S%%+06^N*3!FH!]2(P%G.C6?I#\S:2 MCE-9MAV.I06O*EN4OCH].1A@F M6S'(*F65E'ALT)9\]5;GS9YQ/ MI/BD#NVP(U3LP\<2('(#,,=DC[X>-C>QZ:[:V9/N.V(+SW?&C35@JV=Q]WQF M=ME3( _L2[13!>-.R;/W9!HS.[?P(U];7+UZ!\M;?%G)-;2(I<3 KVP#![U# MVQ]AXOI,0;_)W7V]5\N5J=#LGT0CA@/UTHI]+'2OK(*6A$HZ+V/3KA/+,I[/ M#!4_IQ^!=NV:%;NPB?E6AF7"NAO!;%)EZ+D;?8+D" M>T/2%LLR9X\ !_66"4]I_89D7M[0$[%SP<[RH[1EUHBP&?YCG.\>P,E.\4XEKS5^0U:+ET&8C$(#6VC=RKX!8H5A ;[1+U:5;R>E M^/E)0Z-MB+?42$$P4IJ[-(MOWVFD<4)THSE4XRGUW\\_O-)];N?[%5:C6<7B M&U8#(RI;[F%Q_PA(OYU27R-?-Y>?[J2X1IIC]]X]1PC&U2>*OQ4K<8_K\B3P M"\:XF>LV(;.Y22)"K"0M)/3 B':. 2ZNWW%U,82M_<#H& DW<;68#VX)FA/* M#LD8JO8HG_UIJ450GP^/*9FV:QA%E) LUVK9DH38SMO24 ,^JZ#RJ$)O!C6^ M6':2L*(+*U6)D:) L--ZIL?0(\I/QV(3 K[@+[)OG^^J&XJ14@:IFW0952@6 M7;6W^4I*LG58O>^PBL.P&9\#>0L/S,H-%X*OHKS1;/'N&_>^*&:W$]5FW%%_ M$;W%4-P5CJ/5PA&6W@ 4G4MAJY=#-X"TDI.= ':P0!+T\/@/N_K<:*AC]ON/%:I>>?%'"QJDXGD)\$21==<$B=1;D.W]T>3W*7Y2[=FE?I1'E"UZ(X[(7BCQ#1[HD%7)Y*0MHGMGS M99I'P%XYTT*QW2YK:J,:QDJ?SG-:QLI^)B:9::7P:2/_5NC\0EHY]S/ MJ?UT]&@Y5W'HH^03FZMOV5(%G0\DI,/4'RS&Q^2QNH[AH>Z[*3+"+&X B&3( M:GK'B==E PY8UG&1GO=_$L0<3!J4:/H@:DSKO:;31F.$NVJ3LG"F5>1Z1L&B MB73?0[XL\=(@"^BM$S%2I2I54H&EF M43=GH/@1++3I:H79ZPGZ"'D/3!KN##;_*&5%@W_Q\<$<+2_.I0E/=34V8HR8,: M*ZEDG,T]/D_'!6+;4B, M&E>?*4\A:?K1;379]RR^71C9\4Z111^,F88$N;C9]A$"!!E@1)[]S(4 UVB< M=8=E^'[A#0!OROPN;F9^@#U6= \TB^.LX)J"5HMC*2(M/D/LKZW?^L6XJX'/ M0>)AQ_V3H!BN#J65A]F5U%DOC]27!EPIE,==;J?[F5NTY@&W"7=NY7=0=!U= MM !8HBPE?@W,DEG>DG%9G=2V(RDO3M,U:!SO/Q\HF!C;P]09)'P1*^5=[D3_ M<@8L7RSWP];0_WP^Y)#!%4XL))Y@Q14E.G!/#)TGML5?E?Q"PB+R.O?G=7C' M.Y*7^LN39U_1;#_*%G0E3LO9'SP_1^4Q23RIDA&>2H3J886N;_/:,HY D0(C MW5L>0&-I0P*S$3FGYMHU:VYN=Y*2WHO(^\+=]R97C@- ['KDKW-2BF"X;V!H MS/QI1#AS/E\J:?L:1@(NO1.>]+V)U62J6+.=2RM#L_!E^+.D(HGI].BU@ :\ M *)&)'VF5AS=9I/NB\2)9,YIW'"/G,0P.F+0=":;G-)N,O:Q0$$F]]KN0%^2 MZT.-Z,SW[6+7L3"+*ILBH[WYNI9E!W7'W\;046.XC3/+@/B?$PP#@ 819>\0/@#FL$W\[=V3 M%"JB 4D"6""2"=>$HUGC8Q[UZ1#IL\F4^ZHW[/[&/Y='U;!".PM?32L9S,@ M9ME9W9Z(+F9]&;6>'L*EIIFL''[)WYW)"L<2Q:]B;$*/]MD,$C=0+OERP"$3 MO4I6?"AC1.\@&+-O^K1/S2<]@;$\;4Z]YYZ*1^65D\< M>F\& +%"1RI6V\D)>U;%!\_$R <[&5[_=5->9_H6;<$QQPSR8]@J+E"B#,G* M"+X7*IUJGQ@MQ/">WC4SP44=$)LM? ,@\E._ 7PKN*60GQ[!T!ZP[N7)&\ V MY[?;\O\*A#5A:3)!YA^.UKIFG[6:3-34G&NVE7,7=*@/AUMK(_^G1@>0\@N*!T( [O=LR]X__5*4_R0EK#\U9' M)*](0K.64F^O2G*C6,)F> O+[RE?O9:_+07K"9NIO$F2/PXYW7H5!%O:OFS" 5MXQ%5]#_"^N B1^FX1R,C],-!??2(=&=,#3")^/(#G]J$0 M[_Y#FD?A)5$FWQ>-$\>6,X04F!;]QT7U,C M4IFL5K/6,;WNBUN%#I45Y=_OWYM\)?/YK:>OMQO8 ^W$V9)^+!A>/8^ <]+. M$] OL 2L/4 ^;2!KR73Z!7#A#&*7IDIE ?3^!!"WW3UZS4@J=;K^SJ*OX]]Z M\2-WL)Q6222K8-'X+XYMXU=F9IW3D+?UI.N+H0 CIV6U\^K6=*<%G64I45OE MM\;%-7,A) EPSK$EFOYATH-&\-T50:;&SJY>D7XV%GJH>U83R>CX> 3[^TU& MY0K)/@(6GU5,2V%V<\7']LVU1Y 3YC>)R/M9=']Q\ZA+9/-@0L[5!B'SKHMP M;(#9VX+" _+6]C'Q-II25E8:::TXL&;THAFM2K)TX<@!ZZ2JQ+*24H.L@413 MDQT[6T;*O.)R+75W;61<4^=CT:=I"FH*FW<^]_LC"QN.1ZQV#3>S"DIKJR,8 M.WLTZC?-\[X7$= RNDEN,7)O'M@@8Q/O2L.< @HYM!?L?O?D_GG',#QL8$0# M(+W[J<]%,6:W@\I?OC+>!I$EZRC;PB4\PCAST*.?KL_)6@;X5 MZ]B5#XD,1M5R C2FP8R7YBN? LEV/VS< ,[:6ZVS#>@/>&;CVX:C)Q.YJ87P MB??U:\3N;PUT;LOV_P9#[/(ZXPU[Z3A>QH3;RGKVP)]VGX)5BRFTXE5LD=WG\! #O2(-2/C[D^/[_F@E7B&Q7O"KE MFS%XP/5PG8V23T -^/(/,C'NP[$3#*'VJ3Q"?CJ:W#>X*.;#Y5F?+TOV5]HQ MO _3XG:20V*D/A>N8XW&Z(5TW2_24:1FC-'RF+*:G^/:C/V%I4XZCCR M:>6;%%R5U'B7_PK7)&RV-+>HBC5ICOM;K4'FC+KG([QN%09^5@:;R$)P9M!" M1PAQ\,\$!>EHG^6\*\IMX4&<:JN-NV^HQ>O%HJ$[1UF-71*+2AOAYMPG\"%C MCZU8'_:XHB>X9U]Z0MPD3[N#3P8_]?M_F$C23M)N*LBKSLP7/8[>D*C;&.P M*+%,*+'S>5M^OZB;32<+N>RH#X3> ."/;K7G\>[*^28_CBL.8\X(P@48X;"W M"-*KMW,#2,B^E9Q,RGXXC[8L_HM3E5L9IGD#V#!SEKQ%U<$.;".V\U:8/KT% MNJWICL-A*%8'A.J1@F O&ZXOHFX D96W$,PJ=8[?//#JVIOFQ5+?= M)(>V;MT @KEN $?(XWLXFG#%&T#.+>/L$(2A;_GFOWK5H8[]Y^4CK97CO+F) MVZ]I=Z!T^'&ZCX]S<,2WS&\H;ACX/SBN<0,@ELN[ 8R5PE:^=F!*KB'_\>Z M.FPTSD8%%W [@B[MC@M]HU$81JCR!L '$8 @/GO +DZ=KXZI_]F8P@J2QMT M9,MO ('F-X"UO9,;P'^\_1]#D?F?10)2=3_ZPWS59=>M=*52[J@BC13.$ IH M_:K8 !$'4_2_63VKG#S\WZ.AO9IN_TC5OEPM9V,_??>2Q,2)*Z(\O=1$=,=^ MMW^3\/JSAWE^8)_OU4IC>.*?Z[_2YW\#JA(#K@A\O Z(A>R*?BTF_([._B-M MI;%00;B.I+HL7B_LV%):5_@0/9GTE)4%06H@LD@EY1IL5Y _0,-QS%:1H3;[ MP7XH63E!4RW?2-40VE9:]J$/-UU'72ABCO3C;@/VC>CA"#L0I9U7O&;R/*\O MZN/':+6>/LG^RMIXCZ"8R:'H-G"")U/6?H*4;I)\&^+D$T[S0 $DR9\?_E-]TM1 T8(QN,49*C;NUO+(,47-S'U(<*9!2561^H%BM3+D1J MJ,]-Z*HXN$U$GGJU[,Z)SSDF*+%L6:9:':2KFYB6GT( 8U@*SIGG+P$ 9L!+ MUX_PXBU:YJJ]( +#1!QC^@U@"7(^#$) VSM;JF^R(FJ4T_LUN:8*N:T*2XSAR,E\,-P.,&L"( "P6A M]F=QMWG>_NX&\/#Z[$H$=#P".0RYG7/;?VG;^S+/P58%;J?;O"&S \4).U)< M5<=*B]X FF&'7R'=!50#KP8C/GO!N&%OF7IIMB]2T-,KL!#'8ON]VV M\F]S"O0)\J\.R-W2])'$:IP#\(3JZO#,%K*5#ELAO 'TC/]+>W(]SNHX&G(! M^$]7C*&H-SO!+I0VC+I\<\P-S_W.=B5[/6]7(<5[>H/XC=?S;XA3R.X$D4YC M 03?+ETD&^1?1N[(NR3D85NQ?>KU?J2>?YI::GO&3@9&XJ5S2IRC;/L M@-,4[GB2M 8-''KOW?[.:VPF:F6?WR*/YFRADY9TT_)A68_E:DX&>_TJH(^4 M>W8?8JU4NSW#;17A51W_U!+/Z9TWX%.@(^D/SRW&N&W.SQ8 Y")/X')5_*6W M[!\H+VRPOQ\GN;""'GDHJ'8VS98XL0.)Y/Q13CO'6?XCP="3-R]FA7N9MX'6 MZ+WE0K/A]KQA2^'D*OI*QE[9)R?.CJ#P2EG!?<4.&=LZV8'(\01=[*^<'_'C MA*%>%W)7_;A_T"=F? -X"+JZQ1!QG>]*+ G*@X)*+'5>2HX5"WNEBX%&K-]5 M7J7:YELF;"KB%CAH;]7H^2WZ9(_< &#/;K\K>NZ MO5[2(>\.M>M:L>,]B<[IMR\D %MF^^DMW7VZJSYMCHN/A')*?USNU096#G[_ M*/MB F8393O'M#K0XN/(^/7)AXWF(* $V-)]80$L@X(KC'^V"F*6BGYL._WS M!:O:"]I5) T- U/=KKD(8X544(82M=3M_\TJ#]!2*GR?<+N&60,T:^M4MS/& MWY^\WQN7F75;HM*H,'AQ(?3B'BWC0-?5TH/Y6SZX\VRD!5Q$V_F+&6SS9#W: M/?AP3#G'CE%T?"%YQT[:I*CE:H37RG*_SI&B;4)UP8_]8G]^-[%Y-UZ&"O15 M0&!02:(?? 74PKGNHC.)3SO'9M(3W%QKFI66"A)5%Q1KCN5PK;W?([D^^_3[\1D[V/.@3TT=&D@S\8;R$3./^AOQYT#U MC-E[X/-?6T_=%=1*?[KH("=B5>PS21GZD7%UG.-L* S-<,H6%G:BR<[?(*XP,+/%[ M+RN=[M9&IZO*1RA)'U(F)+JK$9K0=08SHQ6\+_W!'_V87&>B2G]D+:@I\3I37AA7 MM"U K^;W!O-MS 9X#VO3)W6_SSNQL\PWVTFSS(_/CRQ_+^X%ATY;$D80\N&Y4SU M[V=ON?^7_VLWJU>*% A]H\3_>7\_OC&3>#46PM3(.$"%;$Z19Z'YR.+H5EEU M27 /V,+\LW,7R"RA9_*^I;XL8=S=Y)"^MFW9QBLQZZHFKND;SU4B M$#\K_>)7=%;%BG#1A5$C2;\\>R1_)6_6E6U%4Z9O\GK;$GU+??I1P[>DR7'3 MLY8HTZ-IMA\54Y:5OFRS7#.J[$Q^)QKR0D'_RT/EK-!GIN2BN?OBG3)Z]PX> M>EN>CM=(R=/9LJ6#Y5Y129@OZ6JN>$E.:F:*Y%'_,LU2,K+=]8O//6,JXR_" MGV7^HG/S7*'?_#S4(^BJ17F\V8D[W\K7 M=-8KRE[(OU[3SJ%4KZ@DVS_TCY..SE),9P+"VW]0;A5 :4FV(GF@+BRV<<^6 MH&+5_5P)2;(8[<;QP?>JPM#A>]U,NCLW5KQ#WMOCH9X3R]_T.$6_?);I'W_+ M#@M*1M&Z,[U4>)HUF6+2)W@>IT.@84LO"5$94.3V3/%%X1\*3:5"CS,'FTF5 M'Y>RGV]7Z7U*#7G ?VOAN9=T%?M4/S;B./1)%HG?.:V?[G7VO1@#SX["ZB#] M#O^<"<+>DQ.=>M9]";V_36&R;6CQ^N$>$\>4C:HP_(-*6/;(_'R ^=FHR9N^ M(]7'":E'70QC[TM-) .!5.D6* -KJ()/II=%3/?&'RG*Z2TH=70YL\H3.*Z5-\VM&B$\$44&,0I0<@-UR3O+C"JOJAH_ M9M)KT-QO6<&P@_;;9#.^-1S8H <48P(A6-=CL&GZ:(<%_.+FIG:[A M*V\2J9W9^=CLL\DE8Q8[=ZO\&''YAB0Y9V[('@4>"Y4.L1Q%*$,*DOW)G09 MMH(/,V!VES;;H0M+&%$.-P"1K/L[9&U,EZS65/"MU<4,5^]>9-.Z(5&9DO&K MZ#D%X)4X?F3,&P;W-U[,5%']HTEH2J0BB80\CO#+>N S3&40'!U'@4ZE\'&% M7]316&#;?8P#'$NYPPCP4Q2I M&)C8%]:*1O.P.E,P1W4,1^7^0HSS6>YU2FW<9PC)6J.2Z!BC_^-FHR[$DN3Y M\_?KP>I-,\I=C,,I7W-Z'M/Q4!-QA$DW6JZP=NS$[1]?O<9R7A>"B1S00 1_ M)&_=$I.!:D5I@7*$W1H_\6XTU6C,FM/3'PD!S]"/)4T74QJKIGG3I:_Y<$># M^A6@A8K<".215:A5[%O_::X$A:LOX;&O_PC8_B# 5ZY&O/PY] T2VE$;_HD" M1SAPI>8O=5TF2R[/]PE%@81$E@$_H&55T*4QVFF<2\]G&G?'0 M\J5[=,Y?GJB3[DEY%3H[3NC[Y#J6E_(4PF79E W$@&'5.#)D&J+*IQV4 YSJ MTT1D<_>8N6"B=4R9^C9H4X29JADV?8SYV'QEQ?GZ [3H(_,82(4)QS[#WPR) M5_8M$PZ&/[+PZ0"CJ>$TYBA]-?9P"HU.\\:A3]O6C5A9NG"*=\=E#03)_9\E MW/'UJ,/SLE>%&>Z.".A+Y(%^8TCC"T3C_>K;H(1EM\ MBM_K-31]?@G)*R?+;$9Q9O4J]",E@V,]%CA$=H;L9L25QS MI#3JI?67_:IT128\\ 9@>GI!;)R1D.Z:\*&WM_!Q1I3J_GJF84*U74'6O,V) M/SM=E0XSJ\0(.^V+8ZU,P^@\B0&6]$PK6H59XYHHU0*I2(Y2CG_'!3CI_S;\ MO@%P&2I-V<-HPDPZF[#;QNVFT3^O78QH71N7(1F6DJM@97P/04$FL[G6I M[#TLW?0[U'E<^Y,_K&)$+-$.J0[: M$["5XJLJD1L<*-R&.F08-C<8UTWI@JP42 0\+Y"]IDR0ZL!/J'"$7)'!5 E[/T!)9Q*S[G0R]U@IJ&\R%TIO6*[<%,9.\6GP)XUA+8=:J]L^ M3U5:@5T:TOYMKSI^RKNB_H1TN)F@/M:+?WZ\^W?X=*D:["LZA];:0-4XD)HS M/S1/A;5SM0:\)=%O5HHT"P]SCHV%)JQ?B!FI,*9H]6\U9=EQ%GZU]F$HY,WC MX?6'4TB8%_>!7F'YK\L"[_F;SM)WFQ)C/A7F/.ZE,%%97:&T"WR" L70 7K M,]F4Z/I$Q/6'(TIHNEY#=1(\^9B2D)E]>SK:2H[ 2DB:_)<%GA!"YP4.3?^1 MMY&ZBWE3XV((<1L;ND)US#A*ZRRT"I5=AV9?)8BNE1%_CIE%C8@!)Z>@B%'+T[",L:2-N" M.H^H>-89R[UDNBOA^K!/[>*OG!Q!>,]:]85>\IN2>J/KRH]%B$A]?S;?L&SV M)Z,"^MN_NZ3^$(] 21Y8N$@P])-$E*IJYW%YLA1M=#/8Q(VX&@0"I?-"2XD/ M23*T?[EGRI(7&!C10L.KA."N3"^RK&@R=>U4\+.L7*+16N5)UC385.&A'9W2 M\![-4CH@U8J_-:8- 0EB>MB./H_*;T_I(SH05YPX*7\\JJH%14,B6E\4&>V8 M@E K82=%XHOVZ:-5Q<;R=DYXG/64"2HMP?A9M>>$Z 7X7)16;,B=P 0D% G" F&>M49,S]SY]);(S0 M(#CP\38.#VW:R(R/'Y95J2SBIU1(Q$#7\;F,/;1WI)9+EG"V-LNA9X7:DW^> M6P6CAQ[IL 8]\M=%P?H/W'NJL!PHWK$>OSAR#+]ZS?B^I_/#I67LBVI,0YX_ M5PK\#>Y/^A\?J4V$QU#+E0.W;KAFRC*T;/4O_:"@KZ-K6@41@6Z8,,'7F?S8 MX6WMRI#BM%5TCF:7RYF1O(T!V"9])G<@*H4IU,Y:=.99IHLK?+*@BB9G&/L& MV<[:Y2K+S#THS ,GO,Y(MY3P5].)OP'4('6B)6/[-(,WE=(EF)ZX;BX>9_N;OAEK:^BP2(*V+6FY 7,-T M4#EQ6,(U!^U)K,XJA-YV$FS8$.Y9^KJ@,4B=7=#8KCD_N;JHHE> MCY]*M\R=G--K^L4P=\]GAW_?XW[&>QIS76K7$%EM^!5YE6Q)'8FO8\+EN M;WWBA)=:O77ZU$1Y%Y$7UJ\^6;[1TM:8G)7J^'8.SA,Z>G>_84NH:H]PXW$'%N3K-.9'_.4>, MB>I=%7DJ9!]+T9,PZF,M60&A#^F%DT2/ND 6OGJKI4 S-^;8Q HH2'J2Z.KH M)'B&^&/ CEL/ZP2FMA0IN'1TZ=Y>-IC)!^HO^;_"U*$;NJ4*^R%T_B93$,N< MN< _K/U!N;]Y:W=D>7T.%1U2XM30ZA&>Y3;J'>K$^CYI/SZ!I5?;*%ZWS_*3 M.?UEF[ZWW&_?E'VO Y-1M.V]0@:Q[)@/[X'4TF/$3KJ0L"!0+=YC+V^I.3+> MJ729CL]FJ([P5AO49*]>BJG#MKC43&JIK9X>-Y[X.,M+I;TI?_K(4+KJRJ^K MME/P67T>RVF&?K)DJ[D?JQO$.4)C*(Q4FBZ%X%EL-EV9;Q7-&SZN.BG]5D\" MNN6ASD#N5?;/^:>.X:(]JU4T4G,%#_^4?4^!I5M.,5P7^":YA#H:"^\'ZM!I M.ZRMSG=;^[22,A6P\PX<,]E3[@7^'#=]BI)& L,");$BOV6?^IAY2G,[R?-Y M'!@]GP4TH G"_!7S%I4*,.'=N*>A1D/A!N.B*GY1?BFAK:4Y',9&B7CC-7XT MHZ@'%R\&I"-&76,S/Y(J%O>Y1EZ\T061!?6L_=1O%A7 E)$^JZ"F?EFBD45W M N4U_*"L490G3EFHYEXH,2C*.97)2JMR4M8BT+79R,-D\;%'L_>=*\90?Y&- M*V1Q>[9[-L1&H5Q2HFO97E4Y,_=A4CYA=QGG5 B"*$E#WMPKE%+C.?Z_,RK\ M(:?0/YYOZ>F#MASN*BAI_&;Z<0\Z^L_)\;B'OE])%=0@,E1AVFB^NO)M0^_/AFO< ?9/TKT2S9R*X Z%&1Q_\Z:^+AHK M^130K%8VH&X \+_/T-RR_M+PMYVMC@(ZQP^GW1F@4Z@D@49?C9!=G9(B<[9* MW38IU[=Y&O4+_E51\1>P*%,^%"P(*Z@>B1GU33T+\!\")B$$YM0(+="85J]G M68;H?(604H2=@D#NRSJ[J!B"U0"YM5L=\XCM$Z)-LC<]N<'O6DMOZA1X<=^V'31^(+?B M(+5Q4E7KU1R0I/G:3)R:XL+K[,CX!;84B.$!'O3XW@!"#KLYC\D(86'9E,F? M:76)=]Y'YAOA*;S\U'DBNI\#N $X0J-O(;XPVA^*UD(NK80'/I.[>HJEQ82C M]Q =GRQ__W.JM8^-!B;>@2\<82*LCV:M2":&+7#GV4G-E,SP6(1.NX>TVA#9"2S-JS[JIJA3;,XIC#>^J@XTWSZ0Z.Q&(B_"VRJ%9X; MFFWQ%7E4QL;,^#GS,0'AY\J8:%OA:]+(H MY\:?;+9?MIJ_W+8GX.:NE51.\]J194X?51A.,SAMGBH8VS0BD:_K4A3 MYJ]G0T143.Q$9*0N-TE>2C!/L1EMFX[:5I0CTABIY]H?X?XT&%;&@3E1B6?! M&)@K2FM-/?8)=0[)*;>3_5CO"D$[G^'WNFX('/+YS#YE/BQ7)K>NI>%W79%( MEO71\M'CZOK&%,MZ]0W%L]KKLMN2:>8O-Q[(ZC/4W0P*J9P!,^G4@Q[A/QU1O @<4:9+YE M-3P:9@,C]Y&&MP-O &$6UU_9,0,HO[6XL#I5>;!['O;Y=88C6 !'.CL\G]94 M4RV.4RW9DU,+FNIWDCEM?HUW5NETMJAQ\J$RV25%/FT-XWPO=;:'WZ:7F[M7 M2K_]8FW=F3-O@E\F-&$2)SH HHLH_G7GF*B1B2X/; M4S1&&K<^'Y514V_1W*H 51Y%?!69SI(YY\^-'VCLYRK2 ,ZC5Q4=^-OIWQ]XCBLR/@>OTS,)O %I<(]EN@^O5/[ONJ#]A\.H3NPS> M^\)2B4R"=4%A[ST;PIG$4666>';DT+!V*H,@L')1=3T?8^Q! L_H+ROR("KM MR'00AH?ZX)>5/),8ROWU,+'K &H,?E_\R6,WG')WES90\*MR]$#3V[2'#R_L M AYA]2+=+L?NU\ZOWP"B@UJ-\\22.46U6(."B_)I.:9.=4^-'WZ13G(:?N_)EV _)2 XVN()$\^6-VB1"%KC15JH7=9+DZF1I-*]6'/XYO.'5_+$E-(0Q#INR[BJ:B0M;* MN16OQ)^.">%8!JIOES5GL=2%J6_*.W?_]C9E45OE"B+!;C-THUVSIQGMR_>Q M; _+)8]&,Z>^3R5L>MVJHC49E^^1'(!_9S) VC.:@;/U3Q=?9'83):PDS)[] MJKB;BN]2B!?\R"+IR^=UIP6-H/6@%Y#H%93^#2 .1H4C]6?%^"$ZPBXW6Q#< ML(AEOMG:.$J?//BLN!A=+9U7O$W!TISMF51OV9YO?I:FP\4\:N[[TJ+^W&A] M3?]&8^7H#0##XGSP%%W>84]"C3 M10)I,).=*X]$(.1#9=OM3]'W\VXAG5R5 M0KUENMQ?OE"EU'A1-E7(I,RKX=#,_8RSW%)%.LK D_-ID_J"&_\]GV 95*4P M6C?,(5ECZ">1<+DB9RF#7!]2($WVF81C@)VY5A@%@::PFX^_+!N?_H_OQ5/1 M)2\@FTP1<:.W*&(6\0\%._?Y^?%ES2J&WE67"KP5FBC2:1Q_UCIM0YS@B,_0Z M5FV"+Y#%!X+ WH*R)_\C>>=BC/OSG^VUZ,?!B*NKL!IQW<"G+>VV%>\]=-,E M_UI.>0PY^/WA??]C#K^='31^V.L2 =>C3*&W%@+L'F MY_"YW#G1TELLE2QK?/G/(FO;1F9KB7$7[1.W(6QWX"@4I0XDV+L!-(3WC'T, M%$;/%)=C+%9YZU/7]JY*9P;;6C9Z[7'PLW@3A_J!$A.>RQ_S MY6UUO3^X"WDQ#K \E!S)ZAE[*%:YQR<\>:;?NDE-BP>);YC%XV0P,6B'6+Z; M-\0:4JE,)!CK'C-D03.M*J$=7;;]NZR'U77U+0UMD8-K?\]U4W5?%TPXBL2PS;!-\8O* M:(@3T5M%F?=5CWC+M+Z>*!SIJ/'&4OJ=.5X7@BU<4>>=\X51_C)(L?KFCLE6 M"#+@_M#K5-.&R:68B6WO&;J^I@(3DQ?D,L/IC@WUEV4S04911M(9?@X1R-6. MU:+;KGJY==8;QN,7U>T.>*._7-,/QZ5CC&T"05N!P#D6KWY62#S<2/[G&%@;$$6+" M-5-[+H=3N2EG/ZP',K9,(%%>B>^))W8I[,GLI4]_Y.RCY_Y$I.7[-3%KA>-A MG!$5L-5S6O2H:Z]$*SOENBCZD"@XC)]$!1BLG1;G+]=:TNTRU]0TZHT^-^O*ECRNB@13E122X^I*UM>=[;5*#,!>!%\RYJZTR:#E$?T3=B%QW.QTF>+62S"?\-7%S]J=<3.&+ MZ;H8<#'^S)7*S_9LW)2"Y6>EK>Y0);7[OA?>N(<@;S33V)DH9L\5E=7Z/%L@ M#C[_O"$#KK"]5YH+HMKF1'(ZZHZ)O];K)BD'3Q@"ZWC3!U'F9M!?J?MUWNC' MLV>A&'GVKG&W9=G$_FQJ)R$9L%HI)*/,D*_ D\(AG$XDA6VCKLG(+8HJ;4&8 MZPX5?&VS5"?Y5@CJL#Z.^IQOZL'8C KY1-;S,+=*KV_L[A8! M-RD_]-O.>#%7'4)7TROR^S64 9?XM9( J["JAM>%DA6.*$*;@.\STWZ=Z+/@ MF JC%QC-3X0#$]YVK^YJ#0L;2\?-V$_V3FE$LZH#!VAU+KMQIT]_O0/FD67G M%3S_JSCEN58^8Y66-/@F5SS9:8.&:OD!P3N"IP\8+-W$L@E%"Z%!=3:M)A,. MRJIS?,5_YZZ=[B^^G]2\4NV5KY\RF3107E"C8CY[/\CQ/=[L M?V'/$)\HQ04COV@05 ]IOIO"^VN4*N+2)A)[6W:"QL:\()99]Z>X^\U\T4.( MWO8J\=2VW,F.-9B YXN8W0:RE\$;[YBE,XB:]D[GM8X'C@'*'QO!Q=Q3)_T2 MLM/^\'$*#*CAHAT7;>HN E3IIH)D26"%Q,G,,[:&&FY MB7(1&QI!U8(% T5G2PWF"V(5R_C7WP /R?5"S$R(K/0MG5XV$2MHWP5(W/M2 MN$B1XVAQK(@CK+G2W%FA:P?:P8C 4-:^3^B55:=,)CQ,Q&K,AQDG4 _P_D<* MI6HTL93:MZ?M*>)U#0V3=1'FH1TU=59-08?VBPOJD!W+V) [#2Y+T0G?^$@9 MCI 2G8-!8XE9/QXY_%J+!0UCC#X+!X)&BF#=8="OYMNCQH,>KE^R]*1H4ZBI M5*?R/W=::UL1PPFBNM7J*2CDR @UBR5D9/[>7RO+B6E4?[;F']E&U^1E\Q$^ MMOO3#MQ"I1 C85$=;5ZT8.G)B 9 JK0, G4=3M2$_GPGE MIL'((,Z'=#GS5\BX;N<_1 C&M;T!*R2)]!JH?^61W=_W)Y4/;I61HH"M5$UG MI:UJ6]W)94$>U6)9Q_P(8H2-8V,J/WT95(A*O&-$U7\KHG;+V S@M&&@R)JR MP4(A^*I;(&/2,8\U-P6'J%IB.9B7X3X=Q7IQ1&5LWLM,KD&M2 P$5.,H1M2= MS35@(F%^'"C>J;T:2#OP?;+'&JO8F\QA1<,@^S@A1KFN>#4OJC+-HN2E8&%H M]T9R:=/X1L'8U,I_ZZ[-I8\EA(S44=]%S![;-K]/?,#RX26.Z%QCUZ4.5SR MI=H?-&]IM/S&OY@H?WMQM$MFI/@@P?L5[#Z:/Q9LTOUQ^E&_H.;R2$ ,U1A64.P##WV\XB**=-MOR!U-W MO*_38U@>C%Q^&$S@U(TPT$ZC_&( '$E^MYCPXNFG>UR=0JL5BGU2.?O.9HA* M"OMV;LP=M&(?K&9X_GHX=?D)*C6HS(-1#Q%;5:I"J^0ICR)MLQ"+SUM9HMA< M6;8%_LAZZ=(@'B4ZF ;]*^$@,^B"H7E7];,;X3Y\_UF]\+.QJD9'+ZN4=^VM MJ,F^\6&AX?HZ8GG[P8+'HD*MQ@S;;R^7925:V9X)YTN!8M KA.C'XL+%L4,V MD<.-#I*="!KI=E?2(H&0!F2>'+ B,);WF6CO/^ M?H4/^#WU+N:K'EK]/J:_)^=G7UP>1@\)#6JGW(;=.W6XJ@U&0KH"I'O2^>*_ M8;ZKO$KF">3"^/6FCT6*7MEAY5BS1NI3D=S.Y+OUU::]/W8,TPV4O.G%:W'= M@_,KW1!RK%6Z-)'.=5X['^8*61>;4V@:HRPC#F_GR(;+H^K*#XY41/3H\C#. M\ \Z?\N)R2E_3OW]6UL0R^EH%2FN']C?@8K?,Q1KNWKN;XH^/,!K!S7[C3!W M,W&I N$0$O*-'V$.?N50Q T@5.2*%]1+;1@P4E<^DR$>0:]C1/\5[ZPH044R M,1(-A:_0!/Y:9IO!\?@3H\Y*UU:"##=.<$\P_5>R/EY4Z5=P"A-AU7*L*H;Q M1U4L2QO)YFX@'R; ],.H I_ MMI!H"794)P5M0[B9)NN7824QA_'N/G$'LVDEZO6MNF<+(R(-ZJ&?NC9I<7:? M?[F(H"1G%(/A[^Q79_3"0AV1?%UZ/>C';.W.*D3$S:D+IJ(H_I!V%HR1 0SI2/Y_W!*]]&0$GA]$FBB%J43/F4&A,A&6MHBHX>*!7W M% -<6R'Q]\,87?%A',X2K[^+0#YEBV%4T'I]WLND]6CGT+^>)E(K788K02+T M$,)MR"-^++TKK"U_ M([]U?+ *"T=FPYQA<]LE1QTU-@?D;UV$8 @1C&@(WI>F@Z#GHX2.#'&@D!J> M%FS1/I9GOJ#D0A44V-*;K=Z4Z?M9&FO1EO90$3^ ]*F(VAU3=Z(1RM62Z M+TF<5S81&KG*J5,^48DN.-@GA/%1%AW-?.-?]E7_$MH^@Z](ES_1SJ2;BTH$ MD4.[UKYB#A^S^3E[?Y<42DE$8GZYZ9822\$G>F:R8'GMC_TY4: N9_SMP'^( M,@8LBN '*HIX&9HTV?0T" UX^A8M&TO31UUK:;2D&Y4K:K0D&$651C"N6UM; M.^-?M_7.8H78^U+JW%(&LJU^NNGJH?LM:T91!O,FS(B_ M'V<_].XIO!=-G1#9\V5-'42L'+RQH3"K41JLX%QU!XOY9EK[E*GDJ0!5@%]_ MEWX>%B8>(]^;[!X4:$5"R:3J2LSMS#C,!/1+*B0^!,[2MH9SK(*]Y/'E\!6% M?Z$SQ>%I3 ;!Q;H%TM21@VB:-WPZ">M_Z#SV9D/R3;FIB44LU,+N5T!H8WK? MPLL4^(Q7#C)*_?FK,+RH<_563.KJ#2#\IU;^<9#:"(\^!0)4 M+Q^H>K_/OW"95XU!_-1P\GB:.G"4D7P=T^J'6(F$4;=S M^RNC(;'M3 O^[]#A(5CZ;RO^C"A_6<&).GY2'XNN^VNK#O-U'3V\!' F3K1: MGF_)WGLV-/FVQIS!'R6;@H#OBB&_EGU1, 2HM_)/8>^'T<(U8*CIT^O2VG(' M%=19<"[6$?5L.Q5"VWIG=8E I7[\Y 80YFU*B&;**UQD_U1FNKRE,;'233<] MU7 N?EG>5V7&<&!OLQ,HM.2O=EUN@:H(1\'/G#'QJ,0>'!%:-GP-0A0XOD+' M*P*[ _7GGQ*YVFAI:T*-A3EYJNKU9K-'O:T+K,TFZ74W12,"L<]DID+_Q9P]+@?[2G(S[3[]O4]Y&1#X=,(FZ\3G9MS94?1IG3:/M9A! P_FT*J1'(C MAG]"7N*&2FT(>L86N%84.)I9H+6.4/.P<:W]>/LQ%+S+#9.ZC]#;'V)I/EX: M\*@JXO:9N)C+\1.?5V(C%7+SLE)?[NSG4:!F<3^Z1)MRHT"K]<$H>D1%!.KX M96/+E'6-PY)13_NSJ7RA/28>]/L&C]G;6JU6+BTR(GK65#+"N_?4C??[D9-V M27_H&>++H)_'@ RIBYN+HIMLUO-UX$!C%+V;!!)<+DNTV ] M.U&J59J:<55L1N3ZY<:;JC4+-9>S+_D1;XN67BMKXB)6_?/H$U#M.JF;C_+E MZ)4V:19-R6.@SHH$D:/"9<&AQF] MMH:\;_CLO]VNT'5H\:#U%8L9;.)\@M>([^*%^$0L27OORVNN/S70T Z4)A3# M4=FW,N>.!(4'4F&Y?V/9B35]^%70UK=I2&7GMD>^V[&@=UF00166:,>X\26, M1,B$D[6M26B0MHXF+]Z<8!BDT^5/G8/YU$,32(M(IS%6<(J$(P6U[9""23\E MO-7OR>M5CGTN?9A9.;?4JY"L,%\7?W$>T<[FTA#2R@F-]NFNEPI3">];=;N8 M&CJZO$AA-7>GF\P/4R%YJ;U2XY:OH5:VIQDJMK.L.J ;6P@5Q2M<33?[27X MY=+C&]%BQ^KZ*3,3)=P%!O5#%X;.'##B:-A9Z74)8BF'3/G[\9!3<(=P#$O9O35+H7S994I=#!9]=83:N%'&3 M$/RZG BQY8>^.'([Z&.L%:(7=1;NFI<[E8-(:?%CK?]16:3&]R3)+M[,*Q#- MT)!&O^%PR1X.OH/VAK>.":Y='G59-1KGA4E4S?9:&3]/>00>S#_D0 ,-&W:/5_'JQCXO?"8]2 M)0SM:G6[ZJI&]%XI3Z,G0KBT!Q%I9C!O*377/AUX4R"Z%U?5?P/ \[H.,Q$" M$R$3.TC)VKDP"&P_AX'&B^DW&LDZ + M^7,BH=+93)^%LX:R(C!B\AXGHG\LLG8UF*OW?![)A'Z-UZK+ZFN?%,M;\YGBW9OR?%N^( MT2U*\;BJI:_K'CW75)!SAA1AB:<[5K^!Z-O)_,4Q=69H^%G ;U[99QCAYVAM M0]'#+F>=]5"RZ*A JK+_H%\RFMSC<@M67R?XS,, MYM )37?U&@-'$<&+4/'@ :R^UI9^FR$1H#R^5E;]#*^+.9],PIN/9<]!KC?]#'JK'S MZ#-H&4#KU7S*V)Y)$)O>]ZBB?<].$MIGMCM9_C)I;**PN_VACK$T$QW*1@21 M>17AB4BOH37MB/)ESR3P0G7(>@ M&A?M 5TV1#E?ZR5G-9(!@P-,6GZ0%2^<9V+E?=PQ+?G.S;#G06D\ 6685#_Z MNUJPCHD@)5K7*#L'2SBG!6:"6S;B='RS8R/;@5A MR[C@K&1E'"3E7( 8GCD4!3+,^VTVK]3G^AL. UNCPZG\\&D 7(=\G8#& ]'KR=!6,32(#C:&YE@3F@,+5E*H%V2DV[B" M/'*=%^I_0KF7;0W&E,Q['!U6[^\\LBID^V+?/W)O$TP"W\W!R;^NU\LEO/NT M@UX(+16T*+?AQBP'JFI])+Z>U+JBVQZ 1385\+'[![+OJ#&TY_'*#VYEQ ;24$?1 GUV5,H0VUOD5 M8V9J.X:AO()9[4?BB[MU>D%"'QYV?F5H9'EX-=>R,5LK$$06'3BHN807I34P M.0('Y+ GYYQS - 0IG)?A";1I-E'M@@/Y?3Y:U(;)%+Y]?!](KU%JP.C =IB*=RZ)T&JC]$3Y806NB\Z MW2BE8!GL&8Z?0&B-*:1Y)1?T3L*DUZ4;2SS*]F5=DL/E;(N?VL0]*1;)-2]W M3DV\Y9%5HJ:O_Z!M!=KURF,=SV&\H026FH0E2A.T:7,L)G[ YVC18&UH[(\# ML,1V@31'0/*09;A+"3Z$RT<$K?[)RDL7_BOX$SOH5]+'L]^$Q'BX_ :$T?N< MB9"0ZH);IR.[HOB%'LXH=0HAY]J^JDS8N<5,7C.]Q<+]+;3K6Z>/Q[]MV>J! M*&[\[=O^JC0^D\'HVS_YDW;GWFX/9.M>4,5,GW\>/Q""QGU/L[?M';CN+#?D MUJP553\B],HLF>O-B4/H51OU;"!9!G08RZU_+'W.9LS&6I$?#+R^+N2X+&XG MHN.-[')_J2)4T?K'_]\$_:\A2WG1.@#N/0BS?3^K<*.]E=]\C7,'"\Z1:,6N M/XD,-V]G+6.6S/4U*7^_-:5J;KX=:%Q*XMW]^O,9&I4!8$S&%[*]GT5?RH1, MFDU!W72NF4HZVV=*XFY"WKA=LP0>^6I=I5ULFJ5YG(WJKZZ=X7]5TXI?#NWP MAXQH+2$-G>\2H"._M=@0 +@L.2>\4C,QA$A_J85B*3XA[U[K#,V*$B&)!\I= M83-R'XOM])\MXAU+<-0[#+0DR?. Q@?MG)QI*!LSJ^""#V2#?U,MOM7&-4)I MDU)K:0U*(*1BF7!:BS8G-:Q]S?# P?@-5<;7C^74\YC*:^/'@VV-$!P5-9;E MD@6.3SGIT]"6N9(UEI62!7 /6H-2F5YX_95!S5'UJZ66%FZ-!#S/@<".(=T M"C7W$9Q3,N:YH+(=Z,I0R<*US@7L]/9XSS. :P*N94M>Y3JDOGT+;].+HBV&W78LN&.'YJIJ#3Z@ MI^.-/)[)U:9@/BA;,=Q3V9'0/9J9IQ1ACGG!&H3GIZQG49.U'D_PTCJ^W$[2 MFG89XY*?N'RF$Q3YDQ*8E$6T98?./',PKMN'G&+LB47& U^F5L1P4/1Z&I26 MXH<#)6MR_-<,:GA6N3Z0]^Y\+L^8Y:S2H<&)R8(_*&!M[2_:K/VU[FJJ77F. M>_9P=G8?PO.":HBUGQ=&;7)6$JZ5TEX*G%W"JPQL0EC);@[$J.'.*.?-^]-5 M;:=,60&A2O$!2J?/4W>O88<>&W8ML/SQS!+Z%]$ L\&L\9*7"=4/B=#XZCP( M(\6$P,>3EQL1LJ4\SR$@.CU_!SK,.$^H/R\.XEDW;\\X\L@XHGUKM^7!L)X! M;%E$$M=)5\@BIX\I&\CQ\\\\O&9 ^LOEL MM+U_[OID/$?E^Y?W^D82MU4U EL9(,J]/Z*@='A%Z:!$@=N$ZPR3,/ Q^S"% MUCR1$=^J][(^'5TWHO"QM5B E5&#TEDXWUKL;'%6&ULN(FNO1%266"A/"$W< MID1H"PW")G!Z*>2Z*NY,)A:FFQKZ2G8=MH3G6&BLLRQ!'G80SJ"T$XO6 M2_P>PFZ4HSABP-;T*R3[$\XZW@@NH?U;T7*A+?V.^*K58MB9!,@K8W+1V,(4 M.;=92MKX$[QB/QI&E.[@!/S0NW9W.R>$N>JPD^)%M#K//&5$S%Y0(?4.2XA+ MI@[&]'C,HB8U69ZPJF?;>#GB^L]5T,VU/8W*B@27:A^.8,?=L:!6BUO74A2C M9+[X-SE,4#[#+6)S3G3N(7M@E6=^Z?[TN!)6E^T'X1-W8:UCS#I&Q*KG:KU]P*7SB+EHC M;,4F\?!7NHWIHB#A/%\)N_7S[.JZ:5D<.,KSKMQY=6J3R!<(7UNL>AZENO=0/ 3C!4Z+@< M#*SID@[3L-I,K+3:6-!8N+-)L<*+S?7(X)-=:H,O]30LC<,'I?[5\?B%XOB4 M1@*(5D^E% #, :^"1R4>$XX&6L9"R'6Z=B\J"R$ O@!?+>A?+$_:KN79&R*$ MP@G:_+K6$PIZ>M&$2_WYD Y(4?0W.3KBQCA6XG;%I1?5K[9I@V01AH['2$_'MD#VIVF_*AU&*M/&KJXA%^F M!0Q-LKE+9O_S%?G(>!WS)E@R+.PS>[G"Z[)OUD%9DMRV/"@N]65RY/\] 0RO#6)L<%U?0G^CXMB^:.[K;" M%=*GOXL2!\=WPKK;^EI[8R5QT.SJXQQ_\#P2<>T.". MF78O:;PI@"SNKO$TOM)>+)%B$5BHNGP@_3CU8<;^L+.@P_ MRE:]0*&7"_\JRGI'#X&T?,] ]\]2- 5]H]G#G4S)STG^1#8>'E_[P.0Z /1VSUJ:S=JRT^$$0^0W'O MLR-:Z8+*L:5XC)%!1-W5!>P)DONX)6TI7J=L8J34S!R^H,QN<:8P3/P-(-=C M@ \SA,>"F_.TU*="U^0P'LK!V5@W!<8I\/3ES./]99?UZFC(_C5F1$?$: FBL\*#]F?V>]6\YG\+=YR/SUX*_ M1I6JB3'KG]*?2I]/.PN<52/H83:;>HD'T$<=1+:(I\\RLL*# [UF?AT*'/G) M>.FJ0JYW=3KP8L(3PE.8Y:)0-QV[@J9@9:@C\,81_R>UVJ0GZAL__(G3&=0L M1)A!KB#8F<7V0)23/[Y=QA9 MR:FF;WPFW="@4"$WJ7 O2LL^W!HIC,4D<&L0== 7]]YUL;&I^=>R:Q#_5/KOL+N_WX/R_W?J4)!$YUA MJQE1H5,75/8O)$=SA&-O,S"5GV5P\65V/WN9 =#\$I%"@>*@U[UMUH2(F4EM M6O3>]KX]:_O.=_J1$CF=[5(A"@_F=[NRK/ MN]6);6?'$0\_MB4#H>AX"LTI SSPK#'\J^*F*H5-[))NS>YTEYD1.@XF-@X? MG*!+.0F3^<&'*OG5^_D:@>]D'WMTP/*VU^B3P19"V.O'R8*O/=NCNS^2%7(= M*T,@[#O O0XZ@X8[I5=;AZ;X2T(T00S%DC@U/W&+@XB*[/%3'PABB7\8R*N9$F9HUU9IU<7-W."IFRXAIM%6V)!H MEE.P]ECM4K5&+N&UIEW"N%HLYWUI7> 5@^*2T(\(5A/CP#KJN08Q?PS:WA4UC* 'D@LNS[@#UG9P:F^[%5_ M ],SO*"*4]P 9?;*O/G>SFQ7GY!3Z^,L1CAO( WGZ;?W5Y:O(K=0^MN.7YV4 M\F5/.D/^FO][Z/[GQ5"HRJ"EOI3;-M8@W_UV:_Q85LS3Z]0'L/*,EN)N.VMM M)CYT")3!@W(OVU7!8.V. S<&9J0I!DJ0M&SB/@: $^70'LPE1B:\]#F6C85; M9%O3PJ&ERAOSTX9Y3:USRE*S@2"!Y_L3#\X/Q:!+^U,2,E4G MO5TRQ-O=)ZC>!TMN]/%9CTQ=?QA*?7A1I+\9&$JN)P!)M\]*+JC\IEZNJ1(O MJ#+!2JGX($X*C+R*!U+#C0@!<]\U96;:HLG&W^;:N)5.3Y63\8["$N)3S'$HRWKCZL1;P2".X$9@ ML&<$FCN!'C.I@O&@.&36:G&T.H81U1@Z9(:VLFJUXVJ_A1$ JXXZD7,\KQLE/#53.$2P]KWI4A!^*/-*]IE#\ MOC,?**U])3G=+F.C.I=&,/C^Z '7YNX$@MO[@HI;RP=(%BU+^AE$=3Y;V%!# M["$]Z.^;4P)>I80F&D7VVA!(4I4P_Y] YL@(%B=C']?O1)$$I/+/A 5<)IIG MSG9E&?9DE92(UA2;[H6^_>XL0EBLK=XOO-%7\7F?1P!9-;#BCS16.6(K7#R: M?+P,.WHLDLM%Z_)X-X3OB#FE_:DU,==["E_LW1,*?+^E/H MS9'U/%YFR5>;4-E)<0GQS1_P<&D51=J*71AQ_HOD%'TQX4@2WC08Q,_]&A6:.I!36Z*Z^UC3M31@\/SH .%\9&J&Y M!YN47?I4(Q;NI];![6![(C,;%=#JY_7VKT+?UY5G/WTJ#AKRDBLYW_4$5#_] M.FVFPX;]GZ6YZ;\=SN8H-3[9T;6(1W]XL^:#(P7PJ96U3PVMUT9E'!#ZHNO9 M+F?AT3$+?V6'I@S&YY%.6CHSC;_2S4FK1K-A15(E>J8+X;3FO%*\O%)>I4>D M'T_=']4?!FQF1W[S3&=1EI[BB4'C'" KT,U\+"]](RMB"GH3+N)&:*>/[YCI MEX3#B$_+-XREL,/5MA:FA,S$MD/1"RJ'3L+93! Y=U^CU:=IGUM?Z67[.>>QS?[&" MIF^E[TER&?A66!DYNZ6/!1-KU5QJ%C"N]N5:_4Q.Y:Y#*G4OJ"+2O&YB;EQO MGKQR+49M2+3 54B1M:MW^K-C@YE!"\,-$3N[9*XAO@2+P<:T,,B*%Q9QBUB= MT,]_/EO&X-_/L48^.K\G-AC-3 $U#J2>L_O]W;6U!S$XDS,<&$5/4.=W%H2] MG%@ABW4N[8LF'P^"MKM!@0-Z\/OD6L()CBDQ!!^4(J!.&'@1=E/@03B(W4_E M&=BB>.M-2TID_TSDTR1+:8X0QPGUSS.H?E=L(W/V-MF>#.9WO$9D&?>NV3H9 M?._)%LH3W&@=;XN3VA!*JDX.;APU").8"2!P0P[P-+(^:^.RR/&'2(W+5 M!76R0+&ZW1VE5OUHMZ5/'S3DZ\K3T=N-]#: 1)*I;:^F:+@O3I[MK%V()AFC M^VH'^$KS#D69V'APC*^/V(PX.'YCB(?0^:D&?*"$G)4<%$J)@XWY&KD'R*F$ MBH_I'N\HVG/S9P.VA(WV\X_$X;0(^>2VLW#IG?SDHDTMM); ^<)Z:^;P #6 M"HF^HG4P>JKG],6O8Y9?@9\G0 L+I-%J;YMBIC^Y0CBO?=-YJEGO]B&J=&_Q M$)_RR&8B?76ZB%1#W!F^7@A:SMD02^^-\'EJ8$"E/4VZ3+-R0WY.B1_WI+Y3_(!O./P'9X2&GSK YNYX.LM FE)LLA"N+ MZY>D_$,VKO+6E"3D#T'9_<[O$77+_2I@=RU"\%*I16<1T!8R7+E/VW$Q;&D6 M><_B(>%LLA6W&W!8H8CH0]L%2/N'JH6TN\5]#/4'T7N2KZ>62@$GWO9 MI0LSZ-6&9FS)+D0NW]S@ O\;025N3_Y,DUX1N"MYYC4;DX'M/QQ!<2.6-:_P6@]DP1Y$51*VNYMPJ42^ZCF0C4^5*QK= M\(",VL!%A JYD>WAR/.W%+;FO@3N, B=D;F3Y@D>\2[![V/I%EBFVJC?NJ[, MA:)$-MS0BEUCG:.P$DX>MEU>*_'G0F[VBII[3U=_;TG6D7* FT5W88"VW6+# M\K7\[O;RT'N'7\9G(1+"DG] @P,KO(,#S*!C3=XOWOD#=)K2,!6U0^1Q#$*F MM6VF5[]\>04KL[$ UN)C"IMBATD^IML5$")\R^=Q)Q&I4"L/OY5?^7^Z\V'X'9Z&G-Y].(G(A=8)=*^GEWV3F/R\*A% MNE6KJ6-/LG (.L#=M?RNXFLN*H4G_UQ)H*5JX#$+0*KEI#$FMQ$^:?Q (PS= M6>0JJ$?'K 5Z\(T LOT,4HMUOQ"4&/;M+E-YP][B,^/"N\Q0 1 M=F&QH/&407F6[Z4BTW!#%Z8:7+V7 ?%&?C#G07=5^OM5WSSS?(;ZEB.489+3 ME6\:773+C&V/E\8FTS;U%VL>0 "PN5P?EWT(XX0J^X$5#%=YG-&JCUR-")]7X^W;WKS#0ZW"[@_GY5TYUJ_HG2E4+KTK:Z,3?O;[_?Z6_0O/7VT?0051P[;,W MT2[I]".EMZ9[G2K\!I@UI797)C*0U=H:>X5.B2@0BQ_'BA7FD-?Q+#F#L9=.C"ZK4,F*FCU$:D&PN($6_FO-; M_X+J\2TY#-U?9T!C$CJ$B9*B?1*&3RU"1? MA;"%L'E%A'7M&L@8F.5WJ5?_Z2)D;C0F]6N2#<\Y;% #GSE)(I=$7LQ^":Y3 MZ8T>%E FEE2U"Q+.&Z/*)[O3^QK2E03CVIU=D@="U8]'+ MT7BQ^'X&N#I9?E.+Q0FQ4DI';,^Y7*&'YKN<'4!&L."F%IT#F ?YHZBGR$?H MO_KB.PG>\[HG32?0L63([ 554PIBU?Q\2I,O?V/A^&")\T4E,0AC!A_=.G\..]0@[Z;UB7M&GXC!1U#T 'I"@#*"%9:O,]=[# MJ_%L_>R[KTHOT2'17C9Q U(0Z6+Q7)$D>]9!82:F[EEF/U!2Z=^6&+U$L(D]3%@MP^B1DX=E=)[[[1>AT'\N37E] MZ"SQ@LK38UDCC@Q])U7A^E"08].4^:'0G]?"*5HBKRV%KG1L6YER]J3*?[D' MB?>UPKIS%3M#[058HPQ!Y1B[#*8&QP$\=XCA5FTA6G+8:L2$Z2<4B9XIKK8S M^1'2,O)2H4&Z<:2-\%E $N6Q/$$+VP&/*=6BEI]J9/@OI8&YMNQ++5(F"##X MP(JQM'8&+V=2&KNZ1:64LA@!?:-"/#G[@)#TCN;O MC3C5AXT8$ZK3X7T'<2'Z"$MEOV#=60M^,F-"ZH$%+E.R*P7*+Y,#@W+%H2S M1XR]YS6('W=132&SGM,QI94):'DOBM_78AQP(<]W9J6E_W^/)CVO38J=/\@];I1]3 M[GBUS\@W1JU'B@8)>CX)P6OLO$#P[/73D(?+88TD6S(_(1\_-=BX B4Y$73? M?J H]LS#[U?X/H-@@@1@/D@9%97%^L<>_Q7Q<$3,=N8 3"7N<,!U$RMY*UXCT"Q.\.9[ MU*TX-RZLW.5!EUE?]U::@?B[-NG_U:%FD,B4Y85G5+6<#F>/F$-.B/Y^-%_N MA)Z:^\7K4,O;>2TUEE7_^OA;]P<-]4V40=>!K.-D+8+Q*/SNZ1.R-NG1K*:$ M0T,6D1KU@[Q_GQBUDQCHL: 41&^HFI2.S?G@4[:2ZA/^X;-F_/L5V[75O9?* M]$^1O5V)D)*M-LC^HBL)Q]E^TW2PR0/)\ M^3B S(>QO5HZM0FQEG0#<:I-D68P1O %?-": ">;969PULM MDW(PQ&W4AG!GD%PI+R!AV$U0FD.V7\I +FR')T-Y=SZEHIPR\K.0D$F#CP 0 M^F7!O#;IBJ7L^(-\3H9JFM=SG^0[^SFPVTJ.=O,(HC=FG@^_&>8M M$^8D.21L*0^I)Y=9EF(G146$BFSF\X,3(X"C$8C=:5@>38B ?EA-6(\3U&:S M+C?*@SUUSWCT.U/9_5^A%\/J@^=%?T'!0)I-*"2^Q@?@RKXO+O21*) M'^YTV<5FL(+S_%ZB/>>]\7*?Z]#RX\3LFA0,;DVDMS^X4OR'3AGF@LH8RM;[ M< @$( .NQ$SU*N/2HJ^@Y<8['?8[#<+W\%IMS7^D1D/!(R(85[F"<5F;G&_+ M46I;G^'^A "WW85ZDXIJ[IM.G3??*?%;-0NZ8;F:J]O&2B(]BIY3G+WGD$ +9O0?C@>^P:/L%'[W!!!8"]K ,/^9WUE#NOCGDA MDEKUV>+J+/3]4=1J.C<&ZJ%DL9W#H$K$8O1U]R6/Z9]3-+#C08W<)P3 M>W/%Y[51+_ZC]'HR8A[% P+ 8D;C\K(^:-CM+=JO%>0XI2M]F:+8;O!19]-2 MO5!X-'6;Z5O:"[71(ZG?Y>>T@H1H?'[F^37$4C/L[HC&$@I)7*+<[K].",(P M2@3F[>L1HQ-M;!:5QPY%_V*WQ\P=ZH':BVVUM(B12!8=E28K/F-^U 2E\>>[ M#4W&\4[1 =9-ESSW8NV$R18Z.;S$3.-A[2S6=7<+EN2IU.1KU:HG,8:U;"IDLA&+^%Z4!F%Y0&NY<%&.-LP_W-E%[ M]MK:#JHQM/"I=O."*B1G'NOYL^FSY(\\,=K\S1"[4O;-5SOLRIOK'1=4![P M]/%**VXA,0;LXL64>>H M\EC!.C-*R4'W"'+]VYH$)+ MUTOER0F?R#QI/P=YEK8 AT"4AF_Z53-&G231Y M&U%#CCD:.]7<=%S\%?#@^9F%J]:'XU=']- M:)Y5OZV_;\[?M;_D3FE$6\R#5_81L@(^SV=FX+JOX2CY#3*"PXK.8VF(G-C#?N+)DTMJ>HO!C*EQ@.I)]]S>OIO'9F%MQ: !?((/^%IN-#NT<0Q( M-Z>7LMM H)E!:V-'//J:M;\Q!V:"Z#6>>RF&X1;Z';?<)RD,. MEC:GA9UKS:-/?&+$)*4Z%<*9WV-2/D:P$G?YVOBKSII;1WV2]CP$W\&%A_&^ M/"D^D7G+$'1KL=3I7T*>D[5Y.M]("CE3'O4-?B^V3&3[N&#SO,M.^ VAR_F. ML@?/DQHA11(]^=XF:$4(+UOS_Y&C*F"@#6Z([\A>W0#$_[I9;V-,R'P9ABE= MFQNV?H98=)*49YA;]F:9X$?^W#9VP-A$>P<$8G_L[$.9$5_Z>?\3TXP^!+MS M@7V>L@1 )EB0T&I)[@O"RUSS[E;% (%DZYUA3=[I''2]PM[?A#+9DJ MJ)]* MA9VM\3;MK23AD3:X&UE(*V/ *YH3SD .K](1L*J\SPO/FPQ![:BQ>)\0862#XGR>&-8 MY_-;Y9E5;M]V16;UEXD ?_3Q>WS+%(LB?%5MO'B1EU:7V_D^ZC.WWG7M.+(V MC4Z=@!NM"9*.M3+?M/*!;;>< 5?=IP95[H)3@X)"B^@$3P)>ZUJ+)C?N"/BF M,GU2/NQD4G)S/.IZT:;::68H@VMM8?#6,U,4OEFIN8M2:_,V=F0I,(]:L#QF MR"/GK8TT%CNP.W*HKGQ!-01(@]Z\H/+_*K!DMDBA??.=9V2H;(5I73<>U.BO MR0+KL9Z[U'T4W9@5+@$GDS'<3KI_?8-RP<&WR+G["V*]'3D'>?9I-M @'TUE M0E[K&Y\UT5FP%>Y0&_UWH=OY^]^%AN;JB2I?:U7YBO:3W25#]10\;7FIHE B M0 _6^=(1X0N/]_(Z"-8;"3D$VJQ//VY^-H"$ 42I:1B75BYGM!6KX7I[OMZ M@&":<24J3U;7.,)"M=MZHB0Q>RU=S[WG[W6F%4SMK!]:7$:VR>L4,Z(BZ4DK M@5+%SQ]XYZP$#,%UAF=>7?=M7:_?2?H%N>+DJRD^^W/JVG[W0N:82A%'OF9) MS=<5AX?"+1'>-/OEBS"DZ0"]4=?R3;?&HI%2N]8=52?"R6H5!IU$C_ M>FBEP29E<(HW]6W,^%[HUKIY$'5ZI4E%,'GG[PVWM,USID\GLK*XM1OU9>CD MJ$26$!"5^<1[T\E.MV1)C[;R$C<%N*L?H,PE9'VY*YJ48/S 5GHQ,M8N#RJA MS9XZEK^RCFPREWM E1Q-.O)(0=^$NK=%7*#P$1*:&D[/CWKDX,DH)MFZF MK@\6<')!2.%.TMG1'Z#7@S0M4W%K-,@^"AB^%DYK4F!]*>'R<:?!9DKEV6N*#N$W MR6RF[4]XV;(%";74?]O0LQN4@I"'5>-$&CIJ5[XS.SG>Z\^I7/$^5R9&D1(O M0\YR@7_;&?T_G!'T;NQU""=,ED;U?B8*DE)*39[9* (E 1E^?0?KX.K-MX\^ M.^GQ#_FO"TJ6LBC7HR_9GB><#&U4\RGS/?4 ]]#$CO'[VGD" M^)WPQ%",6_,OT3W+::BY]-?1I. M %B37)DQ[K.$P;<Y#^H"DT9\QZCCWN;OQ7I?_MM'-957J-4E< 9 MKRD(T\,(T! 1L5X-,(MA#8^CW$;O)=/\CIZVGO3<,M^VP(ZL)M:5-1WAB+P. M,YUPOQ#V<>9' YE:+:(=FXV?8TG%O6>QYY)^'?8#*!"PH19?MAR-?3;C/3TJ M,K?N"#/8-,^*,WQ>(VS3-%J%9>&^Y ?\?27U-<3P8LAIY):XI-Q]FDA4'M^/ M*X%GIV[9\J.-8P"RY&54D0#;G=Z-1NT1WA2.X8,.IO#\4O]U0[H+!3NII/K5 M[S:3JR8:9)9%4WAYK6*'S<97LV(?#+'^ MB:PO!C=Z;7&]BG 7W%.!?L]-@S:YXQ082YFH4+J:H4*:3^?2V]31S@U"T/(ZOK(, M>QP+I3^7^OS*BK@4UV;\W#1>.'EVU29O6KO.KGKY:Q;/NG4&;$41:7[KA>3' M\=ICY3\D$'7RF'S!> ^O@:5\ 9\GB"85/4GY&6+K:"U$GUQU7(N$*]L(S+SB M6-1R^Z1H)!"1Z]$UZ63G*L?=3DWS>J.VOO;Q"9\H)W]<_>QD R_G@PIND):.EAQVYQI*IF(&@KB%YA%TW@(<"R)R9 N\%G8J%LA$"?OP MV:&1AEP[TFW6BWU@LA_4(2]!*102\T MEM+!]PCK>"V4%G5':M@ *V*R7Y;\<@.02/K[?;%-ZI[8T+G43)@6T/3PSW36P+^OL;7V[/<9 >1U/LV@8F;,<3MQP M#:]K$5,(0:+5TJ'.Z5W8\6809HIYS_S/>MM4+(47B#46PG9?N[WZG4,"%]2J MWTB1-9:=Y#6,A(MYN816GS5$*M_\)?&VU"/U9S]=_8,JJ#8KA#WY?/9C*-_V M%^68OU4 A4D7C*VCJ(.%_*?FKE)%FH1J,#_XGJ.*$&M,PPE<5@#&8.)@/%N; M6A]['D8TI$FK+';[[AILR\,-9-^"WTLLX]IN&E?DRTF4(N2Y%&RW_3C8D?@4 MW-EK(@8HPA.7HQQE^-S%"4>*K!9R:,^"E?#@+F=6WL\P&ES_R_!++/E._)U M":HG/PT"W,>M)Y\K3>,)(^G^\ 70JL)?;IWF5&R&6%LY(*JI>S@9-.!U_:"ROLNA/FS'D0!]+!G 3HH,94 M:J_AO<:$7N8-IYM.>YS4XGD:UF5!['TEE?6]?L+Y$1'^_]KZY/TK7HC'^SDP M"Y \&QHD)IHMF^8^/1D_9K51P4_>;BS;5G=VT(#Y>UJ NV"0<\]I0Y[LUVQI,HUWD/_^U;'74@:MPEKWH#)4:W@RF:)<%KUD9WMF0 M!;Q%86H=4G"=1)2K]\:3NES\DT]JE#E0@FRNH[,0 M=9Z;?.3#8'*QU[L7,?=YWHHX^EMQ_WCUKV8PDR7#K]LY+QS4-O%!RR[KPQ=4 MS!=4?I#4']P<0$[XD^C$;KZ4$?]S/K(([JO64-[V:-\&7+\ T#5<-"7%M17N%X^E3LY2LL!1)H%;"!16_4JT4A&N7DP,A2#A(C]A83]+D+6DK M \)8S:.E5=[B0&RKU%'5!BBNX:WB])"*O6!QY()_X.%K7&,FV(581&HF4XO& M$]PPSORS"$58$3ZAI?_Z65F_DL]QY2Y +.5;RHZI2C0WF)V4Y-Y:ACIGF4,V MS$/F+ V_M:;AGQ(LDCB/[6_/6S=JR'1S>BV@R MG_[SJ!MX:'?*#BNWA=F@S@JTI;8(GK_2WSMG"CY;/GYP^1*FZ2"Y(NB@Q, M3BE8ET6'-+2!6ITR@[$]S+?SBS)MM,=V <^3JN]6MIW;3:MI37:!6J*HD'6: M':Y2@7'%.A/M?#PY1ZA$0\T_T+!HN\"HEM-&8RS$THG/6HK:I,_7#B$EAW9I M'<]4S>.7?MA?[2!9BS\'D]4)VAOC:[?ZR,V$*0RPO?'P'M'&E8^85?69N\^.@XX7#AJ"!SW [PX M9X +D)N]\&7C72^H5MQP"?U_ 2EPUC$C5FX-4FE<+&D FY( MT$L(IQ](+&.& _!.HMM3%JV+;<0(X97PDR]VONT:%9QR]WM.;2['/45N'M-I M$\JQ",TR4AI9ZGG=L"N"DR+12Y[RJ-A=DY\]%"+2Q&O>^7Y!%3BCQ"5-N>_% M5 0V_4HN,IX_.*HS?Q[,YB@4MMX\E8;@3P_".#WF)O):7*VP? MKU)&5,7]^CUTS.I\WZ-Z]7NW1T<\F+K&.-R/,P&N7+DR\GC@LT9IKV>GJD;) MKS]V1,[/5HVEYK@4^'VZK@GP(2X82_5>HP"L(@OKU7ET9ETJD,'3.Z!9'H\SLDE2*V6JAL1S,D+8':XD#D^7&C.@ MVE7493DL0PJ:5 QX+L(U M3]BSG8"6[0HW'MLA7K)TW7:/+3A[)N!P[Q^UV\#@$"C7^9@-1V$U!KK*B^%Y M../HS5-VR"$3MM_)R;$4<0XD!VQD LBYAUM7W$IQ":'I5"6'D0UB] MVK9-XY>8K[$NKXS!>.8VS;/;M]:]Q^WJEEL)FNG][J<9#UDNH]N"C:-ZB; / M?O)#>/E?4=GU!>#R>Y-/[&W_?HASN;\X+A>IRPFTMA2D4Y;$[UN6 SVL;\2S MF3E+_,+]GUD(I67(0,BAQ.E5C<0IBO0%5=I+W;4K%U3Q_/AQ]\"\DMM,]_@ M/.!'\460/?5U!ZEHE^V M?.C3RM5A\^5GY>5DBMF-WI1E/4?!,)8/7+:P2F*<^\1T[6^VW*R"[B\4?6=JZTU=B &1YUHYX6^S&@7 MDH5+6_%V;E0JB9GL=VI"+B(])6!;"4NDVB8R%/>\D8.BS:%YJXP438!FBC25 M GCWW?.>PT MQWD&WD@9%$ZIG7[V=%1.;6CN&M\R%/MT A;PB'NE!DIQ+[W+"A4?=/DP4JK2 M)^WDV7S+RHV=JZML9!IM:0>(D^R'8&$&4-,QG]GA$)6 W,T?TEAVM4MC[DZX M1UH#-,9#8';SE>JZ'X8]"AY)*[]5JL,CTO[;"F_J+/&AW##GX#WVVVD/'J< M+M_XAPR&%Y[#)H$??H31M&<3?__)S,R!*E;C@FI(,=H%R=BQ(9!7WZW/>WZI MH)(?M8*QHH7Z5,1G?WX,Y J(E,'?7WVG9A3[6Z>6L0[SF$H^6_]KJV#S(!7U M;T[U'?4[_4J7?O$% "F*Y%'"[PTOU-3+=&(9=NTN02\%(:C'/H(YY,25).27 MP^S_3IETZ_4O_&3TE4JN*#U264Y:L-SJ-[73XOVDUH@Y.&7Y01E(Z\R#%8:% MO'ZU!DJ3A_&):*CQB2V%%/0ZJRJ,!W?R*+V?3OLPNH2IK-7O3J\^NX_AH]\H M8_"8F0C-9"++)O!4*=+F/K 5N(KR)'_Z7+>I4!,SB)/KE*X5&][TLNYW49N] MH/)XZ[U_R%)5TD>#XSQ(/]6 TP>QZQ.J<8'Y.#'B9$8W9PJW,I1Y+[WA._'/ M06' P;.CK@^NR]40?=YIM[E\:>OPL(>Z!/('&*)U#D2X6OYZT M42=M5\AULDF=Q%_Q9&;C803[#Q*?30'\G[.V =_,^!:8+) '@6YO9R0"L#RJ M+\#B,XAY ;H^583LTK58R%P#RQCN<'/9X:/,*N*MRGZP'):YD[J2*$;J.:M# M,,-XAP>8*>&GC*N["$9"8(DLLM'WZ0"2,R;\;H^3@JIM@ZS@7'WOS4!9X1?C MP@[/GP)4,!G2'_=Y3\EP0"HS9F[X<2=RC!>#?&]:[<"(1VA+ZT9#J4$'Q2)2 M+E;F%L)?;Q/:56D"X]6ZV&EE^Z9*W0-59WSEYMV=^/$5AE2)Q M&1]H7O4)*1^3QNCAIY((":7?'G8HY@J +%4YK]Y\.)O+THVEUL0*]MN?=5PZ MINR%5NO(P0A>!KJQA*[7&K+/3SX7A]/,P>^_7_5%W%D(1/*K0LCY54Z?[0Q# M\(Q0:]CAH6R@9Z':8:DP0%":B6/ "2Q35YW4JXX[>R;NWI[H.*,4$"#CH1GJ MD.YFW#&?1RLL_X^P-V):2*'.F^NMJ)),&YS[@NKZH^L#'A(/7MPG#Q L-9A? MK!.#V_S%_5_4%K.@,VK36(R"H9S$#+<1/L4\3XH-QO9 QD1X3&*SY>!I> '^ M_4(8L;.F&U8(2S,VL(UGL*+MU*VMN6[.]JU^E$8@DQ6N2=B7(@RDG]0EQJ@9 M2F&F-WK76?.V(X,8/-3 GCQJO2K.BT*,]AD\Z09T_?2LW$@#2]'WUO7&G^9J M:/\ T<>,B-GNJ4/.4_]1 @B?C\ZD\IZ&1Q"^V']-S#@7V--4ZID/YR2;;>RZ M=,X=RX -W^IX!/$W,^O[A; /^615ZV^ZUD!O^ZJ4JC5%KZ:,X4VZWL)RL*3U M=N"!#&=2^!2C=POYN\9UL03]?U'$>D@(+U$!41Z M43J2'R)=>J^17@($I$4-!.D=E29=!:0)D=Y!2 ! >G2DR @31)$7"&$/_?K MY[F?_XNY=M_L7&=GSLSY?J[=.>?($!U-X0.R0@T' 7W<]GHW97(>J?E^V6EFB,C]2<"2GA_"EU&NBCH49*15U3=_ X=:'T?X,5WTW! M<&HP)D"[!>].&CH-X&O5S&;]CLHLW5LYB6M?N0OCU32_#2L1M$O'M# M_/-L0H386G(I=I1T])LLG]JFM?I5KEE^1)FW">V.UY7%C@>$N%?UV*>#8TD* MO*^^--CW+G1!XS 3B>1 RZ#VG*!L L*&QX>T?PZJ;^C@J1,%QZ++RB=LI/HM MTA2LV5]GE?*@M$M_#5..UDX4:@P:+_%Y\/ PR0B<@^;DJ 2>Z-YX%FP?2J[0 M/DT*;>*SA]J'?-Q_ONN_[U5; .DI/3X'[6X8=55 1N&'W^^\3_[^]G\Y%G6Y M:2?]P:=EN=?=5U5X\"^^W%=CC%:IS+\NR1#E<)-K5H1OT MK\,6,>BO;3CW/^K\5%'!)9]G]04"OP9EWTRN0R M(-=8F=/],Z@QRYIKZ<[O[(#5-G6-F#5N1OZ B]9T9-T4GT^V/TLCH$-G +?C MI;/&+O"I&* S9.)T:YH@.K#&_[7#!+,66^_HQ-?+6KZ"L75A$!_] M:MS/W^IC>0>)\P/)N\-/1G+*<2'2(?);+]$0%?/W8@Z/XSM)N+-7]XK<'DUW M:9+8\7]3F]ZMR]"1->9#)Q\/Z4V&,@D>SOV:6UVS[,I9W%E4.=B?;(30 [[1E:-NDND"%(5QD MORF?HYYF-$*QG_CSY$'3S7U_EU.H4CC;*+02U3SQN6!M\>YQ.)!-3-"?[:U7 M0+'[$$U*H:.\AGX=/9G/8=6V"ZM"ZO_9^>9RQL]MPE6%?$79VUEK;(ZD^=0S M8I8M,,MB&*11WH_VZ$$/,Y)22N!\;0Q<*=TB^6D8@\B@Q0!.[BFV>W41(I"KOIB(,Q0B//MA%!LE0 S2L>U6N MG] WT$5XSO"\(&DHE"H/_]M9\>OAL,M6]N20^:CLOPA& 95O=G$D6;(2\2_Y MVJD]*2$A!,R)L#DN)N8TX]?8M^T]N]_M7#@8X=X#NF\3UL1MQ%,:,Q',048>[APV . )Q)(;C)B(D#LF%KWGND!:,525FSQF9C[46HQ8Q&H3J=WF0_\Y!N)*UYK'CO/L9 M>W:G#W]B\%N#:[&\S@4X.%-$N_70(])! A+B05T<)Y"1MR$.>^D=Y$.QK#Q< M!.JH*=^:#-7^?9@FD X 2?C^H9_V-HE('P+?4%O\ M&L9>X$-[!2Q?JB4-QGKXJ_F^B>DW]_P=AV%G@;L&:5_#GA4-+!C"IQK254X> M;FK<\>@!3R0'R;"\<;.6\GSCV)G@\:#UJD&3N"7![ZK&!^?#94^>#87M^7+S MU&5KQ8^!=842 ^89ZRIK\="'R)H^QZ4![\!XWAPEJB@[#\<8^7%$#5/**%D[ MG;E%,)?&,\]),@(Y+8&U&J\DN"7'P2,\9GPV+>78,.TS*&5 ET+[JA+8ZC_A M2B5+G)H"=YV(6\GWEIQ@_\U*:?##H!XS1TO?7SL8ID"5!EA--HP8)*N=I0IM:3#Q=W_^.2A=W>O4$B&!*68EUF4'?P0RH=T O/8L16^Z5K%[ M8&:0Y?J8K*W5M,BMER^-.3),NBXF(K.W^4_OX$$\$U'-]ELM\C[A'!15+$"< M*_)0*)RW^([H_+P!UF^:>R6M)7#7=OH/@XM'K5WYQFQ3_V^3S@:Y?W\Y<^QZ MB:8LBR@S(.EY=60?M#$]C@5[D'(.XKRP$,]&FGL'O^7X$\+2!7EVC%HTK''6 MY7^I&=EBSE#D998]UANWUS,9JF[#&]7\0C97\.QF)2+S3>#5N\E!R@9/I2]$ M%3S/NH_X53;/A,9T0'R2X!CF\X?G<96+Z*MS4.NW6K-AU_H&!.U4K4TF]P*1]U_C&HLE!]P: U01(IK$8G:)> 5/1*HK MP8:QI_53^6EJ@_Q7"9MW5W<-?Z"BP43M VKDPWIB*]8A8S$,,U1"KZ[EM:Z*#BRBXV\\\IS M/B0EA:'SRY].Q>+AC>;9HW67H.._>V/$^'6O*N+YR#38L*Z:4_QK(B,E]+US, <GEMC=0Y21A,X1;$4<6Q@1J*C48&7RE6O?,(3P6OCV^((I5>>S;^? MM1F#"3X__H7R,]/(5:3!F1*^XE,Q(PC'1@'S#]0N,/.0K=.K[/V/E*+)U%$D MAO[QZU\ DY0&OU(Z+!F%::N:X#-):A#G$5#'I" T^+7RYX8VV[4=6W-E!]VM M/KU)OKY1X!&":H[LC2FT@LSPZ66]IG/CJ[HM:B&XLORRNL_35%_%[BII\!>" M][+PI?^@';+MDGJ"><*%SYA7:GZ@O\,(+"D:XI21WDM=$>LIOVL0:"@0_D$ M99]M)?UG7\L@?^MA1, )=W\?!Z56L$"PM)+[VG]__]H\$$Z^]Q!=!R.2IR6Q M[@L?8)GK(KQOOE;<&]IX,]SO.%.1,AID=4C6MI?Q,JA])%1E;*]$GS0L%BQT M4IK06 AF=U<197M<95410V L$!__%(B=2I.TE,UK@<9\)1[5WYN=D3"/EY>M MNKZX%9.?>9QL5%W=V9(:X#HVLY%^251ECV;#^'TR7E^*K>'PMS_%O]=Z O;X M_Z=(PN7RA7E4[A[@B^0.Y(T/Y/WE#["?XE0TC[?'.:(F]@9(MQ1N M7-8YE ^\V[1^_Y\R/]5\>:0@D@; $"MPO>3K#A1ZIN>DA"$*(Q#,E5C7PSN$ MK]4=[!&:)"MY5.EZP-3_YBBVVG=OO'O>-G=WAR:]4UB"2(\'D^J> N;1$^; M]K)_1=*L.T.H8@DLE]\5;')+-HI$RKH$Y<5+R _@B^I0M_[MU#@K,JGFXX!C%%\R(''H9?'#X8OPI3>5' MNQ ID>;K<_/&G_R=E;6[GN4UM/H_N-/8[&8XS=W^D-[@NGZVP0_0WVL8[,AI"1:CJ%PRVRDNY> MT#E(5XFH=A'-X3&]_X*L?O4&0+[_\FX1W5?_"=\:4CY';&$<^&06')]=7QY60I;I]12..Q.O]TM6*-SXKB R,;WPRB* M+)<5QOC0?Z9CCY\DPU<)$MX%V:O+K8T^HC^*-U4 M4\$HF'EMU8YA^_UO@ET'Y/NS(8NY)I.T$I[2204(/4+K. J8KD8: \_Q3O;4 M36VMQ%RR4#$W<:,W25IR7LI-*3W@'E\)FTB[,)]AI]IK*D=9] B$!\EVEDG6 M)FE!9XX.EE#'CHV !V',AN X/^V,*-5M QKQ4 :DRUR 0DF2QE5B<5./Y#DH MUG77>'[-?*YI7\9^/J3J#X31YUG1;'=9>..CQB5*OS>D)6//[:T/;V2:SZD1 MF<7AOOC@J%&##E".YRF2/#K5\ZM]K5\VBWW]Y=/G:'VHC,2O5^F;"B?0_SF/ M+?;%>X/,@U'W2AGP0B!;>#:0)LPDO^YTL'B5H5RY$;Z:V,UK*==6N,N:]B2- MM]G'YPCJVSSB@)OIM M-:%QD;L0S>?,DR8H4>,@D(4'4$S9TV]WS=+\=((RAFQJK?_-][@(B2:J:D./&+T*/PD@H12^TF/E?<2>K2PV8UB:@ MM5@-H#L3K'W5;<]F@JZ7E1TR:/3#B[/ MOTOM=_W4EFR8BK#V_0!FCQLP1=,]4-<4E?95J![066SUV#AD(;,V8E6+AO9* M(W 1=HMV&IQ(+R )IV;'7Z)2^S;7>-Y:99!0NO?7?F6VR[KRDW5D2&XW-;VYM?7B,,P ME9>&C/5JV)^G*6C-4PZH-N&PXAS$"DD7-4@EDFJ+NQY5SJ2^,\\1XLG^8;OG M)THWR'%3XL@>Y'#$EW?/Q* $+ZQRLY52#=!HR*AKH*WNH5= M9KPM5^KSC-5-L?XRD=P-@,5+>=S DI85$7(8#Y?_)Z'"J-AGN=@^@X,RI6 M)BH>":Z>J'G%NWO_%3O-Z;$Y^]C# B2LLV"^2'5=JO[N#>'L 0,IF#7V2+;= M_.2[MG; >K_2X&'_J*WVQA3EMO Y#K\>;R<+5(0E6LS M8%T1CVE-Q9CP6!U.C>ZX'79-2_5[6MW.#]G>:-O#4&44V:Z&O$LHLI5^IH]. M(3%0IP\1X_VUI/HGP*DQHT'?1GW$S6L+3$<:4VN4AGX ".LJG31'8_^]\TW^_Y(3"=D)V.8%RO'_@*4#%( 0-6! &:OBH21!OP(*4\ )+6,V)S ME9YYY"/_(PX6O=T]<83Y2]7KDR? ,O&5XD=L=0>1,: MK/)@??FH8+G(AVQAN4;:(XH20@GGM5?NYD9B.0XAY200GQ-"XS8JIS48 0>' M]EGR7=*,@R&,:2AJ$X!6#-?YM?NYN!8?DOA'@-FNMNQI6://3,29 M)+6CHFW;Y2=#ZN<@=AT$MW5IYJ9RND#(;\< *E6L:;RT2EG@&[+,O.RUBCC" MQ)ZD,3O#@U!?L\$(8QDN+>+.OW$P3PF$CK^*V.- $J"6Z",3S"D, M11^YO,87$L'AT3A)1A$M\+G8#([O6*>/&Z25]&X"F'H(_=1/OZEG5EVA?+M% MZ8/(PZX,_9;V0H7/JZLDTC1N+5[C/E)A+E(0D6.DTZ^VX*=PGP7[C&EINUB( MF)L2HM8T0Y8A3##O!&87#]E\"[6]V=F2PPE54-]5R\X?W]FAZPH_=B2"T]&A M:'#DMW,0U]$EW#DH&W+WRD7^!1&#K8'V4S!@O8[/S8!X MF7 @'TZ&C.[6_ 'FB;WW10PMTXH0IK"3/;$($PW$RD/F\]*>& M(M%/-6*V?)8LR$"T+CZI0U>SL/M,K?U<3"\B-#=.KHX=W)_"K_.$'8)<5#T8\V7 PD;7QY7=A+ M6>$[,(:1RXG@CY%$:IHWU7,$37 56O6-LMZ9B?.S;#!H2_+(]DJ,G1'W:+22 MM^$P+GSRT[2"E_6W%]X"G:D;6T,*"P&DL\1D!5VUXFB$JME=''P7>+@,A:FN5JF?I)<&!4G$J!^P^<4)61T= M??G\A5;QI6J("L^.BM G_M/-K(>G-D&C8MS_&@O9)VX\*]'Z-Y6XS/\";#93 M'+4E1%6GW+<[0^C1:$9:WV6UX$NM%?^>JFW0O#M2:E&CVKPEGNVE4J,Y$RHJ MIM]W!W7+;,/PZ&*H:7)Q/ST ?DE96T8F7F[D;2XF&OJ0GY,5QMGBEN_"UNE# MMOOI%%?>+SU!CEO?>9\M%:?R\K0HF0?0[J1_&3;Y$4 MVPD01J 8HS5%?JB$R,"TKO+,^GM--R/RUZ0JUD8>%PI,CEQO4(VN6,97?_?E MF>-$+'M(7N4,N:NNX.AA;UL]0YP:]+#=DZ+_(X;;GL,:%ZG^J5*IMJPV6E'@ MS,I((K%3O?%4%WGCF<:K'$[<&I$9^Y?OR.Y[U#\H'DD&M@4SWWSHQL M5O4LQF5WL+!FKH)&0E1YI7&+Y0JEOX1;@\O;K1]"CPJ ICA3$^^W--?N\MK$ M^U&XD;QS-Z8=[&?0H;"?J":%#$;G->>G\UQ35"(_&N3+'M<(1U)H>:\.O#2+K'+^>;(1RP,%7/DBK8161H&M,=R,\>&TA/HVXI M\!7JG+^=J.T5\,I?^Z5X[HVSJVN--/M9+QPI:QIB'@\*7D5>(]]W^LD3S -Q M?WP]VO+3@_]$HA@1_R0(0PE=$42:XP]G*4B?4QW*#"OR(;&$+ *]SKGD1$J( M)TO@F/CZC8MIDE6S[U1S"_!\/L[%6.@[1?TD]!]U(E*>T8OZ0GK9XI99; MI!\:WQA8ET^7'#"4& %0ZAC/?W4:_'S8>[)K/8ZBL2=CECLSA3ZSV+%97\?Z M;)NKYZ!"1*?X"!!^I\]U&S#!+H-C/P=Q77$1PJJL<1+G/%X1CZVD(?A'UN(P MEL3UU$%N_OO.4"\5W">$;]/C Q7QP%2;_3*JQ^-7%4GC-#?VN47CUP5D02I; M'/_:2>&6TR$F@)C2YP@OAY[&J:8TF6,+8"VBVC<_:]NCXON"/9"B4[RY>7+\ M)&=N;NYX5[B5W5!<4@Z==].*WF2RZM0C-AI)!A*AWQX]A[E511,H:Y$I":Z.'U M$MH5P%K*Q(;$F7#,1&/=$V%MI*K6;3XK+=K:V!Z1^TI7OCUE^,Z:0)^Z"O9> M?=YT+6;9A#X85R>;8I(0O*,@3.)7H[5X9[CX0VXCY^9OG>0J'I7QH"#SM/T3 M:%(AO"^[H9B[(G[=F*7*OB2IF&]NHW0 J>(T>+VM(;2[VT,W4 M=?:VOH%:P8''2D^^&]ZSGG=^5#_*Z*=9S,/VD#G\T@)EX1P$CJ0C6Y^][H7! M:9!*0 T.S@_4]$.9%(9(H@E(&8(3Q&ZVR;UIYG%#9_%Q_[B/EZ&AX/(-SW7-+K2K[7-#WIOQ[QX(_I .]#US7>P=*&LZ9(Q<@OO/-[Z%.# M[5YFC5MD4!MI*Q7)4/TOA\). F-(! B[;ZYJ6NUOR5*]+G\+^YFZNHT(3>1Z MJ-38:=ZM;+2H%;SUPE%9^:&QAQ481W_CZ\H%K)*M2QN(^3\<,FP-]+]S N:9 MIS.D'JE+6);_D=D[*[4.:'*1AH\&&\OU&;*L%_J2AN(YO%+QC!SJ*R[!9+ZG M7TOQ+*QX,4P\.V&DH4)=0[&%C\6)4)IW:I"Q,&!>Y'U(*29+G8->^Q-_4[ 0 MFG/0CDKY/+:$:/G69*^BKP_,U<.D$5:O;"+@\S"U6L4(\T/FD(-1+U1981O* M O&#+$ ?$<$OFD[7%KEPRUPYD0S$YG(L&UF/B)37#8*]W28N:PE;[,J9P(7E M!R>'!6:L?]7VF6H.#:T1S646E7 V ^"%Y-V^9[A?!/5)&/;QQ?@%"_LC>*\1CE FV3K V M\?@^#T'I$G0"!UN6.6;S_F_YFW]GR3/.R*O/4:H/28])?"U^;(/@1 MG*UM*4;.F8$40$,WT"62,31'I""0&@[QA#J^JM0!0ODK]X UG MK^*4-;4*\O5'U*OU3D2QO?5_L=N18D@K((E8 MKUZO@Y@U5G4S@DPRY0[0O6Z2BFJ:V"LA0#D1)=@3KGAUE2?3"#BA).XH39'/ M 4QGZ[/X-(W0F5W8I;WHKNV7IX\JT]V;.'7EO 596L=^>?](>BT&Q6(FD/?# M':E0PP&7*DTKD&?C"MM4H0([G26=@[RAB1+XL[N$C/UL@HP H&5 RHWI*+BBQDG]>W?,TQ$)WK>I?79 M# (%F#=D0<$Z:Q+@Q\*\=237GDXEG ;?VZ/V\S"^CK&JXH73Y0P6!BG_DX'% M5H@9OBZ:R",8LZ'S-WB:^7/[(J5'?W\<8BD>DOP:A'3 6#WY6B)'X#>B\WR: M*G_P9XT][D.]!%_!>-DG%0]UD_H!JQ_Z,X&HTB\VP=51Z$W#0YQ[97:6[$\0 M;EWX\?-@!X[\EH:83G=-#*MZ?->W7.0=5"S\>:9K<4)PC5,IJ(QXDWZEE M^-].8(E_77*G*C8-4?[I(%HL2].ZB%I6._$BR407!+GV23 MHFY3#LBI.S&5*3U!/!BR;.Q^WFWP;5E7H4OUXZ=%A9Y7P>IW,?[/AM4P-YUJ M3ASNZ3Q0MDCKUN?N<]6[P5XG09"6@ #\&&1!D)0G3 MP2NW<]/71Q'@\<9925'+WWL*:1JN[O4]S3DJ[]POE;T6E45_(\9[9?THM, L MM$1<*)2 '^T!P5%#FWE&>([T/E-LU3QFT7G#0=N\^J?5V:J868AX,WT#C*"N M_:4M(0D IR!0<8VMF"[-0B+%(]?]W^)6PK&G2V(I+;ZF.DLER+)(;X@]OBH9 M,Z[PR9"S9LJ\2#CCQSJ%+NW4D&P+6)P:D96!B#)8>$?NBTAY@++V'ZDU]N 7 M6P3$81D-_?G7_76KX#_<"RA YWDLTFECH/78C+0"9Q%.=^689GO+NV9PB M-(#!LL-:GW$4[3+\0> M@\%)>.9ETQF;#UGWF]:89ROP0V:)(1]VC(VY$6)JYC&0FR?2@,/0*COB:3H^ M_?XX<:%%O@65,N2A+*FAV.,6/?QDV5@P3?R-O>U'@PJ5J0&WR.:\"?IL99?J MN2KAE4DK6&62H[9]R ML:XX,MCY_U'K9C&>\:<^!Q6)=X6%F^F]4-4:7&:>5Z$QPK95-J"[XM+,)*UDKR M#E]V$E/7HDN(YBM'F]!^/F26+3Z>67$RB!R5DUO6'0'8IY4N+_GI; MJ(0_\^G@,\H[XN*T]6].!!(LVV(A4M3U4UHJY/F8L\1NK:#H[>7%$<_ZATTY M-Z%HTFVS L #+QI#N4D< KNLAK\R'30K?69982+71]KSWN0N1-/$#6C$//8X+(D Y_YJ@Z&P$"=BFU0J.NJGFK S MTM<=D@(V_0VM9O_WJS7(-U*JDYC5WKG>P;-P@YO?,('LN:W9FCB,:][73 ..#IS5BZ?]6=# MV)_JMI*NY&N/[1D*#,?=<.A/O.$)Q4( D; D$HOU67,/)RR2RDC/QUYB]R^* MM=E)(>#7O4XXK2,0;AYC-JVN>>_2S7;>#_6<>?X5]DVM^-"XIAFA>)TF.QMF M?CQY FM"H_Z8Q)78ML1PUELT-[JS/OO4XAWC?6;Z6@N.7/<_/M\&71PPI"MR MQCE<# G]5AA\);[JR13:O%:GA4 1'28+GV@!-'@96D1H2A5&G>_%H,7G$3:T MEXR&AL.->H5&_Z12;8B'Z+Z?'M]($F1;'/J+*?W$0Y.7<2U%^1P M(N7W8*1J>T/.G;HN&^J)I.;[5R96(PS'A:8=;WDO$@F3EYS'*IS<(&B(COIOM.E!)(Y]OY0GODJL2!D89*>_RM!B2G41?J\/ M2]+J+1)7RCG(B^7ZR@KL O[@T2;)2':%(]I6YVL+:,T*9\!S.3*#2D5]1#2Q]\ 69![,AD-A(SG_J :_<->%HJT@ MIM,;ZX3P'_/M;MN]&8^EH)6G*FRX4N.D'0-\[.-8EO$UF\KQ)([*:?_GQKX- MD5/=#W.CU%D&!?D!&TPA>(CG2#GF_HBU?,FJLXY M-_?),#@H.%A,KS!6Y&GW)"P@.JE&3-36*#/Z)(EJ?@P!1 M<"+E5FM_FNAQ'Z &2;.QR-75^S'3##-A6-VYLTNS<(1.M$_/]B#^M3D'Z;MK M:N01"FIL[&H7I'F\XLI 9QSMJ?J? AC2,(SR/+:@]1LU8HO,<];_'!BU+B7_ MTQKJK=?=*R<9#MB7I&O<(%\%GA/6.'>#M17K"0)N>J?.-96.?8QA]?K!3SR_ MQDF]2Y8Z?<(FXIA*!;6ZO32CXR;.L3PRF7G-U6FR)8!O54$LMO!.,D$^LW_B M>N*LQV/MI51RV4L$S4L=YNONP<#+NTX(R4B(9!V))T"-+ZI6U;S4O(6**_GS M7+:8@<+]PAV\'/?3F83F"F-?^:S7038I38[(U*U;PVTQ3/R<3S,WGJXRLZ5Y MNP2G]E+EN8C-.7X+=8D?Q-?+IH5JM^DTN7&6FIMV9YH#V1!T/$ MP@!/MTY-:U>[).&<-_7#PH>(<;&+C>X7_#N*DI:)5[J I',0:?'4^]:EM+>G M+^G.8%L9URDS:Y>0'*1TE@O0&P!?.^H6(OPYP*#8D- &HF6'3%*=3#D Q[-* M(!*PFY2)AR4/.1>?+#ER-OH_\LV]=-?++>A%YXPC=%#1<=D&._8'M>;3"^(W[3_"W=E'+NS$Q%ZO':6T^N-NA#GK!I, M9%Z@]3VP1H#WH_:I2#1]+3U@4F1F%1!V7P*JP3WC^12IA5\1'+6,'W5*=I)^ M&N)0I".GIGTCF*$L%55+=CD':=NPHPB:1:C?WR$$7D3P.>@A"S6*((8Y!Y%_ MJI0 X4I[D'.0SC"QX!Q$!UQX\S[X_WC1GT?0IP/*FXNGR;%O:?!20)S7"S1HZ^NLPJ&7KT_4/P"Y14>#F=)_(&H>+7W M!/XV?T&C.?6J8\.=&[BT-A7N<4U0:K&N6>HUO3[1D[5!\)%5D!)%F&?^''3_ M(N17)$"._B/:4&X57A@W'D- _5_L?(C"%8$_+7A*G-N0GX^3-$U(^7V\ASD@.AQ($'9:O\\I83] MR@_*"F@,<"_GG Z:U^ZY -IK\YAR6"#-E5]%YZ!99\$.GP5]5+_:G+AYA$S# MFDFY!CN2&W BJF$.$89XI>A[8! 0L&[=/E<7 F>V*Y!@*++_Q:=FU\SCXG-; MZLGQ'.>G>\6>]%CYSOH,I\I8<6Y9F<-UALX-W(] FLJ)#T^>YP0N]\8&V_ K\@NP,.DI! MI0D8EVTSS&0%CW%9UIVI6!ES(YW]E2.;%T#%<2X@AT.G0>E[O4PX$'^-)RGW MR'X-),\:8FL?V_:S,RQ%?EJ=]?UNI!#IX;%J=W%!,'Y?PPBL]4TA30<6 ;.= MKJL3FJHS7US4%U1 AR?EQ7"J8!X+I/'\O-L.WN0_O#OS.#6:[LNNR/_]"^#@ M?.@8!)-OC$;#N&Z-ZGX+Z1R#V?1X?\B3;.I6G-O\:]J)>)MN]\'AN8.=R&%M M:3Y^9%_/+KD&Y#?I+$ID/XX'M$]-D$I3/3)D.E(1&LL2?[*Q6>Y2CBB>UB^FQ= ME;A%#U7U%#&7C*;5ER\3L_2\:L7RLNY!+*UCPY>ZL%3*M$F7 M<9>#;2G=+'7HR7(_614V$=/IWZ]_XV%[I_7.LX MN8WV9V_L+EYY9E?1DVR8827OLS M)Y#-B-"1\CD_"*N#5PV7+FA'5JTA(ZY2DU'XHMT?T M(663(J"QJ.#0F?)F7T $XN-3TO3W-MV^1GFS&;W7S+FN9+A#O%KT,OW;W_\V)Z.QLIX)725G25GN82+[-D7 MHM='$QJ44BF3E,$1T3>JR1_K&T8#-5:M.%Y7J998!-I-9;1_ZKO=1N&?4H020@I/!O'[3C&E#OGBE25^56L1-&V*'S#V";-VV* M/E3>:BER;6OM8!VO_N:HS5C?8V[[+E?WU!*IV'96+=/K-HH@VT?* M?4?RH](SA8M99M>)#@A6=<,RP*@L9="O9.'USNA'6+Z?N>TM[G5V@]H0T=9\ MCA,=_9:K81KVNC$WL\/>6@S#[ZH%)KW^X6$#Y#UH 4F:6<[AASW\JT> QYK4 MUZK$;M)LL:KH0Y[>&BBJ;9)_ZY4C)OB@-ON.Z4L;1CX1>ODVUW*]5)Z ID0*?($F]ASK?G982FFZ L/O;I[1^A(YF& NF9979CE3OA M:(ZF8,>1EA;%>?:F,.*86N+QP/7T!R^9+D9Z(JZDF>OS01KJ2ME9:20W^;\& MDDF?]]$!E^\4<,C$CET,3544O-PQ^[$+>G?[V6I:.1#%Q+RE/5-:Y#XEE/-S M4>53^D]5]BDR*[!%[#U. WSP)JDH:K*#_SHZOD>AN;.;.)&TU[3B99!@U=S8 MW39=D1URH2!\3A2;?7ZL.AA1U6[F47&99!O(JT4]^\-A5N'QTS)*SR^Z]C>G MWLB[?T5.,W'B%5_5M3<9V0;;LIC*KKQ\>9UCI?-OG.-'EZYYK(_DJSO_N>OE M?7_[Q92!?6O$CY\?[;^&5?Z\1=,NH#K/2H!>1>@.RFFQ))/%\&@.!SN#>PR"=:4@N_')3XR?6-U/*5S+5T;RZ?'?O0.C(*N>@Z&3*")15@P>I M 33ZKT.N(R#]O1R1JCLEC:BH?3(4XC'X+R$I3&";'%H% MB7U%:#W,9A]6IGL=+OCNN<=SCMFBQM@*NL%RU_77?7W,XWQ#?*>K.$;O5%E@OV'Q._;O M4]?W/_VVW#!FCROW[,F"1D.NTG-"8\$,>L[UYZ#^3N*3EROZ6P]Q ?SUW,I7 M0-0&D;1D/OJ17KH>[LH0'LW_RGHIA07@?LB-5Y;:"/A-(A MA2=&\B/$_94<\O\.\,J\N+?=#.> .NSD=/B=7"T0?%6Q9!@J^6R\MF(LB!_. M47CWR_=:2G=&6(^:8.Y G5?>B('1XKBAG",I]9Z9_X=:/N'L-D[=3/NU[_\> M^DL)-Z06&^E ,-V''L3.$0.YC&XQY:;BEFE<2=]*34EL+T/&F[!"Y'WBLZ@* MFE+O'VKNH"63K\;[-:D\NGTL,6;U$L0"/$I%)F7+O93W-NM_0#MT(,*5X[S8]@<4!V20E_-\^-!50 M2D@8D.'\64P#1.!JP/LLUQ&-6!L?M_<^BFGWNS^R.1D,;.0\KUFJ<5+MGUOD M2QG3,N]IGO[XMOB7'B$+L3>H7_'&K=4BQ9;\S'G2/MS'DZZL6GA>PEYXM3+[ ME?O)FNBPZWYIO%&6U-PGZQ'V6*L5F7!"18#_C^([P$VB^UTO/$O_1M]P$/&@ M[W/1]R_+BQ*<*J;ZH,=QPX/B[H $,7F*P% @$P=FW-]JS5$AM+42P;&/VY)M MOZL_&;BG>N_)@'R;=;K>@AWW9=E V$2OY]KBWV/_,W0(G'7W'-28,3#!C#2? M[KI9^7U;4#Q!-\%^*C2#T=DW<-G)Y]5NI"!)(^\](L:H=>YF0T>F=G?'%*YA M[D9SY\4*;W-X&@9'.IZ5]] @J4FB_5!:L@/PP@-WP$H.)36W8B9B%_W'7Q&D MS.$\B/'3O2K_]PL]<66^+WT:1A66Y8079T["BNTMH2T!GJ81S^4"(/O !D<( M_NQ=1A:;@[[V>O9R0:9/]SUXWH4ON[K_M1X^3/ 1>[Z@8R8V,NQD\&0$[K,H M]]<\,%E?P7MIF5X2]N9SX/[XYG?]&[A?*B)1PJ"K^-1T.1NI!><;-K_B/;8J MQ0-U N]&TTX$?2%T<1$R]CF(%KB)- T6I#I0M%X#I4.,KO]-E59G(J*TVJ<5 MS@Q,>(">,3_ACLG:@"9_L.FG*>%6)PN3Q-7=>7OGPJFU!Z^M\@*$_9>2^J]> 37$1BS@HH)&N0?I9:.#8CE>'TQ"5Y^5AT?:A(LI MB=Y>.B)\*-H0%9[J7GWEH_T\)8?<8&RS5;0^2LU==M2N;6WG#D%^9RFJTV'FJ/&Y0.GM8NF-4"WM MXA5MI+_,_M]344VBQ> YJ,E]C;NIK8<>J0+$59+%2"498(R&*BT ]M.XEI)B=__T]<;'YV<9IB\CG(.WEGR:*MT<@ M:C1W/.-3?D:J5,$/!O_K;Q'B#-EAT58Z]!NTUC>NL;2Y7H*:M>OS7,K"9= 1 M#_:5B"8#)0(:-R+'G/E)&SDUI$X\*KX)Q05L??8I1>3/[6)6!4E, ]EU295. M,*7\>X*\'8;_T/OFM/?V?0__?24OWDA^<'^XZ OM^LTD:V[-M"U6.6;HMR E.R"B./YD-AA3IHW 0=D+6$ZK? 9S C MLC^ZRU0H]K[UL2]=>,W^]51H1W%>Y_O(9 TDQ^VWY1U_LMRV:U/TL/_^/I:S M7E@,#K]^35A6BY'5+_G.V]1$-[UUT\2794'5<72\U5'*T%0P!X6?S #X$,Y! M*6N<7?HL,1H""!9#WM9DLL73BIW%HKH,5^G])E*H=,G[[<7BFB)'Y1NCZB I9?U'V0U@5_ M=H**#[F6?S6W>D5+HR+T^K# [-=KVW,OM'9L6LSDU6R:J]_=$1M]72%1I6]9 M2\^>%?*W2@4+1,].LPN7MN9JX M*N>LPL):X_1;V7>J#(@!8\\%IQ2K0?51LL$YRD-FF%!E'E&APA"!AM7^S6YZF=KZL&_#*>O\_5-)D\/5R)?TOR\L9FS?I^/Q# M;SQ^L:D7OB=B?RUYJ97;8&1D7PKMGOO:T+UG:VI)0,"A&>V__W7_N%SX#WQ, MPJ'VE_/[=[J>81:3RG[^-^3ZZ+^[CN#U/,W?^GO<>/DT_\7_L]#]11.D.C5# MN/5K:)P54-010D,]RBT #(?F1-XF_8WOLB%=WB$L3JWU/5-LQ$<8C)J1A'.5 M#AT6GMHK?)Q:&[E=+!SRXN4HZ\V$0X&G,%(IA6Z22(-W[B85X#+([.CCD[-X M=2;"&@U,XRI00SR&7MD^!W&Q36UA.R)[\45>QCTSYR \#XFS?-TA+ZVFR48. ML63<:FB[UZ7_T=E'[+@ M2\T&'F-B,[H$B% KB#6,(LVR5U@0C>?V3=U0WQW MP""3KO[,,O"!I8:$L(6>NRZ5+J_9DE3FR6R7 (:@8 M+9;<$O6M[)7#E\=%[]-O7/I73RI8-]E?((4?EUX(1_3/NY]NV-TQ^FV4WD9-@O1-MQ\467J3ZKK!<7J\CYR+MGGVZ1Q82R5;D26K=UR1)[W[^.X7 ''\A.F<2UX]C9J"#D0K7 M$.O]JO 7_AIG$E MYZ"&)@C3.<@3%4N'$X!2KH$7:(8ZE+ '4:HF9$F31-?=?D&%;T)SN,D_ABL> M789G]01@/R%)8=@H(264*=Q$1ET'9L,Y-WB#Y7/)DM(Q\:Q:(CMSAW/J4Y@ MUX!;?[$9B1WC)8\]*6,- ]8'>>J]] =(\A=X$WPVQ((G&]'!25GOY>[TFTE;IISV2I$--+I,-)IN- MH/V_'P2PZ5D_-^'<]C)1HF9L6-$ONY]GHIQ 63P'><$7EO"Z>Q7$W/Y>*@T: MX-EI_SF(DQP,*P<2E+D+:3O))IR ZG5W4[B M2LG?63T+K07;=I#N[FHPYT@4A"(DR3R5WBV*I(_U#CI)0??DHU R8*+Q 37Y M(6!V,;,WSPH@WJ@4LU5$"6%K7_-4@C(+:-@@AWA)HSM5N3?ZF=4(JE4>XR"X>H19;/T&8U!-U>CP)2&@A^3LSM MRZ<4$.!LBXCGF)Y+,[7E]5W?_+M8?&H6 /$=9T!QD:$ 4:/YCFL!&^+: M\>>I"^U=DG .JI_-Q1A&B'ZV(*L3==/K*+=@E-O$GB+T3L<65@W*Y;C=VDKA MBC%]_?QYW&3S?;F;4V"#Z8=S?Y68:ITBK2@#4%:D%0ZUP$ZA;:X # X>33<= M\*+Z3 ^:!,($M/J=V4A,V)/[%SI'_>8[$^JTK62R2O5.)'^WJF)KU?ESO0UOR?RRC MZ-@2#DC Q-+NX%JSS0#Z"JI/LPM\R@OH'D>ITA!KV#\"M MW4>)%YRY\3>EO'Z>D##H$W1GTL]?VF]@9>Q#64H0G$%2$8"T*NT'GVKN] I> M&-%[-7("U0S?1Y4-G(HCJ/Z_\K[]':HV;'N$$!H2LIU*4HEY*IO2F$F>0I)V M*&(JB:%I\D2FC!F176C2AN)ADH3$9"\T@S%4'MD;1IG=T\9FLE:;L3(;W_1^ M/WSO\1W?^[Y_P/?#=1PSZX=UW&O=YW5>Y[G6?:W[3XIAV=P23&I*<@69'? T MGE[]$BQM 6TSRH<60.,N%TF92.SN#5XI/OW-.QY8$/P_H:,-? M#F/.<8H<@+0;J",ED >[KN)J:#Z>XMEV)]2Z:VC7G:LAAY*%OC(##PH#_&Q*(UU!V8(!POY$V2Y1I;:%$8^5JRORU2!:L1<1*22? M>%QQT,0T.!/X*:<\>)(=A#T8,S(0TS@, ):&]Y#21_$;2.* MA %ST]+#4476+M;,"8>*AN.0#3C4&3499;)=LAU;E170Y'3S3Z1[]))KFNH+>FJ;EG+V%^3W%0ABJR0MG?T,9"71DIX F7N WUR2\.>0WP!_^/?]=VY;WYAL^)?6_$AGT[OM>VS^ MGWU#FZ"O*LJQ)^;TR[;PTK&+:5&A98>R**\-9W[F/)^^8CI%*__24G7/-/?^ M\VG.M9"*L@_T0EPY;F' &Q=W)O;B:[ 7%X=' 1\V=Q#_KGB-@I%5*1WJ:%>2 M'M C,^#PPUEXBG">E6TE=%R"9:.NGBDC849DT8)>C%GDM5RZR)8]\.,5DA5P M[<8U]NC7VK#&S(.U38W;>6\5VT*E-&AE])C,NRHH$ R#.F+Z).AK$43 M>4,,(K7(2,F/7 M2FP0'L%V:;M>U@P:/CZ2!_@BQB\'@@&27U7U O-NSMR\F_5];K&[ M$7JG>@W;5'YNUH0Z@ [%&L^*7D?:V&E_+' MF(@J58$2]0E2"](A@-[.4R%Y<&((:8H_.&?E-+(A] (Z-/MG?(;83F8KM/.R M]TAW0*[<^! OU!9?F4D(F[??N$M& !'=<%.H5:%U5TB8]#BEI.W[BH$7B@FL M/MJ1B&4QG"&31^2!%F:R U)[\CWIW/ Z)D!(8\!Q+8VTY\0C,:^6#RM6?6E M:/64]*W,B;))HY>V#%F-XFT4G+;=0)3 -UEA15R"B312E5X1ZP:5@/LG62]( M'N"GNT_<\$*ZV3CDX3G\ ZX="*7Y7=\W]CC&%>X]_"-[N\D_G=JVFG:B6&H4 MO!V3P00\X%Q?44^VS*>$Y MJS*D*Z&GHW5!QF,@W@V*AT%'\PU@'>(C#0+-. M;O@M$2@IY&P3*^T!3(Z^[;-H)@,1"U5U-KPB];T@D.F &"S(!V2OY( MYBLUE>F-,B.#W3NGUD-ON>H_ GNR4!8B^.^7MBS%;D!>W?IL$E+MN5)D![A* M2@4^?\UW*52IK);@:'V1[@/-489!8U:?^Q-BD[XL69D/NY[E+U6_N.+42&:.V MKPW7)"4LL-!K@/DDE.MC**!#83F,3LK]_9\:")<6"8QA'RDT;(X>=X2+ J11*OKF>-) MURJO11#.1MQ:@IFCS(28S"681<,TOBV:'QS>U:0_[7*KN 3GU&CZ/&F8U7)A MMO)+4^.UA.ZJY<_%EZ/PUEV7:N67!;QQWR, 3;::($'+,V,Q5)HAR<*&A84V M-*6AD$H=2U,C^6"NHZ*$FWXP;S%-[7_BM5D,^PB"DCFT(XQ;[I7G3.%P3V>^ M17!]BOY><-H;5X>=3A,@V_N3L; ?A>$LFKK"A+A;D)HAQ!K,%&WGU//4IYWR MK9]6"@L#]RQ6MU[5B=[J;%HUW1OR'FV]Q7GS^\K,8R03R.\R>*5'] \-CK*+ M!O.\@2"2TS!Y(_JAFL*A%K":X>:V*?323D5;]#4FQ18&'1^9],V9TB(T;'[Z M^LS' 8UO>0!/V"3& /,2>X JCE3>%\8NV<$72GC%4CH.*M;)_H RP^FR_>#% MJ@K9,?F=O"[+Y0 M(X:9/BVOE,#3%[NSIFQ&Z*1=5<1N'C;/K77L,;-VQ&K8 M8;>!1@FQK@?1@!0C 3/)A+R.H:<8<:9HM;F"LY(FP*8#,9''4J AZ3.2*="4 M00E'IKH\+17(C^V!O"J)M).-0!J+<)-G^;,GT[\.M'X2@AB]^(.WLK>X*;T^ M)[[B%'W.0XR7&D%2-JW.HPLYP9)8-L@+F>%,724=*,LQ3Y+$ E)L3X'=-T/ M0+1BIQP1P8@8Y#ZPU>9%,Y3WS,$I._99%./@EESQWW]7!^7'I#-J:'V?"3(U9W9LUB368.3YY\3]H@+Y7IE@<1[_MF MW#%Y L+3Z&TG*]_@<,N+6OPKKE[,;[O"/$^Z #K0ZK&_\?@4,I1Z*3XPC9BA M]!O,NJ8.6K)B(Z0JF$_EK2&@852+((@IH*3*@D3,S,#YFZ5MPQ3!:7J*THA' M7=-]E^(Z^JE0MS'9W%D2^GHDD,+514J,Y;=BX#2T>N1$&K\[&PCH7C!J MFK*'PIX2X>[U0%I&]=S'@+J\X"'Q^B17K[E_4W?A0\3G;K(?%FUUJ TOA?JD MZ\F]S/I3#/-6Z+L40]H,-5T5K+X%UYV"9CNXF/3YF..KMH)!XU.\DZ[_^!_V MSCB;?"EI@NN1JKX=S8>SY 3)W=^;)[S'ZE^D,W'46UA#I6MBIO( =Z8Q*32S M:\H$_ =M3>W)KTX!#?CL)Q1+U#9!5+P4<8/#,Z37V\YRAMJ"C#(OS%I6.>PX MM!@FY_)('*F5[ 3TDT^;]%9H?2X?)Y9(JH E6"(EJM!9:-V?V>8JW:.8"-&0 M/T=A0$SG6-'R%^#&#*$E/&O8O/G@W! 0L237DF6A^J[)QR@,*E=K+5 "(3 MA:B8DX/VH9[I M_UE[3O57*+,>^O7;8_/E-92+1 P>.VG9HU1\OZ0$)07/L^ K3I!BP'L(^(7Z M4GFQPI1H^I5UW&R\_ %I M]\B\8[\JT>K4R'ECTUPZ?UYW)O\>;\NOIL75[W+ZQ[_A6 M5(/?6=ON8Q(/^<.>3J:I3&<)EF((C*)U91Y@\,*MMJO ./'\:Z4,+K(;<93O M8#LS-G+J0U=UQ%<'0YGN@S][6]_ 'D1R_4K__VA-5=5S,?^XI["Q(4ES7:/?5O\-D^T?$QTC_E^] M@MW,B+SCD#K8W*BI')(;N/-V>^U]K.KL<_?U24,Z*X^XG=T.\I5$6FK)2P()*L1) >&F MS MTC(FW( @WD'-9P;9C#1,ECONSH;U7\PL8T5'VAN)]X]^5L)>:9Q# MMHYBPN&0%7*N4@CG&O?0:@ES'> D"V/QL_\F8K4" 3&PJ6@K$)$IVRRDFO0) MX"DYLH DX6C;MI45?SE\C!ENT#9[61V;B2N[2BI8D_;SE1+X?$P'+06K[=N! M24/HH!!\^@UD%'V:!U23=CV>G":O,HW+LD<^ >WJIIW:)]M,?W"KBR]3C',S M+W'^TNIT^F3NN# 7+=VBK!G+8WPG^OWD-+1!)$85Y?0)JRNS90#[J;'\PA4) MPP>_3;MLD'S;]_30N=;6#W8%[5^1]H^OAMW"Z252=BI,(*;4.Y*IJAQ.&:(N MKAT[^8*8UTY9IM@ATP?BE#;%G_07].KIEY;J)L2ML-8"H6^[JZTD:]0&;W,< MM)LS]:&GM=D(>U^%F/4A0T;+7N4O]GARZ@LRL1O!)K&9B*JB8#&!H]@;_HL] MXE+ 0Y(.!2AM-;7G+R4AZV$N?)=Z3T_!!]I\P._MEI84/=E&>3')]CEM=<1E M8B,WOI2#YCSA3L$JY=@=1(:8"RPHW?L M?F/]DB8XA58;,.XP=CZX?KE"Q!*7R6\F>.5J$[-E59+ZI"G-LP^/6A^'6)(R M97D-DVT'"7..X+S$1TY5*#68O#"6DH4$%L5?ZWDZ32FD=7$)_/D,AB;('F%8 M%73FVQ=7G=K #4AS]+%O9Y6%>$D*RK.R(^^@7JO\"N-C+",1JDP\$[()IOVV MM!3267E5B;Q::00B,#ALFJ4#Q,)TPU=^X5HT)6UML*6D>O_^,%/M[^TT^#6%(WDD>Q%I^9- 4 M*\Z <'YC@\@B3I27[4Z,[VB9[\88-# SAP,Y*/=+"G.PZ7K]*U-;A#HT$:MI MCS)Y?&KJY/3PQ+XMSY9@0=AE2["S\Q-T_KY_R8Z 1SLV6:$'T2N)OEX#J,N@ M=L>4]M"/A*BNIC]PEW"+(T,S-=-C3=.$\O?LF.^>!X\%!QU4RKJ]X3G[LS_/ MG9%:S2 T/D.JEZ4NI W*:[=)=T288CIGJ1H1"Y8K":MG%N]W5U80LV-VIQN- MN08<'K5'$NSI.8_O?#U9G>]UHJV\'='/$=>!*["FI!"H 0CG4ZF4BS1C+OD- MHA;#"@X]"E'YV,G*#JRJ;)V WBA#MH'*\2(GORPRBI6>5E(Z)CORV%T@QW9S MT])1QPQOO=H:^+>3T3%LB%NNPG-8-L=6MLZ!VO*Y>B30K&:V3)/"X,FEVUBZ&]V%=.3+J2ZODD)[LK*:SY M"N'+#C;V!64.)VI=@FG-D!V5ZD0+JCP*(&XX$�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

    *4.PP$S(@QAWWD2*^ +;#)Z!+Y_4@22I3( MMV]3L5_C:C(&YWL',[ B]&*@H3F^Y)IR;7S)E><.U]&,%X_^6&.H:*WY^-SZETI+@R"F^0"\]]P>IK QB\09/K'862P0HJ1R_NL&IHIUST%< )NM(/ M"$ %>J9G;6]BW@H*U@]^8LM9"0KSU$^^D5"PC42I6HDZ)L)1##51T/[+ 6-N7U?.+TU&]K3$--[ MLY(M*\+VLK;N9NV%H$CY1\ZQ148!\@HQ4B>/*9^A=8@NL@'>M0<<#>4@>2^! M9W/MB!8],N(XAI[S-ZJ+49E=B(/?Q,L$]@7? MI5PB,D1'9Y6O4P1'JQL3*J6S3*="_?%4T*8>%71FEIRA!&4D*9.+*6HD\R9@ M F_,:%CQ$Y;>HP6>.,@7N9>VO+WE23*$1,+5%W?8NLM@?LPZLWA-!8SMA-=! MJ/6(,2J_]''ZB"=A:NL3,1 SANB^&R8&]P*\:V"!_GT.RG;C;GG5L<;3W@USE?: MS@#O%[ ?Y]9;N%^T\+.DXY,4L9EI:]:92=X5,Z$%V\=54TOWJZ0)\7#MODY9 M3 PL*X;(=\2Q:L7-TNR&;362JTG_!9E&*=LGTT7[6I)8[IR3UGX4V;N<(9H\ MN.Y8GKLD:L81"[/$.*!NC"BBA25\"F,ZZ8WC 4C\]3S%[C8&#A>E^F2N?A]F MII/896R>%4WXNGA/*C@.KHF;UDD0 M_1)A1(S^5%46PU*2ME[T3.DS4B2+H[!<0^Z$$]%]8X?DC$-$'O% FYGG&_"A MIJSGGT*XFZ Q\PH$)$:. U9[>+ZT+D&/*%M$Z!GHV M=V]Y,)S%$=)"X@SLIX*8PUA),%J%/@&F^G,,#RL).SA*)5'*:G+?\/:H09+C MR*WDD<7:_"(/B]EGUP<"_"L BX?)_;W(LGXOYPEE,)-><4F8\\"5@^"=+3 N M&^$NQT1RHAV'BQ6%%QII$<]93\(E,ZD@4,V^C"QE6X"!4).97_D[>/Y=>F[2 ME3$K(F<@1;23&)-0W?AI@3'I_IJBAG>I%9\6BX8'7L>URY;1E&]5>*PJ%K? MUF!%E.4!8R56K>:AO4'-/*)?W+7X%SLE>AW]X6(,#$;/?8*&GE7%2#KO94AF M.&^:*Z2L/=*X24@0(QI@<_QP.XRED3V^NE%\BC@F+ZN>72L&5A+ MC34QGOO)N=YL]O.O+R[?KA:0"86'UVCK;0N_#U3BC6*.IBBY M[=34!$!8 #@D!KFJEIG]WEV%<@;!Y-XB?#'ZWK,5MP"IB4FH(0H5'_(SRXWA M'4S\,!&@IR46O3?0073?61+'>'A'JR&[[01T1TDAD(3]>R2)BG4"X(1K*IEU MSFP^\B@W#N4:+D0P9=8-/XG;DN6LD/<$GP_K*>34XH<)4"[A2GGSL4^_Y-NKO<^K:ND]9.Y>8)4 M:V%UOQ/) "^-CO?_D/<(SZV;\)G$M"@LT_783\X[\_&>L (RHG] L=R"7B." M?7VRQH+U_,I-<]O?DU7FC>92S$:<%0Y3&.?(_4SY"&W&#E M,RV];W\EC*;TSE!!Y#>7H8G0YK__A\P;7]B;PCP/YVZ@>2PC0P]:^TD)\(Y. M6!+P8.4@:7^78XCU;#SXY#$@<$#XF;%5D*^Q6YLJNE+DS31U>D6O$$L%.4&F M Q>G$B"NAF:'761DV!4/,"OE[-IFN_VK$L!T9LR2R#QH(0][L7)0VC0:L&7V M-:O7K#8*MT6'.98^+JL)?)?V)D&J[=S;'VUGX7,WI#P1NN-%=E*F_#WU,Y[9K@570SV2_)ED MC"2Z%XD3J#.5O7RUM]+4L@^M,&TQ='?8^JQBF!S0=9JEST*9OM9'JZ]_'R(& M&:HU+=TY'Y$/J>IG*HQ&"5EZLRJ@;%6EY/L7KR_HN=ORI!&-:=I>)L_7Q0JO M#!<_Y8RR2Z2"+#NB>>2P3_9%+61AE4]@TH<=3"*]3K[C&_UL9LM4T"RF"T$P M[H#@D)$HCQ-1D@T0]P%HIX*P%K.R=82%OF/N&M'UM1O ;6)XL:W0,23D$ M]W8Q<]4P03_-8O*9ALEAPH"G J_7PNN0U\:VX.W$5WEY7KP,H(#/ M]DW'S"?F82.(NI%N:/0\9\KBPI890S\BX4CK*LK39003K)T_%;6M<3G (U8T MYT1G7%E&"L-SS+6<$QF_83\98,S6W""9),&UFC]42[: MYUB_'K;O1WHA1<>D(YG[8<,@)ZNAG.2Y9,3!%[X4O*\H+$S8B/:EG: W[Q+; M=*.MRE@5<3FJV3AWM0S!7=(&I&NQ(;@YLN'^)X:W!LR1M14?'HY6KS\,X#2! MO@>GTG.:_'5.1Q>ON#^D[:/HX9_HM'DDI+<8&FT4L@L1C,]Y7TC1E$5LS"Y1 M0?>>5'84DCN$J:#5Y77/.TLI (X**KU[3/.*+#Q C.8NI0MZX7)>4WFTUCG8 M%%[YX"-3\8ENGW5*!$FQ3'_YX9_29W"^L->9+W8U9EZ\_S,\ B!/I-WT I:2 M FU2[X!9 ,='KU[V9X74VB9<.[R^J'^8>1Q^]O++E*$[&.*Q-^WHVC6H.]&F M#*;=UYTN(2=U"M6\ECP[[DR(#5Z3C&QOM-$?P&#/G(JL@H""DD!/!=N4GS?WE8P:>AU M;F6YTO_X9TGU#WG?8G,U-[6'RZ,C9.#XHZ*!L;.]FXSFA O]&/P#%H;6";:G_2BV87G^Q?E MNIF58$?X^9JP4>UR8R<'SU#_]S!W/=-[SD^F:O=/5\-F?(IHJ6SYR:&?6Z89%ULV)Q5 YD_"1 MI?DH3Z+3$ACK[WB8V:DXX9QRB\B,#-_R8KS?HRGAO5\5D@#5$GR:(Y:SP4@% M/5M_#^G7<;[U?[%TWE%--._;CZ(B77H'%1&0)DV*@5@>06KH'2(B($0Z2)"0 MJ/2N5.DB)=*E%X$("2!=>E,@";U(@@(KA/#C^Y[WOSUG=^;LSKWW?7VNL[,S M&2X&H*^9;_],7!)OEE"G*^4;]I,^GH[R8X[K'GSIW8N$IJW\.V29+(\C#(/Z ME02,NPE?U$6@F58%6;ZW(1'*SY MF-2,#E?S5L%U%:OJO@G5SUOAF=#B9>00J("CL,^B\_,',23E*'!,!%G<:W7%K.M9*8)!6C3XOARV-*\G6?8MK ^ $;+3CW;/2 M;68/Z!RXUK1,49T@/89^D#D='(K'SHU2U4#8^.U=_,/3_3 >J4/R0+@3RF-Z7/<5 MO-F3G7V;;99S%+K^*F22NJ'\T>66&3N9D9XD-G8?"7KR?VK8&&Q-\W3X%Q%) M!(9D&>K8+B= ^,U950.F*KQ;5?=BDB]X^VW9G RS.)-[N1Y3HH@BR<#2 0>_ MR,S*$R$PXW@5F#_+ZD<"]4N@1,_?G8R"%X=Z;B#Y3*O760^K3)'R&Q M)#0W)\>+]Z.J?]7X\K+_7_\ \?X+02_.PY?$BQ9S%)Y.7A0'NM.P#5H)E/>B MN$^JZ_5A\6A0A\)F,I2XR)2MQH,&=Z&_7AGJ7:HC MBSE8C2F;A>_]5#D%?4!-YW\9IU[[\0*EB:2?QA*\:/T+MQ,"99EZCIPK=Q;# MGK0TQ_9KRG=[95_&'?R".J"MJ6I51=*CL+V_[[E+W9E M%1V=&1RI\EEXJT@-W;D[N:4;M15D>Z=.&W;AQUD,W)^R9DL:F\VXJJ(.\P\P M)Q$T2=3L#R3/"::#DZK50)9/[) !K+132/EA;5:?YQ$H-N8%._=WMAN.*NGZ MXVOZ[H$E,WT7)].*PULGLEYH7-RR'@CU+96!/#3CQN4Q^EJ >6XV6N 6!"A[ M>/,NIS*]1#89@J-BO]^F?^]X861&@[FBT:V^YP\J'X_A)G$$((ZNSU0A/>0R M$:47R11'2[9G,E/L(ORIDJ;$=;4\V7"NF2B(Z743@A-HP5G#>596G DFF/W$ M:TN)U_ 3A7K6.19"1O+A?\0U3'/4O"J^8-/SR1;5P@C5@R\G<1WTM G%AW#X M\3W KML7*0'\NAC].,.R;;Q^>;)>GLO^7BFS3V_9>HK'W%!X^J@,NVZY1YX M!QC%57_E%*0%8]D/^M%Q%7'70DVL[MF23JCJC1 M!:(H9[%_0..C#9Z"Z"!N0VZ$(!Q;G"I,H$/9]J>CB3R!KUR+$![EFUFC 5&XM& MJ.3>N-HGJGH0T2SXE;.9;IBAYY5H-I#='2_G@&L+_,;?Q-2K6I!AZ%3G*%J< MO=+.L;(LJT2B>J:XE2I;:^PB5)5$"@1$MCBR.JS<2.4K5*HPKU61A. M044T$$DI3Y:,['[3Y1SZKO_"]:@-]79JRAVPF=?$0G^#RZC M>7;@4Q!GS%F7.5!F[AI]N379/)&U]+=4)T#3)A$[JTO\S0X\( M31S"*'_.@,IA]10TF@ SI74OUJ%RCZV0KT:UF#<7I+%DA[R:CPB,C<9!=K$M M7-6XC_#KNJ&N;'?:SDI"2^)R0<)*2(1"4BN#.FR?$S+L]UN@7^G%X9U*L)95 M\A(E.!+";I1@;["^1';O;[#^\3'78RQV:3S6K*]4%K\[+ MM&S]"E&Q&UTGQ&.11B@C2A+I%+48K0C+@][Z$Y62HZ_M4IY_ ]* M_WDC/C\MB6_81YV4USOW[M4KY^FDJGM:[=HAA]6_G,^<3LW)>RSA":0K'_#^ MQ0B)>>^Q0U@C*Q_)XX V@ZQMWXK*HHXDB02G=MKHK?Y'T28O!RD]GY\A<"@W MVO1B;5 BQ'DD3A&I1$$5NA#O"C_4:Z2PA;4YE=BU1V!BJ)K^OKZN7D5C-UL[ MVD8;F&3UAO\83@0,9'_%RJU>R!H[^ /]VM"UC/DPSF^'ET,DE3WK!S MX!&&-T-[0H?7*C^X_$T5MK>T_1./I==7*#;BEIK,^9(&MXTGV8I,):<6'&4( MGX@BC(XM&T_@1 M:]U8UC:;B^W86# W41/>U;K?D#"A$5&D,?SFLV&)A_&=W/LPV:&5;A6#'[D8U3O"LOUOBJ-1 M+H?\M]Q?3ZF2UT@Z4^0GX _&X "45)Y98A0K\<\+(YW(X94'^K+5V4OD5 I0 MT9@G/>>GSQ_5:8&)+==YK\=U2[LP-TL_Z5/:0X5K)C.OC>[5Y_9?2H^%-J.:@[;4).J>4RT_C=F"6_;VYJ?4R=0S<9+D2\H(O??OKQ2&&= M;?I'6*RL9HM+B.//%*.Y+;<+.R4'C4D.PAG2>_NM38MH7-"H2CG$UB">U+*Q MFXC-^+=C9&SS-N+%*2A ZE?B*SFE-V$I88E_M2--P]*8*=I#81%*7LLA"9CG MF\'KB/.KGN(\^R:SL[K-VF/(QH3Q!/MEB, MW6<1. 4]J!NK;)-5:8H"GZL*C>Q:G:/MD4RBATCJ._&'OO./*=8/-?"?7G)3 ME$T8W"+YO:[5)MH4QOS^/;5N-__?7O3<)L'3\[>WP,)%)_"BH<%DH+Z?Z!(7R$)?GHTIT'.^-"',M M4X;@N$R:0[>Z'!VDSRVV,MW5?-.BRQR_ E"_LDN.54?CH'-/ZIAO<@H^T*OB M:2B$L1F9OHVPU@XHT_;.CT.8J2U571ML=M8J#BO,7K&0'.L9_^::Z>H;'K]% M\&GN1_4J]/LV;V,Y>75X'_5;(RT>=WD%E*E98-1N?$H!+_GYQS,G0PW._:JC M:OHFOS+->:U+'T^7%Y;;XDP5N^&G,\UWOKW\J\.CALFB[?JOV-:=NE?S_RWT MKPWM=9PQ+&SJ:*/CS2,ND_;P:\>5?SN/>$#3!^IG)3=,E/)Z\7(O%/A,4Q!1 M2OHGFW\%ZH?.10MY'@JN0_Z*5V\'T1CH3T$WV-A1*^WJ]!YL7(QF MB#(Y!;GT6)R"RKRNGH*4CAM999R^:89=ZYM\NWJ;:UZV<(Z+E#D;6T&(!V*^W8T/J*W&U7 MOB6(N:\^'.C()X^49-#>P5M?>AP<8X='5E;1UTY!M8DM DG\@*W!C=H[&41I M[ANKC^+M-^;*).F2KMY)7V;.4.KO96*0/1#8^^83##,;<*;C6V(?SQ$)V:>6 MD=GBJ]KHB"=LW2\__]'!0*_#YDI^+KBKUC1489X71(IH-[P;@N?<6K2SU>-G MOC>]&5H\F5[@Z?+9/4,JN&1Q_GX(QK%G9.67]<^/R<,N,I\[7S:E;Q(<;!HU MRB_1G=PY$O=M%-0B'YZ853I*JRT->KYB#4L^:/ SF.:/'E0<=%%K"M).E.MP M29M,;BVV31=1\@W<\#\%Q6*A:.::''GB'&E3[55U%%5G@-S\@5C(-(JCW'GT MNLO%9AAF^P#,;,"3_+DKB?GD45C= M(C+I'T>'0OR?W?=AOX/IDS8X#RZD/SN)0[L.)?/WBK(UH/W?X++4$3&('>E/=]PSI>[3X?OYQHGZ1! MEHK.AGZW2WX6N[2(8Q/8A%QY0G%["[[:>J>%)V5)?=]0Q3NQNMR#OV$"TK S MM7K-.Y1ME^>&0V(D1%WB&;X-5WJTB'\9W >,?B!0^^^I+E,EU M)_0$*S?NY&FEBIJ?Z<'^-?T\J\,UOME&5,9?:U+5E24Y94+;2#R N4D 8X7_ M!O:1^0Q0@8FT$=Q3WSC\@F(W6%R@*M?QU2G(LM"RJ6XE[L GM?K9.)K*LS-+ MXT:-%/_*Q1+4@(^*OZU/0=]+"0^4DA]WREU::-%4Z-V"=9Z"_MT09=#LX*9J M;=_KI5Y_=5\B#W?!#WK569C^S^A9$LB=U&E=1DTLT .&A-WPH#R9U@ZR=TR; M9_D6A)R"> IE>R#;<,+T<+SB8GU"2.A!C-8HQG#U(R/[G192[/$N89?*;7;P MB+R&VP4AX!:36N(EI83%"PB=>Q,<\X1)_,% :.&ZI4#H7J?:E#/GO2;+,;[B MN4^/W]ZV&(%D^%I%.EY[VL9,+K_:Y0/EL!SVRQ,C;1NYI1GWK\EXP:(&;QFG M7VJ49B[O'"V.TVWE],NHUZU/RSR&G@?&"7+T&RJD?"[GML<$9E4VMS8IPDO. MFR,*_)-J*[-5TK<*+%P12!XY:]O8=GOF',M;"AAZP_IJB;)_4!K3HU.0>,B! MS^XIB.<4Y#A"$SHW+_0J'[IRP@87H]V_4++K\QATT0!R<,= M$W+*01[PAAR"1S/^;M/U+P:DN[(:WU=!HMONW@GSD_=&FJM$1^369P2AW9.V M7_]^I\L1Q_+:LF8&N)'ZJ>'^;QY'>FDU^-%4T8YEJF(L( MA$75&3CZ&J4S:12FD\._((Y: MV=;M88=ST=PST5[I(:_!-<7O M;]7!1/&!*^=!=G^42#I)]+C="POV\\/7*:QM+&5?%&4'@N'E'F'74A\5 MV1B-2;\SV76K;>S/? /;3KP\* 4$+44QKPHY:'>8B' O(<61:_1Q45]Z?E2& M%\9V.&R[F4*W@(I'!G)T+%%KJ9M/*?52E#(Q@#ESR0I&.5(XTOV+ZU7)?7!SE$T,.TBDN M-=%@A_'BE_]TJ5]:0/VB4)]/# M.O)45"'PLC=;D].H8=P)I9/E9'902L83JN0$=(UN*_:Z+_^F61])K00G\2 R M>A;$5Y4K/IL."6U6N6G;'/*M*O4^]?G[C%AHJB93FV;Y$R7 ?;O*-ZDQ'G9H M-=X$[@/8.I-8J/Q]6QBP(3)9>5V5CRC6M2#JPK77)B?-KJ>(3%(E?4G6CT]+ MLD)B3"\[)]MPF0][*/BEF,0_79,:^MRC$)M:+*5GI!#OS-=OFEK,UZ.06BS9 MHYA<%K!FZA.AUA\H(=G%16 P\L]9X7MP)=Q9ZNR(=/F!0BI&75LA_NQ2"VJ/ M=/UWO-!Y\,;E$7N^_HAO?3T("7K^FV]PYQGLT3S$8EW-#WYL9GDG#'28;2O< M*0BX/KTC3(0PS !)1-$$F@!2J&U"0%X"IR7^=0)\OWP^M"#V_J5R7T)O*.. M\?NN]Y@YN&W]-[W2NYTOQ>OC5B!SBP=TP,ZQ:'MD#2E$4Q5/.S?Y>]QHC'8- MH:T_D,L>>/.-BX#1&>%[7RHE_-(F\! JQ"8(QZPEC=/T>A-5OV5_5WZDDB0H M83BYJR,9+,M4>(HK_\_-J8*HKK'J6.,>JX(@TTB[I.J(P@Q7B^3XN>+7@PJ< M6?&_+D^;Z,%J*6RCQSU>O(12WZ0KB""\.HS-I/ A9WR/%8Y0;">/>_IBG>C_ MHHDM >_:8B2"_)'4-+@W*"NI5ZSB:(WR#B)>NOM&IC..I?A#1>:%%W?C/V]N M.[D?^NI8HJ2SY=TB+4^3%=D7!K"?;LGKO9RVL4F(N M*^-R?.BOCY&@9)UG-Y[$[_F]_"W][CZ-FS[HZMM7;-^FZ[J1#%U"WLQO7BC;D7+\B#8&X\9ZP*+]J=I 7>6\AT;;2_>BYZV6 MF4];W:+:E#[A9)K8-S1XLNJ@XFTL@;Z^(8$J.[\+/B\Z_M3W#PZY?46'/NQ? M_ /"S)MXMGK=U]! 9I#!X=6\]LZ2>!\&44EAIBO-^Z8?JR^\.5D*[A-JKND3 M[.P5VW4^@V=W;;:FJW[!-V*/A*IE!VH-OM*G/@/ =VS27?Y*$7RLF5DD"5^: M[34EY/3,W4V3XY_F%*L[3*1N&A7;IMVRR-D<655JVU4C@A<51NJHO8(Y:^I5 M-ZT'>Y4&RR>ZG7T_E W+691/E^6LW2R\?%_<*%?#?&.LT"A7(&#CGM63;GP4 M&H3-O_J4B^5CQZ_>YTM20H&;1O>LK_1W6\QDZN[!*H3D79WMHA@ZM&Z00Y< M+7W:=&760U5+<$I>.7BW\GJN )$II.7%(%D'LEL8:\X:1.?H*!A3"W[I#XOZ MDIG+;.0=V?=%Z+X9@\Z\N4E?G<>DY,IL@HSY$W+@YZ>;8_FU"*2+;C^X(<=" MJJO^)">(WE?. 0<82?6N<),S192BE;QX"^*KULU2Z[:3$T79LU8"??P^UP!( M[?/I-S,:K7.X^;2]S M5+7/UC(D#=3EU&6K"]BV@/U3[:M/'-Y+]GA==>)^L M^W>8#?7Q-0-]-3AHOW^Z+=O;P;ORU_R^9XOJYOS>=H>E;>-DA][ _Z3"?,3D&]Q2,G(?;H#>8T^2":9+8Q0**I MH3=,M*;^-T-?2]#0^R.Z$X)2L)OGJ9^D<0!;A)=U >\?FTK_[Z^.I6I>!$JZ MM*9&8'4$KW$X\X-C+$YZ_,V*/Q!X+.>QX4*A,QF]\01"D""O[#>TUA#M3FXD MF*HX(GR=18HV4<9?BMJ6WT(:L, M]#;N,VT<0M;-?824+]8M1YR"EB)CEK") M':QU3<;3JKX()8/'R&#GR^[&NK(C.$_][F3;;QSN7M4[,I6RQ#\E.K E#*[U M9#IROYT3?V16D?'JT7YC^7,F[L3 )/@'&S(T+=!KA*Z186_E!5VR--5VR5'2 MGILHST9Q>*3NM&ZQ6>R4A7BZJ5[.T^R< MLW$J$N5$B -)!'IN'Q7^!VI58DL9;P;*+#V4-]:4]P8QM_L\S+/'N IS769? M>.AB_1)>):>LA.^\@YW%!O?P4R M]/UU=9F#KVYEQ&J\Z+&"4BE\JU/\W-MGD3L M[#R-H=#I(Y67G-1U"HK"-K#MB 7?LIN<<_IKH%&ZD- SEN K#\$/EBQZ- K+Y Z<@LBXV'L9(U:1L- R%X+/< MPL>);EV[W @X 9.D\GCIF#X":5%UD@Z'-&H2].^JK_*H'DD<(:>F>OY-0[_F M\E#B0B?)40=WPPX4QE&W:7.B]8[E'ZDAE.FN:'$*- RL3M#T6+-NR,;;]A0< M7$;Z$]MM$<5.Y3 /VWK5(]^OX[\_D7\RE *Y><>F7\99\@].0<)/$7 9THN# M2 G.[ [ND=M"LG@;^7//K*DHAW2@I1=L0.%',2E\?!"D;IDFG7$&(\W3 M8_B?0/F#L8#C+4^=KKKUHX##:\N-4X2P^Z-4H\#UG>4?]7V5EO/D?))J-R1^ MD8OJ%!1*Z>U>D*5 X__R>X,AOJ)Q)2ZM/VZ._S:L*BBK$C_V&]"FUX"GK6SM:#%=!2!%)HC';'I@#1FX&J!#RJQ$3/=_?, M[A I.M'*'\1'E;W/(42Z^K*>(Q4(^?4;D(/*[@D1GJ2=N=46HJS> MP.*+-G%R%(W1G1Q$2L)+=C B( =N%)T(L'=1]1NMNQY9']_BNC->%9^]MK>I M]]K&ZW=XYBW;GCLUU4TM/&_ 8>!:U\?R]2>T1CU]N0^HJMV(?):Z8%.2;;"; M *'97Y[@)4"$7-D;S);&9/EHA>8\W2)(D1,EHA5,\;YL(J.=+OM[?22W-Q9 MU#GM5(]5A%[]E@Z]B);2DH%H?.;YF:>%^4.\ M1Y<3,'=)J>^O;.>--4TF-/LZ?+MZ5O!@%'AS? O>U.@S_XBT&*XE'7P=B"!G MVZ7S*Z.OV/VT'7"6*RSZN3@'Z_T$+_54DLDPF=/%P%^>:2#13O;!=SM]%](I MJ)[^FV@TK,X-7VE'0./C]"55!ICLA/5Z3<:\QHU' W_Q6L1@QALJ;_Z]I9R> MH5>+NV&&\PYV"W8/= OT9*YQ:C\^ )\D)>U<+ >VS(&,("(V4O0RDHU\;$9) M;*#8'8M MG.OK]*Y!17=5&G>J6QHEJ_OGMQU:1PK"?E0*<'3+'@+A=3R%6MDLK7,347^KA%A@SCV#///->/E;ZL%!OY*T+CHMP7) MW?6;]D'?TA<&KG#:=X$OM^!TO/'=27K M69.Y.]MS/(7>H27K*3.-A7(UY0C%L?Z%M3TQ4M"..,6-M(:'\2/U*)A8%6MY MJN.U^N919?B)]LB]\;:[SPPTH)&>%9Y>GCNKX\HS-R2UIIF3%W\9^I?!^+UW M?_^B)9Y4H\!(]@D:#U+X)!WM^G(Z,#\<3;^+O$^TVXW6DJS[.KZ/%D'TXH=N M-&7\<,^*R$TXR'=V%S^HN)1/B%M- 2(4(XZX3RDHDY7H(BY9TD/^8X[NB>9S_E7W=: MV*NG.U'X)^WSV32L#V/SW]+&-%HWT$R__^X]&"+*PO3&GOS[=V76L;L"YOSZ M\EX X44__?GU*PSWH-V+3/7^U51MLF/Z^YC_3;/&]_O6VVVL&AJM#=[X;+$G M>Z//^=T,(U.:V89H?5)" 44UX?H/Y8TIDB[9WDK )^NZ[=W*EV0[_:KA<-!P M>HJ=W49LKV3M'(Q/-_'!7L!B[4C$T&*TR@@_E-6S7IJSR+U6X=^S297P]U[@ M+]8.<.\O$M.P4-=: M=%T8/)E)/TN;1'0EZ@QP1.Z=@B*7R=;[9"C^Y_%:ES_=WV]T*8GM\+VCCJ&3 M-]CGHA=0@Y#ZI*@..>2#&@I/(:%2&I>G..;EV2;O@O$0J'. 'W&U>J;HP,L\ MCL0+OZ6HP=,]'TAQ*'P8T_X'/X[JMO\JFH-P[\VTM JK_N!JD\3H9@UFI6>Z M:,8>WTV\74_287L@]/??ID66;WAHD7I>3O_:OY@E(]\T\BDH?H'/+7@!PI+V M[!]4D$R[JSCHFR8L>_M3"X==G5[Z89/).VWQ&^\=L<<74-,*J%Z( MT"F(\-2C@[^5 @MO>TBHU.GLD!W[^S5.W\%K46\B4%;,-LYJ5.2O;.[0[^RR MYY8R@.& ZR2^?F1(L>MEG M-3CAVS+"BQ^_EBEB%3[D][.QZKY0'5\-P@#LJR;#_4(;KL]1MO+7'2Z.M=_ FFRE$[0H,-NQ^AS58G)_) ); MKTKEQ!V\ $*69/UQK\)Z2=@P$74R.CH0R@CGR;#UFP'0%BWC*!'J+B\&:JG6"W>Y0!NCO [D? MJ6*3,/T,XW;R0DPIHD&9C6U#E--S/Y)<51-ZL?@P:C_4 ^6-:HP7(<<'B@QBO*AAL1,Y=BPX#_OJN(D M/-8M?SZ((-I5?8GV*T^4(I) ^IJ-G;,\Q@=IG?.4UOLA]V2<,%F!NFYK*Q]3 MW$I1B;/6%02JH?#\[>; ]RO=B.AA$R::5=@2FL.=O"O\K!F+1B5TR\#Y*"QNB MV* CD2SIJVH&7OZWE&L'5;Q$NJ$,,3W$VO[@^D]E5H4'F&W!8S8 0([)W1)M%Q8!B0U-7 B,-/L)C M;6^W(;!^ECH=Q #]T&F-IFBQFW=&1*_0^%"C$+)E_CFDS,29L*(C183&.WB M\8,R,B9!;CB?L,CYB%)HC(/R!N3Q_\%JBY)\=8N-4G:*-(;A( MJ6\!4->5-1+QVVULN2V9";(CK$@RKY\J:&A)OQS(-;8R]NSK^%G\T?65Z ?[ M;//0@QL_()Z[X; &2-=(9#XO6$&X8:WG)(14T?2IUWBBS8TH'^W(G/&0/%Q( M.*$S ;(KGFO8I]NV_VX*J7Q4;(^ &;6$V21;UF&_UL=D;P*XKE?_Z(4HGBAN M JO\(%D=&S:[:H/+7&"Z.ZP4&$:2&A]Q)Q9F/_VC)6638#N;:&<9R2E7:,DW M>'>PIKZF64]-!MK82^B0> WV^T;1B1*Z&$%RO+LD4RCZ+O2JHM!:',+_-F$P M3"P1\CH4PZ9_T>S&-Q>\ 1-?+.QX\I4('^;30F@:D_Q*@AR M7\JU(AP4LN832N64[R9P0L?_+@K.VE^490N\)B3GT==1@W_0=##O@ >TT?%E25UY7/QOTBL>Q%X:1RI5.R1%$38RO76;0?HNM -.KA*)AKCW5,0"SP(@VB@ M\9^"NF8H28F7,BY&OJ/)T_JFJ2Q$+*O-HY.%(=K@SC!NCP9K,(;[Q&XWM" M/@CQ$#>E$:XJ$+H879^KY$C>C:G7M#,>M5W9U]<_X3295-8OK2^9+IH,R*$X M"B&2DM%P)R0DBL<%R+M&5I((3I17(#+/:H8^F+ MJ3Y5C]Z61Y'G.=]1F/T,!C@SGJE?<@!O1?A0=< I"KTXOC^,,VML)AV<*2/+1H:M2MJ?^P7P++9HL*;**2AZ9 A6 M<]CI_?KL)/K9R+R?]YPH 19)D[&C7@:P_UMM GA[-(V; Z.4)_XNTJUW"->U MC%,5B"%U+E5 H(KF@RE=8VMXJWNMX8/?_S4G+ YJT5?3)B!D@U -" \BK$OT M(MJCTALOL) 9Z/8)4+4%1HD)])UY_.T3LG+;7M[U@A]0LHAD![GG4W\79E06 M$HC2AHR;8UU0%GMH:?JQFQ>0KOY6)AG\L/<; M630Z$'"^TVG<#\S?&O#]:4,PLX<(W0Q))OKX?5O[C33#VQA)*%"4$O[$@]U= M3'V&? M66!,88XHO&WO=O&Q VU"E MI58D:05^B"2/B<# &*ELA;42T;K6Z>L9#Y"+% M*CI %R6.3: ^"F')Q^VRN<\--[EA[I-/Y'B\+P'YIJ-_[4[<'!IK*+(]V7<* MBBQ/6K6$D0;DM6\L+TG$:BHG:4G^K4KE71@9MXZNU]DF5,[8 /#.K-!5+%RD MD#>&*HC9Z!"EM'%X?+&S6Q= %1-5)JF\-Q:NG<%>XE*!,.;._5G4$55=5VX3@E(3-E(5]PXT/ L):\D M1/P:V,H($JBDNC+EEP\U\\;Z07@59:!,R_;.VZPW!O=@[ JS.P];>IO"16EHSD^,\B73)RFU3,P49HJDA5@.[Z)[@0C72@/#P+/ M6/2YMX!JYY:^?%06) [\Z"1N*9_5=F")+6(4,6TY)>-5+\_KKC&,\6=>X _[ MKVF"*EB6_9 5$P@O?5[GI;JHCN[4:V,@W^W!UDQOXXYMJ'+ (T)2F, A7J>Q M:>*OZ.6-5T:9<+D,(NP\O$/,4]4\!7<@<"FC$DKXY8_K#$!?&2JPV^2]PVN% M;?Z29)P\#'F/AB_.E1-Z>]&OL358')3>?4&VEL+V3?Z<(\*MIPY^H&%8DA'R M>810'?D*[ >@UHRF _7+M\P"ETY,#C=Y-,Q+F=/1+>FZ-ZP/L<_9Y@X)2=WR M,TH'WB>9;9!B8'B12-^EJVP#-OSL,>>50!_Q.S)_:9$'\6KM^#IM&J^:E=L7 M\LMKS-IP-:'DS8NZ?U%(]Z])X4@5HI=H)<$2'=&/:+J8A\;KD%N]V:S5[P/4N_[$YW^!'P7YVK2Z'EMACHO M7Q U[*,B2?07L$;*L9VS8M%F+]3SQ:,R:9.0BS0V1 B-T>*8 5"Z#T#) ]ID M=*PG&"H1"Y8J0M!UM;I%4G44=8G)94&]@K*#$'.X0&'% 1Y7[> M(7A[A'#V@B3A?CGKQ6G_J C,U;PY7K_+A3!1T7TZZ44<[U@8':KPF8#2+;O#%Y6%,41CFO M[]6(KQCQU:SO\.E--FZ!Z9T4_6\#-$"BZ37Z!3I:H+IW9#:_1V.D9S%BX08Y M_@B=B)0H'RD#0KJ'W D05OB"\-29=6$:$04>XOS@MA>"-%#9')LT$0KCT,WW M+J^:!F6VK]91SS3CO9MY&5F5A>+- "3@U1,%.X6F$,,"A.WCV_U_?M[QEK_2 M'.$2G.C"MH^13Y=+Y+'.Z3 -5,A,Z>HJ$>2UNAB'^W'4(#_I+R).R +0[(BF M-XCY+BV>?E_TX[;T/%AWCEG7K*,_[L-@9$:DD(J9:K]?YBFHU";GMDJ-#\[5 M-]Y]R:\AP:?[R6?G+]85T"FXFSVM&UTSC6,#I!JCEJ""UNN-HBRTJT@)[^A\ M9AHW(C+DS5(C4(0T]"4TD=\:?H;IGI27V-NNBURE!$6!I>\[AV!NL M&C.E$Z4[?E:'N6$.#D#LIF[EOCS+ &%_&J_!6NX?]&E^4R.J\?EBT_3VFV-5 MJ@R (4!GI0FGH!VFH&JJ[N@J^2"W$.E,V6[-P%6?F_EIX]'(LX<(TDWIZ9!/ MGUK42[)J29/9#@!4#/WT0P1E[?#OYQX=1*.2N#L[Y)W^L)[K6>6WXO6%)6F54.Q1D'(G()I0&Z&B\WB>1_ORZL_+8C:SF_P*[.H2V 8[-R' M9Q,^+88RT(N^D(B?C\*)!AC>K+$>*X(]A-47=IFDAF;ZT(/X\$1!^?D $Q"I MOA'_&AUWU>7#FUYC>E3XFC0VT]E02N>_S M^%NW+NP7#&YH\2L_8Z4J:16=R>GQ>WCC>6YRZ]=%J[%?CDV3^]K'"7]%CSBF M#^[^;UKB*2B%'M Y2V+>'OD3!_05.$#T;EZ\?PHJD$4[YY,?&T&>H,/1!PI4 MIQ/4'>1];FKFW^]G;6"I\D=5BM4G9K[G3C:.P9#E/Q3ZD^SXK5.059LR*F_T M$3?-0W3G\O^VHK:$1",AGX"Z>]-@6:+AG7';,RH-"(7>F_X+!\*G-!H3*FR& M,!Y9GLL2Y^WLM@1C=KS$;C!<3YO(@S^-!9V"E.0!J<7MB\010")_1[H"J9P^ M;M(&J) L)Z@6QV!@[NB_7+#)DIW5>&(I8>MK<7.>)06&T]]Q',%IW8C\T]_1 MUI"!H]VZ,VJ-^/1-% 3P4DKD+[6AV"D.N"2&G] ;K:B/%LO>S OV]S'';EQ]I_.OW!S;4T0D,B%G]PX!7FB9[!+(SN_R-*PLPX*#?.W59-[*Q%W M>UY!4KR)NY$TE?$QZ+8W/V!$,_>]N)^B+UZ"*?G)$)#$^5S5%A.Y?ZS_B]>B MO2&#NH'U$IV1/WA[5MS05/-34(0;9>1A+.GQU+,V="2,%ZP)5Z2"@:;"69T+ M&0))D<59JWNDA]/U*\V)\IP(.L<6& ?":^W%:.-70L@(&Z()=C1\F82Z2CZ, MN0V&XA#%4;U/E@F6"1922W7,W%9LE2ZS"9>'\YN^$0N,&(O,"VT3; -\$;;U M"M:V*E:=B Q"T__V6N7/O^@;R6C=5JY@4JK#_L"X^,,*?]KEB:-$_U0BAC'? M8M!'J=S4O(B@P9?%K: F%"BD3<\;_0E]#_N%OEMT9NT^8$B)(^SNN*&=@@F[ M?, X 1./E"YT>(Z]$OA5V!SPQM%N?_%TG#L%$98Y!CALG/_#*JL MG5OA^H=V9>-"=[)?'J&*=7 +GP4\5N<@]:KS\KI[=? [X"_I24 M[D56Y%=IJ+0=>?K#V AU\A,N,U@>TAL(VB#:UH#//Q[[#%9MKN\[\^(F]*3 MZID\;N"8/-)]7;GY#.P(G)-"' &+G#J^7->^78@.G ],T&LC +P:+ L!7ZGUXTOGPO\D#P04S=H(>3HW!6 F,IG6X8J'"7",H:K'B7D M,FO9)$;>4G\IXOE4P5IFRLR^@=P@?EGW%)3[TZ7+40U@>N^2 WE+AG9Y"P#R MD5\0\:PFO194M=+N'"CS)YM(]RRS OR_ 6UBC69/,;@DEOY=WCI/RP';"P@ M[ -O!4KPH8WINB'D_^Z/XQ:X>T]B8?4?U^)/0;Q&#!(@5;"0 !300R]%NXE2 MH @SK<(N6/WGJVMO;\\.JXU@OU2O9/B.Z_,5%/-:-S\EI ]2=18SI+_:(^BCMG;2VI" M6;2 P/80W()@TB!%I.7CNE3=H.A<5NS\]\U+00_/O2_)KCDG)H&A4ZO.1;H< M0P%G@U@X[()[+5#R[XWY9*"D?'W"I2FC/=F$"1^/UG*IA8(;489-[VNN._1= M@:D2FG%OP7>7P)IZ/\U(A[$M@;8^_I&V;=KI2NIXO\V"R#X?\QJ;7)NAXHM2 MA"_UUY?;2VZF>HL?>4?1;@#MQ#-UYWV+BLVC=YV0,#$MS]'OTE!'LRZU5!6; M">)M$E[P0*/B.?U3K\7U$(OY5/0OVMK7H(MA3;M)__,;#%1H*T5G>_= 5GYI MC7H]3RC,J&8LX"S$,X;EB*Z[[AFP^K&_IR"!I)U9N>*LQSPAI0_+M=$]#3U-#-&IXF8"/%,?;E>RM-XI^:&Y93E^IWD M=[TB)Y]L#%(R_'_G7T)==$ T;%/-2-(V+ZA"F)&:\1L<=@M D]?^>57+1#@+ MJ]3Y^NGX =G',B'0A*91N"QQ M1 AIW$T>%DUHCBU1#%PG=\"$6'52H0H1,OI+4,8]QCU,;+69(%A9ZJGO&":R MU(Z%P1P/O4;(N2.VU8[=GB1/64.(*W#+'+[.(,H0Y/A*[P MZ\]N='C0#@.[\7IBSQTZVK=&P"^WU?YJM7'^AG98EW&HD6*N1ZI]2I3\%,.C M]C'R6B/?QQ@N':[;/7=P'*":-V]OZ9V"'H#O+ EA<(X< VIVMU"S3JD4]71G M#8^T%_.JW9+ZPA^F8OU6+"0NFW01?NG%,;S&.=VNR?DI;5Y)>PR,$#M"2*JB M:T*^>8^<.IH)87VUL8'%=BSOEOFD+!)M4IU6)[AUM'/U/L2_E#(MHOPKD1=- M2%/3KA)).Q\K6=T^WGH\_2\_-4$B[)UO_5&.D)";-\0>=0EKC%U*0G']0$*/ MO8 ')(>ZQ ,H/4*LM^,VF>H7CQ.-KOA;+LS8OT%03WQ97TNY4Q[JFGSISE%: M0Q[&RW2S:\'Z%"1_+%H@NH9Q/ 5-M4.7T#WR_/];$(.;RDF)^J9DTTO,/[]9 MZV')[G&[?3@3[1V"<5S/ZDDJO9?<+6T-M^4I+WO>Y.TMH^ICN]@^%']P%,[3 MI(#TCK;A<<936;JI=U.?BD4,_ND0&JK]>3%X,DW M_OIERIE@F6%>>XMZT3= M)YN3*\D8?4&-Y+CP6]JP0H0N_I_.12#SF[U-OI-;?%]S4)P?F*2,&R]F?F3S MY(OUS$2E91IC>H+'C(N:L^2HE]94U:4<,7'%/)<\G5XKL!UVO;>43Q6&(T4DEVIDM4>3\2>(S2L_78_^'%-+22!<# M5<63 6M=PAA86R. T1T3!;]FV<*B#RV&(&3#HQJ9 ,;.U2V(FM"ZT;VXRB# M;-S1X]%K'^JU(BBJ8-K\\;TGH2SNL0\QO. MR!=W+%^]W7<*8K8Z%D"PV241#*<*BC<%\N.I!AW2X\X-#I#>.;=N_FE<:U!B M23.%5ET.[Y"O=P_\Y=8S\"E;VKMQSKW5M92GP"6X""W_S+J:W9=_))RJ^9YL MQ>73(QI.0581_5FX,T!^UG&5U-$06YXP3(ZM*V#.F^E/ MXH].[M;GM.2>/A3E("#%NGQV$X7L\ O7R=[\5J0*"3[7'$&\/818S7\*JFJ9 MDM PZ?$)8O"EC^0/Z23T,=GGJLY6]SD5[CJDM[&1X$0+V 8G(YC:'F M6 TI?O(.)4EU QX2DZX@,$3YSG)92T@4ZL+7:=(X[?H6+XH#T$43\_F!'MHA MOE4[UX/&VDR147P^9V]+2_'^[(CH_S?^?^R]>5!37]LE&D4%1(S,,D8%Q &, MBH@@)$Z B!@!!2%"5$2&"!$!B1 2%9F'""HH"/DA B)@5$:9(H1!18S,$H8, M@,A\(A .D*'C^[W=]^O^NNIVW3]O=16G2*5V=IZ]]K/7L];).?M8]WQ_KL5$ M/A/H"3-(GG/];7PK@#KCN^H.(IM@JB:4Q,H*%O 6L=77/+G(T[M@(JRV.FDX M"HL3/N;*ZS3..=4 V1DBH]X0DK)?8+_OX>\9&]*]]U'3>XA^PCJ:#_DA3 NA M1J0C-$$,-Y.U!8M93Y0#R8TP1:-]!,T1BMS?.T(B..3^)?O2#^6U/'(TP?(J M]_2O.@ :_W*5]'"VO/W@K@6P(&U%KWOA5\T2^0%,,KW3Z;Q,/@I@3*>O!MJ, M8&0&"'LRF+@8I I!_B4^ILF%/(S?CRA**,P!:$CM[8I4U=EH4M M6Q$;V^9%AM%H5-3!;W8Y&5=\KGG'MKV_^^K#U])O\X8?\"[1;X +^\MV>S[C MV429Q21JN="7;RA]^E:?C>)DNR!EC5]TZ7.8!&@23\F4X[&A*+-OQ&)\XWLS MA&="8P?]5Y5AAOK0D>O/SP5M[Z^W%$Q5J M;H_E[*#RKKXT%1/T5-PB2M%]4L&O>KRQSJ9)M5*5&=$-ZT_WD$__8LP::EY_ MESHCM7J5^%7B^TG79SSY%L*8OI9ZO1^B'1K]TQ94E(E-@!.%\6((.X\$ M06P6M9I#']0;8BM#D9KU\FB"71F(?HF\1]3%CJ-+:>YH%^#B$\3^'Q;KB_#P MQG@7-"XFGEE?*5O6<>BTB;;SJ>B9AI$F>LO9@IC]@P[T*HS"@>Y;+S M6D<; M"&CWX]F?0(^A$OF>Z5[N=6ERC M0UE?[L/"!2(#3]7^)+B8!&3N:Q[!2]\#*Y.KBJ)N+5LK15[EJJWAH=OQ9#WV M=+.ACB(\X8@.;E?[KB$AHM#5=03E'I&%Z+/ MCWX*Q/ RN:9Q(B5P=L"JMF_?H1IW+*UYVM 8PWV1^T M>L"5V7<#B+>,:^(-VB[2IF?%D/<,.AS T>1PG5S5QU=5GX5WCSTUC"=LI%T?.MJWG,-8&;D U@I\] M2[\J\&#F[?/59L.NSRX$-K50E").[LB+_8IE3SE_R]GS)GF#G\H;QUS$BZ(F MRH8J7&SMKI'AK7F<7OMG^(]<;[EQ@=?]NSBHBV0,3G0)HU_D?)O:5["QRJ^\ MZIP95:$O-YL3I*%\.^,K^?!5^S-/S0I$W<*K'PS-"D?#FN"ZN@/?67AL[]#9_S/,M%V)O4Y!VU&?5-M^8), M?9FR;)D.29H_IZ@A;^)@HO:5]$\D;?PHUEK[\^-K=4>23KSQU^SQ0V9/$,P"[;8GHOW/,_[YNBG M-)5Q_;;;%\ZKNJZHMB^%:#?]VCFEW :S84\4XMN'6H,$=PA6N2)=R%K^,=O!0@P[6(-&1?GM_'N>3T_9;RB)L9PLX.EG;N MZ::^V)'[06G8!^U7#9NO]6*=E/Z09I! VPG0>/6DX ;HPHF;>TLXRD;%:HCN MO[0K;.,G'?.]T[Z MNC9[:'[>QXOB0#V3YQ?RCN1P MR2NJ\%RY6Q!]CV+4F4>C+^)WO:Q/GOJ7<-92=K!2<_^QWBI0#-%)1R[.2/Z_ M.G@A9OF1^8A #'&+'HTJKS;Z\[#BHV'K/VM;SM\.DZ]#.5KN<1M:IC:8DJS\ M"8]O+*C1-L_>ZJ+1M--6:T)^DXC(4E >B/ET_]Y5,40F_][&E*=7@FN\]GP" M+CPX+OU@KP DL:DT #5TDK].6+CH#Z.;&Z;12EM;CI9XM[!*^:^2#"LR BAR MEU CL*A2>\OVGJ:P GJ$RZ7*BJZTV1N4"\"- DZ)M=F-&O+E>+I06@SQ[H0V MPM<\.N;$04%?)%MO?NX7M#).(_11B/V4]^.-L(%,MEI\/43@^:[*7\TUE>4* M,.(67CX"*9RYY. G%)$"0POO/%-_R<1_AUT<^V-9YK7 A5=U;##E0U5Y-+>%.=RWG9PP=ZNHQ%N4<7.B5@E#.TO:=6Y*L M<6^O+_EE\_:6P:7H7$&O2$K@$=.0#N<@E2\?Q*,N5AUD#K=][**'//M_HKJF2,>K (2# FMV$'J,F=BS;,&#;EH2)O5&7< M+T_G$#%9H<#])'*V'J8S6;RZV,$.\[6 M@='.7U7H")O3FRY_7E'-YWWKV#FNB,@,UOCR5883+F582IFD;2#<^?QG.D:T MG1P/'AG74G [0!_K3]:5=]HO:LG=PZ-JT0[0'7'JZ-TY<8F!9D3C-? 9K>3B M"[Y.10^BUM\3::Q8"=6JTH]PGXZ@[JLG@N%-Q8?&$K[?)NP[F.9815;2LGA7 M;GPS5]W5< ,,T7SE!>#Z%O.6GGG06Q:ZY V6]U2\(&CCL.O"(DI=?X,9 M#7KAF4-2'MTA$_F=\!+J# [5)X:H(J\CM0@!/ 8=^L#97*7@[UU@!MZ-N(T^ M];O+(QLRANI+0GA!%VLJW4]/;+\YA[F<<;$^]8YY3]]SK*%;="[7SJY(&'[A MO3MR>3<0TXR$X-FG,M1B2]291H*@%VUV@\:L"^ST2__,=LONV.JG Y MU6S_?7K5\:ZO>V^ZP%4)A,J]__=RT$\N1CCLB>_WGF5J' M9[=FI=1LY)J6H?*_:E%GH$J9UX\,%BF@#C:.@VY4M9A/ORSL-\UKIUP-,I]: M?R(9+A>#6U;U0')!DG'K]6PD:)E!C^5UX^%[N=^ZX-0D]O==W,&$2+_O6R_' MQ-V>GI-UVM4,5!Q.O+7U6]L>]CC=U5MQY.#-O=\"+P*7!E'PJ;Y$HCIC-8@0 M -)XF2/U<3P8WTOX7+2&8%':46;O?1%HN^17$8:*HG;*V>]$6Q*;X;AR>S?3 MWG*[V$.9EA[V.N@DI9-)U+FW1JFKHW,#FOSA>K#4*T^P$=2,X"(W$+]F0P!: MM$"=0Y$9-DTIQ'<.-/Y ZVF,)VCXO.INTHDH>6%.C PI1-V,RV\NGMPOAF G M7?8S05(+:4"7GRW,J47Z%K6]X=N92 M )2S8I9T&24->&U";$S35*,P#G(O[T/'?JNB&)=LLC96R+JA5*#U\9I?5YMO M5U-?LZ?^VSO(APEZ:VG]5![5' F]N@+-1OC+:9F;,[3JG'5 M:Y?334-=% ];FYX>'=>[WC>BS7TZ-/722382&Z.%R\UG& M&JYT4G_PP;/DW4^,S];<#S([?VFZ-U\1B8Z&)TR<*7O7O^]X9#"B/.[K@6<4 MZB\%NKEKG47NKNC#:28KSH\+L6%/H^->H6W#W_BE[_8M8&[?-(_:/ZA&>'7U M&/10U^<[K8IMAXI?%_>LI+-1,I= N4:F2]3T=33Y7:M>W](G%?/H0OQP0$Z8 M5%I(TJM G-]#T:S,B$.R[3S\ 4M:FMYF:\+8\DH1'#G_L'%"ZWV;=%0QY1;% MOBQ[MYM=C&D]LJ56T>T"!/9LI]@IE)5ZMN\ MNU]$Q'3D-A!0$*]+R8;C!,ODVV M1.L>ROLVO#EJDP[:S.)4T'HH@_A<##DM4(O_^$OM7I6!YF+]&HY%R&7GO2;T M+T*7A"/9RI-7/9 ;9U #UUV-U+FWGAMYR]#W-U\+VL1]>H3CYW4.E\MK'26= MD!'NKJFC\4 :6&T:3AKAD7@A0A>L&&(KAE!&2;+Z>K./JT4U\1N./EXA'KL" M_41:3%\)7AF)%$-Z+72B,VL&Q!!8@AB2D!M:*4*JB2%J=NE]*\O4J5'5IW/> M@?U'6L]J+=C3'LRTV!R[)3/3/59E^>YHL%/*B\6!1^&\3Y:OAV;$$'*S&-+< M\?]T]1@]1>I]'VE:*8K B\'=HVU&'\: M'5^^\K_KX&\(M#:/2L5QM %K7$@Z[9"2;"/\4X6,WCC2E^QK0PK*WE\U;N$/ MB< WC"=W#PVS0 %&X*[Y;R#,D"5(ZI^)*TNKEG-B")2Z./$/)^5^]AK&QEPS M,XNH=3H0@Q_0,P&L@IN [(CPI5S8DOK*XK_1"P[@BR&M7#&$^SNPKK(+)]'^ MC'=S"-8#-5A,I4/K.2B$O>G1FI&2K;#7>E?6I'3-WL\NB&SMGK?]KTC:P*FX M*<'E>>\+EXRK"O)G$Y-[T]/,*0;X6X3L)UII8 M(W(L:8L Q_-L,6G4\7)*%E7YQ-2LV9->AWU03M?==TPN9AS.,#G]M M;#'&Y4_PG5,2PD\K?:T\\;4SX YWZ7\%:2II['EX:W$/^Q;N4+*B:]BW;+7- MO*DU>Z:4##>VA,.+B[7>[[ZFHW+Q@G;PFU6XSY.^EZ6)8UZH':YI5X4)A@TW M/GQ%?(P5?4OSU3+M'GE6*UVQDMMJ(S.L?FT(5KQ'OH.?S1A2OG?[;INBK<6X MV23TZ\_O&]B2=7C=,?NXUI_]86O(9WDSUJ/=OZ(DCX4@QIV"O0+<(;\]5 W7QLBDG);!YN!*ZF7YOS M\-U$O0D8QV6H^;RT\MI,#GPYR5>STGSBVJUS.W=9<^*Q1R+!Y//O,Z]4"#8: M; /KQZE.15J'[;+:%/8$#COD;ESP/2NXRDT\Z].= M!I/C#'NA%#P.!#Q5YX*1VZ(U3 R EDMQ/Z@:!_S-JDW,G,X_QKSL=K B91JL M'I0X$\C?0^5/P4P1P.+,-9/ZB[BM#T2[\'OI]4@@BA6Y6&<]3A_>^<$TS>BU M#]-_.._5Y.%.*_TZ_O,WOI6]/'??E8JG=Z^^N70NP2AK%)Y&?3/5B/3%+6\7 M0Y1)TR=XH:)Q,16%]!A4H3KP@3$-B:^$ZY", -,XW&B#8(+ MM+(.@0.N"(M0_4%=O" 1;KN]R@!^R?I?>2&O/="^V?N[:@\'MY'V=(.YCD?O MD! L;>0-'%.3?Z/G50?)!_6 ID#<,CSVS0ELI2\=KE;IM!HK*_4=-GQO*E+J M\>^;V3)+.=M+O98T=GH4/WHM4G@*Z4U9W@:3(DV3"<9B2/?>4U1GVKMW/4;[ M#@G/?>UR>%=#_EK]GE81/?O]UX[C!QC^MU)/'E17WL1T[ILY]W%+V#[EL M8FF#.JQ@)];%)N"5U,<81*)MSV.W/GW[Q]B,Z??>:\U"DAPO <>^.]I5')/1 MVK0%=7F1U^SRUK>K9S$,,DF/\X)&\]]OF\FR2% MZ175]J.CP3K!?]9+C4D%4G=^$$,>F$BR;W_9ZG.X$:)66+E. M'ML.EJ"&E$+H@D$<1,[KX_D#!'M>3/0B?"/^P&Q FN=-)\?>G-*JJLJLG-0C M.".CG1\R9JR>N!B%?9$BY9LV,OKW\CW [8=<,#)(;VHD1GXNYWS*)'&+I#=W M)9?&!>]>PX6J1;/KBVGHRA1:7%)X6DG!):RJ6H9'D:=OX41?[YQ_1 %F@'[7 M,QR[?[>AVIWT VW^0>O>G*EULMJS?ZO7K_(V/Z\J ET6;=+ #>R_''CHS8U+ M%IL/JM\P5H]V% K-CRQS COHU_98,;-WY*LI_C.;IXG*T.H?LAA7>G)#^: 6 M73IMW/%37^[C7^K9:_,#T]D'4N,O[+UVN\KS]@07*/OUHB J-ZEAWN.@X^." M+VA!.P(F^IZM!KRJ8%+BAI%J4X\^M&UR&D!!8Z9W.NN?=2,]FRNV>W#X2[B( MK'7_>G*GP>G!B,W-KVZD+!F_"##ZE:9OO0&]==L^%8B4W]6[+=C56WTT]@O* M>^G8],=7E', OS?/MV,#4.5VJZ")[//!XZ\N+%S_]A*R]4,E]:(4.,FJS/GDW55''_D#^X'"?J[S0V6 M8[@&/Q@3"MSH"!?$"%D-1,8=Z CQO5*0<-D^JF$,M&4P(USV? $^7KX]2)$S MLS8NC/K4X='YZN+9+%)[9H)08.=HRC3?M< 8L@LER(*AC6;V3/;ER[YH?GD=\?[IDO;-4%D'DD[+\0L1,E,1HMCXLACQC)@2D_ M1D2*WQS$D,VMPH>TWX,"W=:WI2./!0)7)S%$Z?DGM=MBR(6J=MLBLUW G]N+ M6!WJO#]_M^@[37GP JF/!IVN1BZ64%/OVJ>M]!MTBW8WKO^=>5SJT>/=_@6Z M!EL#I^9-<+6)N9J!?)^2F&O$L7:E(>DH"@D>QZ MVI_#(4M3-O]*MKE5,_#4TK@;KT,,&:H@@R^^0\K390.SRKO28V;>4E'4/Y.S MK!IJIG^,P(G:C CP;B7"AB=8HH,UOXO+[UX40[0-2[!ZM/A;S]B[';+OZSLD MMP8 M<&2IU>T_A1CF*3KI82Z9^(J8A6]L:2]186#68^?+M9;^VKT4C"\ZUQ8=XOV: MU&PN<*HA3;%BE@A])-[3@CG.I AJ76T$Y[PAP9Q]QO9SLX"HGCJU\C8[$WV%5$IM/FI% MHA)AJY65@J<1[D,TCH'-K^*!TB%8,S(M5ZKM_+/5EV:WCGW1>V"G$Z;U(GFS M]>V;ZX\Q93Y_.O"5KCZJS!Z)?' :HK/<_J^TP?VT*1 8_WNR0#&DL/3GWZ1I M$3XD_1ZLWTO])UZSIJ=Y]@,B M8QJT)T]BF$S:1GZ\!:JMVD3.VB =CD[ MN?4-19!(^N??JU"6U/'QWW@@*8*++T2')(#0KL)63.$R)/9(*U+0>Q&>'PK) M\VHD^*2?RJ4S][6)E!4_].]UU2M._9&^:DYP]*]L]8#YS56J6 Z$U^8M#4TR MN 52/T1.#O=_DW87K3J+(3&>HD;D0H#'EK_;%28CER6+[W_+ "]F)0O\I5,2 M$MC\][D#]VC_WWC$=%J7Q;\-D#G%X&C@WPOP,&&PKJ/W,(+.%[[S9"AQ?%CF#C$_]R);Z+CWT9/Q1X'S@=W/*>',$=G47\;/'06%A.56Y M;?/S-ZZ"G0 \FF!?3+#C%=N-NDWP^3H:/=09"[,\=XM'>:RXD(&B70M5_C?U M,J9L2[/'+] ?5[9E\9N!TZ4=C?#'400R=N M5Y4G2$TH]@G!P8;@L&CH2[PX__ M.#1@:6#[+D:DT.[ W&N)//> ^;U?O7\T4-FNWMK[VN54HFF2Z-FSLW>LDMNJ M8-'S!)II*P?+V?["&Y]8O>5K3FR!N*H50[ MCR]ZJ=,O+CXS&*I(83]9L$>\"Q50.!AT3;LM;^SK8 ^%ELJA*^]$QI M3QH^8 &EC/<^UEUN+]WDH=-;;%#6>T@>=Z[FGDRY]LZ5SKLE^C5=./G>=%*$ M5Z#@/K&; N!P,U; 7..*9)WWWY@6==*@$LVWZ;>.[N,&JP729H$/\&$RXW 6 M*<2O5ZTR Q=-W(8^&6+1(D?;/.BK,9JR+HI@8&S=YRB&^"++*P69E!;JJCY& MLA@6M_1BNQ *I"\&H"0CK\\W8%:2)IY\$D,,&.IX5!,%*K *9U-BB:I]M?+< M&81UPGD@/2G8WH;NL;TLQ=E,?5^P^YW>KT*(K>XM-U7RS=<#]W8[^=8;\6ZD M;+4W:!K>\2[.Q<_*M\1/%=BFM3[YP*U"1>J5V-Q*J?NBMTAEA*Q !QQX:THCM/_&'\JQ=GJRN16 MXBU\C4C&50Q9]X&7]"T]%/.AY>D_@V7B[&W==<>T2KZ^&%U[>CPY J42 M% )EGJI,M]-?G"[*X[*)0#982JAD <0 M4L.>,MN1+)JW/P[]9W3>@J(@N 7.%*.1A@WZ#\:YR'2]DX%K#Z^_!=G&=AD4 M0R2ZYRKRYS@_(&5?O0RQG26+@/D%/KS0MT"3]5W*WG61?%097W#)WJX)?3[- MR^F-RJ;O/P>GSU4)^DS:O=1O/'_KFW$&F@$U_E9J^*4KW=;I;C12^S-WT?%! M8OJ\+F7OYP\62>?,=&Q2KZ<4J6D4Z7^Y37A^,6'8A/3A=O'[GL0T7N'NAL6$ M"<$FT6<,8 ,;*.4WUG26HZ"$O76@%="XF)-*2J"HLZN Z'N&XZYCZ!*IQDH$ M)KG6ZU?L1OK.I)Q]R3?2^@,6V[;N=.U;4J"QAZ!;"9J'ES ;1 =!4^ZY]X&^ MVO6%;PDG?RR2UF#/?]_>'[XY034!GEQ68W1PUB:E,5(UEW_7LZRVIGO=6BYJ MRD[+D[IUO' EXVJ2[1?&^((@?",??S1A/GL]X]:@[:/6/6G8R"2KJ,+,ZZ#6 MKV2=BRI9!$NMVQ6::LJCA9ZW>G9Q)ZQ#=,_5JK@E8TRY\)B/TG$"HT2V:&=1 M%EWOF\&92Y-FJN'/1E5XP1.VME<#0_[\JO]X[\43+S2\Q9%ZO\0\V!L-=;S@ M:XW\8B:9R9VBOGMP :I^XZ[6XR,HQ06&%PQ*Q)P-^J$3)*&8S2@A%?G["F@D MJ0Z4.-KRL,OB^]$"VKA-:K88DD5DUJ<1#X:TWBH50VI0ZRNMQ!!=W66*2&_O M[U4QY,3L 2(NZ4"E&-)S4L 8I8BT**L>I!\- %H,D4,JD>9K<__K6]0ISR\H MTG>ROD0@FR.Y-P6>8L@_PZIB2!-JO40R;Q-#XC:N(,20'S6)))YQBQ@R_T(D MB9/S10PI'Q=N@JVG :4\4S'DZ%?D_^8]487%DR7![S].K/E_)Z;[&II):)TSX:+@N[OGEB562,E[Q. L3H[$-7@@$8&/2$U1$3#2 M;_>6O5V)/)I@'/E<#)$A-:B- FITR:@HBD@?5*P&*LZED;:I?L>4FPN=L2:_ MQK\ X\:N_J@+W KW<4-^=F0TZJADNN-I.NYQ+MGOWGW]3_&WZ]/DWK]B;/#5@97O6 M@VMXGS?Q@' NCH19C\5P7$FE*,$C"66)(?SM>!LQQ$%XF+9MA** IS<16I*] MFOO+2C6JW$)VL6]UOW9H\.J/V/,A<GQ+=63J-VYY*(S]=Y));'49S?Z2_R4Q\X]G-?J MVCH61]6RV'/QTLU#JIKKH_GE>2=E-9Z^Z2V<77"P(MBN7/E[#]#?P^4AL9/U MYZ1HEQCR,XH[)[0IW[,4!I"9:-%I4C-L=4NMNQCRFI]W3(-5VBIX!+U/X]O4 MJXLADRHO7=[UD8D,V)]CB UB2+\.Z"UIZ!SG;MI$CD?*UV\&G:=:,:J$"/9< M=/;&]]5=TSB"ZPA-84)'&1C+FBVYJTK)8PY.N8T-I5'D6W))%JK.YVW-OP2% M'+K5J&-S\9_-L_$\Z$-66>OT%._7JENG2$9P!SS)"W<$QO*>BB&Q-Q$:A%, M)>GM@IV1M>O,--P$C=OLQWQ2'5$^S:_WIEE!3V_'7\Q^0RY/49[Y9;QH&?YH6.Y_TC]OD1Z<6=AQGE7 MWM<:> 9J_JSS/+:#-K]W64H@J2Q)?S?#,11#1BZW1A*WX=6X^OGO26R8.MZS M)0VAP]M9SAX*FVMD_LJDHGV&C8"QSZ4\Z>@0VX6VS&?3(3.*TPG^+F<^^LS= M--BQ]_4U4EKU2O9I/B:8M*QP>YE6)X8\QWR&C5$$/G^DER58:KRWTDJ9KO\M MAOS9WO9+M"3R(FTCI9%XN?]JY->L?-OFPVJN&/(Y!IZYREI^*K@ODFB\%O*_ M&A6I?,%7M@YO #:%;:HWXY&C+;35XFOM7^'A](-XBGO7(3T>-$%P?&]##AYM MY7]N\J339>TZG]M)!%[UP/'MCFN^Z+3-DL60'5KUN#G2K^#Z?X_> MYA&R#0GVQ.\:)7LM27(Z93/&=.F_@N2\*S?5,GT()CIE1F -BR'?J*/0/PS1 MH;O_T>S26S@7UD2*D:Q7@?I;@358,(+;2# #I*.W55;S8$D$''4B6PVHB/0/ M#??/9S**IICM[=G/"TX&OO;H_]F@/_3-UFBHIZY:-A3P-M89E)S]21Q>T_OUYFR M(9UO;:0PH[?RM8HR&-__!>GA_S.D-PR=%MV]T3J_=U&F2,3HBY8P;K%N>Y$_B(;8?26%053/CV.A!+\;% KJN7[D =8B+JICB(& M8I\8(O$SE+]^IH6VDC09/)WV!:Z7ZGXT#/J+15UHYZ<+_T=]O_NF)[^(OT?V*HUOX-= MG@A!G'JS&C/?EAX:6>-W\!]8VLBT !O<2ZU]WJ1BFO,NY06Y'_R9- 8.>EE<]%JW1-3QO[;7I-<_)S7"8M"Z^)-4W;#5TW'X]U4SA:4='?/6CKZ>W_5CWY-^_T?T]\$LS4#%$ M3VHD79@R%T=9B<*&/%X]),E1*"@I8M?4'I(6=;JP:+Z$:&,(3 MY=5?A!FDT1B!9!6\EVM$KI!]R];\K9+_HU\5#JRL\F\5CT=*BGB-)-%GSM0- MU^KRTR0=P7@VHB:X&FG2LO#\ALIIWM\ V#A) -&DE2B?I\N2;Y:6:M9O%2A% M-E7\D+=\&U"/)+:I5L05-08<>@[?5X\ %>5.+Z*]]BR97T]7M,Y(*KNIE]U> M$"43ZB9T$&8C1^\1Y"4KS!)@B"'G2Q1K<.J@4@-,HAX[G\N,P VB1[/*J,0$-%A63?T+9)_%+7(/I1:!Z?(0Q';=JBO50K0.5 MV$@-@:,[E&O03(DS-TT8ZRUCJ?X6:72&^"// >U938X#OYF_:(??AW46*\0 M<$U2PW&2+^G^L$06/+@/ZK+G9LAJ,[Y &_N\, G)T1%6EE.E!6:\%V)(Z4MB M!VS+*Z"O>;G6"4['R$\,KP.KB-IXJZY6C9O.&4%MG)\%Y+-]BL>Q_""AJY]; M *78=XEYKN2JUQO?L*R\%DJA;_738C4F,=M]4Q5 MNUKUC)OFM%Y__E:0"J338=$LJ&"G2 HPH+.D0(-/?S)Y\$@+78Z1%)VH],1O M+/J-'C!++NB?@ I?ZP6^GBU#^F]F^KJ>48\IA+3.A?;26HX!D=ZDP>, M.=\\Y'[0 FC]?9R"!DLW2250^R3IVAFA"[J&KUHV<\GQ,%DQQ!N5!%.TT.=B MHC5LR"%BB/IOQ+9>(Q,Q1,L-G]HP$XQ2OK/]&>(W//M=O/UHFE^O7$N2J.@A.G(\B.8(!A5Y_Q%P7[#N6SF%$CG40 MKHC4NXJ#2?*5\<$%'>TQL9KT%>OG^1-NNGZ >Y:!?=?TS9OV=27%"M9K!'7X M3-'&BSR6!^B^JH;7;11#MM)\W8T;,8HB.+&/LAEA2G"5O&YPLVG-9&D3Y#+/ MU0(%#4AIPEW>]Q+),/@'/W857^D9YHGV3##+S-.;VI7HE>:XZ)O[",>J\RD[ M1<]7@T1]1+-.R;BS8;(B!+%/E?3!@#Z7-'Q46%4L<%J]]CMC:?HI-\E[Y%SD MJJG?L'8">S@&F50K52+P%&8BU$&J8[H3#Q95KW_ITE2H'1>JC)=VZ2K[7+P/ MGO.^1I05 I68$.ER4@R?)5N.BX+)AZ"B[MP:0/<+C+L)LIQP5DSO(]=!S:+3 M1K7J07FVG,_;RZMW_F(>6>@Y;;#3YZF>?KP?:WW]9JQ(IHNHCJ7)UJM/D>07 M?*??EI%BF+1[ J-"O*[MQR[OU"G[JBZ"P=T\^W]^,@H&VXR:$WLK%&RQ%JGV M4C:ZI5N@7^; '9NKJRNGBU:M\8]M>5$QS?.OB8.4\OSW5T=F- 9.=TAX,%X^ MD!LN5X-2F^C-V">4/E/!>_M[,=,G^%XP]M*BGN@[YIWA#MH1T@T:N,M@!L:E M*HB:2&I44H =*9ZE3?*#,0ETBVK%X&]/6Z"B1P_H )S1D&<0.GNA:2 M-@QP:0],*/=U- $A.6F1L15?X%+UCA>\UR(]^5 D25]2Y6TYY UX9(-J=1+E M@<" 0Y5QQ6H,YW'M/1ATCV83<$LR0QH?16S46 M'UZ#[FMUXWF]S5*M>\.TX:/]TY;ZYAM?#D,*5Y]]O4?:SY*A^3 &;L#E16V4 MLM[253_!&5Y D]:M+&9)\<_TDN4QA(W@B>(VL."'>DCT&;:1D-39GO,@V(" M]C4^\EPI\'!WSF326_J^IYZ!GIXXC?97/BQ)!WK0WN M,/YC"M\$M%JU%IP%\W($5X5Y-\OFUC,*P>MXZ4_[\=1/]6L[%UFQYHA*#DQZ M2&#;)]\3(]!S*\DW8G?^2E0W2II6%.6@!2J@J7>>KX9\02,F^DZUSOT1VWH] M'W.3OQFRX>E+PJFJNKKN68OP5[X=OG;>^6!GA)UC=XALK9/W)O/1RNJHF0'6 MH26G+P:)HC[2A['Q&5>VO5K#89H&(0CP/>0?C"U%<7 ;"(K@8\Z<+D.]P,*)_1@P G.V;WMIK_^H::^J(UK"BO6;A"5B")82 M1X0!!@^),")+QX!G./SWF;JMDZ0/<]%(7VVU3TA9D[TX!8$\LK1G*39X_A7> M$'01;0D7[IB[6('8WI6XQ=83\>YJC_]LP,+AA+//667C,SFK)PG&/*I 6;&U M&0G\W5&]OZB5 J!HFP5;?Y"\D?<1!@"F41OM("PB=@&4QNINBC)1UVW* RH: M "E!J\?!SLDEVP^="-7V7%?"GH_=QF_Z4VZF#HHAQY"ER&E3P(6/!=87/+Q: M40\V<*/!$BH!WR(88T/9O]Y\?"D%)CQECVPXIA MM1^/&S3@,4:',/+]S07,$UY5W6_G1(D\:",U2K2/YQ)M$<*E18O6\DR3! H& M66R:.CZF0:3=6WN1(UO;DMD.T&)#C,RGG'_HS;OFL?+F ^M9D5I2@PZ>IK.C\T=:<7LP6>6U&]>NZICB"! MQISCDF;('#%D$[%W@HON1WI38VF ,PXT,&W$] ]P6A,M]K+K,"A )XE-E7XZXM:>0ZLDQ$[1Z[>UTNQP MUM8)B@+<0I-C1XO5V$>^RYF!M9HBM#O&>B857D/L7#T^@K\O6/==)S\2\M0\_3>G/[R@;0_A=#P@?JK )Z__SR M?2&UG-U!\V$->#"'Q!!?=:0_/$Z-J"FI%0+5 B=APE50_34(YZ@PZ#6L2(0! M..3)SBR!7^KU!"X@3.KJ.A;BWAR_K=2($RV@FTYXW0Q9!*_M-5,Q_,NX!T#O6A@CL^E ./$2%!SX8V81:N M!']BCGLSH[X4$'B K"8=R^B5B)WN.N@AQ?GI/^ZM^I3%6P@Y@K;&S6JX8 \I M.M(FLQ7+.^>^#:_4R.I/)9Q3FWA#CNV\E+1W^@,>\$NQ*82JE=DTK14=JA7] M6#UA&#G?QS45*!8U2(IFO=FD&*),-!1U8#0$$<"2.TCFD..8C$_M-G0*9,$= M>KE;H%#\$Z0TZ&SAJ36390E:P%+KG +!$/"./U0'=P,8=']O;M)XS*'^X#H$ M-:-M\"$6T,8<''T'=(QBOPG[#I.H/3$E\KN D+X$_"BH!GA@>->807!9, M%2%E\7,BQ;U&'NUE2 U?\Y:HPA:/H^B>\H\52?K9G>O23DIG*=.25BIGU%9# M)=^):8'&EHJ&2,H6(5ZK>J2&"P3]59T)#P4>\AYB(YI)< -#N=18XN9.DX_U M^_"1MH!^=LGK26][WM7W'22.C@XLYD1\P]B#O0F9O_4[245413R\8?B@N3J/ M]%!@PLWE))'.\;RCR7&'C."7Q9"'X3>*,2!>?CJH#H%'[B@DG M>1L[N0\&6Z)[\P(NN">>T[WX;;"1]NCMD0U=9'=RA]U6*B;S=>;L:W&2-(R@- MP%UY7F((.83\X*^BT?:KCHD)\4>U9*33*=(L?*E##V';#^3#10G%*PSY=$ZI M9<1$ZS"'!$?# ^_J?X__<8)YLZ)E%W^@F[B1H-EKL7L$NF:2)4M4]R-N *-* M//#IK:)-W83U'/3<1OQX4UC24))01!N!;AZ<<)S0T>^=HY:U'^;/7>PMGL.] M#5A8U7P^GHJU"TV46D[GC0N4D?SJ3N0-W "+_Z";J(MG<2@S\FPQA)G)'O_$ MT!!]JQR&@;AP:8'28S8NB>"0?PF/:=T"51!#O$ DUR6Q?B]HOD)W1JH02-PB M4G0*GMSD@,JSY[#D\*$.J7/C9&8NES&CP&L5R2Z*(>LW M0F<@)-T<(&T&7; M))"N0]7QL&:20OTN40-,F;@+_Q"7F843&3H#DXR/&(^2 M*#"#10JNHC OYU95<]!:\O>O3Z05[Q]FILZ?6.'?O M6OM^ 7J?LJ[6@#WDR6%$U4,)1D ?G;4E[^N4Q-V((726[&_1IC[%Z6LS(62Y M":95?5QA0DYSX_!/QOB#4_=;?*38%.8X%]:$B2(!9^%;\#2V]$P"P,7$\H=5 M0/L>3#[9X!GT(PI@R?3?*B1&%F1\B1)773(AI?+D1:H MU/#-@"Q&7/V>*>2'N1DY@\9P,206(U>+Y:)D&6Q2(JQT+L;B*. ]TEQVP!Z> MX,%R[3!:1&W"^!T6;>+=>;Z.&='\E.3F+#%RZ[W9541-5U"W\3!M\\R"%S"J MLZ8"Z$V2?L &_EB-[HR"1KW\8+_94OV*\.N$[Y6*O6JS36L0;K^"R?=CBJ;UI%]:N#[H.UH6>ZOEZ66B[BA;I7.XCE=PE++9Q6+1K8[4K\-SS5 MYR,X**GA.D)1]!FA X[N +5YZ&8UF$QM*/O(8ILD4&9EI !>0- %BS/.U16U MF514YOTVW]HW4[8J9W_&TLRSNM-?#"EHQ[!C&DA;7$$Q!-57OT6PO\\08>CN M&\I2GBXG0T GIS(P/3QGH)_YNY*RQ8@:_)S#>SJ<@BWXB?8-1>C:G\'*&-[D ME.%S*Z(XS(VKOW(%M("K][&\=,3+@ZMVIH&RNA?D'4+8$R\F4M4NW M.C1L3DXQ2 RV/S@LC[3E'?RG=V%*9GM9:7WTL%XBA'0 5B$]\WS51[!-^(KF MB^E?LA'F(O:!?JO\8^!N8.T\VSLNGP<7*(US*J-%EOB$)C%DX[0%>@231"I[ M3.PA;:F'^A%- 6HL8EOK&\&AQW1:J3"I-XO=]\.D[LP?2U-GBEV7A97P# '> M1W#EDJ*'(3P#,L'$G\W0PHKD@>^E(U!9U\D5[UA#@3$W F536ML7O-<^Z!2M MIRSI6I]=]Z^/'RJ[%^J<'+KFKD;M\X?/LE,,4@N21% )TIFO\21G, 4HY3": MM%T:G=I"..ZH%I$,P(A?A&X:_ [4+NG ZOK*VE:S-.YF#P^-I9]+9=KJR+C^ M?/:(FGM^C<==7JC(%BD9TJI!ML2]=^.I%F"-&*)'X9*$CQD:8LBD:>$/ MZ>>B+\@_ :3UI.FG! M)PY/6U-RI<>A_/3D+(7!6T:0O'P5^?T_.\J!_3\[> MJ#/FJ E22=$P/LI"10QY/?SF@>$XW8@&>U4+9(&)0,%7B"= Y#'D3: M]@KL@54W<&4%&5\LB.!BVS?.VMNMG*:]]E]Y9EH\E+69]NSW@WC\T M8*=?UU[2Y'@\X#"\0'#$(JDQG) 6K GK\LZ$:%.W@ &$Q : MYH-RY9TQ$I]?2N-H:O@-K;EM:)W)=[BUKG&[0?LQ6#MLQE12+#: 71(K1.\A MV*\:$WMXDSJ;0!?>DDB6Q,;TK[9D;\C\E'T$\+Y_#:06@>%TC/K-VJ/!&>ZS MF=P(TR8=77\W1O/AOI6T_-)!-,9WQ3DW;UZ/R.(E=_&_Q?"IO+[IPI>DAI/U MYGAO>]!*@AVSF^:3Y-U:C;DG6F\:7[]=8%L)#O%D^K$:>4]9]"_!*+D&U4Q$ M'*>F#27;[QOH 7K3GC+AU][)C&-:^P<^Q^DZ%= MA$/ E:Z00H3V70Q I3B_UX#WEQL !BG2@NTE=Y5;Z3JGD#^C6]O.WE'#0 72 MX5Q+NQ:U;!D@:3Q!4F1,[R_BE-WQ6&M*4UC!@^Q)]#A S'UK?WWEZ5+4,/]N MP !]R<71=^>D:X!\3IK-[37+X6P4$SL2FB2Q/(FB+<+7>> 7@,J):64I$[\P MH=T.2_O@B\MI+?9P6ZX^ MFW$7NT$0C*QDS9A=7=45]61K=")]24DK-C.Z )E+$2C]&<8HXRDMM ^P&5T. M9H,/J\RTA0:>,M%VX?PWYMXTJHDL;!>-(P)"9! 4A+2BHB+$@4$94FTC(M(0 M%0%EBHK($"%M Q(A) I"&(1HVT(+0EJ91(2H$%&&!$@@K;:&&0$EDXH,D2J5 M4)*DN/%;]ZSUW7O.N=]=ZYP?YT?]R:KLJGJ'YWV>VGN_)>K"#B^@VIT]TUI( M=V"%$-_/#(!)D)9' Z25D5!L8POX--]0>@?U2Q%V WX9[,(+,WH,8NBNUI+: M)6WS<=<2]%S:B^S2*Z+#C!]V7\6>2_#&ZK\)"OZD:/(<+I%K@N9D?;[PGPNY MS]]TXK4J$2$&E4#2>JMR[4&6JRQ[.9@QXF"833/H6 *^; \(0S=!OB4IQ.H) M9.,S\%5=KGXNCGNJ.GJ>>B?B@?>9D8Q:>5Y%O^G.M\'NVT]B7C+D:Z%QA1*V M"M<$X/EZC504_\TU96&WRUG;2_*K(V_MZ7^X>,)( X+;YF18S3T M*I_;$)B'6TFY G2OI&&JV3HZ0_@.]P:F"'0P$97H3B5= 0:NPER:.O@TVB- M.?\X1F5.M@:QG\R#%=$LS0BS)-+BU4 U.893@] M$Z,S4LL9AC G%A!\:$G//5JZ_! MO)7&%^E1UK*(@4$FUQ.7*6[;F(J[43$V&AP6/9)0SRZY.=!B:M+= M:7^DZ1)M!V'-T4'\B*?B5N;%TSE[:6+QCQW6^_U>G%B4'0&O!6'3O8C#@;.' M?_/=I;]5M)0KOL-M!/C "/87:&FI+32CL@ZD-08T@Q@!]S$]"]FH"2\<10_4 M2+$5YRBIJ>)7GI(YNFJMC)8[9JRNC^,XD($.Q2-X4MAUC;P!X0F".DM>WRJ+ M+F)DDD[WQW'O*;GI&*V9F40]7Z4$SPM^Y1T(5=(A*_]^.Y6N)*58CI=B,L]) M^E1[9:]^^1R[=;P5JKQ<-3KZ)JITZ[,_0N.]ZM/,B;I3Y-/[ [W!>(FQ)C+\ MI&\74+JX=3Y0D$O4M PNQEY6[;3F;VS(^3<:"JJZ*O(F&=JV!*!.>*[HOQ(= MM>SQ/?I$*UMW1^*.1)<+%-L+>' M>@$%LM)4&'&PS;O=[6'&X%#ZMU?>QP=Y-C)ET)[#0QT4P/:2)^(X4ULKN MM3TG;AIT*!XBM@;ZE>[%)NI6$G.??;R9NRXU4H+OF#$@]_%$AJ[[0%&;\PP? M6-&YW=(8^OQ(/*,_2;4'^4;:^[O)*9U.30GS'W-7WKW(?S31./C\IZ+#XFS, M;UI?&LLT$$Z+65O70&#$(\-A27*G!U31'*W>MUICV *2-F7/<7LFB@=199*W M8TMSL+"GJ?1?'+;7=()D@O#"C.%(+ ](&]L"VF6 S9U4!YH.CY8\(KCBF>7J4PV? M[IT?I.E$SQ>P]0J*-Z5=?!P:$BHD<_M^IVR%0TT9'V 6AD="577:Y"[KK8+_ M+-4')V$DUM;V:*?]<,N9IM\@XR>Z$>LN$,_.WPC./=[[UO/#EB-'.'J4G_X8 M"=Z+6TUQ3/%2D7%;A3'(P?UDNJT^ MS_W5HDM:7V9EPE%SQ4/8&^R3,7DL ^HH=7>/N1BK,G'7I-ZTP$D.R/ K*1N* M^2-.;9@U%&QZE^4VC; ?/V2IW8=@)IU]+R?1XA^$>*7<">I4^.#VU-79-OPU M-G"18$%K/\#5<)LK.$VF<=:H[-3W9YDC=/%,!W.$IG"'_26BT:*7GK"64RYB M 0,R35ZZUZGPX$!C-ON4F#8\3H VTZ4^V/UPBD;+9>%VMO925DMTA2:CKZ2V MP=ZMS)^#@4]<1;HZBV.H2F%()@Z>@D^EB+DC# E=3F!-TM"4G6*UTV'XCFP! ME0$1@HZ/4O8_?=;]&4-HU-!??I]#:I"X,4N_)"(ZFEC-6WK*YE.JEL2Z@Z%+ MWCPC864@:RENX#BO9)_#FIF6)7^3L;QD((T4/JCK^*"0NKKOVVBJS@>' Q=B M/UIG8LH PY5L0@/!]C"9O(^"/6@N(%U'!X%WIAI0=CRNAT29KDYBIOE($%FKHV"0LQ.,3$\H;M7JL#2$CJV: MV&J:U;)3$HH^S.VA./T].76Q(BK91_ZQI&(D:/CM*]U+-">:)4 $LH((G0NH MJP1=K*;>UA1RZ^D\S'"-8C],A!B*1+CS7C0!I0I.4?X^Q=G> !VHD=)RG.>R M["B&I7K0$%UE(W4S>REYP$'!7E51(E+3[DG'@I[G%OUX.:%^3FZ@C$#ZF&QT MVU;72&@J1'VKQ4E+910H!N27(;IX$O9K&\(90)B\#QKB_=(V8)3OW)C='8ZHE:WVSJR;-[)G1_>_5W5Q8"[3Q[Z48_#W)7,8Q MG S"\/:ZSM#--&*#Q]0:BP;0'_[5^PA;^3[M*:\'RXMK:XNIZ7KI9\>6W.ZT M'.L%EI-_P9J\)<]C=> XP"+TTPYRP%17]9V)7.DH:V60R/M^$/R[C)\VI#R; MNGST:&GJ+WJ6WH-]$DY1\%/YH/3 M4LT9Q%XB#;J)*/G:W@(FF*I+@>BT<:J M6(C;B4_3J+?-G\R8/&:VZ'&D #,<*37&F4) ^DOX:QL6Q+=3C>%VY=Z13_.> M64:'^C@6JL"N+F00KP-[E( M=JSW<\500ZAN8-) 0JJ-?TJSQ>ZC%SB/TG0K=UU#?P04S<6*6WVJK9HD/*W^ M$[<9>:/)6D<8PR. OC.+D;ZFLV52VC**9;?#7VR?HU-2"P8#M[:3* &63(PD MT%92K29&5@;Y-E>FWF*7V'B5G.IV:+8X8%X2?(3.$S60KU/G<"*40WN9; MIG1$7O,4:,A:P%A)'U[+Q;DD( \XI#W:HRV+4GARW;&S8/T#MJ?RER+_S&N9O^X']^X_W^!NL]C= ^7O\O/C^??&V>ZAE M*-1RE,!8O&/G1.?_V2M5&)IHDODMH%:BC?\IT@T91OHUEZE57RG=DL?D%8S< M9,IMP3$9OF7HU]AU4-1@8;3Q?(.BEY>H?[L03W+=E7&3Y@M$,OZ?V\9K #/J M,M4&]=T6C;S7HSK!NC_#A>*MB9JKD$MIVG"1=ET#L22^O4E>F$UQ2DDB&H.V M;_H26YU??(^U^_5)H"TJ33'R<<3KY&_H-E$NIC%)96PE=GRFC*-LZG=- KUE M,YJ[#BUC6WLFY7['7_6\XT8S=K^613F5T7]@\H#V*8:(K^ D@KD),C38Z@% MN$\5X(R@\72.(?7?0.>PC*7.C*L.3&WR(M. MB7)Y7VWL.3R=[>E=/!Q!JY]M9#XD\$17""CJ+LI&=7H"00,GC]%7<3LY3/4S MV2"\5ZNSQ(3,;3#4.T]Q%Z?B.Q%CG(T1_,LHR"^L/S+;SY1:_>R0?9 M4H+1Y)']7\J=QM9#EF7W8[X&;_]:P1P9?+&U/'/,\2?,OXI;2F]J+_?A.(\$ M;W621X,I LRB'X*O PUO(_#[("=%+&1]^;-(FM35+,RVW 4'BE\%A&*D'LR< M6L85!^]4(. A%RRI:$QS>.ZP\PY'P@HUW/39(&X%V;R+:H$W(+\\ '$N/823 M.IH&JY/NA;83SR0RC;SNX9BX.Q7')P*D2L5R KQ9,+T>Z/0FY0T1'H]WY,[D M*+BK$ADYCV#9X9Y-_0[9N/53C3O#)BVW-3L-)9DTSN>,=10V_2X*#@GZ-%3K M,,8@G3I__OQ&3LT]Y#FA/K_V#K4;M[:?:D2.F]FGOI]HDT=09/1MC/73$";C M61L6.GK,^&DS9!"Z[\R)"/#SC:KH7^V''N+K@SPS#..N7P*6X:R084SCZ_0J MZN@JY$=_9MPRE2,!=^QU\O)1,Y7FJN6P6LK0HQP!'2MD:F\9ZRH0A1F>.P+W-?*:9#"OPQ#& M=A#0'[P).D$$]RHX;Q9M0COK7L-+)#[PKCI.[7E+[1+5KQZHZB+J,M)+30J$ MBDSXO%AXA6!V\NS !L?,"Y#':JM\-;2,VO,[I%S-I&=I#[,RZSI.Y!66GA/ MXO?(_N-+OGIV,9\0.D7T(4P#(&=*4JTE;(;>S+>IP:N MYR^@3$EE_0GO\+P^\EV\;F.&? 'UA*UM7[MMZ$!C2V.1>62>"Y4"!&2U =4P/N>[K$>;AOD275];N)F-G;VZN2!BA3=UDJHP: M%?LL420Z[B?8K8PL/,!1,W&6U)<<:P[D_[$VY0$L%',[E,6IWATX8\CV0X7Z M:M+.$\3#%C'>N2XI:]_W;[I&]R;8#6OX]%7,8P*/E?6$L'I6(]2C+=$@H8N9 MO8!:5*$N$4F[6L6ANZ6IK0S>7R32K(\5KVBE^ZA&$NH.I)!A81/UG =6 $0@O,2U5UE+,F^90 M]5T[UR-@O.0\N+Z0/P08?J.AHTV^A !YKD$W/@TZ^[_ZEFRAOM:W'G)DV#%K M0B<*"I_O#HD'V&AYGI) Q#3,R%/!%$4"7*UTH0HYINHKR#**"RR0/N/L@9WG M!$$L@=Q=:IKI0#+;E%FR4<-U?J< ()I^SIX >[ Q1A,0G'L$M[7_;E[!QH(5 MMFI L5)3XX]$B1X)NEKC9:];9:0,YYEL4\DI&! #RU7+U$Q3S=6B-6"E-\FQ MP6&A"\]J)@*9QE0L7"/@V$,':HEEOQ0)LEK"%6B]:+/X*"JF=_NW](KA3Z)H M%4V="9S!C)3Q.290H5Q/Z:9R@-E2YO)@!SH]463RB9AT;WBB]D*CX."S4NW8 MU[5EMI.IU0FQ)PD3Y]^Z?JFXV_+U%@I8._/C=1NAD2 WK]4+5*1 51V,81%/ M5Z/EG\ TY<68L74P TR;DU8V1TK?N?,M7=*/@_FY5(XM2/:Q(J3S' L*FKI8 MD?<64)&?OG3>'XZ:"YS+.*G6:E*SJ%N)&/#@B054G!X.JP_39!8ST[\NH#"V M9>F_QN([YDGY#!X&/I1-/\!]BHXOWUR7>?#;:/.S%8VGB)OZ[_Q:JTBJYK:A(HX/E(1>LHZ](5%,CWT4JG $8-Q83]K+].SK%PJZCH-S'A6#8R MC_>7KC@7&QN9$5>ZY[/)ICS#?EI]8_M!ZF+6-->4]TH/M\B:QX*/U8#M/B ( MP_'J:PEH>#\OM5[IJ=RM7%>\4MTLQWD!$^9(,DJU^T>7E0SJJ";N2A]=K$.Z M1^;:12.ZO-*=FM\C89[B$TB[@EM'<1A C AD@#^V J>703%/J7M'KNF*)]]P M'[C1Z97"(B:9))]K"C%IG"LP2VQEW[Y0&!9\ASI*:*1K)-@5D3'%H(;D)=X#5)H4MO=GG"G6)B- MT^9"6IFN:"B%AVSLG5'9RG1#K4*]+4[%?5/;3+IJ/F8M^XT8I+K\ZCK M+=-Y&[BW*";J2[1PS/!H$$3/HNH@KVEZ5$P,X@9^F$M7G8@OBS9\:5DCL3CZ MP6X6JV-;6I&8&E$%$P\_R]E*2K"P&WEYJ"GJ[M?:=1YK#J.+-(%6.,+M?+<; MT8X'@2Z1 =5Z6.4+;1*U69@+<#J#9[KCML]B]G'(V>?*]9(%%)/PN%%E;*Z8^_/'^V_<5@H5 M$K4+DA@.V$P:FJ,?8[D8HJ7/LBX!6FQL=D&@,^WJ1HB9=6=H M%KOV53@IXF(5BVY?@OWUCX_$8%WBY75.+&4KZ*X(A1 _@KW#,:8=UV#1%>0 Q@#TF)#F;8VP?RO:YT$9P=J11E!&D(W3Z)-=]/045VY%'?.<+\C^$896ZIL:XY7_F!O &UJ$@_"&$<#3S!I MU%WM52>B-/PVJ6MF.66/FM$2606C.X-FVIDF)ZC=B!V116/3UU& 69P>/M\^-8_OGKU5@X!D?]0;.]%.RH*'*5]&CN'IP M5!K9H8=7)(%ZXSS"5>;J45DA7[3B^?)[]J(UE*#4(%X(;=TDR;*\,/H!I[KR M1,C>^F=L]IF,VJ(W(SZNAI.TWZANN^3?&2I6WNESE %JU MC;E"%QC+2UUUQ0J(RW\5SQM)O.*<7U+^\KX%EC>VG& 6_86)]PTVN059M MW/"I\Q?B:CG)ZK]I4=Q1D>* ^B8E @J4HN7^2AL5"?(?ZJ2]J3\(5K+ /@E: M9;6*[-(A6LO9-8$S@"NTLJ:QN UPL<\@!?N ''B4 >$V0Z7$YC3ZI0@CMA'>A\3RJ)0309PG:,&-_;Z)(=ZK(?RSC 9P4T",(6W,L/VVM_PQU(#3'=@XY&H16_/V[3MAM2Y>F[@;?Q\^V]NK&!S= MUQ]9^O50SJ T>N-)=#KB0AT%GK!977AXFVD'L T#DN/SXVS@;DR\ RQ>%<'H;]H?$*9YL*I\'7OS3\YO(V%XO MZ>>F[M>S0Z>V86WTCK M<+_(\EQCDGO_[>27,4V51$]S790N:I-+ 8'T-H/HC MZ1ST?T#9CFA R]5=Z4Q6MB??4'EHGGTS(U8\15A-9OG#&23IU%:.X2M9K3=_ MR G03DBUZK#0MSA([HV"@I9)OL%G,I>FTTLK>7)C%E'H0 MOD6D7VMSJ%;00$^!WN*N*>]T/+%9-$)8J[E+-XW*)V4Q32A.4)^ 4._4P5BM M.@'>MK1H[*'$UI%_=U'[A(/Y3%(%V9]]\.SUAIE50DFK8V^OP+T)TBNH3JP8 M#1KUB+2W6;K/F;F6VH5Y/,-?K?X[4(,;%!OI,HV,06>.L.0ZV." )=+2.V"Z M-XAD@X-3_+ #%?K#KNLKR(&\P:!(!>F-<6=%<&IU'.;?:!1@B-M):_<%SHF& M-]/@+<++N.V33"WJ3OBK@HQ_DSDC";SJB@5YG98Z8. 50/)(Y2'%Z\=@P)MP M@*#3T@["YS9@,]&5P>^BSXX>;1Q21299E-Z&WKR=\B:&_Z,ZK7%^$?).M'0! M%2$<#0XZ7PT+.C%+A--)4B"-V<#B$]XT2H>FZ^^22W!.2!\-C3.B^,.A,D+: M LKD8V1Z*#B32?&R+!//&$4YEWQXTO@W_#?Q]V#/:CB.F,(4J8F*P^K;KEY2 M4E[8#@C3+EI&IO.!ALATE848G6]:I"@:^1=CV&(!(J/^#6#89:D/]FC1E%?I M2]XU8M!??;^:.'[MW-3S-+I4NF93;M]4Y' 8Y;;AW#6\(O8W3R1(<=04UTLO[%R@>540[*-I,'2K#MA)LO,A\M( M))D3D_'9L[?,G'(4/'>U$AQKK"(7\YJTLNU3#PP%]KKNNSN1/%98<\+=H;6T MNBIF< ?AS:3CM1#7&^W$E-CSJU^U[/[GJZ?QO3]V3<1=MJ*V#N9(R-K:N5R:;YN"MGJX)VT-=<\C7=T MKCDNS=GH?U#F<6S_X?LHU.&E['&F*>W]#15^ ?7XHHR@/C#K_,WYJS"7^\4+ ML5Y #;M"+*0LN01UD3E]0Y/&XV @\CR0)U3OMX^9QW%^4_]!>_\6T=&M^B8R&G6WY#3Y5KNQ9Z\6Q3$M_@@1 M.G0*)M%=A'1 !P>HG(<08Q413I70LKGZKGC%D3K8O7/^7%!I+F4^]9MS)O,W MT)N>]J4#&1E3=,T/'K2;_GS*2UZ5[Q_ ^@L+B(LQ#_TU4"5$(\(YYN/&CHO( M*G)P5Z!H50-FV9/KO]F>)OY-GD4J@8EY^O0<.#1->/RD!O=,Z1KT M9L*VO!TL]F_NM\\+0KYVG)_8?<*V?C+YR>6RF*;'(;GWV+%XWR?]#EL^LXS_ M]8V:(\#&M._KY['M"ZCK< ^X!-&)4(;#0YH+/ J4:U+,A"H<$;:A1V\H2G,5 ME#[@#$F/['WD,3P $GT@3([K$;%\25BNE C?_4*P(%>U%U(M&X>HFS\%(DN[ MIV,37O8MNUH4'](>'_X/V4KQY0?9(-=AA[D"1\P:X.PXR)*;*A.HW81'N&R) M'DGLV#+'68-;-4C=/E&Z&BYFD7,]X=PJ3JL3W;3-#V]ZY5LQ1G]TJFOOE?YS VD6:[OY>'&0]353:D9.\ MX<2R*-IR5^NJ:)HV;B>U_V2=HZZD]DDE\#IX4]Q,$2C=QQ9="J$'SRT#P^)\YR*4'NIC/C M4[0F+(7L6D,LOO?AF5CT)E>!AU/O4M:#,VG4960,+\BZC6 Y13.F&AR//CRY MPU/,S:)N[)NUM0F#,OYDDJ)9L^^"\0.S-L%3\M,^'I^MFDZ+F_9_BK>;4 U] M3__.VOR &@2G*_K5#1PCZD@R_O*/3YB;?.+J &T(I/ M&8DVC#7M<047QK M?06)W23*B=AUY]U8V77?JF=?ICP]V9JFQI[*D>"X^IY[ MEB:Y/+50II'7@2Z7\,F4E_-#7[COGJ:^[_L%=$_YF[ 9H2/7;& FG2K'&S\_S%Y%+7D MW:?_-*[-?]]V.*65["FWU0P$2!GJK#"[!51_RM&_]4C#,LT-M(DT-[!24Q=U M>K8-\45Y(EV.D[Q<+6-#MMU^-C4P)WLJN55+T0..K=[CJ8=^=V/ M8>>XY_FI&,&B8#UZ)QL='FR:67.5UZX\N%<9XK R0*?VV$1UU[8U]WUW_[GY M;9FI+VT'9I2H"-HC[%3KYC.AK=!A 7*8+ID_2N.=0UY:(3%(A@;$6*MI/CJ< MPIW&DU_S!'E?_G4.W_/\]=Y/*Y:X+GH=%&AE>8Y[I2_]>^;R5C2)Q_VV[37G MQ&<"27T8XS*]1XC0USFJ%E #%-$"ZB[OXR/E.>1%%:N+J<-_J[K!JPM^R?!; MW75CW26,9!/JU!_E.00XEC$(*MI#+*S[YGQ9 MGS(RLU9#6;I(\^=#9V",XX\'>\'\%J1:/]5W? 'U(78',DI[?%:?BJ.X'-WC MPHY>HG_ W28X#?USVZ5CX&_Q!.]S6DC0JP44[0/FGR./:./E(M@ @'OD3U.0 MC.$7&AGX\<1W[_6$:PBKB_9MCZ3FVP+J:OC>1B&RJY+2#<0*AW>DSC!$^HRG M YJB:Q,3H&X$SOR]BQ:%SNQ9E-;K4YL5?IB\[$/!ZFSCTB4NBYB%>_>P*IYL M64 5W*")?=J1L]?X:PPW%J/2SMO#S_]YG[E&Z$M#)\[F6RZ@[EQ(_/+Z,7=H M0^.8$UUVC/UZCR87WCVZ3>%^O(^+ I[,33.ZD1Z:]N6-\1I&=;;4)0'CV-?7 MN)=UQ]5(1ENA\@"["F68Q7"N%Q29P;[W.:+70:TOQS:T>FQGQ36,/FEHSMWY MXJ?^[77R32/4$^*B78M^L=GO,=EW\C9-P!^>/R^ZK7B]([[-+&!R_T']^,;, M[2$RU_>/GK>C%A](CI\09E7??&UP?)W=*?K]RML?\N=LK^,93_1>?N&SA=R>,5.&Q+\[#.H\>C)M4.3]M M&=]9Y4Q]Y6OWYY:.N+C=_L;A6PZ],CX20G]J_)_F=O]'Q^K_5?Y\47T;T9%Q M._[;PO'?K/?(JJRM@$*N%O0W^C:-2/KN!.01%()"' M/!]/X\Z:]]G\NX#ZK\_:LIB0U<3,3R#HCA%4+N"%8AG+>-- 3A Y)0!*P&D] M>O:D5+&1^ZR0OSLJ;*-WY,-'N][R2.H;.SFW#(=>/3$T_XM#Q6AH.O'V5^4. MV$B$:>B\_-.9U%ZJ/HI_5>*]Z-KR#TO9J_T MQ.%*B=_VEX_^B/]=\:;QUK9J!^/JBBNO?CMVT>K%V^"[XQ=?%I47;J/3__JP MYO:%]8%EI>-KSZW>L^C,Y_3S?[Z?Y++>W\JC1>/.5!:L]VM8__(0MD3X M7D/9CW/9/[\&(F;0LB>T*)9^PC3POF0!=305?@Y(3B,#P#?BF": ^=G@S(\. M6?/"F'S1T/=><3+ZGT!/18$1DCU=O(!:/LY4(7N @7\%2*[=9@W7=M4XK;OZ M2YKJH+K*.):I".F[]=RV&#^BV_ZER^A='043L5DU3OZ2<_+JH>'U@8@)08Y= M0!UH1&F25"TF(6>Y:!X$!$RO2Y2IOLZ6;T&S)A",L(@VL@?7 OQ)>,%)+I24 M?,),?M3@L4>5X6A]!WBU]BO%-FE2^.<"2G(6Z[F>V'#=XL=<_ MP)8OO;+]CS.>627=2ERE_;3Z@JYYE>!KXN2[=)$&('0>'N*P8_(YV-]K#7>R);.$?&HSD;=MNU+LW8>=LTS5IP;.G0X*A6M0:'Y_M+@[[\ MSL-]%_3]U#.K0H=A7F+4K\:G9GYTE9W758>^:CI?M4JD?&.I7_AN ;7FW\2O M0W4E@444.PB?3_&OC$D*W"WL$7_RYYV*ZF;ELO)K#MGM M[I2>RJ@*:_YX^\])]V7NNAE7__CS5(S]5L\"@S@[W]^O>Q@'1![\;UV[_B?' M(IFH 5!=0^<3%)ZDJ2I\08_:KQ/+>F_YAC=6LT]_VGH M_X4F8>-:*E-L5^D>T'I:JVX*0%/B900Z;D,K/*'<#4>W^('*3C-!>HL?L0RN MDC'2&O0N] K"NNNFV>;'^NU+?OG<*S&D;8NJB!K/.9Y[0%2V@/KOKJ"E#$.> MN7QR;",8F?.A'X>9>C)F#OG4/1(#1M$#Z(#_O -^.??'IOM1L$O LZ@5%G0MU)'#1\(1D8QCY@9*B9\_=8_GEM'\=M^FSN(3&IE4WZ@RG6L'##E6*ML^CK7&W/5GL\6L?&0= M7"O%K("=)%IRJRJ*O[H"I^T%-DMF U0K>'='\@.. M)4U[*FD0,8-67N"80YXWS]_;]*%QPGIZ2J-*GZG_HD72$,\6NP]RRE"M5SK" M+Q578(8,,US5AIA#E%VC1 ZF&S$@%K%?Y]5\.KKO?+QEX5WR1YKI!&Z=42'X MKN#Z1A-&W&D8&%&@_G45.[!!JSE MI\"@.!8K:K!O-.1$3)/^Y;J187O!M)\R%>DU8TW/*,VI0F8]B[<'YX+TB-:T MN"E#-!;YL;HB!LL8V]+<3=$&R\0+*+D;I"6I*[Y'KI$N#=/N5T7+:N,[S5H" MD'7@V(VJ"0-:AU-L1)R#U^MKU]YVSB\";L MB@:E#7EY\::*Z<*AH9J/)L$)WVG7OT;*Z0NH92=AF=+NY8^N .\HZ]7%L3A; M9E5ZM80"V.IMK!_AJO5TE8E_\FQFXVD#"R M '/7<+&;4=?(8.LIR/>>^=>\- M)+U4,?Y%7Z*!!-8*^&5GTVI&I]I*<>Y)#V)%L8#[H-P.#EI=RHV.W2TC=#'3 M7X'NDC$V1#@.1R@]X+6JG1)VM^J4E+DXJNGF.'V6IA_R-NI),G+]'CDR,,U& MVG57"9J#U5ZF,E=_[N'0KP@@;SR(VT M"N920%Q,6(PL\;D_036'9N2[I3,929;+(%,>>B4B%!G3HA90.;15G"6PED24 M$UN('W3%2)CT)D6SPY.J"@M;(Z]>D:"18]]/<:NZE\Z;&SD1>4%,7:9QGR;) M(V:&IZ2,-FX.L@S"R]?>)V+J(T3\IX@NF21%"YAF% \0>TEE P'MIM3% ZY+ M-/&I W-B P0'P!-R<:=)4$#NJ4KFX(R*=_," MX?<%E-6K'[.^&/ H X/P,4;(:MCT5Y@&"O:#3OF4U;4PZXCZ[P545!Y19II! M76&=_4V>K&?J ^\E2F>N$%;@;*HR*1?OCQY*G$@48C9?E@3;[DK=&UXZ_W'2 MGPTR1IT0W;U2X3"#[PR!S,NT2$R6LVF'IAX NCA[RE&PBPGERM#9E$A:!<6S M9SKQ8[?*5L9 (:]+?X*UQ1.%OIR<&1#D'7HVSEP>DVLGX?TP,CD34TC4^TY@D MC_9HCM],R#*S*[FGHL">8I$&_U:T+ '#I22>*)V[CA(N 1:3-54#T'%='R%& M9S0QA&\V^#+<;A*JLT69E$M>YF(]F4QZS)7MR46VHQ?3K$'6;E4 M9\IV.#>I)B:(F>7 DM-6JK:#=TMO5^P^NE)']^VLON=$DBP M75QKC3SR>$"RW(\">;,5 JT/NX;6 M;D^+F,D*:I1OJB&/>T/="O<_.A[TV8H"^-G@LR^8#N M+&O$1O$>"JM@P>,\@L%=6&/0'VM(#6"VA&L,.[^0^8!OQXP&$U+C/<'7]/(3 MQT/QRRLD?[ENT)36B(XWDYS=O2V>M5$CEA652S04Y31AI)$/L.>FA18[J-T% M'*=!ZF;*(3@=#>]L#O59I?_Z MN+>A)L7-^>V^*D^7=_CS7UH;58;>BH!'&BNSEATG I;?1&A8)@NERXW$]^RY M^9;VO3,_.J5=+3!C9L\60()IR8.)(<(QRE6 M^[V)WSQ/HW!;0)'*=/'+3F[].!]M!),UCA_J8F6*&EA7-(/9^AT&Z5V$',"$ M%CFSSHE!,;U/^1D$^.BT)GK;3!I@3-VI"B(91C7Y?,ZAKH7C)1UD%F]L?5_+ MSV.;N'W;*7NK'T_#\8@.!+T4<+6H*Z80E)I)-2(S9%@^?K2X4_1(OU5RD;.= MS/*"3Z76D9,ZF@19\I:+$LRZ20SZ).18&0$$1>-R M;;$HJX],AG?-' ,%^0X79Q+RC ZT@JZ-I:N>@F=+),&T97I.1_H=O&GH?=*: M*DC/.AT0_P745UTN;OL27;2 ZDH-D+4!;$ZS,GK"F9Y+W1A"Y@;U([O)#%YC MF-F .1_9 )D4WH-S^1R+IX];2C]ZQP;[/QVJOD31E0"P39(\ M5I>"&Z1NH[Z@+:/L%5L BMD?Z\>HJO,0(8/JK!G ["[E\!#%1S\O7(K/X!@S M):]N%7;@UO7--$S)P\8[@[X0IN;\6BN+P\OVK2N\GJ(U+=/ CR\TU\489? ) MCYD,G(7*#+;>1&=PMI'MA!(2GY2%,599*?U8=([EQ-B&)G"<_\ZJ [<)=JI0 M;8!K)-QL[[L301]+RE4[X>K[,6%K-6KB08M/TL4'PQ./2]PG2SP1[3*ERR1U M32MXLZL"VA&=I,D3>:%J1C7)\ QIA MI=Q<9,^^.CNZN+GX>%YK(YVJ0]&!'Y$DH6A_3^Y^N PB\$5H*B9Z_F:A(J1Q M;E?QK0>J&E^-:^Y0NPD-OF6@41OS$6;ZN1AKHO*!"Y4;R)&*%_#U<$@HTQ3[ M-->MH*B=BAV(<]TK >CS!VHE,\MCYI#=$#W;U:N2:&(R+WR3X(8^V%#_N#\Q MA2SKCSO=2Y6H[P G:>F$ALA.6W.97:N4F[> TL>M/ZYR'N"L(C-"8"LHO9.I M\P'.!:L"^B,&!1KB@T&C0ZQB1I87LT)"II+#)V;*8\"P=R$\7'5\)7[395!H M1&O_B1812FM;0"UJV51.9B@NP[%2]+!,8J1:"A(Z&5>8:]DSF=S5#JST0-N/ M,9IBEE@'!XWP/*! ^LQGI]!S3>![IR;_?^?^("=_/8!T]R_KUM**UT29D?I. M F.$(:-W $:($-!3N8&%BF!U*;(*Z2$T"/-IDMC)9&$NU>P3;@<<+&.N@XMIG_\[SQ,#2P*#2Z^6EIA*,:K6N MHK@)\ISN3%&Z4_^AK@*M-4Q@M*8#YPPY33^SYJ'S#"G[84;D SA0DO\(2NK0 M.&Q;5"!'#T1R2M?#96*Y\R+)J\".^?(B7WIMZ&@T;KUW2F[VZ^)Y4[!/L1%> M"]9((SM)V6.6#5!8;2K$$(LTN'%I;"^!-DG>DCM)5?14W M.J/OPU4A_3/?@%4Q)AR[(L983:+MVT*_MZJO( '1UE-:4O2A M@F*IQGD>$)=_G8SM&',!@79 FZS4&)\E96E37^-6P3.0[;TTI>(J"4\1TEVG9(]&NIT]G!#\4F0 )_C,"55&28KW_;18T3*5Q]"L M&TD1"RT37:+LN_M)GJITH[C#MUBKBEY5J/D%'&>8"!5*\!VT;*:N0[!NGK-4 M@->00O_9QER]NNJ4\N>QI,J#-\+A%$3;1NDP$2L+%FI37U>'EHY]&-M_: MWCWF,CEG=AL<]4%I#37\?[YAQN>>&Y=X\J?'F72JX[;\X;O"K*TMQHC7_I2(.MMQX\S21D0GH;9>>Y2UR$&8TN) ?7I$\_O+3BD/O MH>:E9G"?PD.#%26>RL.J& C?X45%-UX*!^LNUT[-65H5"WK@FZ3E#&F>*4_W MC'T%B*>_*@[S>6#;_5=,TH'EEX*W.^EN?N]T4]GVK^^#J5(#': 0>"_$4+*/N9]OWY MJ.?@ZUN7FZVKU[Q'AZ5;0Z\2OI*H+WQ(Q 1U)G9AV$YR=^4NZJL\J _1,9?)M:1OF;HM>V7%7$L.5P:D#3Z& M69W.OGD/@B<4OT?-SW;5;BZ]&QOLWO]MZL;]*$6AA@SWD.2V2CN*H_J^"@"' M> 2CN!8_8A5E&SP*CLK&,PD=R>RZZXG8?)Q)C&D0,_/D0$1SGX-'2_>F9RU_ MQC0E'!D17ERU/V?^3=JK/J0;J!>VLT:8$J<V]BOS_#^7@$ MKI']Z&U_],>*=^J0Z.'R&Z!(P5*745U4]NHZZLY)PB+<3M5:=3GG_V+LS:*: MRKJNX2@J"D)$.@%)5%1*:5(JB$)(1$541.SIA)2%2!,Q98-$B#D*0FB$E%+* M(Y1$14"DB=(J0@(DD+(0(P2(!"%=E?1RCDHXDI/PAV>\%]_XWN_BOSACY()Q MV%E[[37GS-Y[S74#R"E.[X9&<$Q8C 3#0,68M8OU<-)GD% 6MZ1:D>6VEZFV M//J"'+OY:O?$E/4)9*?FH4Z_^F>%;8*#U%LEM$7PI Z)5D$DQ$RIB!< JP9@ MO5U0238MI)PN %;BEX'?E#YIY_8FJ&+C^*>V::!J7);72;J'Z>/7HA)=4I[IJ(MN! M5<@OO5HS:D" Z,N5AR0OF!)=&>KUA'K)UO]@8T-W9:U742@U4[UQZDCW+WV/ M17&Q87US*-Q^72@.:3NT6'B!FJ 52I:PHQ&MXLEI)&NZ/LS+S^% MZ11NT@V:+RAJEEH LA*@QFU26:;#F!;-$^U"ZC;5&*S!MNSTQY!@ M&U*N3MRM(GB,8.OL)_I!TW:N!5'VB%3+=W>;L,-EX$\^U_((V[JU2ZG#"E+F M)-UI:'06:)LRH?I[0ZGI,IM0$SP1(#^*.3XJ%M?7S]P=":#'B82_=:J7J75U MK\6>&(&6>"CJTPEN,6Y8:RU:Q_B2GWZ$XQ7#&<1(=A9])[Q;:H6X%@>&1+O3 MDR'B@0\XZ6[QY.25L@C1DM+HXFBZW2O1WT%#Y/CMJH0K5T_'9\\K?585)6V* ML_(TX@;93RY6;^VGFCF5PM-18VF;-O,UVZ=QS/'1; M$$2HCR^CYIYXTQ#0Z+N:^Z M&';:R^PW?X]')[%[:5::9,XJF@7$;26FJ; K=2\5IF&VPFX@2\#2=[$E*;@Z M_FL!#^)]Y*PT[(H+'+L8=U;V]S0<^7(@SY-E^+KEXJ2/N62=YN/Q8&]DL+:B98*&I M F2O$X )$32@2H%CY8.6JJA\GK0J@WJ8:#M"LN%&A^"2 1MBE!$Y#!QD933Z MRDG]Y.;<(;.>"9K7?$CIZ"PIO78\C>;QR+US?3Q;0I5J#?45 M;#1\65793=L"LENT6^$F'52OHO]UA]X69E7?U[BG.(I;B^61!O)$N]_ -HIA M]?4_$OH>7'N4CB>3H:TV2VW\NG%XR[CEEB^!J*!M&D")@S=,-7/-J:T4S,@< MRIQ+)J6$.4"X6W0LC%,:UX+'507P8[#PB.;1E:E4C%4=""3'46Z[#:%[KXQ/ M!K0G1#)BI8=R! 5FKT'@-KNBLCCCV^F\'1-W13T($9XE9)4]-8S-233H7&9,)Y8^\4WOP9G!S21UM[,?)9 MM-^9YV.7.Y\YER[:?K6O&7N7: ;(.)Q5< "4H\!D50YHWUFPEA&6(>1NK1ZL MWB7F1JE)1O0^C">GON^[= G-"VX"(V6>,PQ[1B <*?.W(@TY<7++J??P_CH* M:QAES4JK$51[7:24:.S=$#.1\GY.G*[F+H;JT^EHV@*0-3&M-J:.*TB\$W"% M4LH,EB:=A>J95_9K,6XW\#O+1E1<8WS$97DL\03&J2&4PJ][ 2=].];GBEX. MA[?H A2W$U=,*:?H%N]#[&)_@6>DDG6+LT;;+36HQ(ED)9RHYCI M)&.. ;@.%K63T(A'F82G*7W.8181,R9IKL_@R]Y0X_U])*O18*0A MM6+C8[=THNQ/;#4NBVY)[Y,N06*+J-PV^@)-#=UA$(F&FXK&"(X-+QM>0D@. ME3"'.M"+-RRC)DB]>Y"M!:O$C8OEI)7P5;>&GC!Q2+F5]%%4E,G M[0JJ?BM]_0=B%#$9,"0X(1O%-8#5&,?V=6\QY'_CW\Q L."U?L:5S$"7R&Y* MW/LYE( (GF1+]JA"^CB>4:PZ8.(MV,'3B>V%?6 MS2I;8&_%*H%$I"%.))3H5_">,GJ7U'(.%0.84W-: M$WPR[2%ZJ4*81L(TQLN%*=8IE:6Q\9'R+ >Y*@5D-[/0WZ>61$O,K.]V7%3T M-D#.SQ=,Z&B4OQ#>7)>O#J%1(=9$E](H1!4,6?)C<7)O1CO;D,I6[=8\CM45 M02S#JO@>10&UUW[N:>&G+G4 MY=5[]C_!%;EM6/@G"F*6K!K4Y#>2U(=H5$T!74_+R_.9T#RA^LN9$Y#2EY)" M<(5+%*PL[G(YG%E..P+E9DV;LMK!,[5]39Z)9*C* ('S5 "$Z-09!MW"<=NC&YH>L"#ZLN/UZYN MB+7DS_H_6&M1#2?O[HFKV(B*O>(7XE=[GQJ!@F>4EI->T!OM,A$XH+JN83V% M9T"VJ@$6*#M8M]WZB&;$J$Q6>H$-E"*\13.LB/XZ&KSOL8S9GR.K;Q\,"$C> M];+/'AS.(&REZNA/"V8E^$^!Y>O>QNCGZ>Q(QF$^2$',F 101WFG^O"Y .6$X3C4:Y!E/:Q51IJW8EA"]5^)FVY/&HO%T. MUQ1Z3R7].'XAS%9?Q_;7KI*_?;(ZOCFGMI0L(AB*"@8YJ+SE/Q]&% M 8">8^/%PBB,/6P)E2G0-Y"+\^J<=AA:7)))6!^%78E0+%Y>5["L6Y3^IH%! MX\'W:X'G;8K!K9\E0]CE,-/K99+-?C5PDPCZX?JEJODO%5&1V.S.X+]F$\]B M4[G6='/:3TP^89,HSH/,6J[+2#]F)G)>B]N/]PC?6/]\8"SO>F."T61Y0W!@ MT(_?/PU(__[\VX(?A8^ ENN(207M6G=-D$AU5L19/*XC'CU ]>$<^;A0XBX9 M4/WMF\A=A=.Q N7T\,3,17F42&M^N$RA2N>^_%5,E&\1(6N)R(:9%4U%-7U9 M>U1D^ PDU!IL YCF00^K1ZC_T?M NZ-^_0 MMA-7Q:GWWTYR MP-Q4)%SNF=BBM7OCM_V+8<7V,<_K@U/?VVI%D^%WYU 3&D"[[*3:$GY"O)WG M_ 8<4TW)A]NG;DCUN)'HE.U4NF6G?0#"/E(U=8*^" M,+"R-I[RO)]\G[[^[A0RVI\M#%'GW M4NH9-1K76K(ZT8-I<4!!?!GLB,+XJ0.!EI/%FCOXR^H] [!4'I>;1L2RH:8LB7?OH\/>OB"XV2W!(].Q88Z+N=%MD*E M\-L^ZG1J&8%4!U$F!Z%"U1Q*M^AJ%C]CTY&Y-UB.K^GK28=@"\/$:1Q^[A2R@,Y*)G>0(M3YQ22QYW>.62 M3WK=:#.'6G13:-R?XRVB[2"L($:+\=4@/O$I^%^J(Q/-%_$0?7@O4NH MJ3Q?7XI)R_K@]70;Z\.LPI'M=#,,IDODEQI2$>#;2]MS_1DY=Q=V*?6;UF M MQ%)AX;<@2;4.3L&V:H+1BY#ML+D\DRD)4-5!4VVL6T>U8LRFOAJR$5'@+FX% M,%%$?16*0:'&(: M(K.?W*E3[2NH'0K@M@XS?]!]M! M\:UPW-LK6I+E3?_W:<:HQ7#6LJK^C^*$?F*+5UQ3'H=G#) M(I()W0S!,UKH*WN^=SKPW;.FVHAIUN@;Y1'=G_OT57&=@P^'WIB_J'#_]_ERAW? >6X_:9?F)=WX(X*![&^[2O5&^TCF!&/:B5 * MKR[XI/;1S!Q*G[Z!2E$L45E!'>LCL1,]?LHQI/ "*_74ES8V/^VBC9*:R@;/,-)8QS5Y]C*>+J*\L MFUV"K &E[3:D93%$ ^1$0^4=1?X=Y>">MEE*YG?-<:T)>V$_^DWL(,J0O,HSO]6V,^P1WPI;,)I MH1BY.'_RC(I6IK 0L\.B8W"+DH5F(V8^?&QU&%>I+W*A&'YRX^WDGI,NH^'! M[,Q8^8+KYY4G&6VG=/CC.!5W7]S)OQ]O?4\27;RC\&9 !\=%%P0;F@T4R2?9 M1HJ :&PZ70\&U+MI@3 %&A!PC6JD*,0"LGV#!,*7+\M&'T'&^9AQ70;)*+H 5R5RM#G64U@U4#SX:32'U2=$4N(&KX\C[RFJ/W6#OD<+ MZJ6A=3BP#=1O%B:Q5N+U*^EMND%Q7*(#2+4G$L0\I_ 6NCG,T+'JI%D<'V#< MC2XP@5S<)'6O%4X),Z?O?XSR:25LZ'(QC-UVN!?O3W5J]#ES)@0PU,FA2HX1 M0V;)%][F.(.4VT@T&*(BP:Y@C$C!GMQ6=!JFC@(6Q&BA=538LIH^@A%M,W@A M/_R7(3MQ>>-QQ:2#'^2?/LGR OY9=;NN,)&NPZWJEDK$#NPOO5 ;*.M3<@JU\ *1[P3 MI6*W=DU(>LB1-P56AL%/H_!N\VQKJU:8YW^+[H:L>P&QLVJD_=]4F; 7R&KF MFA&61M71L5V(,]T!L7[QP1%OK]Y'M?C:_2&,:JKP&XWK96."0DEO-4(D:;Q!+?Y18*/>K9O,TUKG46RU_^2E@A6:@CA<,K:V MI'DJ.1C7'HKE6<^A^,)DDB5M2PG-#G)F7Y-WL+->D+4&XEJ* 5PLE:?6DHWJ MF02+1E78S]'33INE/LPC]4VQNP>^GQ*H&ONTMO3F>&Q=Y*0=F-L&H&M)BQ!, M'^FO(,3E3H9QAE)^$X+?%%0S#A&M[C9ZCR#J686B^IL_*V)SX#AZ8[K3T>/2F,N^[-#!V.^$L<&=\^' M>&0.92J?;]700L*[XB8Z%5*)CX"U,,YV2>M &\N @T5^ F=XW&SN JU["(T, M#;?;##01>1BT#A4RM:NIK=^\P5.O"_UBZ@D[DQ6GPU8FM\XF=L0/CSE%QBTZ M,@2TG$&PFB*.&>(#8\%G]'<84U_BO]2L?<+/LN4T]]XP7WY91]K)@=A<96_:S+ MBQ4ZPJQ=I'E2@\L$S/&1D)U 6G.J$$P.[-5NB ;0G&4Z5MYJ+6S.U$0>@R^7 MCV"7$U8A!'"J]:'OJ0.(5UD0W/JMC;Y2S)5O[\+9=]7^I[-\A@#H0?':9?NY MQL2S[ R,%7RQF%JFN@D/5B"A\%HHLD7";B$:T07 2WL^:0DU66Z9=K1Q9P7B MWD.SFD_[I5\H-&QX.5S"7T&-5YR.#PY(*46"-;>U/]$\H9F)D!)ZNQN& )]Y1CL$4]AC0^NY MFI<<1YTT?_%ALG&3@KC4EPV?FN6UCCJ5I(M.,(_]0+6[3+=$%WTO$# MMB2,RA!G1EVH)C$DK_&,R8P)6,N!6X0Y'-N'2@9F&+>A5M3XZB5IQ! M(V.;WP0!D:SEHQP/L;(;[R!GZ<$&OCU@R:WSN,K:+/]@*'2B03,S0IG4<:A% M3:#;Y()(76$UJ^FE.\%27OK\AC,8V63VY6MR[4 M2KR>?X)3K8S>EV*:5&FQ1:W]FSBL&;B^!U RYCM*"MO8671'>. 1[4 /'4LFF3DU MZ@#'\+)?$VRK=J%%9K8%"VY\]_3@)0#I>+OG-"KL"]D$P,?+R>X;Q0HH1_.G-E)8 -S4@=HQ5S;"&A;A6OC&%5Z3>3^B_K/F,J:EG+PV#L$2B; M(7^XAT?W@#P9_,M/!@9+,FE'8Z%L]8$7X.$465IAZ''YX!R*,4U:26TJOV+S M^56U&E 9:>IU C%VR@ N;+>3V[)X67K>R2VS#$9MIZF2V^*?78"%8MF9:\3# MB>M[""8P*X@+EJ3CMV"RR'.H940&/N)I5.[5:O+]%='?8BZ%Q+PMN10L14PK M]\$S94@"'*\^0J/ 'F6P0$4!A1-*R-0'-&+RKNEGN A1HY@U(BV&*O;OHP7( MIE:.$4PAGUNX1N_$BF#;%1N*)N5?V>O(U];?'M6V2T%_G+'VK=2,OA6YV,-Q MI&8JT6W"K 9T$LU.P3(C(038!\SQ8?)(Z"]QXTT69J!;"W$Q;-D:S$RKK&ST MNCHKO.V:M5U-XF8,=2]JJ&-.9E(7S/ZT!(6Y@?[[_G]]:?_W4US]4WMB@?OT MM.+A_EV>^Z+0?N^NDTXR?*OO?M[EAKIJASE[\?=G)8\N74*M7RXS3>VD+QJ7 M@J=QR06..I'X*)1F %>$4Q0LXY@$3SXX7F!Z5_'>*/%@07O0F5/\8\)8\X&_ M;O[=WMUNGMU-5K&4WO5IV%91*)5TIN]\<9**[TLQ[S&Z:-BVGAY77O)WP;J_ M:'\]71QJ=:_EL .XIXU;+8_LWJY/UE_S+UIA-.$IZ_^+TD.[#@PLD@<2&W^H('9K[= M6BMB!%)NT/3!V0'93+OAH%MS N66RYO0P]>/M[P<&C.!=WMN=8BNK%#FO,T( MJ179):;)<\[';ELJC?F)\@[=KZ=Z!#(FQB&V0&J*#Y!33*F9^Z!XANMUBX%# MX&3? YT2/RVE#O,*<+5Y\NF-%G>]5B>8!GW:O++ER]X7I29W2$^PU8)6(XK M.KY9:@)_4UW6_!G1A<1> ULIIF\CP8#6O-\*>&VF([BR?&#-S;-GZWN<:3E+ MW]DD[R/L9:<2P]D+1S ;X7KU[D _&4F?^O1?25KN'G)P]"9EJ#7>"_@KB#7P .',4W@*1_5Y MD:FN0L-/8Z<2N+5W']^*Z"=Z/:91_*PR_'D8NW_!$J ME?"::$E=/@0O(XNER'>8#<8+"I;!9*6_Y>@DD1K]>'# MGU<-=]>0Q^'U]X="N_Y.\HW F18Z;%J;2[:>!52G81]EA7T02+H=#KN!EUOJ M9Z>2:^XW0=@DSBIJ(L^ZNQ_.WRV:BHMRG#;<^,U1UK1U$55NL$C_[>E-+0@. M+]0R/][.=>6!,XS5UW,C:U^LRKM&./.?BZF65C=;SFV]12]+;Y.''^TP810= M/7@R>OW@WIYK81VSB:D[?$9#;RGP3/,VCC-,^O,WCHUKBUA855YV<\NKY<(M M?RO='"^@];(*,#^W*LC=%[.L17^$'_3-?["Q_[L8,6>H:C6/N6=9-W6X%Z]V MIRXD6HP-;8:G06;ST'KQEUJYQNX;X,\JG1]&':-XPJ]UDW"CBVY"K582 &A'B%?$L*OBN\^,G LK%B.=!GT+PEFC'7SV> M_7(7ET;X&6BQY*RB!<&UY4A,OM*BHH@ZHPAC@%\ZE-J*"MH"S7WZIDXHH(V( M;L0547?CL".1"FG+E'4;&,+7;NZJR=]/"]5OI2([=6PKSO?U%>^&@%LOT5QE0GBSL!VXH=VH8=J-0:>"M9_5])V9)3CT$R M3\=<]67^*V!6BW8Y'"Y+Q!D$&J$%7),Y5)5KTVG?\IB[(S,S5[=K[;KL.!"] M[-JEOJM8*C5'N^RE;:X L*)%:5C<&(!)K.+<@8 ^#(;N0('@$D#\O*AY7!6 M&8(3U<3J\QJR[PYM 7W2IC@VIX=@BE ]2YLB8S*\FJ8/N4?WOQ=@H''!;6$XS* MLI9($D]5-8(3N06H&E&6MOANC$)TM.'W0_892XY$YB*!NO#R2+3-$&-RF1GW M);>-98I8:^YSHTB&M(6P$!+MA5/ ;B=#GCC,!5@20DWD6T7=SRJ*/EY\[X+*+<"];_*@!S6!G4T$ SQMY.C;=.)@%% UW,[*D.J* M09;2R*&95>LVZ2 W.MYR*AC-PYF%!D?-Y TR&00,65+'4DYEF,!6<8-;\)0X MN:?GHZY#.8>S$B-6O,YY S-U=+8>=.,#J7.H.A8O49C)V=%=SHW%2>:MK6OL MTUU]G2QY6X>HIH$@X3$HT8IY=)L,16_%M)']$2"U;\M@Z+BA*T(N'7)9Z>!] M(2 ;UJFU16F@?3O1FA9'1DOV*.=0/.P-5FU\YA6A+;V'5!UPLQ:]%'=31QL+ M_6N[8UU#=W>T)0@9KL0THG%N^Z;'HQ7*$,HB.-,O,^SGMS;7[R[)6(7"6TBU M!I<5V%O86GW$?!F-4DX5*(4\[D+:? .K!,1.DT%?2B-TX5>[ B94D2I/<[_1 M$S(&EL';^+^-6N^M/TI5\BV#N=EQ3H "ES[MZ;&G^XJZIJO24681[#1M($<5,=@GLQ0QR;''U/#CV@><-;3_R(NK1$FSSSC6&AO=ZO[,MHF>+[ZF<2$>[)V)CCP2%!L$4 1?>D-7&F)A2[Z-F MJB\KIR9+U;_0PB%V,W&U%#E&2IM#Z6L7(J>33\#ZBC?7M%8=8,D1#EC\$#S> M#"&N7=.>P,EZL*^L4!*EW?XJ;Y9WJL^E8UQM2SJ($D$DQ()T$@YP$Y IV:R7 MN7QVK1J%_7& M(EO4&^%DN?#&M#!3-+[],IS8KB/H2+3L(T)6 (M@LD_JNU#ORV"'?U/7>7S( M]6NT<.N^ETM8T1>F8JD?M [(%LWO0.S^1GU=@7>"19!:=0%N4GO!PZHZ> OH MH8H#F1,SD(>2-?&X!+D,J3+E\[:"Y';N"EJTDI4Z*V9PSV%3)!N9L9!1W)0! MU:.EX?W+LI!HC'$C^4&CMS(V;-,TM@\+;]252;:V#7C);IU*'B+V5"!>4+8F MCI4FM:4=7_S/+%,UAVKC8F*,RF$FO0@OJJNP3#W_3S?>L"0&2FLO*Z(>YAW/ M6QMW[;>O*.JI^>V9&#"7,8I:+M\3IQ0VHRWA MLD/03/K&-Z)&J^=4M@R=C,15("$@< ,)KY#,H4RA VF!F8)ZS$+P MWSZ6[(^>7R!5[=.8F3[=2'HK"[O.3]!V5#GEJK+9-.NUKPOG]T<;[>136.J> M@ ] %#?]%,F0@-%^3 F"V7,Y%PB6FL8-C"BF[!_H-@Y5!8^J&@0.0;H^4! M,#B'2I\.W3>VOJJ'%K$^X=1#E<-1([C[^P/'Z]9*[;)HV36MI1?(U5K,9(=7 MU\]WIB4B9AM<4[IH/^L8DQQ'29O!F@AXE#42S1]4/TJ)>U3O5>!"_@E3*^1K M\ V"G:9NWNJ#:#4-) $U%M5J>V0-_$9&02&;-"4$$[KP%+&N^S2RIH=F2\RN M(4I(1O%15-[[UU"RJDCS MM-&[.&;("/QRQ[7]/ZZ]O32LK!WV#7@Y-,ZQ)+O M#]NYI3:>T6_'+::2556:1W0,72A=1?>(8M7<+U+O'.D#C%T!1D- VQL@76L! MLQ5^QVP#0L"'TJPI%ZP)E\PB(Y*:[#V?2_"+4/KJZD"L@6=-VO6RH!8>S:Z1I">*LFBE+JF4@ MV/ZX9/>9[G]AWW YV3J$"X:3IH5[H?"LDJ?QUA[3__;N!T:BS8NW/APALF;0TDNJWU5%R"W MR6V00!Y_&SC'6@J'[(8HV;6>>@J+0GDGT&8!&.%=BP]42D1IP8Z'"QG=3 MW*#!)E=?DF%%KS#-T=>G)&;[;S'O5%MH6Q18V$Z;"=G+IR8]BVEQFC*".^TB M+%0?HAF\T.0[$SRI4E\XL623;X^I$.?JRIL'-(GOV00_W*.(-YK<4N,+>Y;254%\>QQ&T3.=@3R,N MT*E55U'R+[I9\ZN\ 2CI^=K.PM!!;W/UK8W7>LL(,;Q3R M ?;2K?_3.>U#/\/1\B80Z]NKH M4;XT7<>W*#532\>M"TK!>OXWJG$?T6PT&'?;:48Z>MSESKN-V3N<=TSU#VL- M;:.AY'9N%2%'AS+'X7MJ3\1-4T? (,<@;K/P=I@+G ER^9A5O209F^>Y1\'E MWQ.[,(W'NJF9K72K;F1#$6EH1(N#(K(9EFF_JLT["^Z8/YTY_G&&J\^5Y4C0 M/*$EX@$1^?Z2'-5-S:-R('+>76@%QU+[]Y 5_.>0'N,@;"B?2B]8W@@G*GS5 M#LQE<,BNGD9 <51&+@*+'U12/T\=R_'O.J-V//)%C:\;]-&E +Q!R)M:"/!J MUNERWAFRS45,0^9=M!$K>2@QZ />645:]5UZF[68HC48UQ>H1J/_'>THCIJ] M):FHJ+OU^T!8&+J*]+3NPE^[-L+5NN#NAWW/5"+&('J"*1\A4HCIK("?!;013>,&K^+TJ-=J'(CF48;A3V/<_[2< M'1QZ;%OQ*.M%)T3Z[]VEXSJ@8B?Y7H1"> 1/6*GV02[,5R$RY18+I5T^'B!= MRC&-D;@ET9>3R>4Q!:LA+E-"-$:[ M#6UH?*T^2+\YOW<('F:C:(%09 LZ [L(253X?YQ16C8;"C$E-[1K:7I@"2^3 MN@&4MOFY>7?KB'@DG[X$(J:XLO3@5&%8+?@EHT^<5Y#IJ6+&_^I<'C'HF$$/ M[R/*TDF+7;E)6AN84DX+@W05&9\HPTH,E9:31C)T%L9#-RQVVFS[0S9RZ4U5 MOL*>@8\$E0*ZL5AK0CL(:KD6^>?$Z0KA(N%%3$7)1W+P^8:(R6YQ&K?\")ZJW(?C@%NJSTF5P&D55!$+I9XR8 C%R$IK1M\"#(;(D?P)*HSU!6"/\R4"+]2&*YU,VR"82O4-R"21B[E53>#W0*X!45;EH[!H M A<.\%DOA>VDU )CN$.]A\I4'8#L^?XKJ /R[+(G-+RF$+_S.37S8'ZS2;0[ MICY>P;0:[1H<<8I]1FT7>'>[V(2,?CD_L:%WX/"K.YI\N119*=:Q4YY8PZ3$ MTC>,Y8P3JR(%N PI)O_(!XX9S12.C)C75>8T4P5K0>BH=B,H;"4MA+&M$N=[ M\H=Z_%,2()6UMTMTO+8;[_EHY+A46!P8$M*R1(?BBUZ VY/ETA0,-EF)SBYF MRGTFU8HYU,#7UJ]^IJWCSFR%U )F\3GV^?)>)#KF)4_NL:SQ@.N?U@^?^5T- M=#IS[<)RMMT1_4VR*=B!<&"J6/:C;6!4[T5GWO6 M="O5(<$7L;K5^S*793HM[/\Z=4J317"$+67UDVBU-U6@"IZ_ZL9-(QFY3J&] MH41>F"/$3CE_?BUX/_^90)DY:'BL"0S]2H)3OWEW35QY>- VW.\&V:%04S6' MNBR/1$PZ6KC+&A-!O2 =1Q"FYTJ7 Q%")L8%'@6/RXU+9+AD5\'CD%N&7&&'1[7MQT6(:5/ZFKNBKJ19;JP M5H-N-^DKZ!VDI;%T''7\J&@.%<$>P/*E=B M[][F]$;6K<9MN)-%S_.WAL:%6ON1U[Y,_ER\-MJ9@'RF_CV8,. MT!E =GO(1F2S#Z3H5 "9*-'G2:M+DN9047,H-%U$,@+.W8D I2?@>)F_531K M1;[B\,LG_>.Y0Z84; S'LJ?VQ[1IX:@[*_W?>E"@>M@[^32^H?!Z S?&_<," M;[,C\X\^\__7F8-:;A3P8PUV-7>"23LT[_\34L[J+]'N!UJGU"L:[>9[Q.3O MPDS]STO_^X29J'V!MVBX<+YS729W&M-3-CC^OYO5H>O&?HK2RW;?S69MITV>BZG\:.KB%]I_A MV]D691VC\ACE2N;+DJR*-)[\Z0]9R23Y3)1BRXJ#+'SAQ$CGWT]NG?UCPR:? M>G5$/:FF3?AJ4F!7<%'Z6GG[-YL.RH\?M[]Z>NX#G#FF@OPY5/MX_<=_L-^M M_M01VOJ?2$F=S +5I^@YU.[YJZ<\X0JN<"/ISO=+@[MVK3M+YVX7X[/1@QX^ M'P"\B-.+GA%I?^0@Y&%OS6UNQ"\_.L:^90ZE_$-S?Q?WLX?[CXB@X_7WYE"U$YI3S$-RB4=Q>#K*%]?8(-'5L6?CP MOSN4BWPVHE=?+F \L\?<^\9"MK F*MUI!G"\CJV?OBDXMKQQ-F$.Y8Z>B%#C MPNUD[.1]_J@]SQ;K)?W\!-G\;&+)!WW4@MV%OQ^<0TW^^#N!\D<$^\N_[TU) MS[];\R\^%ZGM4OY-G.1?^Z13#C?!=Z)O7=<'KF.'?4: J8XYU+;F2?&Z_VPX M7L^P]WQR_D^]#\O#;^8(G@V.SX^#,?&&]6-=@?&X^.\>(O''TB.Z66!.<),L M98);RAW-=[&3@1OV%)0ZNO]QJ9VG'AFY>.?-HF0Z;XWNVV=?'/MZ7B<6"=/J M#]?#LW*1MW!$99GFW'M3\M_(YFEM["MHK^[<8-N&I7,FC6 "RO=E>K$ M N(LS$X$24G(%E#-"R;=HF&?\AY3X_?Y/A6YO+EVX7-J%PY7&>?PJ&KHT^E/ M+^ZKOBJN;O-?:^2P^J%9G-"NAC1N75/R\&7;#17RKZE_X]YNB[ MEU5__O@CH/I*H:75P3!1WN:MWR])/GD=:U3F1_0?-C4N=3M?NYD1$C! M]ELCBJV.E2M*)C[],];>^+FXVW;NJG_W/ M-/OH_\L<'7W\,^GFJ5.E\X9UEQQ_JL1O ;WK8U%3:NRM]P&WI]_^,[S^;LA" M+@L';UQ-MI\,@9I6Z60!/%RJ]<.DAG0[MX1X!IZ82&E:=G3]N:@C[O<7Y-[\O1?,G1@& M?\4N1@+[7"G&R$+0AS75!*=<>QX:G4.61*973MXB;(3:FY[N MKD^H2R_QMQL8_?W='3O>\M]]UNZ99>A![0&\U38*KG'X;Z]F/[[WD+\KL_^[ M[,R9U/N6R]*:/]]M[RO]S\&*!-PG+_TUYF#1C\>K@OUU$M@4O^W] M*Q&?M/ 5STD003W/;=4Z"; MUEAH!L6/.VC'-4\(:,04 EK\%](.0=[2U,8#.F8V"Z1(ESXB+:.*0KH17^7' M*[9[^&5R73*8P(D\27TJ@HV[5A@=G-5^[Z(R-H1WW_V=*B=:^9O#=OE;=&DZO=0._%5M\F6,&F"L"8 MBE5EP.%0N-Q20.R?0PDPSG>_$HW@ (4_#[TZ.OAU8]_BU-R*3V^C2ZGN% N8 MYJ/)>;8K-[BMMK/M(?_4I T]GC9_:7X;G",#)@^HM\#"0Q WI5B33U]!PX % M+Y5"!O1IW$E!,=6*"U;#&Q3"FY: IQ%,QSC4)BPG(&VSB#ZU) MM;J )[KRCY#:V^DIB*Y6)Q726[CFVAW!]/<B"N$MPF"OSQ6UP56_'.Q MCG-:\X@H>SF'6JB '2#+=N)+<:8+\?9\YPYS) RV!X<%8>80DP=D8@!0W$^,5:".J^0;(F'7MV7@\W58T,4U.K]T1>X5K-O!QC&/<4UYK M,X>R@G7XL:A!4T&S+]+.^XS/H?BX#!(*-X<*9WU,5*6^G/\U@]K1BK&&[C$F MC:#=P%(JBS_D L?)L1:CEI?0B^&UWSOC^2*!CAV;C5A_>0,H*MP'_PB6Q 0$ M6/\Q&SR,K!0JVW69LZ@=$D\$X3(YJT=UX\>'J\/)) Q7OJ&[T4OA:[M$V)PG MF&1:"@J-BE\5K(S]5=1>5[#PU(NJ@2=^X=&*M-A8T=%8=W,N"M.FO@"T_*K5 MUPI9^G0G\AQ*KU*J^]]M (-D?077WS\QC4UE892P9Q%RZDU/C9?2B'@"+I6S M4X.9MV@Z6#%"7$N'R FJFS+ -":XLI0=Z T.^[W.%"3<*\Y.3"/**K%5]JV> MIG)!"C%FBCFD!S+;!^/E4SI-BZ'.BINQAD#4.#MU:+&(;M\OB1E:W(N/+Q_G M+H]H@$TC%+$V)[O83BX L[Y #S*Z73\>^TRR5VVEC<25_US!;'$Z@]<6S2N MQ8H(8GFG79LU]U9N2UZ3R"_"4W@OCE"\8-:^%&CQXIYUPJKNO-'9?E(H_ECTMBL."VGK?,) M-2;(I<*.GY!ZKV)<@LE_!F(- %D9]H5E>QU\TYXGE!BWJ@_!X3*_1 602?-3 M$'7BRX* A3<0;.'P8YD^8B1:SK5%O$!L"F*C9!M')]2H9F/?E\EBX_E7G\R. M=?>NOU8Y>9>T9-X#<=%?/31;)7=@F)JOMZ'\#5;F\)I]#/>Q* M[4]1"=AFZ!ES&8M7D\MG]C+WPMC.@*0^[E&-%.P#OE -87^74"BI+ M+DW'VU?0/*#Z+/Q:]NEH@ADXE!)Y1C;NA&L+,_PP;11;VT\9;GHAOG+G@M,% M%-$'.,<:8*E"-6Q<8]!39!',!!2Q\2W6D8PXZ4IJ9!O6F+ )V0B%EJ0B8;EW MJ2%M]^EF,%?&6@ S@T$@[92.[MNUS6(>E%)C-$_Z8Y__]74OFT]+U!6A7"T? MJ+9O6T4P1"+A0F/$C:\2>W@27+YL10Y^V8C M22Y-W>[^:<9"VA]/6C%-6(*].56XH)_0.K M9NCQ4SA3X<1LT1!EW)NT/<7:'F(->U*_U$\^/K62FX'_3?(G8+OFA0AQ?3P> M7/= 'NOC!7(8%+IV->=EW^GQX+LQLN!^,?>L<"! QIW,FF\ .=_/ZC;W7,7Q M5J"NLA!T"(5+2^@?@HG\;0IF"F8=;"_S#8MG-A/MBKNPI]F5]"F?G@/9]V#J8_7Q$:G:!L^8C MS3[%%7V+:UW!L66E-Q3=*R@LH2[0;B?R'H/'L)9#DC&+C=)=^8KE"7]4#^Z) MJOL\R3TR_Z5 QG![!;V2NT'G%Q7#:*(YE_H2^$,([+<7N"):QVR M@O-CKYDGP?%M6!,*W:H%'.>=FDWYIUBZ![)XHZ@@MFK7)B9.33B1CUI?A^J1 M6;A6E[*5FDKZ&H0,L3+8- "<$21LK%#'T%PT3Z\0T[4[X2GU7@E D@FN4NV4JW@=D M""P32EH]<1V9S07;:J!;!,L/-9/;CO=^<Y5UR[B)?R> M_P)S5J,]]![=+^*SS*?]+!77!7Q/G'S]K_,_];?_A[Z:F>'>]S#\^2@1?0X> MHMNRDDYIM_8XUGIZ3C9Z7(2,G8X=^"*KMI">OT@A;41<=%G;1A).Q909==NAOO5=)7Z;WV95]# ^ UDD\."41*D(:&>G$S;G M"@ T/OH1G*L2P='J_=3+"I\LK2>]JV[(7J1%4WT%0Q:0'VMB=@Z%6ELMIB^6 M!-/<1-_3)_"V2NI3UJD^8O7$V8(.WHS;K^.'ZJ$<[;),]04D *R?+%2[AM#V M:O(:=ZJ=M9^ VJETP@[X&[]^.]!1.KJW\;AB MK/MC^3X(,/F %.QP"I2VAE\2M M^IFB_4V:O%I;B@+@WZG@R=E&9*YQHYUJ02FO M;!#9#5:6QFFR V\%$YH$?-W\/))AIV+*?CFWIK0AY\O[[=)OU[2.:F=7>GPJH> MY"U6,A!37U4-2$KAK(89\OH,SB(I[01\0)=]'IHGNO1F&5.!]F!!]B2BIR Q MI-;"K.\/W7;U33>A>9&GNQN#"D?"MMP?^](MVM?C\A;W)/&GN*OU5U_]KC;N>:AHE.6[IWUK=ZZK5KS=4_J?VRB]=6<[8D>,X@9FH5 MI@H. 8>5BXA6[-HI UHP%)^!Z('?]H&45E)6@0=S]"1-',2 ME:V@)-/MJ20>U@+OI N'ON8Q0,;=NNKNQO?/P*+/Z_!2J+H!Q\IPJ4-KP<@T M^B8:7E3#Q2(XJ":!DN(<40?9)Y^G^2XZE3,X4G]$.BJ9G!T0]P"RG#G4*G0+ MSKA?"$I55/CF_\?R$LWG'^/\_G-\9XWP]'\BGS;ZL->MN>9$LX\9*FB;V=V4E:?10:V/ M_G08ZT402K\NVJ62F+"2(D&@_D2LQPTX#!%>VX#0L\^<9^9VW6-1@W'/;#_? MVSC$>?3!ZV[1VS0"E7H833CG5J)Z=#=P0T;U) MTI#USQ3]YZ[;H/3@*X%A&XOZX%U=_59!XF<=.K-;YXM&EHVI^=?F"<+.+#:! MW0LYB$S0AI,(Y:KQ$]C6<%/DK/]ZRKB^QQM".SL@N\;AM 3UV4KDXT?!4/2LX%'GT6_KH0*<_4B2IPW9G?82$;U@7QOS$Y8G$3$,13-7#[#^-SH8? MYPFGN=?*MW=SXHC9.Z'%1KE_BDHNFVG]QK/\+J/1'6'I= M!TJ7SEAC.WL^S!/DID8S+1Y.A@):;[!J0] E/XWR4)NO0>]=;-]O_?">$F96 M@9J3B%3FO[, M/WA+C&1(UI4CC-R&4&64+,^0&TC3AESQ^K@213O^$BRO_6A*ANOK#B%M Y)H ME-P9?B:['7B>FQK; ->A$J.%,T*>)^C"0"OZ5+<=W5^*% ON++C6%#%+:($NQ"^Z*'HW,H:6.40?3 M@D/0E&SQEEAHS0=JGCTCMU3:>WQ"'EFG9)UU<]G7YTK/F4YV#?%H[LVONY,2 M>.D_1C?VH$SO#2]UC#S5K_,$"TAU.N[2L2D< M=5ZHJ&3L*]QZ^;.)2U2O2.VC#DC_,V$6;*/B+S\9)W?BF[0GM_?RS\4OFN/D M_:_S[./0RYBC?@\+=S^&C<#5HXWSN%-&M(37@*G[?LA3M:[&.=VXD24YC+!_ M4FD7]Q[L@9>DU8(_+?0X0P!'2*CIY6E+6QN#U) MVFE2(;"ZAC77H[.4_8CZ3-M:UD7#FF%\!6 MP%(S,U3"O,P0#G)GZ?F#]D*9 YTRP;&#EVB>L:5M"N0GUF=RAD5<6'&V@&,U M52+)3"SU0R-O_S/*"O K/QXLO?3RW_?=)M.="QV.@*F*V0X-?VKL96\%*! M M5!3^_!^CV\')KWPHHL#<+H@Y+$.KK4N!F<2##5.F@6]CPEUT16)=4"]8'H MW@?0MW51TF(AGPVSCDRXGA7<;4S]"=ESG%9E5[GN:L+*V&^>.B_Y'WIG M8F>V0.[)YHZDM2>V,Y=J,+LP=X&KQ!U&QW!/$%SX5X%:U"WMV_F?.(1 MZ!K/3$12^= C!KV)M9/EGUT>I9C-$]KVT8I5?7TP_<'Q/!^[L8-/"8900RFD MO*5X'*I-TD VL!=8@NXXCG(*O$E*+;&S?!O2(41X&JHT,5Q*(;,J-A/U%T6H%1-S)WE M6<*>D",,J8BYT(I/D;)J/BYEN]9.1EH@!24E73E:V/7.1,K I>67='6&Q?_? MW1EA.'%:CW#B&;F21XII7@I:HW*49&X319G*%BK[+3T@BKFC2+CDK*.V\_(B M5R'TG(@'YPV,O4\\T'%Y_U\ET9W#5T.$+SYY'SZR-]_$$*/WYCPG -RUODM5 M\8P589M@'"F7;,3C&D.?8/PCA;$8(ZHEEH :P5/S6ZF4^B?JIQ%'WA^PYTB) MUVAKT-':;[YYU1/0FWKO=6SPZXEWI-\+WJE)OT5G1EPVO;&P\H$3[-\A4_%& MG$(Q-0E$[O0)9R7];NN%>RKI:5?F-I&NTV@^IC*8ZJX9),8UV"&P XV2 M2BPXW\Z83;"W9W26^$D9UF\BXYOWKG J_A0),#M W]-_^<4NY. MGUS&W@P"ZV?U7CE*X1*4O8/3^KG1!0X @?C'0R"E"@M"EOZ2IK^ << Q-+4E M='" O#&58A)K7,15JN,O^>7=%E[MNG@_WE=57:GS;SQVLW]I190NFWRP)5!_ M8,&'H%C*-<5*W+N:>9>-5'ACCW@UIQ5GUS'4I;#'@!O1#GC)'K.Z6B0VQC4P MQ,D>73;P -YW)^&+.(]RL_*!N=!^V#^1EKWMD7=Q2)&==;CAAL#A1V+L($=9 MSWM<4*CD9QJW]IZ'Y-0.^ZY.UY@.SY16:B9MI>%7XY9): UM:ZR"^.$E)13- MYF*.R-OW>WH%3]@.<7;V(U7M9(\!TH%7[J^/J,>DH?8O[P2<+';*Z,%("KGVJ@YD9Y H'[:E;7#SU067:PJ*\]D MJLM68-2+W]+M^D8?: M8(;1;R?8;[P9,46)#W0^Z5(MW>A!\00)1C-G=$9YSE#*WL[NDC2.7:;^+WNB MW-UP5Q2%[ABW G%S]^KJ;*;70]ABJ< MFN%>:.0L 2;M-')O##+3.NXNL65=FE(O+5:/[*>N .''2EOMMVIK_>_%-:5( MAE\_?-+MEBOZ_91NQ@XWB6 HFKZ$1>FD[1PX:]S8Y9$AB2>N9'=>HE_&(&0J M# UM[\K%H[>(FEBCB(]_(*UWG\S%$79B;;0P#^ MC7HP'F;D\D' ?286*)ZMD?A/S@;\+.K6UI22*/P:9&75]J)@]OCGSMEX.CZ MB^&.B'H[CF/3R)#350QL)T5*'>9K4K1YB$1]K+.M[!Q[!:LP$.@73DU:L9U@ M3Q0GNTO0H_+Z*S'J-(> ISL'1]>@D<*[(! 7SBXA8E%)VI%/B95\B?+.!=JG MX+G>T5_YNX!OCI& 1LD?CCH!,I3Z]'XYB!^%:A0Z3VRDO]U$I8<\&0,S1.,YG-ZBO%5Y$YP4 ?*[""FCWJ *.1])\T1<;HVN@YDD+)$.+:L]H;NGV01 M_;+^T;>79#[3L$ZM>]B<2&WWO*7?Q76F1)J!5#7/A,4Y"@GH5S[PS+!=/?"FRI$$XY:R#UU9G\?51M4G ME Q4QMQGE1[,^G,Z[D;\6UVJV%FJ0 *8J^7 PVCV3-E%QO8AHW4JQNM>7;3A M+FT1]EUVFXZ]+B\<7&&B>F51(5*63,QZF13W@]M@O6I2*SV[?-$C ,Y"L3,D4(GKS,6B"#7_,F\%9HGH MU=5ERGD",6%TW: H2:E8S9(>?'7^):-5MQVPT[Z8J("0PKB/]165LONLTVU= MAZ]]2.5I_?5IL)WA)IR&\%6<=JHE'(=RN6)W%D/-O$9S ,%*21M]%18Q*/(E MMIU3>:!!Q>1\Y3AU-CQQKU3C^,7;/Q-*-S<>T+H*O)XQCO%!B&T/!7O\N>L[#;[D.+H6I9$5NZ!1O=/AY8[ M&C!P3_\YX.,D3^@QS=4?BQMU[G:;)YBQ_URHMQ G6<0J;A,6?2P$>>VA\X2U M2A!AEY%Z>^2KFH-9+WP+6TA=M7YW/5]Z#)]Y^7/4VCN$BU<5R+&N(<\9%:F% MDD>V8.)$W78;)VX656!;J%<9%C1+H.F0K/7^=IY@SI]I[+IV"][5VZA*JQS& M/,2][A:<59.71D9Y=_PV-;G5^1XE[3P]1F]C($<5K^<)'7,T1Z85ZZF,1".C MC.EAE*&KZO:.3E,^2_!%M'/2KBN16_I$:]!"WYL^/_AXM8M%S1.)@U&X5_ MOK.6B@RK.MMGLAF-SIWTE5C4XU?;1 EZ3^P;L &5M'E*TIFS"1:__]TC\D^[ MQ2H^DJ66MGO:5=;X5IT<.L]8Q5%FD\H_-Y1#T8Q,L3DH5"JR&"MH=K _4-S' MSJ,QF3%@[/XX9$TCL?L?;BO6'V1!"\M'3VBNV/<@/[&>I?_J%;8A)ND!JUAM MBWG(WQ77@NK_$LWI==6_U!#8-['5.*S=,+Z44 34(3]_$ 45)+^8&;90S&5KV-#?G.\@ MX#0[,_UJ64470)(J(D+W;D#MD2$[102 SN!2U;T M27!@'AVERO+W!-+W-O0L;QIH=GU6]\AN_>;I;_^"8B'@W*EU>6!\!0E(')Y ?PH82L8J0%+-Y1E)\26DZ]CG M3:&]>.!L%F<^F)#+FWZJ2:MGKG2@KV+L.U4Y1/A>L8BCK/F(<9'"#D[C3+[8 MEK5!=;;F?QEG).T+] ?- 814<*H?]E*7,3I>J+C6\25!_+@Z4!CT!/FUX\#Y M$8N6 <^06HW#LV]38Q_4S^[:IE46UZ)^F!T11Y1\MCWV;0/87HF%@Q3T:1OT MF".3R+.E.Z'&F.GWJ$,;F?P8B9&.>([.!*$[:ZHB3X[;<_/<."M]4Q/N@>]9 M.X[TU0DX(M'EX)Z;S^59*'+R"9O M![UM?'-,*]TD 0?\BOMP$#B,AOJ#S@J@P><[0Q#H*QU@N_24GD!&\RUK,F8M MD_;VNS<5I%KD^P:FCX](51PS\0JV7($S$/%7_) M>(IE-/[9R$-*HN%N6W060HRW2Z&,$%%9N/ M9K3B9(2V:20V0];,DW*MX2-H=HY#4+Y[[4L/94&E:F0)#"'#[>N'CPY@@>B1 M6?;JX=UI?-1OT3>%:OUCE9C$4A=36[%JP?N(Y^EOC1I[ZZ^M:XP M2,#B_]V+-1S%W2Z>W7T#/M(-'U9":^_'_W3G8=)F2 M#*<9&L0[L%WXO;^:E B)5Z\ M(C$>2P)7T.M&?\%R^[/OAN_05VIVH&L\W006B9HJ/4,J6=9TVS(UYF M+'-E^["&3X N)$$=TY:X(QRXNW3&4-MG3(ZS7DB;R!M1TRS&T?(70;W:\+V- M*+DA]?Y$4;-5;JU_TC]C<(HA4W01C3*:^3_ C19JY#D OZ]!YCWC2_8RL([$ M37;Q.S=X HM6>8 MPC_Q5@)[;8^WKRJ1_/:]U".EJ6?JQ9*.XHON@JH/PL.7TRP0GM$\3N\!G^@Q M;AP)'Y=0,%,U-8NR_(,B/XPOY>0LM#63=1&Q8!1J?7GNK;";[82Y@;1H55I4 M.\_&>\<#1CB]^JMRL\<#@F''K\*'I\)V%B4[NO+9)PPUD+*NV8JK)QN'YPDK M:8M N-I4RIRN>EZVG+[6..UF1;8%??0X^#)?6R7X?8'+OZ&]IBU MJBL/5U"+GR,NJK&.A5W<%1PF)]>XN;LQ/ZJCG(+RN,/MV;I?#(^,6V)U9!(H M]KAZ/L*F74Q$R%=N18;%S35K)LI="T:-9P2/4T:^-P)*%[%J?[ M&Y1R8]\\X3%7"ETF6R*D%BX!/H(4X_Z;.?HI0N7.0K:3E_ZX1,F%Z6IMD"9@ M4,NWF_Q'XY=&3AUAO_WGG[E]"<^I[F5'3=[0/ELH\4)SBN58SQ.4-3Q3D0OB MU^Y):] [&+M"&"O9UM@>E"3EVI]D'=%WV$&6XG4L23L3+3_!/#_B+*59H4%5 MJGQ;\>+1X?BB0#1I'\,V(DZXN7G+KX94_4)!I "Q%;NO9.Z*6B)"1F=SS.4X#IE?AA?2\LS",*CKH8+-'GM@1.PG\:S#WA65$X_-R M2[!.PR&R>EN-U.(.MCG(1(I5-5S1(N1%&#*8XQ:8JK=G+'V1K#&$AZ._7BK( M2*Z+W*.31]ZPS(N;)\C#LAN!B>]GM%HYPK@3:FJF:&G.H&AZ82'H \F9"H"IDG7*W=4Q)KE#)5&(O]S<#'#*>[H_"NDQO,"0;O_U_& MV?]#XMA@Q6 Y'+&0E81"QN=C^9Q9A[YQDQ>2[T 43_<]V'KSL\>\3(85^&;9 M/.&&[_XNTS[.[)3B5/>'\4WOOVW*I>Q:?MXQ'2OE MM3+TFQA$:';%J]KQCX1_)3H!@?TGP_ZKU28J>OOGID)LO?W+2\PVZK\;<<8" M39>S7.8)AY]](>K2-Y?V)Y)BN *9?HXI[U?#.82-N%;7_RZAW;7:;_]W6KM M^O!=8A_Z_7G"M_N0F[MN*BM9Z.RA,W[95_0IOSY8OOO8S_#""8@ 8(;6:ORF MWZOHMNP_R&MZO4_H#[-?XD*59FE\Q2!@/K63S5;9U2!#%FF*)E=EYS9:!AQ' M:;45XR%A[%IDC(%>/])Y;[+I@K!7&O-=3+I_10GU#^)0DM',5[\7,S,\@+[+ MIP8W<$\8"KU-*H"SC@^>UT4"GC0XOI@B_#,/"9;QS&'Z]Q\/1GY:&-%GTUZ^ M";6L:4]X%A#0_0[;2FU\$5N7G'J$%_4]L9?SFF\TY^J]V /EJT!T3#WH5=%Q M7Y4[J-E5**WW@.&7;>+M($F&PU+E8Y",FG9&$C,.%?P^46XS4,_-=:-_$J@) M\-KEO3W:+2P0M:N['Q9F&3(EA7WP@> ;>(TL(R%.T6A7K*)?&74!6C1*TRE] M[C;%E%LHBV74Y=@72%>K9"V8:['W:%=0P' ;V2DOZ-'"GA1])2#3ETU\3*PJ M^[-.-9,C;&!M.';MQ(?W]R.P5"3%:/9$OP]LT%U[J;4VXYKCJ'0\-[Q^/_;-9\CJS0F1\ JGAUQ#J M(D[;)4XL49ZM@J9'N.!KCHI$L\%QMNSB73E.Q4^;8AO*UQL51JDG>YX _$QU M6_J]1S(B'@X]P<."R!G_D1@$(G=TUFC-JN]5,W!]=OI?Z*P+7RZD@T$E)X?R MB)0)4^,'\O M%SM\&SC]-1Y*N<6@<)2\><+J,^[0T*A^08K(*;KRO(,+]<78?\P3&JD%6K8/ M'(&(GS*1)%6*-)#122K?^AM@VC6*;78V>^Y6I^X3(Z,W/X[EN!_M_#KB9_990P%'>9?2 MH-#2$VZ#F';R=A"*9&CF1ZL87ZF=>;8]9][N^II%7#A\_^<*VZFU#8K13#?6OF#;):U^C^6=0+&?( MMUWB "_24.Q&X56&I_B-2]7%LLWB;>R7(8J&MY5*JMT;..A)#\S4^\#6B*[P M%G8(?,L\/[-BW(ZQ2N2Q\:/[6!Y\)+O]HS 3OIB6S*QCV16W<8#SH%9PE\54 M0M,S:L7K+A74]M*AE8<<(MJP!R/7&QKN@%9<3$$KW*"EX_B F^8:G2?8#@V( MR2/\Z[-E]KW2+37AX#_CH3^*;]PBW%*]SNGW[?YD;B5FDZ]:W>Y_/A1]=&FZ]Y.V$\S*;_!R.A,:V,? 89BK4,;Z$\[KQ,LS+V259S M3N\2[48=U-4%YRTY1W#.LQ\Q9#VS>_)@7&R5_N(P>O[V2XGN=:RGQE$@2WTV$%_G/51L.52BRGPDCMW'0(.40%FYD=KD159[J( MJ?^"0@$\5;;VU'V6$V41%@:2Z^!4I+A#,J2AH\S,#_,$T]'/0)(Z.]-5Y&>: MC86KEYW/I[?27+A!?1J"\1HE&$MBD\6C(:Z/8 M)O-RQ"1\MG+_ZK,_4'>J&_9WJC+\4OM'3_C(UH>OW] W/1(TZ[]N_K M=4]PM-C[N/$A&B',6=_\2KC< \?:(3,(TZ^"3N>8">YRT&^Y@WA M"H\TC2*%NJNO:.ZP$R)L=66JG;5YJ% ]ERDF@PTR]AJ4F]'(6,QZV]N:KP+> MVVM9D;T'!!$KY8E>AWL;]1&^.-OK+[)8\N0I4I3I^/+9+<)'IE2!,X?I%/4S MYT[[N6Q.G.)*! .=YEA72V7['Y1YX>V>I347'=*"[217HA3 M:XFAR/21R;?=$?$#)+L+XO/W%Y6V2IHDT_FHC91G"3.45+FO4G%=Y(KF=?;" M+H"A)BX'<]*/ S'N_Z!2?W)G MU]GG&]BVSMC*!MVU/HGRYT&%A1LGRV@.TO0AL8JF3AR"XVH5Q(@1S+'O+-N= M%2KE-/IQX3ADIFWT,[2CL@(+!DR.M]A\\#QQ)7!ZH:[)@M-4CL1VMB,RD*NA M+O.KD7*6Y/^O<)\'%,_+A1H&M4\UDAQ[DHQN:AR$;+V9>AK\+?B<1S*N-_[. M7M7<2D\7KQC$CO2.8ML'WLUNP0*V/5'1IY^% MM\OK&I&NF/A%^BH-<=A!=Q3 DM6*3JC1HXVRS$_O$\F"@H#*(]<[^=9X-[RU MC_WIA+:6Y1R$WIF;^]'W]B1M2^_AF?,!%L7A3\$JT> Q=* MMM5M^IL_O#(AI)>_[K<#8U+%-S&:WOVBC\.. M&9YP8JF99$?4N66(.DNQQ\(#NI;&EG"DD"U\"N%U4(:&C3:\*Y#E&=BQFK5^ M3&V:B1U3_OV; *7=NQU? N5&=PMB+S&R.$@01;[[ S3$#P-7D$+9)7%E':XD MZ*Z<>(7'Z7U14J1(Q" M-=T$^Q))R=VF&;SAWO2D?W;7;/ZWWQ#?2,S80XS'7*XW24G/&34W5(BM ;^% M9V/<\!JF@#1U%Q$H?/L;J20XN']3;*,B6^YJ^.E-]PAH^K=W9_/J4VENS%7/ MS;)8$7,"ACQ/]T/W>?IU]J9!\9?PY]TB+[T/*WVPC;,V>22A(\RIL!+;@OK, M9F7?.\[B='H655Q,C%$9H@X]1CVRHWL_Z"=N-XL3D_S3>[;44[6W"Q%^)_2P M1IND'&;FEWN"?7HOP&R72S(AY4,QP2!DK\(V"D ATJ7Z"[)C6P*HS7-I\3ER M!K]LSXR4_4D?,YFK=;+G7-=^2-NS^M8SL?&_S26IX6F^+XQ.^/!Y+% MAKOB#0IL,T[^VIC7+PUBJVI4?MH&9$KE5(;&X$2KW=)CX2A@=@O#%'-_VN-& M=P!C+<;M("I10[6 +>K5,D\@L1T3=D3()\K=P45UA(N,O5;4_/ _TK0X\KW*D8AP MUY%?+[N^?%!0*!5_@6;>L+C(N"8Y2WD]U:)8E:=2?NW MCY"N4'!#E4IUB&L^75P!77,WF_'VVG:[^=>58>#"SH&_&E//L.5$0G MH6/8RE[==Z ?B:3+,S2FVD55\'%$(B/*Z6KZ56]_-<42"T:[IEO5VCU&^F*6 MC[>[:?NN1LD0245I@S+*K5'Z];KZ4SWPL9KQ)O+ZYH%3"#,;"W@P-4?[M%_P M(VRC@PR_<.*X0W0-[2D2(Z,\,FWIRH?,!3BQSU//$SI+^6"SE1!-: F+R7?% M/%!OEK1]YURS4&J9U#JZ"?"2T:BV.'4_>Q/64^58P&XW.&UR%1+AA@Z'Q"A#V%W4I"@ M>4(^S:%D2A;IT#LS3TC,TZ:J3=OYMK&>\O@$FO >O!XY+51V97H6U48E)=GQ M*R9]]_:XWPV7ON^Z^"%M;+I!'\_J-)KUHE.Z+TN-9G6(AQ)7[]OUMI'P(I"" M1JG&.ID9'_^L0LLI<7E0D#_KI?F3"1^?X/QWQCM"?SQ+PV_)<]^1- M0))59A4K5X6Z2F:=5:[F' L0+J79/QETY]B\8:5(Y=LRH5S8USLE;)Z0$]-S M?BK53/#RA\G-JH*QT/[R-XK)X,Y5AU^FGO/.M7=90G"T7/>7]>2R23_FX:Z_ M=K^S=%U%.+SO?W^+-(I&"/N16,#0^8F=.).V=0/TZ=YYPD9(E6+(B;2>)_2E M!M;ARL)XP+23JM^@L(%FS0>FG'5Q"[6]D:?&=NJR><*D3W6WZ=-7^_[_MR6$ M_I^5ONRD[:WCTK6TKP7 MFL.+R?$<6_&7K"D_<%'IZO3^Z]YMR2,1S+-AFI!!:D6O6Z*#?\_YTD"_\$'! MLY"/+.T'@X-O;[+C$:VH,^N5)BNF@#HT]G\K_/U6 3;7X%R>(X]2DG]1TLVP MS2 -S0CO%CL#%_427C9\#JU10M":==: MO7LW\L$R;.Q G\AG&V^GH&:J^71M%/PQ^O72ZLK_I:ADNW$OZSB-'??T^P&% M#ESNLIHU+78TUZ<9[85P[D_N>Z;8,XV&:#UI+RCZM=GV[Y?&9S638EMC>Y\WM1Y'!H^4;P=M_%/<=K0T]1@Y MXXR'$+8J87;H,G=/=0/F7V4LQ%GBB9JZ-.P);&V[! M:U0*D]? I1T2;!*V/;-9: Q>B[S0+]:TTQQ ?AV\8=CMTAMY@,RROC ZFC8F M90 GGA:Z!?BZ5/!(8\:V'&:-+FR AVN@X5+-S!61"3^AB6.%:XF8=H69]VYD MLK-58?YW'^9C.Y,ON'NGV*\/WG=7$3=JPSW6QV16Y8:Y?F&1O]=DULO7\%3R MG<*&151*VK5$#?G&79:-+@O<4Q/3.4NQKTI,KU<*T4X9Q1SD=93;#&(;HA.@ M['5];L///-H91._HZN>I]6%QEP[VC >_2+P;F)@4[=,U)KD"*9L@,^-.S'T M3D'\I*,V U3,71\)NQIXR6FDSO(O46:ZEFFTP\+!E60EGX#%(KJ'\P0SOKC_ M'NN=B\7+ "EDR7RP=3;?NUUG=.UWVU*T^2S[%'#!H4"SL!8)B+Z&;-IB5HUT MGM"P=Z$ZU+==PQH9H_$Z8V4CY5JY1S/(1S>TTGS +VB>.G#VORSR/$$E*\A4 ME7(MZ6C D=Z"/.HU]]215';N7Q$3_GJ(K]_I^L=Z$A\H^ZA?04?><905\X1'/CSM*LGCY"ZM(_*.(C<3 M_ 9O8Y-]WE6,=:J?YEG?#0=[.-:6WF"_0C9G-[U2T58XA8*L5*FAS*[D(_>C MZ[F/8YCM#J.90<7/.X*9HZ;:70PN[@H8<(_8W_75P-G$&66/>\"$V\M]B1Q7P4(NX8RV]#Z+ MVL%X](FI[CP>?P)0OI9W3A_2I3\2J*;8UF@WW(F=4]A]"EZEJ.X:U]1<+@3*-9@WZ ZQ!79)!(K:/E:>T MS:$\K2/NP=L09VTPTA,P0QK9'>7<1K?"&("D<=S#6!F?I_)_Y\:TI6:)+-2_ MU\&097T-<^O[X>-EWVX6!.3>(AA*P9Q^/[S*\+.W)?[,#9K.=DMGU5B&(N1A M]]99Q_V*HWTS[HFI1[\P9.SM/D\DOHX?78\NY9];2R*958^7!%6P7%WK^61; M@>!)R39B"Z>I:[H!]9Q1^G OL[?'DKKL5^[+WFE*_CLJ3_TM.M,[P&@.Z7>RAG6%( J9 M^1HQ;>.8+&R@2&=R/W+:+=T2%FKAR:"AI$[VBN;>#XDQ@8THM8UX'3=V;(O& M,;A-[)ZN.7)MRW!DMX!A%3EN>>_U:%QH2LK.I!.8Z1VV3($$<;6-DR3[XTT>(0ZO/'JZ$P^<^WPS\0] &=^(T5&9<\"CBG<[V7J"G9 M[,]Q4LF1\02*JT8G^'"_:)^&NQQP6^RYTWE*RQ29V*,)84@KD-ZC$L!-KHD? M):%6/ZFC$X.EARB#67,=GBDM M+TE2XQ?%+;2=2$WNV\%90[BTW*4/]N7'C9IVGQ_ZT&4VU*4I8W;2''ICJ M"?*R'L&+$2BPK_S%D0*'$9?@X[3=AB*)LI0CX+;Q'7#&[24ZC-I#5[,80Q)= MW4*2,!8'NJA713%U$2]\C64CURFXI*N'BT ,'&=*A6$:^T0U =V$O M\'<=*T2CD4BY7/N9ZP*&=7P#& P'CIHO:2:8']+,NO,:_! G,D,9@>)75?T/ MSDH>;WMW<_HR9Y]DB=@#Q;2]G9TTB'1]V"_6]W7/5/T?K>R(W^^".[E?U,TH.LQN_'CQ6RMHSZ> M_8+WV'WLR@,H=IYPG48&AY/1;5V=H>(E]!4G6.EJ:.4^1!'0,\M=[1MUKC+V M8UFSXO6)J4O>%^PC_G@8SU[7)PAP=)!>*!$_2K;,,WYO_!.R@A(8KPL42G%N M',(_B([E28@WOO*&U"-1 M^\M$WLVE$Y<$-9FS+]*@<..+TJ.-$9^/!*XV'6%OQ"?\EK&E? 4(1 8U_)QY M LZ7LB\QVBAY+S7'Q636QRC^BUL)@QRBFSZ?WF%_IF$XMO#E[?B/[H('C\3Y MZF5N=2'O#Z4F.@R/7^VO%S_.$19#R%TYC9P9M,_MW!8F]<1A;F1;E9VCFG*$,;]!E((QT][)C M(DOD.9N&K1,A'NF8(U)DR9">"U3K7KG7^E .]_'?:;U==.&UM4^?[KZ@LSZI M^('72,%LG'6OT*(,_86%\PA6E89?DKE#?*.Y"3H)Y=,V&V[3/DT@N^1IF*TO M$L^.M#$1-VYJ:SZ1(SO1M>'Q3I>XE M0*<$_&&A+@@9DQ+S)6N2%=?#@HH1C>X'P(-:N?GL3Y]V>T>O%2\"%::YL(?* M1*FE[YDG7/T>%+P/_@UUSL-V5+WVKYRP_ZFH:EM#S#9>H*SB MF7J[(',X8BODQ3*&A?$3%ETYISV!6NB^ZYGY(+%G%:J7&YWZO=L/ONKXQ36K MKHKUQPND,P1D7G3B5SG20Y'"*0^=9T'%<)R M-_Y2]^R\,]2_0(;*2.KB&E% MJV.ZV03\*U,1@7.*MO#BQ40U+R?,H^4911;6B=E15,Y:E3K-N:6.O +I.L89CHLXEWN69 M;QV,]*0YH':9GXS:IQZOJRS?]8 4R4I<7_05L9MBBW_T$4C)PX&U0DU/-VXR MU(A,3J%0&VT;,D^XG#RS;#=3G7;$.-@QZCQP!H:J0-BHYD W]8,V^"0WM"\Q MT;W.R_^9^#?D][AZ^$!)8%75&R1 G\(>OL29]D_4[TP87?\*HT+IM"^,KT:M MP0[41&;_& MGFO["G9Q?N:L8M6$OZJ?D2B+%.8BAMX;/C=P:@&]< GG?>AMNHD:QY "1\!( /K[."K:B@(>@*BV MN1+G]$;JJC97\ONOD)G<9/^:IWVSKI[$;0/2ETU9_LP?_]3E)7R_:&IT+?YR M.6P9>:N!)_+3!\\?'WL!LJ2<_>S;B MBQ>R(O8FT;.^K9_VPM"V].:.:F8B)>AQA!;4^L\=*?D+944Y[GQ MPH7$);-O'IZ("#\9L' RA0$V0=I?T&S_A4.9^!!:XV-%:IV1UZKG"=H;^B_9 M_>4DX(+4=$:NAY9CV_$IA*DHJ57KX9NMV7D/,?[SW@_\I$DCRIJ%W&1JSB'X MT\$/PQS'N.;D/XQD5O+3#F0LN)*S4 8I;B2FM5)F_+SW_"SH1TUT_QINX(0@ M;Z=D!117@8YZS61*&A)+8[./%';8,1KH+2.T]YT_C">]J)XG1 T#]T9#S($> MS"/N7&W<^PGARD@"^P& C.:[]"M8[Y7%[52YEY32F')YF]$>/>=BJ#V,),G$C@!UG2LX8[0!IJT_CH"&UL0'<%#A\9XZ M09<5^'-2WVI?_@Q1 H^VCUD5J$EXAHQF][A/0+$<[S+-UKI;!AQ_=4KTKX?N M!FX$QQ?V)5?C)GN.-=9*C=#[BKKERA_ M9@CH^9+3D!QCY04^;#+@0Q9/SV<\5.3.'@/9^F!B08B1I L=NGK'.1>0;QK,J4+[]V3#C8Z^U0H8B,F[-/ZZAB+9JB.>%O M/AB..0(&VJ4F=G1E0V;4&>-J.?MYH))J!5N#%QK)&MZU8DA S$JF.,K_9(IB M$)L6C\@E/1^XV9[18]S&BW# '=>WPIKCC%B/@1+*0E;4M(#XS)T./B-.V]R. M5UA^"&3H?D0*RNYAH8@B712A?+VMD6._SX&5JO:54J0&/UEHH(K["/,FNZ?F MD-ITDA4UB."=<&SO>7W"Y4EZJT2 $_I2W4VPL+*VY$QQJPV\HY$Q;!-HR*AG M?Q*@IMI.#KR*G)0TK&IVXFO2O#K0XZP?WC',I7(Y16B2GG.RY70?I O=S#FB?H+H,3^BCLN[[S M918G0-(=<&DPLD?\)?OEI;%6,_8J8_].LD/Z8#O-%D2EKI(LK]<@VK?%U-RS MU,@WK\,OLW]B*R3((I;:,NR "WKNN!W(WMB#[[J;Y"91DN(TF&+*N! M^7![B$=3<5@HYEPLMK_YSB&G_,O7G]>G&LUC]%YPM.'./"&&:0682EO^%0'C M&F1EI,%F0*526,'[4*L:%=6<]8AM W_5@P6GJ>I\9?;[L]5>(Y],AH2\7\8L MW-NWJI%Q.E;C8>'-^)7A(%'R>,+R9Q?U%UG.*E[F/"':DJF:)V"K)@=;FF=D M]-7P8;3F^FDT9;H7#WS9GL0K6%0%SGI+D7=OB06C#L@;>?*?E4CEH>(C("FY M8E3P[.^.7\[\_NK (H-MZ/^1GC39U8;'O5:D4\672K*:FNLKZN68#X++&6)B M??R[C?V"G[TWW8K[^(EG?;6*QZZXZ_>-,(7_).-DU[KE287AZAGL)B<7GV>Z M-RXW[X[6?$6.T>,<^?D3#(^0CX\A[^<)ARWMQ5S^K]!WO'\]H'2)[FLQF3.Y MKC+TU8=%[[.U.$P[C:&UQN>A[9!AKWO)AZZKC'_\C:LY0]Y(J+'R4O1%WO_[ M-83DC]5/;H_'13L):R<:'Y=??J*'=NQL6-\&I99#LPB(*(UXN:^YC+O_! M(GSS\F*/)6OWV6C/G)+#OL@2+&RKCO8EDO87>9.DN4?DY5Z3VQB>(S T2Y9/A#D:GS 3D.:V*=F%\IT#F"^Y_!,=F?2XUYVR(;Q_ M>1,:%AZ9>9/5?HLG4UQ7(($6?$N6@^Z?0?$*=D?8P$^:F64+!_@EI_'(_%S( M7@Z8][?Q58KT/ WC2C.O_1E'65;62%_ZBS)I5;GW$S1Q)BOQF]Z_A0U/(_8^ M7YI1[?3K(L/W4![F3,JI0*Z6.R,?V%N?"!.>RAMN<0T7]LQ3BT(1O>\GVOOI9 M[;IOTD+W-CTB54^F,0X&E,;TN?U^.W5XXV]7ZK_)^;I44LCC,AJ(VEUJYK"7 M#++FZ8ZB Z6H"4[7TTMA&Y"KXCG"GQN*V-;SA#8G7D-9<3O1RC<./4*5:W;W M*S2=UT2[U0S3/6=IFUF40\7'D>)T[?2[\W6AK4;+@M6" W-&/$"V^GCOJX=W M&43L'<>-S]D;^SCQ%EU@*RF+M@Y>!:Z<4EJ>,&[I0G:):3!9,@#'(7.'T]?= MY;2943.IWFGWXL,Z;E;2FQ]'^ 6+;L8U#GOE?4Z<'*#;@1"J]6[5&N] %3]W]\/#.[WYB@# MK:8./1K $E2N]OH#C8\D_0]PF3XN3QLMCKXW*I\H27Q;R4Q)7=44TIQ5E19= M\_K-R3O?CXR.ALF'185O]G"Q4O8K1H.S=H>:.^R@AMJ;#/\1<6)0F_WXD%V# MR2!#J5B#N1A^$J^DF ?J:1,T#X166@T?S=8]Z4ZN!C-J(D[;6IH@] >1J7=) M5R;\66UMV.2H!?+@<$#]!&^;<9AB+L*9:O8\H4G'13-TOOW>*?H@EL9HOD%5 MQFAE"+>&S4G+4MOD<^FB0/T>V/,WA"%U-0G.Z"@$8N;:$ZRO/*3#_*'AW4A' M37TL&2[W0>U^NC,$SC#D! ZSF.R,])<_.Z4*EZP8OR!V[D^,$?=@N\[5'O?E MQX?LO!WR1-3[X>(VTF&10!A^49Z:EW!Q?8[OEAM]^_5)75QXN?N!QAT:R-PR M/BU,\U7V =KZ5QWWMCV-2[34#N21RYE+AB=U RD[YU+LX_8/O5^E1 MT,A?.1YJ(C#; ]E3<\I\X"O'[:MO5 6F,>_'-U]X5,.(:T[L^/GI[&9WBZF$W,0S MU;V]8^)K;X^7OV+'#6Q_>2R[DV;VI/N#PF882-MZ ?.$2-C;R%TA55LZ11"/ M]6V;*3TH>-2;_-W3!(NI%V7^%+I0(/BMZ.+,C;KU^\L.1OWK"[2X?)TSW/KP MNT19(UD.1<\,#1Y"A"T)7+E"MQ((5=P,>[_T'JFJJY-YE68&TM*@CI<6"\TV M^=[1"%_*6>7JIK#G9XD8./'-+E)88RO%7Y:V$54NKNS>R#ZW4I?Z,T:I8JUW MG/YSF'6-GLZPC@8G,J2+?!/UVR>@1Z<,-T1$52!))#)H,4SL MD<0SY,'M;-+_Q=S;A\6TOG_#0TA2@U24&EL(J4$E>IE!%)(0HM1L0F\RVTL: M- 3\D.>$;?4,4, 'W5 M&1?3??<2YAV3'<4!>]G60!3G"KF"U4 Q05O)"]SCBVKXQ-E#4M+5TDCN_%-0 MX8^H'%G*19Y1X->)2[<4;XCJ*H\#LGU=HT6=3]8^R!G>TZ[@=E%/) L;AVA< M9H>SKV-0QZASM.7^9UV59=MFU#[M'&M^%:\C34BW_OUMK3IZ>8[TBX'^ZK4; MZLYL/NR,%*(=F$XWBI0UD,&C8B9E&D:\!^^!,9.XC$G<[[(TRG/6M3I;>9"O M'3].DEIGHRC=R=@\C(79$8YO?KI+ZG$0+<&4@* 5/K_SK/IA-W5L]O'\X0/7 M&BF#H9KSK,;]]#EP .$*=UX4&T>WX!JUDQ46,%%)-3Q"LQ$0C"[>,HZFKRZ% MO7U><9^"XYH^KWGXJ[]!3<.J6).WK#R+"@H M.>QU^.WSI\O7+;VV879#<=N6Q1;FS#&BX>"E'$)RI:\MOW;%M;?5KJ2DHIY! MBT,W6QP_OJO.8;"-Z@M?Y"B/AOWE.4<_9]>*WT.\0CG_;4WP_]HEQX!H%=$* MME7TLP@I=$!%,*19;LT]W%:YJ(JWB):X&^R^L;)&:;^WUZO5B39N?_K;^Y9Q MWPL!=97M8^DS_^[#:$17_>V'_L=\ET0+T/],C?\; $-R9U=18-MQX2V'U"(X MQ\-?7Q1VB;S'B$IUC2%6,@K[W&WR-!5 \CS3L"^W:$ M15QV%MR1&%ANDQ.*-)1*ZLC/$IIC(,PJIE^"-S^B>X#]55$*WGS:MV8E]5HY M8GD/3OYYJ*KUR9A]F$ S\3''(?M)<%1 =Z!O=6Y"_,Q/$[<_EV7LJVH1['^& MH2)1PP#/)MVGE39-XJQ(QK2 1G1UU[BO'M_:!K(5R&9^C3-/J>K#^[.W2YR" M#0,ZQU]%DX]T74PX+8VV/?CTZ8O\(?Z!M"#+1P]>ICX@O.,)91_,-25PBP(/ MK[;-Y%JC#2#ZCD30W7.WT^*1=:#W".<>32T_A#VMR?Z"G#5*4!#-$2^87](@ M][-L (L;[TP0^;V^_E[M9062,^,>P/:L@7W)BV->#:=;LLJ!2.J'@B;R7"#R M"UP*RE"#7CF^EZFA=@.G#'AALF3V=">K"W(>WXJ@"8=W_4\,6];@JV0(:Y^3R&!7QL,"[[BOM\T*^!;'5Q$B#9,NLRI3UU1T>=R_+J M;% Z=+9[1S&B!T]E07=,'29"-];]C:%)IJ.&7OT,TR=>P^3GQ"8U;%L\&E 2 M")?RNP.!JXQY] AH;OX&.$QEYQ$@Z/^M=1)7,\;K"8RO#VNH;BD SD3E:#(O M'%^9^G#YX6?+&>G:0*!A'05[:UV1-0N05;D:(]U5[ARZ>6X@1+F. M>-RC'\S5A.GNGZT#IM8Y)=GG:&F2X-9R)$ANA#GK 4E,O9U+\5"<<1E#_21\@L-4.\3870,J1I6S>CX'/2K,3"CVU!7PPG@F ML(N0,)_N#/7*92E< MU=2T%LN9M;N2MAXF&0>6TO6^]8I%Y3_XJ.\=),2S[O M1,WA_&'MB>_B$P4':$V.3BW<5(I9,M / MF(E8@Z?_Y+K"MKH\)9#:OQ"6G5*R%M#\!07RK/H$JB)=9@WK>P'3WI3FNNG( MZ'RW3+> KA@:Q^$LW:7H? YU1%][ N;)U:,*I26K!V-@?%9*_E1:6&P44&%[ MC;2@!];3V, >"F)Z_SIN9Y5'$+_6_C;OM5]&_M)V-8>[:-?9VK"K2 )DA*R3 M9B6I["D^+Z-GV1/_[;I"+HH&-/_HM09*V7 MNJS5*6^.2C!1_;)@:OMRQ_NRRTHK3__GSUM'G:JN[Y7>?E]VP?WPO(CA:2:6 M/6?-/FS;7N1[W1G81*C.1DRTP@F'5.TZL78U0X1N[D#"0 GF?=0K-IU<(V^M M.(K!_3E<3D.#*3:R5# M-K@RF>,RO3ZZ-SB)XW.,$=_*;,6Q6-<09F%4HJ*/DU9&5IATC.=Z+.W]M3HZ MU&D+X>*@K+)F9. )W;6;1!PD$!B&D3R#.H^$6=DAA' ;ZDEP9$; M W=4LTOA]QW'LODYT>/"LI((Z4FS[)P,QV8 .!5^HZJI0TTAR@@7*1-9/Q3K;H $6:J*A!3$YW MR).9T$:M9AT("&2I$^H&Y"(4E<_7#&2M!!G-9R+%(8I2B MH)P677E*&YOB?K#V)OX1#U/=\$IRDWHQ[2!Z?6-@9?ZB]@P+ MQOT5>6-Q+.:8I6&??\#33L[OK?:DC;HR=_UR^I1:Q1[2L*O.34'YX+-55^ON MJ\1_J-&< $FW'@SEKX5]%9@!)YFCFY_"I<5'X/)NM3*_L* NSJODW502'";X=#350Z!Q#ND:(5=D;-@C-_:Y]3O^S[AD.>:.B3NUQ^BR? MQ+'(IL#I5@ 7"&IXAG1B H?6ZWO3 M+ZW:VAPLNJ^RHO(#"Y-SJ?=HRW:Z'R^-/"Q=].)5XB\U/(Z%'Z6.*U,XE('> MP;!'&1)O1@'W3IWKID=: E6]\5&]N;F6J0X%B2,\ M/">,)?/ W7=)TX<(9F=BU(GK(F6S@0@6'K&!"T(?]\-%A'EP?G-3#CN5:Q,4 M&6(-N^BG(];.X0[V59!Y2LQ7]]]./0X.O,+XEV:NX<+KRQ$3V AB*P,RZDQ M8[P4WVB]""(GNJ^&PI04?@+A<,XD3A#G=;?4):ER-%#<%)!O 84\*S(ZW-[_ M"?8+Z+9_>'FT?_7&CX+BUKIX[7;Z-/C0(UD$P03=A!#@+PZ!1O*'#+JERN\$[:>RO-DMFF7!N$#*18+WGA-Y_FB,X/R%(=:#U#=Y%K\[PH"_F/ M.:RZF&BEH?V%UPSSJM9O U LZ"V:^S-IYK4&=Q!N5\6929C552^#2CF4S(( MAHS?X%L-%RG$J _9MR9$GE[:%G->BR]HM6@>@D;OO=,._KHI*M9]#S ME:<\2P+1>'0N*IC$$=!%=#_,-7^G;X/8(\=CH#6]C>2G2W@5 2)^,2R6]S.5 MG&LRL]_9KP?XI V0P\L8E6&"S[[L!M2R+88\%XYOHAA6 ?/@='[$2AF^OX$)]19ZN&F>/Q"IYZ=;Z MD,= *D)^'$' +Z+>^V=YP5K7S M/@Y-Q[E_3GWS[R*])0-+8L:^7%F'>[-IT9M/[)+7XD^KP^]-3UOU__W4_?B/ M"=409LAE*!;=1<8Z0&N;[XR)**K_/;RC[B;PZ2,Z!],C:^#+V)7)F11OR7O" M_RIAE/\_R@/]GZ:+NKW\\/B.5?U6FW]^_Y,L]VS-^#[[<>/G9-*W]9*HV)\- MG_Z9K@]+[*%I2 (AN9RMJ"J^3G0_[' F,X^71:TJ(_-;PB4WC':5.]21CS\: M2OWCCM=1>S.[H\MNJINS8K.6?>/B-9Q>(@>QX56L%U%A'X:=P[E>VX8GL^+" M(D;^N*Q?@<\6F_IV9CG:\0MM\6&9[QXI[%P6LC<4^AL%[LW]4AGV[J_"Q0^S M[:@-[RZ\./4AB7DG@!VZN:214]6\(0X>V?#EPNX%'+_%V]8\N4QTI6?M/Y!X M/C*"^,BW8^X_G$T#H>?7BQ@DMF*71CA.T7Z2O .DA.K5Y.^VC);7,2)D+3%5 MUHR:RA>/?R)L32/)M"> 5K;6!?.]!CAW$O=^H@858B[NZ9[X.4]!^'R=/1^3]'K+N#,3I@T7??/-[S^.[]4V8)HW")MD0M\_+P@$0DY;:DM6/((&](S MQ E;=D6-"@I2KD9H\'Y11_'3 JU957F%^S69QJ.!PQ^JT4H> 64'@:_>3=*Q M2=SA]1-$Q"%2-R(N9G1^5+3^$WO8RK%#PMEB\"D_S^3][^_.7U&Y?[IFGB_" M?EO)W8_) M8\N5GX<;?[$4S9E1T,LQ^?CI_?LFYU\<[ MK/^9JRHWWLLX:3$P>@7XA$X?&CBSY]\GY:?K7W,(6+SH^VLDJ/#H^,(DK$_D- MPY(:JA""164#@Y:N+RQW4SL!,>$V\ MY?WS[0+[$\_K,A4'__I8\"PIP:%NHK)PV\/!W1LW*EV5^JR ^1SV_O M/G#68;?CK;,;KG,BECY(LW-\N.I!&NY_]X'4_^>IF>Z:4?PD;KF>*EMW0YW* MGDB*BKFEQ6+Z&SPT;4'M7_;V-W)<2^1L=#^CO]\/0M()!4=^&>Z'&$Q:= OM&\6MO5S^[-VQ0%'4XNSKB<7A.?6%^R<-(0]RK#F>[H*CAU<=?7EL=D*[+ M)W^Z0C>:Q#WW ,63N'UE"_(@-P6W7O6JS#K!4J4O4"<;%'DFF#9Q^&HX8)OL M:+RP*KRX"U!L@F-5Z8G.*56T4>-<4N[LK*&!T77!Y-O++0XD;>[,L#MADU2D M;@DY:*>T,=Q1F;?$\5#A^_:T3^WV/WSZ]JA$DJ;C3ZOL?G^ZX=VS]7\I%^[F&,P,=!+]\#4\<3UT#T:>[_3.*ZIFN6GNL%]1%'22;OZP@Y MPOA>#*SW40ZT3,?<:C@@K!/$G_F)C5WI.\U] GU!V>PQB5OS*P!=J"]8ON*XKAP(__O!_C]9 M16A+S5K#WV^&O=3E%>7]7/(4;S-CQG+:CD.'"#BNC0K=^T.3,I!_D=KSUR1. M_=*"?133?PG075ZE]>Q%D[@T;\W!<2O12 ^;4V)[=5NCG("( MP2C)&K'DQV[P-F\9M>.0D.B9FYN@K:W36L:,8);B>/8*!>VO?7@(.7QK-3ESNK3[TV[6!\Y]])HI",, 'KO[Z3-^2 M+1MWH0;I:[YAH7K[Z6A,(W$73.(&KB&2QZ07&SCWA[]N&LY'[ZHX)V9%O#6/ MS+^'V^I!&R"]_+>%GD::@810?]5QLF@B N3)>+?YT[E)W$;,Y=Q5'_Z9,^'? M(-U8>(]&W=GNS%H89>W8.:9=45,/>=5'W3LR-/&Q>7F6I$:3;]9&=[L7]/[? MP<6LW6T7M?N>%=B_^.OM]]"4^TD%B]XFAR6+=A_X?-MUT9[VZR6E%.ENVHBS MQ?E,7?^179V^?4U;-]8OJ=GP;OWM2'_AR44C1?^L+FFLMB/<4"H.TX<<,H[? M5D*F]YUG#5WHRH@X7QY"#>_<6_0RB# =MO6!+M6K=(X-_:8==9>592Y>;?3] MJB@"/L(LWP%:R5)T7**3'P[W+Z^I8!WM=NJ;/60^X/6TDWC6_B(__M*9!U<^ MOJ,\?O#2[^2V61>N[+T WZAD:P?2]JU;YVH\<^&^Z?-VRN43(,!>&/IG_!A) ME>_QL@'!>-6,-;/M/@S(;E[(3_@EVMNW"C=]I]6Y6T->WG['?@][(2JT_X^I MZ_]WGOD_5L>'6X?%) R'KJ;OAV/ H-TR;OZ+F>?5[Z.>Z]]F?C6WT^YSL! H2%X2J)@M-K= M XK"V*7!)"XB#]^TD:Q7-[,<.0!G%OO(*>G62Z!+>> PWS7X2T4Y+.+WZT%^ M5YS\+.E;6B_VN0JC[G*XUABS7M48M.K!CY6=%^'RNGC4T!]DBWCS27KTV1 [ MF6L6-?64:5HRVL6;C6ZFQ\)&BO155='Q2FHCWB#S?(=@8VTL\\L-LF)5[A;V MH0K)2E J(FN2;I=][-@6/?+EU"^M)D-72S[)Z0V5 /GS46.H1X+06D.VVC+KIA7" M3+^;T:Y'JG:%5M[1#'5?/J3&* >'./PTAP?*HURC0B(D=R2S1 <[ M1F(,_7]+_M[>KUB>&I>9.01 ,I#SZ4>#AFQ"/BE+(T]; ;LHB=(:I1AQ & ; MHI"7$;(1/@1 -"OBKE11@,4YFD7/\2DMY@W@+ M MWXSUL(%Z.H>1%)]@)=&P6F058B$A99^G=N\1NBO,5R5<:.!BX'UM&Z.58$[W MC%;X9;"K;069^G[PH**T-]U^HZ8Y0%<%HAPX+VP,CX M1T!:\#:^)_C/]V+FB/%.#:** ?>0&B!U=H=V--PX]BQCJ#JRNFAZF,3)1J(=D*.00R4QF;88*<=Z5J M$I=H3"="?OY==::8+B4(I1\O2>GSI%^??I0&-IQZTARSD+OT99?Q$:Q=\L\_ M@/A)W"?6D$P0I[FM(.*C^NV@F:6'D@I+@E?< MR:/&/@IQKL^K;"\KRRQK^=RPU:BJKL/5ZR.U@9?.PW/)B!V(%_*NUX[TKX(C M(#+?(BR#/E]IF6DH"%G$/@I^J<"][.!\!G^F5^;I"R;8)71VR']*W0H59+]C/@='ELAKQ5=0.;<-BC0A(H2Q M_,P;$X+I+DKR0CH15FB)"!G>K'6D[P6I37>C[JYD?G+P!K$,O;AT(19<3G-7S!ABY@TNM4['FH?MP_@6VA2 M'P?"JZKJNXI*CY/R2K]*[K1?&8Z)/A<1[@XWJ B&<&\3]S<=TYVBI:%MM5Z8Z)G1"[]4 MLGJ!!O)\>JQV2T^DE")Z03AAYJ/60TYG4UY(')ZLA/T*AER/ M@+>OU[*9E:/!VYMM[R KX2I(?R_H-RHII*^')2KR0IJ)@ =B@&N)G P B4V3 MN%YS$6K:07*)8#B\:),< /-YVGV1M6*!6A_9V5K9.SA&,3T*FPACXTS['SP8 MLB,811[^3@OE%Z^=:E10BTZ-B$!4Q7G_ [0]AAV_2MX>& M%L\X.SB?U"KU2 ^8.%6O$)!G4,S1#8BW[@F&4>Q%,$N :48+QFHX6Q4V:JKR MB-H&,3.X!N%QDSA^_&P'^N*28Y&,&940OFGS1?'''"SVOBEV6O_B8B(>^)A M#:L#T09 51<@;TUMKD8.J9.0'2J\":ROZ2'4[._@FLEHO9HL'>?B)&XFA=&B M5I4Y$/1A/2\=BVN--N=OUMVF^X/^V(#H>?:$T ]V8OI?E!1 M*%;S_CL)I';#X+A5WXRR;IAK2$FZW**6>.KY M:5KGD 0Y(4UFA*X!&D\PEM D?*X3 >\>JR0FDS9A'"Y^/W,_]A6@-+_^,)FP M '8+_&Z@Q:50$I.?WU1>:$RSQI8T-.L;'$,N/,CL/K7*IIAHVP:=^J$ENTD0[HMG*CU MI9/@ 0497EWSFJP720H0R%C?X>+=NG^<>5)J@X4?GV@=P5T)S1P?8%;)%L(= M/J^@&?TVT(B+5)9!CR[<>NH"-#W:S]/'9)V^YDU(++Y)G!Q ,*4R9C6HV$;- M4*(OZ,P1-&/,TZ#D=;]])0S$E]4DC[H?)V59CJ[_:F[QG73+[%[ O_&?HO[H M[;R*W)\JS:"N4B?VD^$"D,AG.,%J<(C0P]=LZ:#[:3?1U$)V%7F4[R+PRV(X MYQ,(L$@08@_O81LXG(3CE11+NELWN:)2G"HA6]LCM-IOZ5$%GM$N_%&SC@,0 M@]47E>.2,TN/EY!19]46* M@;O?K%)%;N8"NUO@-3$_#KCNE,LSZ:7;PXG&M\#S(J5=A+5-XK8:B%O\\-B> M:;K0BP]X&9P/I4KVZ 6ED==W18'6&'"J3SAK69,$)D*>&I7L&A!-2 M>/.YFX,0CQ@X2-D2II",SM?:(ZZPA]:5'@RRA ;WT_>"WGQV:FU6NI)C%)ES MY^]T98*;9[; HDG=P\4GR18QIDY+<&/,H:_7/0"H"3[[81GHJ7D#9H]>C88X M2K]1CT+O OHYMB8BS6U8-XN5:G,XMP$EPDE// M# @?9 M\X5,T%!1P^\+_@Q]#!1KB*G9$6)U@\V%BL&$#-OD;4'F"1I MLG+47(,;M+-IZ0+@>8#4_2AT8D#!R0(B)W'Z-*K0VKB#;GJNJ#>X#UGW'$S. ME0-&X?U+ZV! =:X(<08LC^U2E98:N$AVZ&C$NT_HQ& M#5#!;A+W4I44UCA5C[X_&YTC4["E_OOAOA*:34/<*(_O4X(XGRN-X)F.?<58 M &O)#J@I=S=HRFS(WM'IOIEPZXF74U#>7E0U9J=Y#!H_@W+1.>/:5?3575P; MY")(;?RBR^*NIWM#MDS4E+X/DO#S])KZEX'F0G52 +JD'3F!FG:N+7,V<@UZ M>>(EMX(853)4[4IK*ZX#C/NCX@X_F*:E>O^: -B1Z";R:5D:NZJ[6'L:V0S^ M%!#-:=D-E!H"LM$\911UC&!X3.T9CFH>-10"TT0ISB_'R=B+?9#5"ET$-5RXJWS'DIED=GJJ&+IL;W5 M@3&W^^]?;/ME=JG&'+_$[\= @[K74W,6_J7DS(%M%'XL-=U/R;) ]," 4;*B MS'6JA*Z -U?T")D')SX2%]*\A;Z/X)H&J7%V\<>A&DU%(SJO4WVF[ES1C!]5 M@-&1+6]L@+7 ,[: FLG=P.UR4AO PTV7GO">3N)&M\EJLJ\PUJ#MA&K6Z#1( M3XG/B$;GAW@J_"RB\J?!/[3K,(IR2+L1"00E3:F_=7A?92RF^V+W6 ";"$@K MF+NI\X-HVX>YR[0BU, MXK+^J(O6T:,I<[S6%IFGTFRMNNQPYNRH*NL;P3HJ M.6JS-2UTIWK9#*?JK$;EBM_RG6=8X-"__F^=1W/49.H*N'/1MV2#<8R1L*WI M850YP.Q?\J+=29NW9W"BJ*8DT@(S1;=HPE80BQ*(Q[T/0W$_4YQ'H_Q?7>L6 M^;0[#;_**XH?OI[H^YQ;5]WQG_-IW#48?%?!^J\)\WDGX_-,E-ZOQ5*RBLT< M(:VB.T(S_F"\^1X(-'Z# X"'4YK75Q2OJYY]Z*LG=V46N>/BL]M7M M[L;8G$7[!.T3 Z.V6D]DG>X6.A?FJ,1"RU&J'WQ9WLR9TS-<$S+=LG[;/"RZSZN>]EA]^N;2-GLXR07;IZ9W%/ MLV:B#5E1B$H)UH+%HAS* M2!+&N$["1\'2!LI"3*!>.%"-=7<$K5G>G:G@]'AJJG5L.D$I7A#)MG#*G<2E MYZ_ C-T#;7<5"]CI#)._\Y:]I2X9[.:N[!JK87DG-JWO^2I=\3GC\-";29P? MTO3V%?$E<$-7];/N>U^Y+?K?PG*,)P_T>>@%@_5+W8X%5 M*E*$C5*?,#X2*O^JK4E&CLMETH"CNB+W]:4, :]R&''4O22M&,J?!7M:_4R* M1@Q/@:4'=?EU)BIQ3SQ_*BV0A?FG%'0A)Z1?[BI;+O&] MLD1?^UP:&+8@$S'] EAC,MBOB2(E"KE.NK+QU*I7&#&@X'AG_*Y-XN:A.+KC M+?Y$5J)M:IV!UN\KUX&MV0XW:=?# ;XU67XS8'.AZ]Y,SK"%47=VH4A>FDD/ M@I_>">:9H\=/]0!R.X0U:-XDLW2?+V>G3^)F,V9''49=LH5LRQ'N4AEMC7HG M2$@?Y\T*XH,=7L\E]%V$]+K8H@B7$!/PT+MN<\AHCDP@K=9D^7VN.93_4OO'5#VG*C]C.%3HVG^U@#Z54O17('SKX'\YI.?C MKX'.W?5:IZ^U0')9G6=)Q.%8B]/9L9S(<(WUDIJNL)H77>.KI!T[?7*KPD6? M>2.VVM61Y&FDJ1WS/)DI@@=EJNSK] BH6!XVNOXAHV>BNX(LC-=N7MH*G+K3 MS;" _93"3&5IJ1J/K&^K(ZLNWQ&_#C%]U4$G%!<5'W\XN-$UX3.:6=ATNCLW MF"[[E2HDTJ:$U[-)G,W$2OBH-IPAII@OT^4?;\6XFWDXZ3==2=UBB"B2S41, M59,XS'[G(S-5Y/FT,/EX?^HI:*7Z8*N[GR*:I&J\!9^F+H 3\IN;\ ^#H\QJ MW^+ LHN2#C\?MCPMJ MON_2FJ'OI+;)*R9QB72&/7)!E\O8V!]";"1FR/#H"C@1-:T1YGD'@"Y-,GWZ M4;"Z2KN2D!9G=F/Z$(!W$AM'<9="7ZJ,7RD3S'>!?<+;]N.2+ =G(WV?BF@W MXEXLX (+&._83PD-D[@L8%I=-!6LPC"W=ZJ^^G$5&\.)$=W]F34"3%-T]Z^D MS*9OZ&3H,=[*YI,6PA6-.>H,]Y5+(=LKW,WT'57=E12#"(G)4 C^^SQ*_<3S M49CWP_C()&XM )JBWN,RI3I+-KMN)I0HE[WV,X.%1C;*@=%IQ?2]75P\[.IK M%US[ KK#!JF[0;0&6O/-Z !_]ZO6RK\18B%.BV2#Z,VB'LU5%7,M!1PUX-_IXNFZA.&@A(!09H_"R*5*#Q. M4V OY-R#KX%M[0.=E;EW*_/VG\G,*@E=[K*Q8OV&)O/O5/"6_'1!.#:VF.QDL?^D=9>1E=S+[@<_WG>AK M$:E?A&!QM'X5F?T+X;G/01V!<-D'OE(RPB]$A>S9I'7(FEP5;T2L8/?$AE#G M'QOJ7ZQ[6AA%]DF(2N65;>AYC"_ MR<)*?.UB@H-X/X"/=#4K*?SH4_0#&X6!1BIK/>*N^]/=1[NE1LB2\E39&.B% M^MIXMJ)F]-VZ&[RS?937[/G(T5)8*PSD77\(>@O5/0.'0+^L25P8IW>6^'6I MG#('"9 PB/#9#K_H;;W;NU9"8P<,2U(*G[5D4O9M9L8[J!LGGU:)5] M;).9*Z'7J734D__S3JTLU2G7ZI33R^6Y^[7V(CE%*+[.M:N;JA-;(813%1Z)_+"U&9H,Z\B5K!>5\^A'X2*KR'>4,Y/$<5LC&<^? G= M!+.>T'*U4<+O7[NEON+4$RQ!0(Y0MV,\.I! /A*5R[K!W03KO?8'&KPG<>%& M@.:7+I\7ST1!9C^ZM MZ#-7\%(KL<&_$64A:O)AI[I(&<67CL@9/>H&B@63X SF?Z:3KX>EWQ#25Q"\S_4Q0N; MRD$6RPFIZ#H^2&YDV'(KX5B'5RJ>'AS?M#$N@%5'5F3Z--6.=[-#%>*YP^=E M01$YYR_7)#,6#.84Y6K#I P,H(S^Z^ \]HB]$OCPBM]O J<;B1K9+&L;F!VO M/1Q"W]=6EQDE+V[@I?=OK(1OJ1+"=L&1$\5,='-DR#QHY=4'PPRKW"-<5A,@ M=0DT3QU?AQ_^DH:N0QQ!T0$)<$*=!8_0&LD?Z0"N2,1PFKQFY#>8V (L9 MJZ7PL$(FX"3Q*F5I:H83LA9(==U;7T3[(6>PH%=*)A,E,M[GX-/&XF5+OD[@ MKZ"KPFL_Y9AV!GJ]NA]NX7V]W$F,OX+OJU4QEM'4?)EAG9Z*DAIBG_--UBC# M(W8VV_EH]%K[V^74LP?>OC]]K7MFQ-GEA@M_KYA& M^1<_D@AV:))!%P'6.!-=#M<2"8<+H%ZAK (3+2%$(%*=R9[.BV3WV&INP+Z0 MYR'P6X&2>OT.H;))(L0O'F(_QX_BE9,X"UK9"&I-,Q10C 9X5.9P6+2R>9B* M&UPW5#NS/VPD&N2K[.N937#=8E#=))NM832R*P'F)"Y2S+R 8++AVO4=2B!3 MMH#*77SL",WXAU(_%J8?F"T K,8(!,O1(-].AA$M_Q?=\QZ8IIOC8?/?C M2A]6(F6)^VYW6[F]IP\H2KKH00GNN(3Q;5ZUO&%"PJSK815Y>E6R]Y_ MU^#;5JWT23F>OWZ-R'W_NW1WD]X]"PX&['>N?W?N6-!;TRLW#919X>R+YX4W M[5:AMEC@L('%%[3K&&V77/T:R1D!%DT_D7EDU$ KS]P@]H$CH.G!@3]%%@2A MV0M)G4E1[U',:V-5OL:MN674QDOGWBBMEKVK$A86]0;=6A$?,%JF_LSEW]@W["HKO(2Y5,I.L=$'LY38*+_VAV:5O,,)FHI<*]R5H%V$TSZJ9D# M-\MS\1G-8)3B)[^9TE,K[%#V)=_ MC#;T>=KM;'7:RI*B.ZKCDJ8',UH)H.<7\'TZ^.,HG U9-A*>%V-RBC<'V7S? M\TD(G(Q/89C"YQYXGRJ-L-B8?<%(DN(<3-[>B6R)'K-,#SX4HW^C('TGKS,I MPVF:%CB>$%URI&=HXP&GZEA-M:3ZN9/_EO:@X,9;KT=G"LX=VR9>F-*R$/)V M.GG[CM,?;^TET#!DHN",:,^5TPFOX'KM*O1CR :LL?2:$:IQMG8!W07> ?[4 MW'\F(2UD=' @$V$-8,D6D?%.5MX^\'VY.)5A*_EVT1#CR"%$^.DM>$.TM4^4 MV#CR5K@9X4P;KX "VY(RM5YPO&:I+F>,(I4.''ZENS\VB4O6K*/OS!:85[NR M4I1U6L:]"2-VZKB1QZ=J+N3!3")L?0:M^'#SZ#?GYOA?U)5W1@=N7"%U_8_/ M?7@WB?N/E.?Q'\R16U/9S& ^B: +]9M=XJ<(%TA_:$KXWWZB#H#/6M@YM1N MOHJ0NV ZNHO,QVMM\^=,;?K;PW'\'UQT#^_Y@&<+R#ED FI+GP&O (\CIE#@ M3\UYT+;)3TI1L#!.0:@RRRL(G_@\B1N9Q(&WFCR/1/LU7=I/2_3M&K-:\$-@ MT7>'*8^GF U;)+04,XN@!;YGHL=S\]9\EWPW%TSB:OR$XNET&UWI1?%,AC1_ M+:S0;D9;V#6V(Y9R&88(U?4C7#.FOZ3.$/)ODGK\'-4#"YID)NZV]R/RY\/I M!;29WQ1MSI3%'WKL2'D5L1?2*?J( M*54XE5!\+OX1S5SQ4S15-*[F&CJ-]E.A3KE(,(<=7Y^C^W;3/12L]#_@S6VG MVZKJ;076RX,#94VU\2''!J7C366:G)H;O6]L.",#H_LG<8:AFJDZ*!>G1NQZ MO*:N'2%#L0TD_4[S'5@'1UZNLRKZ< 2^U41RO7)DB+OI1:N[99@\VBS".^4$ M&'"]N *T@P%/+F#43&9RRNQ75ORC-W;VIS]-%FC"&Y M\]+\@^%2L$ E>ZUF,BS! 0QNJLN=K-RV=U6R4R;F2FL:2WGS(YY'M [6G/G1 M"XM'"Z%$$6#*PQH/K^$U!N&E:A&[2C;R4KL:_JE9THF:,%H#)IA7B _@]"?( M[S!;T6*G9+XFIH9L!CG7QW3Z*K-T4':PV]U%56][&(0[G'T-!7:*3,? +H?* MY37@^+_Z&@)8H\IN8&=.&&W]<;1CH(U3WM1].TJ98!@(CDQW'L\Q,FR,F\52U)L9IM]5G_VM_:(]2>;3 M<3__^[==9\]^R7K?OO#.ER]';?,:[D18>)]V^R#>[/$"N= Q1NI"HH"&+4 T M59JMH7:2PZD&-!---CU M4C>KB^3$D+@6C[[$V,0Y*(#/PFS1!),*L@\L.08R"H@X]76[*!"F!H#Z+/=8 MB*+9#'TICBZ*\K5E?D,NU9K=5C9'L:T)LVF.@6U%D"B]H.USYRFCG )8W20%Y,CB-=J%_+,N;_18^!H*$H.9-##M%M\H5P-QI^O_0&_ M'>#G;VQW:B$.3,&/[>/3L+>PDV>G86]Q;$AB[_RK3HJB68T"W*JS)CNIJ ] ML>;O9!Z%*&EG*D>WZTW$+#?F#5P#_G0.U$R(?9_7=<88_KWVB9,V*+UWN/FN MF664C\_._/C2?1/0&%#G^@ MT^GOW[I&$.+E!Q^'74_T#F:[_G/I4OZ>_@0.VDLQ8:REL12DN]I=J$S*'O&7 M8^'AVG'Z7%U!G?[EAX,R@SIR =J%4>NU-!=_:IHY8^DM$7=^-^*A3+!MK,VK MS[I*:&R9+GT;O%L5='.8#WZ@2'W^P)%+6--HD[@&PD+$4L%+81LA1Q63N"6P MB= BF%NCH)C#00B5>QYB OV1C/H5M#/1,8:Q /&*WES&/R.X1!SN![R,JV%J:!8L#'?JO-] MIE)FWN"Q$4-^_40-?):T%Q$2;O3KP_'J@@?;C/TZ/2E=@O:Q0;WL*S@5PT$L!YU0CM<*-5^(]GQX _-P4[&4OR< M9LX@%L&!9))M.&EZA9]Q#\V;S[4&J==")U:K\ 9?R?,O MIG]I?0B9)F<^:E 2YA:GCM'49R_Z*+O- \P&-7VNBMU-FWX%*"B("443#'LJ MHV26,$.":9M4][,,RV'9;&2]BIQ&J#07BM.M;>$P<%C0_: C$!0WY@4I;;/H MWN? H?[OBT9K*+1C@Q,/3[_O;>;N"#A*GLUP0<)U!9.X4)8%T. UIC:FAW-O MB62&*$8+&Y9SK>B[=47C5/UPDBM$OG*1LD2L),Q&HG4%,7D;$J9'API=]FWU M&-=5E==H=&3^^J&-M1F'#]=>8GXJ/J?U1B4A*V \B.?GV(ZT3%45@^]K3](= M(W$5 MW./$3B.8UWD?5\CT@ASAT!UUB<%IAL%;]"8L=7 M#4WDO7MS*C0T5/]V1!AU+K!5+U_ "+FBL940FK.B?LWJ!,ZH>_V/Z.Z\OQNE MW0O'-Z"$#LST^P(:*$:8G$O%; (_,E/.D7IKTF#;0OI2EE"J;K#TDV;+WU=I MMS'>]\^"Q2!3&'#'59(2PS(Y$FXQP$*7^#Z05FH"LPI(M\L9"-! 1#WP4A^- M QP*;: L0/RAS!]1!!/ZBE+:+=4*"=\^5.2:7"SGI'+MP::N,DDZ:CB80VYD MIP2&).K^SK=HY2Z#+9J<>!:#@_?=SC-1C_ MO3D-:D;__2D0Z[95U;[1Y0"?F(C#).Z982-Y@A515:;UG,2]P<&?IPZ;5X:A M]P/[3J(MY.^>J#GP(4E!T'E72G$_X_[[K?^SID"(.F2^U@=X@X<+IE;ETGGC MUIV/]((TM*G'@R[8X_EDW;;*W9HEXQHY>A3='L!B_&>A #8//,I*XRTDS4-% M4B"52X!_B@BSW:T>T>-A&P5%ZJCRX_NZ1GN*V/J\,/P"&M>>K Q@N6^*?C)N MJ=N@_&!EOH,K<>ISU>YOJZR/G-"T+UJ>,F2VA? @3E_(2N*N@HLA0SF;61?Q M,%)FREWX%36&\ +*C"#G-]WT%0^0K=6=9^L6/QJ*6E$;9 C,ZQVTR*@FA+W( M>RMM_O+0._RT+U2C6$M>;$\.*^$NI9TE9F:CTU_"!6%@F[H1?CR@&"]ZFF_] M$CJV<=',L4BKB).?&#?0-ME,E/@1[>I A1@8 9%$EH2\8)P-K\@6 M<1;3/>"",N3@BTJX- ;*PDN#&AF;P9I43A4+SYX;:)\X?((\(X_4WRC>\ART M_T&CCBB%LU_CT)NK9\_X/2/Q3\9U:UYSUF6.2G9$]XHXIN!M;HTJ*-S^K!-Y9%R'QZ+6)BRT)$)A2O;H;P4T MJFIF=I.ZAX6Q.SCH$8WAX:^IH?3:"0EXDGU4 &K/"JJHAE_9\M4S(R_ H:)^ MZX[[W0-@UK,$I1M+;Q@EO*RHM+:JZLYBGIFF'=\!6+&K6:.7M<&T*,U[W6-D M"<\RAGI-9E5G H4IOMS0SJ?Y8*]89<1L$%^/8U]SMG?\?]K[TJBFMF7=A:" M"*'OA 0!1:03!1$("3: B!H1!8$-V8I;@="(@ 2-B8 TTD5Q"UL4@B*"2*," M(FV$T-C1)0@:A!"R]Z:-K B$)>E>O.?/>^.^'_?,.\X:8_Y8([/6JCFK M9LWZ5F95=7)+="7 !4^Q-E1Z3/1TF909D#-1'<)3ZM(OIEZ].HG+."NX3U1.M)5NGHH?$-(WHO D_D->'YELP^A@R5(C M7$+8Z3G1]3\+6=*P^GY=SR&*&[2%AYC:2J8Y$NU.SZYC=))@R,BG_H0]A=' M[,3.XOY)V;4Z*>@KLKON^.ZMH1>ZTA.W1;A+X$ESI/VT3 [^9/RYZ MTH" ML-O2]7,$4H%Y_D$T:TH@L<4295@RYON-$>'NJ!IQ9;@7ZSD>(1R'WL\ MI%/?+ZFY;3QK[!BU$VX\B'+! MU[Y!;7TME50QE, /YZ$75CDV3&H@#YT=V:Z.F["C=#@T1^>@0P2L&TP8#2-+ M0/*B;O\U1U%LC2^%FI=ZQ$']E&O6C5,N :>&(P%T[7?7_JN;*&6)Y.Z?\:Y* M[3*0_NH4ML=&;Q8.@-N**B'<_C;>GM=1?IC&3ZTA4U8VG<%ZSV\Q [\.3.-0 MIB/UU<:#"H"\;^!L)3EVL^-/L/V M+KLGVPL$SOAH_ETHG++1'AAM?VZG%!/:_'%2H:[ M(D,"FT?5>[M*$%\\:(LY5$6B!90^1;[1;B!]$XUHRS/KP.C!TBE:RT$J4! 6 M4NKI>_QYOI1&W)*Q?D_A;7J\A46'KG7+5O._$P?[#(AE@[EMGG.DW?/#%_&& MK[6$%.%YJ.%G:2,)P/6>Q"B)!ZGJ*)W&G[&VS1+@)?K-DU$Q'.+&(=3QL1TL M5?2%Q0V]U1#V4!AS$7.H=N+4<$]*91@S[7[\5>6V3R,%<28;\=1,A '1D: $ M1G.[00NQ_A@_YX6H2"PG=1N.4<]3;["T2:$6$D ;*SP$<4!9_@GH(1A+HZJB MC'Z6['Z#4_;J<7*_;T:./RKOCC(Z6. ]N%P=@,-MS34\AC\'B-LVR(]*%UM[ M["#1I:WM::R8M"9";Q2:237-BW"Z#DH1'),B_U:'2333CZ/#=1"@(&V;+VHH M.8@F'61FJ]M45L4R3(W@Q%N9SO@3Y$YGQ/6I'PT\])JG_(!)@-N1/9=:<1<> MS3+;1NJF7%^M<5=[J3!J.%8+2A!O["B'=()%9<(@@=Z'D>1$6Z1 MRH(GWW%%.L1%V=I4@O^3+_@#'(<%,PXFE8<_+ '89K3[67M7K YPJ,FM/F&H M.NO[3R"FC7;XJ\;8&;])!-VL YWS'P$#H:RT9E@/(AGN.-1N2MC%&YE\7M8A1XGZI*CF)7>A_ M0XK/"*AAL0OQ4TQX,S$'7#/3,4@]O7DRW1OJA;S9X<4G=JOB4@.$01D,0 MVHV!M'^,)[6+;E$C%V\6.XN:T&>O1=$XBUD1Y3\]QE 6$\>F]D1_&>UA2?T_ M7D'OA 8X?8,H]?E'6\TF![)9=3W/P#MOB(HB"@'[*!RN08\GK_<$.=Y7JQ-H MVA7,+J??64S]!V\0G^W-&H=75E<=%WO/,'(MH&DPO7N16=?! @^ATQ$-W[($ M7D0Z29W!H7(W/X$T^#=XD=/=%7!$$JFNG(9@^O&3P.!2&QK6P%.*EC>'2P"E MS;TZHTYFZ<1MPI#A. F@-^^D4K0M2ZL^(#B+?4V_O_<;%C(;X,H($O #[ M< M/9)@MQ?HS*^"8MBU.2Q8'#K95A@L:K#'9*T2%<%O9>" [PC1#O(Z*2HCV(+) M\]Y0N4YZ:ZP$4("_F P<]_#Z]%?C$($TA=C(PC>O'@GZTVZ3O\@B*I(.&SVA+;4AP[["F7Q&T6/VK6D M+CMQLY 4M,DP*^UG^^_N5DY+C2#[H/]4V@YA"*J"!Q';HEG1^F7 YPB3#\)L91]O2KY/?8:O2%6EG"&;!7J$D3*VWFU%Z/Q1+<10_% MB,_$CJ4PB@)JAWB0:#DH5I]/0,!14O/9Z<-YALEH;DM+G>+N7V.QT6E5!,]( M ?I^T3HNTN*Q:;O*$+&C%+=:<+D$02_X(=VGIJDCY*7E>;'ART3#9S^"1,_$ M1L3Q !+W%$FP^1?"(1ZZ@Y5-!4^14UEUP2_ []'I5*U6[ZF!#>+WQ;:BXA6* M>J_ _P.XV[<-HS1W:R:@MQ.K!/F<*$/V ^DA5(: M:[FR/"P_1%2%CB!I08U3BRE""QVIJWX6_3F3SO"$QIX1=H#H#FI&L:K3$4K# M:+<43H\= 1MSST*)[$BOJ6W/BS5XY-QEBKSGE "ALME+>;<_W=HLCPV@J[!9 M6'VBMG#CH!U64QC(JR%/'I7M(CJ T;1KL),CS+\BXVT,A/M'K0CVDU3EP/N! M5^^I/)PRO,P?/?)<)4OQ]3TY>M>]B]+=AZ4KUB,$1\/-:%CIWF9+2D.K(;U M2N^'QPTT4N?/%,B,??(WA5N?*F48C56&TK\>,&32IOAU$645C_IXZM$34@'@0^TU('5.0NIQ3\\'<;$WEA$:4-> M720$%^G D2+'9+@N#YMM.MR;00CZK2P@J&];^AEV6'R? OY&T%[Y9804&[ZA M@,AL1#V59K-N#J$NW@X5= 2K-L!W0D6<:"5\+$IX)2#C M"FP'@!(50'I-RB1UD[2H>@3_1)X%_X@H6^PB'J8TP'*7:[\(_B-!+.D7B,1& M,W\FZ^/:5T,CBYV(NN(V-EE=;8JE2_@5)"4CX86+W=34XEU#]C 9O 8GJ#'M MT4@MTKD"]G(B'#L6&YX@ 9B1];?ZHN5&EJRZ6Y]W6VH\3CY9K*<6[)AWRO3P MRX=^_C);:!OD4@J!/Z0&:7YZ!4EY^D]5P_Z?^5=$I??T4#U9=?9*6GKM;$!4 MTZ/PD3N?PYM1+T)P3V>O%.6\UZV):%!&\B;EQ M4P911VC?"-I"V&APZ_>&XAU Q)3A&J0S=;\IT_>@5GLE%GF%S!I) +Q!J6) ML_I%B#KM\\;#I\'),UD(;;7B,CJW<;=)@!MAD>R@S0O[395F1O,O%^:4?4I[ MB(N\&G(MVKZ(>_=/M:" 8/^O/8-?F>.!Q\C*W0U=UN" 7 7/2^/EH:HJWZHA M5P.'=*(NP0Y,3[5!*K+1Z<4;0&K2"HPK0YIDJ4!>KD-(KP9/22:P<#FX^ MB(QY!CET-I?G(,VC*P+P@3WZY/3ZK$5-?#C#-^O=I\@X9>+?_4&![HW#[&V& M^PV=OC&=/]<9OG^?KI4"ZZB]H;VF3$Z-%&L*]Z30]*-O4MGVC%8'6%*KC79* M.33 I<]=Z'X5L#\,5\Z$*(+#B0TP[HP5YQ-QW+*1A%OZ,W$S/;0$MI='ZF#= M(*G&*]I'PX664"SGFF\T+ AR#\)TBQ7 @9OQB@3S"B_35;%NWFH ?3$*2QNM MZ[,"4B\5^ M^C+W:KLE$R]9?*'MT M?2])F; +BI[L"^F"&X,)M$4Y/*8+;O5:@,U<86V"?/8-QE,TQA/SCO(IJG.% MIU++^'4QTUZF[9=+73X6G\L5-#IK(+)0VL)=/*ZXX!E^FCV:A RKG,EW&KE7 M&DZT LGI0H^*,.EL64J .J%;^6Q!FOIEE#7[Y5C: M=[]$-^!BOM37(.KY?TAP*:?5K@OH(TV.(=+]Z@+Q!VB@5R(H 8[DXN-8Z\;? M:1?7QDZ.HS;?SZ@BV-I>4Z<[_NUU57?$7]8M%BQEQX\WID1\DR+G=7,,=J=" M.SS@%[P#3?H8%9L7;D]^$#+N%-;[-.7YEO:9, M2@D^D(;2!,44MHT2/F$_.)H:EZ7)L*,HA^J[4THADA?C^*Z:HO+0YOBV5T6_ MG:W\^"PL,M)@H^'U['5N9_%>['0:%IAI+D@3*H&K;R:4P&]U,8F)5:$H=3 _ MB=VG$O@U?EJK\-#RP+GS?/W/\2?MIYN3O:W/N.M^7%F7>[?F<#W,402 M:[W=@,(X7O8HA 8;,:#AM_+(ZF#\MEZI4;W!19HD5/D'C\WY7FD839NDFPS5 MV#L?=:?3Q4QQH%ES,G]D8L[\!-[X]I4!5AZ%>.E3,D@H/>4X6*MX!PS=BQKO)K"87G"YZ$%D912D.9\;FW'X?M\6V.*B@+R\_GZT?=+_??GS]R M6?]:SN.8@"]? @)[#;1?O>)YK&^U?>SMGE'Y:.5_.+]H+=/;7ZP@/'9P?3%F M'?1"S?7=A6NRWB=/&7ZP!6 GMLOZ_.>/@)LVW>DUDNT]OGMT^)+T1WV>!/C' M0?ROJAY"\\6TTT9_2IE4\+WYUB09=GQ?A]:"'4#/V+=>,QDPJNA0RJN\9'O= M\PURW3'SRS6Q2;<4Y&6-U!7UD"L Y80,DC[D"@!QP"6,P:5CGFMYGJC'?]\" M-@"R,[;O',UDA_,P35+#HF$(TY-[,!GG^!9."1;-M@=$?E;;_^VK7SC7[/+W M0SV*5DL:HS'C#Y8PCZZCB*(B"7">!1 _%L*Z$"H$YQ:>VS<*SX9CTT7-)1K? MZ0ZH?O(L7CY;O&/^0##/OKU@:_&]LK*:%$.HIZ#\@V%?]V/3JM'1J"-W%[MC M6Y+R_/)D' W2' WN1IV$__'6F.(&.)PEQ1/Y$J 9)8YM*9\8<&Z>;MN\KW^R M?._D=>*\>M-*KUQ,Q[LY?+PF,'[S';/)4K>H-%]7AHS X"+^P:8%H<$1RE* M80>"B/@*R?KQJ-WD-/9*D5*74T(.:B/!@Z?3N0B?:1Y(CYX:CAN[CU;%$]DF MU+JELVJL4+CQ\U&DP].ND^%.]A]?\?/&!/::,M\;%[H%"(*YZ*X1E'YM\JH$ MR$#MYJWVP%3#)LRA-M[5J=7<>%(&10NU;;X0GF]GH_(57]ZU=B]M?1TXDOST M$41R&ZQOVWR 'J&5SSB:F_AM^O5:2062\R#$)"5[6D]W[T"$5$R;%$H +5=? MRY+M@,:#V[UR^6=/7_)$/?F]@@.2/5G+EK=W*B14L^4.Q^E5-M_:E#5]?Q[9N. MKYX1N>DQII03QZY(F5-LB"UZEK?/3-:T]L"*KJZ+1_B>I%OKKG^QW.EH]M0E M-[%_WT!MY9"KPDFU9!F#BZXN*A[RN3"30?J0&Z#I[09H35-T2'_>$6(DP,M$ M#E;DON*T[+1$S>JRZ21ERMVJ1!E"PWF'@!!:P#TS4Q"0>Y =\@ ,E>W[S]G_ M5Y8*%O[(02QPP6"'$[D4)12\M'33KF;(P\//5V_OCC?)NRZZ6\PP_\OIJT;Y M=1X%_ 2H3S.4[FG3R=(Z<$*NC:R_]CL/^=AE_]+P3VX+#\ M5#GA.FBJ-(\E+]X&.)VCK)_'ZW$0)SQ&7I+.-UB 'NS,G3O>36(42\W9=PM< M&7?OII^M4C 9/B[?\O^DK)#EV7A%AG3J=R>[OVSH?O#B1T02W;-LA[_, MCO>7]#QU:]9*"[<6[KG9&ELIFB!X+*3R5'W'1&125DC:& M6/.7N5'5 XANFS2G7]O:Z1'+\A;Z7_&-[/+T1^DT\8[!PL#JL_,'AZI:+Y,3 M0IZ&]STFWCEWA2P!_+#OJ=+QX:(_?_"$JB.MJY\$)%6,_?)E+I^^SZJO;/S) MTR=?QX)^'CF]=B$^[%K97'/DGVH3LVM/BA+"*L)6O;?VE7U4KWR+V@>RN"Z" M2\2^(W8(C8Y'Q$&Q)L.A.Z1,>.)U&T@FJ_?OW98\T8_.@6O2"8>CMS >YS.] MXSGHU& 'GGN+86D #FZ;*_[.Z;*]3ESQQN8%F FU[G=.Z6#TB'V(S7$X2/A\ MEIUS=7+@9OUHK.XN4?$2%KH[:;6O-/=$B,?KH>J D^M\#"("3)M)DS5H)1D3 ML1Z53]EK>LYAH2,EEX.NG]R+FD0<5P:(S[VQ=UC@JDTJ=3E2 M1+ -&*P$8" M+!\;D@"P2U"@!'!G":3+@X5]*0$DP$&NE&3HWR3_)ODG23CBC1Q0VKNO42SU M<59'%SI$Z##&-^+U3U:QXHT?V.0M.AV4.DQ/=;CX*#N$YTX%HVGZ<1&JOPO< M%M/%)I!8%!*VLVJDV9YCK&&4\U;MN?S\>?>8X97>5ZYFC.R4.0_7&.P#1".L MMV^/N'^>?QB*J;1^RO.8NE;]BLS3CX3_K24(H2B*TQNCNTQ126N'6%V(!@=NG\##(I2H_0)<7>"QVTYG MV$2@=/MB.61X#NK0EC0^0ZP#R[;#J 1^KJGP78R?OB'6@#RZ48@TT(V]J$>K M\O?'WR,V_#R4$:*\FQUA437'[SEZ8N[;TJF6PK^GYL1KJW[#4=;6#2Y^)X<7 M%VMK5Z[YG6@N]NH[<'*X9M%>27!3'_?A:9GS6_D)A-+RG4>0LSM#^ =WA-FC M<(*Y55%3K:P#3&7=W.[8?WJ9-QTX-SV\\>,CY4JGOP>,E50)[-*'D: M*CM -)N5#P"C&GXU]NSN^YWGN2D3;GY[V*3;V.']T/O4TCBC=-\SN9ZU&>BS M-F2F[_WUY0MDGHZW/J9K,>U5@1.&YKF2]<<93!9BDUU,?,S#=^S1VV<^VO.EEYVT9NOGQI^*G_KDNW;;RZD M(W#_7I0=1\V\Z%D5YCL6[QS8XN([XA56$U%;U1"Y:XJYZ/6IOFW_^V]T M"7#XT_+8:Y,V1GSDKK\'CC-J0@+O.U=<.'4+(/ZQ3M'H\OPH2VB. P-IV 8$ M]X-@S^V'^,K1 Z)'2(NR.^OSBW@H7.T&_)JS:>I40P,VNUV=CO2"/]1^<.[5 MN=>\]$ZR#KX\.)?Q=I00$>_54JLZVAY* 7VC-_[8U&XK*B0ZS(SR%OPPF^:I M&Y!>3UI^A_^:O(J%[D]Z\=UNW75O&JK6XZS;?_M%Z.^R*Z\RA10TZ(=(+:U= MD"I],68+]?PF P2)F2 !:N=DWBK^"RR\?Y/\[R:ADR$+MI4IM+59J:W-PQV]Y-B!/ M32%2VK48)O%'RIDV!!>>QI1*R8O6/WQQ1_572C$3FB$W4,JUXF%LHP/7"+$/ M'/]9>^="K7)X]NW@,);2DS8>.7>DFYVVN64#]&YJW(SV+!+^>#:NC\1&I,(5 M>:ATY:FQ&:(5V>=E/<_D^K5400PA@1&?<5YTFV@XY_F,X '=T4HKXAWF''J= MQB9J"ZV&]?L%@2E8VYM'R[-06_&7/5OMV8:J7KBJ V4XOW;D!A9F:$'EZ2J& M%F153U((Y5NI=T9RC;,/7K>,J?$[[(O\NV#E MA!7VY"MYG]=-S9^L?WN=__?:]_F3PU%1-O:&/M[#T5&+-O$N?MXMK_,7O8=7 M-C_K.W"\^=YT2U.AWP5TF6K7+??;[CLSI.#4^4T9*TUOU_7_5]L4Y[]A M1,^ UQM#KOV+3,AD"_>!BS2X20[#A\ZMD5VGLNSHZ/C.N5D*;PQW[IT='W)% M[)A'O\1T]OGZWEVVB+<\=OA9PG%%HT--R'4[/;:^C$U.I FT">:FE(4, 4DV M-X4QT"L! O7Z+1:8VV4Y".CL0"IV68$L_D$2NW@(;2]TUJ[)>4@ E4"P&OK M*DI@V21V%DJ+-&B,%OPE : 5!-A-V4B=44.(ODL X97V?BE@MI4 :9;0*0G@ MFB$!%@LD &>81-,F[) )0=)JQ\D &].( 5T4*]8MX[M)UIG(@':L1* ["T% M*O[@,W&2%/RSI"K8^VQA[M]<_;-<45/]$3SS;-*;G]UR20-79NK)7Q#L\P7& M;PL-6[2,DM_']I!FGX7HN=2-&<6MO'U7 M,'T QR!7#&V#.HU+F%GU@+SAVLHJO/W!9=UK_\!4/G#[6Y$7]1+?&JE>LOU* MLO29*5'1Z$*HM%I-[66Z8 XW-&U20)TCW#HTT/<@.>:=KDO2GX4@-X3O ?E5 MOOV.2H]*'?CH??KBI5VNOY_C5.@*>I6[K_F[ 82S).G,'IP62*>-W<'G]/=^ M1P?W_NO,[[^FU/_EN3J,EMX9)<=EO/VV!VTRMCI^)?;S!3E]P9Y,X(>/AR@/ MI3U[XJ;/@5>73RA\K1Y>M[OKL4KK)K4W"X=0;/;/B"4=\&MXX?F"R,AZ6!," M;;[WSSS8"4>Y24Y#0MQQ636M#5H7 4-GT37,,9)*,N7_D[3R7ZS)2+[\'U!+ M P04 " "TA8-:T.Q6_]?C5JZ M;3"K_\__;=]U+B__]_^>;/T\\. RN-1R_[D]\+S1A_?OGYZ>=I]:N[;3?]\X M/CY^_XS7;(N+/CRG7M>LUQOO__SR^4X?T"'989;K$4NGX4TFLQYF/Q^_#2_M M.B9+7(J?!"]IO9]Z-'QK1#?$+SYX+[Y,7.JE7KHO+O6"2YEK[S4;AR^-0UP1 MWO \Z]H&CAEF2/\\O?T<7>ZE7Q]=^MYSB.7V;&=(/-A"?-+^3KVYTSR(/63' MI7KB0?#W;M]^G/N"=\ 7G M3\@HO+A'W"Y_K/QB\F)O/*)NZM7\F\3EAN=,7)\8.'S]'K_&>YH[]59LME0W MTHH=N^Y3GC](OEEXD;7,>;'CU\F'SJ>,;KX8ODT[R1DWXE?I-<.\^9 MN7_'[^';X,).Y_-9>*5.'*J;MF_LZO:0/Z_1A&5"3*#$.-G2\.=GCWDF/?GY MO?AWZ^^\Y<+R'N]Z+ M1_[\7SL[V@6CIO%!NZ/>1^V*#.D'[=EX_JA=GO%?OM6;Q]^^WOVC>?:IW;Z! M?W!@\,^[)^8-X-_SSAG\EU@&_+?SU]E/VL[.@L]M'7_#^7]+S/M;,._%G[/7 MX3?5&_7&$G?O[W^CP"@P>OA?>T@M _[O79BD_\US?)KA0>W8@\YLW>?/8:Y. MS!OJ,-NX@,_<;Q=_+?G(?_].![>G@ M]M2T2TN'S^&>>D,0POY_+@#'M$8=_ORM_9\SA_2\_]PXMN'KB&W_093C7SZ0 M77CUXD,\. 6:._O6^"9A70P5/LKPB.:WNP&,W?W6_,:%F'B&RS_+\)@S',F- M?%1K:D"O>O;QMQO?H=_VX@\9P2<9'G'^[8[VD=2^[0>_B;N[MC'67&]LTG]N M]P %/L VC3SMG@UAB%?T2;NUA\2JB0]J\ :']1!L#/88W&8P=V22\0?-LBV* MW['G#P@P\^S=TMX_MR\<>XA\N5-OP/\\ MF__>:'(1P !\+XCNU?&GM:U9,$5X+V4?$JRX?8*\^//[Q$OR>NU>_+4S&7?[ MY.*O@@:P'Q] *IMOGT1\/GL0%P[A;">?)J7ZA\^VU;^GSO S*"#7O8Y##>9M M)T;:=J][DZ,#ZFHR),MZX^!H6_,M)JX%D@?IY7ZPF E"!79E^R084?#^^4/J MV,,A\W"=W;9EH,0"+1BT84;=3",[JJ][9*U9(VOD/;)/MFT\,=.\'(X(]0!TKSS;/WA"QUV MJ1-^B=!$W7;:-9/3:AU5;5JGBTWKH$S30B:QK1?'>UBF\;8-@#QX) Z8<:E MU2$CYA%SUMASA[M7C5T'@>2;Q*/&M3>@#JS]R*$#:KGLD8JGSIC'<>[@^)IY MW#N4N+XSYE0C"&C6N'.'SED+A], !9:ROM7Q@04M?7R/QKEX". __\OD=GK; M^-MWN6" 5;CNW9/G=4'<\=Y;79_%L/(X=Q%0BO69#[K'N0N)4DP\&WH?YRYY M2K$(M]0CH+\;Y\2Q0"-U9\T^=]E5BMDO+#SVZKD+/?[.2]?UJ7'F.[#VPBC\ MG9@^/1^.3'M,*;\&3'E]0%QZ8Q)K3;)A#VWHC9S^0M"_5\]=-*YB^G.1?:^> MNTA;Q;PR ?=>/7?IM8HY+H;+>_7W!G(3L!+7D&[Q M\,YE'H4Y/#*=BL6[I;K=M_A3.!VL;;%RY^;JK=1B"D@C=UPHV4K-UU6:N4-+ MR99@09'?;&[X.BRO'31SMU)*MC2+*Q+-W"V6)$Z=L4=F4,MPQ8;<>;!=N$QX MBJ1[ZQ(HS=S5X?7.>C'AT,Q=C!8XZP6 /G=95^!T%@3M5NYG#P7.:7D ;N4N MFPJ.6%U8S/->C^K>=:]MV".\"G[3><0AD!),SC*(8WP= M&3#+U+FUPKFUBD+4_.(-2C3UQ6#U*#=B7M74YV/K4>4H.9NS[R@WM6=E\UL: M;/.+W5C57!='W'7$>12/IOOY^]L+GM9"2+F?OXO]-=.:BX+[^7O-7S/>3 BW MG[\'_%5C7Q:]]O/W%+]F'@LCTWXC=TV^%,C4R-U?4 ID:I0*<.X>KLCZ+867^+N-2K,]\T&U6.; S M+_1N5CG(<_8B+.:?W<__X* 4L\\@/$H<>+("V9"_X[HDTU\,^O-S<*]R^MD MKE7B6,=7XU>KQ$&.1>CHK1+'/>8!QZU5Q3DN%4>W D#>B[M9\HJC>VF/.0&N M;;8K)>>"IKJ8J-E;:03O,E.=;S#LK5196F8."XJ-_=R=F7E/9'D1L;]2E6Z9 MN2TN#O97I9\)I%TK%NX?K!CYQ<=@D\E(O;7)O(.5YIBM8-J+282#E8+0:Z<] M7SH+#2[+Y7;]C2$O%@I1;P:^>YN'0\6*GQ MN^2\ID>]*IU?R-#R2+GCU[X M5[*5FJ]S'>8.IB5;@@55F=.LP5,B&LBDP]+G]!QO: =^IPVH;1( M3['FGT S7*9$]N);=YQ_MN$J9YII3W,C4BX57IAF3/UM#VW'8S_X'->ZS_E% M-I9E]EGV/O]0P*4!Z@7#-L-V[NW$SYY$Q-)=E/YIO.M^V;&/"5/6G8I$ZA4<\_ MENZ5S8,:C%>+[#/$;=6SH*?0@W#K-T-L+^27]1XMP_V2\- M.5CK2\OU'33=@6[A'V;UTU>YF7\22O8I#1Q*\YU4[M(L\Z0N;-_)=4Y[NWH=07QR81CY M?X#SG#YU\VW*%U^(YJ8LQ R*33P;_@#5(EVF3"@ERS!J.D(?'.;NY$DNF%B9 M!:W: J:7NTKY^NEQG#I_QD%Q_9M/:];X\Z_3*H4_:/J)J:QMB_+W5"_,5A.3 M"D<*''X'6E)L2K/&GKOC<-FQY[DAQ?),ADEEX93\"^%E'?7TD'+7Z!<>4O.U ME)W_8?VR8\^1LO,_'E+OROGY5J("P!![3>#H9T]AV M'+1840J?CJ-+I&#F4Q&S C,;WBQ,=:27>[!TKWFA4??*MAYAQ:@!NF9W,@5Q M8J6B("MX'-,]&0_Q%:;JWMY]73I0L'%X& >XW#(4"ENT3_ (S[VT1!!IYOKE M>:]>(LRR_*OW.Z>WTJQ>0D"5?_5 W>Y15JH%+"1]>*V(5_BB'=6+Z%JUWD5K M%K]H&RLU-%!,K726P@-5"OU)8%D>M M0N3L2[G/$W/@BY42)9"3HI93KE;CZ* 4"Q5R751(]<6#\K Z QFB7B]KY:MZ_Z( M44/$:X@SO[9E3!\-IT_Z./\P&!&@YUU0@SK$S"OSK7&:;TIALUXO+/F1ASX -7ZV]0*&G3L]%).S"2/-_; M&"F,442!PB_! M9W+0">7;,N03"HSXQTFIZQ(\SK?X=[7-K/57!:#;SERX9PM[6._5&$:?C&?=Y6KLN M:++[N0>Y9,CJ7=DL\R^_^%IJ7MW4"TM\OX!I\F))9\S53=OUG9=#L(*1A_== M6B/?*148_ MBRJ6JO6!GPV885#\$^?B!(5'7/Z]R:R'#ZX^H$,"S]6>^=\#!U^AZZ:Q@[30 M@'?O/KO&MOS:&X]@"5PV')ET^WWXFL23Q:M%S^X%+4K< M$]X%2,6\GIUV7ZKM]^_%]Y_*W[1,P?!O[ M1\WCH^;/[R=O#E_V/NUM\ETC[O>:&H+K$<<[ \OW))I)\)SHN\F[*(CT\!X^ MX^C=1OR.X./XVX//Y%(NN+S3&E"L=M<-$718WX5ENJ$.-QPE(:YE*Z+U%7(J M^EQ^8\!(GD 38"UB^2H5K#5PAMK\$F[^FC@_/>#K M+6Q^ZLS?%N>KS2_#YA?.^;GU&-D$RA"Y$QC295MXAINDCJ7(0LFF-5#HYF)7 M52CT36/H=.^>S2>]J3F_EERF2CO#4E]]94F;B4MV?-WI[R$\_L2M?*#5(!([%<;I!2IL>_ MBL*5&V3=%%XN-TC%*%RY012Q+$PLR@U21C=(Q8A(N4'*X0:I&-DH-TB5W" 5 M(R[E!BF3&Z1IY7QGOY3;>UTDSZ39SZ6W5$OM@ M%B2>S35G2V]&EI]X9@?!*>0I$_&4,@AN'O$HY%'$,TOAK4\V;+X_[=PX[!%> M\ID-&=@!U247U_$^W,$H#-^DUSVAZWZAWL V+JU'ZGJ1!AS_E-(K,J2QSERS MEF0]6G"]:!-H48H(OK^P?;.W6$VC@!GY+^X.;1^^PI.$M;CC49]'*CUDH) M"L8*(ID-AK#B"3>0P;! W[XPBPW]8;6I\)98?4E2^&=B3AOG3DS;1/*\>9L8 MG].F;V(L+&#D>]1!V!SA1*08V0A.C4)0;%@R;WQCPF(B^@:3/1W?CT=T*F@@ M;45R$Q!O&3JD4$D;YJ\122EHJ*WR[4EI.*-QJ+HP"' M(WA!]%MU*K-.!@ M&D@N6%H]\4J92#5' OLH<51??D MGQ&"UPB)BY M#)M.!@$J\&2IR<5Z8Y00W/3"6FP<.2DQ(WI1,W520C M):Y**ZY*3$ZS(J&4:"N;:%OCH:823>413>N,CU2BI72B96TQS_'8CDT5&Z^. M:5&R:861]V^)"C/%I"@J++Y[]8;1W(:1P\J:F2N%NB-TP*VRN#>(98[LAV/*T=OC1:B/A0OK,*F(X,B MA;*3PLI1X3,E+AW8IG$Y'#GV(\_%J["5NA0AO+ &;P41%!F4D0Q6;4$(#\N5 M[<%ZZ>AZN:/.(Z;IO@U"X/KBRVNPZ7B@"*')H*UG7&6*SUJ42Z\?[(5%R[,A>%J*2Y47+@X%\Z. M?U*R4,G"#>3"*_>F5[;UM<('9+R98U"O]1.U^PX9#; R M:Y)$8K/<]),/M;$;?Y(1;/'&MK 7[5,0&[L@T8C? M(G/N[O?3#D T\RZ(SDS>3+OJU)*<3\P>FS'7=5%*L"E9*"78OL(,C\;13OUX MIU6?0Q^;U8\P=XI95',N7T/!8/\+,X R$=BFM HL#8&MO]=?@00F91V\X%#( MNL5(31'6"F2=W)1,LFZ"4O)WLC44?:R1/F+.F4;!F( O$)B@]KPTF!!L2B9+ MJ5$T)H#YUMQI'BGZ6#EPD3)G9]T0;'\7L*P80C)3/*@0E' M11JG0:]LM=/EV.G".\+7U9Z7#/WC_+WF]O9A*$:]I>BC!)@@-Z(X](<7X)&? MVND2[/1>,?W3YX47JSU7Q^TOE2Q0]+%YD7D+G)&?T:[7[CN4;D;=(HREN.ZU M'0>/A_ QR5U/F:TZ)(^?82H"62N!Q$X3)[8Z_^/JQ>)E5#S$IL9#K(' 4K@K M+)1CP.+#]%7?.(I0N,-D0?JBD05B;[*\U O M-#IIIL#]G0Z8;M(+9A%+9U;_RO:HNXD6QV?;ZGO4&:+ G:B+^,(:;)S=46*! M_VI2W918[I*1ZKHBNDM,JNF>^TO+]4'PZ-'V;#0MSIKNQGGOTW?[!5;GF?U._OJ3ZP;-/NC\\M+ 9FG/HNLZCKWMFFS[NX M59](0I=6.#?QM+A+:WJ%K"LW#4OMT$1=H&$/7N]%6*_$K$5*;]Y4MX<5&:P!%:_;1E?"#/A M-T70JR#HEU==(?2K$5J1M2+KC4/K3X[MCVY\1Q\05]'T2FCZQ257./U*G%8$ MK0BZ@@C]A1I8-_?&(;J';?^(1?H;$G2R".'.F;Y"Q85041%1*8FH6DC4&3BV MQ?0.")%-(* YLNN%V2K06:PQEJ(7A2\9\.66#FV/WA"/X?06@UOON=''_])U1:+D06BK*5Y2_F9B?'NTK MEZHSULVW8(*\--U5TLD:X[LWSLE?%0_[&O?\EO<3(^8%W>"-GI[DIN]NH)%< M>P/J7-F6[CL.C+GMNM2K\#X'XOR4F)B&@U/MLR[S6A,!_8>*;NO>3KX<8-%"?(T5YPEZ1%PB]V3*(8[A?1P9HE-AQ<7,U^#Q_@;Q#(_@;NPG2OZ%.T0B#<+?M5I['QN8IHO M[^/:2#]AZA22L':\TVA$OT7-T^&AU&VG]4P-CUFHXXG*"%A$ :9M5-O(F3K8 M[9C$!8C@4Y_H8#Y[=7*EZ9<*5+RT_.MT2R$9971+)>XIQ"&;G_<# M^H4X#W2#*G3?^5V7&8P )1"3)L!"U*><->F-G$VJ@A><>A2B!&5NB.Y#$65 MY'L=:RW".1LMIM=/PM75&$I)X]-JIJ)Q1>.;I177=QHPJ#WEI"VADU;N39%Q M._7F3F-_$5A[$YN_'&H5YJ''O2EN\_CL)( M794JF3[%4.=^T=1Y(*D3;>T[G5H$GG1A.U0G[H:3)AJ>(4T$4X]LTO3%4!1Y M4#1%'BJ*5!29A2(/"Z/(N=W=A"K;MHP-H\0%Z$&T0%ID 92SX^50+T5,%2&F M$H5^S3N@5<14:F(JEXMJ%C*MASXVDU/%"YK1;Y5>W.82B]LL8'%GY$9M3*?G M!6,-2M!CN< DJ+FG1&J[E0R;$7RD2&,#PXTX%36;T6]ANCL9DI'=MJCK#2BL MGVGWF>NY-YWJ[_\M-8$ C!M@LO$];+&+]3IMR\7%;\RVNQ1MC@6Y8= M-II%*Q +TU$8>J#KCD^-\^<1[%:5"RRLC60" SGC(G6(^MY.JUZ=)4V>9N\5W7C]./"%PV]56J9I M.S:S;YC/N% GP8RZC(.Q"_!%K.K*&#S!NF<>AI!=6@9[9(9/S'C1N>04U:'! M8F4+%6$H>U>1PP;9N!,N3;6Q&^;&G"GCSY^I[GOLD78&A#G#*F_UTO;DC#50 MRL!"RH"BH/)14*FUAL!+'E_+MT4S:?>\#<5"[7WI]KYPW:.Y4S\0DH/_UJH' MDN/"=H:\J"9H9G0$@ ,S.&,.U3W;F2R#OT!.7@=6W#=Y#]J^0S>@LOA+>NL" M:Y>K'[Q$N8$O%O^;10-K$\62^C.)8LDGA2ISS4"9@]^:1XHE%4N^&9:4U)]1 M.^9\LAHO//P6V5>*)15+;CQ++N?RX'Q2*$LV0Y;$W[*PI&*WXMFM6>Q, MW%,0C0<1XOB;HG%%XZ^D\>R!^LUB O73HT<4CBL:?R6-+Q?$4S".IQ_P*1I7 M-+XA1Y"SJ\X3\^'+6<=D%C_*W]R8Z'C-^=0Y*X*)$\Q^2##[DR7^T@K_5)E@ M"BIU5!2Y["]!+OM%'U!/9;,_4@>#_WDZ]X@X//B_8[N;T/'NEKJ>X^N>C]WJ M<4XP2?B,.H_Q)I=SEV#CSBS324&DO[6?L M:6]>I26,KT79=&R 8X/H/Y@W" M)7LK-++\VKP1XN&M(\^?F2>%^IM"D!)3 FW] JW$Y).>)*2$7[F$WRJC?Y7PVC#AM4;B4<)G_<)GE=O?5&*D M(F*DN6)24&)D@\3(JHE'B9%2B9'BMG]^S6(E4,HD4$J?F3[=,]IC%BZTPW MH^ID?'979!BGIZ560[E_%P(J16G5I;3-P[0;\L#0UE#T-G=-%+[EAF^*ZLI/ M=9N'=7<.^TRL!Z*H;NZ:**S+#>L4U96?ZLJ%=<)CWY!5Q<,DGR?[?F#[+K&, M"]MW/$HMX52ZM'2<^"/%Q4UFM(7K>]WK,9TZ;ICAU;8,F75%K$WPDZ008I8% MFTMYBXQE7LI=MMU8STE$0'6%'40U#O$%C;VPG<<0PZ2+?Y>@5! MH:Q"V36$KBZ/LJE51Q715J'T:T5)=[KGA^LY3/?DY+]:S'-O[[YN,K#RF,?I M>CPOKL1;AM.5)91EH\G4FMH;KL16A70++Z9=216ZNHRT<7J*8J0J:TG%,=+, MJ!ZE+Y6>5]:J+Y4_9FAFI-HRYNO+;!!4.H9[KWW/!<*4(02NW;L?T%,;"*KZ M?%$B6W?M+'I!F/,[,7UZ.O[,2)>9R*

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

    GY^2 SE<(ODSRV8BZ'7EOSLO0=O'Y66&/C!E1 M0CZ0)[^1UM!JQO%CTLW+V[XULT$9_R3,'P]*C BQ5'=W:G[V'1(2M2LZ.&-^GD KR*S]*VO7(P8[DG M+_'M0)J5X>M!<[QN'Z%>-OY73=G^#5[ISRK?[9(<,L&PW1R?12 !3B?+1\D/$>T'" '9AJ-">X!E#J2=XPL/\]\3FR] M6X0H.-YU?NOBJP&JC.R(Z/0G1'3F+=MY(S1JK.="^=LQ;):Y\E8_NU<6'O>R$VQO6>".$W5 MY0X*QH[[\"/ZU21P-Q,O%MQ[1CBLX)_S/*;8RT%E40W.DXQLN8\YSP7GW[P% M$=9&PZP(_(&_Z=6'6 C\]OA6'EA>T'2FUUJ6:9&>KK(:L*!A+L+@M(8JXF8/ MEC6WJAPPO6;@U9 "%3!4+-D-%U,%MS'6573;S,,#_R!E:B5 1"#JF8VJ0W@W M Y>L)@C(P>9LESCR_5LC9VGV7:#2^W0?R1,H H+B%4RSP%'@EP61$M99#N94 M)FVB*TVIK:);GXCS]:A$%)=8JO!F4M^D05D6NR_VTV9=LW-1I[)J(IL(E.]@ MP,?$073)=H)0GN<:C-=!L1VJV5"'!I5Y6 M1PE;T0+-&(4MU7H)RRV0^;#.$ MWD36X;4X=\*<'5YMM%(MT3)S9)E!O4:@8'D1:W_7W4;=XW;?YQ"N%POYIHC- M/UJZ]/5.?28#S\F9+;.?%OOR*$O (LTA7"A?M%?7G MO [AKH55R&A5O^>C@!9,B%1FAM73S7R8;Q83 $-!+>_BSX7#6&\]%8!H[(&Q M$!K8X;D/K9"A,L%VSQWXU!QS\0OQ=M#2Y69-,]@X:SL32?;"7)+]Z0G7)OF> MS5GN6\8.*NLH$<##TAE0AFF@9=:+JEE8%$W+ZS\2Y/;$(D,)(\.2^/;;W(Q+ M'M7'FRK/WR"DJ,?'\%6![Q>%FF755!.BC.>Z?'NC]L]O%%@>UA6$FQORDR@) M-T^",>K46C_ZK=L"5FYTV;:]1XZ'AG/3^:0__1(?[Q7I^^1WM^8T&[JKB/K= M[Y_-V^\7GX>_/^GN[\GIJ6)\'O9'JM[_\=U5+ZYJ82[VUB?YZVN9QL9+_%J^ MOZZ)$Z?P>TAUB=KC>WQ4+7>$SUPA>(AYJ(,&_QZ=6^8(WG^,321>\'X2CR7A MB/.$[M\C[=%YWS=-'BXK#H__4RX><0969O\]PIM^OV3#NUU! M*;R"Y50_^BA[_\"0&5[,Q\5_^_)*_B?/Q3"@-QDHRH-7IDI2M%>?\.T?[6_Q M]*[5;M%D0L[1'!!\3YSP@HZ%<(LK+EC;(K?69IN9(UVR_90JO_X*C<'O8O5N M!_O!2SI.L*<=,EBCPA6Y'NZ1[#^R0 X1E(#O;[VX7(*[ MV/ :O(Y:\L8HR\E<6,X=2U;G>C9LT*>"G%M>*[G/30GA%W&>LG]JJYD=OB-EX[65>8$O! M:^^.__#R#C-]BVZ93HZ4J2C@?6/R?WRH'35R/Q M7=+*%B)/#,T/ R+%.1 13L(]<$,3_U[>^:1OT=N!Q!0!YN&!B5[*5AX5O=*< MZ(DG^(L*MC:<"==^\+N Q[7_>J?4U)V[96EDK^3$PZEY,,_.\BKH"?S5+P[ M '\$*LR9C<)$."54>BDB/-=.6H!I3[ZP=B(3 ,*2V0M5Q>7]7IB>VLY!;U0H M0T-,*V?2FAHJO11IG>L2+11.\ D&W6!FS6>Y<^0G.'?],0XO[[S2MV@FBEL> M[>H\V@K+H]UI'FV9Y=&^J#S:]YP!,*0G>,/1?%8<320)_C\3]_C\8N'"_7UU MP_.S'#MZN_"B#M\9N:DN=N[@YH*D0A'<@D.MK_FE=S'C&KBN,D0J5-ID\V@V M M/D>XE@:^0R703U"-8F?T4,*A]]S(5 >./5\B=B43..WGVD\!"ZB1 M]&.X2C9?(^5%]8:(7%Y)_S,PH<-)C>1Q-FPH3V(D<"$9I]" M(Z109#0*(B-S0PN2+/^7:&HEFNN+C.3R)QAS9(+QBL;O_B#6=<4AHM!YFC?:LGTN0F#(A$]N6Y8\PSMF:<_;$.I4]L0XD MFEAHB P;TDZ:WOS=-Y>F;;]EO+1C7KK?#RM5]\1*X=PWOS:0:_QU(:F"<=). M.6D_C"10=02MPB3H1W8>Z93^#,8Y+-]$7>_;?/_-/5PYNSQ7@23X(SO1:-@Y MJ=S$Y-O5?W;@=@$1W;7KA=M%M'B?&V &<+:\1N(+\AK%Q#PR[3ZBM](]=+]# M%LK)7N.8E>&HC=WJ\%%O]H"?AA*>AJ5Y+>MF=6B<:>4T>R$K)?E=1CD'A3D; M6<0L$C'KIS!BY@>3-T)=2(Y]W'?(*UM9>GM;_#(@" O^/# \#PB6IB\=@?I/ M$06(+C\3D'7Y<5L(>9D(N?>BYYQX6)(\L1A3>.HRWNE_;+E@\ 9O(M(W3ZTM MJ+%<60C9K+L[E7DF\!X9F]76_WB&;,72QEX]7#]J@>Z.!9]I9Z\@8Q:>G'KZ MBB="MH@[=;P,'6=LOW_W[N'AX<1&RLFM>?^N9BE#F!7Z#JFWLO4.JZWR.Z%8 M$:L5\1W/\T*A*@E%$2]-D"I%X1UZQ!JS<#)T1E. /\:/.L;OM60%KQ)Y^'3T ML6;# #"BFM>@Q3CYR=.*VXIC$E<:>-*$4IX,1394KH^]#$&2OX-=+S1<[[4]BG'^X@!ROT([]WA_\]^ P8 ^ B#I[Q M9FHS^/B*J7TB+)M"2RR'"LQQ)-_"5D*PHV*P(Y*/OB89'5K"R Q4&*@04!&S M15SJH"(F 96N@^7<(;UZ@@X^FX++5>^TSM7"D]2@1\9)GKM"JO9)UO O+B_K M7JFMINO(,#1WA$$%*O@P>ES-RF\QPIG8MG> 5/"56! 1&8@P$-D;B$C9(BYU M$)&2@ @IR/4&)G;]BK^THXC$4(2AR-Y0I) MXM) D3+^611$C")B,O/F7+-L M!PP/0R5BC.5SA<7S639<&'WKP4DYE1:/N(G!$VRH%&R(H4RJGIQZ^HHGQ6P1 MEQ;*E,O%Y"C313"W;6.8$5\1)9ML"L^H"R;HS!!G-0W;WR;/]JY]= M'6- \'8& :EZ<+?*5$3R&XDO$?.+%,I+ :BP3' M5S!9#^3>$]*& P S0JHF0<\+)^O-5!7]AE6!AV\)#D&*6 MG22M%Y1AQI:=Q67O;(6K>]Y5/W!MDJ-EOX<7=+T1+=-&>,7*E^'"U-:J>WKL)SMN: NT+6+;("+)!'IG'KNZ(\&2?).OZ'NFX_ M^'5=ME!=-]W9E"SP61$P<)]LLP'9\C5+8P=#G?NXK_XL.(5#';Q18BL M*2A8:&PA&R].)M-THB$Y8H^*/*UXF/\X!C0I>W+JZ8NY[?65+P#02$(A<'^5 MDT!-PU:P^"\-L0?RO!1TEF+(B>\+AZ_USKA3V;A;HGV45^("*5V> L,YZEM> MI)Q!0SJ?G'KZ8FAX?44(&!H$01*$#7)R8-+6FDBY4%H'#VU+PY8\=V'J8$?; M4U4%[Q8;*@9WJNDZ= P.90K7S>7?@Y=\NKKBFLW0GRXO\>NV4SA(S!TV4F9H MDLHGIYZ^F,M>7S6"*/"")%5+&U@TQ-U!I@\MPY4(ALR,EE#UP4FH^N!*AJ,E M;4A326($E7-AP9;] .@T6 $%W7 M0CUD._/:Q*7L6C+7]N6^9YHZRD/(_8[K*I9["Y_KR#K2;H?D 5IQIB& M-O=#=@:FI7I0$(MBTQJJA&"T06DE Z,4/SGU],5@]/J*%2)@1*&NYE3J %Y( M3\=9G5(X,NQ%8 LQ8B^ML5[6)!HSX4_7DU-/7RFU+5UH-*/;$X DLH+FL&)6 M+0EMW3?&$>_&]_*'2[$XLMKPH(DCNVSP%_3T2[T@I1JHLH9)K\\G&\&3XG/Q MA)*RXIDH%1\2XD"FQ)25K&# BU!6TNIN3;FR4L4_%OEJO)GXU3T80RD&$@= M#J32VG0FW1@E"CQ?Y@M\JC!JEEI;6AI3V@BG_!+UZA91)094#*CH E5:6^.D M'*B@&1U/2I>DXU)*@"J<>BQNX53"(/6N-J=.^0G (D,IAE('1*G7U[(G@C#; MJ$)UT[*\5AAD+.$R^(&.HAO#SU8*T!1;M@>6G3;H8?T>V IWVZH&LP3K2D.Q M*TV5=:5YA2C%NM)$^L6LZ$I#[P0DZ&\SF\)*8=G[&!H]Q]_IU/.*/%\L"!OH M>?3HLT_G&7'+BT6ZL4C\O*3JH\\#+.&!)3S0AD9HW;,[B'E5:+AY\B<]^B1! MO#,$PS<(WN$G74\1QO:^I=T.'1L^)PC_)>^!$ABN[HY<729-@3I(16A$%)AK M9(V1X\JZ_Q@+!37 @3=/#S(XXM-05U>Q4.N;S8"3 >>N@%-@P+D+X$Q4KD>/ M/G&ST-*%I3/\$SS\*\E:SC#5D!IT:JXN[;R^67%),(EXX_[*#$T9 MFNX*38L,32FB:;4D5@\1>3K7!BD'TRMYP@FKD'2#9HSP+%%@*)KF)Z>>OE11 MM,10E&([?;%:W: ? D6GJ?:8,CS=%9Y2*E-B>!K%T\)^\335D!ENME%*A7X@]1WMC1LR1.2'!!)R?LW2-#WK/-M)GC, M3/W0X[QV2 6R"H:L:7QRZNE+%5E9R=-.O*2'-?B3HF7EI%R]GTL [ M\WYFXLFIIR]5,&352CNQUO=<_[G2^QE3''IH\$Q:0K\S$SW5K>NRU@Z*K9!2 MZZ_5K>L$UKJ.8NNZ$L]:U]'FWU2NT%#6 MAQ-5[Z=&44T:7UI=7D^GX?*,65)OF#+#/T.&/ZL"31-D"H6"R!>$ @_S=Z1W M]U*I6"R4;Q+[56,#2J>38UU^L.?;@FZ4<#1#XY9YPI'HSV*ENS?XW9M-6$B> M"L_@C<';3D2Q<,)B/.E$MXI4JF)T*Y?%$H_1K9 L'D\0!Z.88HY&)NP'E#0E MJAJN1KB"%[B.HMD&4^2A8I+A6ZJ?G'KZTL0W%K9)(;X5^6*U4BV_N\?_JDH> MOB72W@)\6PILE!/,"YZ^MRD:8AQL*XY)DGI(W2,8QPP,T_CDU-.7)ABR%G%I M L-0:E"Y*+X#$$P4#5\+@M2CSX6UT>=:N._0QGD[#/(8Y.T(\ICW+GV0)Y2Q M)E@22QCR!#Z9XO=#MBS9BW1ZD]F0!+:$9<+(A4P#(>#Z,M>'F_J>^.4'+Q30? R?W( M,14T._#K5@K*:P552DW8&*@>S.C&/TI"H42,[D0I-UM@:F .^UUXX:L=UWB0 M)]PGRWQPAEP=V]P8/\]=#']-0SF)M;Q7I\[@*R%NXN3FG7\9M#)H/3PZ%4XH M=69CT)H*:$TT/.-@T%K: [0"LIXP:&70>FAT*IQ0ZM_&H/6 T"J4"B11O'!< MWB14M W$DD3LD@^P#QH&50O98Z0X 6I>X9VJ&B8/?JMARUX991S.;C *J.;> M8M+[K@&FOZ;Z=0QD8T"64E,W!K(' UF)YTO%"D] MIH$9,^0K5C:F, ?QMHN M4EQ+GLJ@O"I#.]G$!E%LKC_RP3HO!9\G&8Y8:@L5M^I:" 4Y*V+ M$QM_76KC,7Z(]LB=+D.U:\M\G&#S'S^=0" $Y94A M4ET=&_R%6HS/4^!91E.:GYQZ^E*%/(E!7EHAKX(13RA+7JZ2D"CZ$]/+ D"+ M!A2&M;ZUL9ZO"T[(RL'2DQCH,="; [T"P[OTX5UD$&\BR[>+%!.C203NKGJG M];P7I=X ]9XYDW&[R;8,X1C"[0KABDRM2QW,+>VV@Q6FC6H5 A[\@66PZ-M;#8FL.4_6GIQZ^E+%Q!+#Q-1AXJQI8TF22LE5 MO]Y0L]0$TVUVHNZ1;!YO!+?(H"V=3TX]?:E"6YE!6^J@S5?W2GR5%R2L[A4D MK/E)?F!WHP8]"_I>[4$&])M3^#;T],6[]E:';V,380I$R2L]&PE3/1UAX[[Y M(NN;3[-OOL#ZYC\/RE+?,3^NLS]K9RQ?(BA8"'+"POE@5_)PY*KOS94/X&&Z4!=$_P>_S MLCQ+-GDDL;QIJ@1#.X9V.RL6X!GFSJT\XK\5(G.^-3C6_6!#*Q0TL=:_<6/X(N_". MB/8R$FG0H(S",O*!3Q._19_D-TGYP,05!)^Z&^)U%K"$8766L)I5;5$VR@M\ M$=KHI]\'N<0HG\9*_"93<5U.-O-$+CZ1::EI?'+JZ4L7^0H,^7:(?&EV1V+M M=SS$O^\:$\AVVPCW-O!$,MS+QI-33U^ZN,<*NG:)>XG*KPZ$>W5K8CNRSOW0 M=%V31_9FR+=NUAQ#OLP].?7TI8M\E.:#,,R;&Q6W9ROWTL0/(GJ#!LG3'J$0J=&,VSS&-VM\DB?U_UQ-^>MJM@8?\/_@O3GI M!*8-S.3MY]0QT,P(:&:M;S(P,)O\$;O^U9V3:<^7VS/"?C8U4@<& .0U@B*8 M>V6J<4U!PY@;,["."NKZ?[A LNX,_:XL))$2?GL-A- 4Q%W)AGQ+%K5KL'[. MN#QJ<,W:-U.1UM>+[6STR&&PO8KQ0BC"P!!AW]#N=[I:C^^G<;BZ":Q.7^KUP(*7,E1-[>L8JL:B*ILU'I=ME!=-UV5? " %EZQF?*\ MC[%]#.<9SJ<"*"$2S#.XXX1DS7(F^?F[\CX/ML-885N,W=8-+/KUJPQC M4_LZAK&Q&"LRC#T(QHJ\(!9+@;\BT4Q3BGY@[3$1L'Z6#<]0+P==:K>&U;63 M4;]&BUK]OKC/1=14-X/,9#.]U>TJ)=:NDF:[2I&UJZ3-OZP99'BY7C-(3Q60 M*/9IW&4Z%J6!XL5BI;*!B=-%]UBLD]R:LQ&-Y6"X]QZLD9E7?=/RXM2E#E)A MGO0G!%*G&@AQ(;5$HR.VDE"H;.*9:&BWPT12ZP\8E(0]RNS,@\!D]A7+;#&U M1*-3(5402WQA YEM:I(KOTUDCI:#?)/STTZ0UF)C61I;R,9/E6S1G8A%;AD40&GQEN*P4;3FE*&=LR8=]6V,NI M)1HE82](_ ;YR#4'^JS>(8=KVK8K@T.J*^O(7F$(%^(E?YIY%LI>FTJ_7^"G M 0W(7Y\IS(NK8<+\"H6Y\G^II1HEQU:I6.']/BR)&K'43<-V]?BK&T842LFN M[0MH=EHG%;GJO6:;%M[MY65]22>5+0:$!88Y$]M7*+;5UR2VB?J(1*:6KI#A MV;T7=/6D*LBK.X,P06:"'!%DB7_9@ES@!;["!X*_FYRK8OY-6PR& )E/UAO+.+7$SH[R:C!YJ&@W0=*3S[/!DZL+L]BLGY4:1/I8ES^LKAR9CT.$A*;-/>S56&:^_:EZO MPGR-E-(LS.E5/T3QL6G8&M0)]2P9//E M\*:4D5M=FM[J=2# -#45,VB<]ZQN'E];FJ%H8UGG&H](<4GR6GN OXAQ=NQ: MD$!#K+3&HS*4C5O$U12'Z[B03R-(\K%0>"._?2<45>^G?/"F679,])OXST)5 M J_VBDA97+2.DG G]V+,2DR<&QL2RY%+)L2L5MWZ1;NKUY$?3,$<3C!$.QB*XS;O*$(UD+I7T MK-:<=>7[70RZV7M-'/$O93[2)^2-9U,>]UI9(ZNU]-. M%2&N32=YSQKGF2/O&1IHAI9ZXJ:W%5L=-&O29]0S<&%4T#WBSK ^CVUFBOPJ:W9+?Q729I;:U_\LU#9C#ZN!O MC69SH> \@024/%UV@A>><%T76\QSNWJ "E58>G^ZD8@5'3:?8Q.OPVO),3;N7Q9QZSTKV!Z-)7=1@OL [C-#N,2]GM,)YNCGYA(IFMI9,G M:>J_1[^O;GA>FFZFBU\H.RXVSPY[UV=:4=EZ\=>^PSWGJP*^QQ[4RJCF(<$% M+13?J&\39RC!ASKH5K,=DB<^Q.J(ZNH33I%=FS2$U$@+2=,BB@A6)FR\2Z3F M\.LT_/8^&LKZ +0)>!#1&[P/Y+U>DBYH%N2!LNL,30OO2J6E"N_[&)Z][+B; M:)E6'U+AV6"'??@=]C)?">\:?OOOD;@Q06FN<-8_DJP,ND2&EYL>=]"4BXI$ M44OE""Q_A=)),>U++)1VOL;TL$XZSX+FJDXG[^FPAP_STSM'H'OG_*-%'T:N M014I_L3T]Y[: *[2HX_O['=D'[43[D)6-:X^E%UU:$VF&]4^,G9CJYJMJG9" M5A'/+(Q#V*H^!@F[9"T+2;N,5PZSJC/9052N+ZI@,K8TW>_;7&2]MC$8YDHJS#^8*MB:FXJ3X6IN8?? M;CHY(RNK8CS!U%P::F[+)+WQ.J8S9#HN6U7LJCP>(2N)\ EC#K:JCWY).5G* MLK)R2+.M!TFNT,#;L4Q=9^HO4W\W4G^7%6"D-S?I1>>W)4QDFV6J019;']KQ M>[EH^&?=? B2U 88$] MWZJD*D3SZT/4][LY Y8#MH]DHQBU>;H'D6[JS#_]Y"KT-/MV>F;]CSNS$V8; M_N^>4[UWMI-"^;^[+8/:Y#![FJ.S@]QR)X6=;V63HP3M9LE),B63K>IEKVK_ MF)(>F4JE@^U*'HYLTRE4O],6++S MLKB0K2H]$OO*M-!UE4]I6&,Z67HZ#28^5Y(II2_^ DWGB;!597U5KUFF4JF4 M)BJN>5D\R%:5'GE]92KIZAJE-*PPG0R]1B%-VW*S(W]IOB_3>2)L55E?U6N6 MJ53JH.LK7UX6 [)5I4=87YD"NJ* * W+2R\O+TX MQJ%:,\PB[R_X4DSGB;!597U5KUFF4JEH?C:'!M2)L55E?U6N6J50JFJ3-JUJ?D[D7QSQ,X4R3J*VX''<\@V;G>X&Q M(KE__N?XF#O7D*Z^YZ[E6_0!?_NO"]+VGBL5/W#?9=W%/Q8KW/&Q?TBJ=A\L MQQ\8$MS-I[JLW,$-S=FFKJG!-J=_+Y$;=S;))#RY9'ZR2?0-BR-)YD:7+%[L M,PB, ;;8:1,S[EL\A\CK\&=#9 L(]H'K3<;X_35+[FO*!ZZ%K62/J"T3J%'EX2K)6<'&,\'\9#N=-UD(69L9KMZ]K M2KC"^%RS1OB=-C+ZR+KE.IHRY$[E.V1QI\@B*[D^J9W\\T[^R+VYKM?:IUSS MC&NY(_QISMN.IOY[]*@^WE1YZ0:I2#L^KKFJAE44>'13O5&P2EO@!5ZXN8&? M!%$2;IZ^=:L_'GMNM:FJ8+$]OC=, S\5[U;!1VL $W=@>^>6.8)O'?,"_C_' M)#\+XK$D')$7G\N*P^/_5*0CSL#H_.\17L'[R *./E:J&%O"KY@)G_<_U([E M[:X4H*DX\"?'XB[MC3B1^C'4')1*.2H&*C305&\D3FZXAJ+5?M2_6DY)$;"1/;,A/<4)36"$T8J&R M1&IVQN1TV5K:-UM3O2FB?%FB&NL)JR>GLBY[CB^$')N3R?#',Z0@PJJ20#P2 M!=*7 MAH2E,Y[<=?R!ZJ1<^\O+,SGRFB<-CM,?(\HS;^FD7F:TZ0;-D<0)_Z M(GAAIQZU/4-!94]L43='8PL-D6%#5\2FH9@CQ+VY-&W[[8OEDU+6,:.Z)^8 MERT:FCJVR>S_][\542A_X!I_7*+\<#!&H^G!688AL#[ESW7QXN5=+ M)>.0(0AT>\'!8.YD+K"LG'!U/Z&"@X8%2A^P&DATP/?PFBY2X!_36(' 0@7A M4,'Y\3;! H'%"JB[GK=89]SIAFG(P^SK.=;E*6>H]#_.?$"!_];?6*=QW>[T MERG\:G9[34ZC3/N^MOI9;/.U>KU]K=6K]GZQ)TW.U>T M(PI1.OUQ;4<;3,),]'SB^P_=._5[9@X4D5-3ME3B[/ CZC9H'U39ZU [#&OG M.:*&6:BNFZZ:!SONY$7LD1(:)%CU$E&@"@?ML6;@"S=G&D1)WG',\+#;?4$G M]P/EAO(]XF1PG6-%%\Y.5A1SA%\P@NVN!=Y19%<9F_-4\L(7B8LNMLE6]/\ 8YT[7P6@EOYQ>^Q\5]C\-[ ML2'B,I U2\>+U0Q.UG5\NOBFAH_B/X_QRFSO>=-'Y,:FK0%%@#SPE[IW"BL] MVM[&;5?WJ*K!_\R\H? )^-6,7!$K%GXP/$N6K!)O#?]Y!#Z0!\T9$D;P T1C MK]NSCBE[BPS\ AU3%?\=C8$,FB?TWPQM:D&3Y=1(U$5^/EZG051>D-1CO#Z5 M;Y;&G%\H$< , "/ /@X_U*?>US\BOJRC3' ])"37"OV"?<# MD97*W-@+/8>090"A9VL6G";( V_SH]0!"H9[RF.+V-9NAXZG N?>1(#GK1^O M?DO@#UYKP;7AHW\?+IA95)R\S0=D^',8=P&W\4LME5R TW5].^F>< .D @CF M;*2X%D9M?)ZZ_&!/,5D>C_'BB:? <@$UX0]XEZ[N0[-_0MW9]^$3C4=E*!NW M9 TCS;:!^,$CR:88E*9L*UB!PM>FZBK @#.67\8\6% ,%?/LE &\4X6L"SO\ M5Y]E\4=DS*2(&V,MC' "OMSACO:8#%X%7&OV'5DS&@9<"N2&6 MJ7,FEOW0#BR2ZX)!X82K89N>0SSV@!0SPR 7O(H4TA.J *_#.I._+ M>\V5#5;T4W;?^;2;7FZ MC$]*6;?-T +N9=V5B=(06+:+!HT+"@N\#^L4AC; U[;AY/!*M1&Q8T:RBKC^ M)*0\Y<$D>T#8IL/_._<*D%.P]GPC4 X;=/&+Q[I1'^D:NO?1?@9>.4Q3H!*F M7 C:"?T(ZH1L4^822]E6L!52!\5.P:=-\A*Y*]G!\OIRO&!T[:PTG%EN>F*> M#C+R3HSH#[.?-7*O#RS34\*P_FX![F+_J+A]2#?., /?".\]3U@Y+KP@,X&]2R,HN2C_G:\N\-[ M[A+C$C_\C?@6P^F]J=_[^BVQE33B_\&VBJYC+8X O.WV_WAZ31[>"CX]'3WB MLU1O9T"G(OQ:?"4@?]5P&2&/&%A=46+)3TMQV654:/T;WMGO%M*F:]&T:0BW MQM<:- <7VI/Q]/?A0:13:U",29N&UQ]]3%!(L:00@0+M]G$0F N)Q]M&%K"T M[PV>U[]ECR98)0 5!>AXDFW^F^>]2I3W+DV%J"KQ_-4N)_THQ M_!ACU\2/MI&3S\&&/\//DUVRW1*27^Z8 M/Q&!=2-U[^/M\FI2$-K?./.FS))L:";9B"S))@TVQ#X*AU.2*?/*SR&:QU2< MYC%YL87Y])I(XGCZ=S>+UN>H),YDFFT.D <39U?MJW8^[>[7?2\^+M=ER_06 M:8/TEI6)+/"49=D9\24&,:]>G_%"7*OP;I'_L#:!A7Q.^+"K_)?&DMZ_%D+SDNN?@_Y':2_<*@\]D9+BS! M)14)+KM*;WFMV2T,&;;)8#EL @N$3E]* LM+RE_A_/05.[>/_)5,>Z9HKA,Z M@L]'^\0ED>:%]EQFSSPO"5_X[L\"C?9;X!1#KKLYQ\!=E2Q03?)11%XH KC!>>Q,HE)/N'GF/UL1ZEX0@"=1N;T? M36I&KT]# "HK ]U-&P.GD2C,G7;4(<'RG!C4IKU!C^ -(S /+34XH4)N'!J,:#/)9H!UBZ&_3O]F-8^05%B.G&2.76(P\[=Y#VMTF,MMO>K%5 M1FD:8J[7.HWZ9?O;63[7;-5/,KW)>KO5;5\VSVJ]QEGNM'99:]4;7/>BT>AU M,[VO6A<2-,X:]<;5::,SJ[ZNMZ[6..?V5!<[OX'?1F0>+ERB! M[X4;-.DR9N@.R.[_=QC:(QO-T&FG'^97=^9?I>,$NK[$\S>"(-R,#A$.],+P>^?(-<^_A6EL?'QS7;QOI)K6\[EJPX M-]KIS9-6^?2S^G0V&7Z[VT)OB>>X7;=UKG6[Q$"D>8C/JKKQ7%C/.\KH$XGQ M0O>1-!;):+=2UL0%6:M[A;XSD>,%+'1*I?^G\^WT^Y.P6Z%[9M/L.!KX&R*A M><=^SQB)"6'*A% *"2%TXL#.M MT?-RP3>F?H$2N 5@F]O3V'^2^%]*C!5X+/X;=WS_>?8ZA=)_8UG-C[N> \Y" M_HD70O59X3V0Z"@2C*W9[<&R6N-JZ0BBD"/9^?=(>W3>&^Y(-1T5*=I(UH\X M_P?[WZ-C"3,1Y@?\)OR3:VC>L[]USXX^%O-"H1C$9H-E?7S^_F/I^EQ!>]U, M$!N'KY8I,(&4ER3A$$P0BXW5L(+BM_OH( 5I]^ R;2''O][G,+/0_GE]H0L_ M>P\HW?I*'% NDBG8.6=-M\X=IW'J0KY2J>SMU->:<75(-L>+^*$YP[IK.]!EA)AV2\%20+K2 MNY)T2RYD6L&,L?U\6GC&'Q.;!+R1&#,%7J0@/06L;3#(3//9QR.G1,7?VPP!YU$H+Z4H>'[Y2RR 396:)A0)0:-Z3OO>*"DXBC9WWFO-9>O M+326-;7Q.$:&C6J&2J@4B87. :98O3,=]U:^WW$"PEY\BTL2?'RJ0!TZD,6K M\S5)3;(20=7MSRUQZM1&Z5(T17$W;TPDJ@FX,CE&"P(-FBI?* M?4.I:G)'S:A6+2[1JGNF RU-J-P"+T>WVA::"S2$II"O\#Q3H5-QS/'82,.# M)$IYL2"EQ\-P;4$+2F=RK<_%9HS-/SS8'8+DJT:7P?I M5ID721+LDFC *-@BB[X'&L1R'M@ !6GDK13S8I6!8"H//1X3:7B.BGE)H&F5 M; &)0MCIZO7D-6XOD6RC#A"S/?B&56NX-N8Q<=*R:Y.A4WK(CH:X2)[ICO&_ M9=)J#._YV!P%O%%LEA4J21KB+E!6E_2@0[]4U./18G11K>FT)> M.G1P2HB$VAW9N-7ZND<,\$0W'J$9(*;6)]-4'S1=GX/+GUK]UT2L7744(6LJ MY&RWLU 4TQY)K'8]&VP CS1R4H1*OE3=7S8?._TM3C\>)JEX4HIY?H]Y&FM3 MDI9@X5!UZNW)X^EM/RLA^Z./P588WV^!;#2R4X1J7JBP0/O!3S@>O6AX0/9\ MPFL#):%H4LLTE&G )*+6N7_DFM@7)J*<+;5N26B1[)G%QG<9M8QEJPW E$8& M2Y%GL?#7RE6Q "[1\,V4"C0++VG%OJ6%V#=@N!_T)B#^^_RS7/]='$Z>LNO* M7*27>%(D\YO:O=HE][P.+DL?OJGTD:]QJNEBJ^EY KA0T;RS]VT06$V.XA*- M;).RD"\)-,V]V%/>!Y0S=DK,3O'P3<-W5"[G*R)-_7LK=HK%\'H(PR\UF4R) MTY!=,]2N8RIW_MC.!AG7&>JVE2V5_.CC9;-VVKQL]IJ-+NET9YIZ]8C409(;KD4Z,3SBWN,Y[.37G?2L49%@8:-6LR7]QB/7AN1 M;(S&NCE!J..5TB[J*7-(>'?V[>IGZX?R>%_*C)Z2&!0M%T$SY1&4S\AP+JD3 ME[V'OM;RQP9 22.B+^0K>TP092>_Z-<@DI7R@<.)6C'-4; 2[6 N;% MF2'VY+\_[.\OH+IXAI)!(3&3DZ6,L $RTL@6*.2K19KA)H:,=$X\'A'I%$OP MATX"EI862P34F<3#XDA0)T^5^L,]?_O"],CY"HK %S;AW@1%MF/3@J-ZRT1I M-<\D1] BE;'"=,N4'GLLC!;I=,(X>+_7\S7]7M> J?5HW^J:K7V[S5P[ MPSARG:$!PMM4.0O=(\-%##B3=?]\!GQ2*;7(BX+(X#/-AQ\/HG3\,E)E?]7: ML2!:"X%HRW30ZI#.]>?Z9>'[W==+].>%*:!D[T%HAV'GHOC$,,<&4$FC=D,2 M6&>#-)UT/"[2\,J(U?U=B6L'KIQI]YJ*#'4U,I;D1LT4:]^<7[L-\1RR'V) MB>=&P%D2_DKY6\)P&Z ME>*.?$&B:>"Q\HYL<58LNI=H>(R LV@VWZ!5XB&L M3#T,]3@$P ?@?S1K-T^__EZ?J;?ZUU^/V7"-(X!Q?]QA;X!U5%I^LGX-J3KI>*2CXN$YF99D/6!VT\6E@RP1K>@;BS &GD#V_ M"L&PQ[(1/.G81LJQ]G@\U%1L*[WG,&N(VF/?TC&35XX^'O_S#C[-(&B'$!26 MN0T@B,I4%C[/'UK9*JS/#XIK)4,PJ5"Y?/C>X;_76UE3O):F #&Y6,L$R36R M,J7DCP++^4GOR=6E9.F_2S%2$L9_F@^C7KH-#MIE$E#-'-9 M0,R1OO]+(M\^:I_+7SM_2+ /: M.$V+E0%_^MDI'MQIU$=)I;S IW'Z8#6B]X]&F@/3=J![%]R2^ W(4'R\;T9@ M_OZQ^.5+62AW].Q$Z&.Z!+6OKIJ]JT:KYW7UJK=;O6;K4Z-5ASY?;UKM7@,_ M^74DJH;=M:IFCW5Y\I[#W.JWTSL>R"--Q[]:L^.D;M\*'W;[,N]O=@Y.V-O! MK1VQO:K%("]DKLG@\J:"K'<90X$#TFZM;7AM^3XR(I'?9=U%LUQN679OGJXN MI2_FO7M>K%:Y_[CP69 E6JD@#)*E6O9:EM=!UJ8$ )=(ZL[ ME"U,J.;-6%-O%+!H!%$2;I[N?MT)'^ \S]27\HSW^MKT MJS$,^U"NW&E?GRZ^@,]U&:_8Y#FA-6S"N*L6X3.L/"Y5ZK7+Q]:WRF:+V( / MYI>1G&&K2=,6H^>_#;,F6F0\DR9U9<8OL@QQ_B6Q_M5,ZAW+"4%>?#RU/*?9 M-K3W@>'(INO8#OX!XMCS'%-;PS%-\IA%EKT)*9%8JL'LK>NRC6E#OEQ[U.SP M9\BR:M$77*%1'UF8[RZT;^/'/R7TN (H?;[S=K7(^)6-MR%1WX8\K/2$XOB[ MIFR]C>4Z@;>-]NPD=WHDGVY+E;^/J"Y^+:_=2XB[%C>T_#I?N2'JA_.GCWKG M%Z=_/OU>CVW1#6V,&QZKK0*V8,TW*Y8\ARM)G;*TP&_%)J2M-[&=RK'])D+, M1?4X1'X[761W.]GV3$3^>;=J(5\42]A62*15;7:EQ5YPG.QP9T@A&^$D(<_! M*9([;OZWTO0N/$U\%Y;V>!>>QN/49Z54^_3U_.NYVX?'J9/LR-7?*<:#Q/E]L77"79R?-N#R%?%(2\5(ZK?U^ME8+ ;6HGT=34 MEC#F\&M!5']?_!;OUUM;RX1L[XK-DKU\T5OVSZO*^%MM/6#L3LCB[Y\DK)DV MG6#KG0C/TPF$?*%4R9=CFTPD,?TVN!GS'/[\&.&'W2.=93+/L0EQ3VW@1Z-1 M8\2*R=)TSK&>G0J-M)@#9RF?S64KF,;2<,.#6:F:O;-^9[S;0>8[B )Z.UL: M8"C%$V&#Z,+]J#W^4K[_-6H*TRLW^M(5H84E9[!!7.%G[TFKWAMEZ:F_-;Q U%,VB9F&TUSTQ7&LJ28M!@F M?H52\=G1 T_#7^#%RBIF6.84>4*_3V]+G7ZG,UK#"%,3:S,2K[?YY\B;M)QA MB8)>RE>KY3POQ35J7V[NSF<(KJ&=+T2?VJA1^OEI7#C=-^GB.7,[: ^1KB3R M^4HU#BVI&#$G7'N%7Z^\Z@Q6>L.>KEMGA;%L#\NGRNJ3V,"V7K6$#=AYNPLL M="9B$5RW<3KIENR\TN?Q=,F+WZW?K8(TU@Y'RECV3CPB?@DIB_E*!0-OK.W. M;'1*14=1P;5A350U6(.O7LJ8VC;H\ MUAQ9GS/3M<^3NEX0+[]?9C@I<+95;!QIZK%F<(JW6R812]@@.?Q)5#K[B4*> M+S O9=I./%Z;H7+A87V]S!_87UD,X6$'.;)F(+4A6P;TA:HIBCMRR4##,S30 M%,V9@\;Z]]ONEZ]/WW];6M8\F*&]X>,BFWL-)+<+VRUA@'(A7ZCL=F3CVX25)"&BM)TALK!* M/;;0$!DVMB2;AF*.T*5IVRWDM <]^7&^RN37@WAUQMO]NV*6%DH%3L<$8/+T?D-6V0!=MZOY7B)\N;\PJM7BL_2ER='S<+SXE,TUQST.RTUKU8[%UAS\,:&Q(AD1:RX$&$NXY].GV M\V7Q6[ET5Y8S:]RM["A'[@B?)D'_#T1HPV1T)[[J12;< /%I- 8K5//E$?)EJ+)A6N[GS^':B-4.-O0Z$T'4PNP9^J97.J?F#+WU/ M^530]=@OGA0)^K=[M4ONLED[;5XV>]!Z#IK1+>\&1>\@_05L*KGD:YQJNGT= M/4]X_Y-(;FF\;],6D;%,F?QZ*-(P",I"OB3L\GH@A-W'!<$8C0*CQ=X811JF M0KF_ULQ;Z79YS6=781RAED\)YC C<1Q8?$E ::(1N*!A9'4+YKGZ1_0S&$ MS_WS/\?'W+F&=/4]=RW?8J'M8HL)&0K^5JGZ@2-V-WX =WSL(XZJW2?5$;T= M3?]>@D7\0WB34Y"N^SS^[Q%_1/Z-UZ4$_XZ^ 6L4NCRV\4*"GSYP#YKJ#&%K M_']C]@IZD_^,>8W%,<=Q@A02T_ ?%7RXR(J\[NCC^7&8;@'%/G"]R1BOH&9A M;%(^<"V,6!Y56R;0KQ#^TKO@6_"7F?@&LOO/.TSG&(I;2+X[[B,,6/C18W)@ M/I7QM@(23YDOQ%*SXQ]''AY>$BR5''1F^#>5Z]S-"J,\Z[$EU57W0]&5WU;J6.->GZ9?O;63[7;-4QU/6SN\EZN]5M7S;/:KW&6:[;P__C]:]NGW/M MZT:GUFOB#W"9WN)YNY/K732X7XU:I\LU6F>-,^ZL46]."2K M6WWSGQR$@H:F:\N&BC^('A4$UP_X 4GL9XRLX%\C;)LZ=N3E9'58P3-AG)6) METAF3<*H2>*'C;8A(I0)H67'U=%Q@)AAC-Z4:/X$#=EUS.FOB X<_"YR]<3< MOP3YMW;0S' 5+@7_O\.W0F2C&>*.Q$<=>])IO%A>]P7XFE>83&D.'(42S]\( M@N3[_IX^CXO?/QEU5((60;8[PFN?D ]BU36P7[ACKAXV<:9_L&'JKC_Q#W]@ M"X]A,AW^*/!V;OS\N9[]\0[*[?V0JWTY?5-7Z7K\,77@Y/\]$F<'6JA6;^#. MY@5>N+F9)=!HEU\O)F+W5GTJSYM,:QSWB=<=A]&P@!V3XV"$;@!YI2FA_7RA M[M=[IS(8/#U>ZWLF]))L%7J$)DZCK03OQ4A::9]G&DY'VLO9;@FK+^9T10:- MF:'=?M!N/JPJ1>K,R(S:<\L!PC Q-P-K_M M].:I\?-/^>>PWT*__F0KT^?HH^^*;WWB&C^O&ZUNH\M&N!U@D8QV*T6Q$2>* M==,F$V #D81$/% 1&T\->73S]/#;.'=%RSV_&V9&0XS.^H9OQ)'K3+.0XG!F M0 A2E_,J"FU7WX!+.6,[G:R4M%O9RMH&K)(5:)8WO&;DH7G\:]2<$I6T2'SX MA^YU%6[#W$6Z#AJ@H5[)UAT*Z3-SV/GE5OSC_)0O'H$,:59HD@&FOV\2J1X% M.V<"LYP=M@1,&@V1H%4FP\L4'O\ZP*3AP:CF2\7=]O=9BY?A'LR?D(&O%!U3 MJ*:.-$,#DP\:A<:#IG-U_OOIH30L6(,7IG#Z="#X*4O00=--@Z 5%UMGDF/"N98DO\I%&=*N7+.^XUQ^!S6PY8 M YYE&JZ;0KX>\Y_-KLZ8-^C__7+PX MSV>(!IXV&J("DZ,5++(=CI:I-+4NY 7F DTE ZR#42H=K@OY K^_XU_;T.>3 M::H/FJXW1V-9L^"B@7Z+8T(#W]\QITTUSRE"V;M'K M"!N%JP6.;:0<:X_'0TU5$?X,YA!1>^Q;.N;WXM''XVE! (,GZF9RK.AMA4PT M'"0%<IN#??KDHC 9]_7%4SI*.+&YRTWC]+F>95LBG"I/BW:;P/"]SJT(C>4?@ MH3LANR=>(X>MN0TJ5-QBI4)>.'1/U;7>DBF]9J,I;C1R'_C7P$AN7I[7VT]7 MIZ6;IV^=05T=V,H/\S8S=LBJG/AFJ]Z^:G!O+MO=[JL87I)0>&;,L"5 TTD6 M$D06GZ-S[FM:Q"<]^'6X274:7*&<%P2:^O1F3>+#B;4MTS"C)/*OETB9D#OZ M\H=O_-$*[FYK5I^I,&, [%TT.JP.B&%&VNJ P@.0FE#,CJU^3][(+"W?*QI2 M2$XEOC?^C3KM'[OMP;W_4'BP?4XC^W\-#+?ZCHKAA^V4DRJ-Y)%*A6DF*3KT M-8I)E8K#H'C@3,LX=/3UD"D\MKRQ>2&(_%FZ,LI?BA-KN-O8T9Y"W5-<]%UU MKT%&UFCO<;RP)3322 BI[CCF^BH,=5I'O@X8J?0ER0O5W4+C*CLMTL8!Z+#4 M6%M4'_GOO%#MN+=?I9>52;G$24S($P G=\P9:.OT]%?OAE[G45G)B5NB,]59 MZV*5I@K+ACQFCM_670W;%2@MX;9*A6:E&H49D&)$F0Z\GD%W)8!&;/1D ^V6@U9>% MQ&_G4UL6^:GF>6FW#K;-K@9,/_\F/44&&FC.#29>@. M^_+OV9GU>-7.C@\Z MH<'@[9YSY$=N;)GWF@V,^*;OT8#IX& M?S.FU"\=F J-JJED2[&1K.OP/\)D6Z(^C2:^Y7RE2%.;9S-_]\9@:\!_/8>M M@WRJGLA")5_:::+L4DY;Q/U,Z.^OR0YF&5QII=W:CB;7%AH@RT+>6/$S[5Y3 MD:%"X1;Q5M?4/Z[MD-EHGCD=:$^25JW4U>:%\C/SVA,Q.J9TP&_ A.!4GQ+, MMMF)_I2<[;94KFA4J IB7A*857J?CVR(4L<+'"N MUNMUFJ??>K73RP;7:W/8.+]JM[CN1:W3N&A?GC4Z6P?:F VUF0VUGD>WNVJ$ M[?)6E]E9^0+5F3R;FEF,#U/*AVLN'F&[&,(2+BP5\E)AEZE'Z;#VGUVDQPV9-=QVTM46^,XY9 MN&V>9[V0/GF!SEWEBR&=NR%;!D91^QI97:".IUF/-?5&B9N8[HC?>\+79O=K M1SWB',V!M:VC-+Y[=-FVO;>/AX9S\TWJ#-5/WYW?/XI\L\[??A6KKB)6;?D' M^?U=\[S%__K9T?L_OKOJQ=5M7_QUVY-.=65TSLL_\&+VRJOV-:9=]#+ M-W;]NW/9__-G/!S<)=F8SSB[VMJ:RS_VT+94-9-6 C1;YTON]FNR!GN=E;SD M2+9<=M)(1()E\R=BG%ZR\ N_?R3U-I+I*VS9+?R(B>%'FDJIY$GI=U[3SRU5 M_-)14@<_]0W@9V%C?XI=_L_$O45E])+@9YV%D=2ENE?P6;-H,6G.8X)%%TYB M$V?W#3V9,(V25HK^0 [2#V6\=+D6Q01'9MS;:1RC@F_'6,66%0&9S)'OI$Z M<-Y9(^5X32H@9\VC9LL=]9'5'G@R1G'\JSBG/[]^+;K6GRG M;752T=/9%[CSZRGB0\H"89;3I"RJQ4GCL?^]IV]+DWB>W1E55F+L1IRRG=HG M)G5)$>R=0FZR.V+#<]UR!QOIVPL[@.%?A5*^6HYKD+2W:^/U^%E6Z:[;(>." MZO?T_>'3Q"A_OW6'643&!'?%6F1/-7C&3K5L./AX]._W]N M[ 4\[7@@CS1]\G[=\\AG;>T)>:^?K=@GQ3BMZ^PBE#-,!W^'"+A!4CIDD.Z! M9LB&HLDZ?@_^!4FR.$G_AG9)^"AK*@C*^VBN_9\^7G'_8V3QN7_^Y_B8.]>0 MKK[GKC%(?,!?_^LB0\%?*^,E?9=U%Y[ '1_[5[ZJW2=-W?&V.?U[B:R""!;> MGJ[[9N&_1]@PAW_C=2G!OZ-OP(:H+H]MO)#@IP_<@Z8Z0]@;_]^XSY;@__SU6CU>MR[7/(:KON-"X:K6[S>R-:@L9E M>L_G[4ZN=]'@?C5JG2[7:)TUSKBS1KUQ==KH<)*0Y\!SP-5:9_"#E-VMOOE/ M3C,X9VBZ-K8+[,B#R9NQ4F]Z/0O>8XT>7\^Z9B#BDHXJZ&37H>NEX^KH.+AB MPI?:I@3Q_>=!IOD3B-(9G^&?A))+YV(PB2WQ/HJ?WW]R?A[_A.^ V](]P1WL&$?!!K M@8$=PQUS];"I,_V#S9D#_*?1V$)#9-C:/>+\A@UO(!GP[1:YS\GTXZ.M@T2J M9H]U&5,>6^)H6$)MXD MBM'9#$I::9]G>H84!$Y.T,?V(%:O1Z;!PKM\/+K(SJ,I7L$K@?XQ)8Z;7@,5_D?A?2@'80#.,7?\7PAF[;G\BT2W+H]W^9"755[6Z MJLVW4H\8ES.:]>3'R."K7W_^_KB2"GKG4LM6PP9_%-:6Y:"#^W[EH6,I1)SY(-V\.4FJ&2?^G$!3=K1X !L3W 0NT/2 BI M439_5BI\;I8&5W>9T:,2=F7QR<0I/ITX9T8:3I[2AHOF.9T7&I@JGZ[5>U7_ MW5.K-OJ1-2[7PF2(=K=LGX-,-\NDY!I3N[08I+ MISM@2]9PJFD,O70K8TU:6=,%;$QUG7C5TU>EK! M=%M>*S1Z.Y7S9:',&K9FD=W6W"R;\MN:ZZ% >UI#D2^EH*%+]G*L-\I=W3BM MA:2E\'%IL_,I+31B3@MIL*#(:(/)$40LG^'%6CC[V(J</WUK#'I/G^^T MW_K@B,J9T;#M_'T HKU[OJ]@2M2Y[0N5FZ?SVX(^*)S6JG=].ML'4!J8I@,I M]QZ ^/\@(()!Y7&DO]=E8%-D''_K'GULF618"!H,D.)P0]G.]1$R. OR?E2D M^Y>UEW?]M9U\T&&3&;Y5M8,VR%?@X 48Y3G-L M +$D-CQ4 H2V$JGYR$72I#.$'6E<)ZO/2$-Z\^HB#($58= LPBBQ(HS42MC^ MT_.KKRT]/]QM]O_];T44RA^XQM=OS=ZO3._XE2;GYSGTJ"#\8@Q%G$'J>R'' MV*NL?LLR\3.;B9]Z!89&9GWY1A *06;]UP%?TT?*I\=69E)4[O?._?^X MQE]7%IO:HV;./18^/4+C"P*>UN3O?9W7*U_K?QA/'PJV M:E@1!^^ZK%_+FMHTZO)8G3T^%T\OFD)W1H62G@QQ9,Y :]+H- M#J?]][>JU1K?JK5M!M6SPXDY''%S 5(4=^3J8&\NRQ<+SNMZ4'N\N+YRAF>"B] MI-:(4?E9K^^9#L;FMO9B\Z0>O6@+W0.7:R'0-AU&9\7+V MJ=+%5;78[G69[F]R^@_;KE0K_ M/?IX*NND8OV8^RP;KFQ-.+]&[-E] X2]]&)=DI!1K13"9[&:H@ M46AA%3?-FK'3BT+G)14K#6V@/#QU5/1[^-+1.98"<^C\S.GP^4*IDB]7:?9M M?#GB].+0.0%#%9(RU"IT9I?]1NA9UO=7=C:'%(^ M;^*]4,J71#Y?J3+>SCY4KF&50I$&!M+LL,H8Y3",LK**<8YIMFOX/LNINR3KQQ95S/$.U_7JYD"]4]G8]/7^N&&.;.,1)6O8YQTD5 MFIPDY2NE*F.D3#/2TGK4.<;9KJ'\$L8IE?;F27CU;$.3:^9,)1KS# L"Y2D# MB369V%$@T@U27-LQ1]@&]@ 6XVF#M)]N#VJJ.8;5X9\4!;*$\(7=!=M3MM1O M8^CY=O/T1;L;]%WQ]Y_/VTP$V;KY&KU Y-''V<:#QMOF@)/)WHU;KM:M-'QH^,=HQVC':,=HQVC':;V\>G,_MX MT750&SC("HSDFR?7$P9?% M:,?XD?%C2FG'^/'@RV*T8[1CM&.T8[1CM$LA[6*MX6K(&IY/1IXSAK5:]7/W M].Q[P=BF(C45QC"]Z6Q)S>I $7OFT&RF13)D>(VT8_QX\&4QVC%^9/S(:,=H MQVC':,=HQVBW5.B5T/OA]6]8[VPQWVMMLZ[AMXYUP M&MG*:V";8R9MVY MXG(YMI%RK#T>#S551?@S6#I$[;%OZ;Q4*1(2/\M+\KHI MS1ATMPQ:8@S*-#%IF#+HG2E<8I9])Z94EG1$5.5K->6Z9(^@*=,P+^/_( M3YMW(ZAL5PH\UX0@7RG2[$'PJMDAH>!5>29X>Z*TP"B="HASS!G(15&LFK1? M;7I0+-8Y4@XY1Y9U @$JG9L6PL^MNY:%#&72LV3#]M9;,U3R+RCYQO]2_[BV M RWB,)';@Y[\>/,T>C@[[]W_'=Y>%3+337N1E#X%.,4G >?,=LW)TVV_!NEB MML1NX;_ X)\Q:)H9E+D+&8.FFD&9NW!?E&9^KWU1FOF]GDGI-1WP=F/^;.A! MV[(Q8Y5J?SU!*NS4*MVZJ5Z6N"VA7!=XYE9[:7*]U&U4X(4,RFFLXVAABEK3 MMEVDGKF69MQ>XR>:ZG=9=U%C--;-"4+D,]>NI0QE&UWKLG'SQ%>_:.-O3>O/ M^"YKV3=D-YQ&MHP/1446A[F,0Z2/!>3E8$Z!!HACO-&TB^!L0D2",_7JE)8> MJIW&$3]+!K#]_%&]']8O6JUOTX$4L%]2660.,*'AB-><+=TD]*17AB"R*V-/ ME[/TFBD]0P;^92+#DN%?QI?V;W1Q.2DUU-1 P_HVS)L?R8:V"9713P7A>;/$ M"F*^6.%9Z'^_,/BJ(Q(S&)12!8,Q4[;N2J/"G?M+N?K\AR%7TDE,!>%Y0[ND MNR,RKD.0.1B3F*; \Y&SE8AR?4? V< MSM)B=@L0[-)C#)IJ!F6Z F/0-#.HR)(U=NH.W+7VN&DV5N+!W 5QN\R.N8FX MA2+S(NY7H%DH?5^4?M6A]+U2^E5'ZU[V);4\M5 L9NP"6MNL*YI+<*;=:YC3 M5=O+WIP&29NC,5[HC=:Z4;6;IT;ANUP>Z6.CD:V4P@_<6%:A[_>Q]U+\%.AT M/26!'[E5 R)L?RBQ[UDAFGW34I$U_?BICHD!7^)L4]=4KSLW7='=S1N?;R#% M4&X7>/3*#RCQ+4^2HFG8"K2-!03\N;6=:.OGBV30HU$I?,8@YI4G2D5%S<[TU2=*15G M.CO3%Z02+/<,2TDKKM)YW&6>%*,#D$\0PI1\CC)&X-8H'&9<-8I+#==5H@^N#5;OZ^4[S7Y:-V0LYV1.UFUUCRAHX!4P[O?KFXTEC)1 M%"LDC6\MJ1O-%\42ED>:_59CI64?-^C!Q?(_B6[0_?'E MKOD3&EI-6#A[I> M7P];+KTMJAF\+98T)Y!_VZ,_2'.EUMUKO2T2=!DHE)]U6PCYHB#DI;+(Q)+= M%E094TK*F*MN"Z;$[/2V*._OMOC_V7O3YK29K 'T.[]"-W?F5E*%/>Q+GN=- M%<9@D]C8,3C;%TH@ ;*%1+08PZ^_?7J16D* +(O-UEOOS,0@6MVGS[X&]'!0 M9\7SQM?Q:"!FWR2#W]",H1"VE>4*SEU*5ZOE=":?:%0)ZPZ)H5JNER.L]E@)$V/"\H?;IG5>RI9C'/)]U;N MF< N@5T"NP1V">P2V"6P2V"7P"Z!70*[7< N,+<[AV/K>2>VG@^1V]WI+48U M:;PPIU/3'AY);C>?Q/U5U&S1F LDA3LO].6A;LB"*.E3[(70AT*M4Q?RN=*A M8YV;1]%#G:TE-K^JO;E_].E(U)&7O/N,AM)<^U%#98M+L$ M[*-AS$M.S/U[*+>#),4XVB F31!Y+EHX0BZZ(G?YJ]RL7JG?:]W6YM2V8^2B M(?(_2V'C2ZL2D_.%0CJ;J[Q'$GD;7#0$DA2C!2&WER1\-"BRDHO6=L=% W)Z MR_)%)3^>*O7VYA*_@V-\&[(G2Z\;Z)@MIJOE3!I95.\17X^ I6VX_F(<0>UL MG*F+R>7'=_DO2&0MQM%F()O/I*N5.%.IWRDVQ)-$Y4>',$FEQ6B-B%=D4.6* MZ5)NNZI,Y&RI=XT*$1,\B]&JI5=@1SZ=R6^7623($04Y0B9;%J,50^XDV?+] MH4*UQ@. MY8%U,ZS1.B'TK\% MS4+"<@.V%FB(=U/)<0H>XO9WY;T76]U_LS>Q&QD%PB" MC*$ -5*D7DH;O;98ZMU/K4FF1Q[X!84=%55)1KH=S9TF1'?@%Q2:Z)*9>T=S MIPG1'?@%A2:Z9"CBV[O30G*GQW*G*[PY]?K5^>Y'CO@$1;3$@@,4%$%E#)ESUY>\ M[%JO#2W98&#M+>JJ7>BW1W_%J](;Z*LEPN&+S#7,<=9#^X4Z:CQY[M77);V]ZV*(+;1( M7(<\ZYGK?K G6HI,4B6QFCD7CYDYKRB7^*WTKVJE7U+QK)\PY_#I\\5,V!RC MI,;BO3'G$,47U3CZ)R:"W5<(O'/F'%"%<6G>BE__5-3NC\H[X:?K<_>+F;!Y M64GIQMOBE!MJ.JJQ-#]\ES4=QXP5+RCVJ,:2T?E^BSVV@";K?+;QXDF8,%\U M6BNZU54@E7<) MI$- NI) >JO="#P*)PY+;N6_*9*/AD MPD?PG;P+UIZH_MOET[&4;KYG2"<(NET$3;Q["8(>-((FWKU=03IQ4QV<3?$B MYTDVUGK-Q'FR8_*K)N2W&TCG$C?5P3$Z+R?+Q=JC>,?.$Z_KI,FY3E;EX0&8 MFKHAHP7KMF'(VF#>-43-)!NM:1+^"TK^T5_2@VU:4'Z!H'PS[(K/O47Q:?3] MK/8MVY\]'DEU>A ,*02$ 06!8+FG%D3GV.^!OA*;8KL"()8F:>\9T@F";A=! M$[=A@J 'C:")VW!7D$[\7[N"=.+_VJY9N!WS9R=E4<5-D=72>. MM;=+UUXJS<7&9*KJ MD: MY.@@-(&1-U-TSD.G/[<'2X@K)7T]5MZI>8BMLU;T-?Q^<7LNVYV\^%!V6KV\ MY%YC;O<24E84DKS*'4$Z'\MTD&.%M*R^_C;TTW"N\KH]4J9"N5)..:3OF@.\Z"N%RP.Q!<<" KG5Z/J-8U;N) MV)43IA6FJUTA; ^9%=PHFTF7DJY4<;&C*/BRWK:,%UORT1I5)>T^]RJ\D@#0 MKB"=!(!V!>DD +0K2"=U^L]13%S_N?9 M>/YMCD_>YBR%M3GII1^>@VV%VUVX+=5<5JNES>71/3PZ6RG?*SQ()(,J0/&D&3K+.]F;A11$GXT1O%8AS# [/I M0BX)<>R6)HM)=L^N(/VNLWMV"NEWG45P-'+&)T%B"7GN5(($NDX+(5VGY..F M;J!7/2D#V>PM[I_NG^H/Y5QC6CBZ]&1L^+'D#W2/@DF/=>CDXOI!,F'](,M7 M=X ^D17.T.JP5AQ?MQ@982.V%7D'[7;5]T?_N MY($^TO JV,'96[1&:LN6G[^KK?P1)X1B7?0$ P&ILBX4TH(F6Y!&-!#-,5+$ M+:2B8VB^!TQ/,B6VZP9)A%Z"H >-H(FND"#H02/HNT[NWKX3<-O:X_92U+$SFYTX3H MD@L*3W2Q.,:3.]W%G6Z8X? 2FV9[[LI*.8ZZJ&+,XSY#(FCDH2OO'C=#\YM8 MFCXD_.:@[C061W=RIX=TI]587.K)G;Y)O< K\:O1)GT?E,0/]E%[QSP1)M_NJ'"O)KAAK0#J[/_YJYQ]?WS./KY7:;&YZ6@I$[8%4+"TR*8+I4JZ7(US0NG[ M)+EBNE175WTB*@6\.?W\V2J1B-6OWA33+X]6T92IG2 MZSAW*5W*96*>M_A^:>1ML.X-G4"J80?JK>7)<38+3!#NN!'N!4'9:EA^MQ;Y M$,LK9^),XDTP<&<8N"%&$!$%[V1+5#19:HB&AN!K!N)>M(0 $^T>?>9'PG(A M7:CL1>S&F!N0H%],'' PL">VBK1@"??Q!0W8D,>R9BI/,HEO!6)DM(JZ%1B9 M3U=*U00A$X1$"-DU9-&TC3G^.5$( Q$PVLB]%0A8*NW%@Y2@WX$HA#[3-H[) M%H5LNKQ_6R,P*)^)%I0?=3KJWUSW:E&-TMM'4LRI*LX_"P@:\H'&Z-\0.:YT MFA6/,,2R(B!?;Y_)HZNOL^[YZ$UZX.()R&?#&@])0#Z1DCL,R)7\I& MRY=/XO%O!OVV%X_/QI'W>T#Q>/3?(H+WEU3JW^G+WSL1C9&"%H='G?_XNE+ M:B=#<:*H\\^;UL//FLI")J]W]TL;5TQAGWC#PD!657KL__N C#_X&STU8']' M/,N)I4_1>9P_&41+ ,^9(EEC6"WS7W1(RWA].P#T-N\U0;]@93C_@&XF"B*P M'2Y=OZ=?"/.2-3.%WF)X,_U[?7_>*O[PIE)$OK./V4^O[C1"SP%\ZW^O[RCL M -5W_&RFM[@\'QH7E\:->3>*Y_C >X:Z;FFZ)1/60?_ GC&DK3]/U,^J"&@J M:R?WG0]?:A/=UBQ3$ T9ACJE]"&>L8K30 :ZB:<\B=.IH3\CWF+)ZESXS[\$ MOI[C5#WSM6[%.>X[3:-3+;I@':UG]J;3S#0X\V9Q5QJ;P\M!H3"L(J*"^!99 M?3K6K-Y]_FXL7?RP_OPL9EKUS.A[KFH/KG?H_N<^/Q8/)#[^>>'__\^KKX.C]K#G[]F$J7CZ-OS3/XSI8NQJITH3[\ M_CF;UFJ]GN,T;?%P,#C86V_D2ZJ(@67M! U G$^A\_898V]RJ_E0WL_ZZ+YA@< M3B^)3T1-6GHT\H-*U:X;;/M<_,NE42 M^*@\QZR*0RB4=$WK!(?1"W"+$RGXU!M_TFZ<_XI$0>DP, M-$;0KN"A]=)@]OVZ_'5^GET&+59.'-"^3_; F?<2IR)]PT!757%JHHVP M?WE-*7$2-"2T_QA?'N M5 )B!_DXE'*O?^I9G-\2;!5?]-'@;VS[]&($N71>A?ESW4/ZQP>'.\=VJ'_[ M7^JUNT;]ZN;^/)UJM>N(D?2_[/Z0<9WEIMVYN6J=U[J-\U2GB_[GNM'N=H2; MIE"O=2Z%YM7-SXYPU$=LWMRENI<-X7>C=M<1&NWSQKEPWJ@WKL\:=ZS+;T&H MM<]IN]]C/>K'_Z043;#&NFTB2]7\Y#T%QS?N;%4^8;R#YU8O#@D!)_XLB+:E M.Q_A< K[S!L66I9$F =&[A'N?[H.>@1W>11JB8A%05F7^8SE5XV MF^M-M;R6[RW^?!W_TA_:9W_$"E(F[ DZP1P_B,0UT]F$$Z'.JW7.%R:XEL&> M$)JJ/C,CA#C#Z2T?6)7VJZ.;1,6*7B2]/C.QKZM2I.CXRGD""!QPU?_W(>?> M8*%:[ 78^8O;TE/NVKK,7]K*^E3^)9(/O>\@\H,-;!D<>P-TI1<4D)S5L]^O MS\K?M>GCC@&]HBE^?( .G&O+=Y)LRQ9V(!@ZF-?2V?S>E*66=C.5#=%"2]? M,ZM8X OIFY:!I]N>]1;WUNC;9>G\*O.\W=&V<;9#6#9];FX;=[5NJWTAU.K= MUH]6M]7H?(Z:4G!,,Z7C7/*]S>/>+NP"";;B)5B2&'NEFV9/09QL(K;KMV?W MBVI-[2V&REEU6"A-OI74PYXY3=6!$G@QED&"3BDH^)C"1Q4=]!6YBO1%N?_& MA&1,CPG<]U(>XLO7+?TW0L*A!RO6>8(MW?4%^_R\<&K^'# =B1 M4PHNH3\7= 8J071@E6A;B;9U:-H6;Q[AJJ1S>8KP71&!4=4TJ3;1$4TN\)^( MQG,^!:Q:J=X;%^7Z?+OD_FH%C-F.Q/<(OPB"%G]VG+@CUGCQ JH,^05H6 M!Y.;X94LFO(R _U;^EI4FO*\5A@ MG!>B2$1V&FN[^7R<=<@QEK$G6/$2?EN,UOYJ!4[$VC+S96Z_0G%WEQ_(3C,< M.V7Z&@F:=,7G!N(DFBF?R9H\5*QECEJJ/Q:ZX[OVS*B\!7V5GA,S48GIKC0X M8HG/[X2'\LF14"UTHCR?C!5)DM$S"&=RRG/?4!'Z%S]\.7EU&X_WS*XV*(4; MJ#$2RXKF9UFA!!9S<)D6V.#8%N+G,OI9W4;0T@;SKB%J)MG.A:AH$/N] MD]'""UD"#M;N24IO8G)<;)&I%>3R8##\5GIC>B&%#-((!V-1&\G"QQ&"R">L M$284]CD\XD14#^.8&9+-!_6&2>SO#5^+!)J8;JS>F7-TN.KPHF1&ISX8, M6Z"B:5E#?*[=57X9O\97@^TF&N](0VQ!ZK=L6H+(3IY0CQ\)HO'*4AP=LHM; M]DN]']TTABO?P!9+F;C( "(H# 0$IGL8HL9QYR[E42"SG;7*G8#J,Q*-BZ>6;6]'? M<4]L"C=U.1--68)V[8A]B\&9D#_ER?GP[M)6[.V:Q3M2W7"#G),^G!MA@GMP M'"Y!,BRAFV#$B*C.Q9'>DS;TS!JV,OHBDH&E\-8IHR]*;6)$&E&0I) M94C"DO8+NXT58\M4S6+!=_) 5IZ@B0>BY_QRN*!4,_/#R:A6^GO@);I>FLZM MH&EV;*@)H^=^#^CWXHRL9?2(IAF58RD.2>=R25A@RVI19!S8H"258YT^E$OG M"GO6ELY>G -= YTAF+W^O?YZ_6=>:LZL_)%J3ZLX+0,$T9@2^GH!JD1DM;&F M.Y1+NW/BO&VTB"4;>C5>;&*_<;@F2M7]Y;ZL9[FOD+\E1QNGI!) )EP5Q^1849+5?#IIIGM5JR^"\TT]KO?P!0K<4Q' MKVPWEWD=3ZRL=]A!@;?;Z@4[K(*9XZ^K@=P^SUX]W&XWHWGWVB>& 776O0<* M>BD!!>%(-"Y:B77@=JF<3]3.P\:(3;PUUG'7"+WV:^WG0WE1;\4Y^$=JFN0% MXY4;(@ .[ TY+XSGF=U9=$VU>&RZZ3(H5[1W=?RM4P(A'#C1,7/FPB?1;S1T MBUVZ^%J_;@B$C2@.HB61K.J_ERX5X_1#!*!+K$IW@I"[1LA- MTBA6IU@>::]Q>I]?AHZ!\JDN*LOKLS[WN*Q]K/1 M-K72S?>'([4+\B\14NVP#2 3MK 5930\WD:427'DZ>0RZ5(A3F4T)/&_UC1( M,&][F+=)^,3B8"RF"Z4XNU1'P+M R5/8+'G 36>N&\^5'LS67#]L" M"JB-:O]H=/S3&(3WX%A(TL .%78;:\>1DDV[AM<&?VW%D!'!(E9GS6]54;.0 M[MU GT[A$5 0/?[B,PG1:VN4;V=F#\:O'V\MU_/6-@9C9)#@H5)3"A7LK) 9 M2-X#?FXPW\+C3S1%K1I+&]ETJ9HT<3MP5-B@.57C*$7*IS.E[483-ACFK).P M"RN:0@_%]1U]:,U$P_%XM#1+U$8*^$!8Q"Z U<75O?2?M;SNG38&E,8MKO" M..& A$P B7.;ZPX@'IE?._=VT8K2!PWOHV$LQ&Y?API2L5T.=9,C,13_":0 M;Y.K_!5[;YI?!O]-NO',T8Q#J^P;>+& M>.C_*<02C_#6 T7AD3:2S"EG8FT07$X7,ON+"R78=V#8MU[HE#/1FO^LP+TL MLG>S<9HY,8B?$*[AIJ*)VF"U:_AOO_']_/[WY9]Y[K -G67(-%OM6KN>N(;W MO\D$=J$KV9C*?3,\5X!0-D]X"C(7L^E3.EI.?33KRO+Z#62)I* M+'UM"NG\ECM"K=-%:@%,[DY614N6NGI7?(8JN[&N OTW=6-ENZ@ 3G>>N=6O MJ\U!L?PFNGUV9,M29=S&3A]"!WAAYH)&T/OH60P,4] UR@$5T[01.[1T09Y, M57TNOX_6=R&)\Z58%M&2C2/)I%A.JMB."BTV,.YL' 5NV70QM[\:-[Y]S9T\ M=01>6[=DEBT_W4U+9KW<-R_*;TP#=>$ +%H#2+#"BH3 /J_"DFA\-1M+ MQ]YRDHEP4->^B6_&T:ZHLN4VS6$];[>&/I!ER82CMY"F)B)3X&88QJIWZM0P M/U477_.Z>M&5;[;+3W>DYS*P"$,$%ZS" F" H<(R:/TSP;7T,4C2@B9CI9@V M3WT72FY86S^;3$;::J5N-"J.Q/SBF4M=R&U7YKUH9@2>GA9G,%#V3:F-7HZG(C ,R/S,M\%@85E996$E>V*E7F(,1*WBJ6X MII N[[M;?6F%H;O$KI8MW>_-JS^M1?7\K'G@]3-!?"HP!<$! '"H>#A5DNP0 MWG[:3)4;[>9<'*.-LIF8IT@D&37'A&0;6'\N#M=,-A^+FUSR""6I&WN*W$N &DC"I=8FTEGLWOMYY&@ MWX&AWR:Q$VMKHVP^G:O$V58W!OG#FR*-X5 >6#?#!IVF?"=:\HT&X(7_0'7? M$SHACF>:EJ$,+%F"+VJ:Y/V >](KEV;=[\5QMS9HJ-N=#!A[AN<**FPTFXUZ M5[AI"HU?]6Y5)V6E=QVX\Z[LH.P M5#@1SN21HFDX=7PH6&-9F,NBD1@_!RB"7HBT7F91,V^&*UE$'-ET^70^O^?V MAPFZOC5TS06B:RS=QW+I7/40#:/BWF11.RUR M J\!':JV(NKH>U[*/?#/!$FW^ZK\.@;RGU"\(X[W'0?["#:QXDB?+*:SA6T& M!? =[4+>)3A[8#@;K*'%4>"[;0TM%,YNK"$#D#95?=;6-4@/<'NY:%) ?! MJ^JF;KB25LTGS9TV3*\:!C^P)*.^]O[V]:EPWVMW:E="^:6.IQ76Q;I\+ M2>.2Q)-U:+ +I.NFVUO5Z7]P+@]4T9"EMF[=BHJ$\_L7@_FC/I_4V_GOA:/1 M.Z-U3J7RU@$'\&X,CS34B;ZJ0TDBW%<)=]RL-9!L\ M]X4XW'+%="&_S:YST96^#-=XFW;UQ_5RP );&E+IH((.&B_43-.>3&'?I'"8 MB(S"]Z^W5U<_?C6[@\-6\5XE)QADR+@##!M!8<#!C5^@N38%#VLVD-#V5FC[ M95@:4:S$T5"_M-5\Q42P'"GR;1(W@"4K M9N\(4PPT*.PF<3_F?B.#\QWS-?8MK2!/I&[XC,T#5.DMDS: MPBSTSH_OW8OQ4]-\)VYC @AH^AIG;>P[E&EK8\#+Z!9-;RK&DJA4C+--4Z(W M'1>.;;#9BW&XB[*%.(L%XE/@&AX)8,F&;%H>]F]D?S7O[^X?IM='Z )>R>') M01/*VQ[E>5 I(FN/(R$GWJZS"6L_(@3;Q-?C\+A48VWP^"J^_C\+.OU^2:7^ MG;[\S1/1&"EH>7C4^8_/+P&KG0S%B:+./V]:#S]K*@N9O-[=,75=3 ]UGQU9 M3I%FXI8.2(4+ *!'/>N=(ZKH/>@#W,#I]/ /% #XU+__S\F)T%1D5?HLW(HC M1*H=^:\-#5,_"^7\/\(/4;5A >'DA/(927D*6RM!3N1\7X)-_(MQ4QC(JDIQ M_/\^9#[@O]&^!NQO[QN09J"*4Q-MA/WK'V&F2-88CI;Y;\!90;>A:_@U#TN? M!A$21Z;\EP,9^(OG=1^^-$]XN#&(_2-TYU.T@YHA]I7!/T(;\2D"U;8.\*OP M/_H?^Q5\XY(OH]U__X?@' !Q0Q8?3_HRXE9HZ2F^, IE="P&8@?Y.)1RKW_J M69S?$FP57_31X&]L^_1B!+ETMG<0%7^N>YEL%GU"WQ[;H?[M?ZG7[AKUJYO[ M\W2JU:XC1M+_LI5#YO*GY24IXCUJ3"=JWW0;G53W1JC?M#LW5ZWS6K?A)-+6 MKH1.%WT GM/.&SALK9.Z:9),X9L[H7O9$'XW:G<=H=$^1X<^;]0;UV>-.R&? M30N@W^(G01/9>/2^KDHQG=\R1,T$%>>S8$^GLC$0@87BKQ1-DN%M)_07VZ98 MHB*U[0GZS2"T-2 CM6L*K-FP9:_R5D+2PJL1WA@C45,6.-90=^0V!!YP0W 3 MXA(D>-]D@KSCR'$WQ;V+]G6F0M=PX*C,4*YX>FG$_:K>0L\UZK.,GOEU68I@ M9:^Y;%Y,8)/8)YTS\5X](HPLS\J$6)=V&3.^D]QY;_%W;OUX6MQ4%_WBAR\W M=Q>U=NL/B<< P9W==UKM1J?CX**/]O#_Q6U:E \GC@E0KMG"$8\I.LV; [TT*?3'!#ZIEN/ Y5?4:V-A$? M9:$O6TC:NJ>"+P;H85#&L5%MXN,+L[&BPJJ2#>I_2I0FZ!D($5O*$UK%1B: M1GZMDV(N;81@;R*;2[BQ#:&C#ZT9VON):)Z()S3U0OA([[4CBAWG8J<(SG"5 M=%]URS\FJ/+ , M'9V4WAYZSP"9,J;S=./RSGW<@1#&K.)G8^,]OHCF>* ;Z,;J=$= VPSP99MSTY^ZO/W*PIDHSPCT(:/T?9-?9*HL6NNV=UX=90 MGN#75\H$LW=&].3+)^M4N+*D4Y>KB()72ZIFSOE&IG^1@)I?(RD,/9&@ZA.8 MP\U,0X0X5J:WZ$Z 68SDGM+J316I)TU[]BW257L#V&8VE\_V>J9AG9QT!F/$ MNE7Y9AB\YO*GL@RND=JS8O9Z+$\43D%/2 ]X+4_ZLH$4._GF[XT\^7UU7?T@ M6(H%>$#6%"9X401#]BY!9P= S-HYPL;^@V%A$51"G*$V"CU);]5!?%9+V(*F M5KOI^)Q/[BPY=J]32HK08FW?\B$GS0#72T$P +IU;- 05=/HT5DA3' M+HG.8,C BD':^A$I=XR(1%[2!02Z&;8T/*?<%E7OKYN8%QB0U/DL#VS00.IC M40'IQ_!Q_GUV];WT^]M3973,^,B^WWAB'^*&S;+8@+B9TZ#B>(JWE%N:,/D5 M\TXOCP,%7?Z+[DZ="P2S^W/\ \+)#I$?/I$0!&=V(M;,YS4@5 MU;'VKYHZXI^2@M0V"ZE!>#_P4@W=]_Q4P+PZ6UK-JVL#=(6F@N^6" B'6]?J M/(MF( %#M-O4M:M9UDQ3'RA@1Y E7,N- MG8>^@1WJ5$ G1)H? C! T[TBCOGP2E):0!JVLT\$+%6?]/4TONP4OFS2C \N MLBGW#1L6H*ZT-'X7.]6JM\V0.H0%, []"I[[19L@IHR,W\>4ZB#S@NGE*7SYH)CB<64W!B#! M)3$-80/;=*(FRN5+E,N6EOHJ:AA/$9)FO"@UI85%$L>)ZCQJB(Y; >&S2570 M&;;4'D$LBY;S &)(FCX3'M%_(=O%Y%:\I%8C1F\',^N7+I$BG/]J([-]W0ZO MT2D1"3FZ+H?UZ.E3A_!$9 BIP", *]&M")=D=K=)Z"OU$8)VA(01?3I\@RS. MW#.PF(E,0@N#W)DTBB@%G#Y5>2TR5T=RAT=XY3[9'P0O@+>)T-%,^B MH*%EB:Q84HO3' UQ(GR)Q[LRW$-)Z(WH*Y>"4@/9 $\&$\B "O)$&'=%)2XK$[T;*ASBMC+A M).@@Z!C,-'QHWMP:[;]-+?]PB*9A+G>2@>@J;QKZ#^&S]L)6*6]V4P3UL0[A MIDCYW!1@/$1VY&[R:Y2/#>-B\VG4M&O]^^-UX7QXK(@;U9\1-O=SHS\C]U)_ MAI<3IF)R:I W@=7 W!?_<]P;HHD[EJ#G^OJ3?"H<9<[B\012J$:*+T1&6"T) MZ'X-B(FB2X,4H!4:Z@I/!J^=7C>HD3 MFHT5I!V/"2((<]D2^O+(UEAD%:UUU-K7_SS915]B3S8J+R4;G8FF8N(V(4ZR M#V(]'812RA"IQYI5&PP0 8,>?ZNKR@#ISZL2BS*<]'G-LKU%X_=(/+>;@[XM M'7L246YW243%WN+Q3FOGBY/GJE7]\.6LUFEU8'+=[5VC V7>3C91IW71;C5; M]5J[*]3J]9O[-NX6>GMSU:JW&F\JR2AV"LKY*1>;Z"0@J>SK5K?M9; M9"XJI1^*+M;&46; [T=<+*-D*8]4LY_EZQ0R3KB$?" MW3Z(5A8527'>?3N7PD=3 8CQWF!D MZ*YQ*3J_8*Y9]#AVC?B_R'[B_)>!<15LZJ00Z9X S1HZ\> JM%@J**@&"P;H MI0+)4@#,(2Y4@+BE4_?.IJH8H::J*?Q6Y@JBJ$/N$$L9HBWSJ">K"C+@1(I M Q[-WU!2#6:N\C/&\R]K"W$*22%.G(4XU6,IQ,'Z+,.0 [70D-1B!_+7,VQ= M&R_X=8F./ *^?KE0I/YZ(PO^\M\J;>?GX:U@U#/'+MXN+R\N?? M;\;#L/L %8_X]"GG^*MT"F:Q/BGRC*1XNO8C.!F UQN*N2EU"&%"7S9NAC=, MOM,-F,2?-L">M$(F"YXT^!?.%5H,'NYJWZ1NH3[K.[XJLA((-5=7,.EBFSQ3 M*W<1K5:]['690@LO<"K-(/U7UI8\2HX;B;[UPQ=KIJ_R) 6<+LV2 $!,M[I$ MBE/%(B!=X30%]S<8*S(/*I:,C?.V#3?.=7/NYA-/=+13G::>&S*Y>E?F\SGR M(DY#-V6V2<38GV259!1#2,D$S$@%:W4X?T6%M!R6YH*^U6UC(&^KQ'8O^;1; M9XT5/VN\AVZF#72X">C@/A[(C[CW/MA;R&/K4KR4K[Z=/1PSLZOT%E>5P;?, M<-:]O2E]^(*."3:4<]!5O(Z800XV;K:@B,8*U #NA%/8T ML.\9T@%3HKGR?:P A'0C?9[*R#0P^59W!A,@$"!0=&1$<)XK][""_[ 3$5E\ M_3E?AT'M0"B2L+ I GY+E086+?VS\!'90@H21XI!@A-#8:3KTDQ150(0'3K! M*$^R1,&4%C[F/D%W50,Q/:P"P[<<'-$#^4^8!\VPP8MN,@6'A E$P@ 9Q K: M@ YL##U9^,0=!RWQ)!ID48 TE.H0Q&$5/J[=A#L@DC>B98J?A"$Z ?HYTO)A M'6AKCXB"K.4F%%BB-E+@(V(BNW_2G2ML)!(Z(-*6L1%%$=<] JWH0><>(KA^ M+'TB.0*T+@ED-[I0EHZ$WO.Q[!P25E:A""@%JYO,4C=HLT MU0:6C3YG'!Z9?JJ$I]U29%#G@J0@[#9(6IN%E:MODHRLK2AS#<-?65#WJ!GI'K5548*4 MT,79]U+CP6QGZR/HVHSA@_3F@8XP&U,<)TZ8-/D)Y74&!.]8U1G&^2%\@M3E M":G,PJH.86MNK>&)K $GX,NTG/(NE^8]Q6RI"9>I!BQO:NA#4+UT#3B^4V$( MS Y\>)BV:?V52C1,YQ'$Y7#!%^-$_->$12 &MB:+-<4>QOX@K*;;AK-=$9E1 MVHA*3V#QA!'IFL,G32)&G5K$4^%:-RVVSJJG\!>08P7[10#AZM@$O8\PB1@L MB,DA_1EJRIRD+'=%27=6F4 VUA38K+B!/-7OL\DB@DD52I8O,\Q]"0%)K@AX0+0H/Y7REXX M-0"?[S35U#WPLJ!'S%F,?C"G\N##7#J6+TO!UI13@''LE."?$3 M]-+;V7\6<*BH4K?A -:T#"H.R9Z#CBBD43DCB*4]6H&$O- M((R"J.!))N8C"$F'1A#Z> VP!UL:4Z!D*<(-V=:.L$JV8@X^?H M76!J,9GNA)$4]$.<^$.< MZ31T[.0O,B60N3$I"6I^V4 M)F*U0!4'^Y7M-$O;_AD@&<'?@R;0_G-S2.CMLT00D7U%VL(2;6YH0R((8N<. M:E++!:D\'5D68#J74$D+U$)/8V<>1+LM8@9S48LME9V\46>3D\5%YW!"IK$3 M0*M#1)?PH1YZHD$2=XZTY.=!$!BHHC+!M#<@P3VRN[3S++3P M46E,@E_+68-T\,'\G:2MI\CY?(YS/PMQ_4H8<" J2*4<4:"(Z',Z'SE3.]$5 M.@#-6]"[R%G1?KG6!8E MVLDJX3WA>4] U@?VWUP0^5#3I)JGA5B#1JC"YY9&6["W.*_FU=NS4?_Q^?&8 MN=1Y;Z&7!@.S+)8N9Q/-$":>1X0P"9SW\Q3I"=C)6V*?$'G[&MB9Z_7_\:2H\-M3< M5](S]Z9:42L%IZ=,KKX/;@V]^_5KQ4E/60^.30DJR^^/EIE2"3URM.A4.I66 M!@NN[C8JE&FJQV,["CT%H]BI?/M^?9KJYR'V"@Y.Q8>W.G7B@_V(XS+$O>C]1+$ M46M/F-KHJ&:$Z5/W-L@.PH:!1/";P*$IJO,%J6C0B3<3_4.R!U0+IMN !T!_ M9-^](;H*GX]>3/+1X\Q'SV:2A/0WD9!>72INP].)$&>Y-V76ISA07#3]T]>" M?M-;C/X^UBOG;3LW.&HAD>DM[HQ93OH&+S%\$F!%9SV%;<"&K&6Z >I42/$_)NYJ6I\$*0[0LH#.:W=? MNMH6N0&Z!G^>054Q?8T#26MH2Z:)W:(T)PDH%"Q8RT1@@<;.=&&\[=2 !/;L M*4[4P6LPS17W/W?>@1 ,,E)&7DL,]UCTW)[?X4/#'P/TBI$A2BS?5!M#F(MX MBR&"G5(L.!02R'TL07"@#8Z,;T!2+!N2;G%"* EEXLB>ZP,>VMJ _!/W=JQS MX"-; JB1_MWD-J>B@=W/2_F7+/:^NN32$Z.#-"81@U@D6('KX4AG$O?-P7C$ M*$;@$1;G/TP@7HDVGP)###JTB]A=CINT]Z&J'+N>\/6R8"N^WZ&MTHQ0UP5O MC0V9#*[&>W72EF7(4\516AR58C^F:;0D]Y^"!)N#Z/\U""63]^.#RLR@X7)W MX39EV!QXZ\'99@B#,80&2%*U8@SL"2 5^ MQ\(H/)<,Z3H[T ,Y(,J%Q$QE^ M2Z?"N7^]D?*JF[= M2RN(;S'7L/N^3<9QF*U%\SE40P_E76,P%T^#1NN%\#E4HH-_R0LQ>\P^2I5R M1_E1.ACP;_!65.-P^%1.2YN #Q,L7$]#FC/*J)F&4_A\<8FI.(>J9)^I!HGJ MM%L-&UQ VYN06FX0CKB##>)<3BH4)S!))#WH5A"=0LK%6S+8MJ_/+E41=4$0 MUS3I!D(UM >)>8<8I_($PG>C;AOJ][W%??7Y3ZYT6;"_YXYS00O#9JQ#DO(KR6[# /<\"0V'IN%*9LF9>6M [-*:WZK01TB3H#4;9I[K V19 MCHS#+H'LO!^5[,WDXI=E1YD:?C"47.HM?L\;UY5?O\XK?T;0B(4 !MDSNF# MB)D]28P7]J2/GD'XI4FV%.0R3FPB$UF5&DF&/^?^ E)# GM '[1-I]$85?A/ M_ H_MHB6%7Y79V=EA)", P*;YHZ!!>#7JXIA4.$>O^(*$3YT2)2LWT2MY08^ MW(%N3WH5XK^OD>TSL2>L*:%XW6C-[JIR_7I0TLY[T?Y&=IFD0K;L4Z<&I#HCIU=G^B /HI5JQ#G;!>,8797O))^ M]OO?+H<'SAF6+)BX.(/'ETF=;N:*JW,E,(AXV6 2%S^-TZ4%6A3HX@0T#-4G MRB %JC/Y@<[YL"Z8DR[M7TDA7CE0OOF/IZKM>L@-].N9J HZ&69&:AN(/XYH M\NP!OB1D[O:SIUFWY-FAJ*@V'B:(.*%L#!23X;?G)3/LIN-BZ,E3Y.A!.GW+[_EWLC^=T@3LU@+'W5B9 M0H8LX@ :=F)ING5BZ2+MH-8RHZ@00,21Y!D M2'$PG1><"C7"I5R%9"F P4=?5DY&Q2R!1D-<3Q^V0(@W3K=A14G&LU[1A\RU M0#N)4UZ().4ZG8?#.!\RKK4K0OS>/)M?0RO'NHH.[>V43LL$ZG!D-]SQ$@TH M_^/ZY\7T=^:\5>:]Q/X^'=NR5V@/]+7GB&K39)=LFC!WM-JH$0*LFD84# A6 M>W>& %[-Z$?^YWE7.;]\FO4C(, VKCJ:XI1=,JG"W?80TOO7:T[A^5"*Z@-+ MS2=T8R1J; F<5;MFA!K/L-8'16'S?I3,[ILI7<#A;YVSWW!'1^HK[?7&6KU% MXUJU_'FG_]2^;"K#/7*MUQTT,EM;,O7"(7IA%5L#=%PW>7( M,^FFJ-X,KW1MA"^*4$R+]4[RDU*8QK%\=L$6WM9;Z%9-_:59%?-FM!,3RY/% M/?Q9E0IG]7KSMOPA+N.K0?*&('M,'PH G1,,'H& 0> S-F-$QZ6LP13K7PI9 M4$L= E>F):U,1H)F3;1C"\T]&XB&@=._G(Y^(AT#B-M7(",PU><2E53Y5&C1 M(GM[ H_;:$D3!SYER8VZ#FW(9H/F%F-AJ.HS[$IVB^P];W:;5#C!':)(88\1 MJ\9FB7&L-PR@@7MT')SUM%CRMBET5L;^,&@()9IK0Q457"YL^^&,/]-G6WM>GZ54R14B[U@+ZI2\(E?)D47 M6E;G'K%$W65UR*TB)JY:I[>![?AZP34\#0XB2[Y$QM2F1,9$I7B!2K%D&%S0 MQK)(O_1+5[ZX<>HW>XK9X^7WV5+S]^GSL7>:EW.3F[D?[S^-%Y<,7 M=LQ40(M,]AU+''1R$R R9CI_.1Y0TA'-B:ZLZ:$+"4V,GH9.&TV9\X^F^(@. MR4]V.@G[- *2S@QS;O!J-P-+)^3VKVE/OYB0!X+^-^T?8XVE)Q'$3_ AK%NEM\L[ZJD/:.REI8SD@Q /K:@Z.IN T $NSMG(2G=XSP,": MVGV$=9#S#:YCB;0$!KZ!LTI&-@(F]I:0YYS!OL2G"Y42= 2/R>=D6XB=C7#+ M'MP*4.+F/N0T:UH]IRP][>OP@^MC39EJ9;[0$=;16+2*=4A">,LO M@+LI\1WOB,^>]!4;(^S3#>Q3(OSW@22H40ULJ7E]FNA*4,>^(@3 Q[LD?::A M=32\3=:OE':U &T2?02)LFD!>\=(#S7:FMG"8#Y-<5H'K:_ R.)B$H\;(M\\ M'#UZ G*4M.7W1C*A%L5I4BB1NP0EV>D[RQ/FNO&IT68[6,W'PE/^A0;R\ MAV@PSF>V.#_#;>>'S^;'?1B^27D6#L$_80YE"35[A"B2J5-YPJ$0 [\^H.*:IE>&6N%W7P,BL,;Z* H&5=O8#U47*VD\T15!(^^G?]B61P0][9 M2)VG>:!0ZQ)[$];7'54W(QU7ZI+-,+PC_W+[X+"Y$&>4_3/2]GJ774"UNLP= M?"2*0D^Y9H-Y1+^11,#S5;"P;CW=M_L_LHVKFA3F5CY__G7^Z_/G$Y]1!ZSZ M1'D^&2L2LHH^"VAC.>6Y;Z@(AL@F:^M>]TC PBG/D?VNAU4EE(G#(;S#H9#Q M-%7L@M9O&_,.6&+K(Q%YMYOBNE_U%@_7OSMRR<[_;1UU_X#SWJ)NY>]&5Q=6 M=9C_\(4=.H5/'=@R@#Y![5H^)8"67["L;C::P$1H+\-CSO0=F$S$9R6Q'N7YOKEH98OW?6V\_BAKI=+FPZPS6P*R MSU?NV$?T-.B>A%0I2,(W M WWFO#H<8;7>HO90^36=/Y;/SY5C%G5GO84X+8E2[?GRZS?YPQ=,D"<8&"D> M&D$#IWASV8GPFMY&FW@F)_1K 1C3$7"TC[LIC Q1L_A"7I*,!\Y3/%70M9E/ MO9MAG6X5OJ$W-Q3!DX876*KX1'V:_-@%=A9)EW$>M9-,!*<8RJ332TIQQR\P MDF?;P9W" PZ*IQYR'E]W.3+'CK2LAS?B\>2<$_E4:.+NON"OQ1%ZPFZP=RG% MYJC>=>Y-9X[J +*S2%=_]%(9BT/BDZ97"4BXEU"S/::4!@I +Z;DKT,EHI,V=_H2G@F.',\Q*JV2*:>%?Q7FWX'VW\B6= M8M6#=-2QXUWG2IF<.J AVP\N$I*)&&/Z2.#N3EFBH%,UM33S&*8)(]7(V[/- M.PB9WXO32\5U[W&"$UY(SDW:U;&!/&A7AH+'5M$(Z5(! ]M@"D^1"CJ,,(&0 M4M\S*!@7U[=UI_F2@;"E(RU,6G>/48Q4R'%3 MNM(IRZ<@(ZO5F;@5] M %PZ4 ;B-<8R,(76317VI*0Y>6F,#SVL#10N]+FE- M]0+)40RH=T48('?%Y_!M;%;]I+=H7BZ^U7[]E3K=HY[D4.\M?LN/#S_*OR,7G5!]W6'4F MTR^]D*1\R9I(1JFAG1%S%9U41J\;N/EC.$;C#$?T;X@QV0%7^VN8).">HBO! M+EBN%4#2>1EPO1# H2YW=[@BS7?A9J52TY&*5'QK5+K!"7%2'$Z9>T-L\F@V MSPUP=2X7G5#ED2P<_- M3*?LA& \4O(P'WFF/2O1F4A+87F"E#)H \1133KE9 5R3 D_3[AE&L-DJHH: M+H/'TX/D$4[K(XH>F:N*<&IEN!9\,S8UU=4A]!0ZL VC'=E- MN+S: 3@,^B5MDI>3^[!G)^@R'.7=*17!;Z?W1 "CL_M*09;@FBTP-8@ "A@4 MG]'K-#-D&COV.26$?B"$;FLLEQ9CM$Y[4C#91EVW(""LF4YF!T M"HNOST(OI<.N*%&"ZUV&P00C4IWGE:0).^(FQ!N.",XB(^_< M*7A.9P\@21L=UL#=SFM6Z+;7DB*EX,18LX(/5F$%G71,K48.0+1MN4R#[:3I MCR)[VHZL6M1G1"H:SV.H@4AJ/S"=R-+L@AW4V21@5D^UQ_ EOCASV[ M-XE9GD)'-*[7-X^44^S%[/,/'L7R7WK)M-'@7_06DYEL=\^KBX&J'K/)5^HM M;KKEIU']^[DRR<.(47K@@ AAROW2XS##^@(T\!&-I;079_;FF2X:V(M'1I/J M!DVG7OXE_,OB? (D1Z:8:9"3L!\))LSFL%7JGF1C MKG7N3=DBS>>U]!&19ASG92W=W$U@P8)?R<"2YBQ69'D;]@J#U3OE76@2?8K" ME'L#JZ)">JR-]32R*';BH6,#>^S;: _PF*-YNS,NN& @'2+B1X>@ZV]IPE=1 M8[=23 <_Z"Z%M(44WCH6S0[TW6.<^F+8V+D+%P#@7#XT.AR/%F@#]%%=HS#" M6@HY/][N-9Y-YF[6F?&@:Q#MHA-9)M!6@XR2\&*J'XN0@ @>5,N'0\FA\)OQ M+AU*<#"+Y';2EF+N\9@QO_+U6/)BM((K=<^ &X6M6N;,3PM\.FLN\^ETZ362 MAVN0_%#TDA%"QTE@^D7E*?$BT=A>: M 0 "(B[20:B/OH*HK2K/A3-1>X3Z,WB+2;U73<5 IZTKT/@1*2CPB, B_IT? M9RS@GTCW%TCW@D>ZU]&"D 7V$]U>G5;)73&V%%KBOV05)#O;#]?/]W^,R^Y1 M]RN'6CKK>[]XL:BHMQ6D!3!7*^T7%CABG%$Y:_VW-,<#LVDG.XCTXZ>!(>D) MBR7*(-D*O'7DA,SZ,N;>2'REEE[IN/W<65[,I> =X\TF?PM#F<49O2:"@*=J MT6V(D HPY]JPZMK(:;9"2@2^K)W05;"!B$UIF-W %[=ZW&G$&N1V3F^'7(Y_*/NJF_29 M>.[];8F%'CVW7.Y<)BH&SC.ZQLFOLCN1(?SL\]!K]!85N6HUQZ.6:O2/F5=" M:L5=8]K]+9W]NAA^^ (02&$0"!P, N-E.#L@E\%9$? S8>EG."W"&P6#\GQ5 M-W$9^9 /#"L:R:7&KJD^Z"N.NR %JI5ATVQ%YC%#+,KCL7!,!H^5D.9Z-;-9 M>;@M&G/A.FF4F(W2,3*\VC74P0-MID1^MQ/WD,)8D0W09[%CBG[!^3JXS;\A M=2A\^E\Y2?^+-?TOEZ3_)=$*)UJQG-SDM[X#.1$.-A!6Q9JG*-K4AH0'EI9$ MU#;<)L,)'G!O<[F>:*8HC_R\%4"6LZ?EXM0*!"?]4-&@W\)?_1P7.H#$!S'E\*O[^=@A*%^H 3L\JWP*])M94Z+BN:""O&@Z$OZ.:KW M)R%.4>LTY-U/U)?*=X-!>- W** M#\U'84+G4!!S:Z@8B'RQOXOI"KMYFX-LW,KO^#8)*\GM"G6VQSLXUD'FHX,' MR,#-6ME??7 ^@"QSO#C4Z4X9#.4LN&Y,0>)3-%:FM_F93SI@#9<7+2_H8TLX M@XEP,<>Y!;8>>4F:J2HZM@-QDH#W=UC+P9H,MK.-R,I7?Z> &UW5/'9(H> MO1W-*\ L_!)L.7LDDF-#>XMC<(DWDK.V89 A4*9"@KGF"L\@&8EK]R&E%A*K M^$(;K/?347J:ZNGNZ>W$3N08G<4EFN-TT/AH[L.I."<#LJ'4B*9=L,*E=*H/ M4FX&86A6\P"3]%1=U)@"H)&H"!YE3=)Z$4AD9]U3X=RE!G.L&Q990A,MZOZU MU@%$(TFZN$Z)VTN?)/.S5#HP@&0@)!Q6(](7I^:G _O2N9WC3)]#XPWY9K J(;,CIA'4?.!O.N@;"$M# Q:YJ$_Z3]8-<'8SQ3T**NV5M.N@%A3Y&F;S$7V4A9HV".4EN-&(,*N'A:PT.AL=-VEV+YX3$+A+-*TP30U8 MFRE:;.P,5B=6"'QMR&,$ %@/]V\.2KGS;A_W#X$D;ZYC,^OB0>?W8CN+(]44 ME]\,JV/6/7"SPZE8XL)T/.QYX>?)TMR\5Z[$2C3A4N:.U)8@RX&E)Z#'$'F2 MU 5T,1HT7Y%)IQ O)O+[PNE>_P.HR8$WQ<.>P)LB6PJ#+?L/+OEXV2$T5AI" M>ZKC383HAWH>BJ=>H,6@&^,=3:OO*>W>=)J99E8TJ_ZUL*Q!@WLV$$2BD7Y5Z@#='_?3CQ7U"YNOZ" MAB^LD4A&DD73$$M+$S3K, :FYF1#04)BXUGA)H;5 ,Q8N-\8=]!3RAY8. 5Z_=6TS_YB:B/'DH/!2WJC'^@XS!P2.,HM(DB/7IQF<0>Y:\954R MTUODQXOKC/QWI'S/@\-&1,*HZR:RH>7N-1VI"5-HB86_%NJTYS;0@P=L H8X M*ZIP_3%]LBZ?(&?ZNW5 \K%\H@^'P"*#1\:G1%8RC^>E0U6J:"#1IBXM?LIO MFGS-&H4[KZ5E;P:KO">/D2I4HIJ0V=&$-X!%29YEG<,@JBL[M6E/XD!D:>6D M=@"W1;<44HSF;Y/J!1MY$6OC ?+?PV^6DT[1?E,FU';@C"9XCNIW.*F4C+SV M91C"ZV'J_(2-B%VA[/M4"P3]H6(QESA_&R0E/H53XK/YG>9T[X1:=NZ[V@T/ MV"V_7TK'1#NM.1V.;@U=TZ&Z$2-4F*S,(C_IXX5+]1;%J\;#X/M,GLP?CMG^ MS_467ZWJX$>F7#>S@P]?[G"I?,H%AN"%1I /H(GM=V)ZSXU M]:R!K1G:3)8RLZ9CS')O[EB(:XB&9*9(C1.K_FC6.D[YA]/$2)001R(+VB8= M'$58*^DI)5%;&DQ1,ACJ7L,#)K#M-%-,DCAJ(VT5FJM J9BJR$_NS$D\*8(T MZB#]!& ^%7TIX?3T0WJRU<=WBL)(J:\ VKN!G9/T#1KM31E4V)IB-;MIOL.! MC].Z RS?DD9Y_!RSI:6^VAJ4?65+Q&L%N,PPIM:YQ]^<9/,DX]DABA;GM6;6 M?1T[Q84K;%]]YG.B 2$\WP)&!2YV"FP;@A-X AE6 )#"$$2"POT4.ZD8#:*] M.B1(]PSJD"H.J-O;T4"(W\>==T Z_B C^;4ZT^+(5(7M=HM<7L!^^!_HDNR MZB9Y*Q,81P^[\34\WCN@RAE8$9M 5WK7BT:\@+C]"8M]$+<* MGUV-)]P ^2+#F[0) (\?9!V YD\+Y&'"&^=WPK/+6$AC+*O2B:6?3"!" 6J0 M)/B>Q#FNZD1O-RGR./J@ MEP/C2^@TZH(Y@2I @QL!1)QW.'T,N_120P7L1.2&(5N&SFST%%[';;.(\3CMM.' MOC;7A^J*#$ 34AE)',BFIZX(9[>X[E-)AGI-R\WG(.NXYJ4!^X '6<9O/=@8ECE?,)%D&'V MX?4YUMS\BFIE?">)I_?KU(*X??#V3[F%*9!XGQJ,KK0N>@0P'@/ME7X MRI%*4CD2:^5(/JD<.6(=.&95E\WG0\PRNTK;S2$>6EG=]5CXV-6GR@!:!']R M-%]./P4^QPK0G>;%B%,ZGUVY =T4CBNS;TSBRF(5Z\ 7E2]8>"*G<_\2:\K M.@+[-HH[3#K:%>ZB0@8).[]V=@I?$G4JY5>GUBE2Z 4S7+S,6:FAVGV2<*7K M9_6HAHEYN@\WD +4Z31(R:^D35!QTL11[U)B(??ILT!&%A%BTE4D#PR(^>'[ M/A%:L(B T(89ERLI*L4H"CM9@CWU2]YGVGED0-^MDNWUT?&@"9XX 1N"\Y.# MDT?FAIC;IHQ4/(%K2I!:\6*J5?G>!^K,%) :FARPL>/T)?09D[V(.:&PG:OB M+#&2',ZZ+(ENJ" %G?*HCDT[(6'*P3D!0[1YUM;6H61J/7NWYZS,9S9@TQ$G M40C*D&2J0 ^J-+]W1-FD;4,J["F6N)"/72XS)9*W$FC*+?.>%)DIF_">M\1[ MO&K!6M93PFK!N5O-W^*($UB0A(<$88.NYD'".VPBN791IU%W?!#N>BGJTL+M MT*!IAKM<"SPCV(1G:@&'U1/:8LS;:0"&V.-8(%F!,C;6R<4QHI]$9/W;)F1F M6 _5&0A8'3O,"?YMT(C=[I+DV#_P68 M#TX('H#B01H5X$16E<$#/>RNR$9(N%XO-U/-X]N11>@-S&[&Z2:*(8=G1?#] MLKD[0E)AHC]!%<^0-;NDS@L7WMRQ2+[@G3RR:;9:Y^07W(?GDV_0)TL'7'4V MFB;@('%?QZWC]K\Z3;6&($2PQS:?P;I0V0':6#1IRL"\WNU"AWMZ.B!(6.!^6"!SKF[D M@67, ^F,:80QS$%*E;%<)?,I[>&+P +(8Q@-76Z'!\CX)7;*)[&I^B.8](7! M!(?.YF81,'U#UL; CG@B-6F7%6Z>F[,R2XPE/?#76C*A%08*33IF!4%_XCA; M@=)QN<7JI5+^I0H>7ZI"2R.H2 G0-KPG!U^_:-*&DVYLDL_<.%+\/7;B"VA? M&DQ\54Q\9*:'@&=Z,+HK%X+HSGV2I[L5CH443W>4>$A3#-#WIR)-3==P9U?2 M%)%8+AIMZ\[U9^81SZ5,3NLP6+!, Q'O"@:R1HJ,':&-)9T>203]F=8#\YF6 MNL>1Z 1W+DMW>(C%*P7K-QV""8B:9B-B8_2\B0T@VFUXY3JT98*L+LN25XZ[ MQ YSS\6@\ZP.TH M,Y[PES,Z*)7:_"Q!$8]*=2P7X$"T7EW1=,.7$=AULC.]>Z&U$&PLB@Z;]IQW M>9EE%T5JI8LBA-\TI"H2@@>E5O @(>%!;X$'\6K^6C:4YS4-AYR=@(>K]]<] M)57T!^RQ!AW#C)0/<30R\ P?'>D[G';PL4/]#D(NESE!6@RS"C9P*6[D!">X MTRRKA!3E@@\A /O2.,/82<-;[L+HE!J39&.N;.[E'L9UY)NB2H2;9Q)6G2AY MK8J7+U#V\X+4LC[BQ.LI=9-Q0-CHZ,LA[8[3]3FY7/IKL=A;?,_<9NO='].% M5#V:'-97A?NK2;@_UG!_(0GWQX79] 9)M (;O@H? MG6?B[?B(;C-_RMVDL,T,_URSMVC]OFY>UY_Z/V_Z'[Y=QZ,U$;Z>894:3XF0"D MV0\WT&_5)&K!VZR5-$0;*J)O$C7ZBFE(LCN!.GA<63KEUJIN2._,!A WR^$D M1=T]YWM'RV5Y/]3);=:>%;/78VFBU[($HNZ6=-26KT5-)'D&]/%KO-G>PNSD MND]=\_LL6W!R0]D6/GSQ;S2("SG)IMO=Z+>KQW/QV\W?V=^'H(VNK9)VG@O* M1Z6\G&ZH%VX_/E[_@CII;_;J*_:=CV'?A:C[7EG+'9R%RQ@V>#'8I'B< JTB M"<6WH*"G$-@Q!/<<3@B$#8Q@S>3]"^'(WZ4LJM9X (9.J\M^2NP%TA$9YP&; M=(C%9 +9W)1%L GI+(V%]2ER!R,Z9UA7LYY:JEGW]6".7>-8*O3KT/E@-T.& M22O4BVJ)(^PUO^HM5*LZ4*]_F6IQ>&RFCU>^GY5Z"_OV6?R3M;.2[@[504;A M5!716]#=( VR4[]LG-]?-5(W3:%^B61^HR-T;X1Z[>[N=ZM](=2N;^[;70%] MR_0#+\KONS%U^35]J3VPV'(?Q*7?]R&O+,PN*40=K3/+ZS)\&T($'+B3__N0 M^^#@0:%:[P4U46DV.\IUY6+:4"2_#;K2RGWAOI>-RP]?8 -;!L=^ ;W4$N7K M;;,S_W.NC0UQQX#.;QO0N&ODX74,["HJ(VJPY@,%%ZV[,KN7C?TB,1K=-9"Z8GV+9+G\1CAS.- *- M^$YOJN6U?&_1FBB=EED9=70EPMF"KR^HH-$8]3_F,H5T+E])YXK%3S&,.RE! M! H7_F!)G0#DR3&8Y10>R\+O??F#IYLY!"X.[_\^I]9DN^A0UE-+;B<#[X M#-"P1;PG>:=?7'ZIGK>:SE9* 8Z$UP(A$+BOXPT))F1RN4!,J,: ":7LOC A MD&V>![#-EM-K QJ&X/Z/F(E*2F]1'I8;:O/[W2\C2M0E/!_]20K#XVSM'RC@ MW;.R/F[1;R*TCO0BO2C*85>Q@.V\D9$;[]HZ,>7!B?)\,E8D24;/(&S+*<]] M0\U4*MD/7TX<1U*,P-X&*WSG=_HQ' _U*0[8-4JP4DS:ZXB4O)3W\,T'2 M[;XJOX[ZEO24K;WO]>I+8#_J2MBXV$X5V M8BZN7L IAC5M$W*)N2[%MT[Q0,?2$;U)RA/DR4B>,2(TPU@2%-P3$.<-.^%R MKC6A!2."<'HTA.^GL@'D068TH->Q4O>\O\':BK!^BRPCR:0!M2RYXU,AL2?E MF<+L7DZKOE0 MYVD>0*Q7]N;F<,W-ANE4*VHEFJ63R;/X6R9*OHX+O5:7Y>8,1G?5:NOV5]4H M+N7F!)PI+'\-I2MG,XC;NO]BZ3#+V_1QY')8CEQT.'+)SY%SIZO[SB':55FY M8*B$KS57ELOF6,@4_A7'E=6SXNC^_OKR]]5R.M76KPQ\1NZ_0E]9:*?2FBLK M9#;?F7>V!#0UYL;;T,8JN(.C_UI+FZ]5>KX*GMHB?[UJ7XWEZ^%?,R'+YKN2\@*8LU.=TV)=,9G"4ZK9G*\I2JIN'.RJOG5.5E- M!6&F? 6S;/UIW%W0K5;E:IT'YFJ%7JVWR$ZZF9]Y^?Q>/IXR MNU)KU\#;#=RVGZKRIC)SWDJ^U9U,)^&.E>F*B.F1LX4= +&C#ZT9,@P3^$6# M'[$#$NA%@UY71U+]/>5,!H-AJWF4VV[:OZ#7QYY>AM 1.'2R( M/M-^Q J4]"S'>NHWG6Z\=_SJA*37ZT4!(;XXE]R\R2CX%L>UQ[W!%X-RO]M- MX)G '6J)W6CY4O__?#EC.0=I7W#K%84UAQP,K03?ZGPE0UK_.$7 M!D[6914/0>&87IAUSN;7XH-NU%71I!$W=^PU]9]YK#\6>\MDY=NF76OW(6P5 M&2JY**G52%SN]DP[+@*@@>J5)_-A?QQ)7[EJ.E^N)M@?$OM+^\9^YU?8J>U_ MGA% =YK]76]WQL,BS$QCX4C:-JL5)*EW)[8=.'Y90*8T+6) G/3XY_^S=E77JE._6%E6K5:AR5:G%SX]TC M2GGOB!)"_=8O%F=U,R?>MOLQ84D(5KT>#H&9H@6G$*X010&O9C(Q/T^F+UKC?M7'$2S?30H?5;3/3R], M&=FVD"@FO1WBQ>B0CH]]8'0(I?SIL:V(S8>'V3?YH- YJA=F,YBWH_.'KNM; MYW3?0V>,=T&BQR!TUMH4L\OII M9AL_I=SL\J"0;C^B8;4)EEF_SOER;1[YI/K [D%2)F)%6SL31/BSLCZ1T*U"#Z68ZR[9A^ M0IAI%U]S=]GKZZ?G[Z.CIYZ765;9.!R4^6(ZFZDDI!,WZ8140W<@>M::3]I9 MY^^/'W??C*\OG:IR>-3STERH:C:.;-BXT*%X59M MO$$I\[,O]HV&Z([UY!'DP[J!QSY!A_;>\VX]E-G%<0/P2'Z6; .:,?G81L7? M'RL,P)$>N=1UE#@U3_QW6=W678K/N[K+Z_S3+_-.:N:N*_'%3Q>-4CY[63;^CEY-'J&LX' 44D@HY, H9+L],@XK MTK6E=BJU>OW^^OZJUFVT^3CS;XX:Z4-FS>R%WZ]U0PP:I8>S2[OZI_G:(>K[Y/>AP_^Y M."H3"NEJ(-^>'<;-$P?W'^,,OE=/TI__/1<9)Q*PDBMU0\_5#VC-$^ M;(UI@G>Q6'QC]:AQIDX'^(NXVQ+D9QC!%WDT[.XKO@L<1?(GN1GZ$71?1L9O M0^O*W=M,YG(GO2_6 R%D!=R+38M\'(TO$.V6=T>[QX#=]3UB=P@[XG;<_B/5 MM//,WRACO?:#VB^S'O)Q%/AD,^EB[EV:S"L1NW0(;'NMK7#U[=OHAS%3Y$K^ M:'#[Q19"/H[BE&R"V2MZ D3&[,4OZZG67TR*^N,XA"T@!JAPAXVTJTLJ\W'D MK&=SZ4PUSK3>0S #DK8T6R'8\Y[,5)V7F[>'VZQ&ZS^*U9O"<)1_.*R. /FD M#4W,&%P[-@P.85J,+\;#Q8_\1;VO[+-LI5Z_.H_@]=I3*YI\'+&.I,QX.U1: M.38J#1E3F0T>QD7EHC@M'IB<*2=R)G:C?4\8O+@MM,M_E.O'UD0)80\=8).: MO0B2-596',&6/4N*XPN^O,N^->L$XJN"J7MK9U.:9K+=[^59#0*U!UU2_9*@ M;.383R&.V$^AF*X6$M5S.Y06LM? +BDMA EXW?I:?33^5)[>(I6]S+ KQ-)G M+IO;77'\!LGLQ1&Q0BSMVA)9MN^>VY$( M;3&^?;;/!@_*+Z4:PLP\JNXZ$:C'1QEQ!.;*^72I]"[ZG:Z-UH4N_?0?+W=: M!*)LRQ9:0W\4GD35CIRMMW+YE](\_ID@Z3;"MO@[9?$I?GZL1H!H/ ]4&TYQ MH>O23%%5J&WG:'S[]J \O[N6GRI_LY9;W>Z]H?6\(0[PA6(/8: 7LVT82_5% MNE3<)L_ \-^%0#U(\BKOC[Q"&($_I_KPOO98&)4K;YRV7F@1QC%#-)M+YPMQ M)B8FE+6J1>J^!-=:V\]HYQ_*QE.I_B"]<>)ZL1U8C,6IF2YGMNEP>=_D%8=> MN.BJ:O7KF?3X^Z[TMDG A]ZQ)/Y6TO\_>W_:G#;2_8_#SWD5^N:^YE\S5=@# M8D_FERH,>(EM< Q>DB?[M:*! +$YC!U73,)H%8O9^]S M/J>8:);E4O2];]> ^Y+2O/O8'H>].^S=8>_V:^_V*?@6C;OVY7NMU>X].^S=G[5W^V=O1X"KY7:.%E: '&%]0KP (SGG=C.W_CN0R?G-R>7Y:5'* MBEL&(HEN(\(O>XM12*(15>(]W/9&Q(61=7';9!WC[L$\K_-5^6&LW"D[3].+ MW1X4DKC+Y[/I0J)I+GM-T#$;36] 3L\.^9>RQGFQ+;[5I9VGZ<6#]DD 7$*_ MLS\2TF"]5#V1<\-\N='O_I2? UW*=@W*;"YE!J@N"9B]4CE=JGPVX+*589&K MDB03RVSGF"4R/W&Z_9,2GH[W:LDZDK+;,MCU\BASES_3?E2%A-@M9EUFH9Q$ M7>;>2-4%RI\V32@Q3. ?C[^4UVPC*_[>G$R>O0VA]8XYIW!^.9#@0A+ED&5L M#F\.NP$C6;!-H?VBT #U)9%V@N5LHNG NV IKQ/B-P;,%\ C?/*ZH7P\ M3W8AF(J-&NP/QN.9V$7C'_V 9-@NVD5,J[^8/Z"Q)$O0,2^&MD'0,1R+UXOK MD^)YN:O6^5TBY[^7#AHMB=2RJN=27*[ QL!3Q9]-1:&R6Z@/_^>3,VIU=QDU MGGMTI@RS'Z^_,W?]8.1V/U1/(@&G@^I9^/)V)8J>5(IF_[9_FG\9"+M$==O7 M$'X%4%K.H=]!!; 7=Q*+@G@MG62T6Z)@7N'H_+O!QK;\)LE4?V?02^OE1MB0 M7DK^WG'IEH^E)("#$L]<^@-U:1@#-;;-0#'\M-ZE>%.M5J3>C\K><\]BGE4I MB5@E7TGG2I4#ZR3-.M,Q]VWIGIF>T_7;[8]?\GUAV%?VGGL6OFHJ)9$U"]E8 MN0/_K!.:8#7^F=Q42^>%NVM!ONX%_+2]PL>:RP !XDXBU;!<3!?Y+6N'_;_? M^O+]SD ]2^'@OG+G,\423[6"D8YZPE!6QE_GC45^:V#+A[[:'LF1"YEXK9WI M?E_)/028"I+YBTH&JD\-W3PZNL4_1U13DK]?X[&&UI#IQ;7Z>^V;ZXR>N33+ MSVX;72^!.#*B:>$A9'&6SL-S?_)//98'YA$,$)?\*EGZ& E!]5CZ$ELZN1O^ MY;NC#=G\O[/0YE'P+./)^"7.4OC8U%F>/V;+EV>5MYHP2.8L?5-/\"PKRYUE MEH\X3 [>8?RQ69*[+23C8?W.9*SUM605^+N&F.GS)RLSS'QW.19OE+/)RKD# M:^PP:R2@<];IC_>O?Q8Z)91YLWHKLTA^0.'+)C'/(92NC7#8(2MLIJ MK79W?7=5[33J7/6Z==NY^%WM7+2:!YHY\-MA[PY[]V?MW;[%UO8<*B5FBG=D M:XBM@:=\:#]^%K*O!5/M;[GT>9$N$4O#J9230)_(5=(%/LF;H;T1@V&D'R]N MNU'2CQ&L.%$SPMAX?1GSVP8-6H;N%TLG*"=Q891/5W)_9/'="LA86Q'W,Z,0 MF>';[>2'HO'5WAZ2_<)Y .4D>H#DTV5^6+N&W;($10>H-8G&&OE*FB\=T%SF+L)[1!SZ&"'56+J;U>8+O[W!;N]* M6KT@56[+L3@[K;:*W59;R_&;X,O9F[ @I$%\=R()\ ZL7_))9N+LC7Z)!62T M:>J.X3N\?)SVS$QUE/V=W1O27LQCJ"0!U5%*Y_DD2WKVGZX;NR"U9_H';Z]O M&54J=AN_NGM#V@M[!94D*E.R!]HVHYKC+DW;DTGKI3*^'G7:8C^&!R"$V'#[ M0K8!DDPB83W+I_.9S>&'[ML5PP&>)A(DP#9Z%O=N=Q>TIOUXHOXH29?\:%/Y M_S%! 2H'/)J$*;BP;Q0ZJ M(P*2(,LGJ4T/F#1V_>1^,6L\SZG3;A?45_WD=?*R8^JF>% WB6/0;(F")^W3 MR2,_D7+-UW(,_V@7T6JVK$\"ZF*Y&Y<=5!=[<@_S1R+8S+);5[I,W1JPS?E- MHU>X'0R-R8:,TXU7OG=QT_:ADV6\2SRV(V2R9"RN<.<%);!1O=BC:;Z;K];JFO[R_YGUDC_PG9 M;,'K, Y_A&,5ELCHTV>F_?W^F-6[?QZCN%A[A7.SA+<$^", M)&[IBMETH9!D@M[>(^_$+@@-KI0_+@!_-I&)Q]!>N#=!L99.XHL/LN;>AXD<+P1C0]1L6 59YHFO6>3B'CP MA72FE-\V?=N>W;^F@#?G>RHU!=0TI"!T*>E_& M$X&?.O_WS_$9:W*Y-TX2^LM>,,MI&,$R1_LR^:J1$C@=&99B+!C[@%A H8?R"I^T!P()OX7XGKX!RG"TC +_(F![!'0AXB0 M1'Z,9)T3!5T?P^SHKP75'45'W+M@<*KF>V.'?@'_PM\$EV=PDD7^!K, N+ 4 M4N%EP'O!>4R<^NY0PU"Q,AD!(HFM_8K#FAKR,$[\2+&EFZ.! ,B%+B^0BL7:P[<4*ZNB A M/.*+<BK=9#@%& "IYKNB[..U():)-HU M[P19\U3/_C)>>C>-QLVU[+8@#)O,W$*$J)>')L/D:3*,J9$_A^G!V/'-@J,' MB]-W;,=A:3 4'A 3I0++@).8VM;J@MLZ%;LV7H3N5(:Q M@SZS-S7,M/!O*G"9+50-+D*JDJVG6@5STPCAH3 SCHG4QC(;C"\D'0EO2!?Z MR%]A,\(R0Y-2LL$%3X[WGAQCNQD>V@-[396^Q8/)*8GA#-,57\R7G'[Y\.RB M,3_$F.Q,5,U9;!&"GOF.+5XL?@*G.P6EO,##P1^T_?N'=9 M,@>PS,Q?83BU[B5+\.K$U$9A]KS'6_!^*2+0H+[7??E^>N3=-WO'OG&=\0C/ MH*H+75G\QC4QA=)=;6JP?]F"]ZE_[-L'V(__[%&QVRY3H27HZZ"',* M'GM$3HQM,UZ7O<<.>7J(SJ6%D6]P[Y1@KG0Z'A))D-S7;? M)W40EO\C.'8= M/&V?G)F">6^+ R19"M)ZLQH_6J:E(Z\*:U 5V(&C[> YG2B:^/+%YQ96O.@2 M2;[F:7)V_G'?OS8D:2COC;>)'3;L(4TITC37(ZL.K4+%BIQN&S8X-:Z+[,\E M#FM/ 9PT1='>C:_[+-^MU5(]4ZY2Z:G6KS[.+DJL%5V^U&IYWF3N\Z=[<-'X(OUWB\:33;#6>S MO'NVD!"/OZ_SQ7T)Q&^RE^B)7Y!G7:!TKT()Q53^\OV7;3>"=^ZE]W54CX3' M3_$NPZO^WQ?^BT-8^4K58PF6KJO:_?!*NNVMNRL@U;=?OO_]/XC(F /-,K#M M;*RQ/LN;E^&L/F;/!R-$^C;Q:CKO2'E#UWB. \.-^0Z%BVJS<39I?Z"G"?IQ M6$8A23Y=K0#,9=[\PBFD M'8=-30^;\K_E]F,A^S*^W9]X8D2.;T539@[O=QIO.&LF J):3A9:ELV5W<(O[7==;<#=SJ!5>;]'5ZKA"\3K_1M1&6/.,; M15#-JBHU7BV9Y#+694-4-,/2HZ[+?9V'%QGF:2+)'Y6WA_-WV5RZ'0_!^ *J M_\I9(_QJ43 "B1@9(+= DQFZF)PU9.$=%WG%+E$AP[<,_-Y; GV]3.E/"K] M&CY_^7YSV[IIW'9^<=5FG6O\O+NXN6XT.PY!!6B+_+/NJW8WP64-N2"YJ9RS M2*J+RO"HQ2%9#Z&V\\^Z_G*)S%^YO1$O]KI2D/&([$7!_ANR 5 &-.^=Y6)@ M$?VYLC$R3Y.>U1X\_Q[=OV5C96/,X:.=R+HHKY)UX5O[HDD8"P8[$D[BB)\L MT? D2]2?N[5>UGK01OT%DR46:](=R)B ":QY$[:[O2S?O&IUVE6I<37>].Y& M ",FM[O$_MQ 9M,.,U5QDV?JS[;:P-EN)&]MAT^7/\C#O=F[S4B[O>"(96]< M0J3:;B1%+GB]'>FKG.F G"U?/ WF__9D#-4104PC;3BR\-*<7]FP$ \MP:Q: MI^:5L;34[LAC,#*2!)GNIKE/TQ^1*9H/YHK'"E+.I;E: TL6("B>O@&.? MQ!U@(5TI)MFWF.Z.JYG+X_SA<,.B1TK M"'<&4C:7?@)LRB>!-I/.)8I5EO1!_-'TD5N-/A*YQDQ7REOI N_*[M.-V.VD M$\Q(TTV!Y'8$!7>[>)=]K/SLOS_LC_4^O=?^11ZD=Z*F^4P*"K!F,AGCV0VR MYH$X5C*\%R&.8C+$ =FVVY3;:[6YG5]?(<% TV1+H8C77NC$$ZVU'XY*XHG MCW?EQJXG>DYOK[,N@$1S%G;@Q00$]0R2"7#BHYB. M3QK)A-ARB2;PKEA"N;; "$O*U$S\:Q&2JO%\W[ K8XOI\B"7'3[WSDOJ_E9; M1EP/T:5SJF9R([)XN.XPZ/(/Z?N[(@8"@9C9].H7!(5$\OB+ZP3\_?-Z'&V$ M"&/U3<8$PF^I;W*HO"\O).^'PLU-M=&<5,O-I\FE<:*UQ)I:ULJ[;4S;>P5; M0I\(C85 208W8GMPB&8G)40#XC&?B'A,9[*'*/6.GGLH6FTAD0A7+EU)% I_ M"8%9\D'2.HW?Z@ B+\=J_+KQW M7L^;J+,_U6XQC> K9!B0]8ET3\JD2_P6 MVE>O$8[O0(=KH\-PW9-$V*Z<+A:VT.'YGQFJJ!+'=F\BD]13#TV/;K$NZZUW MZ:K4R?1WVW2?KU!8Z?--J-W._7__OS*?S7[C5+1"+N*AVGI)&Q'37GQM44PF MRXROK!,"X4_L!;:?-!:J"8I)!.<*Z5QVZ_WF%N['56T_#BZ;A?JM7-B;2MN] M[GBTI]/VVF2IR-Y%TTUVO%E9WC%FM2NZJO"EA][HQ!RYW5>\SWKZZ@3>5I[_ MMJDN/K5+33EY^/'0^CWO93,ED?>9Y=HA%9-HA[3B).'- MAL)Z#F&!.%B^\=">\M]>R[PE>Q#ZV@^&1^ #[0I:2J4#=*.$[>R\3(?4L>;@Q;G<:PU M/G2QPK_=_J@M X"T4U ZA*7[[56L]9H=FY)WY7V M1B!T^-QQJ9#L'NZU;,:G="JK@HJM B4%Y&[ _M,("?^-JQI<6#-H]T^AB='*?(0[P[=+&. M(!!H,ALX3WB)JDB:Y(XYK$<-/"(F&<,2!PY%T8?))(D(Z8XY).#O[X[;QQS8 M?9B"\!:*=/04&%Y=I&CO%% K?$:PRDTU>3YH$S9Y'\<3>A%UA"F6TS'O<^\R M]MP8FQ&*A>;(#A'@;T2$)0) ?4'[9/P^3/*$&&AW5; 7Z6@([''Z#F!.FH^' M] 12AHB5)C2$>F12N&]3$(LX#=HE@E,2_J/14[E.$H%8E9[U]Q74X*5\6B8 MARU@3WLTVI ZY5>'05%>GV6!WF#C$'^ =R/[-)*E)VGT9-U@>S0T?/)DZ.;1 M40<$>*MWXML5YS1PN P MV'RF?NT4UGV=?V8XL?WT\?JOW^ MHYKKQ=[BF7; K$V>%2*;SK2=)E<[$S]R>QPH@]G+#E@7<6NE+YJG3H#KB/>8 M&D SF]\7E\;6M"]QT_/F[$O8_R.46T/Q.7-[\3+(%KN!#8NE.,6NFY6 M*,_=E[4+Y;C!AK4*Y917*-=)>'NARQDWE*ZIR!'G\R^OG8S.Z:5ML,42;D9X1!-[@B MVH32)2R?R8P_[34X:7B 2!L7]/V__SLZXDYEI$A?N1M\^-_P2*\6Q!^_]V7[Z='WGVS=^P;!ZS]E:OJ0E<6OW%-S'%T5YL:[%^VZ'WJ M7_LQ^,I-1K,ST?[[%V]TR);K2'@YZB+,#'CL$3DQ[PTHW6.'/#U$YVUZX1W< M.R68*YV.AT1V-.P[HSO-WG G7L,9TOJZ,!H A89<)WK"L^2CTC>P[P"OC%PS M7!B*,!2Z@I3F+@4LT@8RT:TG0G^0=BY9TN2SFJ9HPZZ6=J];0,Q+EHC9%:]/ MQF,*JDF2SX_H&U+L(@&"QN#Z>VY*PBXO."8X.6S(JB0)Q33@=H:U\?!=D=#G MZ6M@'3!A3C8X11-)(1/^2. DN=?#MJYJIC 'ZK*IZ6,8S+D[HI!QG%^P1 M7U3M'8]@<-4)_O"',!Q:9 \N!6,PE'7Z=O).]@ QIT=(I:_F,YF*L^*1I8\T M R:;HO=-8+ [.R,HG&&- ("(O,"]>H%,/[*9UHA$[D.F.3T-/&TV!%PZ&>0I MN)/ROB]%)=+,$W%)Q3U!^SBFKZO@[L"PNL_LD@&4'MQSD48LDO,\+,]#*"DP M..B=E3D> ?5"J,@P-,B6PV,3?X3>/\DH_)XL?,I=RY!59&"N<:_<@%#)+1Z9 M!4V, C[P4NA0&'-=(*:>8M'[L^Z8'B!61D0!I#F$!]*&LD@Y0D%]/#92WV1= M4X<"\:\0?OF#4Q;9J>@U&=L?N89'1\)@8LR$V.<@9@J[)?'+5F>T5L M#8*$=98!GIN .4 TR5KPG(<:D!XX@/@]F,CP'HD#0>W3B?;ASI.L T\(%BW" M"H)72(KP;K!=[$/U$.R=;QA@065Z!=B1Q(O C*3BK;3O/B4L$NGE+AL-6%2W M%+I)SB1@NTWY"(Z&$C'^U1 )D"$$[[9TS.3B&$X9UNT>\U V3;B?I,?E;OX0 MF0--(HZN*7R0(0_WE&N^IV2)?2E,A"2TC/=>1::=!FC+[6@A0U+\YF2X>"^< MG(:#M->LD_OL\?#(R*2&VJ-# YY54U/O'-BRJWN]=JV.4>NZZWA136<1\UPF M9T:QP+ \+PZX,K$K]V>D!)="4X+]J;^A&3"-^5N<6V6++T^SK^?G]\HOI9CX M%@=!I:*W.#;2W\PM+L[?XNADKU1(*C7(?@.Y:27,PB:,)(-29_D:GGN;D&A> M6&*8'=6X\(SB!DV-!'E(?==RUVE7]:\145V2NV"6J M,_/MP^JD8S!78<(G37O)W_9.>E'UYS6WN(&*S8"5V%>*,@\C&D7(^%DS- MJV8@YI?341!<#@';OL.A0'T+T%L+J;4("9"R7Q_H69AT,G>%#R9SM\4!DL " M:_5"L@E/QO!O>%K3HWI/>BN0EACM::)U1:']?*,]%I:IBMZE'HWYIXE9+%>N M>,UZM&+U:/0E:'/X@]N+]F6:._G%G35:9[?5F_.+6O6*?-KF3JNU3NOVT,!Q M*3B@K748S 2OOQ86W;?5XL^;GE2O-X1#F[-D#J44O/Y9^%#*Y_>MZNEE]K(R M^)3]T_:@>]JA6^229[L7O?$^4Z1N97'OKQQ8@"LBU;+1Y420(FE<]F M#_T:]XH^XH>IDH!3+6?"(L7;:F5A3/22";EM.YW!80)0\P_]LFL_A2/AG@4C[1IC)) M=1XXG9+X'CE_9=1OWW^?6+F/?6FO& CJ!R+*\6/\=HN8%3M$?!X$>KH=*\GK M;"8);-%RNI _-.[:\I''E9W93!)0GY5TII"DC;RBF+R2A:X,28'(#3XT;9DI MR4^38>WZYWNY4F[J_'Z9QVZD07'7^"V2\[.+(1A)N+?N@QL>;@W8J%$ME,$JV@2^G,6IGNT,AD)XDLMES/)A'1 M*J4+Q20=N0UT,LD^3GQJZ+:"]9[-3!0(- M05>A=O0&Z>V!$ WQ[H5RBWSF:2(]_+I2'EJ/5Z5ENA?O%*Y[<7.X[IC]+K+# M\[.+4;7]*&.SI-'AKEKM-G?3N.5JK>OK5I-KGU=O&Y\)XCUQVLY'%;^T>D&* M/1$,6:RJ4EU6+!-)'9"1404P^9 "F 5'?)KD:LV[VNB7^GZ934BZ\L?\E!I8 M@Y3J#%#*+9"B=2@ZU*^+,I0C0@G4.P(-C:0C@:)L)U%8!I#4@%0$ZP!" K>%A!\[ X.6BH9!^[J6,NH-[?"ZN"Q0O-1XFG2K M5XU*YD(63BMQBI=N&U"^='%UX50O/30NSLX[C?I1];YQ6SUK4*'4YEIWG7:G MVJQ?-,^XT]8M=U)M7]0X_ %7O[BZPP]P\R7:3I0[50[E3G,J:TZ?PEJ.7=8Z MD_QM,9M_DPZY]\EL=.TIK-O:7>7.O!Q@N8F>/V6B_AZDZ7^6LJ1?T$"K,04P M>JC'^(15-I],2GY"P;<7'+$S%4K+F_@L@C =/Y@J>TJ3KCU 3<0CP1\1ZY1; M[)^US!3<)38KBK_T#X5Q3+A,:T_O]K]\/W$\3>:.?_T3,E^2'/)/RYQ<[]Z% MWK9ZL;>:R+Q016V(KC3#J+X)LD+B1UJ-Q$3:IB:^#+"^0;I!2-NIC/R=KSYO#,K%NGK;X/+2XN$7!'-,8X/>'3I2;,E,>L*1?R M/?,G.KL>WSXO.V46#)V;QK+@1B_51#V;72Y]"I!@\6>+=5/?S(*62QM8\X(8 M92VW)'ZY'/R()>73^4(8#OYB/4T2*7"-?=&]0JK<0=PO+NYKB8C[J5CFS>A7 M1LZ<\^I),6%QSRFK)]7E6)-?GZM%_9!W$]UZ0C(QN6R&+@I:#(XA84#&?SH56VNV!I-__H$2DNGD(WIY[Q8;!60:2F# 983H* MN41W+M#)$Y\HQ7"!3/(D\PQG-**RSZI*CZIIP:5)JT<20(R6F^[ 5)\LA3L- M/\]?FC^DH7AAO3A:9"DR\!_];#\M8NY,/$TM(7KV95-_J_WJGJG5TK*S#R?= M>3)WH=U?TK2.JQ%)8RE'OM(I+#G_J!-8<@5Q_9WP%62+Z6R^F*Z4"IO3"W]N M$O5N2+C2RA)NRDZN-3_D@71[<5,2UROA8LQ]KH2;FOU'I:X-^[47PU3V3<+- ML2AS<4,'VY)O\^8?U\2/D&Z%=+%82>=#R_MV2;IMQM[=;)U5;!_9O=T\FC9W M/Y'TWWP)S0S3-C2?.=H(?%/K[6$6#>12:;E R-0ASY;MP>DYL9JH"2+K(]\; M_^K4[Y<,S'LG&#=F$[J)R]EQN;B^/VUQ&N;RW\03VQ%;N^2T%S*@9T\[<\S' M"E=L6$XG6*=]$$'9V")HRDK+B:,32\H.V^;:)%!Y 0DT'2O^U=5^UJ]N+NY? M=E$"S;.T%O(C-R5_YDPZOY!Y.WO2^>-0G-\=D3Z+E7?6GR:OS\^OMQ?W6;Z1 M6!>>0S=$3XV4N@AGRRKI]$;+IT8ZZB%=1T U&I:VI$$]PA8OS>UC_7/3'!Z3 M]%?%5*S@L? GWB*IR!JI^0WCO*6==?9RX\:>%;G+(/_R]HP+F%MN$Q6GT4KC MU9+-,;0VU53\5R/0;,4_OMUU!3WDGM'YX/%6J3@R\V;V_LP3+[-6-,O&"<$F M")MS0 #%OH*:U>>,/\[-:W1&.Y!#.D_:#3QE8E>=&DA1EK.HC) M$F'"U1$F0@-.*64/:7CHS*:\D2#COYD#[$3V!]PIZNH6-$KC*_1%:VJZNI5" M[(0G'U[3'&]=4$^&*4I9JH*:5O55S6G!D"9$$90%7BRPJFK*Q.Z0WU ;B99. M('0:M$NE!-Q2(]$N@;: "^KQ*F'/2 _-%075=T&7.N,1"HB(6P3MA*'?,>$W MZ+1GW+;O;%DQS-S<9O,?2$"R(RM@RD?VG%EL;BYT1!++7%"2S%Q:0*0LY A. MA;SX/)\N9*(;)UKJ&YX+(FVTV928G(6A#.YOZ/C,9[[AV9'FSWSVVS_0YE"2 M#=$R#-HAO:F9B,L6N(& =[V+D&KW,I6 MW3%7G99DN7"2K:Z-9(,F_[12OE\TG641,# Y(4"C.F^R9F=RVW,GI1L M51_RJL^LWK:!I)*O!-$FZJAKUK%4Q%Z %8VCXE6P$4\\3<9"^^/JY/%735S& M6=LI%)72YE!4"D\3K35YN;@;C'._^U^^UQLGG84 4V*7],U 39G/$3)VU.!M M1QO"6=D;._P_^7O[_@18]SM8&EG^&U?'J@T+W)9H:F (\)ELB1H!-=;56ALA M[!QS I::;YKR!C]69!6!)!>QB)9-*G_QN%A:8]\;_Q+[+P@=$9]9Z.,_@K/* MO0]D<0!^D"*(<).+#19;^#L#"2*@2(Z/IRR0D@] 5T6M7HT\J&%IK&*1 MW4'ZT"#6A31ZLFXPSX.9D2UE,]3,@#_YS S_,-36L%N*XR7YO[:-C.Q+Z[S7 M.#HE-:23*I,X5>]7X7.C4LN5TRC,<6>6[0$)(.B++(00^ M%=1IS*'):^%#'EK#$WN#:@(@JYAC"O=9I'&>;#E3R656)$C:@/=64/O,6B9_ MOY95>+]-M.>3EV[S4>Y)Y][V]72)D8<\STQ>9-UAN('9\E&F M?.L)4'_LH% Q.B@4EH_EBPA!K'&*"G*[3@7T_385U%4I.Y@4+B[K+WM*!=[U M!*@@=C+W#"K(1COR-AF LQ#F)F?GD$(=V[JZ/((QV:&7F%9*XO@GTLE9X5>G M/NB8A0BME";*"#LZ)E(-/(LX:@D?38FJI7B'%#B24ARUY-F8+]_)%$'^DFD2 M_T[3B6J0)*(.L",#IL7"TCY%I#V?37-ATKYGZ?ACW2/UP[@]GP2W\]DDCOM2 M+/XV+G]JS_=H=SB9SRY#)+$+"&?P+;\\WU87XUM\?(QODSG(-ZW?;UQTI!]B M.3F^A8.@?+O4D11CF9,Q^-9\URC"X#QV=>\ZG# DD&[*8V_Z;+(P[JPDPIVY M#,^75S[4P2O?>!VK]V?*#G%G[BC#'^'%+40*2=A6_'SC*HH[ZPMR)SN^I [R MXK%E"/V71NNZGR!WLH-8]D@*27.G<^5HQP&R.7(A4(ADVT:OAT024*]:?3QW M_Q5"*NA2>N( >!)X[F0.Q(7$CA^,WN3+0T1_,5(L8^$X MP05[R2T>H6K>X"5I4D.5B (! TP^917%^XW/XR?ZN7)K[>KYZA0@;U':?\6 M+",,(I87)0O*"ZN%Q7(/J3 XXCW2 '87&]G'D?+@+Y#L<8Z:3_BH5XX*R;VW M\US#NJU<#7;RJ!<+*!47RTZ+/&K^.-(P^^LX!1$H'2Z9="H<['R;(?7UL7[$ MWTD@0'2X92%BP5 @T5'!'R')$I%$$C4,1(4*C&(XUT=X)T.NW^V39 &%*_L= MM_"*6Q@49EEUAFO :.,ZWFBO7$B*;(:F?G9_^]&I7+H2XCIB^;H]N:G%CCG) M2TBS50_P_0)DX24#>,L0#SJ0A#%H#J3ZR:;D&(ZUVE7]Z^);_.7[M:"+ R>) M(D(!.>9"@+-2$%?436H@RIX+1J*DUWQ)M]$$&@+OSNY O__W?T='W*F,%.DK M=R/TT3<\TJN%5!&/4.:_"8L%@W-$12X"6Y+>X((^!&ZPBN4E8"$!Z/BQT M-@/ 5=,7%FYY3K#HQM1&8=F;GMS0:5A#W^N^?#\]\NZ;O6/?.$@[^,I5=:$K MB]^X)B9GNJM-#?8O6_(^]:_]&'SE9H[:::/__8LW.F3+L6'S[+=U7SIU=[KW/H;5Z(C$V3&DQ(7)P? M$8]8H,?;IBL4'IK%\K."^%[4 N<:22&OFM6J**"W-A0[EE7?C9G!A=!/[CAE M6W=@P9B#Z(@!,8C$ 29^$1NRSPWP QBTV^6P8 M@PNUU>L9 VQ:LOV0D1'.U$F02.EWZ^>OJ[&LF(4HIB:N8+QYSNQ@N0BAE./V M&9S#S,59O$P/D.608M4.#J?&UL095M? 3J^@XV4=6:4%*K(@]84-FR;+T M5\](-$&FDR*B-T$!^L!K#,W09D4%@HV'YDDT@M0;&EV=78R4F2-?;M%0D"&; M.>*>Q*E08D DK49G?'[^4^@7(T6$;@\9F.XR6B!Z>K-H)T T7093P:S%Z2\$9'L7$KX,QZA"(O\ M: XCY3U"6!C#.*W>W:BG:T3M&(!R*(Z]&31:9'4#%<0A;!@+.7YUU6 MO'J6%1<8FK6U#%4LY$M-HPOQA9FD8;=%[!%-;-<%0S%-FI")2.Q"%AT>"9Z, M4_B/_(9T U(0F%$XQ?"E*88W3C6]2@:HNL]CA@+>'V76P_S-J\G@)G=U4](C MO2@OGT=-<0TLOP38;69!YA?(??4Q=V+G&9,T+PCMIUA6L$_,!U.$B: WD+?" M!U+;H1SHA41.1 0U3_CIL,A6T3U_QB!M\N -/+<&&3"X>+AZ_9C4D/(\\Z2G M)Y,8OY:7XE),V3'7? Y=F955:)"R8-T!H$_ M$C@U?R5Y /U1O?'S/CM23P8A0A@2^R.:?,YP@Q<[#,_F0RCWJV3IP #^4ZID M@D[QO+WR9#L''%9:MF'7PF'K296T=R(\562FG,\)V(Q!I2H)<[_!#1.)04ZQ MSK)B6:R(=]+AZ[K@:I&#(LQ;3=9+B(-5@, M',*7'OD,$90TJQ#RI/@%TG3#RS#F95W'2\!/HBXH5AE&\_QUB":ECV*NNSN) M@3%+CN:5851BV_R)EV$DDOJYN3*,8?UR4AFCVW);VB$J2*8,HQ*[PWY^#_?!@TF^?7W;J\JPY^):YI MF*2#[R\#F561MW,>?6P )WNIZF*"M+8 M^/P;=J87$S[+!:_]OG8A&G7)XVLS0*)0$*0V&IED=BF2*\8%4!S<2AO8%$%6 M#4R8.H798/ /!@N&JW31!M?'7Q J]G)9A0$";X0.&P=Z(A,%$++J:B0>7&1 M9!8&#C8[CV59B[I:.S^YY;MG)65>=0:[)J %"0C%1,&,N;J8,';Q#7$^$]<0 MGXJUY_.S[' [WN-2#0/!PJ?OU&>@-T0261P8C\;)1:=>Y:!D.ZJ*(PWI-O 0 M#?@,H7JLBS@#?V?T9"2EW@=(#0*+>-#!PA,C"$V[Q:.VGT<+R4C&JB(30$YJ MZ"F*N[##+?T6)D_K?E.TVH.>&TBQ+A(Q6V'B 9A4@R5;G9*LR!J65A.$Q=6) MH+YP_Y\P''WC.CI0#SMLII]M9H&J1JR,J7!C00)@%$3NAK&88\AM WF4HADJ M0"D$G\@7P/2E*>D,E7KX:#CU)^=V*?H(+C MQ#[9UW%6ZM?2V;AAC!7+Z,."%2?)D!)V.W:,E"KWI[_T'R/KI5G9*5("SV.- MI!0[>W&U #LUST:ZQM*>24:T-^(>S)FQ:S*),Z!Z$J=3,Q*GPZX*AYZMH-:B M;:OY*X#I[Y!TT+);ZLE@:T PGJBO*0K&P,:^AU8-1&G*!*X:&8Z9=%J_J.%/ M#4LG)CF<+FGYI\C87V)Q%N>F!NE [:1;BXP/7.001%H8PK762U&?%8RY-X>T M'"1A\D+9X'HR)A]1%A1X+185ELFD)8)9()HPQFJJ,+$.,&D:!B'.L H_0NK> M3U/3GL< *1+=COD-(KRX4J>"K)-ZW9JF0L:\SC"F;V7CI8:'JZH2_ >"-7@? MP,ZE=.RGV]OU6&K6NA*;JC/3K?'YX,-:$$4P5"9FSJX^'QB)V+SV>6S M1+/9RNQ,,7Q",S7ABOO,"A?EK)PKMOAA1^SMQCZ'E3?RV=AWLE/[S!=FYEQ" M(4WXCO,C J"DXJ[8NIM4X8USZZ@W[9#ECQ/<(F"/:@3JGPQN0 ?1 2^P[9P,8 M>X^6"GG\%A'IH(ZX-SJ (![/K.2#,-X%UCRZ!68=N2ABMT0S8IU0TPSA!7C8[85@ MV\AL=YS-(7NS2"X27WBQ3J^MUJV67^+B9U[L//Z^*FNM1ZVPC6/W9P[%._9RG&,O M1AQ[*O%S)SFR-.YG=Z.P$U1,YV8$2\T71+.1#@ID2PKDPK8%7!427WFXAH2K M/L"B<**^MCTO_23M+78G"DIR"VAC%?/. M%B+.QCC[8DN'EB9\#&[XAO3J9D;720'S(I!E\1<3I^(W:K9^*<$G5/);.LY' M)@S]M29.7C?3)MR?YH$1NBP,D60IJ]:X%DZ6.M7HV*@NA0HB&1W1MJ7BK MDA<=ZFFB59Y/>J_*9:8^2*KWYMK%D[NV%),CW@Y(U,QTN@YB+:,1?&JMBR?D M=O<*#T[HI%U"3U,4[=WXNJ_B^U./Q)C4IP_*)Y6GR>N5/JZ;K8+V5HFRSMJU M\T;][JJ1:IURU]7.W>U%YZ+1YO#?KEK-LZ-.X_::\[7FF?4?0A0+H;G%)YSY MN&\EP&&#-KLNT%O\X8.0@+L%>Q--@\[]8NUA@7&][!C>K3CV MBX(MB[-1KZZ$^[G8Z1PWELU<-6 M+K.5'>G#R^[C/ /.YB__T=C;YIE8)/&^">1 M^:[A)+#JPE39US5+E4!]:?I73N]W_^8S^32?*Z?Y0N&?Y4_+T7[YXE]AZH0" MKR_;Z)Z-S?\5?JC+CI<-G>K_G'DZ3FVY$@( "4:[:_#>HA$#)VCU;G09R[J1 MH%RH33Q\YQTI;^@:((;M^Q8U]S04ZM=+>+FS8E&]R_X3_#/AWUK/N5NSK-V( MCL,+)[ $R=M;E0_L%4D?CPM@N=16Q?&B9^Q&P+E;Y%:.^=$A]W,A/O2*-!U. M@ZN)OAU@F,;.,$QT6$@WWN_.23A H=5P_^Y^J2X?#.E;1F(MP9;5]U MK(HL#)[;DU9W"RP9U_[*YY.POPXTN0F:G)SQ3?GQ1K^Z$[+;(*G-2NJ &$[" M.]VR&-Z_T%-PD?QQ@4 %1.?CK3#JHHQ,'N,DS>HJ:#5>#KN@CKHT(&7;(QEO MP!7 DK3<_/TGN>,PKKD^4^]RLB!S)8"2>S6PH(@>K.2M=$2 MN?I>IW0@N[\)E;B3O%3? B]%&V;-WQWSI5\::-?=3\Y \7*?"DF$4)+-?3JP MCY=]PCJP+\L^$T'2SJ73VPM95CXI]0>H.PG_/9<+PQC?*'7;QN._I+8+BKR" MU?&>\LLJ_S2Y$@L7G8]RYNZREU0-Y9JK6DE9*_H@H+3?__N_HR/N5$:*])6[ M$?J8Z-KHU0)XEZ]<.?>-(] Z>##NZ(CQJ"2_Q?6#Z.J<[XND%G"AHKGYI7#9 M3.:OL))#U_H/VO2F-@JC @^-3==@^%[WY?OID7??[!W[QH%^_,I5=:$KB]^X M)N8XNJM-#?8O6_8^]:_]&'SE$I]->?_]BSZ=$LR53L=#(GM4K[V+\_3/,"A-DJXP+TRA_-^B-Z1: M"(:K:8"/)9H/LCFH$=L%Z1&5Y3XXEKA#/$U$_7>[<]6SALWNLM=>>'C5 %7R ME;-&(Z2+@A&@\0R(\8!L2;IBN?N]?/S?OUT'%RW1H0/UR_S)T^1-*HW*5S_Y M9CWWY?MMX[[1O&LXE-/U$Q'Y9X\JTKL.KP86LMXUA$5MWNF57<)H*::N218Q M5P F94>6^%EVV N8:2/+D4[5.I5*4!H)G^N2BU-?;=>X8J:8YO#Q,.%%\:)M M\670W]D2C&"C'7-517%'!>AI4>NK>"H2P8RP]!0#U20O\D%*Z!X@?CP.%_Y# M&%0 Y+TA=$>!>1.)#Q,BL.A$\B&=P+CC#59%@&'7)&@+8"#]#5J"F%H*NDC0 M::=9DR^&&2L3)%BV1_COV'*R=\*/Y> 4"!1JV M9V!P783)(\60:H=( MN*ZP+ZK=KG1$60AX;3E=+@^DA%.H%\LT;X&?QJ)(\< MR%KRKT"VUL''L5_ 8,7)N]BN$1L2 M 0W,7(-ORPCR4>F;@2W;GOE.D:LXRY052ATF05,U,2'[EH$GSR8^PN=/&BG; M8+\.I#H^YR$!TH-/22\<9V\P9<$HC'0 31W3)Q)TU<53H@#\9-*,D*"M"(5\ M943K[B!,FTU-8GT '3I@ ,0!J*9O% 6639)V(05X:,!8 =17+/-8]Q.ZS_2% MH@)K-5)DOI9BVOBM;-_QO Q-E '/B'(A/.\]YK$SRV.NQE"E#"QW"+@Q/DQG MS]*<86$J$PCB"Q IM@^.*&X4[9EAI%.HUZ,PF\[QZ@YN(;S8'DSR[J ]'@// MI5NG8WN==);!K#K$CK*ES^ 6^PO"A80Z5"SQ"$Z-H&\4>7DC0GKCB&<;6=6U M9IB ,D2(FN'3B7X-8@L5P^X;!,WP,)4I*$('4-'F&84UR7 68? ,2/%90E* MY2G!^ULZM/M;"#MBQU@?>YY" N8-6V_H"#.L0=I[ $ZK]JY&S@_$'B54!3#$ M#439AK2D,E(" >CUM)'WL0UI6P7*VBHP9F#Y,1 M&#.TO1B@)X,IQM;H,P !:'N)R4/E"A,@>PJ1 MES#A)]K01C:$?E]'])! D,?T!=:[OL\B!K$XP;8-6%:Z=UNA$R@H@B'11IC$ ML=;XROV=_8?K('&@XLGTQT=(A2 GEC*605H&0,28]!; [_N;_P>480]_3/M% MNBKM[QQ\)5/Q #R'K5]03BG/3_+_<+#PD0T_2N#0'1,8/_-WX1_'Y&=2+=31 M^2/T5N+QQ^(4YK"/"UL]QH,S82V]%=2QGG^:R/7&_4FC7VY5Q;5B66XLYD%Q M*(E_16Y,/!8 AJP^3E'X;(K*5^I/(2CT$]6Z&8GF];EPUELP370ER#Z8P.>".PQL=,[9:-8Y MIEA\+(^RS7RC7]KP1N- &E;4RIS?5ET^\1(N9G 3K] M?%+S$PK"O>"(96N<0V3;/,DA M]ZG6?_?WSL-4CK&;X>.G6S5(7AX6H%7HO&<@J2-\L"SD@=L,!/K%0#CKA$78 MVJA/"L3\Z?LN7UQT?,VP;FA*2TMOTVB8_S$WDM>@@3SG+788SVE;W1K_>)?? MNIA+D/J7&5'* MZ=J,$ )GW\2EX4!\,XD:J%(N72SQ!Q#;3TB(.8<0>.BOW 47NM\_O6W0_QV7S(K57MK:,*V:L!IP_Q)NQF[D\P"G=6 MD473H5]B%+-)0$AB.LLDJ;K^9#]C9U52;))*HNJ/SZ4S_.9(*E3S-/9,\] 4 MB*HJ7=,$B*#^.7]]&-4ZXOWY17__W*XPI3.=\W%0/KNA?&:38D!>)(%BG$L7 M2DE6P1\TT$YJH(7HJI"$'DI7BEN!J'354&FOU- 9I-G=.%EV01TT5*_.AYFK MYTK_L_E 9U'YA0>1L455-),< _*BE("\J!0.?M ^D=026F@1DDHB,)Q-9PJY M/PDE>84KW6N6PGUCIW!?.RG@\#9M0O>VG9,.\8E-I.X/&);:>_OTJ35 MS;3.1?E366D1:4;7,0H_/B5R[EK?N!NFX1Q:]^OK4B(=X/+I?"Y)*_" \/QY MZ#32WER,3A.YM;Q[Z MCY-,>0FM$:O8<9-*A&W$@7MWG7OGJY$DNG -CSR#WR>E %C61O0[HI!^#LPHGL$?@7*T M_ZORR$#!P R%"3@UER<(;"F%B07X2HKBJ(D@-_'A&U87L/[LM$H7;\@: 0]3 M%%R*C38@-^28 5BC&TI=JHR,E(Q)#VPA!WAHX);:VCBX!G )0?X%:#"&Q1= MB63(KSH@%NF _.H%+/8*A#>-_-H%WM34%.8'O&$#_#V5-CZ 2H9-R1B?P/6Q MN1 9 '"8[F V+*S0UQ&2CBAF,>8U6ET-*,\*,APN\XD,0'DUO.N9EF)$4O3" M+Y\< 4& >14"26MJFF)P?X-$I9* +.^?-(=@*;JFRJ)]-H#EJTM&*N3'07QC MPXN&QJ8TU/"W]N&Y$IE@)=I Q('CTK@N?E2- CI-80TM.GC(@'A-Z1'DEP-O M+;L8HIBQ@D*,;F\$EC:9E6$24A9@6@2>L>>.;<\4GXM@4HANJPMBT)3)J=#C M'-(=)WB0SB<4]A=O[D@PL9RETM5&Y\8+WP1PXTY)T/@]8_*'GC&)]HRI''K& M'&R#V:NZ4,'2''/0*07_S /!CFJC1K#1+E7,IPDC T& M<0_R669]%#0+VY$"UA!I>%1'6%LJ,K89;-!W&!E$.+7:WU&*2%&D8D(3$04M MA' &@\=UX7+3'&@9S>H/*+Z\*3LR%[]/Q?:ICC4Y,M\14NVE4.!?'Y O4R> M?XS%N8I,+D>7VHH!#H^94S$,N&!+B(\1,;U]P+! ME@2SQU-X/9;ZH@(N^ZL%)@J=B]U.0V 0VH"0#7T(D!'FP;K-&QPWD'(5-N,( MMK;[N6.2.M/TM9M(I]XQ(X.?R.2& ]MMVVCAS\&2)$0E#FDJ D3O?U[%=K5M M/<*S>#[XM](WRA^@H]( %4Q7BE)-W?IA$6(#])Q/G&6]W MEXQ&;4)?6PDX M)LTK\%$&6UY$K$CX_=D"W_1UU'%+UFO=,!UB&K6%D M=81UT!"3D;;1IAD' 0N96"NGL432+.F(.MAA?BQT&,#\1,A0 ML+!<,S4XEA/I="+8L"&8 _ODM]XHP+_0@D#K@CGFA&W8 MCA(>9S]-!1Q^&-HD*Y4T(I9F+7AN".F8CDQ: X$QB85V3_X W>,-L="=3I'0 M!@OYI(DE19^PI=2!@W?);0#6EN0^=#1PXCY.,)V:]%W4QR^C/3:(1/?T7.,S M/)]V^EN( QJ-(G$_EX[2K&>-X/U")URJHZ&&S8$WV9!)KRC\>L8\S"_Q6N/. M\)HJR32&1RUS$K*Q1C!O@X7!!6XT&!LR5K>D:&E[%UEC]E#8L=" M-C42QZ7;2BXIQM@6'-K?&4PFX=^P2Y?3>I6V>(%X)P@;'3PEO)$JO0:1$&/T M#@E?LK^R85+VJTT(S%(C5%"P6U_?AC[2@)YL@6U2/N3!Y#+XQ3ZUN@Z:WB9 MTP4D%R?M8M'@F[TSM],YF^+6*P)F3#R0ZA ;3:O@I#H4IX )CL.@M&C_V"%8 MV>1F5)H^W=711^S3#<*EKWRZ:LGJ/"@6&KY6MG6ZD7GTL4^W'#N'?L;I9H\+ M\TXW#0[;B/I5RO@XY9$7W&S9M7L28UE9<4O6>$.7>.VLT*:GGQFC^=)02O?G MN9V3%C.G'J"HN(G>F2G(O5(EGA62KOG'!8 MY##CHH=,'68^DYEUF %Y\-DF.P%@NXS\ O#IR>S$++Y +0%H8 MRRJE(*!T8G8[0=DT-A.1^&*X_8YI=T&DZQI+.#"(;4VN0CSCI-QX [VOUL(2 M,/SAC]#T"&YF>H0W2D(FQ_)"6-QE5C*$Y)#IGX#G9J<+V#;W=#3>G[L5W77;XQ?8?IJ.M_<-XKYDO03LSK[2&8X4 MA-=_"%?L$E]6':_1Z?;GQ+E%3;+3F,B-@*C+(QJ!))X>32D"JF5N+WSEM)Z6 MD(+ELS[V=E&;HC1O5@XCUI0;(YO#@HS[TJ%Y2>XU@[,L1L8=A$42G]9PW\9!<[3J76][4('(KH(V8B\_N M8ISNZ["3[M80&<>B_<$%T"L+R9.6XVDOK/E^C05GCR:0O9.X"#[YE*>',1%[ MQUP#KB=D59*QX*$I881L8#P?U?AOE4CD%4G^!GSAHL;3]]Z1.*E ) +NHMPI M>$2FD_KVV3AWKR] _I-]D,<.T^]SOCF[U)G&<7;"N?A%Y/*47-08R"^>Z(^ M<)N@"!>"/8O8P_\UF?,\-X(<>JBPW+K' ,* M+C.AL[G:3SLW'_*0A#!I4)G<&9.O$?9>W%=AEN_U;'^:7@)YTE$UO8]-)CHS M[RKH3U(TD$J-$RQ>1A">7<2P<-@\XOK2&SZT+T-UB27,VSHB12TT%K,,/R2O M4COF[E2:]>X,C07,:J:LKEPT=S !4?W(F5*7]P8TF]NZ,*PW335653NUT MFEL2O(6[)N-D?$*M=T#*L0Q(LZ.O I?1L#%C5M1..7BYG+E4!A;FIAP"@V Y+84 -D5DOQ9R%^^OM=^ MG3?+6X^L)$62<:L+IT@R.SOJDCA%IE-_6A@G?KIWX9#NG62Z-Y\YI'LG:KO; M"]I;6YWX'Q0+.Q6&?K_/?LCFZUXW%D&VHT$LR@D!T1DM#(B_@F7@($:0AOI4 M@#IR-/_7:4(S3D@J?BR83)FC@8!Y1D06,4E2SDT/S3J39(-X&R3] M%D_AF*L!QT&ZN%UB0O)'?2Y^'NSED.G9ERQ#8I\;=N8[_D%?%X;>U.V4)W6; M!2?8.CAC((]H.1%-@Y*0'?.=>N$Q=PJ)I&2]-'_,NU3.LU2H'A9DB4,RJ2!X MM00=VUC*. 7Y8ZIJD1LQ6_K8YR5(0! &*>EUHB&BJ),P.XVDTUP]!P_ '[H? MD@L];TW LR515%T\7E\@Z6,P3%15@ET(1=)_19-5.2"5W(V3(+R=Z#&/HOQ8 M W@ 41Z1RP=WMTV-EJZPLT.JKI$X$+L;8(>8]CW]IBG6D-;)VG1IT"/KCCG/ M:&X=@)W5)PF)9=&\6J.V!XY)0P0)4N$K&9:M"!/12$WZIH MM#[=7AC>-0'K+RFD7(-68M"RC91=H>T44#C%+S!#CI3A I;,)T[DU M"F>F=SRS%#EU_(A[-DZ1O%\>4#FPQ-UE\.541?O$30KO%J9!V"U?19$C?>P# M#H[EY(9[K[1E8J*\"SJ[TO7QOP4I_\XEK,U,=D&ZI^A(,""43#.AZ.$A05=9 M#B9<-!&69^(% L"D8,BN.2&V $O_95%3<2"C-W)!3RMM&'WCY[''/M 4Z8\H MSOX$JX(Z/"S2G=*KKO;FQLIIZ0>6":R8#%+2(\4GN5Z,2D8/1-]]I4AX@NSZ M+B5[*T7A_I!6=,*= C*8S!IN/89LH"Y240\2XYU$"B:@&7MA33I/DT0M=SIYG=V,>NXBIY 2 M4AZD!",^4()W\>PM[(C=RVY[@?30*9?;-;4 [# 2;*K*H#AFF* MW,VK&F>IKDZ+R/4G6L(MM29J%U"E=!DO"VLKR6(F%U9\D)% Q0+P*J303M>$ MV<8U-IJ\]5 LWP@/"!:;1-)RA3?L?!+CSE'V?4N6R S#9T6M/:BEL&?%BLEA M+K;8.%#J7JP*^[4,GSTUJT?$IEWNH [)=8"#^7FA:%.T(DO1U/X108:8 M_HT7>X)H!_RWZ=R_X]0#\EGC(=F!-F>JEDY +P1I**LRN!NDJ!EL4DW'&K\G MB(#3)L-OF*$*U<^O%O4XTG $+XBF&MS6KM/@+X(K Q^0V!DU.B#:)BHR2<5T M%PP53=0>1E"U*M.B;6V$=!=MPUU51"&TK4Z]M_N>[,E4Z :X@SD>EYL21JY6 MJ+-H-XFA\!8CYJ<:WEPFF@LI#[NPD^2P(!54 S^:F./4[G#HPG9@_!Y[VQ218%$%*T]A2^ACA ../%IF9 M]CHA?*B"&W:0O'NQ*I_T,:@I##X!PTHA*8?&BTN 7L.AYZ% :1:[R"232+ ! M(/TX#Y1_,.6G[#BV_9LI:L>((M(HWJ MI4C^$]@5"@/R(2" D+H89%OJ0]@@=W;%IAU.XDP+F^?TW488OSK.BI/(:CB1 MJY2I'7,GWKFR)*0W&;U3ET)!@F'Z0W,T'.>M%6>+HGGL2 \LP'-<,XIT_86X M4TL)E:,'"; 7JX*\1->Z)NHBCMU!L)S\ 6\\(4^5<3;/"NMT-*2)@Y0^[21I M$6A,H38_,6)2)!^<8%T! (JLB]80_.&I9&_7@9]6?]%Z3Q+&@!,E 3J"#0/A M4C&]$(JU0BJS_SBC/IT)ORM_?(;]Q4MYPU/\H47_F6! MVG\R> W6,8T+\O[SY^W56ZU_512#I?]ISVY$E& M[!"]ED!6>C) ,--0(1SC'P850H#5W2P1A\X"YI?G3M0+).(CN6C*>G.0ESY, M.]@*UA"VQJJSJ:SJH;*P*@(H'C";R*3$E1ME%B0NDCIVX]Q9!LH()KUK63W_ MF1^\G0T([4I%BUB?JZ# M/NR/CG4!2=V)AI(05H!>G81# G]-P?LT7[,6#T0A]F"DL>/LLRY#@LOQSBRF M!O(F<0':*^"80GTL"9:[^3TD:(XG9M_LD"05R'A!'P*D@Z04QGF 0TJ^L"/IQ8#]X2*/\''#@BF_/$X66?$@FB?W@[D[F%)428-!34ZC'&O5#M(F^WG-NV M6(F56E6E.MM^YFQVX#<=/*T311-?OOA:C%9J3\@VKI-_U]/DI'(_;KSF7N[+ MREK;ER8:9O*Y,^63QM/D^:;0+IC7%U>WO+,,7]OM+]_;M?-&_>ZJP;5.N=IY MM7G6:',73:Y:J[7NFITV=]NH-2[NJR=7C317:S4[M]5:AZNVVPW\[V:=JS=. M&[>WC3K^W7VC>==(O'8\0+Q>&EXHBA[_].+%V[_83=47'C^\T?GR_= M;>I&] 7N:HJT5'/@+"&MJ1XORI7T MBB S=3&3(:NT!0==YX@N<[W_K&LIKNQ;:!%'^*VFO?S-T-*!6)<[85NGK8U8 MU\9EH(0/-+8/-&;;20O1%C.J]HXN_V;I=?\<:/- FXG]LS9JA4*!A>8/^:^; MIFW(YPBSE&G;R348S+$'#O&]%GHZX)F$[>86YS+-\]G\EZ6/()2M5YKQW_\C M,R0Q*\TR!%4R_MG5O8PDXN6I-RP=6.]W_^8S^32?*Z?Y0N&?Y5U"QU/-\=A1 M/:'A,8AD:3WNAZ!:T!Z6Y7&$;_8"KX WV%OFI;MEQ\O^%9:9]K^5YYGE P.3 M>&LP;.)'2IR.(V'GB,&%/,EMN+E761,*O>3-V:$[7[ N+G*@YXH]-P4BF$V7R^5H#,%5CRN4##R$ M=J!9EV;+,3,7XI%NMI@K?G3,[H,2DCQ"AC)B$VR,V2Q M[%SBV;0;2&=J>0/ M9+M6LLW'(]O3.61[)0M=*#X=QZ/;4OORN7*5K9MWR*%;VT=PLN<='V\E$@[. M+#8-YS)+I#=-R]YTKCP#OO5 PYNC83XN#3IKM(5V"6,NP,?[S5J^W?C_U\A"^2]G"$PR6,-?Y> ME#K^V-T59W%+%YW:U%3+();(N:Z'(-D$PDKY+([88KMWW5+<)'\<0&X MU'?S0E=(_SU53IO<_K)7+RH@R&.R>1.0ERZ=+I36$PD,I!,WD M *,Y*&G5W%O#Z$=?!,6D^V4O@L+)?[D(1* L-9W+':C_,U%_8^'[I)GD+_Z^ M%LU'U/B)XKE1*W!"K/ND<%9(Y"X_S6?Y RM\(E:8AV40>BTUDQNNRE;_NJ"^ M7YT58_I)2?##G&NI<)9((EB0*Y=VA"'VXHIJ51Y.Z%(X>=$2PFM)#IG$) ][ M=]B[P]YM<^_V+6 U.R5.Y0%M+X@TGQ21" ME_ETKE(Y4.*:*+&V4E[N%"G>B%?7W9^O[QU!VHF\W'"R3"*D"'FY:\AF.I!E M+$S-N:FV4Y1Y^=@4S_IG/*_F=R?5-IP\DPCSY?)K"/+M@F6\J?S:O^OAB3*' MY(Z$6+RP='[M%&^_O%9O3"%_RZ7)Y M&D/YD.VT;PRQ>DKM%&/\&!=/K!$_4BYZ2Z34KC>C=@YKY))P8XN5[3'&(>$\ M4>[()IY+.\4MXONOZ_:@4%M8C2>?2SF.A)-SO[55L'#1+@LD2J^31 M3C%*YT4Y,7YC:GY>/8]V,599))%V'G?X7<9".210;8WTBZMDTDYQ0'4@Z"=JOB!/ M2EO+I TG_QV&5#E0_]:H/[=2)NT4^3^_WEKZC[>6W'O9B4S:4%;([S RRX$5 M=E81S,VDG>*&=HMO9,?Z\.ZVM#N9M.$LL;, +RMETK+VLJF4/2_6!\/78J): M>YJVV9M\9H!1MCTH:M4_U M]*&=W[H(3XUT$F)-@\9(T%FS0*=EK63I\ OG:Z1"@ZFIXEWR&,C0Z?ZSJ:DN MDYFX^L1IWFI/)[PNXZ22J3\W"X5W0)8+:A.VZ)44Q]0\EJM0S\<-K4WUCZQD M*HLW\ZPLO\UNL]_INS,T&+3%L]]Y]+S-S9X3QE6F#01I,0A]( MM(C4(=T(!1VE1&$DFWBI$]HP5> M@;,H[+6@=RRQTO $:2PJ(7"-9!71M[&Y"&3A]BQ( WI?E_J4J,C065&1>PB/ M-9#% ?0@I)V]0<,;QYPCSKV3>8?>IW,:RQ?="S5[C)H[1&BC;T=#L>N-]@ A M\TH3R3IH"VGG)RUH[NHZ<31H:#>3;FB]._U#R+=?*S-1:$(F-K,W-'O[TXR7 M!U1/.8GNW>79#:-#%3Z_P/;G$MY^&7-IYO8R4QIT$]G^W-+;OT0X=VK["]G2 M[.TW9YC ?IL@G;)[G3*Q)]E=2FFO8M)[T^"HN>YT,(5NJ7#C300(:^[)&7 X MK%>IC]V]1CX5N5[.I29\RC;AC25L^&E:\R;(5SUS:?7L$V[#1+STAXDOPH#/ M-LS)<_>R_-QQ\7ZKL1<_<8U MF#D#%%K#5"6;W)6&!>G!W-_:[*OMNQ2?R1:/LCG,1*^6C#F)F<'$D;<%"AB> MQ'QW3%).I">HD!/$YCLP("+6JR9B?4_;=P--A+6QINJP;V%=2;)C%$-+.>_' MMO)(TQ1;R;[+YH S9+Q 9J-&R_0.!Q$ %X3GHU(/0Z[4SG'; T.+T#5AK1) M-&T[CH>"?M]L"1 @HY-GNEG21O KNQDWWAK.WIJ9:R&*U]?%G4RP3]PB_'MK M:%&7 DME691)=&^.GO8&@6X1>#A(:@@ZA/V,JCMBG0[(;$2?OIA*?VEJ)C*N M-.S'5%7I5%;QON/17"X]&;M_[HQ'*&!&$NZ>SEQAAJ3G=6X'^U--QX3(GL'O MNM'Q@5CXN,FW@?'=G[5-?)R"+AEW(S"DX BR.=M@Y<_RN9?ZU4/F3O)FY 2W M>)Z6F[^G$>8MT7".>3M[4^Q?Q5I:0%@3\>%,34=O,MYQ3-(]*M/P:T9()\R#1YJ<3!!&%3&X7=P'ON][U?TC:2OM=]^7YZY-TW>\>^ M<:!)OW)5'?./^(UK8B5$=[6IP?[QO/>I?^W'X"OWXM^^]?_O7[S1(5NN(^'E MJ(LPQ>.Q1^3$O%U8Z1X[Y.DA.I<61K[!O5."N=+I>$@D07(_* ,V^0>4LDP9 M M98 (-9>J2#IS1$YH"&A(=(,"R=Q85M8]MC@Q,;%=F"F(I1\CD91S8X3/ B MLY) X/;Q>TC\^(C<$"N:]@()\BD6A,8"]5V7372D]7K4P':E(EX&IA99V,MF"P.?IQZ0--6/Z ;.41##:L[P["<2W02@;/? MSC:'N!%4B]E>!-EF[$D\(*:2J!HW\)Y@ TS3'2>%11/)0GVZQN",@68I$@3_ MAZ"@F>X98"='TT%>I=SSQ.:C0+T2S^Q>L4F'5W_,7>#9271+TN07-6V("76, M#QX3)81*9&SDVA8 MCSAH@=_8IL6SBV%G41@:G#I(BB*]@Y:-47..80(B2]% MK O7J*!Z'(C)1.!+]K"I@GT>H6>RRQ=[<@,!W,B!@/<#_"A%\9U7#[_3-#Z1 MUOW/E\(5.XZ)#%$8@4K2+11P&DI?YE8:5.TCQ&81#<% !*9#G#[\]A-%$U^^ M^-+)*IF9M11Q!GR:"/=6OO RN,Q57O8F'ZTV$-0^,E(LMN\0/Q=-_'/B!, ' M(QW+!&+DLW&I]=-%>/2O>TK<_NA%^:3Z-.F^#IKC?+.=E0;.@4NR,5*$,?2T M5M&7[^W:>:-^=]7@6J=77'56JUU MU^RT[=U9%U-Z]WXAFS3^^;;X47[SZ^*E=K5L.Y*M)[5Z0#/ M?W&H*U^I/X5=1@VZS8MN?R(W=2'H*\PI2XT][VDGX,OWZ!88B6W'UC:Z^A1V M_?3._VZ*/[HGKSE^PQL=42&9W$:3-.L$2T[WD-.*FSS37^!X-*8B,ALYYD1K MB_?PH#?-O)],2GY"P;<1CEAI*]8!'A@B^9:KPK(G^??_J&6O60;V^(U_N)4. M+_*<'#7M3R[Q>&-US>J:/4N9]ME<<,&)\#YYM=KY%^T<+;'^[2 M,$NYF EM MDGWBU$>P!*SE:[7VK?-[,:+S^^R$GU@D$[_TKI!$87:Y% :2N^K^S&VJ?B"2 MY(DD%!6TF$F"2/@P3.^U$TFH$"[/#)+14-*%>DVB^6Z8K/$Q0JJ!H'9&-P3% M%LK#AX9R;9RUVR_+1,LVV#JERJZO(:1?;=>X'%_<.6C?-?1D\$6@C@PD'LD? M1P-9DA#^#:8'7O[HZ@JF3=/#G,@DI;%N! ):4GTO4&4XCTQRDY[X1QCS) MFD34))L):_VY0V65K.Q*/LJ%*B5Q-'> NUW9A$:X \DE<6.22 MM,\.T*K[3VOA8C^)$%NR-Z@;0"W%PKWY^)JY?_G9OJSN3Y;XQHN.PK35.]56 MZX(S#1Y;TH4+I:G"A;:IB2\#3<%<;31>+8(";**Z;(B*!E50$;4*F5./;1%[ MC*>)<=6K#4=R#667R8(AAT01PC#7?N6LT0CIHF $"O$RP#&! DA/^GPBQ];] M7CG^[]^N4^R=Z-"!-'^>?YJ\W\B7&>W<%/.Y+]_;Y]7;QGGKJMZX;;/Z7*[Q M\^ZB\\LAIZZ?LL@_2;$+GSLN34DEAVG(A[(*E4Y?N2/VVX3WWI8%@57N3R%' M2TVUT_;;/W8! M6^#I.H*N0P*KU[O1 6((ZO!HA=PM:%P#,#AF@2C1IP"8")B\3HH15>D6O^$& MLQY !/;1TTB6GJ01PZZJ9%FY /V31TK@AV#6-44PL%(F P:P*=HTPN=_Z13R M!93ZMGI578.E;.$>\Q MCV).I3D!EDHJ7?'/ 8]R9-^\&3:<3)"<3S\S.;^_&M7LQ_^? MO2];3AS9%GWG*W3KGK[1'8&]F8?J?2J"T<9E@\O@J5X< @F0+22LP1B^_N;* M3(U(0@@QN>AS=K=M1"ISY9I'M2W_*OP9Z%P*ZR#<#SJ;7W4]9*#TELIJCUK1 MCKNU.R8#H_VM%W\A#1PGI$4)DIT*SW(.X0I5T2 B>57#9?SK"-8$$:R,AV#- M'"0G6DRZL^[KJWS)J\-CY"$N_A V>VP%?R@AO=670R16<0A>F?*:SHIN-G!. M^0!S2OFVWB:7=VFAJB*[SSU(KY?;C'?LT M>QHW2\=(0Q'D<%C?670YG$!XZT:B^D$BT:)?7(S>GM[DW&WN&*_?=;5AAT-L MQ$*GT-Q90FO3-O:X-SS]BPDJ.J4%/E''N+N)F\L$3D\)A&(=.@(H%?P&C"9' MP6CTRZ[Z.'FM9Z?IU9CF!M]&6&>'UUXYSUH&K=U9?]L%(*C??F0",!.XSA)2 M-0X4J1;I?'\@Y.^[#[=? QV<5UU>R]CSN>IT*>"R+Y:ZT3%^!#P[>?E_&!^B*@Y[=],>P]X* #-,:$[PARR*P1!6ASU%-PX[YY B.=Z;_8 M5L?P4VMSN\^E*K,*M@_K K)6<1L^IZD)A/\AR+H*'>F@)_<'':!CM.'!%DD\$\X@2U8S;4-5,U .O[0C&?VH%UF]_<;_NM*S-P.3*79]#DE. M1)@C9[<,5H=];6-XJ!;EO2$G6X.7(*AK8XZ=0T=*7G*QP;P1)$8 _1X&GM]^ MT"[73"8/H:QT<2F233D84U$3+ R1T$6-(@B"A/O^U>12N\*@ONV.0]9V\9BYLAEJ-8B&1X&->Q+WE-;HJV5V2?KQ*:/GN)7P&5'DM M\\L40X8(*N92R6+9*R>%1*H'(4X+F@D"-SL:*?P(G)XP! MJB0-JS 0I#NI"WM0%RS6SCEM*I4714:?,EY&>-4J)R3,KJ)K8UF! 8--68') M21;3D0IT0.N29-?[JL )2%C!%QP&CUFKJ*$MWK#*&Z\ASH#;\1N"_=?M1>T^ MGWY]7.27>!=AG!^L(.(8 %A[,!0JL/@IZ!R!8_>HO/?=JH.QY5*AJRH*_N-> M\_ZC+NBT5Y 0@J8ZU3K: ELR FRL=H9N_&R"-VV$0X9T\\S?1ABN=V.&3!.@ M!&*ZQ8VR%2,>LJP5V I.[ZWGK7%:39Y7EWW#.K@K5RF$&Z'-;?WQ31[_NF1G M5H0-;Y"A)[+FAC%#F.PYM9R\0>@3XI!!93C1\2FF()M76QD:@Z?6PTB!3MQ( M51[P/-C%=>>\[1!S)I:0Q.X@METF4E71 N@73)(MW)F\)?4@VY#LC:"+O%5$ M>6C=M:[N/B>_+#R!90 :5 >2\#;Q'XBR1'NH0RLT:Z_N5L'QG-K=HC2N4_?$ MI^:ESE7;I=+&QPY4#M%4L,-6*?=;/MY2F=2ZQRMN M=CQ)]F (WAS"$#V6W]4A=6 <;X+B"!8=,"A999!8 9\"^HEJ'+CY/L[QP*,& M[&:GJJM3FB(R7D[ZL7QU1ZJ&'76:3U!N ;6ZL?TG0^H/2!5V#)]PTF:^:, M2&00=L*61!*X$UCEW,<%9,]\L2^B+JUB9+V8E$;'66AXO#D=E4+' K-JPC;O MF\Y*6?9)TI'E]KTC5@#3Q>TOGBK\&3^9XJ0>D-T&:(F(\M1]5[ Z* !W&0P6),FU4Y]IVY$.4^*S*$ MZ9H\#$](QPFPZGS2ET5#JP9UT$@N.GP#]BMZ$TP!L2.'PO9Y['%NV^E>6+81 M:[[!4['_!/N8XPF:I#W\2PY%YN.6Q4/)>.%A4W[CJ7S!=2@7-2Q^P'C.7A M81@6R:LFPWW-/ H#/#1-C);T)U9\KTJ_=]+/]\R$8>3T>H[>BK>OHD9'U&'9 M2^J]>:[C=%98?M_M>&BBL(:J=SX@#E??00(1^1;^_8;]%";ZQ& ?5S>B5OCU MD,L7+?.D8N.+3B<)SAA:PTFP&J Q.4%<7,<;(.C\+X[CN_A0Z&+] !]VUC\_ MQ^7#]LN(M_S9E=Z-Z;>.QZF0L"4 @9U@?X.9JN_A"%_.AFANSQ&^*=K'Y#-\ M_/F;*]3TZKOXZG2I'XI'/0S*K^==2\>4E^WO=4^$\[K[.-VSSK0-%09O!"72 MKNV&7N&#/A#,%(=/@W+U4^L+!3]O=KA E-&RL0WU,%].%HN^")FP M3" KL=:#)9O.$7==$W!0T!M-1@EC<0V\AC5Q*AJ2.0AUQ/FJ8@+R-0 NW H MH9VA$X05B;.R4_%?D$J2IRK)X:-NNM[5JJ_LQU7&GDU.H87++01Z\*#[,(^OB:3/O9HS.U21L'PWEX3YQB'H!((BC'=0Y$CM M# \C"8_[-0:HVT>LW^*)[<;H]^],J?0O@Q,MT&(P>7UYX/N*IH>N%C-D_OM: M\TQ73RF%H?=>OCEK@)B[U9XF3[WZ1=FZ42T/TW*\[MN/YID=;@;$_F6@<.D[ M4U'8OC#XEVDC&B90;^!H9:F^TJ3)Z5/WW/PC0'B!7>/;MK,_# M3/'OS!3?F+VU#X&QB9XVI+,GL]L7MV\)]DJV8T.1 W4]'[7YWQ7 0;/:G,C!<2WGD:0< C&65 #FB?$A\Z9 MUC QXQTK^ZV$]58) CLJ1EK-:*ACQ7=P:G;2%HO"Q=D#'A*Y(7*&BSD8*X75 ML?>$]QL]G_4X)WH,%X(SHBR-$#3[/ .5YA QTC558TE#%!P.0\^1B!4XPEA: M]4U>(*M\@KX0[]VT4I-0R(2NRNF?,:)OSGTZH&V4L9 2>)]2EB0C#.%2DHB: MYT#Z"7U* UT6=%WU+E](&AW/Y@G-MN4/0K(Y3+&IY4Q\%Y8 )F)R!J>)0<[! MQ"9 /%D&@TB!GZ>LHN$56&; JN.$%4A%FKHP6+<$[L[\^BU\&]GMV-:P>_E3 MZ70J%Z>7__KV]O'^*75?4L7U7/<^F_7TX*?.TDBUS:WOP<^$[6X<5-=V[N_! M7RYM0^PEJ+P-84Z2Z>L:#J62QQAOJP1$%*2$[1-"SJA M#I(CZ1&JQQX)>U >(9^,7JB@;TGH3;(RM[W;$?"G(D0 Q8Z4;#+6-#8HX*1L M%LLCR+V@=:%F&C"\VZ?Q!MF"R@]@X^B,Y_;\B$"I@,,?DDSS4Q*4[5-6#F\5 MA8D 4'$DL WMNZ!LF0C\\#W79":@2B517^"G$N<8 ++0? %_3Q!VEH"00F. M@;,FT-\0GIS9_X0KCI");18C(Z019) /"*0DA =B&_8Q7TH%05:Z+(!8GJ&? MD58-P&=%M)91:P: UQ6/*C10 QPL#-M Z'&C)A4+=15I]&3;,P'P=4IP<1SR M*K \Q?85SEZ_6[LK*LW5(;=T?P]E\ILJR W.N.*HR!W+<8%X:H5 M"DT0\^)H@RA$5W GZ#ELR>!UZ=^ J4Q8CJ]:K75L".])_$$]"F.+^.(\M*6RIRA$X;P0+KXWEJ]E?SXGG_7"V:;"ENB@W4"=@A1N"6\#4;K@N$@ MV!B;$\N&13ALKD;%YKP;FTUO0N,#_0M\9VY<=CX1>X;!HO;S)M5K7L_U._80 MZ"'OI@?/\Z]/+='JI5W4$E#=MAUJ21#S)HA:"L'44HR'6A*>9OB6J:5 J(6V M;*!XWAWP$HM.:\N',?[41&H4VM86B*17%N7BPZB;:A?],_26@+$#/BG[5OR)H1*5&(H'0PS7VGPV_AAU>ZQO M*]C]$$-Q"\20C:&[6)!YN54URVX;+N%S(KZBDL[)-MS?YHV6>VK"[:$#]/&- M\WLQ)_]\>/,E!@'6$,>[9870/9*6F8W9IH%X>BH2%\AU\J6GU%VV_U!\#. Z M5J<^H^C+40Y@$9'EJ(S6WW )#NLEP88ZLXL1Q>#G"C+W_M;&BJR/QHS7S!&$ M2$O(4HJ,+!$:7:Z)+.G+QY_]9J:9JPW\D653LV9M7'!UNMP %V*P_<_3_NV? M(-[ 8Q7J'^^[7]UAV?ON(V6WK7GW_,//]*@YKRRN JII=GOWOB7S4>X^!DLV MZ.ZAO2G20>869!+H2U,R6T6$K S$70=61WN<\6?W:^/<,9)I !U3:?0(UQKC M^ [.=T_BW ,(GPUARR*K6"6Y[O 7#M@D7 $;B>F@'X%+64G%'OT%S;7=H25U M*9X5*"V-O 2#29J6!= SQ.-F_ >O)&%1,_,N[:2-2*"QS00$=MP]F\87U,&8YW0(G,'RUHZ)F91%.N:(QT%' M\YL*/V$%O)A-$QVS6@+[EPTP$XV3G$NU@I^JO4";,W:Y(JW6;BF9Y(91N,JJ M/ =8@EZ"8TM ?+8<6K>$6:1J^=QG253J'U;]I+$D3;0^Z\.B)H!8J_%V$M_( M*O808H?AQ(*+VD-/H@],(_5-GC:[,B&%R(%X!B14.^4NJ0@)0T6 -%0C7,6P M?1DQ!K,_=]*:S03T8=,O,D;&%XUJ]7%EO@\A8$1#>*,/S'BOA3Z)0*_3^NB3 M,=$G\[*X'6=G_:M:5VN,#A-],M9/3O3)Q9.%[#M^P40?$!;XWDYI6?LP 7$* M>$)S\%Y[(B)@CB#IE'!('J(M5V,=44A8O*>,=DBWA"EZ#:( 63"3"9I@P\QA MCIG=88T D#TA YK!3EQ+C7GG G:1G,>9A 3:'A"F)?[A<;A<;8.;1A"Y1>/ MX,79@_%.>7G#*H@EPFM.V+Y?;%]9\. 2'VY5TRL7J*)YK67'1J3L<8DM:B^N M]D/M--MY:U:S0NL0Q4]P&Z-<6*]%D #*KRZ#P73IU$QQ.;FMH3CM D 1P%.1 M9_X&Q^H,#\8R8 G#9$Q%_9\D3:$VJM5EC143X"*ER]K,BY5U8S6K_M:$_[VY M5!!&S#^+Q6*ZU- +@R6,(,6_9(W *E:/=T:\X]!%UT%*1L9?234N.4ES !4> M7:N*E5.L;MJ2L? %6@#XQVYW$ 75(W'>UL5J" EYLL(Y##G$!1)4R75CV =O M.NMM(H5@$6R5)F!J+NSS93_89H;GR39H\\(QR9R$BB)\2MK= NV=YS7R.A8K MQT,1+6-^"9?8B5"ERVJ:(J#'C#P@>W]O>G8D^@"9_61DPJ-[)G:Q>BCCP1W M725[>!%;(9\)XI94(6\/HH1TZ=?O?KN:NLT+'I00U5@TN"-%E1 . MWWP<\ZWR8:9;N5!EV?0[4H/A*W82?,0ZOJ:>6@BNM>VM#+/:>;M"6IX?E&1- M62I%DXZ"F\6:'4+,4J(:*XH\5YT;Z$0?5(VL(]\PW8H^AG0],V6H*SYV'C.M M^[QH,FKCE?0TJQCSA@?R3!ARMW]P[-K%A3?K<%=(%E+99*[D'W>;&> +NP> MD)#T[V%H&WAAG+E!QE_=2_PGKPP$%8S)\ '8]6YVRLJM2^WGXVED.E,*=Y$>IT=&*&[6 5O&OD:%%F@$J>J> MF-^QJKK-%J3R1JU'71<[?,^6;MN9VVOES7VQ]I+RX"$":VX])IQ4WOFW^EL^ M)Q66N(UKZ^MS'-OF0[70#,+$#1OA;V'WZ]!1>==M_!,F93E:&GBX:\W!'E]( M8PW?LJ9\:ED3:\N:W*EES7'88CO5PP4)J9RFED9J<-QMI]&OP*)@)*%*U3?P MXPIX5"E:0)CB3"N=Q'DA5Q+\HD/(%.B?:),'V$_HH##X,!."(@X3L! MOY/. &1]54?+LRI>63.:O2C\"+V-3@[%S^'<*;0+B2=2P\SPP8D_/!:TYM9= M0S;QF9=2=Y9S+QR3T&D>"77O&*W;:K 7V]Q'MV*Z4.\GC]JH7_\4LJ80-[Y, M3K+2E1/PYG#ZI%/B%<(Z8@(F/Q;3@6VNH96ACK%$A8$29GJ_U="5X)/1=)3D MT$T1!^=)X&\$_P;\^4*2;VE(2+3I*CRZDRF("07&YCDN-NLU:T70,/94)*Z& MLR<0: ?(P*P+ZD"455WA>^BM51&:# +K-K"_Y-3=UUKH97&3ZZ7$4F9Z?Y/[ MMOZ5X;O!HZX 3[\S^A0ZVK*J2]J@E9:D?,J:F!.+4Z?_(YU".-@W43O6M9T, MIY3)ORPNB\4[[=?EX%;O?_M1Z]SH2_(XG2, M]$+TQCM>%/@AYKV/2 .6D.1F:ECC-%]V=WOW:+XNR1B#ATBG3F2SX,\30U8P MYPE!SB0(6= 5!V,CQ0E)6A&IP:!\]R&T!_57O/(A#P4CA*=]'.W&OA5]# M>NLC!0)\#^P$R0I\]WPW!"?L#\G0M+8.0P,QW])KGP9O7+8HWE!^ EZ^P*\ ZE@ M7TEZ'LWF.Y*59)#)&+GSZ[& .X3C4YFI()*$O'-!%F50@-%;;VL6;>*'#.+$ MQ#,"QP))G("R7L(?>$FP_H1,2D4#XO=A%!U%0#!C+GE6U,8#"*=U95$'U$4O MO[ZN_?C)7.N.O!D_:FM+KE;G]D^<13_D+$OW>5LSG'W] MAUQOHCS??^2MW/X;G].NLAC6.JR/"8&TS4S&^LFH]%EQ#I="&M9'O61?I-/% MP,GRF.4;J6UX^C2V&J4$1A2,,KCQ%&>XW8DK%C1:JRB0%:O.<)[L",LLU:ODM2K M+F1>7%I44V^5]/OSZ]033VVPHK5&*Y$U#)#\O;RA M4=-L?.YU+A?>ADUO6L+;;";0+C;X(N*TNH('.PVH2P(7Q]LF/@4C)N"W/;/. MR-TSFM![>9.S1C:=5PI> J?@G=2%/6R^ M)Q NXOC)_H!Z(>LN ?F2(A+5G" MV>G$LJNL.,1$E5G2CA$T5U-7QL*>:-76*+$!JZMF$F<"*91CA)]8-2>,3U , M1]TY)[N#>E/""H$/IE-9ZD%#/X$'[;VO M3%,C=3B:6,E1]%B8:D)-@EKQ9D\AF#Y+98D?#?^TY$<+F_NV[#W+!T^)$R3+ MR,'>5J!WI/-/=6VIO-00A0ID#>"F=@+X8ZD2R,*DW#..G:/S(=0XPP$-GDOB MEJ5]@8:>J%Z*FU-7;&4D;D/$5,,L; A,D?4&>ARC)T MT\E"N;02N##EZ0Q#%NN+NG5(.W,;"N9 9M),&6:&X#MP"&1;/4;"X-:8]) U M-)$UHY##,/U?=6Y$ZKVH'X&RT"F@D[Z!C(!>2MHK\XST8-()&H",L#< M]] K#3MM85V%^P M@M@85LO+7#;ULG@K30NEVD3O/_2MQGSD>9IZ'XAECJ7] M6D_FSK(I%SY%-CTRJ6#F3$T*XNO!47J31R>0N(2J8-+Q"",85 3J(JVO/U(- MY:C5JY:4<$<)6=IFD+5&QP@$2)X!R))1UR7G3(+_)?H+;+)5%I!;V"U M^)PT00KU)PX=B+B3.3)W%8Q1RRU.&M0'WUUUA=,(H.=]93^?VM6?'\K;2+32 MM:SOT1T$<[P@!PZ\.-+-1%93L^E"T,TD;NLI@@GAK>GS0-6),AX 9EJ M\;199!\9A1-P/GS ! !\7\3K2A(SIE9$"^G\ HXN4)2!$CS,7@0;=A6 X&[O )TK0#5"_[EI-.-P@4 MYHO$C2Q/Z9!@] P$4:0!K#:5*0-"+\8-/8:B/#,[V1NVF!UEC@=C]I&K4$J[ M=*?7&'X'_=J'1/20=[(=!'/F$$WGDR8LS>&@%;@=@7AT?VP(B% M*?'E(*Z,N:)LT 9YBM1F("L/^MEBES0_F/DYTW$O3@;HX.Q-(F.<#S!WG7NT)-+-@ E#'AX8QJYG1('M MXYFD#(FB2V=+3R;<3PJ$PP=5F+.88P?D63L,8D[FR5 D(EJPB2SAYF*0IU'/ +I!",WW64".\ -582L8>X-1P&!DEK5$;$#HZLY^L(+(VB:\^> =5LV=&5^\@72,B71. MA,-"9P0^39PASE%=F@XM0Y@LO1E:-6+A-BF&MC[BY9'"3LP8P[F0L$\.J,PD?Q5INJ/1R32#)/ M&WIH*W5DHB@"_H)W9Y;'VY_/TL]1]OW>&A-_;9X$,B+-!;Y%-9,X;^HC'8RPI'\1\CH::76+:4/],%D4K M)\G,7Q"[HHU_D0_/F2[X.2B/-5 -;%&1,,"!")%OE>J^9#0P9BH&-N*44^@D MP4(W(PMJ!C,T>9"'Q,5HBYV,4T6 Z05'2K*;U.Z54Z?:O5AK]_*GVKV3)"7Q MK&'",/9ANJ;,"4.($9-!0=@^,)L4$QV.^%9]3'"'83(GHO9L@I[1<<6_:FA] MAO5MTZL23KW*; , -K9D<$6R/ZK)T<@I(NHQ[GBI^K6\M-GCCV G?0@(/+YJ M70)>3UP:Z!%(D1LB)B*;NBGN"\L:F9_009%5A9,:>- M3S7_EA)E2XN[E^3! M0)\B_,<*46V,#L6K9@,)MRK79YN7E?KC///*VY)=C"4,+8(L$IB3X/W>:*WT M2OFP_0>6XG.2S*QH-1#?S>GFD1,..%F*)8N+B*>D*^G*3HK5E;?H64U;KGW. M'W)7O?=?[,ZN<$4Y;2ERY#M=* ?%5^/W\J-M)J!UM<]\=J3M&OXI0PD/H-+@ MQB_V (TS---"+Q44,Y1NM$QQW_3UZ''6GEW7BF/197<)Y@++35MRF[YV-/OY M^NOR?OC:?PUZ;6#T/NC%D3 L=(N2)13;[4;+Z0UX6>@V*LRV>!QQZUKW;&-N M=GH(H[8T5]./)>6P*0L9WJ"HD$W8S,PP+9B+-K2_0 O!!7:DGK5(9XBOV%LN M5C]NZ\/1KXO99][$^3;2#?&6_H;&N_^8.[/;RRLSC8*V$DU:EB.GB:8#LXR( M9V(5QW/>&.Y([ F7$#>6#7MCG.#-J*3'[//EAZC\'*3W?&FKF,(:F9@J4CS_ M]]O94DIF.;#=!!9$JC4KSQV 7(9!DM%=2D/"T&=(MQ%54_2!IMO:GGCYS52C MKY1-&%QZ,T2+7M!R_*.#9N[28(=UQ)1\Y@'\)79(D; M"AM=#Q>*>\6QDTMJ6'I%GLQ*]_?X==K.W_2?[RM67T17Q#]V%WBY&"8WR.$0 MG_$X:S=3(EN"V"B %'399&((]RE8]%OA,A'=N$3.5OG1 M$ 9$KLRHK^5Z!]\'EB$0TA 1,DA$:3A/6.YSL@")T=&T#@[2V4C&'1EM@WWA MY'$%8>D,[9NZIY.>RCLK684_%IY/198VUR&ND(3IVL8^$1PD.-/D,S):!CM& M?+S_),>/#(Q X(1D$#,9EZ3Y46<+WE'Z7VBBP+1EC6?2F:_$$.-.A"N7EY$= M#%+$H'K@SO7)@"N7'93M^8V7Q3Q=_*64M&KN.ATA]6U_S#^D6116LA\N'I5^)8WB2):N5E<7__5!C.V\,^ M9_6=X2,CM&PWQ6)&ML"^PN";$I=S?[\LB%VJ7%*)F!#!M MY\=H97-["#AP)__[C8X,!%3(E1LO7LI,&6DJ,U631S=Y=YS0-Q*YYKZ7 X!0 M49;);1D<>P-T^L7+.!4*%\-G??Q:_MPUH+/;!C1$6A.1"._+4%IAEW?Z#+IT M8\D?LY-KCLAAO\Q%9TY<\FA@MQO&=R 4X0V%H)M>D\J"F-YFF_S[?X@[2-95 M9):K_VQT;;XW9 IH1RVRTX$"!N/+5,I*V9<)>UU;* 5D,?8_'SNU]ZS\N_D: MX<#>]XQ46H3R(T76)0[46EGYSBBC_M^95"Z9R9:2F7S^GTUP@6K%^<)?7ME9 M;F\5N/ZBXHCYKLQ?WN@2=;VTY];_9^-]IDNNA7&5Q'IQ0<"32-&:?"KTV.ZL MV6HZN^3\3^;R7H.[-X6,)\0W8R$G] @?%\JG,K$@1Z'@-<)FZ\CAR6OMO?^Z M8UG1((+FSVO;[U>+[N/P]F-:W"JO?1P+&A^7L"6@P*<[PXGGFW/5F&@E?FI> MFS*6+STBX\S%0!M>4S7C@$0C9Q#A9X3/OB*B M2\M_^W%F>@BW VE/MM.TL9T'5A' +>G/=2XZXW&E,KS3U?S1:'ANH/B8*\;A M8]'T0IM\:YEY<6+U=MX8BM$MH5E$/A=ZCG20#N#5_"W&6]\&FSDAU\;(M4J] M+,6 6MG,?E%KI99IL7FA9W!ZS>#TRNQ"+@B=]_P@BO-BC_KE,JPRY[@?2$^& MRH\S1N*UK?!X^IIU"1%_C>%D'2'M9K2X9-)M[7VA*'%#]IY.Q6/_E[);)$,, MS%WP^!-RK8-<*]A[.A[74C$5IVLI$FH9/)Y6;WKTWK*E_51R+XM.]?WZJI!M M=FZB*/"'DTEU-*DZEK,C80D=JTN,:F2^T98$M.)^P$X%#1I6D-HH=^<9LW<< M;FP!OURQD@X]F(QJ IJ0WN?1D26K*SO-5X8<=(^"_W/&PPBRBN!UC5;X)!UE M^!K[25.?C3F0Z%,&\ATU7K(F%7ZA/+[PI>SI4RE[K*7LA5,I^U%EJ.;3SHXD MW<&8YW21[PR[^G0JTG)L^SR9EM5KB(ZJZJL+6>TP74DD1T.6]QHG[#^H_*H3CE3\=_&KF-A2QE.(/:_ M?E0VSB7_M(CV=F'G&;3(^J8AWL&>.L-[E:] 1RJ8'D0"&8N[7'[*WE1?A=KX ML.,7!L\'6)!OF+I6(14J*='>$UOB_Z#\1'?.9H0$-!<"^*KNEP; MC3-KI#VFI;M,V,[U]:*9*[PL/O6'G_?U067T-CH^+6897+45$SL$7CTX/-Q M$FTH?=P8LH9R$D?^4CJ9*17_Q#3@ []Q;X4C[*"^X!LOE>+,AXS +_U[,)JP M:KU=;_:-)40[#/7V\@VVO\4;QL=53MFD4\K50-#S/SL21 ME(0H.!W6(C# MEYU+(NU]W^AU\EP>A&E^\EP>%>QV0S5;Z"1P2EXX@$V>8+?*+#$RDP.#BQ<* MC!:Q$AA*8G,P>=*[[Y]?RX^%IS#3?(6#0[E=N'YQ(OQJ5%C#.HBC$#Z?3&?B M##8?#9[^J^IN6C\&" ^JK,S^<&1Q1:$[]\!Q+%T^^'97S9:H;C/N)ATLES>;O,CGPSDTUV' MX'O9:$$2O]% 2<1)=W'7?EFM!N]KR@J/OM7X'(QAI+TQ18&44T*$,0="43P9*K_D,E4IS!3_+J)#P*NP83#SE8+C"R=(I='AE)! M;'X=G/)F]M&B'C[,/K]-Y[0/=@6Q?__>ROY%#=+M5:'^^[$[;'_E2&5L]0RG MP-%.2B&R<22[QUT*<8I.'BV2>0N#.)Q<<5=4;!JCM*1!*H(T&+5;;X]=_5$3 MHWA%0HUR.CSAX"Y^PSAX)@_/=!BHN9%7^43+NQ(8<20KGP3&"*#M(]H&-).S1D?;.D#^+=#)T/^<4EY. M=/;EZ6SW.2KNS+(_ 5.<+>[* 3:IP:0JA$?=&2P*?P@C;-)@IG+:\\O :H>6 M_7WULW_Y5)*F_6^,)FBP7S>8DTPH_F>JD%Z-*MV6ATT)A $LWSE= =;ITA8S M[DGJZY[XVX_\>6JI_?)V)[K\6?A8B D?:<^X3^5C>C&<3IK=P2[P,;L>/N8V MQ\?<>7['^'@46I>'CL4)Z@"]06,0A/F31G7B2X>A484IBW\ M,C"JY 7NA9N^Z+>ZPK\LV.O21?52$6XO^"^53/*'JFUK>--68TMX+VXN;-BO MU6Z:'K:SC,W%!MCX[4IE4?FEE=*Y7XMZ@SV:<1R[F+*2SX28LE)CU7%3E&<5B>MH M8UZ).&FEM&K22M3WO"RFC;*4;I1N&I=1NAT>P+25 3HZ,T1GQ^.P9#C]:>;* M!M3BFKE2>5EPWF4J[SG1ZEXV[8YJ\ M4MYD\DHHK7);0?]=303)X>$KJ70J_6(;PW+/?Y?S- SO:?//*LP#8E#LM(^8VD!]OV3E@MFI4 M]\Q&/^N/O8?KT57VF&H]2:P@[ KTV&B,D-%GKC;TVY0RO,'3BORPZAOH3V, M#I]B'#UG,\E<(?K_ M%LILK!X3C-S76$$B9H;9;PCLD).!<0B;/,$NT,"PIRZY:F4[%+%;9@^>IJSX M3<:@5L?OAU_WCZW9Y>7'%\\,30*MBSI\$Z?P"Q(+JL;A98SN%L^3 M[+*+7*9"REWY=,TCG.-]T.N&U70%_3=6NEZZF-UQ85*/;BJ]^[M6 MK]7H,N@WG%#$7+('?X-V-U;MDV"O.]?7MPNU67I99&]R MVMOCJ%\?1V';^S%G*$46O4,G"%'R?XR'.Q/)PQT5A\+76A3B&*.)U--4G-,7 MHGBZ+2(L12!"X*>]F>Q#>^WIK(D&:Y!/ M')'%8F9WL^EC$UL85&.%YWUHII1]YW]-V:LR%R7QZ%"R>="]%T_DLS9.K$% M<31K^O4A?ZV7?K9CLPIG8AF73Q8@V;B<"EF M]STOJQZ59H0//YG3JUU/+F]3]XOL=F=K;5WFE$_DLRY*A">?8AS==-/E[185 M;\7*J0PU7EE!0\+G3_U.2/V2I .W=3P]-+TQK_ L'',''K"MNK0.;+32NF3I M0+4U:#,>=T0FE]KO_*78)-Z+T#/)5+.1Z<^'P>]\>_'R\9C8-XKO$Y M0(]6<%'0B] V*)L37A:-S$?K9_JNF,F4#EONKJ9B+# !)M\983+5-9R/B,0! MK\8X .L/D\H^T^E"D:\?!JY!RW%X:=+)?'Z; R@B#*ZK^)Q&*6'Q3C0+I,Q8?$')=':;(R6C2]GJ:@*M MZ8IB]"XD=)IB7PMJ82)DU?07$J4#^B1^7U:N'>12A>3@YW$>3[=L;\XF:/$'+S8V\ MS@'B;JP@,>R4533L<6%F8V$PQOG-*A 2>@RW7,3]&-5S!BUB?L"P(X7GR=?@ M"Q3[Q3F#2(9E)I 9=J;)9_@'Q#%5087>C@G\+.)0 J)AM+J[;\$YTY05W+0$ M1GM SJFKDQ4#U)3$3QCG4=#'P@=ZSMR;@ NSH=<).YTJ\B>B(XU'6_N?H$D] M7?IM4M4-$H0C4WC323'N%G?2:ZG/E><%Y2F[19BMJ(XI M%9:'R""HS9! 47DI&&22S/C!RXUVP]48G#T_4C[BP01Q)0NI">1__/?_G)TQ M38$7N>_,+3M"LKC+O^N\-$ KE#/_,@^LJ,-BS-D9520XX2.L%DZ.;'Y>P'GM M:Z7^KT[H3Z<@?WBYNL'*[W=KA9H\]9*/-NF[G#SN>-VW'\TS.]P,B/W+].93 MM(.*@I2,P;],&Y$#@6I;!OAEBO9O_/;MK,\C MG$5K3_&-43"C-L9_<9)??90G\S8N534%]>C%;VM\9I;[""\[+HU/E>NSEL-QJ< MJ>FU>0W!">]J9<'T^IL/4I\M+DMW_.+:L)/=EL,ZT5)+=GBV%*13X[[V2[>6 MCN'6W*IVM%O3+E-OVL?=I'^=W^>M+2GPX6XMK"-E^=8R^5B;'0Q(VTYBQX*VENBS(@NJ'*?SGAP!AA^$ MMVPK] UWY@O0U=HC&=/4-&6;.!L-A5[51D5ZJO^\+ U-%++>:!W%.,4JG K: M=9"3+1S*A#6>4Z;KS8/DUZ?X6J1KV82RBQS;R/Y^U]Y3Q?U4[^077\\F_=P M;@KH^@:R,H4*=U"\AL( _BKA5:]X1>71W<-#&C^!AQ2DU\FZ"HY(X/GP"9C$ M:,?,AZ *FJRHH-LA#,;3V8;L +O]R1H0#]*GAB\3(4>"6/GPOBH[&B>1T?XF MJ!HZ+J ;:_.Y$@FSM ?TQ;K>9P4B(>XKC:0A!KS51_#,.A11!L@QP7].>4GE MUQ1C8<1+T\;'C(2]IJS< >ORU"576I[5N?T3)U,SCVRAUN[%U]=,X MB2 AM@$/(6HWB)DV=7<((<1;-!J,01JGQ8C.$1M1<*EWRO%&E.(OK=S7TTF<*%QV3MU!%HA)R$2P M?>'__=]2)EW\5TWT^3$K#J&%FRR)L(YA2:O,3-#&S #1P@*)VK$PA9?\9-7Q M1%!(VS=H^4:2(LRWX&-AH2R R3A"8#AG*J)HD8(QEP4[YK4DU+&L0+8$ M+A\D?B#R.-:^)XA@SQEJ5=-^RV=.XO52 YRVJ*%SJ(R*< &Z\Z$;G1:..>&036)Y#U2GT\/R0BV:[,759[TC M/B[*)J$Y08+,U!?"3U2^FR0J3LB;5A]W/CC@*_^+@K#'?5X=.%RND(EL2 ML>[-*[.BD([N-_=3IKT9B]TQVY<1L:XT:Q.&8DNL9(-[H-V8LV2UF6P3@L!W M.!^['!OA+")/B1V1>4KH$5&>\\3&7D$%)=\LU@;1[;WSC6Z$6>^BT+F0?Z9- M=,3?,DT"M!;)N/+>]GHYC70OD9*2"NG(.FLAF0_06,T3GAQL>]A\BQJO"ZCK"\EN!HF.T5"-(W.\TN&-O>6?Y]74K6G0BVW'IFX-AH8 MD: KO"QOP$4]V:C4D\][ZV,)5[O4V% "7; H#+!OG.H0'K:%>LZX4<U5@X1'LC5"7^[( MBK='3(HJ=S]//?>W6CH0_GK#3I-:MND*Q2";+O;; M329 M@5TSBGU*HS HYJ_P^$FCK>&87"T]EV:I?&N\IL832AJMC61A!YEX2*/,L4JC MK=WM=;N@\Y=R11V+VY%&:U]O9*=%.N=]O0T,9(5QI^M(K4@UVA7 MDP=O+575>8Z<\19!0.:Z8Q;A)OE[4U806#[ "_LR%4B%6B95H!XC]%,V%2Y1 MK(G/@K=XJ_)!''(3#SRRM M!#4MG6%%46#Z$:SHW%;-O*6*<4EF@F%ZK+&9].W3V'++$M @ 0RPP=XOE4)G M93G96K#V](9ESE(%$GS!/R'(T^!+&-@:'#0(:G0Y7Y@X>6TFK!.VU6[:N"TY M,6*X@1$=1B60]@D1! :3'4>K S8BD-PAA$(@ATPI=L1C7.:F+_JMKO#>2!T? M+L9/'M&1^N*NVJI=MQ<":XLF&KN&?+/!&\-1D($7E,)K98 [!,R/ J?#^I,Q M3M/ ^5G&AMZ 4-]^E,Z+7MV@,&K_Q9#],E6FID]TD:3;W/$4 M',BZR"'Y_>98W>A_2 8"D1B?*2OQOB$G2!] 6Z^A+I(-J@))>L0RSWI#'R<7 MT!BL&2V=*HB=&EQ$LW3=[MMOEGR&Y,1%=\IC)%.@7Y" M=[%?[A?65>LCT0/+_&T2W8]]@9O$06"8BDQ28"4[L0:I !$)PQ8*3:7#5D < M'V'HE^G,Z+(__[@Z#+W6GK:(?K*2BO9$!6']D)M0 <+T*U8R$#U',GBHF#+% M$)9 6!8-2-8@,DJ)9&$GLJ+AW^0/7DG@'"8"8LK.2/8!?0PG*6+II, 0/BR> M5*KL@8#GD53$CZ!=;9H1G' E!,.YL)QU*O1^+( [X1+(!&78QI(74!F=DL"%12.<"M"^8)-2S&<+5A4J_ 'ND$O\YT6 MT,'KL+R'%$Z!R'=6P[J*3<-@ACRO)D _F@D(!GVQ[!OR1YB6\PD+1IOH&X]M!B=B*_8><)1W\J;T^A M95+T^0&0)F*X*K;ZW FNV&(QES>D$WE%WOAV33ZKC05^:.5:)SHX25,YN:;W ML'D3'1+&?94-E, "W+)'+9F0\6IJYO)B1W5>@U'.,A-BY%(/=E5F%0Y7IIL^ M:\AG)K(3O?"#5XG%*Q*= 2^)>\"92BB#59=W9)1I5#T-3G:$+].\0M7>62V3 MSA@" 7XZ)(' =CZX-M^XKF:MK$M\#D/M6JF).T[MS];3&>NG[;'U[#KM89U\ M/;BQA95[^C?"5QV7?LC+#4J6$K&]T*%LZ@?E0],/4DI^)F6UB])K>9OH4#:E M?'FK4CZ[3N]1EY@/B0Z6Z.KR4XUP('NQH84M6/=5SR2>YW 1 _2*]!5\_U!+ MRN'DP]*9U1)4&\8-2$ 'H 4*4U%73;T=NS$M3=MD:28_,UDU8I&NER+/+5!SY)3.8K#. M[E&\O*D_PE6@?*1ZWD9],+.G/IBQ]L$LG?I@GLPO>V80XKDI:-=B-7LQ:QA) M()05WV[J3$U$W M:$:$5;RNFAXU\:CC9DEC!P+8\3@5:WUD#SFQSPK(GW 4$/.CN"V(EM1'6@_SP2H"IG1CR)5A M_1F[?V@U3/\@VG5B*$A(]1 0QU;X*7B?(<*F(V! Y1LX$:#,UN;Y,YRCS@0H MFVGJV]?,A"MT2$3Z#-)A-/ V3H :N83="6W%V7&1NLWN'9O:7/B$6M(1NL=^ M\NHMNQPZ"I=LZ=0P>O@D%H(8ZH7T_EGD'CK#CX>,J5Z0UZ/#?U(_T2IMPK7? M];0'[YVY]('(F=N!K4U Z:7%TX#\Y+)QNR0;!+8DT6/N [NG?KZ%K$<_7Z0_ MZ)^J\4??X3>[TPZ_ MW=ED-'R;5K,W+'3X[?;N[FN]^[M6^X*I=;J]];K\'CIU'(T>T)$2'61.X

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end XML 123 form10-ka_htm.xml IDEA: XBRL DOCUMENT 0001582982 2024-01-01 2024-12-31 0001582982 CCLD:CommonStockParValue0.001PerShareMember 2024-01-01 2024-12-31 0001582982 CCLD:Sec8.75SeriesCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember 2024-01-01 2024-12-31 0001582982 CCLD:Sec8.75SeriesBCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember 2024-01-01 2024-12-31 0001582982 2024-06-30 0001582982 2025-03-11 0001582982 2023-01-01 2023-12-31 0001582982 2024-10-01 2024-12-31 0001582982 2024-12-31 0001582982 2023-12-31 0001582982 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001582982 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2024-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001582982 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001582982 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001582982 us-gaap:CommonStockMember 2023-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001582982 us-gaap:RetainedEarningsMember 2023-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001582982 us-gaap:TreasuryStockCommonMember 2023-12-31 0001582982 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001582982 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001582982 us-gaap:CommonStockMember 2022-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001582982 us-gaap:RetainedEarningsMember 2022-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001582982 us-gaap:TreasuryStockCommonMember 2022-12-31 0001582982 2022-12-31 0001582982 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001582982 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001582982 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-12-31 0001582982 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001582982 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001582982 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001582982 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001582982 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001582982 us-gaap:CommonStockMember 2024-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001582982 us-gaap:RetainedEarningsMember 2024-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001582982 us-gaap:TreasuryStockCommonMember 2024-12-31 0001582982 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-12-31 0001582982 CCLD:MTBCPrivateLimitedMember 2004-12-31 0001582982 CCLD:MTBCPrivateLimitedMember CCLD:FounderAndExecutiveChairmanMember 2004-12-31 0001582982 CCLD:MTBCBaghPvtLtdMember 2022-04-01 0001582982 CCLD:MTBCBaghPvtLtdMember CCLD:FounderAndExecutiveChairmanMember 2022-04-01 0001582982 srt:MinimumMember 2024-12-31 0001582982 srt:MaximumMember 2024-12-31 0001582982 srt:MinimumMember us-gaap:ComputerEquipmentMember 2024-12-31 0001582982 srt:MinimumMember CCLD:RevenueCycleManagementMember 2024-12-31 0001582982 srt:MaximumMember CCLD:RevenueCycleManagementMember 2024-12-31 0001582982 srt:MinimumMember CCLD:GroupPurchasingOrganizationAndMedicalPracticeManagementMember 2024-12-31 0001582982 srt:MaximumMember CCLD:GroupPurchasingOrganizationAndMedicalPracticeManagementMember 2024-12-31 0001582982 2023-08-31 2023-08-31 0001582982 CCLD:HealthcareITMember 2023-10-31 2023-10-31 0001582982 CCLD:HealthcareITMember 2023-12-12 2023-12-12 0001582982 2023-01-01 0001582982 CCLD:MedicalPracticeManagementSegmentMember 2024-12-31 0001582982 CCLD:MedicalPracticeManagementSegmentMember 2023-12-31 0001582982 us-gaap:CustomerRelationshipsMember 2023-12-31 0001582982 CCLD:CapitalizedSoftwareMember 2023-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0001582982 us-gaap:CustomerRelationshipsMember 2024-01-01 2024-12-31 0001582982 CCLD:CapitalizedSoftwareMember 2024-01-01 2024-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2024-01-01 2024-12-31 0001582982 us-gaap:CustomerRelationshipsMember 2024-12-31 0001582982 CCLD:CapitalizedSoftwareMember 2024-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2024-12-31 0001582982 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2024-12-31 0001582982 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2024-12-31 0001582982 us-gaap:CustomerRelationshipsMember 2022-12-31 0001582982 CCLD:CapitalizedSoftwareMember 2022-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0001582982 us-gaap:CustomerRelationshipsMember 2023-01-01 2023-12-31 0001582982 CCLD:CapitalizedSoftwareMember 2023-01-01 2023-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2023-01-01 2023-12-31 0001582982 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2023-12-31 0001582982 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2023-12-31 0001582982 us-gaap:ComputerEquipmentMember 2024-12-31 0001582982 us-gaap:ComputerEquipmentMember 2023-12-31 0001582982 CCLD:OfficeFurnitureAndEquipmentMember 2024-12-31 0001582982 CCLD:OfficeFurnitureAndEquipmentMember 2023-12-31 0001582982 us-gaap:TransportationEquipmentMember 2024-12-31 0001582982 us-gaap:TransportationEquipmentMember 2023-12-31 0001582982 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001582982 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001582982 CCLD:AssetsNotPlacedInServiceMember 2024-12-31 0001582982 CCLD:AssetsNotPlacedInServiceMember 2023-12-31 0001582982 CCLD:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001582982 CCLD:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001582982 CCLD:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001582982 CCLD:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001582982 CCLD:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001582982 CCLD:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001582982 us-gaap:NonUsMember 2024-12-31 0001582982 us-gaap:NonUsMember 2023-12-31 0001582982 us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001582982 CCLD:SVBCreditFacilityMember 2017-10-01 2017-10-31 0001582982 srt:MinimumMember CCLD:SVBCreditFacilityMember 2018-09-30 0001582982 srt:MaximumMember CCLD:SVBCreditFacilityMember 2018-09-30 0001582982 CCLD:SVBCreditFacilityMember 2018-07-01 2018-09-30 0001582982 CCLD:SVBCreditFacilityMember 2021-09-30 0001582982 CCLD:SVBCreditFacilityMember 2021-07-01 2021-09-30 0001582982 CCLD:SVBCreditFacilityMember 2023-02-28 0001582982 CCLD:SVBCreditFacilityMember 2023-02-28 2023-02-28 0001582982 CCLD:SVBCreditFacilityMember 2023-08-30 0001582982 CCLD:SVBCreditFacilityMember 2023-08-31 0001582982 CCLD:SVBCreditFacilityMember 2023-08-30 2023-08-31 0001582982 CCLD:SVBCreditFacilityMember 2024-03-31 0001582982 CCLD:SVBCreditFacilityMember 2024-04-01 0001582982 CCLD:SVBCreditFacilityMember 2024-01-01 2024-12-31 0001582982 CCLD:SVBCreditFacilityMember 2024-12-31 0001582982 CCLD:SVBDebtAgreementMember 2017-10-01 2017-10-31 0001582982 CCLD:SVBDebtAgreementMember 2017-10-31 0001582982 srt:MinimumMember CCLD:SVBCreditFacilityMember 2017-10-31 0001582982 CCLD:AdditionalWarrantMember CCLD:SVBDebtAgreementMember 2017-10-31 0001582982 CCLD:SVBDebtAgreementMember 2024-01-01 2024-12-31 0001582982 CCLD:SVBCreditFacilityMember CCLD:NinthLoanModificationAgreementMember 2024-09-30 0001582982 CCLD:SVBCreditFacilityMember CCLD:NinthLoanModificationAgreementMember 2024-10-30 0001582982 srt:MinimumMember CCLD:VehicleFinancingNotesMember 2024-01-01 2024-12-31 0001582982 srt:MaximumMember CCLD:VehicleFinancingNotesMember 2024-01-01 2024-12-31 0001582982 CCLD:InsuranceFinancingMember 2024-12-31 0001582982 CCLD:VehicleFinancingNotesMember 2024-12-31 0001582982 CCLD:TechnologyEnabledBusinessSolutionsMember CCLD:HealthcareITMember 2024-01-01 2024-12-31 0001582982 CCLD:TechnologyEnabledBusinessSolutionsMember CCLD:HealthcareITMember 2023-01-01 2023-12-31 0001582982 CCLD:ProfessionalServicesMember CCLD:HealthcareITMember 2024-01-01 2024-12-31 0001582982 CCLD:ProfessionalServicesMember CCLD:HealthcareITMember 2023-01-01 2023-12-31 0001582982 CCLD:PrintingAndMailingServicesMember CCLD:HealthcareITMember 2024-01-01 2024-12-31 0001582982 CCLD:PrintingAndMailingServicesMember CCLD:HealthcareITMember 2023-01-01 2023-12-31 0001582982 CCLD:GroupPurchasingServicesMember CCLD:HealthcareITMember 2024-01-01 2024-12-31 0001582982 CCLD:GroupPurchasingServicesMember CCLD:HealthcareITMember 2023-01-01 2023-12-31 0001582982 CCLD:MedicalPracticeManagementMember 2024-01-01 2024-12-31 0001582982 CCLD:MedicalPracticeManagementMember 2023-01-01 2023-12-31 0001582982 CCLD:ChronicCareManagementMember 2024-01-01 2024-12-31 0001582982 CCLD:ChronicCareManagementMember 2023-01-01 2023-12-31 0001582982 CCLD:RemotePatientMonitoringMember 2024-01-01 2024-12-31 0001582982 CCLD:RemotePatientMonitoringMember 2023-01-01 2023-12-31 0001582982 CCLD:ProfessionalServicesMember us-gaap:UnbilledRevenuesMember 2024-01-01 2024-12-31 0001582982 CCLD:ProfessionalServicesMember us-gaap:UnbilledRevenuesMember 2023-01-01 2023-12-31 0001582982 CCLD:RevenueCycleManagementMember 2024-12-31 0001582982 CCLD:GroupPurchasingServicesMember 2024-12-31 0001582982 CCLD:ReferralFeesMember 2024-12-31 0001582982 us-gaap:OtherNoncurrentAssetsMember 2024-12-31 0001582982 us-gaap:OtherNoncurrentAssetsMember 2023-12-31 0001582982 us-gaap:TradeAccountsReceivableMember us-gaap:AccountingStandardsUpdate201613Member 2023-01-01 0001582982 us-gaap:SeriesAPreferredStockMember CCLD:CertificateOfAmendmentMember 2024-09-11 2024-09-11 0001582982 us-gaap:SeriesAPreferredStockMember 2024-09-11 2024-09-11 0001582982 us-gaap:SeriesAPreferredStockMember 2024-09-11 0001582982 CCLD:TreasuryStockOneMember 2024-01-01 2024-12-31 0001582982 CCLD:AtTheMarketFacilityMember 2024-12-31 0001582982 CCLD:AtTheMarketFacilityMember 2024-01-01 2024-12-31 0001582982 CCLD:AtTheMarketFacilityMember 2023-01-01 2023-12-31 0001582982 us-gaap:PreferredStockMember 2024-12-31 0001582982 srt:MaximumMember us-gaap:SeriesBPreferredStockMember CCLD:AtTheMarketFacilityMember 2024-01-01 2024-12-31 0001582982 us-gaap:SeriesBPreferredStockMember CCLD:AtTheMarketFacilityMember 2024-01-01 2024-12-31 0001582982 us-gaap:SeriesBPreferredStockMember CCLD:AtTheMarketFacilityMember 2023-01-01 2023-12-31 0001582982 us-gaap:SeriesAPreferredStockMember 2020-11-04 0001582982 us-gaap:SeriesBPreferredStockMember 2024-02-15 0001582982 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2025-02-15 0001582982 srt:ScenarioForecastMember us-gaap:SeriesBPreferredStockMember 2026-02-15 0001582982 srt:ScenarioForecastMember us-gaap:SeriesBPreferredStockMember 2027-02-15 0001582982 CCLD:SeriesAAndSeriesBPreferredStockMember 2024-01-01 2024-12-31 0001582982 CCLD:SeriesAAndSeriesBPreferredStockMember 2024-09-11 2024-09-11 0001582982 CCLD:SeriesAAndSeriesBPreferredStockMember 2023-01-01 2023-12-31 0001582982 2024-09-11 2024-09-11 0001582982 2024-09-12 2024-09-12 0001582982 us-gaap:WarrantMember 2023-12-31 0001582982 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001582982 us-gaap:WarrantMember 2024-12-31 0001582982 CCLD:RamapoAnesthesiologistsPCMember 2023-12-22 2023-12-22 0001582982 CCLD:AccruedExpensesMember CCLD:RamapoAnesthesiologistsPCMember 2023-12-22 0001582982 2021-03-01 2021-03-31 0001582982 2024-04-30 0001582982 2024-09-01 2024-09-30 0001582982 CCLD:PhysicianMember 2024-01-01 2024-12-31 0001582982 CCLD:PhysicianMember 2023-01-01 2023-12-31 0001582982 CCLD:PhysicianMember 2024-12-31 0001582982 CCLD:PhysicianMember 2023-12-31 0001582982 CCLD:ExecutiveChairmanMember 2024-01-01 2024-12-31 0001582982 CCLD:ExecutiveChairmanMember 2023-01-01 2023-12-31 0001582982 us-gaap:RelatedPartyMember 2024-12-31 0001582982 us-gaap:RelatedPartyMember 2023-12-31 0001582982 CCLD:FormerNonIndependentDirectorsMember us-gaap:SeriesBPreferredStockMember CCLD:ConsultingAgreementMember 2022-06-01 2022-06-30 0001582982 CCLD:FormerNonIndependentDirectorsMember us-gaap:SeriesBPreferredStockMember CCLD:ConsultingAgreementMember 2023-02-01 2023-02-28 0001582982 CCLD:FormerNonIndependentDirectorsMember us-gaap:SeriesBPreferredStockMember CCLD:ConsultingAgreementMember 2024-01-01 2024-01-31 0001582982 CCLD:FormerNonIndependentDirectorsMember CCLD:ConsultingAgreementMember 2024-02-01 2024-02-01 0001582982 CCLD:FormerNonIndependentDirectorsMember CCLD:ConsultingAgreementMember 2024-02-12 2024-02-12 0001582982 CCLD:FormerNonIndependentDirectorsMember CCLD:ConsultingAgreementMember 2024-09-01 2024-09-01 0001582982 CCLD:FormerNonIndependentDirectorsMember CCLD:ConsultingAgreementMember 2024-01-01 2024-12-31 0001582982 CCLD:TalkMDCliniciansMember 2024-01-01 2024-12-31 0001582982 us-gaap:SubsequentEventMember 2025-01-01 2025-12-31 0001582982 CCLD:SeveranceAndSeparationCostsMember 2023-12-31 0001582982 CCLD:EquityAwardsAccelerationCostsAssociatedWithSeveranceMember 2023-12-31 0001582982 CCLD:OtherExitRelatedCostsMember 2023-12-31 0001582982 CCLD:SeveranceAndSeparationCostsMember 2024-01-01 2024-12-31 0001582982 CCLD:EquityAwardsAccelerationCostsAssociatedWithSeveranceMember 2024-01-01 2024-12-31 0001582982 CCLD:OtherExitRelatedCostsMember 2024-01-01 2024-12-31 0001582982 CCLD:SeveranceAndSeparationCostsMember 2024-12-31 0001582982 CCLD:EquityAwardsAccelerationCostsAssociatedWithSeveranceMember 2024-12-31 0001582982 CCLD:OtherExitRelatedCostsMember 2024-12-31 0001582982 CCLD:SeveranceAndSeparationCostsMember 2022-12-31 0001582982 CCLD:EquityAwardsAccelerationCostsAssociatedWithSeveranceMember 2022-12-31 0001582982 CCLD:OtherExitRelatedCostsMember 2022-12-31 0001582982 CCLD:SeveranceAndSeparationCostsMember 2023-01-01 2023-12-31 0001582982 CCLD:EquityAwardsAccelerationCostsAssociatedWithSeveranceMember 2023-01-01 2023-12-31 0001582982 CCLD:OtherExitRelatedCostsMember 2023-01-01 2023-12-31 0001582982 CCLD:DefinedContributionRetirementPlanForUSEmployeesMember 2024-01-01 2024-12-31 0001582982 CCLD:DefinedContributionRetirementPlanForUSEmployeesMember 2023-01-01 2023-12-31 0001582982 CCLD:DefinedContributionRetirementPlanForPakistanEmployeesMember 2024-01-01 2024-12-31 0001582982 CCLD:DefinedContributionRetirementPlanForPakistanEmployeesMember 2023-01-01 2023-12-31 0001582982 CCLD:DefinedContributionRetirementPlanForSriLankaEmployeesMember 2024-01-01 2024-12-31 0001582982 CCLD:DefinedContributionRetirementPlanForSriLankaEmployeesMember 2023-01-01 2023-12-31 0001582982 CCLD:EmployeesOfficersDirectorsAndConsultantsMember CCLD:TwoThousandFourteenEquityIncentivePlanMember 2014-04-30 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:CommonStockMember 2017-04-14 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesAPreferredStockMember 2017-04-14 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesAPreferredStockMember 2018-12-31 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:CommonStockMember 2020-05-31 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesAPreferredStockMember 2020-05-31 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:CommonStockMember 2022-12-31 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember CCLD:FiveOutsidesMembersofTheBoardMember CCLD:AmendedAndRestatedEquityIncentivePlanMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember CCLD:FiveOutsidesMembersofTheBoardMember CCLD:AmendedAndRestatedEquityIncentivePlanMember 2023-01-01 2023-12-31 0001582982 CCLD:EmployeeMember 2022-01-01 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember 2023-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2023-02-01 2023-02-28 0001582982 us-gaap:SeriesBPreferredStockMember 2023-10-01 2023-10-31 0001582982 us-gaap:SeriesBPreferredStockMember 2024-03-01 2024-03-31 0001582982 us-gaap:SeriesBPreferredStockMember 2024-05-01 2024-05-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001582982 CCLD:DirectOperatingCostsMember 2024-01-01 2024-12-31 0001582982 CCLD:DirectOperatingCostsMember 2023-01-01 2023-12-31 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001582982 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-12-31 0001582982 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-12-31 0001582982 CCLD:NetLossOnLeaseTerminationsUnoccupiedLeaseChargesAndRestructuringCostsMember 2024-01-01 2024-12-31 0001582982 CCLD:NetLossOnLeaseTerminationsUnoccupiedLeaseChargesAndRestructuringCostsMember 2023-01-01 2023-12-31 0001582982 country:PK 2024-01-01 2024-12-31 0001582982 country:PK 2023-01-01 2023-12-31 0001582982 CCLD:FederalMember 2024-12-31 0001582982 CCLD:FederalMember CCLD:BetweenTwoThousandThirtyOneAndTwoThousandThirtyEightMember 2024-12-31 0001582982 CCLD:FederalMember CCLD:IndefiniteLifeMember 2024-12-31 0001582982 CCLD:CareCloudAndMeridianAcquisitionsMember CCLD:FederalMember 2024-12-31 0001582982 CCLD:StateMember 2024-12-31 0001582982 stpr:NJ 2024-12-31 0001582982 us-gaap:OperatingSegmentsMember CCLD:HealthcareITMember 2024-01-01 2024-12-31 0001582982 us-gaap:OperatingSegmentsMember CCLD:MedicalPracticeManagementMember 2024-01-01 2024-12-31 0001582982 us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 0001582982 us-gaap:OperatingSegmentsMember CCLD:HealthcareITMember 2023-01-01 2023-12-31 0001582982 us-gaap:OperatingSegmentsMember CCLD:MedicalPracticeManagementMember 2023-01-01 2023-12-31 0001582982 us-gaap:OperatingSegmentsMember 2023-01-01 2023-12-31 0001582982 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-12-31 0001582982 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001582982 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001582982 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001582982 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0001582982 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001582982 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001582982 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001582982 us-gaap:SubsequentEventMember 2025-01-30 0001582982 us-gaap:SubsequentEventMember 2025-01-31 0001582982 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2025-03-01 2025-03-31 0001582982 CCLD:IndividualShareholdersMember us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2025-03-31 iso4217:USD shares iso4217:USD shares pure CCLD:Segment true FY 0001582982 http://fasb.org/us-gaap/2024#RestructuringCostsAndAssetImpairmentCharges http://fasb.org/us-gaap/2024#RestructuringCostsAndAssetImpairmentCharges 10-K/A true 2024-12-31 --12-31 2024 false 001-36529 CareCloud, Inc. DE 22-3832302 7 Clyde Road Somerset NJ 08873 (732) 873-5133 Common Stock, par value $0.001 per share CCLD NASDAQ 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share CCLDP NASDAQ 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share CCLDO NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 19100000 42316513 0.001 Portions of the Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025 are incorporated by reference into Part III, Items 10, 11, 12, 13, and 14 of this Annual Report on Form 10-K. This Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) amends the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Annual Report”) of CareCloud, Inc. filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2025 (the “Original Filing Date”). In this Amendment No. 1, unless the context indicates otherwise, the designations “CareCloud,” the “Company,” “we,” “us” or “our” refer to CareCloud, Inc. and its subsidiaries. This Amendment No. 1 is being filed solely to correct a typographical error in the Report of Independent Registered Public Accounting Firm (the “Audit Opinion”) of Rosenberg Rich Baker Berman, P.A. (“RRBB”) contained in the 2024 Annual Report, by replacing “March 13, 2024” with “March 13, 2025” under the signature in the Audit Opinion. In addition, this Amendment No. 1 includes a new consent of RRBB as Exhibit 23.1 hereto, a new consent of Grant Thornton LLP as Exhibit 23.2 hereto and new certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 as Exhibits 31.1, 31.2, 31.3, 32.1, 32.2 and 32.3 hereto.   Pursuant to Rule 12b-15 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we have repeated the entire text of Item 8 of the 2024 Annual Report in this Amendment No. 1. However, there have been no changes to the Company’s financial statements and notes thereto or the text of such item (other than the change stated in the immediately preceding paragraph to replace “March 13, 2024” with “March 13, 2025” under the signature in the Audit Opinion).   Except as described above, no other amendments are being made to the 2024 Annual Report. This Amendment No. 1 does not reflect events occurring after Original Filing Date or modify or update any disclosure contained in the 2024 Annual Report in any way other than to reflect the amendments discussed above and reflected below. Accordingly, this Amendment No. 1 should be read in conjunction with the 2024 Annual Report and our other filings with the SEC.   <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity Risk Management and Strategy</b></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include internal and external threats, data loss, phishing attacks, distributed denial of service attacks, third party risks, unpatched systems, weak authentications and zero-day vulnerabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_gIFCRMPITB-VBVODB_zHhuO3MLmBUf">Identifying and assessing cybersecurity risk is <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_gIFCRMPITB-VBVODB_zzFz1ZaspXNe">integrated</span> into our overall risk management systems and processes. Cybersecurity risks related to our business, technical operations, privacy and compliance issues are identified and addressed through a multi-faceted approach including third party assessments, internal IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity incidents, the Company conducts proactive cybersecurity reviews of systems and applications, audits applicable data policies, performs penetration testing using external third-party tools and techniques to test security controls, conducts employee training, monitors emerging laws and regulations related to data protection and information security and implements appropriate changes.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0F_gIFCRMPITB-VBVODB_z2cc0lgOqsd5"> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0E_gIFCRMPITB-VBVODB_zKNWUCfEOrwj">We have implemented incident response and breach management processes which have four overarching and interconnected stages: 1) preparation for a cybersecurity incident, 2) detection and analysis of a security incident, 3) containment, eradication and recovery, and 4) post-incident analysis. Such incident responses are overseen by leaders from our Information Security, Compliance and Legal teams regarding matters of cybersecurity.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security events and data incidents are evaluated, ranked by severity and prioritized for response and remediation. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240101__20241231_zAPeAHMyie33">Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact. As of the date of this Form 10-K, we have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zr3fxVPVeGwb">not</span> experienced a cybersecurity threat or incident that resulted in a material adverse impact to our business or operations.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">38</td></tr></table></div> <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"> </td></tr></table></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also conduct exercises to simulate responses to cybersecurity incidents. Our team of cybersecurity professionals then collaborate with technical and business stakeholders across our business units to further analyze the risk to the Company, and form detection, mitigation and remediation strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the above processes, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zxCvn5PSjjl3">we regularly engage consultants to assess our internal cybersecurity programs and compliance with applicable practices and standards.</span> For 2024 and 2023, our Information Security Management System is compliant with ISO 27001. We also had SOC 2, Type 2 reviews performed for the years 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_z7PqLRgmQkC7">Our risk management program also assesses third party risks, and we perform third-party risk management to identify and mitigate risks from third parties such as vendors, suppliers, and other business partners associated with our use of third-party service providers.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading “Disruptions in internet or telecommunication service or damage to our data centers could adversely affect our business by reducing our customers’ confidence in the reliability of our services and products” included as part of our risk factor disclosures in Item 1A of this Annual Report on Form 10-K.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Vice President of IT Infrastructure is responsible for overseeing the Company’s cybersecurity. He has a Bachelor’s degree in computer science and has 16 years of extensive experience spanning diverse IT domains, with a specialized emphasis on Information Security across endpoints, servers, data centers, cloud infrastructure, and enterprise applications. He has been actively overseeing the strategic implementation of cybersecurity in accordance with information security management standards, HIPAA, and SOC 2 policies and procedures throughout the entire organization. This multifaceted responsibility involves managing and ensuring compliance with internationally recognized standards such as the ISO 27001 framework, healthcare regulatory guidelines under HIPAA and other recognized standards.</span></p> <span style="font-family: Times New Roman, Times, Serif"> </span> Identifying and assessing cybersecurity risk is <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_gIFCRMPITB-VBVODB_zzFz1ZaspXNe">integrated</span> into our overall risk management systems and processes. Cybersecurity risks related to our business, technical operations, privacy and compliance issues are identified and addressed through a multi-faceted approach including third party assessments, internal IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity incidents, the Company conducts proactive cybersecurity reviews of systems and applications, audits applicable data policies, performs penetration testing using external third-party tools and techniques to test security controls, conducts employee training, monitors emerging laws and regulations related to data protection and information security and implements appropriate changes. We have implemented incident response and breach management processes which have four overarching and interconnected stages: 1) preparation for a cybersecurity incident, 2) detection and analysis of a security incident, 3) containment, eradication and recovery, and 4) post-incident analysis. Such incident responses are overseen by leaders from our Information Security, Compliance and Legal teams regarding matters of cybersecurity. true Incidents are evaluated to determine materiality as well as operational and business impact, and reviewed for privacy impact. As of the date of this Form 10-K, we have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zr3fxVPVeGwb">not</span> experienced a cybersecurity threat or incident that resulted in a material adverse impact to our business or operations. false true true <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity Governance</b></span> <div style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity is an important part of our risk management processes and an area of focus for our Board of Directors and management. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zSSbF5ThA9D8">Our Cybersecurity subcommittee of the Board of Directors is responsible for the oversight of risks from cybersecurity threats.</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zfd8jbyqt4d4">Members of the Cybersecurity subcommittee receive updates on a quarterly basis from senior management, including leaders from our Information Security, Finance, Internal Audit, Compliance and Legal teams regarding cybersecurity matters. This includes existing and new cybersecurity risks, status on how management is addressing and/or mitigating those risks, cybersecurity and data privacy incidents, (if any), and the status on key information security initiatives.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240101__20241231_zmQlcPPctkfh"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_z9Fre5UtmvA3">cybersecurity risk management and strategy processes are overseen by our Vice President of IT Infrastructure and leaders from our Information Technology department.</span></span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zFN6Hny5Z1di">These individuals are informed about, and monitor the prevention, mitigation, detection and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan, and report to the Cybersecurity subcommittee on any appropriate items.</span></span></p> </div> Our Cybersecurity subcommittee of the Board of Directors is responsible for the oversight of risks from cybersecurity threats. Members of the Cybersecurity subcommittee receive updates on a quarterly basis from senior management, including leaders from our Information Security, Finance, Internal Audit, Compliance and Legal teams regarding cybersecurity matters. This includes existing and new cybersecurity risks, status on how management is addressing and/or mitigating those risks, cybersecurity and data privacy incidents, (if any), and the status on key information security initiatives. true cybersecurity risk management and strategy processes are overseen by our Vice President of IT Infrastructure and leaders from our Information Technology department. These individuals are informed about, and monitor the prevention, mitigation, detection and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan, and report to the Cybersecurity subcommittee on any appropriate items. false false false false false false 89 248 Rosenberg Rich Baker Berman, P.A. Somerset, New Jersey GRANT THORNTON LLP Iselin, New Jersey 5145000 3331000 12774000 11888000 4334000 5094000 574000 465000 16000 16000 1957000 2449000 24800000 23243000 5290000 5317000 3133000 4365000 18698000 25074000 19186000 19186000 507000 641000 71614000 77826000 4565000 5798000 1817000 3444000 4951000 5065000 1287000 1888000 1212000 1380000 310000 292000 5438000 5433000 19580000 23300000 26000 37000 10000000 1847000 2516000 387000 256000 21840000 36109000 0.001 0.001 7000000 7000000 4526231 4526231 4526231 4526231 1511372 1511372 1468792 1468792 6000 6000 0.001 0.001 35000000 35000000 16997035 16620891 16256236 15880092 17000 17000 121046000 120706000 -66630000 -74481000 -4003000 -3869000 740799 740799 662000 662000 49774000 41717000 71614000 77826000 110837000 117059000 60842000 70817000 6232000 9650000 16123000 21464000 3781000 4736000 14142000 14402000 42000000 596000 1105000 101716000 164174000 9121000 -47115000 88000 154000 900000 1194000 -298000 -883000 8011000 -49038000 160000 -364000 7851000 -48674000 12310000 15674000 -4459000 -64348000 -0.28 -0.28 -4.11 -4.11 16146975 16146975 15669472 15669472 7851000 -48674000 -134000 -832000 7717000 -49506000 4526231 5000 1468792 1000 16620891 17000 120706000 -74481000 -3869000 -662000 41717000 7851000 7851000 -134000 -134000 42580 376144 345000 345000 5000 5000 4526231 5000 1511372 1000 16997035 17000 121046000 -66630000 -4003000 -662000 49774000 4526231 5000 1344128 1000 15970204 16000 130987000 -25621000 -3037000 -662000 101689000 4526231 5000 1344128 1000 15970204 16000 130987000 -25621000 -3037000 -662000 101689000 -186000 -186000 4526231 5000 1344128 1000 15970204 16000 130987000 -25807000 -3037000 -662000 101503000 -48674000 -48674000 -48674000 -48674000 -832000 -832000 64891 610687 1000 1000 59773 1427000 1427000 40000 3966000 3966000 15674000 15674000 4526231 5000 1468792 1000 16620891 17000 120706000 -74481000 -3869000 -662000 41717000 4526231 5000 1468792 1000 16620891 17000 120706000 -74481000 -3869000 -662000 41717000 71000 2.75 2.19 0 0 7851000 -48674000 14469000 14889000 1994000 2152000 -37000 -92000 334000 454000 -525000 130000 -790000 592000 688000 42000000 115000 4886000 1220000 -2246000 -760000 695000 109000 84000 -673000 -682000 -4650000 -3256000 20642000 15461000 1697000 3063000 5709000 8550000 -7406000 -11613000 14300000 579000 1524000 677000 888000 1427000 14700000 10000000 12700000 -11256000 -13285000 -166000 469000 1814000 -8968000 3331000 12299000 5145000 3331000 5000 5433000 685000 656000 296000 157000 144000 677000 927000 <p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zo2ECw0o0XH6" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82D_zqytVvzO9zb5">ORGANIZATION AND BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CareCloud, Inc., (together with its consolidated subsidiaries, “CareCloud,” the “Company,” “we,” “us” and/or “our”) is a healthcare information technology company that provides a full suite of proprietary cloud-based solutions, related business services, to healthcare providers and hospitals throughout the United States. The Company’s integrated services are designed to help customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. Our Software-as-a-Service (“SaaS”) platform includes revenue cycle management (“RCM”), practice management (“PM”), electronic health records (“EHR”), business intelligence, telehealth, patient experience management (“PXM”) solutions and complementary software tools and business services for high-performance medical groups and health systems. CareCloud has its corporate offices in Somerset, New Jersey and maintains client support teams throughout the U.S., and offshore offices in Pakistan and Azad Jammu and Kashmir, a region administered by Pakistan (the “Pakistan Offices”), and in Sri Lanka.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif; text-transform: none">CareCloud was founded in 1999 under the name Medical Transcription Billing, Corp. and incorporated under the laws of the State of Delaware in 2001. In 2004, the Company formed MTBC Private Limited (“MTBC Pvt. Ltd.”), a <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20041231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MTBCPrivateLimitedMember_zqeOqOemYLM9" title="Equity method investment ownership, percentage">99.9</span>% majority-owned subsidiary of CareCloud based in Pakistan. The remaining <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20041231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MTBCPrivateLimitedMember__srt--TitleOfIndividualAxis__custom--FounderAndExecutiveChairmanMember_zyQwLQ6YKv8g" title="Equity method investment ownership, percentage">0.1</span>% of the shares of MTBC Pvt. Ltd. is equally owned by the founder and Executive Chairman of CareCloud and a local employee who is also a director of this entity. In 2016, the Company formed MTBC Acquisition Corp. (“MAC”), a Delaware corporation, in connection with its acquisition of substantially all of the assets of MediGain, LLC and its subsidiary, Millennium Practice Management Associates, LLC (together “MediGain”). MAC had a wholly owned subsidiary in Sri Lanka, RCM MediGain Colombo, Pvt. Ltd. Effective February 1, 2024, MAC and its wholly owned subsidiary were merged into CareCloud, Inc. In May 2018, the Company formed CareCloud Practice Management, Corp. (“CPM”), a Delaware corporation, to operate the medical practice management business acquired from Orion Healthcorp.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif; text-transform: none">In January 2020, the Company purchased CareCloud Corporation, a company whose name we took. That company is now known as CareCloud Health, Inc. (“CCH”). In June 2020, the Company purchased Meridian Billing Management Co. and its affiliate Origin Holdings, Inc. (collectively “Meridian” and sometimes referred to as “Meridian Medical Management”). Both companies were subsequently merged and the surviving company was renamed Meridian Medical Management, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif; text-transform: none">During March 2021, the Company formed a new wholly-owned subsidiary, CareCloud Acquisition, Corp. (“CAC”). In June 2021, CAC purchased certain assets and assumed certain liabilities of MedMatica Consulting Associates Inc., (“MedMatica”) and purchased the stock of Santa Rosa Staffing, Inc. (“SRS”). The assets and liabilities of MedMatica were merged into SRS and the company was renamed medSR, Inc. (“medSR”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif; text-transform: none">Effective April 1, 2022, the Company formed MTBC Bagh Private Limited (“MTBC Bagh Pvt. Ltd.”), a <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220401__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MTBCBaghPvtLtdMember_zjFOPrNqFn3j" title="Equity method investment ownership, percentage">99.8</span>% majority-owned subsidiary of CareCloud based in Azad Jammu and Kashmir, a region administered by Pakistan. The remaining <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220401__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MTBCBaghPvtLtdMember__srt--TitleOfIndividualAxis__custom--FounderAndExecutiveChairmanMember_zyAnMoQkM4Df" title="Equity method investment ownership, percentage">0.2</span>% of the shares of MTBC Bagh Pvt. Ltd. is equally owned by the founder and Executive Chairman of CareCloud and the same director/employee as noted above. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the second quarter of 2023, the Company formed a wholly owned subsidiary, CareCloud ME Health Consultancy LLC, in the United Arab Emirates, which has not yet begun operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.999 0.001 0.998 0.002 <p id="xdx_800_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zEYgaDuFcbud" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zkRnN35mx9t9">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_z0G86VioaAhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zyW7pwtzn0v5">Principles of Consolidation</span></b> — The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the operating results and financial condition of CareCloud, its wholly-owned subsidiary CPM, its majority-owned subsidiary MTBC Pvt. Ltd, majority-owned subsidiary MTBC Bagh Pvt. Ltd, CCH (since January 2020), Meridian Medical Management (since June 2020), medSR (since June 2021) and the subsidiary in Sri Lanka. The non-controlling interests of MTBC Pvt. Ltd. and MTBC Bagh Pvt. Ltd. are inconsequential to the consolidated financial statements. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z3soNxvfCrra" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zGHHWqKrjfTj">Segment Reporting</span></b> — The Company views its operations as comprising <span id="xdx_902_eus-gaap--NumberOfOperatingSegments_pid_dc_c20240101__20241231_zcjRAKdT4Cwb" title="Number of operating segments">two</span> operating segments, Healthcare IT and Medical Practice Management. The chief operating decision maker (“CODM”) monitors and reviews financial information at these segment levels for assessing operating results and the allocation of resources.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--UseOfEstimates_zehtHaHeLKBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zL8cK0fwTPO6">Use of Estimates</span></b> — The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include, but are not limited to: (1) impairment of goodwill and long-lived assets, (2) depreciable lives of assets, (3) allowance for expected credit losses, (4) estimates of variable consideration related to the contract asset, (5) fair value of identifiable purchased tangible and intangible assets, including determination of expected customer life, (6) stock-based compensation, and (7) estimating lease terms and incremental borrowing rates. Actual results could significantly differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zvxiLKdeeNob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zzBQ6EjsN1Cg">Revenue Recognition </span></b>— We derive revenue from five primary sources: (1) technology-enabled business solutions including revenue cycle management, (2) professional services, (3) printing and mailing services, (4) group purchasing services and (5) medical practice management services. All of our revenue arrangements are based on contracts with customers. Most of our contracts with customers contain single performance obligations, although certain contracts do contain multiple performance obligations where we perform more than one service for the same customer. We account for individual performance obligations separately if they are distinct within the context of the contract. For contracts where we provide multiple services such as where we perform multiple ancillary services, each service represents its own performance obligation. Selling or transaction prices are based on the contractual prices for each service at its stand-alone selling price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A five-step approach is applied in the recognition of revenue under ASC 606: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when we satisfy a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although we believe that our approach to estimates and judgments is reasonable, actual results could differ, and we may be exposed to increases or decreases in revenue that could be material. Our estimates of variable consideration may prove to be inaccurate, in which case we may have understated or overstated the revenue recognized in a reporting period. The amount of variable consideration recognized to date that remains subject to estimation is included within the contract asset within the consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of invoices is due as specified in the underlying customer agreement, typically 30 days from the invoice date, which occurs on the date of transfer of control of the services to the customer. Since payment terms are less than a year, we have elected the practical expedient and do not assess whether a customer contract has a significant financing component.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenue arrangements generally do not include a general right of refund for services provided (See Note 8, Revenue, for additional information).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--DirectOperatingCostsPolicyTextBlock_zJzq2ixadhE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zzKWdhVxKxX5">Direct Operating Costs</span></b> — Direct operating costs consist primarily of salaries and benefits related to personnel who provide services to clients and at our managed medical practices, claims processing costs, medical supplies at our managed practices and other direct costs related to the Company’s services. Costs associated with the implementation of new clients are expensed as incurred. The reported amounts of direct operating costs include allocated amounts for rent expense and overhead costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zD93lPBgbkxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zo6ccs7a6H2l">Selling and Marketing Expenses</span></b> — Selling and marketing expenses consist primarily of compensation and benefits, travel and advertising expenses and are expensed as incurred. The Company incurred approximately $<span id="xdx_90C_eus-gaap--AdvertisingExpense_pn5n6_c20240101__20241231_zmLQcProTJJ8" title="Selling and marketing expenses">2.9</span> million and $<span id="xdx_900_eus-gaap--AdvertisingExpense_pn5n6_c20230101__20231231_zOIQjtVs5Yud" title="Advertising costs">4.0</span> million of advertising costs for the years ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zwTntgA2zpl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zka8SKxPJI73">Research and Development Expenses</span></b> — Research and development expenses consist primarily of personnel-related costs incurred performing market research, analyzing proposed products and developing new products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84F_eus-gaap--InternalUseSoftwarePolicy_zgqkC8DNu2c4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zRr2TbcGzAE9">Internal-Use Software Costs</span></b> — The Company capitalizes certain development costs incurred in connection with its internal-use software. Costs incurred in the preliminary stages of development are expensed as incurred. Once an application has reached the development stage, internal and external costs, if direct, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable that the expenditures will result in additional functionality. Capitalized costs are recorded as part of intangible assets in the accompanying consolidated balance sheets. Maintenance and training costs are expensed as incurred. Internal use software is amortized on a straight line basis over its estimated useful life, generally three years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. During the years ended December 31, 2024 and 2023, the Company capitalized approximately $<span id="xdx_900_eus-gaap--CapitalizedComputerSoftwareAdditions_pn5n6_c20240101__20241231_zriHxbnZd1lb" title="Internal-use software costs capitalized">5.7</span> million and $<span id="xdx_908_eus-gaap--CapitalizedComputerSoftwareAdditions_pn5n6_c20230101__20231231_zwk1kd87SiV6" title="Internal-use software costs capitalized">8.6</span> million, respectively, primarily consisting of salaries and payroll-related costs of employees and consultants who devoted time to the development of internal-use software projects.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zU9xZ26H4uQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zGnaD6GvUBph">Accounts Receivable</span></b> — Accounts receivable are stated at their net realizable value. Accounts receivable are presented in the consolidated balance sheets net of an allowance for expected credit losses, which is established based on a lifetime estimated credit loss expected to occur for trade accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zRV81OmGXtuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zYyEM8XXD8Zg">Property and Equipment</span></b> — Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line basis over the estimated useful lives of the assets ranging from three <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_zaMEIwR9eCv" style="display: none" title="Property and equipment, estimated useful lives">3</span>to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_zsFh8BVBNGb" title="Property and equipment, estimated useful lives">five years</span>. Ordinary maintenance and repairs are expensed as incurred. Depreciation for computers is calculated over <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_z2FtfIAbuJQ4" title="Property and equipment, estimated useful lives">three years</span>, while the remaining assets (except leasehold improvements) are depreciated over <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_zwR5LdWbbKHf" title="Property and equipment, estimated useful lives">five years</span>. The Company amortizes leasehold improvements over the lesser of the lease term or the remaining economic life of those assets. Generally, the lease term is the base lease term plus certain renewal option periods for which renewal is reasonably certain and for which failure to exercise the renewal option would result in an economic penalty to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zW4J2TVgNqW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zdbcc1u6E1E5">Intangible Assets</span></b> — Intangible assets include customer relationships, covenants not-to-compete acquired in connection with acquisitions, software purchase and development costs and trademarks acquired. Amortization for intangible assets related to revenue cycle management is recorded primarily using the double declining balance method over three<span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--RevenueCycleManagementMember__srt--RangeAxis__srt--MinimumMember_z3VMWGpY0DI7" style="display: none" title="Intangible assets, estimated useful lives">3</span> to <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--RevenueCycleManagementMember__srt--RangeAxis__srt--MaximumMember_zV3WDTiDHvwb" title="Intangible assets, estimated useful lives">four years</span>. Amortization for intangible assets related to the group purchasing organization and medical practice management is recorded on a straight line basis over four<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--GroupPurchasingOrganizationAndMedicalPracticeManagementMember__srt--RangeAxis__srt--MinimumMember_zA3DSbvNHFif" style="display: none" title="Intangible assets, estimated useful lives">4</span> and <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--GroupPurchasingOrganizationAndMedicalPracticeManagementMember__srt--RangeAxis__srt--MaximumMember_z0BRj4AVuuCf" title="Intangible assets, estimated useful lives">twelve years</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zotAlXnt8sOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_864_zfW9d4BCCFP7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation of Long-Lived Assets </b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">— The Company reviews its long-lived assets for impairment whenever changes in circumstances indicate that the carrying value of an asset may not be recoverable. If the sum of undiscounted expected future cash flows is less than the carrying amount of the asset group, the Company will recognize an impairment loss based on the fair value of the asset. There was <span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20240101__20241231_zbeb74vE3GV1" title="Impairment charges"><span id="xdx_904_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20230101__20231231_zQKEGRuBqPje" title="Impairment charges">no</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment of internal-use software costs, intangible assets, operating lease right of use assets or property and equipment during the years ended December 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zP5HQwv5PJxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zd2mORVNZkG8">Goodwill </span></b>— Goodwill consists of the excess of the purchase price over the fair value of identifiable net assets of businesses acquired. The Company tests goodwill for impairment annually as of October 31<sup>st</sup>, referred to as the annual test date. The goodwill impairment test for the Healthcare IT segment is performed using the discounted cash flow approach, the trading price of publicly traded stock and the guideline public company method. Conditions that could trigger a more frequent impairment assessment include, but are not limited to, a significant adverse change to the Company in certain agreements, significant underperformance relative to historical or projected future operating results, loss of customer relationships, an economic downturn in customers’ industries, or increased competition. Impairment testing for goodwill is performed at the reporting-unit level. The Company has determined that its business consists of <span id="xdx_907_eus-gaap--NumberOfOperatingSegments_pid_dc_c20240101__20241231_ztFk4Jr1Fvrg" title="Number of operating segments">two</span> operating segments and <span id="xdx_90E_eus-gaap--NumberOfReportableSegments_pid_dc_c20240101__20241231_zUP2zDQT2f2" title="Number of reportable units">two</span> reporting units. The Company had a triggering event at August 31, 2023, but it was determined that <span id="xdx_908_eus-gaap--GoodwillImpairmentLoss_do_c20230831__20230831_zUN7lFe6Qvvj" title="Goodwill impairment">no</span> goodwill impairment existed at that time. The Company had an additional triggering event in December 2023. It was determined that the fair value of the Healthcare IT reporting unit was less than the carrying value at October 31 and at December 12, 2023 (triggering event). Accordingly, impairment charges of approximately $<span id="xdx_909_eus-gaap--GoodwillImpairmentLoss_pn5n6_c20231031__20231031__us-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember_zRezJraF3iW9" title="Goodwill impairment charges">2.0</span> million and $<span id="xdx_901_eus-gaap--GoodwillImpairmentLoss_pn5n6_c20231212__20231212__us-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember_zTejzZvGKgoj" title="Goodwill impairment charges">40.0</span> million, respectively, were recorded. (See Note 3). <span id="xdx_908_eus-gaap--GoodwillImpairmentLoss_doxL_c20240101__20241231_zIvUNbV1ELAd" title="Goodwill impairment charges::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0838">No</span></span> impairment charges were recorded during the year ended December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--TreasuryStockPolicyTextBlock_zjMYSe6u3qI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zCt3RgLGt9f3">Treasury Stock</span></b> — Treasury stock is recorded at cost and represents shares repurchased by the Company. <span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodShares_do_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_ze8ps7k6x9u4" title="Shares repurchased"><span id="xdx_900_eus-gaap--StockRepurchasedDuringPeriodShares_do_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zxUFzI15Ubnh" title="Shares repurchased">No</span></span> shares were repurchased or issued from treasury stock during the years ended December 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zAj8Xpyk7DDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zap6adAxHJKe">Stock-Based Compensation </span></b>— The Company recognizes compensation for all share-based payments granted based on the grant date fair value. Compensation expense is generally recognized on a straight-line basis over the vesting period. The Company does not estimate forfeitures in recognizing the expense for share-based payments, as historical forfeiture rates have not been significant. For restricted stock units (“RSUs”) classified as equity, the market price of our common stock on the date of grant is used in recording the fair value of the award. For RSUs classified as a liability, the earned amount is marked to market based on the end-of-period common stock price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84E_eus-gaap--BusinessCombinationsPolicy_z66z8K5Yxkng" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zXYUsoG01sba">Business Combinations</span></b> — The Company accounts for business combinations under the provisions of ASC 805, <i>Business Combinations</i>, which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed are recorded at the date of acquisition at their respective fair values. ASC 805 also specifies criteria that intangible assets acquired in a business combination must be recognized and reported apart from goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date with changes in the fair value recorded through earnings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zFHzKAXqdSTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zYekjV7YmOyl">Income Taxes</span></b> — The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records net deferred tax assets to the extent that these assets will more likely than not be realized. All available positive and negative evidence is considered in making such a determination, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. A valuation allowance would be recorded to reduce deferred income tax assets when it is determined that it is more likely than not that the Company would not be able to realize its deferred income tax assets in the future in excess of their net recorded amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is greater than 50 percent likely to be realized upon ultimate settlement with the related tax authority. At December 31, 2024 and 2023, the Company did not have any uncertain tax positions that required recognition. Interest and penalties related to uncertain tax positions are recognized in income tax expense. For the years ended December 31, 2024 and 2023, the Company did not recognize any penalties or interest related to unrecognized tax benefits in its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--DividendsPolicyTextBlock_zmweuTD9zcll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zOT7vgCQDim3">Dividends </span></b>— Dividends are recorded when declared by the Company’s Board of Directors. The Board of Directors had declared monthly dividends on the Series A and Series B Preferred Stock through February 2024. However, in December 2023, the dividends on the Preferred Stock were suspended. The dividend scheduled for payment on December 15, 2023 together with the remaining dividends that were declared, have been accrued in the consolidated balance sheet. Future monthly dividends will continue to accrue in arrears but will not be recorded as a liability until declared by the Board of Directors. In January 2025, the Board of Director declared two months of suspended dividends. The Company resumed paying monthly dividends in February 2025, paying one month of arrears. In March 2025, the Company converted the majority of the Series A Preferred Stock into the Company’s common stock. The March 2025 dividend payment will include dividends for the Series A Preferred Stock that were not converted and dividends for the Series B Preferred Stock. (See Note 20). Preferred Stock dividends are charged against paid in capital because the Company does not have sufficient retained earnings. The Company is prohibited from paying dividends on its common stock without the prior written consent of its lender, Silicon Valley Bank, a division of First Citizens Bank (“SVB”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--ContractWithCustomerLiabilityPolicyTextBlock_zONjMxUZrHTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zttQb5Gz8lP8">Deferred Revenue</span></b> — Deferred revenue primarily consists of payments received in advance of the revenue recognition criteria being met. Deferred revenue includes certain deferred implementation services fees that are recognized as revenue ratably over the longer of the life of the agreement or the estimated expected customer life, which is currently estimated to be three years. Deferred revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue and the remaining portion is recorded as non-current. At the time of customer termination, any unrecognized service fees associated with implementation services are recognized as revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z8e9tFhgIlrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zXREpTYdBXGf">Fair Value Measurements</span></b> — ASC 820, <i>Fair Value Measurement</i>, requires the disclosure of fair value information about financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. The Company follows a fair value measurement hierarchy to measure financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s financial instruments is measured using inputs from the three levels of the fair value hierarchy as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 71.75pt; text-align: justify; text-indent: -48pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in; vertical-align: top">Level 1</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 0.25in">— </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Inputs are unadjusted quoted market prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Level 2</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">— </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs are directly or indirectly observable, which include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Level 3</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">— </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs are unobservable inputs that are used to measure fair value to the extent observable inputs are not available.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has certain financial instruments that are not measured at fair value on a recurring basis. These financial instruments are subject to fair value adjustments only in certain circumstances and include cash, accounts receivable, accounts payable and accrued expenses, borrowings under term loans and line of credit, and notes payable. Due to the short term nature of these financial instruments and that the borrowings bear interest at prevailing market rates, the carrying value approximates the fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zMkuthRpqbMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_ztDnF3mDTeu5">Foreign Currency Translation</span></b> — The financial statements of the Company’s foreign subsidiaries are translated from their functional currency into U.S. dollars, the Company’s functional currency. All foreign currency assets and liabilities are translated at the period-end exchange rate, and all revenue and expenses are translated at transaction date exchange rates. The effects of translating the financial statements of the foreign subsidiaries into U.S. dollars are reported as a cumulative translation adjustment, a separate component of accumulated other comprehensive loss in the consolidated statements of shareholders’ equity, except for transactions related to the intercompany receivable for which transaction adjustments are recorded in the consolidated statements of operations as they are not deemed to be permanently reinvested. Foreign currency transaction gains/losses are reported as a component of other expense – net in the consolidated statements of operations and amounted to a gain of approximately $<span id="xdx_90D_eus-gaap--ForeignCurrencyTransactionGainLossRealized_iN_pp0p0_c20240101__20241231_ztXztt20RBg3" title="Foreign exchange (gain) losses">130,000</span> and a loss of approximately $<span id="xdx_902_eus-gaap--ForeignCurrencyTransactionGainLossRealized_iN_pp0p0_di_c20230101__20231231_zocN1CfI2uf" title="Foreign exchange (gain) losses">790,000</span> for the years ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_zpq2maemj4j5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z3hzM0eqgiQ3">Lease Terminations, Unoccupied Lease Charges and Restructuring Costs </span>— </b>Lease terminations represents the write-off of leasehold improvements as the result of early lease terminations. Unoccupied lease charges represent the portion of lease and related costs for that portion of the space that is vacated and not being utilized by the Company. Restructuring costs incurred in 2024 and 2023 primarily consist of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements. (See Note 13).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z5LEjcQwemyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zJt9cV07Cs1c">Recent Accounting Pronouncements</span></b> — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently adopted and recently issued accounting pronouncements will not have a material impact on our consolidated financial position, results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments. </i>The guidance in Accounting Standards Update (“ASU”) 2016-13 replaces the incurred loss impairment methodology under current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. It will apply to all entities. For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate lifetime expected credit losses. This may result in the earlier recognition of credit losses. In November 2019, the FASB issued ASU No. 2019-10, which delayed this standard’s effective date for SEC smaller reporting companies to the fiscal years beginning on or after December 15, 2022. The Company adopted this guidance on January 1, 2023 using a modified retrospective adoption methodology, whereby the cumulative impact of all prior periods is recorded in accumulated deficit or other impacted balance sheet items upon adoption. The impact to the accumulated deficit as of January 1, 2023 for the allowance related to accounts receivable was a charge of approximately $<span id="xdx_907_ecustom--AllowanceForDoubtfulAccountsAdoption_iI_c20230101_zJGuveQdS7cj" title="Allowance for expected credit losses">186,000</span> and a corresponding increase to the allowance for expected credit losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the FASB issued ASU 2021-08, <i>Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.</i> The amendments in this update require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. The amendments are effective for public business entities for fiscal years beginning after December 15, 2022. There was no impact on the consolidated financial statements as a result of this standard.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842): Common Control Arrangements- Issue 2. </i>The amendments in this update require that leasehold improvements associated with common control leases be: (1) amortized by the lessee over the useful life of the leasehold improvements to the common control group as long as the lessee controls the use of the underlying asset through a lease and (2) accounted for as a transfer between entities under common control through an adjustment to equity if, and when, the lessee no longer controls the use of the underlying asset. The amendments in this update are effective for the fiscal years beginning after December 15, 2023. There was no impact on the consolidated financial statements as a result of this standard.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, the FASB issued ASU 2023-06, <i>Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative.</i> This update amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification. The new guidance is intended to align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP for all entities. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027 the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280), Improvements to Reportable Disclosures</i>. The amendments in this update improve segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The impact is only to the financial statement disclosures and has been adopted by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740), Improvements to Income Tax Disclosures.</i> The amendments in this update enhance the transparency and decision usefulness of income tax disclosures primarily related to rate reconciliation and income taxes paid information. The update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect this update to have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2024, the FASB issued ASU 2024-02, <i>Codification Improvements- Amendments to Remove References to the Concepts Statements</i>. This update contains amendments to the Codification that remove references to various FASB Concepts Statements. These Codification updates are for technical corrections such as conforming amendments, clarifications to guidance, simplifications to wording or the structure of guidance and other minor improvements. The resulting amendments are referred to as Codification improvements. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company does not expect this update to have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40)</i>. This update contains amendments that require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. The amendments in this update are effective for public business entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The expected impact would only be to the financial statement disclosures.</span></p> <p id="xdx_855_zQ0P1CTVpzd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b> </b></span></p> <p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_z0G86VioaAhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zyW7pwtzn0v5">Principles of Consolidation</span></b> — The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and include the operating results and financial condition of CareCloud, its wholly-owned subsidiary CPM, its majority-owned subsidiary MTBC Pvt. Ltd, majority-owned subsidiary MTBC Bagh Pvt. Ltd, CCH (since January 2020), Meridian Medical Management (since June 2020), medSR (since June 2021) and the subsidiary in Sri Lanka. The non-controlling interests of MTBC Pvt. Ltd. and MTBC Bagh Pvt. Ltd. are inconsequential to the consolidated financial statements. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z3soNxvfCrra" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zGHHWqKrjfTj">Segment Reporting</span></b> — The Company views its operations as comprising <span id="xdx_902_eus-gaap--NumberOfOperatingSegments_pid_dc_c20240101__20241231_zcjRAKdT4Cwb" title="Number of operating segments">two</span> operating segments, Healthcare IT and Medical Practice Management. The chief operating decision maker (“CODM”) monitors and reviews financial information at these segment levels for assessing operating results and the allocation of resources.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2 <p id="xdx_846_eus-gaap--UseOfEstimates_zehtHaHeLKBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zL8cK0fwTPO6">Use of Estimates</span></b> — The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made by management include, but are not limited to: (1) impairment of goodwill and long-lived assets, (2) depreciable lives of assets, (3) allowance for expected credit losses, (4) estimates of variable consideration related to the contract asset, (5) fair value of identifiable purchased tangible and intangible assets, including determination of expected customer life, (6) stock-based compensation, and (7) estimating lease terms and incremental borrowing rates. Actual results could significantly differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zvxiLKdeeNob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zzBQ6EjsN1Cg">Revenue Recognition </span></b>— We derive revenue from five primary sources: (1) technology-enabled business solutions including revenue cycle management, (2) professional services, (3) printing and mailing services, (4) group purchasing services and (5) medical practice management services. All of our revenue arrangements are based on contracts with customers. Most of our contracts with customers contain single performance obligations, although certain contracts do contain multiple performance obligations where we perform more than one service for the same customer. We account for individual performance obligations separately if they are distinct within the context of the contract. For contracts where we provide multiple services such as where we perform multiple ancillary services, each service represents its own performance obligation. Selling or transaction prices are based on the contractual prices for each service at its stand-alone selling price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A five-step approach is applied in the recognition of revenue under ASC 606: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when we satisfy a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although we believe that our approach to estimates and judgments is reasonable, actual results could differ, and we may be exposed to increases or decreases in revenue that could be material. Our estimates of variable consideration may prove to be inaccurate, in which case we may have understated or overstated the revenue recognized in a reporting period. The amount of variable consideration recognized to date that remains subject to estimation is included within the contract asset within the consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of invoices is due as specified in the underlying customer agreement, typically 30 days from the invoice date, which occurs on the date of transfer of control of the services to the customer. Since payment terms are less than a year, we have elected the practical expedient and do not assess whether a customer contract has a significant financing component.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenue arrangements generally do not include a general right of refund for services provided (See Note 8, Revenue, for additional information).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--DirectOperatingCostsPolicyTextBlock_zJzq2ixadhE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zzKWdhVxKxX5">Direct Operating Costs</span></b> — Direct operating costs consist primarily of salaries and benefits related to personnel who provide services to clients and at our managed medical practices, claims processing costs, medical supplies at our managed practices and other direct costs related to the Company’s services. Costs associated with the implementation of new clients are expensed as incurred. The reported amounts of direct operating costs include allocated amounts for rent expense and overhead costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zD93lPBgbkxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zo6ccs7a6H2l">Selling and Marketing Expenses</span></b> — Selling and marketing expenses consist primarily of compensation and benefits, travel and advertising expenses and are expensed as incurred. The Company incurred approximately $<span id="xdx_90C_eus-gaap--AdvertisingExpense_pn5n6_c20240101__20241231_zmLQcProTJJ8" title="Selling and marketing expenses">2.9</span> million and $<span id="xdx_900_eus-gaap--AdvertisingExpense_pn5n6_c20230101__20231231_zOIQjtVs5Yud" title="Advertising costs">4.0</span> million of advertising costs for the years ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2900000 4000000.0 <p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zwTntgA2zpl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zka8SKxPJI73">Research and Development Expenses</span></b> — Research and development expenses consist primarily of personnel-related costs incurred performing market research, analyzing proposed products and developing new products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84F_eus-gaap--InternalUseSoftwarePolicy_zgqkC8DNu2c4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zRr2TbcGzAE9">Internal-Use Software Costs</span></b> — The Company capitalizes certain development costs incurred in connection with its internal-use software. Costs incurred in the preliminary stages of development are expensed as incurred. Once an application has reached the development stage, internal and external costs, if direct, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable that the expenditures will result in additional functionality. Capitalized costs are recorded as part of intangible assets in the accompanying consolidated balance sheets. Maintenance and training costs are expensed as incurred. Internal use software is amortized on a straight line basis over its estimated useful life, generally three years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. During the years ended December 31, 2024 and 2023, the Company capitalized approximately $<span id="xdx_900_eus-gaap--CapitalizedComputerSoftwareAdditions_pn5n6_c20240101__20241231_zriHxbnZd1lb" title="Internal-use software costs capitalized">5.7</span> million and $<span id="xdx_908_eus-gaap--CapitalizedComputerSoftwareAdditions_pn5n6_c20230101__20231231_zwk1kd87SiV6" title="Internal-use software costs capitalized">8.6</span> million, respectively, primarily consisting of salaries and payroll-related costs of employees and consultants who devoted time to the development of internal-use software projects.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5700000 8600000 <p id="xdx_84F_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zU9xZ26H4uQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zGnaD6GvUBph">Accounts Receivable</span></b> — Accounts receivable are stated at their net realizable value. Accounts receivable are presented in the consolidated balance sheets net of an allowance for expected credit losses, which is established based on a lifetime estimated credit loss expected to occur for trade accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zRV81OmGXtuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zYyEM8XXD8Zg">Property and Equipment</span></b> — Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line basis over the estimated useful lives of the assets ranging from three <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember_zaMEIwR9eCv" style="display: none" title="Property and equipment, estimated useful lives">3</span>to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_zsFh8BVBNGb" title="Property and equipment, estimated useful lives">five years</span>. Ordinary maintenance and repairs are expensed as incurred. Depreciation for computers is calculated over <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_z2FtfIAbuJQ4" title="Property and equipment, estimated useful lives">three years</span>, while the remaining assets (except leasehold improvements) are depreciated over <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20241231__srt--RangeAxis__srt--MaximumMember_zwR5LdWbbKHf" title="Property and equipment, estimated useful lives">five years</span>. The Company amortizes leasehold improvements over the lesser of the lease term or the remaining economic life of those assets. Generally, the lease term is the base lease term plus certain renewal option periods for which renewal is reasonably certain and for which failure to exercise the renewal option would result in an economic penalty to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P3Y P5Y P3Y P5Y <p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zW4J2TVgNqW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zdbcc1u6E1E5">Intangible Assets</span></b> — Intangible assets include customer relationships, covenants not-to-compete acquired in connection with acquisitions, software purchase and development costs and trademarks acquired. Amortization for intangible assets related to revenue cycle management is recorded primarily using the double declining balance method over three<span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--RevenueCycleManagementMember__srt--RangeAxis__srt--MinimumMember_z3VMWGpY0DI7" style="display: none" title="Intangible assets, estimated useful lives">3</span> to <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--RevenueCycleManagementMember__srt--RangeAxis__srt--MaximumMember_zV3WDTiDHvwb" title="Intangible assets, estimated useful lives">four years</span>. Amortization for intangible assets related to the group purchasing organization and medical practice management is recorded on a straight line basis over four<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--GroupPurchasingOrganizationAndMedicalPracticeManagementMember__srt--RangeAxis__srt--MinimumMember_zA3DSbvNHFif" style="display: none" title="Intangible assets, estimated useful lives">4</span> and <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dc_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--GroupPurchasingOrganizationAndMedicalPracticeManagementMember__srt--RangeAxis__srt--MaximumMember_z0BRj4AVuuCf" title="Intangible assets, estimated useful lives">twelve years</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P3Y P4Y P4Y P12Y <p id="xdx_848_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zotAlXnt8sOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_864_zfW9d4BCCFP7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation of Long-Lived Assets </b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">— The Company reviews its long-lived assets for impairment whenever changes in circumstances indicate that the carrying value of an asset may not be recoverable. If the sum of undiscounted expected future cash flows is less than the carrying amount of the asset group, the Company will recognize an impairment loss based on the fair value of the asset. There was <span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20240101__20241231_zbeb74vE3GV1" title="Impairment charges"><span id="xdx_904_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20230101__20231231_zQKEGRuBqPje" title="Impairment charges">no</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment of internal-use software costs, intangible assets, operating lease right of use assets or property and equipment during the years ended December 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zP5HQwv5PJxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zd2mORVNZkG8">Goodwill </span></b>— Goodwill consists of the excess of the purchase price over the fair value of identifiable net assets of businesses acquired. The Company tests goodwill for impairment annually as of October 31<sup>st</sup>, referred to as the annual test date. The goodwill impairment test for the Healthcare IT segment is performed using the discounted cash flow approach, the trading price of publicly traded stock and the guideline public company method. Conditions that could trigger a more frequent impairment assessment include, but are not limited to, a significant adverse change to the Company in certain agreements, significant underperformance relative to historical or projected future operating results, loss of customer relationships, an economic downturn in customers’ industries, or increased competition. Impairment testing for goodwill is performed at the reporting-unit level. The Company has determined that its business consists of <span id="xdx_907_eus-gaap--NumberOfOperatingSegments_pid_dc_c20240101__20241231_ztFk4Jr1Fvrg" title="Number of operating segments">two</span> operating segments and <span id="xdx_90E_eus-gaap--NumberOfReportableSegments_pid_dc_c20240101__20241231_zUP2zDQT2f2" title="Number of reportable units">two</span> reporting units. The Company had a triggering event at August 31, 2023, but it was determined that <span id="xdx_908_eus-gaap--GoodwillImpairmentLoss_do_c20230831__20230831_zUN7lFe6Qvvj" title="Goodwill impairment">no</span> goodwill impairment existed at that time. The Company had an additional triggering event in December 2023. It was determined that the fair value of the Healthcare IT reporting unit was less than the carrying value at October 31 and at December 12, 2023 (triggering event). Accordingly, impairment charges of approximately $<span id="xdx_909_eus-gaap--GoodwillImpairmentLoss_pn5n6_c20231031__20231031__us-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember_zRezJraF3iW9" title="Goodwill impairment charges">2.0</span> million and $<span id="xdx_901_eus-gaap--GoodwillImpairmentLoss_pn5n6_c20231212__20231212__us-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember_zTejzZvGKgoj" title="Goodwill impairment charges">40.0</span> million, respectively, were recorded. (See Note 3). <span id="xdx_908_eus-gaap--GoodwillImpairmentLoss_doxL_c20240101__20241231_zIvUNbV1ELAd" title="Goodwill impairment charges::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0838">No</span></span> impairment charges were recorded during the year ended December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2 2 0 2000000.0 40000000.0 <p id="xdx_843_ecustom--TreasuryStockPolicyTextBlock_zjMYSe6u3qI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zCt3RgLGt9f3">Treasury Stock</span></b> — Treasury stock is recorded at cost and represents shares repurchased by the Company. <span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodShares_do_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_ze8ps7k6x9u4" title="Shares repurchased"><span id="xdx_900_eus-gaap--StockRepurchasedDuringPeriodShares_do_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zxUFzI15Ubnh" title="Shares repurchased">No</span></span> shares were repurchased or issued from treasury stock during the years ended December 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zAj8Xpyk7DDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zap6adAxHJKe">Stock-Based Compensation </span></b>— The Company recognizes compensation for all share-based payments granted based on the grant date fair value. Compensation expense is generally recognized on a straight-line basis over the vesting period. The Company does not estimate forfeitures in recognizing the expense for share-based payments, as historical forfeiture rates have not been significant. For restricted stock units (“RSUs”) classified as equity, the market price of our common stock on the date of grant is used in recording the fair value of the award. For RSUs classified as a liability, the earned amount is marked to market based on the end-of-period common stock price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84E_eus-gaap--BusinessCombinationsPolicy_z66z8K5Yxkng" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zXYUsoG01sba">Business Combinations</span></b> — The Company accounts for business combinations under the provisions of ASC 805, <i>Business Combinations</i>, which requires that the acquisition method of accounting be used for all business combinations. Assets acquired and liabilities assumed are recorded at the date of acquisition at their respective fair values. ASC 805 also specifies criteria that intangible assets acquired in a business combination must be recognized and reported apart from goodwill. Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from the business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date with changes in the fair value recorded through earnings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zFHzKAXqdSTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zYekjV7YmOyl">Income Taxes</span></b> — The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records net deferred tax assets to the extent that these assets will more likely than not be realized. All available positive and negative evidence is considered in making such a determination, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. A valuation allowance would be recorded to reduce deferred income tax assets when it is determined that it is more likely than not that the Company would not be able to realize its deferred income tax assets in the future in excess of their net recorded amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records uncertain tax positions on the basis of a two-step process whereby (1) the Company determines whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is greater than 50 percent likely to be realized upon ultimate settlement with the related tax authority. At December 31, 2024 and 2023, the Company did not have any uncertain tax positions that required recognition. Interest and penalties related to uncertain tax positions are recognized in income tax expense. For the years ended December 31, 2024 and 2023, the Company did not recognize any penalties or interest related to unrecognized tax benefits in its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--DividendsPolicyTextBlock_zmweuTD9zcll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zOT7vgCQDim3">Dividends </span></b>— Dividends are recorded when declared by the Company’s Board of Directors. The Board of Directors had declared monthly dividends on the Series A and Series B Preferred Stock through February 2024. However, in December 2023, the dividends on the Preferred Stock were suspended. The dividend scheduled for payment on December 15, 2023 together with the remaining dividends that were declared, have been accrued in the consolidated balance sheet. Future monthly dividends will continue to accrue in arrears but will not be recorded as a liability until declared by the Board of Directors. In January 2025, the Board of Director declared two months of suspended dividends. The Company resumed paying monthly dividends in February 2025, paying one month of arrears. In March 2025, the Company converted the majority of the Series A Preferred Stock into the Company’s common stock. The March 2025 dividend payment will include dividends for the Series A Preferred Stock that were not converted and dividends for the Series B Preferred Stock. (See Note 20). Preferred Stock dividends are charged against paid in capital because the Company does not have sufficient retained earnings. The Company is prohibited from paying dividends on its common stock without the prior written consent of its lender, Silicon Valley Bank, a division of First Citizens Bank (“SVB”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--ContractWithCustomerLiabilityPolicyTextBlock_zONjMxUZrHTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zttQb5Gz8lP8">Deferred Revenue</span></b> — Deferred revenue primarily consists of payments received in advance of the revenue recognition criteria being met. Deferred revenue includes certain deferred implementation services fees that are recognized as revenue ratably over the longer of the life of the agreement or the estimated expected customer life, which is currently estimated to be three years. Deferred revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue and the remaining portion is recorded as non-current. At the time of customer termination, any unrecognized service fees associated with implementation services are recognized as revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z8e9tFhgIlrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zXREpTYdBXGf">Fair Value Measurements</span></b> — ASC 820, <i>Fair Value Measurement</i>, requires the disclosure of fair value information about financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. The Company follows a fair value measurement hierarchy to measure financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s financial instruments is measured using inputs from the three levels of the fair value hierarchy as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 71.75pt; text-align: justify; text-indent: -48pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in; vertical-align: top">Level 1</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 0.25in">— </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Inputs are unadjusted quoted market prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Level 2</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">— </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs are directly or indirectly observable, which include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">Level 3</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">— </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs are unobservable inputs that are used to measure fair value to the extent observable inputs are not available.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has certain financial instruments that are not measured at fair value on a recurring basis. These financial instruments are subject to fair value adjustments only in certain circumstances and include cash, accounts receivable, accounts payable and accrued expenses, borrowings under term loans and line of credit, and notes payable. Due to the short term nature of these financial instruments and that the borrowings bear interest at prevailing market rates, the carrying value approximates the fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zMkuthRpqbMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_ztDnF3mDTeu5">Foreign Currency Translation</span></b> — The financial statements of the Company’s foreign subsidiaries are translated from their functional currency into U.S. dollars, the Company’s functional currency. All foreign currency assets and liabilities are translated at the period-end exchange rate, and all revenue and expenses are translated at transaction date exchange rates. The effects of translating the financial statements of the foreign subsidiaries into U.S. dollars are reported as a cumulative translation adjustment, a separate component of accumulated other comprehensive loss in the consolidated statements of shareholders’ equity, except for transactions related to the intercompany receivable for which transaction adjustments are recorded in the consolidated statements of operations as they are not deemed to be permanently reinvested. Foreign currency transaction gains/losses are reported as a component of other expense – net in the consolidated statements of operations and amounted to a gain of approximately $<span id="xdx_90D_eus-gaap--ForeignCurrencyTransactionGainLossRealized_iN_pp0p0_c20240101__20241231_ztXztt20RBg3" title="Foreign exchange (gain) losses">130,000</span> and a loss of approximately $<span id="xdx_902_eus-gaap--ForeignCurrencyTransactionGainLossRealized_iN_pp0p0_di_c20230101__20231231_zocN1CfI2uf" title="Foreign exchange (gain) losses">790,000</span> for the years ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 130000 -790000 <p id="xdx_843_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_zpq2maemj4j5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z3hzM0eqgiQ3">Lease Terminations, Unoccupied Lease Charges and Restructuring Costs </span>— </b>Lease terminations represents the write-off of leasehold improvements as the result of early lease terminations. Unoccupied lease charges represent the portion of lease and related costs for that portion of the space that is vacated and not being utilized by the Company. Restructuring costs incurred in 2024 and 2023 primarily consist of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements. (See Note 13).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z5LEjcQwemyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zJt9cV07Cs1c">Recent Accounting Pronouncements</span></b> — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently adopted and recently issued accounting pronouncements will not have a material impact on our consolidated financial position, results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments. </i>The guidance in Accounting Standards Update (“ASU”) 2016-13 replaces the incurred loss impairment methodology under current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. It will apply to all entities. For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate lifetime expected credit losses. This may result in the earlier recognition of credit losses. In November 2019, the FASB issued ASU No. 2019-10, which delayed this standard’s effective date for SEC smaller reporting companies to the fiscal years beginning on or after December 15, 2022. The Company adopted this guidance on January 1, 2023 using a modified retrospective adoption methodology, whereby the cumulative impact of all prior periods is recorded in accumulated deficit or other impacted balance sheet items upon adoption. The impact to the accumulated deficit as of January 1, 2023 for the allowance related to accounts receivable was a charge of approximately $<span id="xdx_907_ecustom--AllowanceForDoubtfulAccountsAdoption_iI_c20230101_zJGuveQdS7cj" title="Allowance for expected credit losses">186,000</span> and a corresponding increase to the allowance for expected credit losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the FASB issued ASU 2021-08, <i>Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.</i> The amendments in this update require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. The amendments are effective for public business entities for fiscal years beginning after December 15, 2022. There was no impact on the consolidated financial statements as a result of this standard.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842): Common Control Arrangements- Issue 2. </i>The amendments in this update require that leasehold improvements associated with common control leases be: (1) amortized by the lessee over the useful life of the leasehold improvements to the common control group as long as the lessee controls the use of the underlying asset through a lease and (2) accounted for as a transfer between entities under common control through an adjustment to equity if, and when, the lessee no longer controls the use of the underlying asset. The amendments in this update are effective for the fiscal years beginning after December 15, 2023. There was no impact on the consolidated financial statements as a result of this standard.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, the FASB issued ASU 2023-06, <i>Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative.</i> This update amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification. The new guidance is intended to align U.S. GAAP requirements with those of the SEC and to facilitate the application of U.S. GAAP for all entities. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure requirement from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027 the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280), Improvements to Reportable Disclosures</i>. The amendments in this update improve segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The impact is only to the financial statement disclosures and has been adopted by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740), Improvements to Income Tax Disclosures.</i> The amendments in this update enhance the transparency and decision usefulness of income tax disclosures primarily related to rate reconciliation and income taxes paid information. The update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments are effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect this update to have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2024, the FASB issued ASU 2024-02, <i>Codification Improvements- Amendments to Remove References to the Concepts Statements</i>. This update contains amendments to the Codification that remove references to various FASB Concepts Statements. These Codification updates are for technical corrections such as conforming amendments, clarifications to guidance, simplifications to wording or the structure of guidance and other minor improvements. The resulting amendments are referred to as Codification improvements. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company does not expect this update to have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40)</i>. This update contains amendments that require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. The amendments in this update are effective for public business entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The expected impact would only be to the financial statement disclosures.</span></p> 186000 <p id="xdx_808_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_z3IuAkgbmR74" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zIYMFMCvbWOb">GOODWILL AND INTANGIBLE ASSETS – NET</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill consists of the excess of the purchase price over the fair value of identifiable net assets of businesses acquired. At December 31, 2024, and 2023, approximately $<span id="xdx_901_eus-gaap--Goodwill_iI_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalPracticeManagementSegmentMember_zsS2TvTsQw14" title="Goodwill"><span id="xdx_908_eus-gaap--Goodwill_iI_c20231231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalPracticeManagementSegmentMember_zKLkDaKOqwqj" title="Goodwill">90,000</span></span> of goodwill was allocated to the Medical Practice Management segment and the balance was allocated to the Healthcare IT segment. The following is the summary of the changes to the carrying amount of goodwill for the years ended December 31, 2024 and 2023:</span></p> <p id="xdx_896_eus-gaap--ScheduleOfGoodwillTextBlock_zlt9clMXsl5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zuPxaZ1u1doc" style="display: none">SCHEDULE OF CHANGES TO CARRYING AMOUNT OF GOODWILL</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231_zFFSiM8GpEid" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zJPFSyZDnhra" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40E_eus-gaap--Goodwill_iS_pn3n3_zImiSIs8gSoi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Beginning gross balance</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">61,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--GoodwillImpairmentLoss_iN_pn3n3_di_z7f7ElFQRXr4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Impairment charges</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(42,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--Goodwill_iE_pn3n3_zFO9JESXfro8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Ending gross balance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_z5VKA4YIJZw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of a triggering event in December 2023 resulting from the suspension of the Preferred Stock dividend, the Company updated its annual goodwill impairment test that was performed as of October 31, 2023 for the Healthcare IT segment. It was determined that the fair value of the Healthcare IT reporting unit was less than the carrying value at both October 31, 2023 and as a result of the December 2023 triggering event. Accordingly, impairment charges of approximately $<span id="xdx_90F_eus-gaap--GoodwillImpairmentLoss_pn5n6_c20231031__20231031__us-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember_zcgR99IPX9r5" title="Goodwill impairment charges">2.0</span> million and $<span id="xdx_901_eus-gaap--GoodwillImpairmentLoss_pn5n6_c20231212__20231212__us-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember_zC1agUUMHYLj" title="Goodwill impairment charges">40.0</span> million, respectively, were recorded. There was <span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_dxL_c20240101__20241231_zeJLNLheMfqa" title="Goodwill impairment charges::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0891">no</span></span> goodwill impairment recorded during the year ended December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z1mT0W3eDUef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below is a summary of intangible asset activity for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zpWK3Gm1fsZc" style="display: none">SCHEDULE OF INTANGIBLE ASSETS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Customer</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Capitalized</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Other Intangible</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Relationships</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Software</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Assets</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="14" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">COST</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Balance, January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z01ePFuANbal" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">47,597</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zHvF69BRPBnl" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">29,379</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zTp1YCNT22ui" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">9,653</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20240101__20241231_zwBmf4Pguxhj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Cost, beginning balance">86,629</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z6KT0HYbO7od" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zoGzBCs2aPNb" style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,709</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zTXF8DkpMWA1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231_zpnHbr0pQONd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, additions">5,709</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Translation gain</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zS4z5jkGIhb9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)"><span style="-sec-ix-hidden: xdx2ixbrl0905">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zvkNiaFjjwKe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)">20</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zwHpx6TyRaT2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)"><span style="-sec-ix-hidden: xdx2ixbrl0909">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231_zjdAurWd2wH" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)">20</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zfjARP6O3Y2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">47,597</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zGJ2R1MMvxQg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">35,108</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_znBSqVVRKrJd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,653</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20240101__20241231_zwwZE2MctuTl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, ending balance">92,358</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Useful lives</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zc60WbabrEa4" title="Useful lives">3</span>-<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zM3vXsRdF2M8" title="Useful lives">12</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zOnRwlGYq2Bh" title="Useful lives">3</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zpzE631H7rqg" title="Useful lives">3</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">ACCUMULATED AMORTIZATION</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zc0YthdJAbg8" style="font: 10pt Times New Roman, Times, Serif; text-align: right">44,372</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zGMiZvjEHHVg" style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,237</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zcE6jBHu9ZF6" style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,946</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20240101__20241231_zDjw22oov3Wk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, beginning balance">61,555</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortization expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zYrnTeTP00Hb" style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,575</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zPhNZdAnD0qf" style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,522</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zLKKgVrwie83" style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20241231_zXtvAbzm5okh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, amortization expense">12,098</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Translation gain</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_znbka9O4fg3j" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zhGhfzV3GCbi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zcwcjh5iG5p5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231_zP4N7ZiMkImi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, translation gain (loss)">7</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z6p01TQ7wAWk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">45,947</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zMIJ9krZ8vk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22,766</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_ze6sf6GXKR5h" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,947</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20240101__20241231_zhPxuBcjiXi9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, ending balance">73,660</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Net book value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zeyRMev8q1tg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">1,650</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zWpofUAk4g78" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">12,342</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zrN3j7rv6Cjd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">4,706</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231_zTll9JBdkYR6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">18,698</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline">COST</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzHPBKHF6d1c" style="font: 10pt Times New Roman, Times, Serif; text-align: right">47,597</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_ztHD2AiWylUl" style="font: 10pt Times New Roman, Times, Serif; text-align: right">21,547</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zr71sH6ScvDd" style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,651</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20230101__20231231_zi3m48EgbQij" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, beginning balance">78,795</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zr8p0U4GoJAa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zJXYlq1E1cZ" style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,548</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zVosBAXUDJB7" style="font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231_zEMQ8q0qvJjb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, additions">8,550</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Translation loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zWsXGcbeyJg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zqIMB6H8bnD2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)">(716</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zGlm1xqZ0Ugj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231_z96tgRgF4kha" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)">(716</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zdtnZ0ekOkPa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">47,597</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zfKcPAA9dfJ9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">29,379</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zMvRJYiV5mgl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,653</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20230101__20231231_zPA7H5UMaiMf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, ending balance">86,629</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Useful lives</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zSPM0r0Kt8jk" title="Useful lives">3</span>-<span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zHX18KG9vCah" title="Useful lives">12</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zPa2UEc0g2B" title="Useful lives">3</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zgMQ5T7e0vuf" title="Useful lives">3</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">ACCUMULATED AMORTIZATION</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxoJQ51q5tng" style="font: 10pt Times New Roman, Times, Serif; text-align: right">39,523</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zBn0aysqky2c" style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,932</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_z0mvRzJlo2Af" style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,820</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20230101__20231231_zG2LWM7eQ9v9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, beginning balance">49,275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortization expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zGFAO6bOSo32" style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,849</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zkxFft0Ap1Z1" style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,426</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zvqv0nd6bEYb" style="font: 10pt Times New Roman, Times, Serif; text-align: right">126</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231_zzOk9yMpTScg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, amortization expense">12,401</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Translation loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zSXBnJ7dK2pe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zDgJAZhZYU8i" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(121</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zTSS5nqrBqzk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231_zSFzX2zd3Nq8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, translation gain (loss)">(121</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zHPEf5Rhmszi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44,372</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zQAzW4hTvw2a" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,237</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zZOnqwk4Q1s4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,946</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20230101__20231231_zjNVVrX1nTYj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, ending balance">61,555</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Net book value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zTg8cUQtqWe3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">3,225</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_z5wDWqis6h78" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">17,142</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zzWCPbV1vUTe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">4,707</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231_zvMBaHcIf7xj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">25,074</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zIdhUNMFk42f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of a triggering event in December 2023, we also reviewed our other long term assets for impairment. We determined that the fair value of these assets exceeded their carrying value and that there was no impairment. There were no triggering events during the year ended December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount for capitalized software represents payroll and development costs incurred for internally developed software. Other intangible assets primarily represent non-compete agreements, purchased and acquired software and trademarks. Amortization expense was approximately $<span id="xdx_900_eus-gaap--AdjustmentForAmortization_pn5n6_c20240101__20241231_zYskfPEEPMi2" title="Amortization expense">12.1</span> million and $<span id="xdx_90A_eus-gaap--AdjustmentForAmortization_pn5n6_c20230101__20231231_zskabL7tUmVl" title="Amortization expense">12.4</span> million for the years ended December 31, 2024 and 2023, respectively. The weighted-average amortization period is <span id="xdx_902_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dc_c20240101__20241231_zbcktk3rKWjh" title="Weighted-average amortization period">three years</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zGHxVgMsddmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024, future amortization expense scheduled to be expensed is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_znWKDJzNbnkb" style="display: none">SCHEDULE OF INTANGIBLE ASSETS, FUTURE AMORTIZATION EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="text-decoration: underline">Years ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20241231_z7MAoVmLdRf9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maIANEGzSxe_zeJKA49Q8NIj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">10,291</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maIANEGzSxe_z0YK6YGEAMae" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,911</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maIANEGzSxe_zNKMMntrZXyk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,746</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maIANEGzSxe_zAVKGRRdmklb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">300</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maIANEGzSxe_ztYh69pWNzt4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2029</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">300</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maIANEGzSxe_zV3eDUHsFUV1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">150</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_pn3n3_mtIANEGzSxe_z2ZiSX51kyRj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">18,698</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zgbOdjzjidGb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 90000 90000 <p id="xdx_896_eus-gaap--ScheduleOfGoodwillTextBlock_zlt9clMXsl5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zuPxaZ1u1doc" style="display: none">SCHEDULE OF CHANGES TO CARRYING AMOUNT OF GOODWILL</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231_zFFSiM8GpEid" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zJPFSyZDnhra" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40E_eus-gaap--Goodwill_iS_pn3n3_zImiSIs8gSoi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Beginning gross balance</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">61,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--GoodwillImpairmentLoss_iN_pn3n3_di_z7f7ElFQRXr4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Impairment charges</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(42,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--Goodwill_iE_pn3n3_zFO9JESXfro8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Ending gross balance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 19186000 61186000 42000000 19186000 19186000 2000000.0 40000000.0 <p id="xdx_89D_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z1mT0W3eDUef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below is a summary of intangible asset activity for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zpWK3Gm1fsZc" style="display: none">SCHEDULE OF INTANGIBLE ASSETS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Customer</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Capitalized</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Other Intangible</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Relationships</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Software</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Assets</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="14" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">COST</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Balance, January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z01ePFuANbal" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">47,597</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zHvF69BRPBnl" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">29,379</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zTp1YCNT22ui" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">9,653</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20240101__20241231_zwBmf4Pguxhj" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Cost, beginning balance">86,629</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z6KT0HYbO7od" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zoGzBCs2aPNb" style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,709</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zTXF8DkpMWA1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20241231_zpnHbr0pQONd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, additions">5,709</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Translation gain</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zS4z5jkGIhb9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)"><span style="-sec-ix-hidden: xdx2ixbrl0905">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zvkNiaFjjwKe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)">20</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zwHpx6TyRaT2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)"><span style="-sec-ix-hidden: xdx2ixbrl0909">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231_zjdAurWd2wH" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)">20</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zfjARP6O3Y2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">47,597</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zGJ2R1MMvxQg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">35,108</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_znBSqVVRKrJd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,653</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20240101__20241231_zwwZE2MctuTl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, ending balance">92,358</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Useful lives</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zc60WbabrEa4" title="Useful lives">3</span>-<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zM3vXsRdF2M8" title="Useful lives">12</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zOnRwlGYq2Bh" title="Useful lives">3</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zpzE631H7rqg" title="Useful lives">3</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">ACCUMULATED AMORTIZATION</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zc0YthdJAbg8" style="font: 10pt Times New Roman, Times, Serif; text-align: right">44,372</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zGMiZvjEHHVg" style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,237</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zcE6jBHu9ZF6" style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,946</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20240101__20241231_zDjw22oov3Wk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, beginning balance">61,555</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortization expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zYrnTeTP00Hb" style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,575</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zPhNZdAnD0qf" style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,522</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zLKKgVrwie83" style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20241231_zXtvAbzm5okh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, amortization expense">12,098</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Translation gain</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_znbka9O4fg3j" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zhGhfzV3GCbi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zcwcjh5iG5p5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20240101__20241231_zP4N7ZiMkImi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, translation gain (loss)">7</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z6p01TQ7wAWk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">45,947</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zMIJ9krZ8vk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22,766</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20240101__20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_ze6sf6GXKR5h" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,947</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20240101__20241231_zhPxuBcjiXi9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, ending balance">73,660</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Net book value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zeyRMev8q1tg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">1,650</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zWpofUAk4g78" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">12,342</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zrN3j7rv6Cjd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">4,706</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231_zTll9JBdkYR6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">18,698</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline">COST</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzHPBKHF6d1c" style="font: 10pt Times New Roman, Times, Serif; text-align: right">47,597</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_ztHD2AiWylUl" style="font: 10pt Times New Roman, Times, Serif; text-align: right">21,547</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zr71sH6ScvDd" style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,651</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pn3n3_c20230101__20231231_zi3m48EgbQij" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, beginning balance">78,795</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zr8p0U4GoJAa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zJXYlq1E1cZ" style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,548</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zVosBAXUDJB7" style="font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231_zEMQ8q0qvJjb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, additions">8,550</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Translation loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zWsXGcbeyJg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zqIMB6H8bnD2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)">(716</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zGlm1xqZ0Ugj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231_z96tgRgF4kha" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, translation gain (loss)">(716</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zdtnZ0ekOkPa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">47,597</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zfKcPAA9dfJ9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">29,379</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zMvRJYiV5mgl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,653</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pn3n3_c20230101__20231231_zPA7H5UMaiMf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cost, ending balance">86,629</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Useful lives</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zSPM0r0Kt8jk" title="Useful lives">3</span>-<span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zHX18KG9vCah" title="Useful lives">12</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zPa2UEc0g2B" title="Useful lives">3</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zgMQ5T7e0vuf" title="Useful lives">3</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">ACCUMULATED AMORTIZATION</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxoJQ51q5tng" style="font: 10pt Times New Roman, Times, Serif; text-align: right">39,523</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zBn0aysqky2c" style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,932</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_z0mvRzJlo2Af" style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,820</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_pn3n3_c20230101__20231231_zG2LWM7eQ9v9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, beginning balance">49,275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortization expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zGFAO6bOSo32" style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,849</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zkxFft0Ap1Z1" style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,426</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zvqv0nd6bEYb" style="font: 10pt Times New Roman, Times, Serif; text-align: right">126</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231_zzOk9yMpTScg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, amortization expense">12,401</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Translation loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zSXBnJ7dK2pe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zDgJAZhZYU8i" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(121</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zTSS5nqrBqzk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsAccumulatedAmortizationForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231_zSFzX2zd3Nq8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, translation gain (loss)">(121</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Balance, December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zHPEf5Rhmszi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44,372</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_zQAzW4hTvw2a" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,237</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20230101__20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zZOnqwk4Q1s4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,946</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_pn3n3_c20230101__20231231_zjNVVrX1nTYj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accumulated amortization, ending balance">61,555</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Net book value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zTg8cUQtqWe3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">3,225</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareMember_z5wDWqis6h78" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">17,142</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zzWCPbV1vUTe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">4,707</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231_zvMBaHcIf7xj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net book value">25,074</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 47597000 29379000 9653000 86629000 5709000 5709000 20000 20000 47597000 35108000 9653000 92358000 P3Y P12Y P3Y P3Y 44372000 12237000 4946000 61555000 1575000 10522000 1000 12098000 7000 7000 45947000 22766000 4947000 73660000 1650000 12342000 4706000 18698000 47597000 21547000 9651000 78795000 8548000 2000 8550000 -716000 -716000 47597000 29379000 9653000 86629000 P3Y P12Y P3Y P3Y 39523000 4932000 4820000 49275000 4849000 7426000 126000 12401000 -121000 -121000 44372000 12237000 4946000 61555000 3225000 17142000 4707000 25074000 12100000 12400000 P3Y <p id="xdx_893_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zGHxVgMsddmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024, future amortization expense scheduled to be expensed is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_znWKDJzNbnkb" style="display: none">SCHEDULE OF INTANGIBLE ASSETS, FUTURE AMORTIZATION EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="text-decoration: underline">Years ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20241231_z7MAoVmLdRf9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maIANEGzSxe_zeJKA49Q8NIj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">10,291</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maIANEGzSxe_z0YK6YGEAMae" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,911</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maIANEGzSxe_zNKMMntrZXyk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,746</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maIANEGzSxe_zAVKGRRdmklb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">300</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maIANEGzSxe_ztYh69pWNzt4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2029</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">300</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maIANEGzSxe_zV3eDUHsFUV1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">150</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_pn3n3_mtIANEGzSxe_z2ZiSX51kyRj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">18,698</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10291000 5911000 1746000 300000 300000 150000 18698000 <p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zdix9vWHwitf" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zVgrGl8p7Ymj">PROPERTY AND EQUIPMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zS4jrrkKetY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zfuShjZpVv1b" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20241231_zDjbCf1uWopg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20231231_zAuTSAdELyg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zWOatAuFtLs6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5,963</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5,510</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zIFPvVbN56ud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office furniture and equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,342</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,985</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--TransportationEquipmentMember_zS6U1X9QgwW6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Transportation equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,185</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,129</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zkG6cBXU8EV1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,358</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,350</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AssetsNotPlacedInServiceMember_z8h31mjfH7nk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Assets not placed in service</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">164</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzA8N_zKsBoOcCn8o8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,012</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,974</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzA8N_zgM5wTqHNeTj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(10,722</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,657</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzA8N_zuKDOwdL7T0g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property and equipment – net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,290</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,317</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zASXhKN5DRi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was approximately $<span id="xdx_90F_eus-gaap--Depreciation_pn5n6_c20240101__20241231_zL927WfpBtph" title="Depreciation expense"><span id="xdx_908_eus-gaap--Depreciation_pn5n6_c20230101__20231231_zCKolBWJWOZ" title="Depreciation expense">2.0</span></span> million for both the years ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of a triggering event in December 2023, we reviewed our property and equipment for impairment at that time. We determined that the fair value of these assets exceeded their carrying value and that there was no impairment. There were no triggering events during the year ended December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zS4jrrkKetY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zfuShjZpVv1b" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20241231_zDjbCf1uWopg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20231231_zAuTSAdELyg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zWOatAuFtLs6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5,963</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">5,510</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zIFPvVbN56ud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Office furniture and equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,342</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,985</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--TransportationEquipmentMember_zS6U1X9QgwW6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Transportation equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,185</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,129</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zkG6cBXU8EV1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,358</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,350</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AssetsNotPlacedInServiceMember_z8h31mjfH7nk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Assets not placed in service</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">164</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzA8N_zKsBoOcCn8o8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,012</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,974</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzA8N_zgM5wTqHNeTj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(10,722</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,657</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzA8N_zuKDOwdL7T0g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property and equipment – net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,290</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,317</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5963000 5510000 2342000 1985000 1185000 1129000 6358000 5350000 164000 16012000 13974000 10722000 8657000 5290000 5317000 2000000.0 2000000.0 <p id="xdx_80B_eus-gaap--ConcentrationRiskDisclosureTextBlock_zCxrc92vRJCb" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zBTVXlWh5ooc">CONCENTRATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Risks</b> — As of December 31, 2024 and 2023, the Company held cash of approximately $<span id="xdx_900_eus-gaap--FairValueConcentrationOfRiskCashAndCashEquivalents_iI_c20241231_zF8qngCNhHrf">119,000</span> and $<span id="xdx_903_eus-gaap--FairValueConcentrationOfRiskCashAndCashEquivalents_iI_c20231231_zvOCi3hQHTgj" title="Offshore bank accounts">255,000</span>, respectively, in the name of its subsidiaries, at banks in Pakistan and Sri Lanka. The banking systems in these countries do not provide deposit insurance coverage. Additionally, from time to time, the Company maintains cash balances at financial institutions in the United States in excess of federal insurance limits. The Company has not experienced any losses on such accounts. The cash held by each U.S. operating company was below the federal insurance limit at December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentrations of credit risk with respect to trade accounts receivable are managed by periodic credit evaluations of customers. The Company does not require collateral for outstanding trade accounts receivable. As of December 31, 2024, two customers each individually accounted for approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--TitleOfIndividualAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSxHy0nemxGa" title="Concentration risk percentage"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--TitleOfIndividualAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXwFWAggXn3f" title="Concentration risk percentage">7</span></span>% of accounts receivable. As of December 31, 2023, two customers each individually accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--TitleOfIndividualAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziag6eqTD2x" title="Concentration risk percentage"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--TitleOfIndividualAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOmcj0RIkh16" title="Concentration risk percentage">7</span></span>% of accounts receivable. During the years ended December 31, 2024 and 2023, there was one customer with sales of approximately <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--TitleOfIndividualAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zMihQ8nvo0G4" title="Concentration risk percentage">10</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--TitleOfIndividualAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwkEAVBpQXN1" title="Concentration risk percentage">9</span>% of total revenue, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geographical Risks</b> — The Company’s offices in Islamabad, Karachi and Bagh, Pakistan, and Colombo, Sri Lanka conduct significant back-office operations for the Company. The Company has no revenue earned outside of the United States. The office in Bagh is located in a different territory of Pakistan from the Islamabad office known as Azad Jammu and Kashmir. The Bagh office was opened in 2009 for the purpose of providing operational support and operating as a backup to the Islamabad office. The Bagh office now operates as the main operational center for the Company. The Company’s operations outside the United States are subject to special considerations and significant risks not typically associated with companies in the United States. The Company’s business, financial condition and results of operations may be influenced by the political, economic, and legal environment in the countries in which it operates and by the general state of these countries’ economies. The Company’s results may be adversely affected by, among other things, changes in governmental policies with respect to laws and regulations, changes in local countries’ telecommunications industries, regulatory rules and policies, anti-inflationary measures, currency conversion and remittance, and rates and methods of taxation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carrying amounts of net assets located outside the United States were approximately $<span id="xdx_906_eus-gaap--AssetsNet_iI_pn5n6_c20241231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zLVrCMnyeOMb" title="Net assets">7.0</span> million and $<span id="xdx_90E_eus-gaap--AssetsNet_iI_pn5n6_c20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zKF1qHHVlYl6" title="Net assets">7.6</span> million as of December 31, 2024 and 2023, respectively. These balances exclude net intercompany receivables of approximately $<span id="xdx_900_ecustom--IntercompanyReceivables_iI_pn5n6_c20241231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_znW1zlT8J6C1" title="Intercompany receivables">2.2</span> million and $<span id="xdx_905_ecustom--IntercompanyReceivables_iI_pn5n6_c20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zk4UgBfd1kq3" title="Intercompany receivables">1.0</span> million as of December 31, 2024 and 2023, respectively. The following is a summary of the net assets located outside the United States as of December 31, 2024 and 2023:</span></p> <p id="xdx_89F_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zobcaSjPoX5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zt689L2ouXub" style="display: none">SCHEDULE OF CONCENTRATION OF RISK, BY GEOGRAPHICAL RISKS FACTOR</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zRA6QPfdDDEa" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_z8HVOAFK1K9h" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_405_eus-gaap--AssetsCurrent_iI_pn3n3_zCpQ2NTwyaHh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Current assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">211</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">806</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AssetsNoncurrent_iI_pn3n3_zqd2FFWoNhoa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Non-current assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,337</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,250</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Assets_iI_pn3n3_zLsDRwZBu3x6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,548</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,056</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_iNI_pn3n3_di_zmCMQw898Nr2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,336</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,250</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesNoncurrent_iNI_pn3n3_di_zWm2NzNZn9Xe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Non-current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(172</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--AssetsNet_iI_pn3n3_zu0EIKS63GH9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,040</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,566</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zGdRvdPYDXR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 119000 255000 0.07 0.07 0.07 0.07 0.10 0.09 7000000.0 7600000 2200000 1000000.0 <p id="xdx_89F_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zobcaSjPoX5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zt689L2ouXub" style="display: none">SCHEDULE OF CONCENTRATION OF RISK, BY GEOGRAPHICAL RISKS FACTOR</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zRA6QPfdDDEa" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20231231__srt--StatementGeographicalAxis__us-gaap--NonUsMember_z8HVOAFK1K9h" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_405_eus-gaap--AssetsCurrent_iI_pn3n3_zCpQ2NTwyaHh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Current assets</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">211</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">806</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AssetsNoncurrent_iI_pn3n3_zqd2FFWoNhoa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Non-current assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,337</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,250</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Assets_iI_pn3n3_zLsDRwZBu3x6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif">Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,548</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,056</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_iNI_pn3n3_di_zmCMQw898Nr2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,336</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,250</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--LiabilitiesNoncurrent_iNI_pn3n3_di_zWm2NzNZn9Xe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Non-current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(172</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--AssetsNet_iI_pn3n3_zu0EIKS63GH9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,040</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,566</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 211000 806000 8337000 8250000 8548000 9056000 1336000 1250000 172000 240000 7040000 7566000 <p id="xdx_809_eus-gaap--EarningsPerShareTextBlock_zdWYLlWOXL78" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_821_zI1mHGIpASXi">NET LOSS PER COMMON SHARE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z3CNUCpYnwK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the weighted-average shares outstanding for basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zbALE90IiaF9" style="display: none">SCHEDULE OF RECONCILIATION OF WEIGHTED-AVERAGE SHARES OUTSTANDING FOR BASIC AND DILUTED NET LOSS PER COMMON SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240101__20241231_zKCTz4R614vd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zU9UtKhnetej" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">($ in thousands, except share and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">per share amounts)</p></td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and Diluted:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zCZ1Cih7URJg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common shareholders</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20240101__20241231_zN1tmGtDuFOg" title="Net loss attributable to common shareholders - basic"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20240101__20241231_z54ftQeGMyRj" title="Net loss attributable to common shareholders - diluted">(4,459</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230101__20231231_zPpY0i0H2nB6" title="Net loss attributable to common shareholders - basic"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20231231_zrHAl6CijqD5" title="Net loss attributable to common shareholders - diluted">(64,348</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted-average common shares used to compute basic and diluted loss per share</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20241231_zQHkNJdmcIuk" title="Weighted-average common shares used to compute basic loss per share"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_z8trvCYbGnA7" title="Weighted-average common shares used to compute diluted loss per share">16,146,975</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zCNxihdRIP7c" title="Weighted-average common shares used to compute basic loss per share"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zx9DomgCkstl" title="Weighted-average common shares used to compute diluted loss per share">15,669,472</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common shareholders per share - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_zvnDSm1ehi77" title="Net loss attributable to common shareholders per share - basic"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zeux4fyYTDVj" title="Net loss attributable to common shareholders per share - diluted">(0.28</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_z3cpBud1mSt" title="Net loss attributable to common shareholders per share - basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zrYboQDLPIVk" title="Net loss attributable to common shareholders per share - diluted">(4.11</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AD_zqjjqRIV12Eg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net loss attributable to common shareholders includes the preferred stock dividend amount earned, but not declared, for the year ended December 31, 2024 of approximately $<span id="xdx_909_eus-gaap--DividendsPreferredStockStock_pn5n6_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zeW3jeHhXRl9" title="Preferred stock dividend amount">12.3</span> million. The dividend payable at December 31, 2024 in the consolidated balance sheet represents dividends declared, but not paid, through February 29, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif; text-transform: none">At December 31, 2024, the <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm0PR14xeaei" title="Anti-dilutive shares">242,500</span> unvested restricted stock units (“RSUs”) as discussed in Note 15 have been excluded from the above calculations as they were anti-dilutive. At December 31, 2023, the <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zz9HCQ7FU5Nl" title="Anti-dilutive shares">733,908</span> unvested equity RSUs excluded from the above calculations as they were anti-dilutive. All of the warrants previously outstanding expired unexercised in 2023 and are excluded from the above calculations. Vested RSUs, vested restricted shares and exercised warrants have been included in the above calculations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif; text-transform: none"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z3CNUCpYnwK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the weighted-average shares outstanding for basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zbALE90IiaF9" style="display: none">SCHEDULE OF RECONCILIATION OF WEIGHTED-AVERAGE SHARES OUTSTANDING FOR BASIC AND DILUTED NET LOSS PER COMMON SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240101__20241231_zKCTz4R614vd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zU9UtKhnetej" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">($ in thousands, except share and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">per share amounts)</p></td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and Diluted:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zCZ1Cih7URJg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common shareholders</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20240101__20241231_zN1tmGtDuFOg" title="Net loss attributable to common shareholders - basic"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20240101__20241231_z54ftQeGMyRj" title="Net loss attributable to common shareholders - diluted">(4,459</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230101__20231231_zPpY0i0H2nB6" title="Net loss attributable to common shareholders - basic"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20231231_zrHAl6CijqD5" title="Net loss attributable to common shareholders - diluted">(64,348</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted-average common shares used to compute basic and diluted loss per share</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20241231_zQHkNJdmcIuk" title="Weighted-average common shares used to compute basic loss per share"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_z8trvCYbGnA7" title="Weighted-average common shares used to compute diluted loss per share">16,146,975</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zCNxihdRIP7c" title="Weighted-average common shares used to compute basic loss per share"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zx9DomgCkstl" title="Weighted-average common shares used to compute diluted loss per share">15,669,472</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common shareholders per share - basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_zvnDSm1ehi77" title="Net loss attributable to common shareholders per share - basic"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zeux4fyYTDVj" title="Net loss attributable to common shareholders per share - diluted">(0.28</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_z3cpBud1mSt" title="Net loss attributable to common shareholders per share - basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zrYboQDLPIVk" title="Net loss attributable to common shareholders per share - diluted">(4.11</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -4459000 -4459000 -4459000 -64348000 -64348000 -64348000 16146975 16146975 15669472 15669472 -0.28 -0.28 -4.11 -4.11 12300000 242500 733908 <p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zyaSxLBXYCcg" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zoOzkIUhy3Zg">DEBT</span></b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SVB </i>— During October 2017, the Company opened a revolving line of credit from SVB under a three-year agreement which replaced the previous credit facility. <span id="xdx_907_eus-gaap--LineOfCreditFacilityCovenantTerms_pid_dp_uPure_c20171001__20171031__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_z1kOHfTB0vC9" title="Line of credit borrowing term">The SVB credit facility is a secured revolving line of credit where borrowings are based on a formula of 200% of repeatable revenue adjusted by an annualized attrition rate as defined in the credit agreement</span>. During the third quarter of 2018, the credit line was increased from $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20180930__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember__srt--RangeAxis__srt--MinimumMember_zHzkbNXifdH3" title="Increase revolving line of credit">5</span> million to $<span id="xdx_903_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20180930__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember__srt--RangeAxis__srt--MaximumMember_zDnd1hz5IKDk" title="Increase revolving line of credit">10</span> million and the <span id="xdx_901_eus-gaap--LineOfCreditFacilityDescription_c20180701__20180930__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_zdBG5YTDhTt5" title="Line of credit, term extension">term was extended for an additional year</span>. During the third quarter of 2021, the credit line was further increased to $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20210930__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_zKc6ZsKQojVe" title="Increase revolving line of credit">20</span> million and the <span id="xdx_90A_eus-gaap--LineOfCreditFacilityDescription_c20210701__20210930__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_zvoggEITdJc8" title="Line of credit, term extension">term was extended for two years</span>. During February 2023, the line of credit was increased to $<span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20230228__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_zvhq2EqynVGl" title="Increase revolving line of credit">25</span> million and the <span id="xdx_90D_eus-gaap--LineOfCreditFacilityDescription_c20230228__20230228__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_zIXOsagkEOMg" title="Line of credit, term extension">term was extended for two years through October 13, 2025</span>. Effective August 31, 2023, the credit facility agreement was amended whereby the interest rate was increased from the prime rate plus <span id="xdx_907_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230830__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_zPJsQnKBYvLj" title="Line of credit facility, interest rate">1.5</span>% to the prime rate plus <span id="xdx_902_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230831__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_zifvH3EuR9Lh" title="Line of credit facility, interest rate">2.0</span>%. The requirement for the minimum liquidity ratio was slightly reduced. These amendments expired on <span id="xdx_90B_ecustom--MinimumLiquidityRatioReductionAmendmentsExpiryDate_c20230830__20230831__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_zmtrGVRxT9Kj" title="Minimum liquidity ratio reduction amendments expiry date">March 31, 2024</span> and the credit facility reverted to its previous terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024, there were <span id="xdx_907_eus-gaap--LongTermLineOfCredit_iI_doxL_c20241231_zctZXMug8YLd" title="Lline of credit::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1173">no</span></span> borrowings under the credit facility, compared to $<span id="xdx_903_eus-gaap--LongTermLineOfCredit_iI_pn6n6_c20231231_zaWN68jle2f" title="Lline of credit">10</span> million in borrowings as of December 31, 2023. Interest on the revolving line of credit was charged at the prime rate plus <span id="xdx_902_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20240331__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_zZtKKaUlBTrg">2.0</span>% for the first quarter of 2024, but decreased to the prime rate plus <span id="xdx_90A_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20240401__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_zzSqwE3vqji7">1.5</span>% on April 1, 2024. <span id="xdx_90C_eus-gaap--LineOfCreditFacilityCommitmentFeeDescription_c20240101__20241231__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_zzLCi8eG42a2" title="Line of credit, description">There is also a fee of one-half of 1% annually for the unused portion of the credit line.</span> The debt is secured by all of the Company’s domestic assets and <span id="xdx_90C_ecustom--PercentageOfSharesInOffshoreFacilities_iI_pid_dp_uPure_c20241231__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember_z7ZOQYLyilt5">65</span>% of the shares in its offshore subsidiaries. Future acquisitions are subject to approval by SVB. At December 31, 2024, the available borrowing base was approximately $<span id="xdx_900_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_pn5n6_c20241231_zCOETyHHQag6" title="Line of credit, remaining borrowing base">10.0 </span>million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the original SVB debt agreement, the Company paid SVB approximately $<span id="xdx_904_ecustom--PaymentOfUpfrontFees_pn3d_c20171001__20171031__us-gaap--TypeOfArrangementAxis__custom--SVBDebtAgreementMember_z4B1lFZgQm7a" title="Upfront fees">50,000</span> of fees upfront and issued warrants for SVB to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20171031__us-gaap--TypeOfArrangementAxis__custom--SVBDebtAgreementMember_zCuNSlCcMYG7" title="Warrants to purchase shares">125,000</span> shares of its common stock, and committed to pay an annual anniversary fee of $<span id="xdx_907_ecustom--PaymentsForAnnualAnniversaryFee_pn3p0_c20171001__20171031__us-gaap--TypeOfArrangementAxis__custom--SVBDebtAgreementMember_zNLzhP3LP7r7">50,000</span> a year. Based on the terms in the original SVB credit agreement, these warrants had a strike price equal to $<span id="xdx_906_ecustom--WarrantStrikePrice_iI_pid_c20171031__us-gaap--TypeOfArrangementAxis__custom--SVBDebtAgreementMember_zhIWLqxzCelj">3.92</span>. They had a five<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20171031__us-gaap--TypeOfArrangementAxis__custom--SVBDebtAgreementMember_zgpDEQV1pnBh" style="display: none" title="Warrants term">5</span>-year exercise window and net exercise rights, and were valued at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20171031__us-gaap--TypeOfArrangementAxis__custom--SVBDebtAgreementMember_zGnlAjJdQV28" title="Warrants exercise price">3.12</span> per warrant. These warrants were exercised during 2022. As a result of the revision in the SVB credit line, which increased the credit line from $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20171031__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember__srt--RangeAxis__srt--MinimumMember_zNHqmez7x63b" title="Increase revolving line of credit">5</span> million to $<span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20180930__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember__srt--RangeAxis__srt--MaximumMember_zmDKz9yeR8Sd" title="Increase revolving line of credit">10</span> million and reduced the interest rate by 25 basis points, the Company paid approximately $<span id="xdx_901_ecustom--PaymentOfUpfrontFees_pn3d_c20171001__20171031__us-gaap--TypeOfArrangementAxis__custom--SVBDebtAgreementMember_z4QWhNNHMbDi" title="Upfront fees">50,000</span> of fees upfront and issued an additional <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20171031__us-gaap--TypeOfArrangementAxis__custom--SVBDebtAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--AdditionalWarrantMember_zCsPBkEnKmb5" title="Warrants to purchase">28,489</span> warrants, with a strike price equal to $<span id="xdx_900_ecustom--WarrantStrikePrice_iI_pid_c20171031__us-gaap--TypeOfArrangementAxis__custom--SVBDebtAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--AdditionalWarrantMember_zycZFiDCjJF1" title="Warrant strike price">5.26</span>, a five<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20171031__us-gaap--TypeOfArrangementAxis__custom--SVBDebtAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--AdditionalWarrantMember_z90xAO3Xuctd" style="display: none" title="Warrants term">5</span>-year exercise window and net exercise rights. The additional warrants were valued at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20171031__us-gaap--TypeOfArrangementAxis__custom--SVBDebtAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--AdditionalWarrantMember_z3ejHFH9sh3j" title="Warrants price per share">3.58</span> per warrant and expired unexercised in September 2023. The SVB credit agreement contains various covenants and conditions governing the revolving line of credit including a current annual fee of $<span id="xdx_906_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SVBDebtAgreementMember_z4ACHBR2bG7l" title="Line of credit facility commitment fee amount">44,000</span>. These covenants include a minimum level of adjusted EBITDA or a minimum liquidity ratio, one of which must be satisfied when borrowings are outstanding. At December 31, 2024 and 2023, the Company was in compliance with all covenants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During March 2023, SVB became a division of First Citizens Bank &amp; Trust Company. The agreements that governed the former SVB relationship remain in place. As a result, there were no changes to the terms of the credit agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During October, 2024, the Company entered into a Ninth Loan Modification agreement with SVB whereby the Company decreased the amount available on its revolving line of credit from $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20240930__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--NinthLoanModificationAgreementMember_zfa04ALmhx74" title="Increase revolving line of credit">25</span> million to $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20241030__us-gaap--CreditFacilityAxis__custom--SVBCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--NinthLoanModificationAgreementMember_z9VFYrJpukN9" title="Increase revolving line of credit">10</span> million which proportionally reduced the anniversary fee and the fee on the unused portion of the credit line. As a result of the modification, one covenant was slightly modified.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances at SVB in excess of the FDIC insurance coverage limits. The Company performs periodic evaluations of the relative credit standing of this financial institution to ensure its credit worthiness. As of December 31, 2024 and December 31, 2023, the Company held cash of approximately $<span id="xdx_904_eus-gaap--FairValueConcentrationOfRiskCashAndCashEquivalents_iI_pn3d_c20241231_zjRRnmOA5bdd" title="Offshore bank accounts">119,000</span> and $<span id="xdx_90B_eus-gaap--FairValueConcentrationOfRiskCashAndCashEquivalents_iI_pn3d_c20231231_zi1i36O2mTcf" title="Offshore bank accounts">255,000</span>, respectively, in the name of its subsidiaries at banks in Pakistan and Sri Lanka. The banking systems in these countries do not provide deposit insurance coverage. The Company has not experienced any losses on its cash accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Vehicle Financing Notes</i> — The Company finances certain vehicle purchases both in the United States and in Pakistan. The vehicle financing notes typically have three <span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--VehicleFinancingNotesMember__srt--RangeAxis__srt--MinimumMember_z25kuFMuORo4" style="display: none">3</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to six<span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dtY_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--VehicleFinancingNotesMember__srt--RangeAxis__srt--MaximumMember_zRPXZL8oOXo5" style="display: none">6</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">year terms and are issued at current market rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Insurance Financing</i> — The Company finances certain insurance purchases over the term of the policy life. The interest rate charged is <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceFinancingMember_zOoaxhP2Edq8" title="Debt interest rate">7.49</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zo9jBfqlK0Dh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities of the outstanding notes payable and other obligations as of December 31, 2024 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zqLryDtO5ov9" style="display: none">SCHEDULE OF MATURITIES OF LONG-TERM DEBT</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Year ending December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Vehicle Financing Notes</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Insurance Financing</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--VehicleFinancingNotesMember_fKg_____z2vOj3Rt8oPc" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="2025">11</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceFinancingMember_zrswUH3memGk" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="2025">299</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDM_c20241231_zKpnvNmmquG2" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="2025">310</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--VehicleFinancingNotesMember_fKg_____zkYf4HLPlo8g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2026">11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceFinancingMember_z5z562H8o2kc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2026"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDM_c20241231_z2NRA1omSDag" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2026">11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--VehicleFinancingNotesMember_fKg_____zHPENzSAb6Og" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2027">8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceFinancingMember_z0YYuJK5A5B1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2027"><span style="-sec-ix-hidden: xdx2ixbrl1238">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maDM_c20241231_zsl2pvbaBcv1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2027">8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--VehicleFinancingNotesMember_fKg_____zvGl32vZupw4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="2028">          7</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceFinancingMember_zTu9iahjSzOb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="2028"><span style="-sec-ix-hidden: xdx2ixbrl1244">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maDM_c20241231_zG2NiXPrLUa1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="2028">7</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--LongTermDebtAndCapitalLeaseObligations_iTI_pn3n3_mtDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--VehicleFinancingNotesMember_fKg_____zKzFrOSO2Kc8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">37</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--LongTermDebtAndCapitalLeaseObligations_iTI_pn3n3_mtDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceFinancingMember_zNZTtkg7hoMb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">299</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--LongTermDebtAndCapitalLeaseObligations_iTI_pn3n3_mtDM_c20241231_zadoHdFRIiil" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">336</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zLc5ITx80UKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> The SVB credit facility is a secured revolving line of credit where borrowings are based on a formula of 200% of repeatable revenue adjusted by an annualized attrition rate as defined in the credit agreement 5000000 10000000 term was extended for an additional year 20000000 term was extended for two years 25000000 term was extended for two years through October 13, 2025 0.015 0.020 2024-03-31 10000000 0.020 0.015 There is also a fee of one-half of 1% annually for the unused portion of the credit line. 0.65 10000000.0 50000 125000 50000 3.92 P5Y 3.12 5000000 10000000 50000 28489 5.26 P5Y 3.58 44000 25000000 10000000 119000 255000 P3Y P6Y 0.0749 <p id="xdx_890_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zo9jBfqlK0Dh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities of the outstanding notes payable and other obligations as of December 31, 2024 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zqLryDtO5ov9" style="display: none">SCHEDULE OF MATURITIES OF LONG-TERM DEBT</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Year ending December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Vehicle Financing Notes</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Insurance Financing</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="10" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--VehicleFinancingNotesMember_fKg_____z2vOj3Rt8oPc" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="2025">11</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceFinancingMember_zrswUH3memGk" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="2025">299</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDM_c20241231_zKpnvNmmquG2" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="2025">310</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--VehicleFinancingNotesMember_fKg_____zkYf4HLPlo8g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2026">11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceFinancingMember_z5z562H8o2kc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2026"><span style="-sec-ix-hidden: xdx2ixbrl1232">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDM_c20241231_z2NRA1omSDag" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2026">11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--VehicleFinancingNotesMember_fKg_____zHPENzSAb6Og" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2027">8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceFinancingMember_z0YYuJK5A5B1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2027"><span style="-sec-ix-hidden: xdx2ixbrl1238">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maDM_c20241231_zsl2pvbaBcv1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="2027">8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--VehicleFinancingNotesMember_fKg_____zvGl32vZupw4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="2028">          7</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceFinancingMember_zTu9iahjSzOb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="2028"><span style="-sec-ix-hidden: xdx2ixbrl1244">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maDM_c20241231_zG2NiXPrLUa1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="2028">7</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--LongTermDebtAndCapitalLeaseObligations_iTI_pn3n3_mtDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--VehicleFinancingNotesMember_fKg_____zKzFrOSO2Kc8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">37</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--LongTermDebtAndCapitalLeaseObligations_iTI_pn3n3_mtDM_c20241231__us-gaap--LongtermDebtTypeAxis__custom--InsuranceFinancingMember_zNZTtkg7hoMb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">299</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--LongTermDebtAndCapitalLeaseObligations_iTI_pn3n3_mtDM_c20241231_zadoHdFRIiil" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">336</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 11000 299000 310000 11000 11000 8000 8000 7000 7000 37000 299000 336000 <p id="xdx_80D_eus-gaap--RevenueFromContractWithCustomerTextBlock_zcrZSTLfumNb" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zvd7p8LQ2ND3">REVENUE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Introduction</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for revenue in accordance with ASC 606, <i>Revenue from Contracts with Customers</i>. All revenue is recognized as our performance obligations are satisfied. A performance obligation is a promise in a contract to transfer a distinct good or service to a customer, and is the unit of account under ASC 606. The Company recognizes revenue when the revenue cycle management services begin on the medical billing claims, which is generally upon receipt of the claim from the provider. For many services the Company recognizes revenue as a percentage of the amount the customer collects on the medical billing claims. The Company’s software is utilized at the time the provider sees the patient, and the Company estimates the value of the consideration it will earn over the remaining contractual period as our services are provided and recognizes the fees over the term; this estimation involves predicting the amounts our clients will ultimately collect associated with the services they provided. Certain significant estimates, such as payment-to-charge ratios, effective billing rates and the estimated contractual payment periods are required to measure revenue cycle management revenue under the new standard.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most of our current contracts with customers contain a single performance obligation. For contracts where we provide multiple services, such as where we perform multiple ancillary services, each service represents its own performance obligation. The standalone selling prices are based on the contractual price for the service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We apply the portfolio approach as permitted by ASC 606 as a practical expedient to contracts with similar characteristics and we use estimates and assumptions when accounting for those portfolios. Our contracts generally include standard commercial payment terms. We have no significant obligations for refunds, warranties or similar obligations and our revenue does not include taxes collected from our customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disaggregation of Revenue from Contracts with Customers</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We derive revenue from five primary sources: (1) Technology-enabled business solutions, (2) professional services, (3) printing and mailing services, (4) group purchasing services and (5) medical practice management services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_ziDEVBEg8OAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents a disaggregation of revenue for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zGmVvIVy4vAd" style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20241231_znuPpctMHaGf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_z66X8p1N4Eg7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Healthcare IT:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember__srt--ProductOrServiceAxis__custom--TechnologyEnabledBusinessSolutionsMember_zfOyJwivbKWc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Technology-enabled business solutions</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">73,672</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">76,640</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember__srt--ProductOrServiceAxis__custom--ProfessionalServicesMember_zOHVOUJcjtW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Professional services</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,202</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23,022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember__srt--ProductOrServiceAxis__custom--PrintingAndMailingServicesMember_zHqWpCTcVHIg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Printing and mailing services</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,579</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,968</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember__srt--ProductOrServiceAxis__custom--GroupPurchasingServicesMember_zmnLHm0Lj9g3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Group purchasing services</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">952</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,053</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Medical Practice Management:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--MedicalPracticeManagementMember_zwwdzOb0OHci" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Medical practice management services</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,432</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,376</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_z1Q4x5tIyJgd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">110,837</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">117,059</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zNTXPWgXz08" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">110,837</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">117,059</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_ztZe6uQobWLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Technology-enabled business solutions:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue derived on an on-going basis from our technology-enabled solutions, which typically includes revenue cycle management services, is billed as a percentage of payments collected by our customers. The fee for our services often includes the ability to use our EHR and practice management software as well as RCM as part of the bundled fee. The SaaS component is not a material portion of the contract compared to the stand-alone value of RCM.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology-assisted revenue cycle management services are the recurring process of submitting and following up on claims with health insurance companies in order for the healthcare providers to receive payment for the services they rendered. The Company typically invoices customers on a monthly basis based on the actual collections received by its customers and the agreed-upon rate in the sales contract. The fee for these services typically includes use of practice management software and related tools (on a SaaS basis), electronic health records (on a SaaS basis), medical billing services and use of mobile health solutions. We consider the services to be one performance obligation since the promises are not distinct in the context of the contract. The performance obligation consists of a series of distinct services that are substantially the same and have the same periodic pattern of transfer to our customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In many cases, our clients may terminate their agreements with 90 days’ notice without cause, thereby limiting the term in which we have enforceable rights and obligations, although this time period can vary between clients. Our payment terms are normally net 30 days. Although our contracts typically have stated terms of one or more years, under ASC 606 our contracts are considered month-to-month and accordingly, there is no financing component.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the majority of our revenue cycle management contracts, the total transaction price is variable because our obligation is to process an unknown quantity of claims, as and when requested by our customers over the contract period. When a contract includes variable consideration, we evaluate the estimate of the variable consideration to determine whether the estimate needs to be constrained; therefore, we include variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with variable consideration is subsequently resolved. Estimates to determine variable consideration such as payment to charge ratios, effective billing rates, and the estimated contractual payment periods are updated at each reporting date. Revenue is recognized over the performance period using the input method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our proprietary, cloud-based practice management application automates the labor-intensive workflow of a medical office in a unified and streamlined SaaS platform. The Company has a large number of clients who utilize the Company’s practice management software, electronic health records software, patient experience management solutions, business intelligence software and/or robotic process automation software on a SaaS basis, but who do not utilize the Company’s revenue cycle management services. SaaS fees may be fixed based on the number of providers, or may be variable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our digital health services, which began generating revenue in 2022, include chronic care management, where a care manager has remote visits with patients with one or more chronic conditions under the supervision of a physician who is our client. The performance obligation for chronic care management is satisfied at a point in time once the patient receives the remote visit. The digital health services also include remote patient monitoring where our system monitors recordings from FDA approved internet connected devices. These devices record patient trends and alerts the physician to changes which might trigger the need for additional follow-up visits. The performance obligations for remote patient monitoring are satisfied over time as the recordings are received and the patient receives the remote visit. The revenue for chronic care management for the years ended December 31, 2024 and 2023 was approximately $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20240101__20241231__srt--ProductOrServiceAxis__custom--ChronicCareManagementMember_zIBS66s2NfGl" title="Revenue">3.0</span> million and $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20230101__20231231__srt--ProductOrServiceAxis__custom--ChronicCareManagementMember_zn7uTWluemq9" title="Revenue">1.5</span> million, respectively. The revenue for remote patient monitoring for the years ended December 31, 2024 and 2023 was approximately $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--RemotePatientMonitoringMember_zQ0sNkEl7VH3" title="Revenue">779,000</span> and $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--RemotePatientMonitoringMember_zXlBZlDkaN78" title="Revenue">400,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The medical billing clearinghouse service takes claim information from customers, checks the claims for errors and sends this information electronically to insurance companies. The Company invoices customers on a monthly basis based on the number of claims submitted and the agreed-upon rate in the agreement. This service is provided to medical practices and providers to medical practices who are not revenue cycle management customers. The performance obligation is satisfied once the relevant submissions are completed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional services such as coding and transcription are rendered in connection with the delivery of revenue cycle management and related medical services. The Company invoices customers monthly, based on the actual amount of services performed at the agreed-upon rate in the contract. These services are only offered to revenue cycle management customers. These services do not represent a material right because the services are optional to the customer and customers electing these services are charged the same price for those services as if they were on a standalone basis. Each individual coding or transcription transaction processed represents a performance obligation, which is satisfied over time as that individual service is rendered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Professional services:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our professional services include an extensive set of services including EHR vendor-agnostic optimization and activation, project management, IT transformation consulting, process improvement, training, education and staffing for large healthcare organizations including health systems and hospitals. The performance obligation is satisfied over time using the input method. The revenue is recorded on a monthly basis as the professional services are rendered. Unbilled revenue at December 31, 2024 and 2023 was approximately $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__custom--ProfessionalServicesMember__us-gaap--AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis__us-gaap--UnbilledRevenuesMember_z6n8SR7oZIWk">338,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--ProfessionalServicesMember__us-gaap--AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis__us-gaap--UnbilledRevenuesMember_zQ54KqwCYHN8">100,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Printing and mailing services:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company provides printing and mailing services for both revenue cycle management customers and a non- revenue cycle management customer, and invoices on a monthly basis based on the number of prints, the agreed-upon rate per print and the postage incurred. The performance obligation is satisfied once the printing and mailing is completed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Group purchasing services:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company provides group purchasing services which enable medical providers to purchase various vaccines directly from selected pharmaceutical companies at a discounted price. Currently, there are approximately 4,000 medical providers who are members of the program. Revenue is recognized as the vaccine shipments are made to the medical providers. Fees from the pharmaceutical companies are paid either quarterly or annually and the Company adjusts its revenue accrual at the time of payment. The Company makes significant judgments regarding the variable consideration which we expect to be entitled to for the group purchasing services which includes the anticipated shipments to the members enrolled in the program, anticipated volumes of purchases made by the members, and the changes in the number of members. The amounts recorded are constrained by estimates of decreases in shipments and loss of members to avoid a significant revenue reversal in the subsequent period. The only performance obligation is to provide the pharmaceutical companies with the medical providers who want to become members in order to purchase vaccines. The performance obligation is satisfied once the medical provider agrees to purchase a specific quantity of vaccines and the medical provider’s information is forwarded to the vaccine suppliers. The Company records a contract asset for revenue earned and not paid as the ultimate payment is conditioned on achieving certain volume thresholds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For all of the above revenue streams other than group purchasing services and chronic care management, revenue is recognized over time, which is typically one month or less, which closely matches the point in time that the customer simultaneously receives and consumes the benefits provided by the Company. For the group purchasing services, revenue is recognized at a point in time. Each service is substantially the same and has the same periodic pattern of transfer to the customer. Each of the services provided above is considered a separate performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no unsatisfied performance obligations for contracts with an original duration greater than one year. The Company has elected to utilize the practical expedient available with the guidance for contracts with an expected duration of one year or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Medical practice management services:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also provides medical practice management services under long-term management service agreements to three medical practices. We provide the medical practices with the nurses, administrative support, facilities, supplies, equipment, marketing, RCM, accounting, and other non-clinical services needed to efficiently operate their practices. Revenue is recognized as the services are provided to the medical practices. Revenue recorded in the consolidated statements of operations represents the reimbursement of costs paid by the Company for the practices and the management fee earned each month for managing the practice. The management fee is based on either a fixed fee or a percentage of the net operating income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assumes all financial risk for the performance of the managed medical practices. Revenue is impacted by the amount of the costs incurred by the practices and their operating income. The gross billing of the practices is impacted by billing rates, changes in current procedural terminology code reimbursement and collection trends which in turn impacts the management fee that the Company is entitled to. Billing rates are reviewed at least annually and adjusted based on current insurer reimbursement practices. The performance obligation is satisfied as the management services are provided.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our contracts for medical practice management services have approximately an additional 14 years remaining and are only cancellable under very limited circumstances. The Company receives a management fee each month for managing the day-to-day business operations of each medical group as a fixed fee or a percentage payment of the net operating income which is included in revenue in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our medical practice management services obligations consist of a series of distinct services that are substantially the same and have the same periodic pattern of transfer to our customers. Revenue is recognized over time, however for reporting and convenience purposes, the management fee is computed at each month end.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Information about contract balances:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024, the estimated revenue expected to be recognized in the future related to the remaining revenue cycle management performance obligations outstanding was approximately $<span id="xdx_90D_eus-gaap--RevenueRemainingPerformanceObligation_iI_pn5n6_c20241231__srt--ProductOrServiceAxis__custom--RevenueCycleManagementMember_zwQQRLvCgL6c" title="Revenue, remaining performance obligation, amount">3.5 </span>million. We expect to recognize substantially all of the revenue for the remaining performance obligations over the next three months. Approximately $<span id="xdx_90A_eus-gaap--ContractWithCustomerAssetNet_iI_pn3p0_c20241231__srt--ProductOrServiceAxis__custom--GroupPurchasingServicesMember_zfMinHQ4hvGh" title="Contract with customer asset">318,000</span> and $<span id="xdx_90B_eus-gaap--ContractWithCustomerAssetNet_iI_c20241231__srt--ProductOrServiceAxis__custom--ReferralFeesMember_zavMWGkSIYu3" title="Contract with customer asset">476,000</span> of the contract asset represents revenue earned, not paid, from the group purchasing services and referral fees, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts that we are entitled to collect under the applicable contract are recorded as accounts receivable. Invoicing is performed at the end of each month when the services have been provided. The contract asset includes our right to payment for services already transferred to a customer when the right to payment is conditional on something other than the passage of time. For example, contracts for revenue cycle management services where we recognize revenue over time but do not have a contractual right to payment until the customer receives payment of their claim from the insurance provider. The contract asset also includes the revenue accrued, not received, for the group purchasing services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the contract asset are recorded as adjustments to net revenue. The changes primarily result from providing services to revenue cycle management customers that result in additional consideration and are offset by our right to payment for services becoming unconditional and changes in the revenue accrued for the group purchasing services. The contract asset for our group purchasing services is reduced when we receive payments from vaccine manufacturers and is increased for revenue earned, not received. The opening and closing balances of the Company’s accounts receivable, contract asset and deferred revenue are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_ecustom--ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueTableTextBlock_zB9VyEq3kV8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zjP5S5tMILR2" style="display: none">SCHEDULE OF CHANGES IN ACCOUNTS RECEIVABLE, CONTRACT ASSET AND DEFERRED REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Accounts</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Receivable - Net</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Contract</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Asset</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Deferred Revenue</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>(current)</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Deferred Revenue</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>(long term)</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td></tr> <tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: normal 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font: normal 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">($ in thousands)</span></td><td style="font: normal 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Balance as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_903_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20240101__20241231_zrN1FwXLoDw4" title="Accounts Receivable - Net, Opening">11,888</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_pn3n3_c20240101__20241231_z1636xTtbWlh" title="Contract Assets, Opening">5,094</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20240101__20241231_z7SKj9L1DtUe" title="Deferred Revenue (current), Opening">1,380</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ContractWithCustomerLiabilityNoncurrent_iS_pn3n3_c20240101__20241231_zvIMaW9uOva5" title="Deferred Revenue (long term), Opening">256</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Increase (decrease), net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--IncreaseDecreaseInReceivables_iN_pn3n3_di_c20240101__20241231_z7dJtPf5gZX7" title="Accounts Receivable - Net, increase (decrease), net">886</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--IncreaseDecreaseInContractWithCustomerAsset_pn3n3_c20240101__20241231_zTmJvDASZXg4" title="Contract Asset, (decrease) increase, net">(760</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--IncreaseDecreaseInContractWithCustomerLiabilityCurrent_iN_pn3n3_di_c20240101__20241231_zG7R5GxEKrGf" title="Deferred Revenue (current), (decrease) increase, net">(168</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--IncreaseDecreaseInDeferredRevenueLongTerm_pn3n3_c20240101__20241231_zG9sxObJpLAf" title="Deferred Revenue (long term), increase (decrease), net">131</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance as of  December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20240101__20241231_zOqddiBIeuw9" title="Accounts Receivable - Net, Closing">12,774</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_pn3n3_c20240101__20241231_zsNh7oA3vEsg" title="Contract Assets, Closing">4,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20240101__20241231_zcZMctXeEQef" title="Deferred Revenue (current), Closing">1,212</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ContractWithCustomerLiabilityNoncurrent_iE_pn3n3_c20240101__20241231_zL8ugM5nwLG6" title="Deferred Revenue (long term), Closing">387</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20230101__20231231_zDxh2S8oSUMa" title="Accounts Receivable - Net, Opening">14,773</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_pn3n3_c20230101__20231231_zbQez3fQP9Ie" title="Contract Assets, Opening">4,399</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20230101__20231231_zPcLMbQqwTad" title="Deferred Revenue (current), Opening">1,386</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ContractWithCustomerLiabilityNoncurrent_iS_pn3n3_c20230101__20231231_zKXNcGgG22n4" title="Deferred Revenue (long term), Opening">342</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">(Decrease) increase, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--IncreaseDecreaseInReceivables_iN_pn3n3_di_c20230101__20231231_zkqAP3iwk6ub" title="Accounts Receivable - Net, increase (decrease), net">(2,885</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--IncreaseDecreaseInContractWithCustomerAsset_pn3n3_c20230101__20231231_zJy6Bup2plIf" title="Contract Asset, (decrease) increase, net">695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--IncreaseDecreaseInContractWithCustomerLiabilityCurrent_iN_pn3n3_di_c20230101__20231231_zcwYMShE60Pd" title="Deferred Revenue (current), increase (decrease), net">(6</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--IncreaseDecreaseInDeferredRevenueLongTerm_pn3n3_c20230101__20231231_zTklBsZCCLjf" title="Deferred Revenue (long term), increase (decrease), net">(86</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance as of  December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20230101__20231231_zau2zmu4NyHf" title="Accounts Receivable - Net, Closing">11,888</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_pn3n3_c20230101__20231231_zAharBn45iz7" title="Contract Assets, Closing">5,094</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20230101__20231231_zjqRurJvOifk" title="Deferred Revenue (current), Closing">1,380</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ContractWithCustomerLiabilityNoncurrent_iE_pn3n3_c20230101__20231231_zSO2E1yrmUR7" title="Deferred Revenue (long term), Closing">256</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zBkLwn6XKb3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred revenue:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount of deferred revenue at the beginning of the year and recognized during the year ended December 31, 2024 and 2023 was approximately $<span id="xdx_900_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20240101__20241231_zB90DjN55w01" title="Deferred revenue">909,000</span> and $<span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn5n6_c20230101__20231231_zJehhScGZ4ej" title="Deferred revenue">1.1</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred commissions:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our sales incentive plans include commissions payable to employees and third parties at the time of the initial contract execution that are capitalized as incremental costs to obtain a contract. The capitalized commissions are amortized over the period the related services are transferred. As we do not offer commissions on contract renewals, we have determined the amortization period to be the estimated client life, which is three years. Deferred commissions were approximately $<span id="xdx_906_ecustom--DeferredCommissions_iI_pn3p0_c20241231__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherNoncurrentAssetsMember_zEofUrxa4Sq9">386,000</span> and $<span id="xdx_902_ecustom--DeferredCommissions_iI_pn3p0_c20231231__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherNoncurrentAssetsMember_ziird0RK07hb">517,000</span> at December 31, 2024 and 2023, respectively, and are included in the other assets amounts in the consolidated balance sheets. The amortization of deferred sales commissions during the years ended December 31, 2024 and 2023 was approximately $<span id="xdx_90C_eus-gaap--AmortizationOfDeferredSalesCommissions_pn3d_c20240101__20241231_z1EtzjbK8jT5" title="Amortization of deferred sales commissions">327,000</span> and $<span id="xdx_906_eus-gaap--AmortizationOfDeferredSalesCommissions_pn3d_c20230101__20231231_zqX21i9ikip7" title="Amortization of deferred sales commissions">487,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trade Accounts Receivable – Estimate of Credit Losses:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASU 2016-13 requires the recognition of lifetime estimated credit losses expected to occur for trade accounts receivable. The guidance also requires we pool assets with similar risk characteristics and consider current economic conditions when estimating losses. The adoption of the ASU 2016-13 for trade accounts receivable was recorded as a charge to accumulated deficit of approximately $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn3d_c20230101__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--TradeAccountsReceivableMember__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201613Member_z2G43kDLW0Ud" title="Accumulated deficit">186,000</span> as of January 1, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At adoption, we segmented the accounts receivable population into pools based on their risk assessment. Risks related to trade accounts receivable are a customer’s inability to pay or bankruptcy. Each pool was defined by their internal credit assessment and business size. The pools are aligned with management’s review of financial performance. For the years ended December 31, 2024 and 2023, no adjustment to the pools was necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We utilize a loss-rate method to measure the expected credit loss for each pool. The loss rate is calculated using a three-year lookback period of write-offs and adjustments, divided by the revenue for each pool by aging category, net of customer payments during that period. We consider current and future economic conditions, internal forecasts, customer collection experience and credit memos issued during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data for the current quarter. In addition, the Company uses specific account identification in determining the total allowance for expected credit losses. Trade receivables are written off only after the Company has exhausted all collection efforts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zaVu45khK39k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the allowance for expected credit losses for trade accounts receivable are presented in the table below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zbqhNy4NS1dh" style="display: none">SCHEDULE OF TRADE ALLOWANCE FOR DOUBTFUL ACCOUNTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20241231_zhbNIbgziNra" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zw2ZNcJbBq32" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands) </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_406_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_pn3n3_zawzquS4koHe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Beginning balance</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">879</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">823</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccountsReceivableChangeInMethodCreditLossExpenseReversal_pn3n3_zmWElMsGSSkk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Adoption of ASC 326</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">186</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ProvisionForDoubtfulAccounts_pn3n3_z4WJgxx3N07j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Provision</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">334</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AllowanceForDoubtfulAccountsReceivableRecoveriesAdjustments_pn3n3_zIKwKQ31ejp7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Recoveries/adjustments</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">107</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_pn3n3_di_zANBkZYslUaa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Write-offs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(378</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(691</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_pn3n3_zT5Oj2Jl7ND9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Ending balance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">837</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">879</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zNXq0VkQSKAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_89A_eus-gaap--DisaggregationOfRevenueTableTextBlock_ziDEVBEg8OAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents a disaggregation of revenue for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zGmVvIVy4vAd" style="display: none">SCHEDULE OF DISAGGREGATION OF REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20241231_znuPpctMHaGf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_z66X8p1N4Eg7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Healthcare IT:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember__srt--ProductOrServiceAxis__custom--TechnologyEnabledBusinessSolutionsMember_zfOyJwivbKWc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Technology-enabled business solutions</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">73,672</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">76,640</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember__srt--ProductOrServiceAxis__custom--ProfessionalServicesMember_zOHVOUJcjtW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Professional services</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18,202</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23,022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember__srt--ProductOrServiceAxis__custom--PrintingAndMailingServicesMember_zHqWpCTcVHIg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Printing and mailing services</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,579</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,968</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember__srt--ProductOrServiceAxis__custom--GroupPurchasingServicesMember_zmnLHm0Lj9g3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Group purchasing services</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">952</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,053</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Medical Practice Management:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--MedicalPracticeManagementMember_zwwdzOb0OHci" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Medical practice management services</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,432</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,376</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_z1Q4x5tIyJgd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">110,837</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">117,059</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zNTXPWgXz08" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">110,837</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">117,059</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 73672000 76640000 18202000 23022000 3579000 2968000 952000 1053000 14432000 13376000 110837000 117059000 110837000 117059000 3000000.0 1500000 779000 400000 338000 100000 3500000 318000 476000 <p id="xdx_89C_ecustom--ScheduleOfChangesInAccountsReceivableContractAssetAndDeferredRevenueTableTextBlock_zB9VyEq3kV8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zjP5S5tMILR2" style="display: none">SCHEDULE OF CHANGES IN ACCOUNTS RECEIVABLE, CONTRACT ASSET AND DEFERRED REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Accounts</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Receivable - Net</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Contract</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Asset</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Deferred Revenue</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>(current)</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Deferred Revenue</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>(long term)</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td></tr> <tr style="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: normal 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td><td style="font: normal 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font: normal 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">($ in thousands)</span></td><td style="font: normal 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Balance as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_903_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20240101__20241231_zrN1FwXLoDw4" title="Accounts Receivable - Net, Opening">11,888</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_pn3n3_c20240101__20241231_z1636xTtbWlh" title="Contract Assets, Opening">5,094</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20240101__20241231_z7SKj9L1DtUe" title="Deferred Revenue (current), Opening">1,380</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_902_eus-gaap--ContractWithCustomerLiabilityNoncurrent_iS_pn3n3_c20240101__20241231_zvIMaW9uOva5" title="Deferred Revenue (long term), Opening">256</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Increase (decrease), net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--IncreaseDecreaseInReceivables_iN_pn3n3_di_c20240101__20241231_z7dJtPf5gZX7" title="Accounts Receivable - Net, increase (decrease), net">886</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--IncreaseDecreaseInContractWithCustomerAsset_pn3n3_c20240101__20241231_zTmJvDASZXg4" title="Contract Asset, (decrease) increase, net">(760</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--IncreaseDecreaseInContractWithCustomerLiabilityCurrent_iN_pn3n3_di_c20240101__20241231_zG7R5GxEKrGf" title="Deferred Revenue (current), (decrease) increase, net">(168</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--IncreaseDecreaseInDeferredRevenueLongTerm_pn3n3_c20240101__20241231_zG9sxObJpLAf" title="Deferred Revenue (long term), increase (decrease), net">131</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance as of  December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20240101__20241231_zOqddiBIeuw9" title="Accounts Receivable - Net, Closing">12,774</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_pn3n3_c20240101__20241231_zsNh7oA3vEsg" title="Contract Assets, Closing">4,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20240101__20241231_zcZMctXeEQef" title="Deferred Revenue (current), Closing">1,212</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ContractWithCustomerLiabilityNoncurrent_iE_pn3n3_c20240101__20241231_zL8ugM5nwLG6" title="Deferred Revenue (long term), Closing">387</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_c20230101__20231231_zDxh2S8oSUMa" title="Accounts Receivable - Net, Opening">14,773</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_pn3n3_c20230101__20231231_zbQez3fQP9Ie" title="Contract Assets, Opening">4,399</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_c20230101__20231231_zPcLMbQqwTad" title="Deferred Revenue (current), Opening">1,386</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ContractWithCustomerLiabilityNoncurrent_iS_pn3n3_c20230101__20231231_zKXNcGgG22n4" title="Deferred Revenue (long term), Opening">342</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">(Decrease) increase, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--IncreaseDecreaseInReceivables_iN_pn3n3_di_c20230101__20231231_zkqAP3iwk6ub" title="Accounts Receivable - Net, increase (decrease), net">(2,885</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--IncreaseDecreaseInContractWithCustomerAsset_pn3n3_c20230101__20231231_zJy6Bup2plIf" title="Contract Asset, (decrease) increase, net">695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--IncreaseDecreaseInContractWithCustomerLiabilityCurrent_iN_pn3n3_di_c20230101__20231231_zcwYMShE60Pd" title="Deferred Revenue (current), increase (decrease), net">(6</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--IncreaseDecreaseInDeferredRevenueLongTerm_pn3n3_c20230101__20231231_zTklBsZCCLjf" title="Deferred Revenue (long term), increase (decrease), net">(86</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance as of  December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_c20230101__20231231_zau2zmu4NyHf" title="Accounts Receivable - Net, Closing">11,888</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_pn3n3_c20230101__20231231_zAharBn45iz7" title="Contract Assets, Closing">5,094</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_c20230101__20231231_zjqRurJvOifk" title="Deferred Revenue (current), Closing">1,380</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ContractWithCustomerLiabilityNoncurrent_iE_pn3n3_c20230101__20231231_zSO2E1yrmUR7" title="Deferred Revenue (long term), Closing">256</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 11888000 5094000 1380000 256000 -886000 -760000 168000 131000 12774000 4334000 1212000 387000 14773000 4399000 1386000 342000 2885000 695000 6000 -86000 11888000 5094000 1380000 256000 909000 1100000 386000 517000 327000 487000 186000 <p id="xdx_890_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zaVu45khK39k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the allowance for expected credit losses for trade accounts receivable are presented in the table below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zbqhNy4NS1dh" style="display: none">SCHEDULE OF TRADE ALLOWANCE FOR DOUBTFUL ACCOUNTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20241231_zhbNIbgziNra" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zw2ZNcJbBq32" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands) </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_406_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iS_pn3n3_zawzquS4koHe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Beginning balance</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">879</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">823</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccountsReceivableChangeInMethodCreditLossExpenseReversal_pn3n3_zmWElMsGSSkk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Adoption of ASC 326</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">186</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ProvisionForDoubtfulAccounts_pn3n3_z4WJgxx3N07j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Provision</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">334</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AllowanceForDoubtfulAccountsReceivableRecoveriesAdjustments_pn3n3_zIKwKQ31ejp7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Recoveries/adjustments</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">107</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllowanceForDoubtfulAccountsReceivableWriteOffs_iN_pn3n3_di_zANBkZYslUaa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Write-offs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(378</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(691</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iE_pn3n3_zT5Oj2Jl7ND9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Ending balance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">837</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">879</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 879000 823000 186000 334000 454000 2000 107000 378000 691000 837000 879000 <p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zsLfCmpiCe1e" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zwPiK0oHtc43">SHAREHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 11, 2024 a Certificate of Amendment (the “Amendment”) to the Certificate of Designations, Preferences and Rights of <span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20240911__20240911__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificateOfAmendmentMember_zcBcQDporWl2" title="Preferred stock dividend rate">11</span>% Series A Cumulative Redeemable Preferred Stock (the “Existing Certificate”) became effective, amending certain provisions of the <span id="xdx_90F_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20240911__20240911__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificateOfAmendmentMember_zwqsA1xsNoQ6" title="Preferred stock dividend rate">11</span>% Series A Cumulative Redeemable Preferred Stock (the “Series A Preferred Stock”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The title of the Existing Certificate was amended to read “Amended and Restated Certificate of Designations, Preferences and Rights of <span id="xdx_902_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20240911__20240911__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zmSwSjjoHesf" title="Preferred stock dividend rate">8.75</span>% Series A Cumulative Redeemable Perpetual Preferred Stock.” Holders of Series A Preferred Stock will now receive similar change of control protections to those afforded to holders of the Company’s Series B Preferred Stock. The dividend of Series A Preferred Stock was amended from <span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20240911__20240911__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificateOfAmendmentMember_zoNWRaXwXhF8" title="Preferred stock dividend rate">11</span>% to <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20240911__20240911__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zb7zgkXko4P4" title="Preferred stock dividend rate">8.75</span>% per annum and the per annum dividend amount per share was amended from $<span id="xdx_900_eus-gaap--PreferredStockDividendRatePerDollarAmount_pid_c20240911__20240911__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificateOfAmendmentMember_zuHSsWmjD3p1" title="Preferred stock dividend amount per share">2.75</span> to $<span id="xdx_90E_eus-gaap--PreferredStockDividendRatePerDollarAmount_pid_c20240911__20240911__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z15bci5USVP1" title="Preferred stock dividend amount per share">2.1875</span> per share per annum. Also, the Company now has the right to exchange the shares of Series A Preferred Stock for common stock at the liquidation preference value of $<span id="xdx_905_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20240911__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkKHUvJv05ga" title="Preferred stock liquidation preference">25</span> per share, plus accrued and unpaid dividends. (See Note 20)</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Treasury stock</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors of the Company previously approved common stock repurchase programs. The last program expired <span id="xdx_903_esrt--StockRepurchaseProgramExpirationDate_dd_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--TreasuryStockOneMember_z3uNkeQJu3Mc" title="Stock repurchase program expiration date">January 25, 2017</span>. As a result of these stock repurchases, the Company has <span id="xdx_909_eus-gaap--TreasuryStockCommonShares_iI_pid_c20241231_zLNNmjmj2GP4" title="Common shares held as treasury stock, shares">740,799</span> common shares held as treasury stock at an aggregate cost of $<span id="xdx_901_eus-gaap--TreasuryStockValue_iI_pp0p0_c20241231_zeXqJ8iSiffh" title="Common shares held as treasury stock, cost">662,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common stock</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had the right to sell up to $<span id="xdx_90B_ecustom--SharesAuthorizedForSaleValue_iI_pn6n6_c20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketFacilityMember_zQPGCU51jWz5" title="Common stock available for sale">50</span> million of its common stock using an “at-the-market” facility (“ATM”). The underwriter receives <span id="xdx_90D_ecustom--UnderwriterCommissionFeesPercentage_pid_dp_uPure_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketFacilityMember_zPDWkohQHawf" title="Under writer commission fees percentage">3</span>% of the gross proceeds. During the years ended December 31, 2024 and 2023, <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_do_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketFacilityMember_zVIRIJRxmQf" title="Sale of stock, number of shares issued in transaction"><span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_do_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketFacilityMember_zTlXFHudBN88" title="Sale of stock, number of shares issued in transaction">no</span></span> shares of common stock were issued under this ATM. This right terminated when the Company suspended the Preferred Stock dividends.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--CommonStockVotingRights_c20240101__20241231_zjEAwMOsNuGa" title="Common stock, voting rights">Holders of our common stock are entitled to one vote for each share held on all matters properly submitted to a vote of shareholders on which holders of common stock are entitled to vote.</span> Holders of common stocks are entitled to receive dividends only at times and amounts as determined by the Board of Directors. The common stock is not entitled to pre-emptive rights, and is not subject to conversion, redemption or sinking fund provisions. The common stock is listed on the Nasdaq Global Market under the trading symbol “CCLD.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Preferred stock</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_pid_dc_uShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z2b22Apjmm6h" title="Number of shares authorized">seven million</span> authorized shares of preferred stock of which <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zceX4Oimpsf4" title="Preferred stock, shares authorized">4,560,000</span> have been designated as Series A shares and the balance have been designated as Series B shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also had the right to sell up to $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn6n6_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketFacilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--RangeAxis__srt--MaximumMember_zJMlt6QV457a" title="Authorized sale of stock, value">35</span> million of its Series B Preferred Stock using an ATM facility. This right terminated when the Company suspended the Preferred Stock dividends. The ATM facility’s underwriter received <span id="xdx_90F_ecustom--UnderwriterCommissionFeesPercentage_pid_dp_uPure_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketFacilityMember_zWKZd6CuBqlj" title="Underwriter commission fees percentage">3</span>% of the gross proceeds. During the year ended December 31, 2023, the Company sold <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketFacilityMember_zlfXc9Bxtbi6" title="Sale of stock, shares">59,773</span> of shares of Series B Preferred Stock under the Company’s ATM and received net proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn5n6_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketFacilityMember_z1DStBjavJ21" title="Proceeds from issuance of Series B Preferred Stock, net of expenses">1.4</span> million. During the year ended December 31, 2024, no shares of Series B Preferred Stock were issued under this ATM.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since September 11, 2024, we may, at our option, convert the majority of the Series A Preferred Stock into common stock at any time. If we convert the Series A Preferred Stock, then subsequent to the conversion date, dividends will cease to accrue on shares of the Series A Preferred Stock, the shares of the Series A Preferred Stock shall no longer be deemed outstanding and all rights as a holder of those shares will terminate, except the right to receive the shares of common stock plus accumulated and unpaid dividends, if any, payable upon the conversion. (See Note 20).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since November 4, 2020, the Company has the right to redeem, at its option, the Series A Preferred Stock, in whole or in part, at a cash redemption price of $<span id="xdx_905_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20201104__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLPPWUX0U8sl">25.00</span> per share, plus all accrued and unpaid dividends to, but not including, the redemption date. The Series A Preferred Stock has no stated maturity, is not subject to any sinking fund or other mandatory redemption, and is not convertible at the option of the holder into or exchangeable for any of the Company’s other securities. Holders of the Series A Preferred Stock have no voting rights except for limited voting rights if dividends payable on the Series A Preferred Stock are in arrears for eighteen or more consecutive or non-consecutive monthly dividend periods, at which time they are entitled to appoint two additional directors to our Board of Directors. If the Company were to liquidate, dissolve or wind up, the holders of the Series A Preferred Stock will have the right to receive $<span id="xdx_909_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20201104__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTfrfSgyq402">25.00</span> per share, plus any accumulated and unpaid dividends to, but not including, the date of payment, before any payment is made to the holders of the common stock. The Series A Preferred Stock is listed on the Nasdaq Global Market under the trading symbol “CCLDP.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since February 15, 2024 and prior to February 15, 2025, we were able to redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $<span id="xdx_909_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20240215__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zXCOvvg0er67" title="Accrued unpaid dividend per share">25.75</span> per share, plus all accrued and unpaid dividends to, but not including, the redemption date. On or after February 15, 2025 and prior to February 15, 2026, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $<span id="xdx_90B_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20250215__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCKM0TFLyuRa" title="Accrued unpaid dividend per share">25.50</span> per share, plus all accrued and unpaid dividends to, but not including, the redemption date. On or after February 15, 2026 and prior to February 15, 2027, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $<span id="xdx_90B_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20260215__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zT9lo7VgS0N7" title="Preferred stock, redemption price per share">25.25</span> per share, plus all accrued and unpaid dividends to, but not including, the redemption date. On or after February 15, 2027, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $<span id="xdx_90A_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20270215__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLtywhvgSTaf" title="Preferred stock, redemption price per share">25.00</span> per share, plus all accrued and unpaid dividends to, but not including, the redemption date. The Series B Preferred Stock is listed on the Nasdaq Global Market under the trading symbol “CCLDO.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends on the Series A and Series B Preferred Stock of $<span id="xdx_904_eus-gaap--PreferredStockDividendsPerShareCashPaid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAndSeriesBPreferredStockMember_z58X0R3bV7Wf" title="Preferred stock, per share amounts of preferred dividends in arrears">2.75</span> (through September 11, 2024 and $<span id="xdx_908_eus-gaap--PreferredStockDividendsPerShareCashPaid_c20240911__20240911__us-gaap--StatementClassOfStockAxis__custom--SeriesAAndSeriesBPreferredStockMember_z1HWKbF2F4Cc" title="Preferred stock, dividend per share">2.19</span> thereafter) and $<span id="xdx_90D_eus-gaap--PreferredStockDividendsPerShareCashPaid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAAndSeriesBPreferredStockMember_zeVK1gFyAzJ4" title="Preferred stock, dividend per share">2.19</span> annually per share respectively, are cumulative from the date of issue and are payable each month when, as and if declared by the Company’s Board of Directors. In October 2023, the Board of Directors declared monthly dividends on the Series A and Series B Preferred Stock payable through February 2024. However, on December 11, 2023, the Board of Directors suspended the monthly cash dividends for Series A Preferred Stock and Series B Preferred Stock beginning with the payment scheduled for December 15, 2023 together with the remaining dividends that were declared. The suspension of these dividends deferred approximately $<span id="xdx_90A_eus-gaap--DividendsShareBasedCompensationCash_pn5n6_c20240911__20240911_z0C54x8lrDvh" title="Dividend, share-based payment arrangement, cash">1.3</span> million in cash dividend payments each month through September 11, 2024. Due to the above Amendment, effective on September 12, 2024, the combined monthly cash dividends were reduced to approximately $<span id="xdx_90B_eus-gaap--DividendsShareBasedCompensationCash_pn5n6_c20240912__20240912_zPh3wbJCStEg" title="Dividend, share-based payment arrangement, cash">1.1</span> million per month.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the suspension, dividends continued to accrue in arrears on the Series A and Series B Preferred Stock. The Company’s Board of Directors declared payment of two months of dividends in January 2025 and the Company resumed payment of the dividends in February 2025, paying one month of dividends in arrears at that time. The second payment is scheduled for March 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2024, no dividends were declared by the Board of Directors. At December 31, 2024, the Company owed approximately $<span id="xdx_90A_eus-gaap--DividendsShareBasedCompensationCash_pn5n6_c20240101__20241231_zN1aOkFB3iIg" title="Dividend, share-based payment arrangement, cash">5.4</span> million for dividends that had previously been declared through February 2024 (but whose payment was suspended), and also had total undeclared dividends of approximately $<span id="xdx_90C_ecustom--DividendsUndeclared_pn5n6_c20240101__20241231_zyx77718Eu6c" title="Dividends undeclared">12.3</span> million, which represents the accumulated (but undeclared) dividends due to Preferred Stock shareholders of record on December 31, 2024. Dividends that have accrued in arrears but which have not been declared by the Board of Directors are not recorded in the consolidated balance sheets but are reflected in the net loss attributable to common shareholders. Total dividends in arrears at December 31, 2024 amounted to approximately $<span id="xdx_901_eus-gaap--PreferredStockAmountOfPreferredDividendsInArrears_pn5n6_c20240101__20241231_z18QZbNB0P5i" title="Dividends in arrears">17.7</span> million or $<span id="xdx_90A_eus-gaap--PreferredStockPerShareAmountsOfPreferredDividendsInArrears_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdmga0Nktlk2" title="Dividends in arrears, per share">3.04</span> per share for the Series A Preferred Stock and $<span id="xdx_905_eus-gaap--PreferredStockPerShareAmountsOfPreferredDividendsInArrears_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zSdnGDlOVzEd" title="Dividends in arrears, per share">2.55</span> per share for the Series B Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Warrants</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has issued <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLSlWOW2IU5l" title="Warrants issued">6,603,489</span> warrants for its common stock, of which <span id="xdx_90B_ecustom--WarrantsExpiredUnexercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpaoIHtKWxO2" title="Warrants expired unexercised">1,128,489</span> warrants expired unexercised during 2023. There were <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_do_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfq38PN2PLrk" title="Warrant outstanding"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_do_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrqekDk54n6l" title="Warrant outstanding">no</span></span> warrants outstanding at December 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurs common and preferred stock offering costs which consist principally of professional fees, primarily legal and accounting, and other costs such as printing and registration costs. In connection with the 2023 equity offerings, the Company incurred approximately $<span id="xdx_90E_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20230101__20231231_zsUmWtgbDxi3" title="Issuance costs">71,000</span> of such costs, including underwriting commissions and placement agent fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.11 0.11 0.0875 0.11 0.0875 2.75 2.1875 25 2017-01-25 740799 662000 50000000 0.03 0 0 Holders of our common stock are entitled to one vote for each share held on all matters properly submitted to a vote of shareholders on which holders of common stock are entitled to vote. 7000000 4560000 35000000 0.03 59773 1400000 25.00 25.00 25.75 25.50 25.25 25.00 2.75 2.19 2.19 1300000 1100000 5400000 12300000 17700000 3.04 2.55 6603489 1128489 0 0 71000 <p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zM4T0l82pUM4" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_825_zH77RtQHcPub">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal Proceedings</b> — On December 9, 2022, an arbitrator rendered a decision in favor of MTBC Acquisition Corp. (“MAC”) and dismissed the claims brought against MAC by Randolph Pain Relief and Wellness Center (“RPRWC”), determining that RPRWC failed to prove any breach of the applicable billing services agreement and failed to prove that any alleged damages were due. The deadline for RPRWC to file a summary action in Superior Court of New Jersey seeking to overturn the arbitrator’s decision was April 5, 2023 and no summary action was filed by such deadline. As such, the arbitrator’s decision dismissing RPRWC’s claims is final.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 22, 2023, an arbitrator rendered a decision in favor of Ramapo Anesthesiologists, PC (“Ramapo”) and granted in part and denied in part certain claims brought against Origin Healthcare Solutions, LLC; Meridian Medical Management, Inc.; and the Company for alleged breach of contract and other allegations. Ramapo was awarded mitigation related costs of $<span id="xdx_905_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20231222__20231222__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RamapoAnesthesiologistsPCMember_zbV4TmrYUv5h" title="Mitigation related costs">117,000</span>. The payment for such an award was made during the first quarter of 2024. The Company’s portion of the settlement is approximately $<span id="xdx_90E_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_c20231222__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RamapoAnesthesiologistsPCMember__us-gaap--BalanceSheetLocationAxis__custom--AccruedExpensesMember_z7s0kA1qYjph" title="Mitigation settlement payable">32,000</span> and the insurance company paid the balance. The Company’s portion was recorded in accrued expenses at December 31, 2023 in the consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A former customer filed a complaint against the Company in New Jersey State Court to recover damages claimed to have been caused by the mishandling of their account. Plaintiff alleged at least approximately $<span id="xdx_900_eus-gaap--LossContingencyDamagesPaidValue_c20210301__20210331_zqbrp0gsfgm" title="Damages paid value">750,000</span> in damages which was disputed by the Company. The parties participated in a one-day court-ordered, non-binding arbitration. At that time, the arbitrator awarded Plaintiff $<span id="xdx_901_eus-gaap--LossContingencyDamagesSoughtValue_c20210301__20210331_z0CSC7D0xXD6" title="Claim damages">288,750</span> on its contract claims, and awarded the Company $<span id="xdx_908_ecustom--LossContingencyUnpaidFees_c20210301__20210331_z2o0jcedk0zg" title="Unpaid fees">21,698</span> on its cross-claim for unpaid fees. Plaintiff filed to reject this award. The Company previously filed a partial motion for summary judgment on the alleged punitive damages, but the court denied that motion finding there is an issue of fact as to whether those can be awarded at trial. The Company filed an offer of judgment for $<span id="xdx_901_ecustom--AdvanceAmount_iI_c20240430_zk8p68CmubVb" title="Advance amount">200,000</span> during April 2024 which was accepted and paid in July 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with a prior acquisition, the seller had alleged that the Company owed approximately $<span id="xdx_902_eus-gaap--LossContingencyDamagesSoughtValue_c20240901__20240930_zbyZSfIi6sRa" title="Damages sought transition related costs">800,000</span> in transition related costs to them. The parties agreed to settle the claim for approximately $<span id="xdx_90B_eus-gaap--LitigationSettlementLoss_c20240901__20240930_zKXNBKvrkgll" title="Settlement claim amount">316,000</span>, which was paid in September 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, we may become involved in other legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of our management, would individually or taken together have a material adverse effect on our business, consolidated results of operations, financial position or cash flows of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 117000 32000 750000 288750 21698 200000 800000 316000 <p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zL4QKvYRBrF3" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_zRbv8AYADzRk">LEASES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We determine if an arrangement is a lease at inception. We have operating leases for office and temporary living space as well as for some office equipment. Operating leases are included in operating lease ROU assets, current operating lease liability and non-current operating lease liability in our consolidated balance sheets as of December 31, 2024 and 2023. The Company does not have any finance leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of the lease payments over the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rates, which are derived from information available at the lease commencement date, in determining the present value of lease payments. We give consideration to our bank financing arrangements, geographical location and collateralization of assets when calculating our incremental borrowing rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our lease terms include options to extend the lease when it is reasonably certain that we will exercise that option. <span id="xdx_900_ecustom--LeaseTermDescription_c20240101__20241231_zWPKYnKg3qU1" title="Lease term, description">Leases with a term of less than 12 months are not recorded in the consolidated balance sheets.</span> Our lease agreements do not contain any residual value guarantees. For real estate leases, we account for the lease and non-lease components as a single lease component. Some leases include escalation clauses and termination options that are factored in the determination of the lease payments when appropriate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a lease is modified after the effective date, the operating lease ROU asset and liability is re-measured using the current incremental borrowing rate. There was one lease modification during both years ended December 31, 2024 and 2023. We review our incremental borrowing rate for our portfolio of leases on a quarterly basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2024, there were <span id="xdx_909_ecustom--UnoccupiedLeaseCharges_do_c20240101__20241231_zbaFHADWy2je" title="Unoccupied lease charges">no </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unoccupied lease charges recorded as compared to approximately $<span id="xdx_90B_ecustom--UnoccupiedLeaseCharges_c20230101__20231231_z9CxyV4JTqQa" title="Unoccupied lease charges">169,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for two of the Company’s facilities for the year ended December 31, 2023. There were <span id="xdx_90C_eus-gaap--OperatingLeaseImpairmentLoss_do_c20230101__20231231_zLgWwNwLC7hl" title="Lease impairment"><span id="xdx_904_eus-gaap--OperatingLeaseImpairmentLoss_do_c20230101__20231231_zgwKjQHUfjbj" title="Lease impairment">no</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lease impairments recorded for the years ended December 31, 2024 and 2023. For the year ended December 31, 2024, there was a gain on lease terminations of approximately $<span id="xdx_907_eus-gaap--GainLossOnTerminationOfLease_c20240101__20241231_zBvPDfgQGwx5" title="Net gain (loss) on lease terminations">10,000</span>. For the year ended December 31, 2023, there was a loss on lease terminations of approximately $<span id="xdx_903_eus-gaap--GainLossOnTerminationOfLease_di_c20230101__20231231_znW3YHvlrKc1" title="Net gain (loss) on lease terminations">291,000</span>. These amounts are included in lease terminations, unoccupied lease charges and restructuring costs in the consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease expense is included in direct operating costs, general and administrative expense, selling and marketing expense and research and development expense in the consolidated statements of operations based on the nature of the expense. As of December 31, 2024, <span id="xdx_901_eus-gaap--LesseeOperatingLeaseDescription_c20240101__20241231_zhjpN5MbYUA2" title="Operating lease description">we had 28 leased properties, five in Medical Practice Management and 23 in Healthcare IT, with the remaining terms ranging from less than one year to eleven years. Our lease terms are determined taking into account lease renewal options, the Company’s anticipated operating plans and leases that are on a month-to-month basis</span>. We also have some related party leases – see Note 12.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_zy17Qr8tB4L1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of lease expense were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zUUX6fyNfbd4" style="display: none">SCHEDULE OF LEASE EXPENSE</span></span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240101__20241231_z9deswstogM5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231_zi6GfYuhj9x5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseCost_pn3n3_maLCzr6k_zbxWOCq3oZFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left">Operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">2,451</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">2,669</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzr6k_zNqJzSWfPvp7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short-term lease cost</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1505">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--VariableLeaseCost_pn3n3_maLCzr6k_zGOhhAAfRus5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Variable lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_mtLCzr6k_zrwGo6iOq5c6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total - net lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,483</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,701</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zOBqLJ63FOM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term lease cost represents leases that were not capitalized as the lease term as of the later of January 1, 2024 or the beginning of the lease was less than 12 months. Variable lease costs include utilities, real estate taxes and common area maintenance costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zCqZtttsICq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental balance sheet information related to leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zQfdgSoI4179" style="display: none">SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: italic bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20241231_zkCNxGbXwa5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20231231_zEdOnlaffIdg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating leases:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zR45paMBjiCh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Operating lease ROU assets, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,133</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">4,365</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzF46_zxuVKUDcAgkg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Current operating lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,287</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,888</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzF46_z1iW3byDDBIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Non-current operating lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,847</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,516</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzF46_zNMGoghVCLy5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,134</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,404</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating leases:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--OperatingLeaseRightOfUseAssetGross_iI_pn3n3_z8lFcmXuSqxb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">ROU assets</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,125</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,571</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AssetLeaseExpense_iI_pn3n3_zbTTJUCu5H7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Asset lease expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,994</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,152</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--ForeignExchangeGainLoss_iI_pn3n3_zku6jocHevHj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Foreign exchange gain/(loss)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(54</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_znPJ6DZWSfN5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">ROU assets, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,133</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,365</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zgNIkWSuWtli" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Operating lease right-of-use assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,133</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,365</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted average remaining lease term (in years):</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating leases</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_z3ZJKbHX8npb" title="Operating leases, Weighted average remaining lease term">5.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zxrvpGfpmFSc" title="Operating leases, Weighted average remaining lease term">4.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Weighted average discount rate:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zaL8GBHriPGe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating leases</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zrACeAFlLq9j" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating leases, Weighted average discount rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> </table> <p id="xdx_8A0_zAQt814QzDEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_ecustom--ScheduleOfSupplementalCashFlowAndOtherInformationRelatedToLeasesTableTextBlock_zpE9n1E8MEHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow and other information related to leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zdS2mPws1MC8" style="display: none">SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zUdvwqo5MVaf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231_zjsdpBUIxnDc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_zwgKDWTVLgJ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Operating cash flows from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">2,467</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,244</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">ROU assets obtained in exchange for lease liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zZVQUWIwHHv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating leases, excluding terminations</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">864</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,682</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zYdnSLVxMfng" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zb4wPdguFRrd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities of lease liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B0_zp1YI1D8GwRd" style="display: none">SCHEDULE OF MATURITIES OF LEASE LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="text-decoration: underline">Operating leases - Years ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241231_zHlol3G0HO9k" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzsF8_z3M4tkWgbDhd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: right">1,601</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzsF8_zN4HVnN4TG17" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">727</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzsF8_z83qeQpaJ9d6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">557</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzsF8_zMiYTQL0Guk6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">371</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzsF8_zTCLmHP0Uz3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2029</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">193</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzsF8_zixKuRi0Qnn7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzsF8_zKVcZ5NzYE4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total lease payments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,689</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zE2vIK1R7228" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,555</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zJaXWiKE7Cdk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total lease obligations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,134</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_z0aj6s6mi3s1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: current obligations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,287</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zfHSCzsuVESi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Long-term lease obligations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,847</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zdlklvHBJVy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases certain apartments which are subleased to others. The sublease agreements are currently on a month-to-month basis and are considered operating leases. For the year ended December 31, 2024, the Company received sublease income of approximately $<span id="xdx_900_eus-gaap--SubleaseIncome_pn3d_c20240101__20241231_zpcFNcIMSAmj" title="Sublease income">94,000</span>. There was <span id="xdx_90D_eus-gaap--SubleaseIncome_pn3d_do_c20230101__20231231_znj8bd9y6rX3" title="Sublease income">no </span>sublease income for the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b> </b></span></p> Leases with a term of less than 12 months are not recorded in the consolidated balance sheets. 0 169000 0 0 10000 -291000 we had 28 leased properties, five in Medical Practice Management and 23 in Healthcare IT, with the remaining terms ranging from less than one year to eleven years. Our lease terms are determined taking into account lease renewal options, the Company’s anticipated operating plans and leases that are on a month-to-month basis <p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_zy17Qr8tB4L1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of lease expense were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zUUX6fyNfbd4" style="display: none">SCHEDULE OF LEASE EXPENSE</span></span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240101__20241231_z9deswstogM5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231_zi6GfYuhj9x5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseCost_pn3n3_maLCzr6k_zbxWOCq3oZFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left">Operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">2,451</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">2,669</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzr6k_zNqJzSWfPvp7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Short-term lease cost</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1505">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--VariableLeaseCost_pn3n3_maLCzr6k_zGOhhAAfRus5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Variable lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_mtLCzr6k_zrwGo6iOq5c6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total - net lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,483</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,701</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2451000 2669000 4000 28000 32000 2483000 2701000 <p id="xdx_89F_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zCqZtttsICq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental balance sheet information related to leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zQfdgSoI4179" style="display: none">SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: italic bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20241231_zkCNxGbXwa5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20231231_zEdOnlaffIdg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating leases:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zR45paMBjiCh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Operating lease ROU assets, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,133</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">4,365</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzF46_zxuVKUDcAgkg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Current operating lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,287</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,888</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzF46_z1iW3byDDBIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Non-current operating lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,847</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,516</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzF46_zNMGoghVCLy5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,134</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,404</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating leases:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--OperatingLeaseRightOfUseAssetGross_iI_pn3n3_z8lFcmXuSqxb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">ROU assets</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,125</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,571</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AssetLeaseExpense_iI_pn3n3_zbTTJUCu5H7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Asset lease expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,994</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,152</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--ForeignExchangeGainLoss_iI_pn3n3_zku6jocHevHj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Foreign exchange gain/(loss)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(54</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_znPJ6DZWSfN5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">ROU assets, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,133</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,365</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zgNIkWSuWtli" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Operating lease right-of-use assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,133</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,365</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted average remaining lease term (in years):</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating leases</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_z3ZJKbHX8npb" title="Operating leases, Weighted average remaining lease term">5.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zxrvpGfpmFSc" title="Operating leases, Weighted average remaining lease term">4.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Weighted average discount rate:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zaL8GBHriPGe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating leases</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zrACeAFlLq9j" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating leases, Weighted average discount rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> </table> 3133000 4365000 1287000 1888000 1847000 2516000 3134000 4404000 5125000 6571000 -1994000 -2152000 2000 -54000 3133000 4365000 3133000 4365000 P5Y P4Y6M 0.142 0.133 0.142 0.133 <p id="xdx_898_ecustom--ScheduleOfSupplementalCashFlowAndOtherInformationRelatedToLeasesTableTextBlock_zpE9n1E8MEHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow and other information related to leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zdS2mPws1MC8" style="display: none">SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zUdvwqo5MVaf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231_zjsdpBUIxnDc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash paid for amounts included in the measurement of lease liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_zwgKDWTVLgJ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Operating cash flows from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">2,467</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,244</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">ROU assets obtained in exchange for lease liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zZVQUWIwHHv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating leases, excluding terminations</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">864</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,682</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> 2467000 3244000 864000 1682000 <p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zb4wPdguFRrd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities of lease liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B0_zp1YI1D8GwRd" style="display: none">SCHEDULE OF MATURITIES OF LEASE LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="text-decoration: underline">Operating leases - Years ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241231_zHlol3G0HO9k" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzsF8_z3M4tkWgbDhd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: right">1,601</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzsF8_zN4HVnN4TG17" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">727</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzsF8_z83qeQpaJ9d6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">557</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzsF8_zMiYTQL0Guk6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">371</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzsF8_zTCLmHP0Uz3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2029</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">193</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzsF8_zixKuRi0Qnn7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzsF8_zKVcZ5NzYE4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total lease payments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,689</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zE2vIK1R7228" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,555</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zJaXWiKE7Cdk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total lease obligations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,134</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_z0aj6s6mi3s1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: current obligations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,287</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_zfHSCzsuVESi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Long-term lease obligations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,847</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1601000 727000 557000 371000 193000 1240000 4689000 1555000 3134000 1287000 1847000 94000 0 <p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zn8ZaDRtRi5l" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_zkPO0ueBRcqd">RELATED PARTIES</span></b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had sales to a related party, a physician who is the wife of the Executive Chairman. Revenues from this customer were approximately $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--TitleOfIndividualAxis__custom--PhysicianMember_zODeTNFfNEEd" title="Net revenue">138,000</span> and $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--TitleOfIndividualAxis__custom--PhysicianMember_ztH0ktvRmbL5" title="Net revenue">125,000</span> for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, the accounts receivable balance due from this customer was approximately $<span id="xdx_900_eus-gaap--AccountsReceivableNetCurrent_iI_pp0p0_c20241231__srt--TitleOfIndividualAxis__custom--PhysicianMember_zjsEAnXDKH8f" title="Receivable due from customer">13,000</span> and $<span id="xdx_90C_eus-gaap--AccountsReceivableNetCurrent_iI_pp0p0_c20231231__srt--TitleOfIndividualAxis__custom--PhysicianMember_z7daE3Zqtq07" title="Receivable due from customer">18,000</span>, respectively, and is included in accounts receivable - net in the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases its corporate offices in New Jersey, its temporary housing for its foreign visitors, a storage facility, its backup operations center in Bagh, Pakistan and an apartment for temporary housing in Dubai, the UAE, from the Executive Chairman. The related party rent expense for the years ended December 31, 2024 and 2023 was approximately $<span id="xdx_90F_eus-gaap--PaymentsForRent_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveChairmanMember_z8tgN4Yq3t6d" title="Rent expense">281,000</span> and $<span id="xdx_90F_eus-gaap--PaymentsForRent_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveChairmanMember_zglJaf0oH6Yf" title="Rent expense">256,000</span>, respectively, and is included in direct operating costs and general and administrative expense in the consolidated statements of operations. During the years ended December 31, 2024 and 2023, the Company spent approximately $<span id="xdx_90B_eus-gaap--PaymentsForCapitalImprovements_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveChairmanMember_zdCAPl16uJye" title="Operating lease upgradations">979,000</span> and $<span id="xdx_901_eus-gaap--PaymentsForCapitalImprovements_pn5n6_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveChairmanMember_zocWrenxLpPf" title="Operating lease upgradations">1.8</span> million, respectively, to upgrade the related party leased facilities. During the year ended December 31, 2023, the Company temporarily advanced the Executive Chairman approximately $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExecutiveChairmanMember_zQV8IfwM78nh" title="Payments to related party">330,000</span>, to purchase vacant land surrounding the Bagh facility for the sole use and benefit of the Company in order to expedite the purchase on the Company’s behalf as only individuals with citizenship in Kashmir are allowed to purchase land in this region. All advanced amounts were repaid shortly after the advance was made. Current assets-related party in the consolidated balance sheets includes security deposits related to the leases of the Company’s corporate offices in the amount of approximately $<span id="xdx_90E_eus-gaap--OtherReceivablesNetCurrent_iI_c20241231_zFaGJxDOlWz9" title="Current assets - related party"><span id="xdx_90B_eus-gaap--OtherReceivablesNetCurrent_iI_c20231231_zm9tnDfSxOlg" title="Current assets - related party">16,000</span></span> for both the years ended December 31, 2024 and 2023. The Company also leases two facilities used for temporary housing from a management employee for approximately $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zMiwTG6OGoK1" title="Lease expense per month for temporary housing">6,500</span> per month.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included in the ROU asset at December 31, 2024 is approximately $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zk5qyA0CX6C4">550,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applicable to the related party leases. Included in the current and non-current operating lease liability at December 31, 2024 is approximately $<span id="xdx_907_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zpvDv7usGfi9">181,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSMm7sdUy0Yb">367,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, applicable to the related party leases. Included in the ROU asset at December 31, 2023 is approximately $<span id="xdx_90C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztMc1QBYVDf2">331,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applicable to the related party leases. Included in the current and non-current operating lease liability at December 31, 2023 is approximately $<span id="xdx_903_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zoB8Y8w05Ih4">182,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_906_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zLN6ueHoAshl">142,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, applicable to the related party leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During June 2022, the Company entered into a one-year consulting agreement with an entity owned and controlled by one of its former non-independent directors whereby that director received <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220601__20220630__srt--TitleOfIndividualAxis__custom--FormerNonIndependentDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zj1hta21PXhg" title="Shares issued for services">10,000</span> shares of the Company’s <span id="xdx_901_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220601__20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--TitleOfIndividualAxis__custom--FormerNonIndependentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zGRBICLNziah" title="Preferred stock dividend percentage">8.75</span>% Series B Cumulative Redeemable Perpetual Preferred Stock (“Series B Preferred Stock”) in exchange for assisting the Company to identify and acquire additional companies, including performing due diligence. In addition, the Company could make additional payments under the agreement for any successful acquisitions by the Company based on the purchase price of the transaction. No such additional payments were made in 2022. During February 2023, the agreement was amended and extended through December 2024 whereby the former director received <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230201__20230228__srt--TitleOfIndividualAxis__custom--FormerNonIndependentDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zDymigKCkPFk" title="Stock issued during period shares new issues">14,000</span> shares of Series B Preferred Stock in February 2023 and received an additional <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20240101__20240131__srt--TitleOfIndividualAxis__custom--FormerNonIndependentDirectorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuH12gHbyvJ" title="Shares issued for services">14,000</span> shares in January 2024. All of the payments made were capitalized and amortized over the service period. The amortization was recorded as stock compensation in general and administrative expense in the consolidated statement of operations. All such shares of the Series B Preferred Stock were issued in accordance with the Company’s Amended and Restated 2014 Equity Incentive Plan. In addition to the extension of the consulting agreement, the amendment provided that any transaction fees due will be offset against the last two above payments before any amounts are due to that former director. Effective February 1, 2024, the Company added an additional Statement of Work (“SOW”) to the consulting agreement with the same entity. As compensation for the SOW, the entity received $<span id="xdx_902_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240201__20240201__srt--TitleOfIndividualAxis__custom--FormerNonIndependentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zldO7Hfbwtth" title="Compensation for statement of work per month">25,000</span> per month. The SOW was cancelable with ten days’ notice. The consulting agreement and SOW, through mutual consent, were terminated as of April 30, 2024. There were no transaction fees paid through that date. Effective May 1, 2024, the former non-independent director became President of the Company and effective January 1, 2025 became Co-Chief Executive Officer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective January 9, 2024, and as amended February 12, 2024, the Company entered into a consulting agreement with an entity owned and controlled by a member of its Board of Directors to provide investor relations and other services as requested for $<span id="xdx_908_eus-gaap--OtherExpenses_pn3d_c20240212__20240212__srt--TitleOfIndividualAxis__custom--FormerNonIndependentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zaOvdNeELB31" title="Other expenses">8,000</span> per month (reduced to $<span id="xdx_90B_eus-gaap--OtherExpenses_pn3d_c20240901__20240901__srt--TitleOfIndividualAxis__custom--FormerNonIndependentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z0r5wn3tG8j9" title="Other expenses">2,000</span> per month effective September 1, 2024 and reduced to an as-needed basis effective January 1, 2025). The agreement was paid at the contractual amount plus amounts for additional services requested, and as of January 1, 2025, is paid on an hourly basis. The consulting agreement is cancelable with ten days’ notice. For the year ended December 31, 2024, the expense recorded under this agreement was approximately $<span id="xdx_905_eus-gaap--GeneralAndAdministrativeExpense_c20240101__20241231__srt--TitleOfIndividualAxis__custom--FormerNonIndependentDirectorsMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z6il3MIN8ce9" title="General and administrative expense">75,000</span> and is included in general and administrative expense in the consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2020, a New Jersey corporation, talkMD Clinicians, PA (“talkMD”), was formed by the wife of the Executive Chairman, who is a licensed physician, to provide telehealth services. talkMD was determined to be a variable interest entity (“VIE”) for financial reporting purposes because the entity will be controlled by the Company. As of December 31, 2024, talkMD had not yet commenced operations. Cumulatively, the Company has paid approximately $<span id="xdx_903_eus-gaap--IncomeTaxesPaid_c20240101__20241231__us-gaap--RelatedPartyTransactionAxis__custom--TalkMDCliniciansMember_znqx7dVOfvV2" title="Income taxes paid">6,000</span> on behalf of talkMD for income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 138000 125000 13000 18000 281000 256000 979000 1800000 330000 16000 16000 6500 550000 181000 367000 331000 182000 142000 10000 0.0875 14000 14000 25000 8000 2000 75000 6000 <p id="xdx_80C_eus-gaap--RestructuringAndRelatedActivitiesDisclosureTextBlock_zhNNw1YfU0Ce" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_zSwmgfkpB3Ma">RESTRUCTURING COSTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 2, 2023, the Company committed to effectively align resources with business priorities and improve profitability through a reduction in the workforce for the Healthcare IT segment. The Company identified opportunities for improvements in its workforce realignment, strategy and staffing, and increased its focus on performance management, to ensure it has the right skillsets and number of employees to execute its long-term vision. In addition, the Company instituted certain other expense reductions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A majority of the impacted employees exited in the fourth quarter of 2023. The Company estimates that it will incur expenses of approximately $<span id="xdx_904_eus-gaap--RestructuringAndRelatedCostExpectedCost1_iI_pn4n6_c20231231_z1ZlXXCXCX5f" title="Estimated restructuring expense">1.35</span> million related to the reduction in workforce of which approximately $<span id="xdx_908_eus-gaap--RestructuringCharges_pn3d_c20240101__20241231_zxZw5MIoPvc6" title="Restructuring expense incurred">606,000</span> and $<span id="xdx_90E_eus-gaap--RestructuringCharges_pn3d_c20230101__20231231_zcyEmMTD1RA4" title="Restructuring expense incurred">645,000</span> were incurred in 2024 and 2023, respectively, with the remaining expenses of approximately $<span id="xdx_909_eus-gaap--RestructuringCharges_pn3d_c20250101__20251231__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdyztinZCQc" title="Restructuring expense incurred">100,000</span> to be incurred in 2025. These restructuring expenses consisted of one-time termination benefits, including but not limited to, severance payments and healthcare benefits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z8euDxND69Il" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes restructuring costs for 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_z0V4oxok8FX9" style="display: none">SCHEDULE OF RESTRUCTURING COSTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240101__20241231_zx6xwsAjrb6a" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_zBKpAmFcchf7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40A_eus-gaap--SeveranceCosts1_pn3n3_maRCzvPp_zwVuPEku2FNg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Severance and separation costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">606</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">439</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EquityAwardsAccelerationCostsAssociatedWithSeverance_pn3n3_maRCzvPp_z82npNCYxgv7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity awards acceleration costs associated with severance</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1653">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">170</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherRestructuringCosts_pn3n3_maRCzvPp_zwU98e0Ylyl8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other exit related costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1656">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">36</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RestructuringCharges_iT_pn3n3_mtRCzvPp_zcG8wuanrMC4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFU1RSVUNUVVJJTkcgQ09TVFMgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20230101__20231231_zjS5mQX1Nu1k" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23RestructuringCostsAndAssetImpairmentCharges"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFU1RSVUNUVVJJTkcgQ09TVFMgKERldGFpbHMpAA__" id="xdx_904_eus-gaap--RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20240101__20241231_zv2bRz8p7mEb" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23RestructuringCostsAndAssetImpairmentCharges"><span style="-sec-ix-hidden: xdx2ixbrl1661"><span style="-sec-ix-hidden: xdx2ixbrl1662">Total restructuring and other costs</span></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">606</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">645</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zlcheXoIMEb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expense associated with the restructuring is included in lease terminations, unoccupied lease charges and restructuring costs in the consolidated statement of operations for the years ended December 31, 2024 and 2023. This line also includes $<span id="xdx_906_eus-gaap--GainLossOnTerminationOfLease_di_c20230101__20231231_zWoHIfmV8GOa" title="Net gain (loss) on lease terminations">291,000</span> for loss on lease terminations and $<span id="xdx_90B_ecustom--UnoccupiedLeaseCharges_c20230101__20231231_zcGSinF7qnJ8" title="Unoccupied lease charges">169,000</span> for unoccupied lease charges for the year ended December 31, 2023. The liabilities associated with restructuring costs are included in accrued expenses in the consolidated balance sheet. The following table summarizes activity related to liabilities associated with restructuring costs:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_ecustom--ScheduleOfLiabilitiesAssociatedWithRestructuringCostsTableTextBlock_ze6Czot7iHIg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zO9BXttvoWz5">SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B3_us-gaap--RestructuringCostAndReserveAxis_custom--SeveranceAndSeparationCostsMember_zcXlj8uEUSU4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Severance and separation costs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B7_us-gaap--RestructuringCostAndReserveAxis_custom--EquityAwardsAccelerationCostsAssociatedWithSeveranceMember_z3KeoGxrelm6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Equity awards acceleration costs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B5_us-gaap--RestructuringCostAndReserveAxis_custom--OtherExitRelatedCostsMember_z7BtCnZg5AWk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Other exit</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>related costs</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B5_z8W1OG9Wn31f" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total restructuring and other costs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="14" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_43D_c20240101__20241231_eus-gaap--RestructuringReserve_iS_pn3n3_zib2MGLzZ4S3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Balance as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">145</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1671">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">26</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">171</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RestructuringCharges_pn3n3_zGKChBX7fOq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">606</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1676">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1677">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">606</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PaymentsForRestructuring_iN_pn3n3_di_zWWBmzL4D9Bj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Payments and other adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(751</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1681">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(26</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(777</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43A_c20240101__20241231_eus-gaap--RestructuringReserve_iE_pn3n3_zL867nkJlet2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance as of  December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1685">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1686">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1687">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1688">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_430_c20230101__20231231_eus-gaap--RestructuringReserve_iS_pn3n3_zihqa1bVt0j1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1690">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1691">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1692">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1693">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RestructuringCharges_pn3n3_zYc6RNhhBcl7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">439</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">170</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">36</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">645</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PaymentsForRestructuring_iN_pn3n3_di_z9bUkNjSwsLe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Payments and other adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(294</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(170</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(10</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(474</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43B_c20230101__20231231_eus-gaap--RestructuringReserve_iE_pn3n3_zIZFOkeyX1n8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance as of  December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">145</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1706">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">171</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zlwWBarvzZm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> 1350000 606000 645000 100000 <p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z8euDxND69Il" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes restructuring costs for 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_z0V4oxok8FX9" style="display: none">SCHEDULE OF RESTRUCTURING COSTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240101__20241231_zx6xwsAjrb6a" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_zBKpAmFcchf7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40A_eus-gaap--SeveranceCosts1_pn3n3_maRCzvPp_zwVuPEku2FNg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Severance and separation costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">606</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">439</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EquityAwardsAccelerationCostsAssociatedWithSeverance_pn3n3_maRCzvPp_z82npNCYxgv7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Equity awards acceleration costs associated with severance</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1653">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">170</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherRestructuringCosts_pn3n3_maRCzvPp_zwU98e0Ylyl8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other exit related costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1656">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">36</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RestructuringCharges_iT_pn3n3_mtRCzvPp_zcG8wuanrMC4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFU1RSVUNUVVJJTkcgQ09TVFMgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20230101__20231231_zjS5mQX1Nu1k" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23RestructuringCostsAndAssetImpairmentCharges"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFU1RSVUNUVVJJTkcgQ09TVFMgKERldGFpbHMpAA__" id="xdx_904_eus-gaap--RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_dxL_c20240101__20241231_zv2bRz8p7mEb" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23RestructuringCostsAndAssetImpairmentCharges"><span style="-sec-ix-hidden: xdx2ixbrl1661"><span style="-sec-ix-hidden: xdx2ixbrl1662">Total restructuring and other costs</span></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">606</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">645</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 606000 439000 170000 36000 606000 645000 -291000 169000 <p id="xdx_89D_ecustom--ScheduleOfLiabilitiesAssociatedWithRestructuringCostsTableTextBlock_ze6Czot7iHIg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zO9BXttvoWz5">SCHEDULE OF LIABILITIES ASSOCIATED WITH RESTRUCTURING COSTS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B3_us-gaap--RestructuringCostAndReserveAxis_custom--SeveranceAndSeparationCostsMember_zcXlj8uEUSU4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Severance and separation costs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B7_us-gaap--RestructuringCostAndReserveAxis_custom--EquityAwardsAccelerationCostsAssociatedWithSeveranceMember_z3KeoGxrelm6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Equity awards acceleration costs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B5_us-gaap--RestructuringCostAndReserveAxis_custom--OtherExitRelatedCostsMember_z7BtCnZg5AWk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>Other exit</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><b>related costs</b></p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B5_z8W1OG9Wn31f" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total restructuring and other costs</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="14" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_43D_c20240101__20241231_eus-gaap--RestructuringReserve_iS_pn3n3_zib2MGLzZ4S3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Balance as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">145</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1671">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">26</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">171</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RestructuringCharges_pn3n3_zGKChBX7fOq4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">606</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1676">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1677">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">606</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PaymentsForRestructuring_iN_pn3n3_di_zWWBmzL4D9Bj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Payments and other adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(751</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1681">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(26</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(777</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43A_c20240101__20241231_eus-gaap--RestructuringReserve_iE_pn3n3_zL867nkJlet2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance as of  December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1685">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1686">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1687">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1688">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_430_c20230101__20231231_eus-gaap--RestructuringReserve_iS_pn3n3_zihqa1bVt0j1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1690">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1691">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1692">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1693">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RestructuringCharges_pn3n3_zYc6RNhhBcl7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Additions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">439</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">170</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">36</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">645</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PaymentsForRestructuring_iN_pn3n3_di_z9bUkNjSwsLe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Payments and other adjustments</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(294</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(170</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(10</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(474</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_43B_c20230101__20231231_eus-gaap--RestructuringReserve_iE_pn3n3_zIZFOkeyX1n8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance as of  December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">145</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1706">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">171</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 145000 26000 171000 606000 606000 751000 26000 777000 439000 170000 36000 645000 294000 170000 10000 474000 145000 26000 171000 <p id="xdx_804_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zZ0wmz6mvJxh" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zOduqkEfGOy7">EMPLOYEE BENEFIT PLANS</span></b></span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has qualified 401(k) plans covering all U.S. employees who have completed one month of service. The plans provide for matching contributions by the Company for employees of the Company and most U.S. subsidiaries, although there is no match for CPM employees. Employer contributions to the plans for the years ended December 31, 2024 and 2023 were approximately $<span id="xdx_903_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20240101__20241231__us-gaap--RetirementPlanNameAxis__custom--DefinedContributionRetirementPlanForUSEmployeesMember_zOtoHYQpDVng" title="Defined benefit plan, contributions by employer">449,000</span> and $<span id="xdx_903_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20230101__20231231__us-gaap--RetirementPlanNameAxis__custom--DefinedContributionRetirementPlanForUSEmployeesMember_z7mOS03a5h9h" title="Defined benefit plan, contributions by employer">587,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, the Company has a defined contribution retirement plan covering all employees located in our Pakistan Offices who have completed three months of service. <span id="xdx_905_ecustom--EmployeeBenefitPlanDescription_c20240101__20241231__us-gaap--RetirementPlanNameAxis__custom--DefinedContributionRetirementPlanForPakistanEmployeesMember_z3s8jJVcD5n" title="Employee benefit plan, description">The plan provides for monthly contributions by the Company which are equal to 10% of qualified employees’ basic monthly compensation</span>. The Company’s contributions for the years ended December 31, 2024 and 2023 were approximately $<span id="xdx_907_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20240101__20241231__us-gaap--RetirementPlanNameAxis__custom--DefinedContributionRetirementPlanForPakistanEmployeesMember_zrRMJYxxCXi8" title="Defined benefit plan, contributions by employer">438,000</span> and $<span id="xdx_909_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20230101__20231231__us-gaap--RetirementPlanNameAxis__custom--DefinedContributionRetirementPlanForPakistanEmployeesMember_zmSCBi9Uji5j" title="Defined benefit plan, contributions by employer">394,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains a defined contribution retirement plan covering all employees in Sri Lanka. The employee and employer contribute <span id="xdx_90B_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_pid_dp_uPure_c20240101__20241231__us-gaap--RetirementPlanNameAxis__custom--DefinedContributionRetirementPlanForSriLankaEmployeesMember_zJNZr99KYdL3" title="Defined contribution plan, employee matching contribution, on gross pay"><span id="xdx_901_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_pid_dp_uPure_c20230101__20231231__us-gaap--RetirementPlanNameAxis__custom--DefinedContributionRetirementPlanForSriLankaEmployeesMember_zERNyt0cVhs8" title="Defined contribution plan, employee matching contribution, on gross pay">8</span></span>% and <span id="xdx_90E_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_uPure_c20240101__20241231__us-gaap--RetirementPlanNameAxis__custom--DefinedContributionRetirementPlanForSriLankaEmployeesMember_zL7W2D9Rg8Ta" title="Defined contribution plan, employer matching contribution, on gross pay"><span id="xdx_904_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_uPure_c20230101__20231231__us-gaap--RetirementPlanNameAxis__custom--DefinedContributionRetirementPlanForSriLankaEmployeesMember_zwAnn4qPF33d" title="Defined contribution plan, employer matching contribution, on gross pay">12</span></span>%, respectively, of the employee’s gross salary. The Company’s contribution for the years ended December 31, 2024 and 2023 was approximately $<span id="xdx_909_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20240101__20241231__us-gaap--RetirementPlanNameAxis__custom--DefinedContributionRetirementPlanForSriLankaEmployeesMember_zfnqEowM4Kx" title="Defined benefit plan, plan assets, contributions by employer">28,000</span> and $<span id="xdx_90F_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20230101__20231231__us-gaap--RetirementPlanNameAxis__custom--DefinedContributionRetirementPlanForSriLankaEmployeesMember_ziTtAYHh0SHj" title="Defined benefit plan, plan assets, contributions by employer">24,000</span>, respectively. The contributions are required to be deposited with the Employees’ Provident Fund Organization, a government owned entity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 449000 587000 The plan provides for monthly contributions by the Company which are equal to 10% of qualified employees’ basic monthly compensation 438000 394000 0.08 0.08 0.12 0.12 28000 24000 <p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zgk0McFNjEEe" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_z35dqwJjxgDi">STOCK-BASED COMPENSATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2014, the Company adopted the Medical Transcription Billing, Corp. 2014 Equity Incentive Plan (the “Original Plan”), reserving a total of <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20140430__us-gaap--PlanNameAxis__custom--TwoThousandFourteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_z5hpnDIwHrBg" title="Number of shares reserved for future issuance">1,351,000</span> shares of common stock for grants to employees, officers, directors and consultants. On April 14, 2017, the Original Plan was amended and restated whereby an additional <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20170414__us-gaap--PlanNameAxis__custom--AmendedAndRestatedEquityIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVQtgvyNHpDh" title="Shares added to the A&amp;R Plan for future issuance">1,500,000</span> shares of common stock and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20170414__us-gaap--PlanNameAxis__custom--AmendedAndRestatedEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zO1SCtHo3Wyl" title="Shares added to the A&amp;R Plan for future issuance">100,000</span> shares of Series A Preferred Stock were added to the plan for future issuance (the “A&amp;R Plan”). During 2018, an additional <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20181231__us-gaap--PlanNameAxis__custom--AmendedAndRestatedEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzqQSxfDjI5e" title="Shares added to the A&amp;R Plan for future issuance">200,000</span> shares of Series A Preferred Stock were added to the A&amp;R Plan for future issuance. In May 2020, an additional <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20200531__us-gaap--PlanNameAxis__custom--AmendedAndRestatedEquityIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAZUgjiyn3d9" title="Shares added to the A&amp;R Plan for future issuance">2,000,000</span> shares of common stock and an additional <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20200531__us-gaap--PlanNameAxis__custom--AmendedAndRestatedEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8qgnIHipbN" title="Shares added to the A&amp;R Plan for future issuance">300,000</span> shares of Series A Preferred Stock were added to the A&amp;R Plan for future issuance. During 2022, an additional <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestatedEquityIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfjWguNJrCu5" title="Shares added to the A&amp;R Plan for future issuance">1,000,000</span> shares of common stock and <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20221231__us-gaap--PlanNameAxis__custom--AmendedAndRestatedEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlm6H9ipfFfe" title="Shares added to the A&amp;R Plan for future issuance">200,000</span> shares of Series B Preferred Stock were added to the A&amp;R Plan for future issuance. As of December 31, 2024, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zm52lwwUZ7x2" title="Number of shares available for grant">499,683</span> shares of common stock, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zYialuhwdCla" title="Number of shares available for grant">33,769</span> shares of Series A Preferred Stock and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFGtoCNzSaGc" title="Number of shares available for grant">16,000</span> shares of Series B Preferred Stock are available for grant. Permissible awards include incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, RSUs, performance stock and cash-settled awards and other stock-based awards in the discretion of the Compensation Committee of the Board of Directors including unrestricted stock grants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The equity based RSUs contain a provision in which the units shall immediately vest and become converted into common shares at the rate of one common share per RSU, immediately after a change in control, as defined in the award agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Common stock</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2024, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpBPV4pDi4zh" title="Share-based compensation restricted stock, grants in period">226,894 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSUs of common stock were granted to employees and independent contractors to vest at different dates during the years 2024 through 2026. Included therein were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20241231__us-gaap--PlanNameAxis__custom--AmendedAndRestatedEquityIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--FairValueByLiabilityClassAxis__custom--FiveOutsidesMembersofTheBoardMember_zevIjjqLt2P5" title="Share-based compensation restricted stock, grants in period">30,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSUs of common stock granted over two years equally to each of the five outside members of the Board of Directors with <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20240101__20241231__us-gaap--PlanNameAxis__custom--AmendedAndRestatedEquityIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--FairValueByLiabilityClassAxis__custom--FiveOutsidesMembersofTheBoardMember_zEnDeoIXYbtg" title="Shares vesting percentage">25</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the shares vesting every six months. During 2023, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhfdklRml4Hg" title="Share-based compensation restricted stock, grants in period">1,098,976 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSUs of common stock were granted to employees and independent contractors to vest at different dates during the years 2023 through 2025. Included therein were <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--PlanNameAxis__custom--AmendedAndRestatedEquityIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--FairValueByLiabilityClassAxis__custom--FiveOutsidesMembersofTheBoardMember_zC2dADMROX65" title="Share-based compensation restricted stock, grants in period">30,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSUs of common stock granted over two years equally to each of the five outside members of the Board of Directors with <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--AmendedAndRestatedEquityIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--FairValueByLiabilityClassAxis__custom--FiveOutsidesMembersofTheBoardMember_zI204V1f50F2" title="Shares vesting percentage">25</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the shares vesting every six months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During December 2022, it was agreed that certain bonuses to employees of medSR that were originally going to be paid in cash would be paid in common stock. The change of paying the bonuses in common stock resulted in approximately <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeeMember_zUEapKZXsQ41" title="Share-based compensation restricted stock, grants in period">135,000</span> shares being issued in February 2023. This change resulted in approximately $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeeMember_zSEdfMnLaXn6" title="Stock-based compensation">404,000</span> of stock compensation expense, which offset the amounts previously accrued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z3Gh09MoZ3n7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the RSU and restricted stock transactions related to the common and Preferred Stock under the A&amp;R Plan for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zjjoKRCmLNR4" style="display: none">DISCLOSURE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD</span></span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Series A Preferred Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Series B Preferred Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%">Outstanding and unvested shares at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znSPlcY6mI8f" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Outstanding and unvested at beginning">753,495</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zP8gYjbgkmoe" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Outstanding and unvested at beginning"><span style="-sec-ix-hidden: xdx2ixbrl1778">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zud6cL5BaT96" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Outstanding and unvested at beginning">57,199</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAlIZm8hhWA4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted">226,894</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwjJd56muh7i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1784">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zvvxR4AHf529" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted">46,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Vested</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLpzqEYWuYm1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Vested">(513,190</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zP6XDWkOzTa8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl1790">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zh15Y3ebzyOi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Vested">(60,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMGMHsp1Cfhk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited">(224,699</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIA8lYMMlM2c" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited">         <span style="-sec-ix-hidden: xdx2ixbrl1796">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsnvQSvBWYT8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited">(24,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding and unvested shares at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zK8LBGYwrvOd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at ending">242,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7fMDONtSIB8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at ending"><span style="-sec-ix-hidden: xdx2ixbrl1802">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJAdJI8DbqSj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at ending">19,199</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Outstanding and unvested shares at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoYAEc1ruCp7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at beginning">645,475</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgfukuqC3xu7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at beginning"><span style="-sec-ix-hidden: xdx2ixbrl1808">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUC8w2y5X6Ih" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at beginning">80,462</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXUUbVYPckCl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted">1,098,976</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5Ar0Y5igaCa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1814">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwtOxUeRm7Zi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted">62,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Vested</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgdX754DLJMa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Vested">(896,893</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zILPUJXiHEnf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl1820">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8RQ7AhN939b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Vested">(85,263</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziHxm34SdOL1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited">(94,063</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUBCzb3YDdAl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1826">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGVQgeh7xI96" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1828">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding and unvested shares at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDuDZbALFBse" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at ending">753,495</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zRRl28bvMVMa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at ending"><span style="-sec-ix-hidden: xdx2ixbrl1832">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfhOm6bzb9ac" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at ending">57,199</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zdy6mCAQhaKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024 and 2023, there was approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zETmcEm5USed" title="Share-based payment arrangement, nonvested award, cost not yet recognized, amount">416,000</span> and $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zG7Sv6gLPHX5" title="Share-based payment arrangement, nonvested award, cost not yet recognized, amount">1.3</span> million, respectively, of total unrecognized compensation cost related to the common stock RSUs classified as equity that will be expensed through 2026. As of December 31, 2024, there was <span id="xdx_90D_ecustom--ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWhZPcVKULO9" title="Sharebased compensation nonvested awards total compensation cost not yet recognized">no</span> unrecognized compensation cost as compared to approximately $<span id="xdx_901_ecustom--ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHLPVMO5KqFi" title="Share-based compensation nonvested awards total compensation cost not yet recognized">351,000</span> of total unrecognized compensation cost as of December 31, 2023 related to the Series B Preferred Stock RSUs classified as equity that was expensed through the following year. There was no unrecognized compensation cost related to the Series A Preferred Stock RSUs for both the years ended December 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of the total outstanding and unvested common stock RSUs at December 31, 2024, <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z4P6LO4LTcY7" title="Unvested stock option award, equity">242,500</span> are classified as equity and at December 31 2023, <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBoIMfEe4Uyl" title="Unvested stock option award, equity">733,908</span> RSUs are classified as equity and <span id="xdx_90A_ecustom--RestrictedStockAwardClassifiedAsLiability_iI_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zXSctcJHEcS8" title="Restricted stock award classified as liability"><span id="xdx_907_ecustom--RestrictedStockAwardClassifiedAsLiability_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zeHbNxutCl7i" title="Restricted stock award classified as liability">19,587</span></span> RSUs are classified as a liability. For both 2024 and 2023, all of the Preferred Stock RSUs are classified as equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zqY7xldDfMqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the share activity during the years ended December 31, 2024 and 2023 and the amount of common and preferred shares available for grant at December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zxFYMJmHpjrd" style="display: none">SCHEDULE OF SHARE-BASED COMPENSATION, RESTRICTED STOCK UNITS AWARD ACTIVITY</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Series A Preferred Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Series B Preferred Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%">Shares available for grant at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjvZO4L5SMGb" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Outstanding and unvested shares, beginning">493,579</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAQp359twz22" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Outstanding and unvested shares, beginning">33,769</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zERx7dJJF2G1" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Outstanding and unvested shares, beginning">38,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">RSUs granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdRfNyoovocc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs granted">(226,894</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzYvebhED0Lf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1862">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zySbt5fnHcU1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs granted">(46,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">RSUs forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVwkR8wpc5nc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs forfeited">232,998</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3mOastkmJFl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1868">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUR4tDpPlCB8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs forfeited">24,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Shares available for grant at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z97skLjCPtXd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, ending">499,683</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJ4PPSDPP6n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, ending">33,769</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWAnUTc0K4Jl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, ending">16,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Shares available for grant at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGGsGVqN6pWh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, beginning">1,498,492</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSuzfXoIISGh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, beginning">33,769</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJacJvga3Xt" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, beginning">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">RSUs granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyfFG45nen3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs granted">(1,098,976</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMVqkbnt0sPf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1886">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zT6aByXvtLfi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs granted">(62,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">RSUs forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLMyd6h7Bos7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs forfeited">94,063</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOMNTA13bjHl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1892">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8DVEUrSOXke" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1894">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Shares available for grant at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEMuflGuvSsa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, ending">493,579</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zf0Lem6uP0fa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, ending">33,769</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsvJPnXTqMOj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, ending">38,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zM7JMIo9c7lk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The liability for the cash-settled awards and accrued payroll taxes on equity awards was approximately $<span id="xdx_902_ecustom--LiabilityForCashSettledAmount_iI_c20241231_zC8ntMNCRUv9" title="Liability for cash settled amount">6,000</span> and $<span id="xdx_90B_ecustom--LiabilityForCashSettledAmount_iI_c20231231_zXlQbXiw9t99" title="Liability for cash settled amount">767,000</span> at December 31, 2024 and 2023, respectively, and is included in accrued compensation in the consolidated balance sheets. During the years ended December 31, 2024 and 2023, approximately $<span id="xdx_901_ecustom--CashSettlement_iI_c20241231_zFRM94WswHHc" title="Cash settlement">45,000</span> and $<span id="xdx_90C_ecustom--CashSettlement_iI_c20231231_zILa60r8KRr3" title="Cash settlement">19,000</span>, respectively, were paid in connection with the cash-settled awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Preferred Stock</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023, the Compensation Committee granted executive bonuses to be paid in <span id="xdx_906_ecustom--ShareBasedGoodsAndNonemployeeServicesTransactionShareApprovedForIssuance_pid_c20230201__20230228__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zpiUoxsY0sT8" title="Share-based payment award, number of shares issuance">34,000</span> shares of Series B Preferred Stock, with the number of shares and the amount based on specified criteria being achieved during the year 2023. During October 2023, the Compensation Committee approved for issuance <span id="xdx_90E_ecustom--ShareBasedGoodsAndNonemployeeServicesTransactionShareApprovedForIssuance_pid_c20231001__20231031__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgbTaKJFJQT1" title="Share-based payment award, number of shares issuance">10,000</span> of the above shares to one of the executives who retired. The remaining shares were not issued and previously accrued amounts were reversed during 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2024, the Compensation Committee approved executive bonuses to be paid in shares of Series B Preferred Stock with the number of shares and the amount based on specified criteria being achieved for the year 2024. There were <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240301__20240331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZfBvLBOSWPa" title="Share-based payment award, number of shares grant">34,000</span> shares awarded. During May 2024, an additional executive bonus with similar terms was approved and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240501__20240531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKbLudddTkG4" title="Share-based payment award, number of shares grant">12,000</span> shares were awarded. During December 2024, the Compensation Committee determined that the financial objectives were attained and all of the performance bonus shares were issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Stock-based compensation expense</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation expense on a straight-line basis over the total requisite service period for the entire award. For stock awards classified as equity, the market price of our common stock or Preferred Stock on the date of grant is used to record the fair value of the award and includes the related taxes. For stock awards classified as a liability, the earned amount is marked to market based on the end of period common stock price. The weighted average grant date fair value of the common stock price in connection with the RSUs classified as equity was $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUR3W8e87Kij" title="Weighted average grant date fair value">2.16</span> and $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhYQp430J2xg" title="Weighted average grant date fair value">3.40</span> for the years ended December 31, 2024 and 2023, respectively. For the Series B Preferred Stock, the weighted average grant date fair value was $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zD36dMMOzbDb" title="Weighted average grant date fair value">6.33</span> and $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zXU9NuxTDKwi" title="Weighted average grant date fair value">25.07</span> for the years ended December 31, 2024 and 2023, respectively. The following table summarizes the components of stock-based compensation expense for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z38H8r7fBUld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zcE5Ii0zUBgj" style="display: none"><span>SCHEDULE OF EMPLOYEE SERVICE SHARE-BASED COMPENSATION, ALLOCATION OF RECOGNIZED PERIOD COSTS</span></span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based compensation included in the consolidated statements of operations:</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Direct operating costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--DirectOperatingCostsMember_zpRoXSTlnaa6" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Direct operating costs">(27</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--DirectOperatingCostsMember_zn6dAU0d03Yl" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Direct operating costs">891</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zAe5hLnNqBXb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="General and administrative">72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zIx5nfxM3hTe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="General and administrative">2,835</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znGz0CYXips1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Research and development">(4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zABvHfshcay7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Research and development">135</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Selling and marketing</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zwQX1eTZ15F2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Selling and marketing">74</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zHsKkVoSzFW" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Selling and marketing">855</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Lease terminations, unoccupied lease charges and restructuring costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--NetLossOnLeaseTerminationsUnoccupiedLeaseChargesAndRestructuringCostsMember_zZ0xJN0W2SLf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Selling and marketing"><span style="-sec-ix-hidden: xdx2ixbrl1944">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--NetLossOnLeaseTerminationsUnoccupiedLeaseChargesAndRestructuringCostsMember_zXnrWRuXTUf8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Selling and marketing">170</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231_zJjb4VIosEua" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock-based compensation">115</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231_zCmk4rtZqGma" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock-based compensation">4,886</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_z5tSLN4OiZFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1351000 1500000 100000 200000 2000000 300000 1000000 200000 499683 33769 16000 226894 30000 0.25 1098976 30000 0.25 135000 404000 <p id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z3Gh09MoZ3n7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the RSU and restricted stock transactions related to the common and Preferred Stock under the A&amp;R Plan for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zjjoKRCmLNR4" style="display: none">DISCLOSURE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD</span></span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Series A Preferred Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Series B Preferred Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%">Outstanding and unvested shares at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znSPlcY6mI8f" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Outstanding and unvested at beginning">753,495</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zP8gYjbgkmoe" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Outstanding and unvested at beginning"><span style="-sec-ix-hidden: xdx2ixbrl1778">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zud6cL5BaT96" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Outstanding and unvested at beginning">57,199</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAlIZm8hhWA4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted">226,894</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwjJd56muh7i" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1784">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zvvxR4AHf529" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted">46,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Vested</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLpzqEYWuYm1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Vested">(513,190</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zP6XDWkOzTa8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl1790">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zh15Y3ebzyOi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Vested">(60,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMGMHsp1Cfhk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited">(224,699</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIA8lYMMlM2c" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited">         <span style="-sec-ix-hidden: xdx2ixbrl1796">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsnvQSvBWYT8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited">(24,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding and unvested shares at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zK8LBGYwrvOd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at ending">242,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7fMDONtSIB8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at ending"><span style="-sec-ix-hidden: xdx2ixbrl1802">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJAdJI8DbqSj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at ending">19,199</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Outstanding and unvested shares at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoYAEc1ruCp7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at beginning">645,475</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zgfukuqC3xu7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at beginning"><span style="-sec-ix-hidden: xdx2ixbrl1808">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUC8w2y5X6Ih" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at beginning">80,462</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXUUbVYPckCl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted">1,098,976</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5Ar0Y5igaCa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1814">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwtOxUeRm7Zi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Granted">62,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Vested</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgdX754DLJMa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Vested">(896,893</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zILPUJXiHEnf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl1820">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8RQ7AhN939b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Vested">(85,263</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziHxm34SdOL1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited">(94,063</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUBCzb3YDdAl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1826">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGVQgeh7xI96" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1828">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding and unvested shares at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDuDZbALFBse" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at ending">753,495</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zRRl28bvMVMa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at ending"><span style="-sec-ix-hidden: xdx2ixbrl1832">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfhOm6bzb9ac" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested at ending">57,199</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 753495 57199 226894 46000 513190 60000 224699 24000 242500 19199 645475 80462 1098976 62000 896893 85263 94063 753495 57199 416000 1300000 0 351000 242500 733908 19587 19587 <p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zqY7xldDfMqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the share activity during the years ended December 31, 2024 and 2023 and the amount of common and preferred shares available for grant at December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zxFYMJmHpjrd" style="display: none">SCHEDULE OF SHARE-BASED COMPENSATION, RESTRICTED STOCK UNITS AWARD ACTIVITY</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Series A Preferred Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Series B Preferred Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%">Shares available for grant at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjvZO4L5SMGb" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Outstanding and unvested shares, beginning">493,579</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAQp359twz22" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Outstanding and unvested shares, beginning">33,769</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zERx7dJJF2G1" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Outstanding and unvested shares, beginning">38,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">RSUs granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdRfNyoovocc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs granted">(226,894</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzYvebhED0Lf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1862">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zySbt5fnHcU1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs granted">(46,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">RSUs forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVwkR8wpc5nc" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs forfeited">232,998</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z3mOastkmJFl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1868">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUR4tDpPlCB8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs forfeited">24,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Shares available for grant at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z97skLjCPtXd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, ending">499,683</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJ4PPSDPP6n3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, ending">33,769</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWAnUTc0K4Jl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, ending">16,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Shares available for grant at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGGsGVqN6pWh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, beginning">1,498,492</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSuzfXoIISGh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, beginning">33,769</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJacJvga3Xt" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, beginning">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">RSUs granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyfFG45nen3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs granted">(1,098,976</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMVqkbnt0sPf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1886">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zT6aByXvtLfi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs granted">(62,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">RSUs forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLMyd6h7Bos7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs forfeited">94,063</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOMNTA13bjHl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1892">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8DVEUrSOXke" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="RSUs forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1894">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Shares available for grant at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEMuflGuvSsa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, ending">493,579</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zf0Lem6uP0fa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, ending">33,769</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsvJPnXTqMOj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Outstanding and unvested shares, ending">38,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 493579 33769 38000 226894 46000 232998 24000 499683 33769 16000 1498492 33769 100000 1098976 62000 94063 493579 33769 38000 6000 767000 45000 19000 34000 10000 34000 12000 2.16 3.40 6.33 25.07 <p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z38H8r7fBUld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zcE5Ii0zUBgj" style="display: none"><span>SCHEDULE OF EMPLOYEE SERVICE SHARE-BASED COMPENSATION, ALLOCATION OF RECOGNIZED PERIOD COSTS</span></span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based compensation included in the consolidated statements of operations:</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Direct operating costs</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--DirectOperatingCostsMember_zpRoXSTlnaa6" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Direct operating costs">(27</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--DirectOperatingCostsMember_zn6dAU0d03Yl" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Direct operating costs">891</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zAe5hLnNqBXb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="General and administrative">72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zIx5nfxM3hTe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="General and administrative">2,835</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_znGz0CYXips1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Research and development">(4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zABvHfshcay7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Research and development">135</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Selling and marketing</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zwQX1eTZ15F2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Selling and marketing">74</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zHsKkVoSzFW" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Selling and marketing">855</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Lease terminations, unoccupied lease charges and restructuring costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__custom--NetLossOnLeaseTerminationsUnoccupiedLeaseChargesAndRestructuringCostsMember_zZ0xJN0W2SLf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Selling and marketing"><span style="-sec-ix-hidden: xdx2ixbrl1944">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__custom--NetLossOnLeaseTerminationsUnoccupiedLeaseChargesAndRestructuringCostsMember_zXnrWRuXTUf8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Selling and marketing">170</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231_zJjb4VIosEua" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock-based compensation">115</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231_zCmk4rtZqGma" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock-based compensation">4,886</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -27000 891000 72000 2835000 -4000 135000 74000 855000 170000 115000 4886000 <p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zXcZe3hMaf5h" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zXh7RyVa1Ek">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2024 and 2023, the Company estimated its income tax provision based upon the annual pre-tax income or loss. Although the Company reported GAAP earnings in 2024, it incurred losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all federal and state deferred tax assets as of December 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The annual adjusted earnings and profits of our foreign affiliates pass through to the U.S. as federal and state taxable income under the Global Intangible Low-Taxed Income (“GILTI”) regime. For the tax years ended December 31, 2024 and 2023, the net GILTI from our foreign affiliates was absorbed against our current year U.S. consolidated loss. For state tax purposes, the Company’s foreign earnings may be taxable depending on each individual state’s legislative stance on the recent tax reform legislation. The activity in the deferred tax valuation allowance was as follows for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--SummaryOfValuationAllowanceTextBlock_z9hedy7YW3mi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zzHwvMKYub9j" style="display: none">SCHEDULE OF DEFERRED TAX VALUATION ALLOWANCE</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Beginning balance</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_pn3n3_c20240101__20241231_zc48xi93kFe3" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance">87,597</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_pn3n3_c20230101__20231231_zcCb1auZHdN7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance">92,091</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Current year valuation allowance increase (decrease)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20240101__20241231_z9VEsoJQzGR5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current year valuation allowance increase (decrease)">2,067</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20230101__20231231_zwLk707YHyje" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current year valuation allowance increase (decrease)">(4,494</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Ending balance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_pn3n3_c20240101__20241231_zvoppG1PpSDc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">89,664</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_pn3n3_c20230101__20231231_zlVyFGQ5Bop9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">87,597</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zAJXqJh7labf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zWWBRVc3si5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The income (loss) before provision (benefit) for income taxes for financial reporting purposes during the years ended December 31, 2024 and 2023 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zCiQFlOLKFE9" style="display: none">SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAX, DOMESTIC AND FOREIGN</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">United States</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_c20240101__20241231_zKCrbttzGP4e" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="United States">7,191</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_c20230101__20231231_zILKlQzXo7B" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="United States">(48,985</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Foreign</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_c20240101__20241231_zTB1Fp3ksZwg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign">820</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_c20230101__20231231_zaeY7Ud4wvXh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign">(53</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_c20240101__20241231_zdPPnRyVdzf8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">8,011</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_c20230101__20231231_zlv5Y2Q7qVCg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">(49,038</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A5_z5fMAKOUzL1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zG1mb63NIKi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provision (benefit) for income taxes for the years ended December 31, 2024 and 2023 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zafQ19wLSG0k" style="display: none">SCHEDULE OF COMPONENTS OF INCOME TAX PROVISION (BENEFIT)</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Current:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Federal</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20240101__20241231_zrg27hTCQpr5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current tax, Federal"><span style="-sec-ix-hidden: xdx2ixbrl1984">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20230101__20231231_zMvboBlSU5v1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current tax, Federal"><span style="-sec-ix-hidden: xdx2ixbrl1986">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%">State</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_c20240101__20241231_zek9rMenIPha" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Current tax, State">120</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_c20230101__20231231_zywGfNuZ1Yy7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Current tax, State">123</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Foreign</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20240101__20241231_zYqNzscfKzTa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current tax, Foreign">40</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20230101__20231231_zAww5yF7bfRk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current tax, Foreign">38</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zPj0jRsMmU37" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Provision for current income taxes">160</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_zdKff9MMwLfl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Provision for current income taxes">161</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Deferred:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Federal</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zkVl2obyBOa7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax, Federal"><span style="-sec-ix-hidden: xdx2ixbrl2000">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_zkBTLVLJtOm2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax, Federal">(252</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">State</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zBA3gsc5DxT2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax, State"><span style="-sec-ix-hidden: xdx2ixbrl2004">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_zoxEEO5BrtAd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax, State">(273</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zXkGzn7A2w37" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Benefit for deferred income taxes"><span style="-sec-ix-hidden: xdx2ixbrl2008">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_zpPFJ1cp1yag" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Benefit for deferred income taxes">(525</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total income tax provision (benefit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_znNtpXsGW6z3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total income tax provision (benefit)">160</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_zNPU0UJvBvva" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total income tax provision (benefit)">(364</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A1_zM6tSjFHlGfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zEUeWL0xTBoh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the Company’s deferred income taxes as of December 31, 2024 and 2023 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zibzMCIrYD32" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax assets:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Allowance for expected credit losses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_pn3n3_c20241231_ztHlwylkdEPe" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Allowance for expected credit losses">213</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_pn3n3_c20231231_zEanOdl0Yfqh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Allowance for expected credit losses">228</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred revenue</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_c20241231_zTjEAKkJz7da" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred revenue">103</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_c20231231_z2ouSmL05jOh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred revenue">68</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Property and intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pn3n3_c20241231_znqhBql55wTh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Property and intangible assets">3,015</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pn3n3_c20231231_z6eJF3TM7rL9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Property and intangible assets">1,933</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">State net operating loss (“NOL”) carryforwards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn3n3_c20241231_zXDx0GphZTLa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State net operating loss (&quot;NOL&quot;) carryforwards">20,981</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn3n3_c20231231_zLuxckGqvS3a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State net operating loss (&quot;NOL&quot;) carryforwards">19,749</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Federal net operating loss (“NOL”) carryforwards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn3n3_c20241231_zPXEby8DtFI1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Federal net operating loss (&quot;NOL&quot;) carryforwards">55,569</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn3n3_c20231231_zOvavn56c2A7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Federal net operating loss (&quot;NOL&quot;) carryforwards">57,562</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Section 163(j) interest limitation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--DeferredTaxAssetsInterestLimitation_iI_pn3n3_c20241231_zNp8CyHz5Zxh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Section 163(j) interest limitation">1,669</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--DeferredTaxAssetsInterestLimitation_iI_pn3n3_c20231231_z2bhNUyB6iFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Section 163(j) interest limitation">2,731</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iNI_pn3n3_di_c20241231_zqfUgQWxCTu8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock based compensation">(173</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iNI_pn3n3_di_c20231231_zV3qBS3Z1Cgd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock based compensation"><span style="-sec-ix-hidden: xdx2ixbrl2044">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">ASC 842 - ROU asset</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--DeferredTaxAdjustment_iI_pn3n3_c20241231_zRTla5qD2dBg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="ASC 842 - ROU asset">(559</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--DeferredTaxAdjustment_iI_pn3n3_c20231231_z6nRuGZzwLw6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="ASC 842 - ROU asset">(1,026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Prepaid commissions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--DeferredTaxAssetPrepaidCommissions_iI_pn3n3_c20241231_z6aOVe5iEAi7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Prepaid commissions">(267</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--DeferredTaxAssetPrepaidCommissions_iI_pn3n3_c20231231_zUuHLFitfTCe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Prepaid commissions">(303</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Cumulative balance translation adjustment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pn3n3_c20241231_zbx6hXZXerpi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative balance translation adjustment">1,015</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pn3n3_c20231231_zqtITXYOzNH5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative balance translation adjustment">988</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Section 267 limitation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--DeferredTaxAssetsTaxCreditLimitation_iI_pn3n3_c20241231_zDhQ5WMuxKdg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Section 267 limitation">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--DeferredTaxAssetsTaxCreditLimitation_iI_pn3n3_c20231231_zmYFMjEog8oh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Section 267 limitation">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Credit carryovers</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_c20241231_zbidHYedNKFg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit carryovers">2,498</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_c20231231_zNeoYHz5tE7c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit carryovers">2,498</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">ASC 842 - Lease liability</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--DeferredTaxLeaseLiability_iI_pn3n3_c20241231_zGgCnhWafkVi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="ASC 842 - Lease liability">558</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--DeferredTaxLeaseLiability_iI_pn3n3_c20231231_z50lOguVsWQf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="ASC 842 - Lease liability">1,031</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accrued compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_c20241231_zRPEiaOnS7nh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued compensation">86</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_c20231231_z2Cwq2K1Stda" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued compensation">80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_c20241231_z650Zfx2DKvk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other">(46</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_c20231231_z9JLkSbqqU6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other">(59</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Section 174 costs</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--DeferredTaxAssetsTaxCreditCost_iI_pn3n3_c20241231_zyqHXX1L19D1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Section 174 costs">4,996</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--DeferredTaxAssetsTaxCreditCost_iI_pn3n3_c20231231_zPUGMGLenBh5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Section 174 costs">3,799</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_c20241231_z2w5YJOaixwd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance">(89,664</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_c20231231_z3zW50XYAroe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance">(87,597</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Total deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_c20241231_zRR2kBwjikg7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax assets"><span style="-sec-ix-hidden: xdx2ixbrl2086">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_c20231231_zu3LWTFpMOUe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax assets">1,688</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Goodwill amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_iNI_pn3n3_di_c20241231_zaQO1ov9l6X3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Goodwill amortization"><span style="-sec-ix-hidden: xdx2ixbrl2090">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_iNI_pn3n3_di_c20231231_zTJ0fLCkydhf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Goodwill amortization">(1,688</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net deferred tax liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--DeferredTaxLiabilities_iNI_pn3n3_di_c20241231_zj4S2JYypfd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net deferred tax liability"><span style="-sec-ix-hidden: xdx2ixbrl2094">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--DeferredTaxLiabilities_iNI_pn3n3_di_c20231231_z3kItpOmXCba" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net deferred tax liability"><span style="-sec-ix-hidden: xdx2ixbrl2096">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zjYzP0AsW7L2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their tax bases, as well as from net operating loss carryforwards. Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has recorded goodwill as a result of its acquisitions. Goodwill is generally not amortized for financial reporting purposes. However, in 2023 the Company recorded a $<span id="xdx_901_eus-gaap--GoodwillImpairmentLoss_pn6n6_c20230101__20231231_z0vD1TQRDBzh" title="Goodwill impairment charge">42</span> million goodwill impairment charge, which partially reduced the basis of the tax-deductible goodwill. For tax purposes, goodwill from asset acquisitions is tax deductible and amortized over <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20231231_zFWEECYhER64" title="Goodwill amortization period for tax purposes">15</span> years. As such, deferred income tax expense and a deferred tax liability arise as a result of the tax-deductibility of this indefinitely lived asset (also known as a naked credit). Typically, the resulting deferred tax liability, which is expected to continue to increase over the amortization period, will have an indefinite life. As a result of the Company having indefinite life net operating losses under the recent tax reform legislation, the federal deferred tax liability resulting from the amortization of goodwill was offset against these indefinite federal operating net losses deferred tax assets to the extent allowable prior to 2023. As a result of the goodwill impairment charge in 2023, the entire deferred tax liability was reversed at that time and no additional deferred tax liability was recorded for 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zsWdjoHBFeRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the federal statutory income tax rate (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIElOQ09NRSBUQVhFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_c20240101__20241231_z0kwgpG0P3el" title="Federal statutory income tax rate">21</span>%) to the Company’s effective income tax rate (determined in dollars) for the years ended December 31, 2024 and 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zDmt7cenak6c" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Federal provision (benefit) at statutory rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_pn3n3_c20240101__20241231_z7wO38UvrLz5" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Federal provision (benefit) at statutory rate">1,682</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_pn3n3_c20230101__20231231_zeNoPg9KSIV7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Federal provision (benefit) at statutory rate">(10,298</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Increase (decrease) in income taxes resulting from:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">State tax expense, net of federal benefit</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_c20240101__20241231_zDmPw4KEKDzj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State tax expense, net of federal benefit">94</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_c20230101__20231231_z3P16jbMyVmb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State tax expense, net of federal benefit">7,383</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Non-deductible items</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_pn3n3_c20240101__20241231_zdtvb8PwFtoj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-deductible items">30</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_pn3n3_c20230101__20231231_zeStxiQeySr6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-deductible items">26</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Impact of foreign operations</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_c20240101__20241231_zIJrG8eb51g2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Impact of foreign operations">(132</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_c20230101__20231231_z5aSTdWlCgWb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Impact of foreign operations">50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Subpart F GILTI inclusion</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_pn3n3_c20240101__20241231_zuYFmeULFMI8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Subpart F GILTI inclusion">1,066</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_pn3n3_c20230101__20231231_zeAqMtP5bI75" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Subpart F GILTI inclusion">804</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_c20240101__20241231_zW1c9fcbZnZ1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock based compensation">(177</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_c20230101__20231231_zX1FtknO9Bsl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock based compensation">18</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Goodwill impairment charges</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_pn3n3_c20240101__20241231_zwYlewD7WYH8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Goodwill impairment charges"><span style="-sec-ix-hidden: xdx2ixbrl2130">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_pn3n3_c20230101__20231231_z2krfgLo5Wci" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Goodwill impairment charges">5,692</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred true-up</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pn3n3_di_c20240101__20241231_zzpd3iYJM8eh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred true-up">(2,708</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pn3n3_c20230101__20231231_zaflh8ZoAnU9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred true-up">455</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20240101__20241231_z7rMasqLZP62" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance">305</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20230101__20231231_ziKTPWZIIBSk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance">(4,494</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total income tax provision (benefit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zqnjhU9qSXH9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total income tax provision (benefit)">160</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_z7HYnVZMUXh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total income tax provision (benefit)">(364</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AA_zIDp3B7Is2Ub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2024 and 2023, the Company did not record any uncertain tax positions based on the technical merits. Therefore, a tabular roll forward was excluded and there has been no accrued interest and penalties. The Company is subject to taxation in the United States, various states, Pakistan and Sri Lanka. As of December 31, 2024, all tax years since 2014 remain open to examination due to the carryover of unused net operating losses and tax credits in the United States by major taxing jurisdictions in which <span id="xdx_90F_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231_zx9kCluE31Rf" title="Income tax examination description">the Company is subject to tax. IT companies in Pakistan are subject to a 0.25% tax deducted at the source on receipts received from foreign sources with no further tax being due</span>. It is the Company’s policy that any assessed penalties and interest on uncertain tax positions would be charged to income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Pakistan foreign receipts tax does not have a significant impact on the Company’s effective tax rate as all of its earnings in Pakistan have been fully included in the U.S. federal tax rate reconciliation at <span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231__srt--StatementGeographicalAxis__country--PK_zGHaTyci3KLc" title="Federal statutory income tax rate"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231__srt--StatementGeographicalAxis__country--PK_zMR7nOCz4bmb" title="Federal statutory income tax rate">21</span></span>% for 2024 and 2023. The Pakistan statutory corporate tax rate is <span id="xdx_907_ecustom--PakistanStatutoryCorporateTaxRate_pid_dp_uPure_c20240101__20241231__srt--StatementGeographicalAxis__country--PK_zE1SqRvI6Zbe" title="Pakistan statutory corporate tax rate">29</span>% before consideration of the aforementioned tax credit and the foreign receipts tax.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024, the Company has a total federal NOL carry forward of approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_znOvoWxUvTS1" title="Net operating loss carry forwards">265</span> million of which approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember__us-gaap--TaxPeriodAxis__custom--BetweenTwoThousandThirtyOneAndTwoThousandThirtyEightMember_zN7bEFHg6oI6" title="Net operating loss carry forwards">187</span> million will expire between 2031 and 2038, and the balance of approximately $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember__us-gaap--TaxPeriodAxis__custom--IndefiniteLifeMember_zxwxYmrCg5hc" title="Net operating loss carry forwards">78</span> million has an indefinite life. Out of the total federal NOL carry forward, approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember__us-gaap--BusinessAcquisitionAxis__custom--CareCloudAndMeridianAcquisitionsMember_zkbAhBLdukSe" title="Net operating loss carry forwards">237</span> million is from the CareCloud and Meridian acquisitions and is subject to the federal Section 382 NOL annual usage limitations. The Company has state NOL carry forwards of approximately $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--StateMember_zGm2ITEAdqYg" title="Net operating loss carry forwards">211</span> million, of which $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn6n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__stpr--NJ_z8XhUdr0yJC7" title="Net operating loss carry forwards">84</span> million relates to the State of New Jersey. These NOLs expire starting in 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a full valuation allowance on its deferred tax assets in the U.S. which results in there being no U.S. deferred tax assets or liabilities recorded in the consolidated balance sheets at December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--SummaryOfValuationAllowanceTextBlock_z9hedy7YW3mi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zzHwvMKYub9j" style="display: none">SCHEDULE OF DEFERRED TAX VALUATION ALLOWANCE</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Beginning balance</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_pn3n3_c20240101__20241231_zc48xi93kFe3" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance">87,597</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iS_pn3n3_c20230101__20231231_zcCb1auZHdN7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance">92,091</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Current year valuation allowance increase (decrease)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20240101__20241231_z9VEsoJQzGR5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current year valuation allowance increase (decrease)">2,067</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20230101__20231231_zwLk707YHyje" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current year valuation allowance increase (decrease)">(4,494</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Ending balance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_pn3n3_c20240101__20241231_zvoppG1PpSDc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">89,664</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsValuationAllowance_iE_pn3n3_c20230101__20231231_zlVyFGQ5Bop9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">87,597</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 87597000 92091000 2067000 -4494000 89664000 87597000 <p id="xdx_899_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zWWBRVc3si5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The income (loss) before provision (benefit) for income taxes for financial reporting purposes during the years ended December 31, 2024 and 2023 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zCiQFlOLKFE9" style="display: none">SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAX, DOMESTIC AND FOREIGN</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">United States</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_c20240101__20241231_zKCrbttzGP4e" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="United States">7,191</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_c20230101__20231231_zILKlQzXo7B" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="United States">(48,985</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Foreign</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_c20240101__20241231_zTB1Fp3ksZwg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign">820</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_c20230101__20231231_zaeY7Ud4wvXh" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign">(53</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_c20240101__20241231_zdPPnRyVdzf8" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">8,011</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_c20230101__20231231_zlv5Y2Q7qVCg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total">(49,038</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 7191000 -48985000 820000 -53000 8011000 -49038000 <p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zG1mb63NIKi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provision (benefit) for income taxes for the years ended December 31, 2024 and 2023 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zafQ19wLSG0k" style="display: none">SCHEDULE OF COMPONENTS OF INCOME TAX PROVISION (BENEFIT)</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Current:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Federal</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20240101__20241231_zrg27hTCQpr5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current tax, Federal"><span style="-sec-ix-hidden: xdx2ixbrl1984">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_c20230101__20231231_zMvboBlSU5v1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current tax, Federal"><span style="-sec-ix-hidden: xdx2ixbrl1986">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%">State</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_c20240101__20241231_zek9rMenIPha" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Current tax, State">120</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_c20230101__20231231_zywGfNuZ1Yy7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Current tax, State">123</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Foreign</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20240101__20241231_zYqNzscfKzTa" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current tax, Foreign">40</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_c20230101__20231231_zAww5yF7bfRk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Current tax, Foreign">38</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zPj0jRsMmU37" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Provision for current income taxes">160</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--CurrentIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_zdKff9MMwLfl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Provision for current income taxes">161</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Deferred:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Federal</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zkVl2obyBOa7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax, Federal"><span style="-sec-ix-hidden: xdx2ixbrl2000">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_zkBTLVLJtOm2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax, Federal">(252</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">State</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zBA3gsc5DxT2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax, State"><span style="-sec-ix-hidden: xdx2ixbrl2004">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_zoxEEO5BrtAd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred Tax, State">(273</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zXkGzn7A2w37" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Benefit for deferred income taxes"><span style="-sec-ix-hidden: xdx2ixbrl2008">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_zpPFJ1cp1yag" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Benefit for deferred income taxes">(525</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total income tax provision (benefit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_znNtpXsGW6z3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total income tax provision (benefit)">160</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_zNPU0UJvBvva" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total income tax provision (benefit)">(364</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 120000 123000 40000 38000 160000 161000 -252000 -273000 -525000 160000 -364000 <p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zEUeWL0xTBoh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the Company’s deferred income taxes as of December 31, 2024 and 2023 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zibzMCIrYD32" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax assets:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Allowance for expected credit losses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_pn3n3_c20241231_ztHlwylkdEPe" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Allowance for expected credit losses">213</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_iI_pn3n3_c20231231_zEanOdl0Yfqh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Allowance for expected credit losses">228</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred revenue</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_c20241231_zTjEAKkJz7da" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred revenue">103</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_c20231231_z2ouSmL05jOh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred revenue">68</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Property and intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pn3n3_c20241231_znqhBql55wTh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Property and intangible assets">3,015</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pn3n3_c20231231_z6eJF3TM7rL9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Property and intangible assets">1,933</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">State net operating loss (“NOL”) carryforwards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn3n3_c20241231_zXDx0GphZTLa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State net operating loss (&quot;NOL&quot;) carryforwards">20,981</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pn3n3_c20231231_zLuxckGqvS3a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State net operating loss (&quot;NOL&quot;) carryforwards">19,749</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Federal net operating loss (“NOL”) carryforwards</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn3n3_c20241231_zPXEby8DtFI1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Federal net operating loss (&quot;NOL&quot;) carryforwards">55,569</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_pn3n3_c20231231_zOvavn56c2A7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Federal net operating loss (&quot;NOL&quot;) carryforwards">57,562</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Section 163(j) interest limitation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_ecustom--DeferredTaxAssetsInterestLimitation_iI_pn3n3_c20241231_zNp8CyHz5Zxh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Section 163(j) interest limitation">1,669</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_ecustom--DeferredTaxAssetsInterestLimitation_iI_pn3n3_c20231231_z2bhNUyB6iFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Section 163(j) interest limitation">2,731</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iNI_pn3n3_di_c20241231_zqfUgQWxCTu8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock based compensation">(173</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iNI_pn3n3_di_c20231231_zV3qBS3Z1Cgd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock based compensation"><span style="-sec-ix-hidden: xdx2ixbrl2044">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">ASC 842 - ROU asset</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--DeferredTaxAdjustment_iI_pn3n3_c20241231_zRTla5qD2dBg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="ASC 842 - ROU asset">(559</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--DeferredTaxAdjustment_iI_pn3n3_c20231231_z6nRuGZzwLw6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="ASC 842 - ROU asset">(1,026</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Prepaid commissions</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_ecustom--DeferredTaxAssetPrepaidCommissions_iI_pn3n3_c20241231_z6aOVe5iEAi7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Prepaid commissions">(267</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--DeferredTaxAssetPrepaidCommissions_iI_pn3n3_c20231231_zUuHLFitfTCe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Prepaid commissions">(303</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Cumulative balance translation adjustment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pn3n3_c20241231_zbx6hXZXerpi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative balance translation adjustment">1,015</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pn3n3_c20231231_zqtITXYOzNH5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative balance translation adjustment">988</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Section 267 limitation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--DeferredTaxAssetsTaxCreditLimitation_iI_pn3n3_c20241231_zDhQ5WMuxKdg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Section 267 limitation">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--DeferredTaxAssetsTaxCreditLimitation_iI_pn3n3_c20231231_zmYFMjEog8oh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Section 267 limitation">6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Credit carryovers</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_c20241231_zbidHYedNKFg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit carryovers">2,498</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwards_iI_pn3n3_c20231231_zNeoYHz5tE7c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit carryovers">2,498</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">ASC 842 - Lease liability</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--DeferredTaxLeaseLiability_iI_pn3n3_c20241231_zGgCnhWafkVi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="ASC 842 - Lease liability">558</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_ecustom--DeferredTaxLeaseLiability_iI_pn3n3_c20231231_z50lOguVsWQf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="ASC 842 - Lease liability">1,031</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accrued compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_c20241231_zRPEiaOnS7nh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued compensation">86</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_pn3n3_c20231231_z2Cwq2K1Stda" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued compensation">80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_c20241231_z650Zfx2DKvk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other">(46</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_c20231231_z9JLkSbqqU6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other">(59</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Section 174 costs</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--DeferredTaxAssetsTaxCreditCost_iI_pn3n3_c20241231_zyqHXX1L19D1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Section 174 costs">4,996</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_ecustom--DeferredTaxAssetsTaxCreditCost_iI_pn3n3_c20231231_zPUGMGLenBh5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Section 174 costs">3,799</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_c20241231_z2w5YJOaixwd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance">(89,664</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_c20231231_z3zW50XYAroe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance">(87,597</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Total deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_c20241231_zRR2kBwjikg7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax assets"><span style="-sec-ix-hidden: xdx2ixbrl2086">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_c20231231_zu3LWTFpMOUe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total deferred tax assets">1,688</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Goodwill amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_iNI_pn3n3_di_c20241231_zaQO1ov9l6X3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Goodwill amortization"><span style="-sec-ix-hidden: xdx2ixbrl2090">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_iNI_pn3n3_di_c20231231_zTJ0fLCkydhf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Goodwill amortization">(1,688</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net deferred tax liability</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--DeferredTaxLiabilities_iNI_pn3n3_di_c20241231_zj4S2JYypfd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net deferred tax liability"><span style="-sec-ix-hidden: xdx2ixbrl2094">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--DeferredTaxLiabilities_iNI_pn3n3_di_c20231231_z3kItpOmXCba" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net deferred tax liability"><span style="-sec-ix-hidden: xdx2ixbrl2096">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 213000 228000 103000 68000 3015000 1933000 20981000 19749000 55569000 57562000 1669000 2731000 173000 -559000 -1026000 -267000 -303000 1015000 988000 6000 6000 2498000 2498000 558000 1031000 86000 80000 -46000 -59000 4996000 3799000 89664000 87597000 1688000 1688000 42000000 P15Y <p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zsWdjoHBFeRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the federal statutory income tax rate (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIElOQ09NRSBUQVhFUyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_c20240101__20241231_z0kwgpG0P3el" title="Federal statutory income tax rate">21</span>%) to the Company’s effective income tax rate (determined in dollars) for the years ended December 31, 2024 and 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zDmt7cenak6c" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Federal provision (benefit) at statutory rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_pn3n3_c20240101__20241231_z7wO38UvrLz5" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Federal provision (benefit) at statutory rate">1,682</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_pn3n3_c20230101__20231231_zeNoPg9KSIV7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Federal provision (benefit) at statutory rate">(10,298</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Increase (decrease) in income taxes resulting from:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">State tax expense, net of federal benefit</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_c20240101__20241231_zDmPw4KEKDzj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State tax expense, net of federal benefit">94</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_c20230101__20231231_z3P16jbMyVmb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State tax expense, net of federal benefit">7,383</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Non-deductible items</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_pn3n3_c20240101__20241231_zdtvb8PwFtoj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-deductible items">30</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_pn3n3_c20230101__20231231_zeStxiQeySr6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-deductible items">26</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Impact of foreign operations</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_c20240101__20241231_zIJrG8eb51g2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Impact of foreign operations">(132</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_c20230101__20231231_z5aSTdWlCgWb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Impact of foreign operations">50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Subpart F GILTI inclusion</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_pn3n3_c20240101__20241231_zuYFmeULFMI8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Subpart F GILTI inclusion">1,066</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationGiltiAmount_pn3n3_c20230101__20231231_zeAqMtP5bI75" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Subpart F GILTI inclusion">804</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_c20240101__20241231_zW1c9fcbZnZ1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock based compensation">(177</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_c20230101__20231231_zX1FtknO9Bsl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock based compensation">18</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Goodwill impairment charges</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_pn3n3_c20240101__20241231_zwYlewD7WYH8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Goodwill impairment charges"><span style="-sec-ix-hidden: xdx2ixbrl2130">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_pn3n3_c20230101__20231231_z2krfgLo5Wci" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Goodwill impairment charges">5,692</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred true-up</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pn3n3_di_c20240101__20241231_zzpd3iYJM8eh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred true-up">(2,708</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pn3n3_c20230101__20231231_zaflh8ZoAnU9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred true-up">455</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20240101__20241231_z7rMasqLZP62" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance">305</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20230101__20231231_ziKTPWZIIBSk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance">(4,494</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total income tax provision (benefit)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_c20240101__20241231_zqnjhU9qSXH9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total income tax provision (benefit)">160</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_c20230101__20231231_z7HYnVZMUXh" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total income tax provision (benefit)">(364</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 0.21 1682000 -10298000 94000 7383000 30000 26000 -132000 50000 1066000 804000 -177000 18000 5692000 2708000 455000 305000 -4494000 160000 -364000 the Company is subject to tax. IT companies in Pakistan are subject to a 0.25% tax deducted at the source on receipts received from foreign sources with no further tax being due 0.21 0.21 0.29 265000000 187000000 78000000 237000000 211000000 84000000 <p id="xdx_802_eus-gaap--OtherNonoperatingIncomeAndExpenseTextBlock_zDwfOe8YGJT7" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zzjJt1hCdpvg">OTHER EXPENSE – NET</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_z5RQPigoXV42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other expense - net for the years ended December 31, 2024 and 2023 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_ztZDnkIgAIk9" style="display: none">SCHEDULE OF OTHER (EXPENSE) INCOME - NET</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zFq3juGX6wY" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20230101__20231231_z5UjEfHvjsJ9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_406_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_pn3n3_maONIEzhwF_zzHyrqzXv5A5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Foreign exchange gains (losses)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">130</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(790</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OtherNonoperatingExpense_iN_pn3n3_di_msONIEzhwF_zJnGSimhrs0j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(428</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(93</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_iT_pn3n3_mtONIEzhwF_zRrL73FVu2Ja" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Other expense - net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(298</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(883</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A1_z4z43YIOOfc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Foreign currency transaction gains and losses primarily result from transactions in foreign currencies other than the functional currency. These transaction gains and losses are recorded in the consolidated statements of operations related to the recurring measurement and settlement of such transactions. Other expense primarily represents legal settlements made by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b> </b></span></p> <p id="xdx_895_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_z5RQPigoXV42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other expense - net for the years ended December 31, 2024 and 2023 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_ztZDnkIgAIk9" style="display: none">SCHEDULE OF OTHER (EXPENSE) INCOME - NET</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zFq3juGX6wY" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20230101__20231231_z5UjEfHvjsJ9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_406_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_pn3n3_maONIEzhwF_zzHyrqzXv5A5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Foreign exchange gains (losses)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">130</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(790</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OtherNonoperatingExpense_iN_pn3n3_di_msONIEzhwF_zJnGSimhrs0j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(428</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(93</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_iT_pn3n3_mtONIEzhwF_zRrL73FVu2Ja" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Other expense - net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(298</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(883</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 130000 -790000 428000 93000 -298000 -883000 <p id="xdx_80C_eus-gaap--SegmentReportingDisclosureTextBlock_zbIwctxA5sj7" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zqLZODlLf1ui">SEGMENT REPORTING</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From January 1, 2023 through April 30, 2024, the Chief Executive Officer (“CEO”) and Executive Chairman served as the Chief Decision Maker (“CODM”), organizing the Company, managing resource allocations and measuring performance among two operating and reportable segments: (i) Healthcare IT and (ii) Medical Practice Management. As of May 1, 2024, the Company’s President, CEO and Executive Chairman served as the CODM. We report our segment information based on the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The CODM evaluates the financial performance of the business units on the basis of revenue, certain individual and total operating expenses and operating income (loss) excluding unallocated amounts, which are mainly corporate overhead costs, for assessing operating results and the allocation of resources. Our CODM does not evaluate operating segments using asset or liability information. The CODM uses segment revenue, certain segment operating expenses and segment operating income (loss) to manage the segments, comparing actual results to forecasted amounts and investigating the reasons for significant variances. Currently, a focus is being placed on reducing costs and managing global headcount. The segment revenue and segment operating income (loss) is also used to assess the performance of personnel and in establishing their compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Healthcare IT segment includes technology-assisted revenue cycle management, SaaS solutions and professional and other services. The Medical Practice Management segment includes the management of three medical practices. Each segment is considered a reporting unit. The Company does not have intra-entity sales or asset transfers, however, there are intracompany bank transfers. The accounting policies of the segments are the same as those disclosed in the summary of significant accounting policies. The following tables present revenues, operating expenses and operating income (loss) by reportable segment for the years ended December 31, 2024 and 2023:</span></p> <p id="xdx_89A_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zZyLP8ixaTmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zJVb8udNH0F1" style="display: none">SCHEDULE OF REVENUES, OPERATING EXPENSES AND OPERATING INCOME (LOSS) BY REPORTABLE SEGMENT</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z2YI7fScuCw3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Healthcare IT</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalPracticeManagementMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zJdH5nbCaNT4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Medical Practice Management</b></span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z0KLtuXwWsi3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Healthcare IT</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Medical Practice Management</b></span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_maOILzkUG_zWpVkb06AHNh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left">Net revenue</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">96,405</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">14,432</td> <td id="xdx_F23_zz5C567FQvSb" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> (a)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">110,837</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingCostsAndExpenses_pn3n3_maOEzlFw_z1aoAJBBM1Uf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: left">Direct operating costs</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,945</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,897</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">60,842</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--SellingAndMarketingExpense_pn3n3_maOEzlFw_ziOX99ZNsKDe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Selling and marketing</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,201</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,232</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_maOEzlFw_zRNIdt1nYc32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,093</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,911</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,004</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_maOEzlFw_z71CDx2X9kqj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,781</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2200">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,781</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DepreciationAndAmortization_pn3n3_maOEzlFw_z5CGoqqk2Usa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,813</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">329</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,142</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GoodwillImpairmentLoss_pn3n3_maOEzlFw_zUKXCVGUdwt1" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Goodwill impairment charges</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RestructuringCostsAndAssetImpairmentCharges_pn3n3_maOEzlFw_zhAFgGhnzhXd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Lease terminations, unoccupied lease charges and restructuring costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">596</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2212">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">596</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpenses_iT_pn3n3_msOILzkUG_mtOEzlFw_zN876xLgKWfd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">83,429</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,168</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">96,597</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_pn3n3_mtOILzkUG_maILFCOzDzi_z6A9hb1PgyYk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Segment operating income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12,976</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,264</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Reconciliation of profit or loss (segment profit/loss):</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--UnallocatedCorporateExpenses_iN_pn3n3_di_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_msILFCOzDzi_zwhy9Kxs3qa4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Unallocated corporate expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,119</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--InterestIncomeExpenseNonoperatingNet_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_maILFCOzDzi_zWcn6N0uiCg1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Net interest expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(812</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_maILFCOzDzi_zjVKvPfgyZr2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(298</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_mtILFCOzDzi_zKkWu3Bvjehe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Income before income taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,011</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span id="xdx_F0E_zQHxGDBLWqA3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zth0kJDUax52" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This revenue represents fees based on our actual costs plus a percentage of the operating profit.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zkV2CSrWk6Hj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Healthcare IT</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalPracticeManagementMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zzgwbrIS48Ge" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Medical Practice <span style="text-decoration: underline">Management</span></b></span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_499_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zvj8c9OhpZR8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Healthcare IT</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Medical Practice Management</b></span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_maOILzkUG_zogKTbdgHM44" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left">Net revenue</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">103,683</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">13,376</td> <td id="xdx_F2B_zv8Zy3CmieG3" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> (a)</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">117,059</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingCostsAndExpenses_pn3n3_maOEzSKG_z5p93nsPuDi7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Direct operating costs</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">60,319</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,498</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">70,817</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_pn3n3_maOEzSKG_zSbGzIvdpnx1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Selling and marketing</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,614</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">36</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,650</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_maOEzSKG_ze2UVKAKfGcl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,992</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,854</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,846</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_maOEzSKG_zIuuAMWSFdFb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,736</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2257">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,736</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DepreciationAndAmortization_pn3n3_maOEzSKG_zb7vuNw8oT4b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,046</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">356</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,402</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--GoodwillImpairmentLoss_pn3n3_maOEzSKG_zXbOZK1YknE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Goodwill impairment charges</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2265">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RestructuringCostsAndAssetImpairmentCharges_pn3n3_maOEzSKG_znnXQsSKk8Dj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Lease terminations, unoccupied lease charges and restructuring costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,105</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2269">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,105</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_iT_pn3n3_msOILzkUG_mtOEzSKG_zjBx9wblhNjj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">142,812</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,744</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">155,556</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_iT_pn3n3_mtOILzkUG_maILFCOzqBu_zBJ3iJ0SOTRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Segment operating (loss) income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(39,129</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">632</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(38,497</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Reconciliation of profit or loss (segment profit/loss):</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--UnallocatedCorporateExpenses_iN_pn3n3_di_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zsYCN6xxzGy8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Unallocated corporate expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,618</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--InterestIncomeExpenseNonoperatingNet_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_maILFCOzqBu_zVAd0X7Z4lC5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Net interest expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,040</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_maILFCOzqBu_zdi2fKQuVXLh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(883</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_mtILFCOzqBu_zT1wZAIWBkB9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Loss before income taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(49,038</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span id="xdx_F01_zoihR77Nr3Nc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zeeTYdENX2e5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This revenue represents fees based on our actual costs plus a percentage of the operating profit.</span></td> </tr></table> <p id="xdx_8A0_znNDXpQEnzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_89A_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zZyLP8ixaTmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zJVb8udNH0F1" style="display: none">SCHEDULE OF REVENUES, OPERATING EXPENSES AND OPERATING INCOME (LOSS) BY REPORTABLE SEGMENT</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z2YI7fScuCw3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Healthcare IT</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalPracticeManagementMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zJdH5nbCaNT4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Medical Practice Management</b></span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z0KLtuXwWsi3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Healthcare IT</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Medical Practice Management</b></span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_maOILzkUG_zWpVkb06AHNh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left">Net revenue</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">96,405</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">14,432</td> <td id="xdx_F23_zz5C567FQvSb" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> (a)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">110,837</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingCostsAndExpenses_pn3n3_maOEzlFw_z1aoAJBBM1Uf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: left">Direct operating costs</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49,945</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,897</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">60,842</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--SellingAndMarketingExpense_pn3n3_maOEzlFw_ziOX99ZNsKDe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Selling and marketing</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,201</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">31</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,232</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_maOEzlFw_zRNIdt1nYc32" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,093</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,911</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,004</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_maOEzlFw_z71CDx2X9kqj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,781</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2200">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,781</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DepreciationAndAmortization_pn3n3_maOEzlFw_z5CGoqqk2Usa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">13,813</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">329</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,142</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GoodwillImpairmentLoss_pn3n3_maOEzlFw_zUKXCVGUdwt1" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Goodwill impairment charges</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RestructuringCostsAndAssetImpairmentCharges_pn3n3_maOEzlFw_zhAFgGhnzhXd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Lease terminations, unoccupied lease charges and restructuring costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">596</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2212">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">596</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpenses_iT_pn3n3_msOILzkUG_mtOEzlFw_zN876xLgKWfd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">83,429</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,168</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">96,597</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_pn3n3_mtOILzkUG_maILFCOzDzi_z6A9hb1PgyYk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Segment operating income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12,976</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,264</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Reconciliation of profit or loss (segment profit/loss):</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--UnallocatedCorporateExpenses_iN_pn3n3_di_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_msILFCOzDzi_zwhy9Kxs3qa4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Unallocated corporate expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,119</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--InterestIncomeExpenseNonoperatingNet_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_maILFCOzDzi_zWcn6N0uiCg1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Net interest expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(812</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_maILFCOzDzi_zjVKvPfgyZr2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(298</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_mtILFCOzDzi_zKkWu3Bvjehe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Income before income taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,011</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span id="xdx_F0E_zQHxGDBLWqA3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zth0kJDUax52" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This revenue represents fees based on our actual costs plus a percentage of the operating profit.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--HealthcareITMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zkV2CSrWk6Hj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Healthcare IT</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalPracticeManagementMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zzgwbrIS48Ge" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Medical Practice <span style="text-decoration: underline">Management</span></b></span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_499_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zvj8c9OhpZR8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Healthcare IT</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Medical Practice Management</b></span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_maOILzkUG_zogKTbdgHM44" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left">Net revenue</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">103,683</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">13,376</td> <td id="xdx_F2B_zv8Zy3CmieG3" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> (a)</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">117,059</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingCostsAndExpenses_pn3n3_maOEzSKG_z5p93nsPuDi7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Direct operating costs</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">60,319</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,498</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">70,817</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_pn3n3_maOEzSKG_zSbGzIvdpnx1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Selling and marketing</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,614</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">36</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,650</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_maOEzSKG_ze2UVKAKfGcl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">General and administrative</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,992</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,854</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,846</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_maOEzSKG_zIuuAMWSFdFb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,736</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2257">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,736</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DepreciationAndAmortization_pn3n3_maOEzSKG_zb7vuNw8oT4b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,046</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">356</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,402</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--GoodwillImpairmentLoss_pn3n3_maOEzSKG_zXbOZK1YknE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Goodwill impairment charges</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2265">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">42,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RestructuringCostsAndAssetImpairmentCharges_pn3n3_maOEzSKG_znnXQsSKk8Dj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Lease terminations, unoccupied lease charges and restructuring costs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,105</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2269">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,105</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_iT_pn3n3_msOILzkUG_mtOEzSKG_zjBx9wblhNjj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">142,812</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,744</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">155,556</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_iT_pn3n3_mtOILzkUG_maILFCOzqBu_zBJ3iJ0SOTRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Segment operating (loss) income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(39,129</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">632</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(38,497</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Reconciliation of profit or loss (segment profit/loss):</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--UnallocatedCorporateExpenses_iN_pn3n3_di_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zsYCN6xxzGy8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Unallocated corporate expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,618</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--InterestIncomeExpenseNonoperatingNet_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_maILFCOzqBu_zVAd0X7Z4lC5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Net interest expense</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,040</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_maILFCOzqBu_zdi2fKQuVXLh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(883</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_mtILFCOzqBu_zT1wZAIWBkB9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Loss before income taxes</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(49,038</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right"><span id="xdx_F01_zoihR77Nr3Nc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zeeTYdENX2e5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This revenue represents fees based on our actual costs plus a percentage of the operating profit.</span></td> </tr></table> 96405000 14432000 110837000 49945000 10897000 60842000 6201000 31000 6232000 9093000 1911000 11004000 3781000 3781000 13813000 329000 14142000 596000 596000 83429000 13168000 96597000 12976000 1264000 14240000 5119000 -812000 -298000 8011000 103683000 13376000 117059000 60319000 10498000 70817000 9614000 36000 9650000 10992000 1854000 12846000 4736000 4736000 14046000 356000 14402000 42000000 42000000 1105000 1105000 142812000 12744000 155556000 -39129000 632000 -38497000 8618000 -1040000 -883000 -49038000 <p id="xdx_802_eus-gaap--FairValueDisclosuresTextBlock_znGc9ydWsxNl" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zPFuCBOShDYk">FAIR VALUE OF FINANCIAL INSTRUMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgement associated with the inputs used to measure their value in one of the following three categories:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. We held no Level 1 financial instruments at December 31, 2024 or 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Quoted prices for similar instruments in active markets with inputs that are observable, either directly or indirectly. Our Level 2 financial instruments include notes payable which are carried at cost and approximate fair value since the interest rates being charged approximate market rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 instruments include the fair value of contingent consideration related to completed acquisitions. There was no contingent consideration recorded at December 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zHu0yc3p6ymi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides the assets and liabilities carried at fair value measured on a non-recurring basis as of December 31, 2024 and 2023. Refer to Note 2 - Basis of Presentation and Significant Accounting Policies, for a description of the valuation techniques used to determine the fair value of the assets measured on a non-recurring basis in the table below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_zdUzPPwIpzze" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">FAIR VALUE OF THE ASSETS MEASURED ON A NON-RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements at December 31, 2024 </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Expense for the year ended</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="18" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left">Goodwill - Healthcare IT</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_zOTGIJy2BO5c" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT, Carrying Value">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxRQt5B111g8" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT"><span style="-sec-ix-hidden: xdx2ixbrl2303">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zsnS905TkHu4" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT"><span style="-sec-ix-hidden: xdx2ixbrl2305">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOIhXLRzD20g" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20241231_zweduaukeRKg" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT"><span style="-sec-ix-hidden: xdx2ixbrl2309">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements at December 31, 2023 </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Expense for the year ended</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td colspan="17" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($ in thousands)</span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left">Goodwill - Healthcare IT</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_zBuIXrSucX4i" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT, Carrying Value">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zrceiv570xwa" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT"><span style="-sec-ix-hidden: xdx2ixbrl2313">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zyFvyTTwIRW9" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT"><span style="-sec-ix-hidden: xdx2ixbrl2315">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8ebm0mXgsej" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20231231_z24PlG60k4vl" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT">42,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A6_z2sFz1vwMZc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zHu0yc3p6ymi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides the assets and liabilities carried at fair value measured on a non-recurring basis as of December 31, 2024 and 2023. Refer to Note 2 - Basis of Presentation and Significant Accounting Policies, for a description of the valuation techniques used to determine the fair value of the assets measured on a non-recurring basis in the table below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B9_zdUzPPwIpzze" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">FAIR VALUE OF THE ASSETS MEASURED ON A NON-RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements at December 31, 2024 </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Expense for the year ended</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="18" style="font: 10pt Times New Roman, Times, Serif; text-align: center">($ in thousands)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left">Goodwill - Healthcare IT</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_zOTGIJy2BO5c" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT, Carrying Value">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxRQt5B111g8" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT"><span style="-sec-ix-hidden: xdx2ixbrl2303">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zsnS905TkHu4" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT"><span style="-sec-ix-hidden: xdx2ixbrl2305">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOIhXLRzD20g" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20241231_zweduaukeRKg" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT"><span style="-sec-ix-hidden: xdx2ixbrl2309">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements at December 31, 2023 </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Expense for the year ended</b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Carrying Value</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td colspan="17" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($ in thousands)</span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left">Goodwill - Healthcare IT</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementBasisAxis__us-gaap--CarryingReportedAmountFairValueDisclosureMember_zBuIXrSucX4i" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT, Carrying Value">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zrceiv570xwa" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT"><span style="-sec-ix-hidden: xdx2ixbrl2313">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zyFvyTTwIRW9" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT"><span style="-sec-ix-hidden: xdx2ixbrl2315">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8ebm0mXgsej" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT">19,186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_c20231231_z24PlG60k4vl" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Goodwill - Healthcare IT">42,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> </table> 19186000 19186000 19186000 19186000 42000000 <p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zJQdA9Jb0ddi" style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zTZ9FCCfTbt1">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2025, the Company’s common stock shareholders approved an increase in the number of authorized common shares from <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_pn5n6_c20250130__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDRu5yjirHc" title="Common stock shares authorized">35</span> million to <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pn5n6_c20250131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJMx3bpj6Byb" title="Common stock shares authorized">85</span> million. An amended certificate of incorporation was filed by the Company. Also, in January 2025, the Company’s Board of Directors declared Preferred Stock dividends for January and February 2025, whereby the payment for these two months would be credited to the arrearage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2025, the Company resumed monthly payment of the dividends on the Series A and B Preferred Stock, paying one month of dividends in arrears. The second monthly payment is scheduled to be paid in March 2025, which after the conversion as discussed below, will include dividends for the Series A Preferred Stock that were not converted and dividends for the Series B Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In </span>March 2025, the Board of Directors elected to exercise its conversion rights, which provide for the conversion of each share of Series A Preferred Stock into <span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_c20250301__20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhXE9OvQsPW8" title="Conversion of shares">7.3358</span> shares of common stock, inclusive of all accumulated and unpaid dividends. Dividends on the converted Series A Preferred shares ceased to accrue as of the conversion date. Individual shareholders who, at the exchange date, owned at least <span id="xdx_906_eus-gaap--SharesOutstanding_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--IndividualShareholdersMember_z1GbmqlvlXk" title="Shares outstanding">100,000</span> shares of Series A Preferred Stock did not have their shares automatically converted to common stock so long as they were held by the Company’s transfer agent, unless they consented to the conversion. There were approximately <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--IndividualShareholdersMember_zbRrLrDYnaH9" title="Shares remaining outstanding">985,000</span> shares of Series A Preferred Stock remaining after the Conversion. Also in March 2025, the Company announced that it will be delisting the Series A Preferred Stock from the Nasdaq Global Market.</p> 35000000 85000000 7.3358 100000 985000 No tax effect has been recorded as the Company recorded a valuation allowance against the tax benefit from its foreign currency translation adjustments. Amounts are net of issuance cost of approximately $71,000. This revenue represents fees based on our actual costs plus a percentage of the operating profit. This revenue represents fees based on our actual costs plus a percentage of the operating profit.